B O O K - American College of Rheumatology
B O O K - American College of Rheumatology
B O O K - American College of Rheumatology
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
program<br />
B O O K<br />
Pre-Conference Courses: Saturday, November 6 - Sunday, November 7, 2010<br />
Annual Scientific Sessions: Monday, November 8 - Thursday, November 11, 2010<br />
Exhibits: Monday, November 8 - Wednesday, November 10, 2010
Maximize Your Annual Meeting Experience with SessionSelect!<br />
Stay current with the latest information presented at<br />
this year’s ACR/ARHP Annual Scientific Meeting. Within<br />
24 hours <strong>of</strong> virtually every live session, video recordings<br />
<strong>of</strong> the presentations, including oral abstract sessions,<br />
will be available online to view as webcasts during the<br />
meeting. This special <strong>of</strong>fer is only extended to 2010<br />
scientific attendees.<br />
To learn more about SessionSelect<br />
visit the ACR Resource Center<br />
located in the International Boulevard<br />
Lobby or the ACR website at<br />
www.rheumatology.org/education.<br />
As scientific attendee, you<br />
get FREE ACCESS to over<br />
200 hours <strong>of</strong> online annual<br />
meeting content –<br />
Over $500 <strong>of</strong><br />
added value!<br />
ACR SessionSelect
program<br />
B O O K<br />
ABOUT ACR/ARHP EDUCATION<br />
The <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong> and the Association <strong>of</strong> <strong>Rheumatology</strong> Health Pr<strong>of</strong>essionals, a<br />
division <strong>of</strong> the ACR, are organizations <strong>of</strong> physicians, health pr<strong>of</strong>essionals and scientists serving members<br />
through programs, including education and research. Through these programs, the ACR and the ARHP foster<br />
excellence in the care <strong>of</strong> people with rheumatic and musculoskeletal diseases. The 2010 ACR/ARHP Annual<br />
Scientific Meeting programs have been independently planned by the ACR Committee on Education, the ACR<br />
Annual Meeting Planning Committee, the ARHP Annual Meeting Program Committee, and the ARHP Clinical<br />
Focus Course Task Force.<br />
This program is sponsored by the <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong> for educational purposes only. The<br />
material presented is not intended to represent the only or the best methods appropriate for the medical<br />
conditions being discussed, but rather are intended to present the opinions <strong>of</strong> the authors/ presenters, which<br />
may be helpful to other healthcare pr<strong>of</strong>essionals. Attendees participating in this medical education program<br />
do so with the full knowledge that they waive any claim they may have against the ACR for reliance on any<br />
information presented during these educational activities. The ACR does not guarantee, warrant or endorse<br />
any commercial products or services.<br />
PROGRAM OBJECTIVES<br />
At the conclusion <strong>of</strong> the 2010 ACR/ARHP annual meeting, participants should be able to:<br />
• identify recent developments in the diagnosis and management <strong>of</strong> patients with rheumatic diseases<br />
• outline new technologies for the treatment <strong>of</strong> rheumatologic problems<br />
• describe potential challenges in the delivery <strong>of</strong> care to patients with rheumatic diseases and to specify<br />
possible solutions<br />
• utilize new research data to improve the quality <strong>of</strong> care <strong>of</strong> patients with rheumatic diseases<br />
Printing <strong>of</strong> this publication is supported by Amgen, Inc. and Pfizer Inc.<br />
This publication was printed by an FSC validated printer on eco-friendly paper.
ACR/ARHP 2010 ANNUAL SCIENTIFIC MEETING<br />
OVERALL NEEDS ASSESSMENT/PRACTICE GAPS<br />
The <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong> and the<br />
Association <strong>of</strong> <strong>Rheumatology</strong> Health Pr<strong>of</strong>essionals are<br />
committed to providing comprehensive education to<br />
improve the knowledge and performance <strong>of</strong> physicians,<br />
health pr<strong>of</strong>essionals and scientists. Through evidencebased<br />
educational programs, the organization strives to<br />
enhance practice performance and improve the quality<br />
<strong>of</strong> care in those with or at risk for arthritis, rheumatic and<br />
musculoskeletal diseases. The 2010 annual meeting program<br />
has been developed independent <strong>of</strong> commercial influence.<br />
The following groups were involved in the planning process:<br />
the ACR Committee on Education; the ACR Annual Meeting<br />
Planning Committee; the ARHP Education Committee and the<br />
ARHP Annual Meeting Program Planning Committee.<br />
The program is the result <strong>of</strong> a planning process that identified<br />
educational needs to change or enhance the knowledge,<br />
competence or performance <strong>of</strong> rheumatology pr<strong>of</strong>essionals.<br />
The program’s content was derived from both needs<br />
assessment and practice gap analysis based on pr<strong>of</strong>essional<br />
activities, practice setting, ABIM recertification requirements<br />
and physician attributes.<br />
PROGRAM HIGHLIGHTS<br />
• Educational tracks to help attendees identify content<br />
targeted to them. Tracks include: business <strong>of</strong> rheumatology,<br />
clinical, clinical and research, clinical practice, educators,<br />
fellow-in-training, pediatrics, pediatrics and clinical, and<br />
research<br />
• Latest science and best-practices presented through peerreviewed<br />
and selected clinical and scientific abstracts, and<br />
invited speakers providing clinical, evidence-based and<br />
quality focused content<br />
• Diverse formats <strong>of</strong> education delivery, including: didactic<br />
lectures, debates, and interactive sessions, such as poster<br />
tours, Meet the Pr<strong>of</strong>essors and Workshop sessions<br />
• A larger forum for discussion <strong>of</strong> practical management<br />
issues such as the Curbside Consults – Ask the Pr<strong>of</strong>essors<br />
session and Medical Aspects lectures<br />
• Extensive learning opportunities in the basic science <strong>of</strong><br />
rheumatology, an area <strong>of</strong> the program developed by a<br />
subcommittee <strong>of</strong> US and internationally prominent basic<br />
scientists. Offerings include: Basic Science Symposia, State<strong>of</strong>-the-Art<br />
Lectures, a series <strong>of</strong> Immunology Updates for the<br />
Clinicians, and a Basic Science pre-meeting course<br />
• Clinical management sessions, including the Thieves’<br />
Market and basic management <strong>of</strong> difficult issues<br />
• A specific pediatric rheumatology track plus content<br />
integrated throughout the program designed to<br />
provide a high-level educational program to pediatric<br />
rheumatologists; and relevant updates to adult<br />
rheumatologists<br />
• Formal presentations <strong>of</strong> new practice guidelines provided<br />
to alert the membership and explain, in an open forum, the<br />
data supporting the guidelines and propose approaches for<br />
implementation<br />
• Over 40 workshops designed to provide hands-on skills<br />
training
TABLE OF CONTENTS<br />
ACCREDITATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8<br />
Meeting Evaluations, CME Credit, ARHP Certificates <strong>of</strong> Participation and<br />
Certificates <strong>of</strong> Attendance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8<br />
Conflict <strong>of</strong> Interest/Disclosure Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8<br />
Copyright Materials Policy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8<br />
ACR/ARHP Abstract Embargo Policy . . . . . . . . . . . . . . . . . . . . . . . . . . . 9<br />
Important Locations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9<br />
MEETING INFORMATION . . . . . . . . . . . . . . . . . . . . . . . .10<br />
Ask Me Staff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Cell Phone, Pages, PDAs & Other Electronic Devices . . . . . . . . . . . . . . . . . . . 10<br />
Attire . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Food Service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Meeting Room Capacity/Important Fire Safety Information . . . . . . . . . . . . 10<br />
Photography and Videotaping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Special Needs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Name Badges . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Emergency Contact Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
No Smoking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Opening Event at the Georgia Aquarium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Shuttle Bus Service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11<br />
Session Descriptions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11<br />
Guide to Help Navigate the Meeting . . . . . . . . . . . . . . . . . . . . . . . . . .11<br />
MEETING SERVICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .12<br />
ACR Resource Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12<br />
ACR Practice Advocacy Coding Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12<br />
ACR/ARHP Membership Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Lost and Found . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Announcements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
REF Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
REF Donor’s Lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Electronic Syllabus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Wireless Access . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
2010 REF 5K Run/Walk. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
In-Room Encore Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14<br />
Replay Café (Exhibit Hall) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14<br />
ACR/ARHP Meeting Hotels + Map . . . . . . . . . . . . . . . . . . . . . . . . . . . .15<br />
Special Offers at the Annual Scientific Meeting . . . . . . . . . . . . . . . .16<br />
POSTER SESSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16<br />
Poster Presenter Instructions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16<br />
Poster Session Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16<br />
Guided Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16<br />
PRE-CONFERENCE PROGRAM . . . . . . . . . . . . . . . . . . .17<br />
Saturday, November 6, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .17<br />
ACR Musculoskeletal Ultrasound Course for Rheumatologists -<br />
Day One . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17<br />
ACR Clinical Research Conference . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19<br />
ACR Certified <strong>Rheumatology</strong> Coder Course – Day One . . . . . . . . . . . . . . . . . 20<br />
ACR Basic Research Conference - Day One . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20<br />
ACR/ABIM Maintenance <strong>of</strong> Certification Learning Session -<br />
2010 Update . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21<br />
Sunday, November 7, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22<br />
ACR/ARHP Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
ACR Musculoskeletal Ultrasound Course for Rheumatologists -<br />
Day Two . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
ACR Basic Research Conference – Day Two . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23<br />
ACR Review Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23<br />
ARHP Clinical Focus Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25<br />
ACR Certified <strong>Rheumatology</strong> Coder Exam – Day Two . . . . . . . . . . . . . . . . . . . 26<br />
ACR/ARHP Opening Lecture and Awards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
ACR/ARHP Opening Event . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
ACR/ARHP ANNUAL SCIENTIFIC MEETING . . . . .27<br />
Monday, November 8, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .27<br />
ARHP Special Session: ARHP First-Time Attendee Orientation . . . . . . . . . . 27<br />
ARHP Special Session: Moderator Orientation . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />
ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />
ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />
ACR REF Special Session: REF Oscar S. Gluck, MD, Memorial<br />
Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28<br />
ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28<br />
ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28<br />
ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29<br />
ARHP Special Session: ARHP Networking Forum . . . . . . . . . . . . . . . . . . . . . . . 30<br />
ACR Practice Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
ACR Immunology Updates for Clinicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
ACR Medical Aspects <strong>of</strong> Rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . 31<br />
ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31<br />
ACR Poster Session A and Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31<br />
Exhibits and Replay Cafe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
Morning Snack Breaks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
ARHP General Session I - Keynote Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33<br />
ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33<br />
2010 Program Book 3
TABLE OF CONTENTS<br />
ACR Plenary Session I: Discovery 2010. . . . . . . . . . . . . . . . . . . . . . . . . . . . 33<br />
ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34<br />
ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34<br />
Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35<br />
ARHP Special Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35<br />
ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35<br />
ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37<br />
ACR State-<strong>of</strong>-the-Art Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37<br />
ACR REF Special Session - REF Memorial Lectureship: <strong>Rheumatology</strong><br />
Education 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37<br />
ACR/ARHP Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Exhibit Hall Afternoon Snack Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
ACR Clinical Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39<br />
ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39<br />
ACR/ARHP Combined Abstract Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45<br />
ACR REF Special Session - ACR REF “Within Our Reach” Lecture:<br />
Finding a Cure for Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45<br />
ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45<br />
ARHP Concurrent Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46<br />
REF 25th Anniversary Celebration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />
ACR/ARHP Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />
ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />
ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />
ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />
ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
ACR Special Session: Legislative Update from Capitol Hill . . . . . . . . . . . . . . 52<br />
ACR REF Special Session: ACR REF Clinician Scholar Educator<br />
Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53<br />
ACR Special Session: REF Edmond L. Dubois, MD, Memorial<br />
Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53<br />
ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53<br />
REF Industry Roundtable-Supported Symposia . . . . . . . . . . . . . . . . . . . . . . . . 54<br />
Tuesday, November 9, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .55<br />
REF 5K Run /Walk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />
ACR/ARHP Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />
ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />
ACR Immunology Updates for Clinicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />
ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />
ACR Special Session - News from the National Institutes <strong>of</strong> Health:<br />
Updates and Opportunities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56<br />
ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56<br />
ACR/ARHP Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57<br />
ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58<br />
ACR Medical Aspects <strong>of</strong> Rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />
ACR State-<strong>of</strong>-the-Art Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />
ACR/ARHP Poster Session B and Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />
Exhibits and Replay Café . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60<br />
Morning Snack Breaks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60<br />
ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60<br />
ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />
Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />
ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />
ARHP General Session II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62<br />
ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62<br />
ACR Plenary Session II: Discovery 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63<br />
ARHP Special Session: Networking at Noon . . . . . . . . . . . . . . . . . . . . . . . . . . . 63<br />
Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />
ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />
ACR Special Session: Contract Negotiations for Physicians . . . . . . . . . . . . . 65<br />
ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66<br />
ACR Practice Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66<br />
ACR Special Session: Clinical Teaching Strategies in the Outpatient Clinic<br />
Setting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66<br />
ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67<br />
ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67<br />
Exhibit Hall Afternoon Snack Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68<br />
Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68<br />
ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68<br />
ACR Clinical Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68<br />
ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70<br />
ACR/ARHP Combined Abstract Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74<br />
ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75<br />
ACR/ARHP Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76<br />
ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76<br />
ACR Clinical Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77<br />
ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78<br />
ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
ACR Special Session: ILAR Global Health Project . . . . . . . . . . . . . . . . . . . . . . . 84<br />
ACR REF Special Session: REF Marshall J. Schiff, MD, Memorial<br />
Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84<br />
ACR Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />
ARHP Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />
Wine and Cheese Reception (Exhibit Hall). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86<br />
ACR Study Groups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86<br />
Wednesday, November 10, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .94<br />
ACR Medical Aspects <strong>of</strong> Rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . 94<br />
ACR Special Session: The Changing Faces <strong>of</strong> the <strong>Rheumatology</strong><br />
Workforce . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94<br />
ACR Special Session: Insurance Roundtable Discussion . . . . . . . . . . . . . . . . 94<br />
ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96<br />
ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97<br />
ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98<br />
ACR Immunology Updates for Clinicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98<br />
ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98<br />
ACR REF Special Session: REF Paul Klemperer, MD, Memorial<br />
Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98<br />
4<br />
2010 Program Book
TABLE OF CONTENTS<br />
ACR/ARHP Poster Session C and Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . 98<br />
Exhibits and Replay Café . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99<br />
Morning Snack Breaks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99<br />
ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99<br />
ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100<br />
ACR Practice Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
ACR State-<strong>of</strong>-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
ACR State-<strong>of</strong>-the-Art Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102<br />
ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102<br />
ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />
ACR Plenary Session III: Discovery 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104<br />
ACR Practice Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104<br />
ARHP Special Sessions: ARHP Occupational and Physical Therapy<br />
Networking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />
ARHP Special Sessions: ARHP Office Nurse Networking . . . . . . . . . . . . . . . 105<br />
Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />
ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />
ACR Special Session: ACR Leadership Town Hall Meeting . . . . . . . . . . . . . . 106<br />
ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106<br />
ACR Study Groups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107<br />
ACR Special Session: Career Opportunities in <strong>Rheumatology</strong>: Making a<br />
Choice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112<br />
ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113<br />
ACR Basic Science Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113<br />
ACR Clinical Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114<br />
ACR Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115<br />
ACR/ARHP Combined Abstract Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118<br />
ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119<br />
ARHP Concurrent Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119<br />
ACR Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120<br />
ARHP Concurrent Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120<br />
ACR Basic Science Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121<br />
ACR Clinical Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121<br />
ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123<br />
ACR Meet the Pr<strong>of</strong>essor Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129<br />
ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130<br />
REF Industry Roundtable-Supported Symposia . . . . . . . . . . . . . . . . . . . . . . . 132<br />
Thursday, November 11, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .133<br />
ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133<br />
ACR Immunology Updates for Clinicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133<br />
ACR Practice Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133<br />
ACR State-<strong>of</strong>-the-Art Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133<br />
ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134<br />
ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134<br />
ACR Basic Science Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135<br />
ACR Clinical Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136<br />
ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137<br />
ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142<br />
ARHP Concurrent Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142<br />
ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143<br />
ACR Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143<br />
ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146<br />
ARHP Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147<br />
Industry-Supported Post Conference Symposia . . . . . . . . . . . . . . . . . . . . . . . 147<br />
ACR POSTER SESSION<br />
(ABSTRACTS # 1-619) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148<br />
Antiphospholipid Syndrome I<br />
(Abstracts #1 - 14) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148<br />
Cytokines, Mediators, Gene Regulation I<br />
(Abstracts #15 - 39) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149<br />
Education<br />
(Abstracts #40 - 48) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150<br />
Epidemiology and Health Services Research: Inflammatory Arthritis<br />
(Abstracts #49 - 91) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150<br />
Fibromyalgia and S<strong>of</strong>t Tissue Disorders I<br />
(Abstracts #92 - 117) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153<br />
Imaging <strong>of</strong> Rheumatic Disease I: X-ray, CT and MRI<br />
(Abstracts #118 - 143) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154<br />
Metabolic and Crystal Arthropathies - Therapeutics and Outcomes<br />
(Abstracts #144 - 166) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157<br />
Orthopedics, Low Back Pain, and Rehabilitation<br />
(Abstracts #167 - 178) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158<br />
Osteoarthritis - Clinical Aspects: Biomechanics, Function, and Imaging I<br />
(Abstracts #179 - 205) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159<br />
Pediatric <strong>Rheumatology</strong> - Clinical and Therapeutic Aspects: Juvenile<br />
Idiopathic Arthritis I<br />
(Abstracts #206 - 241) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161<br />
Pediatric <strong>Rheumatology</strong> - Pathogenesis and Genetics: Bench to Bedside-<br />
The Science <strong>of</strong> Pediatric <strong>Rheumatology</strong> (Abstracts #242- 268) . . . . . . . . . 163<br />
Rheumatoid Arthritis - Animal Models: Cytokines, Novel Therapeutics and<br />
Mechanisms <strong>of</strong> Action<br />
(Abstracts #269 - 293) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165<br />
Rheumatoid Arthritis - Clinical Aspects: Drug Studies, Drug Safety, Disease<br />
Activity and Remission, Infections I<br />
(Abstracts #294 - 347) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166<br />
Rheumatoid Arthritis - Human Etiology and Pathogenesis I<br />
(Abstracts #348 - 372) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170<br />
Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene<br />
Therapy: Safety, Non-Biologic DMARDs, Switching Biologics I<br />
(Abstracts #373 - 421) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172<br />
Systemic Lupus Erythematosus - Animal Models<br />
(Abstracts #422 - 443) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176<br />
Systemic Lupus Erythematosus - Clinical Aspects and Treatment I<br />
(Abstracts #444 - 485) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177<br />
Systemic Lupus Erythematosus - Human Etiology and Pathogenesis:<br />
Genetics and Mechanisms<br />
(Abstracts #486 - 511) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180<br />
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and<br />
Treatment I<br />
(Abstracts #512 - 559) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182<br />
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects<br />
and Therapeutics I<br />
(Abstracts #560 - 599) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186<br />
2010 Program Book 5
TABLE OF CONTENTS<br />
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis and<br />
Animal Models I<br />
(Abstracts #600 - 619) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189<br />
ACR/ARHP POSTER SESSION B<br />
(ABSTRACTS #733-1345) . . . . . . . . . . . . . . . . . . . . . . .191<br />
B-Cell Biology and Targets in Autoimmune Disease<br />
(Abstracts #733 - 753) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191<br />
Epidemiology and Health Services Research: MSK, CTD and SLE<br />
(Abstracts #754 - 796) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192<br />
Fibromyalgia and S<strong>of</strong>t Tissue Disorders II<br />
(Abstracts #797 - 821) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195<br />
Genetics, Genomics and Proteomics in the Rheumatic Diseases<br />
(Abstracts #822 - 843) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196<br />
Innate Immunity and Rheumatic Disease<br />
(Abstracts #844- 868) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 198<br />
Metabolic and Crystal Arthropathies - Pathogenesis, Epidemiology, and<br />
Clinical Manifestations II<br />
(Abstracts #869 - 889) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200<br />
Miscellaneous Rheumatic and Inflammatory Diseases I<br />
(Abstracts #890- 912) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201<br />
Muscle Biology, Myositis and Myopathies: New Developments in the<br />
Diagnosis, Pathogenesis and Treatment <strong>of</strong> Myositis<br />
(Abstracts #913- 935) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203<br />
Osteoarthritis - Clinical Aspects: Pain and Treatment II<br />
(Abstracts #936 - 955) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205<br />
Osteoporosis and Metabolic Bone Disease: Clinical Aspects and<br />
Pathogenesis<br />
(Abstracts #956 - 983) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206<br />
Quality Measures and Innovation in Practice Management and Care<br />
Delivery<br />
(Abstracts #984 - 1014) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208<br />
Rheumatoid Arthritis - Clinical Aspects: Clinical Features, Disease Risk<br />
Factors, Bone in RA, CVD II<br />
(Abstracts #1015 - 1068) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209<br />
Rheumatoid Arthritis - Human Etiology and Pathogenesis II<br />
(Abstracts #1069 - 1094) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213<br />
Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene<br />
Therapy: Predicting and Measuring Outcomes, Novel Compounds II<br />
(Abstracts #1095 - 1138) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215<br />
Systemic Lupus Erythematosus - Clinical Aspects and Treatment II<br />
(Abstracts #1139 - 1180) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219<br />
Systemic Lupus Erythematosus - Human Etiology and Pathogenesis:<br />
Cardiovascular Disease and Clinical<br />
(Abstracts #1181- 1200) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221<br />
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects<br />
and Therapeutics II<br />
(Abstracts #1201- 1239) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223<br />
T-Cell Biology and Targets in Autoimmune Disease<br />
(Abstracts #1240 - 1274) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225<br />
Large-Vessel Vasculitis and Behçet’s Disease I<br />
(Abstracts #1275 - 1315) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227<br />
ARHP Poster Session B: Osteoporosis<br />
(Abstracts #1316 - 1319) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230<br />
ARHP Poster Session B: Behavioral Science<br />
(Abstracts #1320 - 1326) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230<br />
ARHP Poster Session B: Foot<br />
(Abstracts #1327 - 1331) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231<br />
ARHP Poster Session B: Patient Education/Support<br />
(Abstracts #1332 - 1338) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231<br />
ARHP Poster Session B: Pediatrics<br />
(Abstracts #1339- 1345) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232<br />
ACR/ARHP POSTER SESSION C<br />
(ABSTRACTS #1466-2079) . . . . . . . . . . . . . . . . . . . . . .233<br />
Biology and Pathology <strong>of</strong> Bone and Joint: Osteoarthritis-Cartilage<br />
Degradation and Skeletal Turnover<br />
(Abstracts #1466 - 1503) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233<br />
Cell-Cell Adhesion, Cell Trafficking and Angiogenesis<br />
(Abstracts #1504- 1509) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235<br />
Cytokines, Mediators, Gene Regulation II<br />
(Abstracts #1510 - 1536) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236<br />
Epidemiology and Health Services Research: OP/OA<br />
(Abstracts #1537 - 1576) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 237<br />
Genetics, Genomics and Proteomics: Rheumatoid Arthritis and SLE<br />
(Abstracts #1577 - 1612) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 240<br />
Imaging <strong>of</strong> Rheumatic Disease II: Ultrasound, PET, Capillary Microscopy<br />
and Molecular Imaging<br />
(Abstracts #1613 - 1637) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244<br />
Infection-Related Rheumatic Disease<br />
(Abstracts #1638 - 1649) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 246<br />
Miscellaneous Rheumatic and Inflammatory Diseases II<br />
(Abstracts #1650- 1671) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247<br />
Pediatric <strong>Rheumatology</strong> - Clinical and Therapeutic Aspects: Pediatric<br />
Rheumatic Diseases II<br />
(Abstracts #1672 - 1706) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248<br />
Rheumatoid Arthritis - Animal Models: Pathogenesis, Novel Targets and<br />
Technology<br />
(Abstracts #1707 - 1733) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 252<br />
Rheumatoid Arthritis - Clinical Aspects: Classification, Biomarkers,<br />
Predictors <strong>of</strong> Response, Disease Activity, Severity III<br />
(Abstracts #1734 -1787) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254<br />
Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene<br />
Therapy: Biologic DMARDs III<br />
(Abstracts #1788 - 1841) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 257<br />
Systemic Lupus Erythematosus - Clinical Aspects and Treatment-<br />
Epidemiology and Health Services III<br />
(Abstracts #1842 - 1882) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 262<br />
Sjögren’s Syndrome<br />
(Abstracts #1883- 1918) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 265<br />
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and<br />
Treatment II<br />
(Abstracts #1919 - 1964) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268<br />
Spondylarthritis and Psoriatic Arthritis - Pathogenesis, Etiology, and<br />
Animal Models<br />
(Abstracts #1965- 1986) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271<br />
6<br />
2010 Program Book
TABLE OF CONTENTS<br />
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis and<br />
Genetics II<br />
(Abstracts #1987 - 2008) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 272<br />
Vasculitis<br />
(Abstracts #2009 - 2049) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 274<br />
Epidemiology and Health Services Research<br />
(Abstract #2089) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277<br />
ARHP Poster Session C: Physical Exercise<br />
(Abstracts #2050-2061) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277<br />
ARHP Poster Session C: Research Methods<br />
(Abstracts #2062-2068) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 278<br />
ARHP Poster Session C: Quality <strong>of</strong> Life<br />
(Abstracts #2069-2079) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 278<br />
REF Industry Roundtable-Supported Symposia . . . . . . . . . . . . . . .280<br />
Industry-Supported Post-Conference Symposia . . . . . . . . . . . . . . .284<br />
RECOGNITION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .286<br />
2010 ACR Annual Meeting Leadership . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 287<br />
2010 ARHP Annual Meeting Leadership . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289<br />
Floor Plans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .290<br />
Exhibitor Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .292<br />
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297<br />
ACR/ARHP and REF Staff Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 299<br />
INDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .301<br />
Invited Speaker/Moderator Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301<br />
ACR/ARHP Abstract Author Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315<br />
ACR/ARHP Abstract Keyword Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 357<br />
ACR/ARHP Abstract Moderator Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375<br />
The most comprehensive<br />
online collection <strong>of</strong><br />
rheumatology-related images.<br />
Serving as a centralized resource for clinicians, researchers<br />
and health care pr<strong>of</strong>essionals, the <strong>Rheumatology</strong> Image Bank<br />
provides invaluable assistance in self-study or the education<br />
<strong>of</strong> others.<br />
Start your visual exploration <strong>of</strong> rheumatology today!<br />
To learn more about the <strong>Rheumatology</strong> Image Bank,<br />
visit the Resource Center located in the International<br />
Boulevard Lobby or http://images.rheumatology.org.<br />
2010 Program Book 7
CERTIFICATES OF CME CREDIT<br />
OR PARTICIPATION<br />
Accreditation Statement: The <strong>American</strong> <strong>College</strong> <strong>of</strong><br />
<strong>Rheumatology</strong> is accredited by the Accreditation Council for<br />
Continuing Medical Education (ACCME) to provide continuing<br />
medical education for physicians.<br />
Statement <strong>of</strong> Designation: The ACR designates this educational<br />
activity for a maximum <strong>of</strong> 48.5 AMA PRA Category 1 credits.<br />
Physicians should only claim credit commensurate with the<br />
extent <strong>of</strong> their participation in the activity.<br />
International Physicians: International physicians who register<br />
as part <strong>of</strong> a group and require AMA PRA Category 1 Credit(s),<br />
must provide the following information to your tour leader: full<br />
name, mailing address, telephone and fax numbers, and e-mail<br />
address. The information will be used to verify your meeting<br />
attendance.<br />
Health Pr<strong>of</strong>essional participants may claim hours to receive a<br />
Certificate <strong>of</strong> Participation for an activity designated for AMA<br />
PRA Category 1 Credit(s) credit.<br />
For non-CME sessions, attendees may also request a certificate<br />
<strong>of</strong> participation.<br />
MEETING EVALUATIONS, CME CREDIT/<br />
CERTIFICATES OF PARTICIPATION<br />
Computers are available for you to complete your CME/<br />
Certificate <strong>of</strong> Participation application and meeting evaluation<br />
form online during the meeting. In addition, you can complete<br />
the evaluation and print your certificate after you return home.<br />
If you are an international physician and require a Certificate<br />
<strong>of</strong> Attendance, this is enclosed in your meeting bag. If your<br />
country recognizes AMA PRA Category 1 Credit(s) TM in<br />
accordance with AMA PRA requirements, please complete a<br />
meeting evaluation and CME application.<br />
Your evaluation <strong>of</strong> the meeting is very important. The ACR/<br />
ARHP annual meeting planning committees use feedback from<br />
attendees to assist in the development <strong>of</strong> future educational<br />
activities; therefore, we encourage you to complete your<br />
evaluation and CME/Certificate application online.<br />
Conflict <strong>of</strong> Interest/Disclosure Statements<br />
As an educational provider accredited by the Accreditation<br />
Council for Continuing Medical Education (ACCME), the<br />
<strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong> must ensure balance,<br />
independence, objectivity and scientific rigor in all its<br />
educational activities. Therefore, all speakers and moderators<br />
participating in an ACR-sponsored activity are required to<br />
disclose to the planning committee and audience any financial<br />
or other relationships including, but not limited to:<br />
None: Nothing to disclose<br />
1. Stock, stock options or bond holdings in a for-pr<strong>of</strong>it<br />
corporation or self-directed pension plan<br />
2. Research grants<br />
3. Employment (full or part-time)<br />
4. Ownership or partnership<br />
5. Consulting fees or other remuneration (payment)<br />
6. Non-remunerative positions <strong>of</strong> influence such as <strong>of</strong>ficer,<br />
board member, trustee or public spokesperson<br />
7. Receipt <strong>of</strong> royalties<br />
8. Speakers’ bureau<br />
9. Other<br />
Speakers, moderators and abstract authors submitted their<br />
disclosure online prior to publication. Disclosures for invited<br />
speakers are listed in the indices by presenters’ last name.<br />
Abstract author disclosures are published online and in a<br />
supplement to the October issue <strong>of</strong> Arthritis & Rheumatism.<br />
Disclosures for the Late-Breaking abstracts are published<br />
online and in the December issue <strong>of</strong> Arthritis & Rheumatism.<br />
Any individual who refuses to disclose relevant financial<br />
relationships will be disqualified from being a planning<br />
committee member, a presenter, an author <strong>of</strong> a CME<br />
activity, and cannot have control <strong>of</strong>, or responsibility for, the<br />
development, management, presentation or evaluation <strong>of</strong> the<br />
CME activity.<br />
ACR Disclosure Policy<br />
It is the policy <strong>of</strong> the <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong> to<br />
ensure that its CME activities are independent and free <strong>of</strong><br />
commercial bias.<br />
To ensure content objectivity and balance, and guarantee that<br />
the content presented is in the best interest <strong>of</strong> its learners<br />
and the public, the ACR requires that everyone in a position<br />
to control content disclose all relevant financial relationships<br />
with any commercial interest if the relationship is financial and<br />
occurred within the past 12 months. If there are relationships<br />
that create a conflict <strong>of</strong> interest, these must be resolved in<br />
accordance with the ACR’s CME Resolution <strong>of</strong> Conflict policy<br />
prior to the participation <strong>of</strong> the individual in the development<br />
or presentation <strong>of</strong> CME content.<br />
COPYRIGHT MATERIALS POLICY<br />
The annual meeting is not a public event. Programs presented<br />
at the meeting are for the education <strong>of</strong> attendees and<br />
purchasers <strong>of</strong> recorded presentations as authorized by the<br />
ACR. The information and materials displayed and presented<br />
during this meeting are the property <strong>of</strong> the <strong>American</strong> <strong>College</strong> <strong>of</strong><br />
<strong>Rheumatology</strong> and the presenter and cannot be photographed,<br />
copied, photocopied, transformed to electronic format,<br />
reproduced, or distributed without written permission <strong>of</strong> the<br />
<strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong> and the presenter. Any<br />
use <strong>of</strong> the program content for commercial purposes, which<br />
includes, but is not limited to oral presentations, audiovisual<br />
materials used by speakers, and program handouts without<br />
8<br />
2010 Program Book
the written consent <strong>of</strong> the ACR is prohibited. This policy applies<br />
before, during and after the meeting. The ACR will enforce its<br />
intellectual property rights and penalize those who infringe upon it.<br />
The names, insignias, logos and acronyms <strong>of</strong> the ACR, the ARHP<br />
and the REF are proprietary marks. Use <strong>of</strong> the names in any<br />
fashion, by any entity, for any purpose, is prohibited without<br />
the express written permission <strong>of</strong> the <strong>American</strong> <strong>College</strong> <strong>of</strong><br />
<strong>Rheumatology</strong>.<br />
MEDIA<br />
Credentialed media attend the annual meeting to cover stories for<br />
consumer, trade and other media outlets, and are easily identified<br />
by their black press ribbons. Media has access to all general<br />
sessions and limited access (at the discretion <strong>of</strong> speakers) to Meet<br />
the Pr<strong>of</strong>essor and Workshop sessions.<br />
Media may use hand-held audio recorders and still cameras;<br />
moving video recording is also permitted with the permission <strong>of</strong><br />
the presenter(s). The exception to this policy is that an exhibit<br />
may not be photographed or videotaped without the permission<br />
<strong>of</strong> the authorized exhibitor. Annual meeting attendees who have<br />
questions about the ACR’s media policies should contact Erin<br />
Latimer at elatimer@rheumatology.org.<br />
EMBARGO POLICY<br />
Accepted abstracts are made available to the public online in<br />
advance <strong>of</strong> the meeting and are published in a special supplement<br />
<strong>of</strong> Arthritis & Rheumatism. Information contained in those<br />
abstracts may not be released until the abstracts appear online.<br />
Academic institutions, private organizations and companies<br />
with products whose value may be influenced by information<br />
contained in an abstract may issue a press release to coincide<br />
with the availability <strong>of</strong> an ACR abstract online.<br />
However, the ACR continues to require that information that<br />
goes beyond that contained in the abstract, e.g., discussion <strong>of</strong><br />
the abstract done as part a scientific presentation or presentation<br />
<strong>of</strong> additional new information that will be available at the time<br />
<strong>of</strong> the meeting, is under embargo until 5:00 pm Eastern Time on<br />
Sunday, November 7th. Violation <strong>of</strong> this policy may result in the<br />
abstract being withdrawn from the meeting and other measures<br />
deemed appropriate.<br />
Authors are responsible for notifying financial and other sponsors<br />
about this policy.<br />
IMPORTANT LOCATIONS<br />
ACR Office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A308<br />
telephone: 404-222-5800<br />
ACR Resource Center . . . . . . . . . . . International Blvd. Foyer<br />
Announcements . . . . . . . . . . . . . . . . .Hall A and B Connector<br />
Business Center . . . . . . . . . . . . . . . International Blvd. Foyer<br />
CME Center . . .International Blvd. Foyer (Registration Hall)<br />
Coat /Baggage . . . . International Blvd. Foyer (Concourse B)<br />
Exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Halls A1-A2<br />
First Aid . . . . . . . . . . . . . . . . . . Entrance to Hall A1 (Sat. & Sun.)<br />
B410 (Mon. thru Thur.)<br />
Health Information Technology<br />
Demo Station . . . . . . . . . . . . . . . . . . . . . . Hall A-B Connector<br />
Health Information Technology Theater . . . . . . . . . . . . B402<br />
Hotel Reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . International Blvd. Foyer (Registration Hall)<br />
Industry-Supported Symposia Information . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . Hallway opposite Sydney Marcus Auditorium<br />
Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . .Halls A1 – A2 (Exhibit Hall Booth 555)<br />
Job Opportunities . . . . . . . . . . . . . . . . Opposite Room A312<br />
Lost and Found . . . . . . . . . . . . . . . . . . . . . . A308 (ACR Office)<br />
Membership Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . International Blvd. Foyer (Registration Hall)<br />
Newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B212<br />
telephone: 404-222-5804<br />
Nursing Mothers’ Lounge . . . . . . . . . . . . . . . . . . . . . . . . B411<br />
Philanthropy Showcase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . Halls A1 and A2 (Exhibit Hall Booth 1331)<br />
Prayer Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A408<br />
Recharge Stations . . . . . . . . . . . . . . . . . . . . . Halls A1 and A2<br />
REF 5K Run/Walk Registration . . . International Blvd. Foyer<br />
REF Booth . . . . . . . . . . . . . . . . . . . . International Blvd. Foyer<br />
REF Donors’ Lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . Executive Board Room (near Starbucks)<br />
Registration . . .Registration Hall (International Blvd. Foyer)<br />
Replay Café . . . . . . . Halls A1-A2 (Exhibit Hall – Booth 123)<br />
Restaurant Reservations . . . . . . . . International Blvd. Foyer<br />
Ribbon Distribution . . . . . . . . . . . . . . . . .Membership Booth<br />
. . . . . . . . . . . . . . International Blvd. Foyer (Registration Hall)<br />
Shuttle Bus and Taxi Lobby . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . International Blvd. Driver (near Concourse B)<br />
Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . A302<br />
Trainee Lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A305<br />
Visitor Information . . . . . . . . . . . . . International Blvd. Foyer<br />
2010 Program Book 9
10<br />
MEETING INFORMATION<br />
Ask Me Staff<br />
If you have a question about the meeting or need directions to<br />
a room, look for one <strong>of</strong> the Ask Me staff who will be available<br />
throughout the convention center.<br />
Cell Phones, Pages, PDAs & Other Electronic Devices<br />
As a courtesy to meeting attendees, electronic devices must be<br />
operated in silent/vibrate mode within educational sessions;<br />
devices that beep, ring, etc. are prohibited. Cell phone<br />
conversations are not permitted in meeting rooms.<br />
Attire<br />
Attire is business casual. Suits and ties are not required.<br />
However, we suggest you bring a jacket or sweater as the<br />
temperatures in the meeting rooms vary.<br />
Children<br />
Children are not permitted in the educational sessions. To be<br />
admitted in the Exhibit Hall and social events, individuals 18<br />
years <strong>of</strong> age and over are required to pay the guest fee. An<br />
adult must accompany children at all times. Strollers, roller<br />
blades and children’s scooters are not permitted in the Exhibit<br />
Hall. You may arrange for child care through your hotel’s guest<br />
services department.<br />
Exhibit Hall<br />
Exhibitors provide the latest information on products and<br />
services available to rheumatologists, researchers and other<br />
health pr<strong>of</strong>essionals. The 2010 Exhibit Hall is located in Halls A1<br />
and A2 <strong>of</strong> the Georgia World Congress Center.<br />
New this year in the Exhibit Hall is the Replay Café. Visit the<br />
Replay Café to see missed sessions and grab a snack or lunch. In<br />
addition, visit one <strong>of</strong> the networking lounges in the Exhibit Hall<br />
to meet and catch up with your colleagues.<br />
NEW HOURS! We have revised Exhibit Hall hours based on your<br />
feedback:<br />
Monday, November 8: 9:00 am – 5:00 pm<br />
Tuesday, November 9: 9:00 am – 7:00 pm<br />
Wine and Cheese Reception from 5:15 – 6:45 pm<br />
Wednesday, November 10: 9:00 am – 2:00 pm<br />
The Innovation Theater is back by popular demand. Join<br />
participating exhibitors as they present a variety <strong>of</strong> topics in<br />
45-minute sessions.<br />
Food Service<br />
Pre-conference courses include a continental breakfast<br />
and a box lunch. Beverages are provided for Meet the<br />
Pr<strong>of</strong>essor and Workshop sessions. Morning snack will be<br />
available in the poster hall from 9:00 – 10:30 am, Monday –<br />
Wednesday. Afternoon refreshment breaks will be available<br />
in the Exhibit Hall on Monday and Tuesday from 2:00 – 3:00<br />
pm. Complimentary c<strong>of</strong>fee and light refreshments will be<br />
available in the exhibit hall from 9:00 – 10:00 am, Monday –<br />
Wednesday. On Thursday, complimentary c<strong>of</strong>fee will be served<br />
from 7:30–9:00 am in the International Boulevard Foyer <strong>of</strong><br />
the convention center. Food outlets will be open in several<br />
locations throughout the Georgia World Congress Center,<br />
including the Exhibit Hall. On Monday through Thursday, the<br />
Terrace Restaurant (Building B) will be open for breakfast from<br />
2010 Program Book<br />
6:30 – 10:30 am and will <strong>of</strong>fer a continental breakfast for $9.95<br />
and a hot buffet breakfast for $14.95. A luncheon buffet will be<br />
served from 11:30 am – 3:00 pm for $14.95.<br />
Meeting Room Capacity/Important Fire Safety Information<br />
Attendance at scientific sessions is on a first-come, first-served<br />
basis. Rooms which have reached the maximum capacity<br />
may be closed according to local fire and safety regulations.<br />
Standing in the aisle or against the walls is not permitted. If<br />
overcrowding occurs, staff/security personnel will close the<br />
session. If space does not permit you to attend a session, the<br />
session may be available on SessionSelect or replayed in the Inroom<br />
Encore Theater or the Replay Café in the Exhibit Hall.<br />
Photography and Videotaping<br />
Photographers will be present at the meeting. Registration<br />
and attendance at, or participation in, ACR meetings and other<br />
activities constitutes an agreement by the registrant for the<br />
ACR’s use and distribution (both now and in the future) <strong>of</strong><br />
the registrant or attendee’s image or voice in photographs,<br />
videotapes, electronic reproductions, and audio tapes <strong>of</strong><br />
such events and activities. Visual reproduction <strong>of</strong> sessions is<br />
prohibited without prior written permission <strong>of</strong> the ACR. The<br />
ACR reserves the rights to audio and video reproduction at the<br />
2010 ACR/ARHP Annual Scientific Meeting. See copyrighted<br />
materials policy for more information on page 8.<br />
Special Needs<br />
If you require special arrangements, please contact Ron Olejko<br />
in the ACR Office (Room A304) at (404) 222-5800.<br />
Wheelchair & Scooter Rentals<br />
If you did not make advance arrangements for an electric<br />
wheelchair or scooter, you can do so by calling ScootAround<br />
at (888) 441-7575 or by visiting the FedEx/Kinkos Business<br />
Center in the International Boulevard Lobby entrance <strong>of</strong> the<br />
Georgia World Congress Center.<br />
Name Badges<br />
For security reasons, your badge will be required for<br />
admittance to all sessions, exhibits, social events and shuttle<br />
buses. Please wear your badge so it can be easily seen at all<br />
times. Lost badges should be reported to the registration staff<br />
immediately.<br />
Emergency Contact Information<br />
Space is provided on the back <strong>of</strong> your badge to list name<br />
and telephone numbers <strong>of</strong> your emergency contacts. Please<br />
complete this information before inserting your badge in your<br />
badge holder.<br />
No Smoking<br />
All meeting facilities at the convention center, hotel meeting<br />
rooms and other venues have been designated as non-smoking<br />
areas.<br />
Opening Event at the Georgia Aquarium<br />
Sunday, November 7 at 7:00 pm<br />
Mingle with friends and colleagues as your walk alongside<br />
spectacular aquatic wonders in the largest indoor aquarium in<br />
the world. The Georgia Aquarium will be open to an exclusive<br />
audience - you! Tickets are $40 and are available on a firstcome,-first-served<br />
basis. To pick up or purchase ticket(s), please<br />
visit the registration hall in the International Boulevard foyer.
Shuttle Bus Service<br />
See shuttle signs in ACR hotel lobbies or at the International<br />
Boulevard Lobby entrance.<br />
SESSION DESCRIPTIONS<br />
ACR Clinical Symposia provide instruction to improve patient<br />
care. Developments from other specialties and practical patient<br />
management skills will be emphasized. Included are the<br />
following: Clinicopathologic Conference, Curbside Consults –<br />
Ask the Pr<strong>of</strong>essors, Great Debate, Clinical Reviews and Thieves’<br />
Market.<br />
ACR and ARHP Concurrent Abstract Sessions are the main<br />
forum for didactic presentation <strong>of</strong> original research related to<br />
rheumatic diseases.<br />
ACR and ARHP Poster Sessions feature poster presentation<br />
<strong>of</strong> abstracts, facilitating one-on-one interaction between the<br />
presenter and the audience.<br />
ACR and ARHP Pre-Conference Courses are designed to<br />
<strong>of</strong>fer attendees, with a specific interest, a unique learning<br />
opportunity. A separate registration is required.<br />
ACR Basic Science Symposia provide an update <strong>of</strong> the most<br />
recent scientific developments in the field <strong>of</strong> rheumatology.<br />
ACR Immunology Updates for Clinicians is a series <strong>of</strong> three one<br />
hour lectures designed to provide clinicians with an update <strong>of</strong><br />
the new developments in immunology.<br />
ACR Medical Aspects <strong>of</strong> Rheumatic Diseases Sessions cover<br />
topics in other subspecialty areas in internal medicine that are<br />
<strong>of</strong> importance to the practice <strong>of</strong> rheumatology, presented by<br />
experts from other medical subspecialties.<br />
ACR Meet the Pr<strong>of</strong>essor Sessions provide an opportunity for<br />
interaction and consultation with highly respected pr<strong>of</strong>essionals<br />
who have expertise in a particular area. Several sessions are<br />
designated for trainees only. A separate registration is required.<br />
ACR Plenary Sessions: Discovery 2010 – three plenary sessions<br />
will be <strong>of</strong>fered and each session will have a separate focus and<br />
will highlight abstracts <strong>of</strong> significant novelty and importance.<br />
ACR Practice Issues are sessions that address the major<br />
changes in the practice <strong>of</strong> rheumatology with the introduction<br />
<strong>of</strong> new medications, devices, and diagnostic and ancillary<br />
services for patients.<br />
ACR State-<strong>of</strong>-the-Art Lectures present current information<br />
about topics related to rheumatology and are presented by<br />
leading experts in their respective fields.<br />
ACR Study Groups are designed to bring together attendees<br />
with a common interest in one disease, a group <strong>of</strong> related<br />
disorders, or a specialized field <strong>of</strong> study for discussion and<br />
dissemination <strong>of</strong> information.<br />
ACR/ARHP Workshops are designed to bring attendees<br />
together to foster hands-on learning, and provide an<br />
opportunity for interaction and consultation with highly<br />
respected pr<strong>of</strong>essionals who have expertise in a particular area.<br />
Several sessions are designated for trainees only. A separate<br />
registration is required.<br />
ACR Year in Review highlights publications <strong>of</strong> major interest<br />
to the membership that have appeared in rheumatology<br />
literature since the last meeting. Both basic science and clinical<br />
perspectives are represented.<br />
ARHP Concurrent Sessions <strong>of</strong>fer educational programs <strong>of</strong><br />
interest to various health pr<strong>of</strong>essionals. Concurrent sessions<br />
include invited speakers; peer-reviewed programs and lectures;<br />
and research and special interest abstract sessions.<br />
ARHP General Sessions are interdisciplinary sessions scheduled<br />
without competing programs. The topics are <strong>of</strong> expansive<br />
interest or the speaker is <strong>of</strong> such status as to appeal to the<br />
membership at large.<br />
2010 SPECIAL SESSIONS<br />
ACR<br />
• ACR Leadership Town Hall Meeting . . . . . . . . . . . . . . . . . . .106<br />
• Career Opportunities in <strong>Rheumatology</strong>: Making a Choice . . 112<br />
• Clinical Teaching Strategies in the Outpatient Clinic Setting . .66<br />
• Contract Negotiations for Physicians . . . . . . . . . . . . . . . . . . .65<br />
• ILAR Global Health Project . . . . . . . . . . . . . . . . . . . . . . . . . . .84<br />
• Insurance Roundtable Discussion . . . . . . . . . . . . . . . . . . . . . .94<br />
• Legislative Update from Capitol Hill . . . . . . . . . . . . . . . . . . . .52<br />
• News from the National Institutes <strong>of</strong> Health:<br />
Updates and Opportunities . . . . . . . . . . . . . . . . . . . . . . . . . 56<br />
• The Changing Face <strong>of</strong> the <strong>Rheumatology</strong> Workforce:<br />
Gender Issues in the Workplace . . . . . . . . . . . . . . . . . . . . . .94<br />
ACR REF<br />
• ACR REF Clinician Scholar Educators Lecture . . . . . . . . . . . .53<br />
• ACR REF Memorial Lecture: <strong>Rheumatology</strong> Education 2010 . .37<br />
• REF Edmond L. Dubois, MD, Memorial Lectureship . . . . . . .53<br />
• REF Marshall J. Schiff, MD, Memorial Lectureship: Everything<br />
a Rheumatologist Should Know About Spine Surgery but Was<br />
Afraid to Ask . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .84<br />
• REF Oscar S. Gluck, MD, Memorial Lectureship -<br />
Osteoimmunology: Crosstalk Between the Immune<br />
and Bone Systems: Biologic and Clinical Implications . . . . .28<br />
• REF Paul Klemperer, MD, Memorial Lectureship: Systemic<br />
Sclerosis: Genetic? Autoimmune? One Disease? . . . . . . . . .98<br />
• REF “Within Our Reach” Lecture: Finding a Cure for<br />
Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .45<br />
ARHP<br />
• ARHP First-time Attendees Orientation . . . . . . . . . . . . . . . . .27<br />
• ARHP Moderators Orientation . . . . . . . . . . . . . . . . . . . . . . . .27<br />
• ARHP Networking at Noon . . . . . . . . . . . . . . . . . . . . . . . . . . .63<br />
• ARHP Networking for Georgia Health Pr<strong>of</strong>essionals and<br />
Physicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .35<br />
• ARHP Networking Forum . . . . . . . . . . . . . . . . . . . . . . . . . . . .30<br />
• ARHP Occupational and Physical Therapy Networking . . 105<br />
• ARHP Office Nurse Networking . . . . . . . . . . . . . . . . . . . . . 105<br />
• ARHP Pediatrics Networking . . . . . . . . . . . . . . . . . . . . . . . . .35<br />
• ARHP Research Coordinators Networking . . . . . . . . . . . . . .35<br />
2010 Program Book 11
GUIDE TO HELP NAVIGATE<br />
THE MEETING<br />
To navigate the meeting by track, look for these icons.<br />
BR Business <strong>of</strong> <strong>Rheumatology</strong><br />
C Clinical<br />
c/r Clinical and Research<br />
cP Clinical Practice<br />
Ed. Educators<br />
f Fellow-In-Training<br />
P Pediatrics<br />
P/C Pediatrics and Clinical<br />
R Research<br />
ARS<br />
AUDIENCE RESPONSE SYSTEM<br />
Audience Response System will be used in selected<br />
sessions to allow attendees to actively participate.<br />
PM PAIN MANAGEMENT<br />
The ACR designates certain sessions for pain<br />
management credit as required by the Medical Board <strong>of</strong><br />
California (AB487). This designation is identified by the<br />
icon shown and will be placed next to the session title.<br />
PS PATIENT SAFETY<br />
The ACR designates certain sessions that will satisfy<br />
patient safety/risk management requirements <strong>of</strong> the<br />
Medical Board <strong>of</strong> Pennsylvania. This designation is<br />
identified by the icon shown and will be placed next to<br />
the session title.<br />
In-ROOM ENCORE THEATER – no need to miss a<br />
session!<br />
Select ACR sessions will be recorded and replayed<br />
during the meeting in designated hotels. Therefore,<br />
if you missed one <strong>of</strong> the designated sessions you can<br />
watch the session later that day or the next day in the<br />
In-room Encore Theater. The sessions that have been<br />
scheduled to be replayed in the In-room Encore Theater<br />
are indicated with the icon above. Additional sessions<br />
may be added on site. Check the ACR/ARHP Daily News<br />
for new sessions. Please see page 14 for a tentative list<br />
<strong>of</strong> sessions.<br />
MEETING SERVICES<br />
ACR Resource Center – The Spot for All Things ACR!<br />
Located in the International Boulevard Foyer. Need information<br />
on upcoming educational activities in 2011? Would you like<br />
to view demos <strong>of</strong> popular ACR and ARHP online resources<br />
including CARE, the Advanced <strong>Rheumatology</strong> Course,<br />
SessionSelect or the <strong>Rheumatology</strong> Image Bank? Or do you just<br />
need directions to your next session? You’re in luck… the ACR<br />
Resource Center has it all.<br />
• Advocacy<br />
Stop by the Advocacy kiosk to get the most up-to-date<br />
information on the legislative and regulatory issues affecting<br />
your pr<strong>of</strong>ession. We have talking points on all ACR legislative<br />
priorities, instructions on how to contact your Members<br />
<strong>of</strong> Congress and tips on how to get more involved with the<br />
ACR’s advocacy efforts. You can also receive information on<br />
RheumPAC – the ACR’s political action committee.<br />
• Lupus Initiative<br />
New to the ACR Resource Center this year is the Lupus<br />
Initiative. This educational initiative, designed to reduce<br />
health disparities in lupus based on gender, race and<br />
ethnicity, will <strong>of</strong>fer demonstrations <strong>of</strong> its various educational<br />
resources for medical and health pr<strong>of</strong>essionals in training and<br />
in practice. Resources include: complimentary CME activities,<br />
physician-patient dialogue cards, suggested reading lists and<br />
much more. Lupus experts are encouraged to drop by to<br />
participate in our weekly online discussion.<br />
• Practice Management & Coding<br />
Visit with ACR certified coders and practice management<br />
experts for any coding, billing, insurance or practice<br />
management questions. We have all the resources you need<br />
for an efficient rheumatology practice. You can also pick up<br />
the latest copy <strong>of</strong> the ACR’s monthly RheumWATCH.<br />
• Publications<br />
The editorial <strong>of</strong>fice staff <strong>of</strong> the Arthritis & Rheumatism and<br />
Arthritis Care & Research journals will be available to answer<br />
questions concerning online article submission and article<br />
review processes for the journals.<br />
• Quality & Informatics<br />
Learn how enrollment in the RCR can benefit you. The<br />
RCR provides hands-on measurement tools and reports<br />
that enable you to comparatively assess the quality and<br />
outcome <strong>of</strong> rheumatologic care you provide. Find out how<br />
to incorporate this tool with the ACR’s practice improvement<br />
module.<br />
• Recertification<br />
Need help navigating Maintenance <strong>of</strong> Certification? Let<br />
the ACR guide you. We have answers to help steer your<br />
route to success with the <strong>American</strong> Board <strong>of</strong> Internal<br />
Medicine’s Maintenance <strong>of</strong> Certification program. An ABIM<br />
representative will be on-site for the entire meeting to help<br />
answer your questions.<br />
12<br />
2010 Program Book
ACR Resource Center Hours:<br />
Sunday, November 7<br />
Monday, November 8<br />
Tuesday, November 9<br />
Wednesday, November 10<br />
Thursday, November 11<br />
Noon – 6:00 pm<br />
7:00 am to 6:00 pm<br />
7:00 am to 6:00 pm<br />
7:00 am to 6:00 pm<br />
7:00 am to 1:30 pm<br />
Membership Booth<br />
Located in the registration hall (International Boulevard<br />
entrance). This is the place to go if you want to become a<br />
member, pay dues, reinstate your membership, learn more<br />
about member benefits and awards, or volunteer to serve on a<br />
committee.<br />
Lost and Found<br />
Found items should be returned to the ACR Office, room A308.<br />
If you are looking for a lost item, go to the ACR Office or call<br />
(404) 222-5800.<br />
Newsroom<br />
Located in room B212, use <strong>of</strong> the Newsroom is limited to media<br />
representatives with press passes.<br />
Announcements<br />
Located in the Hall A-B Connector, display boards will be<br />
available for posting announcements and events <strong>of</strong> interest.<br />
Posted materials are limited to 8.5” x 11” in size.<br />
Registration<br />
Registration counters are located in the registration hall<br />
(International Boulevard Foyer).<br />
Hours <strong>of</strong> operation are:<br />
Saturday, November 6 6:30 am – 6:00 pm<br />
Sunday, November 7 6:30 am – 7:45 pm<br />
Monday, November 8 6:30 am – 5:00 pm<br />
Tuesday, November 9 6:30 am – 5:00 pm<br />
Wednesday, November 10 6:30 am – 5:00 pm<br />
Thursday, November 11 7:00 am – 1:00 pm<br />
REF Booth<br />
Visit the REF Booth in the International Boulevard Foyer to find<br />
out more about what the REF is doing to ensure the future <strong>of</strong><br />
rheumatology. View and order the latest poster in the Rodnan<br />
Commemorative Gout Print poster series, learn more about<br />
REF programs and initiatives, and even receive a gift just for<br />
stopping by!<br />
REF Booth Hours:<br />
Sunday, November 7 Noon to 5:00 pm<br />
Monday, November 8 7:00 am to 5:00 pm<br />
Tuesday, November 9 7:00 am to 5:00 pm<br />
Wednesday, November 10 7:00 am to 5:00 pm<br />
Thursday, November 11 7:00 am to 1:00 pm<br />
REF Donors’ Lounge<br />
REF donors should plan to spend time in the Donors’ Lounge,<br />
located in the Executive Board Room (between Starbucks<br />
and Concourse A), and take advantage <strong>of</strong> special perks! Enjoy<br />
breakfast each morning and gourmet c<strong>of</strong>fee throughout<br />
the day; catch up on work and check e-mail at one <strong>of</strong> our<br />
private computer stations; grab refreshments or enjoy a<br />
complimentary chair massage. Donors must have <strong>of</strong>ficial donor<br />
access pass to gain entry and these passes can be claimed at<br />
the Donors’ Counter just outside the entrance to the Lounge.<br />
Donors who contributed a minimum cumulative amount <strong>of</strong><br />
$500 during fiscal year 2010 (July 1, 2009 through June 30,<br />
2010) are eligible to enjoy the Donors’ Lounge.<br />
Donors’ Lounge hours are:<br />
Sunday, November 7 Noon - 5:00 pm<br />
Monday, November 8 7:00 am - 6:00 pm<br />
Tuesday, November 9 7:00 am - 6:00 pm<br />
Wednesday, November 10 7:00 am - 6:00 pm<br />
Thursday, November 11 7:00 am - Noon<br />
Speaker Ready Room<br />
Located in room A302. Check-in is expected <strong>of</strong> all speakers.<br />
Plan to check-in 24 hours prior to your presentation time. In<br />
the Speaker Ready Room, you can review your presentation<br />
and approve the file to be uploaded to the central server.<br />
Pr<strong>of</strong>essional audiovisual technicians will be available to<br />
assist you. Computers in the Speaker Ready Room will be<br />
configured with hardware and s<strong>of</strong>tware exactly like the ones<br />
in the meetings rooms and will allow you to preview your<br />
presentation, identify problems and make corrections as<br />
necessary before your presentation.<br />
Hours <strong>of</strong> operation are:<br />
Saturday, November 6 6:30 am – 5:30 pm<br />
Sunday, November 7 6:30 am – 6:30 pm<br />
Monday, November 8 6:30 am – 6:00 pm<br />
Tuesday, November 9 6:30 am – 8:00 pm<br />
Wednesday, November 10 6:30 am – 6:00 pm<br />
Thursday, November 11 7:00 am – 12:30 pm<br />
Electronic Syllabus<br />
View, download and print speaker syllabi during and after the<br />
annual meeting.<br />
Wireless Access<br />
Free wireless access is available in the public hallways <strong>of</strong> the<br />
Georgia World Congress Center. Search for “ACR/ARHP 10” –<br />
no password required.<br />
2010 REF 5K RUN/WALK<br />
Tuesday, November 9, 2010<br />
6:00 – 8:00 am<br />
Your annual meeting experience will be just “peachy” when<br />
you decide to participate in the 2010 REF 5K Run/Walk.<br />
Discover Atlanta while helping the ACR Research and Education<br />
Foundation raise money to ensure the future <strong>of</strong> rheumatology.<br />
Complimentary shuttle service to and from the run event will<br />
be provided and all participants will receive an <strong>of</strong>ficial REF 5K<br />
Run/Walk T-shirt. Participants may register at the REF 5K Run/<br />
Walk Booth located in the registration area until 5:00 PM,<br />
Monday, November 8, or until the event sells out. A minimum<br />
donation <strong>of</strong> $50 is required and the event is limited to 350<br />
participants. Proceeds raised from this event will support<br />
grants, awards and activities provided by the REF.<br />
2010 Program Book 13
IN-ROOM ENCORE THEATER<br />
The following ACR/ARHP sessions will be recorded and replayed in<br />
select hotels. See page 15, for the list <strong>of</strong> hotels that <strong>of</strong>fer the In-room<br />
Encore Theater.<br />
Monday, November 8<br />
9:00 pm – Tuesday, November 9 • 9:00 pm<br />
ACR/ARHP Opening Lecture and Awards: An Infectious Etiology<br />
<strong>of</strong> Rheumatoid Arthritis<br />
From Sunday, November 7 • 5:45 – 6:30 pm<br />
ACR Clinical Symposium: Year in Review<br />
From Monday, November 8 • 7:15 - 8:30 am<br />
ACR Immunology Updates for the Clinicians: Innate Immunity<br />
and Inflammation<br />
From Monday, November 8 • 9:00 - 10:00 am<br />
ACR Medical Aspects <strong>of</strong> Rheumatic Diseases: Heparin and<br />
Antiphospholipid Syndrome-induced Thrombocytopenia<br />
From Monday, November 8 • 9:00 - 10:00 am<br />
ACR State-<strong>of</strong>-the-Art Lecture: Genetic Disorders <strong>of</strong> Connective<br />
Tissue and Joint Hypermobility<br />
From Monday, November 8 • 1:00 - 2:00 pm<br />
TOTAL HOURS: 5.0<br />
Wednesday, November 10 • 9:00 pm<br />
Thursday, November 11 • 9:00 pm<br />
ACR Clinical Symposium: The Brain and Systemic Lupus Erythematosus:<br />
2010 Update<br />
From Tuesday, November 9 • 1:00 - 2:00 pm<br />
ACR Clinical Symposium: Inflammatory Myopathy Update<br />
From Tuesday, November 9 • 4:30 - 6:00 pm<br />
ACR State-<strong>of</strong>-the-Art Lecture: From Fat to Joints – The Vicious Side <strong>of</strong><br />
Adipokines<br />
From Wednesday, November 10 • 8:45 - 9:45 am<br />
ACR Clinical Symposium: Controversies in Osteoporosis and Low Bone<br />
Mass: Who Do We Treat, For How Long, and at What Risks?<br />
From Wednesday, November 10 • 11:00 am - 12:30 pm<br />
ACR Clinical Symposium: Perioperative Management <strong>of</strong> Selected<br />
Problems in Patients with Rheumatic Disease<br />
From Wednesday, November 10 • 4:30 - 6:00 pm<br />
TOTAL HOURS: 6.5<br />
Tuesday, November 9 • 9:00 pm<br />
Wednesday, November 10 • 9:00 pm<br />
ACR Clinical Symposium: The Great Debate: Is it Time to Use Biologics<br />
as First-line Therapy in Rheumatoid Arthritis?<br />
From Monday, November 8 • 2:30 - 4:00 pm<br />
ACR State-<strong>of</strong>-the-Art Lecture: Methotrexate 2010<br />
From Tuesday, November 9 • 7:15 - 8:15 am<br />
ARHP Concurrent Session: Daltroy Memorial Lectureship: Adherence<br />
to Medical Regimens for Rheumatic Diseases and the Importance <strong>of</strong><br />
Patient-Clinician Communication<br />
From Tuesday, November 9 • 9:15 - 10:15 am<br />
ACR Clinical Symposium: Curbside Consults - Ask the Pr<strong>of</strong>essors<br />
From Tuesday, November 9 • 11:00 am - 12:30 pm<br />
TOTAL HOURS: 5.0<br />
14<br />
2010 Program Book
ACR Hotels + Map<br />
Complimentary shuttle service will be provided from designated<br />
hotels and the Georgia World Congress Center during peak times in<br />
the early morning and late afternoon. Service will also be provided<br />
for the opening event at the Georgia Aquarium. During those times<br />
the complimentary shuttle does not operate, transportation options<br />
include:<br />
Taxi: The flat fare with the Downtown, Midtown or Buckhead zones<br />
is $8 plus $2 for each additional person. Travel from one zone to<br />
another zone is metered. Approx. fare between Downtown and<br />
Midtown is $12; approx. fare from downtown to Buckhead is $27.<br />
MARTA: Most ACR hotels are with a short walk <strong>of</strong> the following<br />
MARTA (rail) stations: Peachtree Center, Civic Center, North Avenue,<br />
Midtown, Buckhead and Lenox Square. Fare is $2 plus .50 cents for a<br />
reusable Breeze card.<br />
Shuttle: Check the posted schedule in the lobbies <strong>of</strong> participating<br />
hotels and the Georgia World Congress Center for detailed shuttle<br />
times and information.<br />
If you require accessible transportation assistance, please call<br />
the ACR Shuttle bus desk (404) 903-0007 or stop at the ACR Shuttle<br />
Counter in the International Boulevard Foyer (near Concourse B).<br />
1. Atlanta Marriott Downtown<br />
160 Spring Street NW (404) 688-8600<br />
2. Atlanta Marriott Marquis (co-headquarters)*<br />
265 Peachtree Center Avenue (404) 521-0000<br />
3. Cancelled<br />
4. Days Inn Atlanta Downtown<br />
300 Spring Street (404) 523-1144<br />
5. Embassy Suites at Centennial Olympic Park*<br />
267 Marietta Street (404) 223-2300<br />
6. Georgian Terrace<br />
659 Peachtree Street (800) 651-2316<br />
7. Glenn<br />
110 Marietta Street (404) 521-2250<br />
8. Hampton Inn & Suites Atlanta Downtown<br />
161 Spring Street (404) 589-1111<br />
9. Hilton Atlanta*<br />
255 Courtland Street (404) 659-0000<br />
10. Hilton Garden Inn Atlanta Downtown*<br />
275 Baker Street (404) 577-2001<br />
11. Holiday Inn Atlanta Downtown<br />
101 Andrew Young Intl Boulevard (404) 524-5555<br />
12. Hotel Midtown<br />
125 10th Street (404) 873-4800<br />
13. Hyatt Regency Atlanta*<br />
265 Peachtree Street (404) 577-1234<br />
14. Loews Atlanta<br />
1065 Peachtree Street (404) 745-5000<br />
15. Omni Hotel at CNN Center (headquarters)*<br />
100 CNN Center (404) 659-0000<br />
16. Residence Inn Atlanta Downtown<br />
134 Peachtree Street (404)522-0950<br />
17. Ritz Carlton Atlanta*<br />
181 Peachtree Street (404) 659-0400<br />
18. Sheraton Atlanta*<br />
165 Courtland Street (404) 659-6500<br />
19. W Atlanta Downtown*<br />
45 Ivan Allen Jr. Boulevard (404) 582-5789<br />
20. Westin Peachtree Plaza Hotel<br />
210 Peachtree Street (404) 659-1400<br />
21. Cancelled<br />
*Hotels that <strong>of</strong>fer the in-room encore theater.<br />
Additional ACR/ARHP Housing:<br />
Courtyard by Marriott – Buckhead<br />
3332 Peachtree Road (404) 869-0818<br />
Embassy Suites - Buckhead<br />
3285 Peachtree Road (404) 261-7733<br />
Four Season Hotel Midtown<br />
75 14th Street (404) 881-9898<br />
Grand Hyatt Atlanta - Buckhead<br />
3300 Peachtree Road (404) 237-1234<br />
Mansion on Peachtree – Buckhead<br />
3376 Peachtree Road (404) 995-7500<br />
Marriott Buckhead Hotel & Conference Center<br />
3405 Lenox Road (404) 261-9250<br />
Regency Suites Hotel - Midtown<br />
975 West Peachtree Street (404) 876-5003<br />
Ritz-Carlton Buckhead<br />
3434 Peachtree Road (404) 237-2700<br />
W Atlanta – Buckhead<br />
3377 Peachtree Road (404) 500-3100<br />
Westin Buckhead<br />
3391 Peachtree Road (404) 365-0065<br />
2010 Program Book 15
SPECIAL OFFERS AT THE<br />
ANNUAL SCIENTIFIC MEETING<br />
Enhanced SessionSelect – no need to miss a session!<br />
Within 24 hours <strong>of</strong> virtually every live session at the annual<br />
meeting, recordings <strong>of</strong> the sessions will be made available<br />
through SessionSelect, your source for ACR education, online.<br />
For the 3rd year running, as a scientific attendee, you get FREE<br />
ACCESS to over 200 hours <strong>of</strong> online annual meeting content –<br />
over $500 <strong>of</strong> added value.<br />
Select sessions will be recorded and available to view as webcasts<br />
during and after the meeting. Therefore, if you missed one <strong>of</strong><br />
the designated sessions, you can watch it the next day through<br />
SessionSelect. The sessions that will be available through<br />
SessionSelect are indicated with the webcast icon above.<br />
Recordings <strong>of</strong> individual sessions are subject to change.<br />
<strong>College</strong> Showcase – NEW<br />
During intermissions <strong>of</strong> the scientific sessions, ACR staff and<br />
representatives will present live demonstrations <strong>of</strong> educational<br />
resources and tools at the ACR Resource Center, located in the<br />
International Boulevard Foyer. Presentations <strong>of</strong> educational<br />
resources and tools include the <strong>Rheumatology</strong> Image Bank<br />
SessionSelect; the Lupus Initiative; CARE (ACR’s self-assessment<br />
module); AIM (ACR’s practice improvement module);<br />
<strong>Rheumatology</strong> Clinical Registry and many more. Plan to stop<br />
by the ACR Resource Center for a brief demo on the way to<br />
your next session.<br />
Complimentary Information<br />
Attendees can stop by the ACR Resource Center for<br />
complimentary product brochures and patient education<br />
materials – to come discover all the <strong>College</strong> <strong>of</strong>fers you, your<br />
patients and your practice.<br />
Abstracts on ACR Web site<br />
Abstracts are available online at www.rheumatology.org.<br />
Medical Bag<br />
Don’t forget to pick up a Medical Bag prior to visiting the<br />
exhibits. Each bag contains special <strong>of</strong>fers and invitations from our<br />
exhibitors and will be distributed from the exhibition entrance<br />
while supplies last.<br />
Recharge Areas<br />
Recharge areas will include workstations with power outlets<br />
designed for you to connect your laptop, recharge your mobile or<br />
check e-mail via the complimentary Wi-fi-enabled Internet access.<br />
Free Give-a-Ways<br />
Looking for a souvenir to take home? Visit the ACR Resource Center<br />
to learn more about ACR and ARHP programs, resources and<br />
initiatives—and while there, pick up a free gift just for stopping by!<br />
POSTER SESSIONS<br />
Poster presentations facilitate one-on-one interaction between<br />
the presenter and the attendee. There will be one poster session<br />
per day on Monday, Tuesday and Wednesday. Posters will remain<br />
in the Georgia World Congress Center Halls B1 & B2 from 9:00<br />
am–6:00 pm, with presenters in attendance to answer questions<br />
about their abstracts from 9:00–11:00 am each day. There is no<br />
poster session on Thursday. The number on the poster boards<br />
refers to the abstract presentation number, and this number will<br />
change for each poster session.<br />
Poster Session Presenter Instructions<br />
If you are presenting a poster, please set up and remove your<br />
poster during the times listed below.<br />
Poster presenter ribbons will be available in the Speaker Ready<br />
Room – Room# A302.<br />
Posters must be removed by 6:30 pm. Posters not removed by<br />
6:30 pm will be removed and discarded. ACR is not responsible for<br />
lost, damaged or discarded posters.<br />
Poster Sessions - Monday, November 8 – Wednesday, November 10<br />
from 9:00 am–6:00 pm<br />
Set Up: 7:00–9:00 am<br />
Presentation: 9:00–11:00 am<br />
Poster Tours: 9:00–9:45 am; 10:15 – 11:00 am and 4:30 – 5:30 pm<br />
Posters to remain up until 6:00 pm<br />
Removal: 6:00–6:30 pm<br />
Guided Poster Tours<br />
Guided poster tours provide an opportunity for scientific<br />
attendees to ask questions and gain insights from leaders in the<br />
field while earning CME credits. Morning tours will <strong>of</strong>fer insights<br />
from both poster presenters and tour guides, while afternoon<br />
tours will exclusively feature the tour guide’s expert opinion.<br />
Although there is no fee to participate, pre-registration is required<br />
and each tour is limited to 20 registered scientific attendees. If<br />
you would like to participate and have not registered you can<br />
check tour availability and request a ticket in the registration area,<br />
located in the International Boulevard Foyer. If you registered<br />
in advance <strong>of</strong> the meeting your ticket was included with your<br />
meeting materials. Once you have your ticket, plan to collect<br />
your headset and meet your group 10 minutes before your tour<br />
departs from the entrance <strong>of</strong> the poster hall, located in Halls B1<br />
& B2.<br />
16<br />
2010 Program Book
to the premier meeting in rheumatology<br />
2011 ACR/ARHP Annual Scientific Meeting Call for Proposals<br />
Don’t miss the opportunity to propose a session concept,<br />
topic idea or speaker suggestion for the ACR/ARHP 2011<br />
Annual Scientific Meeting. Your ideas will assist the ACR/<br />
ARHP annual meeting planning committees in selecting<br />
quality topics and speakers for the 2011 annual meeting;<br />
therefore, we encourage you to submit<br />
your ideas/suggestions online.<br />
To view instructions and submit a proposal, visit<br />
www.rheumatology.org/education.<br />
2011 Study Groups Application<br />
Coordinate a study group and create a unique opportunity<br />
to network with peers that share your interest in a disease,<br />
disorder or specialized field <strong>of</strong> study.<br />
To view the guidelines and submit an application, visit<br />
www.rheumatology.org/education.<br />
ACR/ARHP proposals and study group applications must be<br />
submitted online by Monday, November 15, 2010.<br />
GO<br />
ACR/ARHP Scientific Sessions<br />
SATURDAY, NOVEMBER 6, 2010<br />
ACR/ARHP Registration<br />
6:30 am - 6:00 pm<br />
International Blvd. Foyer<br />
ACR Musculoskeletal Ultrasound<br />
Course for Rheumatologists –<br />
dAy One C<br />
7:30 am - 4:30 pm<br />
A412<br />
Admission to the ACR Musculoskeletal Ultrasound Course<br />
requires a separate registration.<br />
Moderator: Ralf G. Thiele, MD; University <strong>of</strong> Rochester;<br />
Rochester, NY<br />
Faculty: Rany Al Haj, MD; Shore Arthritis and Rheumatism<br />
Associates; Ocean, NJ<br />
Marina Backhaus, MD; University Medicine Berlin: Campus<br />
Charité Mitte; Berlin, Germany<br />
P. Scott Pollock, MD; Seattle, WA<br />
David A. Bong, MD; Instituto Poal de Reumatologia; Bruce, WI<br />
Jurgen Craig-Muller, MD; CentraCare Clinic; St. Cloud, MN<br />
Paul J. DeMarco, MD; Arthritis & Rheumatism Associates PC;<br />
Wheaton, MD<br />
Amy M. Evangelisto, MD; Arthritis Rheumatic and Back Disease<br />
Association; Philadelphia, PA<br />
David E. Feinstein, DO; Cooper Health System, Robert Wood<br />
Johnson Medical School; Camden, NJ<br />
Emilio Filippucci, MD, PhD; Università Politecnica delle Marche -<br />
Ancona; Jesi, Ancona, Italy<br />
Janak R. Goyal, MD; University <strong>of</strong> Medicine and Dentistry <strong>of</strong> New<br />
Jersey, Robert Wood Johnson Medical School; Perth Amboy, NJ<br />
Jay B. Higgs, MD; Wilford Hall Medical Center, Department <strong>of</strong> Air<br />
Force; San Antonio, TX<br />
Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine,<br />
Jacksonville; Ponte Vedra Beach, FL<br />
Eugene Y. Kissin, MD; Boston University; Boston, MA<br />
Esperanza Naredo, MD; Hospital Universitario Severo Ochoa,<br />
Madrid, Spain<br />
Midori Jane Nishio, MD; John Muir Medical Center; Walnut<br />
Creek, CA<br />
Anthony M. Reginato, PhD, MD; University Medicine Foundation,<br />
Rhode Island Hospital; Providence, RI<br />
2010 Program Book 17
saturday<br />
Johannes Roth, MD; Children’s Hospital Eastern Ontario; Ottawa,<br />
ON, Canada<br />
Jonathan Samuels, MD; New York University Hospital for Joint<br />
Disease; New York, NY<br />
Wolfgang A. Schmidt, MD; Medical Center for <strong>Rheumatology</strong><br />
Berlin-Buch; Berlin, Germany<br />
Darren Tabechian, MD; University <strong>of</strong> Rochester School <strong>of</strong><br />
Medicine; Rochester, NY<br />
Mihaela Taylor, MD; University <strong>of</strong> California Los Angeles; Los<br />
Angeles, CA<br />
Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />
Session Overview:<br />
Musculoskeletal ultrasound has been an imaging modality <strong>of</strong><br />
continuously growing importance over the last 15 years. Of<br />
all imaging modalities in rheumatology, ultrasound receives<br />
the greatest attention by rheumatologist researchers. More<br />
papers on musculoskeletal ultrasound are being published<br />
by rheumatologist than by any other specialty. Trained<br />
rheumatologists can agree more readily on ultrasound findings<br />
than musculoskeletal radiologists can on MRI findings, based<br />
on available literature. This suggests that operator dependency<br />
is less <strong>of</strong> a concern for rheumatologists, if they are adequately<br />
trained. However, such training opportunities continue to be<br />
scarce in the United States. This course is designed to help<br />
address the need for additional education.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• demonstrate the proper probe position and ultrasound<br />
machine settings to reliably obtain images<br />
• identify and describe normal sonographic anatomy for each<br />
joint area applying standardized protocols<br />
• explain how fundamental sonographic pathology <strong>of</strong> rheumatic<br />
diseases is distinguished from normal findings<br />
• assess standardized sonographic scanning protocols for each<br />
anatomical region, according to published guidelines<br />
• apply appropriate indications for the use <strong>of</strong> ultrasound in<br />
rheumatology<br />
• explain the requirements for billing, report generation and<br />
record keeping as they relate to musculoskeletal ultrasound<br />
• demonstrate evidence-based technique for ultrasound-guided<br />
procedures<br />
• cite the possibilities and limitations <strong>of</strong> implementation <strong>of</strong><br />
musculoskeletal ultrasound into clinical practice and patient<br />
care<br />
7:00 - 7:30 AM<br />
Continental Breakfast<br />
8:35 AM<br />
The Scope <strong>of</strong> Ultrasound in <strong>Rheumatology</strong><br />
Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />
9:05 AM<br />
The Shoulder - Lecture: Standard Scans, Sonographic Anatomy<br />
and Basic Sonographic Pathology<br />
Esperanza Naredo, MD; Hospital Universitario Severo Ochoa,<br />
Madrid, Spain<br />
9:35 - 9:50 AM<br />
Break<br />
9:50 AM<br />
Practice <strong>of</strong> Scanning: How to Position the Probe and Optimize<br />
the Image<br />
Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />
10:05 AM<br />
Live Demonstration: Scanning <strong>of</strong> the Shoulder<br />
Esperanza Naredo, MD; Hospital Universitario Severo Ochoa,<br />
Madrid, Spain<br />
10:20 AM<br />
Hands on Scanning: The Shoulder<br />
Faculty<br />
11:45 AM - 12:30 PM<br />
Boxed Lunch<br />
12:30 pm<br />
The Elbow - Lecture: Standard Scans, Sonographic Anatomy<br />
and Basic Sonographic Pathology<br />
Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine,<br />
Jacksonville; Ponte Vedra Beach, FL<br />
1:00 pm<br />
Live Demonstration: Scanning <strong>of</strong> the Elbow<br />
Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine,<br />
Jacksonville; Ponte Vedra Beach, FL<br />
1:15 PM<br />
Hands on Scanning: The Elbow<br />
Faculty<br />
2:25 - 2:40 PM<br />
Break<br />
2:40 PM<br />
Hand and Wrist - Lecture: Standard Scans, Sonographic<br />
Anatomy and Basic Sonographic Pathology<br />
Emilio Filippucci, MD, PhD; Università Politecnica delle Marche -<br />
Ancona; Jesi, Ancona, Italy<br />
7:30 AM<br />
Introduction<br />
Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />
7:35 AM<br />
Principles <strong>of</strong> Musculoskeletal Ultrasound for Rheumatologists<br />
Wolfgang A. Schmidt, MD; Medical Center for <strong>Rheumatology</strong><br />
Berlin-Buch; Berlin, Germany<br />
8:05 AM<br />
Ultrasound in Pediatric <strong>Rheumatology</strong><br />
Johannes Roth, MD; Children’s Hospital Eastern Ontario; Ottawa,<br />
ON, Canada<br />
3:10 PM<br />
Live Demonstration: Hand and Wrist<br />
Emilio Filippucci, MD, PhD; Università Politecnica delle Marche -<br />
Ancona; Jesi, Ancona, Italy<br />
3:25 PM<br />
Hands on Scanning: Hand and Wrist<br />
Faculty<br />
18<br />
2010 Program Book
ACR Clinical Research Conference<br />
c/r PS<br />
8:00 am - 5:00 pm<br />
B406<br />
Admission to the ACR Clinical Research Conference requires a<br />
separate registration.<br />
Quality Improvement and Evidence Implementation<br />
Research<br />
Session Overview:<br />
Few topics in modern medicine evoke as much heated<br />
discussion and debate among both clinicians and researchers<br />
as quality measurement and quality improvement. While<br />
international efforts to tie reimbursement to health care quality<br />
are accelerating, there is also a growing body <strong>of</strong> research<br />
supporting methodology to implement evidence into practice. In<br />
the era <strong>of</strong> comparative effectiveness research, even the National<br />
Institutes <strong>of</strong> Health is expressing interest in type II translational<br />
research that utilizes methods <strong>of</strong> epidemiology, health services<br />
research and behavioral medicine. A growing number <strong>of</strong><br />
rheumatologists throughout the world have been engaged<br />
in such investigations and this conference will have special<br />
appeal to this expanding cadre, along with epidemiologists and<br />
outcomes researchers. Given the direct relevance <strong>of</strong> this topic to<br />
clinical care, it is anticipated that it will be <strong>of</strong> special interest to<br />
practicing clinicians as well.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe current research on quality improvement in<br />
rheumatic diseases<br />
• examine the research methods appropriate to assessment <strong>of</strong><br />
quality improvement and identify strengths and weaknesses<br />
<strong>of</strong> various study designs<br />
• describe the evidence for successful quality improvement<br />
interventions including cluster randomized trials, academic<br />
detailing, registries in persons with rheumatic diseases<br />
• assess the ACR approaches to fostering the documentation <strong>of</strong><br />
quality indicators<br />
7:00 - 8:00 AM<br />
Continental Breakfast<br />
8:00 AM<br />
Introduction<br />
Kenneth G. Saag, MD, MSc; University <strong>of</strong> Alabama-Birmingham;<br />
Birmingham, AL<br />
Session I: The Essentials<br />
Moderator: Maria E. Suarez-Almazor, MD, PhD; University <strong>of</strong><br />
Texas, MD Anderson Cancer Center; Houston, TX<br />
8:15 AM<br />
Overview <strong>of</strong> Translating Evidence Into Practice<br />
Jeroan Allison, MD, MS; University <strong>of</strong> Massachusetts Medical<br />
School; Worchester, MA<br />
8:45 AM<br />
Measuring Performance and Care Gaps in Musculoskeletal<br />
Medicine<br />
Catherine H. MacLean, MD, PhD; WellPoint, Inc.; Westlake<br />
Village, CA<br />
9:30 AM<br />
Group Randomized Trial Designs to Improve Quality<br />
David M. Murray, PhD; Ohio State University, <strong>College</strong> <strong>of</strong> Public<br />
Health; Columbus, OH<br />
10:00 - 10:15 AM<br />
Break<br />
10:15 AM<br />
Popular Methods to Improve Care: Benefit or Boondoggle?<br />
Stephen Soumerai, ScD; Harvard Medical School; Boston, MA<br />
11:00 AM<br />
Implementation Research and Functional Status<br />
John Ware, PhD; University <strong>of</strong> Massachusetts Medical School;<br />
Worchester, MA<br />
11:45 AM - 12:30 PM<br />
Boxed Lunch<br />
12:30 PM<br />
Quality Improvement vs. Evidence Implementation: Point-<br />
Counterpoint<br />
Richard S. Gitomer, MD, MBA; Emory University Hospital<br />
Midtown; Atlanta, GA<br />
Catarina Kiefe, MD, PhD; University <strong>of</strong> Massachusetts Medical<br />
School; Worchester, MA<br />
1:30 PM<br />
Persuading National Healthcare Providers to Improve Use<br />
<strong>of</strong> Drugs <strong>of</strong> and Devices in Musculoskeletal Disorders in the<br />
United Kingdom<br />
Alastair R. McLellan, MD; University <strong>of</strong> Glasgow, Western<br />
Infirmary; Glasgow, United Kingdom<br />
Session II: Applications to Musculoskeletal Medicine<br />
Moderator: J. Timothy Harrington, MD; University <strong>of</strong> Wisconsin,<br />
Madison, WI<br />
2:00 pm<br />
Adherence to Musculoskeletal Therapy and Methods to<br />
Improve It<br />
Jeffrey R. Curtis, MD, MPH; University <strong>of</strong> Alabama – Birmingham,<br />
Birmingham, AL<br />
2:30 PM<br />
Approaches to Improve Osteoporosis Quality <strong>of</strong> Care<br />
Daniel Solomon, MD, MPH; Brigham and Women’s Hospital;<br />
Boston, MA<br />
3:00 - 3:15 PM<br />
Break<br />
3:15 PM<br />
Rapid Cycle Quality Improvement in Arthritis and Osteoporosis<br />
Eric Newman, ScD; Harvard Medical School; Boston, MA<br />
4:00 PM<br />
Using Registries to Improve Quality: The Example <strong>of</strong> Building a<br />
Pediatric Network<br />
Esi Morgan DeWitt, MD; Geisinger Medical Center, Danville, PA<br />
4:30 PM<br />
ACR Efforts to Document and Improve Quality: RCR and Beyond<br />
Salahuddin Kazi, MD; Dallas Veterans Affairs Medical Center;<br />
Dallas, TX<br />
5:00 - 6:00 PM<br />
Networking Reception<br />
2010 Program Book 19<br />
saturday
saturday<br />
ACR Certified <strong>Rheumatology</strong> Coder<br />
Course – Day One cP<br />
9:00 am - 5:00 pm<br />
B313<br />
Admission to the ACR Certified <strong>Rheumatology</strong> Coder Course<br />
requires a separate registration. Registration includes CRHC<br />
review materials, examination and a boxed lunch. This course is<br />
not eligible for CME credit.<br />
Speakers: Antanya Chung; <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong>;<br />
Atlanta, GA<br />
Melesia Tillman; <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong>; Atlanta, GA<br />
Session Overview:<br />
The US Department <strong>of</strong> Labor anticipates the demand for<br />
individuals with a solid background in medical coding will<br />
increase as physician practices and hospitals continue to require<br />
accurate coding for appropriate reimbursement and to reduce<br />
audit risk. To help address this need, the <strong>American</strong> <strong>College</strong> <strong>of</strong><br />
<strong>Rheumatology</strong>, in collaboration with the <strong>American</strong> Academy<br />
<strong>of</strong> Pr<strong>of</strong>essional Coders, has developed a rheumatology coding<br />
specialty credential to help coders demonstrate a superior<br />
level <strong>of</strong> expertise in the field <strong>of</strong> rheumatology. To receive the<br />
credential, coders must participate in the two-day rheumatology<br />
coding course and pass the examination. The course is designed<br />
to increase coding knowledge and help participaants prepare for<br />
the examination.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• exhibit pr<strong>of</strong>iciency in adjudicating claims for accurate medical<br />
coding for diagnoses, procedures, and services<br />
• demonstrate knowledge <strong>of</strong> medical coding rules and<br />
regulations along with keeping current on issues regarding<br />
medical coding, compliance, and reimbursement for<br />
rheumatology services<br />
• discuss human anatomy, physiology, and medical terminology<br />
commensurate with ability to correctly code provider services<br />
and diagnoses<br />
extends beyond their capacity to produce immunoglobulin.<br />
Their involvement in the initiation and regulation <strong>of</strong> the<br />
adaptive immune response comprises a burgeoning topic <strong>of</strong><br />
research. There has been intense interest in recent years in the<br />
participation <strong>of</strong> B-cells in autoimmune disease. In addition, it is<br />
increasingly recognized that regulatory B-cells may participate<br />
in numerous settings to down-regulate the immune response.<br />
These disparate aspects <strong>of</strong> B-cell biology are <strong>of</strong> high interest<br />
for potential application to the treatment <strong>of</strong> inflammation and<br />
autoimmunity.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify key concepts and major advances in B cell biology,<br />
including B cell development and regulation<br />
• explain approaches used to identify and quantify B cell<br />
subpopulations<br />
• describe examples <strong>of</strong> rheumatic diseases where B cells play<br />
important roles in pathogenesis<br />
• list the major pathways involved in B cell signaling<br />
• recite the concepts and rationale underlying the use <strong>of</strong> B celldirected<br />
therapies in autoimmune disease<br />
• state the major findings from clinical trials using B celldirected<br />
therapies in rheumatic disease<br />
• describe the challenges faced in therapeutic targeting <strong>of</strong> B<br />
cells, including potential toxicities<br />
1:00 PM<br />
Introduction<br />
B cells: An Evolutionary and Historic Perspective<br />
Max D. Cooper, MD; Emory University School <strong>of</strong> Medicine;<br />
Atlanta, GA<br />
Session I: B cell Development<br />
Moderator: Shiv Pillai, MD, PhD; Massachusetts General<br />
Hospital; Boston, MA<br />
1:45 PM<br />
Early B cell Development<br />
Paul Kincade, PhD; Oklahoma Medical Research Foundation;<br />
Oklahoma City, OK<br />
ACR Basic Research Conference –<br />
dAy One R<br />
1:00 - 5:30 pm<br />
B402<br />
Admission to the ACR Basic Research Conference requires a<br />
separate registration.<br />
The Immunobiology <strong>of</strong> B Cells: From Antibodies to<br />
Immunoregulation<br />
Moderators: Ann Marshak-Rothstein, PhD; University <strong>of</strong><br />
Massachusetts Medical School; Worcester, MA<br />
E. William St.Clair, MD; Duke University Medical Center; Durham,<br />
NC<br />
Session Overview:<br />
B cells are a heterogeneous subset <strong>of</strong> lymphocytes that are<br />
classically studied for their participation in humoral immunity.<br />
However, it is becoming increasingly apparent that B-cell<br />
participation in immune responses and in autoimmunity<br />
2:20 PM<br />
Molecular Regulation <strong>of</strong> B cell Subsets and Their Development<br />
Richard Hardy, PhD; Fox Chase Cancer Center; Philadelphia, PA<br />
2:55 PM<br />
B cell Receptor Stimulation and Lineage Decisions<br />
Shiv Pillai, MD, PhD; Massachusetts General Hospital; Boston,<br />
MA<br />
3:30 - 3:45 PM<br />
Break<br />
Session II: B cell Activation and Trafficking<br />
Moderator: David Rawlings, MD; University <strong>of</strong> Washington;<br />
Seattle, WA<br />
3:45 PM<br />
B cell Receptor and Signaling Pathways<br />
David Rawlings, MD; University <strong>of</strong> Washington; Seattle, WA<br />
20<br />
2010 Program Book
4:20 PM<br />
Germinal Center Reactions<br />
Ann Haberrman, PhD; Yale School <strong>of</strong> Medicine; New Haven, CT<br />
4:55 PM<br />
Memory Plasma Cells and Protective and Pathogenic Immune<br />
Responses<br />
Andreas Radbruch, PhD; Forschungszentrum; Berlin, Germany<br />
5:30 - 6:30 PM<br />
Networking Reception<br />
ACR/ABIM Maintenance <strong>of</strong><br />
CertifiCAtion Learning Session - 2010<br />
Update in rheumatology c/r ARS<br />
1:00 - 5:30 PM<br />
A311<br />
Admission to the ACR/ABIM Maintenance <strong>of</strong> Certification<br />
Learning Session - 2010 Update requires a separate registration.<br />
Moderator: Carol A. Langford, MD, MHS; Cleveland Clinic;<br />
Cleveland, OH<br />
Session Overview:<br />
The <strong>American</strong> Board <strong>of</strong> Internal Medicine’s Maintenance <strong>of</strong><br />
Certification program requires rheumatologists certified after<br />
1990 to renew their certificates every ten years. Because <strong>of</strong> this,<br />
the ACR is dedicated to providing tools to rheumatologists to<br />
help fulfill their Maintenance <strong>of</strong> Certification requirements. The<br />
ACR/ABIM Maintenance <strong>of</strong> Certification Learning Session will<br />
review the ABIM 2010 Update Module worth 10 MOC points<br />
in the medical knowledge category. This live activity will help<br />
promote physicians lifelong learning efforts with while assisting<br />
them in preparing for the <strong>Rheumatology</strong> Maintenance <strong>of</strong><br />
Certification exam.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• assess strengths and weaknesses in rheumatology medical<br />
base knowledge<br />
• state the major developments in rheumatology over the past<br />
10 years<br />
• satisfy a self-evaluation requirement for the ABIM MOC<br />
program<br />
1:00 PM<br />
Introduction<br />
Carol A. Langford, MD, MHS; Cleveland Clinic; Cleveland, OH<br />
1:15 PM<br />
Session I<br />
Carol A. Langford, MD, MHS; Cleveland Clinic; Cleveland, OH<br />
3:00 PM<br />
Session II<br />
Mary Chester Wasko, MD, MSc; University <strong>of</strong> Pittsburgh;<br />
Pittsburgh, PA<br />
4:15 PM<br />
Session III<br />
Robert A. Kalish, MD; Tufts Medical Center; Boston, MA<br />
5:30 PM<br />
Conclusion<br />
Carol A. Langford, MD, MHS; Cleveland Clinic; Cleveland, OH<br />
saturday<br />
2010 Program Book 21
sunday<br />
SUNDAY, NOVEMBER 7, 2010<br />
ACR/ARHP Registration<br />
6:30 am - 7:00 pm<br />
International Blvd. Foyer<br />
ACR Musculoskeletal Ultrasound<br />
Course for Rheumatologists –<br />
dAy Two C<br />
7:30 am - 4:30 pm<br />
A412<br />
Admission to the ACR Musculoskeletal Ultrasound Course<br />
requires a separate registration. See Day One for session<br />
overview and learning objectives.<br />
Moderator: Ralf G. Thiele, MD; University <strong>of</strong> Rochester;<br />
Rochester, NY<br />
Faculty: Rany Al Haj, MD; Shore Arthritis and Rheumatism<br />
Associates; Ocean, NJ<br />
Marina Backhaus, MD; University Medicine Berlin: Campus<br />
Charité Mitte; Berlin, Germany<br />
P. Scott Pollock, MD; Seattle, WA<br />
David A. Bong, MD; Instituto Poal de Reumatologia; Bruce, WI<br />
Jurgen Craig-Muller, MD; CentraCare Clinic; St. Cloud, MN<br />
Paul J. DeMarco, MD; Arthritis & Rheumatism Associates PC;<br />
Wheaton, MD<br />
Amy M. Evangelisto, MD; Arthritis Rheumatic and Back Disease<br />
Associates; Philadelphia, PA<br />
David E. Feinstein, DO; Cooper Health System, Robert Wood<br />
Johnson Medical School; Camden, NJ<br />
Emilio Filippucci, MD; Università Politecnica delle Marche -<br />
Ancona; Jesi, Ancona, Italy<br />
Janak R. Goyal, MD; University <strong>of</strong> Medicine and Dentistry <strong>of</strong> New<br />
Jersey, Robert Wood Johnson Medical School; Perth Amboy, NJ<br />
Jay B. Higgs, MD; Wilford Hall Medical Center, Department <strong>of</strong> Air<br />
Force; San Antonio, TX<br />
Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine,<br />
Jacksonville; Ponte Vedra Beach, FL<br />
Eugene Y. Kissin, MD; Boston University; Boston, MA<br />
Esperanza Naredo, MD; Hospital Universitario Severo Ochoa,<br />
Madrid, Spain<br />
Midori Jane Nishio, MD; John Muir Medical Center; Walnut<br />
Creek, CA<br />
Anthony M. Reginato, PhD, MD; University Medicine Foundation,<br />
Rhode Island Hospital; Providence, RI<br />
Johannes Roth, MD; Children’s Hospital Eastern Ontario; Ottawa,<br />
ON, Canada<br />
Jonathan Samuels, MD; New York University Hospital for Joint<br />
Disease; New York, NY<br />
Wolfgang A. Schmidt, MD; Medical Center for <strong>Rheumatology</strong><br />
Berlin-Buch; Berlin, Germany<br />
Darren Tabechian, MD; University <strong>of</strong> Rochester School <strong>of</strong><br />
Medicine; Rochester, NY<br />
Mihaela Taylor, MD; University <strong>of</strong> California Los Angeles; Los<br />
Angeles, CA<br />
Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />
7:00 - 7:30 AM<br />
Continental Breakfast<br />
7:30 AM<br />
Introduction<br />
Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />
7:35 AM<br />
Billing, Coding and Report Generation<br />
Jay B. Higgs, MD; Wilford Hall Medical Center, Department <strong>of</strong> Air<br />
Force; San Antonio, TX<br />
8:00 AM<br />
The Hip - Lecture: Standard Scans, Sonographic Anatomy and<br />
Basic Sonographic Pathology<br />
Wolfgang A. Schmidt, MD; Medical Center for <strong>Rheumatology</strong><br />
Berlin-Buch; Berlin, Germany<br />
8:30 AM<br />
Live Demonstration: Scanning <strong>of</strong> the Hip<br />
Wolfgang A. Schmidt, MD; Medical Center for <strong>Rheumatology</strong><br />
Berlin-Buch; Berlin, Germany<br />
8:45 AM<br />
Hands on Scanning: The Hip<br />
Faculty<br />
9:45 - 10:00 AM<br />
Break<br />
10:00 AM<br />
The Knee - Lecture: Standard Scans, Sonographic Anatomy and<br />
Basic Sonographic Pathology<br />
Marina Backhaus, MD; University Medicine Berlin: Campus<br />
Charité Mitte;Berlin, Germany<br />
10:30 AM<br />
Live Demonstration: Scanning <strong>of</strong> the Knee<br />
Marina Backhaus, MD; University Medicine Berlin: Campus<br />
Charité Mitte; Berlin, Germany<br />
10:45 AM<br />
Hands on Scanning: The Knee<br />
Faculty<br />
Noon - 12:45 PM<br />
Boxed Lunch<br />
12:45 PM<br />
Foot and Ankle - Lecture: Standard Scans, Sonographic<br />
Anatomy and Basic Sonographic Pathology<br />
Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />
1:15 PM<br />
Live Demonstration: Scanning <strong>of</strong> Foot and Ankle<br />
Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />
1:30 PM<br />
Hands on Scanning: Foot and Ankle<br />
Faculty<br />
2:45 - 3:00 PM<br />
Break<br />
3:00 PM<br />
Ultrasound Needle Guidance - Lecture: Ultrasound Guidance <strong>of</strong><br />
Procedures<br />
Eugene Y. Kissin, MD; Boston University; Boston, MA<br />
22<br />
2010 Program Book
3:30 PM<br />
Live Demonstration: Ultrasound Needle Guidance<br />
Eugene Y. Kissin, MD; Boston University; Boston, MA<br />
3:45 PM<br />
Hands on Scanning: Ultrasound Needle Guidance<br />
Faculty<br />
ACR Basic Research Conference –<br />
dAy Two R<br />
8:00 am - 4:30 pm<br />
B402<br />
Admission to the ACR Basic Research Conference requires a<br />
separate registration. See Day One for session overview and<br />
learning objectives.<br />
Session III: Factors Promoting B Cell Autoreactivity<br />
and Protective Immunity<br />
Moderator: Ann Marshak-Rothstein, PhD; University <strong>of</strong><br />
Massachusetts Medical School; Worcester, MA<br />
7:00 - 8:00 AM<br />
Continental Breakfast<br />
8:00 AM<br />
Toll Like Receptor Signaling in B cells and Autoimmune Disease<br />
Ann Marshak-Rothstein, PhD; University <strong>of</strong> Massachusetts<br />
Medical School; Worcester, MA<br />
8:35 AM<br />
Ectopic Lymphoid Tissue<br />
Troy Randall, PhD; University <strong>of</strong> Rochester; Rochester, NY<br />
9:10 AM<br />
Memory B cells<br />
Inaki Sanz, MD; University <strong>of</strong> Rochester; Rochester, NY<br />
9:45 - 10:00 AM<br />
Break<br />
Session IV: B Cell Regulation and B Cell Regulators<br />
Moderator: Garnett Kelsoe, PhD; Duke Univeristy Medical<br />
Center; Durham, NC<br />
12:30 PM<br />
B cell Lymphocyte Survival Factors<br />
Michael P. Cancro, PhD; University <strong>of</strong> Pennsylvania; Philadelphia,<br />
PA<br />
1:05 PM<br />
CD20-focused Therapies - Mechanisms <strong>of</strong> Action<br />
Martin J. Glennie, PhD; Univesity <strong>of</strong> Southampton - UK;<br />
Southampton, United Kingdom<br />
1:40 PM<br />
Innate B cells and Natural Antibodies<br />
Gregg J. Silverman, MD; University <strong>of</strong> California - San Diego; La<br />
Jolla, CA<br />
Session VI: Role <strong>of</strong> B cells in Autoimmunity: Lessons<br />
from Clinical Trials<br />
Moderator: E. William St.Clair, MD; Duke University Medical<br />
Center; Durham, NC<br />
2:15 PM<br />
Rheumatoid Arthritis<br />
Jonathan C.W. Edwards, MD; University <strong>College</strong> London; London,<br />
United Kingdom<br />
2:45 PM<br />
Lupus<br />
Jennifer H. Anolik, MD, PhD; University <strong>of</strong> Rochester; Rochester,<br />
NY<br />
3:15 PM<br />
Sjögren’s Syndrome<br />
E. William St.Clair, MD; Duke University Medical Center; Durham,<br />
NC<br />
3:45 PM<br />
ANCA-associated Vasculitis<br />
John H. Stone, MD, MPH; Massachusetts General Hospital;<br />
Boston, MA<br />
4:15 PM<br />
Wrap-up: Take Home Messages and Future Directions<br />
Betty Diamond, MD; Feinstein Institute for Medical Research;<br />
Manhasset, NY<br />
sunday<br />
10:00 AM<br />
Insights from Immunodeficiencies<br />
Eric Meffre, PhD; Yale University School <strong>of</strong> Medicine; New<br />
Haven, CT<br />
10:35 AM<br />
Role <strong>of</strong> Activation-induced Cytidine Deaminase in Tolerance<br />
Garnett Kelsoe, PhD; Duke Univeristy Medical Center; Durham,<br />
NC<br />
ACR Review Course C<br />
8:00 am - 4:00 pm<br />
Hall A3<br />
Admission to the Review Course requires a separate registration.<br />
Moderators: Mary E. Cronin, MD; Medical <strong>College</strong> <strong>of</strong> Wisconsin;<br />
Milwaukee, WI<br />
Gregory C. Gardner, MD; University <strong>of</strong> Washington; Seattle, WA<br />
11:10 AM<br />
Regulatory B cells<br />
Thomas F. Tedder, PhD; Duke University Medical Center;<br />
Durham, NC<br />
11:45 AM - 12:30 PM<br />
Boxed Lunch<br />
Session V: Emerging Concepts in B cell Directed<br />
Therapies<br />
Moderator: Michael P. Cancro, PhD; University <strong>of</strong> Pennsylvania;<br />
Philadelphia, PA<br />
7:00 - 8:00 AM<br />
Continental Breakfast<br />
8:00 AM<br />
Mixed Connective Tissue Disease is Not Really that Mixed<br />
Virginia D. Steen, MD; Georgetown University Medical Center;<br />
Washington, DC<br />
Talk Overview:<br />
Mixed connective tissue disease was first described in 1972. The<br />
concept has evolved over the years and the current approach to<br />
the diagnosis and treatment in adults and children has changed<br />
as well.<br />
2010 Program Book 23
sunday<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review the classification criteria and clinical manifestations <strong>of</strong><br />
mixed connective tissue disease<br />
• discuss diagnostic and treatment plans for patients with mixed<br />
connective tissue disease<br />
• determine if classification to mixed connective tissue disease<br />
vs. undifferentiated vs. overlap categories affects treatment<br />
and outcome<br />
8:45 AM<br />
Bowel Associated Rheumatologic Diseases<br />
Filip E. Van den Bosch, MD, PhD; University Hospital; Gent,<br />
Belgium<br />
Talk Overview:<br />
Inflammatory arthritis is associated with bowel disease and the<br />
gut inflammation is <strong>of</strong>ten subclinical. Rheumatologists must<br />
know the bowel disorders associated with arthritis in order to<br />
develop a treatment plan that will improve the arthritis and not<br />
worsen the gut disease. Disorders such as Celiac disease involve<br />
the gastrointestinal tract as well as joints and is present in up<br />
to one percent <strong>of</strong> the population. Rheumatologists should be<br />
aware <strong>of</strong> the possible associations with arthritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the role <strong>of</strong> gut inflammation in the pathogenesis <strong>of</strong><br />
inflammatory arthritis<br />
• explain the therapeutic options for patients with arthritis and<br />
bowel disease<br />
• discuss the relationship <strong>of</strong> celiac disease to arthritis and<br />
current diagnostic assessment<br />
9:30 AM<br />
Rheumatoid Arthritis: From Bench to Bed side in 40 Minutes<br />
Daniel E. Furst, MD; University <strong>of</strong> California-Los Angeles Medical<br />
School; Los Angeles, CA<br />
Talk Overview:<br />
Rheumatoid arthritis is a common condition seen in<br />
rheumatology practice. There are new diagnostic and treatment<br />
guidelines, diagnostic tests, genetic information, medications,<br />
currently available. In addition, new medications are about to<br />
be released and a whole new family <strong>of</strong> drugs are under study<br />
for therapy. The purpose <strong>of</strong> this talk is to review how far we<br />
have come in the last 10 years, review current best practice<br />
for diagnosis and treatment, and look into the near future <strong>of</strong><br />
rheumatoid arthritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review recent additions to understanding <strong>of</strong> the<br />
pathophysiology <strong>of</strong> rheumatoid arthritis<br />
• discuss current evidence-based treatment paradigms<br />
• discuss new or soon to be new medications and where they<br />
might be utilized<br />
10:15 - 10:45 AM<br />
Break<br />
10:45 AM<br />
Hepatitis C for the Rheumatologist<br />
Amy M. Joseph, MD; Veterans Affair Medical Center, Washington<br />
University; St. Louis, MO<br />
Talk Overview:<br />
Hepatitis C infection can cause and/or mimic a variety <strong>of</strong><br />
rheumatologic diseases. It is important that the clinical<br />
rheumatologist be familiar with the spectrum <strong>of</strong> illness caused<br />
by hepatitis C and understand current diagnostic and treatment<br />
approaches.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the pathophysiology and natural history <strong>of</strong> hepatitis<br />
C infection<br />
• review rheumatologic manifestations <strong>of</strong> hepatitis C<br />
• apply the current therapeutic approaches to hepatitis C<br />
associated rheumatologic illnesses<br />
11:30 AM<br />
Autoinflammatory Diseases for the Adult Rheumatologist<br />
Daniel L. Kastner, MD, PhD; NIAMS/NIH; Bethesda, MD<br />
Talk Overview:<br />
Autoinflammatory diseases are becoming more widely<br />
recognized in clinical medicine. Rheumatologists are <strong>of</strong>ten asked<br />
to see patients with unusual inflammatory syndromes. The<br />
purpose <strong>of</strong> this session is to review the pathophysiology, clinical<br />
manifestations, diagnostic options, and treatment <strong>of</strong> the more<br />
common autoinflammatory syndromes.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review the pathophysiology <strong>of</strong> the autoinflammatory diseases<br />
• identify clinical manifestations and diagnostic evaluation for<br />
the autoinflammatory diseases<br />
• assess treatment options currently available or soon to be<br />
available<br />
12:15 - 1:15 PM<br />
Boxed Lunch<br />
1:15 PM<br />
<strong>Rheumatology</strong> Laboratory Testing: How it is Done and Why We<br />
Need to Know<br />
Mark H. Wener, MD; University <strong>of</strong> Washington; Seattle, WA<br />
Talk Overview:<br />
Newer diagnostic tests and new methods are being employed<br />
in the immunology laboratory; however, the limitations<br />
and benefits <strong>of</strong> such testing are important to understand in<br />
interpreting and utilizing immunology laboratory testing.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review recent advances/changes in immunology laboratory<br />
testing<br />
• discuss the probabilistic nature <strong>of</strong> laboratory testing<br />
• describe the pearls and pitfalls <strong>of</strong> testing in 2010<br />
2:00 PM<br />
Rheumatic Manifestations <strong>of</strong> Neoplastic Diseases<br />
Joanne Valeriano-Marcet, MD; University <strong>of</strong> South Florida;<br />
Tampa, FL<br />
Talk Overview:<br />
Rheumatologists are frequently asked to consult on patients<br />
with cancer and arthritis or autoimmune phenomenon. Adult<br />
and pediatric patients with cancer also frequently present first<br />
with a rheumatic complaint.<br />
24<br />
2010 Program Book
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe possible clinical presentations <strong>of</strong> patients with<br />
undiagnosed cancer<br />
• describe the common paraneoplastic syndromes<br />
• discuss rheumatologic complications <strong>of</strong> neoplastic diseases<br />
and their therapies<br />
2:45 - 3:15 PM<br />
Break<br />
3:15 PM<br />
Evidence-based Snacks for Rheumatologists<br />
George V. Lawry, MD; University <strong>of</strong> California-Irvine; Mission<br />
Viejo, CA<br />
Talk Overview:<br />
Many everyday processes that occur in a clinic are a result <strong>of</strong><br />
fellowship training. The purpose <strong>of</strong> this presentation is to cover<br />
three mini-topics and present evidence <strong>of</strong> best practice data for<br />
processes/issues clinicians take for granted.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss factors influencing efficacy <strong>of</strong> methotrexate therapy<br />
and review evidence for splitting high-dose oral methotrexate<br />
• establish side effect pr<strong>of</strong>ile <strong>of</strong> azathioprine and review<br />
evidence for thiopurine S-methyltransferase testing prior to<br />
azathioprine therapy<br />
• determine evidence for risk <strong>of</strong> pneumocystis pneumonia<br />
in immunosuppressed patients with rheumatic diseases<br />
and review practical strategy for pneumocystis pneumonia<br />
prophylaxis<br />
<strong>of</strong> new classes <strong>of</strong> treatment options, clinical practice has<br />
changed dramatically. Health care pr<strong>of</strong>essionals must have a<br />
fundamental knowledge <strong>of</strong> immunology and the mechanisms<br />
<strong>of</strong> action <strong>of</strong> these biologic agents. Familiarity with the pre-drug<br />
screening recommended for these agents and the appropriate<br />
safety and disease monitoring necessary when a person uses<br />
theses products is essential for the best patient outcomes. In<br />
addition, knowing how to obtain drug plan authorization for the<br />
use <strong>of</strong> biologics and educating patients and their support team<br />
members about the financial considerations <strong>of</strong> these treatments<br />
helps to ensure best rheumatology practice.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• explain immunologic principles and identify biologic targets<br />
for treatment <strong>of</strong> rheumatic diseases<br />
• discuss the safety and adverse effects <strong>of</strong> biotherapies<br />
• develop and apply patient education strategies to clinical<br />
practice<br />
• analyze complex cases and formulate patient care plans<br />
7:00 - 8:00 AM<br />
Continental Breakfast<br />
8:00 AM<br />
Introduction<br />
Sandra J. Watcher, BSN; Children’s Hospital <strong>of</strong> Los Angeles; Los<br />
Angeles, CA<br />
8:15 AM<br />
Immunology Background for Biotherapies<br />
Troy R. Torgerson, MD, PhD; Children’s Hospital; Seattle, WA<br />
sunday<br />
ARHP Clinical Focus Course<br />
8:00 am - 4:30 pm<br />
c/r PS ARS<br />
A411<br />
Admission to the ARHP Clinical Focus Course requires a separate<br />
registration.<br />
Integrating Immunology and Biologics into Clinical<br />
Practice<br />
Moderator: Sandra J. Watcher, BSN; Children’s Hospital <strong>of</strong> Los<br />
Angeles; Los Angeles, CA<br />
Session Overview:<br />
The National Arthritis Data Workgroup recently reviewed<br />
data from national and regional surveys to estimate national<br />
prevalence rates <strong>of</strong> various rheumatic diseases based on 2005<br />
U.S. Census data. The results were published in an article<br />
titled, “Estimates <strong>of</strong> the Prevalence <strong>of</strong> Arthritis and Other<br />
Rheumatic Conditions in the United States” in the January<br />
2008 issue <strong>of</strong> Arthritis & Rheumatism. Estimates include 1.3<br />
million adults with rheumatoid arthritis, 0.6 to 2.4 million with<br />
spondylarthritides, 161 to 322,000 with systemic lupus, and<br />
294,000 children with juvenile arthritis. Treatments for these<br />
rheumatic conditions include tumor necrosis factor inhibitors,<br />
which were first available clinically in the late 1990s, and other<br />
pharmacologic options including B cell targeted therapies, costimulatory<br />
molecules and cytokine antagonists that have more<br />
recently been approved. Other specific molecules are currently<br />
in various stages <strong>of</strong> study. With this rapid expansion<br />
9:15 AM<br />
Targeted Therapies: How Do They Work?<br />
Anne M. Stevens, MD, PhD; University <strong>of</strong> Washington; Seattle,<br />
WA<br />
10:15 - 10:30 AM<br />
Break<br />
10:30 AM<br />
Screening Patients for Safe Practice<br />
Josephine C. Garnoc, BSN; Beaumont Grosse Pointe Hospital;<br />
Grosse Pointe, MI<br />
11:15 AM<br />
Side Effects and Adverse Reactions<br />
Susan P. Bruce, PharmD; Northeastern Ohio Universities;<br />
Rootstown, OH<br />
Noon - 1:00 PM<br />
Lunch<br />
1:00 PM<br />
Cutting Through the Red Tape to Obtain Treatment<br />
Karen M. Ferguson, MS; Arthritis Northwest <strong>Rheumatology</strong>,<br />
PLLC; Spokane, WA<br />
1:45 PM<br />
Patient Education Applying What You’ve Learned<br />
Jane M. Denay, BSN, MSN, CFNP; Harbor Arthritis Center;<br />
Petoskey, MI<br />
Elizabeth L. Roth-Wojcicki, RN, MS, CPNP; Medical <strong>College</strong> <strong>of</strong><br />
Wisconsin; Wauwatosa, WI<br />
2010 Program Book 25
sunday<br />
2:45 - 3:00 PM<br />
Break<br />
3:00 PM<br />
Managing Complex Cases: Answering the Hard Questions<br />
Salahuddin Kazi, MD; Dallas Veterans Affairs Medical Center;<br />
Dallas, TX<br />
Andreas O. Reiff, MD; Children’s Hospital <strong>of</strong> Los Angeles; Los<br />
Angeles, CA<br />
4:15 PM<br />
Summary<br />
Sandra J. Watcher, BSN; Children’s Hospital <strong>of</strong> Los Angeles; Los<br />
Angeles, CA<br />
ACR Certified <strong>Rheumatology</strong> Coder<br />
Course Examination – Day Two cP<br />
11:00 am - 5:00 pm<br />
A311<br />
Admission to the ACR Certified <strong>Rheumatology</strong> Coder Course<br />
requires a separate registration. Registration includes CRHC<br />
review materials, examination and a boxed lunch. This course is<br />
not eligible for CME credit. See Day One for session overview and<br />
learning objectives.<br />
Speaker: Antanya Chung; <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong>;<br />
Atlanta, GA<br />
ACR/ARHP Opening Lecture and<br />
Awards<br />
5:00 - 6:30 pm<br />
Hall A3<br />
Moderators: Stanley B. Cohen, MD; <strong>Rheumatology</strong> Associates;<br />
Dallas, TX<br />
Linda S. Ehrlich-Jones, PhD, RN; Rehabilitation Institute <strong>of</strong><br />
Chicago; Chicago, IL<br />
Session Overview:<br />
Auto-immunity is the consequence <strong>of</strong> anti-bacterial defenses<br />
gone awry. We combat bacteria in two ways: innate and<br />
acquired immunity. These are mediated, respectively, by<br />
phagocytosis (via Fc receptors and/or toll-like receptors) and<br />
by anaphylaxis (via C5a and/or C3a). Rheumatoid arthritis<br />
results when these defenses, genetically regulated, incite acute<br />
inflammation that is perpetuated by cytokines. Rheumatologists<br />
should be aware <strong>of</strong> the evidence that oral bacteria, such as<br />
Porphyromonas gingivalis, may play an early role in this process.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• cite the historical basis <strong>of</strong> phagocytosis and anaphylaxis<br />
• discuss the signal transduction mechanisms whereby immune<br />
complexes and anaphylatoxins found in rheumatoid arthritis<br />
joints lead to release <strong>of</strong> mediators such as prostaglandins and<br />
cytokines<br />
• state how steroidal and non-steroidal agents act to blunt<br />
these signal transduction pathways<br />
• relate the microbiology <strong>of</strong> oral bacteria such as<br />
Porphyromonas gingivalis to the chronic inflammation <strong>of</strong><br />
rheumatoid arthritis<br />
ACR/ARHP Opening Event<br />
7:00 - 10:00 pm<br />
Georgia Aquarium<br />
Admission to the ACR/ARHP Opening Event at the Georgia<br />
Aquarium is ticketed and requires a separate registration.<br />
Purchase your tickets in the ACR/ARHP registration area before<br />
7:45 PM to ensure you have access to this VIP event. Tickets will<br />
not be available for purchase at the Georgia Aquarium. For more<br />
information see pages 10 & 15.<br />
5:00 PM<br />
Presidential Address<br />
Stanley Cohen, MD; <strong>Rheumatology</strong> Associates; Dallas, TX<br />
Recognition <strong>of</strong> 2010 ACR Masters<br />
Recognition <strong>of</strong> 2010 Distinction Recipients<br />
Recognition <strong>of</strong> ARHP Merit Awards, Lifetime Achievement<br />
Award and President’s Award<br />
Recognition <strong>of</strong> Fellows Award<br />
5:45 PM<br />
An Infectious Etiology <strong>of</strong> Rheumatoid Arthritis<br />
Gerald Weissmann, MD; New York University Medical<br />
Center; New York, NY<br />
26<br />
2010 Program Book
MONDAY, NOVEMBER 8, 2010<br />
ACR/ARHP Registration<br />
6:30 am - 5:00 pm<br />
International Blvd. Foyer<br />
ARHP Special Sessions<br />
7:00 - 8:00 am<br />
B309<br />
First-Time Attendees Orientation<br />
First time ARHP annual meeting attendees are invited to an<br />
orientation to learn the ‘ins and outs’ <strong>of</strong> the annual meeting. The<br />
ARHP Membership and Nominations Committee will be on hand<br />
to provide advice to assist you in planning how to get the most<br />
out <strong>of</strong> your first annual meeting.<br />
This session is not eligible for CME credit. C<strong>of</strong>fee and tea will be<br />
provided.<br />
Moderator: Pamela J. Degotardi, PhD; Queens <strong>College</strong> City<br />
University <strong>of</strong> New York Honors; Flushing, NY<br />
B308<br />
Moderators Orientation<br />
This session is not eligible for CME credit. C<strong>of</strong>fee and tea will be<br />
provided.<br />
Moderator: Janet L. Poole, PhD, OTR; University <strong>of</strong> New Mexico;<br />
Albuquerque, NM<br />
ACR Basic Science Symposium<br />
7:15 - 8:45 am<br />
B402<br />
Molecular Mechanisms <strong>of</strong> Inflammatory Signaling in<br />
Cartilage Destruction R<br />
Moderators: Richard F. Loeser, MD; Wake Forest University;<br />
Winston-Salem, NC<br />
Anna H. Plaas, PhD; Rush University; Chicago, IL<br />
7:15 AM<br />
ESE:1: Transcriptional and Epigenetic Regulation <strong>of</strong> Cartilage<br />
Remodeling<br />
Mary B. Goldring, PhD; Hospital for Special Surgery; Weill Cornell<br />
Medical <strong>College</strong>; New York, NY<br />
7:45 AM<br />
Chemokines, Cytokines, and their Modulation During Joint<br />
Degeneration<br />
Qian Chen, PhD; Brown University, Rhode Island Hospital;<br />
Providence, RI<br />
8:15 AM<br />
Stimulation <strong>of</strong> Cartilage Destruction by S100 Proteins in<br />
Experimental Arthritis<br />
Peter Van Lent, MD; Radbound University Medical Centre;<br />
Nijmegen, Netherlands<br />
Session Overview:<br />
Cartilage destruction is a central feature <strong>of</strong> many types <strong>of</strong><br />
arthritis. Currently there are no therapies proven to slow or<br />
prevent cartilage destruction. An improved understanding <strong>of</strong><br />
the mechanisms <strong>of</strong> inflammatory signaling in cartilage will<br />
potentially lead to new therapeutic targets for diseases affecting<br />
cartilage, including osteoarthritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the role <strong>of</strong> transcription factors activated by<br />
inflammatory mediators in mediating cartilage destruction<br />
• assess the roles <strong>of</strong> chemokines and cytokines in cartilage<br />
matrix destruction<br />
• analyze the role <strong>of</strong> the S100 proteins, which include the<br />
alarmins, in mediating cartilage destruction<br />
ACR Clinical Symposium<br />
7:15 - 8:30 am<br />
Hall A3<br />
Year in Review c/r<br />
Moderator: Joel A. Block, MD; Rush University Medical Center;<br />
Chicago, IL<br />
7:15 AM<br />
Image Competition Presentation<br />
Alan N. Baer, MD, Audiovisual Aids Subcommittee Chair; Johns<br />
Hopkins University; Baltimore, MD<br />
7:30 AM<br />
Clinical Perspective<br />
Michael H. Weisman, MD; Cedars-Sinai Medical Center; Los<br />
Angeles, CA<br />
8:00 AM<br />
Basic Science Perspective<br />
John P. Atkinson, MD; Washington University School <strong>of</strong><br />
Medicine; St. Louis, MO<br />
Session Overview:<br />
<strong>Rheumatology</strong> is a rapidly advancing field, with substantive<br />
scientific breakthroughs being translated into clinical use<br />
constantly. Therefore, it is important for rheumatologist to<br />
maintain knowledge <strong>of</strong> the most important advances. During<br />
this session, leaders in the field will review and summarize the<br />
most important publications from the previous year in the basic<br />
science and the clinical practice <strong>of</strong> rheumatology.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss selected recent publications on the pathophysiological<br />
basis <strong>of</strong> rheumatic diseases by literature review <strong>of</strong> important<br />
publications<br />
• identify selected treatment modalities for rheumatic diseases<br />
from the recent published literature<br />
• enumerate how these new advances may impact the practice<br />
<strong>of</strong> rheumatology<br />
monday<br />
2010 Program Book 27
monday<br />
ACR REF Special Session<br />
7:15 - 8:15 am<br />
B406<br />
REF Oscar S. Gluck, MD, Memorial Lectureship -<br />
Osteoimmunology: Crosstalk Between the Immune<br />
and Bone Systems: Biologic and Clinical Implications<br />
c/r<br />
Moderator: Michael J. Maricic, MD; Catalina Pointe<br />
<strong>Rheumatology</strong>; Tucson, AZ<br />
Speaker: Hiroshi Takayanagi, MD, PhD; Tokyo Medical and<br />
Dental University; Tokyo, Japan<br />
Session Overview:<br />
Many <strong>of</strong> the molecules and signal pathways controlling the<br />
differentiation and activity <strong>of</strong> osteoclasts also are involved in<br />
regulating immune cell function and activity. The integration <strong>of</strong><br />
knowledge from the fields <strong>of</strong> immunology and bone cell biology<br />
has reshaped our understanding <strong>of</strong> the mechanisms involved<br />
in osteoclast-mediated bone resorption and identified new<br />
approaches for treating clinical conditions associated with bone<br />
loss.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the signal pathways involved in osteoclast<br />
differentiation and activation<br />
• discuss the common mechanism by which cytokines and<br />
signal pathways regulate immune and bone cells<br />
• describe the potential applications <strong>of</strong> discoveries in the field<br />
<strong>of</strong> osteoimmunology for treating clinical disorders associated<br />
with bone loss<br />
ACR State-<strong>of</strong>-the-Art Lecture<br />
7:30 - 8:30 am<br />
B313<br />
Toll-like Receptors Activation <strong>of</strong> B cells in<br />
Autoimmune Disease R<br />
Moderator: Jennifer H. Anolik, MD, PhD; University <strong>of</strong> Rochester;<br />
Rochester, NY<br />
Speaker: Ann Marshak-Rothstein, PhD; University <strong>of</strong><br />
Massachusetts Medical School; Worcester, MA<br />
Session Overview:<br />
In recent years it has become clear that toll-like receptors play<br />
a key role in the initiation and perpetuation <strong>of</strong> autoimmune<br />
responses. Thus, immune complexes such as those found in<br />
autoimmune disease contain ligands for toll-like receptors,<br />
including ribonucleic acid or deoxyribonucleic acid, which can<br />
provide costimulatory signals for autoreactive B cells, promoting<br />
their inappropriate activation and survival. Moreover, toll-like<br />
receptors represent important therapeutic targets. Thus, a state<strong>of</strong>-the-art<br />
review <strong>of</strong> interactions between B cells and toll-like<br />
receptors is timely.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the role <strong>of</strong> toll-like receptors pathways in B cell<br />
activation and contributions to autoimmune disease<br />
• identify how the balance <strong>of</strong> stimulatory and inhibitory signals<br />
on B cells may define the outcome <strong>of</strong> toll-like receptors<br />
activation<br />
• provide the rationale for toll-like receptors targeted therapies<br />
in autoimmunity and the potential limitations <strong>of</strong> such<br />
approaches<br />
ACR Meet the Pr<strong>of</strong>essor Sessions<br />
7:45 - 9:15 am<br />
Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />
separate registration and ticket. To verify which session you<br />
registered for, check to make sure the registration code on your<br />
ticket matches the code listed below in parentheses.<br />
B207<br />
Ankylosing Spondylitis: Disease Modification (001)<br />
Speaker: Walter P. Maksymowych, MD; University <strong>of</strong> Alberta;<br />
Edmonton, AB, Canada<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• outline what is known about the pathophysiology <strong>of</strong> disease<br />
modification in spondylarthritis<br />
• review outcomes relevant to the concept <strong>of</strong> disease<br />
modification in spondylarthritis and assess their relevance to<br />
clinical practice<br />
• review therapeutic issues relevant to the concept <strong>of</strong> disease<br />
modification<br />
• discuss assessment <strong>of</strong> disease modification clinical trial<br />
B208<br />
Behçet’s Disease (002)<br />
Speaker: Hasan Yazici, MD; Cerrahpasa Medical Faculty; Istanbul,<br />
Turkey<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the epidemiology and diagnostic evaluation <strong>of</strong><br />
Behçet’s syndrome<br />
• describe current approaches to the management <strong>of</strong> patients<br />
with Behçet’s syndrome<br />
B209<br />
Central Nervous System Vasculitis (003)<br />
Speaker: Rula Hajj-Ali, MD; Cleveland Clinic; Cleveland, OH<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss an approach to the evaluation <strong>of</strong> a patient referred<br />
with possible central nervous system vasculitis<br />
• review the major entities in the differential diagnosis <strong>of</strong><br />
primary angiitis <strong>of</strong> the central nervous system<br />
• create a consistent therapeutic approach to the treatment <strong>of</strong><br />
vasculitis involving the brain and/or spinal cord<br />
B210<br />
Controversies in Sjögren’s Syndrome (004)<br />
Speaker: Frederick B. Vivino, MD; Pennsylvania Presbyterian<br />
Medical Center; Philadelphia, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify major morbidities in Sjögren’s syndrome patients<br />
• discuss current treatment algorithms for dry eyes, dry mouth<br />
and systemic manifestations<br />
• determine strategies to prevent Sjögren’s related<br />
complications<br />
28<br />
2010 Program Book
B301<br />
Dermatological Manifestations <strong>of</strong> Rheumatic Diseases<br />
(005) f<br />
Speaker: Nicole Fett, MD; Perelman Center for Advanced<br />
Medicine; Philadelphia, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• cite the diagnostic criteria for skin diseases with<br />
rheumatologic implications<br />
• construct a differential diagnosis for these conditions<br />
• design a strategy for management <strong>of</strong> skin disease seen in<br />
patients with rheumatologic diseases<br />
B302<br />
Pain: Difficult Patient Interactions (006) PM<br />
Speaker: Dennis J. Boyle, MD; Denver Health Medical Center;<br />
Denver, CO<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• determine what constitutes a difficult patient interaction<br />
• describe how to diagnosis relationship issues<br />
• discuss opioid use and the legal issues that surround them<br />
B303<br />
Pediatrics: Difficult to Treat Juvenile Idiopathic<br />
Arthritis (007) P<br />
Speaker: Murray H. Passo, MD; Medical University <strong>of</strong> South<br />
Carolina; Charleston, SC<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• utilize laboratory testing in the management <strong>of</strong> patients with<br />
systemic lupus erythematosus<br />
• determine the most relevant and beneficial therapeutic<br />
approach<br />
• identify appropriate assessment tools for use in management<br />
and prognosis<br />
B304<br />
Pulmonary Hypertension in the Rheumatic Diseases<br />
(008)<br />
Speaker: Dinesh Khanna, MD, MSc; University <strong>of</strong> California-Los<br />
Angeles; Los Angeles, CA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• determine the epidemiology <strong>of</strong> pulmonary arterial<br />
hypertension in rheumatic diseases<br />
• discuss the algorithm for diagnosis <strong>of</strong> pulmonary arterial<br />
hypertension in rheumatic diseases<br />
• describe the available treatments for pulmonary arterial<br />
hypertension in rheumatic diseases<br />
B305<br />
Rheumatoid Arthritis: Challenging Cases (009)<br />
Speaker: Edward C. Keystone, MD; University <strong>of</strong> Toronto;<br />
Toronto, ON, Canada<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss management <strong>of</strong> patients with refractory rheumatoid<br />
arthritis<br />
• identify novel treatment options for those failing conventional<br />
therapies<br />
B306<br />
Rheumatoid Arthritis: Difficult Rheumatoid Arthritis<br />
(010)<br />
Speaker: Nancy A. Shadick, MD, MPH; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• define difficult to treat rheumatoid arthritis<br />
• create effective management plans for complicated<br />
rheumatoid arthritis patients<br />
ACR Workshops<br />
7:45 - 9:45 am<br />
Admission to each Workshop requires a separate registration<br />
and ticket. To verify which session you registered for, check to<br />
make sure the registration code on your ticket matches the code<br />
listed below in parentheses.<br />
B201<br />
Creating Presentations Using PowerPoint: Basic (201)<br />
Speaker: Steve W. Blevins, MBA; <strong>American</strong> <strong>College</strong> <strong>of</strong><br />
<strong>Rheumatology</strong>; Atlanta, GA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• demonstrate advanced slide transition techniques<br />
• integrate audio, video and narration into slides<br />
• create presentations that can be published on a local Web site<br />
and be viewed in a browser<br />
B204<br />
Joint Injection Techniques (202) cP PS<br />
Speakers: Atul A. Deodhar, MD; Oregon Health & Science<br />
University; Portland, OR<br />
Kenneth S. O’Rourke, MD; Wake Forest University School <strong>of</strong><br />
Medicine; Winston-Salem, NC<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss indications and contraindications for joint aspirations<br />
and injections<br />
• identify and avoid common mistakes in joint injection<br />
procedures<br />
• perform common joint and s<strong>of</strong>t tissue injections on upper and<br />
lower extremities<br />
B203<br />
Musculoskeletal Ultrasonography: Basic (203) f<br />
Speakers: Janak R. Goyal, MD; University <strong>of</strong> Medicine and<br />
Dentistry <strong>of</strong> New Jersey, Robert Wood Johnson Medical School;<br />
Perth Amboy, NJ<br />
Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine;<br />
Ponte Vedra Beach, FL<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the indications for ultrasound in rheumatic diseases<br />
• discuss the techniques <strong>of</strong> ultrasonography<br />
• identify normal and abnormal anatomical structures by<br />
ultrasound imaging<br />
monday<br />
2010 Program Book 29
monday<br />
30<br />
B202<br />
Synovial Fluid Analysis and Crystal Identification<br />
(204) f<br />
Speakers: Brian F. Mandell, MD, PhD; The Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
Lan X. Chen, MD, PhD; Pennsylvania Presbyterian Medical<br />
Center; Blue Bell, PA<br />
Gilda M. Clayburne, MLT; Veterans Affairs Medical Center;<br />
Philadelphia, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• prepare synovial fluid samples for microscopic examination<br />
• identify various components <strong>of</strong> synovial fluid<br />
• identify crystals in synovial fluid<br />
ARHP Special Session<br />
8:00 - 9:45 am<br />
A411<br />
All ARHP attendees are invited to this kick-<strong>of</strong>f forum for the<br />
annual meeting. A continental breakfast will be served.You will<br />
have an opportunity to meet and network with other health<br />
pr<strong>of</strong>essionals and the ARHP leadership. This session is not<br />
eligible for CME credit. The ARHP thanks Amgen, Inc. and Pfizer<br />
Inc for supporting the Networking Forum.<br />
ARHP Networking Forum<br />
8:00 AM<br />
Breakfast<br />
8:35 AM<br />
Membership Recruitment Award Presentation<br />
The ARHP Membership Recruitment Award is presented to<br />
one ARHP and one ACR member who have recruited the most<br />
members in the current year.<br />
Jeanne F. Boyle, BSN, University <strong>of</strong> New Mexico Medical Center,<br />
Albuquerque, New Mexico<br />
Arthur D. Bankhurst, MD, University <strong>of</strong> New Mexico Medical<br />
Center, Albuquerque, New Mexico<br />
ARHP Graduate Student Recognition Award Presentation<br />
The ARHP Graduate Student Recognition Award recognizes<br />
creative research or clinical project efforts that merge theory<br />
and clinical practice in assessing and/or improving the lives<br />
<strong>of</strong> patients with theumatic disease, broadly defined and<br />
encourages the interest <strong>of</strong> non-medical graduate student in the<br />
field <strong>of</strong> rheumatology.<br />
Shilpa Bhupathiraju, MS, Tufts University, Malden, MA<br />
Lisa R. Jewett, BA, McGill University & Jewish General Hospital,<br />
Montreal, QC, Canada<br />
8:45 am<br />
Presidental Welcome<br />
Linda S. Ehrlich-Jones, PhD, RN; Rehabilitation Institute <strong>of</strong><br />
Chicago; Chicago, IL<br />
8:50 am<br />
Program Overview<br />
Benjamin J. Smith, PA-C; McIntosh Clinic PC; Thomasville, GA<br />
2010 Program Book<br />
ACR Practice Issues<br />
8:30 - 10:00 am<br />
A311<br />
Transforming Rheumatologic Care with the Electronic<br />
Health Record BR C PS<br />
Moderator: Charles M. King, MD; Internal Medicine Associates;<br />
Belden, MS<br />
8:30 AM<br />
State <strong>of</strong> the Current HIT Landscape<br />
Stacey Empson, JD, MHA; Courtyard Group; Evanston, IL<br />
9:05 AM<br />
EHR 1.0: EHR in Your Office-Let’s Get Started (Breakout Session<br />
A)<br />
Salahuddin Kazi, MD; Dallas Veterans Affairs Medical Center;<br />
Dallas, TX<br />
Matthew W. Morgan, MD; Courtyard Group; Toronto, ON,<br />
Canada<br />
9:05 AM<br />
EHR 2.0: Making Health Technology Work for You - EHR Users<br />
Group (Breakout Session B)<br />
Christi J. Inman, MD; University<strong>of</strong> Utah; Salt Lake City, UT<br />
Session Overview:<br />
The successful adoption <strong>of</strong> health information technology/<br />
electronic health record systems will serve rheumatology<br />
practices by supporting efforts to reduce risk, improve<br />
coordination for care, improve adherence to recommended<br />
guidelines, and improve health outcomes for patients. But for<br />
many practices, successfully selecting and implementing an<br />
electronic health record system can be difficult. Often in small<br />
groups or solo practices the clinician or administrator has little<br />
technical knowledge and access to limited resources. They don’t<br />
have a proven process, the tools, or the experience for selecting<br />
an electronic health record system and for fully integrating the<br />
system into practice workflows. As a result, many practices<br />
struggle to realize the financial and operational benefits <strong>of</strong> an<br />
electronic health record. The cost <strong>of</strong> failure will be high in terms<br />
<strong>of</strong> dollars and morale.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the business cases for electronic health record systems<br />
that are relevant to rheumatology<br />
• describe the technology components that support improved<br />
quality and efficiency <strong>of</strong> care delivery in the rheumatology<br />
practice<br />
• articulate the effect <strong>of</strong> these technologies on improving<br />
patient care processes, enhancing clinical outcomes and<br />
promoting patient and practice safety<br />
ACR Immunology Updates for<br />
Clinicians<br />
9:00 - 10:00 am<br />
B406<br />
Innate Immunity and Inflammation c/r<br />
Moderator: Richard J. Looney, MD; University <strong>of</strong> Rochester;<br />
Rochester, NY<br />
Speaker: Harris R. Perlman, PhD; Northwestern University;<br />
Chicago, IL
Session Overview:<br />
The innate immune system can sense “danger” and induce<br />
inflammation and initiate tissue repair. Sensing danger in the<br />
setting <strong>of</strong> infection or tissue damage is important for normal<br />
host defenses and homeostasis. Moreover, in vaccine adjuvants<br />
can be used to boost immune responses by activating cells <strong>of</strong><br />
the innate immune system. However, there are clinical settings<br />
in which innate immunity goes awry triggering unnecessary<br />
inflammation, injury, and disease. Thus, the molecular<br />
mechanism leading from uric acid or calcium pyrophosphate<br />
crystals to gout or pseudogout are similar to those triggered by<br />
infection or tissue necrosis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the inflammasome, how it is activated and how it<br />
induces inflammation<br />
• discuss how crystals, such as urate, calcium pyrophosphate or<br />
even aluminum hydroxide, trigger activation <strong>of</strong> inflammation<br />
and why IL-1ra works for gout<br />
• explain the importance <strong>of</strong> innate immunity in resolution <strong>of</strong><br />
inflammation<br />
ACR Medical Aspects <strong>of</strong> Rheumatic<br />
Diseases<br />
9:00 - 10:00 am<br />
Hall A3<br />
Heparin and Antiphospholipid Syndrome-induced<br />
Thrombocytopenia cP ARS<br />
Moderator: Alexandra Villa-Forte, MD, MPH; Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
Speaker: John R. Bartholomew, MD; Cleveland Clinic; Cleveland,<br />
OH<br />
Session Overview:<br />
Heparin-induced thrombocytopenia and the antiphospholipid<br />
syndrome are disorders with distinct pathogenesis; however<br />
they share several clinical features, including thrombocytopenia<br />
and thrombotic events. Evaluation <strong>of</strong> patients with<br />
thrombocytopenia and thrombosis and distinguishing these two<br />
disorders require careful clinical assessment, as well as focused<br />
laboratory evaluation. An algorithmic approach to the evaluation<br />
and the differential diagnosis <strong>of</strong> patients with thrombocytopenia<br />
and thrombosis can be helpful to the rheumatologist.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the important elements <strong>of</strong> the clinical features and<br />
appropriate laboratory testing in the diagnosis <strong>of</strong> heparininduced<br />
thrombocytopenia and antiphospholipid syndrome<br />
• describe the clinical utility and limitations <strong>of</strong> auto-antibodies<br />
testing in the diagnosis <strong>of</strong> thrombocytopenia<br />
• discuss treatment options in heparin-induced<br />
thrombocytopenia<br />
Moderator: Kathleen M. O’Neil, MD; Oklahoma University<br />
Health Science Center; Oklahoma City, OK<br />
Speaker: Ann M. Reed, MD; Mayo Clinic; Rochester, MN<br />
Session Overview:<br />
Childhood-onset dermatomyositis shares many features with<br />
adult dermatomyositis, but there are also important differences.<br />
New insights into the pathophysiology <strong>of</strong> this disease include<br />
the roles played by matern<strong>of</strong>etal microchimerism, Treg and<br />
B lymphocytes in the inflammatory infiltrates, and new data<br />
from gene expression arrays, giving insights into this perplexing<br />
disease. Data from clinical trials including B cell depletion in<br />
juvenile dermatomyositis will be available in 2010; therefore,<br />
an update on current understanding <strong>of</strong> relevant pathogenic<br />
pathways in this disease is important.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the clinical spectrum <strong>of</strong> juvenile dermatomyositis and<br />
its multi-organ involvement<br />
• discuss the current knowledge <strong>of</strong> the pathophysiology <strong>of</strong><br />
juvenile dermatomyositis<br />
• assess the efficacy and safety <strong>of</strong> aggressive treatment<br />
modalities in juvenile dermatomyositis, and the role these<br />
therapies may play in treatment <strong>of</strong> patients with this disease<br />
Sidney J. Marcus Auditorium<br />
T cell Memory R<br />
Moderators: Keith B. Elkon, MD; University <strong>of</strong> Washington;<br />
Seattle, WA<br />
Michael Ehrenstein, PhD; University <strong>College</strong> London School <strong>of</strong><br />
Medicine; London, United Kingdom<br />
Speaker: Rafi Ahmed, PhD; Emory University School <strong>of</strong> Medicine;<br />
Atlanta, GA<br />
Session Overview:<br />
Most autoimmune disorders are driven by T cells. Memory<br />
T cells are expanded and presumably provide a reservoir for<br />
autoreactivity that persists even when biologic therapy is<br />
used to block acute inflammation. It is therefore necessary<br />
to understand how memory T cells are generated and what<br />
strategies may prove effective in selectively impairing their<br />
function in autoimmune diseases.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify differences between naive and memory T cells<br />
phenotype and function<br />
• determine how T memory cells are generated in virus<br />
infections<br />
• describe which cytokines and ligands influence the function <strong>of</strong><br />
memory T cells<br />
ACR Poster Session A and Poster<br />
Tours<br />
9:00 am - 6:00 pm<br />
monday<br />
ACR State-<strong>of</strong>-the-Art Lectures<br />
9:00 - 10:00 am<br />
Thomas J. Murphy Ballroom<br />
Juvenile Dermatomyositis in 2010 - From Bench to<br />
Bedside P PS<br />
Halls B1 & B2<br />
Poster presenters will be available from 9:00 - 11:00 AM. Poster<br />
tours will be held 9:00 - 9:45 AM, 10:15 - 11:00 AM and 4:30 -<br />
5:30 PM.<br />
2010 Program Book 31
monday<br />
9:00 - 11:00 AM – Poster Presentations (Abstracts # 1 – 619)<br />
Guided Poster Tours<br />
Guided poster tours provide an opportunity for scientific<br />
attendees to ask questions and gain insights from leaders in<br />
the field while earning CME credits. Morning tours will <strong>of</strong>fer<br />
insights from both poster presenters and tour guides, while<br />
afternoon tours will exclusively feature the tour guide’s expert<br />
opinion. Although there is no fee to participate, pre-registration<br />
is required and each tour is limited to 20 registered scientific<br />
attendees. If you would like to participate and have not<br />
registered you can check tour availability and request a ticket<br />
in the registration area, located in the International Boulevard<br />
Foyer. If you registered in advance <strong>of</strong> the meeting your ticket was<br />
included with your meeting materials. Once you have your ticket,<br />
plan to collect your headset and meet your group 10 minutes<br />
before your tour departs from the entrance <strong>of</strong> the poster hall,<br />
located in Halls B1 & B2.<br />
Headsets: Each tour participant will receive a wireless headset.<br />
Participants who do not return their headsets within 10 minutes<br />
after the tour has ended will incur a fee.<br />
9:00 - 9:45 AM<br />
Antiphospholipid Syndrome<br />
Projen Chen, PhD; University <strong>of</strong> California - Los Angeles School <strong>of</strong><br />
Medicine; Los Angeles, CA<br />
Osteoarthritis: Clinical Aspects<br />
Roy D. Altman, MD; University <strong>of</strong> California – Los Angeles, Los<br />
Angeles, CA<br />
Pediatric P<br />
(Attendance limited to Pediatric Resident Program recipients.)<br />
Rayfel Schneider, MBBCh; Hospital for Sick Children; Toronto,<br />
ON, Canada<br />
Rheumatoid Arthritis: Clinical Aspects<br />
Ernest Choy, MD; Kings <strong>College</strong> Hospital; London, United<br />
Kingdom<br />
Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects<br />
and Treatment<br />
Christopher Ritchlin, MD; University <strong>of</strong> Rochester Medical<br />
Center; Rochester, NY<br />
Systemic Lupus Erthymatosus: Clinical Aspects<br />
Elena Massarotti, MD; Brigham and Women’s Hospital; Boston,<br />
MA<br />
10:15 - 11:00 AM<br />
Fellows Only: How to Navigate the Poster Hall f<br />
Calvin R. Brown, MD; Northwestern University, Chicago, IL<br />
Osteoarthritis - Clinical Aspects<br />
Joanne M. Jordan, MD, MPH; University <strong>of</strong> North Carolina<br />
Thurston ARC, Chapel Hill, NC<br />
Rheumatoid Arthritis Human Etiology and Pathogenesis<br />
Gary S. Firestein, MD; University California-San Diego School <strong>of</strong><br />
Medicine; La Jolla, CA<br />
Rheumatoid Arthritis Treatment: Small Molecules, Biologics<br />
and Gene Therapy<br />
S. Louis Bridges, Jr., MD; University <strong>of</strong> Alabama-Birmingham;<br />
Birmingham, AL<br />
Rheumatoid Arthritis: Clinical Aspects<br />
Neal S. Birnbaum, MD; Pacific <strong>Rheumatology</strong> Association; San<br />
Francisco, CA<br />
Systemic Lupus Erythematosus: Clinical Aspects<br />
Rosalind Ramsey-Goldman, MD; Northwestern University<br />
Medical School; Chicago, IL<br />
4:30 - 5:30 PM<br />
Metabolic and Crystal Arthropathies<br />
N. Lawrence Edwards, MD; University <strong>of</strong> Florida; Gainesville, FL<br />
Orthopedics, Low Back Pain and Rehabilitation<br />
Jeffrey N. Katz, MD; Brigham and Women’s Hospital; Boston, MA<br />
Rheumatoid Arthritis: Clinical Aspects<br />
John J. Cush, MD; Baylor Research Institute; Dallas, TX<br />
Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects<br />
and Treatment<br />
Desiree M. Van Der Heijde, MD, PhD; Leiden University Medical<br />
Center; Meerssen, Netherlands<br />
Exhibits and Replay Café<br />
9:00 am - 5:00 pm<br />
Halls A1 & A2<br />
Exhibits<br />
Halls A1 & A2 (Booth #123)<br />
Replay Café<br />
Exhibit Hall Morning SnACk Break<br />
9:00 - 10:00 am<br />
Halls A1 & A2<br />
Poster Hall Morning SnACk Break<br />
9:00 - 10:30 am<br />
Halls B1 & B2<br />
ARHP General Session I – Keynote<br />
Address<br />
10:00 - 11:00 am<br />
B313<br />
The Real Doc Hollywood Presents...Laughter is Good<br />
Medicine c/r PS<br />
Moderator: Janet L. Poole, PhD, OTR; University <strong>of</strong> New Mexico;<br />
Albuquerque, NM<br />
Speaker: Neil Shulman, MD; Emory University School <strong>of</strong><br />
Medicine; Atlanta, GA<br />
Session Overview:<br />
Diverse literature suggests that humor has been reported to<br />
have positive effects on various outcomes such as stress, health<br />
and immune function. Use <strong>of</strong> humor can be easily implemented.<br />
This session will provide participants with how to use humor<br />
effectively in their practices to improve patient outcomes and<br />
communication.<br />
32<br />
2010 Program Book
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• promote awareness about the importance <strong>of</strong> humor in<br />
maintaining good health and combating stress<br />
• identify tools and practices which can provide humor in one’s<br />
life<br />
• demonstrate an attitude <strong>of</strong> creativity and fun in healthcare<br />
and in everyday settings<br />
InnoVAtion Theater<br />
10:00 - 10:45 am<br />
Halls A1 & A2 (Booth #555)<br />
The following non-CME activity has been planned and will be<br />
implemented in accordance with the requirements <strong>of</strong> the FDA<br />
and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />
with Healthcare Pr<strong>of</strong>essionals by Forest Pharmaceuticals.<br />
Please visit the Forest Pharmaceuticals exhibit booth for more<br />
information or see page 292. Seating and light refreshments are<br />
subject to availability.<br />
A Treatment Option for the Management <strong>of</strong><br />
Fibromyalgia<br />
ACR Workshops<br />
10:30 - 12:30 pm<br />
Admission to each Workshop requires a separate registration<br />
and ticket. To verify which session you registered for, check to<br />
make sure the registration code on your ticket matches the code<br />
listed below in parentheses.<br />
B201<br />
Designing a Web Site for Your Practice (205)<br />
Speaker: Peter J. Embi, MD, MS; University <strong>of</strong> Cincinnati;<br />
Cincinnati, OH<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the basics <strong>of</strong> creating Web sites on the internet<br />
• describe how to secure a Web address or domain name for a<br />
practice Web site<br />
• design a basic Web site using online or PC-based tools<br />
B204<br />
Osteoporosis: Interpreting Dual Energy X-ray<br />
Absorptiometry and Clinical Risk Factors: The New<br />
Fracture Risk Assessment Algorithm (206) PS<br />
Speaker: Stuart L. Silverman, MD; Cedars-Sinai Medical Center,<br />
University <strong>of</strong> California-Los Angeles; Beverly Hills, CA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• determine how to combine bone mineral density and clinical<br />
risk factors in determination <strong>of</strong> absolute risk<br />
• discuss the concept <strong>of</strong> intervention threshold used in National<br />
Osteoporosis Foundation guidelines<br />
• review International Society for Clinical Densitometry<br />
guidelines for DXA interpretation<br />
• create a report for bone densitometry results<br />
B206<br />
Peripheral Magnetic Resonance Imaging in<br />
<strong>Rheumatology</strong> Practice (207)<br />
Speakers: Philip G. Conaghan, MD, PhD; Chapel Allerton<br />
Hospital; Leeds, United Kingdom<br />
Mikkel Østergaard, MD, PhD, DMSc; Hvidovre University<br />
Hospital; Hvidovre, Denmark<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the logistics <strong>of</strong> implementation <strong>of</strong> peripheral MRI in<br />
the outpatient setting<br />
• review the merits and pitfalls <strong>of</strong> this technology<br />
B202<br />
Renal Histopathology in Systemic Lupus<br />
Erythematosus and Vasculitis (208)<br />
Speaker: Megan Troxell, MD; Oregon Health & Science<br />
University; Portland, OR<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the pathologic changes that occur in lupus nephritis<br />
• discuss the pathologic basis for the classification <strong>of</strong> lupus<br />
nephritis and how it relates to clinical management<br />
• describe the histological changes in the kidneys <strong>of</strong> patients<br />
with vasculitis<br />
ACR Plenary Session I: Discovery 2010<br />
c/r<br />
11:00 am - 12:30 pm<br />
Hall A3<br />
Moderators: Stanley B. Cohen, MD; <strong>Rheumatology</strong> Associates;<br />
Dallas, TX<br />
E. William St.Clair, MD; Duke University Medical Center; Durham,<br />
NC<br />
11:00 AM<br />
ACR REF Industry Roundtable Awards<br />
11:10 AM<br />
ACR Abstract Presentations Introduction<br />
11:15 AM<br />
620. Platelet C4d Is Associated with All-Cause Mortality in<br />
Patients with Systemic Lupus Erythematosus.<br />
Christine A. McBurney 5 , Amy H. Kao 2 , Abdus Sattar 3 , Apinya<br />
Lertratanakul 6 , Nicole L. Wilson 4 , Rutman Sarah 6 , Barbara Paul 6 ,<br />
Jeannine S. Navratil 6 , Joseph M. Ahearn 1 and Susan Manzi 7 ,<br />
1<br />
Wexford, PA, 2 Allegheny Singer Research Institute, Pittsburgh,<br />
PA, 3 Case Western University, 4 Magee Womens Hospital <strong>of</strong><br />
UPMC, Pittsburgh, PA, 5 University <strong>of</strong> Pittsburgh Medical Center,<br />
Pittsburgh, PA, 6 University <strong>of</strong> Pittsburgh School <strong>of</strong> the Health<br />
Sciences, 7 West Penn Allegheny Health System, Pittsburgh, PA<br />
11:30 AM<br />
621. β2-Glycoprotein Exists in a Distinct Molecular Post-<br />
Translational Oxidative State in the Antiphospholipid<br />
Syndrome: Novel Prognostic Assays and Insights into<br />
Antigenicity.<br />
Yiannis Ioannou 10 , Jing-Yun Zhang 8 , Miao Qi 11 , Gao Lu 12 , Jian<br />
Cheng Qi 11 , De-min Yu 7 , Herman Lau 6 , Allan D. Sturgess 5 ,<br />
Panayiotis Vlachoyiannopoulos 4 , Haralampos M. Moutsopoulos 3 ,<br />
monday<br />
2010 Program Book 33
monday<br />
Anisur Rahman 9 , Pericleous Charis 9 , Tatsuya Atsumi 1 , Takao<br />
Koike 2 , Bill Giannakopoulos 11 and Krilis A. Steven 11 , 1 Hokkaido<br />
University, Sapporo, Japan, 2 Hokkaido University, Japan, 3 Natl<br />
Univ <strong>of</strong> Athens Med Schl, Athens, Greece, 4 Natl Univ <strong>of</strong> Athens<br />
Med Schl, 5 St. George Hospital, Sydney, NSW, Australia, 6 St.<br />
George Hospital, 7 Tianjin Medical University, 8 Tianjin Medical<br />
University, University <strong>of</strong> New South Wales, 9 University <strong>College</strong><br />
London, 10 University <strong>College</strong> London, University <strong>of</strong> New South<br />
Wales, 11 University <strong>of</strong> New South Wales, 12University <strong>of</strong> New<br />
South Wales, Tianjin Medical University<br />
11:45 AM<br />
622. Normal Monocyte and Fibrocyte Behavior in Scleroderma<br />
Is Restored by Caveolin-1 Scaffolding Domain (CSD) Peptide:<br />
Implications for Treating Scleroderma Lung Disease.<br />
Elena Tourkina, James Oates, Ann H<strong>of</strong>bauer, Michael Bonner,<br />
Richard P. Visconti, Jing Zhang, Richard M. Silver and Stanley<br />
H<strong>of</strong>fman, Medical University <strong>of</strong> SC<br />
12:00 PM<br />
623. Clinical, Radiographic and Biomolecular Features <strong>of</strong> B Cell<br />
Synovitis in Rheumatoid Arthritis.<br />
Serena Bugatti 2 , Antonio Manzo 2 , Barbara Vitolo 2 , Chiara Fusetti 2 ,<br />
Roberto Caporali 2 , Costantino Pitzalis 1 and Carlomaurizio<br />
Montecucco 2 , 1 Centre for Experimental Medicine and<br />
<strong>Rheumatology</strong>, John Vane Science Centre, William Harvey<br />
Research Institute, St. Bartholomew’s and Royal London School<br />
<strong>of</strong> Medicine, London, 2 Chair and Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Laboratory <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Pavia, Fondazione<br />
IRCCS Policlinico San Matteo, Pavia, Italy<br />
12:15 PM<br />
624. Association <strong>of</strong> FRZB Variants with Hip Shape and<br />
Radiographic Hip Osteoarthritis: Preliminary Results.<br />
Julie Baker-LePain 4 , Kali Luker 2 , John A. Lynch 4 , Neeta Parimi 1 ,<br />
Michael C. Nevitt 3 , Mary Corr 6 and Nancy E. Lane 5 , 1 California<br />
Pacific Medical Center, 2 Stanford, 3 UCSF, San Francisco, CA,<br />
4<br />
UCSF, 5 Univ <strong>of</strong> California at Davis, Hillsborough, CA, 6 Univ <strong>of</strong><br />
California-San Diego, La Jolla, CA<br />
ARHP Concurrent Abstract Session<br />
11:15 am - 12:15 pm<br />
B311<br />
Issues in Lupus<br />
Moderator: Patricia J. Cornell, BSc; Poole Hospital; Poole Dorset,<br />
United Kingdom<br />
11:15 AM<br />
625. The Assessment <strong>of</strong> Health-Related Family Functioning in<br />
Systemic Lupus Erythematosus: Preliminary Validation <strong>of</strong> the<br />
SLE-FAMILY.<br />
Afton L. Hassett 6 , Tracy Li 1 , Diane C. Radvanski 3 , Steven Buyske 2 ,<br />
Samuel A. Schiff 4 and Patricia P. Katz 5 , 1Bristol-Myers Squibb,<br />
Princeton, NJ, 2 Rutgers University, 3 UMDNJ-Robert Wood<br />
Johnson Medical School, Union City, NJ, 4 UMDNJ-Robert<br />
Wood Johnson Medical School, 5 Univ <strong>of</strong> CA San Francisco, San<br />
Francisco, CA, 6 University <strong>of</strong> Michigan Medical School, Ann<br />
Arbor, MI<br />
11:30 AM<br />
626. Heart-Rate Recovery Immediately after Graded Exercise in<br />
Woman with Systemic Lupus Erythematosus.<br />
Danilo M. L. Prado 1 , Fabio Baptista 1 , Renata Miossi 1 , Fernanda R.<br />
Lima 1 , Ana Lucia S. Pinto 1 , Eduardo F. Borba 3 and Eloisa Bonfa2,<br />
1<br />
USP, Sao Paulo, SP, Brazil, 2 USP, Sao Paulo, Brazil, 3 USP<br />
11:45 AM<br />
627. Body Composition, Lower Extremity Strength, and Fatigue<br />
in SLE.<br />
Patricia Katz, Laura Julian, Jinoos Yazdany, Holly Wing, Sandi<br />
Kaplan, Laura Trupin and Ed Yelin, UCSF<br />
12:00 PM<br />
628. Physical Exercise Improves Endothelial Function in<br />
Patients with Systemic Lupus Erythematosus.<br />
Edgard T. Reis Neto, Aline E. Silva, Carlos M. C. Monteiro, Luciano<br />
M. Camargo, Neusa P. Silva, Marcelo M. Pinheiro and Emilia I.<br />
Sato, Universidade Federal de São Paulo, Brazil<br />
ARHP Concurrent Sessions<br />
11:15 am - 12:15 pm<br />
B309<br />
Evidence-based Non-pharmacological Treatment for<br />
Hip, Knee, and Hand Osteoarthritis: The New ACR<br />
Guidelines c/r PS PM<br />
Moderator: Marc C. Hochberg, MD, MPH; University <strong>of</strong><br />
Maryland; Baltimore, MD<br />
Speakers: Catherine L. Backman, PhD, OT(C); University <strong>of</strong> British<br />
Columbia; Vancouver, BC, Canada<br />
G. Kelley Fitzgerald, PhD, PT; University <strong>of</strong> Pittsburgh; Pittsburgh,<br />
PA<br />
Carol A. Oatis, PT, PhD; Arcadia University; Glenside, PA<br />
Marc C. Hochberg, MD, MPH; University <strong>of</strong> Maryland; Baltimore,<br />
MD<br />
Session Overview:<br />
Osteoarthritis is the primary cause <strong>of</strong> physical disability in<br />
adults and is a diagnosis commonly seen by physical therapists.<br />
It is critical that physical and occupational therapists use the<br />
best available evidence when choosing treatment strategies<br />
for osteoarthritis <strong>of</strong> the hip, knee and hand. The new ACR<br />
treatment guidelines, Recommendations for Non-pharmacologic<br />
and Pharmacologic Therapies in Hand, Hip and Knee<br />
Osteoarthritis,derived from a critical review <strong>of</strong> available research<br />
and consensus <strong>of</strong> a panel <strong>of</strong> experts from medicine, surgery<br />
and rehabilitation, provide a powerful framework within which<br />
therapists can choose an appropriate treatment regimen.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the review process used to evaluate the research<br />
evidence for non-pharmacological management <strong>of</strong><br />
osteoarthritis <strong>of</strong> the hip, knee and hand<br />
• identify which treatments have sufficient evidence <strong>of</strong> efficacy<br />
in osteoarthritis treatment to recommend their use in<br />
rehabilitation; which require additional research to determine<br />
their efficacy in treating osteoarthritis; and which have<br />
evidence <strong>of</strong> limited or no efficacy in treating osteoarthritis <strong>of</strong><br />
the hip, knee and hand<br />
34<br />
2010 Program Book
B308<br />
Inflammatory Eye Disease P/C<br />
Moderator: Sandra J. Watcher, BSN; Children’s Hospital <strong>of</strong> Los<br />
Angeles; Los Angeles, CA<br />
Speakers: Andreas O. Reiff, MD; Children’s Hospital <strong>of</strong> Los<br />
Angeles; Los Angeles, CA<br />
Sukesh Sukumaran, MBBS, MD, DPMR; Children’s Hospital <strong>of</strong> Los<br />
Angeles; Los Angeles, CA<br />
Session Overview:<br />
Uveitis is the third leading cause <strong>of</strong> preventable, irreversible<br />
blindness in the developed world. Frequently, localized therapy<br />
is not sufficient to treat these complicated inflammatory<br />
processes. With the availability <strong>of</strong> chemotherapy and biologic<br />
treatments for these conditions, ophthalmologists are<br />
increasingly consulting with rheumatologists for input on<br />
systemic therapy and management. Therefore the rheumatology<br />
community must become familiar with the etiology and effects<br />
<strong>of</strong> treatment in inflammatory eye diseases.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• use a case study model to analyze and apply uveitis principles<br />
in the clinical context<br />
• review the etiology and common subtypes <strong>of</strong> uveitis<br />
• define the role <strong>of</strong> the rheumatologist in the uveitis treatment<br />
team<br />
• review the traditional pharmacologic treatment<br />
recommendations for uveitis and compare them to advanced<br />
treatments with biologics<br />
B310<br />
Physical Activity: The Arthritis Pain Reliever – The<br />
Revised Centers for Disease Control and Prevention<br />
Health Communications Campaign c/r PM PS<br />
Moderator: Gail C. Davis, RN, EdD; Texas Woman’s University;<br />
Denton, TX<br />
Speaker: Teresa J. Brady, PhD; Center for Disease Control;<br />
Atlanta, GA<br />
Session Overview:<br />
Enticing people with arthritis to increase their physical activity<br />
is a priority for both clinicians and public health practitioners.<br />
However, our collective efforts have been marginally effective<br />
as 44 percent <strong>of</strong> people with arthritis report no leisure time<br />
activity. Describing the required activity levels in concrete<br />
understandable terms, addressing the unique concerns <strong>of</strong><br />
people with arthritis, and highlighting the most desired potential<br />
benefits <strong>of</strong> physical activity can all help address this gap. In 2010<br />
the Centers for Disease Control and Prevention Arthritis Program<br />
released a revised version <strong>of</strong> the health communications<br />
campaign Physical Activity, The Arthritis Pain Reliever. The<br />
campaign was based on research findings related to physical<br />
activity attitudes, perceptions, and preferences among people<br />
with arthritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe key learnings derived from qualitative audience<br />
research about physical activity conducted among people with<br />
arthritis<br />
• discuss how these key learnings can be utilized in clinical<br />
practice<br />
• identify key elements <strong>of</strong> the revised Physical Activity: The<br />
Arthritis Pain Reliever health communications campaign<br />
• develop individual physical activity-related counseling and<br />
instruction plans<br />
InnoVAtion Theater<br />
12:15 - 1:00 pm<br />
Halls A1 & A2 (Booth #555)<br />
The following non-CME activity has been planned and will be<br />
implemented in accordance with the requirements <strong>of</strong> the FDA<br />
and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />
with Healthcare Pr<strong>of</strong>essionals by Centocor Ortho Biotech Inc.<br />
Please visit the Centocor Ortho Biotech Inc. exhibit booth for<br />
more information or see page 292. Seating and boxed lunches<br />
are subject to availability.<br />
Choices and Challenges in Managing Psoriatic<br />
Arthritis<br />
ARHP Special Sessions<br />
12:30 - 1:30 pm<br />
The ARHP is <strong>of</strong>fering informal networking opportunities for<br />
rheumatology health pr<strong>of</strong>essional disciplines and students. These<br />
networking opportunities, led by facilitators, will allow open<br />
discussion and interaction with fellow attendees. Bring your<br />
lunch and join a group.<br />
These sessions are not eligible for CME credit.<br />
B310<br />
ARHP Networking for Georgia Health Pr<strong>of</strong>essionals<br />
and Physicians<br />
Facilitator: Joyce P. Carlone, MN, RN, FNP-BC; Emory University;<br />
Atlanta, GA<br />
B309<br />
ARHP Pediatrics Networking<br />
Facilitator: Karla B. Jones, MS, RN, CPNP; Nationwide Children’s<br />
Hospital; Columbus, OH<br />
B311<br />
ARHP Research Coordinators Networking<br />
Facilitators: Donah Z. Crawford, BS, MA; The Arthritis Group;<br />
Philadelphia, PA<br />
Lisa M. Kastanek, RN, CCRC; Physician Research Collaboration;<br />
Lincoln, NE<br />
ACR Meet the Pr<strong>of</strong>essor Sessions<br />
12:45 - 2:15 pm<br />
Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />
separate registration and ticket. To verify which session you<br />
registered for, check to make sure the registration code on your<br />
ticket matches the code listed below in parentheses.<br />
B207<br />
Adult Inflammatory Myopathy (011)<br />
Speaker: Mary E. Cronin, MD; Medical <strong>College</strong> <strong>of</strong> Wisconsin;<br />
Milwaukee, WI<br />
2010 Program Book 35<br />
monday
monday<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review the clinical manifestations <strong>of</strong> inflammatory myopathies<br />
including important extra-muscle manifestations<br />
• discuss diagnostic pearls for the evaluation <strong>of</strong> someone<br />
suspected <strong>of</strong> having an inflammatory myopathy<br />
• discuss the treatment paradigm for inflammatory myopathies<br />
B208<br />
Ankylosing Spondylitis: 2010 Update (012) PS<br />
Speaker: Desiree M. Van Der Heijde, MD, PhD; Leiden University<br />
Medical Center; Meerssen, Netherlands<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the natural history <strong>of</strong> ankylosing spondylitis and its<br />
early diagnosis<br />
• describe clinical and radiographic outcome measures used in<br />
ankylosing spondylitis trials<br />
• summarize available guidelines in the management <strong>of</strong><br />
ankylosing spondylitis<br />
• review the scientific data on biologic agents as possible<br />
disease modifying agents in the treatment <strong>of</strong> ankylosing<br />
spondylitis<br />
B209<br />
Cutaneous Vasculitis (013)<br />
Speaker: Nicole Fett, MD; Perelman Center for Advanced<br />
Medicine; Philadelphia, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• distinguish the clinical features <strong>of</strong> small and medium-sized<br />
vasculitides that involve the skin<br />
• gain insight into the pathological features <strong>of</strong> cutaneous<br />
vasculitis, which lead directly to clinical disease observable on<br />
the skin<br />
• identify vasculitis mimickers with cutaneous involvement<br />
• develop a rational approach to the evaluation and<br />
management <strong>of</strong> cutaneous vasculitis<br />
B301<br />
Osteoporosis: Novel Treatments (014) PS<br />
Speaker: Michael J. Maricic, MD; Catalina Pointe <strong>Rheumatology</strong>;<br />
Tucson, AZ<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review bone physiology and immunology emphasizing<br />
potential areas amenable to intervention<br />
• discuss current therapies for osteoporosis and their limitations<br />
• identify newer treatments available and therapies just over<br />
the horizon for osteoporosis<br />
B302<br />
Pain: Evaluation and Treatment <strong>of</strong> Back Pain (015) PM<br />
Speaker: David G. Borenstein, MD; Arthritis & Rheumatism<br />
Association; Washington, DC<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• determine the appropriate use <strong>of</strong> diagnostic tests in the<br />
evaluation <strong>of</strong> low back pain<br />
• review effective therapies for low back pain<br />
• identify the types <strong>of</strong> exercises that prevent and treat low back<br />
pain<br />
B303<br />
Pediatrics: Juvenile Idiopathic Arthritis for Adult<br />
Rheumatologists (016) P<br />
Speaker: AnneMarie C. Brescia, MD; DuPont Hospital for<br />
Children; Wilmington, DE<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review the International League <strong>of</strong> Associations for<br />
<strong>Rheumatology</strong> classification for juvenile rheumatoid arthritis/<br />
juvenile idiopathic arthritis<br />
• discuss current therapeutic strategies for juvenile rheumatoid<br />
arthritis/juvenile idiopathic arthritis<br />
• describe the role <strong>of</strong> interleukin-1 in the pathogenesis<br />
<strong>of</strong> systemic onset juvenile rheumatoid arthritis/juvenile<br />
idiopathic arthritis<br />
B304<br />
Pregnancy in Rheumatic Diseases (017)<br />
Speaker: Megan E.B. Clowse, MD, MPH; Duke University Medical<br />
Center; Durham, NC<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the effects <strong>of</strong> pregnancy on the activity <strong>of</strong> rheumatic<br />
diseases<br />
• describe the challenging management issues unique to<br />
pregnancy<br />
B305<br />
Rheumatoid Arthritis: Early Rheumatoid Arthritis<br />
(018) PS<br />
Speaker: Johanna Hazes, MD, PhD; Erasmus Medical Centre<br />
Rotterdam; Rotterdam, Netherlands<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the clinical syndrome <strong>of</strong> rheumatoid arthritis early in<br />
its course<br />
• determine which modalities are <strong>of</strong> use in diagnosis and<br />
determining prognosis<br />
• evaluate which therapeutic regimens yield the best long-term<br />
outcomes<br />
B210<br />
Systemic Lupus Erythematosus: Difficult to Treat<br />
Systemic Lupus Erythematosus (019) P<br />
Speaker: Elena M. Massarotti, MD; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• utilize laboratory testing in the management <strong>of</strong> patients with<br />
systemic lupus erythematosus<br />
• determine the most relevant and beneficial therapeutic<br />
approach<br />
• identify appropriate assessment tools for use in management<br />
and prognosis<br />
B306<br />
Vitamin D and Bone Health (020)<br />
Speaker: Karen E. Hansen, MD; University <strong>of</strong> Wisconsin;<br />
Madison, WI<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the metabolic consequences <strong>of</strong> vitamin D deficiency<br />
36<br />
2010 Program Book
and insufficiency<br />
• recall sources <strong>of</strong> controversy regarding the optimal vitamin D<br />
level for bone health<br />
• recall vitamin D assay variability and the challenges this<br />
provides in diagnosing deficiency<br />
• prescribe standard and alternative treatments for vitamin D<br />
deficiency<br />
ACR Clinical Symposium<br />
1:00 - 2:00 pm<br />
Thomas J. Murphy Ballroom<br />
Clinical Review: Immunizations and Rheumatic<br />
Diseases - An Update c/r cP PS<br />
Moderators: Zsuzsanna H. McMahan, MD; Johns Hopkins<br />
University; Baltimore, MD<br />
Arthur Kavanaugh, MD; University <strong>of</strong> California-San Diego; La<br />
Jolla, CA<br />
Speaker: Clifton O. Bingham, MD; Johns Hopkins University;<br />
Baltimore, MD<br />
Session Overview:<br />
This review is designed to provide an update on safety and<br />
efficacy issues as they relate to the immunization <strong>of</strong> patients<br />
with rheumatic disease. The diversity <strong>of</strong> the available<br />
treatments for rheumatic disease, as well as the increase in<br />
the recommended immunizations for adults, makes it critical<br />
to provide regular updates for clinicians. Rheumatologists are<br />
frequently required to render an opinion about the safety and<br />
efficacy <strong>of</strong> immunizations for their patients. The goals <strong>of</strong> this<br />
clinical review are to provide clinicians with updates on the<br />
effects <strong>of</strong> rheumatic drugs/biologics on vaccinations; evidence<br />
for efficacy <strong>of</strong> immunizations in rheumatic diseases; and safety<br />
<strong>of</strong> immunizations for patients with rheumatic diseases.<br />
in the physiological regulation <strong>of</strong> endogenous glucocorticoids<br />
and in understanding the cellular and molecular mechanisms <strong>of</strong><br />
glucocorticoid action.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the physiological mechanisms <strong>of</strong> glucocorticoid<br />
regulation<br />
• explain cellular and molecular mechanisms <strong>of</strong> glucocorticoid<br />
action<br />
• identify pharmacological approaches for optimizing the clinical<br />
efficacy <strong>of</strong> glucocorticoids in reducing potential adverse side<br />
effects in inflammatory and musculoskeletal conditions<br />
B406<br />
Genetic Disorders <strong>of</strong> Connective Tissue and Joint<br />
Hypermobility R<br />
Moderator: Rodney Grahame, MD; University <strong>College</strong> Hospital;<br />
London, United Kingdom<br />
Speaker: Peter H. Byers, MD; University <strong>of</strong> Washington; Seattle,<br />
WA<br />
Session Overview:<br />
Genetic alterations in connective tissue matrix proteins result<br />
in a number <strong>of</strong> conditions seen by both pediatric and adult<br />
rheumatologists. These conditions include Marfan’s and<br />
various types <strong>of</strong> Ehler-Danlo’s syndrome that result in joint<br />
hypermobility and contribute to the development <strong>of</strong> arthritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• define the common genetic disorders in connective tissue<br />
proteins<br />
• describe the contribution <strong>of</strong> genetic disorders in connective<br />
tissue proteins to joint disorders<br />
• analyze how mutations in connective tissue proteins can result<br />
in joint hypermobility<br />
monday<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the efficacy and safety issues related to immunizations<br />
in adults with rheumatic diseases<br />
• examine the impact <strong>of</strong> specific rheumatic treatments on the<br />
efficacy <strong>of</strong> vaccinations<br />
• review the latest recommendations and guidelines for the<br />
immunization <strong>of</strong> adults<br />
ACR State-<strong>of</strong>-the-Art Lectures<br />
1:00 - 2:00 pm<br />
B313<br />
2010 Hench Lecture: Glucocorticoids-Physiologic<br />
Regulation, Mechanisms <strong>of</strong> Action and Optimizing<br />
Therapeutic Applications c/r<br />
Moderator: Steven R. Goldring, MD; Hospital for Special Surgery;<br />
New York, NY<br />
Speaker: George P. Chrousos, MD; Athens University<br />
Medical School; Patras, Greece<br />
Session Overview:<br />
Glucocorticoids have diverse and complex effects on the<br />
function and activity <strong>of</strong> multiple cells types and tissues. There<br />
have been major advances in dissecting mechanisms involved<br />
ACR REF Special Session<br />
1:00 - 2:00 pm<br />
A311<br />
ACR REF Memorial Lectureship: <strong>Rheumatology</strong><br />
Education 2010 Ed.<br />
The 2010 REF Memorial Lectureship is in honor <strong>of</strong> Walter Barr,<br />
MD.<br />
Moderator: David I. Daikh, MD, PhD; University <strong>of</strong> California, San<br />
Francisco, Veterans Affairs Medical Center; San Francisco, CA<br />
Speaker: Dennis W. Boulware, MD; Kaiser Permanente<br />
Medical Center; Honolulu, HI<br />
Session Overview:<br />
Many rheumatologists are currently unaware <strong>of</strong> the impact <strong>of</strong><br />
the Residency Review Committee on the field <strong>of</strong> rheumatology<br />
and how recent changes in the program requirements<br />
for rheumatology are impacting the new generation <strong>of</strong><br />
rheumatologists. This session will increase the awareness <strong>of</strong><br />
the issues relevant to rheumatology currently being addressed<br />
by the Residency Review Committee, the importance <strong>of</strong><br />
competency-based education and issues that the Accreditation<br />
Council for Graduate Medical Education is addressing for all<br />
graduate medical education.<br />
2010 Program Book 37
monday<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the crucial issues that are being addressed by the<br />
Accreditation Council for Graduate Medical Education in 2010<br />
• discuss the recent changes in the program requirements by<br />
the Residency Review Committee for rheumatology<br />
• explain the important issues related to competency based<br />
education in rheumatology<br />
ACR/ARHP Workshops<br />
1:15 - 3:15 pm<br />
Admission to each Workshop requires a separate registration<br />
and ticket. To verify which session you registered for, check to<br />
make sure the registration code on your ticket matches the code<br />
listed below in parentheses.<br />
B203<br />
Adult Musculoskeletal Upper/Lower Examinations<br />
(209)<br />
Speaker: Arthur M. Mandelin, MD, PhD; Northwestern<br />
University; Chicago, IL<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss principles <strong>of</strong> adult musculoskeletal physical<br />
examination<br />
• detect and describe normal and abnormal adult<br />
musculoskeletal physical examination findings<br />
• demonstrate rheumatologic upper and lower musculoskeletal<br />
examinations for adult patients using patient volunteers<br />
B201<br />
Histopathology <strong>of</strong> Vasculitis (210)<br />
Speakers: Allen Burke, MD; University <strong>of</strong> Maryland Medical<br />
Center; Baltimore, MD<br />
Fabio Tavora, MD; <strong>American</strong> International Pathology<br />
Laboratories; Silver Spring, MD<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe histological features <strong>of</strong> normal blood vessels<br />
• distinguish pathologic reactions to vascular injury<br />
• identify histological features <strong>of</strong> major vasculitis syndromes<br />
B206<br />
Peripheral Magnetic Resonance Imaging in Clinical<br />
<strong>Rheumatology</strong> (211)<br />
Speakers: Ewa Olech, MD; Oklahoma Medical Research<br />
Foundation; Oklahoma City, OK<br />
Orrin M. Troum, MD; University <strong>of</strong> Southern California; Santa<br />
Monica, CA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the logistics <strong>of</strong> implementation <strong>of</strong> peripheral MRI in<br />
the outpatient setting<br />
• review the merits and pitfalls <strong>of</strong> this technology<br />
B204<br />
<strong>Rheumatology</strong> Physical Examination <strong>of</strong> Lower<br />
Extremity and Lumbosacral Spine: Anatomical<br />
Correlates (212) f<br />
Speakers: Robert A. Kalish, MD; Tufts Medical Center; Boston,<br />
MA<br />
Pablo Villasenor Ovies, MD; Instituto Nacional de Ciencias<br />
Medicas y Nutricion; Tlalpan, Mexico<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review clinical and surface anatomy important to the<br />
rheumatologist<br />
• describe human anatomy to clinical syndromes seen in the<br />
practice <strong>of</strong> rheumatology<br />
• integrate these physical examination skills into a<br />
rheumatology practice<br />
Exhibit Hall Afternoon SnACk<br />
Break<br />
2:00 - 3:00 pm<br />
Halls A1 & A2<br />
InnoVAtion Theater<br />
2:00 - 2:45 pm<br />
Halls A1 & A2 (Booth #555)<br />
The following non-CME activity has been planned and will be<br />
implemented in accordance with the requirements <strong>of</strong> the FDA<br />
and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />
with Healthcare Pr<strong>of</strong>essionals by Centocor Ortho Biotech Inc.<br />
Please visit the Centocor Ortho Biotech Inc. exhibit booth<br />
for more information or see page 292. Seating and light<br />
refreshments are subject to availability.<br />
New Way RA – Empowering Your Patients to Live<br />
Well with RA<br />
ACR Basic Science Symposium<br />
2:30 - 4:00 pm<br />
B406<br />
Toll-like Receptors and Inflammation: Towards<br />
Innovative Treatment <strong>of</strong> Rheumatoid Arthritis R<br />
Moderators: Paul P. Tak, MD, PhD; Academic Medical Center,<br />
University <strong>of</strong> Amsterdam; Amsterdam, Netherlands<br />
Timothy R.D.J. Radstake, MD, PhD; Radboud University Nijmegen<br />
Medical Centre; Nijmegen, Netherlands<br />
2:30 pm<br />
The Role <strong>of</strong> Toll-like Receptors in Rheumatoid Arthritis:<br />
Macrophages<br />
Richard M. Pope, MD; Northwestern University Medical School;<br />
Chicago, IL<br />
3:00 pm<br />
The Role <strong>of</strong> Toll-like Receptors in Rheumatoid Arthritis:<br />
Fibroblast-like Synoviocyte<br />
Diego Kyburz, MD; Center <strong>of</strong> Experimental <strong>Rheumatology</strong>;<br />
Zurich, Switzerland<br />
3:30 pm<br />
Therapeutic Targeting <strong>of</strong> Toll-like Receptors for Inflammatory<br />
Diseases<br />
Luke A. O’Neill, PhD; Trinity <strong>College</strong> Dublin; Dublin, Ireland<br />
38<br />
2010 Program Book
Session Overview:<br />
The advent <strong>of</strong> biological therapies has dramatically improved the<br />
treatment <strong>of</strong> rheumatoid arthritis, providing pro<strong>of</strong> <strong>of</strong> principle<br />
that targeted interventions may be effective. Still, not all<br />
patients respond and there is a need to develop new therapies.<br />
This symposium will address the role <strong>of</strong> toll-like receptors in the<br />
pathogenesis <strong>of</strong> rheumatoid arthritis as well as their potential<br />
as a new therapeutic target for the treatment <strong>of</strong> inflammatory<br />
disease.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• appraise the role <strong>of</strong> toll-like receptors in two key effector<br />
cells involved in the pathogenesis <strong>of</strong> rheumatoid arthritis -<br />
macrophages and fibroblast-like synoviocytes<br />
• identify the toll-like receptors as a new therapeutic target in a<br />
variety <strong>of</strong> immune-mediated inflammatory disorders<br />
ACR Clinical Symposia<br />
2:30 - 4:00 pm<br />
Thomas J. Murphy Ballroom<br />
Mouse to House: Lessons Learned About Lupus<br />
Therapeutics P PS<br />
Moderator: Richard A. Furie, MD; North Shore Long Island<br />
Jewish Health System; Lake Success, NY<br />
2:30 pm<br />
Protective and Pathogenic Functions for B Cells During Systemic<br />
Autoimmunity in Mice<br />
Thomas Tedder, PhD; Duke University Medical Center; Durham,<br />
NC<br />
2:55 pm<br />
Do Biologic Responses to Therapeutic Interventions in Mice<br />
Predict Results in Human Lupus?<br />
Anne Davidson, MB, BS; Feinstein Institute for Medical Research;<br />
Manhasset, NY<br />
Hall A3<br />
The Great Debate: Is it Time to Use Biologics as Firstline<br />
Therapy in Rheumatoid Arthritis? cP PS ARS<br />
Moderator: Eric M. Ruderman, MD; Northwestern University<br />
School; Chicago, IL<br />
2:30 pm<br />
Resolved: Aggressive Use <strong>of</strong> Non-biologic DMARDs is as<br />
Effective as Biologics in the Management <strong>of</strong> Rheumatoid<br />
Arthritis (Con)<br />
Daniel E. Furst, MD; University <strong>of</strong> California-Los Angeles School<br />
<strong>of</strong> Medicine; Los Angeles, CA<br />
3:15 pm<br />
Resolved: Aggressive Use <strong>of</strong> Non-biologic DMARDs is as<br />
Effective as Biologics in the Management <strong>of</strong> Rheumatoid<br />
Arthritis (Pro)<br />
Marc D. Cohen, MD; National Jewish Medical and Research<br />
Center; Denver, CO<br />
Session Overview:<br />
Biologic therapy has unquestionably altered the landscape <strong>of</strong><br />
treatment for rheumatoid arthritis, and some have even begun<br />
to suggest that it is time for these agents to supplant nonbiologic<br />
therapy as first-line therapy. Addressing this question<br />
involves complicated and intertwining issues <strong>of</strong> efficacy,<br />
toxicity and cost. The presenters <strong>of</strong> this session will debate<br />
whether biologic therapy should be the initial therapy for the<br />
management <strong>of</strong> rheumatoid arthritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the data supporting first-line use <strong>of</strong> biologic therapy<br />
in rheumatoid arthritis<br />
• identify the limitations <strong>of</strong> biologic therapies that make their<br />
use as first-line therapy inadvisable<br />
• identify gaps in data that will need to be filled in order to<br />
resolve question <strong>of</strong> biologic use as first-line therapy<br />
monday<br />
3:30 pm<br />
Lessons Learned from Clinical Trials in Human Systemic Lupus<br />
Erythematosus<br />
Bevra H. Hahn, MD; University <strong>of</strong> California-Los Angeles School<br />
<strong>of</strong> Medicine; Los Angeles, CA<br />
Session Overview:<br />
Significant advances in our knowledge <strong>of</strong> immune system<br />
disturbances in lupus have been made over the last several<br />
decades. However, understanding the science has not yet<br />
translated into a new drug for this potentially devastating illness.<br />
Addressing mouse models and human studies, this symposium<br />
will relate pathogenetic concepts to strategies for therapeutic<br />
interventions.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss animal models <strong>of</strong> lupus and how they have advanced<br />
the development <strong>of</strong> therapeutics for human disease<br />
• describe humoral and cellular effects <strong>of</strong> therapeutic<br />
interventions in patients with lupus<br />
• summarize clinical trial data and reconcile the variability <strong>of</strong><br />
observed responses<br />
ACR Concurrent Abstract Sessions<br />
2:30 - 4:00 pm<br />
A402<br />
Biology and Pathology <strong>of</strong> Bone and Joint: Molecular<br />
Basis <strong>of</strong> Osteoarthritis<br />
Moderators: Tariq M. Haqqi, MPH, PhD; Metro Health Medical<br />
Center; Richmond Heights, OH<br />
Hiroshi Asahara, MD, PhD; The Scripps Research Institute; La<br />
Jolla, CA<br />
2:30 pm<br />
629. TNF and IL-6 Differentially Regulate the Production <strong>of</strong><br />
DKK-1, a Master Regulator <strong>of</strong> Bone Remodelling, by Fibroblast-<br />
Like Synoviocytes.<br />
Nataliya Yeremenko 2 , Karin Polzer 3 , Gemma Righter 2 , Radjesh<br />
Bisoendial 2 , Jochen Zwerina 3 , Georg Schett 3 , Paul P. Tak 1 and<br />
Dominique Baeten 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam,<br />
Amsterdam, The Netherlands, 2 Division <strong>of</strong> Clinical Immunology<br />
and <strong>Rheumatology</strong>, Academic Medical Centre/University <strong>of</strong><br />
Amsterdam, Amsterdam, The Netherlands, 3 Internal Medicine 3 ,<br />
Erlangen, Germany<br />
2010 Program Book 39
monday<br />
2:45 pm<br />
630. Adipogenic and Osteogenic Switch in Differentiation<br />
<strong>of</strong> Human Mesenchymal Stem Cells (hMSCs) Is Triggered by<br />
Hypoxia in a HIF-1 Dependent Manner.<br />
Markus Wagegg 3 , Timo Gaber 1 , Ferenz Lohanatha 1 , Manuela<br />
Jakstadt 1 , Grit Kasper 2 , Georg Duda 2 , Paula Kolar 3 , Gerd R.<br />
Burmester 4 and Frank Buttgereit 5 , 1Berlin-Brandenburg Center<br />
for Regenerative Therapies (BCRT), 2 Charité University Hospital,<br />
Center for Musculoskeletal Surgery, Berlin, Germany, 3 Charité<br />
University Hospital, Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />
Immunology, Berlin, Germany, 4 Charité University Hospital,<br />
Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Berlin,<br />
Germany, 5 Charite University Med-Berlin, Berlin, Germany<br />
3:00 pm<br />
631. Mitochondrial 8-Oxoguanine DNA Glycosylase (Ogg1)<br />
Regulates the Cellular Function and Survival <strong>of</strong> Osteoarthritic<br />
Chondrocytes in Response to Catabolic Stresses in<br />
Osteoarthritis.<br />
Kazuo Yudoh 2 and Rie Karasawa 1 , 1 Kawasaki, Japan, 2 St.<br />
Marianna University School Medicine, Kawasaki City, Japan<br />
3:15 pm<br />
632. Advanced Glycation End Products (AGEs)-Induced<br />
Expression <strong>of</strong> IL-6 and IL-8 in Human Osteoarthritis<br />
Chondrocytes Correlates with the Induction <strong>of</strong> Endoplasmic<br />
Reticulum Stress.<br />
Zafar Rasheed, Nahid Akhtar and Tariq M. Haqqi, Department <strong>of</strong><br />
Medicine, Metrohealth/CWRU, Cleveland, OH<br />
3:30 pm<br />
633. MicroRNA-199a-*Mediated Regulation <strong>of</strong><br />
Cyclooxygenase-2 Expression in Human OA Chondrocytes.<br />
Nahid Akhtar 1 , Zafar Rasheed 2 and Tariq M. Haqqi 1 , 1 Metrohealth<br />
Medical Center/CWRU, Cleveland, OH, 2 Metrohealth Medical<br />
Center/CWRU<br />
3:45 pm<br />
634. The Unfolded Protein Response (UPR) Is Impaired in Aging<br />
and Osteoarthritic Cartilage Chondrocytes.<br />
Matthew Husa 1 , Ru Liu-Bryan 2 , Shawn Grogan 3 , Haitao Yang 2 ,<br />
Bing Yang 2 , Martin Lotz 3 and Robert Terkeltaub 2 , 1 San Diego<br />
VA/UCSD, La Jolla, CA, 2 San Diego VA/UCSD, 3 Scripps Research<br />
Institute<br />
A315<br />
Cytokines, Mediators, Gene Regulation I<br />
Moderators: Alison Finnegan, PhD; Rush University Medical<br />
Center; Chicago, IL<br />
Oliver Distler, MD; University Hospital Zurich; Zurich, Switzerland<br />
2:30 pm<br />
Introductory Talk<br />
John J. O’Shea, MD; NIAMS/NIH; Bethesda, MD<br />
2:45 pm<br />
635. Decreased Collagen Induced Arthritis (CIA) Severity in<br />
MAPK Kinase 6 Deficient Mice: Pivotal Role <strong>of</strong> Th1 and Th17<br />
Cytokines.<br />
Deepa Hammaker 1 , Katharyn Topolewski 2 , Meghan Edgar 2 , David<br />
L. Boyle 1 and Gary S. Firestein 1 , 1UCSD School <strong>of</strong> Medicine, La<br />
Jolla, CA, 2 UCSD School <strong>of</strong> Medicine<br />
3:00 pm<br />
636. IL-7-Related TSLP: A Novel Potent Proinflammatory<br />
Mediator in Rheumatoid Arthritis That Activates Myeloid<br />
Dendritic Cells To Stimulate Th1 and Th17 Activity.<br />
F. M. Moret, C. E. Hack, K. M. G. van der Wurff-Jacobs,<br />
F. P. J. G. Lafeber and J. A. G. van Roon, <strong>Rheumatology</strong> &<br />
Clinical Immunology, University Medical Center Utrecht, The<br />
Netherlands<br />
3:15 pm<br />
637. Interleukin-12, Not the ITGAM Polymorphism (rs1143679),<br />
Correlates with Atherosclerosis Independent <strong>of</strong> Disease Activity<br />
in SLE.<br />
Manish Jain, Erin McDonnell, Jill P. Buyon and Robert M. Clancy,<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, New York University School <strong>of</strong><br />
Medicine<br />
3:30 pm<br />
638. Pro-Inflammatory Properties <strong>of</strong> IL-35 and Its Association<br />
with Disease Activity in Patients with Rheumatoid Arthritis.<br />
Maria Filkova 2 , Hana Hulejova 3 , Marketa Polanska 3 , Lucie Andres<br />
Cerezo 3 , Jiri Vencovsky 2 , Karel Pavelka 4 , Steffen Gay 1 and Ladislav<br />
Senolt 3 , 1 Center <strong>of</strong> Experimental <strong>Rheumatology</strong>, University<br />
Hospital and Zurich Center <strong>of</strong> Integrative Human Physiology<br />
(ZIHP), Zurich, Switzerland, 2 Institute <strong>of</strong> <strong>Rheumatology</strong> and<br />
Connective Tissue Research Laboratory, Department <strong>of</strong><br />
<strong>Rheumatology</strong> <strong>of</strong> the 1st Faculty <strong>of</strong> Medicine, Charles University<br />
in Prague, Prague, Czech Republic, 3 Institute <strong>of</strong> <strong>Rheumatology</strong><br />
and Connective Tissue Research Laboratory, Department <strong>of</strong><br />
<strong>Rheumatology</strong> <strong>of</strong> the 1st Faculty <strong>of</strong> Medicine, Charles University<br />
in Prague, Czech Republic, Czech Republic, 4 Institute <strong>of</strong><br />
<strong>Rheumatology</strong>, Department <strong>of</strong> <strong>Rheumatology</strong> <strong>of</strong> the 1st Faculty<br />
<strong>of</strong> Medicine, Charles University in Prague, Czech Republic, Czech<br />
Republic<br />
3:45 pm<br />
639. MAPK Kinase 3 (MKK3) Regulates Osteoclast<br />
Differentiation and Activation.<br />
David L. Boyle 3 , Meghan Edgar 4 , Mario M. Zaiss 1 , Georg Schett 2<br />
and Gary S. Firestein 3 , 1 Department <strong>of</strong> Internal Medicine 3 ,<br />
University <strong>of</strong> Erlangen-Nuremberg, 2 Friedrich Alexander Univ,<br />
Erlangen, Germany, 3 UCSD School <strong>of</strong> Medicine, La Jolla, CA,<br />
4<br />
UCSD School <strong>of</strong> Medicine<br />
A411<br />
Epidemiology and Health Services Research:<br />
Rheumatoid Arthritis<br />
Moderators: Kaleb D. Michaud, PhD; University <strong>of</strong> Nebraska<br />
Medical Center; Omaha, NE<br />
Ted R. Mikuls, MD; University <strong>of</strong> Nebraska Medical Center;<br />
Omaha, NE<br />
2:30 pm<br />
640. Tumor Necrosis Factor Inhibition Reduces the Incidence <strong>of</strong><br />
Alzheimer’s Disease in Rheumatoid Arthritis Patients.<br />
Richard C. Chou 2 , Michael A. Kane 3 , Shiva Gautam 1 and Sanjay<br />
Ghirmire 4 , 1Beth Israel Deaconess Medical Center, 2 Dartmouth-<br />
Hitchcock Medical Center, Milton, MA, 3 Massachusetts<br />
General Hospital and Massachusetts Institute <strong>of</strong> Technology,<br />
Georgetown, MA, 4 Verisk Health<br />
40<br />
2010 Program Book
2:45 pm<br />
641. Major Improvements in Outcomes <strong>of</strong> Rheumatoid Arthritis<br />
Since the Biologic Era and beyond: An Historical Overview from<br />
1989 until 2008 in a Large Inception Cohort <strong>of</strong> RA Patients.<br />
Wietske Kievit 1 , Jaap Fransen 2 , Maarten De Waal Malefijt 2 ,<br />
Alfons Den Broeder 3 and Piet van Riel 2 , 1 Radboud University<br />
Nijmegen Medical Centre, Nijmegen, The Netherlands, 2 Radboud<br />
University Nijmegen Medical Centre, 3 Sint Maartenskliniek<br />
3:00 pm<br />
642. Propensity-Adjusted Medication Effects on Survival in<br />
Rheumatoid Arthritis: 22-Year Follow-Up <strong>of</strong> 5629 Patients.<br />
Mary Chester Wasko 3 , Abhijit Dasgupta 1 , Helen Hubert 2 ,<br />
Bharathi Lingala 2 , James Fries 2 and Michael Ward 1 , 1 NIAMS/NIH,<br />
Bethesda, MD, 2 Stanford University, Palo Alto, CA, 3 University <strong>of</strong><br />
Pittsburgh, Pittsburgh PA<br />
3:15 pm<br />
643. Renal Dysfunction in Rheumatoid Arthritis Is Associated<br />
with Incident Cardiovascular Disease, Independently <strong>of</strong><br />
Traditional Risk Factors: The CARRE Study.<br />
Alper M. van Sijl 3 , Ingrid M. Visman 1 , Inge A. M. van den Oever 1 ,<br />
Mike J. L. Peters 5 , Alexandre E. Voskuyl 5 , Ben A. C. Dijkmans 4<br />
and Michael T. Nurmohamed 2 , 1 Jan van Breemen Institute, 2 Jan<br />
van Breemen Institute and VU Medical Centre, Amsterdam, The<br />
Netherlands, 3 Jan van Breemen Institute and VU Medical Centre,<br />
4<br />
VU Medical Centre, Amsterdam, The Netherlands, 5 VU Medical<br />
Centre<br />
3:30 pm<br />
644. Do Structural Damage and Inflammation Impact Physical<br />
Functioning Differently Based on Duration <strong>of</strong> Rheumatoid<br />
Arthritis?<br />
Martin J. Bergman 2 , Sanjoy Roy 1 , Naijun Chen 1 and Mary A.<br />
Cifaldi 1 , 1 Abbott Laboratories, Abbott Park, IL, 2 Arthritis and<br />
<strong>Rheumatology</strong>, Ridley Park, PA<br />
3:45 pm<br />
645. Common Vaccinations among Adults and the Risk <strong>of</strong><br />
Developing Rheumatoid Arthritis; Results from the Swedish<br />
EIRA Study.<br />
Camilla Bengtsson 2 , Meliha Kapetanovic 1 , Henrik Källberg 2 ,<br />
Berit Sverdrup 2 , Birgitta Nordmark 3 , Lars Klareskog 3 and Lars<br />
Alfredsson 2 , 1 Institute for Clinical Sciences, Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Lund University, Lund, Sweden, 2 Institute <strong>of</strong><br />
Environmental Medicine, Karolinska Institutet, Stockholm,<br />
Sweden, 3 <strong>Rheumatology</strong> Unit, Department <strong>of</strong> Medicine,<br />
Karolinska Institutet, Karolinska University Hospital, Stockholm,<br />
Sweden<br />
A412<br />
Fibromyalgia and S<strong>of</strong>t Tissue Disorders<br />
Moderators: Daniel J. Clauw, MD; University <strong>of</strong> Michigan Chronic<br />
Pain & Fatigue Research; Ann Arbor, MI<br />
Don L. Goldenberg, MD; Newton-Wellesley Hospital; Newton,<br />
MA<br />
2:30 pm<br />
646. Individually Tailored Exercise and Telephone-Delivered<br />
Cognitive Behaviour Therapy in the Management <strong>of</strong> Chronic<br />
Widespread Pain (CWP): Results from a Primary Care Based<br />
Randomised Controlled Trial.<br />
Gary J. Macfarlane 1 , Chrysa Gkazinou 2 , Marcus Beasley 2 ,<br />
Elizabeth A. Jones 2 , Gordon J. Prescott 2 , Phil Hannaford 2 ,<br />
Phil Keeley 3 , Karina Lovell 3 , Paul McNamee 2 , Deborah P. M.<br />
Symmons 3 , Steve Woby 3 , John McBeth 3 and the MUSICIAN Study<br />
Team, 1 University <strong>of</strong> Aberdeen, Aberdeen, Scotland, United<br />
Kingdom, 2 University <strong>of</strong> Aberdeen, 3 University <strong>of</strong> Manchester<br />
2:45 pm<br />
647. Non-Invasive Cortical Electrostimulation in the Treatment<br />
<strong>of</strong> Fibromyalgia.<br />
Jeffrey B. Hargrove 2 , Robert M. Bennett5, David G. Simons 1 ,<br />
Susan J. Smith 3 , Sunil Nagpal 3 and Donald E. Deering 4 , 1 Emory<br />
University, 2 Kettering University, Flint, MI, 3 Michigan State<br />
University, 4 NeuroHealth Associates, 5 Oregon Health & Science<br />
Univ, Portland, OR<br />
3:00 pm<br />
648. Effect <strong>of</strong> Adding Milnacipran to Pregabalin for Managing<br />
Fibromyalgia: A Randomized, Open-Label, Controlled Study.<br />
Mildred V. Farmer 3 , Joel M. Trugman 2 , Yong Wang 2 and R.<br />
Michael Gendreau 1 , 1 Cypress Bioscience, Inc., San Diego, CA,<br />
2<br />
Forest Research Institute, 3 Meridien Research, St. Petersburg, FL<br />
3:15 pm<br />
649. Hypothalamic-Pituitary-Adrenal Axis Response to Mental<br />
Stress Predicts Chronic Widespread Pain Onset – Results from<br />
the SPICE Study.<br />
Gareth T. Jones, Gordon D. Waiter, Marcus Beasley, Chrysa<br />
Gkazinou and Gary J. Macfarlane, University <strong>of</strong> Aberdeen,<br />
Aberdeen, United Kingdom<br />
3:30 pm<br />
650. Altered Resting Connectivity between Individuals with<br />
Fibromyalgia and Healthy Controls.<br />
Tobias Schmidt-Wilcke 2 , Rupal Bhavsar 2 , Daniel J. Clauw 1 and<br />
David A. Williams 1 , 1 University <strong>of</strong> Michigan, Ann Arbor, MI,<br />
2<br />
University <strong>of</strong> Michigan<br />
3:45 pm<br />
651. Mortality in Fibromyalgia: An 8,186 Patient Study over 35<br />
Years.<br />
Frederick Wolfe 1 , Afton L. Hassett 3 , Brian T. Walitt 4 and Kaleb D.<br />
Michaud 2 , 1 National Data Bank for Rheumatic Diseases, Wichita,<br />
KS, 2 Univ <strong>of</strong> Nebraska Med Ctr, Omaha, NE, 3 University <strong>of</strong><br />
Michigan Medical School, Ann Arbor, MI, 4 Washington Hospital<br />
Center, Washington, DC<br />
A410<br />
Pediatric <strong>Rheumatology</strong> - Pathogenesis and Genetics:<br />
Biological Basis for Pediatric Rheumatic Disease<br />
Moderators: Barbara S. Adams, MD; University <strong>of</strong> Michigan<br />
Health System; Ann Arbor, MI<br />
Nora G. Singer, MD; MetroHealth Medical Center; Cleveland, OH<br />
2:30 pm<br />
652. Detection <strong>of</strong> Specific Markers Using Proteomics: Our<br />
Research on the Marker in Patients with Kawasaki Disease<br />
(KD).<br />
Rie Karasawa 3 , Mikiya Fujieda 1 , Kazuhide Ohta 2 and Kazuo<br />
Yudoh 3 , 1 Department <strong>of</strong> Pediatrics, Kochi Medical School, Kochi<br />
University, Japan, 2 Department <strong>of</strong> Pediatrics, National Hospital<br />
Organization Kanazawa Medical Center, 3 Institute <strong>of</strong> Medical<br />
Science, St. Marianna University School <strong>of</strong> Medicine, Kawasaki,<br />
Japan<br />
2010 Program Book 41<br />
monday
monday<br />
2:45 pm<br />
653. Specific Subgroup <strong>of</strong> New-Onset Systemic Juvenile<br />
Idiopathic Arthritis without Overt Macrophage Activation<br />
Syndrome Shares Similar Gene Expression Signature<br />
with a Distinct Subset <strong>of</strong> Familial Hemophagocytic<br />
Lymphohistiocytosis.<br />
Keith A. Sikora, Ndate Fall, Michael G. Barnes, Janos Sumegi,<br />
Alexandra H. Filipovich and Alexei A. Grom, Cincinnati Children’s<br />
Hospital Medical Center, Cincinnati, OH<br />
3:00 pm<br />
654. A Genome-Wide Association Study for Juvenile Idiopathic<br />
Arthritis Identifies Chromosome Region 3q13 near the T Cell<br />
Receptor Co-Stimulatory Molecule CD80.<br />
Susan D. Thompson 1 , Miranda Marion 10 , Marc Sudman 2 , Paula<br />
S. Ramos 10 , Wendy Thomson 8 , Anne Hinks 8 , J. Peter Haas 7 ,<br />
Sampath Prahalad 4 , John F. Bohnsack 9 , Carol Wise 6 , Marilynn G.<br />
Punaro 5 , Carlos D. Rose 3 , Mary Ryan 2 , Monica Tsoras 2 , Michael<br />
Wagner 2 , Mehdi Keddache 2 , Timothy Howard 10 , Carl Langefeld 10<br />
and David N. Glass 1 , 1 Childrens Hospital Med Ctr, Cincinnati, OH,<br />
2<br />
Cincinnati Children’s Hospital Medical Center, 3 duPont Hospital<br />
for Children, Wilmington, DE, 4 Emory Children’s Center, Atlanta,<br />
GA, 5 Texas Scottish Rite Hospital for Children, Dallas, TX, 6 Texas<br />
Scottish Rite Hospital for Children, 7 University <strong>of</strong> Greifswald,<br />
8<br />
University <strong>of</strong> Manchester, 9 University <strong>of</strong> Utah, Salt Lake City, UT,<br />
10<br />
Wake Forest University<br />
3:15 PM<br />
655. Gene Expression Pr<strong>of</strong>iling in Peripheral Blood<br />
Mononuclear Cells Predicts Disease Flares in Children with<br />
Polyarticular Juvenile Idiopathic Arthritis Who Have Achieved<br />
Clinical Remission on Medication.<br />
Nicholas Knowlton 2 , Mark Barton Frank 2 , Nicholas E. Armstrong 1 ,<br />
Kaiyu Jiang 1 , Yanmin Chen 1 , Jeanette Osban 2 and James N.<br />
Jarvis 1 , 1 Dept <strong>of</strong> Pediatrics, U <strong>of</strong> OK <strong>College</strong> <strong>of</strong> Medicine,<br />
2<br />
Oklahoma Medical Research Foundation<br />
3:30 PM<br />
656. Levels <strong>of</strong> beta2-Glycoprotein-I May Reflect a Protective<br />
Effect on the Development <strong>of</strong> Heart Block in Fetuses Exposed<br />
to Maternal Anti-Ro Antibodies.<br />
Joanne H. Reed, Tom P. Gordon, Robert M. Clancy and Jill P.<br />
Buyon, New York University School <strong>of</strong> Medicine<br />
3:45 PM<br />
657. Pathogenic Consequences <strong>of</strong> Mutations <strong>of</strong> NLRP12 Gene.<br />
A New Cold-Induced Autoinflammatory Disease.<br />
Silvia Borghini 2 , Sara Tassi 1 , Sabrina Chiesa 3 , Francesco Caroli 2 ,<br />
Sonia Carta 1 , Roberta Caorsi 3 , Marco Di Duca 2 , Denise Lasigliè 3 ,<br />
Alberto Martini 3 , Isabella Ceccherini 2 , Anna Rubartelli 1 and<br />
Marco Gattorno 3 , 1 Institute for Cancer Research, Genoa, Italy,<br />
2<br />
Lab <strong>of</strong> Molecular Genetics, G. Gaslini Institute, Genoa, Italy,<br />
3<br />
<strong>Rheumatology</strong> Unit, G. Gaslini Institute, Genoa, Italy<br />
Sidney J. Marcus Auditorium<br />
Rheumatoid Arthritis - Clinical Aspects: Preclinical<br />
RA and Early RA I<br />
Moderators: Neal S. Birnbaum, MD; Pacific <strong>Rheumatology</strong><br />
Association; San Francisco, CA<br />
Jonathan Kay, MD; UMass Memorial Medical Center; Worcester,<br />
MA<br />
2:30 PM<br />
658. Application <strong>of</strong> the New ACR/EULAR Classification Criteria<br />
for Rheumatoid Arthritis to At-Risk Populations May Identify<br />
RA Prior to Clinical Presentation.<br />
Jason R. Kolfenbach 5 , Lezlie Derber 5 , Kevin D. Deane 9 , Jan<br />
Hughes-Austin 4 , Michael H. Weisman 3 , Jane Buckner 2 , Ted<br />
R. Mikuls 11 , James R. O’Dell 8 , Peter K. Gregersen 6 , Richard<br />
M. Keating 1 , Jill Norris 10 and V. Michael Holers 7 , 1O ak Park, IL,<br />
2<br />
Benaroya Research Institute at Virginia Mason, 3 Cedars-Sinai<br />
Medical Center, Los Angeles, CA, 4 Department <strong>of</strong> Epidemiology,<br />
Colorado School <strong>of</strong> Public Health, University <strong>of</strong> Colorado Denver,<br />
5<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Colorado at Denver,<br />
Aurora, CO, 6 N Shore Univ Hosp Rsch Ctr, Manhasset, NY, 7 Univ<br />
<strong>of</strong> Colorado School <strong>of</strong> Med, Aurora, CO, 8 University <strong>of</strong> Nebraska<br />
Medical Center, Omaha, NE, 9 University <strong>of</strong> Colorado at Denver,<br />
Aurora, CO, 10 University <strong>of</strong> Colorado Denver, Aurora, CO,<br />
11<br />
University <strong>of</strong> Nebraska Medical Center, Omaha, NE<br />
2:45 PM<br />
659. The Revised 2010 ACR/EULAR Diagnostic Criteria for<br />
Rheumatoid Arthritis Identify Many More Patients Who Are<br />
Eligible for Treatment and for Clinical Trials.<br />
Vivian P. Bykerk 5 , Gilles Boire 2 , Boulos Haraoui 4 , Carol A.<br />
Hitchon 8 , Ed C. Keystone 9 , J. Carter Thorne 6 , Diane S. Ferland 3 ,<br />
Janet E. Pope 7 and CATCH Investogators 1 , 1 Canada, Canada,<br />
2<br />
CHUS - Sherbrooke University, Sherbrooke, QC, Canada, 3 Hopital<br />
Maisonneuve Rosement, Montreal, LaSalle, QC, Canada, 4 Institut<br />
de Rhumatologie, Montreal, QC, Canada, 5 Mt Sinai Hospital,<br />
University <strong>of</strong> Toronto, Toronto, ON, Canada, 6 Southlake Regional<br />
Health Care, Newmarket, ON, Canada, 7 St Joseph Health<br />
Care London, London, ON, Canada, 8 University <strong>of</strong> Manitoba,<br />
Winnipeg, MB, Canada, 9 University <strong>of</strong> Toronto, Toronto, ON,<br />
Canada<br />
3:00 PM<br />
660. A Novel Diagnostic Marker for RA, Anti-MCV.<br />
Rong W. Zablocki 1 , Annette Van der Helm – van Mil 3 , Tom<br />
Huizinga 3 and Srinivas Rao 2 , 1 Cypress Bioscience Inc, San Diego,<br />
CA, 2 Cypress Bioscience Inc, 3 Leiden University Medical Center,<br />
The Netherlands<br />
3:15 PM<br />
661. Smoking Is a Predictor <strong>of</strong> Very Early Presentation with<br />
Rheumatoid Arthritis.<br />
David W. Sharpley 1 , Sarang Chitale 2 , Cristina Estrach 2 , Robert N.<br />
Thompson 2 , Robert J. Moots 2 and Nicola J. Goodson 2 , 1Academic<br />
<strong>Rheumatology</strong> Department, Aintree University Hospitals,<br />
University <strong>of</strong> Liverpool, Liverpool, Merseyside, United Kingdom,<br />
2<br />
Academic <strong>Rheumatology</strong> Department, Aintree University<br />
Hospitals, University <strong>of</strong> Liverpool<br />
3:30 PM<br />
662. Long-Term Remission in Daily Clinical Practice: Excellent 2<br />
Year Results with Treatment To Target in Very Early Rheumatoid<br />
Arthritis, Results <strong>of</strong> the DREAM Remission Induction Cohort.<br />
Marloes Vermeer 5 , Ina H. Kuper 5 , Monique Hoekstra 1 , Hein<br />
J. Bernelot Moens 6 , Marcel D. Posthumus 4 , Herman L. M.<br />
Brus 3 , Piet L. C. M. van Riel 2 and Mart A. F. J. van de Laar 5 ,<br />
1<br />
Isala Klinieken, Zwolle, The Netherlands, 2 Radboud University<br />
Nijmegen Medical Centre, Nijmegen, The Netherlands,<br />
3<br />
TweeSteden Ziekenhuis, Tilburg, The Netherlands, 4 University<br />
Medical Center Groningen, Groningen, The Netherlands,<br />
42<br />
2010 Program Book
5<br />
University <strong>of</strong> Twente and Medisch Spectrum Twente, Enschede,<br />
The Netherlands, 6 Ziekenhuisgroep Twente, Almelo/Hengelo,<br />
The Netherlands<br />
3:45 PM<br />
663. The Association <strong>of</strong> Joint Damage and Treatment Response<br />
with ACPA Status in Recent Onset RA.<br />
M. van den Broek 3 , N. B. Klarenbeek 4 , M. L. Westedt 1 , H.<br />
D. Boom 5 , P. J. S. M Kerstens 2 , T. W. J. Huizinga 4 , B. A. C.<br />
Dijkmans 6 and C. F. Allaart 4 , 1 Bronovo Hospital, The Hague, The<br />
Netherlands, 2 JBI, Amsterdam, The Netherlands, 3 LUMC, Leiden,<br />
The Netherlands, 4 LUMC, Leiden, The Netherlands, 5 Spaarne<br />
Hospital, Ho<strong>of</strong>ddorp, The Netherlands, 6 VU Medical Centre,<br />
Amsterdam, The Netherlands<br />
B402<br />
Spondylarthropathies and Psoriatic Arthritis - Clinical<br />
Aspects and Treatment - Imaging I<br />
Moderators: Desiree M. Van Der Heijde, MD, PhD; Leiden<br />
University Medical Center; Meerssen, The Netherlands<br />
Juergen Braun, MD; Rheumazentrum Ruhrgebiet; Herne,<br />
Germany<br />
2:30 PM<br />
664. Methotrexate Is Not Disease Modifying in Psoriatic<br />
Arthritis: The MIPA Trial.<br />
Gabrielle H. Kingsley 3 , Anna Kowalczyk 4 , Helen Taylor 4 , Fowzia<br />
Ibrahim 4 , Jonathan C. Packham 2 , Neil J. McHugh 7 , Diarmuid M.<br />
Mulherin 1 , George D. Kitas8, Kuntal Chakravarty 6 , Brian D. M.<br />
Tom 5 , Peter J. Maddison 9 and David L. Scott 4 , 1 Cannock Chase<br />
Hospital, Cannock, United Kingdom, 2 Haywood Hospital, Stoke<br />
on Trent, UK, 3 Kings <strong>College</strong> London, London, United Kingdom,<br />
4<br />
Kings <strong>College</strong> London, UK, 5 MRC Biostatistics Unit, University<br />
<strong>of</strong> Cambridge, UK, 6 Queens Hospital, Romford, UK, 7 Royal<br />
National Hospital for Rheumatic Diseases, Bath, UK, 8 Russells<br />
Hall Hospital, Dudley, UK, 9 Sport, Health and Exercise Science,<br />
University <strong>of</strong> Bangor, UK<br />
2:45 PM<br />
665. Rates and Predictors <strong>of</strong> Radiographic Sacroiliitis<br />
Progression over Two Years in Patients with Axial<br />
Spondyloarthritis.<br />
Denis Poddubnyy 1 , Martin Rudwaleit 1 , Hildrun Haibel 1 , Anja<br />
Weiss 3 , Elisabeth Märker-Hermann 4 , Henning Zeidler 5 , Jürgen<br />
Braun 6 and Joachim Sieper 2 , 1 Charité - Campus Benjamin<br />
Franklin, Berlin, Germany, 2 Charite Campus Benjamin Frankl,<br />
Berlin, Germany, 3 Deutsches Rheumaforschungszentrum,<br />
Berlin, Germany, 4 Dr. Horst Schmidt Kliniken, Wiesbaden,<br />
Germany, 5 Medizinische Hochschule, Hannover, Germany,<br />
6Rheumazentrum Ruhrgebiet, Herne, Germany<br />
3:00 PM<br />
666. High Prevalence <strong>of</strong> Axial Spondyloarthritis in Patients with<br />
Familial Mediteranean Fever, and a Greater Allelic Frequency<br />
<strong>of</strong> M694V in Familial Mediteranean Fever Patients with<br />
Radiograpic Sacroiliitis.<br />
Servet Akar 2 , Ozgul Soysal 2 , Feride Yuksel 1 , Dilek Solmaz 2 , Gercek<br />
Can 2 , Merih Birlik 2 , Mehmet Tunca 1 , Fatos Onen 2 and Nurullah<br />
Akkoc 2 , 1 Internal Medicine, Dokuz Eylul University Faculty <strong>of</strong><br />
Medicine, Izmir, Turkey, 2 <strong>Rheumatology</strong>, Dokuz Eylul University<br />
Faculty <strong>of</strong> Medicine, Izmir, Turkey<br />
3:15 PM<br />
667. Evidence That New Focal Fat Lesions Follow Resolution <strong>of</strong><br />
Spinal Inflammation in AS but Existing Lesions Are More Likely<br />
To Resolve with TNF Blocking Agents.<br />
Praveena Chiowchanwisawakit 1 , Robert G. W. Lambert 2 and<br />
Walter P. Maksymowych 2 , 1 Mahidol University, Bangkok,<br />
Thailand, 2 University <strong>of</strong> Alberta, Edmonton, AB, Canada<br />
3:30 PM<br />
668. New Bone Formation in the Spine <strong>of</strong> Patients with<br />
Diffuse Idiopathic Skeletal Hyperostosis (DISH) and Ankylosing<br />
Spondylitis (AS) – A Detailed Comparative Analysis <strong>of</strong> the Rates<br />
<strong>of</strong> Radiographic Progression over 6 Years.<br />
Xen<strong>of</strong>on Baraliakos 3 , Joachim Listing 1 , Jana Buschmann 3 , Anna<br />
von der Recke 3 and Juergen Braun 2 , 1 German Rheumatism<br />
Research Center, 2 Rheumazentrum Ruhrgebiet, Herne, Germany,<br />
3<br />
Rheumazentrum Ruhrgebiet Herne<br />
3:45 PM<br />
669. Relationship between Active Inflammatory Lesions<br />
in the Spine and Sacroiliac Joints and New Development<br />
<strong>of</strong> Fatty Infiltration on Whole-Body MRI in Early Axial<br />
Spondyloarthritis– Results <strong>of</strong> the ESTHER Trial at Week 48.<br />
In-Ho Song 1 , Kay-Geert Hermann 2 , Hildrun Haibel 1 , Christian<br />
Alth<strong>of</strong>f 2 , Joachim Listing 3 , Bruce Freundlich 4 , Martin<br />
Rudwaleit 1 and Joachim Sieper 1 , 1 Charite Campus Benjamin-<br />
Franklin, Medical Clinic I, <strong>Rheumatology</strong>, Berlin, Germany,<br />
2<br />
Charite Campus Mitte, Radiology, Berlin, Germany, 3 German<br />
Rheumatism Research Center, Berlin, Germany, 4 Wyeth/ Pfizer<br />
Inc., <strong>College</strong>ville, PA<br />
A311<br />
Systemic Sclerosis, Fibrosing Syndromes, and<br />
Raynaud’s - Pathogenesis, Animal Models and Genetics<br />
Moderators: David Abraham, PhD, BSc; University <strong>College</strong><br />
London; London, United Kingdom<br />
Robert A. Lafyatis, MD; Boston University School <strong>of</strong> Medicine;<br />
Arlington, MA<br />
2:30 PM<br />
670. Growth Differentiation Factor-9 Induced by Insulin-Like<br />
Growth Factor Binding Protein-5 May Contribute to Fibrosis in<br />
Systemic Sclerosis.<br />
Yukie Yamaguchi 2 and Carol A. Feghali-Bostwick 1 , 1 University <strong>of</strong><br />
Pittsburgh, Pittsburgh, PA, 2 University <strong>of</strong> Pittsburgh, Yokohama<br />
City University, Yokohama, Kanagawa, Japan<br />
2:45 PM<br />
671. Epithelial Cells Undergoing Epithelial Mesenchymal<br />
Transition (EMT) in Systemic Sclerosis Lack Caveolin-1 and<br />
Modulate WNT Signaling in the Dermis by Secreting SFRP4.<br />
Ilaria Tinazzi, Justin Gillespie, Giuseppina Abignano, Chiara<br />
Colato, Domenico Biasi, Paul Emery and Francesco Del Galdo,<br />
University <strong>of</strong> Leeds<br />
3:00 PM<br />
672. The Notch Pathway Controls Fibroblast Activation and<br />
Tissue Fibrosis in Systemic Sclerosis.<br />
Clara Dees 2 , Pawel Zerr 2 , Michal Tomcik 2 , Christian Beyer 2 ,<br />
Angelika Horn 2 , Alfiya Akhmetshina 2 , Katrin Palumbo 2 , Nicole<br />
Reich 2 , Jochen Zwerina 2 , Mark P. Mattson 3 , Oliver Distler 1 ,<br />
Georg Schett 2 and Joerg H. W. Distler 2 , 1 Center <strong>of</strong> Experimental<br />
<strong>Rheumatology</strong> and Zurich Center <strong>of</strong> Integrative Human<br />
monday<br />
2010 Program Book 43
monday<br />
Physiology, University Hospital Zurich, Switzerland, 2 Department<br />
<strong>of</strong> Internal Medicine 3 , University Erlangen-Nuremberg,<br />
Germany, 3 Laboratory <strong>of</strong> Neurosciences, National Institute on<br />
Aging Intramural Research Program, Baltimore, MD<br />
3:15 PM<br />
673. My<strong>of</strong>ibroblast Specific Gene Expression Signature in<br />
Systemic Sclerosis, More Than TGF-beta Induced Activation.<br />
Giuseppina Abignano 2 , Heidi Hermes, Justin Gillespie, Sergio<br />
A. Jimenez, Paul Emery and Francesco Del Galdo 1 , 1 Leeds,<br />
2<br />
University <strong>of</strong> Leeds<br />
3:30 PM<br />
674. Perturbed VEGF Signalling within the Pulmonary<br />
Vasculature <strong>of</strong> a TGFβ Dependent Mouse Model <strong>of</strong> Systemic<br />
Sclerosis.<br />
Emma C. Derrett-Smith 2 , Audrey Dooley 2 , Reshma Baliga 1 ,<br />
Adrian Hobbs 1 , Raymond MacAllister 1 , David Abraham 4 and<br />
Christopher P. Denton 3 , 1 Centre for Clinical Pharmacology, Rayne<br />
Institute, UCL, London, Canada, 2 Centre for <strong>Rheumatology</strong> and<br />
Connective Tissue Diseases, Royal Free Campus, UCL Medical<br />
School, London, 3 Royal Free Hospital, London, United Kingdom,<br />
4University <strong>College</strong> London, London, United Kingdom<br />
3:45 PM<br />
675. The IL13/IL4RA/CCL2 Pathway Drives Sclerodermatous<br />
Graft Versus Host Disease in Mice and Correlates with Disease<br />
Activity in Scleroderma Patients.<br />
Antonios O. Aliprantis 4 , Matthew Greenblatt 3 , Jennifer Sargent 2 ,<br />
Giuseppina Farina 6 , Kelly Tsang 3 , Robert A. Lafyatis 1 , Michael<br />
Whitfield 2 and Laurie Glimcher 5 , 1 Boston University School <strong>of</strong><br />
Medicine, Arlington, MA, 2 Department <strong>of</strong> Genetics, Dartmouth<br />
Medical School, 3 Department <strong>of</strong> Immunology and Infectious<br />
Diseases, Harvard School <strong>of</strong> Public Health, 4 Department <strong>of</strong><br />
Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Allergy and Immunology,<br />
Brigham and Women’s Hospital and Harvard Medical School and<br />
Department <strong>of</strong> Immunology and Infectious Diseases, Harvard<br />
School <strong>of</strong> Public Health, Boston, MA, 5 Department <strong>of</strong> Medicine,<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, Allergy and Immunology, Brigham and<br />
Women’s Hospital and Harvard Medical School and Department<br />
<strong>of</strong> Immunology and Infectious Diseases, Harvard School <strong>of</strong> Public<br />
Health, 6 <strong>Rheumatology</strong> Section, Boston University School <strong>of</strong><br />
Medicine<br />
United Kingdom, 2 Addenbrooke’s Hospital, 3 Charles University,<br />
4<br />
Immunologie-Zentrum Zürich, Zurich, Switzerland, 5 Maastricht<br />
University Medical Center, Maastricht, The Netherlands,<br />
6<br />
Maastricht University Medical Center, 7 Nuffield Orthopaedic<br />
Centre, Oxford, United Kingdom, 8 Royal Adelaide Hospital,<br />
Adelaide, Australia, 9 University Hospital <strong>of</strong> Skane and Lund<br />
University, Lund, 10 University Hospital <strong>of</strong> Skane and Lund<br />
University, 11 University <strong>of</strong> Birmingham, Birmingham, United<br />
Kingdom<br />
2:45 PM<br />
677. Increased Circulating Osteoclast Precursors and Lesional<br />
Osteoclast-Like Multinucleated Giant Cells in the Lung <strong>of</strong><br />
Patients with Wegener’s Granulomatosis.<br />
Jin Kyun Park 1 , Frederic Askin 2 , Antony Rosen 3 and Stuart M.<br />
Levine 1 , 1 Johns Hopkins University, Baltimore, MD, 2 Johns<br />
Hopkins University, 3 The Johns Hopkins University, Baltimore,<br />
MD<br />
3:00 PM<br />
678. Protocolised Versus Non-Protocolised Rituximab<br />
Treatment for Refractory ANCA-Associated Vasculitis.<br />
Rachel B. Jones 1 , Rona Smith 2 , Mary-Jane Guerry 2 , Simona<br />
Laurino 2 , Fausta Catapano 2 , Afzal Chaudhry 2 and David R. W.<br />
Jayne 1 , 1 Addenbrooke’s Hospital, Cambridge, United Kingdom,<br />
2<br />
Addenbrooke’s Hospital<br />
3:15 PM<br />
679. Xenografted Nasal Mucosa from Wegener’s<br />
Granulomatosis Patients Induces Destruction <strong>of</strong> Human<br />
Cartilage in Immunodeficient Mice.<br />
Nina Kesel 2 , Dorothee Köhler 2 , Martin Laudien 5 , Konstanze Holl-<br />
Ulrich 3 , Astrid Jüngel 1 , Michel Neidhart 1 , Steffen Gay 1 , Renate<br />
E. Gay 1 , Elena Csernok 6 , Wolfgang L. Gross 6 , Udo Schumacher 4<br />
and Sebastian Ullrich 4 , 1 Center <strong>of</strong> Experimental <strong>Rheumatology</strong>,<br />
University Hospital Zurich, Switzerland, 2 Dept. <strong>of</strong> Anatomy II:<br />
Experimental Morphology, University Medical Center Hamburg,<br />
Hamburg, Germany, 3 Dept. <strong>of</strong> Pathology, University Hospital<br />
<strong>of</strong> Schleswig-Holstein, Campus Lübeck, Lübeck, Germany,<br />
4<br />
University Medical Center Hamburg, 5University <strong>of</strong> Kiel, Dept.<br />
<strong>of</strong> Otorhinolaryngology, Head and Neck Surgery, Kiel, Germany,<br />
6<br />
University <strong>of</strong> Lübeck, Dept. For <strong>Rheumatology</strong>, Vasculitis Center<br />
UKSH & Clinical Center Bad Bramstedt, Lübeck, Germany<br />
A314<br />
ANCA-associated Vasculitis I<br />
Moderators: Simon Carette, MD; Toronto Western Hospital;<br />
Toronto, ON, Canada<br />
Loic P. Guillevin, MD; Hôpital Cochin-Paris Université; Paris,<br />
France<br />
2:30 PM<br />
676. Two Year Follow-Up Results from a Randomised Trial <strong>of</strong><br />
Rituximab Versus Cyclophosphamide for ‘Generalized’ ANCA-<br />
Associated Vasculitis: RITUXVAS.<br />
Rachel B. Jones 1 , Jan Willem Cohen Tervaert 5 , Thomas Hauser 4 ,<br />
Raashid Luqmani 7 , Matthew D. Morgan 11 , Chen Au Peh 8 , Caroline<br />
O. Savage 11 , Mårten Segelmark 9 , Vladimir Tesar 3 , Pieter van<br />
Paassen 6 , Dorothy Walsh2, Michael Walsh 2 , Kerstin Westman 10<br />
and David R. W. Jayne 1 , 1 Addenbrooke’s Hospital, Cambridge,<br />
3:30 PM<br />
680. Rituximab for Remission Induction and Maintenance<br />
in ANCA-Associated Vasculitis: A Single-Center Ten-Year<br />
Experience in 108 Patients.<br />
Rodrigo Cartin-Ceba 3 , Jason Golbin 1 , Karina A. Keogh 3 , Tobias<br />
Peikert 3 , Fernando C. Fervenza 3 , Steven R. Ytterberg 2 and Ulrich<br />
Specks 3 , 1 Long Island Lung Center, 2 Mayo Clinic, Rochester, MN,<br />
3<br />
Mayo Clinic<br />
3:45 PM<br />
681. Hsp60 Proteolysis by Proteinase 3 Induces Neutrophil<br />
Degranulation: Implications for Amplification <strong>of</strong> Injury in<br />
Wegener’s Granulomatosis.<br />
Shinji Sato 4 , Jin Kyun Park 1 , Frederic Askin 3 , Antony Rosen 2<br />
and Stuart M. Levine 1 , 1 Johns Hopkins University, Baltimore,<br />
MD, 2 The Johns Hopkins University, Baltimore, MD, 3 The Johns<br />
Hopkins University, 4 Tokai University, Kamakura, Japan<br />
44<br />
2010 Program Book
ACR/ARHP Combined Abstract<br />
Session<br />
2:30 - 4:00 PM<br />
B310<br />
ACR/ARHP Combined Epidemiology and Health<br />
Services Research: Impact on Osteoarthritis<br />
Moderators: Joanne M. Jordan, MD, MPH; University <strong>of</strong> North<br />
Carolina Thurston ARC; Chapel Hill, NC<br />
Robert R. McLean, DSc, MPH; Hebrew Senior Life; Boston, MA<br />
2:30 PM<br />
682. Unpredictability <strong>of</strong> Intermittent Knee OA Pain – Impact on<br />
Pain, Function and Mood.<br />
Gillian A. Hawker 2 , Melissa R. French 3 , Joy G. Elkayam 3 and<br />
Aileen M. Davis 1 , 1 Toronto Western Research Insti, Toronto,<br />
ON, Canada, 2 Women’s <strong>College</strong> Hospital, Toronto, ON, Canada,<br />
3<br />
Women’s <strong>College</strong> Hospital, Toronto, Canada<br />
2:45 PM<br />
683. Low Positive Affect Predicts the Development <strong>of</strong> Disability<br />
over 30-Months: The MOST Study.<br />
Julie J. Keysor 1 , Lisa Fredman 4 , Bin Zhang 2 , Daniel K. White 3 ,<br />
James C. Torner 8 , Cora E. Lewis 6 , Irina Tolstykh 7 and David T.<br />
Felson 5 , 1 Boston Univ Sargent <strong>College</strong>, Boston, MA, 2 Boston Univ<br />
Schl <strong>of</strong> Medicine, Boston, MA, 3 Boston Univ School <strong>of</strong> Med,<br />
Boston, MA, 4 Boston University, 5 Boston University School <strong>of</strong><br />
Medicine, Boston, MA, 6 University <strong>of</strong> Alabama-Birmingham,<br />
Birmingham, AL, 7 University <strong>of</strong> California and San Francisco, San<br />
Francisco, CA, 8 University <strong>of</strong> Iowa, Iowa City, IA<br />
3:00 PM<br />
684. Potential Gender Effect on the Association between Knee<br />
Osteoarthritis and Risk <strong>of</strong> Indoor and Outdoor Falls in Elderly<br />
Men and Women.<br />
Uyen-Sa D. T. Nguyen 4 , Marian T. Hannan 5 , Robert H. Shmerling 2 ,<br />
Douglas P. Kiel 7 , Suzanne G. Leveille 8 , Carol A. Oatis 1 , Lien Quach 6<br />
and Yuqing Zhang 3 , 1 Arcadia University, Glenside, PA, 2 Beth<br />
Israel Deaconess Med Ctr., Boston, MA, 3 Boston Univ School <strong>of</strong><br />
Medicine, Boston, MA, 4 Boston University School <strong>of</strong> Medicine,<br />
Boston, MA, 5 Hebrew SL & Harvard Med Sch, Boston, MA,<br />
6<br />
Institute for Aging Research, Hebrew SeniorLife, 7 Institute for<br />
Aging Research, Hebrew SeniorLife and Harvard Medical School,<br />
Boston, MA, 8 University <strong>of</strong> Massachusetts-Boston<br />
3:15 PM<br />
685. Increasing Prevalence <strong>of</strong> Knee Pain and Symptomatic Knee<br />
Osteoarthritis.<br />
Uyen-Sa D. T. Nguyen 5 , Yuqing Zhang 2 , Jingbo Niu 3 , Bin Zhang 1<br />
and David T. Felson 4 , 1 Boston Univ Schl <strong>of</strong> Medicine, Boston, MA,<br />
2<br />
Boston Univ School <strong>of</strong> Medicine, Boston, MA, 3 Boston University<br />
Schol <strong>of</strong> Medicine, Boston, MA, 4 Boston University School <strong>of</strong><br />
Medicine, Boston, MA, 5 Boston University School <strong>of</strong> Medicine,<br />
Boston, MA<br />
Alabama-Birmingham, Birmingham, AL, 5 University <strong>of</strong> California<br />
at San Francisco, San Francisco, CA, 6 University <strong>of</strong> Iowa, Iowa<br />
City, IA<br />
3:45 PM<br />
687. When 1st Is Worst: Musculoskeletal Conditions Maintain<br />
15 Year Reign as the Most Common Cause <strong>of</strong> Disability in US<br />
Adults.<br />
Kristina Theis 4 , Jennifer M. Hootman 3 , Charles G. Helmick 2 and<br />
Matthew Brault 1 , 1Bureau <strong>of</strong> the Census, 2 CDC, Atlanta, GA,<br />
3<br />
Centers for Disease Control, Kennesaw, GA, 4 Centers for Disease<br />
Control and Prevention<br />
ACR REF Special Session<br />
2:30 - 4:00 PM<br />
A404<br />
ACR REF “Within Our Reach”: Finding a Cure for<br />
Rheumatoid Arthritis c/r<br />
Moderator: David R. Karp, MD, PhD; University <strong>of</strong> Texas<br />
Southwestern Medical Center; Dallas, TX<br />
2:30 PM<br />
CD154 CA Repeat Polymorphisms and Rheumatoid Arthritis<br />
Pathogenesis<br />
William F. C. Rigby, MD; Dartmouth-Hitchcock Medical Center;<br />
Lebanon, NH<br />
3:00 PM<br />
Periodontal Disease as an Initiation or Propagation Factor for<br />
Rheumatoid Arthritis<br />
Clifton O. Bingham, MD; Johns Hopkins University; Baltimore,<br />
MD<br />
3:30 PM<br />
Regulatory Antibody Treatment <strong>of</strong> Inflammatory Arthritis<br />
Gregg J. Silverman, MD; University <strong>of</strong> California - San Diego; La<br />
Jolla, CA<br />
Session Overview:<br />
This session includes results from cutting-edge research funded<br />
by the Within Our Reach campaign providing insight into the<br />
pathogenesis, diagnosis and treatment <strong>of</strong> rheumatoid arthritis.<br />
As this research has yielded dramatic results that will impact<br />
patient care, early exposure is vital to quickly move these<br />
discoveries from laboratory to the bedside.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• distinguish the role <strong>of</strong> repeat polymorphisms in the<br />
pathogenesis <strong>of</strong> rheumatoid arthritis<br />
• identify the role <strong>of</strong> periodontal disease as a factor in the<br />
pathogenesis <strong>of</strong> rheumatoid arthritis<br />
• describe how naturally occurring antibodies may prevent the<br />
development <strong>of</strong> inflammatory conditions<br />
monday<br />
3:30 PM<br />
686. Community Mobility Barriers Predict the Development <strong>of</strong><br />
30-Month Disability: The MOST Study.<br />
Julie J. Keysor 1 , Bin Zhang 2 , James C. Torner 6 , Cora E. Lewis 4 , Irina<br />
Tolstykh 5 and David T. Felson 3 , 1Boston Univ Sargent <strong>College</strong>,<br />
Boston, MA, 2 Boston Univ Schl <strong>of</strong> Medicine, Boston, MA, 3 Boston<br />
University School <strong>of</strong> Medicine, Boston, MA, 4 University <strong>of</strong><br />
ARHP Concurrent Abstract Session<br />
2:30 - 4:00 PM<br />
B311<br />
Physical Activity: Just “Move It”<br />
Moderator: Nadine M. Fisher, EdD; SUNY at Buffalo; Buffalo, NY<br />
2010 Program Book 45
monday<br />
2:30 PM<br />
688. Does Physical Activity Dose Predict Physical and Mental<br />
Health-Related Quality <strong>of</strong> Life in People with Arthritis?<br />
Dina L. Jones, Ruoxin Zhang, Melissa Himes and Jennifer L.<br />
Eicher, Morgantown, WV<br />
2:45 PM<br />
689. Ready and Waiting: Adults with Arthritis Are Interested in<br />
Population-Based Physical Activity Programs.<br />
Louise Murphy 2 , Teresa J. Brady 2 , Kristina A. Theis 2 , Julie Bolen 2<br />
and Patience White 1 , 1Arthritis Foundation, 2 Centers for Disease<br />
Control and Prevention<br />
3:00 PM<br />
690. Evaluation <strong>of</strong> Tai Chi Course Effectiveness for People with<br />
Arthritis.<br />
Leigh F. Callahan 1 , Jack H. Shreffler 3 , Betsy S. Hackney 3 , Kathryn<br />
Remmes Martin 2 and Brian Charnock 3 , 1 Univ <strong>of</strong> North Carolina,<br />
Chapel Hill, NC, 2 University <strong>of</strong> North Carolina, Chapel Hill, Chapel<br />
Hill, NC, 3 University <strong>of</strong> North Carolina, Chapel Hill<br />
3:15 PM<br />
691. Walk with Ease Program: One-Year Follow-Up.<br />
Leigh F. Callahan 2 , Jack H. Shreffler 4 , Mary Altpeter 4 , Laura<br />
O. Houenou 4 , Britta Schoster 4 , Kathryn Remmes Martin 3 ,<br />
Jennifer M. Hootman 1 and Todd Schwartz 4 , 1 Centers for Disease<br />
Control, Kennesaw, GA, 2 Univ <strong>of</strong> North Carolina, Chapel Hill,<br />
NC, 3 University <strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC,<br />
4<br />
University <strong>of</strong> North Carolina, Chapel Hill<br />
3:30 PM<br />
692. Fit and Strong!: Bolstering Maintenance <strong>of</strong> Physical<br />
Activity among Older Adults with Lower-Extremity<br />
Osteoarthritis.<br />
Susan L. Hughes 4 , Rachel B. Seymour 4 , Richard T. Campbell 3 ,<br />
Pankaja Desai 3 , Gail Huber 2 and Justina Chang 1 , 1 JAMA,<br />
2<br />
Northwestern University, 3 University <strong>of</strong> Illinois Chicago,<br />
4<br />
University <strong>of</strong> Illinois Chicago, Chicago, IL<br />
3:45 PM<br />
693. Characteristics <strong>of</strong> Persons with or at High Risk <strong>of</strong> Knee OA<br />
Achieving Recommended Physical Activity Levels: The MOST<br />
Study.<br />
Daniel K. White 1 , Tuhina Neogi 2 , Jingbo Niu 2 , Michael Nevitt 3 ,<br />
C. Elizabeth Lewis 4 , James Torner 5 and Doug Gross 2 , 1 Boston<br />
University, Boston, MA, 2 Boston University, 3 University California<br />
San Francisco, 4 University <strong>of</strong> Alabama, 5 University <strong>of</strong> Iowa<br />
ARHP Concurrent Sessions<br />
2:30 - 4:00 PM<br />
B313<br />
CAM is a SCAM! Complementary and Alternative<br />
“Medicince” Has No Place in <strong>Rheumatology</strong> c/r PM<br />
Moderator: Atul A. Deodhar, MD; Oregon Health & Science<br />
University; Portland, OR<br />
Pro<br />
Donald M. Marcus, MD; Baylor <strong>College</strong> <strong>of</strong> Medicine; Houston, TX<br />
Con<br />
Steven S. Overman, MD, MPH; The Seattle Arthritis Clinic;<br />
Seattle, WA<br />
Session Overview:<br />
The prevailing attitudes and practices <strong>of</strong> rheumatologists<br />
in the US toward complementary and alternative medicine<br />
treatments vary. In a recently published national survey <strong>of</strong> 345<br />
rheumatologists practicing in the US, a widespread favorable<br />
opinion toward many types <strong>of</strong> complementary and alternative<br />
medicines was found, but not to all. Most rheumatology<br />
pr<strong>of</strong>essionals were unsure <strong>of</strong> the scientific underpinning <strong>of</strong><br />
the complementary and alternative medicines treatments and<br />
worried that most, if not all, therapies had no background <strong>of</strong><br />
rigorous testing. Despite these reservations, complementary and<br />
alternative medicines have become a multi-billion dollar industry<br />
within musculoskeletal medicine therapeutics. The speakers will<br />
debate whether complementary and alternative medicines are<br />
viable treatment options for people with rheumatic disease.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• state the prevalent use <strong>of</strong> complementary and alternative<br />
medicines by patients seen in a typical rheumatology practice<br />
• explain the scientific basis <strong>of</strong> commonly used complementary<br />
and alternative medicines therapies in musculoskeletal<br />
medicine<br />
• discuss the side effect pr<strong>of</strong>ile <strong>of</strong> complementary and<br />
alternative medicines therapies used by patients with<br />
rheumatologic problems<br />
B308<br />
Money Talks: How to Incentivize Staff cP<br />
Moderator: Debra Bancr<strong>of</strong>t Rizzo, MSN, FNP-C; Rheumatic<br />
Disease Center; Glendale, WI<br />
Speaker: Nancy A. Ho, MHA; Northwest Regional Ambulatory<br />
Service Center; Westminster, CO<br />
Session Overview:<br />
To provide more information about the management <strong>of</strong> a<br />
practice/clinic and the tools and resources available, this session<br />
is designed to inform attendees on how to create, implement<br />
and administer a gain sharing and/or incentive program into<br />
a rheumatology practice. Gain sharing/incentive programs<br />
are growing in popularity because they allow organizations to<br />
reward employees for goals that are critical to the success <strong>of</strong><br />
a practice. The goal is to improve the efficiency and quality <strong>of</strong><br />
the staff. Information will be provided about different types <strong>of</strong><br />
incentive goals that may be considered. Objectives suited to a<br />
physician practice and specific examples from one practice and<br />
their success story will be shared.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• develop an effective employee incentive plan<br />
• explain how staff incentive programs can be used across all<br />
tiers <strong>of</strong> employees<br />
• define the different parameters <strong>of</strong> measurable goals that<br />
might be used to determine performance<br />
• illustrate how the various elements <strong>of</strong> the program’s<br />
effectiveness that may enhance an employee’s individual and<br />
team performance<br />
• discuss specific ideas for enhancing teamwork and efficiency<br />
in a rheumatology practice<br />
46<br />
2010 Program Book
REF 25th Anniversary Celebration<br />
2:45 - 3:30 PM<br />
Halls A1 & A2<br />
REF Philanthropy Showcase (Booth#1325)<br />
ACR/ARHP Workshops<br />
4:00 - 6:00 PM<br />
Admission to each Workshop requires a separate registration<br />
and ticket. To verify which session you registered for, check to<br />
make sure the registration code on your ticket matches the code<br />
listed below in parentheses.<br />
B203<br />
Musculoskeletal Ultrasound (213)<br />
Speaker: Eugene Y. Kissin, MD; Boston University; Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the indications for ultrasound in rheumatic diseases<br />
• discuss the techniques <strong>of</strong> ultrasonography<br />
• identify normal and abnormal anatomical structures by<br />
ultrasound imaging<br />
B204<br />
Pediatric Musculoskeletal Upper/Lower Examinations<br />
(214)<br />
Speaker: Christine W. Kennedy, MSN, RN, CPNP; Emory<br />
Children’s Center; Decatur, GA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss principles <strong>of</strong> pediatric musculoskeletal physical<br />
examination<br />
• detect and describe normal and abnormal pediatric<br />
musculoskeletal physical examination findings<br />
• demonstrate rheumatologic upper and lower musculoskeletal<br />
examinations for pediatric patients using patient volunteers<br />
B202<br />
Renal Histopathology in Systemic Lupus<br />
Erythematosus and Vasculitis (215)<br />
Speaker: Megan Troxell, MD; Oregon Health & Science<br />
University; Portland, OR<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the pathologic changes that occur in lupus nephritis<br />
• discuss the pathologic basis for the classification <strong>of</strong> lupus<br />
nephritis and how it relates to clinical management<br />
• describe the histological changes in the kidneys <strong>of</strong> patients<br />
with vasculitis<br />
ARHP Concurrent Session<br />
4:00 - 6:00 PM<br />
B201<br />
You’ve Got the Power: How to Use and Teach<br />
Statistical Power for Studies and Grants R<br />
Moderator: Annette M. Oeser, BS, CCRP; Vanderbilt University<br />
Medical Center; Nashville, TN<br />
Speakers: Alyssa B. Dufour, MA; Hebrew Senior Life; Boston, MA<br />
Marian T. Hannan, DSc, MPH; Hebrew Senior Life and Harvard<br />
Medical School; Boston, MA<br />
Robert R. McLean, DSc, MPH; Hebrew Senior Life; Boston, MA<br />
Session Overview:<br />
Understanding the concept <strong>of</strong> statistical power is critical not only<br />
when designing a research study, but also when interpreting<br />
the results <strong>of</strong> a study. Often researchers have only rudimentary<br />
knowledge <strong>of</strong> calculating and interpreting power, and rely solely<br />
on statisticians to contend with power issues. The web-based<br />
activities covered in this session will allow participants to<br />
practice conducting power calculations with freely available<br />
power calculators.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the underlying concepts <strong>of</strong> statistical power and why<br />
it is important for research studies<br />
• utilize the methods <strong>of</strong> calculating statistical power, sample<br />
size, and minimal detectable difference when appropriate<br />
• effectively interpret and communicate results <strong>of</strong> statistical<br />
power calculations as both a rheumatology researcher and a<br />
consumer <strong>of</strong> the research literature in study design, grantwriting,<br />
IRB applications<br />
• utilize methods for teaching statistical power to students,<br />
including an interactive experience <strong>of</strong> conducting power<br />
analyses for case studies using web-based calculators<br />
ACR Basic Science Symposium<br />
4:30 - 6:00 PM<br />
A411<br />
The Revolution <strong>of</strong> Epigenetics in Autoimmunity R<br />
Moderator: Jennifer H. Anolik, MD, PhD; University <strong>of</strong> Rochester;<br />
Rochester, NY<br />
4:30 PM<br />
The Relevance <strong>of</strong> Epigenetics for <strong>Rheumatology</strong><br />
Bruce C. Richardson, MD, PhD; University <strong>of</strong> Michigan; Ann<br />
Arbor, MI<br />
5:00 PM<br />
Epigenetic Influences in Systemic Lupus Erythematosus<br />
Revealed by Twin Studies<br />
Esteban Ballestar, PhD; Bellvitge Biomedical Research Institute;<br />
L’Hospitalet de Llobregat, Barcelona, Spain<br />
5:30 PM<br />
Epigenetic Influences in Rheumatoid Arthritis<br />
Steffen Gay, MD; University Hospital Zurich Switzerland; Zurich,<br />
Switzerland<br />
Session Overview:<br />
The term epigenetics refers to changes in gene expression<br />
caused by mechanisms other than changes in the underlying<br />
DNA sequence, examples include chromatin structure, histone<br />
modifications, DNA methylation, and microRNA regulation.<br />
It has become increasingly clear that epigenetics provides a<br />
critical alternative mechanism for modulating gene function<br />
to those arising from genetic changes and may explain the<br />
variable penetrance <strong>of</strong> autoimmune phenotypes. Epigenetic<br />
mechanisms are essential for normal development and function<br />
<strong>of</strong> the immune system. Similarly, a failure to maintain epigenetic<br />
monday<br />
2010 Program Book 47
monday<br />
homeostasis in the immune response due to factors including<br />
environmental influences, leads to aberrant gene expression,<br />
contributing to immune dysfunction and in some cases the<br />
development <strong>of</strong> autoimmunity in genetically predisposed<br />
individuals.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the variety <strong>of</strong> epigenetic mechanisms controlling gene<br />
expression<br />
• describe examples <strong>of</strong> dysregulation <strong>of</strong> epigenetic pathways in<br />
systemic lupus erythematosus and rheumatoid arthritis<br />
• define the relevance <strong>of</strong> DNA methylation epigenetic changes<br />
to the clinical expression <strong>of</strong> autoimmune disease such as<br />
systemic lupus erythematosus<br />
ACR Clinical Symposium<br />
4:30 - 6:00 PM<br />
Hall A3<br />
Treatment <strong>of</strong> Wegener’s Granulomatosis/Microscopic<br />
Polyangiitis: Understanding and Applying the Data<br />
from Recent Clinical Trials cP P/C PS ARS<br />
Moderators: Robert Spiera, MD; Hospital for Special Surgery;<br />
New York, NY<br />
Carol A. Langford, MD, MHS; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
• describe the data with the use <strong>of</strong> biologic agents in Wegener’s<br />
granulomatosis /microscopic polyangiitis<br />
• apply the results from clinical trials in Wegener’s<br />
granulomatosis /microscopic polyangiitis to the treatment <strong>of</strong><br />
patients with severe, non-severe, and relapsing disease<br />
ACR Concurrent Abstract Sessions<br />
4:30 - 6:00 PM<br />
A402<br />
Infection-related Rheumatic Disease<br />
Moderators: Daniel H. Solomon, MD, MPH; Brigham and<br />
Women’s Hospital; Boston, MA<br />
Cem Gabay, MD; University Hospital <strong>of</strong> Geneva; Geneva,<br />
Switzerland<br />
4:30 PM<br />
694. Parvovirus B19 Non-Structural Protein NS1 Forms<br />
Adducts with Cellular DNA, Induces Apoptosis, and Is<br />
Condensed in Apoptotic Bodies: A Model for Viral Induction <strong>of</strong><br />
Autoantibodies and Systemic Lupus Erythematosus.<br />
Leona Gilbert 3 , Pavan K. Dhanyamraju 3 , Eoin Wallace 3 , Elina<br />
Dadu 3 , Liping Wang 3 , Harry J. Whitlow 3 , Violetta Kivovich 1 and<br />
Stanley J. Naides 2 , 1 Pennsylvania State University, Milton S.<br />
Hershey Medical Center, 2 Quest Diagnostics Nichols Institute,<br />
San Juan Capistrano, CA, 3 University <strong>of</strong> Jyväskylä, Finland.<br />
48<br />
4:30 PM<br />
Data for the Use <strong>of</strong> Conventional Immunosuppressive Agents<br />
in the Treatment <strong>of</strong> Wegener’s Granulomatosis/Microscopic<br />
Polyangiitis<br />
Philip Seo, MD; Johns Hopkins Bayview Medical Center;<br />
Baltimore, MD<br />
4:55 PM<br />
Data for the Use <strong>of</strong> Biologic Agents in the Treatment <strong>of</strong><br />
Wegener’s Granulomatosis/Microscopic Polyangiitis<br />
Ulrich Specks, MD; Mayo Clinic; Rochester, MN<br />
5:20 PM<br />
So How do I Apply the Findings <strong>of</strong> these Trials to My Patient?:<br />
Opinions from a Case-based Panel Discussion<br />
John H. Stone, MD, MPH; Massachusetts General Hospital;<br />
Boston, MA<br />
David Jayne, MD; Addenbrookes Hospital University <strong>of</strong><br />
Cambridge; Cambridge, United Kingdom<br />
Session Overview:<br />
Wegener’s granulomatosis and microscopic polyangiitis are<br />
complex systemic vasculitides for which treatment is commonly<br />
directed by the rheumatologist. In recent years, a number <strong>of</strong><br />
important clinical trials have been conducted to investigate<br />
conventional and biologic immunosuppressive therapies. It is<br />
important for the rheumatologist to understand the efficacy<br />
and toxicity <strong>of</strong> different treatment options and to be able to<br />
apply the findings from recent trials to the care <strong>of</strong> patients with<br />
Wegener’s granulomatosis or microscopic polyangiitis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• explain the data for the efficacy and toxicity <strong>of</strong> conventional<br />
immunosuppressive agents in the treatment <strong>of</strong> Wegener’s<br />
granulomatosis /microscopic polyangiitis<br />
2010 Program Book<br />
4:45 PM<br />
695. Occurrence <strong>of</strong> Rheumatoid Arthritis-Associated<br />
Autoantibodies in Leishmania Donovani Infection.<br />
Erik Åhlin 1 , Amir Elshafie 2 , Musa A. M. Nur 4 , Sayda Hassan El<br />
Safi 3 and Johan Rönnelid 1 , 1 Clinical Immunology Unit, Uppsala<br />
University, Uppsala, Sweden, 2 Clinical Immunology Unit,<br />
Uppsala University, Uppsala, Sweden. Department <strong>of</strong> Pathology<br />
and Microbiology, Alribat University Hospital, Khartoum,<br />
Sudan, 3 Department <strong>of</strong> Microbiology and Parasitology,<br />
Faculty <strong>of</strong> Medicine, University <strong>of</strong> Khartoum, Sudan, 4 Unit <strong>of</strong><br />
<strong>Rheumatology</strong>, Alribat University Hospital, Khartoum, Sudan<br />
5:00 PM<br />
696. IL-12p70 Alteration in Antibiotic Treatment <strong>of</strong> Chlamydia-<br />
Induced Reactive Arthritis (ReA).<br />
Robert D. Inman 1 , Basil Chiu, Alan P. Hudson 3 and John D.<br />
Carter 2 , 1 Toronto Western Hospital, Toronto, ON, Canada, 2 Univ<br />
<strong>of</strong> South Florida, Tampa, FL, 3 Wayne State Univ Schl <strong>of</strong> Med,<br />
Detroit, MI<br />
5:15 PM<br />
697. The Efficacy and Safety <strong>of</strong> Vaccination Against H1N1<br />
in Patients with Rheumatoid Arthritis, Systemic Lupus<br />
Erythematosus, Psoriatic Arthritis and Ankylosing Spondylitis.<br />
Ori Elkayam 2 , Sharon Amir 2 , Michal Mandelboim 1 , Ella<br />
Mendelson 1 , Jonathan Wollman 2 , Uri Arad 2 , Daphna Paran 2 ,<br />
David Levartovsky 2 , Irena Wigler 2 and Dan Caspi 2 , 1 Center <strong>of</strong><br />
Virology, Sheba Medical Center, 2 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Tel Aviv Medical Center<br />
5:30 PM<br />
698. Serious Infection in Rheumatoid Arthritis Patients<br />
Switching Anti-Tumor Necrosis Factor Drugs.<br />
Bao-Anh Nguyen-Khoa 2 , Earl L. Goehring, Jr 2 , Kimberly<br />
Alexander 1 , Wei Dong 1 , Pavel Napalkov 1 and Judith K. Jones 2 ,<br />
1<br />
Genentech, South San Francisco, CA, 2 The Degge Group Ltd,<br />
Arlington, VA
5:45 PM<br />
699. Defining Latent and/or Disseminated Active Tuberculous<br />
Infection with TST, Quantiferon Gold and Multisite Cultures in<br />
TNFi Exposed Individuals.<br />
Dilrukshie Cooray 2 , James S. Louie 4 , Rosalinda C. Moran 1 and<br />
George A. Karpouzas 3 , 1 Harbor- UCLA Medical Center, Carson,<br />
CA, 2 Harbor-UCLA Medical Center, Torrance, CA, 3 Harbor-UCLA<br />
Medical Center, Long Beach, CA, 4 University <strong>of</strong> California Los<br />
Angeles, Los Angeles, CA<br />
A404<br />
Miscellaneous Rheumatic and Inflammatory Diseases<br />
Moderators: W. Winn Chatham, MD; University <strong>of</strong> Alabama-<br />
Birmingham; Birmingham, AL<br />
Kristine M. Lohr, MD, MS; Kentucky Clinic; Lexington, KY<br />
4:30 PM<br />
700. Progressive Multifocal Leukoencephalopathy Associated<br />
with Biologic and Synthetic DMARD Therapy in Rheumatic<br />
Diseases: An Analysis <strong>of</strong> the FDA Adverse Event Reporting<br />
System Database.<br />
Eamonn S. Molloy 2 and Leonard H. Calabrese 1 , 1 Cleveland Clinic<br />
Foundation, Cleveland, OH, 2 St Vincent’s University Hospital,<br />
Dublin, Ireland<br />
4:45 PM<br />
701. Tocilizumab in Refractory Adult Still’s Disease: A Cohort<br />
Study.<br />
Xavier Puéchal, Michel de Bandt, Jean-Marie Berthelot, Maxime<br />
Breban, Jean-Jacques Dubost, Olivier Fain, Jean-Emmanuel Kahn,<br />
Laurence Lequen, Maïté Longy-Boursier, Aleth Perdriger, Thierry<br />
Schaeverbeke, Eric Toussirot, Jean Sibilia and The CRI, Center<br />
for Rare Systemic and Auto-immune Diseases, Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Le Mans, France<br />
5:00 PM<br />
702. Clinical Implications <strong>of</strong> the NMO-IgG Antibody and<br />
Overlapping Neuromyelitis Optica Spectrum Disorder in<br />
Patients with Connective Tissue Disease and Myelitis.<br />
Jason R. Kolfenbach 1 , Brian J. Horner 3 and Sterling G. West 2 ,<br />
1<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Colorado at Denver,<br />
Aurora, CO, 2 University <strong>of</strong> Colorado at Denver, Aurora, CO,<br />
3<br />
University <strong>of</strong> Colorado Denver School <strong>of</strong> Medicine<br />
5:15 PM<br />
703. Diagnostic Significance <strong>of</strong> Serum Interleukin-18 Level in<br />
Adult-Onset Still’s Disease.<br />
Junko Maruyama 3 , Shigeko Inokuma 1 and Noboru Hagino 2 ,<br />
1<br />
Japanese Red Cross Medical Center, 2 The University <strong>of</strong> Tokyo<br />
Hospital, 3 Tokyo Metropolitan Komagome Hospital, Tokyo, Japan<br />
5:30 PM<br />
704. Extrapulmonary Course <strong>of</strong> Connective Tissue Disease and<br />
Survival after Lung Transplant.<br />
Troy K. Takagishi, Iffat Ahmed and Rodney Tehrani, Loyola<br />
University Medical Center<br />
5:45 PM<br />
705. Idiopathic Retroperitoneal Fibrosis: Treatment-Related<br />
Outcomes and Predictors <strong>of</strong> Clinical Response.<br />
Tanaz A. Kermani 1 , Cynthia S. Crowson 2 , Sara Achenbach 2 and<br />
Harvinder S. Luthra 1 , 1 Mayo Clinic, Rochester, MN, 2 Mayo Clinic<br />
A314<br />
Osteoarthritis - Clinical Aspects: Genetics, Novel<br />
Approaches, and Therapy<br />
Moderators: Timothy E. McAlindon, MD, MPH; Tufts Medical<br />
Center; Boston, MA<br />
Tuhina Neogi, MD, PhD; Boston University School <strong>of</strong> Medicine;<br />
Boston, MA<br />
4:30 PM<br />
706. Clinical Trial <strong>of</strong> Vitamin D To Reduce Pain and Structural<br />
Progression <strong>of</strong> Knee Osteoarthritis (OA).<br />
Timothy E. McAlindon 3 , Bess Dawson-Hughes 5, Jeffrey Driban 4 ,<br />
Michael LaValley 2 , Ji Yeon Lee 4 , Grace H. Lo 1 , Melynn Nuite 4 and<br />
Lori Lyn Price 4 , 1 Baylor <strong>College</strong> <strong>of</strong> Medicine, 2 Boston University<br />
School <strong>of</strong> Public Health, 3 Tufts Medical Center, Boston, MA,<br />
4<br />
Tufts Medical Center, 5 USDA HNRC; Tufts University<br />
4:45 PM<br />
707. Interleukin-1 Receptor Antagonist (IL-1RN) Gene<br />
Variations Predict the Severity and Progression <strong>of</strong> Knee<br />
Osteoarthritis.<br />
Mukundan Attur 8 , Cheongun Oh 7 , Svetlana Krasnokutsky 6 ,<br />
Jonathan Samuels 5 , Leon Rybak 9 , Jenny Bencardino 9 , Jeffrey<br />
D. Greenberg 1 , Virginia Kraus 2 , Kenneth Kornman 4 and Steven<br />
B. Abramson 3 , 1 Millburn, NJ, 2 Duke University Medical Center,<br />
Durham, NC, 3 Hospital for Joint Dis/NYU, New York, NY,<br />
4<br />
Interleukin Genetics, 5 New York University Hospital for Joint<br />
Disease, New York, NY, 6 NYU Hospital for Joint Disease, New<br />
York, NY, 7 NYU-Hospital for Joint Diseases, 8 NYU-Hospital for<br />
Joint Diseases, New York, NY, 9 NYU-Hospital for Joint Diseases<br />
Radiology Dept.<br />
5:00 PM<br />
708. Hand Osteoarthritis (OA) a Predictor <strong>of</strong> Accelerated<br />
Progression in Knee OA?<br />
Jonathan Samuels 3 , Catherine Petchprapa 6 , Elizabeth L.<br />
Carpenter 6 , Svetlana Krasnokutsky 4 , Mukundan Attur 2 , Leon<br />
Rybak 5 , Jenny Bencardino 5 , Cheongeun Oh 6 and Steven B.<br />
Abramson 1 , 1 Hospital for Joint Dis/NYU, New York, NY, 2 Hospital<br />
for Joint Dis/NYU Langone Medical Center, 3 New York University<br />
Hospital for Joint Disease, New York, NY, 4 NYU Hospital for Joint<br />
Disease, New York, NY, 5 NYU Hospital for Joint Diseases, 6 NYU<br />
Langone Medical Center<br />
5:15 PM<br />
709. Bone Marrow Lesions (BMLs) Are Strongly Associated with<br />
Increased Bone Volume Fraction; “Virtual Bone Biopsy” Using<br />
MRI.<br />
Anna M. Tassinari 3 , Grace H. Lo 1 , Jeffrey Driban 3 , Lori Lyn Price 3 ,<br />
Erika Schneider 2 and Timothy E. McAlindon 3 , 1 Baylor <strong>College</strong> <strong>of</strong><br />
Medicine, Houston, TX, 2 The Cleveland Clinic, Cleveland, OH,<br />
3<br />
Tufts Medical Center, Boston, MA<br />
5:30 PM<br />
710. REGN475/SAR164877, a Nerve Growth Factor Inhibitor,<br />
in Osteoarthritis Patients with Moderate to Severe Knee Pain:<br />
Results <strong>of</strong> a Phase 2, Randomized, Double-Blind, Placebo-<br />
Controlled Study.<br />
Paul Tiseo 4 , Alan J. Kivitz 1 , John E. Ervin 2 , Scott J. Mellis 3 ,<br />
Haobo Ren 4 , Damir Skific 4 , Richard Wu 4 and Peter Powchik 4 ,<br />
1<br />
Altoona Arthritis & Osteo Ctr, Duncansville, PA, 2 Center<br />
for Pharmaceutical Res, Kansas City, MO, 3 Regeneron<br />
Pharmaceuticals, Inc., Tarrytown, NY, 4 Regeneron<br />
Pharmaceuticals, Inc.<br />
2010 Program Book 49<br />
monday
5:45 PM<br />
711. Novel Biomarkers <strong>of</strong> Knee Osteoarthritis Identified Using a<br />
Non-Targeted Metabolomic Approach.<br />
Guangju Zhai, Karsten Suhre, Deborah Hart, Christian Gieger,<br />
Nicole Soranzo and Tim D. Spector, King’s <strong>College</strong> London,<br />
London, United Kingdom<br />
A410<br />
Rheumatoid Arthritis - Animal Models: Insight in<br />
Pathogenesis and Novel Therapeutic Targets I<br />
Moderators: Wim B. Van Den Berg, PhD; Radboud University<br />
Nijmegen Medical Center; Nijmegen, The Netherlands<br />
Pierre Miossec, MD, PhD; Hopital E Herriot; Lyon, France<br />
Sidney J. Marcus Auditorium<br />
Rheumatoid Arthritis Treatment - Small Molecules,<br />
Biologics and Gene Therapy: Safety and Efficacy I<br />
Moderators: Maya H. Buch, MD, PhD; University <strong>of</strong> Leeds; Leeds,<br />
United Kingdom<br />
Martin Aringer, MD; Uniklinikum TU Dresden; Dresden, Germany<br />
4:30 PM<br />
718. Certolizumab Pegol Use in Pregnancy: Low Levels Detected<br />
in Cord Blood.<br />
Douglas Wolf 1 and Uma Mahadevan 2 , 1 Atlanta Gastroenterology<br />
Associates, Atlanta, GA, 2 UCSF Center for Colitis and Crohn’s<br />
Disease, San Francisco, CA<br />
monday<br />
50<br />
4:30 PM<br />
712. Anti-CD20 Therapy Inhibits the Progression <strong>of</strong> Synovitis<br />
and Focal Erosion in the Knee Joints but Not in the Ankle Joints<br />
<strong>of</strong> TNF-Tg Mice.<br />
Jie Li, Igor Kuzin, Christopher Ritchlin, Ignacio Sanz, Andrea<br />
Bottaro, Lianping Xing and Edward Schwarz, University <strong>of</strong><br />
Rochester, Rochester, NY<br />
4:45 PM<br />
713. Identifying the TLR4 Bearing Target Cell in Experimental<br />
Arthritis.<br />
Ben T. van den Brand, Shahla Abdollahi-Roodsaz, Miranda B.<br />
Bennink, Onno J. Arntz, Wim B. van den Berg and Fons A. J. van<br />
de Loo, Radboud University Nijmegen Medical Centre<br />
5:00 PM<br />
714. Local Expression <strong>of</strong> IL-27 Reduces Collagen Induced<br />
Arthritis through Reduction <strong>of</strong> Monocyte Migration and<br />
Vascularization.<br />
Sarah R. Pickens 4 , Michael V. Volin 1 , Arthur M. Mandelin 2<br />
and Shiva Shahrara 3 , 1 Midwestern University, 2 Northwester<br />
University, Chicago, IL, 3 Northwestern Univ Feinberg, Chicago, IL,<br />
4<br />
Northwestern University<br />
5:15 PM<br />
715. Impaired B Cell Immunity in IL-22 Knock-Out Mice in<br />
Collagen Induced Arthritis.<br />
Odilia Corneth 1 , Anne-Marie Mus 2 , Patrick Asmawidjaja 2 ,<br />
Laurens Kil 2 , Wenjun Ouyang 3 , Rudi Hendriks 2 and Erik Lubberts 2 ,<br />
1<br />
Erasmus MC, University Medical Center, Rotterdam, ZH,<br />
The Netherlands, 2 Erasmus MC, University Medical Center,<br />
3<br />
Genentech<br />
5:30 PM<br />
716. Repair <strong>of</strong> Bone Erosions in Inflammatory Arthritis Occurs<br />
as Inflammation Resolves, Accompanied by Alterations in the<br />
Wnt Signaling Pathway.<br />
M. M. Matzelle 4 , M. A. Gallant 3 , K. W. Condon 2 , N. C. Walsh 5 ,<br />
C. A. Manning 1 , J. B. Lian 1 , D. B. Burr 2 and Ellen M. Gravallese 1 ,<br />
1<br />
Worcester, MA, 2 Indianapolis, IN, 3 Department <strong>of</strong> Anatomy and<br />
Cell Biology, Indiana University School <strong>of</strong> Medicine, Indianapolis,<br />
IN, 4 Department <strong>of</strong> Medicine and Department <strong>of</strong> Cell Biology,<br />
University <strong>of</strong> Massachusetts Medical School, Worcester, MA, 5 St.<br />
Vincent’s Institute, Fitzroy, VIC, Australia<br />
5:45 PM<br />
717. SB1578, a Novel Selective JAK2 Inhibitor, Is Highly<br />
Efficacious in Rodent Models <strong>of</strong> Rheumatoid Arthritis.<br />
Kee Chuan Goh, Stefan Hart, Yung Kiang Loh, Yong Cheng Tan,<br />
Chithra Amalini, Ramesh Jayaraman, Kantharaj Ethirajulu and<br />
Jeanette Wood, S*BIO Pte Ltd.<br />
2010 Program Book<br />
4:45 PM<br />
719. Anti-TNF Therapy Reduces Adipocytokine Levels and<br />
Improves the Lipid Pr<strong>of</strong>ile in Patients with Rheumatoid<br />
Arthritis: A Possible Mechanism Contributing to Lowered<br />
Cardiovascular Risk.<br />
Marieke Herenius 2 , Ruth Klaasen 2 , Wilco de Jager 4 , Berent<br />
Prakken4, Daniëlle Gerlag 3 and Paul P. Tak 1 , 1 Academic Med Ctr/<br />
Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands, 2 Department<br />
<strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic Medical<br />
Center, University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />
3Department <strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>,<br />
Academic Medical Center, University <strong>of</strong> Amsterdam, The<br />
Netherlands, 4 Department <strong>of</strong> Pediatric Immunology, University<br />
Medical Center Utrecht, Wilhelmina Children’s Hospital, Utrecht,<br />
The Netherlands<br />
5:00 PM<br />
720. Biologics and Risk <strong>of</strong> Lymphoma in Patients with<br />
Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.<br />
Lindsay C. Burns 1 , Mary De Vera 1 , Vidula Bhole 1 , Yanyan Zhu 3 ,<br />
Peter Grayson 2 , Devyani Misra 3 and Hyon K. Choi 4 , 1 Arthritis<br />
Research Centre <strong>of</strong> Canada, 2 Boston University, 3 Boston<br />
University School <strong>of</strong> Medicine, 4 Univ <strong>of</strong> British Columbia,<br />
Vancouver, BC, Canada<br />
5:15 PM<br />
721. The Comparative Incidence <strong>of</strong> Serious Infections among<br />
Rheumatoid Arthritis Patients Who Switch Biologic Agents.<br />
Jeffrey R. Curtis 3 , Fenglong Xie 2 , Lang Chen 2 , John Baddley 2 ,<br />
Timothy Beukelman 4 , Kenneth G. Saag 5 , Kevin Winthrop 1 and<br />
Elizabeth Delzell 2 , 1 OHSU, 2 Univ <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, 3 University <strong>of</strong> Alabama - Brimingham, Birmingham,<br />
AL, 4 University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />
5<br />
University <strong>of</strong> Alabama-Birmingham, Birmingham, AL<br />
5:30 PM<br />
722. Characteristics <strong>of</strong> Cases <strong>of</strong> PML among Patients with<br />
Selected Rheumatic and Autoimmune Diseases.<br />
Timothy Beukelman 5 , Fenglong Xie 3 , Lang Chen 3 , John Baddley 3 ,<br />
Elizabeth Delzell 3 , Carlos G. Grijalva 7 , Nivedita M. Patkar 2 ,<br />
Kenneth G. Saag 6 , Kevin Winthrop 1 and Jeffrey R. Curtis 4 , 1 OHSU,<br />
2<br />
Univ <strong>of</strong> AL at Birmingham, Birmingham, AL, 3 Univ <strong>of</strong> AL at<br />
Birmingham, 4 University <strong>of</strong> Alabama - Brimingham, Birmingham,<br />
AL, 5 University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />
6<br />
University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />
7<br />
Vanderbilt<br />
5:45 PM<br />
723. Consequence <strong>of</strong> Remission Misclassification Due to<br />
Reduced Joint Counts Omitting the Forefeet.
Lilian H. D. van Tuyl 8 , Karin Britsemmer 3 , David T. Felson 2 , George<br />
A. Wells 6 , Josef S. Smolen 4 , Bin Zhang 1 , Julia Funovits 5 , Dirkjan<br />
van Schaardenburg 3 and Maarten Boers 7 , 1 Boston Univ Schl <strong>of</strong><br />
Medicine, Boston, MA, 2 Boston University School <strong>of</strong> Medicine,<br />
Boston, MA, 3 Jan van Breemen Institute, 4 Krankenhaus Lainz,<br />
Vienna, Austria, 5 Medical University <strong>of</strong> Vienna, 6 Univ <strong>of</strong> Ottawa<br />
Faculty <strong>of</strong> Med, Ottawa, ON, Canada, 7 VU University Medical<br />
Center, Amsterdam, The Netherlands, 8 VU University Medical<br />
Center, Amsterdam<br />
A311<br />
Systemic Sclerosis, Fibrosing Syndromes, and<br />
Raynaud’s - Clinical Aspects and Therapeutics I<br />
Moderators: Laura K. Hummers, MD; Johns Hopkins University;<br />
Baltimore, MD<br />
Maureen D. Mayes, MD, MPH; University <strong>of</strong> Texas-Houston;<br />
Houston, TX<br />
4:30 PM<br />
724. Use <strong>of</strong> Serum Clara Cell 16-kDa (CC16) Levels as a Potential<br />
Indicator <strong>of</strong> Active Pulmonary Fibrosis in Systemic Sclerosis.<br />
Minoru Hasegawa, Manabu Fujimoto and Kazuhiko Takehara,<br />
Kanazawa University<br />
4:45 PM<br />
725. HLA DRB1*0407 and *1304 Are Predictive Biomarkers for<br />
Scleroderma Renal Crisis.<br />
Binh Y. Nguyen 1 , Maureen D. Mayes 6 , Frank C. Arnett 7 , Deborah<br />
J. del Junco 2 , Emilio B. Gonzalez 4 , Hilda T. Draeger 3 , Marilyn<br />
Perry 2 , Amir Hendiani 2 , John D. Reveille 5 and Shervin Assassi 1 ,<br />
1<br />
Univ <strong>of</strong> Texas Health Science Center Houston, Houston, TX,<br />
2<br />
Univ <strong>of</strong> Texas Health Science Center Houston, 3 Univ <strong>of</strong> Texas<br />
Health Science Center San Antonio, San Antonio, TX, 4 Univ <strong>of</strong><br />
Texas Medical Branch, Galveston, TX, 5 Univ Texas Health Sci Ctr,<br />
Houston, TX, 6 University <strong>of</strong> Texas-Houston, Houston, TX, 7 UT<br />
Medical School, Houston, TX<br />
5:00 PM<br />
726. GAVE (Gastric Antral Vascular Ectasia) in Early<br />
Diffuse SSc: Updated Report from the SCOT (Scleroderma<br />
Cyclophosphamide or Transplant) Trial.<br />
Emily W. Hung 9 , Maureen D. Mayes 10 , Lynette Keyes-Elstein 5 ,<br />
Leslie J. Cr<strong>of</strong>ford 6 , Mary Ellen Csuka 3 , Daniel E. Furst 8 , Ellen<br />
Goldmuntz 4 , Peter McSweeney 11 , Richard Nash 2 , Victor<br />
Machicao 7 and Keith Sullivan 1 , 1 Duke University Medical Center,<br />
for the SCOT Trial Investigators, Durham, NC, 2 Fred Hutchinson<br />
Cancer Research Center, 3 Medical <strong>College</strong> <strong>of</strong> Wisconsin,<br />
Milwaukee, WI, 4 NIAID, 5 Rho Federal Systems Inc., 6 Univ <strong>of</strong><br />
KY, Lexington, KY, 7 Univ <strong>of</strong> Texas Health Science Center at<br />
Houston, 8 University <strong>of</strong> California Los Angeles Medical School,<br />
Los Angeles, CA, 9 University <strong>of</strong> Texas at Houston, Houston, TX,<br />
10<br />
University <strong>of</strong> Texas-Houston, Houston, TX, 11 US Oncology<br />
5:15 PM<br />
727. A Formula To Predict Mean Pulmonary Artery Pressures<br />
in Patients with Connective Tissue Disease Based on<br />
Echocardiography, NTproBNP and O2 Saturation.<br />
Benjamin E. Schreiber 3 , Christopher J. Valerio 3 , Clive Handler 3 ,<br />
Greg Keir 1 , Athol U. Wells 1 , Christopher P. Denton 2 and J. Gerry<br />
Coghlan 3 , 1 Royal Brompton Hospital, London, 2 Royal Free<br />
Hospital, London, United Kingdom, 3 Royal Free Hospital, London,<br />
London, United Kingdom<br />
5:30 PM<br />
728. Predictive Factors <strong>of</strong> Hand Radiographic Lesions in<br />
Systemic Sclerosis: A Prospective Study.<br />
Jerome Avouac 4 , Giulia Mogavero 1 , Henri Guérini 2 , Jean-Luc<br />
Drapé 2 , Alessandro Mathieu 1 , Andre Kahan 3 and Yannick<br />
Allanore 3 , 1 2nd Chair <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Cagliari,<br />
Cagliari, Italy, 2 Paris Descartes University, Radiology B<br />
Department, Cochin Hospital, APHP, Paris, France, 3 Paris<br />
Descartes University, <strong>Rheumatology</strong> A Department, Cochin<br />
Hospital, APHP, Paris, France, 4 Paris Descartes University,<br />
<strong>Rheumatology</strong> A Department, Cochin Hospital, APHP, Paris,<br />
France<br />
5:45 PM<br />
729. Predictive Value <strong>of</strong> Non-Invasive Tests for the Diagnosis<br />
<strong>of</strong> Scleroderma-Associated Pulmonary Hypertension: PHAROS<br />
Registry.<br />
Dinesh Khanna 4 , Rajeev Saggar 4 , Daniel E. Furst 4 , Yannick<br />
Allanore 3 , James R. Seibold 5 , Philip J. Clements 4 , Rajan Saggar 4 ,<br />
Chi-hong Tseng 4 , Paul Maranian 4 , Monique Hinchcliff 2 , Virginia<br />
Steen 1 and PHAROS Investigators, 1 Georgetown University,<br />
2<br />
Northwestern Univ, 3 Paris Descartes University, 4 UCLA, 5 Univ <strong>of</strong><br />
Connecticut<br />
ACR Meet the Pr<strong>of</strong>essor Sessions<br />
4:30 - 6:00 PM<br />
Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />
separate registration and ticket. To verify which session you<br />
registered for, check to make sure the registration code on your<br />
ticket matches the code listed below in parentheses.<br />
B207<br />
Antiphospholipid Syndrome (021) f PS<br />
Speaker: Doruk Erkan, MD; Hospital for Special Surgery; New<br />
York, NY<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the spectrum <strong>of</strong> antiphospholipid syndrome<br />
• determine the diagnostic utility <strong>of</strong> antiphospholipid antibody<br />
tests<br />
• describe the controversial aspects <strong>of</strong> primary and secondary<br />
thrombosis prevention in antiphospholipid syndrome<br />
• discuss the management <strong>of</strong> catastrophic antiphospholipid<br />
syndrome patients<br />
B208<br />
Crystal: Management <strong>of</strong> Gout (022) PS<br />
Speaker: Hyon K. Choi, MD, DrPH; University <strong>of</strong> British Columbia;<br />
Vancouver, BC, Canada<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the management <strong>of</strong> gout in patients with renal<br />
insufficiency or organ transplants<br />
• identify strategies to treat patients who are intolerant <strong>of</strong><br />
approved therapies<br />
• cite agents in development for the treatment <strong>of</strong><br />
hyperuricemia and gout<br />
B209<br />
Fibromyalgia (023) PM<br />
Speaker: Manuel Martinez-Lavin, MD; National Cardiology<br />
Institute; Mexico City, Mexico<br />
2010 Program Book 51<br />
monday
monday<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the most recent thoughts regarding the<br />
pathophysiology <strong>of</strong> fibromyalgia and related disorders<br />
• prescribe a treatment program for the typical fibromyalgia<br />
patient and serve as a consultant to that patient and the<br />
primary care provider<br />
• describe the principles <strong>of</strong> a comprehensive treatment<br />
program for the more challenging fibromyalgia patient<br />
B210<br />
Immunodeficiency Syndromes (024)<br />
Speaker: Alton Melton, MD; Cleveland Clinic; Cleveland, OH<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review the immunology and clinical manifestations <strong>of</strong> the<br />
major immune deficiency syndromes that both adult and<br />
pediatric rheumatologist might encounter<br />
• discuss the diagnostic evaluation for someone suspected <strong>of</strong><br />
having an immune deficiency syndrome<br />
• illustrate therapeutic options with cases<br />
B301<br />
Myopathy: Issues in Diagnosis and Treatment (025)<br />
f<br />
Speaker: Mark F. Gourley, MD; NIAMS; Bethesda, MD<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• distinguish inflammatory myopathies from other muscles<br />
diseases<br />
• plan a diagnostic work-up for a patient with signs and<br />
symptoms <strong>of</strong> muscle disease<br />
• design a treatment program for a patient with myositis<br />
B304<br />
Rheumatoid Arthritis: Outcome Measures in Clinical<br />
Practice (028) PS<br />
Speaker: Martin J. Bergman, MD; Arthritis and <strong>Rheumatology</strong>;<br />
Ridley Park, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss outcome measures used in rheumatoid arthritis<br />
• integrate outcome measures into an <strong>of</strong>fice-based practice<br />
B305<br />
Systemic Lupus Erythematosus: Central Nervous<br />
System (029)<br />
Speaker: F. Jorge Sanchez-Guerrero, MD; Instituto Nacional<br />
Nutricion; Mexico City, Mexico<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify manifestations <strong>of</strong> central nervous system lupus<br />
• select appropriate diagnostic tests in patients with central<br />
nervous system lupus<br />
• formulate a treatment plan<br />
B306<br />
Temporal Arteritis (030)<br />
Speaker: Gene G. Hunder, MD; Mayo Clinic; Rochester, MN<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the most current concepts in diagnosis <strong>of</strong> temporal<br />
arteritis, including the use <strong>of</strong> imaging modalities<br />
• identify evolving concepts in treatment <strong>of</strong> temporal arteritis,<br />
including appropriate use <strong>of</strong> corticosteroids, as well as the<br />
data regarding the efficacy <strong>of</strong> other “steroid sparing” agents<br />
• describe controversial areas in diagnosis and management <strong>of</strong><br />
temporal arteritis<br />
52<br />
B302<br />
Pediatric Systemic Lupus (026) P<br />
Speaker: Ilona S. Szer, MD; Rady Children’s Hospital; San Diego,<br />
CA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss differences in presentation, disease course and<br />
treatment options between childhood-onset and adult-onset<br />
systemic lupus erythematosus<br />
• cite recent and ongoing research efforts in childhood-onset<br />
systemic lupus erythematosus<br />
• describe important developmental issues in the care <strong>of</strong><br />
children and adolescents with a chronic disease<br />
B303<br />
Psoriatic Arthritis (027)<br />
Speaker: Dafna D. Gladman, MD; Toronto Western Hospital;<br />
Toronto, ON, Canada<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss advances in diagnosis and classification <strong>of</strong> psoriatic<br />
arthritis<br />
• determine if patients with psoriatic arthritis should be treated<br />
aggressively<br />
• determine treatment options for patients with psoriatic<br />
arthritis<br />
2010 Program Book<br />
ACR Special Session<br />
4:30 - 6:00 PM<br />
B313<br />
Legislative Update from Capitol Hill<br />
Moderator: Sharad Lakhanpal, MB, MD; University <strong>of</strong> Texas<br />
Southwestern; Dallas, TX<br />
This session is not eligible for CME credit.<br />
4:30 PM<br />
Health Policy Discussion<br />
Speaker to be announced<br />
Session Overview:<br />
Advocacy is a top priority <strong>of</strong> the <strong>American</strong> <strong>College</strong> <strong>of</strong><br />
<strong>Rheumatology</strong>. Legislative and regulatory actions include<br />
Medicare physician reimbursement, increased research funding<br />
for arthritis or lupus, health care reform, incentives for health<br />
information technology, and directly patients with rheumatic<br />
affect diseases. This session has been designed to provide<br />
rheumatologists and health pr<strong>of</strong>essionals a forum to discuss<br />
what is on the congressional agenda that could affect them and<br />
their patients.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss legislative actions that Congress has taken in the past<br />
year<br />
• explain Congress and the Administration’s role in creating<br />
health policy<br />
• assess health care legislation and its effects on the<br />
rheumatology pr<strong>of</strong>ession
ACR REF Special Sessions<br />
4:30 - 6:00 PM<br />
A315<br />
ACR REF Clinician Scholar Educator Lecture Ed.<br />
Moderators: Abby Goulder Abelson, MD; Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
Terry M. Wolpaw, MD, MHPE; Case Western School <strong>of</strong> Medicine;<br />
Cleveland, OH<br />
4:30 PM<br />
Introduction<br />
William T. Branch, Jr., MD; Emory School <strong>of</strong> Medicine; Atlanta,<br />
GA<br />
5:00 PM<br />
Rethinking <strong>Rheumatology</strong> Education: Focusing the Options for<br />
Medical Students<br />
Sharon L. Kolasinski, MD; Hospital <strong>of</strong> University Pennsylvania;<br />
Philadelphia, PA<br />
5:30 PM<br />
A Web-based Educational Tool to Teach a Standardized<br />
Musculoskeletal Examination in Children<br />
Yukiko Kimura, MD; Hackensack University Medical Center;<br />
Hackensack, NJ<br />
Session Overview:<br />
This session includes an overview on current issues in medical<br />
education, as well as an opportunity for clinician scholar<br />
educators to share their final project results with the broader<br />
audience. The purpose <strong>of</strong> this session is for rheumatologists<br />
to expand their repertoire <strong>of</strong> scholarship methods through<br />
interactive skill-based learning <strong>of</strong> principles and specific<br />
approaches, for collecting and analyzing qualitative data. This<br />
session will also serve to inform rheumatology educators, most<br />
importantly Training Program Directors, about new educational<br />
methods and curricula, including those developed via the ACR<br />
REF Clinician Scholar Educator Award recipients.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss novel approaches to curriculum development for<br />
medical students and residents in the musculoskeletal and<br />
rheumatic diseases<br />
• implement new approaches to teaching in the rheumatic and<br />
musculoskeletal diseases<br />
• discuss important areas <strong>of</strong> overlap in medical education<br />
between geriatric medicine and rheumatology and the impact<br />
<strong>of</strong> this education on quality <strong>of</strong> care<br />
• describe the unique and important roles <strong>of</strong> the clinician<br />
scholar educator in medical education and training<br />
B402<br />
REF Edmond L. Dubois, MD, Memorial Lectureship:<br />
The Path from Gene to Function: Analysis <strong>of</strong> a Lupus<br />
Susceptibility Gene c/r<br />
Moderator: E. William St.Clair, MD; Duke University Medical<br />
Center; Durham, NC<br />
4:30 PM<br />
Single-Nucleotide Polymorphisms Associated with Systemic<br />
Lupus Erythematosus (SLE) Skew Alternative Splicing <strong>of</strong> Human<br />
Complement Receptor 2 (CR2/CD21) towards an Is<strong>of</strong>orm with<br />
Increased Ligand Binding Ability (Abstract #730).<br />
Susan A. Boackle, MD; University <strong>of</strong> Colorado Denver<br />
School <strong>of</strong> Medicine; Denver, CO<br />
Kara M. Lough 3 , Katherine B. Douglas 3 , Carissa L. Homme 3 ,<br />
Daniela Ulgiati 1 and Betty P. Tsao 2 , 1 School <strong>of</strong> Biomedical,<br />
Biomolecular and Chemical Sciences, University <strong>of</strong> Western<br />
Australia, 2 University <strong>of</strong> California, Los Angeles, 3 University <strong>of</strong><br />
Colorado Denver School <strong>of</strong> Medicine<br />
5:30 PM<br />
731. Further Defining Cancer Risk in Systemic Lupus: Updated<br />
Results in an Expanded International Multi-Centre Cohort.<br />
Sasha R. Bernatsky 4 , Ann E. Clarke 7 , Michelle A. Petri 1 , Murray B.<br />
Urowitz 14 , Paul R. Fortin 16 , Dafna D. Gladman 16 , Søren Jacobsen 12,<br />
Susan Manzi 20 , Graciela S. Alarcon 2 , Ellen M. Ginzler 13 , Christine<br />
A. Peschken 18 , Mary Anne Dooley 3 , John G. Hanly 10 , Ola Nived 19 ,<br />
Gunnar K. Sturfelt 17 , Jean-Luc Senecal 9 , Jeremy Labrecque 5 ,<br />
Elizabeth M. Turnbull 6 , Jennifer L. F. Lee 11 and Rosalind Ramsey-<br />
Goldman 8 , 1Timonium, MD, 2 Oakland, CA, 3 Capital Health<br />
and Dalhousie University, Chapel Hill, NC, 4 McGill UHC/RVH,<br />
Montreal, QC, Canada, 5 McGill University, Montreal, Canada,<br />
6<br />
McGill University Health Ctr, Montreal, QC, Canada, 7 Montreal<br />
General Hospital, Montreal, QC, Canada, 8 Northwestern<br />
University, Chicago, IL, 9 Notre-Dame Hospital, M-4243, Montreal,<br />
QC, Canada, 10 Queen Elizabeth II Health Services Center,<br />
Halifax, NS, Canada, 11 RI McGill Univ Health Ctr, Montreal, QC,<br />
Canada, 12 Rigshospitalet - 4242, Copenhagen, Denmark, 13 SUNY-<br />
Downstate Medical Center, Brooklyn, NY, 14 The Toronto Western<br />
Hospital, Toronto, ON, Canada, 15 Toronto Western Hospital,<br />
Toronto, ON, Canada, 16 Toronto Western Hospital, Toronto,<br />
ON, Canada, 17 UCL Div <strong>of</strong> Medicine, Room 331, 3rd Floor, Lund,<br />
Sweden, 18 Univ <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 19 University<br />
Hospital, Lund, Sweden, 20 West Penn Allegheny Health System,<br />
Pittsburgh, PA<br />
5:45 PM<br />
732. Hydroxychloroquine and Prevention <strong>of</strong> Anti-SSA/Ro<br />
Associated Cardiac Disease in Mothers with a Previous Child<br />
with Neonatal Lupus.<br />
Peter M. Izmirly 4 , Cecilia Pisoni 2 , Mimi Y. Kim 1 , Deborah Friedman 3 ,<br />
Carolina Llanos 5 , Nathalie Costedoat-Chalumeau 7 , Munther A.<br />
Khamashta 6 and Jill P. Buyon 4 , 1 Albert Einstein <strong>College</strong> <strong>of</strong> Medicine,<br />
2<br />
King’s <strong>College</strong> <strong>of</strong> London, 3 New York Medical <strong>College</strong>, 4 NYU School<br />
<strong>of</strong> Medicine, New York, NY, 5 Pontificia Universidad Catolica de<br />
Chile, 6 The Rayne Institute, London, United Kingdom, 7 Universite<br />
Paris VI Pierre et Marie Curie<br />
ARHP Concurrent Sessions<br />
4:30 - 6:00 PM<br />
B309<br />
Juvenile Fibromyalgia P/C PM<br />
Moderator: Elizabeth G. Salt, PhD ARNP; University <strong>of</strong> Kentucky;<br />
Lexington, KY<br />
Speakers: Susmita Kashikar-Zuck, PhD; Cincinnati Children’s<br />
Hospital Medical Center; Cincinnati, OH<br />
Tracy V. Ting, MD; Cincinnati Children’s Hospital; Cincinnati, OH<br />
Session Overview:<br />
Juvenile fibromyalgia, a prevalent chronic pain syndrome,<br />
is characterized by widespread pain, fatigue, and sleep<br />
disturbance. A physical and emotional impact has been<br />
attributed to this health condition that results in altered peer<br />
relationships, irregular school attendance, and emotional issues.<br />
The diagnosis and evidence-based management <strong>of</strong> this health<br />
condition is important to improving patient outcomes.<br />
2010 Program Book 53<br />
monday
monday<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• define the diagnostics criteria for juvenile fibromyalgia<br />
• state the prevalence and rates <strong>of</strong> disability due to this health<br />
condition<br />
• describe the suspected etiology <strong>of</strong> this health condition<br />
• define the role <strong>of</strong> family members in the management <strong>of</strong><br />
juvenile fibromyalgia<br />
• explain interventions used to treat juvenile fibromyalgia<br />
B310<br />
Osteoporosis Treatment Update C PS<br />
Moderator: Kori A. Dewing, MN, ARNP; VA Mason Medical<br />
Center; Everett, WA<br />
Speaker: Julie L. Carkin, MD; The Seattle Arthritis Clinic; Seattle,<br />
WA<br />
Session Overview:<br />
<strong>Rheumatology</strong> nurse practitioners, physician assistants and<br />
other health care team members serve a critical role in<br />
diagnosing and managing patients with osteoporosis. There is<br />
much debate about who should be treated and for how long.<br />
Therefore, it is important for rheumatology health care providers<br />
to be knowledgeable <strong>of</strong> the evidence-based data to ensure that<br />
treatment decisions are implemented to best meet the goal <strong>of</strong><br />
fracture prevention.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the clinical risk factors with bone mineral density to<br />
more accurately identify fracture risk<br />
• describe the scientific data supporting length <strong>of</strong> osteoprorsis<br />
treatment<br />
• define the rationale for continuing or discontinuing<br />
osteoporosis therapy<br />
B308<br />
Rehabilitation in the Age <strong>of</strong> Biologics C PS<br />
Moderator: Mary Wright, BS, OT; The Toledo Hospital; Toledo,<br />
OH<br />
Speakers: Kamala M. Nola, PharmD, MS; Lipscomb <strong>College</strong> <strong>of</strong><br />
Pharmacy; Nashville, TN<br />
Maura D. Iversen, PT, DPT, SD, MPH; Northeastern University;<br />
Boston, MA<br />
Session Overview:<br />
There has been a national decline in referrals to occupational<br />
and physical therapy since the introduction <strong>of</strong> biologic therapies<br />
for the treatment <strong>of</strong> rheumatic diseases. As a result, patients<br />
are missing access to information to help with the management<br />
<strong>of</strong> their disease. Exercise, joint protection and activities <strong>of</strong><br />
daily living ideas are examples <strong>of</strong> what are missing from the<br />
management <strong>of</strong> their disease.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• cite the development and progression <strong>of</strong> the biologic<br />
medications<br />
• distinguish the different classes <strong>of</strong> biologics and how they<br />
treat the rheumatic diseases<br />
• describe the different methods <strong>of</strong> how these medications are<br />
administered<br />
• identify appropriate therapy treatments for patients on<br />
biologic medications<br />
• describe to physicians how therapy can complement the<br />
medical treatment for maximum positive outcomes <strong>of</strong> the<br />
patient<br />
• explain to patients how therapy can help minimize problems<br />
associated with the diseases these medications treat<br />
B311<br />
Reproductive and Sexual Health Issues for Women<br />
with Rheumatic Disease c/r<br />
Moderator: Susan M. Oliver, RN MSc; Pennine Musculoskeletal<br />
Partnership; Oldham, United Kingdom<br />
Speakers: Wendy Marder, MD; University <strong>of</strong> Michigan; Ann<br />
Arbor, MI<br />
W. Tracy Talmadge, PhD; Atlanta, GA<br />
Senait Fisseha, MD, JD; University <strong>of</strong> Michigan; Ann Arbor, MI<br />
Session Overview:<br />
Among wom en with autoimmune disease, issues relating to<br />
premature ovarian failure, reproductive viability and general<br />
sexual health <strong>of</strong>ten get overlooked due to underlying severe<br />
disease activity or lack <strong>of</strong> awareness on the part <strong>of</strong> the health<br />
care provider. Autoimmune disease <strong>of</strong>ten affects women during<br />
their reproductive years, and the consequences <strong>of</strong> therapies<br />
administered during this time have larger implications that will<br />
impact them throughout their lives. It is important for health<br />
care providers to be aware <strong>of</strong> methods to preserve fertility<br />
among these patients and the burden <strong>of</strong> disease associated<br />
with premature ovarian failure and be prepared to discuss the<br />
options with patients.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the epidemiology, comorbidities, and public<br />
health burden <strong>of</strong> premature ovarian failure in patients<br />
with systemic disease exposed to gonadotoxic agents (e.g.,<br />
cyclophosphamide)<br />
• identify sexual health implications and management strategies<br />
for patients with early menopause and/or infertility<br />
• explain the emerging options for ovarian protection and<br />
fertility preservation and assess the pros and cons<br />
REF Industry Roundtable-<br />
Supported Symposia<br />
6:30 - 9:30 PM<br />
The REF would like to thank the industry leaders that have made<br />
a significant multi-year commitment to the REF for participation<br />
in the Industry Roundtable.<br />
In appreciation for their commitment, these industry leaders<br />
have been invited to host a symposium during the annual<br />
meeting. In 2010, there are two types <strong>of</strong> symposia <strong>of</strong>fered to<br />
attendees: CME-accredited and non-CME accredited. For CMEaccredited<br />
symposia, the sponsoring organization is responsible<br />
for planning and providing CME credit. The non-CME accredited<br />
symposia have been planned and will be implemented in<br />
accordance with the requirements <strong>of</strong> the FDA and applicable<br />
standards <strong>of</strong> the PhRMA Code on Interactions with Healthcare<br />
Pr<strong>of</strong>essionals. Please visit the organization’s exhibit booth, the<br />
industry-supported symposia booth or see page 280 for more<br />
information.<br />
54<br />
2010 Program Book
REF 5K Run/Walk<br />
6:00 - 8:00 am<br />
See page 13 for more information.<br />
TUESDAY, NOVEMBER 9, 2010<br />
ACR/ARHP Registration<br />
6:30 am - 5:00 PM<br />
International Blvd. Foyer<br />
ACR Clinical Symposium<br />
7:15 - 8:15 am<br />
Hall A3<br />
Clinicopathologic Conference: A 62-year-old Male with<br />
Ulcerative Rash and Joint Pain cP PM PS ARS<br />
Moderator: S. Sam Lim, MD, MPH; Emory University; Atlanta, GA<br />
7:15 am<br />
Case Presentation<br />
Karen Law, MD; Emory University School <strong>of</strong> Medicine; Atlanta,<br />
GA<br />
7:30 am<br />
Case Presentation<br />
Abeer Moanna, MD; Emory University School <strong>of</strong> Medicine;<br />
Atlanta, GA<br />
7:45 am<br />
Case Presentation<br />
Brian P. Pollack, MD, PhD; Emory University School <strong>of</strong> Medicine;<br />
Atlanta, GA<br />
8:00 am<br />
Case Presentation<br />
Karen Atkinson, MD; Emory University School <strong>of</strong> Medicine;<br />
Atlanta, GA<br />
Ulrich Specks, MD; Mayo Clinic; Rochester, MN<br />
Session Overview:<br />
Clinical problem-solving is fundamental to the practice <strong>of</strong><br />
rheumatology. Rheumatologists need to be able to develop<br />
a differential diagnosis and initiate a targeted diagnostic<br />
plan based on clinical presentation alone. The myriad<br />
<strong>of</strong> rheumatologic diseases with primary dermatologic<br />
manifestations require a coordinated approach combining<br />
input from consulting specialties with thoughtful laboratory<br />
and pathology interpretation. This session will provide the<br />
framework for diagnosing such a process in an efficient,<br />
conscientious, and cost-effective manner.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss clinical clues in a rheumatologic presentation that<br />
might lead a practitioner towards a more unusual diagnosis<br />
than that which is originally recognized<br />
• recognize the limitations and specificity <strong>of</strong> both common and<br />
newer laboratory testing in making a clinical diagnosis<br />
• integrate the anatomic and pathologic diagnosis with the<br />
preceding evaluation and discuss clinical follow-up<br />
ACR Immunology Updates for<br />
Clinicians<br />
7:15 - 8:15 am<br />
Sidney J. Marcus Auditorium<br />
Macrophage Differentiation c/r<br />
Moderator: Richard J. Looney, MD; University <strong>of</strong> Rochester;<br />
Rochester, NY<br />
Speaker: John A. Hamilton, PhD, DSc; The University <strong>of</strong><br />
Melbourne; Parkville, VIC, Australia<br />
Session Overview:<br />
Macrophages are extraordinarily versatile playing beneficial<br />
roles in normal homeostasis, wound repair, and host defenses,<br />
but also playing important roles in tissue damage, fibrosis,<br />
chronic infection, atherosclerosis, and Alzheimer’s disease.<br />
In rheumatoid arthritis, macrophages are a major source <strong>of</strong><br />
tumor necrosis factor and other pro-inflammatory cytokines,<br />
but they are also capable <strong>of</strong> down-regulating and controlling<br />
inflammation. In systemic lupus erythematosus, defects in<br />
macrophage-mediated clearance <strong>of</strong> apoptotic debris allows<br />
activation <strong>of</strong> the α-interferon pathway and the deposition <strong>of</strong><br />
immune complexes in tissue. On the other hand, overly activated<br />
macrophages can be very destructive as seen in macrophage<br />
activation syndrome. Thus, if we are to follow the advice <strong>of</strong> Elie<br />
Metchnik<strong>of</strong>f, winner <strong>of</strong> the 1906 Nobel Prize and “stimulate the<br />
phagocyte”, we need to be very careful. Fortunately, there has<br />
been rapid progress in the study <strong>of</strong> macrophage differentiation<br />
and activation so that the factors responsible for different type<br />
<strong>of</strong> macrophages are beginning to become clear.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the characteristics and functions <strong>of</strong> classically<br />
activated macrophages, wound-healing macrophages,<br />
regulatory macrophages, and osteoclasts<br />
• describe the origin <strong>of</strong> macrophages and the factors that<br />
regulate activation/differentiation into the major macrophage<br />
populations<br />
• identify how different macrophage populations are important<br />
in host defenses and how infecting organisms try to use<br />
macrophages to subvert immunity<br />
• identify the beneficial and detrimental role <strong>of</strong> macrophages in<br />
rheumatologic disease<br />
ACR State-<strong>of</strong>-the-Art Lecture<br />
7:15 - 8:15 am<br />
Thomas J. Murphy Ballroom<br />
Methotrexate 2010 cP P/C PS<br />
Moderator: Eric M. Ruderman, MD; Northwestern University<br />
School; Chicago, IL<br />
7:15 AM<br />
Methotrexate: The Clear Standard <strong>of</strong> Care for Rheumatoid<br />
Arthritis<br />
Michael E. Weinblatt, MD; Brigham and Women’s Hospital;<br />
Boston, MA<br />
tuesday<br />
2010 Program Book 55
tuesday<br />
7:25 AM<br />
New Insights into Mechanisms <strong>of</strong> Action and Method <strong>of</strong><br />
Administration<br />
Joel M. Kremer, MD; The Center for <strong>Rheumatology</strong>; Albany, NY<br />
7:55 am<br />
Re-evaluating Methotrexate Toxicity and Monitoring in the<br />
Changing Landscape <strong>of</strong> Rheumatoid Arthritis Therapy<br />
Michael E. Weinblatt, MD; Brigham and Women’s Hospital;<br />
Boston, MA<br />
Session Overview:<br />
Methotrexate has become the mainstay <strong>of</strong> therapy in<br />
rheumatoid arthritis and psoriatic arthritis, both as monotherapy<br />
and as the anchor drug for additional biologic agents, and<br />
is frequently used as primary or adjunctive therapy in other<br />
rheumatologic diseases. Since the development <strong>of</strong> the ACR<br />
guidelines for monitoring hepatoxicity with methotrexate over<br />
10 years ago, new information has become available on the<br />
mechanism, toxicities, and the value <strong>of</strong> monitoring strategies<br />
for this drug. The current and future use <strong>of</strong> other agents in<br />
combination with methotrexate, which may share some <strong>of</strong><br />
the same organ toxicities, creates a challenge for practitioners<br />
trying to safely prescribe and monitor methotrexate therapy.<br />
This presentation will review the history <strong>of</strong> methotrexate use,<br />
update the data on its mechanism(s) <strong>of</strong> action and toxicity, and<br />
explore the challenges inherent in the use <strong>of</strong> methotrexate in<br />
combination with other agents.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify potential mechanisms for the effect <strong>of</strong> methotrexate<br />
in rheumatic diseases<br />
• describe the rationale for modifying the dose and method <strong>of</strong><br />
administration <strong>of</strong> methotrexate<br />
• identify potential toxicities associated with methotrexate,<br />
along with the rationale for, and details <strong>of</strong>, the existing<br />
guidelines for monitoring methotrexate therapy<br />
ACR Special Session<br />
7:30 - 8:30 am<br />
A411<br />
News from the National Institutes <strong>of</strong> Health: Updates<br />
and Opportunities R<br />
Moderators: Mariana J. Kaplan, MD; University <strong>of</strong> Michigan<br />
Medical Center; Ann Arbor, MI<br />
Raymond L. Yung, MD; University <strong>of</strong> Michigan Medical Center;<br />
Ann Arbor, MI<br />
7:30 am<br />
Cartilage Research at the National Institute on Aging<br />
John Williams, PhD; National Institute on Aging; Bethesda, MD<br />
7:50 am<br />
Enhancements to Peer Review and You<br />
Laura K. Moen, PhD; National Institute <strong>of</strong> Arthritis and<br />
Musculoskeletal and Skin; Bethesda, MD<br />
8:10 am<br />
Current and Future Needs and Opportunities for <strong>Rheumatology</strong><br />
Clinical Trials<br />
Robert H. Carter, MD; National Institute <strong>of</strong> Arthritis and<br />
Musculoskeletal and Skin/Nationl Institutes <strong>of</strong> Health; Bethesda,<br />
MD<br />
Session Overview:<br />
The National Institutes <strong>of</strong> Health represents the premier agency<br />
funding arthritis research. However, there is a gap in the ACR<br />
members’ knowledge <strong>of</strong> National Institutes <strong>of</strong> Health funding<br />
opportunities outside <strong>of</strong> National Institute <strong>of</strong> Arthritis and<br />
Musculoskeletal and Skin and National Institute <strong>of</strong> Allergy and<br />
Infectious Diseases. Additionally, recent major changes in the<br />
National Institutes <strong>of</strong> Health grant application process have<br />
significant impact on rheumatology researchers.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review funding opportunities and resources for basic arthritis<br />
research at the National Institute on Aging<br />
• describe the impact <strong>of</strong> recent changes in the National<br />
Institutes <strong>of</strong> Health grant application system<br />
• define the priorities for clinical research in rheumatic diseases<br />
ACR Meet the Pr<strong>of</strong>essor Sessions<br />
7:45 - 9:15 am<br />
Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />
separate registration and ticket. To verify which session you<br />
registered for, check to make sure the registration code on your<br />
ticket matches the code listed below in parentheses.<br />
B207<br />
Antiphospholipid Syndrome (031) PS<br />
Speaker: Robert A. S. Roubey, MD; University <strong>of</strong> North Carolina;<br />
Chapel Hill, NC<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the diverse clinical subsets within the spectrum <strong>of</strong><br />
antiphospholipid syndrome<br />
• discuss the laboratory tests used to confirm antiphospholipid<br />
syndrome<br />
• analyze the therapeutic alternatives for the different<br />
manifestations <strong>of</strong> antiphospholipid syndrome, including the<br />
benefit/risk, adverse effects and limitations<br />
B208<br />
Crystal: Management <strong>of</strong> Gout (032) PS<br />
Speaker: Peter A. Simkin, MD; University <strong>of</strong> Washington; Seattle,<br />
WA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• critique recent changes in the epidemiology and complexity <strong>of</strong><br />
gout relevant to clinical practice<br />
• determine the basis and status <strong>of</strong> novel drugs for lowering<br />
serum urate in refractory patients<br />
• determine new developments in gout inflammation<br />
pathophysiology and how they point to novel treatment<br />
strategies<br />
B209<br />
Infections in Patients on Tumor Necrosis Factor<br />
Therapy (033) PS<br />
Speaker: Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the risks <strong>of</strong> infections, including opportunistic<br />
infections, with biological response modifier therapies for<br />
rheumatoid arthritis<br />
56<br />
2010 Program Book
• discuss the principles <strong>of</strong> early detection and management <strong>of</strong><br />
infections in patients who develop infections<br />
• determine ways to reduce the risk <strong>of</strong> occurrence <strong>of</strong> infections<br />
in patients with rheumatoid arthritis<br />
B210<br />
Osteoarthritis: Update 2010 (034)<br />
Speaker: Richard F. Loeser, MD; Wake Forest University;<br />
Winston-Salem, NC<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the potential causes and exacerbating factors <strong>of</strong> the<br />
disease<br />
• discuss the appropriate use <strong>of</strong> laboratory testing and imaging<br />
modalities<br />
• design an efficacious, safe and cost-effective therapeutic<br />
strategy<br />
B302<br />
Pediatric <strong>Rheumatology</strong> for Adult Rheumatologists<br />
(035) P f<br />
Speaker: Peter A. Nigrovic, MD; Harvard Medical School; Boston,<br />
MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• diagnose the various forms <strong>of</strong> arthritis that are unique to<br />
children<br />
• identify how the evaluation <strong>of</strong> children with rheumatic<br />
diseases may be different from that <strong>of</strong> adults<br />
• describe current treatments <strong>of</strong> arthritis in children<br />
B301<br />
Pediatrics: Dermatomyositis (036) P<br />
Speaker: Adam Huber, MD; IWK Health Centre; Halifax, NS,<br />
Canada<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss recent research developments regarding juvenile<br />
dermatomyositis<br />
• describe the clinical assessment and management <strong>of</strong> juvenile<br />
dermatomyositis<br />
B303<br />
Reactive Arthritis: An Update (037)<br />
Speaker: Atul A. Deodhar, MD; Oregon Health & Science<br />
University; Portland, OR<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify various causes <strong>of</strong> reactive arthritis<br />
• discuss mechanisms <strong>of</strong> disease pathogenesis<br />
• describe current treatment options for reactive arthritis<br />
B304<br />
Rheumatoid Arthritis: Biological Agents (038) PS<br />
Speaker: Larry W. Moreland, MD; University <strong>of</strong> Pittsburgh<br />
Medical Center; Pittsburgh, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify biologic agents in use for the treatment <strong>of</strong> rheumatoid<br />
arthritis<br />
• describe the risk/benefit pr<strong>of</strong>iles <strong>of</strong> biologic agents<br />
• discuss the emerging biologics and their advantages for the<br />
therapeutic algorithm<br />
B305<br />
Scleroderma: Systemic Sclerosis (039) PM<br />
Speaker: Christopher P. Denton, MD, PhD; Royal Free Hospital;<br />
London, United Kingdom<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the classification <strong>of</strong> systemic sclerosis and its impact<br />
on treatment and prognosis<br />
• apply cardiopulmonary testing to determine the relative<br />
contributions <strong>of</strong> alveolitis, fibrosis and vasculopathy<br />
• formulate a therapeutic regimen to improve quality <strong>of</strong> life and<br />
organ-specific symptomatology<br />
B306<br />
Vasculitis Mimics (040)<br />
Speaker: Alexandra Villa-Forte, MD, MPH; Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify clinical settings in which vasculitis should be<br />
suspected<br />
• describe the different medical conditions that could mimic<br />
clinical presentations <strong>of</strong> vasculitis<br />
• identify the challenges in the diagnostic process and how<br />
ancillary test results could be misleading<br />
• discuss the process to distinguish between a vasculitic<br />
syndrome and a “vasculitis mimic”<br />
ACR/ARHP Workshops<br />
7:45 - 9:45 am<br />
Admission to each Workshop requires a separate registration<br />
and ticket. To verify which session you registered for, check<br />
tomake sure the registration code on your ticket matches the<br />
code listed below in parentheses.<br />
B202<br />
Dermatopathology <strong>of</strong> Rheumatic Diseases (216)<br />
Speaker: Lynne Goldberg, MD; Boston University Medical<br />
Center; Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review dermatopathology in rheumatic diseases<br />
• describe the importance <strong>of</strong> dermatopathology in clinical<br />
decision-making in patients with rheumatic diseases<br />
• apply the knowledge gained to clinical practice<br />
B201<br />
Excel Spreadsheets: Basic Concepts to Elevate Your<br />
Skills Beyond Those <strong>of</strong> Your Children (217)<br />
Speaker: Richard A. Furie, MD; North Shore Long Island Jewish<br />
Health System; Lake Success, NY<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• create a spreadsheet despite having no prior knowledge <strong>of</strong><br />
spreadsheet function or design<br />
• design a graph using spreadsheet date<br />
• distinguish between a database and a spreadsheet<br />
2010 Program Book 57<br />
tuesday
tuesday<br />
B206<br />
Joint Injections (Shoulder and Wrist Prosthetics) (218)<br />
Speaker: Gregory C. Gardner, MD; University <strong>of</strong> Washington;<br />
Seattle, WA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe indications for upper extremity joint injection and<br />
aspiration<br />
• identify anatomic landmarks for injection <strong>of</strong> the shoulder and<br />
wrist using joint prosthetics<br />
• apply principles <strong>of</strong> joint aspiration and injection using<br />
shoulder and wrist joint prosthetics<br />
ARHP Concurrent Sessions<br />
7:45 - 8:45 am<br />
B310<br />
Clinical Trial Essentials: Budgets, Contracts and<br />
Regulations c/r<br />
Moderator: Lisa M. Kastanek, RN, CCRC; Physician Research<br />
Collaboration; Lincoln, NE<br />
Speaker: Donah Z. Crawford, BS, MA; The Arthritis Group;<br />
Philadelphia, PA<br />
Session Overview:<br />
For all members <strong>of</strong> the clinical trials team to be effective it<br />
is necessary for each member to understand the essentials<br />
required for successfully managing clinical trial sites and to be<br />
aware <strong>of</strong> the contract and budgetary considerations.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the elements required to legally and ethically<br />
conduct a clinical trial in the US<br />
• define the basic elements <strong>of</strong> a clinical trial contract, and<br />
budget<br />
• explain the roles <strong>of</strong> the members <strong>of</strong> a clinical trials team<br />
B308<br />
Hand X-ray Review and Interpretation cP<br />
Moderator: Aimee Wiener, ARNP C, MSN; Arthritis Autoimmune<br />
& Asthma; Daytona Beach, FL<br />
Speaker: Andrew J. Sulich, MD; Shores <strong>Rheumatology</strong>; St. Clair<br />
Shores, MI<br />
Session Overview:<br />
The ability to read and interpret hand X-rays is fundamental<br />
in understanding, diagnosing and managing rheumatologic<br />
conditions. For most health care pr<strong>of</strong>essionals in a rheumatology<br />
practice these skills are obtained on the job. This session will<br />
assist health care pr<strong>of</strong>essionals in developing their knowledge<br />
to better treat their patients.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe changes commonly seen in hand osteoarthritis<br />
including joints commonly affected, joint space narrowing,<br />
osteophytes, and mucous cysts<br />
• describe changes commonly seen in inflammatory arthritis<br />
conditions including juxtaarticular osteoporosis, generalized<br />
osteopenia, erosions, angulation, ankylosis, pencil-in-cup<br />
deformity, lysis <strong>of</strong> terminal phalanges, fluffy periostitis, new<br />
bone formation at enthesitis, and effusions<br />
• identify changes seen in hemachromatosis and pseudogout<br />
including chondrocalcinosis, squared <strong>of</strong>f bone ends and hooklike<br />
osteophytes in the 2nd and 3rd metacarpophalangeal<br />
joints<br />
• distinguish between erosive and classic osteoarthritis and<br />
rheumatoid arthritis and other inflammatory conditions,<br />
utilizing a systematic method for reading hand X-ray images<br />
B313<br />
Rheumatic Disease Update: Sjögren’s Syndrome c/r<br />
Moderator: Benjamin J. Smith, PA-C; McIntosh Clinic PC;<br />
Thomasville, GA<br />
Steven E. Carsons, MD; Winthrop University Hospital; Mineola,<br />
NY<br />
Session Overview:<br />
Sjögren’s syndrome is a common autoimmune disease seen<br />
in rheumatology practice. This potentially debilitating disease<br />
is <strong>of</strong>ten missed and/or treated inappropriately because <strong>of</strong><br />
confusion regarding diagnostic criteria and treatment strategies.<br />
This timely review will address these deficiencies.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the immunologic basis for primary Sjögren’s syndrome<br />
• describe the classification criteria for primary Sjögren’s<br />
syndrome<br />
• develop a management plan for a patient with Sjögren’s<br />
syndrome<br />
B309<br />
The Multidisciplinary Approach to Hereditary<br />
Periodic Fever Syndromes P/C<br />
Moderator: Bernadette McNally, MS, PAC; University <strong>of</strong> Utah;<br />
Salt Lake City, UT<br />
Speakers: Beverly K. Barham, RN MSN CCRC; NIAMS; Bethesda,<br />
MD<br />
Nicole D. Plass, BSN, MPA; National Institutes <strong>of</strong> Health;<br />
Bethesda, MD<br />
Session Overview:<br />
Hereditary periodic fever syndromes are rare diseases caused by<br />
genetic mutations that cause episodic inflammation. This lecture<br />
will provide health care providers with a basic overview <strong>of</strong> the<br />
phenotypic and genotypic presentations, health care needs, and<br />
treatment options for patients with familial Mediterranean fever,<br />
tumor necrosis factor-receptor associated periodic syndrome,<br />
hyper-immunoglobulinemia D with periodic fever syndrome and<br />
others.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the genotypic and phenotypic presentation <strong>of</strong><br />
familial Mediterranean fever, hyper-immunoglobulinemia D<br />
with periodic fever syndrome, tumor necrosis factor-receptor<br />
associated periodic syndrome and other periodic fever<br />
syndromes<br />
• develop a management plan for the health care needs <strong>of</strong><br />
families experiencing a member with a rare hereditary<br />
periodic fever syndrome<br />
• define treatment options and other resources for patients<br />
with hereditary periodic fever syndromes<br />
58<br />
2010 Program Book
ACR Medical Aspects <strong>of</strong> Rheumatic<br />
Diseases<br />
8:45 - 9:45 am<br />
Hall A3<br />
Update on Multiple Sclerosis<br />
cP P/C PS ARS<br />
Moderator: Nancy Y. Liu, MD; University <strong>of</strong> Massachusetts;<br />
Worcester, MA<br />
Speaker: Peter Riskind, MD, PhD; University <strong>of</strong> Massechussetts<br />
Memorial Health Center; Worcester, MA<br />
Session Overview:<br />
Multiple sclerosis is a primary inflammatory, autoimmune<br />
disease <strong>of</strong> the central nervous system. The manifestations <strong>of</strong><br />
multiple sclerosis may have clinical overlap with our patients<br />
with connective tissue disorders who have central nervous<br />
system involvement. As practicing rheumatologists, it is<br />
important to be familiar with new advances in pathogenesis,<br />
genetics, diagnosis, and therapeutics <strong>of</strong> multiple sclerosis. This<br />
knowledge should assist the clinician to differentiate patients<br />
with multiple sclerosis from the rheumatic patient with central<br />
nervous system manifestations.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• apply the recent advances in diagnosis <strong>of</strong> multiple sclerosis in<br />
evaluating patients with neurologic complaints<br />
• differentiate the clinical manifestations <strong>of</strong> multiple sclerosis<br />
from other central nervous system manifestations <strong>of</strong><br />
connective tissue disorders<br />
• review the recent advances in therapy for multiple sclerosis<br />
ACR State-<strong>of</strong>-the-Art Lectures<br />
8:45 - 9:45 am<br />
Sidney J. Marcus Auditorium<br />
Autophagy and Immune Function R<br />
Moderators: Roberto Caricchio, MD; Temple University;<br />
Philadelphia, PA<br />
Keith B. Elkon, MD; University <strong>of</strong> Washington; Seattle, WA<br />
Speaker: Vojo Deretic, PhD; University <strong>of</strong> New Mexico Health<br />
Sciences Center; Albuquerque, NM<br />
Session Overview:<br />
It has only been realized recently that, in addition to apoptosis<br />
and necrosis, a third form <strong>of</strong> cell death, autophagy occurs in<br />
specific physiological and pathophysiological circumstances.<br />
These circumstances include cancer, autoimmunity and<br />
infectious diseases. It is important for rheumatologists to<br />
understand what stimuli induce autophagy, how to identify cells<br />
dying by autophagy the interactions between toll-like receptor<br />
stimulation and autophagy that impacts inflammation.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• determine how the morphology <strong>of</strong> autophagy differs from<br />
apoptosis and necrosis<br />
• describe under what circumstances cells die by autophagy<br />
• discuss the pathophysiological implications <strong>of</strong> autophagy<br />
are and how this form <strong>of</strong> death may impact rheumatologic<br />
diseases<br />
B402<br />
Kinases as Therapeutic Targets R<br />
Moderator: Gary S. Firestein, MD; University California - San<br />
Diego School <strong>of</strong> Medicine; La Jolla, CA<br />
Speaker: John J. O’Shea, MD; NIAMS/NIH; Bethesda, MD<br />
Session Overview:<br />
Targeting kinases may be a new approach to treat various<br />
immune-mediated inflammatory diseases. Several targeted small<br />
molecules interfering with intracellular signaling pathways are<br />
under clinical development.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the therapeutic potential <strong>of</strong> targeted small molecules<br />
interfering with intracellular signaling pathway for the<br />
treatment <strong>of</strong> inflammatory disorders<br />
• define the mechanism <strong>of</strong> action <strong>of</strong> novel targeted small<br />
molecules interfering with kinases<br />
ACR/ARHP Poster Session B and<br />
Poster Tours<br />
9:00 am - 6:00 PM<br />
Halls B1 & B2<br />
Poster presenters will be available from 9:00 - 11:00 am. Poster<br />
tours will be held 9:00 - 9:45 am, 10:15 - 11:00 am and 4:30 -<br />
5:30 PM.<br />
9:00 – 11:00 am – Poster Presentations (Abstracts # 733 – 1345)<br />
Guided Poster Tours<br />
Guided poster tours provide an opportunity for scientific<br />
attendees to ask questions and gain insights from leaders in<br />
the field while earning CME credits. Morning tours will <strong>of</strong>fer<br />
insights from both poster presenters and tour guides, while<br />
afternoon tours will exclusively feature the tour guide’s expert<br />
opinion. Although there is no fee to participate, pre-registration<br />
is required and each tour is limited to 20 registered scientific<br />
attendees. If you would like to participate and have not<br />
registered you can check tour availability and request a ticket<br />
in the registration area, located in the International Boulevard<br />
Foyer. If you registered in advance <strong>of</strong> the meeting your ticket was<br />
included with your meeting materials. Once you have your ticket,<br />
plan to collect your headset and meet your group 10 minutes<br />
before your tour departs from the entrance <strong>of</strong> the poster hall,<br />
located in Halls B1 & B2.<br />
Headsets: Each tour participant will receive a wireless headset.<br />
Participants who do not return their headsets within 10 minutes<br />
after the tour has ended will incur a fee.<br />
9:00 - 9:45 am<br />
Quality <strong>of</strong> Life<br />
Jennifer M. Hootman, PhD, Centers for Disease Control,<br />
Kennesaw, GA<br />
Physical Activity/Exercise<br />
Mary E. Christenson, Pt, PhD, Regis University, Westminster, CO<br />
Fibromyalgia and S<strong>of</strong>t Tissue Disorder<br />
Don L. Goldenberg, MD; Newton-Wellesley Hospital; Newton,<br />
MA<br />
tuesday<br />
2010 Program Book 59
Rheumatoid Arthritis: Clinical Aspects<br />
Deborah P. Symmons, MD; Arthritis Research UK Epidemiology<br />
Unit; Manchester, United Kingdom<br />
Rheumatoid Arthritis Treatment: Small Molecules, Biologic and<br />
Gene Therapy<br />
Martin Aringer, MD; Uniklinikum TU Dresden; Dresden, Germany<br />
Systemic Lupus Erythematosus: Clinical Aspects<br />
Eliza Chakravarty, MD; Stanford University; Mountain View, CA<br />
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s:<br />
Clinical Aspects and Therapeutics<br />
Maureen D. Mayes, MD, MPH; University <strong>of</strong> Texas-Houston;<br />
Houston, TX<br />
Exhibits and Replay Café<br />
9:00 am - 7:00 pm<br />
Halls A1 & A2<br />
Exhibits<br />
Halls A1 & A2 (Booth #123)<br />
Replay Café<br />
Exhibit Hall Morning SnACk Break<br />
9:00 - 10:00 AM<br />
Halls A1 & A2<br />
tuesday<br />
10:15 - 11:00 am<br />
Behavioral Science<br />
Susan J. Bartlett, PhD, McGill University, Montreal, Canada<br />
Pain<br />
Carol L. Baird, DNS, ARPN, BC, Indiana University, Indianapolis,<br />
IN<br />
Muscle Biology, Myositis and Myophathies<br />
Frederick W. Miller, MD, PhD; National Institute <strong>of</strong><br />
Environmental Health Sciences, NIH, Kennsington, MD<br />
Osteoporosis and Metabolic Bone Disease: Clinical Aspects and<br />
Pathogenesis<br />
Nancy E. Lane, MD; University <strong>of</strong> California-Davis, Hillsborough,<br />
CA<br />
Rheumatoid Arthritis: Clinical Aspects<br />
Larry W. Moreland, MD; University <strong>of</strong> Pittsburgh Medical Center;<br />
Pittsburgh, PA<br />
Rheumatoid Arthritis Treatment: Small Molecules, Biologic and<br />
Gene Therapy<br />
Eric M. Ruderman, MD; Northwestern University School;<br />
Chicago, IL<br />
Systemic Lupus Erythematosus: Human Etiology and<br />
Pathogenesis<br />
Mary K. Crow, MD; Hospital for Special Surgery; New York, NY<br />
4:30 - 5:30 PM<br />
Fibromyalgia and S<strong>of</strong>t Tissue Disorder<br />
Daniel J. Clauw, MD; University <strong>of</strong> Michigan Chronic Pain &<br />
Fatigue Research; Ann Arbor, MI<br />
Osteoarthritis - Clinical Aspects<br />
Timothy E. McAlindon, MD, MPH; Tufts Medical Center, Boston,<br />
MA<br />
Rheumatoid Arthritis: Clinical Aspects<br />
Jonathan Kay, MD; UMass Memorial Medical Center; Worcester,<br />
MA<br />
Vasculitis<br />
Alexandra Villa-Forte, MD, MPH; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
Poster Hall Morning SnACk Break<br />
9:00 - 10:30 am<br />
Halls B1 & B2<br />
ARHP Concurrent Abstract Session<br />
9:15 - 10:15 am<br />
B311<br />
Physical and Psychosocial Challenges in Scleroderma<br />
Moderator: Jane S. Brandenstein, BS, PT; Freedom, PA<br />
9:15 am<br />
1346. Frequency and Impact <strong>of</strong> Symptoms Experienced by<br />
Patients with Systemic Sclerosis: Results from a Canadian<br />
National Survey.<br />
Marielle Bassel 1 , Marie Hudson 3 , Suzanne S. Taillefer 4 , Orit<br />
Schieir 1 , Murray Baron 1 and Brett D. Thombs 2 , 1 Jewish General<br />
Hospital, Montreal, QC, Canada, 2 McGill University, Montreal,<br />
QC, Canada, 3 McGill University and Jewish General Hospital,<br />
4<br />
SMBD Jewish General Hospital, Montreal, QC, Canada<br />
9:30 am<br />
1347. Sociodemographic and Disease Correlates <strong>of</strong> Body Image<br />
in Systemic Sclerosis (SSc).<br />
Lisa R. Jewett 2 , Marie Hudson 3 , Murray Baron 1 , Brett D. Thombs 2<br />
and Canadian Scleroderma Research Group (CSRG), 1 Jewish<br />
General Hospital, Montreal, QC, Canada, 2 McGill University,<br />
Montreal, QC, Canada, 3 McGill University and Jewish General<br />
Hospital<br />
9:45 am<br />
1348. Development and Validation <strong>of</strong> the Brief-Satisfaction<br />
with Appearance Scale (Brief-SWAP) for Measuring Body Image<br />
in Systemic Sclerosis (SSc).<br />
Lisa R. Jewett 4 , Marie Hudson 5 , Jennifer A. Haythornthwaite 3 ,<br />
Leslie Heinberg 1 , Fredrick M. Wigley 3 , Murray Baron 2 , Brett D.<br />
Thombs 4 and Canadian Scleroderma Research Group (CSRG),<br />
1<br />
Cleveland Clinic Lerner <strong>College</strong> <strong>of</strong> Medicine <strong>of</strong> Case Western<br />
Reserve University, 2 Jewish General Hospital, Montreal, QC,<br />
Canada, 3 Johns Hopkins University School <strong>of</strong> Medicine, 4 McGill<br />
University, Montreal, QC, Canada, 5 McGill University and Jewish<br />
General Hospital<br />
60<br />
2010 Program Book
10:00 am<br />
1349. Work as a Daily Challenge: Working with Scleroderma.<br />
Cindy F. Mendelson 2 , Janet L. Poole 3 and Saralynn H. Allaire 1 ,<br />
1<br />
Boston Univ School <strong>of</strong> Medicine, Boston, MA, 2 Univ <strong>of</strong><br />
New Mexico, Albuquerque, NM, 3 University <strong>of</strong> New Mexico,<br />
Albuquerque, NM<br />
ARHP Concurrent Sessions<br />
9:15 - 10:15 am<br />
B309<br />
Daltroy Memorial Lecture: Adherence to Medical<br />
Regimens for Rheumatic Diseases and the Importance<br />
<strong>of</strong> Patient-Clinician Communication P/C PS<br />
Moderator: Maura D. Iversen, PT, DPT, SD, MPH; Northeastern<br />
University; Boston, MA<br />
Speaker: Michael A. Rap<strong>of</strong>f, PhD; University <strong>of</strong> Kansas<br />
Medical Center; Kansas City, KS<br />
Session Overview:<br />
Good patient-clinician communication is critical for optimal<br />
medical management and treatment outcomes for patients<br />
with rheumatic diseases. However, a clinician must be prepared<br />
to try various communication methods or techniques in order<br />
to attain good mutual understanding <strong>of</strong> the patient’s condition<br />
and treatment. This puts the patient at ease and allows for a<br />
better dialogue between the clinician and patient about the<br />
patient’s medical management. Clinicians who are successful<br />
communicators will enhance their patients’ adherence to the<br />
prescribed medical regimen.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the types and prevalence <strong>of</strong> adherence problems to<br />
medical regimens for rheumatic diseases<br />
• contrast the strengths and weaknesses <strong>of</strong> different methods<br />
for assessing adherence<br />
• document the importance <strong>of</strong> patient-clinician communication<br />
in enhancing adherence to medical regimens for rheumatic<br />
diseases<br />
B308<br />
Living with Osteoporosis cP PM<br />
Moderator: Janet S. Austin, PhD; NIAMS/NIH/DHHS; Bethesda,<br />
MD<br />
Speaker: Judith R. Gale, MPH, DPT, PT; Creighton University;<br />
Omaha, NE<br />
Session Overview:<br />
According to the National Osteoporosis Foundation,<br />
osteoporosis is the most common bone disease. There are an<br />
estimated 10 million people in the US with osteoporosis and an<br />
additional 34 million with osteopenia. Fifty percent <strong>of</strong> Caucasian<br />
women and 20 percent <strong>of</strong> men will experience a fracture related<br />
to osteoporosis, possibly leading to chronic pain, disability or<br />
death. The health care cost <strong>of</strong> these fractures was estimated at<br />
$17 billion in 2005.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the risk factors associated with osteoporosis<br />
• identify the clinical presentation <strong>of</strong> osteoporosis<br />
• describe the functional limitations related to this disease<br />
• discuss the management <strong>of</strong> osteoporosis<br />
B313<br />
Rheumatic Disease Update: Viral Arthritis c/r<br />
Moderator: Karen Huisinga, MN, ARNP, FNP; VA Puget Sound<br />
HCS; Bainbridge Island, WA<br />
Speaker: Leonard H. Calabrese, DO; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
Session Overview:<br />
Arthritis and arthralgias are well recognized and relatively<br />
common symptoms <strong>of</strong> viral infections. The most common viruses<br />
causing arthritis/arthralgias are parvovirus B-19, hepatitis B,<br />
hepatitis C, rubella, and the human immunodeficiency virus.<br />
Health care providers need a reappraisal <strong>of</strong> the diagnosis and<br />
advances in treatment <strong>of</strong> these diseases<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the common presentations <strong>of</strong> the human<br />
immunodeficiency virus related musculoskeletal syndrome<br />
• discuss the treatment options <strong>of</strong> hepatitis C arthritis<br />
• define the pathophysiology <strong>of</strong> hepatitis B and C related<br />
arthritis<br />
InnoVAtion Theater<br />
10:00 - 10:45 am<br />
Halls A1 & A2 (Booth #555)<br />
The following non-CME activity has been planned and will be<br />
implemented in accordance with the requirements <strong>of</strong> the FDA<br />
and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />
with Healthcare Pr<strong>of</strong>essionals by Genentech and Biogen Idec.<br />
Please visit the Genentechand Biogen Idec exhibit booth for more<br />
information or see page 292. Seating and light refreshments are<br />
subject to availability.<br />
Bridging the Gap: A Peer-led Discussion on Effective<br />
Physician/Patient Dialogue<br />
ACR Workshops<br />
10:30 - 12:30 PM<br />
Admission to each Workshop requires a separate registration<br />
and ticket. To verify which session you registered for, check to<br />
make sure the registration code on your ticket matches the code<br />
listed below in parentheses.<br />
B201<br />
Creating Presentations Using PowerPoint: Advanced<br />
(219)<br />
Speaker: Steve W. Blevins, MBA; <strong>American</strong> <strong>College</strong> <strong>of</strong><br />
<strong>Rheumatology</strong>; Atlanta, GA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• demonstrate advanced slide transition techniques<br />
• integrate audio, video and narration into slides<br />
• create presentations that can be published on a local Web site<br />
and be viewed in a browser<br />
B203<br />
Musculoskeletal Ultrasound (220) f<br />
Speaker: Eugene Y. Kissin, MD; Boston University; Boston, MA<br />
2010 Program Book 61<br />
tuesday
tuesday<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the indications for ultrasound in rheumatic diseases<br />
• discuss the techniques <strong>of</strong> ultrasonography<br />
• identify normal and abnormal anatomical structures by<br />
ultrasound imaging<br />
B204<br />
Osteoporosis: Interpreting Dual Energy X-ray<br />
Absorptiometry and Clinical Risk Factors: The New<br />
Fracture Risk Assessment Algorithm (221) PS<br />
Speaker: Stuart L. Silverman, MD; Cedars-Sinai Medical Center,<br />
University <strong>of</strong> California-Los Angeles; Beverly Hills, CA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• determine how to combine bone mineral density and clinical<br />
risk factors in determination <strong>of</strong> absolute risk<br />
• discuss the concept <strong>of</strong> intervention threshold used in National<br />
Osteoporosis Foundation guidelines<br />
• review International Society for Clinical Densitometry<br />
guidelines for DXA interpretation<br />
• create a report for bone densitometry results<br />
B206<br />
Peripheral Magnetic Resonance Imaging in Clinical<br />
<strong>Rheumatology</strong> (222)<br />
Speakers: Ewa Olech, MD; Oklahoma Medical Research<br />
Foundation; Oklahoma City, OK<br />
Orrin M. Troum, MD; University <strong>of</strong> Southern California, Keck<br />
School <strong>of</strong> Medicine; Santa Monica, CA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the logistics <strong>of</strong> implementation <strong>of</strong> peripheral MRI in<br />
the outpatient setting<br />
• review the merits and pitfalls <strong>of</strong> this technology<br />
findings, clinicians and public health practitioners have been<br />
recommending participation in exercise programs for people<br />
with arthritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the health-related benefits <strong>of</strong> physical activity<br />
programs for people with arthritis<br />
• describe the evidence that supports the value <strong>of</strong> physical<br />
activity programs for people with arthritis<br />
• identify challenges and rewards in working with communities<br />
to conduct physical activity intervention trials<br />
• define the need for ongoing physical activity opportunities<br />
and choices for people with arthritis<br />
• discuss recommendations for forming and using community<br />
partnerships to disseminate physical activity interventions<br />
ACR Clinical Symposium<br />
11:00 am - 12:30 PM<br />
Hall A3<br />
Curbside Consults - Ask the Pr<strong>of</strong>essors<br />
cP PM PS ARS<br />
Moderator: Brian F. Mandell, MD, PhD; The Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
11:00 am<br />
Vasculitis<br />
John H. Stone, MD, MPH; Massachusetts General Hospital;<br />
Sudbury, MA<br />
11:30 am<br />
Osteoporosis<br />
Kenneth G. Saag, MD, MSc; University <strong>of</strong> Alabama-Birmingham;<br />
Birmingham, AL<br />
ARHP General Session II<br />
10:45 - 11:45 am<br />
B313<br />
ARHP Distinguished Lecturer c/r PS<br />
Moderator: Janet L. Poole, PhD, OTR; University <strong>of</strong> New Mexico;<br />
Albuquerque, NM<br />
Speaker: Leigh F. Callahan, PhD; University <strong>of</strong> North<br />
Carolina; Chapel Hill, NC<br />
Session Overview:<br />
Numerous studies have shown that engaging in physical<br />
activity is beneficial for people with arthritis and physical<br />
activity programs have been developed specifically for people<br />
with arthritis. However, less than 1 percent <strong>of</strong> <strong>American</strong>s with<br />
arthritis have enrolled in or participated in these programs.<br />
Although persons with arthritis tend to be less fit than their<br />
peers without this condition, studies have demonstrated that<br />
persons with arthritis can safely participate in appropriate<br />
exercise programs to improve their cardiovascular fitness,<br />
muscular strength, psychosocial status, and functional status.<br />
The surgeon general’s report on physical activity and health<br />
indicated that exercise programs <strong>of</strong> moderate intensity<br />
are effective in individuals with rheumatoid arthritis or<br />
osteoarthritis. On the basis <strong>of</strong> this report and other research<br />
12:00 PM<br />
Rheumatic Therapeutics<br />
Iain B. McInnes, PhD; University <strong>of</strong> Glasgow; Glasgow, United<br />
Kingdom<br />
Session Overview:<br />
This session focuses on discussing difficult management<br />
decisions that must be made in the absence <strong>of</strong> strong data.<br />
Approaches are discussed that employ the synthesis <strong>of</strong><br />
published evidence and clinical experience. The topics were<br />
chosen following discussion with clinicians practicing in different<br />
environments, and input was solicited from the Annual Meeting<br />
Planning Committee members and the ACR membership, asking<br />
for suggestion <strong>of</strong> specific topics or case vignettes that pose<br />
particularly difficult treatment decision. Attendees will compare<br />
their personal management approaches regarding selected<br />
clinical problems with those <strong>of</strong> academic expert consultants and<br />
other clinicians in the audience.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• compare their personal management approaches to selected<br />
clinical problems with those <strong>of</strong> the presenters<br />
• develop an approach to treating patients experiencing<br />
relapses in giant cell arteritis or Wegener’s granulomatosis<br />
• describe therapeutic choices in patients with persistent pain<br />
following vertebral compression fractures<br />
• discuss alternative options in patients with anti-TNF therapy<br />
exacerbated psoriasis<br />
62<br />
2010 Program Book
ACR Plenary Session II: Discovery<br />
2010 c/r<br />
11:00 am - 12:30 PM<br />
Thomas J. Murphy Ballroom<br />
Moderators: Joel A. Block, MD; Rush University Medical Center;<br />
Chicago, IL<br />
Richard A. Furie, MD; North Shore Long Island Jewish Health<br />
System; Lake Success, NY<br />
11:00 am<br />
1350. Suppression <strong>of</strong> Collagen-Induced Arthritis in Mice by<br />
Anti-CD19 Antibody That Co-Engages BCR and Inhibitory<br />
Receptor FcγRIIb: Efficacy Does Not Require B Cell Depletion.<br />
Saso Cemerski 1 , Seung Y. Chu 2 , Erik Pong 2 , Holly M. Horton 2 , John<br />
R. Desjarlais 2 and David E. Szymkowski 1 , 1 Xencor, Inc., Monrovia,<br />
CA, 2 Xencor, Inc.<br />
11:15 am<br />
1351. Micro RNA 155 Deficiency Protects from the<br />
Development <strong>of</strong> Inflammatory Arthritis.<br />
Stephan Blüml 1 , Michael Bonelli 2 , Birgit Niederreiter 1 , Antonia<br />
Puchner 1 , Georg Mayr 1 , Marije Koenders 3 , Smolen Josef 1 and<br />
Redlich Kurt 1 , 1 Medical University Vienna, Austria, 2 Medical<br />
University Vienna, Austria 3 Radboud University Nijmegen<br />
Medical Center, Nijmegen, The Netherlands<br />
11:30 am<br />
1352. Down-Regulated MicroRNA-152 Induces Aberrant DNA<br />
Methylation in Scleroderma Endothelial Cells by Targeting DNA<br />
Methyltransferase 1.<br />
Yongqing Wang, Omar R. Kahaly and Bashar Kahaleh, University<br />
<strong>of</strong> Toledo, Toledo, OH<br />
11:45 am<br />
1353. SNAPIN: A Novel Endogenous TLR Ligand in Rheumatoid<br />
Arthritis.<br />
Bo Shi 3 , Qiquan Huang 3 , Margriet J. Vervoordeldonk 1 , Paul P. Tak 2<br />
and Richard M. Pope 4 , 1 Academic Medical Center, University <strong>of</strong><br />
Amsterdam, Amsterdam, The Netherlands, 2 Academic Medical<br />
Center, University <strong>of</strong> Amsterdam, 3 Northwestern University,<br />
Chicago, IL, 4 Northwestern University<br />
12:00 PM<br />
1354. TLR9 Induced Macrophage Activation Syndrome Is Driven<br />
by IFNγ Produced by Lymphocytes and Natural Killer Cells but Is<br />
Dampened by Lymphocyte Produced IL-10.<br />
Edward M. Behrens 2 , Katharine Slade 3 , Sheila Rao 3 , Portia A.<br />
Kreiger 1 , Michele Paessler 3 , Taku Kambayashi 5 and Gary A.<br />
Koretzky 4 , 1 A.I. DuPont Hospital for Children, 2 Childrens Hospital<br />
<strong>of</strong> Phil, Philadelphia, PA, 3 The Children’s Hospital <strong>of</strong> Philadelphia,<br />
4<br />
University <strong>of</strong> Pennsylvania, Philadelphia, PA, 5 University <strong>of</strong><br />
Pennsylvania<br />
12:15 PM<br />
1355. Genome-Wide Association Study <strong>of</strong> Ankylosing<br />
Spondylitis Identifies New Loci, a Tag SNP for HLA-B27, and an<br />
Interaction between HLA-B27 and Variants in ERAP1.<br />
Matthew A. Brown, on Behalf <strong>of</strong> the Wellcome Trust<br />
Case-Control Consortium 2 and Australo-Anglo-<strong>American</strong><br />
Spondyloarthritis Consortium, The University <strong>of</strong> Queensland<br />
Diamantina Institute, Brisbane, Queensland, Australia<br />
ARHP Special Session<br />
12:15 - 2:00 PM<br />
Omni Hotel – International Ballroom DEF<br />
Sit down with your colleagues, enjoy a light lunch and participate<br />
in an open discussion on various pre-selected research, practice<br />
and clinical topics. Each roundtable discussion will be facilitated<br />
by a rheumatology expert. All ARHP attendees are welcome.<br />
ARHP Networking at Noon<br />
The ARHP thanks Genentech, A Member <strong>of</strong> the Roche Group, for<br />
supporting Networking at Noon.<br />
ARHP Business Meeting<br />
Speaker: Linda S. Ehrlich-Jones, PhD, RN; Rehabilitation Institute<br />
<strong>of</strong> Chicago; Chicago, IL<br />
Inaguration <strong>of</strong> 41 st ARHP President<br />
Nadine T. James, RN, MSN, PhD; William Carey University;<br />
Hattiesburg, MS<br />
Table Topics: This is a tentative listing <strong>of</strong> topics and facilitators<br />
are subject to change.<br />
Adult Form Sharing<br />
Jane M. Denay, BSN, MSN, CFNP; Harbor Arthritis Center;<br />
Petoskey, MI<br />
Advanced Practice Roles in Physical Therapy<br />
Karen Huisinga, MN, ARNP, FNP; VA Puget Sound HCS;<br />
Bainbridge Island, WA<br />
Leslie J. Soever, BSc, PT, MSc; Mount Sinai Hospital; Toronto, ON,<br />
Canada<br />
Advocacy and Access to Care<br />
Deborah A. McCloskey, RN, BSN; University <strong>of</strong> Medicine and<br />
Dentistry <strong>of</strong> New Jersey, Robert Wood Johnson Medical School;<br />
New Brunswick, NJ<br />
Ankylosing Spondylitis<br />
Lori C. Guthrie, RN-C, BSN; DHHS/NIH/NIAMS; Bethesda, MD<br />
ARHP Grant/Award Opportunities<br />
Mary E. Christenson, PT, PhD; Regis University; Westminster, CO<br />
Arthritis and Employment<br />
Kristina A. Theis, MPH; Centers for Disease Control and<br />
Prevention; Atlanta, GA<br />
Clinical Research Coordinators<br />
Donah Z. Crawford, BS, MA; The Arthritis Group; Philadelphia, PA<br />
Lisa M. Kastanek, RN, CCRC; Physician Research Collaboration;<br />
Lincoln, NE<br />
Community-based Physical Activity Programs: What Data to<br />
Collect and Why<br />
Dina L. Jones, PhD, PT; West Virginia University; Morgantown,<br />
WV<br />
Diversity/Cultural Issues<br />
Jillian A. Rose; Hospital for Special Surgery; New York, NY<br />
Enhancing Patient Adherence<br />
Michael A. Rap<strong>of</strong>f, PhD; University <strong>of</strong> Kansas Medical Center;<br />
Kansas City, KS<br />
Epidemiology/Public Health<br />
Jennifer M. Hootman, PhD; Centers for Disease Control;<br />
Kennesaw, GA<br />
tuesday<br />
2010 Program Book 63
tuesday<br />
Forms Exchange for Those New to <strong>Rheumatology</strong><br />
Annelle B. Reed, MSN, CRNP; Children’s Hospital <strong>of</strong> Alabama;<br />
Birmingham, AL<br />
Georgia Health Pr<strong>of</strong>essionals<br />
Joyce P. Carlone, MN, RN, FNP-BC, Emory University, Atlanta, GA<br />
Hip and Knee Arthroplasty: Patient Discharge Instructions<br />
Victoria Gall, PT, MEd; Partners Healthcare; Hyde Park, MA<br />
Infusion and Injectable Therapies<br />
Sandra J. Watcher, BSN; Children’s Hospital <strong>of</strong> Los Angeles; Los<br />
Angeles, CA<br />
International Nursing Developments<br />
Susan M. Oliver, RN MSc; Pennine Musculoskeletal Partnership;<br />
Oldham, United Kingdom<br />
Patricia J. Cornell, BSc; Poole Hospital; Poole Dorset, United<br />
Kingdom<br />
Measurements <strong>of</strong> Physical Activity<br />
Elizabeth A. Schlenk, PhD, RN; University <strong>of</strong> Pittsburgh;<br />
Pittsburgh, PA<br />
Susan L. Murphy, ScD, OTR; University <strong>of</strong> Michigan; Ann Arbor,<br />
MI<br />
Medications for Rheumatic Diseases<br />
Kamala M. Nola, PharmD, MS; Lipscomb <strong>College</strong> <strong>of</strong> Pharmacy;<br />
Nashville, TN<br />
Nurse Practioner Issues<br />
Christine A. Stamatos;Private Practice; Babylon, NY<br />
Nurse Practioner Issues - Pediatrics<br />
Karen L. Kerr, MSN NP CPNP PNP; Children’s Hospital <strong>of</strong><br />
Michigan; Detroit, MI<br />
Office Manager/Practice Administrator<br />
Stacey Busch, RN, BSN, MA; Family Arthritis Center; Jupiter, FL<br />
Office Nurse<br />
Lee A. Anderson, BSN; University <strong>of</strong> Minnesota Physicians;<br />
Champlin, MN<br />
Physician Assistant Issues<br />
Barbara A. Slusher, PA-C, MSW; League City, TX<br />
Pain Management<br />
Gail C. Davis, RN, EdD; Texas Woman’s University; Denton, TX<br />
Pediatrics<br />
Bernadette McNally, MS, PAC; University <strong>of</strong> Utah; Salt Lake City,<br />
UT<br />
Qualitative Research<br />
Laura Robbins; Hospital for Special Surgery; New York, NY<br />
Regional <strong>Rheumatology</strong> Network for NPs and PAs<br />
Susan L. Williams Judge; Seattle <strong>Rheumatology</strong> Associate;<br />
Seattle, WA<br />
Research Mentoring<br />
Marian T. Hannan, DSc, MPH; Hebrew Senior Life and Harvard<br />
Medical School; Boston, MA<br />
Technology/Internet/Web Applications<br />
Laura E. Ray, MA, MLS; Cleveland State University; Cleveland, OH<br />
Volunteering/Mentoring ARHP<br />
Pamela J. Degotardi, PhD; Queens <strong>College</strong> City University <strong>of</strong> New<br />
York Honors; Flushing, NY<br />
InnoVAtion Theater<br />
12:15 - 1:00 PM<br />
Halls A1 & A2 (Booth #555)<br />
The following non-CME activity has been planned and will be<br />
implemented in accordance with the requirements <strong>of</strong> the FDA<br />
and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />
with Healthcare Pr<strong>of</strong>essionals by Lilly USA, LLC. Please visit the<br />
Lilly USA, LLC exhibit booth for more information or see page<br />
292. Seating and boxed lunches are subject to availability.<br />
Pathophysiology <strong>of</strong> Pain: Mechanisms and<br />
Manifestations<br />
ACR Meet the Pr<strong>of</strong>essor Sessions<br />
12:45 - 2:15 PM<br />
Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />
separate registration and ticket. To verify which session you<br />
registered for, check to make sure the registration code on your<br />
ticket matches the code listed below in parentheses.<br />
B207<br />
Basic Immunology for Clinical Rheumatologists (041)<br />
f<br />
Speaker: David M. Lee, MD, PhD; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe how the immune system functions in normal<br />
individuals<br />
• identify abnormalities <strong>of</strong> immune regulation that lead to<br />
autoimmunity<br />
B208<br />
Crystal: Pseudogout (042)<br />
Speaker: Geraldine M. McCarthy, MD; Mater Misericordiae<br />
University Hospital; Dublin, Ireland<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the pathophysiology <strong>of</strong> calcium pyrophosphate disease<br />
• describe disease associations with calcium pyrophosphate<br />
dihydrate<br />
• identify agents used for the treatment <strong>of</strong> pseudogout<br />
B209<br />
Osteoporosis: Applying FRAX Methodology (043)<br />
Speaker: Thomas P. Olenginski, MD; Geisinger Medical Center;<br />
Danville, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• appreciate the fracture risk assessment tool model <strong>of</strong><br />
estimating absolute 10 year fracture probabilities<br />
• apply fracture risk assessment tool relative to new National<br />
Osteoporosis Foundation clinician guidelines for osteoporosis<br />
care<br />
• realize the ‘limitations’ <strong>of</strong> the fracture risk assessment tool<br />
model<br />
• integrate fracture risk assessment tool into dual energy X-ray<br />
absorptiometry reporting and clinical care<br />
64<br />
2010 Program Book
B210<br />
B301<br />
Pediatrics: Periodic Fevers in Children (044) P<br />
Speaker: Polly J. Ferguson, MD; University <strong>of</strong> Iowa Carver <strong>College</strong><br />
<strong>of</strong> Medicine; Iowa City, IA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the differential diagnosis and expanding spectrum <strong>of</strong><br />
these syndromes<br />
• relate the pathogenesis <strong>of</strong> these syndromes to knowledge <strong>of</strong><br />
the various gene functions<br />
• discuss the treatment rationale based on the pathogenesis<br />
and to expand on practical issues in the management <strong>of</strong> these<br />
patients<br />
Psoriatic Arthritis (045)<br />
Speaker: John D. Reveille, MD; University Texas Health Science<br />
Center; Houston, TX<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the molecular basis for the pathogenesis <strong>of</strong> psoriatic<br />
arthritis<br />
• discuss the recent advances in the treatment <strong>of</strong> patients with<br />
psoriatic arthritis<br />
B302<br />
Pulmonary Manifestations <strong>of</strong> Rheumatic Disease (046)<br />
Speaker: Paul F. Dellaripa, MD; Brigham and Women’s Hospital;<br />
Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify emerging concepts regarding the pathophysiology <strong>of</strong><br />
inflammation and fibrosis in autoimmune lung disease<br />
• determine the appropriate use <strong>of</strong> diagnostic tests in<br />
the evaluation <strong>of</strong> patients with rheumatic disorders and<br />
autoimmune lung disease<br />
• discuss the limits <strong>of</strong> traditional therapeutic options and<br />
possible emerging therapies in managing autoimmune lung<br />
disease<br />
B303<br />
Raynaud’s and Digital Ischemia (047)<br />
Speaker: Janet E. Pope, MD, MPH; St. Joseph Health Care<br />
London; London, ON, Canada<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the pathogenesis<br />
• describe the appropriate diagnostic evaluation for this<br />
condition<br />
• review treatment options and means <strong>of</strong> evaluating treatment<br />
B304<br />
Rheumatoid Arthritis: Safety <strong>of</strong> Novel Therapies (048)<br />
PS<br />
Speaker: Daniel H. Solomon, MD, MPH; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the management <strong>of</strong> patients with refractory<br />
rheumatoid arthritis<br />
• identify novel treatment options for those failing conventional<br />
therapies<br />
B305<br />
Scleroderma Mimics (049)<br />
Speaker: Alan G. Tyndall, MD; University <strong>of</strong> Basel; Basel,<br />
Switzerland<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• create a differential diagnosis for conditions simulating<br />
scleroderma<br />
• formulate strategies to distinguish these various conditions<br />
• discuss why these various conditions may have similar<br />
manifestations<br />
B306<br />
Vasculitis: Update (050)<br />
Speaker: Peter A. Merkel, MD, MPH; Boston University School <strong>of</strong><br />
Medicine; West Newton, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the classification <strong>of</strong> vasculitis according to affected<br />
vessel size<br />
• utilize the various available laboratory tests, with emphasis on<br />
anti-neutrophilic cytoplasmic antibodies testing<br />
• identify current and novel therapeutic modalities<br />
ACR Special Session<br />
12:45 - 2:15 PM<br />
A410<br />
Contract Negotiations for Physicians BR f PS<br />
Moderator: Seth M. Berney, MD; Louisana State University;<br />
Shreveport, LA<br />
12:45 PM<br />
Contract Negotiations for Academics: How to Optimize Your<br />
Industrial Letter <strong>of</strong> Offer/Contract<br />
Robert Ortmann, MD, University <strong>of</strong> Arkansas; Fayetteville, AK<br />
1:05 PM<br />
Contract Negotiations for Industry: How to Optimize Your<br />
Industrial Letter <strong>of</strong> Offer/Contract<br />
Gregory J. Dennis, MD; Potomac, MD<br />
1:25 PM<br />
Contract Negotiations for Private Practice: How to Identify a<br />
Fair Private Practice or Hospital Practice Contract and How<br />
to Successfully Modify It to Correspond with Their Individual<br />
Needs<br />
Herbert Baraf, MD; Arthritis & Rheumatism Association;<br />
Wheaton, MD<br />
1:50 PM<br />
Contract Negotiations and the Legal Ramifications <strong>of</strong> the<br />
Contract: How to Optimize the Contract and Protect Yourself<br />
Joan M. Roediger, JD, LLM; Obermayer, Rebmann, Maxwell &<br />
Hippel LLP; Philadelphia, PA<br />
Session Overview:<br />
It is widely believed that physicians are not the ideal<br />
businesspeople for several years after the completion <strong>of</strong> their<br />
training because most internal medicine and rheumatology<br />
postgraduate programs do not prepare their fellows for the<br />
business <strong>of</strong> medicine. As physicians, we are expected to behave<br />
tuesday<br />
2010 Program Book 65
tuesday<br />
honorably and pr<strong>of</strong>essionally and frequently assume that all<br />
contracts and letters <strong>of</strong> employment will contain everything<br />
that we want and need. As a result, we do not realize that the<br />
responsibilities and expectations <strong>of</strong> the employee and employer<br />
are different. The employer’s priority is the financial stability <strong>of</strong><br />
the institution (practice, hospital, medical school or company). In<br />
order to create the best working relationship, the expectations<br />
and needs <strong>of</strong> both parties must be clearly and legally stated<br />
resulting in the final contract. However, because physicians are<br />
relatively untrained in contract negotiation, they frequently<br />
do not anticipate the implications <strong>of</strong> their actions or inactions,<br />
resulting in a suboptimal agreement. This session, is designed<br />
to educate fellows and post-fellowship rheumatologists on the<br />
practical and legal aspects <strong>of</strong> negotiating contacts and letters <strong>of</strong><br />
<strong>of</strong>fer with private practices, academic institutions and industry.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• explain the value <strong>of</strong> legal advice prior to signing a contract and<br />
the legal ramifications <strong>of</strong> the contract<br />
• identify a fair private practice or hospital practice contract<br />
and how to successfully modify it to correspond with their<br />
individual needs<br />
• negotiate a fair academic or industrial letter <strong>of</strong> <strong>of</strong>fer/contract<br />
ACR Clinical Symposium<br />
1:00 - 2:00 PM<br />
Thomas J. Murphy Ballroom<br />
The Brain and Systemic Lupus Erythematosus: 2010<br />
Update cP P/C PM PS<br />
Moderator: F. Jorge Sanchez-Guerrero, MD; Instituto Nacional<br />
Nutricion; Mexico City, DF, Mexico<br />
Speaker: John G. Hanly, MD; Queen Elizabeth II Health Services<br />
Center; Halifax, NS, Canada<br />
Session Overview:<br />
Patients with neuropsychiatric lupus are a diagnostic and<br />
therapeutic challenge for the practicing rheumatologist. The<br />
major challenges include: identifying the range <strong>of</strong> manifestations<br />
that are seen in neuropsychiatric lupus; making the accurate<br />
attribution (e.g., related to lupus, medications, comorbid<br />
conditions; and choosing the most appropriate therapeutic<br />
options. This review will focus on all aspects <strong>of</strong> neuropsychiatric<br />
lupus from diagnosis, to management.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• explain the clinical diversity <strong>of</strong> neuropsychiatric events in<br />
systemic lupus erythematosus<br />
• identify attribution <strong>of</strong> neuropsychiatric events and their<br />
impact on quality <strong>of</strong> life<br />
• describe the immunopathogenesis <strong>of</strong> primary<br />
neuropsychiatric lupus<br />
• explain therapeutic options for patients with neuropsychiatric<br />
lupus<br />
ACR Practice Issues<br />
1:00 - 2:00 PM<br />
A402<br />
Recovery Audit Contractor vs. Comprehensive Error<br />
Rate Testing Audits – Do You Know the Difference?<br />
BR C PS<br />
Moderator: Cynthia A. Weaver, MD; Rapid City Medical Center;<br />
Rapid City, SD<br />
1:00 PM<br />
Recovery Audit Contractor<br />
To be announced<br />
1:30 PM<br />
Comprehensive Error Rate Testing Audits<br />
James Cope, MD; AdvanceMed; Richmond, VA<br />
Session Overview:<br />
In an era <strong>of</strong> uncertainty for health care, rheumatologists are<br />
faced with working harder to increase compliance with complex<br />
Medicare rules. Most physician practices will need to process<br />
re-design to understand and prevent significant recoupment<br />
<strong>of</strong> payments deemed incorrect by Medicare. The Centers for<br />
Medicare and Medicaid Services increased scrutiny over all types<br />
<strong>of</strong> claims in an effort to reduce the payment error rate submitted<br />
for reimbursement. Their action plan delegated responsibility<br />
to several contractors, mainly through the Recovery Audit<br />
Contractors and Comprehensive Error Rate Testing, to identify<br />
and return improper payments to the Medicare Beneficiary<br />
Trust Fund. Since 2005, Centers for Medicare and Medicaid<br />
Services has collected nearly $440 million in improper<br />
Medicare payments through the Recovery Audit Contractors<br />
demonstration program.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify how and why the Recovery Audit Contractor or<br />
Comprehensive Error Rate Testing target sample claims for<br />
review<br />
• discuss how to effectively track medical necessity and coding<br />
errors<br />
• develop a system for appropriate corrective action as<br />
warranted to lower the error rate and improve the accuracy in<br />
billing, processing, and payment <strong>of</strong> Medicare claims<br />
ACR Special Session<br />
1:00 - 2:00 PM<br />
A406<br />
Clinical Teaching Strategies in the Outpatient Clinic<br />
Setting Ed.<br />
Moderator: Abby Goulder Abelson, MD; Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
Speaker: Terry M. Wolpaw, MD, MHPE; Case Western School <strong>of</strong><br />
Medicine; Cleveland, OH<br />
66<br />
2010 Program Book
Session Overview:<br />
As a clinical educator, it is important to consider the<br />
development <strong>of</strong> time efficient teaching methods in the<br />
clinical setting that provide insights into the students’ clinical<br />
reasoning strategies and uncertainties while remaining fully<br />
engaged in the priorities <strong>of</strong> patient care. This need spans both<br />
the outpatient and inpatient settings. It also spans the range<br />
<strong>of</strong> learners from first through fourth year medical students.<br />
This session will highlight the learner-centered model for<br />
case presentations, which depends mostly on students for its<br />
successful implementation, and follows a six step mnemonic<br />
called SNAPPS.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• demonstrate the SNAPPS case presentation technique to<br />
learners<br />
• implement learner-driven educational techniques in a clinical<br />
setting<br />
• realize the importance <strong>of</strong> expressing diagnostic reasoning<br />
and case-related uncertainties as part <strong>of</strong> developing clinical<br />
expertise<br />
ACR State-<strong>of</strong>-the-Art Lecture<br />
1:00 - 2:00 PM<br />
Sidney J. Marcus Auditorium<br />
Scleroderma: The Promise <strong>of</strong> Anti-fibrotic Therapies -<br />
A Translational Approach C PS<br />
Moderator: John R.P. Tesser, MD; Arizona Arthritis <strong>Rheumatology</strong><br />
Association; Paradise Valley, AZ<br />
Speaker: John Varga, MD; Northwestern University Feinberg<br />
School; Chicago, IL<br />
Session Overview:<br />
New advances in our understanding <strong>of</strong> scleroderma have<br />
elucidated underlying processes <strong>of</strong> vascular injury and aberrant<br />
wound healing. Immune activation and endothelial injury<br />
leading to overly abundant fibrosis <strong>of</strong> various tissues and organs<br />
result in the clinical manifestations <strong>of</strong> the disease. Treatment<br />
<strong>of</strong> already present fibrosis has proved to be a most difficult and<br />
<strong>of</strong>ten ineffective approach other than to control symptoms.<br />
Newer insights into the pathophysiologic mechanisms, both<br />
extracellular and intracellular, that lead to the fibrotic process<br />
<strong>of</strong>fer a new translational approach that identifies key target<br />
molecules. Therapeutic strategies that employ novel agents<br />
which affect these targets may allow for treatment intervention<br />
earlier in the disease process. Utilizing these new strategies in<br />
turn may improve our chances <strong>of</strong> clinical success.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• depict the transcriptional pr<strong>of</strong>iling that has identified potential<br />
key pathways involved in the fibrotic process<br />
• delineate the multiple extra-cellular cytokines, membrane<br />
receptors and intracellular enzyme cascades that drive fibrosis<br />
• identify available medications <strong>of</strong> different drug classes that<br />
have potential therapeutic activity to intervene in the fibrotic<br />
process, and review what evidence may be available as to<br />
their clinical therapeutic outcomes<br />
• characterize potential agents on the horizon and their<br />
mechanisms <strong>of</strong> action<br />
ACR Workshops<br />
1:15 - 3:15 PM<br />
Admission to each Workshop requires a separate registration<br />
and ticket. To verify which session you registered for, check to<br />
make sure the registration code on your ticket matches the code<br />
listed below in parentheses.<br />
B204<br />
Diagnostic Errors in <strong>Rheumatology</strong>: Why They<br />
Happen and How We Can Avoid Them (223) PS<br />
Speakers: Joan Marie Von Feldt, MD, MS Ed; University <strong>of</strong><br />
Pennsylvania-Philadelphia, Veterans Affairs Medical Center;<br />
Philadelphia, PA<br />
Jennifer S. Myers, MD; University <strong>of</strong> Pennsylvania Hospital;<br />
Philadelphia, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the difference between systems errors and cognitive<br />
errors<br />
• illustrate the clinical decision making patterns <strong>of</strong> physicians<br />
• cite the most common biases that can lead to diagnostic error<br />
• develop skills in cognitive error recognition and self-reflection<br />
to reduce diagnostic errors in your practice<br />
B206<br />
Joint Simulator (224) f<br />
Speakers: Joanne Valeriano-Marcet, MD; University <strong>of</strong> South<br />
Florida; Tampa, FL<br />
Helen E. Bateman, MD; James A. Haley Veterans Affairs Hospital,<br />
University <strong>of</strong> Southern Florida; Tampa, FL<br />
Ashley G. Sterrett, MD; James A. Haley Veterans Affairs Hospital;<br />
Tampa, FL<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the anatomy relative to various joint, bursa, and<br />
tendon injections<br />
• perform and instruct others on the techniques<br />
• design a successful joint injection workshop using simulators<br />
B203<br />
Musculoskeletal Exam Skills I: General<br />
Musculoskeletal Examination Skills for Educators<br />
(225)<br />
Speakers: George V. Lawry, MD; University <strong>of</strong> California-Irvine;<br />
Mission Viejo, CA<br />
Paul C. Utrie, MD; Orthopedic and Sports Medicine Specialists;<br />
Appleton, WI<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• participate in a hands-on, skill building workshop where<br />
participants are paired together for one-on-one practice<br />
• practice the “General MS Exam”, a systematic, efficient,<br />
clinically effective examination taking 6-8 minutes<br />
• review strategies for increasing exposure <strong>of</strong> medical students,<br />
resident and fellow trainees to basic musculoskeletal physical<br />
examination skills<br />
tuesday<br />
2010 Program Book 67
B202<br />
Synovial Fluid Analysis and Crystal Identification<br />
(226)<br />
Speakers: Brian F. Mandell, MD, PhD; The Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
Lan X. Chen, MD, PhD; Pennsylvania Presbyterian Medical<br />
Center; Blue Bell, PA<br />
Gilda M. Clayburne, MLT; Veterans Affairs Medical Center;<br />
Philadelphia, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• prepare synovial fluid samples for microscopic examination<br />
• identify various components <strong>of</strong> synovial fluid<br />
• identify crystals in synovial fluid<br />
Session Overview:<br />
Citrullination is an important post-translational protein<br />
modification, but citrullinated peptides may be the target <strong>of</strong><br />
autoantibodies in many individuals with rheumatoid arthritis.<br />
The presence <strong>of</strong> anti-cyclic citrullinated peptide antibodies in the<br />
serum is a harbinger <strong>of</strong> likely future development <strong>of</strong> rheumatoid<br />
arthritis, and <strong>of</strong>ten precedes disease onset by years.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe protein citrullination<br />
• explain the genetic susceptibility loci which may influence<br />
citrullination in rheumatoid arthritis, including the PADI4 locus<br />
• explain how abnormalities in citrullination may trigger an<br />
aberrant immune response in rheumatoid arthritis<br />
tuesday<br />
68<br />
Exhibit Hall Afternoon SnACk<br />
Break<br />
2:00 - 3:00 PM<br />
InnoVAtion Theater<br />
2:00 - 2:45 PM<br />
Halls A1 & A2 (Booth #555)<br />
The following non-CME activity has been planned and will be<br />
implemented in accordance with the requirements <strong>of</strong> the FDA<br />
and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />
with Healthcare Pr<strong>of</strong>essionals by Actelion Pharmaceuticals US,<br />
Inc. Please visit the Actelion Pharmaceuticals US, Inc. exhibit<br />
booth for more information or see page 292. Seating and light<br />
refreshments are subject to availability.<br />
Clinical Perils in <strong>Rheumatology</strong>: Uncovering<br />
Pulmonary Arterial Hypertension in Your High-Risk<br />
Patient Populations—The Importance <strong>of</strong> Aggressive<br />
Screening and Early Diagnosis<br />
ACR Basic Science Symposium<br />
2:30 - 4:00 PM<br />
B313<br />
The Biology <strong>of</strong> Citrullination R<br />
Moderators: Alisa E. Koch, MD; Unversity <strong>of</strong> Michigan; Ann<br />
Arbor, MI<br />
Thomas W.J. Huizinga, MD; Leiden University Medical Centre;<br />
Leiden, Netherlands<br />
2:30 PM<br />
Biology <strong>of</strong> Protein Citrullination<br />
Ger Pruijn, PhD; Radboud University Nijmegen; Nijmegen,<br />
Netherlands<br />
3:00 PM<br />
Experimental Arthritis and Anti-CCP<br />
V. Michael Holers, MD; University <strong>of</strong> Colorado School <strong>of</strong><br />
Medicine; Aurora, CO<br />
3:30 PM<br />
Peptidylarginine Deiminases and the Relationship to<br />
Citrullination in Rheumatoid Arthritis<br />
Guy B. Serre, MD, PhD; University <strong>of</strong> Toulouse; Toulouse, France<br />
2010 Program Book<br />
ACR Clinical Symposia<br />
2:30 - 4:00 PM<br />
A404<br />
Autologous Stem Cell Transplantation in Pediatric<br />
<strong>Rheumatology</strong>: Indications and Associated Morbidity<br />
P PS<br />
Moderators: Alexei A. Grom, MD; Children’s Hospital Medical<br />
Center; Cincinnati, OH<br />
B. Anne Eberhard, MB; Schneider Children’s Hospital; New Hyde<br />
Park, NY<br />
2:30 PM<br />
Rationale for the Use <strong>of</strong> Autologous Stem Cell Transplantation<br />
in Childhood Rheumatic Diseases<br />
Lucy R. Wedderburn, MD, PhD; University <strong>College</strong> London;<br />
London, United Kingdom<br />
3:00 PM<br />
Review <strong>of</strong> Existing Protocols and Safety Data in Pediatric Stem<br />
Cell Transplantation<br />
Lisa Filipovich, MD; Cincinnati Children’s Medical Center;<br />
Cinncinatti, OH<br />
3:30 PM<br />
Update on the Autologous Stem Cell Transplantation<br />
Experience in Pediatric Rheumatic Diseases<br />
Nico M. Wulffraat, MD; University Medical Center Utrecht;<br />
Utrecht, Netherlands<br />
Session Overview:<br />
In pediatric rheumatology, autologous stem cell transplantation<br />
has been used in patients with systemic rheumatologic<br />
conditions refractory to more conventional treatments. The<br />
outcome studies show variable results that depend on the<br />
conditioning regimens and the specific underlying rheumatic<br />
disease. The identification <strong>of</strong> patients who might benefit from<br />
autologous stem cell transplantation is difficult, in part due<br />
to the fact that many pediatric rheumatologists have limited<br />
understanding <strong>of</strong> the risk/benefit ratio for the procedure.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review the clinical rationale for the use <strong>of</strong> autologous stem<br />
cell transplantation in pediatric rheumatic diseases<br />
• identify patients for whom autologous stem cell<br />
transplantation might be an appropriate therapy<br />
• describe potential morbidity and mortality <strong>of</strong> autologous stem<br />
cell transplantation
Thomas J. Murphy Ballroom<br />
Giant Cell Arteritis - Diagnosis and Therapy C PS<br />
Moderator: Robert Spiera, MD; Hospital for Special Surgery; New<br />
York, NY<br />
2:30 PM<br />
Imaging in the Diagnosis <strong>of</strong> Giant Cell Arteritis: State <strong>of</strong> the Art<br />
Thornsten Alexander Bley, MD, PhD; University Hospital<br />
Freiburg; Freiburg, Germany<br />
3:00 PM<br />
Giant Cell Arteritis: Just Temporal Arteries, or So Much More?<br />
Gary S. H<strong>of</strong>fman, MD; Cleveland Clinic Foundation; Cleveland,<br />
OH<br />
3:30 PM<br />
Therapy <strong>of</strong> Giant Cell Arteritis: Beyond Steroids, or Using<br />
Steroids Better?<br />
Stephen A. Paget, MD; Hospital for Special Surgery; New York,<br />
NY<br />
Session Overview:<br />
Giant cell arteritis is the most frequently encountered vasculitis<br />
in persons over 50 years <strong>of</strong> age, and is among the more common<br />
vasculitides encountered by practicing rheumatologists. The<br />
disease is associated with significant disease and treatment<br />
related morbidities. The spectrum <strong>of</strong> disease and recognition<br />
<strong>of</strong> late vascular complications is expanding. Newer diagnostic<br />
modalities have been utilized that may facilitate early diagnosis.<br />
A number <strong>of</strong> therapies have been examined in well-done<br />
randomized trials hoping to demonstrate disease controlling/<br />
steroid sparing benefit, at times with conflicting results. This<br />
session will review the information regarding examined and<br />
emerging steroid sparing approaches, as well as update the<br />
“state <strong>of</strong> the art” with regard to diagnostic modalities, which has<br />
relevance to our evolving understanding <strong>of</strong> the spectrum <strong>of</strong> this<br />
disease and the potential for late vascular complications.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review data regarding the potential merits and pitfalls <strong>of</strong><br />
imaging modalities utilized in diagnosis and management,<br />
including positron emission tomography, Doppler ultrasound,<br />
and magnetic resonance imaging<br />
• discuss the role <strong>of</strong> these imaging modalities in diagnosis<br />
and management, and how this may impact diagnostic<br />
confirmation by biopsy<br />
• review understanding <strong>of</strong> spectrum <strong>of</strong> large vessel vasculitis, in<br />
particular recognition <strong>of</strong> late vascular complications, as well as<br />
early large vessel involvement<br />
• review the concepts <strong>of</strong> disease and treatment related damage<br />
• review recent trials <strong>of</strong> “steroid sparing” modalities<br />
(methotrexate, infliximab, “pulse” steroids)<br />
B402<br />
Psoriatic Disease: Clinical Spectrum and<br />
Comprehensive Treatment Strategies C PS<br />
Moderators: Christopher T. Ritchlin, MD; University <strong>of</strong> Rochester<br />
Medical Center; Rochester, NY<br />
Philip J. Mease, MD; Seattle <strong>Rheumatology</strong> Associate; Seattle,<br />
WA<br />
Hall A3<br />
2:30 PM<br />
Psoriasis: The Skin and Beyond<br />
Wolf-Henning Boehncke, MD; Johann Wolfgang Goethe<br />
University; Frankfurt, Germany<br />
3:00 PM<br />
Psoriatic Arthritis: Insights from the iPART Registry<br />
Dafna D. Gladman, MD; Toronto Western Hospital; Toronto, ON,<br />
Canada<br />
3:30 PM<br />
A Comprehensive Approach to the Treatment <strong>of</strong> Psoriatic<br />
Disease<br />
Arthur Kavanaugh, MD; University <strong>of</strong> California-San Diego; La<br />
Jolla, CA<br />
Session Overview:<br />
Psoriasis affects 3 to 5 percent <strong>of</strong> the US population and<br />
recent data indicate that this inflammatory skin disease is<br />
associated with an array <strong>of</strong> comorbidities that include not only<br />
arthritis but also obesity, cardiovascular disease, diabetes and<br />
anxiety/depression. In addition, psoriatic arthritis patients<br />
develop diverse musculoskeletal manifestations and in some<br />
cases, inflammatory bowel and eye disease. It is essential to<br />
accurately identify relevant extra-cutaneous manifestations<br />
and comorbidities and to implement comprehensive treatment<br />
strategies to maximize efficacy and compliance.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the association <strong>of</strong> psoriasis with obesity, metabolic<br />
syndrome and cardiovascular disease from an epidemiologic<br />
and pathophysiologic perspective<br />
• describe the risk factors for arthritis in psoriasis patients<br />
• summarize the data regarding the prevalence <strong>of</strong> the cardinal<br />
musculoskeletal manifestations, extra-articular features and<br />
comorbidities in psoriatic arthritis<br />
• demonstrate knowledge <strong>of</strong> comprehensive evidence-based<br />
treatment strategies that address the entire spectrum <strong>of</strong><br />
psoriatic disease<br />
Thieves’ Market: Show Me Your Best Cases<br />
ARS<br />
cP P/C<br />
Moderators: Richard A. Furie, MD; North Shore Long Island<br />
Jewish Health System; Lake Success, NY<br />
Zsuzsanna H. McMahan, MD; Johns Hopkins; Baltimore, MD<br />
Speakers: Korey R. Ullrich, MD; University <strong>of</strong> Colorado-Denver;<br />
Aurora, CO<br />
Elena Bagachuk, DO; North Shore University Hospital, Lake<br />
Success, NY<br />
Shawn M. Rose, MD, PhD; Northwestern University, Chicago, IL<br />
Hirenkumar Patel, MD, MBBS; Stonybrook University Hospital;<br />
Stonybrook, NY<br />
Benjamin Scheiber, MB, BS; Royal Free Hospital, London;<br />
London, United Kingdom<br />
Session Overview:<br />
During this session, five unique cases solicited from the<br />
ACR membership will be concisely presented. Cases chosen<br />
for presentation will be <strong>of</strong> the highest educational value to<br />
attendees. The presenter will provide a brief description <strong>of</strong> the<br />
case. This will be followed by a pictorial-laden discussion. This<br />
session will be <strong>of</strong> most interest to those who engage in patient<br />
care.<br />
tuesday<br />
2010 Program Book 69
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe unique and challenging diagnostic dilemmas<br />
• discuss the differential diagnosis<br />
• review methods used to identify the underlying diagnosis<br />
ACR Concurrent Abstract Sessions<br />
2:30 – 4:00 PM<br />
3:30 PM<br />
1360. Apolipoprotein E Receptor (apoER2) Is Involved<br />
for Thrombotic Complications in a Murine Model <strong>of</strong><br />
Antiphospholipid Syndrome.<br />
Z. Romay Penabad 1 , T. Shilagard 1 , G. Vargas 1 , R. Aguilar<br />
-Valenzuela 1 , P. de Groot 2 and S. Pierangeli 1 , 1 Univ <strong>of</strong> TX Med<br />
Branch, Galveston, TX, 2 University Hospital Utrecht, Utretch, The<br />
Netherlands<br />
tuesday<br />
A402<br />
Antiphospholipid Syndrome I<br />
Moderators: Pojen P. Chen, PhD; University <strong>of</strong> California-Los<br />
Angeles School <strong>of</strong> Medicine; Los Angeles, CA<br />
Robert A.S. Roubey, MD; University <strong>of</strong> North Carolina; Chapel<br />
Hill, NC<br />
2:30 PM<br />
1356. TLR-4 and Annexin A2 Involvement in Endothelial Cell<br />
Activation by Anti-Phospholipid Antibodies: Specific Silencing<br />
by Small Interfering RNAs.<br />
Elena Raschi 2 , Valentina Broggini 3 , Maria Orietta Borghi 4 , Claudia<br />
Grossi 2 and Pierluigi Meroni 1 , 1Instituto G. Pini University,<br />
Milano, Italy, 2 IRCCS Istituto Auxologico Italiano, Milan, Italy,<br />
3<br />
University <strong>of</strong> Milan, Italy, 4 University <strong>of</strong> Milan; IRCCS Istituto<br />
Auxologico Italiano, Milan, Italy<br />
2:45 PM<br />
1357. Role <strong>of</strong> Reactive Oxigen Species and ROS-Dependent<br />
Downstream Signalling in the Prothrombotic State Elicited by<br />
Antiphospholipid Antibodies from Primary Antiphospholipid<br />
Syndrome Patients.<br />
Chary Lopez-Pedrera 1 , Patricia Ruiz-Limon 1 , Maria Angeles<br />
Aguirre 1 , Nuria Barbarroja 1 , Antonio Rodriguez-Ariza 1 , Carlos<br />
Perez-Sanchez 1 , Eduardo Collantes-Estevez 1 , Jose Manuel<br />
Villalba 4 , Francisco Velasco 1 , Munther A. Khamashta 2 and Maria<br />
Jose Cuadrado 3 , 1Reina S<strong>of</strong>ia Hospital-IMIBIC, Cordoba, Spain,<br />
2<br />
The Rayne Institute, London, United Kingdom, 3 The Rayne<br />
Institute, London, United Kingdom, 4 University <strong>of</strong> Cordoba,<br />
Cordoba, Spain<br />
3:00 PM<br />
1358. Peptide & NMR Spectroscopy Studies <strong>of</strong> Recombinant<br />
Domain I Confirm Conformationally Correct Domain I and<br />
Non-Linear Epitope Binding to Anti-Domain I Antiphospholipid<br />
Antibodies.<br />
Charis Pericleous 2 , Toluwape Disu 4 , Jennifer Miles 1 , Diego<br />
Esposito 1 , Acely Garza-Garcia 1 , Paul C. Driscoll 1 , David S.<br />
Latchman 4 , David A. Isenberg 3 , Ian Giles 4 , Anisur Rahman 4<br />
and Yiannis Ioannou 4 , 1 National Institute <strong>of</strong> Medical Research,<br />
London, UK, 2 University <strong>College</strong> London, London, United<br />
Kingdom, 3 University <strong>College</strong> London, London, United Kingdom,<br />
4<br />
University <strong>College</strong> London, London, UK<br />
3:45 PM<br />
1361. C6-Deficient Mice Are Protected from the Pathogenic<br />
Effects <strong>of</strong> Antiphospholipid Antibodies.<br />
A. L. Carrera-Marin, R. Aguilar-Valenzuela, Z. Romay Penabad, E.<br />
Papalardo and S. Pierangeli, Univ <strong>of</strong> TX Med Branch, Galveston,<br />
TX<br />
A410<br />
Epidemiology and Health Services Research: Gout<br />
Moderators: Lisa G. Suter, MD; Yale University; New Haven, CT<br />
Jeffrey R. Curtis, MD, MPH; University <strong>of</strong> Alabama - Birmingham;<br />
Birmingham, AL<br />
2:30 PM<br />
1362. Short-Term Effects <strong>of</strong> Caffeinated Beverage Intake on Risk<br />
<strong>of</strong> Recurrent Gout Attacks.<br />
Tuhina Neogi 1 , Clara Chen 3 , Christine Chaisson 3 , David J. Hunter 4<br />
and Yuqing Zhang 2 , 1 Boston Univ Schl <strong>of</strong> Med, Boston, MA,<br />
2<br />
Boston Univ School <strong>of</strong> Medicine, Boston, MA, 3 Boston Univ<br />
School <strong>of</strong> Medicine, 4 University <strong>of</strong> Sydney, Boston, MA<br />
2:45 PM<br />
1363. Prevalence <strong>of</strong> Hyperuricemia in the US General<br />
Population: The National Health and Nutrition Examination<br />
Survey (NHANES) 1999-2008.<br />
Yanyan Zhu 1 , Bhavik Pandya 2 and Hyon Choi 1 , 1 Boston University<br />
<strong>of</strong> School <strong>of</strong> Medicine, Boston, MA, 2 Takeda Pharmaceuticals<br />
International, Inc, Deerfield, IL<br />
3:00 PM<br />
1364. Obesity Is Associated with a Younger Age at Gout<br />
Incidence.<br />
Mara A. McAdams 4 , Janet W. Maynard 2 , Judith A. Bolton<br />
H<strong>of</strong>fman 4 , Alan N. Baer 3 , Allan C. Gelber 1 and Josef Coresh 4 ,<br />
1<br />
Baltimore, MD, 2 Johns Hopkins Univ, Baltimore, MD, 3 Johns<br />
Hopkins University, Baltimore, MD, 4 Johns Hopkins, Bloomberg<br />
School <strong>of</strong> Public Health<br />
3:15 PM<br />
1365. Health Related Quality <strong>of</strong> Life (HRQOL) in Tophaceous vs.<br />
Non-Tophaceous Gout.<br />
Puja Khanna 2 , Jay Persselin 3 , Ron Hays 1 , Daniel Furst 1 , Harold<br />
Paulus 1 , Paul Maranian 1 and Dinesh Khanna 1 , 1UCLA, 2 UCLA and<br />
West LA VA, 3 West LA VA<br />
3:15 PM<br />
1359. A Novel, Simple Fluid Phase Binding Assay for the<br />
Detection <strong>of</strong> Serum Anti-Domain I Antibodies in Patients with<br />
the Antiphospholipid Syndrome.<br />
Charis Pericleous 2 , Acely Garza-Garcia 1 , Paul C. Driscoll 1 , David<br />
S. Latchman 4 , David A. Isenberg 3 , Ian P. Giles 4 , Anisur Rahman 4<br />
and Yiannis Ioannou 4 , 1National Institute <strong>of</strong> Medical Research,<br />
London, UK, 2 University <strong>College</strong> London, London, United<br />
Kingdom, 3 University <strong>College</strong> London, London, United Kingdom,<br />
4<br />
University <strong>College</strong> London, London, UK<br />
3:30 PM<br />
1366. Cherry Consumption and Risk <strong>of</strong> Recurrent Gout Attacks.<br />
Yuqing Zhang 3 , Clara Chen 1 , David J. Hunter 4 , Christine E.<br />
Chaisson 1 , Hyon K. Choi 5 and Tuhina Neogi 2 , 1Boston Univ<br />
Medical Ctr, Boston, MA, 2 Boston Univ Schl <strong>of</strong> Med, Boston,<br />
MA, 3 Boston Univ School <strong>of</strong> Medicine, Boston, MA, 4 Sydney<br />
University, Sydney, Australia, 5 Univ <strong>of</strong> British Columbia,<br />
Vancouver, BC, Canada<br />
70<br />
2010 Program Book
3:45 PM<br />
1367. Serum Urate Levels in Young Adults Are Associated with<br />
the Risk <strong>of</strong> Incident Hypertension: Findings from the Coronary<br />
Artery Risk Development in Young Adults (CARDIA) Cohort.<br />
Angelo L. Gaffo 1 , David R. Jacobs 6 , Femke Sijtsma 5 , Cora E. Lewis 3 ,<br />
Ted R. Mikuls 2 and Kenneth G. Saag 4 , 1 Birmingham VAMC and<br />
University <strong>of</strong> Alabama at Birmingham, Birmingham, AL, 2 Univ<br />
<strong>of</strong> Nebraska Med Ctr, Omaha, NE, 3 University <strong>of</strong> Alabama at<br />
Birmingham, 4 University <strong>of</strong> Alabama-Birmingham, Birmingham,<br />
AL, 5 University <strong>of</strong> Minnesota, 6 University <strong>of</strong> Minnesota and<br />
University <strong>of</strong> Oslo<br />
A412<br />
Imaging <strong>of</strong> Rheumatic Disease: X-ray and MRI<br />
Moderators: Mikkel Ostergaard, DMSc, MD, PhD; Copenhagen<br />
University Hospital<br />
Barbara N. Weissman, MD; Brigham and Women’s Hospital;<br />
Boston, MA<br />
2:30 PM<br />
1368. Two-Year Radiographic Results from the TEAR Trial.<br />
Larry W. Moreland 7 , James R. O’Dell 9 , Harold E. Paulus 1 , Jeffrey<br />
R. Curtis 8 , Joan M. Bathon 3 , E. William St Clair 2 , S. Louis Bridges 6 ,<br />
Xiao Zhang 5 , George Howard 5 , Desiree M. Van Der Heijde 4 ,<br />
Stacey S. C<strong>of</strong>ield 5 and for the TEAR Trial Investigators, 1 Encino,<br />
CA, 2 Duke University, Durham, NC, 3 Johns Hopkins Univ Ste,<br />
Baltimore, MD, 4 Leiden University Medical Center, Meerssen,<br />
The Netherlands, 5 The University <strong>of</strong> Alabama at Birmingham,<br />
6<br />
Univ <strong>of</strong> Alabama-Birmingham, Birmingham, AL, 7 Univ <strong>of</strong><br />
Pittsburgh Med Ctr, Pittsburgh, PA, 8 University <strong>of</strong> Alabama -<br />
Brimingham, Birmingham, AL, 9 University <strong>of</strong> Nebraska Medical<br />
Center, Omaha, NE<br />
2:45 PM<br />
1369. Development and Validation <strong>of</strong> an MRI Joint Space<br />
Narrowing Score for Use in Rheumatoid Arthritis: A Potential<br />
Adjunct to the OMERACT RA MRI Scoring System.<br />
Mikkel Østergaard 4 , Pernille Bøyesen 5 , Iris Eshed 10 , Frédérique<br />
Gandjbakhch 7 , Siri Lillegraven 5 , Paul Bird 6 , Violaine Foltz 8 ,<br />
Annelies Boonen 9 , Marissa N. Lassere 12 , Kay-Geert Hermann 2 ,<br />
Allen Anandarajah 16 , Uffe Møller Døhn 3 , Jane Freeston 15 ,<br />
Charles G. Peterfy 11 , Harry K. Genant 14 , Espen Haavardsholm 5 ,<br />
Fiona M. McQueen 13 and Philip G. Conaghan 1 , 1 Chapel Allerton<br />
Hospital, Leeds, United Kingdom, 2 Charité University Hospital,<br />
Berlin, Germany, 3 Copenhagen University Hospitals at Hvidovre<br />
and Glostrup, Denmark, 4 Copenhagen University Hospitals at<br />
Hvidovre and Glostrup, Hvidovre, Denmark, 5 Diakonhjemmet<br />
Hospital, University <strong>of</strong> Oslo, Oslo, Norway, 6 Division <strong>of</strong> Medicine,<br />
St. George Hospital, University <strong>of</strong> NSW, Sydney, Australia,<br />
7<br />
Hôpital Pitié-Salpétrière, Université PARIS VI - UPMC, Paris,<br />
France, 8 Hôpital Pitié-Salpétrière, Université PARIS VI - UPMC,<br />
Paris, France, 9 Maastricht University Hospital, Maastricht,<br />
10<br />
Sheba Medical Centre, Tel Aviv University, Tel Aviv, Israel,<br />
11<br />
Spire Sciences LLC, Kentfield, CA, 12 St. George Hospital,<br />
University <strong>of</strong> NSW, Sydney, Kogarah, Australia, 13 University<br />
<strong>of</strong> Auckland School <strong>of</strong> Medicine, Auckland, New Zealand,<br />
14<br />
University <strong>of</strong> California San Francisco, Tiburon, CA, 15 University<br />
<strong>of</strong> Leeds, Leeds, UK, 16 University <strong>of</strong> Rochester, Rochester<br />
3:00 PM<br />
1370. Patterns <strong>of</strong> MRI Bone Erosion in Rheumatoid Arthritis<br />
– Which Bones Are Most Frequently Involved and Show Most<br />
Change?<br />
Mikkel Østergaard 3 , Uffe Møller Døhn 4 , Anne Duer-Jensen 3 ,<br />
Merete L. Hetland 3 , Kim Hørslev-Petersen 5 , Kristian Stengaard-<br />
Pedersen 1 , Peter Junker 6 , Jan Pødenphant 2 and Bo Ejbjerg 7 ,<br />
1<br />
Århus University Hospital, Åarhus, Denmark, 2 Copenhagen<br />
University Hospitals at Gent<strong>of</strong>te, Copenhagen, Denmark,<br />
3<br />
Copenhagen University Hospitals at Hvidovre and Glostrup,<br />
Copenhagen, Denmark, 4 Copenhagen University Hospitals at<br />
Hvidovre and Glostrup, Copenhagen, Denmark, 5 KIng Christian<br />
X’s Rheumatism Hospital, University <strong>of</strong> Southern Denmark,<br />
Gråsten, Denmark, 6 Odense University Hospital, Odense C,<br />
Denmark, 7 Slagelse Hospital, Denmark<br />
3:15 PM<br />
1371. MRI-Proven Bone Edema <strong>of</strong> Wrist and Finger Joints at<br />
Entry Is the Strongest Predictor toward Further Radiografic<br />
Progression in Patients with Undifferentiated Arthritis: Results<br />
from the Prospective Cohort at Nagasaki University.<br />
Junko Kita 7 , Atsushi Kawakami 7 , Mami Tamai 1 , Naoki Iwamoto 7 ,<br />
Shin-ya Kawashiri 8 , Kazuhiko Arima 2 , Akitomo Okada 7 , Tomohiro<br />
Koga 7 , Satoshi Yamasaki 7 , Hideki Nakamura 7 , Tomoki Origuchi 5 ,<br />
Kiyoshi Aoyagi 3 , Masataka Uetani 4 and Katsumi Eguchi 6 , 1 Center<br />
for Health Community Medicine, Nagasaki University, Nagasaki,<br />
Japan, 2 Department <strong>of</strong> Medical Gene Technology, Atomic Bomb<br />
Disease Institute, Nagasaki University Graduate School <strong>of</strong><br />
BIomedical Sciences, 3 Department <strong>of</strong> Public Health, Graduate<br />
School <strong>of</strong> Biomedical Sciences, Nagasaki University, Nagasaki,<br />
Japan, 4 Department <strong>of</strong> Radiology and Radiation Research,<br />
Graduate School <strong>of</strong> Biomedical Sciences, Nagasaki University,<br />
Nagasaki, Japan, 5 Nagasaki University School <strong>of</strong> Health Sciences,<br />
Nagasaki University, Nagasaki, Japan, 6 Sasebo City General<br />
Hospital, Sasebo, Nagasaki, 7 Unit <strong>of</strong> Translational Medicine,<br />
Department <strong>of</strong> Immunology and <strong>Rheumatology</strong>, Graduate School<br />
<strong>of</strong> Biomedical Sciences, Nagasaki University, Nagasaki, Japan,<br />
8<br />
Unit <strong>of</strong> Translational Medicine, Department <strong>of</strong> Immunology<br />
and <strong>Rheumatology</strong>, Graduate School <strong>of</strong> Biomedical Sciences,<br />
Nagasaki University, Nagasaki, Japan<br />
3:30 PM<br />
1372. Zoledronic Acid Does Not Reduce Erosive Progression in<br />
PsA but May Suppress MRI Bone Oedema.<br />
Richard Lloyd 3 , Anthony Doyle 3 , Nicola Dalbeth 3 , Maria Lobo 1 ,<br />
Elizabeth Robinson 5 , William Taylor 6 , Peter Jones 2 and Fiona M.<br />
McQueen 4 , 1 Auckland District Health Board, 2 QEHealth, 3 Univ<br />
<strong>of</strong> Auckland, 4 Univ <strong>of</strong> Auckland Sch <strong>of</strong> Med, Auckland, New<br />
Zealand, 5 University <strong>of</strong> Auckland, 6 University <strong>of</strong> Otago<br />
3:45 PM<br />
1373. Cartilage Damage and Osteophytes: MRI-Defined<br />
Atrophic and Hypertrophic Phenotypes <strong>of</strong> Knee Osteoarthritis<br />
in the Framingham Cohort.<br />
Frank Roemer, Ali Guermazi, Jingbo Niu, Yuqing Zhang and David<br />
Felson, Boston University<br />
A314<br />
Muscle Biology, Myositis and Myopathies: Insights into<br />
the Pathogenesis and Outcomes <strong>of</strong> Myositis<br />
Moderators: Ann M. Reed, MD; Mayo Clinic; Rochester, MN<br />
Robert G. Cooper, MD; Hope Hospital; Salford, United Kingdom<br />
tuesday<br />
2010 Program Book 71
tuesday<br />
2:30 PM<br />
1374. The Influence <strong>of</strong> Regulatory T-Cell Deficiency and<br />
Endogenous Muscle Tissue Antigens on the Development <strong>of</strong><br />
Inflammatory Myopathy in Mice.<br />
N. A. Young, R. Sharma, B. Kaffenberger, A. Friedman and W. N.<br />
Jarjour, The Ohio State University Medical Center, Columbus, OH<br />
2:45 PM<br />
1375. Blockade <strong>of</strong> TNFα or IL-1 Ameliorates Established<br />
C-Protein Induced Myositis <strong>of</strong> Mice.<br />
Takahiko Sugihara 2 , Naoko Okiyama 2 , Naoto Watanabe 2 ,<br />
Nobuyuki Miyasaka 1 and Hitoshi Kohsaka 1 , 1Department <strong>of</strong><br />
Medicine and <strong>Rheumatology</strong>, Graduate School <strong>of</strong> Medical and<br />
Dental Sciences, Tokyo Medical and Dental University, Tokyo,<br />
Japan, 2 Department <strong>of</strong> Medicine and <strong>Rheumatology</strong>, Graduate<br />
School <strong>of</strong> Medical and Dental Sciences, Tokyo Medical and<br />
Dental University, Japan<br />
3:00 PM<br />
1376. UPR Activation and IFNb Production in Myocytes in Adult<br />
and Juvenile Myositis.<br />
Ann M. Reed 1 , Molly S. Hein 1 and Robert A. Colbert 2 , 1Mayo<br />
Clinic, 2 NIH, NIAMS<br />
3:15 PM<br />
1377. A New ELISA System for Detecting Autoantibodies to<br />
aminoacyl-tRNA Synthetases: Usefulness in Myositis and<br />
Interstitial Pneumonia.<br />
Ran Nakashima 2 , Nakashima 2 , Yoshitaka Imura 4 , Shio Kobayashi 3 ,<br />
Yuji Hosono 4 , Naoichiro Yukawa 4 , Daisuke Kawabata 4 , Takaki<br />
Nojima 4 , Koichiro Ohmura 2 , Takashi Usui 4 , Takao Fujii 1 , Minae<br />
Seto 6 , Akihiro Murakami 5 and Tsuneyo Mimori 2 , 1 Department<br />
<strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Kyoto University<br />
Graduate School <strong>of</strong> Medicine, Sakyo-ku Kyoto, Japan,<br />
2<br />
Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology,<br />
Kyoto University Graduate School <strong>of</strong> Medicine, Kyoto, Japan,<br />
3<br />
Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology,<br />
Kyoto University Graduate School <strong>of</strong> Medicine, Kyoto, Japan,<br />
4<br />
Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Kyoto<br />
University Graduate School <strong>of</strong> Medicine, 5 Medical and Biological<br />
Laboratories CO., LTD, 6 Medical and Biological Laboratories Co.,<br />
Ltd., Nagano, Japan<br />
3:30 PM<br />
1378. Atherosclerotic Cardiovascular Disease among<br />
Hospitalized Dermatomyositis Patients in the US.<br />
Eleni Linos 3 , David Fiorentino3, Bharathi Lingala 3 , Eswar<br />
Krishnan 2 and Lorinda Chung 1 , 1 Stanford Univ Medical Center,<br />
Palo Alto, CA, 2 Stanford University, Palo Alto, CA, 3 Stanford<br />
University School <strong>of</strong> Medicine<br />
3:45 PM<br />
1379. Predictors <strong>of</strong> Response to B Cell Depleting Therapy in<br />
Adult and Juvenile Myositis.<br />
Ann M. Reed 1 , Kelly T. McNallan 1 , Cindy S. Crowson 1 and Chester<br />
V. Oddis 2 , 1 Mayo Clinic, 2 University <strong>of</strong> Pittsburgh<br />
A315<br />
Orthopedics, Low Back Pain and Rehabilitation<br />
Moderators: Beth L. Jonas, MD; University <strong>of</strong> North Carolina-<br />
Chapel Hill; Chapel Hill, NC<br />
Jeffrey N. Katz, MD; Brigham and Women’s Hospital; Boston, MA<br />
2:30 PM<br />
1380. Clinical Improvement and Structural Tissue Repair<br />
by Joint Distraction, in Treatment <strong>of</strong> End-Stage Knee<br />
Osteoarthritis.<br />
F. Intema 2 , K. Wiegant 3 , P. M. van Roermund 3 , A. C. A.<br />
Marijnissen 3 , S. Cot<strong>of</strong>ana 1 , F. Eckstein 1 , S. C. Mastbergen 3 and<br />
F. P. J. G. Lafeber 3 , 1 Institute <strong>of</strong> Anatomy and Muscoskeletal<br />
Research, Paracelsus Medical University, Salzburg, Austria,<br />
2<br />
<strong>Rheumatology</strong> & Clinical Immunology, University Medical<br />
Center Utrecht, Utrecht, The Netherlands, 3 <strong>Rheumatology</strong> &<br />
Clinical Immunology, University Medical Center Utrecht, The<br />
Netherlands<br />
2:45 PM<br />
1381. TNF Blockade during Elective Orthopaedic and Hand<br />
Surgery in Arthritis Patients: Friend or Foe?<br />
Elisabet Pettersson, Pierre Geborek and Anders Gülfe,<br />
Lund University, Dept <strong>of</strong> Clinical Sciences, Lund, Section for<br />
<strong>Rheumatology</strong>, Lund, Sweden<br />
3:00 PM<br />
1382. Guided Mesenchymal Stem Cell Layering Technique for<br />
Treatment <strong>of</strong> Osteoarthritis <strong>of</strong> the Knee.<br />
Nathan Wei 1 , Sheila Beard 1 , Sheila K. Delauter 1 , Carla Bitner 1 ,<br />
Rebecca Gillis 1 , Laura Rau 1 , Colleen Miller 1 and Thomas B. Clark 2 ,<br />
1<br />
Arthritis Treatment Center, Frederick, MD, 2 Musculoskeletal<br />
Ultrasound, Vista, CA<br />
3:15 PM<br />
1383. Increased Fat Mass Is Associated with High Levels <strong>of</strong> Low<br />
Back Pain Intensity and Disability.<br />
Donna Urquhart 4 , Patricia Berry 4 , Anita Wluka 4 , Boyd Strauss 3 ,<br />
Yuanyuan Wang 4 , Joseph Proietto 5 , Graeme Jones 2 , John Dixon 1<br />
and Flavia Cicuttini 4 , 1 Baker IDI Heart and Diabetes Institute,<br />
2<br />
Menzies Research Institute, 3 Monash Medical Centre, 4 Monash<br />
University, 5 University <strong>of</strong> Melbourne<br />
3:30 PM<br />
1384. Creatine Supplementation Associated to Resistance<br />
Training in Post-Menopausal Women with Knee Osteoarthritis<br />
Improves Physical Function: A Randomized, Double-Blinded,<br />
Placebo-Controlled Clinical Trial.<br />
Manoel Tavares Neves Junior 1 , Bruno Gualano 2 , Hamilton<br />
Roschel 2 , Marcelo Tatit Sapienza 2 , Fernanda Rodrigues Lima 2 ,<br />
Ana Lucia de Sa Pinto 2 , Ricardo Fuller 2 , Rosa Maria Rodrigues<br />
Pereira 2 , Antonio Herbert Lancha Junior 2 and Eloisa Silva Dutra<br />
de Oliveira Bonfa 2 , 1 Universidade de Sao Paulo, Sao Paulo, SP,<br />
Brazil, 2 Universidade de Sao Paulo<br />
3:45 PM<br />
1385. Role <strong>of</strong> Central Sensitization in Persistent Pain Post-Knee<br />
Replacement: The MOST Study.<br />
Tuhina Neogi 3 , Jingbo Niu 4 , Laura Frey-Law 9 , Lars Arendt-<br />
Nielsen 1 , Jasvinder Singh 8 , Joachim Scholz 2 , Clifford Woolf 2 , Irina<br />
Tolstykh 7 , Jessica L. Maxwell 4 , Barton Wise 6 and David T. Felson 5 ,<br />
1<br />
Aalborg University, Denmark, 2 Boston Childrens Hospital,<br />
3<br />
Boston Univ Schl <strong>of</strong> Med, Boston, MA, 4 Boston Univ School <strong>of</strong><br />
Medicine, Boston, MA, 5 Boston University School <strong>of</strong> Medicine,<br />
Boston, MA, 6 UCDavis, Sacramento, CA, 7 UCSF, 8 University <strong>of</strong><br />
Alabama at Birmingham, Minneapolis, MN, 9 University <strong>of</strong> Iowa<br />
72<br />
2010 Program Book
A411<br />
Rheumatoid Arthritis - Human Etiology and<br />
Pathogenesis: RA Human Etiology and Pathogenesis I<br />
Moderators: Gary S. Firestein, MD; University <strong>of</strong> California – San<br />
Diego School <strong>of</strong> Medicine; La Jolla, CA<br />
Ellen M. Gravallese, MD; University <strong>of</strong> Massachusetts Medical<br />
School, Worchester, MA<br />
2:30 PM<br />
1386. Thrombin-Activatable Carboxypeptidase B (CPB) Plays a<br />
Central Role in Down-Regulating Inflammatory Responses in<br />
Rheumatoid Arthritis by Cleaving C5a.<br />
Jason J. Song 3 , Inyong Hwang 3 , Tiffany Wang 4 , Annette T.<br />
Lee 1 , S. Louis Bridges 5 , Peter K. Gregersen 1 , Lawrence Leung 4<br />
and William Robinson 2 , 1North Shore-LIJ Research Institute,<br />
Manhasset, NY, 2 Stanford Univ School <strong>of</strong> Med, Stanford, CA,<br />
3<br />
Stanford University, Palo Alto, CA, 4 Stanford University, 5 Univ <strong>of</strong><br />
Alabama-Birmingham, Birmingham, AL<br />
2:45 PM<br />
1387. The Liver X Receptor (LXR) Regulates Arthritis Fibroblast-<br />
Like Synoviocyte NFB Activity, IL-6 Production and Cell Invasion.<br />
Carl Petrus Linge 2 , Teresina Laragione 3 and Percio S. Gulko 1 ,<br />
1<br />
Feinstein Institutue Med Rsch, Manhasset, NY, 2 The Feinstein<br />
Institute for Medical Research, Manhasset, NY, 3 The Feinstein<br />
Institute for Medical Research<br />
3:00 PM<br />
1388. Cadherin-11 Engagement Increases Matrix<br />
Metalloproteinase Production by Rheumatoid Arthritis<br />
Fibroblast-Like Synoviocytes.<br />
Erika H. Noss, Sook-Kyung Chang and Michael B. Brenner,<br />
Brigham and Women’s Hospital, Boston, MA<br />
3:15 PM<br />
1389. Rheumatoid Synovial Fibroblasts Support Aid Expression<br />
and IG Class-Switching in B Cells Via a BAFF-Dependent TLR3-<br />
Stimulated Pathway.<br />
Michele Bombardieri 1 , Yvone N. W. Kam 1 , Fabia Brentano 1 ,<br />
Ken Choi 1 , Diego Kyburz 3 , Steffen Gay 3 , Iain B. McInnes 2 and<br />
Costantino Pitzalis 1 , 1 Queen Mary University London, London,<br />
United Kingdom, 2 University <strong>of</strong> Glasgow, Glasgow, United<br />
Kingdom, 3 University <strong>of</strong> Zurich, Zurich, Switzerland<br />
3:30 PM<br />
1390. Characteristic Oral and Intestinal Microbiota in<br />
Rheumatoid Arthritis (RA): A Trigger for Autoimmunity?<br />
Jose U. Scher 7 , Carles Ubeda 3 , Michael H. Pillinger 2 , Walter<br />
Bretz 6 , Yvonne Buischi 6 , Pamela B. Rosenthal 7 , Soumya M.<br />
Reddy 7 , Jonathan Samuels 4 , Peter M. Izmirly 7 , Rennie N. G.<br />
Howard 7 , Gary Solomon 8 , Yusuf Yazici 8 , Mukundan Attur 8 ,<br />
Michele Equinda 3 , Nicholas Socci 3 , Agnes Viale 3 , Eric Pamer 1 ,<br />
Dan R. Littman 9 , Gerald Weissmann 5 and Steven B. Abramson 10 ,<br />
1<br />
Lucille Castori Center for Microbes, Inflammation, and Cancer/<br />
MSKCC, 2 Manhattan VA Med Hospital, New York, NY, 3 Memorial<br />
Sloan-Kettering Cancer Center (MSKCC), 4 New York University<br />
Hospital for Joint Disease, New York, NY, 5 New York University<br />
Medical Center, New York, NY, 6 NYU <strong>College</strong> <strong>of</strong> Dentistry, 7 NYU<br />
Hospital for Joint Diseases, New York, NY, 8 NYU Hospital for Joint<br />
Diseases, 9 NYU School <strong>of</strong> Medicine, 10 NYU School <strong>of</strong> Medicine,<br />
NYU Hospital for Joint Diseases, New York, NY<br />
3:45 PM<br />
1391. Toll-Like Receptor 2 Activation Induces Angiogenesis,<br />
ICAM-1 Expression and EC Invasion in Rheumatoid Arthritis.<br />
Tajvur P. Saber 2 , Sinead NicUltaigh 3 , Jennifer McCormick 2 ,<br />
Douglas J. Veale 4 , Mary Connolly 2 and Ursula Fearon 1 , 1 Dublin,<br />
Ireland, 2 Dublin Academic Medical Centre, Dublin, Ireland,<br />
3<br />
Dublin Academic Medical Centre, Dublin, Ireland, 4 St Vincents<br />
Univ Hospital, Dublin, Ireland<br />
Sidney J. Marcus Auditorium<br />
Rheumatoid Arthritis Treatment - Small Molecules,<br />
Biologics and Gene Therapy: Existing Non-Biologic<br />
DMARDs II<br />
Moderators: Eric M. Ruderman, MD; North Western University<br />
<strong>of</strong> School <strong>of</strong> Medicine; Chicago, IL<br />
Alvin F. Wells, MD, PhD; <strong>Rheumatology</strong> and Immunotherapy<br />
Center; Oak Creek, WI<br />
2:30 PM<br />
1392. Radiological Progression in Patients with Early RA and a<br />
Good Clinical Response to MTX Monotherapy: Predictors and<br />
Clinical Implications.<br />
Hamed Rezaei 3 , Ronald Van Vollenhoven 2 , Kristina Forslind 1 ,<br />
Kristina Albertsson 3 , Helena Wallin 3 , Pierre Geborek 4 , S<strong>of</strong>ia<br />
Ernestam 3 , Ingemar Petersson 5 and Johan Bratt 3 , 1 Helsingborgs<br />
Hospital, 2 Karolinska University Hospital, Stockholm, Sweden,<br />
3<br />
Karolinska University Hospital, 4 Lund University Hospital,<br />
5<br />
Spenshult Hospital<br />
2:45 PM<br />
1393. In Early RA, Patients with a Good Initial Response to MTX<br />
Monotherapy Have Excellent Clinical Outcomes over Two Years<br />
<strong>of</strong> Therapy, but Radiological Progression Is Not Completely<br />
Prevented.<br />
Helena Wallin 4 , Ronald Van Vollenhoven 2 , Kristina Albertsson,<br />
Kristina Forslind, S<strong>of</strong>ia Ernestam, Ingemar F. Petersson 3 , Pierre<br />
Geborek, Hamed Rezaei, Johan Bratt 1 and The SWEFOT Study<br />
Group, 1 Karolinska Univ Hosp Huddinge, Stockholm, Sweden,<br />
2<br />
Karolinska University Hospital, Stockholm, Sweden, 3 Lund<br />
University Hosp, Lund, Sweden, 4 The Karolinska Institute,<br />
Stockholm, Sweden<br />
3:00 PM<br />
1394. Genetic Polymorphisms in Key Methotrexate (MTX)<br />
Pathway Genes Associated with Response to MTX Treatment in<br />
Rheumatoid Arthritis.<br />
Sally-Anne Owen 2 , Stephen Eyre 2 , Paul Martin 2 , Samantha<br />
Hider 1 , Ian N. Bruce 2 , Anne Barton 2 and Wendy Thomson 2 , 1 ARC<br />
National Primary Care Centre, Keele University, Staffordshire,<br />
United Kingdom, 2 Arthritis Research UK Epidemiology Unit, The<br />
University <strong>of</strong> Manchester, Manchester, United Kingdom<br />
3:15 PM<br />
1395. Observational Study To Evaluate the Relationship <strong>of</strong><br />
Methotrexate to Interstitial Lung Disease in Rheumatoid<br />
Arthritis.<br />
Liron Caplan 7 , Anne E. Hines 15 , Jay R. McDonald 10 , Angelique L.<br />
Zeringue 10 , Alyse Mann 6 , Paul H. Sufka 13 , Kevin G. Osgood 2 , Ted<br />
R. Mikuls 14 , Jasvinder Singh 3 , Itziar Quinzanos 5 , Lela Mansoori 11 ,<br />
Chrysoula Pappa 12 , Leah M. Haverhals 6 , Andre Barkhuizen 8 ,<br />
Douglas Phelps 1 , Roderick S. Hooker 4 , Hong Xian 10 , Prabha<br />
Ranganathan 9 , Fran Cunningham 17 and Seth Eisen 16 , 1 Albancy<br />
tuesday<br />
2010 Program Book 73
tuesday<br />
74<br />
VAMC, 2 Austin Diagnostic Clinic, Austin, TX, 3 Birmingham VAMC,<br />
Minneapolis, MN, 4 Dallas VAMC, Dallas, TX, 5 Denver Health,<br />
6<br />
Denver VAMC, 7 Denver VAMC, Aurora, CO, 8 Portland Rheum<br />
Clinic LLC, Lake Oswego, OR, 9 St. Louis VAMC, St. Louis, MO, 10 St.<br />
Louis VAMC, 11 Univ <strong>of</strong> Colorado, 12 Univ <strong>of</strong> Florida Jacksonville,<br />
Saint Augustine, FL, 13 Univ <strong>of</strong> Minneapolis, Minneapolis,<br />
MN, 14 Univ <strong>of</strong> Nebraska Med Ctr, Omaha, NE, 15 University <strong>of</strong><br />
Colorado, 16 VA HSR&D, 17 VA PBM<br />
3:30 PM<br />
1396. Induction Therapy with Methotrexate and Prednisone in<br />
Rheumatoid or Very Early Arthritic Disease: IMPROVED Study.<br />
K. V. C. de Boer 5 , K. Visser 6 , H. K. Ronday 4 , A. A. Schouffoer 3 , J.<br />
H. L. M. Groenendael 2 , A. J. Peeters 9 , I. Speyer 1 , G. Collée 7 , P.<br />
B. J . Sonnaville 8 , B. A. M. Grillet 10 , T. W. J. Huizinga 6 and C. F.<br />
Allaart 5 , 1 Bronovo Hospital, The Hague, 2 Franciscus Hospital,<br />
Roosendaal, 3 Groene Hart Hospital, Gouda, 4 Haga Hospital, The<br />
Hague, 5 LUMC, Leiden, The Netherlands, 6 LUMC, Leiden, 7 MCH,<br />
the Hague, 8 Oosterschelde Hospital, Goes, 9 Reinier de Graaf<br />
Gasthuis, Delft, 10 Zorgsaam, Terneuzen<br />
3:45 PM<br />
1397. The Role <strong>of</strong> Low-Dose Oral Prednisone Treatment in Early<br />
Rheumatoid Arthritis: Effects on Clinical and Ultrasonographic<br />
Remission and Functional Outcome.<br />
Garifallia Sakellariou 1 , Monica Todoerti 2 , Carlo A. Scirè 2 , Serena<br />
Bugatti 2 , Carlomaurizio Montecucco 2 and Roberto Caporali 2 ,<br />
1<br />
Chair and Division <strong>of</strong> <strong>Rheumatology</strong>, Università degli Studi<br />
di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia,<br />
Lombardia, Italy, 2 Chair and Division <strong>of</strong> <strong>Rheumatology</strong>, Università<br />
degli Studi di Pavia, Fondazione IRCCS Policlinico San Matteo,<br />
Pavia, Italy<br />
A311<br />
Systemic Lupus Erythematosus - Clinical Aspects and<br />
Treatment: Renal<br />
Moderators: Frederic A. Houssiau, MD, PhD; Universite<br />
Catholique Louvain; Brussels, Belgium<br />
Eliza F. Chakravarty, MD; Stanford University; Mountain View, CA<br />
2:30 PM<br />
1398. Repeat Kidney Biopsies Fail To Detect Differences<br />
between Azathioprine and Mycophenolate M<strong>of</strong>etil<br />
Maintenance Therapy for Lupus Nephritis: Data from the<br />
MAINTAIN Nephritis Trial.<br />
Maria Stoenoiu 1 , Selda Aydin 1 , Carlos Vasconcelos 4 , Maria<br />
Tektonidou 5 , Isabelle Ravelingien 6 , Véronique le Guern 2 ,<br />
Geneviève Depresseux 1 , Ricard Cervera 3 , Jean-Pierre Cosyns 1<br />
and Frédéric A. Houssiau 1 , 1 Cliniques Universitaires Saint-Luc,<br />
Université Catholique de Louvain, Bruxelles, Belgium, 2 Hôpital<br />
Cochin, Paris, France, 3 Hospital Clinic, Barcelona, Spain, 4 Hospital<br />
Santo Antonio, Porto, Portugal, 5 National University <strong>of</strong> Athens,<br />
Athens, Greece, 6O.L. Vrouwziekenhuis, Aalst, Belgium<br />
2:45 PM<br />
1399. C4d on Circulating Cells and Renal Tissues in Lupus<br />
Nephritis as Novel Biomarkers.<br />
Kelly V. Liang 4 , Ibrahim Batal 2 , Sheldon Bastacky 4 , Lawrence<br />
Kiss, Theresa McHale, Nicole Wilson, Barbara Paul, Apinya<br />
Lertratanakul, Joseph M. Ahearn 1 , Susan Manzi 5 and Amy H.<br />
Kao 3 , 1 Wexford, PA, 2 Pittsburgh, PA, 3 Allegheny Singer Research<br />
Institute, Pittsburgh, PA, 4 University <strong>of</strong> Pittsburgh, Pittsburgh, PA,<br />
2010 Program Book<br />
5<br />
West Penn Allegheny Health System, Pittsburgh, PA<br />
3:00 PM<br />
1400. Are the Current Thresholds for SLE Proteinuric Flare<br />
Set Too High? Determining the 99% Confidence Intervals for<br />
Spontaneous Variation in Urine Protein/Creatinine Ration in<br />
SLE GN Patients Who Are Clinically Stable (Not Flaring).<br />
Stacy P. Ardoin 1 , Dan J. Birmingham 2 , Brad H. Rovin 2 , P. Hebert 3 ,<br />
C.-Y. Yu 2 and Lee A. Hebert 2 , 1 Ohio State University, Columbus,<br />
OH, 2 Ohio State University, 3 University <strong>of</strong> Washington<br />
3:15 PM<br />
1401. Systematic Review and Meta-Analysis <strong>of</strong><br />
Immunosuppressant Therapy Clinical Trials in Membranous<br />
Lupus Nephritis.<br />
Vikas Majithia 2 , Josh T. Swan 1 and Daniel Riche 3 , 1 Methodist<br />
Hospital, Houston, 2 University <strong>of</strong> Mississippi Medical Center,<br />
Jackson, MS, 3 University <strong>of</strong> Mississippi Medical Center<br />
3:30 PM<br />
1402. Treatment <strong>of</strong> Lupus Nephritis with Enteric-Coated<br />
Mycophenolate Sodium (EC-MPS) – MyLupus Exploratory<br />
Study.<br />
Andrea Doria, For the MyLupus Study Group, Padova, Italy<br />
3:45 PM<br />
1403. Machine Learning Models Using Multiple Low<br />
Abundance Protein Biomarker Levels Are Superior to Those<br />
Using Clinical Laboratory Values in Diagnosing ISN/RPS Class <strong>of</strong><br />
Lupus Nephritis.<br />
Jim C. Oates 2 , Michelle A. Petri 1 , Jonas S. Almeida 4 , Thomas W.<br />
Fleury 3 , Janech G. Michael 3 and John M. Arthur 3 , 1 Timonium,<br />
MD, 2 Medical University <strong>of</strong> South Carolina, Charleston, SC,<br />
3<br />
Medical University <strong>of</strong> South Carolina, 4 The University <strong>of</strong> Texas<br />
M. D. Anderson Cancer Center<br />
ACR/ARHP Combined Concurrent<br />
Abstract Session<br />
2:30 - 4:00 PM<br />
B311<br />
ACR/ARHP Combined Pediatric <strong>Rheumatology</strong> -<br />
Clinical and Therapeutic Aspects Abstracts: Quality <strong>of</strong><br />
Life in Children and Adolescents with Arthritis<br />
Moderators: Karen L. Kerr, MSN, NP, CPNP, PNP; Children’s<br />
Hospital <strong>of</strong> Michigan; Detroit, MI<br />
Hermine Brunner, MD, MSc.; Cincinnati Children’s Hospital<br />
Medical Center; Cincinnati, OH<br />
2:30 PM<br />
1404. Investigating Medication Adherence in Pediatric<br />
<strong>Rheumatology</strong> Using a Medical Claims Database.<br />
Caitlin M. Sgarlat 3 , Jorge M. Lopez-Benitez 2 , Emily Cox 1 and Ira<br />
B. Wilson 4 , 1 Express Scripts Inc. Research and Analysis, St. Louis,<br />
MO, 2 Tufts Medical Center and Floating Hospital for Children:<br />
Division <strong>of</strong> Pediatric <strong>Rheumatology</strong>, Boston, MA, 3 Tufts Medical<br />
Center and Floating Hospital for Children: Division <strong>of</strong> Pediatric<br />
<strong>Rheumatology</strong>; Tufts University Sackler School <strong>of</strong> Graduate<br />
Biomedical Sciences, Boston, MA, 4Tufts Medical Center and<br />
Floating Hospital for Children; Tufts University Sackler School <strong>of</strong><br />
Graduate Biomedical Sciences
2:45 PM<br />
1405. Development <strong>of</strong> a Vision Related Quality <strong>of</strong> Life<br />
Instrument for Children with Juvenile Idiopathic Arthritis-<br />
Associated Uveitis.<br />
Sheila Angeles-Han 4 , Kenneth Griffin 7 , Melanie J. Harrison 5 ,<br />
Kerrie Fields 2 , Lori Ponder 2 , Rachel Reeves-Robb 3 , Marla<br />
Shainberg 3 , Phoebe Lenhart 3 , Amy Hutchinson 3 , Sunil Srivastava 3 ,<br />
Sampath Prahalad1, Scott Lambert 3 and Carolyn Drews-Botsch 6 ,<br />
1<br />
Emory Children’s Center, Atlanta, GA, 2 Emory Children’s Center,<br />
3<br />
Emory Eye Center, 4 Emory University, Atlanta, GA, 5 Pfizer, Blue<br />
Bell, PA, 6 Rollins School <strong>of</strong> Public Health, 7 Weill Cornell Medical<br />
<strong>College</strong><br />
3:00 PM<br />
1406. Sleep in Polyarticular Juvenile Idiopathic Arthritis: An<br />
Electronic Daily Diary Study.<br />
Maggie H. Bromberg 5 , Cecelia R. Valrie 4 , Mark Connelly 1 ,<br />
Kelly K. Anthony 3 , Lindsey Franks 3 , Karen M. Gil 6 and Laura<br />
E. Schanberg 2 , 1 Children’s Mercy Hospital and Clinics, 2 Duke<br />
Univ Medical Center, Durham, NC, 3 Duke University Medical<br />
Center, Durham, NC, 4 East Carolina University, 5 University <strong>of</strong><br />
North Carolina at Chapel Hill, Carrboro, NC, 6 University <strong>of</strong> North<br />
Carolina at Chapel Hill<br />
3:15 PM<br />
1407. Clinically Meaningful Improvements in Health-<br />
Related Quality <strong>of</strong> Life, Pain and Sleep Quality in Children<br />
with Polyarticular Juvenile Idiopathic Arthritis Treated with<br />
Abatacept over the Long Term.<br />
Daniel J. Lovell 3 , Nicolino Ruperto 15 , Pierre Quartier 19 , Eliana<br />
Paz 13 , Nadina Rubio-Perez 10 , Clovis A. Silva 5 , Carlos Abud-<br />
Mendoza 6 , Ruben Burgos Vargas 7 , Valeria Gerloni 16 , José A.<br />
Melo-Gomes (Andre Dos Santos) 14 , Claudia S. Magalhães 18 ,<br />
Flavio Sztajnbok 12 , Claudia Goldenstein-Schainberg 17 , Morton<br />
Scheinberg 8 , Inmaculada Calvo Penadés 11 , Michel Fischbach 4 ,<br />
Javier Orozco 9 , Lisa Rosenblatt 1 , Monica Mody 1 , Marleen Nys 2 ,<br />
Edward H. Giannini 3 and Alberto Martini 15 , 1Bristol-Myers<br />
Squibb, NJ, 2 Bristol-Myers Squibb, Braine-l’Alleud, Belgium,<br />
3<br />
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH,<br />
4<br />
Hôpital Universitaire Hautepierre, Strasbourg, France, 5 Hospital<br />
Das Clinicas, Sao Paulo, Brazil, 6 Hospital General “Dr Ignacio<br />
Morones Prieto”, San Luis Potosì, Mexico, 7 Hospital General<br />
de México and Universidad Nacional Autónoma de México,<br />
Mexico City, Mexico, 8 Hospital Israelita Albert Einstein, Research<br />
Institute, São Paulo, Brazil, 9 Hospital San Javier, <strong>Rheumatology</strong>,<br />
Guadalajara, Jalisco, Mexico, 10 Hospital Universitario “Dr. J. E.<br />
Gonzalez”, Monterrey, Mexico, 11 Hospital Universitario La Fe,<br />
Valencia, Spain, 12 Hospital Universitario Pedro Ernesto, Rio<br />
de Janeiro, Brazil, 13 Instituto de Salud del Nino, Lima, Peru,<br />
14<br />
Instituto Portugues de Reumatologia, Lisbon, Portugal, 15 IRCCS<br />
G Gaslini, Pediatria II-PRINTO, Università di Genova, Genova,<br />
Italy, 16 Istituto Gaetano Pini, Milan, Italy, 17 Universidade de<br />
São Paulo, São Paulo, Brazil, 18 Universidade Estadual Paulista,<br />
Botucatu, Brazil, 19 Universite Paris-Descartes and Centre de<br />
Reference National Pour les Arthrites, Paris, France<br />
3:30 PM<br />
1408. Jointly Managing Arthritis: Information Needs <strong>of</strong> Children<br />
with Juvenile Idiopathic Arthritis (JIA) and Their Parents.<br />
Jennifer Stinson 4 , Brian M. Feldman 5 , Ciaran Duffy 3 , Adam<br />
Huber 2 , Lori Tucker 1 , Patrick McGrath 2 , Shirley M. Tse 5 , Ross<br />
Hetherington 5 , Lynn Spiegel 5 , Sarah Campillo 3 , Susanne<br />
Benseler 5 , Navreet Gill 5 , Meghan E. White 5 and Abi Vijenthira 5 ,<br />
1<br />
BC Children’s Hospital, 2 IWK Health Centre, 3 Montreal Children’s<br />
Hospital, 4 The Hospital for Sick Children, Toronto, ON, Canada,<br />
5<br />
The Hospital for Sick Children<br />
3:45 PM<br />
1409. Follow-Up Survey on Adolescent <strong>Rheumatology</strong> Patients’<br />
Online Activities and Social Support Systems: Opportunities for<br />
Transition Program Development.<br />
Peter Chira, Stanford University, Palo Alto, CA<br />
ARHP Concurrent Sessions<br />
2:30 - 4:00 PM<br />
B309<br />
From Managed Care to Medicare: Understanding<br />
Reimbursement cP<br />
Moderator: Barbara A. Slusher, PA-C, MSW; League City, TX<br />
Speaker: Kamala M. Nola, PharmD, MS; Lipscomb <strong>College</strong> <strong>of</strong><br />
Pharmacy; Nashville, TN<br />
Session Overview:<br />
The role <strong>of</strong> managed care and Medicare are an ever<br />
increasing component <strong>of</strong> rheumatology practice. Patient care<br />
considerations based on coverage decisions by managed care<br />
and Medicare occur daily. While there are regional variations in<br />
managed care and Medicare plans, both use similar population<br />
management tools to control cost while managing access to<br />
needed medical services and pharmaceuticals. Understanding<br />
the coverage and reimbursement process for medical and<br />
pharmaceutical products and services is critical to rheumatology<br />
health care providers.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the structure and function <strong>of</strong> commercial managed<br />
care companies and Medicare<br />
• differentiate between managed care and Medicare in<br />
coverage <strong>of</strong> medical and pharmaceutical benefits<br />
• describe the impact rheumatology pr<strong>of</strong>essionals can have on<br />
the process<br />
B308<br />
Musculoskeletal Pain and Cognitive Issues Related to<br />
Returning Military Personnel C PM<br />
Moderator: Mary Wright, BS, OT; The Toledo Hospital; Toledo,<br />
OH<br />
Speakers: Daniel J. Clauw, MD; University <strong>of</strong> Michigan Chronic<br />
Pain & Fatigue Research; Ann Arbor, MI<br />
Mary W. Erickson, OTR, MAOL; Office <strong>of</strong> the Surgeon General<br />
Health Policy and Services; Falls Church, VA<br />
Session Overview:<br />
Pain, joint stiffness, fatigue, lethargy, headaches, and cognitive<br />
problems are common symptoms experienced by those having<br />
served in the US military during the Gulf War. Similar postdeployment<br />
musculoskeletal and somatic symptoms have<br />
been noted in veterans <strong>of</strong> nearly every war. The Veteran’s<br />
Administration has developed the Musculoskeletal Action Plan<br />
with the purpose <strong>of</strong> reducing injury rates, improving medical<br />
readiness, preventing injuries, optimizing performance, and<br />
providing program recommendations.<br />
tuesday<br />
2010 Program Book 75
tuesday<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the symptoms commonly experienced by those<br />
serving the US and UK military during the Gulf War and other<br />
wars<br />
• explain the therapies that have been found to be effective for<br />
the treatment <strong>of</strong> these symptoms<br />
• describe the Veteran’s Administration’s Musculoskeletal<br />
Action Plan and how this plan can be utilized<br />
B310<br />
What’s New and Noteworthy in 2010: A Review <strong>of</strong><br />
<strong>Rheumatology</strong> Research for Health Pr<strong>of</strong>essionals C<br />
Moderator: Beverly K. Barham, RN, MSN, CCRC; NIAMS;<br />
Bethesda, MD<br />
2:30 PM<br />
Nursing<br />
Speaker: Elizabeth A. Schlenk, PhD, RN; University <strong>of</strong> Pittsburgh;<br />
Pittsburgh, PA<br />
3:00 PM<br />
Physical Therapy<br />
Speaker: Susan E. Klepper, PhD, PT; Columbia University; New<br />
York, NY<br />
3:30 PM<br />
Europe<br />
Speaker: Christina H. Opava, PhD; Karolinska Institutet;<br />
Huddinge, Sweden<br />
Session Overview:<br />
Based on the volume <strong>of</strong> information available, there is a need to<br />
summarize the most important and innovative research findings<br />
for health care providers to assist them in applying the research<br />
finding into practice.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify important research advances published in the<br />
rheumatology nursing, rehabilitation and European<br />
rheumatology arenas within the past 12 months<br />
• describe the significance <strong>of</strong> these advances for the individual<br />
practitioner<br />
• describe the significance <strong>of</strong> these advances for rheumatology<br />
research<br />
ACR/ARHP Workshops<br />
4:00 - 6:00 PM<br />
Admission to each Workshop requires a separate registration<br />
and ticket. To verify which session you registered for, check to<br />
make sure the registration code on your ticket matches the code<br />
listed below in parentheses.<br />
B206<br />
Joint Injections (Knee and Ankle Prosthetics) (227)<br />
Speaker: Gregory C. Gardner, MD; University <strong>of</strong> Washington;<br />
Seattle, WA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe indications for lower extremity joint injection and<br />
aspiration<br />
• identify anatomic landmarks for injection <strong>of</strong> the knee and<br />
ankle using joint prosthetics<br />
• apply principles <strong>of</strong> joint aspiration and injection using ankle<br />
and knee joint prosthetics<br />
B204<br />
Knee Braces and Foot Orthosis for Knee Osteoarthritis<br />
(228)<br />
Speakers: Howard J. Hillstrom, PhD; Hospital for Special Surgery;<br />
New York, NY<br />
Kelly D. Krohn, MD; Lilly USA, LLC; Indianapolis, IN<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review the biomechanical rationale for the use <strong>of</strong> knee braces<br />
and foot orthoses for knee osteoarthritis<br />
• discuss the clinical data to support these modalities<br />
• apply these modalities to their patients<br />
B202<br />
Synovial Fluid Analysis and Crystal Identification<br />
(229)<br />
Speakers: Brian F. Mandell, MD, PhD; The Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
Lan X. Chen, MD, PhD; Pennsylvania Presbyterian Medical<br />
Center; Blue Bell, PA<br />
Gilda M. Clayburne, MLT; Veterans Affairs Medical Center;<br />
Philadelphia, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• prepare synovial fluid samples for microscopic examination<br />
• identify various components <strong>of</strong> synovial fluid<br />
• identify crystals in synovial fluid<br />
B203<br />
Systemic Sclerosis: How to Perform Skin Scores (230)<br />
f<br />
Speakers: Daniel E. Furst, MD; University <strong>of</strong> California-Los<br />
Angeles Medical School; Los Angeles, CA<br />
Philip J. Clements, MD, MPH; University <strong>of</strong> California-Los Angeles<br />
School <strong>of</strong> Medicine; Los Angeles, CA<br />
Dinesh Khanna, MD, MSc; University <strong>of</strong> California-Los Angeles;<br />
Los Angeles, CA<br />
Maureen D. Mayes, MD, MPH; University <strong>of</strong> Texas-Houston;<br />
Houston, TX<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review the usefulness and reasons to do a modified Rodman<br />
skin score<br />
• explain how to do a modified Rodman skin score<br />
• perform a modified Rodman skin score under the supervision<br />
<strong>of</strong> experts<br />
ACR Basic Science Symposium<br />
4:30 - 6:00 PM<br />
B313<br />
The Preclinical Stage <strong>of</strong> Rheumatoid Arthritis:<br />
Towards Prevention <strong>of</strong> Disease? R<br />
Moderators: Paul P. Tak, MD, PhD; Academic Medical Center,<br />
University <strong>of</strong> Amsterdam; Amsterdam, Netherlands<br />
Karim Raza, BA, PhD; University <strong>of</strong> Birmingham; Edgbaston,<br />
Birmingham, United Kingdom<br />
76<br />
2010 Program Book
4:30 PM<br />
Anti-citrullinated Protein Antibodies in the Earliest Stages <strong>of</strong><br />
Rheumatoid Arthritis: Pathology and Promise<br />
Lars Klareskog, MD, PhD; Karolinska University Hospital;<br />
Stockholm, Sweden<br />
5:00 PM<br />
The Earliest Stage <strong>of</strong> Rheumatoid Arthritis in a North <strong>American</strong><br />
Native Population<br />
Hani S. El-Gabalawy, MD; University <strong>of</strong> Manitoba; Winnipeg, MB,<br />
Canada<br />
5:30 PM<br />
Preclinical Rheumatoid Arthritis: Where Does the Disease Start<br />
and Could the Disease be Prevented?<br />
Danielle M. Gerlag, MD, PhD; Academic Medical Center;<br />
Amsterdam, Noord-Holland, Netherlands<br />
Session Overview:<br />
It has recently become possible to study the earliest phases <strong>of</strong><br />
rheumatoid arthritis, including preclinical rheumatoid arthritis.<br />
Studies on early rheumatoid arthritis may provide crucial<br />
insights into its pathogenesis and may <strong>of</strong>fer the perspective<br />
<strong>of</strong> preventive strategies in the future. In this session, recent<br />
data on the pathogenesis <strong>of</strong> early and preclinical rheumatoid<br />
arthritis will be discussed and the outline <strong>of</strong> a recently started<br />
exploratory study aimed at prevention <strong>of</strong> rheumatoid arthritis<br />
will be presented.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the role <strong>of</strong> specific anti-citrullined protein antibodies<br />
in the earliest phase <strong>of</strong> rheumatoid arthritis<br />
• describe the immunogenetic risk in relationship to<br />
autoantibody positivity in a North <strong>American</strong> Native population<br />
with rheumatoid arthritis and their first-degree relatives<br />
• explain the changes in different compartments, including the<br />
synovial tissue, in the preclinical phase <strong>of</strong> rheumatoid arthritis<br />
ACR Clinical Symposia<br />
4:30 - 6:00 PM<br />
Thomas J. Murphy Ballroom<br />
Inflammatory Myopathy Update C PM PS<br />
Moderator: Chester V. Oddis, MD; University <strong>of</strong> Pittsburgh;<br />
Pittsburgh, PA<br />
4:30 PM<br />
Diagnostic Modalities in the Inflammatory Myopathies:<br />
Emerging Concepts<br />
Lisa Christopher-Stine, MD; Johns Hopkins University; Baltimore,<br />
MD<br />
4:55 PM<br />
Autoantibodies in Myositis: Clinical Relevance and Pathogenic<br />
Considerations<br />
Harsha Gunawardena, MD; University <strong>of</strong> Bath; Bath, United<br />
Kingdom<br />
5:50 PM<br />
Exercise Intervention in the Management <strong>of</strong> Myositis<br />
Ingrid E. Lundberg, MD, PhD; Karolinska Institutet; Stockholm,<br />
Sweden<br />
Session Overview:<br />
Patients with myositis continue to present challenges from a<br />
diagnostic and management standpoint. The topics covered in<br />
this symposium will aid the practicing rheumatologist in their<br />
assessment <strong>of</strong> patients with polymyositis and dermatomyositis.<br />
In addition to the routine diagnostic tools, there are important<br />
imaging options to consider in the assessment <strong>of</strong> myositis.<br />
Autoantibodies in myositis are important in the classification<br />
and prognosis <strong>of</strong> patients and many rheumatologists struggle<br />
with the clinical relevance <strong>of</strong> autoantibody assessment. Newer<br />
specificities may be more clinically useful. The management<br />
<strong>of</strong> myositis rarely included an exercise program, but recent<br />
data has shifted the paradigm and this symposium will review<br />
the importance <strong>of</strong> exercise in the treatment <strong>of</strong> inflammatory<br />
myopathy.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify and interpret newer diagnostic modalities in the<br />
assessment and management <strong>of</strong> patients with inflammatory<br />
myopathy<br />
• utilize autoantibodies in the clinical assessment <strong>of</strong> myositis<br />
and recognize their importance in the pathogenesis <strong>of</strong> disease<br />
• distinguish the beneficial effects <strong>of</strong> an exercise program in the<br />
treatment <strong>of</strong> patients with both active and inactive myositis<br />
Hall A3<br />
Update on Safety Issues in the Treatment <strong>of</strong><br />
Rheumatic Diseases – From the Food and Drug<br />
Administration and Beyond cP PS<br />
Moderators: Daniel J. Lovell, MD, MPH; Children’s Hospital<br />
Medical Center; Cincinnati, OH<br />
Eric M. Ruderman, MD; Northwestern University School;<br />
Chicago, IL<br />
4:30 PM<br />
Introduction - Update on Newly Identified Drug Safety Issues<br />
and Initiatives from the ACR Drug Safety Subcommittee<br />
Daniel J. Lovell, MD, MPH; Children’s Hospital Medical Center;<br />
Cincinnati, OH<br />
4:50 PM<br />
Update on Safety Issues and Food and Drug Administration<br />
Initiatives, Including Risk Evaluation and Mitigation Strategies<br />
Larissa Y. Lapteva, MD, MHS; Food and Drug Administration;<br />
Rockville, MD<br />
5:40 PM<br />
Question and Answer<br />
Session Overview:<br />
Timely communication <strong>of</strong> evolving safety information is a<br />
critical element in the ability <strong>of</strong> practitioners to provide the best<br />
care for their patients with rheumatic diseases. This session<br />
will provide an update to rheumatologists on late-breaking or<br />
evolving topics in patient safety, including any relevant Food and<br />
Drug Administration analysis or response to these issues.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify important safety issues in the drug treatment <strong>of</strong><br />
rheumatic diseases<br />
• integrate knowledge <strong>of</strong> new safety issues into their treatment<br />
strategies<br />
tuesday<br />
2010 Program Book 77
tuesday<br />
78<br />
• advise patients about the safety issues related to treatments<br />
for rheumatic diseases<br />
• describe the evolutions at the Food and Drug Administration<br />
that will affect drug safety monitoring and reporting<br />
ACR Concurrent Abstract Sessions<br />
4:30 - 6:00 PM<br />
A402<br />
B-Cell Biology and Targets in Autoimmune Disease<br />
Moderators: Chaim Putterman, MD; Albert Einstein <strong>College</strong> <strong>of</strong><br />
Medicine; Bronx, NY<br />
Yehuda Shoenfeld, MD; Sheba Medical Center; Ramat Gan, Israel<br />
4:30 PM<br />
1410. TLR7 and IFNα Influence B Cell Selection in the Germinal<br />
Center.<br />
Ioana Moisini 1 , Weiqing Huang 1 , Tony Marion 3 and Anne<br />
Davidson 2 , 1 Feinstein Institute, 2 Feinstein Institute for Medical<br />
Research, Manhasset, NY, 3 University <strong>of</strong> Tennessee<br />
4:45 PM<br />
1411. Impaired Somatic Hypermutation in Pre-Switch Memory<br />
B Cells and Modulation <strong>of</strong> Mutational Targeting in Memory B<br />
Cells during Tocilizumab Treatment in RA Patients.<br />
Khalid Muhammad 1 , Petra Roll 1 , Stefan Kleinert 2 , Thomas<br />
Seibold 2 , Martin Feuchtenberger 2 , Thomas Dörner 3 and Hans-<br />
Peter Tony 2 , 1 Department <strong>of</strong> Medicine II, <strong>Rheumatology</strong>/Clinical<br />
Immunology, University <strong>of</strong> Würzburg, Würzburg, Bayern,<br />
Germany, 2 Department <strong>of</strong> Medicine II, <strong>Rheumatology</strong>/Clinical<br />
Immunology, University <strong>of</strong> Würzburg, Würzburg, Germany,<br />
3<br />
Dept. <strong>of</strong> Medicine/<strong>Rheumatology</strong> and Clinical Immunology<br />
Charite Universitätsmedizin Berlin and DRFZ Berlin, Berlin,<br />
Germany<br />
5:00 PM<br />
1412. IL-17 Downregulates NF-КкB1/p50 and Upregulates<br />
BCL6 To Promote Germinal Center B Cell Differentiation in<br />
Autoimmune BXD2 Mice.<br />
Shutao Xie 2 , Hui-Chen Hsu 2 , Jun Li 2 , Qi Wu 2 , PingAr Yang 2 and<br />
John D. Mountz 1 , 1 Univ Alabama at Birmingham, Birmingham,<br />
AL, 2 Univ Alabama at Birmingham<br />
5:15 PM<br />
1413. Targeting the Splicing <strong>of</strong> mRNA in Autoimmune Diseases:<br />
BAFF Inhibition in Sjögren’s Syndrome as a Pro<strong>of</strong> <strong>of</strong> Concept.<br />
Nienke Roescher 5 , Jelle L. Vosters 2 , Ghada Al Saleh 6 , Patrick<br />
Dreyfus 7 , Sebastien Jacques 4 , Luis Garcia 7 , Gilles Chiocchia 4 ,<br />
Antoine Francois 6 , Jean Sibilia 6 , Paul P. Tak 1 , Jay A. Chiorini 5 ,<br />
Xavier Mariette 3 and Jacques-Eric Gottenberg 6 , 1 Academic<br />
Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />
2<br />
Academic Medical Center/University <strong>of</strong> Amsterdam, 3 Bicetre<br />
Hospital, 4 Cochin Hospital, 5 National Institutes <strong>of</strong> Health,<br />
National Institute <strong>of</strong> Dental and Crani<strong>of</strong>acial Research,<br />
6<br />
Strasbourg Hospital, EA 4438, 7 UMR 7215 CNRS, Institut de<br />
Myologie<br />
5:30 PM<br />
1414. Adoptive Transfer <strong>of</strong> Long-Lived Plasma Cells from<br />
NZB/W Mice Causes Immune Complex Nephritis in Recipient<br />
Rag1-/- Mice.<br />
IImtiaz M. Mumtaz 1 , Bimba F. Hoyer 1 , Andreas Radbruch 4 and<br />
Falk Hiepe 2 , 1 Charité - Universitätsmedizin, Berlin, Germany,<br />
2010 Program Book<br />
2<br />
Charité - Universitätsmedizin, Berlin, Berlin, Germany,<br />
3<br />
Charité - Universitätsmedizin Berlin, Berlin, Germany, 4 German<br />
Rheumatism Research Center, Berlin, Germany<br />
5:45 PM<br />
1415. B Cells Induced Proteinuria and Glomerulopathy in<br />
Absence <strong>of</strong> Immune Complexes Similar to Minimal Change<br />
Disease.<br />
Alfred H. Kim 1 and Andrey S. Shaw 2 , 1 Washington Univ School <strong>of</strong><br />
Med, St. Louis, MO, 2 Washington Univ School <strong>of</strong> Med<br />
A411<br />
Cell-Cell Adhesion, Cell Trafficking and Angiogenesis<br />
Moderators: Bruce N. Cronstein, MD; New York University<br />
Medical Center; New York, NY<br />
Zoltan Szekanecz, MD, PhD, DSC; University <strong>of</strong> Debrecen Medical<br />
Center; Debrecen, Hungary<br />
4:30 PM<br />
1416. Nuclear Factor-кB Inducing Kinase Is Preferentially<br />
Expressed in Rheumatoid Arthritis Synovial Tissue Containing<br />
Ectopic Lymphoid Neogenesis.<br />
Ae-Ri Noort 2 , Katinka P. M. van Zoest 3 , Mariagrazia Modesti 4 ,<br />
Sander W. Tas 2 and Paul P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong><br />
Amsterdam, Amsterdam, The Netherlands, 2 Academic Medical<br />
Center/University <strong>of</strong> Amsterdam, The Netherlands, 3 Academic<br />
Medical Center/University <strong>of</strong> Amsterdam, 4 University <strong>of</strong> Rome<br />
4:45 PM<br />
1417. CXCL16 as an Early Response Chemokine in Rat Adjuvant<br />
and K/BxN Serum Induced Arthritis Models.<br />
Jeffrey H. Ruth 2 , Chrisitian S. Haas 1 , M. Asif Amin 2 , G.<br />
Kenneth Haines III 4 and Alisa E. Koch 3 , 1 University <strong>of</strong> Luebeck<br />
- Department <strong>of</strong> Medicine I, Luebeck, Germany, 2 University <strong>of</strong><br />
Michigan Medical School, Ann Arbor, MI, 3 Unversity <strong>of</strong> Michigan,<br />
Ann Arbor, MI, 4 Yale University Medical School<br />
5:00 PM<br />
1418. Angiogenic Potential <strong>of</strong> HMECs Is Driven by HIF-2α<br />
Overcoming the Effects <strong>of</strong> HIF-1α.<br />
Martin Hahne 2 , Steffi Luetkecosmann 1 , Cam Loan Tran 1 , Ferenz<br />
Lohanatha 1 , Manuela Jakstadt 6 , Grit Kasper 4 , Georg Duda 4 , Paula<br />
Kolar 4 , Timo Gaber 1 , Gerd R. Burmester 3 and Frank Buttgereit 5 ,<br />
1<br />
Berlin-Brandenburg Center for Regenerative Medicine, 2 Berlin-<br />
Brandenburg School for Regenerative Medicine, Germany,<br />
3<br />
Charite - University Medicine, Berlin, Germany, 4 Charite -<br />
University Medicine, 5 Charite University Med-Berlin, Berlin,<br />
Germany, 6 German Rheumatism Research Center<br />
5:15 PM<br />
1419. Soluble Junctional Adhesion Molecule-A Promotes<br />
Angiogenesis in Rheumatoid Arthritis.<br />
Bradley J. Rabquer 1 , George Boychev 2 , Jeffrey H. Ruth 2 , Thilo<br />
Stehle 3 and Alisa E. Koch 4 , 1University <strong>of</strong> Michigan, Ann Arbor,<br />
MI, 2 University <strong>of</strong> Michigan, 3 University <strong>of</strong> Tubingen, 4 Unversity<br />
<strong>of</strong> Michigan, Ann Arbor, MI.<br />
5:30 PM<br />
1420. Invasiveness <strong>of</strong> Rheumatoid Arthritis Synovial Fibroblasts<br />
Is Affected by Extracellular RNA and DNA.<br />
Birgit Zimmermann 3 , Silvia Fischer 1 , Stephanie Lefèvre 4 , Angela<br />
Lehr 6 , Jürgen Steinmeyer 5 , Henning Stürz 2 , Thomas Umscheid 7 ,<br />
Ulf Müller-Ladner 3 , Klaus T. Preissner 1 and Elena Neumann 3 ,<br />
1<br />
Dept <strong>of</strong> Biochemistry, Justus-Liebig-University Giessen, 2 Dept
<strong>of</strong> Experimental Orthopedics, University Hospital Giessen<br />
and Marburg, 3 Dept <strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>,<br />
Justus-Liebig-University Giessen, Kerckh<strong>of</strong>f-Klinik, Bad Nauheim,<br />
Germany, 4 Dept <strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, Justus-<br />
Liebig-University Giessen, Kerckh<strong>of</strong>f-Klinik, Bad Nauheim, 5 Dept<br />
<strong>of</strong> Orthopedics and Orthopedic Surgery, University Hospital<br />
Giessen and Marburg, 6 Dept <strong>of</strong> Orthopedics and Trauma Surgery,<br />
Markuskrankenhaus Frankfurt, Germany, 7 Dept <strong>of</strong> Vascular<br />
Surgery, Helios William Harvey Klinik<br />
5:45 PM<br />
1421. Citrullination <strong>of</strong> Extracellular Matrix Proteins Inhibits<br />
Synovial Fibroblast Invasion and Migration.<br />
Miriam A. Shelef 1 , David A. Bennin 3 and Anna Huttenlocher 2 ,<br />
1<br />
Department <strong>of</strong> Medicine, University <strong>of</strong> Wisconsin, Madison,<br />
WI, 2 Medical Microbiology & Immunology and Pediatrics,<br />
University <strong>of</strong> Wisconsin, Madison, WI, 3 Medical Microbiology &<br />
Immunology and Pediatrics, University <strong>of</strong> Wisconsin, Madison,<br />
WI<br />
A410<br />
Cytokines, Mediators, Gene Regulation II<br />
Moderators: Erik Lubberts, PhD; Erasmus MC; Rotterdam, ZH,<br />
The Netherlands<br />
Carla R. Scanzello, MD, PhD; Rush University Medical Center;<br />
Chicago, IL<br />
4:30 PM<br />
1422. The Role <strong>of</strong> miR-155 in the Activation <strong>of</strong> RA and PsA<br />
Synovial Fluid Monocytes.<br />
Mariola S. Kurowska-Stolarska 3 , Lucy Ballantine 3 , Bartosz E.<br />
Stolarski3, John Hunter 1 , Foo Y. Liew 4 , J. Alastair Gracie 4 and<br />
Iain B. McInnes 2 , 1 Gartnavel General Hospital, United Kingdom,<br />
2<br />
University <strong>of</strong> Glasgow, Glasgow, United Kingdom, 3 University<br />
<strong>of</strong> Glasgow, Glasgow, United Kingdom, 4 University <strong>of</strong> Glasgow,<br />
United Kingdom<br />
I. Kone-Paut 4 , H. J. Lachmann 12 , J. B. Kuemmerle-Deschner 6 ,<br />
E. Hachulla 3 , R. Cartwright 1 , J. Hoyer 2 , P. Quartier 11 , J. Smith 13 ,<br />
M. Gattorno 5 , K. Leslie 10 , J. Braun 9 , A. Widmer 7 , A. Ferreira 7 ,<br />
N. Patel 8 , R. Preiss 8 and P. N. Hawkins 12 , 1 Allergy Center at<br />
Brookstone, Columbus, GA, 2 Department <strong>of</strong> Internal Medicine<br />
and Nephrology, Universitaetsklinikum Giessen und Marburg<br />
GmbH, Marburg, Germany, 3 Hôpital Claude Huriez CHRU, Lille<br />
Cedex, France, 4 Hôpital Kremlin Bicetre, CEREMAI, Le Kremlin<br />
Bicetre, France, 5 Istituto Giannina Gaslini, Genova, Italy,<br />
6<br />
Klinik fuer Kinder-und Jugendmedizin, Universitaetsklinikum,<br />
Tuebingen, Germany, 7 Novartis Pharma AG, Basel, Switzerland,<br />
8<br />
Novartis Pharmaceuticals Corporation, East Hanover, NJ,<br />
9<br />
Rheumazentrum Ruhrgebiet, Herne, Germany, 10 UCSF School<br />
<strong>of</strong> Medicine, San Francisco, CA, 11 Unit’e d’Immunologie,<br />
Hematologie et Rhumatologie Pediatrique, Hopital Necker-<br />
Enfants Malades, Paris, France, 12 University <strong>College</strong> London<br />
Medical School, London, United Kingdom, 13 University <strong>of</strong><br />
Wisconsin Hospital and Clinics, Madison, WI<br />
5:30 PM<br />
1426. Osteoarthritis-Associated Basic Calcium Phosphate<br />
Crystals Activate the NLRP3 Inflammasome in a Syk Kinase<br />
Dependent Manner.<br />
Aisling Dunne 2 , Lisa Mielke 2 , Jurg Tschopp 3 , Kingston H. G. Mills 2<br />
and Geraldine M. McCarthy 1 , 1 Royal <strong>College</strong> <strong>of</strong> Surgeons, Ireland<br />
& Mater Hospital, Ireland, 2 Trinity <strong>College</strong> Dublin, Ireland,<br />
3<br />
University <strong>of</strong> Luasanne, Switzerland<br />
5:45 PM<br />
1427. Lipid-Cytokine-Chemokine Cascade Drives Neutrophil<br />
Recruitment in a Murine Model <strong>of</strong> Inflammatory Arthritis.<br />
Nancy D. Kim 3 , Richard C. Chou 1 , Christian Sadik 2 , Edward Seung 2 ,<br />
Yinan Lan 2 , Yoichiro Iwakura 4 and Andrew Luster 2 , 1 Dartmouth-<br />
Hitchcock Medical Center, Lebanon, NH, 2 Massachusetts<br />
General Hospital, 3 Massachusetts General Hospital, Boston, MA,<br />
4<br />
University <strong>of</strong> Tokyo<br />
tuesday<br />
4:45 PM<br />
1423. Rapid Improvement in Health-Related Quality <strong>of</strong> Life<br />
(HRQoL) in Gouty Arthritis Patients Treated with Canakinumab<br />
(ACZ885) Compared to Triamcinolone Acetonide.<br />
A. So 6 , M. De Meulemeester 4 , A. Pikhlak 2 , A. E. Yücel 1 , U.<br />
Arulmani 3 , D. Richard 3 , K. Stricker 3 , A. Ferreira3, V. Murphy 3 , P.<br />
Sallstig 3 and N. Schlesinger 5 , 1 Baskent University, Ankara, Turkey,<br />
2<br />
Moscow State University <strong>of</strong> Medicine and Dentistry, Moscow,<br />
Russian Federation, 3 Novartis Pharma AG, Basel, Switzerland,<br />
4<br />
Private PracticeGozée, Gozée, Belgium, 5 UMDNJ-Robert Wood<br />
Johnson Medical School, New Brunswick, NJ, 6 University <strong>of</strong><br />
Lausanne, Lausanne, Switzerland<br />
5:00 PM<br />
1424. Toll-Like Receptor Signals Modify the ER Stress Response.<br />
Jane C. Goodall 1 , Louise McNeill 2 , Lou Ellis 2 and J. Hill Gaston 2 ,<br />
1<br />
Cambridge University, Cambridge, Cambs, United Kingdom,<br />
2<br />
Cambridge University<br />
5:15 PM<br />
1425. Canakinumab (ILARIS®) Improves Health-Related Quality<br />
<strong>of</strong> Life (HRQoL) in Patients with Cryopyrin-Associated Periodic<br />
Fever Syndrome (CAPS): Results <strong>of</strong> a Phase III, Open-Label<br />
Study in a Large Cohort <strong>of</strong> CAPS Patients.<br />
A315<br />
Education<br />
Moderators: Abby Goulder Abelson, MD; Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
Joan Marie Von Feldt, MD, MS Ed; University <strong>of</strong> Pennsylvania-<br />
Philadelphia, Veterans Affairs Medical Center; Philadelphia, PA<br />
4:30 PM<br />
1428. The Impact <strong>of</strong> Patient-Physician Relationship<br />
Components on Physician Trust and Treatment Adherence in<br />
Patients with Rheumatic Disease.<br />
S<strong>of</strong>ia de Achaval 1 , Michael A. Kallen 1 , Vanessa L. Cox 1 , Marsha<br />
N. Richardson 1 and Maria E. Suarez-Almazor 2 , 1 The University <strong>of</strong><br />
Texas M. D. Anderson Cancer Center, Houston, TX, 2 University <strong>of</strong><br />
Texas, MD Anderson Cancer Center, Houston, TX<br />
4:45 PM<br />
1429. Development <strong>of</strong> an ACMGE Core Competency-Based<br />
Electronic Portfolio at the USC-LAC <strong>Rheumatology</strong> Fellowship<br />
Program.<br />
Karina Marianne D. Torralba 2 , Francisco P. Quismorio 3 , Beatrice<br />
A. Boateng 1 and Shylaja Rachabattula 4 , 1 Arkansas Children’s<br />
Hospital-University <strong>of</strong> Arkansas for Medical Sciences, 2 University<br />
<strong>of</strong> Southern California-Los Angeles County Medical Center,<br />
Pasadena, CA, 3 University <strong>of</strong> Southern California-Los Angeles<br />
2010 Program Book 79
tuesday<br />
County Medical Center, Los Angeles, CA, 4 University <strong>of</strong> Southern<br />
California-Los Angeles County Medical Center<br />
5:00 PM<br />
1430. An Updated Immunology Curriculum for <strong>Rheumatology</strong><br />
Fellows.<br />
Rahul K. Patel 1 , Lisa Hodge 1 , Jerry Simecka 1 and Bernard R.<br />
Rubin 2 , 1 UNT Health Science Center, Fort Worth, TX, 2 UNT Health<br />
Science Center, Birmingham, MI<br />
5:15 PM<br />
1431. A Case-Controlled Study <strong>of</strong> a Multimodal <strong>Rheumatology</strong><br />
Elective for Medical Residents.<br />
Deana M. Lazaro 4 , Sheen Yee Lim 2 , David R. Blumenthal 3 , Joshua<br />
Scheers-Masters 1 , Jeanne Macrae 1 and Matthew Avitable 1 ,<br />
1<br />
SUNY Downstate Medical Center, 2 SUNY Downstate-Brooklyn,<br />
Brooklyn, NY, 3 VA New York Harbor Healthcare System, Short<br />
Hills, NJ, 4 VA New York Harbor Healthcare System and SUNY<br />
Downstate Medical Center, Brooklyn, NY<br />
5:30 PM<br />
1432. Effect <strong>of</strong> Internal Medicine Resident Participation<br />
in Team-Based Learning on In-Training Exam Scores in<br />
<strong>Rheumatology</strong>.<br />
Karina Marianne D. Torralba 2 , Beatrice A. Boateng 1 , Ron Ben-Ari 3<br />
and Francisco P. Quismorio 2 , 1 Arkansas Children’s Hospital-<br />
University <strong>of</strong> Arkansas for Medical Sciences, 2 University <strong>of</strong><br />
Southern California-Los Angeles County Medical Center, Los<br />
Angeles, CA, 3 University <strong>of</strong> Southern California-Los Angeles<br />
County Medical Center<br />
5:45 PM<br />
1433. “Rheumapalooza”: An Intensive <strong>Rheumatology</strong><br />
Curriculum for Second Year Medical Students.<br />
Helen Emery 1 and Gregory Gardner 2 , 1 Seattle Children’s Hospital,<br />
2<br />
University <strong>of</strong> Washington<br />
A404<br />
Pediatric <strong>Rheumatology</strong> - Clinical and Therapeutic<br />
Aspects-Therapeutics<br />
Moderators: Egla C. Rabinovich, MD, MPH; Duke University<br />
Medical Center; Durham, NC<br />
Norman T. Ilowite, MD; Children’s Hospital Montefiore; Bronx,<br />
NY<br />
4:30 PM<br />
1434. Tocilizumab in Patients with Systemic Juvenile Idiopathic<br />
Arthritis: Efficacy Data from the Placebo-Controlled 12-Week<br />
Part <strong>of</strong> the Phase 3 TENDER Trial.<br />
Fabrizio De Benedetti 1 , Hermine Brunner 4 , Nicola Ruperto 9 ,<br />
Inmaculada Calvo 5 , Ruben Cuttica 10 , Clara Malattia 11 , Rayfel<br />
Schneider 2 , Patricia Woo 7 , Carine H. Wouters 8 , Ricardo Xavier 6 ,<br />
Lawrence S. Zemel 3 , Stephen Wright 12 , Andrew Kenwright 12 ,<br />
Alberto Martini 9 and Daniel J. Lovell 4 , 1 IRCCS Ospedale Pediatrico<br />
Bambino Gesu, Rome, Italy, 2 PRCSG, Toronto, ON, Canada,<br />
3<br />
PRCSG, Hartford, CT, 4 PRCSG, Cincinnati, OH, 5 PRINTO, Valencia,<br />
Spain, 6 PRINTO, Porto Alegre, Brazil, 7 PRINTO, London, United<br />
Kingdom, 8 PRINTO, Leuven, Belgium, 9 PRINTO, Genova, Italy,<br />
10<br />
PRINTO, Buenos Aires, Argentina, 11 PRINTO, 12 Roche, Welwyn,<br />
UK, Welwyn, United Kingdom<br />
4:45 PM<br />
1435. Canakinumab (ILARIS ® ) Provides Rapid Response and<br />
Sustained Remission in Children across Different Disease<br />
Severity Phenotypes <strong>of</strong> Cryopyrin Associated Periodic<br />
Syndrome (CAPS).<br />
P. Quartier 13 , E. Hachulla 2 , M. Gattorno 5 , R. Cartwright 1 , I. Kone-<br />
Paut 4 , F. Zulian 15 , E. Weisbarth-Riedel 6 , L. Lepore 10 , J. Hoyer 12 , I.<br />
Foeldvari 16 , E. Ramos 3 , P. N. Hawkins 14 , K. Leslie 11 , G. Krammer 8 ,<br />
R. Preiss 9 , A. Widmer 8 and J. B. Kuemmerle-Deschner 7 , 1Allergy<br />
Center at Brookstone, Columbus, GA, 2 Department <strong>of</strong> Internal<br />
Medicine, Hôpital Claude Huriez CHRU, Lille Cedex, France,<br />
3<br />
Department <strong>of</strong> Pediatrics, Hospital Central de Asturias, Oviedo,<br />
Spain, 4 Hôpital Kremlin Bicetre, CEREMAI, Le Kremlin Bicetre,<br />
France, 5 Istituto Giannina Gaslini, Genova, Italy, 6 Kinderklinik,<br />
Rheum. Ambulanz, Universitätsklinikum Hamburg-Eppendorf,<br />
Hamburg, Germany, 7 Klinik fuer Kinder-und Jugendmedizin,<br />
Universitaetsklinikum, Tuebingen, Germany, 8 Novartis Pharma<br />
AG, Basel, Switzerland, 9 Novartis Pharmaceuticals Corporation,<br />
East Hanover, NJ, 10 S.C.U. Clinica Pediatrica, IRCCS Burlo<br />
Gar<strong>of</strong>olo, Trieste, Italy, 11 UCSF School <strong>of</strong> Medicine, San Francisco,<br />
CA, 12 Universitaetsklinikum Giessen und Marburg GmbH,<br />
Marburg, Germany, 13 Universite Paris-Descartes and Unite<br />
d’Immuno-Hematologie et Rhumatologie Pediatrique, Necker-<br />
Enfants Malades, Assistance Publique Hopitaux de Paris, Paris,<br />
France, 14 University <strong>College</strong> London Medical School, London,<br />
UK, 15 University <strong>of</strong> Padova School <strong>of</strong> Medicine, Padova, Italy,<br />
16<br />
Zentrum für Reumatologie, Hamburger Zentrum fuer Kinderund<br />
Jugendrheumatologie, Hamburg, Germany<br />
5:00 PM<br />
1436. Prevention <strong>of</strong> Flare Recurrences in Childhood Refractory<br />
Chronic Uveitis: An Open-Label Comparative Study <strong>of</strong><br />
Adalimumab Versus Infliximab.<br />
Gabriele Simonini 5 , Andrea Taddio 1 , Marco Cattalini 4 , Roberto<br />
Caputo 3 , Cinzia De Libero 2 , Cecilia Bresci 5 , Monica Lorusso 5 ,<br />
Samuele Naviglio 1 , Loredana Lepore1 and Rolando Cimaz 5 ,<br />
1<br />
Department <strong>of</strong> Sciences <strong>of</strong> Reproduction and Development,<br />
Institute <strong>of</strong> Child Health, IRCCS Burlo Gar<strong>of</strong>olo, University <strong>of</strong><br />
Trieste, Trieste, Italy, 2 Opthalmology Unit, A.Meyer’s Children’s<br />
Hospital, Firenze, Italy, 3 Opthalmology Unit, A.Meyer’s Childrens<br />
Hospital, Firenze, Italy, 4 Pediatric Clinic, University <strong>of</strong> Brescia,<br />
Brescia, Italy, 5 <strong>Rheumatology</strong> Unit, Dpt <strong>of</strong> Pediatrics, University<br />
<strong>of</strong> Florence, A.Meyer’s Childrens Hospital, Firenze, Italy<br />
5:15 PM<br />
1437. Safety and Low Seroprotection/Seroconversion Rates <strong>of</strong><br />
Pandemic Influenza A Vaccine (Anti-H1N1/2009) in Juvenile<br />
Systemic Lupus Erythematosus.<br />
Lucia M. Campos 3 , Clovis A. A. Silva 3 , Nadia Aikawa 3 , Eloisa<br />
Bonfa 5 , Guilherme Trudes 3 , Ana Cristina M. Ribeiro 5 , Carla<br />
Gonçalves Saad 5 , Vilma Trindade Viana 5 , Maria do Carmo<br />
Timenetsky 1 , Alexander R. Precioso 2 and Rosa M. R. Pereira 4 ,<br />
1<br />
Instituto Adolpho Lutz, 2 Instituto Butantã, 3 Paediatric<br />
<strong>Rheumatology</strong> Unit, Faculdade de Medicina da Universidade de<br />
São Paulo, 4 <strong>Rheumatology</strong> Division, Faculdade de Medicina da<br />
Universidade de São Paulo, São Paulo, SP, Brazil, 5 <strong>Rheumatology</strong><br />
Division, Faculdade de Medicina da Universidade de São Paulo<br />
80<br />
2010 Program Book
5:30 PM<br />
1438. Mortality/Morbidity in Cardiac Neonatal Lupus and<br />
Associated Maternal/Fetal Risk Factors.<br />
Peter M. Izmirly 1 , Amit Saxena 1 , Zoey Smith 2 and Jill P. Buyon 1 ,<br />
1<br />
NYU School <strong>of</strong> Medicine, New York, NY, 2 NYU School <strong>of</strong><br />
Medicine<br />
5:45 PM<br />
1439. Methotrexate in Children with Juvenile Localized<br />
Scleroderma: A Randomized, Double-Blind, Placebo-Controlled<br />
Trial.<br />
Francesco Zulian 7 , Cristina Vallongo 8 , Giorgia Martini 8 , Fernanda<br />
Falcini 5 , Annalisa Patrizi 4 , Maria Alessio 3 , Francesco La Torre 6 ,<br />
Mario Cutrone 1 , Anna Belloni-Fortina 8 , Mauro Paradisi 2 , Silvana<br />
Martino 9 , Fabio Vittadello 8 and Giorgio Perilongo 8 , 1 Children’s<br />
Hospital <strong>of</strong> Mestre, 2 Dermatology, IDI IRCCS, Rome, 3 University<br />
Federico II Naples, 4 University <strong>of</strong> Bologna, 5 University <strong>of</strong><br />
Florence, Florence, Italy, 6 University <strong>of</strong> Messina, 7 University <strong>of</strong><br />
Padua, Padua, Italy, 8 University <strong>of</strong> Padua, 9 University <strong>of</strong> Turin<br />
Sidney J. Marcus Auditorium<br />
Rheumatoid Arthritis - Clinical Aspects: Outcomes<br />
Associated with Biologic Therapy for RA II<br />
Moderators: Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />
Joseph A. Markenson, MD, MPH; Hospital for Special Surgery;<br />
New York, NY<br />
4:30 PM<br />
1440. Methotrexate but Not TNF-Blockers Reduces Immune<br />
Response Following Pneumococcal Vaccination Using 7-Valent<br />
Conjugate Pneumococcal Vaccine (Prevenar®) in Adult Patients<br />
with Established Arthritis.<br />
Meliha C. Kapetanovic 5 , Carmen Roseman 5 , Göran Jönsson 1 ,<br />
Lennart Truedsson 4 , Tore Saxne 3 and Pierre Geborek 2 , 1 Dept<br />
<strong>of</strong> Clinical Sciences Lund, Section <strong>of</strong> Infectious Diseases, Lund<br />
University, Lund, Sweden, 2 Dept <strong>of</strong> Clinical Sciences Lund,<br />
Section <strong>of</strong> <strong>Rheumatology</strong>, Lund University, Lund, Sweden,<br />
3<br />
Dept <strong>of</strong> Clinical Sciences Lund, Section <strong>of</strong> <strong>Rheumatology</strong>, Lund<br />
University, Sweden, 4 Dept <strong>of</strong> Laboratory Medicine, Section <strong>of</strong><br />
Microbiology, Immunology and Glycobiology, Lund University,<br />
Lund, Sweden, 5 Section <strong>of</strong> <strong>Rheumatology</strong>, Lund University, Lund,<br />
Sweden<br />
4:45 PM<br />
1441. Lipid and Inflammation Parameters: A Translational,<br />
Randomized Placebo-Controlled Study To Evaluate Effects <strong>of</strong><br />
Tocilizumab: The MEASURE Study.<br />
Iain B. McInnes 7 , Janet S. Lee 6 , Wen Wu 6 , Jon T. Giles 5 , Joan<br />
M. Bathon 5 , Jane E. Salmon 4 , Andre D. Beaulieu 2 , Christine E.<br />
Codding 3 , Christian Delles 1 and Naveed Sattar 1 , 1 British Heart<br />
Foundation, Glasgow, United Kingdom, 2 Centre de Rhumatologie<br />
St-Louis, Montreal, QC, Canada, 3 Health Research <strong>of</strong> Oklahoma,<br />
Oklahoma City, OK, 4 Hospital for Special Surgery, New York, New<br />
York, NY, 5 Johns Hopkins University, Baltimore, MD, 6 Roche,<br />
Nutley, NJ, 7 University <strong>of</strong> Glasgow, Glasgow, United Kingdom<br />
5:00 PM<br />
1442. Tumor Necrosis Factor-α Inhibitors and Reduced Risk <strong>of</strong><br />
Developing Diabetes in Patients with Rheumatoid Arthritis.<br />
Jana Antohe 1 , Androniki Bili 1 , Jennifer A. Sartorius 2 , H. Lester<br />
Kirchner 2 , Stephanie J. Morris 1 , Sorina Dancea 1 and Mary Chester<br />
Wasko 3 , 1 Geisinger Health System, Danville, PA, 2 Geisinger Health<br />
System, 3 Univ <strong>of</strong> Pittsburgh, Pittsburgh, PA<br />
5:15 PM<br />
1443. Superior Protection Against “Vulnerable” Coronary<br />
Plaque in Asymptomatic TNFi-Responders vs. DMARD<br />
Responders with Rheumatoid Arthritis (RA).<br />
George A. Karpouzas 1 , Naser Ahmadi2, Tae-Young Choi 2 ,<br />
Fereshteh Hajsadeghi 2 , Silvia Munoz 2 and Mathew Bud<strong>of</strong>f 2 ,<br />
1<br />
Harbor-UCLA, Long Beach, CA, 2Harbor-UCLA<br />
5:30 PM<br />
1444. Discontinuation <strong>of</strong> TNF-Inhibitor Treatment in Clinical<br />
Practice Has a Negative Impact on Radiographic Progression 2<br />
Years after Initiation <strong>of</strong> Therapy. Results from the Nationwide<br />
Danish DANBIO Registry.<br />
Lykke M. Ørnbjerg 1 , Mikkel Østergaard 1 , Pernille Bøyesen 13 ,<br />
Anja Thormann 1 , Ulrik Tarp 6 , Wolfgang Böhme 14 , Ditte<br />
Dencker 14 , Hanne Lindegaard 16 , Uta Poulsen 15 , Anette Hansen 2 ,<br />
Vibeke Ringsdal 5 , Anette Schlemmer 5 , Niels Graudal 10 , Anne<br />
R. Andersen 12 , Jakob Espesen 4 , Gina Kollerup 7 , Torben G.<br />
Christensen 11 , Randi Pelck 3 , Bente Glintborg 3 , Ole R. Madsen 2 ,<br />
Dorte V. Jensen 8 , Ole Majgaard 9 and Merete L. Hetland 1 ,<br />
1<br />
DANBIO Registry and Depts. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen<br />
University Hospitals at Hvidovre and Glostrup, Denmark,<br />
2<br />
Dept. <strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, Gent<strong>of</strong>te<br />
University Hospital, Denmark, 3 Dept. <strong>of</strong> Internal Medicine,<br />
Copenhagen University Hospital at Holbæk, Denmark, 4 Dept.<br />
<strong>of</strong> Internal Medicine, Hospital Lillebaelt at Vejle, Denmark,<br />
5<br />
Dept. <strong>of</strong> <strong>Rheumatology</strong>, århus University Hospital at ålborg,<br />
Denmark, 6 Dept. <strong>of</strong> <strong>Rheumatology</strong>, århus University Hospital,<br />
Denmark, 7 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University<br />
Hospital at Frederiksberg, Denmark, 8 Dept. <strong>of</strong> <strong>Rheumatology</strong>,<br />
Copenhagen University Hospital at Hørsholm, Denmark, 9 Dept.<br />
<strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University Hospital at Næstved,<br />
Denmark, 10 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University<br />
Hospital at Rigshospitalet, Denmark, 11 Dept. <strong>of</strong> <strong>Rheumatology</strong>,<br />
Copenhagen University Hospital at Slagelse, Denmark, 12 Dept. <strong>of</strong><br />
<strong>Rheumatology</strong>, Copenhagen University Hospitals at Hvidovre and<br />
Glostrup, Denmark, 13 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Diakonhjemmet<br />
Hospital, Oslo, Norway, 14 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Hospital<br />
<strong>of</strong> South West Jutland at Esbjerg, Denmark, 15 Dept. <strong>of</strong><br />
<strong>Rheumatology</strong>, King Christian Xth Hospital, Gråsten, Denmark,<br />
16<br />
Dept. <strong>of</strong> <strong>Rheumatology</strong>, Odense University Hospital, Denmark<br />
5:45 PM<br />
1445. Immunogenicity in a 3-Year Follow-Up Cohort <strong>of</strong><br />
Adalimumab Treated Rheumatoid Arthritis Patients.<br />
Geertje M. Bartelds 1 , Charlotte L. Krieckaert 1 , Michael T.<br />
Nurmohamed 1 , Pauline van Schouwenburg 2 , Ben A. Dijkmans 3<br />
and Gerrit J. Wolbink 1 , 1 Jan van Breemen Institute, 2 Sanquin<br />
Research, 3 VU Medical Center<br />
A314<br />
Spondylarthritis and Psoriatic Arthritis: Pathogenesis,<br />
Etiology, and Animal Models<br />
Moderators: Walter P. Maksymowych, MD; University <strong>of</strong> Alberta;<br />
Edmonton, AB, Canada<br />
Maxime A. Breban, MD, PhD; Hôpital Ambroise Pare;<br />
Courbevoie, France<br />
4:30 PM<br />
1446. Fungal beta-Glucan Triggers Spondyloarthropathy and<br />
Crohn’s Disease in SKG Mice.<br />
2010 Program Book 81<br />
tuesday
tuesday<br />
Merja Ruutu 4 , Bijesh Yadav 4 , Gethin Thomas 4 , Roland Steck 2 ,<br />
Ge<strong>of</strong>frey Strutton 3 , Ai Tran 4 , Jared Velasco 4 , Mariapia Degli<br />
Esposti 1 , Martin Zinkernagel 1 , Matthew A. Brown 4 and Ranjeny<br />
Thomas 4 , 1 Lions Eye Institute, 2 Queensland University <strong>of</strong><br />
Technology, 3 Queenslande Health Pathology, 4 University <strong>of</strong><br />
Queensland Diamantina Institute<br />
4:45 PM<br />
1447. Deficiency in IFNγHas Markedly Different Effects on<br />
Uveitis Versus Arthritis in the Aggrecan-Induced Mouse Model<br />
<strong>of</strong> Spondyloarthropathy.<br />
Holly L. Rosenzweig 3 , Jelena M. Kezic 2 , Tibor T. Glant 5 , Stephen<br />
R. Planck 2 , Tammy M. Martin 1 , Michael P. Davey 6 and James T.<br />
Rosenbaum 4 , 1 Oregon Health & Science University, Portland,<br />
OR, 2 Oregon Health & Science University, 3 Oregon Health &<br />
Science University/VA Medical Ctr, Portland, OR, 4 Oregon Health<br />
Science Univ, Portland, OR, 5 Rush Med Ctr Cohn Bldg Rm 708,<br />
Chicago, IL, 6 VA Medical Ctr/Oregon Health & Science University,<br />
Portland, OR<br />
5:00 PM<br />
1448. Autoimmunity to Sperm and Testicular Antigens Precedes<br />
Onset <strong>of</strong> Spondyloarthritis in HLA-B27/Hu-β2-Microglobulin<br />
Transgenic Rats.<br />
Joel D. Taurog 1 , Claudia Rival 3 , Martha Dorris 2 , Nimman<br />
Satumtira 2 , Margaret Sun 3 and Kenneth S. K. Tung 3 , 1 U-Texas SW<br />
Med Ctr, Dallas, TX, 2 U-Texas SW Med Ctr, 3U-Virginia HSC<br />
5:15 PM<br />
1449. Mast Cells Contribute to Synovial Inflammation in Non-<br />
Psoriatic and Psoriatic Spondyloarthritis.<br />
Troy Noordenbos 1 , Nataliya Yeremenko 1 , Tineke Cantaert 1 ,<br />
Christine Teitsma 1 , Marleen van de Sande 1 , Paul P. Tak 1 , Juan<br />
Canete 2 and Dominique Baeten 1 , 1 Academic Medical Center/<br />
University <strong>of</strong> Amsterdam, 2 University Hospital Barcelona<br />
5:30 PM<br />
1450. Gene Silencing <strong>of</strong> ERAP1 and ERAP2 Displays Differential<br />
Effects on Intracellular Free Heavy Chain Accumulation and<br />
Peptide Presentation in B*27 Subtypes Associated with<br />
Ankylosing Spondylitis (AS).<br />
Nigil Haroon, Florence W. Tsui and Robert D. Inman, Toronto<br />
Western Hospital and Research Institute, University <strong>of</strong> Toronto,<br />
Toronto, Canada<br />
5:45 PM<br />
1451. Multiplex Assay <strong>of</strong> a Panel <strong>of</strong> 58 Biomarkers in<br />
Ankylosing Spondylitis: Identification <strong>of</strong> High Priority<br />
Candidates for Prediction <strong>of</strong> Structural Damage.<br />
Walter P. Maksymowych 4 , Nathalie Morency 4 , Stephanie<br />
Wichuk 4 , Proton Rahman 1 , Dafna D. Gladman 2 and Robert D.<br />
Inman 3 , 1 Memorial University Newfoundland, St. Johns, NL,<br />
Canada, 2 Toronto Western Hospital, Toronto, ON, Canada,<br />
3<br />
Toronto Western Hospital, Toronto, ON, Canada, 4 University <strong>of</strong><br />
Alberta, Edmonton, AB, Canada<br />
A311<br />
Systemic Lupus Erythematosus - Clinical Aspects and<br />
Treatment: New Therapies<br />
Moderators: Elena M. Massarotti, MD; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Maria DallEra, MD; University California San Francisco; San<br />
Francisco, CA<br />
4:30 PM<br />
1452. Epratuzumab Demonstrates Clinically Meaningful<br />
Improvements in Patients with Moderate to Severe Systemic<br />
Lupus Erythematosus (SLE): Results from EMBLEM, a Phase<br />
IIb Study.<br />
Daniel J. Wallace 1 , Kenneth C. Kalunian 5 , Michelle A. Petri 2 ,<br />
Vibeke Strand 3 , Brian Kilgallen 4 , Lexy Kelley 4 and Caroline P.<br />
Gordon 6 , 1 West Hollywood, CA, 2 Timonium, MD, 3 Division <strong>of</strong><br />
Immunology and <strong>Rheumatology</strong>, Stanford University School <strong>of</strong><br />
Medicine, Palo Alto, CA, 4 UCB, Smyrna, GA, 5 UCSD School <strong>of</strong><br />
Medicine, La Jolla, CA, 6 University <strong>of</strong> Birmingham, Birmingham,<br />
United Kingdom<br />
4:45 PM<br />
1453. Aspreva Lupus Management Study (ALMS): Extra-Renal<br />
Activity Results from the Maintenance Phase.<br />
David A. Isenberg 4 , Gerald B. Appel 1 , Mary Anne Dooley 6 , Ellen<br />
M. Ginzler 3 , David Jayne 2 , David W<strong>of</strong>sy 5 , Neil Solomons 7 and<br />
Laura Lisk 8 , 1Columbia University, 2 Renal Unit, Addenbrooke’s<br />
Hospital, 3 SUNY-Downstate Medical Center, Brooklyn, NY,<br />
4<br />
University <strong>College</strong> London, London, United Kingdom, 5 University<br />
<strong>of</strong> California, San Francisco, San Francisco, CA, 6 University <strong>of</strong><br />
North Carolina at Chapel Hill, Chapel Hill, NC, 7 Vifor Pharma<br />
(formerly Aspreva Pharmaceuticals), Canada, 8 Vifor Pharma, UK<br />
5:00 PM<br />
1454. Belimumab, a BLyS-Specific Inhibitor, Reduced Disease<br />
Activity and Severe Flares in Seropositive SLE Patients: BLISS-76<br />
Study Results through Wk 76.<br />
R. A. Furie 6 , O. Zamani 8 , D. J. Wallace 1 , D. Tegzova 4 , M. Petri 5 , J. T.<br />
Merrill 7 , W. W. Chatham 10 , W. Stohl 12 , A. Schwarting 11 , S. Cooper 2 ,<br />
Z. J. Zhong 3 , W. Freimuth 2 , D. R. Hough 2 , R. van Vollenhoven 9 and<br />
for the BLISS-76 Study Group, 1 Cedars-Sinai/UCLA, Los Angeles,<br />
CA, 2 Human Genome Sciences, Rockville, Rockville, MD, 3 Human<br />
Genome Sciences, Rockville, MD, Rockville, MD, 4 Institute <strong>of</strong><br />
<strong>Rheumatology</strong> and Rheumatological Clinic, Prague, Prague,<br />
Czech Republic, 5 Johns Hopkins University School <strong>of</strong> Medicine,<br />
Timonium, MD, 6 North Shore LIJ Health System, Lake Success,<br />
NY, 7 Oklahoma Medical Research Foundation, Oklahoma City,<br />
OK, 8 Rheumazentrum Favoriten, Wien, Wien, Austria, 9 The<br />
Karolinska Institute, Stockholm, Sweden, 10 UAB Arthritis Clinical<br />
Intervention Program, Birmingham, AL, 11 Universitätsmedizin der<br />
Johannes-Gutenberg-Universität Mainz, Sana Rheumazentrum<br />
Rheinland-Pfalz, Bad Kreuznach, Germany, Germany, 12 USC Keck<br />
School <strong>of</strong> Medicine, Los Angeles, CA<br />
5:15 PM<br />
1455. Efficacy and Safety <strong>of</strong> Ocrelizumab, a Humanized<br />
antiCD20 Antibody, in Patients with Active Proliferative Lupus<br />
Nephritis (LN): Results from the Randomized, Double-Blind<br />
Phase III BELONG Study.<br />
Eduardo F. Mysler 6 , Alberto J. Spindler 9 , Renato Guzman 2 ,<br />
Marc Bijl 8 , David Jayne 1 , Richard A. Furie 5 , Romeo Maciuca 3 ,<br />
Saba Shahdad 7 , David Close 4 , Paul Brunetta 3 and Jorn Drappa 3 ,<br />
1<br />
Addenbrookes Hospital, 2 Dept <strong>Rheumatology</strong>, 3 Genentech,<br />
4<br />
MedImmune Limited, 5 North Shore Long Island Jewish Health<br />
System, Lake Success, NY, 6 OMI, Buenos Aires, Argentina, 7 Roche,<br />
8<br />
Univ <strong>of</strong> Groningen, 9 Universidad Nacional Tucumán, Yerba<br />
Buena Tucuman, Argentina<br />
82<br />
2010 Program Book
5:30 PM<br />
1456. Belimumab, a BLyS-Specific Inhibitor, Reduced Disease<br />
Activity across Multiple Organ Domains: Combined Efficacy<br />
Results from the Phase 3 BLISS-52 and -76 Studies.<br />
S. Manzi 10 , J. Sanchez-Guerrero 2 , J. T. Merrill 5 , R. A. Furie 4 , D.<br />
Gladman 8 , S. Navarra 11 , E. M. Ginzler 7 , D. D’Cruz 6 , A. Doria 9 , S.<br />
Cooper 1 , Z. J. Zhong 1 , D. Hough 1 , W. Freimuth 1 , M. Petri 3 and on<br />
Behalf <strong>of</strong> the BLISS-52 and -76 Study Groups, 1 Human Genome<br />
Sciences, Inc, Rockville, MD, 2 Instituto Nacional de Ciencias<br />
Médicas y Nutricíon Salvador Zubirán, Tlalpan, Mexico City, DF,<br />
Mexico, 3 Johns Hopkins School <strong>of</strong> Medicine, Baltimore, MD,<br />
4<br />
North Shore LIJ Health System, Lake Success, NY, 5 Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK, 6 St. Thomas’<br />
Hospital, London, London, United Kingdom, 7 SUNY Downstate<br />
Medical Center, Brooklyn, NY, 8 Toronto Western Hospital,<br />
Toronto, ON, Canada, 9 Universita’ di Padova, Padova, Italy,<br />
10<br />
University <strong>of</strong> Pittsburgh School <strong>of</strong> Medicine, PA, 11 University <strong>of</strong><br />
Santo Tomas Hospital, Manila, Philippines<br />
5:45 PM<br />
1457. Five-Year Experience with Belimumab, a BLyS-Specific<br />
Inhibitor, in Patients with Systemic Lupus Erythematosus (SLE).<br />
J. T. Merrill 6 , D. J. Wallace 1 , R. A. Furie 4 , M. A. Petri 3 , W. Stohl 10 ,<br />
W. W. Chatham 8 , J. McCune 9 , A. Weinstein 11 , J. McKay 5 , Z. J.<br />
Zhong 2 , L. Pineda 2 , J. Klein 2 , W. Freimuth 2 , E. M. Ginzler 7 and for<br />
the LBSL02/99 Study Group, 1 Cedars-Sinai/UCLA, Los Angeles,<br />
CA, 2 Human Genome Sciences, Inc, Rockville, Rockville, MD,<br />
3<br />
Johns Hopkins University School <strong>of</strong> Medicine, Timonium, MD,<br />
4<br />
North Shore LIJ Health System, Lake Success, NY, 5 Oklahoma<br />
Center for Arthritis Therapy & Research, Tulsa, OK, 6 Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK, 7 SUNY<br />
Downstate Medical Center, Brooklyn, NY, 8 UAB Arthritis Clinical<br />
Intervention Program, Birmingham, AL, 9 University <strong>of</strong> Michigan<br />
Health System, Ann Arbor, MI, 10 USC Keck School <strong>of</strong> Medicine,<br />
Los Angeles, CA, 11 Washington Hospital Center, Washington, DC<br />
ACR Meet the Pr<strong>of</strong>essor Sessions<br />
4:30 - 6:00 PM<br />
B207<br />
Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />
separate registration and ticket. To verify which session you<br />
registered for, check to make sure the registration code on your<br />
ticket matches the code listed below in parentheses.<br />
Controversies in Sjögren’s Syndrome (051)<br />
Speaker: Frederick B. Vivino, MD; Pennsylvania Presbyterian<br />
Medical Center; Philadelphia, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify major morbidities in Sjögren’s syndrome patients<br />
• discuss current treatment algorithms for dry eyes, dry mouth<br />
and systemic manifestations<br />
• determine strategies to prevent Sjögren’s related<br />
complications<br />
B208<br />
Fibromyalgia (052) PM<br />
Speaker: Manuel Martinez-Lavin, MD; National Cardiology<br />
Institute; Mexico City, Mexico<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the most recent thoughts regarding the<br />
pathophysiology <strong>of</strong> fibromyalgia and related disorders<br />
• prescribe a treatment program for the typical fibromyalgia<br />
patient and serve as a consultant to that patient and the<br />
primary care provider<br />
• describe the principles <strong>of</strong> a comprehensive treatment<br />
program for the more challenging fibromyalgia patient<br />
B209<br />
Inflammatory Eye Disease/Uveitis (053)<br />
Sunil Kumar Srivastava, MD; Emory University; Atlanta, GA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review the clinical manifestations <strong>of</strong> inflammatory eye disease<br />
encountered by rheumatologists<br />
• discuss diagnostic pearls for the evaluation <strong>of</strong> someone with<br />
inflammatory eye disease<br />
• discuss the treatment paradigms used for the inflammatory<br />
eye diseases<br />
B210<br />
Rheumatoid Arthritis: Difficult Cases (054) f<br />
Speaker: John J. Cush, MD; Baylor Research Institute; Dallas, TX<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the management <strong>of</strong> patients with refractory<br />
rheumatoid arthritis<br />
• identify novel treatment options for those failing conventional<br />
therapies<br />
• create effective management plans for complicated<br />
rheumatoid arthritis patients<br />
B301<br />
Rheumatoid Arthritis: Early Rheumatoid Arthritis<br />
(055) PS<br />
Speaker: Johanna Hazes, MD, PhD; Erasmus Medical Centre<br />
Rotterdam; Rotterdam, Netherlands<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the clinical syndrome <strong>of</strong> rheumatoid arthritis early in<br />
its course<br />
• determine which modalities are <strong>of</strong> use in diagnosis and<br />
determining prognosis<br />
• evaluate which therapeutic regimens yield the best long-term<br />
outcomes<br />
B302<br />
Spondylarthropathy: An Update (056)<br />
Speaker: Juergen Braun, MD; Rheumazentrum Ruhrgebiet;<br />
Herne, Germany<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the challenge in the early diagnosis <strong>of</strong><br />
spondylarthropathy<br />
• discuss mechanisms <strong>of</strong> disease pathogenesis<br />
• describe current treatment options for spondylarthropathy<br />
B303<br />
Still’s Disease, Febrile Illnesses (057)<br />
Speaker: Rayfel Schneider, MBBCh; Hospital for Sick Children;<br />
Toronto, ON, Canada<br />
tuesday<br />
2010 Program Book 83
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the clinical features <strong>of</strong> Still’s disease and other febrile<br />
syndromes<br />
• describe the immunogenetic mechanisms and treatment for<br />
adult Still’s disease and related syndromes<br />
5:00 PM<br />
Training in Pediatric <strong>Rheumatology</strong>: A Proposal for Latin<br />
America<br />
Carlos D. Rose, MD; duPont Hospital for Children; Wilmington,<br />
DE<br />
tuesday<br />
B304<br />
Systemic Lupus Erythematosus: Lupus Nephritis (058)<br />
Speaker: Frederic A. Houssiau, MD, PhD; Universite Catholique<br />
Louvain; Brussels, Belgium<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify lupus nephritis in early stages<br />
• describe poor prognostic factors<br />
• evaluate lupus nephritis therapy<br />
B305<br />
Systemic Lupus Erythematosus: Novel Treatments<br />
(059) PS<br />
Speaker: Robert G. Lahita, MD, PhD; Newark Beth Israel Hospital;<br />
Newark, NJ<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• determine the <strong>of</strong>f-label use <strong>of</strong> commercially available agents<br />
for features <strong>of</strong> systemic lupus erythematosus<br />
• discuss investigational therapies for systemic lupus<br />
erythematosus<br />
• identify potential risks <strong>of</strong> new therapies for systemic lupus<br />
erythematosus<br />
• identify host factors which may influence response to new<br />
therapies<br />
B306<br />
Vasculitis: An Update (060) f<br />
Speaker: Stuart M. Levine, MD; Johns Hopkins University;<br />
Baltimore, MD<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• understand the strengths and limitations <strong>of</strong> the current blood<br />
vessel size-based vasculitis classification system<br />
• utilize various imaging and laboratory tests in the diagnosis<br />
<strong>of</strong> vasculitis, with emphasis on antineutrophilic cytoplasmic<br />
antibodies<br />
• identify standard and novel therapeutic modalities in the<br />
treatment <strong>of</strong> the systemic vasculitides<br />
ACR Special Session<br />
4:30 - 6:00 PM<br />
A412<br />
ILAR Global Health Project P/C<br />
Moderators: Luis R. Espinoza, MD; Louisianna State University<br />
Medical Center; New Orleans, LA<br />
Antonio C. Ximenes, PhD; Hospital Geral Goiânia; Goiania, Brazil<br />
4:30 PM<br />
ILAR: Past, Present and Future<br />
David A. Fox, MD; University <strong>of</strong> Michigan Medical Center; Ann<br />
Arbor, MI<br />
Mark Andrejeski; <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong>; Atlanta,<br />
GA<br />
5:30 PM<br />
ILAR-East Africa <strong>Rheumatology</strong> Initiative<br />
Fotios Koumpouras, MD; Univeristy <strong>of</strong> Pittsburgh Medical<br />
Center; Pittsburgh, PA<br />
Omondi G. Oyoo, MD, MMed; University <strong>of</strong> Nairobi; Nairobi,<br />
Kenya<br />
Session Overview:<br />
The International League <strong>of</strong> Associations for <strong>Rheumatology</strong> has<br />
incurred a significant reorganization on its function, role, goals<br />
and mission in the past few years. Its member’s base (ACR,<br />
EULAR, PANLAR, APLAR); however, lacks a basic knowledge<br />
and understanding <strong>of</strong> these changes. ILAR, in order to fulfill<br />
its objectives need full support <strong>of</strong> its base and this session will<br />
assist a great deal to accomplish them.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the rationale for the reorganization<br />
• discuss the changes made<br />
• gain a better understanding <strong>of</strong> ILARS’s mission and goals<br />
• learn <strong>of</strong> funding opportunities for clinical research and<br />
education<br />
ACR REF Special Session<br />
4:30 - 6:00 PM<br />
B402<br />
REF Marshall J. Schiff, MD, Memorial Lectureship:<br />
Everything a Rheumatologist Should Know About<br />
Spine Surgery but Was Afraid to Ask c/r<br />
Moderator: Stephen A. Paget, MD; Hospital for Special Surgery;<br />
New York, NY<br />
Speaker: Scott D. Boden, MD; Emory Orthopaedics &<br />
Spine Center; Atlanta, GA<br />
Session Overview:<br />
Back pain represents one <strong>of</strong> the leading causes <strong>of</strong> loss <strong>of</strong> work<br />
days in the US, and is a common complaint in the outpatient<br />
setting. Rheumatologists need to be familiar with the latest<br />
evidence regarding diagnosis, prognosis, and indications for<br />
surgical intervention. This session will review current and<br />
emerging practices regarding spine surgery.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• distinguish the different etiologies <strong>of</strong> back pain, and their<br />
common presentations<br />
• identify the indications for surgical intervention<br />
• describe the role <strong>of</strong> recent findings concerning bone<br />
morphogenetic proteins in spine fusion<br />
5:30 PM<br />
1458. Effectiveness <strong>of</strong> the Global Posture Reeducation Method<br />
(GPR) and Segmental Stretching in the Treatment <strong>of</strong> Chronic<br />
Back Pain: A Randomized Controlled Trial.<br />
Marilene M. dos Santos 3 , Larissa S. Guimarães 5 , Lorena O.<br />
Souza 5 , Mariana M. Vasconcelos 5 , Taís M. Camargo 1 , Priscylla C.<br />
84<br />
2010 Program Book
Develly 5 , Bernardo L. F. Fernandes 4 and Virgínia F. M. Trevisani 2 ,<br />
1<br />
Brazil, 2 Federal University <strong>of</strong> São Paulo - UNIFESP/EPM, São<br />
Paulo, SP, Brazil, 3 Federal University <strong>of</strong> São Paulo - UNIFESP/<br />
EPM, Poços de Caldas, MG, Brazil, 4 Pontifical Catholic University<br />
<strong>of</strong> Minas Gerais - PUC Minas, Poços de Caldas, MG, Brazil,<br />
5<br />
Pontifical Catholic University <strong>of</strong> Minas Gerais - PUC Minas, Brazil<br />
5:45 PM<br />
1459. Epidemiology <strong>of</strong> Restricting Back Pain in Older Persons<br />
and Associations with Age, Sex, Obesity, and Depressive<br />
Symptoms.<br />
Una E. Makris 3 , Liana Fraenkel 1 , Ling Han 2 and Thomas M. Gill 3 ,<br />
1<br />
Department <strong>of</strong> Veterans Affairs, West Haven, CT, 2 Program on<br />
Aging, New Haven, CT, 3 Yale University School <strong>of</strong> Medicine<br />
ARHP Concurrent Abstract Session<br />
4:30 – 6:00 PM<br />
5:30 PM<br />
1464. Radiographic Knee Osteoarthritis and Knee Pain: Findings<br />
from 5 Racial/Ethnic Populations.<br />
Ke Wang 2 , Noriko Yoshimura 7 , Ling Xu 5 , Jianhao Lin 6 , Inje Kim 4 ,<br />
Michael Nevitt 8 , Hiroshi Kawaguchi 7 , David Felson 1 , Xiaozheng<br />
Kang 6 , Yuqing Zhang 1 and Hyun Ah Kim 3 , 1 BU. Sch. <strong>of</strong> Med.,<br />
Boston, 2 BU. Sch. <strong>of</strong> Med., 3 Hallym Univ., Sacred Heart Hosp.,<br />
Anyang, Korea, Republic <strong>of</strong>, 4 Hallym Univ., Sacred Heart Hosp.,<br />
Korea, Republic <strong>of</strong>, 5 Peking Union Medical <strong>College</strong>, Beijing, China,<br />
6<br />
Peking University, Beijing, China, 7 The University <strong>of</strong> Tokyo,<br />
Tokyo, Japan, 8 Univ. <strong>of</strong> California at San Francisco, San Francisco,<br />
CA<br />
5:45 PM<br />
1465. Impact <strong>of</strong> Buenos Dias, Artritis, a Spanish Health<br />
Communications Campaign Promoting Physical Activity among<br />
Spanish-Speaking People with Arthritis.<br />
Teresa J. Brady 2 and Jed Lam 1 , 1 Aeffect Inc., 2 Center for Disease<br />
Control, Atlanta, GA<br />
B311<br />
Don’t Despair Over Health Disparities<br />
Moderator: David A. Williams, PhD; University <strong>of</strong> Michigan<br />
Health System; Ann Arbor, MI<br />
4:30 PM<br />
1460. Life Course Socioeconomic Position and Health Outcomes<br />
in People with Self-Reported Arthritis.<br />
Jack H. Shreffler 3 , Britta Schoster 3 , Kathryn Remmes Martin 2<br />
and Leigh F. Callahan 1 , 1 Univ <strong>of</strong> North Carolina, Chapel Hill, NC,<br />
2<br />
University <strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC,<br />
3<br />
University <strong>of</strong> North Carolina, Chapel Hill<br />
4:45 PM<br />
1461. Perceived Helplessness as a Mediator between<br />
Household Income and Health Status in People with Self-<br />
Report Arthritis.<br />
Kathryn Remmes Martin 2 , Britta Schoster 3 and Leigh F. Callahan 1 ,<br />
1<br />
Univ <strong>of</strong> North Carolina, Chapel Hill, NC, 2 University <strong>of</strong> North<br />
Carolina at Chapel Hill, Chapel Hill, NC, 3 University <strong>of</strong> North<br />
Carolina at Chapel Hill<br />
5:00 PM<br />
1462. An Examination <strong>of</strong> How Coping with Prescription<br />
Medication Costs and Medication Underuse Influences Physical<br />
and Mental Health <strong>of</strong> Individuals with Arthritis.<br />
Kathryn Remmes Martin 2 , Britta Schoster 2 , Jack Shreffler 3 and<br />
Leigh F. Callahan 1 , 1 Univ <strong>of</strong> North Carolina, Chapel Hill, NC,<br />
2<br />
University <strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC,<br />
3<br />
University <strong>of</strong> North Carolina at Chapel Hill<br />
5:15 PM<br />
1463. Disability and Knee Osteoarthritis: Associations with<br />
Individual and Community Socioeconomic Status.<br />
Leigh F. Callahan 2 , Joshua B. Knight 3 , Jack H. Shreffler 3 , Britta<br />
Schoster 3 , Jordan B. Renner 3 and Joanne M. Jordan 1 , 1 Chapel Hill,<br />
NC, 2 Univ <strong>of</strong> North Carolina, Chapel Hill, NC, 3 University <strong>of</strong> North<br />
Carolina, Chapel Hill<br />
ARHP Concurrent Sessions<br />
4:30 - 6:00 PM<br />
B308<br />
Iatrogenic Misadventures: Complex Cases C PS<br />
Moderator: Atul A. Deodhar, MD; Oregon Health & Science<br />
University; Portland, OR<br />
4:30 PM<br />
Osteonecrosis<br />
Kenneth J. Scalapino, MD; Portland VA Medical Center; Portland,<br />
OR<br />
5:00 PM<br />
Transplant-related Musculoskeletal Syndromes<br />
Pascale Schwab, MD; Oregon Health & Science University;<br />
Portland, OR<br />
5:30 PM<br />
Biologics and Serious Infections<br />
Kevin L. Winthrop, MD, MPH; Oregon Health & Science<br />
University; Portland, OR<br />
Session Overview:<br />
Iatrogenic diseases occur in the treatment <strong>of</strong> patients with<br />
rheumatologic conditions and other diseases. Iatrogenic disease<br />
can vary but are the result <strong>of</strong> the treatments rheumatology<br />
pr<strong>of</strong>essionals use to care for their patients. <strong>Rheumatology</strong><br />
providers need to be aware <strong>of</strong> all potential complications related<br />
to the diagnosis and treatment <strong>of</strong> the disease, regardless <strong>of</strong><br />
whether the condition occurs as a known risk or side effect <strong>of</strong><br />
treatment.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the late side effects <strong>of</strong> using systemic corticosteroid<br />
treatment<br />
• describe various musculoskeletal symptoms as they relate to<br />
post transplant complications<br />
• describe the various infections associated with use <strong>of</strong> biologics<br />
and to identify and implement appropriate screening tests<br />
tuesday<br />
2010 Program Book 85
tuesday<br />
B309<br />
Practice Potpourri<br />
cP PS<br />
Moderator: Janet L. Poole, PhD, OTR; University <strong>of</strong> New Mexico;<br />
Albuquerque, NM<br />
4:30 PM<br />
Should I Be Doing QuantiFERON ® -TB Gold Test Instead <strong>of</strong> the<br />
PPD Skin Testing on All My Patients Before Starting Biologics?<br />
Kevin L. Winthrop, MD, MPH; Oregon Health & Science<br />
University; Portland, OR<br />
4:45 PM<br />
What is the Final Word on Non-steroidal Anti-inflammatory<br />
Drugs Causing Heart Attacks and Should I Avoid Using<br />
Altogether in my Arthritis Patients?<br />
Elaine Husni, MD, MPH; Cleveland Clinic Foundation; Cleveland,<br />
OH<br />
5:00 PM<br />
Should I Worry That My Patient Will Develop an Infusion<br />
Reaction, Having Stopped Infliximab For 3 Months For a Hip<br />
Replacement?<br />
Joyce M. Kortan, RN; Arthritis & Rheum Consultants; Edina, MN<br />
5:15 PM<br />
Is Splinting Appropriate for the Scleroderma Hand?<br />
Carole V. Dodge, OT CHT; University <strong>of</strong> Michigan Medical Center;<br />
Ann Arbor, MI<br />
5:30 PM<br />
What Should I Tell My Patient With Polymyositis Who Wants to<br />
Exercise and Lift Weights?<br />
Lisa G. Rider, MD; National Institute <strong>of</strong> Environmental Health<br />
Sciences; Garrett Park, MD<br />
5:45 PM<br />
Questions and Answers<br />
Session Overview:<br />
Health pr<strong>of</strong>essionals rely on the evidence-based literature and<br />
their own experiences to determine best treatment options for<br />
patient care. However, consulting with colleagues is an option<br />
that provides clinically relevant information and is convenient<br />
and readily available. The ARHP annual scientific meeting allows<br />
colleagues to network and share information with each other.<br />
The format <strong>of</strong> this session will allow for a formal sharing <strong>of</strong><br />
information about current practice problems.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify current strategies for practice management for<br />
selected clinical problems<br />
• discuss evidence for best practice solutions for current clinical<br />
problems<br />
Terence W. Starz, MD; Arthritis & Internal Medical Associates;<br />
Pittsburgh, PA<br />
Session Overview:<br />
Rheumatoid arthritis can severely limit functional activities,<br />
through various articular and extra-articular pathophysiologic<br />
mechanisms. A comprehensive approach to understanding the<br />
effects <strong>of</strong> impairments on functional activity and best methods<br />
for measuring and treating limitations in function is challenging.<br />
The purpose <strong>of</strong> this session is to review current knowledge <strong>of</strong><br />
how rheumatoid arthritis affects functional activity and the<br />
best evidence-based methods available to measure and treat<br />
patients with rheumatoid arthritis. This session will provide<br />
an overview <strong>of</strong> the definition <strong>of</strong> functional activities and will<br />
relate pathophysiologic mechanisms involved in rheumatoid<br />
arthritis with activities <strong>of</strong> daily living, vocation, avocation, and<br />
approaches and tools available for assessing function.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss pathophysiologic mechanisms <strong>of</strong> rheumatoid arthritis<br />
and their effect on functional activity<br />
• define and discuss the elements involved in various selfcare,<br />
work, and community activities that are measured by<br />
common patient-report instruments including an analysis <strong>of</strong><br />
their physical, mental and social components and potential<br />
adaptations<br />
• review the tools for assessing functional activity including the<br />
significance and grouping <strong>of</strong> the different elements<br />
• discuss strategies for treatment interventions that focus on<br />
activities <strong>of</strong> self-care, vocational and community activities<br />
Exhibit Hall Wine and Cheese<br />
Reception<br />
5:15 - 6:45 PM<br />
Halls A1 & A2<br />
ACR Study Groups<br />
6:45 - 8:00 PM<br />
B408<br />
Study Group sessions are planned by ACR members in an effort<br />
to network with those who share a common interest in an area<br />
<strong>of</strong> rheumatology. Study Groups are non-CME activites.<br />
ACR/EULAR Academic Exchange Program<br />
Moderators: Mariana J. Kaplan, MD; University <strong>of</strong> Michigan<br />
Medical Center; Ann Arbor, MI<br />
Martin Aringer, MD; Uniklinikum TU Dresden; Dresden, Germany<br />
B310<br />
Understanding Functional Activity in Rheumatoid<br />
Arthritis: What We Know and What We Don’t Know<br />
c/r<br />
Moderator: Patricia P. Katz, PhD; University <strong>of</strong> California - San<br />
Francisco; San Francisco, CA<br />
Speakers: Nancy A. Baker, ScD OTR/L; University <strong>of</strong> Pittsburgh;<br />
Pittsburgh, PA<br />
Joan C. Rogers, PhD, OTR/ L; University <strong>of</strong> Pittsburgh; Pittsburgh,<br />
PA<br />
6:45 PM<br />
Aspects <strong>of</strong> IL-1 Signaling Pathways in Inflammatory Diseases<br />
Cem Gabay, MD; University Hospital <strong>of</strong> Geneva; Geneva,<br />
Switzerland<br />
7:10 PM<br />
What is New and in the Horizon in the Treatment <strong>of</strong><br />
Autoinflammatory Diseases<br />
Hasan Yazici, MD; Cerrahpasa Medical Faculty; Istanbul, Turkey<br />
86<br />
2010 Program Book
7:30 PM<br />
Role <strong>of</strong> IL-1 in Human Articular Cartilage: Lessons from<br />
Osteoarthritis<br />
Dirk Elewaut, MD, PhD; Universitair Ziekenhuis Gent; Ghent,<br />
Belgium<br />
7:45 PM<br />
Anakinra for the Treatment <strong>of</strong> Macrophage Activation<br />
Syndrome<br />
Randy Q. Cron, MD, PhD; Children’s Hospital <strong>of</strong> Alabama;<br />
Birmingham, AL<br />
Session Overview:<br />
The ACR/EULAR Academic Exchange Program seeks to bring<br />
together young academic rheumatologists from Europe and<br />
the United States to discuss basic and translational research<br />
programs in order to foster exchange <strong>of</strong> ideas and collaboration.<br />
The annual meeting <strong>of</strong> the ACR is an ideal forum in which to<br />
promote and encourage this kind <strong>of</strong> interaction. This particular<br />
session aims to highlight the new developments on the role<br />
<strong>of</strong> inflammatory diseases. This will be the 11th year <strong>of</strong> the<br />
study group meeting at the ACR Annual Scientific Meeting. Last<br />
year was highly successful with invited speakers, Drs. Thomas<br />
Huizinga and Robert Winchester, as well as two speakers from<br />
within the exchange group. The attendance was high and it was<br />
a great opportunity for interactions and exchanges between<br />
researchers from both sides <strong>of</strong> the Atlantic. This year’s session<br />
promises to be equally stimulating and productive.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify new developments in the treatment <strong>of</strong><br />
autoinflammatory diseases<br />
• identify novel molecular mechanisms <strong>of</strong> IL-1 signaling<br />
pathways in inflammatory diseases<br />
Session Overview:<br />
The antiphospholipid syndrome is a rapid evolving field <strong>of</strong> high<br />
interest to rheumatologists. The disease affects a significant<br />
proportion <strong>of</strong> SLE patients. APS is associated with thrombosis,<br />
pregnancy losses and aPL antibody positivity. A significant<br />
number <strong>of</strong> questions particularly with respect to treatment and<br />
diagnostic tests remain unanswered that will be discussed in<br />
this study group by internationally and well-recognized scientists<br />
in the field. Importantly new findings on pathogenesis <strong>of</strong> the<br />
disease may lead to the development <strong>of</strong> novel therapies to treat<br />
clinical manifestations <strong>of</strong> APS.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss new pathogenic mechanisms <strong>of</strong> thrombosis in APS<br />
• describe new targeted therapies to be used in treatment <strong>of</strong><br />
APS<br />
• discuss updates on antiphospholipid testing used in diagnosis<br />
<strong>of</strong> APS<br />
• describe clinical trials and studies in APS<br />
A411<br />
Autoantibodies in Diagnosis and Follow Up <strong>of</strong><br />
Rheumatic Diseases<br />
Moderator: Pierluigi Meroni, MD; Instituto G. Pini University;<br />
Milano, Italy<br />
6:45 PM<br />
Opening Comments<br />
Pierluigi Meroni, MD; Instituto G. Pini University; Milano, Italy<br />
6:50 PM<br />
Clinical Use <strong>of</strong> Anti-Citrullinated Peptide Antibodies for Setting<br />
a Phenotypic Diagnosis <strong>of</strong> RA<br />
Solbritt M. Rantapaa-Dahlqvist, MD, PhD; Umea, Sweden<br />
tuesday<br />
A314<br />
Antiphospholipid Syndrome<br />
Moderator: Silvia S. Pierangeli, PhD; University <strong>of</strong> Texas Medical<br />
Branch; Galveston, TX<br />
6:45 PM<br />
Pathogenic Mechanisms in APS - Can They Lead us to New<br />
Therapies?<br />
Anisur Rahman, MD; University <strong>College</strong> London; London, United<br />
Kingdom<br />
7:00 PM<br />
A New Mechanism in the Pathogenesis <strong>of</strong> the Antiphospholipid<br />
Syndrome: Implications for Thrombotic Risks Ratification<br />
Steven Krillis, MD; The University <strong>of</strong> New South Wales; Syndey,<br />
Kogarah, NSW, Australia<br />
7:15 PM<br />
Antiphospholipid Antibodies: Diagnostic Strategies for the<br />
Clinical Laboratory<br />
Tom Ortel, MD; Duke University Health System; Durham, NC<br />
7:30 PM<br />
The PROMISSE Study<br />
Jane E. Salmon, MD; Hospital for Special Surgery; New York, NY<br />
7:45 PM<br />
The APLA 2010 Congress: Update on Wet Workshop and APL<br />
Testing Task Force Recommendations<br />
E. Nigel Harris, MD; The University <strong>of</strong> the West Ind; Kingston,<br />
Jamaica<br />
7:15 PM<br />
Autoantibodies as Diagnostic and Prognostic Markers in Early<br />
Arthritis<br />
Gunter Steiner, PhD; Medical University <strong>of</strong> Vienna; Vienna,<br />
Austria<br />
7:35 PM<br />
Update on Inaccurate ANA in Southeast<br />
Merlin R. Wilson, MD; Wilson & Sanders Inc. Group Lab; New<br />
Orleans, LA<br />
7:45 PM<br />
FDA Update on ANA Testing<br />
Marilyn Lightfoote, PhD; Food and Drug Administration; Silver<br />
Spring, MD<br />
Session Overview:<br />
This is the fifth year that the Autoantibody Standardization<br />
Committee has organized this study group. For the 2007<br />
meeting we had 250 participants; for 2008 and 2009, we had<br />
400 participants. The goal <strong>of</strong> our committee is to promote<br />
the accurate use <strong>of</strong> autoantibodies with a clear focus on the<br />
relevance to practicing clinicians and clinical laboratories. There<br />
is a continuing need for rheumatologists to keep up-to-date with<br />
the rapidly progressing field <strong>of</strong> autoantibody diagnostics and<br />
their relevance to the diagnosis and management <strong>of</strong> rheumatic<br />
diseases.<br />
2010 Program Book 87
tuesday<br />
88<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe appropriate autoantibody testing requests and<br />
interpretation <strong>of</strong> results relevant to an early diagnosis and<br />
management <strong>of</strong> RA<br />
• identify the clinical value <strong>of</strong> measuring IgA RF in RA<br />
• describe the predictive value <strong>of</strong> RA marker antibodies<br />
• review the current status <strong>of</strong> “inaccurate ANA results”<br />
A412<br />
Behçet’s Disease<br />
Moderators: Yoshiaki Ishigatsubo, MD; Yokohama City Graduate<br />
School <strong>of</strong> Medicine; Yokohama, Japan<br />
Ahmet Gul, MD; Istanbul University; Istanbul, Turkey<br />
6:45 PM<br />
Genomewide Association Studies in Behçet’s Disease<br />
Daniel L. Kastner, MD, PhD; NIAMS, NIH; Bethesda, MD<br />
7:00 PM<br />
HLA-B51 and Behçet’s Disease<br />
Yeong W. Song, MD; Seoul National University Hospital; Seoul,<br />
Republic <strong>of</strong> Korea<br />
7:15 PM<br />
Immunological Features <strong>of</strong> Behçet’s Disease<br />
Mitsuhiro Takeno, MD, PhD; Yokohama City University, Japan<br />
7:30 PM<br />
Vascular Involvement in Behçet’s Disease<br />
Dorian O. Haskard, DM; Imperial <strong>College</strong>; London, United<br />
Kingdom<br />
7:45 PM<br />
Unmet Needs and Clinical Trials in Behçet’s Disease<br />
Ahmet Gul, MD; Istanbul University; Istanbul, Turkey<br />
Session Overview:<br />
Since the cause <strong>of</strong> Behçet’s Disease is still unknown, current<br />
treatment is aimed at easing the symptoms, reducing<br />
inflammation, and controlling the immune system. Recently,<br />
new idea such as auto inflammatory disease has been induced<br />
as the pathogenesis the disease. To understand current findings<br />
is helpful to find new treatment for Behçet’s Disease. Although<br />
Behçet’s Disease is common in the Middle East and Asia and<br />
rare in the United State and other regions, new insights need to<br />
be shared with the attendees so that everyone is aware <strong>of</strong> the<br />
latest developments.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the genetic aspect <strong>of</strong> Behçet’s Disease<br />
• discuss the immunological features <strong>of</strong> Behçet’s Disease<br />
• analyze <strong>of</strong> the endothelial cells and vascular involvement in<br />
Behçet’s Disease<br />
• discuss unmet need and clinical trials in Behçet’s Disease<br />
A406<br />
Economic Evaluations<br />
Moderators: Annemarie Braakman-Jansen, PhD; University <strong>of</strong><br />
Twente; Enschede, Netherlands<br />
Mart A. van de Laar, MD; University Twente and Medisch<br />
Sprectrum Twente; Enschede, Netherlands<br />
6:45 PM<br />
QALYs: Why use Them?<br />
Nick Bansback, PhD; St. Paul’s Hospital; Vancouver, Canada<br />
2010 Program Book<br />
7:00 PM<br />
QALYs: To Use or Not to Use<br />
Deborah P. Symmons, MD; University <strong>of</strong> Manchester;<br />
Manchester, United Kingdom<br />
7:15 PM<br />
The Patient’s Perspective<br />
Laurien Buitinga, MSc; University <strong>of</strong> Twente, Enschede,<br />
Netherlands; Enschede, Netherlands<br />
7:30 PM<br />
Much Ado About QALYs<br />
Annelies Boonen, MD, PhD; Maastricht University Medical<br />
Centre, Maastricht; Maastricht, Netherlands<br />
7:45 PM<br />
Discussion<br />
Session Overview:<br />
Economic evaluations are increasingly being used for decision<br />
making regarding treatment for patients. There are different<br />
methods for valuing health states in order to calculate “QALYs”<br />
for use in cost utility analysis. These methods can lead to<br />
very different results and might influence decision making.<br />
Another key issue is that <strong>of</strong> whose preferences should be used<br />
as the source <strong>of</strong> values: patients, doctors, decision-makers<br />
or those <strong>of</strong> the general public? Which method and values a<br />
researcher should use is dependent on the context <strong>of</strong> the<br />
research question. Should the research guide a clinical or policy<br />
decision? In this workshop the state <strong>of</strong> the art <strong>of</strong> health state<br />
valuations and implications for future research within the field <strong>of</strong><br />
rheumatology will be interactively discussed with the audience.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe how to value health states<br />
• analyze different perspectives used in economic evaluations<br />
• determine the proper valuation technique for use, based on<br />
the context <strong>of</strong> the research question<br />
• evaluate the use <strong>of</strong> tariffs<br />
B313<br />
Epidemiology <strong>of</strong> Axial Spondyloarthritis<br />
Moderators: John D. Reveille, MD; University Texas Health<br />
Science Center; Houston, TX<br />
Michael H. Weisman, MD; Cedars-Sinai Medical Center; Los<br />
Angeles, CA<br />
6:45 PM<br />
The GESPIC Experience<br />
Martin Rudawaleit, MD; University Hospital Charité – Campus<br />
Benjamin Franklin; Steglitz, Berlin, Germany<br />
7:10 PM<br />
Axial SpA in the US: The NHANES Survey<br />
Rosemarie Hirsch, MD, MPH; CDC - National Center for Health<br />
Statistics; Silver Spring, MD<br />
7:35 PM<br />
A Population Based Survey <strong>of</strong> Axial SpA in Mexico<br />
R. Burgos Vargas, MD; Hospital General de Mexico; Mexico City,<br />
Mexico<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• develop a better understanding <strong>of</strong> the presentation<br />
epidemiology <strong>of</strong> axial spondyloarthritis in a prospectively<br />
followed longitudinal cohort <strong>of</strong> patients from Germany<br />
• review the new data from NHANES 2009 on the prevalence <strong>of</strong><br />
axial spondyloarthritis in the United States
• compare the prevalence and epidemiology <strong>of</strong> SpA in a<br />
population-based questionnaire study from Mexico<br />
A402<br />
Genetics <strong>of</strong> Autoimmune Rheumatic Diseases in Latin<br />
America<br />
Moderator: Juan-Manuel Anaya, MD; CIB-Rosario University;<br />
Medellin, Colombia<br />
6:45 PM<br />
Admixture and Diversity in Latin America<br />
Maurico Arcos-Burgos, MD, PhD; University <strong>of</strong> Miami; Miami, FL<br />
7:10 PM<br />
Genetics <strong>of</strong> Rheumatoid Arthritis in Latin <strong>American</strong>s<br />
Angelica M. Delgado-Vega, MD; Uppsala University, Sweden<br />
7:30 PM<br />
Genetics <strong>of</strong> Systemic Lupus Erythematosus in Latin <strong>American</strong>s:<br />
Its Impact on ITGAM Association and Implications for<br />
Admixture Mapping in SLE<br />
Swapan K. Nath, PhD; Oklahoma Medical Research Foundation;<br />
Oklahoma City, OK<br />
7:50 PM<br />
The Common Autoimmunity Genes in Latin <strong>American</strong>s<br />
Juan-Manuel Anaya, MD; CIB-Rosario University; Medellin,<br />
Colombia<br />
Session Overview:<br />
Autoimmune rheumatic diseases are complex traits in which<br />
both genetic and environmental factors are incriminated<br />
in their etiopathogenesis. The expression <strong>of</strong> these diseases<br />
varies depending upon ethnicity and geography. The large and<br />
diverse population <strong>of</strong> Latin America is a powerful resource for<br />
elucidating the genetic basis <strong>of</strong> these complex traits.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• learn about the genetic landscape <strong>of</strong> Latin America and the<br />
genetic susceptibility <strong>of</strong> autoimmune rheumatic diseases in<br />
this population.<br />
A316<br />
Geriatric <strong>Rheumatology</strong><br />
Moderators: Yuri R. Nakasato, MD, MBA; University <strong>of</strong> North<br />
Dakota; Fargo, ND<br />
Raymond L. Yung, MD; University <strong>of</strong> Michigan; Ann Arbor, MI<br />
6:45 PM<br />
Does Frailty in Old Age Amplify Glucocorticoid Toxicity?<br />
Eswar Krishnan, MD; Stanford University; Palo Alto, CA<br />
7:10 PM<br />
Use <strong>of</strong> DMARDs and Biological Therapy in the Older Population<br />
Richard Brasington, MD; Washington University School <strong>of</strong><br />
Medicine; St. Louis, MO<br />
7:35 PM<br />
Ideal <strong>Rheumatology</strong> Practice for the Older Patient<br />
Yuri R. Nakasato, MD, MBA; MeritCare/University <strong>of</strong> North<br />
Dakota; Fargo, ND<br />
Session Overview:<br />
<strong>Rheumatology</strong> faces an increasingly older, frail and complex<br />
population. The current structure is not prepared to sustain this<br />
challenge. Older patients have atypical presentations <strong>of</strong> common<br />
rheumatic conditions and diseases that may be the result <strong>of</strong><br />
the process <strong>of</strong> aging or associated with it. There is a higher life<br />
expectancy, but a higher morbidity and disability, most <strong>of</strong> them<br />
related to arthritis. <strong>Rheumatology</strong> struggles between improving<br />
quality <strong>of</strong> life versus not causing harmful side effects due to<br />
medications. Innovation <strong>of</strong> care, research, education and health<br />
policy <strong>of</strong> the older adult is critical to the future <strong>of</strong> rheumatology.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the phenomenon <strong>of</strong> frailty, how it differs from<br />
disability and increases propensity to drug toxicity in the<br />
elderly<br />
• distinguish important considerations in the management <strong>of</strong><br />
older patients with Disease Modifying Antirheumatic Drugs<br />
and biological therapy<br />
• analyze features <strong>of</strong> an ideal rheumatology practice for the<br />
older patient<br />
B409<br />
Global Musculoskeletal Health Initiatives<br />
Moderators: Lyn March, MD; University <strong>of</strong> Sydney Medical<br />
School; Sydney, Australia<br />
Anthony Woolf, MBBS; Royal Cornwall Hospital; Truro Cornwall,<br />
United Kingdom<br />
Richard H. Osborne, PhD; Deakin University; Melbourne,<br />
Australia<br />
Sherine E. Gabriel, MD, MSc; Mayo Clinic; Rochester, MN<br />
Peter Tugwe, MD; Institute <strong>of</strong> Population Health; Ottawa, ON,<br />
Canada<br />
6:45 PM<br />
Global Prevalence and Treatment <strong>of</strong> RA - Identifying Knowledge<br />
Gaps<br />
Marita Cross, MPH, PhD; Institute <strong>of</strong> Bone and Joint Research,<br />
University <strong>of</strong> Sydney; St. Leonards, NSW, Australia<br />
7:00 PM<br />
Global Bone Density and Osteoporotic Fracture Risk -<br />
Identifying Regional Variations for Priority Setting<br />
Lidia Sanchez-Riera, MD; Institute <strong>of</strong> Bone and Joint Research,<br />
University <strong>of</strong> Sydney; St. Leonards, NSW, Australia<br />
7:15 PM<br />
Other MSK Disorders - Towards Better Definitions and<br />
Representations<br />
Emma Smith, MSc(Phty), PhD; Institute <strong>of</strong> Bone and Joint<br />
Research, University <strong>of</strong> Sydney; St. Leonards, Australia<br />
7:30 PM<br />
Bridging the Knowledge Gaps - Strategies for Developing<br />
Consensus for Standardised Population-based Measurment <strong>of</strong><br />
MSK Conditions<br />
Anthony D. Woolf, MBBS; Royal Cornwall Hospital; Truro<br />
Cornwall, United Kingdom<br />
7:45 PM<br />
Beyond the Burden - Strategies for Identifying Global Inequity<br />
in Access to Evidence-Based MSK Health Care<br />
To be announced<br />
Session Overview:<br />
Much data are being collated across many countries in support<br />
<strong>of</strong> the Global Burden <strong>of</strong> Disease, Injuries and Risk Factors study.<br />
tuesday<br />
2010 Program Book 89
tuesday<br />
These collated data will provide the most comprehensive map<br />
<strong>of</strong> the presence and relative importance <strong>of</strong> MSK disease ever<br />
developed. There is a great need to allow international groups<br />
access to the findings and support individuals and organizations<br />
to use these data to guide local and global policymakers. This<br />
study group will provide an update <strong>of</strong> the GBD Study progress<br />
through presentations on systematic reviews <strong>of</strong> the global<br />
prevalence <strong>of</strong>, and DALYs associated MSK conditions. Global<br />
strategies for bridging gaps in the availability <strong>of</strong> MSK populationbased<br />
data and the inequity <strong>of</strong> access to evidence-based MSK<br />
health care and education will be discussed.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the key data required for the calculation <strong>of</strong> DALYs for<br />
MSK conditions<br />
• identify the regions <strong>of</strong> the world where population-based MSK<br />
data are deficient<br />
• explain the importance <strong>of</strong> collecting standardized MSK data<br />
from population-based health surveys<br />
• explain the principles involved in measuring equity and access<br />
to minimum standards <strong>of</strong> care for MSK conditions<br />
A315<br />
Joint Hypermobility Syndrome<br />
Moderators: Jaime F. Bravo, MD; Nuestra Sra de Los Angeles;<br />
Santiago, Chile<br />
Rodney Grahame, MD; University <strong>College</strong> Hospital; London,<br />
United Kingdom<br />
6:45 PM<br />
Are Some Joint Hypermobility Criteria More Closely Associated<br />
with Anxiety than Others?<br />
Antonio Bulbena, MD; Hospital del Mar and University; Bilbao,<br />
Spain<br />
7:00 PM<br />
Why is Joint Hypermobility Syndrome so Frequently Missed?<br />
Rodney Grahame, MD; University <strong>College</strong> Hospital; London,<br />
United Kingdom<br />
7:15 PM<br />
Treatment <strong>of</strong> Dysautonomia (Chronic Fatigue, Dizziness and<br />
Syncope)<br />
Jaime F. Bravo, MD; Nuestra Sra de Los Angeles; Santiago, Chile<br />
7:45 PM<br />
An Integrated Approach to the Physiotherapy Assessment and<br />
Management <strong>of</strong> Joint Hypermobility Syndrome<br />
Jane Simmonds, MCSP, MMACP; University <strong>of</strong> Herfordshire;<br />
Hatfield, Herfordshire, United Kingdom<br />
Session Overview:<br />
The interest about Joint Hypermobility Syndrome among<br />
rheumatologists has increased, but still in most cases the<br />
diagnosis <strong>of</strong> these patients is not made. There is a need not only<br />
to increase awareness about the condition, but also to learn<br />
how to treat these patients.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• appreciate that anxiety is very frequently associated to JHS<br />
and explains many symptoms<br />
• explain that JHS is frequent also in children and that the<br />
diagnosis is seldom made<br />
• treat effectively patients with Dysautonomia, improving<br />
significantly the quality <strong>of</strong> life <strong>of</strong> these patients<br />
• appreciate the role <strong>of</strong> physiotherapy and other allied health<br />
pr<strong>of</strong>essionals in the management <strong>of</strong> hypermobility syndrome<br />
B310<br />
Kawasaki Disease in the 21st Century - Genes,<br />
Pathogenesis, and Biologics<br />
Moderators: Anne M. Stevens, MD, PhD; Pediatrics, University <strong>of</strong><br />
Washington; Seattle, WA<br />
Polly J. Ferguson, MD; University <strong>of</strong> Iowa Carver <strong>College</strong> <strong>of</strong><br />
Medicine; Iowa City, IA<br />
6:45 PM<br />
The Pathogenesis <strong>of</strong> Kawasaki Disease: Novel Insights from<br />
Genetics and Immunology<br />
Rae S.M. Yeung, MD, PhD; Hospital for Sick Children; Toronto,<br />
ON, Canada<br />
7:15 PM<br />
Novel Strategies for Treatment and Monitoring for Kawasaki<br />
Disease<br />
Robert P. Sundel, MD; Children’s Hospital Medical Center;<br />
Boston, MA<br />
7:35 PM<br />
ACR Pediatrics Section Business Meeting<br />
Marisa S. Klein-Gitelman, MD, MPH; Children’s Memorial<br />
Hospital/North Western University; Chicago, IL<br />
Session Overview:<br />
Kawasaki disease is one <strong>of</strong> the most common forms <strong>of</strong> vasculitis<br />
affecting children, with coronary artery sequelae leading into<br />
adult years. Over the past decade progress has been made<br />
in identifying patients with atypical Kawasaki disease and<br />
in managing patients resistant to standard therapy. Biologic<br />
immunosuppressive and anticoagulation treatments provide<br />
novel options for treatment. Further, genetic and immunologic<br />
studies provide new insights into the pathogenesis <strong>of</strong> Kawasaki<br />
disease. A better understanding <strong>of</strong> the evidence for treatment<br />
and the recent basic science advances will aid adult and<br />
pediatric rheumatologists in the care <strong>of</strong> patients with Kawasaki<br />
Disease.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• recognize the signs and symptoms <strong>of</strong> typical and atypical KD<br />
and the risk factors for coronary aneurysms in children with<br />
fevers<br />
• describe the genes associated with Kawasaki disease risk, and<br />
hypotheses for pathogenesis<br />
• identify the indications for and recommendations for secondline<br />
immunosuppressive therapy for Kawasaki Disease<br />
patients who do not respond to IVIG, including corticosteroids,<br />
cyclophosphamide, and anti-TNF agents<br />
• know the evidence for recommendations for acute and<br />
chronic anticoagulation for KD<br />
A311<br />
Macrophage Activation Syndrome<br />
Moderators: Randy Q. Cron, MD, PhD; Children’s Hospital <strong>of</strong><br />
Alabama; Birmingham, AL<br />
Edward M. Behrens, MD; Children’s Hospital <strong>of</strong> Philadelphia;<br />
Philadelphia, PA<br />
90<br />
2010 Program Book
6:45 PM<br />
Macrophage Activation Syndrome in the Adult ICU<br />
Bita Shakoory, MD; University <strong>of</strong> Alabama-Birmingham;<br />
Birmingham, AL<br />
7:10 PM<br />
Distinguishing Sepsis from MAS<br />
Joseph Carcillo, MD; Children’s Hospital <strong>of</strong> Pittsburgh; Pittsburgh,<br />
PA<br />
7:35 PM<br />
Infectious Models <strong>of</strong> MAS<br />
Michael Jordan, MD, PhD; Children’s Hospital Medical Center,<br />
Cincinnati; Cincinnati, OH<br />
Session Overview:<br />
Macrophage activation syndrome is an <strong>of</strong>ten lethal entity<br />
associated with a variety <strong>of</strong> pediatric and adult infectious,<br />
oncologic, rheumatic (lupus, Still disease, vasculitis, etc.),<br />
and primary genetic disorders. Early recognition <strong>of</strong> MAS and<br />
institution <strong>of</strong> aggressive immunosuppressive therapy are keys to<br />
optimizing survival. Experts from different medical subspecialties<br />
have different perspectives <strong>of</strong> this end common pathway <strong>of</strong><br />
MAS. Genetic propensities for developing MAS, and animal<br />
models <strong>of</strong> MAS pathophysiology are being explored. What we<br />
learn about MAS from clinical and scientific experts in nonrheumatic<br />
fields will benefit adult and pediatric rheumatologists<br />
in diagnosing and treating patients who develop MAS.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the various infectious triggers <strong>of</strong> macrophage<br />
activation syndrome<br />
• discuss the diagnostic criteria for macrophage activation<br />
syndrome in the setting <strong>of</strong> infection<br />
• distinguish sepsis from macrophage activation syndrome<br />
• articulate the proposed pathophysiologic events leading to<br />
macrophage activation syndrome<br />
B311<br />
MRI<br />
Moderator: Mikkel Østergaard, MD, PhD, DMSc; Hvidovre<br />
University Hospital; Hvidovre, Denmark<br />
6:45 PM<br />
MRI <strong>of</strong> Cartilage in Osteoarthritis and Rheumatoid Arthritis -<br />
Introduction<br />
Mikkel Østergaard, MD, PhD, DMSc; Hvidovre University<br />
Hospital; Hvidovre, Denmark<br />
7:00 PM<br />
Function and Structure <strong>of</strong> Cartilage in Health and Disease: A<br />
MRI Perspective<br />
Deborah Burstein, PhD; Beth Israel Deaconess Medical Center;<br />
Boston, MA<br />
7:20 PM<br />
What Have We Learned about Cartilage from MRI Studies <strong>of</strong><br />
Osteoarthritis and How Can We Get?<br />
To be announced<br />
7:40 PM<br />
Challenges in MRI Assessment <strong>of</strong> Cartilage in RA and What<br />
Lessons to Learn from Studies in Osteoarthritis<br />
Philip G. Conaghan, MD, PhD; Chapel Allerton Hospital; Leeds,<br />
United Kingdom<br />
Session Overview:<br />
Increasing amounts <strong>of</strong> data on MRI in arthritides are emerging,<br />
and the technique is increasingly used in clinical trials and<br />
practice, making a forum for update on and discussion <strong>of</strong> this<br />
topic at ACR very relevant. An ACR study group addressing<br />
different aspects <strong>of</strong> MRI has existed since 2006, with varying<br />
focus and content. This year it is proposed to focus on “MRI <strong>of</strong><br />
cartilage in OA and RA”, and is expected to provide novel insights<br />
on MRI assessment <strong>of</strong> cartilage involvement in osteoarthritis and<br />
rheumatoid arthritis, and provide an option for crossfertilizatioin<br />
between the OA and RA research areas.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the current concepts MRI assessment <strong>of</strong> function and<br />
structure <strong>of</strong> cartilage in health and disease<br />
• discuss what has been learnt from MRI studies about cartilage<br />
and non-cartilage structures in osteoarthritis<br />
• describe the challenges <strong>of</strong> MRI assessment <strong>of</strong> cartilage in<br />
rheumatoid arthritis and which lessons can be learnt from<br />
MRI studies in osteoarthritis<br />
B308<br />
Neuro Endocrine Immunology<br />
Moderator: Frank Buttgereit, MD; Charite University Med-Berlin;<br />
Berlin, Germany<br />
6:45 PM<br />
The Immunomodulatory Properties <strong>of</strong> Adipokines and<br />
Adiponectin<br />
Ulf Muller-Ladner, MD; University Giessen/Kerckh<strong>of</strong>f-Clinic; Bad<br />
Nauheim, Germany<br />
7:05 PM<br />
Knowing the Fat for Fighting Diseases - Leptin: At the Crossroad<br />
<strong>of</strong> Energy Homeostasis, Immune Response and Systemic<br />
Inflammation<br />
Oreste Gualillo, PharmD, PhD; Santiago University Clinical<br />
Hospital; Santiago de Compostela, Spain<br />
7:25 PM<br />
The Impact <strong>of</strong> Abnormal Body Composition on Disease Activity<br />
in Rheumatoid Arthritis<br />
Jon T. Giles, MD; Johns Hopkins University; Baltimore, MD<br />
7:45 PM<br />
Panel Discussion<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe how adipokines modulate inflammation in adipose<br />
and mesenchymal tissue<br />
• identify the pathophysiology <strong>of</strong> white adipose tissue<br />
• explain useful concepts in counseling patients about<br />
behavioral changes to fight diseases<br />
• discuss how adiposity and adipokines affect inflammation and<br />
articular damage in rheumatoid arthritis<br />
A404<br />
Polymyalgia Rheumatica<br />
Moderators: Bhaskar Dasgupta, MD; Southend University<br />
Hospital; Essex, United Kingdom<br />
Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />
tuesday<br />
2010 Program Book 91
tuesday<br />
6:45 PM<br />
Results from the PMR Classification Criteria Study<br />
Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />
7:05 PM<br />
Update on Trials <strong>of</strong> Biologic Agents and Leflunomide in PMR<br />
and GCA<br />
Bhaskar Dasgupta, MD; Southend University Hospital; Essex,<br />
United Kingdom<br />
7:25 PM<br />
A Study <strong>of</strong> Educational Needs <strong>of</strong> Patients with PMR and GCA<br />
Richard Watts, DM; Ipswich Hospital; Ipswich, United Kingdom<br />
7:45 PM<br />
Update on Study <strong>of</strong> Temporal Artery Ultrasound Versus Biopsy<br />
in GCA<br />
Raashid Luqmani, DM; Nuffield Department <strong>of</strong> Orthopaedics,<br />
<strong>Rheumatology</strong> and Musculoskeletal Sciences; Oxford, United<br />
Kingdom<br />
Session Overview:<br />
The study group will be the forum for presenting results from<br />
the Prospective PMR Classification Criteria Study. It will also<br />
feature updates on therapeutic trials in PMR and GCA with<br />
leflunomide and biologic agents. A study <strong>of</strong> educational needs <strong>of</strong><br />
patients with PMR and GCA will be presented. Attendees will be<br />
updated on study <strong>of</strong> temporal artery ultrasound versus biopsy<br />
in GCA.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe results from the PMR classification criteria study<br />
• update on trials <strong>of</strong> leflunomide and biologic agents in PMR<br />
and GCA<br />
• explain a study <strong>of</strong> educational needs <strong>of</strong> patients with PMR and<br />
GCA<br />
• explain the study <strong>of</strong> temporal artery ultrasound versus biopsy<br />
in GCA<br />
B314<br />
Psoriatic Arthritis and Periarticular Imaging: Focus on<br />
Enthesitis, Dactylitis, and Nail Disease<br />
Moderators: Elaine Husni, MD, MPH; Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
Philip Helliwell, MD, PhD; University <strong>of</strong> Leeds; Leeds, United<br />
Kingdom<br />
6:45 PM<br />
The Role <strong>of</strong> Enthesitis in the Pathogenesis <strong>of</strong> Psoriatic Arthritis<br />
Dennis McGonagle, PhD; University <strong>of</strong> Leeds; Leeds, United<br />
Kingdom<br />
7:10 PM<br />
Clinical Assessment <strong>of</strong> Enthesitis: How Should This Be Done?<br />
Philip Helliwell, MD, PhD; University <strong>of</strong> Leeds; Leeds, United<br />
Kingdom<br />
7:35 PM<br />
Use <strong>of</strong> Ultrasound and Magnetic Resonance Imaging: Focus on<br />
Periarticular Disease in Patients with Psoriatic Arthritis<br />
Ralf G. Thiele, MD; University <strong>of</strong> Rochester; Rochester, NY<br />
Session Overview:<br />
Psoriatic arthritis is a unique inflammatory arthritis that<br />
encompasses both skin and joint involvement with common<br />
periarticular manifestations such as enthesitis and dactylitis. In<br />
fact, the initial insult may be enthesitis rather than the synovium<br />
and current area <strong>of</strong> research interest is in the early evaluation<br />
and detection <strong>of</strong> these clinical parameters. Therapeutic decisions<br />
may be influenced by the presence <strong>of</strong> active enthesis/dactylitis<br />
and current techniques <strong>of</strong> clinical examination and standard<br />
radiographs may underestimate the overall inflammatory<br />
burden. With the advances <strong>of</strong> imaging modalities, we will<br />
explore the utility <strong>of</strong> ultrasound and MRI for psoriatic diseases.<br />
We hope to bring together multidisciplinary disciplines in<br />
musculoskeletal radiologist and rheumatologist to help advance<br />
the field <strong>of</strong> psoriatic arthritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the overview <strong>of</strong> advances in imaging such as<br />
ultrasound in the utility <strong>of</strong> periarticular tissues in psoriatic<br />
arthritis<br />
• explore the relationship <strong>of</strong> immunohistology and imaging <strong>of</strong><br />
skin and joints for psoriatic diseases<br />
• identify the pathobiology and immuno-pathology underlying<br />
enthesitis in psoriatic disorders<br />
• appreciate the several clinical scoring methods for enthesitis,<br />
their reliability, sensitivity and specificity<br />
B309<br />
Sjögren’s Syndrome<br />
Moderators: Gabor G. Illei, MD; NIDCR/NIH; Bethesda, MD<br />
Nikolay P. Nikolov, MD; FDA/CDER/OND; Silver Spring, MD<br />
6:45 PM<br />
Animal Models in Sjögren’s Syndrome: Are They Any Good?<br />
Umesh Desmukh, PhD; University <strong>of</strong> Virginia; Charlottesville, VA<br />
7:10 pm<br />
From Bench to Bedside: Biological Markers <strong>of</strong> Disease Activity<br />
and Prognosis in Primary Sjögren’s Syndrome<br />
Jacques-Eric Gottenberg, MD, PhD; University <strong>of</strong> Strasbourg,<br />
France<br />
7:35 pm<br />
Autonomic Dysfunction: An Often Overlooked Feature <strong>of</strong><br />
Primary Sjogren’s Syndrome<br />
Thomas Mandl, MD, PhD: Malmo University Hospital; Malmo,<br />
Sweden<br />
Session Overview:<br />
The study group will address three topics ranging from animal<br />
models to clinical aspects <strong>of</strong> Sjögren’s syndrome providing inside<br />
in both the pathogenesis and clinical management <strong>of</strong> Sjögren’s<br />
syndrome. Speakers will discuss the role <strong>of</strong> B lymphocyte<br />
subsets and inflammatory mediators in the pathogenesis <strong>of</strong><br />
Sjögren’s and their potential as biomarkers, the advantages<br />
and limitations <strong>of</strong> various animal models and their relevance<br />
to human disease and the pathogenesis and treatment<br />
<strong>of</strong> autonomic dysfunction, one <strong>of</strong> the most challenging<br />
manifestation <strong>of</strong> Sjögren’s Syndrome. All three speakers will<br />
cover the basic aspects and the clinical implications <strong>of</strong> their<br />
topics.<br />
92<br />
2010 Program Book
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the advantages and limitations <strong>of</strong> animal models <strong>of</strong><br />
Sjögren’s syndrome and their relevance to human disease<br />
• identify the role <strong>of</strong> B cells, B cell directed cytokines and<br />
inflammatory mediators in the pathogenesis <strong>of</strong> Sjögren’s<br />
syndrome and their potential as biomarkers <strong>of</strong> disease activity<br />
and/or prognosis<br />
• develop a better understanding <strong>of</strong> the relationship between<br />
autonomic dysfunction and Sjögren’s syndrome and its clinical<br />
implications<br />
A410<br />
Skin Diseases<br />
Moderator: Jan P. Dutz, MD; University <strong>of</strong> Bristish Columbia;<br />
Vancouver, BC, Canada<br />
6:45 PM<br />
Cutaneous Side Effects <strong>of</strong> Anti-TNF Therapy<br />
David Wetter, MD; Mayo Clinic; Rochester, MN<br />
7:00 PM<br />
Multicentric Reticulocytosi a Dermatomyositis Mimic?<br />
Nicole Fett, MD; Perelman Center for Advanced Medicine;<br />
Philadelphia, PA<br />
7:15 PM<br />
Diagnosing and Treating Morphea<br />
Heidi Jacobe, MD; UT Southwestern Medical Center at Dallas;<br />
Dallas, TX<br />
7:30 PM<br />
Dematomyositis and Malignancy<br />
Jeffrey P. Callen, MD; University Louisville School Medicine;<br />
Louisville, KY<br />
7:40 PM<br />
Treatment <strong>of</strong> Raynaud’s in Patients with Low-Normal Blood<br />
Pressure<br />
Andrew G. Franks, MD; New York University; New York, NY<br />
tuesday<br />
7:50 PM<br />
Acquired Cutis Laxa<br />
Christan Vera Kellet, MD; Pontificia Universidad Catolica de<br />
Chile; Santigo, Chile<br />
Session Overview:<br />
Skin manifestations <strong>of</strong> rheumatic disease are common. This<br />
session will present six clinical cases involving the cutaneous<br />
manifestations <strong>of</strong> rheumatic diseases and their treatment.<br />
The range <strong>of</strong> diseases covered will include vascular disorders,<br />
dermatomyositis, sclerotic conditions, and skin drug reactions.<br />
Clinical features, importance <strong>of</strong> histopathology and treatment<br />
approaches will be covered and presented for discussion<br />
amongst attendees.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify common and unusual cutaneous manifestations <strong>of</strong><br />
rheumatic disease<br />
• describe the possible role <strong>of</strong> the dermatologist in comanagement<br />
<strong>of</strong> these conditions<br />
• identify the value and limitations <strong>of</strong> skin biopsy<br />
2010 Program Book 93
wednesday<br />
WEDNESDAY, NOVEMBER 10, 2010<br />
ACR/ARHP Registration<br />
6:30 am - 5:00 PM<br />
International Blvd. Foyer<br />
ACR Medical Aspects <strong>of</strong> Rheumatic<br />
Diseases<br />
7:15 - 8:15 am<br />
Hall A3<br />
Diabetes 2010: More than Autoimmunity and<br />
Adipocytes C PS<br />
Moderator: Gregory C. Gardner, MD; University <strong>of</strong> Washington;<br />
Seattle, WA<br />
Speaker: Irl B. Hirsch, MD; University <strong>of</strong> Washington School <strong>of</strong><br />
Medicine; Seattle, WA<br />
Session Overview:<br />
Rheumatologists <strong>of</strong>ten care for patients with co-existing<br />
diabetes. A better understanding <strong>of</strong> the autoimmune nature<br />
<strong>of</strong> certain forms <strong>of</strong> diabetes may give us insight to our own<br />
diseases. Greater knowledge <strong>of</strong> this field in general will allow us<br />
to better care for our patients with diabetes spectrum illnesses.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the classification and pathophysiology <strong>of</strong> the various<br />
forms <strong>of</strong> diabetes<br />
• develop current and future treatment strategies for diabetes<br />
in its various forms including steroid associated diabetes<br />
• explain how medications used by rheumatologists might<br />
impact patients with diabetes<br />
ACR Special Session<br />
7:15 - 8:45 am<br />
A404<br />
The Changing Face <strong>of</strong> the <strong>Rheumatology</strong> Workforce:<br />
Gender Issues in the Workplace BR Ed.<br />
Moderator: Giovanni Franchin, MD, PhD; Feinstein Institute;<br />
Manhasset, NY<br />
7:15 am<br />
The New Face <strong>of</strong> <strong>Rheumatology</strong><br />
Abby Goulder Abelson, MD; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
7:30 am<br />
Gender Inequality and Barriers to a Successful Career: What<br />
Can We Learn from the Private Sector Initiative?<br />
Anne Camille Talley, MBA; Healthcare Businesswomen’s<br />
Association; Pittsgrove, NJ<br />
8:00 am<br />
Retention <strong>of</strong> Women in the <strong>Rheumatology</strong> Workplace<br />
Christy I. Sandborg, MD; Stanford Medical Center; Stanford, CA<br />
Robin K. Dore, MD; Robin K. Dore Incorporated; Tustin, CA<br />
8:30 am<br />
Panel Discussion<br />
Session Overview:<br />
The number <strong>of</strong> female physicians in the US has increased<br />
dramatically over the past thirty years. This trend is particularly<br />
pronounced in rheumatology as in 2009, 60 percent <strong>of</strong> all<br />
fellowship applicants were women. However, women still<br />
remain a minority in academic medicine <strong>of</strong> any kind as well as<br />
rheumatology, especially in more senior positions. According<br />
to the 2007-2008 Academic Workforce Study, although women<br />
represent 28.8 percent <strong>of</strong> academic appointments, only 15<br />
percent <strong>of</strong> full pr<strong>of</strong>essors are women, and only 7 percent <strong>of</strong><br />
adult rheumatology division chiefs are women. Additionally<br />
a recent study by The Center for Work-Life Policy, The Athena<br />
Project found that 52 percent <strong>of</strong> women ages 30-40 are leaving<br />
not only academic medicine, but also jobs in the private sector.<br />
Assuming that women will comprise a significant number,<br />
if not the majority <strong>of</strong> the workforce in rheumatology in the<br />
near future, the field needs to understand what factors are<br />
influencing women to choose rheumatology as a career,<br />
and more importantly, why women may not remain and/<br />
or advance in rheumatology in either academic or private<br />
practice settings. Identifying gender-related career barriers<br />
will guide the formulation <strong>of</strong> strategies to increase retention<br />
and promote the advancement <strong>of</strong> women in rheumatology,<br />
helping to ensure that the rheumatology workforce remains<br />
sufficient to meet anticipated future needs. This session<br />
intends to bring awareness to division chiefs, program<br />
directors and rheumatologists on the issue <strong>of</strong> gender in the<br />
rheumatology workforce, and its potential effect on the future <strong>of</strong><br />
rheumatology.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify workforce issues regarding women in academic<br />
medicine and in the private sector<br />
• describe the challenges to women in obtaining leadership<br />
positions<br />
• propose possible solutions to increase the recruitment<br />
and retention <strong>of</strong> women in academic medicine and their<br />
advancement in both the academic and private sector<br />
ACR Special Session<br />
7:15 - 9:15 am<br />
A412<br />
Insurance Roundtable Discussion BR<br />
This session is not eligible for CME credit.<br />
Moderators: Alex Limanni, MD; Arthritis Centers <strong>of</strong> Texas; Dallas,<br />
TX<br />
Gary R. Feldman, MD; Pacific Arthritis Care Center; Los Angeles,<br />
CA<br />
Speakers: Randall S. Krakauer, MD; Aetna; Princeton, NJ<br />
Alexander P. Ruggieri, MD; Anthem Care Management; Simi<br />
Valley, CA<br />
Erin McKenna PharmD; Anthem Care Management; Pittsburgh,<br />
PA<br />
Eileen M. Moynihan, MD; Highmark Medicare Services;<br />
Woodbury, MD<br />
94<br />
2010 Program Book
Session Overview:<br />
This roundtable discussion has been organized as part <strong>of</strong> the<br />
ACR’s initiative to encourage transparency and collaboration<br />
with insurance company respresentatives to ensure the needs<br />
<strong>of</strong> the patient are best addressed. Topics <strong>of</strong> discussion will<br />
include quality, transparency, tier 4 drug policies and priorauthorizations.<br />
The discussion is designed to generate candid<br />
dialogue regarding the needs and operational systems <strong>of</strong><br />
insurance companies and physicians, in an attempt to develop<br />
solutions that will streamline administrative processes, reduce<br />
costs and ensure effective deliverly <strong>of</strong> the appropriate care to<br />
patients. This session will be an open forum with questions and<br />
answers to follow.<br />
ACR State-<strong>of</strong>-the-Art Lecture<br />
7:15 - 8:15 am<br />
Sidney J. Marcus Auditorium<br />
Walk this Way: Biomechanics and Osteoarthritis R<br />
Moderator: Richard F. Loeser, MD; Wake Forest University;<br />
Winston-Salem, NC<br />
Speaker: Thomas Andriacchi, PhD; Stanford University; Stanford,<br />
CA<br />
Session Overview:<br />
Osteoarthritis is the result <strong>of</strong> biomechanical factors that cause<br />
abnormal or excessive joint loading. A better understanding<br />
<strong>of</strong> these factors has been gained over the past few years using<br />
advanced imaging and gait analysis. This lecture will present<br />
data based on these advances and review the latest findings as<br />
they relate to the pathogenesis <strong>of</strong> osteoarthritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• analyze the biomechanical factors that predispose to knee<br />
and/or hip osteoarthritis<br />
• identify advances in technologies that utilize joint imaging<br />
with gait analysis<br />
• describe advances in understanding <strong>of</strong> biomechanical factors<br />
that will influence the management <strong>of</strong> osteoarthritis<br />
ARHP Concurrent Sessions<br />
7:45 - 8:45 am<br />
B309<br />
Disparities and Pain: Examining Research, Practice<br />
and Policy cP PM<br />
Moderator: Kristine Phillips, MD, PhD; University <strong>of</strong> Michigan;<br />
Ann Arbor, MI<br />
Speakers: Carmen R. Green, MD; University <strong>of</strong> Michigan; Ann<br />
Arbor, MI<br />
David A. Williams, PhD; University <strong>of</strong> Michigan Health System;<br />
Ann Arbor, MI<br />
Session Overview:<br />
Pain affects 100 million <strong>American</strong>s and is the most common<br />
cause <strong>of</strong> health care utilization. However, disparities exist in pain<br />
assessment and treatment, related to social determinants such<br />
as age, gender, class, and place <strong>of</strong> residence. Moreover, nonpharmacological<br />
interventions, such as aerobic exercise<br />
and cognitive-behavioral therapy, are underutilized in the<br />
management <strong>of</strong> chronic pain conditions, though response rates<br />
rival those <strong>of</strong> pharmacologic agents. Novel therapeutic delivery<br />
methods are overcoming barriers, and increasing accessibility <strong>of</strong><br />
therapeutic options in non-urban communities.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• outline disparities in pain care in the US and the role <strong>of</strong> social<br />
determinants on pain assessment, treatment and outcomes<br />
• summarize the current status <strong>of</strong> US health care reform related<br />
to pain and disparities, including relevant federal and state<br />
initiatives<br />
• describe why the combination <strong>of</strong> pharmacological and nonpharmacological<br />
interventions represents optimal care in<br />
chronic pain, and become familiar with intervention delivery<br />
methods suitable for both urban and rural environments<br />
B310<br />
Patient Education on the Run cP PS<br />
Moderator: Lee A. Anderson, BSN; University <strong>of</strong> Minnesota<br />
Physicians; Champlin, MN<br />
Speaker: Victoria L. Ruffing, RN; Johns Hopkins University;<br />
Baltimore, MD<br />
Session Overview:<br />
The need for health care pr<strong>of</strong>essionals to be aware <strong>of</strong> the<br />
alternative methods for educating adult patients in busy<br />
practices is ongoing and the available resources are constantly<br />
changing. Therefore, a summary <strong>of</strong> resources and methods to<br />
indentify the best management plans will be discussed.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss need for varied formats in patient education for adults<br />
• review patient learning styles<br />
• prioritize educational needs <strong>of</strong> adult patients with rheumatic<br />
diseases<br />
• identify available educational resources<br />
• discuss strategies for implementing educational programs<br />
B311<br />
Physical Activity and Osteoarthritis: Learning with the<br />
Community cP PS<br />
Moderator: Nadine M. Fisher, EdD; SUNY at Buffalo; Buffalo, NY<br />
Speakers: Mary E. Christenson, PT, PhD; Regis University;<br />
Westminster, CO<br />
Maura D. Iversen, PT, DPT, SD, MPH; Northeastern University;<br />
Boston, MA<br />
Session Overview:<br />
Incorporating appropriate physical activity into an individual’s<br />
routine for those living with osteoarthritis plays a key role<br />
in promoting health, enhancing functional activities, and<br />
improving the quality <strong>of</strong> life. Living in rural communities may<br />
<strong>of</strong>fer distinct challenges for people with arthritis to participate<br />
in physical activity, so involving the community to investigate<br />
factors associated with physical activity in this subpopulation is<br />
unique. Speakers will present the state <strong>of</strong> the evidence regarding<br />
physical activity in rural US communities in persons with arthritis<br />
and the results from a cross-sectional study informed by a rural<br />
advisory committee that investigated physical activity in adults<br />
with arthritis living in rural communities.<br />
wednesday<br />
2010 Program Book 95
wednesday<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• define the state <strong>of</strong> the evidence regarding physical activity in<br />
adults with arthritis living in rural communities<br />
• describe the development <strong>of</strong> a community-based approach<br />
to learn about the levels <strong>of</strong> physical activity in a rural<br />
environment in persons with arthritis<br />
• examine perceived barriers/facilitators <strong>of</strong> physical activity in<br />
persons with arthritis in rural communities<br />
• identify benefits <strong>of</strong> physical activity in this subpopulation<br />
B308<br />
Using Pharmacogenomics to Improve Therapy for<br />
Pediatric Patients P/C PS<br />
Moderator: Bernadette McNally, MS, PAC; University <strong>of</strong> Utah;<br />
Salt Lake City, UT<br />
Speaker: Mara L. Becker, MD; Children’s Mercy Hospital; Kansas<br />
City, MO<br />
Session Overview:<br />
In the emerging field <strong>of</strong> personalized medicine, it is important to<br />
recognize that there is significant variability in drug response and<br />
toxicity between adults and children. Targeted therapy-based on<br />
age, genetics and development <strong>of</strong> the child may be the future<br />
<strong>of</strong> prescribing medications for rheumatic disease for children,<br />
specifically methotrexate. Ontogeny, the normal developmental<br />
process may affect aspects <strong>of</strong> pharmacological response in<br />
children including drug absorption, distribution, metabolism and<br />
excretion. Developmental expression <strong>of</strong> different pathways at<br />
different times may lead to variability in medication response.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe differences in disease expression and drug response<br />
in pediatric patients<br />
• define what makes children different, including developmental<br />
pharmacokinetics, pharmacogenetics in children and the role<br />
<strong>of</strong> ontogeny<br />
• summarize new pharmacogenomic data in commonly<br />
used medications in pediatrics and identify gaps in current<br />
knowledge<br />
ACR Meet the Pr<strong>of</strong>essor Sessions<br />
7:45 - 9:15 am<br />
Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />
separate registration and ticket. To verify which session you<br />
registered for, check to make sure the registration code on your<br />
ticket matches the code listed below in parentheses.<br />
B207<br />
Adult Inflammatory Myopathy (061)<br />
Speaker: Mary E. Cronin, MD; Medical <strong>College</strong> <strong>of</strong> Wisconsin;<br />
Milwaukee, WI<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss diagnostic pearls for the evaluation <strong>of</strong> someone<br />
suspected <strong>of</strong> having an inflammatory myopathy<br />
• discuss the treatment paradigm for inflammatory myopathies<br />
B208<br />
Crystal: Management <strong>of</strong> Gout (062) PS<br />
Speaker: Hyon K. Choi, MD, DrPH; University <strong>of</strong> British Columbia;<br />
Vancouver, BC, Canada<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the management <strong>of</strong> gout in patients with renal<br />
insufficiency or organ transplants<br />
• identify strategies to treat patients who are intolerant <strong>of</strong><br />
approved therapies<br />
• cite agents in development for the treatment <strong>of</strong><br />
hyperuricemia and gout<br />
B209<br />
Pediatrics: Spondyloarthritis in Children (063) P<br />
Speaker: Shirley Tse, MD; Hospital for Sick Children; Toronto, ON,<br />
Canada<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe differences between spondylarthritis in children and<br />
adults<br />
• discuss the approach to diagnosis and treatment <strong>of</strong> children<br />
with spondylarthritis<br />
B210<br />
Pregnancy in Rheumatic Diseases (064)<br />
Speaker: Megan E.B. Clowse, MD, MPH; Duke University Medical<br />
Center; Durham, NC<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the effects <strong>of</strong> pregnancy on the activity <strong>of</strong> rheumatic<br />
diseases<br />
• describe the challenging management issues unique to<br />
pregnancy<br />
B301<br />
Pulmonary Manifestations <strong>of</strong> Rheumatic Disease (065)<br />
Speaker: Paul F. Dellaripa, MD; Brigham and Women’s Hospital;<br />
Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify emerging concepts regarding the pathophysiology <strong>of</strong><br />
inflammation and fibrosis in autoimmune lung disease<br />
• determine the appropriate use <strong>of</strong> diagnostic tests in<br />
the evaluation <strong>of</strong> patients with rheumatic disorders and<br />
autoimmune lung disease<br />
• discuss the limits <strong>of</strong> traditional therapeutic options and<br />
possible emerging therapies in managing autoimmune lung<br />
disease<br />
B302<br />
Rheumatoid Arthritis: Biological Agents (066) PS<br />
Speaker: Larry W. Moreland, MD; University <strong>of</strong> Pittsburgh<br />
Medical Center; Pittsburgh, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify biologic agents in use for the treatment <strong>of</strong> rheumatoid<br />
arthritis<br />
• describe the risk/benefit pr<strong>of</strong>iles <strong>of</strong> biologic agents<br />
• discuss the emerging biologics and their advantages for the<br />
therapeutic algorithm<br />
96<br />
2010 Program Book
B303<br />
Scleroderma: Systemic Sclerosis (067) PM<br />
Speaker: Christopher P. Denton, MD, PhD; Royal Free Hospital;<br />
London, United Kingdom<br />
B202<br />
Dermatopathology <strong>of</strong> Rheumatic Diseases (231)<br />
Speaker: Lynne Goldberg, MD; Boston University Medical<br />
Center; Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the classification <strong>of</strong> systemic sclerosis and its impact<br />
on treatment and prognosis<br />
• apply cardiopulmonary testing to determine the relative<br />
contributions <strong>of</strong> alveolitis, fibrosis and vasculopathy<br />
• formulate a therapeutic regimen to improve quality <strong>of</strong> life and<br />
organ-specific symptomatology<br />
B304<br />
Systemic Lupus Erythematosus: Difficult to Treat<br />
Systemic Lupus Erythematosus (068) P f<br />
Speaker: Elena M. Massarotti, MD; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• utilize laboratory testing in the management <strong>of</strong> patients with<br />
systemic lupus erythematosus<br />
• determine the most relevant and beneficial therapeutic<br />
approach<br />
• identify appropriate assessment tools for use in management<br />
and prognosis<br />
B305<br />
Temporal Arteritis (069)<br />
Speaker: Gene G. Hunder, MD; Mayo Clinic; Rochester, MN<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the most current concepts in diagnosis <strong>of</strong> temporal<br />
arteritis, including the use <strong>of</strong> imaging modalities<br />
• identify evolving concepts in treatment <strong>of</strong> temporal arteritis,<br />
including appropriate use <strong>of</strong> corticosteroids, as well as the<br />
data regarding the efficacy <strong>of</strong> other “steroid sparing” agents<br />
• describe controversial areas in diagnosis and management <strong>of</strong><br />
temporal arteritis<br />
B306<br />
Vasculitis: Update (070) f<br />
Speaker: Peter A. Merkel, MD, MPH; Boston University School <strong>of</strong><br />
Medicine; West Newton, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the classification <strong>of</strong> vasculitis according to affected<br />
vessel size<br />
• utilize the various available laboratory tests, with emphasis on<br />
anti-neutrophilic cytoplasmic antibodies testing<br />
• identify current and novel therapeutic modalities<br />
ACR Workshops<br />
7:45 - 9:45 am<br />
Admission to each Workshop requires a separate registration<br />
and ticket. To verify which session you registered for, check to<br />
make sure the registration code on your ticket matches the code<br />
listed below in parentheses.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review dermatopathology in rheumatic diseases<br />
• describe the importance <strong>of</strong> dermatopathology in clinical<br />
decision making in patients with rheumatic diseases<br />
• apply the knowledge gained to clinical practice<br />
B206<br />
Joint Simulator (232) f<br />
Speakers: Joanne Valeriano-Marcet, MD; University <strong>of</strong> South<br />
Florida; Tampa, FL<br />
Helen E. Bateman, MD; James A. Haley Veterans Affairs Hospital,<br />
University <strong>of</strong> Southern Florida; Tampa, FL<br />
Ashley G. Sterrett, MD; James A. Haley Veterans Affairs Hospital;<br />
Tampa, FL<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the anatomy relative to various joint, bursa, and<br />
tendon injections<br />
• perform and instruct others on the techniques<br />
• design a successful joint injection workshop using simulators<br />
B203<br />
Musculoskeletal Exam Skills II: Regional Examinations<br />
<strong>of</strong> the Shoulder and Low Back (233)<br />
Speakers: George V. Lawry, MD; University <strong>of</strong> California-Irvine;<br />
Mission Viejo, CA<br />
Paul C. Utrie, MD; Orthopedic and Sports Medicine Specialists;<br />
Appleton, WI<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• participate in a hands-on, skill building workshop where<br />
participants are paired together for one-on-one practice<br />
• apply a systematic, efficient, clinically effective examination <strong>of</strong><br />
the shoulder and low back taking 3-4 minutes each<br />
• practice techniques for assessing SC and AC joints, bursitis,<br />
rotator cuff tendinitis, impingement signs and glenohumeral<br />
rotation<br />
• practice techniques for inspection, palpation, ROM, hip<br />
examination, suspected nerve root irritation and Waddell’s<br />
categories<br />
B204<br />
<strong>Rheumatology</strong> Physical Examination <strong>of</strong> Upper<br />
Extremity and Cervical Spine: Anatomical Correlates<br />
(234) f<br />
Speakers: Robert A. Kalish, MD; Tufts Medical Center; Boston,<br />
MA<br />
Pablo Villasenor Ovies, MD; Instituto Nacional de Ciencias<br />
Medicas y Nutricion; Tlalpan, Mexico<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review clinical and surface anatomy important to the<br />
rheumatologist<br />
• describe human anatomy to clinical syndromes seen in the<br />
practice <strong>of</strong> rheumatology<br />
• integrate these physical examination skills into a<br />
rheumatology practice<br />
2010 Program Book 97<br />
wednesday
ACR Clinical Symposium<br />
8:45 - 9:45 am<br />
ACR State-<strong>of</strong>-the-Art Lecture<br />
8:45 - 9:45 am<br />
wednesday<br />
98<br />
Hall A3<br />
Myositis 2010: A to Z c/r cP P/C PS<br />
Moderator: Chester V. Oddis, MD; University <strong>of</strong> Pittsburgh;<br />
Pittsburgh, PA<br />
Speaker: Frederick W. Miller, MD, PhD; National Institute <strong>of</strong><br />
Environmental Health Sciences, NIH; Kennsington, MD<br />
Session Overview:<br />
Patients with myositis are a diagnostic and therapeutic challenge<br />
for the practicing rheumatologist. ACR members frequently<br />
request updates on the inflammatory myopathies and the<br />
different subsets such as polymyositis, dermatomyositis, overlap<br />
syndromes and inclusion body myositis. This review will focus on<br />
all aspects <strong>of</strong> myositis including diagnosis, ongoing assessment<br />
and management considerations. The mimics <strong>of</strong> myositis will<br />
be considered along with the assessment and treatment <strong>of</strong> the<br />
refractory myositis patient.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify patients with the various clinical syndromes<br />
associated with the inflammatory myopathies<br />
• outline a diagnostic and therapeutic plan in patients<br />
diagnosed with idiopathic inflammatory myopathy<br />
• identify the mimics <strong>of</strong> myositis and assess and treat the<br />
patient with refractory disease<br />
ACR Immunology Updates for<br />
Clinicians<br />
8:45 - 9:45 am<br />
Thomas J. Murphy Ballroom<br />
Epigenetics 101 c/r<br />
Moderator: Richard J. Looney, MD; University <strong>of</strong> Rochester;<br />
Rochester, NY<br />
Speaker: Robert A. Colbert, MD, PhD; NIAMS/NIH; Bethesda, MD<br />
Session Overview:<br />
Epigenetics is the regulation <strong>of</strong> gene expression without<br />
altering the nucleotide sequence <strong>of</strong> the genome. Epigenetics<br />
determines gene expression in cellular differentiation, e.g.,<br />
differential cytokine production in T cell subsets, and is involved<br />
in gene silencing including X chromosome inactivation in<br />
females. Epigenetics also explains the pathogenesis <strong>of</strong> druginduced<br />
lupus. Inhibitors <strong>of</strong> histone deacetylases target one<br />
mechanism <strong>of</strong> epigenetic regulation <strong>of</strong> gene expression. Histone<br />
deacetylases inhibition is being tested in a wide variety <strong>of</strong><br />
human malignancies and has shown promise in animal models<br />
<strong>of</strong> lupus.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe how different epigenetic mechanisms regulate gene<br />
expression<br />
• describe the important <strong>of</strong> epigenetics in the<br />
immunopathogenesis <strong>of</strong> human disease<br />
• discuss potential therapeutic applications <strong>of</strong> epigenetics<br />
2010 Program Book<br />
B406<br />
From Fat to Joints - The Vicious Side <strong>of</strong> Adipokines<br />
R<br />
Moderator: David S. Pisetsky, MD, PhD; Duke University Medical<br />
Center; Durham, NC<br />
Speaker: Ulf Muller-Ladner, MD; University Giessen/Kerckh<strong>of</strong>f-<br />
Clinic; Bad Nauheim, Germany<br />
Session Overview:<br />
Recent studies revealed several links between adipose tissue,<br />
adipocytokines, and arthritis. This presentation will review<br />
the evidence indicating that adipose tissue is not an innocent<br />
bystander tissue and may influence the inflammatory process.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• illustrate the variety <strong>of</strong> adipokines operative in non-metabolic<br />
inflammatory rheumatic diseases<br />
• describe the role <strong>of</strong> adipokines in inflammatory processes<br />
• visualize the potential <strong>of</strong> anti-adipokine targeted therapies in<br />
inflammatory conditions<br />
ACR REF Special Session<br />
8:45 - 9:45 am<br />
Sidney J. Marcus Auditorium<br />
REF Paul Klemperer, MD, Memorial Lectureship:<br />
Systemic Sclerosis: Genetic? Autoimmune? One<br />
Disease? c/r<br />
Moderator: E. William St.Clair, MD; Duke University Medical<br />
Center; Durham, NC<br />
Speakers: Frank C. Arnett, MD; University <strong>of</strong> Texas Medical<br />
School; Houston, TX<br />
Session Overview:<br />
Progressive systemic sclerosis is a devastating disease that<br />
all rheumatologists see regularly. It is essential that clinicians<br />
be familiar with the latest data concerning etiopathogenesis<br />
and disease classification in order to educate their patients<br />
and to manage the disease optimally. This lecture will update<br />
the attendees on current thinking about the genetic basis <strong>of</strong><br />
progressive systemic sclerosis and how that relates to diagnosis<br />
and management.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the aspects <strong>of</strong> systemic sclerosis that suggest a<br />
genetic etiology<br />
• review the autoimmune aspects <strong>of</strong> the disease<br />
• discuss which aspects <strong>of</strong> the clinical presentation suggest that<br />
there are several underlying disease processes and which<br />
suggest a single unifying etiology<br />
ACR/ARHP Poster Session C and<br />
Poster Tours<br />
9:00 am - 6:00 PM<br />
Halls B1 & B2<br />
Poster presenters will be available from 9:00 - 11:00 am.<br />
Poster tours will be held 9:00 - 9:45 am, 10:15 - 11:00 am<br />
and 4:30 - 5:30 PM.
9:00 - 10:30 am - Poster Hall Morning Snack Break<br />
9:00 - 11:00 am (Abstracts #1466 – 2079)<br />
Guided Poster Tours<br />
Guided poster tours provide an opportunity for scientific<br />
attendees to ask questions and gain insights from leaders in<br />
the field while earning CME credits. Morning tours will <strong>of</strong>fer<br />
insights from both poster presenters and tour guides, while<br />
afternoon tours will exclusively feature the tour guide’s expert<br />
opinion. Although there is no fee to participate, pre-registration<br />
is required and each tour is limited to 20 registered scientific<br />
attendees. If you would like to participate and have not<br />
registered you can check tour availability and request a ticket<br />
in the registration area, located in the International Boulevard<br />
Foyer. If you registered in advance <strong>of</strong> the meeting your ticket was<br />
included with your meeting materials. Once you have your ticket,<br />
plan to collect your headset and meet your group 10 minutes<br />
before your tour departs from the entrance <strong>of</strong> the poster hall,<br />
located in Halls B1 & B2.<br />
Headsets: Each tour participant will receive a wireless headset.<br />
Participants who do not return their headsets within 10 minutes<br />
after the tour has ended will incur a fee.<br />
9:00 - 9:45 am<br />
Pediatric P<br />
(Attendance limited to Pediatric Resident Program recipients.)<br />
Egla C. Rabinovich, MD, MPH; Duke University Medical Center;<br />
Durham, NC<br />
Rheumatoid Arthritis: Clinical Aspects<br />
Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />
Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects<br />
and Treatment<br />
Atul A. Deodhar, MD; Oregon Health & Science University;<br />
Portland, OR<br />
Systemic Lupus Erythematosus: Clinical Aspects<br />
Barri J. Fessler, MD; Univeristy <strong>of</strong> Alabama – Birmingham<br />
<strong>Rheumatology</strong>; Birmingham, AL<br />
Vasculitis<br />
Simon Carette, MD; Toronto Western Hospital; Toronto, ON,<br />
Canada<br />
Quality <strong>of</strong> Life<br />
Edward H. Yelin, PhD, University <strong>of</strong> California, San Francisco, CA<br />
Physical Activity/Exercise<br />
Mary E. Christenson, PT, PhD; Regis University; Westminster, CO<br />
10:15 - 11:00 am<br />
Epidemiology and Health Services Research<br />
Liana Fraenkel, MD, MPH; Yale University, Newtown, CT<br />
Miscellaneous Rheumatic and Inflammatory Diseases<br />
W. Winn Chatham, MD; University <strong>of</strong> Alabama at Birmingham;<br />
Birmingham, AL<br />
Pediatric <strong>Rheumatology</strong>: Clinical Aspects<br />
Balu H. Athreya, MD; DuPont Hospital for Children; Wilmington,<br />
DE<br />
Rheumatoid Arthritis: Clinical Aspects<br />
Inmaculada Del Rincon, MD, MS; University <strong>of</strong> Texas Health<br />
Science Center - San Antonio; San Antonio, TX<br />
Systemic Lupus Erythematosus: Clinical Aspects<br />
Bevra H. Hahn, MD; University <strong>of</strong> California Los Angeles School<br />
<strong>of</strong> Medicine; Los Angeles, CA<br />
Pain<br />
Carol L. Baird, DNS, ARPN, BC; Indiana University; Indianapolis,<br />
IN<br />
Behavioral Science<br />
Susan J. Bartlett, PhD; McGill University; Montreal, QC, Canada<br />
4:30 - 5:30 PM<br />
Rheumatoid Arthritis: Clinical Aspects<br />
Iain B. McInnes, PhD; University <strong>of</strong> Glasgow; Glasgow, United<br />
Kingdom<br />
Sjögren’s Syndrome<br />
Jacques-Eric Gottenberg, MD, PhD; Strasbourg Hospitals;<br />
Strasbourg, France<br />
Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects<br />
and Treatment<br />
Luis Espinoza, MD; Louisiana State University; New Orleans, LA<br />
Systemic Lupus Erythematosus: Clinical Aspects<br />
David A. Isenberg, MD; University <strong>College</strong> <strong>of</strong> London; London,<br />
United Kingdom<br />
Exhibits and Replay Café<br />
9:00 am - 2:00 pm<br />
Halls A1 & A2<br />
Exhibits<br />
Halls A1 & A2 (Booth #123)<br />
Replay Café<br />
Exhibit Hall Morning SnACk Break<br />
9:00 - 10:00 am<br />
Halls A1 & A2<br />
Poster Hall Morning SnACk Break<br />
9:00 - 10:30 am<br />
Halls B1 & B2<br />
ARHP Concurrent Abstract Session<br />
9:15 – 10:15 am<br />
B311<br />
Be Creative with Rheumatic Education: Where and<br />
How to Get It<br />
Moderator: Elizabeth Schlenk, PhD, RN; University <strong>of</strong> Pittsburgh;<br />
Pittsburgh, PA<br />
9:15 am<br />
2080. Where Do Adults with Arthritis Get Information about<br />
Arthritis?<br />
Louise Murphy 3 , Kristina A. Theis 3 , Teresa J. Brady 2 , Julie Bolen 3<br />
and Patience White 1 , 1 Arthritis Foundation, 2 Center for Disease<br />
Control, Atlanta, GA, 3 Centers for Disease Control and Prevention<br />
wednesday<br />
2010 Program Book 99
wednesday<br />
100<br />
9:30 am<br />
2081. Rheuma on the Road – The Rheuma Truck Mass<br />
Communication, Educational Advertising and Creative<br />
Community Care.<br />
Matthias K. Schneider 2 and Martina Blumenroth 1 , 1 Cooperative<br />
<strong>Rheumatology</strong> Association Rhine-Ruhr MNR-Klinik, Duesseldorf,<br />
Germany, 2 MNR-Klinik, Duesseldorf, Germany<br />
9:45 am<br />
2082. A Study <strong>of</strong> Pictorial Representation (Mind Map) To<br />
Convey Health Education on Osteomalacia to People with Low<br />
Language Literacy Skills.<br />
Adewale O. Adebajo 5 , David Walker 3 , Sandra Robinson 4 ,<br />
Yogenjagat Singh 3 , Philip Helliwell 2 and Anisur Rahman 1 ,<br />
1<br />
University <strong>College</strong> London, London, United Kingdome,<br />
2<br />
University <strong>of</strong> Leeds, Leeds, United Kingdom, 3 University<br />
<strong>of</strong> Newcastle, Newcastle, United Kingdom, 4 University <strong>of</strong><br />
Newcastler, Newcastle, United Kingdom, 5 University <strong>of</strong> Sheffield<br />
Medical School Sheffield United Kingdom, Sheffield, United<br />
Kingdom<br />
10:00 am<br />
2083. Using Social Media To Recruit for a Translational Lupus<br />
Research Study for the Millennial Generation – The SisSLE<br />
Experience.<br />
Marlene H. Kern 2 , Sally Kaplan 2 , Bonnie Gonzales 2 , Betty<br />
Diamond 1 and Peter K. Gregersen 2 , 1 Feinstein Institute for<br />
Medical Research, Manhasset, NY, 2 The Feinstein Institute for<br />
Medical Research, Manhasset, NY<br />
ARHP Concurrent Sessions<br />
9:15 - 10:15 am<br />
B309<br />
Building Effective Teams: Recommended Leadership<br />
Strategies cP PS<br />
Moderator: Michael J. Jennings, RT, CBDT; Arthritis Care; Troy, NY<br />
Speakers: Basia Belza, PhD, RN; University <strong>of</strong> Washington;<br />
Seattle, WA<br />
Marian T. Hannan, DSc, MPH; Hebrew Senior Life and Harvard<br />
Medical School; Boston, MA<br />
Maura D. Iversen, PT, DPT, SD, MPH; Northeastern University;<br />
Boston, MA<br />
Session Overview:<br />
Regardless <strong>of</strong> work setting or discipline, working collaboratively<br />
as a team enhances productivity, increases satisfaction, and<br />
leads to improved outcomes.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• compose clear objectives for team work and measurable<br />
outcomes<br />
• define the attributes <strong>of</strong> a successful team<br />
• build and/or transform team culture and define the context <strong>of</strong><br />
group interaction<br />
B308<br />
Pain Management In the Age <strong>of</strong> Abuse and Litigation<br />
c/r PS PM<br />
Moderator: Kori A. Dewing, MN, ARNP; VA Mason Medical<br />
Center; Everett, WA<br />
Speaker: Allan Gib<strong>of</strong>sky, MD, JD; Hospital for Special Surgery;<br />
New York, NY<br />
2010 Program Book<br />
Session Overview:<br />
Efforts to identify pain management barriers and attempts to<br />
modify those barriers through quality improvement programs<br />
have increased dramatically within health care organizations<br />
in recent years. National clinical practice guidelines for the<br />
management <strong>of</strong> acute pain and cancer pain have been published<br />
by numerous pr<strong>of</strong>essional societies including the <strong>American</strong> Pain<br />
Society and by the Agency for Health Care Policy and Research.<br />
There is general agreement, however, that the implementation<br />
<strong>of</strong> pain management strategies has proven problematic.<br />
Research on barriers to effectively manage pain indicates that<br />
problems fall into three main categories: those related to health<br />
care pr<strong>of</strong>essionals; those related to patients and families;<br />
and, those related to health care systems. Thus, health care<br />
pr<strong>of</strong>essionals may under treat pain for several reasons, including<br />
inadequate knowledge <strong>of</strong> pain management, inadequate<br />
knowledge <strong>of</strong> the side effects <strong>of</strong> analgesics, poor assessment <strong>of</strong><br />
pain, and concern about regulation <strong>of</strong> controlled substances.<br />
Despite efforts by organizations like Joint Commission on<br />
Accreditation <strong>of</strong> Healthcare Organizations to identify pain as<br />
“the fifth vital sign”, the health care system gives low priority<br />
to (and low reimbursement for) effective pain management<br />
strategies. This session will address strategies to effectively<br />
manage musculoskeletal and inflammatory pain in the clinical<br />
rheumatology setting and identify strategies to reduce the<br />
likelihood <strong>of</strong> litigation and administrative sanction related to use<br />
<strong>of</strong> controlled substances.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the incidence <strong>of</strong> prescription drug abuse in<br />
rheumatology<br />
• design strategies to reduce prescription drug abuse in a<br />
rheumatology practice<br />
• describe best practice strategies to protect against litigation<br />
related to prescription medication abuse<br />
B402<br />
Rheumatic Disease Update: Juvenile Idiopathic<br />
Arthritis P/C<br />
Moderator: Karen L. Kerr, MSN, NP, CPNP, PNP; Children’s<br />
Hospital <strong>of</strong> Michigan; Detroit, MI<br />
Speaker: Helen M. Emery, MD; Children’s Hospital & Regional<br />
Medicine; Seattle, WA<br />
Session Overview:<br />
Juvenile idiopathic arthritis remains the most common<br />
musculoskeletal problem in children below the age <strong>of</strong> 16 years.<br />
Many patients show frequent flares or persistent disease activity<br />
with significant morbidity and serious complications. Recent<br />
investigations in the pathophysiology <strong>of</strong> juvenile idiopathic<br />
arthritis have focused on mediators <strong>of</strong> the innate immune<br />
system and IL-1beta, IL-6 and IL-18 as well as phagocyte-specific<br />
S100-proteins are correlated with disease activity and secondary<br />
complications. These insights have lead to new promising<br />
treatment approaches, like application <strong>of</strong> recombinant anti-IL-1<br />
receptor antagonist or anti-IL-6 receptor antibodies in patients<br />
resistant to conventional anti-inflammatory treatment. With<br />
these new discoveries, rheumatology pr<strong>of</strong>essionals need to keep<br />
up with the pathophysiology and novel treatment options <strong>of</strong><br />
juvenile idiopathic arthritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the pathophysiology <strong>of</strong> systemic onset juvenile<br />
idiopathic arthritis
• describe the role <strong>of</strong> IL-1 and IL-6 in the development <strong>of</strong><br />
juvenile idiopathic arthritis and its therapeutic implications<br />
• develop a plan for management <strong>of</strong> ‘resistant cases’ <strong>of</strong> juvenile<br />
idiopathic arthritis<br />
ACR Practice Issues<br />
9:30 - 11:00 am<br />
A411<br />
CORC Forum: Health Care Reform – Where Are We<br />
Heading? BR cP PS<br />
Moderators: Matthew P. Bunyard, MD; Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
Raymond Hong, MD, MBA; Ohio Permanente Medical Group;<br />
Richfield, OH<br />
9:30 am<br />
Where Are We Heading? Health Care Reform – A Workable<br />
Approach<br />
J. B. Silvers, PhD; Case Western Reserve University; Cleveland,<br />
OH<br />
Nan Shen, MD; Shanghai Ren Ji Hospital; Shanghai, China<br />
Speaker: Angus W. Thomson, PhD; Univesity <strong>of</strong> Pittsburgh<br />
Medical School; Pittsburgh, PA<br />
Session Overview:<br />
Dendritic cells are pivotal regulators <strong>of</strong> the immune response.<br />
Dendritic cells sense pathogens and danger signals in the<br />
environment and trigger antigen specific immune responses.<br />
They also present antigens from self-tissues to induce immune<br />
tolerance. Recent studies have unveiled the mechanisms<br />
by which dendritic cells promote and maintain tolerance. In<br />
addition, tolerogenic dendritic cells can promote or restore<br />
antigen-specific tolerance in animal models and these cells hold<br />
promise for the treatment <strong>of</strong> human autoimmune diseases.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss how dendritic cells establish and maintain immune<br />
tolerance<br />
• explain how manipulation <strong>of</strong> dendritic cells can generate<br />
tolerogenic dendritic cells<br />
• describe how tolerogenic dendritic cells can be effective for<br />
the treatment <strong>of</strong> human autoimmune disease<br />
10:15 am<br />
The Need for Strategic Planning in a Time <strong>of</strong> Change<br />
John Freedman, MD, MBA; Freedman Healthcare, LLC; Newton,<br />
MA<br />
Session Overview:<br />
Health care reform is at the forefront <strong>of</strong> health care discussion<br />
today. The business case for quality and efficiency in health care<br />
has never been clearer. It has been postulated that the new<br />
system will encourage payers to reimburse only for consistent<br />
and efficient care. Increasing transparency will stimulate more<br />
patient ownership <strong>of</strong> their health concerns and finances.<br />
Patients will in turn demand care that meets their needs.<br />
Preparing for the future <strong>of</strong> health care is therefore critical to<br />
the survival <strong>of</strong> many organizations. This changing health care<br />
landscape will have implications for medical providers. Many<br />
agree that the current system is not working and something<br />
will need to be done in order to protect the physician-patient<br />
relationship. So where are we heading?<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the role <strong>of</strong> performance measurement in payment<br />
health care reform<br />
• identify opportunities for providers in the changing medical<br />
landscape<br />
• describe the risks for clinicians, medical equipment and<br />
pharmaceutical suppliers, and others as a result <strong>of</strong> health care<br />
reform<br />
ACR State-<strong>of</strong>-the-Art Lecture<br />
9:30 - 10:30 am<br />
B313<br />
Tolerogenic Dendritic Cells: Regulators <strong>of</strong> Immune<br />
Reactivity and Therapeutic Agents in Autoimmune<br />
Disease R<br />
Moderators: Christopher T. Ritchlin, MD; University <strong>of</strong> Rochester<br />
Medical Center; Rochester, NY<br />
InnoVAtion Theater<br />
10:00 - 10:45 am<br />
Halls A1 & A2 (Booth #555)<br />
The following non-CME activity has been planned and will be<br />
implemented in accordance with the requirements <strong>of</strong> the FDA<br />
and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />
with Healthcare Pr<strong>of</strong>essionals by Covidien. Please visit the<br />
Covidien exhibit booth for more information or see page 292.<br />
Seating and light refreshments are subject to availability.<br />
An Alternative for Patients with Signs and Symptoms<br />
<strong>of</strong> Osteoarthritis <strong>of</strong> the Knee(s)<br />
ACR Workshops<br />
10:30 am - 12:30 PM<br />
Admission to each Workshop requires a separate registration<br />
and ticket. To verify which session you registered for, check to<br />
make sure the registration code on your ticket matches the code<br />
listed below in parentheses.<br />
B201<br />
Electronic Health Record (235) PS<br />
Speaker: Salahuddin Kazi, MD; Dallas Veterans Affairs Medical<br />
Center; Dallas, TX<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the key elements in current clinical processes and<br />
workflow to help select the features <strong>of</strong> an electronic health<br />
record that will be most useful for the clinical practice<br />
• define “meaningful use” <strong>of</strong> EHR<br />
• establish the principles <strong>of</strong> medical informatics and how to<br />
apply them to a clinical setting<br />
B202<br />
Muscle Involvement in Rheumatic Diseases (236)<br />
Speaker: Sakir Humayun Gultekin, MD; Oregon Health & Science<br />
University; Portland, OR<br />
2010 Program Book 101<br />
wednesday
wednesday<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the histological appearance <strong>of</strong> muscle in different<br />
rheumatic diseases<br />
• identify the histologic abnormalities <strong>of</strong> steroidmyopathy,<br />
polymyositis, dermatomyositis, and inclusion body myositis<br />
B203<br />
Musculoskeletal Exam Skills III: Regional<br />
Examinations <strong>of</strong> the Knee (237)<br />
Speakers: Paul C. Utrie, MD; Orthopedic and Sports Medicine<br />
Specialists; Appleton, WI<br />
George V. Lawry, MD; University <strong>of</strong> California-Irvine; Mission<br />
Viejo, CA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• participate in a hands-on, skill building workshop where<br />
participants are paired together for one-on-one practice<br />
• apply a systematic, efficient, clinically effective examination <strong>of</strong><br />
the knee (2 parts) taking 3-4 minutes each<br />
• practice techniques for assessing synovial swelling,<br />
patell<strong>of</strong>ermoral and ligamentous problems, Lachman and<br />
McMurray maneuvers<br />
B204<br />
Patient Questionnaires to Monitor Status and<br />
Document Improvement in Standard Care: Practical<br />
Considerations (238) PS<br />
Speaker: Theodore Pincus, MD; New York University Hospital for<br />
Joint Disease; Hastings-on-Hudson, NY<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• utilize patient questionnaires to monitor and document<br />
patient status in everyday rheumatology practice<br />
• describe how questionnaires can identify incomplete<br />
responses to therapies, and a need for changes in tight control<br />
<strong>of</strong> inflammation<br />
• increase awareness <strong>of</strong> the significance <strong>of</strong> patient<br />
questionnaire data in the prognosis <strong>of</strong> long-term<br />
ACR State-<strong>of</strong>-the-Art Lecture<br />
10:45 - 11:45 am<br />
B406<br />
Stem Cell Reprogramming: Molecular Mechanisms<br />
and Clinical Applications and Implications R<br />
Moderator: Lionel B. Ivashkiv, MD; Hospital for Special Surgery;<br />
New York, NY<br />
Speaker: Rocky S. Tuan, PhD; University <strong>of</strong> Pittsburgh; Pittsburgh,<br />
PA<br />
Session Overview:<br />
Stem cell technologies are rapidly evolving and have potential<br />
clinical applications in treating autoimmune disorders and in<br />
repairing and regenerating connective tissues. An understanding<br />
<strong>of</strong> these molecular and cellular processes will be important for<br />
clinicians and scientists working in the field <strong>of</strong> rheumatology.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the stem cell niche and its role in maintaining stem<br />
cell survival<br />
• discuss the cellular and molecular events associated with stem<br />
cell reprogramming<br />
• identify potential clinical applications <strong>of</strong> cellular<br />
reprogramming<br />
ARHP Concurrent Sessions<br />
10:45 - 11:45 am<br />
B308<br />
Adaptations and Solutions to Help People with<br />
Scleroderma Continue to Work c/r PM<br />
Moderator: Patricia A. MacDonald, BSN, NP; Takeda Global R&D<br />
Inc.; Lake Forest, IL<br />
Speakers: Nancy A. Baker, ScD OTR/L; University <strong>of</strong> Pittsburgh;<br />
Pittsburgh, PA<br />
Janet L. Poole, PhD, OTR; University <strong>of</strong> New Mexico;<br />
Albuquerque, NM<br />
Session Overview:<br />
Work is a major part <strong>of</strong> life for most adults and the role <strong>of</strong><br />
worker is highly valued not only as a means to provide income,<br />
but also as a major source <strong>of</strong> social interaction, structure and<br />
identity. The impact <strong>of</strong> rheumatic conditions such as rheumatoid<br />
arthritis, osteoarthritis, and lupus, on working ability and work<br />
cessation has been studied extensively. However, systemic<br />
sclerosis or scleroderma, another rheumatic disease which<br />
starts during the years <strong>of</strong> peak earning power, has only limited<br />
research. A few recent studies have examined factors related<br />
to work disability, such as disease severity and duration,<br />
symptoms, such as pain and fatigue, and physical function<br />
in scleroderma, but little is known about how workers with<br />
scleroderma cope. Studies on other rheumatic disorders suggest<br />
that adaptations made in the work environment and outside the<br />
work environment were key factors in preventing work disability<br />
in persons. Thus, it is important to understand the challenges<br />
individuals with scleroderma encounter in a work environment<br />
and what accommodations and adaptations can be made, so<br />
that they can continue to work.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the symptoms <strong>of</strong> scleroderma and the challenges to<br />
remaining in the workforce such as environmental constraints,<br />
fatigue and pain, commuting, and lifestyle issues<br />
• identify and evaluate the available computer and ergonomic<br />
adaptations accommodations that may be appropriate<br />
recommendations for people with scleroderma<br />
• recognize the barriers and solutions from the perspective <strong>of</strong><br />
the person with scleroderma<br />
B309<br />
Evidence-based Practice: Creating and Using<br />
<strong>Rheumatology</strong> Critically Appraised Topics<br />
(RheumCAts) R<br />
Moderator: Jennifer M. Hootman, PhD; Centers for Disease<br />
Control; Kennesaw, GA<br />
Speakers: Laura D. Bilek, PhD, PT; University Nebraska Medical<br />
Center; Omaha, NE<br />
Mary E. Christenson, PT, PhD; Regis University; Westminster, CO<br />
Jennifer M. Hootman, PhD; Centers for Disease Control;<br />
Kennesaw, GA<br />
102<br />
2010 Program Book
Session Overview:<br />
For the clinician, it is virtually impossible to keep up-to-date on<br />
all the published research in rheumatology. The sheer volume<br />
<strong>of</strong> information available to us due to technological advances can<br />
be overwhelming to busy clinicians. Critically appraised topics<br />
are concise syntheses <strong>of</strong> the literature on a topic based on a<br />
clinically relevant question. This session will provide an overview<br />
<strong>of</strong> rheumatology critically appraised topics.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• define the purpose <strong>of</strong> rheumatology critically appraised topics<br />
• describe the process for proposing and creating rheumatology<br />
critically appraised topics<br />
• define how rheumatology critically appraised topics can be<br />
used to promote evidence-based clinical practice<br />
aware <strong>of</strong> the advances in the imaging and management options<br />
for this common condition taking into consideration the nature<br />
and location <strong>of</strong> the patient’s individual pathology.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the prevalence <strong>of</strong> osteoarthritis <strong>of</strong> spine in a typical<br />
rheumatology clinic<br />
• describe the role <strong>of</strong> imaging and its appropriate use in<br />
investigating osteoarthritis <strong>of</strong> the spine<br />
• list the indications for a surgical referral in a patient with<br />
osteoarthritis <strong>of</strong> spine<br />
ACR Clinical Symposium<br />
11:00 am - 12:30 PM<br />
B310<br />
Finding and Using Secondary Data Resources for<br />
Research: Beyond the National Health and Nutrition<br />
Examination Survey and the Usual Suspects c/r<br />
Moderator: Robert R. McLean, DSc, MPH; Hebrew Senior Life;<br />
Boston, MA<br />
Speakers: Michael M. Ward, MD; NIH/NIAMS/IRP; Bethesda, MD<br />
Grant H. Louie, MD, MHS; Johns Hopkins University; Baltimore,<br />
MD<br />
Session Overview:<br />
Secondary data are data collected by someone else, <strong>of</strong>ten used<br />
by researchers to address research questions different from<br />
their own. A wide range <strong>of</strong> secondary data is available from<br />
governmental and non-governmental sources that can be used<br />
to address health, social, and economic concerns relevant to<br />
rheumatology researchers.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• list secondary data resources<br />
• describe the types <strong>of</strong> research questions for which secondary<br />
data analysis is well suited<br />
• identify strengths and limitations <strong>of</strong> using secondary data<br />
B402<br />
Rheumatic Disease Update: Osteoarthritis <strong>of</strong> the Spine<br />
c/r PM<br />
Moderator: Kimberly F. Kimpton, PT; Centennial, CO<br />
Speaker: Rajiv K. Dixit, MD; Northern California Arthritis Center;<br />
Walnut Creek, CA<br />
Session Overview:<br />
Degenerative disorders in the spine are normal, age-related<br />
phenomena and largely asymptomatic in most cases, yet they<br />
are a major source <strong>of</strong> work disability and cause billions <strong>of</strong> dollars<br />
in lost productivity annually. Lumbar and cervical spondylosis<br />
also forms one <strong>of</strong> the most common consults in clinical practice<br />
for rheumatology pr<strong>of</strong>essionals. Conservative management <strong>of</strong><br />
lumbar and cervical spondylosis is the mainstay <strong>of</strong> treatment,<br />
and surgical intervention can be considered an appropriate and<br />
viable option only when conservative measures have failed.<br />
Although current standards in the surgical management <strong>of</strong><br />
lumbar and cervical degenerative disorders include discectomy,<br />
neural decompression, and instrumented spinal arthrodesis,<br />
new approaches that address this <strong>of</strong>ten-challenging clinical<br />
entity are on the horizon. <strong>Rheumatology</strong> pr<strong>of</strong>essionals should be<br />
Thomas J. Murphy Ballroom<br />
Controversies in Osteoporosis and Low Bone Mass:<br />
Who Do We Treat, For How Long, and at What Risks?<br />
C PS<br />
Moderators: Thomas P. Olenginski, MD; Geisinger Medical<br />
Center; Danville, PA<br />
John R.P. Tesser, MD; Arizona Arthritis <strong>Rheumatology</strong><br />
Association; Paradise Valley, AZ<br />
11:00 am<br />
Who Should We Currently Target for Treatment and<br />
Prevention?<br />
Chad L. Deal, MD; Cleveland Clinic Foundation; Cleveland, OH<br />
11:30 am<br />
Osteoporosis Prescription Treatment: Monitoring Strategies<br />
and Treatment Duration<br />
Nelson B. Watts, MD; University <strong>of</strong> Cincinatti; Cincinatti, OH<br />
12:00 PM<br />
Potential Risks <strong>of</strong> Osteoporosis Therapies: Focus on Atypical<br />
Femoral Fractures and Osteonecrosis <strong>of</strong> the Jaw<br />
Stuart L. Silverman, MD; Cedars-Sinai Medical Center, University<br />
<strong>of</strong> California-Los Angeles; Beverly Hills, CA<br />
Session Overview:<br />
Currently, there are seven FDA-approved medications to reduce<br />
osteoporosis fracture risks. In February 2008, the National<br />
Osteoporosis Foundation published an Updated Clinician’s Guide<br />
to the Prevention and Treatment <strong>of</strong> Osteoporosis. Along with<br />
this, the World Health Organization formulated an absolute<br />
fracture risk predictive methodology, which each country<br />
individually applies. Despite this new consensus on treatment<br />
intervention, important unanswered questions remain<br />
concerning duration <strong>of</strong> osteoporosis therapy, whether primarily<br />
as treatment or prevention. Similarly, our patients continue to<br />
have questions and concerns regarding medication side effects<br />
and long term risks. While osteonecrosis <strong>of</strong> the jaw continues<br />
to be a concern, more recently, atypical femoral fractures have<br />
appeared in the literature and have become a topic <strong>of</strong> clinical<br />
interest.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• summarize 2008 National Osteoporosis Foundation guidelines<br />
for treatment intervention and appraise prevention strategies<br />
• apply fracture risk predictive methodology <strong>of</strong> absolute<br />
fracture risk assessment<br />
wednesday<br />
2010 Program Book 103
wednesday<br />
• appraise strategies to monitor drug treatment response<br />
• develop potential strategies where one would limit duration<br />
<strong>of</strong> prescription treatment and other strategies where one<br />
would endorse indefinite therapy, whether for treatment and/<br />
or prevention <strong>of</strong> osteoporosis<br />
• discuss concerns and possible long-term risks associated with<br />
bisphosphonate, selective estrogen receptor modulators, and<br />
anabolic therapies<br />
ACR Plenary Session III: Discovery<br />
2010 c/r<br />
11:00 am - 12:30 PM<br />
Hall A3<br />
Moderators: Carol A. Langford, MD, MHS; Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
Alisa E. Koch, MD; Unversity <strong>of</strong> Michigan; Ann Arbor, MI<br />
11:00 am<br />
Introductory Talk<br />
Daniel E. Furst, MD; University <strong>of</strong> California-Los Angeles Medical<br />
School; Los Angeles, CA<br />
11:15 am<br />
2084. Rates <strong>of</strong> Malignancy Associated with Juvenile Idiopathic<br />
Arthritis and Its Treatment: An Observational Study <strong>of</strong> National<br />
U.S. Medicaid Administrative Claims Data.<br />
Timothy Beukelman 4 , Kevin Haynes 2 , Jeffrey R. Curtis 3 , Fenglong<br />
Xie 1 , Lang Chen 1 , Elizabeth Delzell 1 , Hopiy Kim 2 , Kenneth G. Saag 5<br />
and James D. Lewis 2 , 1 Univ <strong>of</strong> Alabama at Birmingham, 2 Univ <strong>of</strong><br />
Pennsylvania, 3 University <strong>of</strong> Alabama - Brimingham, Birmingham,<br />
AL, 4 University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />
5<br />
University <strong>of</strong> Alabama-Birmingham, Birmingham, AL<br />
11:30 am<br />
2085. Aspreva Lupus Management Study (ALMS): Maintenance<br />
Results.<br />
Ellen M. Ginzler 4 , Gerald B. Appel 1 , Mary Anne Dooley 7 , David<br />
A. Isenberg 5 , David Jayne 3 , David W<strong>of</strong>sy 6 , Neil Solomons 8 ,<br />
Laura Lisk 9 and David R. Close 2 , 1 Columbia University, New<br />
York, 2 MedImmune Ltd, 3 Renal Unit, Addenbrooke’s Hospital,<br />
Cambridge, United Kingdom, 4 SUNY-Downstate Medical Center,<br />
Brooklyn, NY, 5 University <strong>College</strong> London, London, United<br />
Kingdom, 6 University <strong>of</strong> California, San Francisco, San Francisco,<br />
CA, 7 University <strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC,<br />
8<br />
Vifor Pharma (formerly Aspreva Pharmaceuticals), BC, Canada,<br />
9<br />
Vifor Pharma, UK, Bagshot, Surrey, United Kingdom<br />
11:45 am<br />
2086. Efficacy <strong>of</strong> Tadalafil in Raynaud’s Phenomenon Secondary<br />
to Systemic Sclerosis: A Double Blind Randomized Placebo<br />
Controlled Parallel Group Multicentric Study.<br />
Vikas Agarwal 8 , Parasar Ghosh 6 , Aman Sharma 7 , Darshan Singh<br />
Bhakuni 5 , Sudeep Kumar 1 , Upendra Narayan Singh 1 , Rajesh<br />
Vijayvergiya 3 , Mukesh Kumar Yadav 4 , Geetabali Devi Laishram 2 ,<br />
Alakendu Ghosh 2 , Bhuban Majhi 2 , Dipankar Mukherjee, S.<br />
S. Islam and Aditya Kapoor, 1 Lucknow, India, 2 Kolkata, India,<br />
3<br />
Chandigarh, India, 4 Chandigarh, India, 5 Army Hospital Research<br />
& Refferal, New Delhi, India, 6 IPGMER, Kolkata, 7 PGIMER,<br />
Chandigarh, India, 8 SGPGIMS, Lucknow, UP, India<br />
12:00 pm<br />
2087. Efficacy <strong>of</strong> Canakinumab (ACZ885), a Fully Human Anti-<br />
Interleukin (IL)-1beta Monoclonal Antibody, in the Prevention<br />
<strong>of</strong> Flares in Gout Patients Initiating Allopurinol Therapy.<br />
Naomi Schlesinger 8 , Hsiao-Yi Lin 7 , Marc De Meulemeester 6 ,<br />
Evgeny L. Nasonov 2 , Jozef Rovensky 4 , Eduardo F. Mysler 5 ,<br />
Udayasankar Arulmani 3 , Gerhard Krammer 3 , Alison Balfour 3 ,<br />
Dominik Richard 3 , Peter Sallstig 3 and Alexander K. So 1 , 1 CHUV<br />
Vaudois, Lausanne, Switzerland, 2 Institue <strong>of</strong> <strong>Rheumatology</strong><br />
RAMS, Moscow, Russian Federation, 3 Novartis Pharma AG, Basel,<br />
Switzerland, 4 NURCH, Piestany, Slovakia, 5 OMI Organizacion<br />
Medica de Investigacion, Buenos Aires, Argentina, 6 Private<br />
Practice, Gozée, Belgium, 7 Taipei Veterans General Hospital,<br />
Taipei, 8 UMDNJ-Robert Wood Johnson Medical School, New<br />
Brunswick, NJ<br />
12:15 PM<br />
2088. Effects <strong>of</strong> Urate Lowering Therapy on Cardiovascular<br />
Mortality: A Taiwanese Cohort Study.<br />
Jiunn-Horng Chen 1 and Wen-Harn Pan 2 , 1 China Medical<br />
University, Taichung City, Taichung, Taiwan, 2 Institute <strong>of</strong><br />
Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Province<br />
<strong>of</strong> China<br />
ACR Practice Issues<br />
Noon - 1:00 PM<br />
B313<br />
The Ideal <strong>Rheumatology</strong> Practice BR C PS<br />
Moderator: Michael J. Maricic, MD; Catalina Pointe<br />
<strong>Rheumatology</strong>; Tucson, AZ<br />
12:00 PM<br />
Small, Single Specialty <strong>Rheumatology</strong> Practice<br />
David J. Ridley, MD; St. Paul Rheumatoloy PA; Eagan, MN<br />
12:20 PM<br />
Large, Single-Specialty <strong>Rheumatology</strong> Practice<br />
Herbert Baraf, MD; Arthritis & Rheumatism Association;<br />
Wheaton, MD<br />
12:40 PM<br />
Multi-Specialty <strong>Rheumatology</strong> Practice<br />
Carmen Perez-Masuelli, MD; Northwest Diagnostic; Houston, TX<br />
Session Overview:<br />
During the past 50 years, private practitioners have witnessed<br />
many substantial changes to the US health care system<br />
and have been pressured to change the way they practice<br />
medicine. What can be done to return the locus <strong>of</strong> control to<br />
rheumatology practices and ensure adequate compensation<br />
for work? Rheumatologists will have to redesign their practices<br />
to optimize efficiency and show that they can not only deliver<br />
superb care but also lower the total cost <strong>of</strong> health care. The<br />
“ideal medical practice” model can move us closer to this goal.<br />
Rheumatologists need to know what it takes to manage a<br />
practice in today’s financially challenged economy. To reach the<br />
ideal practice, physicians can learn from each other better than<br />
any text book.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify practical strategies that can be incorporated into a<br />
rheumatology practice for efficiency<br />
104<br />
2010 Program Book
• identify the aspects for day-to-day management <strong>of</strong> a practice<br />
• describe the process and benefits for establishing a<br />
compliance program<br />
ARHP Special Sessions<br />
Noon - 1:00 PM<br />
The ARHP is <strong>of</strong>fering informal networking opportunities for<br />
rheumatology health pr<strong>of</strong>essional disciplines and students. These<br />
networking opportunities, led by facilitators, will allow open<br />
discussion and interaction with fellow attendees. Bring your<br />
lunch and join a group.<br />
B311<br />
ARHP Occupational and Physical Therapy<br />
Networking<br />
Facilitators: Linda C. Li, BSc (PT) MSc PhD; University <strong>of</strong> British<br />
Columbia; Vancouver, BC, Canada<br />
Jan K. Richardson; PT, PhD, Duke University Medical<br />
Center,Durham, NC<br />
B310<br />
ARHP Office Nurse Networking<br />
Facilitator: Marilee K. Phillips, RN; Louisville, KY<br />
B208<br />
Antiphospholipid Syndrome (072) f PS<br />
Speaker: Doruk Erkan, MD; Hospital for Special Surgery; New<br />
York, NY<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the spectrum <strong>of</strong> antiphospholipid syndrome<br />
• determine the diagnostic utility <strong>of</strong> antiphospholipid antibody<br />
tests<br />
• describe the controversial aspects <strong>of</strong> primary and secondary<br />
thrombosis prevention in antiphospholipid syndrome<br />
• discuss the management <strong>of</strong> catastrophic antiphospholipid<br />
syndrome patients<br />
B209<br />
Basic Immunology for Clinical Rheumatologists (073)<br />
f<br />
Speaker: David M. Lee, MD, PhD; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe how the immune system functions in normal<br />
individuals<br />
• identify abnormalities <strong>of</strong> immune regulation that lead to<br />
autoimmunity<br />
InnoVAtion Theater<br />
12:15 - 1:00 PM<br />
Halls A1 & A2 (Booth #555)<br />
The following non-CME activity has been planned and will be<br />
implemented in accordance with the requirements <strong>of</strong> the FDA<br />
and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />
with Healthcare Pr<strong>of</strong>essionals by Pfizer Inc. Please visit the Pfizer<br />
Inc. exhibit booth for more information or see page 292. Seating<br />
and boxed lunches are subject to availability.<br />
New Insights into the Role <strong>of</strong> the JAK Pathways in<br />
Rheumatoid Arthritis<br />
ACR Meet the Pr<strong>of</strong>essor Sessions<br />
12:45 - 2:15 PM<br />
Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />
separate registration and ticket. To verify which session you<br />
registered for, check to make sure the registration code on your<br />
ticket matches the code listed below in parentheses.<br />
B207<br />
Ankylosing Spondylitis: 2010 Update (071) PS<br />
Speaker: Desiree M. Van Der Heijde, MD, PhD; Leiden University<br />
Medical Center; Meerssen, The Netherlands<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the natural history <strong>of</strong> ankylosing spondylitis and its<br />
early diagnosis<br />
• describe clinical and radiographic outcome measures used in<br />
ankylosing spondylitis trials<br />
• summarize available guidelines in the management <strong>of</strong><br />
ankylosing spondylitis<br />
• review the scientific data on biologic agents as possible<br />
disease modifying agents in the treatment <strong>of</strong> ankylosing<br />
spondylitis<br />
B210<br />
Myopathy: Issues in Diagnosis and Treatment (074)<br />
Speaker: Mark F. Gourley, MD; NIAMS; Bethesda, MD<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• distinguish inflammatory myopathies from other muscles<br />
diseases<br />
• plan a diagnostic work-up for a patient with signs and<br />
symptoms <strong>of</strong> muscle disease<br />
• design a treatment program for a patient with myositis<br />
B301<br />
Osteoarthritis: Update 2010 (075)<br />
Speaker: Richard F. Loeser, MD; Wake Forest University;<br />
Winston-Salem, NC<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the potential causes and exacerbating factors <strong>of</strong> the<br />
disease<br />
• discuss the appropriate use <strong>of</strong> laboratory testing and imaging<br />
modalities<br />
• design an efficacious, safe and cost-effective therapeutic<br />
strategy<br />
B302<br />
Raynaud’s and Digital Ischemia (076)<br />
Speaker: Janet E. Pope, MD, MPH; St. Joseph Health Care<br />
London; London, ON, Canada<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the pathogenesis<br />
• describe the appropriate diagnostic evaluation for this<br />
condition<br />
• review treatment options and means <strong>of</strong> evaluating treatment<br />
2010 Program Book 105<br />
wednesday
B303<br />
Rheumatoid Arthritis: Challenging Cases (077)<br />
Speaker: Edward C. Keystone, MD; University <strong>of</strong> Toronto;<br />
Toronto, ON, Canada<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss management <strong>of</strong> patients with refractory rheumatoid<br />
arthritis<br />
• identify novel treatment options for those failing conventional<br />
therapies<br />
B304<br />
Scleroderma: Systemic Sclerosis (078) f PM<br />
Speaker: Michael R. York, MD; Boston University Medical Center;<br />
Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the classification <strong>of</strong> systemic sclerosis and its impact<br />
on treatment and prognosis<br />
• apply cardiopulmonary testing to determine the relative<br />
contributions <strong>of</strong> alveolitis, fibrosis and vasculopathy<br />
• formulate a therapeutic regimen to improve quality <strong>of</strong> life and<br />
organ-specific symptomatology<br />
Speakers: Stanley B. Cohen, MD; <strong>Rheumatology</strong> Associates;<br />
Dallas, TX<br />
David G. Borenstein, MD; Arthritis & Rheumatism Association;<br />
Washington, DC<br />
James R. O’Dell, MD; University <strong>of</strong> Nebraska Medical Center;<br />
Omaha, NE<br />
Audrey B. Uknis, MD; Temple University School <strong>of</strong> Medicine;<br />
Philadelphia, PA<br />
E. William St.Clair, MD; Duke University Medical Center; Durham,<br />
NC<br />
David I. Daikh, MD, PhD; University <strong>of</strong> California, San Francisco,<br />
Veterans Affairs Medical Center; San Francisco, CA<br />
Session Overview:<br />
The leadership town hall meeting will provide an open forum for<br />
members to discuss issues <strong>of</strong> importance to them directly with<br />
ACR leadership.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• have direct contact with ACR leadership to ask questions and<br />
voice concerns<br />
• have a better understanding about ACR initiatives and what<br />
the ACR is doing to address various practice and other issues<br />
wednesday<br />
106<br />
B305<br />
Systemic Lupus Erythematosus: Central Nervous<br />
System (079)<br />
Speaker: F. Jorge Sanchez-Guerrero, MD; Instituto Nacional<br />
Nutricion; Mexico City, DF, Mexico<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify manifestations <strong>of</strong> central nervous system lupus<br />
• select appropriate diagnostic tests in patients with central<br />
nervous system lupus<br />
• formulate a treatment plan<br />
B306<br />
Systemic Lupus Erythematosus: Novel Treatments<br />
(080) f PS<br />
Speaker: Ellen M. Ginzler, MD, MPH; SUNY-Downstate Medical<br />
Center; Brooklyn, NY<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• determine the <strong>of</strong>f-label use <strong>of</strong> commercially available agents<br />
for features <strong>of</strong> systemic lupus erythematosus<br />
• discuss investigational therapies for systemic lupus<br />
erythematosus<br />
• identify potential risks <strong>of</strong> new therapies for systemic lupus<br />
erythematosus<br />
• identify host factors which may influence response to new<br />
therapies<br />
ACR Special SessionS<br />
12:45 - 4:00 PM<br />
Thomas J. Murphy Ballroom<br />
This session is not eligible for CME credit.<br />
12:45 PM<br />
ACR Leadership Town Hall Meeting<br />
Moderator: Stanley B. Cohen, MD; <strong>Rheumatology</strong> Associates;<br />
Dallas, TX<br />
2010 Program Book<br />
2:00 PM<br />
Business Meeting<br />
2:30 pm<br />
ACR Late-breaking Abstract Presentation<br />
Moderator: Brian F. Mandell, MD, PhD; The Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
ACR Clinical Symposium<br />
1:00 - 2:00 PM<br />
Sidney J. Marcus Auditorium<br />
Clinical Review: Osteoporosis Therapeutics:<br />
ACR Glucocorticorticoid-induced Osteoporosis<br />
Recommendations and Therapy Update cP P/C PS<br />
Moderator: Thomas P. Olenginski, MD; Geisinger Medical<br />
Center; Danville, PA<br />
1:00 PM<br />
Treatment <strong>of</strong> Glucocorticoid-induced Osteoporosis: The New<br />
Guidelines<br />
Jennifer M. Grossman, MD; University <strong>of</strong> California Los Angeles;<br />
Sherman Oaks, CA<br />
Session Overview:<br />
Glucocorticoid-induced osteoporosis represents the most<br />
common cause <strong>of</strong> drug-induced osteoporosis. Glucocorticoidinduced<br />
osteoporosis is extremely relevant and pertinent to our<br />
daily practices. In 2010, updated ACR GIOP Recommendations<br />
were published and our FDA-approved glucocorticoid-induced<br />
osteoporosis treatment arsenal has expanded. This session<br />
will highlight the ACR GIOP Recommendations, <strong>of</strong>fer a concise<br />
treatment update, and introduce potential new agents in<br />
development.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• summarize new ACR Glucocorticoid-induced Osteoporosis<br />
Recommendations<br />
• appraise currently available osteoporosis treatments<br />
• discuss emerging therapeutic agents in development
ACR Study Groups<br />
1:00 - 2:00 PM<br />
B309<br />
Capillaroscopy in Rheumatic Diseases<br />
Moderators: Maurizio E. Cutolo, MD; University <strong>of</strong> Genova;<br />
Genova, Italy<br />
Ariane L. Herrick, MD; Rheumatic Diseases Centre; Trust Salford,<br />
United Kingdom<br />
1:00 PM<br />
Introduction with Brief History <strong>of</strong> Capillaroscopy<br />
Maurizio E. Cutolo, MD; University <strong>of</strong> Genova; Genova, Italy<br />
1:05 PM<br />
The Technique <strong>of</strong> Videocapillaroscopy<br />
Alberto Sulli, MD; University <strong>of</strong> Genoa, Italy<br />
1:20 PM<br />
Quantification <strong>of</strong> Microcirculatory Abnormalities using<br />
Capillaroscopy<br />
Ariane L. Herrick, MD; Rheumatic Diseases Centre; Trust Salford,<br />
United Kingdom<br />
1:30 PM<br />
Capillaroscopic Patterns: From Normal to Pathologic<br />
Maurizio E. Cutolo, MD; University <strong>of</strong> Genova; Genova, Italy<br />
1:40 PM<br />
Discussion<br />
1:45 PM<br />
Practical ‘Live’ Demonstration <strong>of</strong> Videocapillaroscopy<br />
Ariane L. Herrick, MD; Rheumatic Diseases Centre; Trust Salford,<br />
United Kingdom<br />
Maurizio E. Cutolo, MD; University <strong>of</strong> Genova; Genova, Italy<br />
Session Overview:<br />
Nailfold capillaroscopy provides a unique and noninvasive/<br />
safe window into the microcirculation, and abnormal nailfold<br />
capillaries are highly predictive <strong>of</strong> an underlying connective<br />
tissue disorder. Typical changes include widened capillaries<br />
and areas <strong>of</strong> avascularity. Recent advances in capillaroscopy,<br />
including videocapillaroscopy (which allows high magnification)<br />
and computerised s<strong>of</strong>tware, are revitalizing interest in<br />
capillaroscopy amongst rheumatologists. The ability to<br />
quantify abnormality means that capillaroscopy has the<br />
potential <strong>of</strong> becoming an early diagnostic tool and biomarker<br />
in scleroderma-spectrum disorders. A study group will inform<br />
attendees <strong>of</strong> these advances and stimulate the international<br />
dialogue necessary to standardize techniques and further<br />
broaden their clinical application.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss advantages and disadvantages <strong>of</strong> different<br />
capillaroscopy methods (dermoscopy, widefield<br />
capillaroscopy, videocapillaroscopy)<br />
• describe major capillaroscopic abnormalities suggestive <strong>of</strong> a<br />
scleroderma-spectrum disorder and score them<br />
• identify current and future clinical and research applications<br />
B308<br />
Childhood Vasculitis<br />
Moderators: Susanne M. Benseler, MD, PhD; The Hospital for<br />
Sick Children; Toronto, ON, Canada<br />
David A. Cabral, MBBS; British Columbia Children’s Hospital;<br />
Vancouver, BC, Canada<br />
1:00 PM<br />
Novel Approaches to Classifying Systemic Childhood Vasculitis<br />
David A. Cabral, MBBS; BC Children’s Hospital; Vancouver, BC,<br />
Canada<br />
1:15 PM<br />
Novel Biomarkers <strong>of</strong> Childhood Vasculitis<br />
Paul Brogan, BSc, MBCHB, PhD; <strong>Rheumatology</strong> Unit, Institute <strong>of</strong><br />
Child Health; London<br />
1:30 PM<br />
Disease Activity in Childhood Vasculitis<br />
Pavla Dolezalova, MD; 1st Faculty <strong>of</strong> Medicine and General<br />
Faculty Hospital; Praha, Czech Republic<br />
1:45 PM<br />
Measurement and Study Conduct in Childhood Vasculitis<br />
Raashid Luqmani, DM; Nuffield Department <strong>of</strong> Orthopaedics,<br />
<strong>Rheumatology</strong> and Musculoskeletal Sciences; Oxford, United<br />
Kingdom<br />
Session Overview:<br />
Successful international collaboration and the development<br />
<strong>of</strong> innovative, web-based data collection tools have recently<br />
advanced the field <strong>of</strong> childhood vasculitis. The international<br />
pediatric vasculitis investigator network was established,<br />
which is currently conducting important studies aiming to<br />
enhance disease recognition, validate classification proposals,<br />
develop and validate measures <strong>of</strong> disease activity and damage,<br />
standardize treatment protocols and ultimately improve the<br />
outcome <strong>of</strong> children with vasculitis worldwide. The study group<br />
application aims to formalize the strong association <strong>of</strong> the<br />
investigators with the ACR. The focus <strong>of</strong> the first study group<br />
session is classification and diagnostic challenges <strong>of</strong> childhood<br />
vasculitis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• recognize distinct entities in the spectrum <strong>of</strong> childhood<br />
vasculitis<br />
• classify pediatric vasculitis patients based on the newly<br />
validated classification system<br />
• identify novel biomarkers <strong>of</strong> childhood vasculitis<br />
• assess disease activity <strong>of</strong> pediatric vasculitis patients using the<br />
novel PVAS tool<br />
B311<br />
Clinical Research Methodology<br />
Moderator: Theodore Pincus, MD; New York University Hospital<br />
for Joint Disease; Hastings-on-Hudson, NY<br />
1:00 PM<br />
Improved Outcome Criteria for Rheumatic Diseases: The Role<br />
<strong>of</strong> IRT and CAT<br />
James F. Fries, MD; Stanford University Medical Center; Palo<br />
Alto, CA<br />
1:20 PM<br />
Diagnostic Criteria for Rheumatoid Arthritis - The New and The<br />
Old<br />
Yusuf Yazici, MD; Hospital for Joint Diseases; Hastings on<br />
Hudson, NY<br />
2010 Program Book 107<br />
wednesday
wednesday<br />
108<br />
1:40 PM<br />
Diagnosis is Classification <strong>of</strong> the Individual Patient - The Behçet<br />
Experience<br />
Hasan Yazici, MD; Cerrahpasa Medical Faculty; Istanbul, Turkey<br />
Session Overview:<br />
Recent changes to diagnostic criteria for rheumatoid arthritis will<br />
have an impact on how RCT and clinical research is conducted.<br />
We believe a forum where the impact <strong>of</strong> these changes and<br />
their every day rheumatology care applicability can be discussed<br />
would be <strong>of</strong> interest to the ACR membership.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss and compare new and old diagnostic criteria for RA<br />
• differentiate between diagnostic and classification criteria for<br />
rheumatologic conditions<br />
• explain real world application <strong>of</strong> the new criteria<br />
A412<br />
Crystalline Arthropathy<br />
Moderators: N. Lawrence Edwards, MD; University <strong>of</strong> Florida;<br />
Gainesville, FL<br />
Lan X. Chen, MD, PhD; Pennsylvania Presbyterian Medical<br />
Center; Blue Bell, PA<br />
1:00 PM<br />
Update on Renal Handling <strong>of</strong> Uric Acid and Mechanisms <strong>of</strong><br />
Hyperuricemia<br />
David Mount, MD, PhD; Brigham and Women’s Hospital; Boston,<br />
MA<br />
1:30 PM<br />
The Genetics <strong>of</strong> Hyperuricemia<br />
Anthony M. Reginato, PhD, MD; University Medicine Foundation,<br />
Rhode Island Hospital; Providence, RI<br />
Session Overview:<br />
The intense recent interest in gout and other medical conditions<br />
associated with hyperuricemia is evident by the marked increase<br />
in abstract submissions on these topics and the number <strong>of</strong> goutrelated<br />
symposia at ACR Annual meetings. The explosion <strong>of</strong> new<br />
science in these areas requires venues like the study group to<br />
foster discussion.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe new developments in the mechanisms <strong>of</strong> renal<br />
handling <strong>of</strong> uric acid<br />
• identify how these newly recognized transporters participate<br />
in disease states and their role pharmacologic interventions<br />
• recognize newly discovered genetic mechanisms <strong>of</strong><br />
hyperuricemia<br />
• discuss how genetics may help dictate individualized therapy<br />
in gout<br />
A411<br />
Hypermobility<br />
Moderators: Rodney Grahame, MD; University <strong>College</strong> Hospital;<br />
London, United Kingdom<br />
Jaime F. Bravo, MD; Nuestra Sra de Los Angeles; Santiago, Chile<br />
1:00 PM<br />
Genetic Approaches to the Dissection <strong>of</strong> Hypermobility<br />
Syndromes<br />
Peter H. Byers, MD; University <strong>of</strong> Washington; Seattle, WA<br />
2010 Program Book<br />
1:15 PM<br />
Why is Joint Hypermobility Syndrome So Frequently Missed?<br />
Rodney Grahame, MD; University <strong>College</strong> Hospital; London,<br />
United Kingdom<br />
1:30 PM<br />
Medical Treatment <strong>of</strong> Joint Hypermobility Syndrome<br />
Alan Hakim, MD; Whipps Cross University Hospital; London,<br />
United Kingdom<br />
1:45 PM<br />
Key Points in the Physical Therapy <strong>of</strong> Patients with Joint<br />
Hypermobility Syndrome<br />
Jane Simmonds, MCSP, MMACP; University <strong>of</strong> Herfordshire;<br />
Herfordshire, United Kingdom<br />
Session Overview:<br />
As rheumatologists become more aware <strong>of</strong> the high prevalence<br />
<strong>of</strong> hypermobility syndromes and as patients have higher<br />
expectations for diagnosis and treatment <strong>of</strong> these conditions,<br />
there is a greater need for rheumatologists and other health<br />
pr<strong>of</strong>essionals in rheumatology to equip themselves with<br />
knowledge about the scientific basis, the clinical presentation,<br />
treatment and natural history <strong>of</strong> these conditions, subject<br />
matter that in not widely available in training programs.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the genetic basis for the heritable disorders <strong>of</strong><br />
connective tissue<br />
• appreciate the pitfalls in the diagnosis <strong>of</strong> hypermobility<br />
syndromes and how a sound knowledge <strong>of</strong> the clinical<br />
classification and diagnostic criteria, combined with an<br />
understanding <strong>of</strong> the value <strong>of</strong> genetic testing can lead to<br />
precise diagnosis<br />
• cite the principles on which rational medical therapies are<br />
based<br />
• identify the role <strong>of</strong> physical therapy in the management <strong>of</strong><br />
hypermobility syndromes<br />
B310<br />
Imaging<br />
Moderators: Nikolay Tzaribachev, MD; Center for Rheumatic<br />
Diseases; Bad Bramstedt, Germany<br />
Johannes Roth, MD; Children’s Hospital Eastern Ontario; Ottawa,<br />
ON, Canada<br />
1:00 PM<br />
Advantages <strong>of</strong> Ultrasonography in Patients with RA and<br />
Implications in JIA<br />
Marina Backhaus, MD; University Medicine Berlin: Campus<br />
Charité Mitte; Berlin, Germany<br />
1:15 PM<br />
Clinical vs. Ultrasound Synovitis in Patients with JIA<br />
Silvia Magni-Manzoni, MD; Clinica Pediatrica; Pavia, Italy<br />
1:30 PM<br />
MRI Characteristics in Patients with JIA<br />
Marion A.J. van Rossum, MD, PhD; Emma Children’s Hospital;<br />
Amstrerdam, Netherlands<br />
1:45 PM<br />
The Silent Arthritis Concept - MRI Monitoring for Subclinical<br />
Arthritis<br />
Nikolay Tzaribachev, MD; Center for Rheumatic Diseases; Bad<br />
Bramstedt, Germany
Session Overview:<br />
Ultrasound and magnetic resonance imaging are sensitive<br />
imaging tools to define the degree <strong>of</strong> arthritis in patients with<br />
juvenile idiopathic arthritis. Data from adult patients with<br />
rheumatoid arthritis point to the importance <strong>of</strong> ultrasound and<br />
MRI for early diagnosis and therapeutic monitoring. In JIA both<br />
ultrasound and MRI criteria for arthritis urgently need to be<br />
defined and implemented in the remission criteria <strong>of</strong> JIA since<br />
the disease tends to progress silently in a group <strong>of</strong> patients<br />
leading to joint destruction and early arthrotic changes.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the advantages/disadvantages <strong>of</strong> ultrasound and MRI<br />
for the detection <strong>of</strong> arthritis in adults with RA and possible<br />
application in children with JIA<br />
• identify the risk <strong>of</strong> developing silent arthritis in patients with<br />
RA and children with JIA<br />
• articulate the benefits <strong>of</strong> monitoring the treatment by<br />
ultrasound/MRI in patients with RA and possible application in<br />
children with JIA<br />
• discuss the possible application <strong>of</strong> ultrasound/MRI for early<br />
diagnosis <strong>of</strong> JIA and treatment monitoring<br />
A314<br />
Interstitial Lung Diseases in the Rheumatic Diseases<br />
Moderators: Paul F. Dellaripa, MD; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Kristin B. Highland, MD; Medical University <strong>of</strong> South Carolina;<br />
Charleston, SC<br />
1:00 PM<br />
Update on OMERACT in the Rheumatic Diseases<br />
Kristine Phillips, MD, PhD; University <strong>of</strong> Michigan; Ann Arbor, MI<br />
Shikha Mittoo, MD, MHS; Univeristy <strong>of</strong> Manitoba; Winnipeg, MB,<br />
Canada<br />
Lesley Ann Saketkoo, MD, MPH; LSU Health Science Center;<br />
Highland Beach, FL<br />
1:20 PM<br />
RA and ILD: Results <strong>of</strong> Open Label Trials<br />
Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />
1:40 PM<br />
Antisynthetase Syndrome and ILD: Environmental Factors<br />
Kristin B. Highland, MD; Medical University <strong>of</strong> South Carolina;<br />
Charleston, SC<br />
Session Overview:<br />
Interstitial lung disease is a feared manifestation <strong>of</strong> a variety<br />
<strong>of</strong> rheumatic diseases. While studies and a consortium exist<br />
for ILD/scleroderma, our understanding <strong>of</strong> the natural history,<br />
pathophysiology and treatment <strong>of</strong> ILD in other rheumatic<br />
disorders such as RA and dermatomyositis is poorly understood<br />
and no such consortium exists. A study group provides a<br />
forum for collaboration for clinical investigators to enhance<br />
our knowledge <strong>of</strong> and treatment <strong>of</strong> these life threatening<br />
manifestations <strong>of</strong> rheumatic diseases. This will be our third year<br />
and already our collaboration has netted the development <strong>of</strong> an<br />
OMERACT project and one prospective study in ILD. The group<br />
has become truly multidisciplinary and growing in size and scope<br />
and we would like to maintain that momentum.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify emerging epidemiologic and genetic mechanisms in<br />
ILD associated with myositis and antisynthetase syndrome<br />
• describe progress in the area <strong>of</strong> outcomes research regarding<br />
OMERACT in ILD and the rheumatic diseases<br />
B314<br />
JAW (Juvenile Arthritis Workgroup)<br />
Moderators: Randy Q. Cron, MD, PhD; Children’s Hospital <strong>of</strong><br />
Alabama; Birmingham, AL<br />
Marinka Twilt, MD, PhD; Erasmus MC Sophia Children’s Hospital/<br />
Leiden University Medical Center; Rotterdam, Netherlands<br />
1:00 PM<br />
Prevalence and Outcome <strong>of</strong> TMJ Arthritis in JIA Subtypes<br />
Rotraud K. Saurenmann, MD; University Children’s Hospital;<br />
Zurich, Switzerland<br />
1:15 PM<br />
Imaging Modalities for Detecting TMJ Arthritis<br />
Tore Larheim, DDS, PhD; University <strong>of</strong> Oslo; Oslo, Norway<br />
1:30 PM<br />
TMJ Arthritis and Intraarticular Corticosteroid Injections<br />
Randy Q. Cron, MD, PhD; Children’s Hospital <strong>of</strong> Alabama;<br />
Birmingham, AL<br />
1:45 PM<br />
Early Orthodontic Treatment <strong>of</strong> TMJ Arthritis<br />
Volkan Ozkan, MD; University <strong>of</strong> Frankfurt; Kronberg, Germany<br />
Session Overview:<br />
Temporomandibular joint arthritis occurs in up to 87 percent <strong>of</strong><br />
the children with juvenile idiopathic arthritis, many cases are<br />
asymptomatic. Late recognition leads to condylar destruction<br />
resulting in micro-/retrognathia, facial asymmetry and early<br />
arthritic changes. Several studies have tried to define the<br />
most sensitive clinical and imaging screening tool for early<br />
detection <strong>of</strong> TMJA, but the optimal screening tool and timing<br />
remain unclear. Recently intraarticular corticosteroids and early<br />
application <strong>of</strong> orthodontic devices have shown promising results.<br />
However, optimal therapy for prevention <strong>of</strong> short and long term<br />
consequences <strong>of</strong> TMJA in JIA remains unanswered.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the risk <strong>of</strong> developing TMJ arthritis in patients with JIA<br />
• discuss the advantages/disadvantages <strong>of</strong> clinical examination<br />
and imaging modalities to detect TMJ arthritis in children with<br />
JIA<br />
• articulate the benefits <strong>of</strong> intraarticular corticosteroid injection<br />
for the treatment <strong>of</strong> TMJ arthritis in patients with JIA<br />
• articulate the benefits <strong>of</strong> early orthodontic treatment<br />
A311<br />
Musculoskeletal Ultrasound<br />
Moderator: Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong><br />
<strong>of</strong> Medicine; Ponte Vedra Beach, FL<br />
1:00 PM<br />
Use <strong>of</strong> Ultrasound in Fibrosing Diseases<br />
Eugene Y. Kissin, MD; Boston University; Boston, MA<br />
wednesday<br />
2010 Program Book 109
1:15 PM<br />
<strong>American</strong> <strong>Rheumatology</strong> Focus Group for Ultrasound<br />
Presentation<br />
Gurjit S. Kaeley, MBBS; University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine;<br />
Ponte Vedra Beach, FL<br />
1:30 PM<br />
Use <strong>of</strong> Sonography for the Evaluation <strong>of</strong> Osteoarthritis<br />
Ingrid Moller, MD; Instituto Poal de Reumatologia; Barcelona,<br />
Spain<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• cite current research regarding gene therapies for inclusion<br />
body myositis and muscular dystrophies<br />
• describe the possible future application <strong>of</strong> gene therapy to<br />
patients with myositis<br />
• describe new developments in the cutaneous pathophysiology<br />
<strong>of</strong> dermatomyositis<br />
• review new approaches to evaluation and treatment <strong>of</strong> skin<br />
findings in dermatomyositis<br />
wednesday<br />
1:45 PM<br />
Comparison <strong>of</strong> Sonographic Scoring Systems in Rheumatoid<br />
Arthritis<br />
Marina Backhaus, MD; University Medicine Berlin: Campus<br />
Charité Mitte; Berlin, Germany<br />
Session Overview:<br />
Musculoskeletal sonography is an established imaging<br />
technique in rheumatology. It allows the assessment <strong>of</strong> s<strong>of</strong>t<br />
tissue pathology, and can detect destructive joint lesions earlier<br />
than conventional radiography. It is helpful in guidance <strong>of</strong><br />
therapy and needle biopsy. It adds an invaluable diagnostic and<br />
pathologic insight into daily rheumatologic practice. The interest<br />
in musculoskeletal sonography is growing in North America.<br />
We have identified a need to present a technological update<br />
in sonography as applied to rheumatology as well as novel<br />
sonographic concepts in the evaluation <strong>of</strong> some rheumatologic<br />
disease processes.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe how sonography can be used to asses disease activity<br />
in systemic sclerosis<br />
• recount the different ultrasound scoring systems for synovitis<br />
and erosions in rheumatoid arthritis<br />
• describe the uses and limitations <strong>of</strong> sonography in the<br />
evaluation <strong>of</strong> osteoarthritis<br />
• discuss issues facing rheumatologists performing sonography<br />
such as billing, certification, and credentialing<br />
B409<br />
Myositis<br />
Moderators: Frederick W. Miller, MD, PhD; National Institute <strong>of</strong><br />
Environmental Health Sciences, NIH; Kennsington, MD<br />
Lisa G. Rider, MD; National Institute <strong>of</strong> Environmental Health<br />
Sciences; Garrett Park, MD<br />
1:00 PM<br />
Prospects for Gene Therapies in Myositis and Other<br />
Myopathies<br />
Jerry R. Mendell, MD; The Research Institute at Nationwide<br />
Children’s Hospital; Columbus, OH<br />
1:30 PM<br />
New Understandings in the Pathogenesis, Clinical Findings, and<br />
Therapy <strong>of</strong> Cutaneous Dermatomyositis<br />
Victoria P. Werth, MD; University <strong>of</strong> Pennsylvania; Philadelphia,<br />
PA<br />
Session Overview:<br />
The goal <strong>of</strong> this session is to increase attendee awareness <strong>of</strong> new<br />
advances in the pathogenesis and treatment <strong>of</strong> myositis and<br />
related myopathies. This will be a combined adult and pediatric<br />
rheumatology study group that will also be <strong>of</strong> interest to allied<br />
health pr<strong>of</strong>essionals.<br />
A402<br />
Osteoarthritis<br />
Moderator: Anna H. Plaas, PhD; Rush University; Chicago, IL<br />
1:00 PM<br />
Post-Traumatic Joint Tissue Responses Correlated with Clinical<br />
Findings <strong>of</strong> Human OA Progression<br />
Carla R. Scanzello, MD, PhD; Rush University Medical Center;<br />
Chicago, IL<br />
1:20 PM<br />
Effects <strong>of</strong> Dynamic Loading on Injured Articular Cartilage In<br />
Vitro and In Vivo<br />
Rachel M. Miller Travis, BS; Longview, TX<br />
1:40 PM<br />
Glucocorticoid Receptor Pathways as Targets for Enhancing S<strong>of</strong>t<br />
Tissue Repair in Osteoarthritic Joints<br />
Christian Stehlik, PhD; Northwestern University; Chicago, IL<br />
B408<br />
Patient Involvement - Six Years Experience - The<br />
Practical Aspects and Impact on Service<br />
Moderators: Taher Mahmud, MD, MSc; Pembury Hospital;<br />
Tunbridge Wells, United Kingdom<br />
David P. D’Cruz, MD; St. Thomas Hospital; London, United<br />
Kingdom<br />
1:00 PM<br />
Patient Feedback Experience in the UK<br />
Taher Mahmud, MD, MSc; Pembury Hospital; Tunbridge Wells,<br />
United Kingdom<br />
1:10 PM<br />
Impact on the Service<br />
Taher Mahmud, MD, MSc; Pembury Hospital; Tunbridge Wells,<br />
United Kingdom<br />
1:30 PM<br />
Patient Feedback Experience London<br />
David P. D’Cruz, MD; St. Thomas Hospital; London, United<br />
Kingdom<br />
1:40 PM<br />
Patient Feedback from Other Clinical Settings and Discussion <strong>of</strong><br />
the Patient Feedback Approaches and Experiences <strong>of</strong> Others<br />
To be announced<br />
1:50 PM<br />
Future for Patient Feedback<br />
Taher Mahmud, MD, MSc; Pembury Hospital; Tunbridge Wells,<br />
United Kingdom<br />
110<br />
2010 Program Book
Session Overview:<br />
Fifty percent <strong>of</strong> patients with long term conditions do not take<br />
their medications. Furthermore patients can have variable clinic<br />
experience. Patient feedback is valuable but is it possible to<br />
survey every patient on every health care pr<strong>of</strong>essional contact/<br />
clinic visit? This session will discuss the impact on systems<br />
improvement and effects on team productivity and well as<br />
improving patient experience.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• explain approaches to acquiring systematic patient feedback<br />
• identify issues and develop solutions<br />
• identify practical approaches to measuring patient feedback in<br />
your practice settings<br />
B313<br />
Patient Perspective on Outcomes: Patients as Partners<br />
in the Research Process<br />
Moderators: John R. Kirwan, MD; Bristol Royal Infirmary; Bristol,<br />
United Kingdom<br />
Ingemar F. Petersson, MD; Lund University Hosp; Lund, Sweden<br />
Robert Marshall, MD; University Hospitals Bristol NHS<br />
Foundation Trust; Bristol, United Kingdom<br />
Christina H. Opava, PhD; Karolinska Institutet; Huddinge, Sweden<br />
1:00 PM<br />
Introduction: Including the Patient Perspective in Outcomes by<br />
Including Patients in the Research Process<br />
Ingemar F. Petersson, MD; Lund University Hosp; Lund, Sweden<br />
1:05 PM<br />
Working With Patients at a Local Level<br />
John R. Kirwan, MD; Bristol Royal Infirmary; Bristol, United<br />
Kingdom<br />
1:15 PM<br />
Personal Experience <strong>of</strong> Patient Involvement in Priority Setting<br />
in a National Research Granting Agency<br />
Robert Marshall, MD; University Hospitals Bristol NHS<br />
Foundation Trust; Bristol, United Kingdom<br />
1:25 PM<br />
A Nationwide Program <strong>of</strong> Patient Involvement<br />
Christina H. Opava, PhD; Karolinska Institutet; Huddinge, Sweden<br />
1:35 PM<br />
Panel Discussion/Summary<br />
Ingemar F. Petersson, MD; Lund University Hosp; Lund, Sweden<br />
Session Overview:<br />
The Patient Perspective in Outcomes Research Study Group has<br />
had good support at previous meetings. Over 60 participants<br />
attended in 2009. It has contributed to furthering research in<br />
the field through dissemination <strong>of</strong> findings and discussions that<br />
led to new research initiatives. The measurement <strong>of</strong> the broader<br />
impact <strong>of</strong> arthritis has become an important issue, particularly in<br />
relation to clinical trial outcomes. There is increasing recognition<br />
that including patients directly in the process <strong>of</strong> formulating,<br />
funding, conducting and interpreting research aids in the<br />
inclusion and consideration <strong>of</strong> outcomes directly relevant to<br />
patients.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the challenges faced by patients who become<br />
partners in the research process<br />
• describe the challenges faced by researchers when they work<br />
with patient partners<br />
• identify ways in which patients have enhanced research<br />
in:research groups, research funding allocation in<br />
<strong>Rheumatology</strong> and research promotion and development in a<br />
national movement<br />
• incorporate the patient perspective through the use <strong>of</strong> patient<br />
research partners<br />
A315<br />
Rehabilitative <strong>Rheumatology</strong><br />
Moderators: Helen M. Emery, MD; Children’s Hospital & Regional<br />
Medicine; Seattle, WA<br />
J. Carter Thorne, MD; Southlake Regional Health Care;<br />
Newmarket, ON, Canada<br />
Speaker: Helen M. Emery, MD; Children’s Hospital & Regional<br />
Medicine; Seattle, WA<br />
Session Overview:<br />
This Study Group session allows attendees interested in<br />
rehabilitative rheumatology to share their ideas on how<br />
to include rehabilitation in multiple facets <strong>of</strong> the specialty<br />
including discussion on proposed educational curriculum for<br />
rheumatology trainees in rehabilitation.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• <strong>of</strong>fer input into the proposed educational curriculum for<br />
rheumatology trainees in rehabilitation<br />
• participate in the multidisciplinary mangement <strong>of</strong> rheumatic<br />
diseases<br />
A316<br />
Scleroderma-Biomarkers<br />
Moderator: Robert A. Lafyatis, MD; Boston University School <strong>of</strong><br />
Medicine; Arlington, MA<br />
1:00 PM<br />
Chemokines as Scleroderma Biomarkers<br />
Timothy R.D.J. Radstake, MD, PhD; Radboud University Nijmegen<br />
Medical Centre; Nijmegen, Netherlands<br />
1:20 PM<br />
Biomarkers <strong>of</strong> Pulmonary Hypertension<br />
Harrison Farber, MD; Boston University Medical Center; Boston,<br />
MA<br />
1:40 PM<br />
Proteomic Approaches in Scleroderma Biomarkers<br />
Sergio A. Jimenez, MD; Thomas Jefferson University;<br />
Philadelphia, PA<br />
Session Overview:<br />
Biomarkers <strong>of</strong> disease activity and progression are needed to<br />
stratify patients for treatment<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify emerging biomarkers for pulmonary hypertension<br />
• understand challenges for biomarker discovery<br />
• discuss biomarkers that predict future disease complications<br />
wednesday<br />
2010 Program Book 111
wednesday<br />
A410<br />
Takayasu’s Arteritis<br />
Moderators: Peter A. Merkel, MD, MPH; Boston University<br />
School <strong>of</strong> Medicine; West Newton, MA<br />
Rafi Haner Direskeneli, MD; Marmara Medical University School<br />
<strong>of</strong> Medicine; Istanbul, Turkey<br />
1:00 PM<br />
Takayasu’s Arteritis and Giant-Cell Arteritis - Two Diseases or<br />
Part <strong>of</strong> the Same Spectrum?<br />
Cornelia M. Weyand, MD, PhD; Stanford University School <strong>of</strong><br />
Medicine; Stanford, CA<br />
1:10 PM<br />
Disease Assessment in Takayasu’s Arteritis<br />
Rafi Haner Direskeneli, MD; Marmara Medical University School<br />
<strong>of</strong> Medicine; Istanbul, Turkey<br />
1:20 PM<br />
Treatment <strong>of</strong> Takayasu’s Arteritis<br />
Peter A. Merkel, MD, MPH; Boston University School <strong>of</strong><br />
Medicine; West Newton, MA<br />
1:30 PM<br />
Clinical Trials in Takayasu’s Arteritis<br />
Carol A. Langford, MD, MHS; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
1:40 PM<br />
Panel Discussion<br />
Session Overview:<br />
Diagnosis, disease assessment, and management <strong>of</strong> Takayasu’s<br />
Arteritis is currently dependant on limited evidence and<br />
there are no sufficiently-validated disease assessment tools<br />
or controlled drug trials. Recent data suggests that giant-cell<br />
arteritis and Takayasu’s Arteritis might both be in a spectrum<br />
<strong>of</strong> vasculitis with overlapping clinical and pathophysiologic<br />
features. There is increased world-wide interest in research<br />
into Takayasu’s Arteritis as evidenced by recent publications<br />
<strong>of</strong> large patient series, adoption <strong>of</strong> new imaging modalities,<br />
development <strong>of</strong> new disease assessment tools, and initiation<br />
<strong>of</strong> international multicenter clinical trials. Past ACR Vasculitis<br />
Study Groups have attracted large audiences <strong>of</strong> both clinical<br />
investigators and clinicians.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• recognize the similarities and differences <strong>of</strong> giant cell<br />
arteritis and Takayasu’s arteritis both clinically and<br />
pathophysiologically; discuss the impact <strong>of</strong> these data on<br />
treatment and research<br />
• review current criteria for activity/remission and damage in<br />
Takayasu’s arteritis and the challenges to disease assessment<br />
• review the clinical data on treatment <strong>of</strong> Takayasu’s arteritis<br />
and discuss the unmet medical needs in the treatment <strong>of</strong><br />
Takayasu’s arteritis<br />
• outline current clinical trials in Takayasu’s arteritis and the<br />
challenges for conducting such trials<br />
A404<br />
Teaching and Assessing Arthrocentesis<br />
Moderators: Joanne Valeriano-Marcet, MD; University <strong>of</strong> South<br />
Florida; Tampa, FL<br />
Helen E. Bateman, MD; James A. Haley Veterans Affairs Hospital,<br />
University <strong>of</strong> Southern Florida; Tampa, FL<br />
Ashley G. Sterrett, MD; James A. Haley Veterans Affairs Hospital;<br />
Tampa, FL<br />
1:00 PM<br />
Achievement and Maintenance <strong>of</strong> Procedural Competency<br />
Through a Cadaver-based Mini-procedural Evaluation Exercise<br />
(mini-PEX)<br />
Kenneth S. O’Rourke, MD; Wake Forest University School <strong>of</strong><br />
Medicine; Winston-Salem, NC<br />
1:20 PM<br />
Do or Do Not, There is No Try: Teaching Arthrocentesis and<br />
Injection Skills Using Competency<br />
Gregory C. Gardner, MD; University <strong>of</strong> Washington; Seattle, WA<br />
1:40 PM<br />
Validating Simulators - or How Hard Can it Be?<br />
Maren L. Mahowald, MD; University <strong>of</strong> Minnesota Medical<br />
School; Minneapolis, MN<br />
Session Overview:<br />
Joint injection training is a necessary part <strong>of</strong> the skills required<br />
for internal medicine residents and advanced subspecialty<br />
rheumatology fellows. Additionally the decreasing numbers <strong>of</strong><br />
rheumatology specialists will require primary care providers to<br />
perform these procedures. Prior studies in the literature support<br />
the use <strong>of</strong> joint injection training to increase comfort levels for<br />
internal medicine residents, primary care providers, and medical<br />
students in performing these procedures.The importance <strong>of</strong><br />
this study group is to increase interest and awareness in using<br />
simulation as a safe way to practice and assess competency in<br />
the necessary skills prior to injection on real patients. Further<br />
research is necessary to define the exact role and limitation <strong>of</strong><br />
simulation to teach and assess competency <strong>of</strong> arthrocentesis<br />
skillsand are hoping to raise enthusiasm for further research<br />
efforts in this area.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the importance <strong>of</strong> validating a simulator<br />
• discuss whether all <strong>of</strong> the key elements in a joint injection<br />
procedure can be measured with a simulator<br />
• learn how to assess competency in joint injection training<br />
• describe the incorporation <strong>of</strong> rubric scoring <strong>of</strong> competency<br />
into a formative assessment <strong>of</strong> procedural skills <strong>of</strong><br />
rheumatology fellows<br />
ACR Special Session<br />
1:00 - 2:30 PM<br />
A406<br />
Career Opportunities in <strong>Rheumatology</strong>: Making a<br />
Choice BR Ed. f<br />
Moderator: David D. Sherry, MD; The Children’s Hospital <strong>of</strong><br />
Philadelphia; Philadelphia, PA<br />
1:00 PM<br />
Basic Research <strong>Rheumatology</strong><br />
James N. Jarvis, MD; Oklahoma University Health Sciences;<br />
Oklahoma City, OK<br />
112<br />
2010 Program Book
1:20 PM<br />
Academic <strong>Rheumatology</strong><br />
Seth M. Berney, MD; Louisana State University; Shreveport, LA<br />
1:40 PM<br />
Private Practice<br />
Joseph Flood, MD; Musculoskeletal Medical Specialists;<br />
Columbus, OH<br />
2:00 PM<br />
Government – Food and Drug Administration<br />
To be announced<br />
Session Overview:<br />
<strong>Rheumatology</strong> fellows who are completing their fellowship<br />
training <strong>of</strong>ten need direction in making career choices.<br />
Information regarding career choices may not be available to<br />
fellows within the Division <strong>of</strong> <strong>Rheumatology</strong> in which they are<br />
training. This special session presents several speakers from<br />
different career paths in rheumatology including private practice<br />
rheumatology, academic rheumatology, basic research, and<br />
government.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• provide examples <strong>of</strong> different career choices available to<br />
young rheumatologists<br />
• discuss the pros and cons <strong>of</strong> the various career choices in<br />
rheumatology<br />
ACR Workshops<br />
1:15 - 3:15 PM<br />
Admission to each Workshop requires a separate registration<br />
and ticket. To verify which session you registered for, check to<br />
make sure the registration code on your ticket matches the code<br />
listed below in parentheses.<br />
B201<br />
Histopathology <strong>of</strong> Vasculitis (239)<br />
Speakers: Allen Burke, MD; University <strong>of</strong> Maryland Medical<br />
Center; Baltimore, MD<br />
Fabio Tavora, MD; <strong>American</strong> International Pathology<br />
Laboratories; Silver Spring, MD<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe histological features <strong>of</strong> normal blood vessels<br />
• distinguish pathologic reactions to vascular injury<br />
• identify histological features <strong>of</strong> major vasculitis syndromes<br />
B204<br />
Joint Injection Techniques (240) cP f PS<br />
Speakers: Atul A. Deodhar, MD; Oregon Health & Science<br />
University; Portland, OR<br />
Kenneth S. O’Rourke, MD; Wake Forest University School <strong>of</strong><br />
Medicine; Winston-Salem, NC<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss indications and contraindications for joint aspirations<br />
and injections<br />
• identify and avoid common mistakes in joint injection<br />
procedures<br />
• perform common joint and s<strong>of</strong>t tissue injections on upper and<br />
lower extremities<br />
B202<br />
Musculoskeletal Imaging (241) f<br />
Speaker: William Morrison, MD; Thomas Jefferson University<br />
Hospital; Philadelphia, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the potential causes and exacerbating factors <strong>of</strong> the<br />
disease<br />
• discuss the appropriate use <strong>of</strong> laboratory testing and imaging<br />
modalities<br />
• design an efficacious, safe and cost-effective therapeutic<br />
strategy<br />
ACR Basic Science Symposia<br />
2:30 - 4:00 PM<br />
B402<br />
B cell Effectors and Regulators R<br />
Moderator: Nan Shen, MD; Shanghai Ren Ji Hospital; Shanghai,<br />
China<br />
2:30 PM<br />
New Insights into B cell Tolerance<br />
Eric Meffre, PhD; Yale University School <strong>of</strong> Medicine; New<br />
Haven, CT<br />
3:00 PM<br />
Ectopic Lymphoneogenesis and Effector B cells in Target Tissue<br />
in Lupus Nephritis<br />
Marcus R. Clark, MD; University <strong>of</strong> Chicago; Chicago, IL<br />
3:30 PM<br />
Regulatory B cells in Health and Disease<br />
Claudia Mauri, PhD; University <strong>College</strong> London; London,<br />
England, United Kingdom<br />
Session Overview:<br />
B cells play a critical role in the pathogenesis <strong>of</strong> many<br />
autoimmune diseases by multiple mechanisms and are also<br />
targets <strong>of</strong> emerging therapies. In addition to pathogenic<br />
effector functions, recent data has suggested anti-inflammatory<br />
regulatory roles for B cells as well. These functions can be<br />
mediated by antibodies and multiple antibody independent<br />
mechanisms including B cell cytokine secretion and direct<br />
interaction with other immune cells. This symposium will focus<br />
on new advances in our understanding <strong>of</strong> B cell regulation and<br />
effector functions with direct application to the rheumatic<br />
diseases and emerging therapies.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• define the mechanisms by which autoreactive B cells are<br />
normally censored and how this may go awry in autoimmune<br />
disease<br />
• describe examples <strong>of</strong> B cell dysregulation in target tissue<br />
in lupus nephritis and other autoimmune diseases and the<br />
concept <strong>of</strong> ectopic lymphoneogenesis<br />
• identify the diversity <strong>of</strong> B cell subsets and function, including<br />
the ability to act in an anti-inflammatory regulatory role<br />
wednesday<br />
2010 Program Book 113
A412<br />
Cell Death: Receptors, Sensors and Inflammatory<br />
Pathways R<br />
Moderators: Keith B. Elkon, MD; University <strong>of</strong> Washington;<br />
Seattle, WA<br />
Dror Mevorach, MD; Hadassah University Hospital; Jerusalem,<br />
Israel<br />
2:30 PM<br />
TAM Receptors and Innate Immune Function<br />
Greg E. Lemke, PhD; Salk Institute; La Jolla, CA<br />
3:00 PM<br />
Intracellular Sensors <strong>of</strong> Nucleic Acids and the Regulation <strong>of</strong><br />
Innate Immunity by microRNAs<br />
Luke A. O’Neill, PhD; Trinity <strong>College</strong> Dublin; Dublin, Ireland<br />
3:30 PM<br />
Necrosis and Inflammation - Pathways Uncovered<br />
Kenneth L. Rock, MD; University <strong>of</strong> Massachusetts; Worcester,<br />
MA<br />
Session Overview:<br />
Autoimmune responses in systemic and, perhaps, some<br />
organ-specific diseases are thought to arise from stimulation<br />
by self antigen derived from dead or dying cells. Recent<br />
studies have elucidated specific cellular receptors as well as<br />
intracellular sensors that recognize distinct products <strong>of</strong> dying<br />
cells. Depending on which receptors and sensors are triggered,<br />
different patterns <strong>of</strong> cytokine are produced resulting in<br />
suppression or enhancement <strong>of</strong> immune response to self.<br />
3:30 PM<br />
New Treatments and Beyond for Acute and Chronic Gout<br />
Robert Terkeltaub, MD; VA Medical Center; San Diego, CA<br />
Session Overview:<br />
Gout is a common disease. Treatment protocols have been<br />
unchanged for many years. However, there remain patients who<br />
are difficult to treat due to co-morbidities. Further, advances in<br />
diagnosis, and new and potential therapeutic agents justify an<br />
examination <strong>of</strong> how these options can be applied currently and<br />
in the future.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• develop treatment strategies for patients with co-morbidities<br />
• explain novel diagnostic modalities in gout<br />
• assess new treatment options for gout<br />
Hall A3<br />
Rheumatoid Arthritis Treatment 2010: Traditional<br />
DMARDs, Biologic DMARDs and Newer Treatment<br />
Strategies C PM PS<br />
Moderators: Thomas P. Olenginski, MD; Geisinger Medical<br />
Center; Danville, PA<br />
John M. Davis, MD; Mayo Clinic; Rochester, MN<br />
2:30 PM<br />
Non-biologic Rheumatoid Arthritis Therapy: Traditional<br />
DMARDs<br />
James R. O’Dell, MD; University <strong>of</strong> Nebraska Medical Center;<br />
Omaha, NE<br />
wednesday<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the different effects <strong>of</strong> apoptotic and necrotic cells<br />
on immune cell function<br />
• identify which molecules are critically involved in engaging<br />
cellular responses<br />
• explain how different receptors and intracellular sensors cells<br />
trigger anti- or pro-inflammatory responses in macrophages<br />
and dendritic cells<br />
• discuss how aberrations in these pathways lead to systemic<br />
autoimmune responses<br />
ACR Clinical Symposia<br />
2:30 - 4:00 PM<br />
Sidney J. Marcus Auditorium<br />
Crystallizing Your Assessment and Treatment <strong>of</strong><br />
Difficult to Treat Gout C PM PS<br />
Moderators: Bruce I. H<strong>of</strong>fman, MD; Philadelphia, PA<br />
Naomi Schlesinger, MD; University <strong>of</strong> Medicine and Dentistry<br />
<strong>of</strong> New Jersey/Robert Wood Johnson Medical School; New<br />
Brunswick, NJ<br />
2:30 PM<br />
Treatment <strong>of</strong> Gout in the Difficult Patient-Transplant, and other<br />
Co-morbidities<br />
N. Lawrence Edwards, MD; University <strong>of</strong> Florida; Gainesville, FL<br />
3:00 PM<br />
New and Old Modalities Used to Diagnose Gout<br />
Naomi Schlesinger, MD; University <strong>of</strong> Medicine and Dentristry<br />
<strong>of</strong> New Jersery/Robert Wood Johnson Medical School; New<br />
Brunswick, NJ<br />
3:00 PM<br />
Biologic DMARD Therapy in Rheumatoid Arthritis: Applying an<br />
Expanded Arsenal<br />
Josef S. Smolen, MD; Krankenhaus Lainz; Vienna, Austria<br />
3:30 PM<br />
Newer Rheumatoid Arthritis Treatment Strategies<br />
Duncan Porter, MD; Gartnavel General Hospital; Glasgow, United<br />
Kingdom<br />
Session Overview:<br />
Since 1998, the use <strong>of</strong> new, targeted biologic therapies has<br />
revolutionized the treatment <strong>of</strong> rheumatoid arthritis. Currently,<br />
agents that inhibit the action <strong>of</strong> tumor necrosis factor alpha,<br />
IL-1, IL-6, as well as selective co-stimulatory blockade and B-cell<br />
depleting therapies are available. However, early diagnosis and<br />
use <strong>of</strong> methotrexate, sulfasalazine, or hydroxychloroquine still<br />
constitute many initial treatment strategies. In 2008, the ACR<br />
published recommendations for the use <strong>of</strong> non-biologic and<br />
biologic disease-modifying antirheumatic drugs in rheumatoid<br />
arthritis. Rheumatologists have an expanded treatment arsenal<br />
and seek to apply the best evidence to treat their patients.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• define the role and supportive evidence for non-biologic<br />
DMARD treatment in rheumatoid arthritis<br />
• appraise rheumatoid arthritis treatment goals and the current<br />
ACR treatment recommendations<br />
• assess the evidence supporting biologic DMARD therapy<br />
• review data from combination DMARD therapy<br />
• determine situations where DMARD may be tapered and/or<br />
withdrawn<br />
114<br />
2010 Program Book
ACR Concurrent Abstract Sessions<br />
2:30 - 4:00 PM<br />
A402<br />
Epidemiology and Health Services Research:<br />
Osteoarthritis<br />
Moderators: John D. FitzGerald, MD, PhD; University <strong>of</strong><br />
California-Los Angeles School <strong>of</strong> Medicine Rehabilitation; Los<br />
Angeles, CA<br />
Elena Losina, PhD; Brigham and Women’s Hospital; Boston, MA<br />
2:30 PM<br />
2090. Quality-Adjusted Life Expectancy Losses Due to<br />
Disparities in Total Knee Replacement (TKR) Offer and<br />
Acceptance Rates in African <strong>American</strong> (AA) Men and Women.<br />
Elena Losina 4 , Lisa G. Suter 6 , Alexander M. Weinstein 2 , Ilya<br />
Golovaty 2 , William M. Reichmann 3 , Sara A. Burbine 2 , Edward H.<br />
Yelin 5 and Jeffrey N. Katz 1 , 1Brigham & Womens Hosp, Boston,<br />
MA, 2 Brigham and Women’s Hospital, 3 Brigham and Women’s<br />
Hospital, Boston University, Boston, MA, 4 Brigham and Women’s<br />
Hospital, Boston University, Harvard Medical School, 5 University<br />
<strong>of</strong> California, San Francisco, CA, 6 Yale University, New Haven, CT<br />
2:45 PM<br />
2091. Age <strong>of</strong> Symptomatic Knee OA Onset: Impact on Costs and<br />
Quality <strong>of</strong> Life.<br />
Elena Losina 5 , William M. Reichmann 3 , Ilya Golovaty 2 , Edward H.<br />
Yelin6, Hanna Gerlovin 2 , Elizabeth A. Wright 2 , David J. Hunter 7 ,<br />
Daniel H. Solomon 4 and Jeffrey N. Katz 1 , 1 Brigham & Womens<br />
Hosp, Boston, MA, 2 Brigham and Women’s Hospital, 3 Brigham<br />
and Women’s Hospital, Boston University, Boston, MA, 4 Brigham<br />
and Women’s Hospital, Harvard Medical School, 5 Brigham and<br />
Womens Hospital, Boston, MA, 6 University <strong>of</strong> California, San<br />
Francisco, CA, 7 University <strong>of</strong> Sydney<br />
3:00 PM<br />
2092. Projecting Lifetime Risk <strong>of</strong> Symptomatic Knee OA<br />
and Total Knee Replacement (TKR) in Persons Sustaining<br />
a Complete Anterior Cruciate Ligament (ACL) Tear in Early<br />
Adulthood.<br />
Elena Losina 4 , Hanna Gerlovin 2 , Lisa G. Suter 7 , David J. Hunter 6 ,<br />
Sara A. Burbine 2 , William M. Reichmann 5 , Laurel Donnell-Fink 2 ,<br />
Daniel Hal Solomon 3 and Jeffrey N. Katz 1 , 1 Brigham & Womens<br />
Hosp, Boston, MA, 2 Brigham and Women’s Hospital, 3 Brigham<br />
and Womens Hospital, Boston, MA, 4 Brigham and Womens<br />
Hospital, Boston, MA, 5 Brigham and Womens Hospital, Boston<br />
University, Boston, MA, 6 University <strong>of</strong> Sydney, 7 Yale University,<br />
New Haven, CT<br />
3:15 PM<br />
2093. Validation <strong>of</strong> an Internet-Based Questionnaire for<br />
Ascertaining Cases <strong>of</strong> Hip and Knee Osteoarthritis.<br />
Charles R. Ratzlaff 2 , Jacek Kopec 2 and Mieke Koehoorn 1 ,<br />
1<br />
University <strong>of</strong> British Columbia, 2 University <strong>of</strong> British Columbia /<br />
Arthritis Research Centre <strong>of</strong> Canada<br />
3:30 PM<br />
2094. Prevalence <strong>of</strong> Symptomatic Knee and Hip OA: A<br />
Population-Based Survey in France.<br />
Francis Guillemin 4 , Anne-Christine Rat 5 , Bernard Mazières 10 ,<br />
Jacques Pouchot 6 , Liana Euller Ziegler 8 , Bruno Fautrel 11 , Patrice<br />
Fardellone 3 , Johanne Morvan 9 , Christian H. Roux 8 , Evelyne<br />
Verrouil 2 , Alain Saraux 1 , Joel Coste 7 and (the KHOALA Group),<br />
1<br />
Brest University, Brest, France, 2 C.H.U Toulouse, Toulouse,<br />
France, 3 INSERM ERI 12, C.H.U Amiens, Amiens, France,<br />
4<br />
INSERM, CIC-EC CIE6, Nancy-Université, Paul Verlaine Metz,<br />
Paris Descartes, EA 4360 Apemac, Vandoeuvre les Nancy,<br />
France, 5 INSERM, CIC-EC CIE6, Nancy-Université, Paul Verlaine<br />
Metz, Paris Descartes, EA 4360 Apemac, Nancy, France,<br />
6<br />
Nancy-Université, Paul Verlaine Metz, Paris Descartes, EA 4360<br />
Apemac, Toulouse, France, 7 Nancy-Université, Paul Verlaine<br />
Metz, Paris Descartes, EA 4360 Apemac, Paris, France, 8 Nice-<br />
University, Nice, France, 9 Quimper Hospital, Quimper, France,<br />
10<br />
Toulouse-University, Toulouse, France, 11 UPMC, C.H.U Pitie<br />
Salpetriere, Paris, France<br />
3:45 PM<br />
2095. Modifiable Predictors <strong>of</strong> Racial Differences in Gait<br />
Velocity in an Elderly Urban Cohort.<br />
Irene Blanco 2 , Joe Verghese 2 , Richard B. Lipton 2 , Chaim<br />
Putterman 1 and Carol A. Derby 2 , 1 Albert Einstein <strong>College</strong> <strong>of</strong> Med,<br />
Bronx, NY, 2 Albert Einstein <strong>College</strong> <strong>of</strong> Medicine, Bronx, NY<br />
A311<br />
Osteoarthritis - Clinical Aspects: Pain and<br />
Biomechanics<br />
Moderators: Joel A. Block, MD; Rush University Medical Center;<br />
Chicago, IL<br />
Gillian A. Hawker, MD, MSc; Women’s <strong>College</strong> Hospital; Toronto,<br />
ON, Canada<br />
2:30 PM<br />
2096. Physical Activity Assessed by Accelerometry in Persons<br />
with Knee OA Compared to National Guidelines: The<br />
Osteoarthritis Initiative (OAI).<br />
Dorothy D. Dunlop 6 , Jing Song 5 , Pamela Semanik 8 , Leena<br />
Sharma5, Rowland W. Chang 4 , Joan M. Bathon 3 , Charles Eaton 1 ,<br />
Marc C. Hochberg 11 , W. Jerry Mysiw 7 , Rebecca Jackson 7 , C.<br />
Kent Kwoh 10 , Michael C. Nevitt 9 and Jennifer M. Hootman 2 ,<br />
1<br />
Brown University, 2 Centers for Disease Control, Kennesaw, GA,<br />
3<br />
Johns Hopkins Univ Ste, Baltimore, MD, 4 Northwestern Univ,<br />
Chicago, IL, 5 Northwestern University, Chicago, IL, 6 Northwestern<br />
University Medical School, Chicago, IL, 7 Ohio State University,<br />
8<br />
Rehabilitation Institute <strong>of</strong> Chicago, Chicago, IL, 9 UCSF, San<br />
Francisco, CA, 10 Univ <strong>of</strong> Pittsburgh, Pittsburgh, PA, 11 University <strong>of</strong><br />
Maryland, Baltimore, MD<br />
2:45 PM<br />
2097. Brain Activity in Patients with Chronic Knee Pain Due to<br />
Osteoarthritis: Dissociating Evoked from Spontaneous Pain.<br />
Elle L. Parks 2 , Marwan N. Baliki 2 , Paul Y. Geha 3 , Thomas J.<br />
Schnitzer 1 and Apkar V. Apkarian 2 , 1 Northwestern University,<br />
Chicago, IL, 2 Northwestern University, 3 Yale University<br />
3:00 PM<br />
2098. Central Sensitization and Knee Pain in Osteoarthritis:<br />
Preliminary Results from the MOST Study.<br />
Tuhina Neogi 3 , Jingbo Niu 4 , Lars Arendt-Nielsen 1 , Joachim<br />
Scholz 2 , Laura Frey-Law 9 , Clifford Woolf 2 , Yuqing Zhang 4 , Larry<br />
Bradley 8 , Irina Tolstykh 7 , Michael C. Nevitt 6 and David T. Felson 5 ,<br />
1<br />
Aalborg University, Denmark, 2 Boston Childrens Hospital,<br />
3<br />
Boston Univ Schl <strong>of</strong> Med, Boston, MA, 4 Boston Univ School <strong>of</strong><br />
Medicine, Boston, MA, 5 Boston University School <strong>of</strong> Medicine,<br />
Boston, MA, 6 UCSF, San Francisco, CA, 7 UCSF, 8 University <strong>of</strong><br />
Alabama at Birmingham, 9 University <strong>of</strong> Iowa<br />
2010 Program Book 115<br />
wednesday
wednesday<br />
3:15 PM<br />
2099. Gait Adaptation after 6 Months <strong>of</strong> Specialized Shoes in<br />
Knee Osteoarthritis.<br />
Najia Shakoor 3 , Roy H. Lidtke 4 , Markus A. Wimmer 2 , Kharma C.<br />
Foucher 2 , Rachel A. Mikolaitis 2 , Louis F. Fogg 2 , Alan J. Shoelson 2<br />
and Joel A. Block 1 , 1 Rush University Medical Center, Chicago,<br />
IL, 2 Rush University Medical Center, 3 Rush-University Medical<br />
Center, Chicago, IL, 4 University <strong>of</strong> Iowa<br />
3:30 PM<br />
2100. The Role <strong>of</strong> Varus and Valgus Alignment in the Initial<br />
Development <strong>of</strong> Cartilage Damage at the Knee: The MOST<br />
Study.<br />
Leena Sharma 3 , Orit Almagor 4 , Joan S. Chmiel 4 , David T. Felson 1 ,<br />
Ali Guermazi 2 , Frank Roemer 2 , James Torner 9 , Cora E. Lewis 6 , Neil<br />
Segal 9 , John A. Lynch 8 , Derek Cooke5, Jean Hietpas 8 and Michael<br />
C. Nevitt 7 , 1 Boston University, Boston, MA, 2 Boston University,<br />
3<br />
Northwestern University, Chicago, IL, 4 Northwestern University,<br />
5<br />
Queens University, 6 UAB, 7 UCSF, San Francisco, CA, 8 UCSF,<br />
9<br />
University <strong>of</strong> Iowa<br />
3:45 PM<br />
2101. Varus Thrust Is Associated with Worse Physical Function.<br />
William F. Harvey 3 , Grace H. Lo 1 , Erica McAdams 4 , Melanie<br />
A. Ripley 4 , Melynn Nuite 3 and Timothy E. McAlindon 2 , 1 Tufts<br />
Medical Center, Houston, TX, 2 Tufts Medical Center Box 406,<br />
Boston, MA, 3 Tufts Medical Ctr, Boston, MA, 4 Tufts Medical Ctr.<br />
A314<br />
Pediatric <strong>Rheumatology</strong> - Clinical and Therapeutic<br />
Aspects-Outcomes<br />
Moderators: Daniel J. Lovell, MD, MPH; Children’s Hospital<br />
Medical Center; Cincinnati, OH<br />
Carol A. Wallace, MD; University <strong>of</strong> Washington and Seattle<br />
Childrens’s Hospital; Seattle, WA<br />
2:30 PM<br />
2102. Pediatric Rheumatic Disease in the Intensive Care Unit:<br />
Lessons Learned from 15 Years Experience in a Tertiary Care<br />
Pediatric Hospital.<br />
Suhas M. Radhakrishna 2 , Bracha Shaham 2 , Katherine A. B.<br />
Marzan 2 , Diane E. Brown 3 and Andreas O. Reiff 1 , 1 Childrens Hosp<br />
LA MS60, Los Angeles, CA, 2 Childrens Hospital <strong>of</strong> Los Angeles,<br />
Los Angeles, CA, 3 Childrens Hospital <strong>of</strong> Los Angeles<br />
2:45 PM<br />
2103. Rates <strong>of</strong> Hospitalized Bacterial Infection in Juvenile<br />
Idiopathic Arthritis and Its Treatment: An Observational Study<br />
<strong>of</strong> National U.S. Medicaid Administrative Claims Data.<br />
Timothy Beukelman 5 , Fenglong Xie 2 , Lang Chen 2 , John W.<br />
Baddley 2 , Elizabeth Delzell 2 , Carlos G. Grijalva 3 , Nivedita M.<br />
Patkar 2 , Kenneth G. Saag 2 , Kevin L. Winthrop 1 and Jeffrey R.<br />
Curtis 2 , 1 Oregon Health & Science University, 2 Univ <strong>of</strong> Alabama at<br />
Birmingham, Birmingham, AL, 3 Vanderbilt University<br />
Hospital, Foxboro, MA, 4 Brigham and Women’s Hospital,<br />
5<br />
Brigham and Womens Hospital, Boston, MA, 6 Harvard School<br />
<strong>of</strong> Public Health, Boston, MA, 7 Stanford University School <strong>of</strong><br />
Medicine, 8 University <strong>of</strong> North Carolina, Chapel Hill<br />
3:15 PM<br />
2105. The Clinical Significance <strong>of</strong> a Single MVK Mutation in<br />
HIDS.<br />
Karyl S. Barron 2 , Amanda K. Ombrello 4 , Donald P. Goldsmith 1 ,<br />
Ivona Aksentijevich 4 , Anne Jones 5 , Beverly K. Barham 6 and Daniel<br />
L. Kastner 3 , 1 Drexel Univ <strong>College</strong> Med, Philadelphia, PA, 2 NIAID/<br />
NIH, Bethesda, MD, 3 NIAMS, NIH, Bethesda, MD, 4 NIAMS/NIH,<br />
5<br />
NIH, NIAMS, Damascus, MD, 6 Ntl Inst <strong>of</strong> Arthritis & MSK SD,<br />
Bethesda, MD<br />
3:30 PM<br />
2106. Biomarkers for Global and Renal Disease Activity in<br />
Juvenile Systemic Lupus Erythematosus (jSLE).<br />
Rina Mina 4 , Michael Bennett 3 , Joseph M. Ahearn 1 , Joshua<br />
Pendl 3 , Jamie Eaton 3 , Nicole Wilson 5 , Prasad Devarajan 3 and<br />
Hermine Brunner 2 , 1 Wexford, PA, 2 Cincinnati Child Hosp Med Ctr,<br />
Cincinnati, OH, 3 Cincinnati Children’s Hospital Medical Center,<br />
4<br />
Cincinnati Children’s Med Ctr, Cincinnati, OH, 5 Univerisity <strong>of</strong><br />
Pittsburgh<br />
3:45 PM<br />
2107. Childhood Primary Angiitis <strong>of</strong> the CNS: Identifying<br />
Disease Trajectories and Early Risk Factors for Persistently<br />
Higher Disease Activity.<br />
Tania Cellucci, Pascal N. Tyrrell, Suzanne Laughlin, Derek<br />
Armstrong, William Halliday, Shehla Sheikh and Susanne M.<br />
Benseler, The Hospital for Sick Children, University <strong>of</strong> Toronto,<br />
Toronto, ON, Canada<br />
A315<br />
Quality Measures and Innovation in Practice<br />
Management and Care Delivery<br />
Moderators: J. Timothy Harrington, MD; University <strong>of</strong> Wisconsin;<br />
Madison, WI<br />
Matthew P. Bunyard, MD; Cleveland Clinic Foundation; Moreland<br />
Hills, OH<br />
2:30 PM<br />
2108. Predictive Validity <strong>of</strong> the New Preliminary ACR/EULAR<br />
Definitions for Remission in Rheumatoid Arthritis.<br />
David T. Felson 2 , Josef S. Smolen 3 , George A. Wells 5 , Bin Zhang 1 ,<br />
Lilian H. D. van Tuyl 7 , Julia Funovits 4 , Maarten Boers 6 and for the<br />
ACR/EULAR Commission To Redefine Remission in Rheumatoid<br />
Arthritis, 1 Boston Univ Schl <strong>of</strong> Medicine, Boston, MA, 2 Boston<br />
University School <strong>of</strong> Medicine, Boston, MA, 3 Krankenhaus Lainz,<br />
Vienna, Austria, 4 Medical University <strong>of</strong> Vienna, 5 Univ <strong>of</strong> Ottawa<br />
Faculty <strong>of</strong> Med, Ottawa, ON, Canada, 6 VU University Medical<br />
Center, Amsterdam, The Netherlands, 7 VU University Medical<br />
Center, Amsterdam<br />
3:00 PM<br />
2104. Outcomes <strong>of</strong> End-Stage Renal Disease Due to Lupus<br />
Nephritis among Children in the U.S., 1995-2006.<br />
Linda T. Hiraki 6 , Bing Lu 3 , M. Alan Brookhart 8 , Tamara<br />
Shaykevich 4 , Graciela S. Alarcon 1 , Daniel Hal Solomon 5 , Wolfgang<br />
Winkelmayer 7 and Karen H. Costenbader 2 , 1 Oakland, CA,<br />
2<br />
Brigham & Women, Boston, MA, 3 Brigham and Women’s<br />
2:45 PM<br />
2109. Three Physician-Assigned Global Estimates for<br />
Inflammation, Damage and Non-Inflammatory Symptoms/<br />
Fibromyalgia Help To Clarify Overall Physician Global Estimates<br />
<strong>of</strong> Status in Patients with Different Rheumatic Diseases.<br />
Martin J. Bergman 1 and Theodore Pincus 2 , 1 Arthritis and<br />
<strong>Rheumatology</strong>, Ridley Park, PA, 2 New York University Hospital for<br />
Joint Disease, Hastings-on-Hudson, NY<br />
116<br />
2010 Program Book
3:00 PM<br />
2110. Rheumatologists on the Road: A Subspecialist’s Role in<br />
Caring for the Homebound.<br />
Ruchi Jain 1 , Suma Dasari 2 , Theresa Soriano 2 , Linda DeCherrie 2<br />
and Leslie Dubin Kerr 2 , 1 Mount Sinai Medical Center, New York,<br />
NY, 2 Mount Sinai Medical Center<br />
3:15 PM<br />
2111. Validation <strong>of</strong> Electronic Audiovisual Media Assessments<br />
<strong>of</strong> Patients with Rheumatic Diseases.<br />
Sarah McNamara 1 , Lorraine O’ Neill 3 , John J. Carey 2 and Robert<br />
J. Coughlan 1 , 1 N.U.I Galway University Hospitals, Galway, Ireland,<br />
2<br />
N.U.I Galway University Hospitals, Galway, Ireland, 3 N.U.I.<br />
Galway University Hospitals, Galway, Ireland<br />
3:30 PM<br />
2112. See online itinerary builder for more information<br />
3:45 PM<br />
2113. Quality <strong>of</strong> Care in Patients with Systemic Lupus<br />
Erythematosus.<br />
Jinoos Yazdany 4 , Laura Trupin 5 , Chris Tonner 5 , Gabriela<br />
Schmajuk 3 , Joann Z. Gillis 2 , Pantelis Panopalis 1 , Laura J. Julian 5 ,<br />
Lindsey A. Criswell 5 , Patricia Katz5 and Edward Yelin 5 , 1 McGill<br />
University, 2 National Jewish Medical Center, 3 Stanford University,<br />
4<br />
UCSF, San Francisco, CA, 5 UCSF<br />
B406<br />
Rheumatoid Arthritis - Human Etiology and<br />
Pathogenesis: Anti-CCP in RA Etiology and<br />
Pathogenesis II<br />
Moderators: Andrew P. Cope, MD, PhD; Surrey, United Kingdom<br />
Ulf Müller-Ladner, MD; University Giessen/Kerckh<strong>of</strong>f-Clinic; Bad<br />
Nauheim, Germany<br />
2:30 PM<br />
2114. The Gene-Environment Interaction between HLA-SE and<br />
Smoking Plays an Important Role in Shaping the Reactivity <strong>of</strong><br />
the ACPA Response to Several Citrullinated Antigens.<br />
Annemiek Willemze 2 , Diane van der Woude 3 , Wendim Ghidey<br />
Alemayehu 1 , René R. P de Vries 4 , Tom W. J. Huizinga 3 , Leendert<br />
A. Trouw 3 and René E. M Toes 3 , 1 Leiden University Medical<br />
Center, Department <strong>of</strong> Medical Statistics, 2 Leiden University<br />
Medical Center, Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden, The<br />
Netherlands, 3 Leiden University Medical Center, Department <strong>of</strong><br />
<strong>Rheumatology</strong>, 4 Leiden University Medical Center. Department<br />
<strong>of</strong> Immunohematology and Blood Transfusion<br />
2:45 PM<br />
2115. Antibodies <strong>of</strong> IgG, IgA and IgM Isotypes Against Cyclic<br />
Citrullinated Peptide Precede the Development <strong>of</strong> Rheumatoid<br />
Arthritis.<br />
Heidi Kokkonen 2 , Mohammed Mullazehi 4 , Ewa Berglin 2 ,<br />
Göran Hallmans 1 , Göran Wadell 3 , Johan Rönnelid 4 and Solbritt<br />
Rantapää-Dahlqvist 2 , 1 Department <strong>of</strong> Nutritional Research,<br />
Umeå University, Umeå, 2 Department <strong>of</strong> Public Health and<br />
Clinical Medicine/<strong>Rheumatology</strong>, Umeå University, Umeå,<br />
3<br />
Department <strong>of</strong> Virology, Umeå University, Umeå, 4 Division<br />
<strong>of</strong> Clinical Immunology, Uppsala University, Uppsala<br />
3:00 PM<br />
2116. Epitope Spreading <strong>of</strong> the Autoantibody Response in the<br />
Pre-Clinical Phase Predicts Progression to Rheumatoid Arthritis<br />
(RA).<br />
Jeremy Sokolove 2 , Reuven Bromberg 3 , Kevin D. Deane 5 , Piyanka<br />
Chandra 3 , Leslie Derber 6 , Jess D. Edison 7 , William R. Gilliland 8 , Jill<br />
Norris 5 , V. Michael Holers 4 and William Robinson 1 , 1 Stanford Univ<br />
School <strong>of</strong> Med, Stanford, CA, 2 Stanford University, Mountain<br />
View, CA, 3 Stanford University, 4 Univ <strong>of</strong> Colorado School <strong>of</strong><br />
Med, Aurora, CO, 5 University <strong>of</strong> Colorado Denver, Aurora, CO,<br />
6<br />
University <strong>of</strong> Colorado Denver, 7 Walter Reed Army Med Ctr,<br />
Washington, DC, 8 Walter Reed Army Med Ctr, Potomac, MD<br />
3:15 PM<br />
2117. Citrullinated Epitopes within the Atherosclerotic Plaque:<br />
A Target for Anti-Citrulline Protein Antibodies?<br />
Jeremy Sokolove 2 , Orr Sharpe 3 , Matthew Brennan 3 , Andrew J.<br />
Connolly 3 and William Robinson 1 , 1 Stanford Univ School <strong>of</strong> Med,<br />
Stanford, CA, 2 Stanford University, Mountain View, CA, 3 Stanford<br />
University<br />
3:30 PM<br />
2118. Risk Factors in Different Subsets <strong>of</strong> Rheumatoid Arthritis.<br />
Karin Lundberg 3 , Camilla Bengtsson 1 , Lena Israelsson 4 , Iskra<br />
Pollak-Dorocic 4 , Leonid Padyukov 4 , Lars Alfredsson 1 , Vivianne<br />
Malmström 4 and Lars Klareskog 2 , 1 Institute for Environmental<br />
Medicine, Karolinska Institutet, 2 Karolinska University Hospital,<br />
Stockholm, Sweden, 3 Reumatology Unit, Karolinska Institutet,<br />
Stockholm, Sweden, 4 Reumatology Unit, Karolinska Institutet<br />
3:45 PM<br />
2119. Anti-CCP Positivity in Patients with Lung Disease but No<br />
Apparent Articular RA: A Pre-RA State?<br />
Joshua J. Solomon 1 , Allen Stevens 1 , Mary Gill 1 , Jennifer<br />
Brandorff 1 , Jeffrey J. Swigris 1 , Kevin Deane 2 , Richard Martin 1 ,<br />
Roland M. du Bois 1 and Aryeh Fischer 1 , 1 National Jewish Health,<br />
2<br />
University <strong>of</strong> Colorado<br />
B313<br />
Systemic Lupus Erythematosus - Clinical Aspects and<br />
Treatment: SLE and Cardiovascular Disease<br />
Moderators: Christine Peschken, MD, MSc; University <strong>of</strong><br />
Manitoba; Winnipeg, MB, Canada<br />
Paola De Pablo, MD, MPH; University <strong>of</strong> Birmingham;<br />
Birmingham, United Kingdom<br />
2:30 PM<br />
2120. Prevalence <strong>of</strong> Flow Mediated Dilatation and Its<br />
Association with Framingham Risk Score in a Population <strong>of</strong><br />
Women with Systemic Lupus Erythematosus.<br />
Valentina Peeva 4 , Paula Harvey 3 , Jiandong Su 3 , Ellie Aghdassi 3 , Ali<br />
Al-Dhanhani 3 , Stacey Morrison 3 , Christian Pineau 2 , Janet Pope 1 ,<br />
Debbie Da Costa 2 and Paul R. Fortin 3 , 1 London, ON, Canada,<br />
2<br />
Montreal, QC, Canada, 3 Toronto, ON, Canada, 4 University Health<br />
Network, Toronto Western Hospital, Toronto, ON, Canada<br />
wednesday<br />
2010 Program Book 117
wednesday<br />
2:45 PM<br />
2121. Protection from Cardiovascular Events and Nephritis in<br />
SLE Correlates with Levels <strong>of</strong> IgM Natural Autoantibodies to<br />
Different Apoptosis-Associated Antigens.<br />
Caroline Gronwall 3 , Ehtisham Akhter 2 , Michelle A. Petri 1 and<br />
Gregg J. Silverman 3 , 1 Johns Hopkins University School <strong>of</strong><br />
Medicine, Timonium, MD, 2 Johns Hopkins University School <strong>of</strong><br />
Medicine, Baltimore, MD, 3 Univ <strong>of</strong> California San Diego, La Jolla,<br />
CA<br />
3:00 PM<br />
2122. Non-Calcified Coronary Plaque (NCP) in Systemic Lupus<br />
Erythematosus (SLE): Quantitative Analysis.<br />
Adnan N. Kiani 2 , Jens Vogel-Claussen 2 , Margaret Yew 2 , Laurence<br />
S. Magder 3 and Michelle A. Petri 1 , 1 Timonium, MD, 2 Johns<br />
Hopkins University, School <strong>of</strong> Medicine, Baltimore, MD,<br />
3<br />
University <strong>of</strong> Maryland, School <strong>of</strong> Medicine<br />
3:15 PM<br />
2123. Aspirin Response Is Impaired in Patients with Systemic<br />
Lupus Erythematosus.<br />
Vivian K. Kawai 1 , Ingrid B. Avalos 2 , Annette M. Oeser 5 , John<br />
Oates 4 , Ginger Milne 4 , Cecilia P. Chung 3 and C. Michael Stein 1 ,<br />
1<br />
Vanderbilt University, Nashville, TN, 2 Vanderbilt University,<br />
Brookline, MA, 3 Vanderbilt University, Baltimore, MD, 4 Vanderbilt<br />
University, 5 VUMC 23rd Ave South Pierce, Nashville, TN<br />
3:30 PM<br />
2124. Rates <strong>of</strong> Adverse Cardiovascular Events among SLE<br />
Patients Are Higher during Episodes <strong>of</strong> Disease Activity.<br />
Laurence S. Magder 2 and Michelle A. Petri 1 , 1 Timonium, MD,<br />
2<br />
Department <strong>of</strong> Epidemiology and Preventive Medicine,<br />
University <strong>of</strong> Maryland, School <strong>of</strong> Medicine, Baltimore, MD<br />
3:45 PM<br />
2125. Atherosclerosis Is Associated with Low 25(OH) Vitamin D<br />
Levels, Lack <strong>of</strong> Angiotensin Converting Enzyme Inhibitor Use,<br />
and Hyperlipidemia in African-<strong>American</strong> Lupus Patients.<br />
Roneka L. Ravenell 3 , Diane L. Kamen 4 , Spence David 5 , Hollis<br />
Bruce 2 , Almeida Jonas 1 and Jim C. Oates 3 , 1 Department <strong>of</strong><br />
Bioinformatics and Computational Biology, The University <strong>of</strong><br />
Texas M. D. Anderson Cancer Center, Houston, TX, 2 Department<br />
<strong>of</strong> Pediatrics, Medical University <strong>of</strong> South Carolina, Charleston,<br />
SC, 3 MUSC, Charleston, SC, 4 MUSC PO Box 250637, Charleston,<br />
SC, 5 Robarts Research Stroke Prevention and Atherosclerosis<br />
Research Centre, London, ON, Canada<br />
A410<br />
T Cell Biology and Targets in Autoimmune Disease<br />
Moderators: Jorg J. Goronzy, MD, PhD; Stanford University<br />
School <strong>of</strong> Medicine; Stanford, CA<br />
Joseph Holoshitz, MD; University <strong>of</strong> Michigan; Ann Arbor, MI<br />
2:30 PM<br />
2126. Dipyridamole Inhibits SLE T Cell Activation and Alleviates<br />
Nephritis in Lupus-Prone Mice.<br />
Vasileios C. Kyttaris, Zheng Zhang, Ourania Kampagianni and<br />
George C. Tsokos, Beth Israel Deaconess Medical Center<br />
2:45 PM<br />
2127. Defective T Cell Tolerance in Rheumatoid Arthritis Due to<br />
Increased B-Raf and K-Ras Expression.<br />
Pratima Deshpande 2 , Karnail Singh 1 , Mingcan Yu 2 , Guangjin Li 2 ,<br />
Cornelia M. Weyand 3 and Jorg J. Goronzy 3 , 1 Emory University,<br />
Atlanta, GA, 2 Stanford University, Stanford, CA, 3 Stanford<br />
University School <strong>of</strong> Medicine, Stanford, CA<br />
3:00 PM<br />
2128. SLAP Deficiency Enhances Both Number and Function <strong>of</strong><br />
FoxP3+ Regulatory T Cells and Inhibits Chronic Arthritis in SKG<br />
Mice.<br />
Lisa K. Peterson 2 , Laura A. Shaw 2 , Anthony Joetham 3 , Shimon<br />
Sakaguchi 1 , Erwin W. Gelfand 5 and Leonard Dragone 4 , 1 Kyoto<br />
University; Osaka University, 2 National Jewish Health, Denver,<br />
CO, 3 National Jewish Health, 4 National Jewish Health; University<br />
<strong>of</strong> Colorado Denver; The Children’s Hospital, Denver, CO,<br />
5<br />
National Jewish Health; University <strong>of</strong> Colorado Denver; The<br />
Children’s Hospital<br />
3:15 PM<br />
2129. The Role <strong>of</strong> BAFF in Promoting the Development <strong>of</strong> IL-17-<br />
Producing Cells and Th17-Mediated Disease.<br />
Xiaohui Zhou 2 , Julie Wang 4 , Zhongmin Liu 1 , William Stohl 3 and<br />
Song Guo Zheng 4 , 1 Tongji University Medical School, 2 Univ S Calif<br />
Keek Schl <strong>of</strong> Med, Los Angeles, CA, 3 Univ Southern California, Los<br />
Angeles, CA, 4 USC Keck School <strong>of</strong> Medicine, Los Angeles, CA<br />
3:30 PM<br />
2130. Activated Th17 Cells Drive Rheumatoid Inflammation<br />
and Are Resistant to Inhibition by Natural Antagonists <strong>of</strong> Their<br />
Development.<br />
Jan Leipe 2 , Mathias Grunke 2 , Claudia Dechant 2 , Christiane<br />
Reindl 2 , Hendrik Schulze-Koops 1 and Alla Skapenko 2 , 1 University<br />
<strong>of</strong> Munich, Munich, Germany, 2 University <strong>of</strong> Munich, Germany<br />
3:45 PM<br />
2131. Regulatory T Cell Recovery in HCV-Related Autoimmunity<br />
through IL-2 Treatment.<br />
David Saadoun 2 , Michelle Rosenzwajg 1 , Lucile Musset 1 , Fabrice<br />
Carrat 1 , David Klatzmann 1 and Patrice Cacoub 1 , 1 Internal<br />
Medicine Department, 2 Internal Medicine Department and<br />
Immunology Laboratory Pitie Salpetriere Hospital<br />
ACR/ARHP Combined Abstract<br />
Session<br />
2:30 - 4:00 PM<br />
B310<br />
ACR/ARHP Combined Orthopedics, Low Back<br />
Pain and Rehabilitation: Hips and Knees: Focus on<br />
Function<br />
Moderator: Kimberly F. Kimpton, PT; Centennial, CO<br />
2:30 PM<br />
2132. Progressive Resistance Exercise in Women with Knee<br />
Osteoarthritis.<br />
Renata Jorge 1 , Marcelo Souza 2 , Aline Chiari 2 , Anamaria Jones 2 ,<br />
Império Lombardi, Jr 2 , Artur Fernandes2 and Jamil Natour 2 ,<br />
1<br />
UNIFESP, Sao Paulo, SP, Brazil, 2 UNIFESP<br />
118<br />
2010 Program Book
2:45 PM<br />
2133. Reasons for Decline in Walking Despite Improvements in<br />
Knee Pain: The MOST Study.<br />
Daniel K. White 2 , David T. Felson 4 , Jingbo Niu 3 , Michael C.<br />
Nevitt5, C. Elizabeth Lewis 6 , James Torner 7 and Tuhina Neogi 1 ,<br />
1<br />
Boston Univ Schl <strong>of</strong> Med, Boston, MA, 2 Boston Univ School<br />
<strong>of</strong> Med, Boston, MA, 3 Boston University, Boston, MA, 4 Boston<br />
University School <strong>of</strong> Medicine, Boston, MA, 5 UCSF, San Francisco,<br />
CA, 6 University <strong>of</strong> Alabama, 7 University <strong>of</strong> Iowa<br />
3:00 PM<br />
2134. Reduction <strong>of</strong> the Foot Plantar Maximum Vertical Force<br />
Using Medial-Wedge Insoles in Valgus Knee Osteoarthritis.<br />
Priscilla Teixeira Rodrigues 2 , Rosa M. R. Pereira 2 , Julia M. D.<br />
Greve 1 and Ricardo Fuller 2 , 1 Rheabilitation Division, Faculdade de<br />
Medicina da Universidade de São Paulo, 2 <strong>Rheumatology</strong> Division,<br />
Faculdade de Medicina da Universidade de São Paulo<br />
3:15 PM<br />
2135. Functional Benefits Following Dynamic Exercise in<br />
Patients with RA Taking Anti-TNFα Therapy Reflected in Lower<br />
Limb Function Tests but Not the HAQ.<br />
Angela Reid 1 , Audrey Brady 2 , Tara Cusack 5 , Catherine Blake 5 ,<br />
Anne Barbara Mongey 3 , Douglas J. Veale 4 and Oliver FitzGerald 3 ,<br />
1<br />
Our Lady’s Hospice, Dublin, Ireland, 2 Our Lady’s Hospice, 3 St.<br />
Vincent’s University Hospital, 4 St. Vincent’s University Hospital,<br />
5<br />
University <strong>College</strong> Dublin, Ireland<br />
3:30 PM<br />
2136. Co-Morbid Pain in Hips, Low Back, and Non-Operative<br />
Knee Associated with Physical Function before and after TKR.<br />
Patricia D. Franklin 2 , Wenjun Li 2 , David C. Ayers 2 and Carol A.<br />
Oatis 1 , 1 Arcadia University, Glenside, PA, 2 Univ <strong>of</strong> MA Med Schl,<br />
Worcester, MA<br />
3:45 PM<br />
2137. Predictors <strong>of</strong> 12 Year Revision Risk Following Primary<br />
THR for Osteoarthritis in the US Medicare Population.<br />
Jeffrey N. Katz 1 , Elizabeth A. Wright 1 , Akosua A. Nti 1 , John<br />
Wright 2 , Henrik Malchau 5 , John A. Baron 4 and Elena Losina 3 ,<br />
1<br />
Brigham and Women’s Hospital, Boston, MA, 2 Brigham and<br />
Women’s Hospital, 3 Brigham and Women’s Hospital, Boston, MA,<br />
4<br />
Dartmouth Medical School, 5 Massachusetts General Hospital<br />
ARHP Concurrent Abstract Session<br />
2:30 - 4:00 PM<br />
B311<br />
Keep Working with Arthritis<br />
Moderator: Catherine L. Backman, PhD, OT(C); University <strong>of</strong><br />
British Columbia; Vancouver, BC, Canada<br />
2:30 PM<br />
2138. Too Young? Arthritis Is “Main Cause” <strong>of</strong> Disability for<br />
Millions <strong>of</strong> Working-Age U.S. Adults.<br />
Kristina Theis 3 , Charles G. Helmick 1 , Jennifer M. Hootman 2 and<br />
Matthew Brault, 1 CDC, Atlanta, GA, 2 Centers for Disease Control,<br />
Kennesaw, GA, 3 Centers for Disease Control and Prevention<br />
2:45 PM<br />
2139. Arthritis and Labor Force Attachment among Working-<br />
Age Australians.<br />
Kristina A. Theis, Lucy Busija, Ross Wilkie, Gerald Elsworth and<br />
Richard H. Osborne, Deakin University<br />
3:00 PM<br />
2140. Association <strong>of</strong> Depressive Symptoms and Helplessness<br />
with Socioeconomic Status in People with Knee Osteoarthritis.<br />
Leigh F. Callahan 2 , Jack H. Shreffler 4 , Kathryn Remmes Martin 3 ,<br />
Britta Schoster 4 , Jordan Renner 4 and Joanne M. Jordan 1 , 1 Chapel<br />
Hill, NC, 2 Univ <strong>of</strong> North Carolina, Chapel Hill, NC, 3 University<br />
<strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC, 4 University <strong>of</strong><br />
North Carolina, Chapel Hill<br />
3:15 PM<br />
2141. The Effect <strong>of</strong> a 6 Week Walking Program on Work Activity<br />
Limitations in Adults with Arthritis.<br />
Brian L. Charnock 3 , Kathryn Remmes Martin 2 , Jack Shreffler 3 ,<br />
Mary Altpeter 3 and Leigh F. Callahan 1 , 1 Univ <strong>of</strong> North Carolina,<br />
Chapel Hill, NC, 2 University <strong>of</strong> North Carolina at Chapel Hill,<br />
Chapel Hill, NC, 3 University <strong>of</strong> North Carolina at Chapel Hill<br />
3:30 PM<br />
2142. The Effect <strong>of</strong> Structural Deformities on Typing Styles <strong>of</strong><br />
Touch Typists with Rheumatoid Arthritis.<br />
Nancy A. Baker 2 , Norman P. Gustafson 2 , Hyekyoung Shin 3 and<br />
Joan C. Rogers 1 , 1Pittsburgh, PA, 2 University <strong>of</strong> Pittsburgh,<br />
Pittsburgh, PA, 3 University <strong>of</strong> Pittsburgh<br />
3:45 PM<br />
2143. Formation <strong>of</strong> Solutions for Rheumatic Condition-Related<br />
Work Barriers by Occupational and Physical Therapists (OTs/<br />
PTs).<br />
Saralynn H. Allaire 2 , Julie J. Keysor 1 , Nancy A. Baker 5 , Jingbo Niu 3<br />
and Michael P. LaValley 4 , 1 Boston Univ Sargent <strong>College</strong>, Boston,<br />
MA, 2 Boston Univ School <strong>of</strong> Medicine, Boston, MA, 3 Boston<br />
University, Boston, MA, 4 BU School <strong>of</strong> Public Health, Boston, MA,<br />
5<br />
University <strong>of</strong> Pittsburgh, Pittsburgh, PA<br />
ARHP Concurrent Sessions<br />
2:30 - 4:00 PM<br />
B308<br />
Patient Participation in Research c/r<br />
Moderator: Mary E. Christenson, PT, PhD; Regis University;<br />
Westminster, CO<br />
Speakers: Christina H. Opava, PhD; Karolinska Institutet;<br />
Huddinge, Sweden<br />
Nadine T. James, RN, MSN, PhD; William Carey University;<br />
Hattiesburg, MS<br />
Session Overview:<br />
Participatory research is defined as a systematic inquiry<br />
with collaboration <strong>of</strong> those who are affected by the issue<br />
being studied. This session will provide an opportunity for<br />
international and North <strong>American</strong> members to collaborate and<br />
exchange ideas regarding research methods for people with<br />
arthritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss successful examples, from both past and present<br />
literature, <strong>of</strong> patient involvement in research teams<br />
• identify the potential issues surrounding patient participation<br />
in research<br />
• compare research studies with and without patient research<br />
team members by examining the results for application in<br />
practice<br />
• generate four research projects using people with arthritis as<br />
part <strong>of</strong> the research team<br />
2010 Program Book 119<br />
wednesday
wednesday<br />
B309<br />
When Pieces Don’t Fit C<br />
PM PS<br />
Moderator: Joyce P. Carlone, MN, RN, FNP-BC; Emory University;<br />
Atlanta, GA<br />
2:30 PM<br />
Undifferentiated Connective Tissue Disease<br />
Michael R. Liebling, MD; Los-Angeles Biomedical Research<br />
Institute; Torrance, CA<br />
3:00 PM<br />
Undifferentiated Spondylarthritis<br />
Luis R. Espinoza, MD; Louisianna State University Medical<br />
Center; New Orleans, LA<br />
3:30 PM<br />
Fibromyalgia Mimics<br />
Eduardo S. Paiva, MD; Universidade Federal do Parana; Curitiba<br />
Parana, Brazil<br />
Session Overview:<br />
Rheumatologic diseases are <strong>of</strong>ten difficult to diagnose and<br />
classify as there are various guidelines throughout the<br />
rheumatology pr<strong>of</strong>ession. Patients are referred to rheumatology<br />
pr<strong>of</strong>essionals because <strong>of</strong> their common symptoms and <strong>of</strong>ten<br />
times there is not one test alone which will confirm a diagnosis.<br />
Because <strong>of</strong> the many “grey” areas <strong>of</strong> rheumatology, it can be<br />
challenging to classify these patients and develop appropriate<br />
treatment for them. <strong>Rheumatology</strong> pr<strong>of</strong>essionals continually<br />
need to be apprised <strong>of</strong> diagnosis criteria and what to do when<br />
patients “don’t fit.”<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the classification for connective tissue diseases and<br />
recognize when patients do not meet full criteria<br />
• distinguish between ankylosing spondylitis and<br />
spondylarthropathies that fall outside the parameters <strong>of</strong> the<br />
disease<br />
• describe and identify other causes for diffuse musculoskeletal<br />
pain<br />
ACR Workshops<br />
4:00 - 6:00 PM<br />
Admission to each Workshop requires a separate registration<br />
and ticket. To verify which session you registered for, check to<br />
make sure the registration code on your ticket matches the code<br />
listed below in parentheses.<br />
B202<br />
Basic Statistical Concepts for the Medical Researcher<br />
(242)<br />
Speaker: Dorothy D. Dunlop, PhD; Northwestern University<br />
Medical School; Chicago, IL<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify factors influencing sample size and power<br />
• interpret confidence intervals, odds ratio and relative risk<br />
• describe factors that confound study results<br />
B204<br />
Osteoporosis: Focus on Dual Energy X-ray<br />
Absorptiometry Interpretation (243) f PS<br />
Speaker: Chad L. Deal, MD; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• determine how to combine bone mineral density and clinical<br />
risk factors in determination <strong>of</strong> absolute risk<br />
• discuss the concept <strong>of</strong> intervention threshold used in National<br />
Osteoporosis Foundation guidelines<br />
• review International Society for Clinical Densitometry<br />
guidelines for DXA interpretation<br />
• create a report for bone densitometry results<br />
B206<br />
Peripheral Magnetic Resonance Imaging in<br />
<strong>Rheumatology</strong> Practice (244)<br />
Speakers: Philip G. Conaghan, MD, PhD; Chapel Allerton<br />
Hospital; Leeds, United Kingdom<br />
Mikkel Østergaard, MD, PhD, DMSc; Hvidovre University<br />
Hospital; Hvidovre, Denmark<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the logistics <strong>of</strong> implementation <strong>of</strong> peripheral MRI in<br />
the outpatient setting<br />
• review the merits and pitfalls <strong>of</strong> this technology<br />
B203<br />
Physical Examination Skills for Improved Detection <strong>of</strong><br />
Synovitis and Cervical Thoracolumbar Disorders (245)<br />
Speaker: Edward C. Keystone, MD; University <strong>of</strong> Toronto;<br />
Toronto, ON, Canada<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss sensitive techniques for the detection <strong>of</strong> synovitis in<br />
peripheral joints, especially elbows, wrists, hands, feet and<br />
knees<br />
• demonstrate techniques to determine the origin <strong>of</strong> referred<br />
pain from the neck and thoracolumbar spine<br />
• describe simple techniques to improve the symptoms <strong>of</strong><br />
mechanical neck and back pain at the bedside<br />
ARHP Concurrent Session<br />
4:00 - 6:00 PM<br />
B201<br />
Web-based Support <strong>of</strong> Clinical Practice and Teaching:<br />
Twittering, Blogging, and Doing the Wiki cP PS<br />
Moderator: Annette M. Oeser, BS, CCRP; Vanderbilt University<br />
Medical Center; Nashville, TN<br />
Speakers: Laura E. Ray, MA, MLS; Cleveland State University;<br />
Cleveland, OH<br />
Melanie Zibit, MEd, MBA; Brigham and Women’s Hospital;<br />
Lexington, MA<br />
120<br />
2010 Program Book
Session Overview:<br />
We are witnessing a rapid increase in the use <strong>of</strong> web-based tools<br />
by health care practitioners and educators to facilitate clinical<br />
activities and instructional sessions. The ease <strong>of</strong> use and speed<br />
<strong>of</strong> deployment makes Twitter, blogs, and wikis effective forums<br />
for communication. However, determining the most appropriate<br />
format for the specific needs <strong>of</strong> your practice, lecture, or class<br />
can be overwhelming. This interactive session will review key<br />
features for evaluating technological formats, demonstrate the<br />
use <strong>of</strong> Twitter, blogs, and wikis, and discuss how practitioners<br />
and educators have specifically used these technologies.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify features <strong>of</strong> web-based tools such as content<br />
integration and discussion forums for evaluating technological<br />
formats<br />
• describe how to create Twitter accounts, blogs, and wikis<br />
• discuss how Twitter, blogs, and wikis can enhance clinical<br />
practice and instructional sessions<br />
ACR Basic Science Symposia<br />
4:30 - 6:00 PM<br />
B402<br />
A Critical Role for Lipid Metabolism in the Interplay<br />
between Atherosclerosis and Autoimmune Disorders<br />
R<br />
Moderators: Radjesh Bisoendial, MD, PhD; Academic Medical<br />
Center University <strong>of</strong> Amsterdam; Amsterdam, Netherlands<br />
Zoltan Szekanecz, MD, PhD, DSC; University <strong>of</strong> Debrecen Medical<br />
Center; Debrecen, Hungary<br />
4:30 PM<br />
High-Density Lipoprotein Regulates Cellular Immune Responses<br />
via Adenosine Triphosphate-binding Cassette<br />
Alan Tall, MD; Columbia University; New York, NY<br />
5:00 PM<br />
The Dual Function <strong>of</strong> High Density Lipoproteins to Suppress<br />
Inflammatory Activity and Protect Against Heart Disease<br />
in Rheumatoid Arthrititis and Other Immune-mediated<br />
Inflammatory Diseases<br />
Kerry-Anne Rye, PhD; The Heart Research Institute; Newtown,<br />
Sydney, New South Wales, Australia<br />
5:30 PM<br />
Liver X Receptor Signaling at the Crossroads Between Immunity<br />
and Cholesterol Homeostasis<br />
Uwe JF. Tietge, MD; University Medical Center Groningen;<br />
Groningen, Netherlands<br />
Session Overview:<br />
Cardiovascular disease represents a major cause <strong>of</strong> increased<br />
morbidity and mortality in various immune-mediated<br />
inflammatory disorders. This symposium will provide insight into<br />
the factors involved in the increased cardiovascular risk and the<br />
underlying mechanisms.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the key players that integrate metabolic and<br />
inflammatory signaling in increased cardiovascular disease<br />
among individuals with immune-mediated inflammatory<br />
diseases<br />
• define the basics <strong>of</strong> the pathogenic mechanisms that drive<br />
atherosclerosis in immune-mediated inflammatory diseases<br />
B313<br />
Molecular Mechanisms <strong>of</strong> Ocular Inflammation R<br />
Moderators: James T. Rosenbaum, MD; Oregon Health & Science<br />
University; Portland, OR<br />
Holly L. Rosenzweig, PhD; Oregon Health & Science University;<br />
Portland, OR<br />
4:30 PM<br />
Is Macular Degeneration, the Leading Cause <strong>of</strong> Acquired<br />
Blindness, an Autoimmune Disease?<br />
Jayakrishna Ambati, MD; University <strong>of</strong> Kentucky; Lexington, KY<br />
5:00 PM<br />
The Role <strong>of</strong> IL-17 in Autoimmune Uveitis<br />
Rachel Caspi, PhD; National Eye Insitute; Bethesda, MD<br />
5:30 PM<br />
Are Biologic Therapies Indicated to Treat Inflammatory Eye<br />
Diseases?<br />
James T. Rosenbaum, MD; Oregon Health & Science University;<br />
Portland, OR<br />
Session Overview:<br />
The majority <strong>of</strong> rheumatologic diseases include a component <strong>of</strong><br />
ocular inflammation. A better understanding <strong>of</strong> the pathogenesis<br />
<strong>of</strong> ocular inflammation will lead to insights into inflammation in<br />
other organs involved in rheumatic diseases.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the relative contributions <strong>of</strong> TH1, TH2, and TH17 T cell<br />
subsets in an animal model <strong>of</strong> uveitis<br />
• describe the role <strong>of</strong> growth factors, toll receptors,<br />
chemokines, and monocytes in the pathogenesis <strong>of</strong> macular<br />
degeneration<br />
• define the role <strong>of</strong> biologic therapies in the treatment <strong>of</strong><br />
inflammatory eye diseases<br />
ACR Clinical Symposia<br />
4:30 - 6:00 PM<br />
Sidney J. Marcus Auditorium<br />
New Development in Systemic Juvenile Idiopathic<br />
Arthritis - From Bench to Effective Interventions P<br />
PS<br />
Moderators: Alexei A. Grom, MD; Children’s Hospital Medical<br />
Center; Cincinnati, OH<br />
Sampath Prahalad, MD, MSc; Emory Children’s Center; Atlanta,<br />
GA<br />
4:30 PM<br />
Introduction: Systemic Juvenile Idiopathic Arthritis as an<br />
Autoinflammatory Syndrom<br />
Sampath Prahalad, MD, MSc; Emory Children’s Center; Atlanta,<br />
GA<br />
4:40 PM<br />
IL-1 and Systemic Juvenile Idiopathic Arthritis<br />
Norman T. Ilowite, MD; Children’s Hospital Montefiore; Bronx,<br />
NY<br />
2010 Program Book 121<br />
wednesday
wednesday<br />
122<br />
5:10 PM<br />
IL-6 and Systemic Juvenile Idiopathic Arthritis<br />
Fabrizio De Benedetti, MD, PhD; IRCCS Ospedale Pediatrico<br />
Bambino Gesù; Rome, Italy<br />
5:40 PM<br />
Panel Discussion: Optimal Use and Timing <strong>of</strong> Biologic Therapies<br />
in Systemic Juvenile Idiopathic Arthritis<br />
Session Overview:<br />
The extraordinary progress in auto-inflammatory diseases has<br />
spilled over into systemic juvenile idiopathic arthritis, providing<br />
exciting new avenues for disease mechanisms. The extraordinary<br />
state <strong>of</strong> cytokine upregulation in systemic juvenile idiopathic<br />
arthritis and in its most severe complication, macrophage<br />
activation syndrome has been mirrored by the development<br />
<strong>of</strong> effective biological agents for the first time in history.<br />
Modulation <strong>of</strong> IL-1 and IL-6 became feasible and at the same<br />
time promising for the most severe form <strong>of</strong> juvenile arthritis.<br />
Soon, these treatments may be available to the pediatrician.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the main pathways involved in the pathogenesis <strong>of</strong><br />
systemic juvenile idiopathic arthritis<br />
• describe the distinct pattern <strong>of</strong> cytokine pr<strong>of</strong>iles in systemic<br />
juvenile idiopathic arthritis<br />
• explain the indications and the timing for intervention with<br />
biologic therapy<br />
A411<br />
Osteoarthritis - What is New in Old Joints C PM<br />
Moderators: Mary E. Cronin, MD; Medical <strong>College</strong> <strong>of</strong> Wisconsin;<br />
Milwaukee, WI<br />
Mariko L. Ishimori, MD; Cedars Sinai Medical Center; Los<br />
Angeles, CA<br />
4:30 PM<br />
Biomechanical Pathways in Osteoarthritis and Impact on<br />
Treatment<br />
Najia Shakoor, MD; Rush University Medical Center; Chicago, IL<br />
4:55 PM<br />
Current Pharmacologic Therapies in Osteoarthritis<br />
Marc C. Hochberg, MD, MPH; University <strong>of</strong> Maryland; Baltimore,<br />
MD<br />
5:20 PM<br />
Emerging Therapies for Osteoarthritis<br />
Thomas J. Schnitzer, MD, PhD; Northwestern University; Chicago,<br />
IL<br />
Session Overview:<br />
Osteoarthritis is the most common disability <strong>of</strong> aging. As the<br />
demographics shift to an older majority, osteoarthritis will<br />
continue to cause significant personal and societal burdens.<br />
Rheumatologists must remain current in the approach to care<br />
and potential future therapeutic options in order to advise<br />
referring physicians and patients.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the connection between biomechanical forces and the<br />
development <strong>of</strong> osteoarthritis<br />
• develop individualized treatment plans for patients with<br />
osteoarthritis<br />
• describe future therapies in osteoarthritis<br />
2010 Program Book<br />
Hall A3<br />
Perioperative Management <strong>of</strong> Selected Problems in<br />
Patients with Rheumatic Disease C PS<br />
Moderator: Brian F. Mandell, MD, PhD; The Cleveland Clinic<br />
Foundation; Cleveland, OH<br />
4:30 PM<br />
Recognizing and Managing Disease Associated Cardiovascular<br />
Risks and Postoperative Cardiac Complications in Patients with<br />
Rheumatic Disease<br />
Howard H. Weitz, MD; Thomas Jefferson University, Jefferson<br />
Medical <strong>College</strong>; Philadelphia, PA<br />
5:00 PM<br />
Anti-Inflammatory and Immunomodulatory Medications in the<br />
Perioperative Period<br />
Tim Bongartz, MD; Mayo Clinic; Rochester, MN<br />
5:30 PM<br />
Anticoagulation <strong>of</strong> Patients with Antiphospholipid Antibodies<br />
in the Perioperative Period<br />
Mark A. Crowther, MD, MSc; McMaster University; Hamilton,<br />
ON, Canada<br />
Session Overview:<br />
Patients with rheumatic diseases frequently require orthopedic<br />
and other surgical procedures. There are guidelines and<br />
published studies relating to the management <strong>of</strong> surgical<br />
patients, but they mainly deal with non-rheumatologic aspects<br />
<strong>of</strong> perioperative care. Despite the fact that rheumatologists may<br />
be providing chronic care for these patients and prescribing<br />
medications, which may impact perioperative outcome,<br />
perioperative management has not been an integral part <strong>of</strong> the<br />
training <strong>of</strong> rheumatology fellows in most programs, and has not<br />
been reviewed in-depth at the annual meeting in recent years.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• manage a patient’s anti-inflammatory and immunomodulatory<br />
medications in the perioperative period<br />
• provide appropriate anticoagulation therapy in the presence<br />
<strong>of</strong> antiphospholipid antibodies in the perioperative period<br />
• assess and minimize the effect <strong>of</strong> the perioperative cardiac<br />
risks in patients with rheumatic disease<br />
Thomas J. Murphy Ballroom<br />
Systemic Sclerosis: New Therapeutic Approaches P/C<br />
PS<br />
Moderator: Robert W. Simms, MD; Boston University School <strong>of</strong><br />
Medicine; Boston, MA<br />
4:30 PM<br />
Emerging Therapies in Interstitial Lung Disease Associated with<br />
Scleroderma<br />
Richard M. Silver, MD; Medical University <strong>of</strong> South Carolina;<br />
Charleston, SC<br />
5:00 PM<br />
Cardiovascular and Vascular Therapies in Scleroderma<br />
Fredrick M. Wigley, MD; Johns Hopkins University; Baltimore,<br />
MD<br />
5:30 PM<br />
Advances in Stem Cell Therapy in Systemic Sclerosis<br />
Alan G. Tyndall, MD; University <strong>of</strong> Basel; Basel, Switzerland
Session Overview:<br />
Systemic sclerosis remains a major therapeutic challenge for<br />
clinicians with significant potential morbidity and mortality.<br />
Emerging therapies provide significant potential opportunities<br />
for improved outcomes. Identifying which <strong>of</strong> these therapies<br />
<strong>of</strong>fers the greatest promise is <strong>of</strong> key importance.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• explain the pathogenesis <strong>of</strong> interstitial lung disease<br />
associated with scleroderma and outline the spectrum <strong>of</strong> new<br />
therapeutic options in interstitial lung disease associated with<br />
scleroderma<br />
• identify and synthesize the emerging data on cardiovascular<br />
complications including pulmonary hypertension to develop a<br />
therapeutic approach<br />
• describe the emerging role <strong>of</strong> stem cell therapy in scleroderma<br />
and synthesize new clinical trial data on stem cell therapy<br />
ACR Concurrent Abstract Sessions<br />
4:30 - 6:00 PM<br />
A402<br />
Genetics, Genomics and Proteomics: SLE<br />
Moderator: Betty P. Tsao, PhD; University <strong>of</strong> Californina-Los<br />
Angeles School <strong>of</strong> Medicine; Los Angeles, CA<br />
4:30 PM<br />
2144. Exome Resequencing in a Densely Affected<br />
Multigenerational SLE Pedigree.<br />
Graham Wiley 2 , Chee Paul Lin 2 , Indra Adrianto 3 , Jennifer A.<br />
Kelly 3 , Kathy L. Moser 2 , Kenneth M. Kaufman 3 , John B. Harley 4 ,<br />
Courtney Gray-McGuire 2 and Patrick M. Gaffney 1 , 1 Oklahoma<br />
Med Research Foundation, Oklahoma City, OK, 2 Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK, 3 Oklahoma<br />
Medical Research Foundation, 4 Univ <strong>of</strong> OK Hlth Sci Ctr,<br />
Oklahoma City, OK<br />
4:45 PM<br />
2145. Large-Scale Mapping <strong>of</strong> Systemic Lupus Erythematosus<br />
(SLE) Variants across Different Ethnicities Reveals That the IRF5-<br />
TNPO3 Region Is the Strongest Common Risk Factor.<br />
Timothy J. Vyse 8 , Paula S. Ramos 3 , Kenneth M. Kaufman 2 ,<br />
Jennifer A. Kelly 2 , Caroline Gallant 7 , Angelica Delgado 6 , Sharon<br />
A. Chung 10 , Lindsey A. Criswell 12 , Robert P. Kimberly 4 , Mary E.<br />
Comeau 3 , Adrienne H. Williams 3 , Laurie P. Russell 3 , Chaim O.<br />
Jacob 9 , Betty P. Tsao 11 , Marta E. Alarcon-Riquelme 5 , Kathy L.<br />
Moser 1 , Patrick M. Gaffney 1 , John B. Harley 13 , Carl D. Langefeld 3<br />
and SLEGEN Consortium, 1 Arthritis and Immunology Program,<br />
Oklahoma Medical Research Foundation, Oklahoma City,<br />
OK, 2 Arthritis and Immunology Program, Oklahoma Medical<br />
Research Foundation, 3 Dept Biostatistical Sciences, Wake<br />
Forest University Health Sciences, 4 Dept Medicine, University<br />
<strong>of</strong> Alabama at Birmingham, Birmingham, AL, 5 Dept <strong>of</strong> Genetics<br />
and Pathology, Uppsala University, Uppsala, Sweden, 6 Dept <strong>of</strong><br />
Genetics and Pathology, Uppsala University, 7 Dept <strong>of</strong> Genetics<br />
and Pathology, Uppsala University, Sweden, 8 Faculty <strong>of</strong> Medicine,<br />
Imperial <strong>College</strong>, London, UK, 9 Keck School <strong>of</strong> Medicine,<br />
University <strong>of</strong> Southern California, Los Angeles, CA, 10 Rosalind<br />
Russell Medical Research Center for Arthritis, University <strong>of</strong><br />
California, San Francisco, San Francisco, CA, 11 UCLA School <strong>of</strong><br />
Medicine, Los Angeles, CA, 12 UCSF-Box 0500, San Francisco, CA,<br />
13<br />
Univ <strong>of</strong> OK Hlth Sci Ctr, Oklahoma City, OK<br />
5:00 PM<br />
2146. Targeted Resequencing in Systemic Lupus Erythematosus<br />
Genetic Risk Loci: Initial Results from the REVEAL<br />
(Resequencing Variants Enhancing Autoimmunity and Lupus)<br />
Resource.<br />
Patrick M. Gaffney 1 , Graham Wiley 2 , Jennifer A. Kelly 2 , Kenneth<br />
M. Kaufman 2 , John B. Harley 3 , Ekta Rai 4 and Edward K.<br />
Wakeland 4 , 1 Oklahoma Medical Research Foundation, Oklahoma<br />
City, OK, 2 Oklahoma Medical Research Foundation, Oklahoma<br />
City, OK, 3 Univ <strong>of</strong> OK Hlth Sci Ctr, Oklahoma City, OK, 4 University<br />
<strong>of</strong> Texas Southwestern Medical Center, Dallas, TX<br />
5:15 PM<br />
2147. Identification <strong>of</strong> a Novel Systemic Lupus Erythematosus<br />
Susceptibility Locus at 11p13 near CD44 in a Multi-Ethnic Study.<br />
Christopher J. Lessard 3 , Indra Adrianto 1 , Jennifer A. Kelly 1 ,<br />
Kenneth M. Kaufman 1 , Marta E. Alarcon-Riquelme for the<br />
BIOLUPUS Network 2 , Juan-Manuel Anaya 4 , Sang-Cheol Bae 10 ,<br />
Elizabeth E. Brown for PROFILE 6 , Lindsey A. Criswell 14 , Jeffrey C.<br />
Edberg 8 , Barry I. Freedman 7 , Chaim O. Jacob 9 , Judith A. James 1 ,<br />
Robert P. Kimberly 8 , Javier Martin 13 , Joan T. Merrill 5 , Timothy<br />
B. Niewold 16 , Bernardo A. Pons-Estel 15 , Betty P. Tsao 12 , Timothy<br />
J. Vyse 11 , Courtney G. Montgomery 1 , John B. Harley 17 , R. Hal<br />
Sc<strong>of</strong>ield 1 , Patrick M. Gaffney 1 and Kathy L. Moser 1 , 1 Arthritis and<br />
Immunology Research Program, Oklahoma Medical Research<br />
Foundation, 2 Arthritis and Immunology Research Program,<br />
Oklahoma Medical Research Foundation and Center for<br />
Genomics and Oncological Research (GENyO), Granada, Spain,<br />
3<br />
Arthritis and Immunology Research Program, Oklahoma Medical<br />
Research Foundation and Department <strong>of</strong> Pathology, University<br />
<strong>of</strong> Oklahoma Health Sciences Center, Oklahoma City, OK, 4 Center<br />
for Autoimmune Diseases Research (CREA), Universidad del<br />
Rosario, Bogota, Columbia, 5 Clinical Pharmacology, Oklahoma<br />
Medical Research Foundation, 6 Department <strong>of</strong> Epidemiology,<br />
University <strong>of</strong> Alabama at Birmingham, Birmingham, AL,<br />
7<br />
Department <strong>of</strong> Internal Medicine, Wake Forest University<br />
Health Sciences, Winston-Salem, NC, 8 Department <strong>of</strong> Medicine,<br />
University <strong>of</strong> Alabama at Birmingham, Birmingham, AL,<br />
9<br />
Department <strong>of</strong> Medicine, University <strong>of</strong> Southern California, Los<br />
Angeles, CA, 10 Department <strong>of</strong> <strong>Rheumatology</strong>, Hanyang University<br />
Hospital for Rheumatic Diseases, Seoul, Korea, 11 Division <strong>of</strong><br />
Medicine, Imperial <strong>College</strong> <strong>of</strong> London, London, UK, 12 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Department <strong>of</strong> Medicine, University <strong>of</strong> California<br />
Los Angeles, Los Angeles, CA, 13 Instituto de Parasitologia y<br />
Biomedicina Lopez-Neyra, Consejo Superior de Investigaciones<br />
Cientificas (CSIC), Granada, Spain, 14 Rosalind Russell Medical<br />
Research Center for Arthritis, University <strong>of</strong> California San<br />
Francisco, 15 Sanatorio Parque, Rosario, Argentina, 16 Section<br />
<strong>of</strong> <strong>Rheumatology</strong> and Gwen Knapp Center for Lupus and<br />
Immunology Research, University <strong>of</strong> Chicago, 17 US Department<br />
<strong>of</strong> Veterans Affairs Medical Center, Department <strong>of</strong> Medicine,<br />
University <strong>of</strong> Oklahoma Health Sciences Center, and Cincinnati<br />
Children’s Hospital Medical Center<br />
5:30 PM<br />
2148. Study <strong>of</strong> Systemic Lupus Erythematosus Susceptibility<br />
Genes in a Hispanic Population: Identification <strong>of</strong> Six New<br />
Candidate Susceptibility Loci.<br />
Elena Sanchez-Rodriguez 1 , Kenneth M. Kaufman 3 , Jennifer<br />
A. Kelly 1 , Adrienne H. Williams 11 , Paula S. Ramos 11 , Astrid<br />
Rasmussen 1 , Chaim O. Jacob 9 , Patrick M. Gaffney 1 , Kathy<br />
2010 Program Book 123<br />
wednesday
wednesday<br />
L. Moser 1 , Betty P. Tsao 7 , Lindsey A. Criswell 8 , Robert P.<br />
Kimberly 6 , Timothy J. Vyse 4 , Carl D. Langefeld 11 , John B.<br />
Harley 10 , Bernardo Pons-Estel 5 , Marta E. Alarcon-Riquelme 2 and<br />
SLEGEN International Consortium, 1 Arthritis and Immunology<br />
Program, Oklahoma Medical Research Foundation, Oklahoma<br />
City, OK, 2 Arthritis and Immunology Program, Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK and Center<br />
for Genomics and Oncological Research (GENyO), Granada,<br />
Spain, 3 Arthritis and Immunology Program, Oklahoma Medical<br />
Research Foundation, Oklahoma City, OK and US Department <strong>of</strong><br />
Veterans Affairs Medical Center, Oklahoma City, OK, 4 Imperial<br />
<strong>College</strong> London, Hammersmith Hospital, London, UK, 5 Sanatorio<br />
Parque, Rosario, Argentina, 6 University <strong>of</strong> Alabama, Birmingham,<br />
AL, 7 University <strong>of</strong> California, Los Angeles, CA, 8 University <strong>of</strong><br />
California, San Francisco, CA, 9 University <strong>of</strong> Southern California,<br />
Los Angeles, CA, 10 US Department <strong>of</strong> Veterans Affairs Medical<br />
Center, Oklahoma City, OK and University <strong>of</strong> Oklahoma Health<br />
Sciences Center, Oklahoma City, OK, 11 Wake Forest University<br />
Health Sciences, NC<br />
5:45 PM<br />
2149. Peripheral Blood Expression Signatures Reflect Current<br />
Lupus Activity and Likelihood <strong>of</strong> Future Flare.<br />
Carolyn Meyer 4 , Jason W. Bauer 4 , Thearith Koeuth 4 , Joseph<br />
Wilson 4 , Michelle A. Petri 1 , Peter K. Gregersen 3 , Timothy W.<br />
Behrens 2 and Emily C. Baechler 4 , 1 Timonium, MD, 2 Genentech<br />
Inc, South San Francisco, CA, 3 The Feinstein Institute for Medical<br />
Research, Manhasset, Manhasset, NY, 4 University <strong>of</strong> Minnesota<br />
Department <strong>of</strong> Medicine, Minneapolis, MN<br />
A404<br />
Metabolic and Crystal Arthropathies - Pathogenesis,<br />
Prevalence, Imaging, and New Therapy<br />
Moderators: Frederic P. Liote, MD, PhD; Hopital Lariboisiere;<br />
Paris, France<br />
George Nuki, MB; Western General Hospital; Edinburgh, United<br />
Kingdom<br />
4:30 PM<br />
2150. The NALP3 Inflammasome Is Activated by Sodium<br />
Overload and Water Influx in Gouty Arthritis.<br />
Christine Schorn 1 , Benjamin Frey 2 , Christina Janko 1 , Georg<br />
Schett 3 and Martin Herrmann 1 , 1 Department <strong>of</strong> Internal<br />
Medicine III and Institute for Clinical Immunology, University<br />
<strong>of</strong> Erlangen-Nuremberg, Erlangen, Germany, 2 Department <strong>of</strong><br />
Radiation Oncology, Friedrich-Alexander University <strong>of</strong> Erlangen-<br />
Nuremberg, Erlangen, Germany, 3 Friedrich Alexander Univ,<br />
Erlangen, Germany<br />
4:45 PM<br />
2151. Octacalcium Phosphate (OCP) Crystals Induce Synovial<br />
Inflammation and Cartilage.<br />
Nathalie Busso 1 , Véronique Chobaz 3 , Nathaliane Bagnoud 3 , Peter<br />
Van Lent 5 , Christelle Nguyen 4 , Frédéric Lioté 4 , Alexander So 2<br />
and Hang-Korng Ea 4 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>, DAL CHUV,<br />
Lausanne, Switzerland, 2 Department <strong>of</strong> <strong>Rheumatology</strong>, DAL,<br />
CHUV, Lausanne, Switzerland, 3 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
DAL, CHUV, Lausanne, Switzerland, 4 INSERM U606, Hospital<br />
Lariboisière, University Paris VII, Paris, France, 5 Radboud<br />
University Nijmegen Medical Centre, Nijmegen, The Netherlands<br />
5:00 PM<br />
2152. Quantitative Documentation <strong>of</strong> Tophus Volume Change<br />
Using Dual Energy Computed Tomography Scans.<br />
Mohammed Abufayyah 3 , Savvas Nicolaou 3 , Arash Eftekhari 3 ,<br />
Graham Reid 3 , Kamran Shojania 2 , Steven Co 3 and Hyon K. Choi 1 ,<br />
1<br />
Boston University School <strong>of</strong> Medicine, Vancouver, BC, Canada,<br />
2<br />
Univ <strong>of</strong> British Columbia, Vancouver, BC, Canada, 3 University <strong>of</strong><br />
British Columbia, Vancouver, BC, Canada<br />
5:15 PM<br />
2153. Lead and Gout – Going, Going…Not Gone!<br />
Eswar Krishnan 2 , Bharathi Lingala 3 , James F. Fries 1 and Vivek<br />
Bhalla 3 , 1 Stanford Univ Medical Ctr, Palo Alto, CA, 2 Stanford<br />
University, Palo Alto, CA, 3 Stanford University<br />
5:30 PM<br />
2154. Increasing Gout Prevalence in the US over the Last Two<br />
Decades: The National Health and Nutrition Examination<br />
Survey (NHANES).<br />
Yanyan Zhu 1 , Bhavik Pandya 2 and Hyon Choi 1 , 1 Boston University<br />
<strong>of</strong> School <strong>of</strong> Medicine, Boston, MA, 2 Takeda Pharmaceuticals<br />
International, Inc, Deerfield, IL<br />
5:45 PM<br />
2155. Independent Impact <strong>of</strong> Hyperuricemia on the Future Risk<br />
<strong>of</strong> Hypertension: A Systematic Review and Meta-Analysis.<br />
Peter C. Grayson 1 , Seo Young Kim 3 , Michael P. LaValley 2 and<br />
Hyon K. Choi 4 , 1 Boston University School <strong>of</strong> Medicine, 2 Boston<br />
University School <strong>of</strong> Public Health, Boston, MA, 3 Brigham &<br />
Women’s Hospital, Boston, MA, 4 Univ <strong>of</strong> British Columbia,<br />
Vancouver, BC, Canada<br />
A410<br />
Osteoporosis and Metabolic Bone Disease: Clinical<br />
Aspects and Pathogenesis<br />
Moderators: Berna Goker, MD; Gazi University Medical School;<br />
Ankara, Turkey<br />
Nancy E. Lane, MD; University <strong>of</strong> California at Davis;<br />
Hillsborough, CA<br />
4:30 PM<br />
2156. Effectiveness <strong>of</strong> Zoledronic Acid in the Prevention and<br />
Treatment <strong>of</strong> Glucocorticoid-Induced Osteoporosis in Men and<br />
Premenopausal Women.<br />
K. Saag 5 , C. Roux 2 , J.-P. Devogelaer 3 , C.-S. Lau 6 , J.-Y. Reginster 7 ,<br />
C. Bucci-Rechtweg 1 , G. Su 1 , P. N. Sambrook 8 and D. M. Reid 4 ,<br />
1<br />
Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2 Paris-<br />
Descartes University, Paris, France, 3 Universite Catholique de<br />
Louvain, Brussels, Belgium, 4 University <strong>of</strong> Aberdeen, Aberdeen,<br />
UK, 5 University <strong>of</strong> Alabama at Birmingham, Birmingham, AL,<br />
6<br />
University <strong>of</strong> Dundee, Dundee, UK, 7 University <strong>of</strong> Liege, Liege,<br />
Belgium, 8 University <strong>of</strong> Sydney, Sydney, NSW, Australia<br />
4:45 PM<br />
2157. Long-Term Denosumab Treatment <strong>of</strong> Postmenopausal<br />
Women with Osteoporosis: Results from the First Year<br />
Extension Study <strong>of</strong> the FREEDOM Trial.<br />
Roland Chapurlat 6 , Socrates Papapoulos 11 , Henry G. Bone 12 ,<br />
Maria L. Brandi 16 , Jacques Brown 10 , Edward Czerwinski 9 , Nadia<br />
S. Daizadeh 1 , Andreas Grauer 1 , Christine Haller 2 , Marc-Antoine<br />
Krieg 4 , Cesar Libanati 3 , Zulema Man 5 , Dan Mellstrom 13 , Sebastiao<br />
Radominski 7 , Jean-Yves Reginster 17 , Heinrich Resch 15 , Jose A.<br />
Roman Ivorra 8 and Steven R. Cummings 14 , 1 Amgen Inc, Thousand<br />
124<br />
2010 Program Book
Oaks, CA, 2 Amgen Inc., San Francisco, CA, 3 Amgen Inc., Thousand<br />
Oaks, CA, 4 Centre Hospitalier Universitaire Vaudois, Lusanne,<br />
Switzerland, 5 Centro TIEMPO, Buenos Aires, Argentina, 6 Hopital<br />
E. Herriot, Lyon, France, 7 Hospital de Clinicas da Universidade<br />
Federal do Parana, Curitiba, Brazil, 8 Jefe Servicio Reumatologia,<br />
Valencia, Spain, 9 Krakowskie Centrum Medyczne, Krakow,<br />
Poland, 10 Laval University Department <strong>of</strong> Medicine, Quebec,<br />
QC, Canada, 11 Leiden University Medical Center, Leiden, The<br />
Netherlands, 12 Michigan Bone and Mineral Clinic, PC, Detroit,<br />
MI, 13 Osteoporosis Clinic, Center for Bone Research at the<br />
Sahlgrenska, Goteborg, Sweden, 14 SF Coordinating Center, San<br />
Francisco, CA, 15 St. Vincent Hospital Medical University, Vienna,<br />
Austria, 16 University <strong>of</strong> Florence, Florence, Italy, 17 University <strong>of</strong><br />
Leige, Leige, Belgium<br />
5:00 PM<br />
2158. IL-3 Inhibits Osteoclast Differentiation by Inducing <strong>of</strong> ID<br />
Expression.<br />
Chang Hoon Lee 5 , Myeung Su Lee 6 , Yun Kyung Hong 3 , Jin-<br />
Jeong Choi 2 , Min-Ho Whang 4 , Han-Bok Kwak 1 and Jae Min<br />
Oh 1 , 1 Anatomy, Wonkwang University, Iksan, Korea, Republic<br />
<strong>of</strong>, 2 <strong>Rheumatology</strong>, Cha University Hospital, Sungnam,<br />
3<br />
<strong>Rheumatology</strong>, Chonbuk University Hospital, 4 <strong>Rheumatology</strong>,<br />
Presbyterian Medical Center, Chonju, 5 <strong>Rheumatology</strong>,<br />
Wonkwang University Hospital, Iksan, Jeollabukdo, Republic <strong>of</strong><br />
Korea, 6 <strong>Rheumatology</strong>, Wonkwang University Hospital<br />
5:15 PM<br />
2159. Raloxifene for Prevention <strong>of</strong> Glucocorticoid-Induced<br />
Bone Loss: A 12-Month Randomized Double-Placebo-<br />
Controlled Trial.<br />
Chi Chiu Mok, Chi Hung To, Ling Yin Ho, Ka Lung Yu and Kwok<br />
Man Ma, Tuen Mun Hospital<br />
5:30 PM<br />
2160. Unsuppressed Parathyroid Hormone in Patients with<br />
Autoimmune Rheumatic Diseases: Implications for Vitamin D<br />
Supplementation.<br />
Pier Paolo Sainaghi 1 , Mattia Bellan 2 , Giuseppina Antonini 3 ,<br />
Giorgio Bellomo 3 and Mario Pirisi 1 , 1 Immuno-<strong>Rheumatology</strong><br />
Outpatient Unit, DMCS, “A. Avogadro” University and IRCAD<br />
(Interdisciplinary Reseach Center <strong>of</strong> Autoimmune Diseases),<br />
Novara, Novara, Italy, 2 Immuno-<strong>Rheumatology</strong> Outpatient Unit,<br />
DMCS, “A. Avogadro” University, Novara, Italy, 3 Laboratory <strong>of</strong><br />
Chemistry and Clinical Research, DSM, “A. Avogadro” University<br />
and “Maggiore della Carità” Hospital, Novara, Italy<br />
5:45 PM<br />
2161. Bone Remodeling in Postmenopausal Women Who<br />
Discontinued Denosumab Treatment.<br />
Rachel B. Wagman 1 , Jaques Brown 4 , David W. Dempster 2 , Beiying<br />
Ding 1 , Ricardo Dent 1 , Javier San Martin 1 , Andreas Grauer 1 and<br />
Jose R. Zanchetta 3 , 1 Amgen Inc., Thousand Oaks, CA, 2 Helen<br />
Hayes Hospital, West Haverstraw, NY, 3 Instituto de Ivestigaciones<br />
Metabolicas, Buenos Aires, Argentina, 4 Laval University<br />
Department <strong>of</strong> Medicine, Quebec, QC, Canada<br />
A314<br />
Rheumatoid Arthritis - Clinical Aspects: RA and<br />
Cardiovascular Disease III<br />
Moderators: Paul F. Dellaripa, MD; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Deborah P. Symmons, MD; University <strong>of</strong> Manchester;<br />
Manchester, United Kingdom<br />
4:30 PM<br />
2162. Longitudinal Predictors <strong>of</strong> Progression <strong>of</strong> Subclinical<br />
Carotid Atherosclerosis in Rheumatoid Arthritis.<br />
Jon T. Giles 3 , Wendy Post 5 , Roger S. Blumenthal 5 , Joseph Polak 6 ,<br />
Michelle A. Petri 1 , Allan C. Gelber 2 , Moyses Szklo 5 and Joan M.<br />
Bathon 4 , 1 Timonium, MD, 2 Baltimore, MD, 3 Johns Hopkins Univ,<br />
Baltimore, MD, 4 Johns Hopkins University, Baltimore, MD, 5 Johns<br />
Hopkins University, 6 Tufts-New England Medical Center<br />
4:45 PM<br />
2163. At What Age Is Carotid Ultrasound Most Effective in<br />
Predicting Cardiovascular Events and Mortality in Rheumatoid<br />
Arthritis?<br />
Inmaculada Del Rincon 3 , Mrisa Sahai 4 , Daniel H. O’Leary 2 , Daniel<br />
F. Battafarano 1 and Agustin Escalante 3 , 1 Brooke Army Medical<br />
Ctr, San Antonio, TX, 2 Tufts School <strong>of</strong> Medicine, 3 UTHSCSA, San<br />
Antonio, TX, 4 UTHSCSA<br />
5:00 PM<br />
2164. Higher Prevalence, Extent and Severity <strong>of</strong> “Vulnerable”<br />
Coronary Plaque in Asymptomatic Patients with Rheumatoid<br />
Arthritis (RA).<br />
George A. Karpouzas 1 , Naser Ahmadi 2 , Tae-Young Choi 2 ,<br />
Fereshteh Hajsadeghi 2 , Silvia Munoz 2 and Mathew Bud<strong>of</strong>f 2 ,<br />
1<br />
Harbor-UCLA, Long Beach, CA, 2 Harbor-UCLA<br />
5:15 PM<br />
2165. Anti-b2-Glycoprotein-1 (b2GP1) IgA Ab Are Highly<br />
Prevalent and Predict “Vulnerable” Coronary Plaque in<br />
Asymptomatic Patients with Rheumatoid Arthritis (RA).<br />
George A. Karpouzas 1 , Naser Ahmadi 2 , Tae-Young Choi 2 ,<br />
Fereshteh Hajsadeghi 2 , Silvia Munoz 2 and Mathew Bud<strong>of</strong>f 2 ,<br />
1<br />
Harbor-UCLA, Long Beach, CA, 2 Harbor-UCLA<br />
5:30 PM<br />
2166. Increased Epicardial and Thoracic Pre-Aortic Fat Depots<br />
Predict “Vulnerable” Coronary Plaque in Asymptomatic<br />
Patients with Rheumatoid Arthritis (RA).<br />
George A. Karpouzas 1 , Naser Ahmadi 2 , Fereshteh Hajsadeghi 2 ,<br />
Tae-Young Choi 2 , Silvia Munoz 2 and Mathew Bud<strong>of</strong>f 2 , 1 Harbor-<br />
UCLA, Long Beach, CA, 2 Harbor-UCLA<br />
5:45 PM<br />
2167. Citrullination Is Present in the Perivascular Interstitium<br />
<strong>of</strong> the Myocardium and Is Increased in Rheumatoid Arthritis<br />
Compared to Controls.<br />
Jon T. Giles 1 , Marc K. Halushka 4 , Fox-Talbot K. Mary 4 , Clifton<br />
O. Bingham 2 , Felipe Andrade 5 , Jin Kyun Park 3 , Antony Rosen 2 ,<br />
Justyna Fert-Bober 4 , Jennifer van Eyk 4 and Joan M. Bathon 2 ,<br />
1<br />
Johns Hopkins Univ, Baltimore, MD, 2 Johns Hopkins University,<br />
Baltimore, MD, 3 Johns Hopkins University, Baltimore, MD,<br />
4<br />
Johns Hopkins University, 5 Johns Hopkins University School <strong>of</strong><br />
Medicine, Baltimore, MD<br />
B406<br />
Rheumatoid Arthritis Treatment - Small Molecules,<br />
Biologics and Gene Therapy: Novel Compounds III<br />
Moderators: Jeffrey D. Greenberg, MD, MPH; New York<br />
University Hospital for Joint Disease; Millburn, NJ<br />
Vibeke Strand, MD; Stanford University; Portola Valley, CA<br />
wednesday<br />
2010 Program Book 125
wednesday<br />
4:30 PM<br />
2168. ALD518 (BMS945429), a High Affinity Monoclonal<br />
Antibody Directed Against Interleukin-6, Reduces Disease<br />
Activity and Achieves Remission in Patients with Rheumatoid<br />
Arthritis and Inadequate Response to Methotrexate.<br />
Philip Mease 5 , Vibeke Strand 4 , Levan Shalamberidze 6 ,<br />
Aleksandar Dimic 3 , Richard Aranda 2 and Jeff Smith 1 , 1 Alder<br />
Biopharmaceuticals Inc., Bothell, WA, 2 Bristol-Myers Squibb,<br />
Princeton, NJ, 3 Institute <strong>of</strong> Rehabilitation and Treatment, Niska<br />
Banja, Serbia, 4 Stanford University, Palo Alto, CA, 5 Swedish<br />
Medical Center and University <strong>of</strong> Washington, Seattle, WA, 6 V.<br />
Tsitlanadze Scientific Practical Centre <strong>of</strong> <strong>Rheumatology</strong>, Tbilisi,<br />
Georgia<br />
4:45 PM<br />
2169. Efficacy and Safety <strong>of</strong> Ocrelizumab in Patients with Active<br />
Rheumatoid Arthritis Who Have an Inadequate Response to at<br />
Least One TNF Inhibitor: Results from the Phase III SCRIPT Trial.<br />
Paul P. Tak 1 , Philip J. Mease 7 , Mark C. Genovese 8 , Joel M.<br />
Kremer 9 , Boulos Haraoui 4 , Yoshiya Tanaka 10 , Clifton O. Bingham 5 ,<br />
Ali Ashrafzadeh 2 , Helen Travers 6 , Simon Safa-Leathers 6 , Sanjeev<br />
Kumar 6 and Wolfgang Dummer 3 , 1 Academic Med Ctr/Univ <strong>of</strong><br />
Amsterdam, Amsterdam, The Netherlands, 2 Genentech, San<br />
Francisco, CA, 3 Genentech, 4 Institut de Rhumatologie, Montreal,<br />
QC, Canada, 5 Johns Hopkins University, Baltimore, MD, 6 Roche,<br />
7<br />
Seattle <strong>Rheumatology</strong> Associate, Seattle, WA, 8 Stanford Univ,<br />
Sunnyvale, CA, 9 The Center for <strong>Rheumatology</strong>, Albany, NY, 10 U<br />
Occupa & Environ Hlth, Kitakyushu, Japan<br />
5:00 PM<br />
2170. Safety, Tolerability, Pharmacokinetics,<br />
Pharmacodynamics and Efficacy <strong>of</strong> the Monoclonal Antibody<br />
ASK8007 Blocking Osteopontin in Patients with Rheumatoid<br />
Arthritis in a Randomized, Placebo-Controlled, Combined Firstin-Man<br />
and Pro<strong>of</strong>-<strong>of</strong>-Concept Study.<br />
M. Boumans 5 , J. Houbiers 1 , P. Verschueren 10 , A. Ishikura 2 , R.<br />
Westhovens 10 , E. Brouwer 4 , B. Rojkovich 8 , S. Kelly 3 , M. Den<br />
Adel 2 , J. Isaacs 7 , J. Gomez-Reino 9 , G. Holtkamp 2 , D. Gerlag 6 and<br />
P. Tak 6 , 1 Astellas Pharma Global Development, the Netherlands<br />
and Japan, Leiderdorp, The Netherlands, 2 Astellas Pharma<br />
Global Development, the Netherlands and Japan, 3 Centre for<br />
Experimental Medicine and <strong>Rheumatology</strong>, Queen Mary’s School<br />
<strong>of</strong> Medicine, London, 4 Department <strong>Rheumatology</strong>, University<br />
Medical Center Groningen, Groningen, The Netherlands,<br />
5<br />
Division <strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic<br />
Medical Center / University <strong>of</strong> Amsterdam, Amsterdam,<br />
Noord-Holland, The Netherlands, 6 Division <strong>of</strong> Clinical<br />
Immunology and <strong>Rheumatology</strong>, Academic Medical Center<br />
/ University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />
7<br />
Musculoskeletal Research Group, Institute <strong>of</strong> Cellular Medicine,<br />
Newcastle University, Newcastle upon Tyne, United Kingdom,<br />
8<br />
<strong>Rheumatology</strong>, Buda Charity Hospital, Budapest, Hungary,<br />
9<br />
<strong>Rheumatology</strong>, Hospital Clinico Universitario, Santiago de<br />
Compostela, Spain, Santiago, Spain, 10 University Hospital Leuven,<br />
Leuven, Belgium<br />
5:15 PM<br />
2171. Tasocitinib (CP-690,550) Appears To Be Effective<br />
and Tolerated When Administered Either as Long-Term<br />
Monotherapy or on Background Methotrexate in Patients with<br />
Rheumatoid Arthritis.<br />
Carol A. Connell 1 , Richard Riese 2 , Susan Wood 2 , John Bradley 2<br />
and Samuel H. Zwillich 2 , 1Pfizer Inc, New London, CT, 2 Pfizer Inc.<br />
5:30 PM<br />
2172. A Randomized Dose-Ranging, Placebo-Controlled Study<br />
<strong>of</strong> INCB028050, a Selective JAK1 and JAK2 Inhibitor in Subjects<br />
with Active Rheumatoid Arthritis.<br />
Maria W. Greenwald 1 , Rosanne Fidelus-Gort 4 , Rich Levy 4 , Jinjin<br />
Liang 4 , Kris Vaddi 4 , William V. Williams 3 , Robert Newton 4 ,<br />
Swamy Yeleswaram 4 , Robert Flores 4 , Edward McKeever 4 , James<br />
Rodgers 4 , Stacey Shepard 4 , Pierre-Yves Berclaz 2 , Chin Hyok Lee 2<br />
and Monica E. Luchi 3 , 1 Desert Medical, Palm Desert, CA, 2 Eli<br />
Lilly & Company, 3 Incyte Corporation, Wilmington, DE, 4 Incyte<br />
Corporation<br />
5:45 PM<br />
2173. A Large, Phase IIIb Non-Inferiority Trial <strong>of</strong> Subcutaneous<br />
(SC) Abatacept Compared with Intravenous (IV) Abatacept, in<br />
Patients with Rheumatoid Arthritis (RA).<br />
Mark C. Genovese 13 , Jose Arturo Covarrubias 3 , Gustavo Leon 5 ,<br />
Eduardo F. Mysler 8 , Mauro W. Keiserman 10 , Robert M. Valente 9 ,<br />
Peter Nash 15 , J. Abraham Simon 2 , Wieslawa Porawska 11 , Jane H.<br />
Box 14 , Clarence W. Leggerton 6 , Evgeny Nasonov 7 , Patrick Durez 4 ,<br />
Richard Aranda 1 , Ramesh Pappu 1 , Ingrid Delaet 1 , Julie Teng 1 and<br />
Rieke Alten 12 , 1 Bristol-Myers Squibb Co, Princeton, NJ, 2 Centro<br />
de Especialidades Médicas, Merida, Mexico, 3 Centro Medico de<br />
Las Americas, Merida, Yucatan, Mexico, 4 Cliniques Universitaires<br />
Saint-Luc, Université Catholique de Louvain, Brussels, Belgium,<br />
5<br />
De Ginecologia Y Reproduccion, Lima, Peru, 6 Department <strong>of</strong><br />
Medicine, Medical University <strong>of</strong> South Carolina, Charleston,<br />
SC, 7 Institute <strong>of</strong> <strong>Rheumatology</strong>, Moscow, Russia, 8 Organización<br />
Médica de Investigación, Buenos Aires, Argentina, 9 Physician<br />
Research Collaboration, Lincoln, Lincoln, NE, 10 Pontificial Catholic<br />
University, School <strong>of</strong> Medicine, Porto Alegre, Brazil, 11 Poznanski<br />
Osrodek Medyczny Novamed, Ponzan, Poland, 12 Schlosspark-<br />
Klinik, Charité, University Medicine Berlin, Department <strong>of</strong><br />
Internal Medicine II <strong>Rheumatology</strong>, Berlin, Germany, 13 Stanford<br />
University, Palo Alto, Sunnyvale, CA, 14 The Arthritis Clinic &<br />
Carolina Bone & Joint, Charlotte, NC, 15 University <strong>of</strong> Queensland,<br />
Brisbane, Australia<br />
A406<br />
Sjögren’s Syndrome<br />
Moderators: Alan N. Baer, MD; Johns Hopkins University;<br />
Baltimore, MD<br />
Athanasios G. Tzioufas, MD; Medical School-University <strong>of</strong><br />
Athens; Athens, Greece<br />
4:30 PM<br />
2174. Receptor-Mediated Small Interfering RNA Delivery in<br />
Sjögren’s Syndrome.<br />
Kaleb M. Pauley, Adrienne E. Gauna and Seunghee Cha,<br />
University <strong>of</strong> Florida, Gainesville, FL<br />
4:45 PM<br />
2175. Structure and Antigenicity <strong>of</strong> the Ro/La RNP Particle.<br />
hY1 RNA Differentiates the Recognition <strong>of</strong> Epitopes in Systemic<br />
Lupus Erythematosus and Sjögren’s Syndrome.<br />
John G. Routsias1, Nikos C. Kyriakidis 1 , Stathis Kotsakis 1 and<br />
Athanasios G. Tzioufas 2 , 1 Department <strong>of</strong> Pathophysiology,<br />
Medical School, University <strong>of</strong> Athens, Athens, Greece, 2 Medical<br />
School-Univ <strong>of</strong> Athens, Athens, Greece<br />
126<br />
2010 Program Book
5:00 PM<br />
2176. A Role <strong>of</strong> Autoimmune Response to M3 Muscarinic<br />
Acethylcholine Receptor in the Pathogenesis <strong>of</strong> Sjögren’s<br />
Syndrome Like Autoimmune Sialoadenitis.<br />
Mana Iizuka 2 , Hiroto Tsuboi 2 , Yumi Nakamura 2 , Naomi Matsuo 2 ,<br />
Isao Matsumoto 2 and Takayuki Sumida 1 , 1 Univ <strong>of</strong> Tsukuba/Inst<br />
Clin Med, Tsukuba City, Japan, 2 Univ <strong>of</strong> Tsukuba/Inst Clin Med<br />
5:15 PM<br />
2177. Δ4BAFF, an Alternate-Splice Is<strong>of</strong>orm That Acts as a<br />
Transcription Factor To Enhance BAFF Production in Primary<br />
Sjögren’s Syndrome.<br />
Jacques-Olivier Pers, Gabriel J. Tobon, Laëtitia Le Pottier and<br />
Pierre Youinou, Brest University, Brest, France<br />
5:30 PM<br />
2178. Local TACI-Ig Gene Therapy <strong>of</strong> the Salivary Gland <strong>of</strong> NOD<br />
Mice Reduces Auto-Immune Inflammation by Affecting the B<br />
Cell Compartment.<br />
Nienke Roescher 2 , Jelle L. Vosters 2 , Marco Guadagnoli 2 , Jan<br />
P. Medema 2 , Gabor G. Illei 4 , John A. Chiorini 3 and Paul P.<br />
Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam,<br />
The Netherlands, 2 Academic Medical Center-University <strong>of</strong><br />
Amsterdam, 3 National Insitutes <strong>of</strong> Health-National Institute<br />
<strong>of</strong> Dental and Crani<strong>of</strong>acial Research, 4 NIDCR, NIH #10 1N114,<br />
Bethesda, MD<br />
5:45 PM<br />
2179. EBV-mir-Bart13 Downregulates Stim1, a Protein Involved<br />
in Calcium Signaling, in Human Salivary Gland Cells and May<br />
Contribute to the Pathogenesis <strong>of</strong> Sjögren’s Syndrome.<br />
Alessia Gallo 1 , Mayank Tandon 1 , Gabor G. Illei 2 and Ilias Alevizos 1 ,<br />
1<br />
National Insitutes <strong>of</strong> Health-National Institute <strong>of</strong> Dental and<br />
Crani<strong>of</strong>acial Research, 2 NIDCR, NIH #10 1N114, Bethesda, MD<br />
A311<br />
Spondylarthropathies and Psoriatic Arthritis - Clinical<br />
Aspects and Treatment - Biomarkers II<br />
Moderators: Daniel O. Clegg, MD; University <strong>of</strong> Utah Medical<br />
Center; Salt Lake City, UT<br />
Robert Landewe, MD; University Hospital Maastricht;<br />
Maastricht, The Netherlands<br />
4:30 PM<br />
2180. Striking Prevalence <strong>of</strong> Axial Spondyloarthritis in Primary<br />
Care Patients with Chronic Low Back Pain; a Cross-Sectional<br />
Study.<br />
Lonneke van Hoeven 3 , Jolanda Luime 1 , Huub Han 2 and Angelique<br />
Weel 4 , 1 Erasmus Medical Centre, 2 Maasstadziekenhuis,<br />
3<br />
Maasstadziekenhuis / Erasmus Medical Centre, Rotterdam, The<br />
Netherlands, 4 Maasstadziekenhuis Rotterdam, Rotterdam, The<br />
Netherlands<br />
4:45 PM<br />
2181. Screening for Axial Spondyloarthritis in a Primary Care:<br />
Comparison <strong>of</strong> Two Strategies in a Multicenter Prospective<br />
Study.<br />
Denis Poddubnyy 1 , Janis Vahldiek 1 , Inge Spiller 1 , Beate Buss 1 ,<br />
Martin Rudwaleit 1 and Joachim Sieper 2 , 1 Charité - Campus<br />
Benjamin Franklin, Berlin, Germany, 2 Charite Campus Benjamin<br />
Frankl, Berlin, Germany<br />
5:00 PM<br />
2182. Do the New EULAR/ACR Rheumatoid Arthritis<br />
Classification Criteria Identify Early Psoriatic Arthritis Patients?<br />
Laura C. Coates 2 , Philip G. Conaghan 2 , Paul Emery 2 , Michael J.<br />
Green 3 , Gamal Ibrahim 1 , Helen MakIver 1 and Philip S. Helliwell 2 ,<br />
1<br />
Bradford Hospitals NHS Trust, UK, Bradford, United Kingdom,<br />
2<br />
LIMM, Section <strong>of</strong> Musculoskeletal Disease, University <strong>of</strong> Leeds,<br />
Leeds, UK, 3 York Hospitals NHS Trust, York, UK<br />
5:15 PM<br />
2183. The CASPAR Criteria Can Be Used To Identify Early<br />
Psoriatic Arthritis.<br />
Laura C. Coates 2 , Philip G. Conaghan 3 , Paul Emery 3 , Michael J.<br />
Green 4 , Gamal Ibrahim 1 , Helen MakIver 1 and Philip S. Helliwell 3 ,<br />
1<br />
Bradford Hospitals NHS Trust, UK, Bradford, United Kingdom,<br />
2<br />
LIMM, Section <strong>of</strong> Musculoskeletal Disease, University <strong>of</strong> Leeds,<br />
Leeds, United Kingdom, 3 LIMM, Section <strong>of</strong> Musculoskeletal<br />
Disease, University <strong>of</strong> Leeds, UK, 4 York Hospital NHS Trust, York,<br />
UK<br />
5:30 PM<br />
2184. Supppression <strong>of</strong> Both DKK-1 and SOST in a Mouse<br />
Model <strong>of</strong> Ankylosing Spondylitis Implicates the WNT-Signalling<br />
Pathway in the Linkage <strong>of</strong> Inflammation and Bony Ankylosis in<br />
Spondyloarthritis.<br />
Gethin P. Thomas 2 , Ran Duan 3 , Allison Pettit 4 , Tibor Glant 1 and<br />
Matthew A. Brown 2 , 1 Rush University Medical Center, 2 The<br />
University <strong>of</strong> Queensland Diamantina Institute, 3 The University<br />
<strong>of</strong> Queensland Diamantina Institute, 4 University <strong>of</strong> Queensland<br />
Centre for Clinical Research<br />
5:45 PM<br />
2185. Genetic and Clinical Correlates in African <strong>American</strong>s with<br />
Ankylosing Spondylitis.<br />
Shervin Assassi 4 , Julie T. Dang 3 , Michael M. Ward 2 , Joel D.<br />
Taurog 6 , Michael H. Weisman 1 and John D. Reveille 5 , 1 Cedars-<br />
Sinai Medical Center, Los Angeles, CA, 2 NIH, NIAMS, IRP,<br />
Bethesda, MD, 3 Univ <strong>of</strong> Texas Health Science Center at Houston,<br />
4<br />
Univ <strong>of</strong> Texas Health Science Center at Houston, Houston, TX,<br />
5<br />
Univ Texas Health Sci Ctr, Houston, TX, 6 U-Texas SW Med Ctr,<br />
Dallas, TX<br />
A315<br />
Systemic Lupus Erythematosus - Animal Models<br />
Moderators: Philip L. Cohen, MD; Temple University;<br />
Philadelphia, PA<br />
Jane E. Salmon, MD; Hospital for Special Surgery; New York, NY<br />
4:30 PM<br />
2186. Neutrophil Gelatinase Associated Lipocalin (NGAL) and<br />
Its Role in the Pathogenesis <strong>of</strong> Nephritis Induced by Pathogenic<br />
Antibodies.<br />
Rahul Pawar 4 , Simona Gindea 4 , Arlene T. Tieng 3 , MIlena<br />
Pitashny 4 , Leal Herlitz 5 , Benjamin E. Levine 2 , Thorsten Berger 6 ,<br />
Tak W. Mak 6 and Chaim Putterman 1 , 1 Albert Einstein <strong>College</strong><br />
<strong>of</strong> Med, Bronx, NY, 2 Albert Einstein <strong>College</strong> <strong>of</strong> Medicine,<br />
Woodmere, NY, 3 Albert Einstein <strong>College</strong> <strong>of</strong> Medicine, Bronx, NY,<br />
4<br />
Albert Einstein <strong>College</strong> <strong>of</strong> Medicine, 5 Columbia-Presbyterian<br />
School <strong>of</strong> Medicine, 6 The Campbell Family Institute for Breast<br />
Cancer Research, Toronto, ON, Canada<br />
wednesday<br />
2010 Program Book 127
wednesday<br />
4:45 PM<br />
2187. Dependence <strong>of</strong> IFNα-Exaggerated Immunopathology and<br />
Clinical Disease on B Cells and BAFF in SLE-Prone NZM 2328<br />
Mice.<br />
Noam Jacob 6 , Shunhua Guo 6 , Alexis Mathian 3 , Michael N. Koss 6 ,<br />
Simona Gindea 2 , Chaim Putterman 1 , Chaim O. Jacob 5 and William<br />
Stohl 4 , 1 Albert Einstein <strong>College</strong> <strong>of</strong> Med, Bronx, NY, 2 Albert<br />
Einstein <strong>College</strong> <strong>of</strong> Medicine, 3 Hôpital de la Pitié-Salpêtrière,<br />
4<br />
Univ Southern California, Los Angeles, CA, 5 University <strong>of</strong><br />
Southern California Keck School <strong>of</strong> Medicine, Los Angeles, CA,<br />
6University <strong>of</strong> Southern California Keck School <strong>of</strong> Medicine<br />
5:00 PM<br />
2188. IFNα Induced SLE in NZB/W Mice Is T Cell Dependent but<br />
Blockade <strong>of</strong> TFH Does Not Prevent Disease.<br />
Zheng Liu 1 , Ramalingam Bethunaickan 1 , Weiqing Huang 1 and<br />
Anne Davidson 2 , 1 Feinstein Institute, 2 Feinstein Institute for<br />
Medical Research, Manhasset, NY<br />
5:15 PM<br />
2189. Type I IFN-Dependent CD86high Marginal Zone-Precursor<br />
B Cells Are Potent T Cell Costimulators in the BXD2 Mouse<br />
Model <strong>of</strong> Lupus.<br />
John S. Wang 3 , Qi Wu 3 , PingAr Yang 1 , Hao Li 1 , Jun Li 1 , John D.<br />
Mountz 2 and Hui-Chen Hsu 1 , 1 Univ Alabama at Birmingham,<br />
2<br />
Univ Alabama at Birmingham and VA Medical Center,<br />
Birmingham, AL, 3 Univ <strong>of</strong> Alabama at Birmingham<br />
5:30 PM<br />
2190. Identification <strong>of</strong> a Genetic Locus on New Zealand<br />
Black Chromosome 1 Congenic Mice That Leads to Increased<br />
Generation <strong>of</strong> T Follicular Helper and TH17 Cells.<br />
Nafiseh Talaei 4 , Yui-Ho Cheung 3 , Carolina Landolt-Marticorena 4 ,<br />
Babak Noamani 1 and Joan E. Wither 2 , 1 Toronto Western Research<br />
Institute, 2 University Health Network, Toronto, ON, Canada,<br />
3<br />
University <strong>of</strong> Toronto, 4 University <strong>of</strong> Toronto, Toronto, ON,<br />
Canada<br />
5:45 PM<br />
2191. Histone Deacetylase 9 Acts as an Epigenetic Switch<br />
in Aberrant CD4 T Cell Plasticity and PPAR-g Regulation in<br />
Systemic Lupus Erythematosus.<br />
Nilamadhab Mishra 3 , Kailin Yan 5 , Qiang Cao 6 , Christopher M.<br />
Reilly 2 , Jennifer Cann 4 and Benjamin A. Garcia 1 , 1 Princeton<br />
University, 2 Virginia Polytechnic Institute and State University<br />
and Edward Via <strong>College</strong> <strong>of</strong> Osteopathic Medicine, 3 Wake Forest<br />
Univ Health Scienc, Winston-Salem, NC, 4 Wake Forest University<br />
School <strong>of</strong> Medicine, 5 Wake Forest Unv Health Sciences, 6 Wake<br />
Forest UnvHealth Sciences<br />
A412<br />
Systemic Sclerosis, Fibrosing Syndromes, and<br />
Raynaud’s - Clinical Aspects and Therapeutics II<br />
Moderators: Murray Baron, MD; Jewish General Hospital; McGill,<br />
Canada<br />
Eric Hachulla, MD, PhD; National Scleroderma Centre; Lille<br />
Cedex, France<br />
4:30 PM<br />
2192. Long-Term Benefit <strong>of</strong> Mycophenolate M<strong>of</strong>etil for<br />
Treatment <strong>of</strong> Diffuse Cutaneous Systemic Sclerosis.<br />
Elizabeth Le 3 , Fredrick M. Wigley 1 , Ami A. Shah 2 , Francesco Boin 2<br />
and Laura K. Hummers 2 , 1 Johns Hopkins University, Baltimore,<br />
MD, 2 Johns Hopkins University, Baltimore, MD, 3 Johns Hopkins<br />
University<br />
4:45 PM<br />
2193. Imatinib Mesylate (Gleevec) in the Treatment <strong>of</strong> Diffuse<br />
Cutaneous Systemic Sclerosis: Results <strong>of</strong> a One Year, Phase IIa,<br />
Single Arm, Open Label Clinical Trial.<br />
Robert F. Spiera 1 , Jessica K. Gordon 2 , Jamie Mersten 2 , Cynthia<br />
Magro 3 , Mansi Mehta 2 , Horatio Wildman 3 , Stacey Kloiber 2 ,<br />
Kyriakos A. Kirou 2 , Stephen Lyman 2 and Mary K. Crow 2 , 1 Hospital<br />
for Special Surgery, New York, NY, 2 Hospital for Special Surgery,<br />
3<br />
Weill-Cornell Medical <strong>College</strong><br />
5:00 PM<br />
2194. Serious Complications and Mortality among 158 Patients<br />
with Systemic Sclerosis (SSc) in the Scleroderma Lung Study<br />
(SLS) Followed for up to 9 Years.<br />
Daniel E. Furst 4 , Dinesh Khanna 3 , Philip J. Clements 5 , Keith<br />
Sullivan 1 and Donald P. Tashkin 2 , 1 Duke, Durham, NC, 2 UCLA,<br />
3<br />
University <strong>of</strong> California Los Angeles, Los Angeles, CA, 4 University<br />
<strong>of</strong> California Los Angeles Medical School, Los Angeles, CA,<br />
5<br />
University <strong>of</strong> California Los Angeles School <strong>of</strong> Medicine, Los<br />
Angeles, CA<br />
5:15 PM<br />
2195. Productivity at Home and Work Place in Scleroderma –<br />
Analysis from the UCLA Scleroderma Quality <strong>of</strong> Life Study.<br />
Manjit K. Singh, Philip J. Clements, Daniel Furst, Paul Maranian<br />
and Dinesh Khanna, UCLA, Los Angeles, CA<br />
5:30 PM<br />
2196. Results <strong>of</strong> the Delphi for EULAR/ACR Classification<br />
Criteria Working Group in Systemic Sclerosis.<br />
Jaap Fransen 4 , Sindhu R. Johnson 5 , Alan Tyndall 6 , Murray<br />
Baron 1 , Marco Matucci-Cerinic 8 , Frank van den Hoogen 2 ,<br />
Janet E. Pope 3 and Dinesh Khanna 7 , 1 Jewish General Hospital,<br />
Montreal, QC, Canada, 2 Sint Maartenskliniek, 3 St Joseph Health<br />
Care London, London, ON, Canada, 4 The Radboud University<br />
Nijmegen Medical Centre, 5 Toronto Western Hospital, Toronto,<br />
ON, Canada, 6 University <strong>of</strong> Basel, 7 University <strong>of</strong> California Los<br />
Angeles, Los Angeles, CA, 8 University <strong>of</strong> Florence, Firenze, Italy<br />
5:45 PM<br />
2197. Antinuclear Antibody Screening in Systemic Sclerosis.<br />
Donna Rose Swistowski 2 , Nicole Saddic 3 , Victoria K. Shanmugam 1<br />
and Virginia D. Steen 4 , 1 Georgetown University Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Immunology, and Allergy, Great Falls, VA,<br />
2<br />
Georgetown University Division <strong>of</strong> <strong>Rheumatology</strong>, Immunology,<br />
and Allergy, Bethesda, MD, 3 Georgetown University Hospital<br />
Department <strong>of</strong> Medicine, 4 Georgetown University Medical<br />
Center, Washington, DC<br />
B408<br />
Vasculitis II<br />
Moderators: Paul A. Monach, MD; Boston University; Boston,<br />
MA<br />
Cornelia M. Weyand, MD, PhD; Stanford University School <strong>of</strong><br />
Medicine; Stanford, CA<br />
128<br />
2010 Program Book
4:30 PM<br />
2198. Association between Vascular Physical Examination<br />
Findings and Angiographically-Detected Arterial Lesions in<br />
Subjects with Large Vessel Vasculitis.<br />
Peter C. Grayson 4 , Gunnar Tomasson 3 , David Cuthbertson 11 ,<br />
Simon Carette 9 , Gary S. H<strong>of</strong>fman 6 , Nader A. Khalidi 10 , Carol A.<br />
Langford 5 , Carol McAlear 4 , Paul A. Monach 1 , Philip Seo 7 , Kenneth<br />
J. Warrington 8 , Steven R. Ytterberg 8 and Peter A. Merkel 2 ,<br />
1<br />
Boston University, Boston, MA, 2 Boston University School <strong>of</strong><br />
Medicine, West Newton, MA, 3 Boston University School <strong>of</strong><br />
Medicine, Boston, MA, 4 Boston University School <strong>of</strong> Medicine,<br />
5<br />
Cleveland Clinic Foundation, Cleveland, OH, 6 Cleveland Clinic<br />
Foundation, Pepper Pike, OH, 7 Johns Hopkins Bayview Medical<br />
Center, Baltimore, MD, 8 Mayo Clinic, Rochester, MN, 9 Toronto<br />
Western Hospital, Toronto, ON, Canada, 10 University <strong>of</strong> Hamilton,<br />
Hamilton, ON, Canada, 11 University <strong>of</strong> South Florida<br />
4:45 PM<br />
2199. Sex, Age, and Birth Cohort Effects on Incidence <strong>of</strong> Giant<br />
Cell Arteritis.<br />
Maureen Dubreuil 1 , Hyon K. Choi 2 , Yuqing Zhang 2 and Yanyan<br />
Zhu 2 , 1 Boston Medical Center, Boston, MA, 2 Boston University<br />
School <strong>of</strong> Medicine, Boston, MA<br />
5:00 PM<br />
2200. Identification <strong>of</strong> JAK1 as a Candidate Inflammatory<br />
Signalling Pathway by Genome-Wide Expression Pr<strong>of</strong>iling in<br />
Monocytes from Patients with Behcet’s Disease.<br />
Haner Direskeneli 3 , Joseph J. Boyle 1 , Filiz T. Ozdemir 3 , Vuslat<br />
Yilmaz 2 , Emel Eksioglu-Demiralp 3 , Dorian Haskard 1 and Guher<br />
Saruhan-Direskeneli 2 , 1 Cardiovascular Sciences Centre, Imperial<br />
<strong>College</strong>, London, United Kingdom, 2 Istanbul University, Istanbul<br />
Faculty <strong>of</strong> Medicine, Istanbul, Turkey, 3 Marmara University,<br />
School <strong>of</strong> Medicine, Istanbul, Turkey<br />
5:15 PM<br />
2201. A Randomized, Controlled, Multicenter Phase III Study<br />
<strong>of</strong> the Efficacy and Safety <strong>of</strong> Rituximab (RTX) Monotherapy<br />
Versus the Best Available Treatment in Patients with Mixed<br />
Cryoglobulinemia Syndrome.<br />
Salvatore De Vita 15 , Luca Quartuccio 15 , Miriam Isola 8 , Paola<br />
Masolini 16 , Stefania Sacco 15 , Ginevra De Marchi 15 , Cesare<br />
Mazzaro 6 , Patrizia Scaini 13 , Marco Lenzi 4 , Mauro Campanini 1 ,<br />
Salvatore Scarpato 21 , Antonio Tavoni 20 , Maurizio Pietrogrande 9 ,<br />
Clodoveo Ferri 19 , Maria Teresa Mascia 18 , Dario Roccatello 3 , Anna<br />
Linda Zignego 2 , Paolo Pioltelli 11 , Armando Gabrielli 12 , Davide<br />
Filippini 14 , Oreste Perrella 5 , Sergio Migliaresi 17 , Massimo Galli 7 ,<br />
Giuseppe Monti 10 and Stefano Bombardieri 20 , 1 A.O. Maggiore-<br />
Medicina II, Novara, Italy, 2 Center for Systemic Manifestations<br />
<strong>of</strong> Hepatitis Viruses (MaSVE), Department <strong>of</strong> Internal Medicine,<br />
University <strong>of</strong> Florence, Florence, Italy, 3 Centro di Ricerche<br />
di Immunopatologia e Documentazione su Malattie Rare,<br />
Struttura Complessa a Direzione Universitaria di Immunologia<br />
Clinica, Ospedale S.G. Bosco, Torino, Italy, 4 Department <strong>of</strong><br />
Clinical Medicine, University <strong>of</strong> Bologna, S. Orsola-Malpighi<br />
Hospital, Bologna, Italy, 5 Department <strong>of</strong> Infectious Diseases and<br />
Immunology, Cotugno Hospital, Naples, Italy, 6 Department <strong>of</strong><br />
Internal Medicine, Pordenone General Hospital, Pordenone,<br />
Italy, 7 Dipartimento di Scienze Cliniche Luigi Sacco, Sezione di<br />
Malattie Infettive e Immunopatologia, Università degli Studi,<br />
Ospedale Luigi Sacco, Milano, Italy, 8 Institute <strong>of</strong> Statistics,<br />
University <strong>of</strong> Udine, Udine, Italy, Italy, 9 Internal Medicine Unit,<br />
Policlinico San Marco, Bergamo, Italy, Italy, 10 Internal Medicine<br />
Unit, Saronno Hospital, Azienda Ospedaliera di Busto Arsizio,<br />
Saronno, VA, Italy, Italy, 11 Internal Medicine, Donizetti Hospital,<br />
Monza, Italy, Italy, 12 Internal Medicine, Università Politecnica<br />
delle Marche, Ancona, Italy, Italy, 13 Nephrology Unit, Spedali<br />
Riuniti, Brescia, Italy, Italy, 14 <strong>Rheumatology</strong> Clinic, A.O. Niguarda<br />
Ca’ Granda Hospital, Milan, Italy, 15 <strong>Rheumatology</strong> Clinic, Azienda<br />
Ospedaliero-Universitaria “S. Maria della Misericordia”, Udine,<br />
Italy, 16 <strong>Rheumatology</strong> Clinic, Azienda Ospedaliero-Universitaria<br />
“S. Maria della Misericordia”, Udine, Italy, 17 <strong>Rheumatology</strong><br />
Clinic, University <strong>of</strong> Naples, Italy, Italy, 18 <strong>Rheumatology</strong> Unit,<br />
Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Modena e Reggio<br />
Emilia, Italy, Italy, 19 <strong>Rheumatology</strong> Unit, Department <strong>of</strong> Internal<br />
Medicine, University <strong>of</strong> Modena, Italy, Italy, 20 <strong>Rheumatology</strong><br />
Unit, Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Pisa, Pisa,<br />
Italy, Italy, 21 <strong>Rheumatology</strong> Unit, M. Scarlato Hospital, Scafati,<br />
Salerno, Italy, Italy<br />
5:30 PM<br />
2202. A New Polymorphism <strong>of</strong> the Fibroblast Growth Factor<br />
(FGF)23 Gene: A Promising Predictor <strong>of</strong> Coronary Damage in<br />
Kawasaki Disease (KD).<br />
Fernanda Falcini 1 , Laura Masi 3 , Francesco Franceschelli 3 , Gigliola<br />
Leoncini 3 , Serena Capannini 1 , Francesco La Torre 4 , Giuseppina<br />
Calcagno 4 , Marco Matucci Cerinic 2 and Maria Luisa Brandi 3 ,<br />
1<br />
Department <strong>of</strong> BioMedicine, Section <strong>of</strong> <strong>Rheumatology</strong>,<br />
Transition Clinic, University <strong>of</strong> Florence, Florence, Italy,<br />
2<br />
Department <strong>of</strong> BioMedicine, Section <strong>of</strong> <strong>Rheumatology</strong>,<br />
Transition Clinic, University <strong>of</strong> Florence, Florence, Italy,<br />
3<br />
Department <strong>of</strong> Internal Medicine, Metabolic Bone Diseases<br />
Unit, University <strong>of</strong> Florence, Italy, 4 Department <strong>of</strong> Paediatrics,<br />
<strong>Rheumatology</strong> Unit, University <strong>of</strong> Messina<br />
5:45 PM<br />
2203. Mepolizumab, a Humanized Anti-IL-5 Antibody, Has<br />
Steroid-Sparing Potential in Churg-Strauss Syndrome.<br />
Frank Moosig 1 , Kristina Butherus 1 , Bernhard Hellmich 2 and<br />
Wolfgang L. Gross 1 , 1 University Hospital Schleswig Holstein<br />
& Klinikum Bad Bramstedt, 2 University <strong>of</strong> Tübingen &<br />
Kreiskrankenhaus Plochingen<br />
ACR Meet the Pr<strong>of</strong>essor Sessions<br />
4:30 - 6:00 PM<br />
Admission to each Meet the Pr<strong>of</strong>essor session requires a<br />
separate registration and ticket. To verify which session you<br />
registered for, check to make sure the registration code on your<br />
ticket matches the code listed below in parentheses.<br />
B207<br />
Dermatological Manifestations <strong>of</strong> Rheumatic Diseases<br />
(081) f<br />
Speaker: Nicole Fett, MD; Perelman Center for Advanced<br />
Medicine; Philadelphia, PA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• cite the diagnostic criteria for skin diseases with<br />
rheumatologic implications<br />
• construct a differential diagnosis for these conditions<br />
• design a strategy for management <strong>of</strong> skin disease seen in<br />
patients with rheumatologic diseases<br />
wednesday<br />
2010 Program Book 129
wednesday<br />
B208<br />
Infections in Patients on Tumor Necrosis Factor<br />
Therapy (082) PS<br />
Speaker: Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the risks <strong>of</strong> infections, including opportunistic<br />
infections, with biological response modifier therapies for<br />
rheumatoid arthritis<br />
• discuss the principles <strong>of</strong> early detection and management <strong>of</strong><br />
infections in patients who develop infections<br />
• determine ways to reduce the risk <strong>of</strong> occurrence <strong>of</strong> infections<br />
in patients with rheumatoid arthritis<br />
B209<br />
Pain: Evaluation and Treatment <strong>of</strong> Back Pain (083) PM<br />
Speaker: David G. Borenstein, MD; Arthritis & Rheumatism<br />
Association; Washington, DC<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• determine the appropriate use <strong>of</strong> diagnostic tests in the<br />
evaluation <strong>of</strong> low back pain<br />
• review effective therapies for low back pain<br />
• identify the types <strong>of</strong> exercises that prevent and treat low back<br />
pain<br />
B210<br />
Psoriatic Arthritis (084)<br />
Speaker: Dafna D. Gladman, MD; Toronto Western Hospital;<br />
Toronto, ON, Canada<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss advances in diagnosis and classification <strong>of</strong> psoriatic<br />
arthritis<br />
• determine if patients with psoriatic arthritis should be treated<br />
aggressively<br />
• determine treatment options for patients with psoriatic<br />
arthritis<br />
B301<br />
Rheumatoid Arthritis: Difficult Cases (085) f<br />
Speaker: Nancy A. Shadick, MD, MPH; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the management <strong>of</strong> patients with refractory<br />
rheumatoid arthritis<br />
• identify novel treatment options for those failing conventional<br />
therapies<br />
• create effective management plans for complicated<br />
rheumatoid arthritis patients<br />
B302<br />
Rheumatoid Arthritis: Safety <strong>of</strong> Novel Therapies (086)<br />
PS<br />
Speaker: Daniel H. Solomon, MD, MPH; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the management <strong>of</strong> patients with refractory<br />
rheumatoid arthritis<br />
• identify novel treatment options for those failing conventional<br />
therapies<br />
B303<br />
<strong>Rheumatology</strong> Practice 101: Starting Out in Practice<br />
for The Graduating Fellow (087) f<br />
Speaker: Michael J. Maricic, MD; Catalina Pointe <strong>Rheumatology</strong>;<br />
Tucson, AZ<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• appraise contracts with managed care companies and<br />
negotiating opportunities<br />
• evaluate how to buy in to an existing practice, hire a new<br />
associate, and meet the needs <strong>of</strong> a retiring partner<br />
• discuss the pros and cons <strong>of</strong> adding ancillary services (e.g.,<br />
infusion center, densitometry service, etc.), an <strong>of</strong>fice manager<br />
or practice administrator<br />
B304<br />
Spondylarthropathy: An Update (088)<br />
Speaker: Juergen Braun, MD; Rheumazentrum Ruhrgebiet;<br />
Herne, Germany<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the challenge in the early diagnosis <strong>of</strong><br />
spondylarthropathy<br />
• discuss mechanisms <strong>of</strong> disease pathogenesis<br />
• describe current treatment options for spondylarthropathy<br />
B305<br />
Systemic Lupus Erythematosus: Lupus Nephritis (089)<br />
Speaker: Frederic A. Houssiau, MD, PhD; Universite Catholique<br />
Louvain; Brussels, Belgium<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify lupus nephritis in early stages<br />
• describe poor prognostic factors<br />
• evaluate lupus nephritis therapy<br />
B306<br />
Vasculitis: An Update (090)<br />
Speaker: Stuart M. Levine, MD; Johns Hopkins University;<br />
Baltimore, MD<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• understand the strengths and limitations <strong>of</strong> the current blood<br />
vessel size-based vasculitis classification system<br />
• utilize various imaging and laboratory tests in the diagnosis<br />
<strong>of</strong> vasculitis, with emphasis on antineutrophilic cytoplasmic<br />
antibodies<br />
• identify standard and novel therapeutic modalities in the<br />
treatment <strong>of</strong> the systemic vasculitides<br />
130<br />
2010 Program Book
ARHP Concurrent Sessions<br />
4:30 - 6:00 PM<br />
B309<br />
A Foot Orthotic Is Not Just a Foot Orthotic c/r<br />
Moderator: Marian T. Hannan, DSc, MPH; Hebrew Senior Life,<br />
Harvard Medical School; Boston, MA<br />
Speaker: Dennis J. Janisse, C Ped; Medical <strong>College</strong> <strong>of</strong> Wisconsin;<br />
Milwaukee, WI<br />
Session Overview:<br />
Pedorthics is an integral component for treatment/management<br />
<strong>of</strong> rheumatology patients. This session will provide education<br />
about how to lower friction and provide cushioning and support<br />
for the foot and new materials that are being used for foot<br />
orthoses, including ones that are antifungal and antibacterial,<br />
will be discussed.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe pedorthic care and modalities including footwear,<br />
shoe modifications, hosiery, and foot orthoses<br />
• identify new options in foot orthoses for arthritis patients and<br />
other related complications that occur<br />
• discuss ways to provide good care at a lower cost with<br />
innovative premade orthoses<br />
B311<br />
Labs and Treatment Options: What Do They Mean<br />
and How Do You Use? cP<br />
Moderator: Seetha U. Monrad, MD; University <strong>of</strong> Michigan<br />
Medical Center; Ann Arbor, MI<br />
Speakers: Robert W. Lightfoot, MD; University <strong>of</strong> Kentucky<br />
<strong>College</strong> <strong>of</strong> Medicine; Lexington, KY<br />
Mark H. Wener, MD; University <strong>of</strong> Washington; Seattle, WA<br />
Session Overview:<br />
Laboratory testing is an important evaluation tool used in<br />
rheumatology practices. Laboratory tests are frequently used<br />
to screen for, diagnose, and measure disease activity in those<br />
patients with suspected or diagnosed rheumatic disease. A<br />
patient’s history and physical exam along with the sensitivity,<br />
specificity, and the positive and negative predictive value <strong>of</strong> the<br />
specified test guides the interpretation <strong>of</strong> laboratory tests. It is<br />
important that members <strong>of</strong> the rheumatology health care team<br />
understand the principles, the interpretation, and the strengths<br />
and weaknesses <strong>of</strong> the laboratory tests used.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the laboratory tests used to screen for suspected<br />
rheumatic disease<br />
• explain how laboratory tests can assist to diagnose suspected<br />
rheumatic disease<br />
• define how laboratory tests are used to measure disease<br />
activity in those with diagnosed rheumatic disease<br />
B310<br />
Ready, Aim, Get Funded! R<br />
Participants will be limited to 20 and are asked to bring a onepage<br />
draft <strong>of</strong> specific aims for an actual grant proposal with<br />
them for review.<br />
Moderator: Laura D. Bilek, PhD, PT; University Nebraska Med<br />
Center; Omaha, NE<br />
Speakers: Jennifer M. Hootman, PhD; Centers for Disease<br />
Control; Kennesaw, GA<br />
Susan L. Murphy, ScD, OTR; University <strong>of</strong> Michigan; Ann Arbor,<br />
MI<br />
Session Overview:<br />
Successful grant applications start with specific aims that are<br />
clear, feasible and answer the proposed research question.<br />
Specific aims are one <strong>of</strong> the most important pieces <strong>of</strong> the grant<br />
application but <strong>of</strong>ten the most difficult to write. This session<br />
will be a hands-on approach to writing specific aims including<br />
examples <strong>of</strong> good and bad specific aims as well as small group<br />
peer and expert feedback for each participant.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• list characteristics <strong>of</strong> strong specific aims as part <strong>of</strong> the grant<br />
application<br />
• identify the components <strong>of</strong> good and bad specific aims<br />
• apply feedback from experienced grant writers and reviewers<br />
B308<br />
Work Assessments: A ‘How-To’ That Could Save Your<br />
Patient’s Life/Job c/r PS PM<br />
Moderator: Kristina A. Theis, MPH; Centers for Disease Control<br />
and Prevention; Atlanta, GA<br />
4:00 PM<br />
Work Experience Survey: Rheumatic Conditions<br />
Julie J. Keysor, PhD, PT; Boston University Sargent <strong>College</strong>;<br />
Boston, MA<br />
4:30 PM<br />
The Ergonomic Assessment Tool for Arthritis<br />
Catherine L. Backman, PhD, OT(C); University <strong>of</strong> British<br />
Columbia; Vancouver, BC, Canada<br />
5:00 PM<br />
Demonstration on Computer Ergonomics Assessment<br />
Nancy A. Baker, ScD OTR/L; University <strong>of</strong> Pittsburgh; Pittsburgh,<br />
PA<br />
5:30 PM<br />
Questions and Answers<br />
Session Overview:<br />
People with rheumatic conditions are <strong>of</strong>ten at-risk for work<br />
disability, especially in jobs involving repetitive hand-intensive<br />
or manual work and this makes them a prime target for<br />
interventions designed to mediate against job loss. While health<br />
pr<strong>of</strong>essionals may be willing to help patients with their work<br />
challenges, they may not have had the training to do this.<br />
wednesday<br />
2010 Program Book 131
Despite advances in ergonomics and universal design, more<br />
<strong>of</strong>ten than not, people are expected to fit their jobs, rather<br />
than jobs being designed to fit people. Use <strong>of</strong> assessment tools<br />
and knowing the details <strong>of</strong> computer ergonomic assessments<br />
could aid health pr<strong>of</strong>essionals in helping patients to identify<br />
and overcome modifiable arthritis-related work challenges.<br />
This session will describe, from the macro to the micro, how to<br />
perform work assessments using existing tools and techniques<br />
that standardize the process and <strong>of</strong>fer support to health<br />
pr<strong>of</strong>essionals in these situations. Participants will learn what<br />
makes a good assessment tool, including why and how tools can<br />
be useful, when to use the tools and how to apply computer<br />
ergonomic assessment principles to be better able to assist<br />
patients/clients in making their job fit them and their arthritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify at least two currently available work challenge<br />
assessment tools and recognize the purpose and utility <strong>of</strong><br />
each tool<br />
• identify features that make an assessment tool relevant and<br />
useful to the arthritis population<br />
• define the key features <strong>of</strong> a computer ergonomic assessment<br />
• describe simple fixes that can be applied to improve work<br />
space without fear <strong>of</strong> disclosure<br />
wednesday<br />
REF Industry Roundtable-<br />
Supported Symposia<br />
6:30 - 9:30 PM<br />
The REF would like to thank the industry leaders that have made<br />
a significant multi-year commitment to the REF for participation<br />
in the Industry Roundtable.<br />
In appreciation for their commitment, these industry leaders<br />
have been invited to host a symposium during the annual<br />
meeting. In 2010, there are two types <strong>of</strong> symposia <strong>of</strong>fered to<br />
attendees: CME-accredited and non-CME accredited. For CMEaccredited<br />
symposia, the sponsoring organization is responsible<br />
for planning and providing CME credit. The non-CME accredited<br />
symposia have been planned and will be implemented in<br />
accordance with the requirements <strong>of</strong> the FDA and applicable<br />
standards <strong>of</strong> the PhRMA Code on Interactions with Healthcare<br />
Pr<strong>of</strong>essionals. Please visit the organization’s exhibit booth, the<br />
industry-supported symposia booth or see page 282 for more<br />
information.<br />
132<br />
2010 Program Book
THURSDAY, NOVEMBER 11, 2010<br />
ACR/ARHP Registration<br />
6:30 am - 5:00 PM<br />
International Blvd. Foyer<br />
ACR Clinical Symposium<br />
7:30 - 8:30 am<br />
Hall A3<br />
<strong>Rheumatology</strong> Roundup: Highlights from the 2010<br />
Annual Scientific Meeting c/r cP<br />
Speakers: John J. Cush, MD; Baylor Research Institute; Dallas, TX<br />
Arthur Kavanaugh, MD; University <strong>of</strong> California-San Diego; La<br />
Jolla, CA<br />
Session Overview:<br />
This session is intended to be an informative overview and<br />
will help attendees summarize the most interesting, novel,<br />
significant abstracts that were presented during the 2010 annual<br />
meeting. The session is presented by two rheumatologists,<br />
highlighting their respective subjective opinions.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• list research highlights from the scientific presentations<br />
• discuss the clinical impact <strong>of</strong> selected research reports<br />
presented at the meeting<br />
• evaluate the therapeutic potential <strong>of</strong> selected clinical trials<br />
presented at the meeting<br />
ACR Immunology Updates for<br />
Clinicians<br />
7:30 - 8:30 am<br />
B402<br />
Therapeutic Use <strong>of</strong> Mesenchymal Stem Cells in<br />
Rheumatologic Diseases c/r<br />
Moderator: Richard J. Looney, MD; University <strong>of</strong> Rochester;<br />
Rochester, NY<br />
Speaker: Christian Jorgensen, MD, PhD; Hospital Lapeyronie;<br />
Montpellier, France<br />
Session Overview:<br />
Mesenchymal stem cells have the capacity to differentiate<br />
into multiple cell types including chondrocytes, osteoblasts,<br />
adipocytes, myocytes, and fibroblasts. Surprisingly, in<br />
experimental models mesenchymal stem cells have also been<br />
found to ameliorate inflammation, improve angiogenesis, and<br />
prevent fibrosis. Mesenchymal stem cells can be isolated from<br />
bone marrow or fat and can be easily expanded in vitro. There<br />
are now approximately 100 clinical trials using mesenchymal<br />
stem cells including trials for Sjögren’s syndrome, systemic<br />
sclerosis, and lupus nephritis.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the phenotype, distribution, isolation, and in vitro<br />
culture <strong>of</strong> mesenchymal stem cells<br />
• discuss how mesenchymal stem cells have been used in<br />
animal models <strong>of</strong> human disease<br />
• explain how mesenchymal stem cells are being tested as<br />
therapy for human rheumatologic disease<br />
ACR Practice Issues<br />
7:30 - 8:30 am<br />
B406<br />
ICD -10 Preparation - Developing a Blueprint for<br />
Implementation BR cP<br />
Moderators: Christopher L. Colglazier, MD; Kunath, Burte and<br />
Temming MD; Cincinnati, OH<br />
Raymond Hong, MD, MBA; Ohio Permanente Medical Group;<br />
Richfield, OH<br />
Speaker: Gloryanne Bryant, BS, RHIA, RHIT, CCS; Kaiser<br />
Foundation Health Plan Inc. and Hospitals; Oakland, CA<br />
Session Overview:<br />
The Department <strong>of</strong> Health and Human Services announced the<br />
date <strong>of</strong> October 1, 2013 for ICD-10-CM implementation. ICD-10<br />
implementation will ripple across many departments in health<br />
care organizations including health information management,<br />
coding, revenue cycle, billing and patient financial services. ICD-<br />
10 will also stretch into the information technology department,<br />
where s<strong>of</strong>tware and hardware upgrades and solutions will be<br />
needed to manage the new codes. Medical staff leadership<br />
needs to be on board to help reinforce the physician and<br />
clinical documentation changes required to ensure accurate<br />
coding, billing and reimbursement. It is necessary to have an<br />
implementation plan established and begun well in advance to<br />
ensure a successful transition to ICD-10-CM and ICD-10-PCS. A<br />
key to successful planning is the timeliness <strong>of</strong> training and other<br />
activities. It is important for physicians to establish reasonable<br />
plan to prepare themselves and their staff.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• identify the basic variances between ICD-9-CM and ICD-10<br />
• discuss how to locate the necessary resources and information<br />
that is important for physician practices to transition to ICD-10<br />
• identify an appropriate impact assessment plan<br />
ACR State-<strong>of</strong>-the-Art Lectures<br />
7:30 - 8:30 am<br />
B313<br />
Clinical Review: New Insights into Primary Central<br />
Nervous System Vasculitis in Children P<br />
Moderator: Kathleen M. O’Neil, MD; Oklahoma University<br />
Health Science Center; Oklahoma City, OK<br />
Speaker: Susanne M. Benseler, MD, PhD; The Hospital for Sick<br />
Children; Toronto, ON, Canada<br />
Session Overview:<br />
Among the most perplexing and potentially devastating diseases<br />
faced by rheumatologists are the inflammatory diseases <strong>of</strong> the<br />
central nervous system. Collaborative work among neurologists<br />
and rheumatologists, radiology and pathology have helped<br />
identify subsets <strong>of</strong> children with primary central nervous system<br />
vasculitis with differing clinical presentation and diagnostic<br />
findings that impact how one approaches and treats these<br />
extremely ill children.<br />
2010 Program Book 133<br />
thursday
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the clinical spectrum <strong>of</strong> inflammatory central nervous<br />
system disease in children<br />
• discuss the current diagnostic evaluation <strong>of</strong> these children<br />
• review the data on treatment <strong>of</strong> children with different<br />
presentations <strong>of</strong> central nervous system vasculitis and how<br />
this affects outcome<br />
Sidney J. Marcus Auditorium<br />
Pain, the Brain, and the Immune System: Links to<br />
Understanding Pain Management R PM<br />
Moderator: James P. Witter, MD, PhD; NIH/NIAMS; Bethesda,<br />
MD<br />
Speaker: Joyce A. DeLeo, PhD; Dartmouth Medical School;<br />
Hanover, NH<br />
Session Overview:<br />
Treatment <strong>of</strong> pain remains a major clinical challenge due to the<br />
chronic nature <strong>of</strong> many <strong>of</strong> the diseases and conditions cared<br />
for by rheumatologists. Clinicians face a dilemma, due to the<br />
recognition that pain is <strong>of</strong>ten not adequately treated, but yet at<br />
the same time current treatments are under scrutiny due to a<br />
rise in complications. Better treatment approaches are needed.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• distinguish between acute pain and chronic pain<br />
• describe the mechanisms <strong>of</strong> chronic pain including peripheral,<br />
spinal and supraspinal sites <strong>of</strong> modulation<br />
• translate the knowledge <strong>of</strong> mechanisms <strong>of</strong> chronic pain into<br />
different therapeutic approaches with a focus on glia and the<br />
immune system<br />
8:00 am<br />
2205. Safety without Borders: Upper and Lower<br />
Gastrointestinal Safety <strong>of</strong> Celecoxib in a Pooled Analysis <strong>of</strong><br />
52 Prospective, Randomised, Double-Blinded, Parallel-Group<br />
Clinical Trials.<br />
Gurkirpal Singh 3 , George Triadafilopoulos 3 , Naurang Agrawal 1 ,<br />
Ge<strong>of</strong>f Makinson 2 , Chunming Li 2 and Ha Nguyen 2 , 1 KUMC, 2 Pfizer,<br />
3<br />
Stanford University<br />
8:15 am<br />
2206. Dose Matters: The Risk <strong>of</strong> Complicated Gastroduodenal<br />
Ulcers with Naproxen Is Dose-Dependent.<br />
Gurkirpal Singh 3 , Ajitha Mannalithara, Amrita Sehgal 4 , Alka<br />
Mithal 2 , Mark Sostek 1 and George Triadafilopoulos 3 , 1 Astra<br />
Zeneca, 2 ICORE, 3 Stanford University, 4 University <strong>of</strong> California<br />
Berkeley<br />
8:30 am<br />
2207. Disappointing Responsiveness <strong>of</strong> the SF-6D to<br />
Improvement in Patients Receiving a First TNF-Blocker: Results<br />
<strong>of</strong> the DREAM Registry.<br />
Laurien Buitinga 3 , Louise M. A. Braakman-Jansen 4 , Erik Taal 4 ,<br />
Wietske Kievit 1 , Henk Visser 2 , Piet L. C. M . Van Riel 1 and Mart A.<br />
F. J. van de Laar 5 , 1 Radboud University Nijmegen Medical Centre,<br />
2<br />
Rijnstate Hospital, Arnhem, 3 University <strong>of</strong> Twente, Enschede,<br />
Overijssel, The Netherlands, 4 University <strong>of</strong> Twente, Enschede,<br />
The Netherlands, 5 University <strong>of</strong> Twente; Medical Spectrum<br />
Twente, Enschede<br />
ARHP Concurrent Sessions<br />
7:45 - 8:45 am<br />
thursday<br />
ARHP Concurrent Abstract Session<br />
7:45 - 8:45 am<br />
B311<br />
Rheumatic Medications: More or Less?<br />
Moderator: Donald R. Miller, PharmD; North Dakota State<br />
University; Fargo, ND<br />
7:45 am<br />
2204. Periodontal Disease Hampers Anti-TNF Treatment<br />
Response in Rheumatoid Arthritis.<br />
Cynthia Savioli 1 , Gisele Maria Campos Fabri 2 , Ana Luisa Calich 5 ,<br />
Ana Cristina Medeiros Ribeiro 5 , Julio Cesar Moraes 5 , Carla<br />
Gonçalves Saad 5 , Jozélio Freire Carvalho 5 , Clovis Almeida Silva 4 ,<br />
Eloísa Bonfá 5 and José Tadeu Tesseroli Siqueira 3 , 1 Dentistry and<br />
<strong>Rheumatology</strong> Division (CEDMAC), Faculdade de Medicina da<br />
Universidade de São Paulo, Osasco, São Paulo, Brazil, 2 Dentistry<br />
and <strong>Rheumatology</strong> Division (CEDMAC), Faculdade de Medicina<br />
da Universidade de São Paulo, 3 Dentistry Division, Faculdade<br />
de Medicina da Universidade de São Paulo, 4 Paediatric<br />
<strong>Rheumatology</strong> Unit, <strong>Rheumatology</strong> Division (CEDMAC),<br />
Faculdade de Medicina da Universidade de São Paulo,<br />
5<br />
<strong>Rheumatology</strong> Division (CEDMAC), Faculdade de Medicina da<br />
Universidade de São Paulo<br />
B308<br />
How to Understand and Apply the Results <strong>of</strong> a Journal<br />
Article: What You Really Need to Know About<br />
Statistics c/r<br />
Moderator: Robert R. McLean, DSc, MPH; Hebrew Senior Life;<br />
Boston, MA<br />
Speaker: Nancy A. Baker, ScD OTR/L; University <strong>of</strong> Pittsburgh;<br />
Pittsburgh, PA<br />
Session Overview:<br />
As health care moves towards making evidence-based practice a<br />
standard <strong>of</strong> care, it is increasingly necessary for practitioners to<br />
have the tools for integrating evidence into practice. To achieve<br />
evidence-based practice health care practitioners must be able<br />
to read and understand the results <strong>of</strong> a research study so they<br />
can apply the results to clinical practice. Unfortunately, many<br />
health care practitioners are unable to interpret the statistics<br />
used in a typical journal article. Interpreting and communicating<br />
the evidence to patients, clinical associates and third party<br />
payers is difficult without the ability to understand statistics. This<br />
presentation will assist practitioner to link evidence to practice<br />
by providing practitioners with a concrete explanation <strong>of</strong> basic<br />
statistics and their interpretation. From this knowledge <strong>of</strong><br />
statistics, the results <strong>of</strong> a research article will be interpreted and<br />
then applied to a case study drawn from clinical practice.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the basic types <strong>of</strong> statistics and how to interpret<br />
them<br />
134<br />
2010 Program Book
• apply these basic statistics to interpret the results section <strong>of</strong> a<br />
journal article<br />
• apply the results <strong>of</strong> the journal article to a case study<br />
B309<br />
Measure by Measure: Assessing Psychological Health<br />
and Well-Being in Scleroderma c/r PM PS<br />
Moderator: Janet L. Poole, PhD, OTR; University <strong>of</strong> New Mexico;<br />
Albuquerque, NM<br />
Speakers: Ghassan El Baalbaki, PhD; Jewish General Hospital;<br />
Montreal, QC, Canada<br />
Katherine Milette, BSc; Jewish General Hospital; Montreal, QC,<br />
Canada<br />
Brett D. Thombs, BA, MA, PhD; McGill University; Montreal, QC,<br />
Canada<br />
Session Overview:<br />
Patient-reported outcomes relate to patient health, well-being,<br />
and response to treatment based on patient perspectives.<br />
Patient-reported outcomes may reflect broad constructs, such<br />
as quality <strong>of</strong> life or disability, or narrower constructs, such<br />
as individual symptoms including pain or fatigue. There is<br />
relatively little research on important patient-reported outcomes<br />
related to psychological health and well-being in scleroderma,<br />
including pain, pruritus (itching), sexual function, body image,<br />
depression, and fatigue. One factor that has hindered research<br />
on patient-reported outcomes related to psychological health<br />
and well-being in scleroderma is the lack <strong>of</strong> assessment tools<br />
validated for use with scleroderma patients. Since scleroderma is<br />
a uniquely complex, multi-system disease that impacts patients<br />
in many different ways, it is important to have measures that are<br />
validated specifically for use in scleroderma. There are validation<br />
data for broad measures <strong>of</strong> quality <strong>of</strong> life and disability, as well<br />
as data supporting the use <strong>of</strong> a visual analog scale to measure<br />
pain in scleroderma. Until recently, however, there were no<br />
validation data on any other patient-reported outcomes,<br />
including depression, fatigue, pruritus, sexual function, or body<br />
image. The low prevalence <strong>of</strong> scleroderma has historically made<br />
funding for research difficult. However, with startup funds<br />
from a Canadian Institutes <strong>of</strong> Health Research (CIHR) Team<br />
Development grant and ongoing funding from a CIHR Team grant<br />
(2007-2012), the Canadian Scleroderma Research Group (CSRG)<br />
established a pan-Canadian, multi-center Registry to recruit<br />
patients for annual assessments. There are currently 15 centers<br />
involved, and over 1,000 patients enrolled, with expected<br />
ongoing enrollment <strong>of</strong> 100-150 new patients per year. Data from<br />
this registry including the core concerns related to psychological<br />
health and well-being <strong>of</strong> patients with scleroderma and the<br />
validated assessment strategies will be discussed.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• define the characteristics <strong>of</strong> core psychosocial concerns <strong>of</strong><br />
patients with scleroderma<br />
• describe the validated tools to assess symptoms <strong>of</strong><br />
depression, fatigue, pain, pruritus, body image distress and<br />
body image avoidance, and sexual function among patients<br />
with scleroderma<br />
• describe strengths and limitations <strong>of</strong> validated assessment<br />
tools for use among patients with scleroderma<br />
• select publicly-available, validated measures for use in their<br />
own scleroderma studies<br />
B310<br />
Successful Coping with Rheumatic Disease c/r PS<br />
Moderator: Christina Bode, PhD; University <strong>of</strong> Twente;<br />
Enschede, Netherlands<br />
7:45 am<br />
Goal-Management Strategies in Rheumatic Diseases<br />
Christina Bode, PhD; University <strong>of</strong> Twente; Enschede,<br />
Netherlands<br />
8:05 am<br />
Adaptation and Self-Management<br />
Stanton P. Newman, PhD; University <strong>College</strong> London; London,<br />
United Kingdom<br />
8:15 am<br />
Successful Adaptation from the <strong>Rheumatology</strong> Health Care<br />
Provider Perspective<br />
Mart A. van de Laar, MD; University Twente and Medisch<br />
Sprectrum Twente; Enschede, Netherlands<br />
Session Overview:<br />
Unless significant improvements in medical treatment for<br />
inflammatory rheumatic diseases are made, living with arthritis<br />
means taking medication, making life style changes, coping<br />
with pain, fatigue, and decreases in physical functioning.<br />
Besides effects that are directly related to arthritis, patients<br />
have to cope with changes in social relationships, work abilities,<br />
possibilities for participation, the image <strong>of</strong> themselves and also<br />
with changes in their personal, future perspective. Patients <strong>of</strong>ten<br />
describe these demands as “a job on top <strong>of</strong> all other aspects<br />
<strong>of</strong> my life.” Criteria for successful adjustment can be defined in<br />
relation to coping with symptoms <strong>of</strong> arthritis or from a more<br />
comprehensive perspective that includes all aspects <strong>of</strong> life.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe different criteria for successful adaptation to a<br />
rheumatic disease<br />
• compare the contribution <strong>of</strong> self-management and goalmanagement<br />
strategies and interventions to successful<br />
adaptation<br />
• discuss how the application <strong>of</strong> self-management and goalmanagement<br />
strategies fit with clinical practice<br />
ACR Basic Science Symposia<br />
9:00 - 10:30 am<br />
B313<br />
Bisphosphonates: Mechanism <strong>of</strong> Action and<br />
Optimizing Clinical Use R<br />
Moderator: Steven R. Goldring, MD; Hospital for Special Surgery;<br />
New York, NY<br />
9:00 AM<br />
Structural and Functional Properties <strong>of</strong> Bisphosphonates<br />
R. Graham Russell, MD, PhD, FRS; The Botnar Research Centre,<br />
Univesity <strong>of</strong> Oxford; Headington, Oxford, United Kingdom<br />
9:30 AM<br />
Effects <strong>of</strong> Bisphosphonates on Bone Remodeling and Quality<br />
David B. Burr, PhD; Indiana University School <strong>of</strong> Medicine;<br />
Indianapolis, IN<br />
thursday<br />
2010 Program Book 135
thursday<br />
10:00 AM<br />
Optimal use <strong>of</strong> Bisphosphonates in Clinical Disorders<br />
Felicia Cosman, MD; Helen Hayes Hospital; West Haverstraw, NY<br />
Session Overview:<br />
The mechanism <strong>of</strong> action <strong>of</strong> bisphosphonates has been<br />
elucidated and has led to new insights and potential applications<br />
for treatment <strong>of</strong> skeletal disorders. Optimizing their clinical use<br />
and avoidance <strong>of</strong> potential complications is critically important<br />
in the treatment <strong>of</strong> patients with skeletal disorders.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the mechanism <strong>of</strong> action <strong>of</strong> bisphosphonates<br />
• discuss the optimal therapeutic use in treating skeletal<br />
disorders<br />
• describe potential novel bisphosphonates and their clinical<br />
application<br />
Thomas J. Murphy Ballroom<br />
Immunopathogenesis <strong>of</strong> Systemic Sclerosis R<br />
Moderator: Robert A. Lafyatis, MD; Boston University School <strong>of</strong><br />
Medicine; Arlington, MA<br />
9:00 AM<br />
Gene Expression Analyses - Insights into Immune Dysreguation<br />
in Systemic Sclerosis<br />
Filemon K. Tan, MD, PhD; University <strong>of</strong> Texas - Houston Medical<br />
School; Houston, TX<br />
9:30 AM<br />
Connecting Inflammation and Fibrosis - Innate Immunity in<br />
Systemic Sclerosis<br />
Robert A. Lafyatis, MD; Boston University School <strong>of</strong> Medicine;<br />
Arlington, MA<br />
10:00 AM<br />
The Basic Biology <strong>of</strong> IL-33 and Its Potential Role in<br />
Inflammation and Fibrosis<br />
Foo Y. Liew, BSc, PhD, DSc; University <strong>of</strong> Glasgow, Glasgow<br />
Biomedical Research Centre; Glasgow, Scotland, United Kingdom<br />
Session Overview:<br />
Our understanding <strong>of</strong> immunity and autoimmunity in systemic<br />
sclerosis pathogenesis has made rapid progress in both<br />
innate adaptive immune mechanisms contributing to fibrosis.<br />
Immune regulatory gene associations with scleroderma have<br />
re-emphasized the importance <strong>of</strong> immune pathogenesis in this<br />
disease.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe basic immune pathogenesis in systemic sclerosis<br />
• identify how innate immunity might lead to inflammation and<br />
fibrosis in target organs<br />
• interpret key pr<strong>of</strong>ibrotic cytokines, their sources and their<br />
roles in fibrosis<br />
• discuss key alterations in gene regulation seen in patients with<br />
systemic sclerosis<br />
ACR Clinical Symposia<br />
9:00 - 10:30 AM<br />
B406<br />
Pediatric Spondylarthropathies: From Genetics to the<br />
Clinic P<br />
Moderators: Larry B. Vogler, MD; Emory University School <strong>of</strong><br />
Medicine; Atlanta, GA<br />
Carlos D. Rose, MD; duPont Hospital for Children; Wilmington,<br />
DE<br />
9:00 AM<br />
Advances in the Genetics and Pathogenesis <strong>of</strong> the<br />
Spondylarthropathies<br />
Robert A. Colbert, MD, PhD; NIAMS/NIH; Bethesda, MD<br />
9:30 AM<br />
Enthesitis Related Arthritis in the Context <strong>of</strong> Juvenile Idiopathic<br />
Arthritis: Clinical Features<br />
Shirley Tse, MD; Hospital for Sick Children; Toronto, ON, Canada<br />
10:00 AM<br />
Using and Interpreting Imaging in the Diagnosis and Monitoring<br />
<strong>of</strong> the Spondylarthropathies<br />
Thomas J. Learch, MD; Cedar-Sinai Medical Center; Los Angeles,<br />
CA<br />
Session Overview:<br />
There have been new developments in disease mechanism for<br />
the spondylarthropathies resulting mainly form work on the<br />
transgenic rat model and the processing <strong>of</strong> the B27 molecule.<br />
The availability <strong>of</strong> new imaging techniques has certainly shed<br />
light on the nature <strong>of</strong> enthesitis and the new discoveries on<br />
the contribution <strong>of</strong> bone in the pathologic process. Finally, the<br />
pediatric spondylarthropathies have been reclassified and now<br />
constitute a new category <strong>of</strong> juvenile idiopathic arthritis; a<br />
critical review <strong>of</strong> the new classification is worthy <strong>of</strong> re-visiting.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• discuss the most widely accepted possible mechanisms <strong>of</strong><br />
disease associated with HLA-B27 moiety<br />
• discuss the clinical features <strong>of</strong> enthesitis related arthritis and<br />
the most characteristic radiologic findings that distinguishes<br />
this group from the other forms <strong>of</strong> chronic arthritis<br />
• discuss the pros and cons <strong>of</strong> classifying the<br />
spondylarthropathies with the rest <strong>of</strong> the subsets <strong>of</strong> juvenile<br />
idiopathic arthritis<br />
Hall A3<br />
Remission in Rheumatoid Arthritis c/r PS<br />
Moderators: David T. Felson, MD, MPH; Boston University School<br />
<strong>of</strong> Medicine; Boston, MA<br />
Maarten Boers, MD, PhD, MSc; VU University Medical Center;<br />
Amsterdam, The Netherlands<br />
9:00 AM<br />
Why Do We Need a New Definition <strong>of</strong> Remission in<br />
Rheumatoid Arthritis?<br />
Maarten Boers, MD, PhD, MSc; VU University Medical Center;<br />
Amsterdam, The Netherlands<br />
136<br />
2010 Program Book
9:15 AM<br />
The ACR/EULAR Definition <strong>of</strong> Rheumatoid Arthritis Remission:<br />
How was it Developed and How Will it Work?<br />
David T. Felson, MD, MPH; Boston University School <strong>of</strong> Medicine;<br />
Boston, MA<br />
9:50 AM<br />
Working Towards a Definition <strong>of</strong> Remission in Juvenile<br />
Idiopathic Arthritis<br />
Carol A. Wallace, MD; University <strong>of</strong> Washington and Seattle<br />
Childrens’s Hospital; Seattle, WA<br />
10:10 AM<br />
Applying Remission Criteria to Clinical Practice<br />
Josef S. Smolen, MD; Krankenhaus Lainz; Vienna, Austria<br />
Session Overview:<br />
As increasingly effective therapies are developed for rheumatoid<br />
arthritis and juvenile idiopathic arthritis, it is more important<br />
than ever to identify patients who achieve remission in<br />
response to these therapies, and to develop tools to measure<br />
and document this response. Recognizing the limitations <strong>of</strong><br />
the existing Pinal’s definition <strong>of</strong> rheumatoid arthritis remission<br />
and the definition based on the Disease Activity Score,<br />
representatives from ACR and EULAR have now developed<br />
a new definition <strong>of</strong> remission. This session will present the<br />
development <strong>of</strong> this definition and review the evidence that<br />
supports it. In addition, work that has been done to develop a<br />
definition <strong>of</strong> disease remission in juvenile idiopathic arthritis will<br />
also be discussed.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the need for a consistent definition <strong>of</strong> remission in<br />
rheumatoid arthritis<br />
• define rheumatoid arthritis remission using the new<br />
definition, in clinical trials and clinical practice<br />
• contrast the elements <strong>of</strong> remission in rheumatoid arthritis<br />
with those in juvenile idiopathic arthritis<br />
• explain the utility <strong>of</strong> defining remission in clinical practice<br />
ACR Concurrent Abstract Sessions<br />
9:00 - 10:30 AM<br />
A404<br />
Epidemiology and Health Services Research: General<br />
Interest<br />
Moderators: Jolanda Cibere, MD, PhD; Arthritis Research Center<br />
<strong>of</strong> Canada; Vancouver, BC, Canada<br />
Shikha Mittoo, MD, MHS; University <strong>of</strong> Manitoba; Winnipeg, MB,<br />
Canada<br />
9:00 AM<br />
2208. Multiple Medications Use in Adults with Chronic Disease,<br />
with and without a Musculoskeletal Condition.<br />
Gillian A. Hawker 3 , Ruth Croxford 1 and Elizabeth M. Badley 2 ,<br />
1<br />
Institute <strong>of</strong> Clinical and Evaluative Sciences, Toronto, Canada,<br />
2<br />
Toronto Western Research Institute, Toronto, ON, Canada,<br />
3<br />
Women’s <strong>College</strong> Hospital, Toronto, ON, Canada<br />
9:15 AM<br />
2209. Population-Based Estimates <strong>of</strong> Common Comorbidities<br />
and Cardiovascular Disease in Ankylosing Spondylitis.<br />
Ann B. I. Bremander 2 , Ingemar F. Petersson 1 , Stefan Bergman4<br />
and Martin Englund 3 , 1 Lund University Hosp, Lund, Sweden,<br />
2<br />
Musculoskeletal Sciences, Department <strong>of</strong> Orthopedics,<br />
Clinical Sciences Lund, Lund University, Oskarstrom, Sweden,<br />
3<br />
Musculoskeletal Sciences, Department <strong>of</strong> Orthopedics, Clinical<br />
Sciences Lund, Lund University, Lund, Sweden, 4 Research and<br />
Development Center, Spenshult Hospital for Rheumatic Diseases,<br />
Oskarstrom, Sweden<br />
9:30 AM<br />
2210. Elevated Maternal Serum Alpha Fetoprotein Predicts<br />
Reduction in RA Disease Symptoms during Pregnancy but Does<br />
Not Reduce Risk for Preterm Delivery.<br />
Don Nguyen 4 , Gretchen Bandoli 1 , Diana Johnson 3 and Christina<br />
D. Chambers 2 , 1 San Diego State University, 2 University <strong>of</strong><br />
California San Diego, San Diego, CA, 3 University <strong>of</strong> California San<br />
Diego, 4 University <strong>of</strong> California SanDiego<br />
9:45 AM<br />
2211. Cardiovascular Disease Prevalence in a Primary Care<br />
Cohort <strong>of</strong> Individuals with Inflammatory Arthritis, Diabetes,<br />
and Osteoarthritis: A Comparative Cross-Sectional Study.<br />
Mark M. J. Nielen 4 , Alper M. van Sijl 3 , Mike J. L. Peters 1 , Robert<br />
A. Verheij 4 , Francois G. Schellevis 4 and Michael T. Nurmohamed 2 ,<br />
1<br />
Department <strong>of</strong> Internal Medicine, VU Medical Centre,<br />
Amsterdam, The Netherlands, 2 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Jan van Breemen Institute, Amsterdam, Netherlands,<br />
Amsterdam, The Netherlands, 3 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Jan van Breemen Institute, Amsterdam, Netherlands,<br />
4<br />
Netherlands Institute for Health Services Research (NIVEL),<br />
Utrecht, The Netherlands<br />
10:15 AM<br />
2212. Impact <strong>of</strong> Age, Gender, Obesity, and Steroid Use on<br />
Quinolone-Associated Tendon Disorders.<br />
Barton Wise 3 , Christine Peloquin 2 , Hyon K. Choi 4 , Nancy E. Lane 5<br />
and Yuqing Zhang 1 , 1 Boston Univ School <strong>of</strong> Medicine, Boston,<br />
MA, 2 Boston University School <strong>of</strong> Medicine, Boston, MA, 3 Ctr<br />
for Healthy Aging-UC Davis, Sacramento, CA, 4 Univ <strong>of</strong> British<br />
Columbia, Vancouver, BC, Canada, 5 Univ <strong>of</strong> California at Davis,<br />
Hillsborough, CA<br />
10:30 AM<br />
2213. Bisphosphonate (BisP) Use May Be a Risk Factor<br />
for Osteonecrosis (ON) in Those Who Have Not Used<br />
Glucocorticoids (GCs): Data from the Health Improvement<br />
Network (THIN).<br />
Steven C. Vlad 2 , Hyon K. Choi 3 , Christine Peloquin 2 and Yuqing<br />
Zhang 1 , 1 Boston Univ School <strong>of</strong> Medicine, Boston, MA, 2 Boston<br />
University School <strong>of</strong> Medicine, Boston, MA, 3 Univ <strong>of</strong> British<br />
Columbia, Vancouver, BC, Canada<br />
A411<br />
Genetics, Genomics and Proteomics: RA and Other<br />
Rheumatic Diseases<br />
Moderators: Lindsey A. Criswell, MD, MPH; University <strong>of</strong><br />
California-San Francisco; San Francisco, CA<br />
John B. Harley, MD; University <strong>of</strong> Oklahoma Health Science<br />
Center; Oklahoma City, OK<br />
thursday<br />
2010 Program Book 137
thursday<br />
9:00 AM<br />
2214. Genome-Wide Association Study <strong>of</strong> Systemic Sclerosis<br />
Clinical Features Identifies New Disease Risk Variants.<br />
Olga Gorlova 16 , Jose-Ezequiel Martin 15 , Blanca Rueda 15 , Bobby P.<br />
C. Koeleman 19 , Maria Teruel 15 , Lina-Marcela Diaz-Gallo 15 , Jasper<br />
C. Broen 12 , Madelon C. Vonk 17 , Carmen P. Simeon 14 , Behrooz Z.<br />
Alizadeh 8 , Marieke J. H. Coenen 8 , Alexandre E. Voskuyl 9 , Annemie<br />
J. Schuerwegh 8 , Piet L. C. M . van Riel 8 , Ruben van ‘t Slot 8 , Annet<br />
Italiaander 8 , Roel A. Oph<strong>of</strong>f 8 , Nico Hunzelmann 3 , Norberto<br />
Ortego-Centeno 6 , Miguel A. González-Gay 6 , María F González-<br />
Escribano 6 , Paolo Airo 4 , Jaap van Laar 1 , Jane Worthington 1 ,<br />
Roger Hesselstrand 7 , Vanessa Smith 2 , Filip de Keyser 2 , Fredric<br />
Houssiau 2 , Meng May Chee 1 , Rajan Madhok 1 , Paul Shiels 1 , Rene<br />
Westhovens 2 , Alexander Kreuter 3 , Hans Kiener 10 , Elfride de<br />
Baere 2 , Torsten Witte 3 , Leonid Padykov 7 , Lars Klareskog 7 , Rafaella<br />
Scorza 4 , Benedicte A. Lie 5 , Anna-Maria H<strong>of</strong>fmann-Vold 3 , Patricia<br />
Carreira 6 , John Varga, Monique Hinchcliff, Annette T. Lee, Pravitt<br />
Gourh, Christopher I. Amos, Gabriella Riemekasten 11 , Ariane<br />
Herrick 20 , Lorenzo Beretta 21 , Peter K. Gregersen 13 , Sandeep<br />
Agarwal 18 , Shervin Assassi 18 , Filemon K. Tan 18 , Frank C. Arnett 18 ,<br />
Timothy R. D. J. Radstake 17 , Maureen D. Mayes 18 and Javier<br />
Martin 15 , 1 United Kingdom, 2 Belgium, 3 Germany, 4 Italy, 5 Norway,<br />
6<br />
Spain, 7 Sweden, 8 The Netherlands, 9 The The Netherlands,<br />
10<br />
Austria, 11 Charité University Hospital, Germany, 12 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Radboud University Nijmegen Medical Center,<br />
The Netherlands, 13 Feinstein Institute <strong>of</strong> Medical Research,<br />
14<br />
Hospital Valle de Hebron, Spain, 15 Instituto de Parasitologia<br />
y Biomedicina Lopez-Neyra, Spain, 16 MD Anderson, 17 Radboud<br />
University Nijmegen Medical Center, The Netherlands, 18 The<br />
University <strong>of</strong> Texas Health Science Center–Houston, 19 University<br />
Medical Center Utrecht, The Netherlands, 20 University <strong>of</strong><br />
Manchester, Manchester Academic Health Science Centre,<br />
United Kingdom, 21 University <strong>of</strong> Milan, Italy<br />
9:15 AM<br />
2215. Genetic Markers <strong>of</strong> Rheumatoid Arthritis Susceptibility<br />
in Anti-Citrullinated Peptide Antibody Negative and Shared<br />
Epitope Negative Patients.<br />
Sebastien Viatte 1 , Darren Plant 2 , John Bowes 2 , Anne Barton 2 and<br />
Jane Worthington 1 , 1 Arthritis Research UK Epidemiology Unit,<br />
The University <strong>of</strong> Manchester, Manchester, United Kingdom,<br />
2<br />
Arthritis Research UK Epidemiology Unit, The University <strong>of</strong><br />
Manchester<br />
9:30 AM<br />
2216. A Signature <strong>of</strong> Aberrant Responsiveness <strong>of</strong> the Peripheral<br />
Immune System Predicts the 6-Month Risk <strong>of</strong> Infections in<br />
Rheumatoid Arthritis.<br />
Megan L. Krause, John M. Davis III, Michael A. Strausbauch,<br />
Cynthia S. Crowson, Terry M. Therneau, Eric L. Matteson, Keith L.<br />
Knutson and Sherine E. Gabriel, Mayo Clinic, Rochester, MN<br />
9:45 AM<br />
2217. Homozygous 3.2kb Deletion in LEPREL1 (P3H2) Intron<br />
1 Reduces Cytokine Production and Protects from Multiple<br />
Inflammatory Diseases.<br />
Yohei Kirino 14 , Michael J. Ombrello 15 , Ahmet Gul 11 , Kai Wang 1 ,<br />
Akira Meguro 7 , Barbara Yang 14 , Massimo Gadina 14 , Fulya Cosan 11 ,<br />
Neslihan Abaci 3 , Katherine Siminovitch 9 , Peter K. Gregersen 12 ,<br />
Phaedon Kaklamanis 8 , Young-Hun Cho 10 , Dongsik Bang 2 , Hongwei<br />
Sun 14 , Christopher Amos 16 , Massa Hama 4 , Mitsuhiro Takeno 4 ,<br />
Nobuhisa Mizuki 7 , Hidetoshi Inoko 5 , Shigeaki Ohno6, Yoshiaki<br />
Ishigatsubo 17 , Hakon Hakonarson 1 , Daniel L. Kastner 13 and<br />
Elaine Remmers 14 , 1 Center for Applied Genomics, The Children’s<br />
Hospital <strong>of</strong> Philadelphia, 2 Department <strong>of</strong> Dermatology, Yonsei<br />
University <strong>College</strong> <strong>of</strong> Medicine, 3 Department <strong>of</strong> Genetics,<br />
Institute for Experimental Medicine, 4 Department <strong>of</strong> Internal<br />
Medicine and Clinical Immunology, Yokohama City University<br />
Graduate School <strong>of</strong> Medicine, 5 Department <strong>of</strong> Molecular Life<br />
Science, Division <strong>of</strong> Molecular Medical Science and Molecular<br />
Medicine, Tokai University School <strong>of</strong> Medicine, 6 Department<br />
<strong>of</strong> Ocular Inflammation and Immunology, Hokkaido University<br />
Graduate School <strong>of</strong> Medicine, 7 Department <strong>of</strong> Ophthalmology<br />
and Visual Science, Yokohama City University Graduate School<br />
<strong>of</strong> Medicine, 8 Department <strong>of</strong> <strong>Rheumatology</strong>, Athens Medical<br />
Center, Athens, Greece, 9 Departments <strong>of</strong> Medicine, Immunology<br />
and Molecular Genetics, Department <strong>of</strong> Medicine, University <strong>of</strong><br />
Toronto, Mount Sinai Hospital and University Health Network,<br />
10<br />
Graduate School <strong>of</strong> Medical Science and Engineering, KAIST,<br />
11<br />
Istanbul Faculty <strong>of</strong> Medicine, Department <strong>of</strong> Internal Medicine,<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, Istanbul University, 12 N Shore Univ<br />
Hosp Rsch Ctr, Manhasset, NY, 13 NIAMS, NIH, Bethesda, MD,<br />
14<br />
NIAMS/National Institute <strong>of</strong> Health, 15 NIAMS/National Institute<br />
<strong>of</strong> Health, Bethesda, MD, 16 University <strong>of</strong> Texas M. D. Anderson<br />
Cancer Center, 17 Yokohama City Grad Sch <strong>of</strong> Med, Yokohama,<br />
Japan<br />
10:00 AM<br />
2218. Association <strong>of</strong> IL2RB Polymorphisms with Erosive Disease<br />
in ACPA Positive Early Rheumatoid Arthritis (RA): Results from<br />
the ESPOIR Cohort.<br />
Adeline Ruyssen-Witrand 3 , Delphine Nigon 4 , Alain G . Cantagrel 5 ,<br />
Cédric Lukas 7 , Jacques Morel 7 , Jean Sibilia 6 , Anne Cambon-<br />
Thomsen 1 and Arnaud L. Constantin 2 , 1 INSERM, U558,<br />
Toulouse, France, 2 Purpan University Hospital, Toulouse, France,<br />
3<br />
<strong>Rheumatology</strong> Center, Purpan Teaching Hospital, Toulouse,<br />
Toulouse, France, 4 <strong>Rheumatology</strong> Center, Purpan Teaching<br />
Hospital, Toulouse, France, 5 <strong>Rheumatology</strong> Center, Purpan<br />
Teaching Hospital, Toulouse, University Paul Sabatier, Toulouse,<br />
France, 6 <strong>Rheumatology</strong> Department, Hautepierre Teaching<br />
Hospital, Strasbourg, France, 7 <strong>Rheumatology</strong> Department,<br />
Lapeyronie Teaching Hospital, Montpellier, France<br />
10:15 AM<br />
2219. Discovery and Replication <strong>of</strong> JIA Predisposition Genes<br />
by Genome-Wide Association and Validation <strong>of</strong> Candidates in<br />
Fibroblast-Like Synoviocytes.<br />
Terri H. Finkel 9 , Haitao Zhang 1 , Benedicte A. Lie 10 , Edward M.<br />
Behrens 3 , Mara L. Becker 2 , Carol Wise 6 , Marilynn Punaro 7 ,<br />
Emma Reuschel 8 , Debra Shivers 8 , Berit Flatø 4 , Øystein Førre 4 ,<br />
Jane Munro 11 , Justine Ellis 11 and Hakon Hakonarson 5 , 1 Center<br />
for Applied Genomics, The Children’s Hospital <strong>of</strong> Philadelphia,<br />
2<br />
Children’s Mercy Hospital, Kansas City, MO, 3 Childrens Hospital<br />
<strong>of</strong> Phil, Philadelphia, PA, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Oslo University Hospital, Rikshospitalet, Norway, 5 Division <strong>of</strong><br />
Genetics, The Children’s Hospital <strong>of</strong> Philadelphia, University <strong>of</strong><br />
Pennsylvania, 6 Division <strong>of</strong> Medical Genetics, Texas Scottish Rite<br />
Hospital for Children, 7 Division <strong>of</strong> <strong>Rheumatology</strong>, Texas Scottish<br />
Rite Hospital for Children, 8 Division <strong>of</strong> <strong>Rheumatology</strong>, The<br />
Children’s Hospital <strong>of</strong> Philadelphia Research Institute, 9 Division<br />
<strong>of</strong> <strong>Rheumatology</strong>, The Children’s Hospital <strong>of</strong> Philadelphia,<br />
University <strong>of</strong> Pennsylvania, Philadelphia, PA, 10 Institute <strong>of</strong><br />
138<br />
2010 Program Book
Immunology, Oslo University Hospital, Rikshospitalet, Norway,<br />
11<br />
Murdoch Childrens Research Institute, Royal Children’s<br />
Hospital, Melbourne, Australia<br />
A410<br />
Imaging <strong>of</strong> Rheumatic Disease: Ultrasound<br />
Moderators: Wolfgang A. Schmidt, MD; Medical Center for<br />
<strong>Rheumatology</strong> Berlin-Buch; Berlin, Germany<br />
Anna Maria Iagnocco, MD; Sapienza University <strong>of</strong> Rome, Rome,<br />
Italy<br />
9:00 AM<br />
2220. High Frequency <strong>of</strong> Subclinical Ultrasound-Detected<br />
Synovitis in Juvenile Idiopathic Arthritis Patients with Clinically-<br />
Defined Inactive Disease.<br />
Silvia Magni-Manzoni 1 , Carlo A. Scirè 3 , Angelo Ravelli 2 , Catherine<br />
Klersy 4 , Silvia Rossi 3 , Valentina Muratore 1 , Chiara Visconti 1 ,<br />
Stefano Lanni 1 , Pietro Merli 1 and Carlomaurizio Montecucco 3 ,<br />
1<br />
Dep.Pediatrics, Fondazione IRCCS Policlinico S. Matteo, Pavia,<br />
Italy, 2 II Pediatric Unit, IRCCS Gaslini, Genova, Italy, 3 Reumatology<br />
Unit, Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy,<br />
4<br />
Scientific Dep, Fondazione IRCCS Policlinico S.Matteo, Pavia,<br />
Italy<br />
9:15 AM<br />
2221. Ultrasonography at the Onset <strong>of</strong> Early Arthritis Predicts<br />
Joint Erosions at One Year: Results <strong>of</strong> the ESPOIR Cohort<br />
Ultrasound Study.<br />
Thomas Funck-Brentano 4 , Fréderique Gandjbakhch 4 , Fabien<br />
Etchepare 4 , Sandrine Jousse 2 , Cedric Lukas 3 , Violaine Foltz 4 , Alain<br />
Saraux 2 , Philippe Goupille 5 , Patrick Boumier 1 , Pierre Bourgeois 4<br />
and Bruno Fautrel 4 , 1 Amiens, 2 Brest Universitary Hospital,<br />
3<br />
Immuno-rhumatologie, Hopital Lapeyronie, Montpellier, France,<br />
4<br />
<strong>Rheumatology</strong> Department, Pitié-Salpetrière Hospital, Paris 6<br />
University, France, 5 Tours Universitary Hospital<br />
9:30 AM<br />
2222. CRP-Levels and Duration <strong>of</strong> Morning Stiffness as<br />
Predictors <strong>of</strong> Active Rheumatoid Arthritis as Verified by<br />
Ultrasound in Routine Clinical Practice.<br />
Christian Dejaco 5 , Christina Duftner 2 , Edith Wipfler-Freißmuth 3 ,<br />
Helmut Weiss 4 , Winfried B. Graninger 5 and Michael Schirmer 1 ,<br />
1<br />
Department <strong>of</strong> Internal Medicine I, Medical University<br />
Innsbruck, Innsbruck, Austria, 2 Department <strong>of</strong> Internal Medicine,<br />
General Hospital <strong>of</strong> the Elisabethinen Klagenfurt, Klagenfurt,<br />
Austria, 3 Department <strong>of</strong> Internal Medicine, Hospital <strong>of</strong> the<br />
Barmherzige Brüder Marschallgasse Graz, Graz, Austria,<br />
4<br />
Department <strong>of</strong> Radiology, General Hospital <strong>of</strong> the Elisabethinen<br />
Klagenfurt, Klagenfurt, Austria, 5 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Medical University Graz, Graz, Austria<br />
9:45 AM<br />
2223. Resistant Tennis Elbow (RTE) Due to Radial Tunnel<br />
Syndrome: Clinical Presentation, Sonographic Findings and<br />
Surgical Correlation.<br />
David A. Bong 3 , Jordi Palau 1 , Ingrid Möller 1 and Esperanza<br />
Naredo 2 , 1 Barcelona Sonoanatomy Group, 2 Hosptial Universitario<br />
Severo Ochoa, Madrid, Spain, 3 Instituto Poal de Reumatologia,<br />
Bruce, WI<br />
10:00 AM<br />
2224. Clinic Based MSK Ultrasound in the Diagnosis and<br />
Treatment <strong>of</strong> Shoulder Pain – A Randomized Prospective Study.<br />
Aamir Saeed 2 , Mumtaz Khan, Siobhan Morrissey and Alexander<br />
D. Fraser 1 , 1 Castleroberts, County Limerick, Ireland, 2 Mid<br />
Western Regional Hospital, Limerick, Ireland<br />
10:15 AM<br />
2225. Sonographic Needle Guidance and Cost-Effectiveness <strong>of</strong><br />
Intraarticular Injections for Osteoarthritis <strong>of</strong> the Knee.<br />
Natalia R. Chavez-Chiang 3 , Wilmer L. Sibbitt 4 , Suzanne Delea 2 ,<br />
Kye Park 6 , Arthur D. Bankhurst 5 , Philip A. Band 1 and Hillary<br />
Norton 3 , 1 New York University School <strong>of</strong> Medicine, 2 University<br />
<strong>of</strong> New Mexico, Albuquerque, NM, 3 University <strong>of</strong> New Mexico,<br />
4<br />
University <strong>of</strong> New Mexico HSC, Albuquerque, NM, 5 University<br />
<strong>of</strong> NM Med Ctr, Albuquerque, NM, 6 Univresity <strong>of</strong> New Mexico,<br />
Albuquerque, NM<br />
A311<br />
Innate Immunity and Rheumatic Disease<br />
Moderators: Robert M. Clancy, PhD ; New York University School<br />
<strong>of</strong> Medicine; New York, NY<br />
George C. Tsokos, MD; Harvard Medical School/Beth Israel<br />
Hospital; Boston, MA<br />
9:00 AM<br />
2226. Identification <strong>of</strong> NLRP1 as a Systemic Sclerosis<br />
Susceptibility Gene: A New Clue for the Contribution <strong>of</strong> Innate<br />
Immunity in SSc Pathogenesis.<br />
Philippe Dieudé 7 , Mickaël Guedj 4 , Julien Wipff 6 , Gabriela<br />
Riemekasten 2 , Paolo Airo 8 , Inga Melchers 1 , Marco Matucci-<br />
Cerinic 10 , Eric Hachulla 5 , Catherine Boileau 9 , Yannick Allanore 3<br />
and and the GENESYS Consortium, 1 Clinical Research Unit for<br />
<strong>Rheumatology</strong>, University Medical Center, Freiburg, Germany,<br />
2<br />
Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Charité<br />
University Hospital, Schumannstr. 20/21, D-10117, Berlin,<br />
Germany, 3 Hopitaux de Paris Cochin, Paris, France, 4 Laboratoire<br />
Statistique et Génome, UMR CNRS-8071 / INRA-1152 /<br />
Université d’Evry Val d’Essonne, France, 5 National Scleroderma<br />
Centre, Lille Cedex, France, 6 Paris Descartes University,<br />
Department <strong>of</strong> <strong>Rheumatology</strong> A, Cochin Hospital, Paris, France,<br />
7<br />
Paris Diderot University, Department <strong>of</strong> <strong>Rheumatology</strong>, Bichat<br />
Claude Bernard Hospital, APHP, Paris, France, 8 <strong>Rheumatology</strong><br />
and Clinical Immunology, Spedali Civili, Brescia, Italy, 9 Saint<br />
Quentin Yvelines University, Laboratoire de Biochimie<br />
Hormonale et Génétique, Ambroise Paré Hospital, AP-HP,<br />
Boulogne, France, 10 University <strong>of</strong> Florence, Firenze, Italy<br />
9:15 AM<br />
2227. MASP-1 and Pro-Factor D Proteins Are Present in<br />
Synoviocytes and May Locally Activate the Complement<br />
Alternative Pathway To Induce Inflammatory Arthritis in Mice.<br />
Nirmal K. Banda 4 , Minoru Takahashi 2 , Magdalena J. Glogowska 4 ,<br />
Kazue Takahashi 3 , Gregory L. Stahl 1 , Teizo Fujita 2 , William<br />
P. Arend 4 and V. Michael Holers 4 , 1 Center for Experimental<br />
Therapeutics and Reperfusion Injury, Brigham and Women’s<br />
Hospital, Boston, MA, 2 Department <strong>of</strong> Immunology, Fukushima<br />
Medical University School <strong>of</strong> Medicine, Fukushima, Japan,<br />
3<br />
Department <strong>of</strong> Immunology, Massachusetts General Hospital<br />
for Children, Boston, MA, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, University<br />
<strong>of</strong> Colorado at Denver, Aurora, CO<br />
thursday<br />
2010 Program Book 139
9:30 AM<br />
2228. Mutated NLRP3 in Cryopyrin-Associated Periodic<br />
Syndromes Is Released from Restriction by CARD8.<br />
Sayaka Ito 2 , Yukichi Hara 3 , Yukio Shima 1 and Tetsuo Kubota 3 ,<br />
1<br />
Kyorin University, 2 Tokyo Medical and Dental University, Tokyo,<br />
Japan, 3 Tokyo Medical and Dental University<br />
Jochen Zwerina 5 , Georg Schett 5 , Stefan Dübel 3 and Reinhard<br />
Voll5, 1 Georg-August-University <strong>of</strong> Göttingen, 2 Johann Wolfgang<br />
Goethe University Frankfurt am Main, 3 Technical University<br />
<strong>of</strong> Braunschweig, 4 University <strong>of</strong> Erlangen-Nürnberg, Erlangen,<br />
Germany, 5 University <strong>of</strong> Erlangen-Nürnberg, 6 University <strong>of</strong><br />
Münster<br />
thursday<br />
9:45 AM<br />
2229. Complement Component C5 Plays a Central Role in<br />
Osteoarthritis.<br />
William Robinson 3 , Andrew L. Rozelle 1 , Tamsin M. Lindstrom,<br />
Reuben Gobezie, V. Michael Holers 4 , David M. Lee 2 and Qian<br />
Wang, 1 Menlo Park, CA, 2 Brigham and Womens Hospital, Boston,<br />
MA, 3 Stanford Univ School <strong>of</strong> Med, Stanford, CA, 4 Univ <strong>of</strong><br />
Colorado School <strong>of</strong> Med, Aurora, CO<br />
10:00 AM<br />
2230. Toll-Like Receptor 2 Negatively Regulates FCg Receptor<br />
Response in Macrophages and Inhibits FCgR-Mediated<br />
Arthritis.<br />
Shahla Abdollahi-Roodsaz 3 , Marije I. Koenders 2 , Fons A. J. van de<br />
Loo 4 and Wim B. Van Den Berg 1 , 1 Radboud Univ Nijmegen Med<br />
Cntr, Nijmegen, The Netherlands, 2 <strong>Rheumatology</strong> Research and<br />
Advanced Therapeutics, Radboud University Nijmegen Medical<br />
Centre, Nijmegen, 3 <strong>Rheumatology</strong> Research and Advanced<br />
Therapeutics, Radboud University Nijmegen Medical Centre,<br />
Nijmegen, The Netherlands, Nijmegen, The Netherlands,<br />
4<br />
<strong>Rheumatology</strong> Research and Advanced Therapeutics, Radboud<br />
University Nijmegen Medical Centre, Nijmegen, The Netherlands<br />
10:15 AM<br />
2231. A Novel Role <strong>of</strong> Endothelin-1 in Linking Ro60-ssRNA<br />
Immune Complexes to Cardiac Fibrosis in Congenital Heart<br />
Block.<br />
David Alvarez-Carbonell 4 , Jiri Zavadil 5 , Rosanna Abellar 1 , Franck<br />
Barrat 2 , Robert Clancy 3 and Jill Buyon 5 , 1 Columbia University<br />
Medical Center, 2 Dynavax Technologies, 3 New York University<br />
School <strong>of</strong> Mediciine, 4 New York University School <strong>of</strong> Medicine,<br />
New York, NY, 5 New York University School <strong>of</strong> Medicine<br />
B402<br />
Rheumatoid Arthritis - Animal Models: T cell<br />
Pathogenesis and Novel Therapeutic Targets II<br />
Moderators: Linda K. Myers, MD; Univeristy <strong>of</strong> Tennessee<br />
Medical Group Inc.; Memphis, TN<br />
Paul H. Wooley, PhD; Christi Regional Medical Center,<br />
Orthopaedic Research Instititue; Wichita, KS<br />
9:00 AM<br />
2232. Mucosal Associated Invariant T Cells Contribute to the<br />
Pathogenesis <strong>of</strong> Arthritis.<br />
Asako Chiba, Ryohsuke Tajima, Yusei Miyazaki, Takashi<br />
Yamamura and Sachiko Miyake, Department <strong>of</strong> Immunology,<br />
National Institute <strong>of</strong> Neuroscience, NCNP<br />
9:15 AM<br />
2233. WITHDRAWN<br />
9:30 AM<br />
2234. An Endothelium-Specific NF-kappaB Inhibitor<br />
Ameliorates Inflammatory Joint Diseases.<br />
Bettina Sehnert 4 , Harald Burkhardt 2 , Falk Nimmerjahn 5 , Johannes<br />
Wessels 1 , Agnes Machnik 5 , Dietmar Vestweber 6 ,<br />
9:45 AM<br />
2235. Citrullination <strong>of</strong> Mouse Collagen Breaks Tolerance and<br />
Induces an Inflammatory Arthritis in the Absence <strong>of</strong> Adjuvant.<br />
Jordan P. Lacy, Michael J. Duryee, Carlos D. Hunter, James R.<br />
O’Dell, Ted R. Mikuls, Ge<strong>of</strong>frey M. Thiele and Lynell W. Klassen,<br />
University <strong>of</strong> Nebraska Medical Center<br />
10:00 AM<br />
2236. Differentiation and Activation <strong>of</strong> Regulatory<br />
T-Lymphocytes in a TNF-alpha Transgenic Model <strong>of</strong> Arthritis,<br />
and the Impact <strong>of</strong> Passive or Active Anti-TNF Therapies.<br />
Jerome Biton 2 , Luca Semerano 3 , Laure Delavallée 2 , Geraldine<br />
Grouard-Vogel 1 , Delphine Lemeiter 2 , Marie-Christophe Boissier 3<br />
and Natacha Bessis 2 , 1 Neovacs, Paris, France, 2 Paris 13 University,<br />
Bobigny, France, 3 Paris 13 University and APHP, Bobigny, France<br />
10:15 AM<br />
2237. The TRAF6 Binding Molecule p62/SQSTM1 Controls<br />
Inflammatory Bone Destruction in hTNFtg Mice.<br />
Adelheid Korb 7 , Marianne Niedermeier 3 , Anja Hillmann 7 ,<br />
Susanne Bürgis 1 , George Kollias 5 , Sven Herrmann 2 , Thomas Pap 4 ,<br />
Thomas Weide 7 , André Gessner 6 and Herrmann Pavenstädt 7 ,<br />
1<br />
Department <strong>of</strong> Immunology, University Erlangen, Erlangen,<br />
Germany, 2 European Institute <strong>of</strong> Molecular Imaging, University<br />
Muenster, Germany, 3 Institute for Experimental Musculoskeletal<br />
Medicine, University Hospital Muenster, Muenster, Germany,<br />
4<br />
Institute for Experimental Musuculoskeletal Medicine,<br />
University Hospital Muenster, Muenster, Germany, 5 Institute <strong>of</strong><br />
Immunology, Biomedical Science Research Center, Vari, Greece,<br />
6<br />
Institute <strong>of</strong> Microbiology - Clinical Microbiology, Immunology<br />
and Hygiene, University Hospital Erlangen, Erlangen,<br />
Germany, 7 Internal Medicine D, Department <strong>of</strong> Nephrology<br />
and <strong>Rheumatology</strong>, University Hospital Muenster, Muenster,<br />
Germany<br />
A412<br />
Systemic Lupus Erythematosus - Clinical Aspects and<br />
Treatment<br />
Moderators: Murat Inanc, MD; Istanbul University, Istanbul<br />
Faculty <strong>of</strong> Medicine; Istanbul, Turkey<br />
Diane L. Kamen, MD; Medical University <strong>of</strong> South Carolina;<br />
Charleston, SC<br />
9:00 AM<br />
2238. Low Blood Concentration <strong>of</strong> Hydroxychloroquine Is<br />
Associated with Failure <strong>of</strong> Hydroxychloroquine Treatment in<br />
Patients with Cutaneous Lupus: Results <strong>of</strong> a Prospective Study.<br />
Camille Francès 1 , Anne Cosnes 1 , Pierre Duhaut 2 , Noël Zahr 3 ,<br />
Boutros Soutou 1 , Saskia Oro 1 , Didier Bessis 1 , Jacqueline<br />
Chevrant-Breton 1 , Nadege Cordel 1 , Dan Lipsker 1 and Nathalie<br />
Costedoat-Chalumeau 3 , 1 Department <strong>of</strong> Dermatology, Hôpital<br />
Tenon, Paris, France, 2 Department <strong>of</strong> Dermatology, Hôpital<br />
Tenon, 3 Internal Medicine Department, French National<br />
Reference Center for SLE, Pitié-Salpêtrière Hospital (GHPS), Paris,<br />
France<br />
140<br />
2010 Program Book
9:15 AM<br />
2239. Factors Associated with Low Blood Concentration <strong>of</strong><br />
Hydroxychloroquine in 523 Patients with Systemic Lupus<br />
Erythematosus: Data from the PLUS Study.<br />
Nathalie Costedoat-Chalumeau 2 , Lionel Galicier 2 , Camille<br />
Francès 2 , Olivier Aumaître 2 , Frédéric Lioté 2 , Véronique Le Guern 2 ,<br />
Nicolas Limal 2 , Amar Smail 2 , J. Ninet 2 , Laurent Perard 2 , Du Le Thi<br />
Huong 2 , Bouchra Asli 2 , Catherine Grandpeix 2 , Laurent Sailler 2 ,<br />
F. Ackermann 2 , Thomas Papo 2 , Benoit Brihaye 2 , Olivier Fain 2 ,<br />
Jérome Stirnemann 2 , Moez Jallouli 2 , Gaelle Leroux 2 , Jean-<br />
Sébastien Hulot 2 , Philippe Lechat 2 , Lucile Musset 2 , Jean-Charles<br />
Piette 2 , Zahir Amoura 2 and The Investigators <strong>of</strong> the PLUS Study 1 ,<br />
1<br />
Internal Medicine Department, French National Reference<br />
Center for SLE, Pitié-Salpêtrière Hospital, Paris, France, 2 Internal<br />
Medicine Department, French National Reference Center for<br />
SLE, Pitié-Salpêtrière Hospital<br />
9:30 AM<br />
2240. Mortality in a Multinational Inception Cohort <strong>of</strong> SLE.<br />
Murray B. Urowitz 33 , Dafna D. Gladman 22 , Dominique Ibanez 32 ,<br />
Caroline P. Gordon 29 , Sang-Cheol Bae 6 , Ann E. Clarke 15 , Sasha<br />
R. Bernatsky 15 , F. Jorge Sanchez-Guerrero 9 , John G. Hanly 19 ,<br />
David A. Isenberg 24 , Anisur Rahman 25 , Paul R. Fortin 33 , Daniel<br />
J. Wallace 1 , Ellen M. Ginzler 20 , Joan T. Merrill 18 , Graciela S.<br />
Alarcón 28 , Barri J. Fessler 23 , Ian N. Bruce 13 , Gunnar K. Sturfelt 27 ,<br />
Ola Nived 27 , Kristjan Steinsson 12 , Munther A. Khamashta 21 ,<br />
Michelle A. Petri 2 , Rosalind Ramsey-Goldman 17 , Susan Manzi34,<br />
Mary Anne Dooley 31 , Ronald V. Vollenhoven 11 , Cynthia B.<br />
Aranow 4 , Thomas Stoll 10 , Manuel Ramos 7 , Kenneth C. Kalunian 26 ,<br />
Asad A. Zoma 5 , Guillermo Ruiz-Irastorza 8 , Peter J. Maddison 16 ,<br />
Diane L. Kamen 14 , S. Sam Lim 3 and Christine A. Peschken 30 , 1 West<br />
Hollywood, CA, 2 Timonium, MD, 3 Emory University, Atlanta,<br />
GA, 4 Feinstein Institute, Manhasset, NY, 5 Hairmyres Hospital,<br />
East Kilbride, United Kingdom, 6 Hanyang University Medical<br />
Center, Seoul, Korea, Republic <strong>of</strong>, 7 Hospital Clinico I Provincial,<br />
8<br />
Hospital de Cruces, Universidad del Pais Vasco, 9 Instituto<br />
Nacional Nutricion, Mexico City, DF, Mexico, 10 Kantonsspital<br />
Schaffhausen, Schaffhausen, Switzerland, 11 Karolinska University<br />
Hospital, 12 Landspitalinn University Hospital, 13 Manchester Royal<br />
Infirmary, Manchester, United Kingdom, 14 Medical University<br />
South Carolina, Charleston, SC, 15 Montreal General Hospital,<br />
Montreal, QC, Canada, 16 North West Wales NHS Trust, Colwyn<br />
Bay, United Kingdom, 17 Northwestern University, Chicago, IL,<br />
18<br />
Oklahoma Med Research Foundation, Oklahoma City, OK,<br />
19<br />
Queen Elizabeth II Health Services Center, Halifax, NS, Canada,<br />
20<br />
SUNY-Downstate Medical Center, Brooklyn, NY, 21 The Rayne<br />
Institute, London, United Kingdom, 22 Toronto Western Hospital,<br />
Toronto, ON, Canada, 23 UAB <strong>Rheumatology</strong>, Birmingham, AL,<br />
24<br />
UCL Div <strong>of</strong> Medicine, London, United Kingdom, 25 UCL Div <strong>of</strong><br />
Medicine, 26 UCSD School <strong>of</strong> Medicine, La Jolla, CA, 27 University<br />
Hospital Lund, Lund, Sweden, 28 University <strong>of</strong> Alabama, Oakland,<br />
CA, 29 University <strong>of</strong> Birmingham, Birmingham, United Kingdom,<br />
30<br />
University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 31 University<br />
<strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC, 32 University <strong>of</strong><br />
Toronto Lupus Clinic, Toronto Western Hospital, 33 University <strong>of</strong><br />
Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON,<br />
Canada, 34 West Penn Allegheny Health System, Pittsburgh, PA<br />
9:45 AM<br />
2241. Mycophenolate M<strong>of</strong>etil and Hydroxychloroquine but Not<br />
Azathioprine Improve HDL Function in Women with SLE.<br />
Maureen McMahon 3 , Jennifer M. Grossman 4 , Jessica Gomez 3 ,<br />
Lori Sahakian 3 , Weiling Chen 3 , John Fitzgerald 3 , Brian Skaggs 2 ,<br />
Joan T. Merrill 1 and Bevra H. Hahn 5 , 1 Oklahoma Med Research<br />
Foundation, Oklahoma City, OK, 2 UCLA, Los Angeles, CA, 3 UCLA<br />
School <strong>of</strong> Medicine, Los Angeles, CA, 4 University <strong>of</strong> California Los<br />
Angeles, Sherman Oaks, CA, 5 University <strong>of</strong> California Los Angeles<br />
School <strong>of</strong> Medicine, Los Angeles, CA<br />
10:00 AM<br />
2242. Screening for Cognitive Impairment in Systemic Lupus<br />
Erythematosus.<br />
John G. Hanly 2 , Li Su 3 , Vern Farewell 3 , Tina Linehan 1 and John D.<br />
Fisk 2 , 1 Capital Health, Halifax, NS, Canada, 2 Capital Health and<br />
Dalhousie University, Halifax, NS, Canada, 3 MRC Biostatistics<br />
Unit, Institute <strong>of</strong> Public Health, University Forvie Site,<br />
Cambridge, UK<br />
10:15 AM<br />
2243. Autoantibodies as Biomarkers for the Prediction <strong>of</strong><br />
Neuropsychiatric Events in Systemic Lupus Erythematosus.<br />
John G. Hanly 2 , Murray B. Urowitz 20 , Li Su 13 , Sang Cheol-Bae 6 ,<br />
Caroline Gordon 26 , Jorge Sanchez-Guerrero 7 , Ann Clarke 12 , Sasha<br />
Bernatsky 12 , Archana Vasudevan 17 , David Isenberg 23 , Anisur<br />
Rahman 23 , Daniel J. Wallace 3 , Paul Fortin 20 , Dafna Gladman 20 ,<br />
Mary Anne Dooley 28 , Ian Bruce 19 , Kristjan Steinsson 10 , Munther<br />
Khamashta 18 , Susan Manzi 29 , Rosalind Ramsey-Goldman 14 ,<br />
Gunnar Sturfelt 24 , Ola Nived 24 , Cynthia Aranow 4 , Ronald van<br />
Vollenhoven 9 , Manuel Ramos-Casals 16 , Ken Kalunian 21 , Graciela<br />
Alarcon 25 , Barri J. Fessler 25 , Guillermo Ruiz-Irastorza 22 , Michelle<br />
Petri 8 , Sam Lim 5 , Diane Kamen 11 , Christine Peschken 27 , Vern<br />
Farewell 13 , Kara Thompson 2 , Chris Theriault 1 and Joan Merrill 15 ,<br />
1<br />
Capital Health, Halifax, NS, Canada, 2 Capital Health and<br />
Dalhousie University, Halifax, NS, Canada, 3 Cedars-Sinai/David<br />
Geffen School <strong>of</strong> Medicine at UCLA, Los Angeles, CA, 4 Columbia<br />
University Medical Center, New York, NY, 5 Emory University,<br />
Atlanta, GA, 6 Hanyang University Hospital for Rheumatic<br />
DIseases, Seoul, Korea, 7 Instituto Nacional de Ciencias Medicas<br />
y Nutricion, Mexico City, Mexico, 8 John Hopkins University<br />
School <strong>of</strong> Medicine, Baltimore, MD, 9 Karolinska Institute,<br />
Stockholm, Sweden, 10 Landspitali University Hospital, Reykjavik,<br />
Iceland, 11 Medical University <strong>of</strong> South Carolina, Charleston, SC,<br />
12<br />
Montreal General Hospital, McGill University Health Centre,<br />
Montreal, QC, Canada, 13 MRC Biostatistics Unit, Institute<br />
<strong>of</strong> Public Health, University Forvie Site, Cambridge, United<br />
Kingdom, 14 Northwestern University and Feinberg School <strong>of</strong><br />
Medicine, Chicago, IL, 15 Oklahoma Medical Research Foundation,<br />
Oklahoma City, OK, 16 Servicio Enfermedades Autoinmunes<br />
Hospital Clínico y Provincial, Barcelona, Spain, 17 SUNY Downstate<br />
Medical Center, Brooklyn, NY, 18 The Rayne Institute, St. Thomas’<br />
Hospital, King’s <strong>College</strong> London School <strong>of</strong> Medicine, London,<br />
United Kingdom, 19 The University <strong>of</strong> Manchester, Manchester,<br />
United Kingdom, 20 Toronto Western Hospital and University<br />
<strong>of</strong> Toronto, ON, Canada, 21 UCSD School <strong>of</strong> Medicine, La Jolla,<br />
CA, 22 Universidad del Pais Vasco, Barcelona, Spain, 23 University<br />
<strong>College</strong>, London, United Kingdom, 24 University Hospital<br />
Lund, Lund, Sweden, 25 University <strong>of</strong> Alabama at Birmingham,<br />
thursday<br />
2010 Program Book 141
thursday<br />
Birmingham, AL, 26 University <strong>of</strong> Birmingham, Birmingham,<br />
United Kingdom, 27 University <strong>of</strong> Manitoba, Winnipeg, Canada,<br />
28<br />
University <strong>of</strong> North Carolina, Chapel Hill, NC, 29 University <strong>of</strong><br />
Pittsburgh School <strong>of</strong> Medicine, Pittsburgh, PA<br />
ARHP Concurrent Abstract Session<br />
9:15 - 10:45 AM<br />
B311<br />
What a Pain Rheumatic Diseases Can Be!<br />
Moderator: Brett D. Thombs, MA, PhD; McGill University;<br />
Montreal, QC, Canada<br />
9:15 AM<br />
2244. Patell<strong>of</strong>emoral Osteoarthritis in Middle-Aged Adults:<br />
What Are the Best Measures <strong>of</strong> Physical Performance and Pain<br />
for Use in the Clinic and in Research?<br />
Lisa T. Hoglund 3 , Margery A. Lockard 1 , Jinsup Song 2 and Mary<br />
F. Barbe 2 , 1 Drexel University, Dresher, PA, 2 Temple University,<br />
Philadelphia, PA, 3 University <strong>of</strong> the Sciences in Philadelphia,<br />
Morrisville, PA<br />
9:30 AM<br />
2245. Differences in Muscle Strength and Pain Thresholds<br />
between Postmenopausal Women with and without RA.<br />
Ulrika Thoors, Christina H. Opava, Birgitta Glenmark, Eva Kosek,<br />
Ingrid E. Lundberg and Cecilia Fridén, Karolinska Institutet,<br />
Stockholm, Sweden<br />
9:45 AM<br />
2246. Fibromyalgia Diagnosis Is Significantly Impacted by the<br />
Number <strong>of</strong> Tender Points Presented on Patient Physical Exam.<br />
Terence W. Starz 1 , Robert J. Sanchez 2 , Bruce Duncan 3 , Kaite Ka 3 ,<br />
Elizabeth Pinner 2 , Shera D. Gruen 2 and Dennis C. Turk 4 , 1 Arthritis<br />
& Internal Med Associates, Pittsburgh, PA, 2 Pfizer, 3 Roger Green<br />
and Associates, 4 University <strong>of</strong> Washington, Seattle, WA<br />
10:00 AM<br />
2247. Measuring Pain in Systemic Sclerosis: The Short-Form<br />
McGill Pain Questionnaire or a Single Item Measure <strong>of</strong> Pain? A<br />
Confirmatory Factor Analysis.<br />
Ghassan El Baalbaki 1 , Janie Lober 2 , Marie Hudson 4 , Murray<br />
Baron 1 , Brett D. Thombs 3 and Canadian Scleroderma Research<br />
Group (CSRG), 1 Jewish General Hospital, Montreal, QC, Canada,<br />
2<br />
McGill University, 3 McGill University, Montreal, QC, Canada,<br />
4<br />
McGill University and Jewish General Hospital<br />
10:15 AM<br />
2248. Daily Electronic Reports <strong>of</strong> Pain and Activity Difficulties<br />
in Children with JIA Versus Children with Other Rheumatic<br />
Diseases.<br />
Mark Connelly 1 , Maggie H. Bromberg 4 , Kelly K. Anthony 3 , Lindsey<br />
Franks 2 , Karen M. Gil 4 and Laura E. Schanberg 2 , 1 Children’s Mercy<br />
Hospital and Clinics, Kansas City, MO, 2 Duke University Medical<br />
Center, Durham, NC, 3 Duke Unviversity Medical Center, Durham,<br />
NC, 4 University <strong>of</strong> North Carolina at Chapel Hill<br />
10:30 AM<br />
2249. How Do Patients Approach Risk-Benefit Trade-Offs: A<br />
Qualitative Analysis Using a Think Aloud Protocol.<br />
Liana Fraenkel, Paul Falzer and Kristin Mattocks, Yale University,<br />
Newtown, CT<br />
ARHP Concurrent Sessions<br />
9:15 - 10:45 AM<br />
B310<br />
Putting ACR Osteoarthritis Guidelines into Practice:<br />
Clinical Applications for the Hip and Knee c/r PM<br />
PS<br />
Moderator: Donald R. Miller, PharmD; North Dakota State<br />
University; Fargo, ND<br />
Speakers: G. Kelley Fitzgerald, PhD, PT; University <strong>of</strong> Pittsburgh;<br />
Pittsburgh, PA<br />
Carol A. Oatis, PT, PhD; Arcadia University; Glenside, PA<br />
Kyle Gibson; University <strong>of</strong> Missouri; Columbia, MO<br />
Session Overview:<br />
Osteoarthritis is the primary cause <strong>of</strong> physical disability in adults<br />
and is a diagnosis commonly seen by therapists. Evidencebased<br />
practice is a pr<strong>of</strong>essional expectation, and the soon to be<br />
released ACR Guidelines for the Management <strong>of</strong> Osteoarthritis<br />
<strong>of</strong> the Hip, Knee and Hand, <strong>of</strong>fer practitioners a rich resource<br />
for clinical decision-making. However, the appropriate use <strong>of</strong><br />
evidence in practice requires both knowledge <strong>of</strong> the evidence<br />
and skills to apply the evidence in a clinical setting. For a busy<br />
practitioner, evidence-based practice behaviors are influenced<br />
by a number <strong>of</strong> factors, including belief in the relevance <strong>of</strong><br />
the evidence and self-efficacy for evidence-based practice.<br />
The purpose <strong>of</strong> this session is to provide therapists with the<br />
knowledge and skills to effectively apply the ACR osteoarthritis<br />
guidelines to management <strong>of</strong> hip and knee osteoarthritis in<br />
clinical practice.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the clinical relevancy <strong>of</strong> the guidelines<br />
• select best tests/measures and interventions consistent with<br />
the guidelines<br />
• determine client characteristics that influence response to<br />
specific interventions<br />
• describe treatment plans consistent with guideline<br />
recommendations and specific patient characteristics<br />
B309<br />
Teaching Our Pediatric Patients: Making the Complex<br />
Simple P/C PS<br />
Moderator: Karla B. Jones, MS, RN, CPNP; Nationwide Children’s<br />
Hospital; Columbus, OH<br />
Speakers: Sandra J. Watcher, BSN; Children’s Hospital <strong>of</strong> Los<br />
Angeles; Los Angeles, CA<br />
Session Overview:<br />
Treatment success in children with rheumatic conditions<br />
requires that both parents and the children have an<br />
understanding <strong>of</strong> these very complex diseases. Health care<br />
providers are faced with assessing and educating not only<br />
the parents but the child or adolescent. This requires an<br />
interdisciplinary team with specific skills to evaluate the child’s<br />
psychological development level to best meet their educational<br />
needs with those <strong>of</strong> their adult parents. In addition, determining<br />
age appropriate materials that meet the needs <strong>of</strong> both children<br />
and parents is essential.<br />
142<br />
2010 Program Book
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• review the disease process <strong>of</strong> systemic lupus erythematosus<br />
and juvenile idiopathic arthritis and the most common<br />
medications utilized<br />
• discuss age appropriate methods to educate children and<br />
adolescents regarding SLE and JIA<br />
• discuss age appropriate methods to educate children and<br />
adolescents regarding common treatments used for SLE and<br />
JIA<br />
• identify available age appropriate materials and resources for<br />
patient, family, and educators use<br />
ACR Clinical Symposium<br />
11:00 AM - 12:30 PM<br />
B406<br />
2010 ACR Recommendations for the Treatment <strong>of</strong><br />
Juvenile Idiopathic Arthritis P PS<br />
Moderator: Liana Fraenkel, MD, MPH; Yale University; Newtown,<br />
CT<br />
11:00 AM<br />
ACR Recommendations for the Treatment <strong>of</strong> Juvenile Idiopathic<br />
Arthritis<br />
Timothy Beukelman, MD, MSCE; University <strong>of</strong> Alabama-<br />
Birmingham; Birmingham, AL<br />
12:00 PM<br />
Panel Discussion<br />
Timothy Beukelman, MD, MSCE; University <strong>of</strong> Alabama-<br />
Birmingham; Birmingham, AL<br />
Daniel J. Lovell, MD, MPH; Children’s Hospital Medical Center;<br />
Cincinnati, OH<br />
Norman T. Ilowite, MD; Children’s Hospital Montefiore; Bronx,<br />
NY<br />
Session Overview:<br />
Major advances in treatment over the last 15 years have<br />
greatly improved outcomes for children with juvenile idiopathic<br />
arthritis, yet there are no prior validated guidelines <strong>of</strong>fering<br />
recommendations for the safest and most effective treatment<br />
<strong>of</strong> juvenile idiopathic arthritis. Clinical practice guidelines are an<br />
important way to promote effective care and to improve patient<br />
outcomes. This symposium will present the methodology and<br />
results <strong>of</strong> the newly developed evidence and consensus-based<br />
ACR recommendations for the treatment <strong>of</strong> juvenile idiopathic<br />
arthritis and seek public feedback and discussion.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe the recommended treatment approach for different<br />
juvenile idiopathic arthritis phenotypes: 4 or fewer affected<br />
joints; 5 or more affected joints; presence <strong>of</strong> sacroiliitis;<br />
systemic arthritis<br />
• apply the recommended indications for biologic agents in the<br />
treatment <strong>of</strong> juvenile idiopathic arthritis<br />
• review the recommendations for monitoring <strong>of</strong> adverse<br />
effects <strong>of</strong> therapeutics in juvenile idiopathic arthritis<br />
ACR Concurrent Abstract Sessions<br />
11:00 AM – 12:30 PM<br />
A410<br />
Antiphospholipid Syndrome II<br />
Moderators: Silvia Pierangeli, MD; University <strong>of</strong> Texas Medical<br />
Branch, Galeston, TX<br />
Robert A.S. Roubey, MD; University <strong>of</strong> North Carolina; Chapel<br />
Hill, NC<br />
11:00 AM<br />
2250. Evaluation <strong>of</strong> ‘Non-Criteria” Antiphospholipid (aPL)<br />
Assays at a Wet Workshop during the 13th International<br />
Congress on Antiphospholipid Antibodies.<br />
Roger Albesa 1 , Victoria Nelson 1 , Zakera Shums 1 , Gary Norman 1 ,<br />
X.-X. Gu 2 , Jacob Rand 2 , Walter Binder 1 , Bas deLaat 4 and Silvia<br />
S. Pierangeli 3 , 1 INOVA Diagnostics, San Diego, CA, 2 Montefiore,<br />
Albert Einstein School <strong>of</strong> Medicine, New York, NY, 3 Univ <strong>of</strong> TX<br />
Med Branch, Galveston, Galveston, TX, 4 Utretch Medical Center,<br />
Utrecht, The Netherlands<br />
11:15 AM<br />
2251. Evaluation <strong>of</strong> the Performance <strong>of</strong> Monoclonal and<br />
Polyclonal Antibody Standards in Different Assays for the<br />
Detection <strong>of</strong> Antiphospholipid (aPL) Antibodies: Report<br />
<strong>of</strong> a Wet Workshop at the 13th International Congress on<br />
Antiphospholipid Antibodies.<br />
Ricardo Forastiero 8 , Elizabeth Papalardo 6 , Michael Watkins 1 ,<br />
Hoang Nguyen 1 , Maria Crisostomo 1 , Wendy Vandam 1 , JOel<br />
Hardy 1 , Roger Albesa 2 , Victoria Nelson 2 , Zakera Shums 2 , Gary<br />
Norman 2 , Walter Binder 2 , Kerrie Morin 3 , Catherine Kirbach 3 ,<br />
Karl Mattias 4 , Gabriella Lakos 5 and Sivia S. Pierangeli 7 , 1Bio-Rad<br />
Laboratories, Hercules, CA, 2 INOVA Diagnostics, San Diego, Ca,<br />
3<br />
Instrumentation Laboratories, Bedford, MA, 4 Phadia GMBH,<br />
Freiburg, Germany, 5 TherTest, Lombard, IL, 6 Univ <strong>of</strong> TX Med<br />
Branch, Galveston, Galveston, TX, 7 Univ <strong>of</strong> TX Med Branch,<br />
Galveston, TX, 8 Universidad Favaloro, Buenos Aires, Argentina<br />
11:30 AM<br />
2252. Comparative Evaluation <strong>of</strong> Different Immunoassays<br />
for the Detection <strong>of</strong> Antiphospholipid Antibodies: Report <strong>of</strong><br />
a Wet Workshop during the 13th International Congress on<br />
Antiphospholipid Antibodies.<br />
Ricardo Forastiero 9 , Elizabeth Papalardo 8 , Kerrie Morin 4 ,<br />
Catherine Quirbach 4 , Gabriella Lakos 6 , Karl Mattias 5 , Roger<br />
Albesa 3 , Victoria Nelson 3 , Zakera Shums 3 , Gary Norman 3 ,<br />
Walter Binder 3 , Bruno Larida 1 , Maria Crisostomo 2 , Michael<br />
Watkins 2 , Hoang Nguyen 2 , Wendy Vandam 2 , Joel Hardy 2 and<br />
Silvia S. Pierangeli 7 , 1 Bio-Rad Laboratories, Hercules, CA, 2 Bio-<br />
Rad Laboratories, Her, 3 INOVA Diagnostics, San Diego, CA,<br />
4<br />
Instrumentation Laboratories, Bedford, MA, 5 Phadia GMBH,<br />
Freiburg, Germany, 6 TheraTest Laboratories, Lombard, IL, 7 Univ<br />
<strong>of</strong> TX Med Branch, Galveston, Galveston, TX, 8 Univ <strong>of</strong> TX Med<br />
Branch, Galveston, TX, 9 Universidad Favaloro, Buenos Aires<br />
Argentina<br />
11:45 AM<br />
2253. Elevated Cytokines and Chemokine Levels in<br />
Antiphospholipid Antibody (aPL)-Positive Patients.<br />
Vijaya L. Murthy, Shraddha Jatwani, Renan A. Aguilar-Valenzuela,<br />
Ellis D. Doan, Elizabeth Papalardo, Emilio B. González and Silvia<br />
S. Pierangeli, University <strong>of</strong> Texas Medical Branch, Galveston, TX<br />
thursday<br />
2010 Program Book 143
12:00 PM<br />
2254. The Involvement <strong>of</strong> CD36 in the Monocyte Activation by<br />
Antiphospholipid Antibodies.<br />
Masaru Kato 1 , Tatsuya Atsumi 2 , Kenji Oku 3 , Olga Amengual 3 ,<br />
Yuichiro Fujieda 3 , Kotaro Otomo 3 , Tetsuya Horita 3 , Shinsuke<br />
Yasuda 3 and Takao Koike 3 , 1 Department <strong>of</strong> Medicine II, Hokkaido<br />
University Graduate School <strong>of</strong> Medicine, Sapporo, Hokkaido,<br />
Japan, 2 Department <strong>of</strong> Medicine II, Hokkaido University<br />
Graduate School <strong>of</strong> Medicine, Sapporo, Japan, 3 Department <strong>of</strong><br />
Medicine II, Hokkaido University Graduate School <strong>of</strong> Medicine<br />
12:15 PM<br />
2255. Potential Protein Targets for the Treatment<br />
<strong>of</strong> the Antiphospholipid Syndrome with Statins and<br />
Hydroxychloroquine.<br />
Anastasia Lambrianides 2 , Silvia S. Pierangeli 1 , Katie Bell 3 , Wendy<br />
Heywood 3 , David S. Latchman 3 , David A. Isenberg 3 , Anisur<br />
Rahman 3 and Ian Giles 3 , 1 Univ <strong>of</strong> TX Medical Branch, Galveston,<br />
TX, 2 University <strong>College</strong> London, London, United Kingdom,<br />
3<br />
University <strong>College</strong> London, London, UK<br />
B313<br />
Rheumatoid Arthritis - Clinical Aspects: Radiographic<br />
and Other Outcomes in RA IV<br />
Moderators: Earnest Choy, MD; Kings <strong>College</strong> Hospital; London,<br />
United Kingdom<br />
Piet L. Van Riel, MD, PhD; University Hospital Nijmegen;<br />
Nijmegen, The Netherlands<br />
12:00 PM<br />
2260. Interleukin-6 Levels Are Associated with Elevated Ankle<br />
Brachial Index in Rheumatoid Arthritis.<br />
Cecilia P. Chung 4 , Jon T. Giles 3 , Moyses Szklo 5 , Wendy Post 5 ,<br />
Michelle A. Petri 1 , Roger Blumenthal 5 , Allan C. Gelber 2 , Russell<br />
Tracy 6 and Joan M. Bathon 4 , 1 Timonium, MD, 2 Baltimore, MD,<br />
3<br />
Johns Hopkins Univ, Baltimore, MD, 4 Johns Hopkins University,<br />
Baltimore, MD, 5 Johns Hopkins University, 6 University <strong>of</strong><br />
Vermont<br />
12:15 PM<br />
2261. Diagnostic Accuracy <strong>of</strong> the 2010 ACR/EULAR Used at<br />
Baseline after a 10 Year Follow Up in a Cohort <strong>of</strong> Patients with<br />
Recent-Onset Arthritis.<br />
Divi Cornec 5 , Sophie Varache 6 , Johanne Morvan 5 , Valérie<br />
Devauchelle-pensec 5 , Jean-Marie Berthelot 7 , Sandrine Joussejoulin<br />
5 , Catherine Le Henaff 2 , Sylvie Hoang 4 , Jean-Baptiste<br />
Thorel 1 , Antoine Martin 3 , Gérard Chalès 8 , Pierre Youinou 5 and<br />
Alain Saraux 5 , 1 CH Lorient, 2 CH Morlaix, 3 CH St Brieuc, 4 CH<br />
Vannes, 5 CHU Brest, 6 CHU Brest, 7 CHU Nantes, 8 CHU Rennes<br />
B402<br />
Rheumatoid Arthritis Treatment - Small Molecules,<br />
Biologics and Gene Therapy: Existing Biologics IV<br />
Moderators: Daniel E. Furst, MD; University <strong>of</strong> California Los<br />
Angeles Medical School; Los Angeles, CA<br />
Veena K. Ranganath, MD; University <strong>of</strong> California Los Angeles<br />
Medical School; Los Angeles, CA<br />
thursday<br />
11:00 AM<br />
2256. Irreversible Physical Disability in Rheumatoid Arthritis<br />
(RA) Is Determined by Cartilage Damage Rather Than Bone<br />
Destruction.<br />
Josef S. Smolen 2 and Daniel Aletaha 1 , 1 Medical University <strong>of</strong><br />
Vienna, Austria, 2 Medical University <strong>of</strong> Vienna and Hietzing<br />
Hospital, Vienna, Austria<br />
11:15 AM<br />
2257. The Impact <strong>of</strong> Body Weight on the Progression <strong>of</strong><br />
Radiographic Joint Damage in Rheumatoid Arthritis Patients.<br />
Axel Finckh 4 , Almut Scherer 1 , Anne Lubbeke-Wolff 3 , Hans<br />
Schwarz 1 and Cem Gabay 2 , 1 SCQM Foundation, Switzerland,<br />
2<br />
Univ Hosp <strong>of</strong> Geneva, Geneva, Switzerland, 3 University <strong>of</strong><br />
Geneva, Switzerland, 4 University <strong>of</strong> Geneva, Geneva, Switzerland<br />
11:30 AM<br />
2258. Clinical Rather Than Serologic Measures <strong>of</strong> Inflammation<br />
Determine Radiographic Progression in Rheumatoid Arthritis<br />
(RA).<br />
Daniel Aletaha 1 and Josef S. Smolen 2 , 1 Medical University <strong>of</strong><br />
Vienna, Austria, 2 Medical University <strong>of</strong> Vienna and Hietzing<br />
Hospital, Vienna, Austria<br />
11:45 AM<br />
2259. Coronary Atherosclerosis in Patients with RA and Acute<br />
Coronary Events: No Different Than in the Rest <strong>of</strong> Us?<br />
Marie E. Holmqvist 1 , Lennart T. H. Jacobsson 3 , Lars Alfredsson 1 ,<br />
Stefan James 4 and Johan Askling 2 , 1 Karolinska Institutet,<br />
2<br />
Karolinska University Hospital, 3 Malmö University Hospital,<br />
4<br />
Uppsala University Hospital<br />
11:00 AM<br />
2262. Tocilizumab (TCZ) Plus Methotrexate (MTX) in<br />
Rheumatoid Arthritis (RA) Patients (pts) Who Increased TCZ<br />
Dose from 4 mg/kg to 8 mg/kg: LITHE Radiographic and Safety<br />
Data.<br />
Roy M. Fleischmann 4 , Ricardo Blanco 2 , Geraldo Castelar-<br />
Pinheiro 3 , Emma Vernon 5 , Christopher Mela 5 and Joel M.<br />
Kremer 1 , 1 Albany Medical <strong>College</strong>, Albany, NY, 2 Hospital Marqués<br />
de Valdecilla Cantabria, 3 Hospital Universitario Pedro Ernesto,<br />
Rio de Janeiro, Brazil, 4 Metroplex Clinical Research Center,<br />
Dallas, TX, 5 Roche, Welwyn, United Kingdom<br />
11:15 AM<br />
2263. Rituximab Treatment Induces the Expression <strong>of</strong> Genes<br />
Involved in Healing Processes in the Rheumatoid Arthritis<br />
Synovium.<br />
Ilse Gutierrez-Roelens 4 , Christine Galant 3 , Ivan Theate 3 , Rik J.<br />
Lories 2 , Patrick Durez 4 , Adrien Nzeusseu Toukap 4 , Benoît Van<br />
den Eynde 1 , Frédéric A. Houssiau 4 and Bernard R. Lauwerys 4 , 1 de<br />
Duve Institute & Ludwig Institute for Cancer Research, Brussels<br />
Branch, 2 Department <strong>of</strong> Musculoskeletal Sciences, Division<br />
<strong>of</strong> <strong>Rheumatology</strong>, Laboratory for Skeletal Development and<br />
Joint Disorders, Katholieke Universiteit Leuven, 3 Department<br />
<strong>of</strong> Pathology, Cliniques Universitaires Saint-Luc, Université<br />
Catholique de Louvain, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, Cliniques<br />
Universitaires Saint-Luc, Université Catholique de Louvain<br />
11:30 AM<br />
2264. Golimumab and Methotrexate Combination Therapy<br />
Significantly Improves Synovitis, Osteitis and Bone Erosion<br />
Compared to Methotrexate Alone – A Magnetic Resonance<br />
Imaging Study <strong>of</strong> Methotrexate-Naïve Rheumatoid Arthritis<br />
Patients.<br />
144<br />
2010 Program Book
Mikkel Østergaard 6 , Paul Emery 4 , Philip G. Conaghan 5 , Roy M.<br />
Fleischmann 7 , Weichun Xu 2 , Elizabeth C. Hsia 3 , Anna Beutler 1 and<br />
Mahboob U. Rahman 3 , 1 Centocor Research and Development,<br />
Inc., <strong>College</strong>ville, PA, 2 Centocor Research and Development, Inc.,<br />
3<br />
Centocor Research and Development, Inc./Univ. <strong>of</strong> Pennsylvania<br />
School <strong>of</strong> Medicine, Malvern, PA, 4 Chapel Allerton Hospital,<br />
Leeds, United Kingdom, 5 Chapel Allerton Hospital, Leeds, United<br />
Kingdom, 6 Copenhagen University Hospital at Glostrup and<br />
Hvidovre, Hvidovre, Denmark, 7 University <strong>of</strong> Texas SW Medical<br />
Center, Dallas, TX<br />
11:45 AM<br />
2265. Changes in CRP Levels Are Associated with Clinical<br />
Response Patterns during Treatment with Infliximab — A<br />
Potential Role for CRP in Guiding Dose Optimization.<br />
Cees Meeuwisse 5 , Josef S. Smolen 4 , Dimitrios Boumpas 7 , E.<br />
William St Clair 2 , Mahboob U. Rahman 1 , Nathan Vastesaeger 6 ,<br />
Wilbert van Duijnhoven 5 , Robert L. H. Nelissen 5 and Ronald Van<br />
Vollenhoven 3 , 1 Centocor, Malvern, PA, 2 Duke University Medical<br />
Center, Durham, NC, 3 Karolinska University Hospital, Stockholm,<br />
Sweden, 4 Krankenhaus Lainz, Vienna, Austria, 5 MSD, Oss, The<br />
Netherlands, 6 MSD, Brussels, Belgium, 7 University Hospital <strong>of</strong><br />
Heraklion, Crete, Greece<br />
Gilles Hayem 7 , Rim Ben M’Barek 8 , Eric Toussirot 4 , Christian<br />
Compaoré 6 , Thao Pham 9 , Eric Houvenagel 13 , Antoine Martin 3 ,<br />
Nathalie Balandraud 9 , Jean-Marie Berthelot 10 , Grégoire Cormier 2 ,<br />
Anne Dubois 1 , Rose-Marie Javier 11 , Sylvain Lanot 12 , Marie-<br />
José Wattiaux 7 , Olivier C. Meyer 8 and Daniel Wendling 5 , 1 CH<br />
Brive, France, 2 CH La Roche sur Yon, France, 3 CH Saint-Brieuc,<br />
France, 4 CHU Besançon, France, 5 CHU Besançon, for the “Club<br />
Rhumatismes et Inflammation”, Besancon, France, 6 CHU Bichat,<br />
Paris, France, 7 CHU Bichat, Paris, France, 8 CHU Bichat, Paris,<br />
Tunisia, 9 CHU Marseille, France, 10 CHU Nantes, France, 11 CHU<br />
Strasbourg, France, 12 Private Office, Paris, France, 13 UC Lille,<br />
France<br />
11:30 AM<br />
2270. Radiographic Findings after 5 Years <strong>of</strong> Infliximab<br />
Treatment in Patients with Ankylosing Spondylitis.<br />
Xen<strong>of</strong>on Baraliakos 6 , Frank Heldmann 6 , Desiree M. Van<br />
Der Heijde 4 , Joachim Listing 3 , Joachim Sieper 2 , Alessandra<br />
Oortwijn 1 , Rebecca Bolce 1 and Juergen Braun 5 , 1 Centocor Inc,<br />
2<br />
Charite Campus Benjamin Frankl, Berlin, Germany, 3 German<br />
Rheumatism Research Center, 4 Leiden University Medical Center,<br />
Meerssen, The Netherlands, 5 Rheumazentrum Ruhrgebiet,<br />
Herne, Germany, 6 Rheumazentrum Ruhrgebiet Herne<br />
12:00 PM<br />
2266. Comparative Effectiveness <strong>of</strong> Biologic Therapies for<br />
Treating Rheumatoid Arthritis (RA) in Patients Who Failed an<br />
Anti–Tumor Necrosis Factor Agent: A Meta-Regression Analysis.<br />
A. Benedict 2 , D. J. Vanness 3 , S. Roy 1 and M. A. Cifaldi 1 , 1 Abbott<br />
Laboratories, 2 United BioSource Corporation, 3 University <strong>of</strong><br />
Wisconsin<br />
12:15 PM<br />
2267. Clinical and Radiological Efficacy <strong>of</strong> Biologics in<br />
Rheumatoid Arthritis Patients Naive or Inadequate Responders<br />
to Methotrexate: A Metanalysis.<br />
Pierreisnard Audrey, Issa Nahema, Barnetche Thomas, Richez<br />
Christophe and Schaeverbeke Thierry, Bordeaux University<br />
Hospital, <strong>Rheumatology</strong> Department, France<br />
A404<br />
Spondylarthropathies and Psoriatic Arthritis - Clinical<br />
Aspects and Treatment - Therapy III<br />
Moderators: Luis R. Espinoza, MD; Louisianna State University<br />
Medical Center; New Orleans, LA<br />
Maxime Dougados, MD; Hospital Cochin; Paris, France<br />
11:00 AM<br />
2268. Outcome <strong>of</strong> an Education and Home Exercise Program<br />
for Ankylosing Spondylitis Patients: A Nationwide Randomized<br />
Study.<br />
Carlos Rodríguez-Lozano 2 , Xavier Juanola 2 , Juan Cruz-<br />
Martínez 1 , Andrés Peña-Arrébola 4 , Juan Mulero 2 and Eduardo<br />
Collantes 3 , 1 for the Spondylarthropathies Study Group <strong>of</strong><br />
the Spanish Society <strong>of</strong> <strong>Rheumatology</strong> (GRESSER), 2 for the<br />
Spondylarthropathies Study Group <strong>of</strong> the Spanish Society <strong>of</strong><br />
<strong>Rheumatology</strong> (GRESSER), 3 for the Spondylarthropathies Study<br />
Group <strong>of</strong> the Spanish Society <strong>of</strong> <strong>Rheumatology</strong> (GRESSER);<br />
Hospital Ramón y Cajal. Madrid, 4 Hospital Ramón y Cajal. Madrid<br />
11:15 AM<br />
2269. SAPHO Syndrome Treated by TNF alpha-Blocking Agents.<br />
Report <strong>of</strong> 45 Cases.<br />
11:45 AM<br />
2271. Effects <strong>of</strong> Etanercept vs. Sulfasalazine on Acute<br />
Inflammatory Lesions as Detected by Whole Body MRI in Early<br />
Axial Spondyloarthritis – A 48 Week Randomized Controlled<br />
Trial.<br />
In-Ho Song 2 , Kay-Geert Hermann 4 , Hildrun Haibel 3 , Christian<br />
Alth<strong>of</strong>f 4 , Joachim Listing 7 , Gerd-Rüdiger Burmester 5 , Andreas<br />
Krause 6 , Martin Bohl-Bühler 9 , Bruce Freundlich 8 , Martin<br />
Rudwaleit 3 and Joachim Sieper 1 , 1 Charite Benjamin-Franklin,<br />
Med. Clinic I, <strong>Rheumatology</strong>, Berlin, Germany, 2 Charite Campus<br />
Benjamin, Med. Clinic I, <strong>Rheumatology</strong>, Berlin, Germany, 3 Charite<br />
Campus Benjamin-Franklin, Med. Clinic I, <strong>Rheumatology</strong>, Berlin,<br />
Germany, 4 Charite Campus Mitte, Radiology, Berlin, Germany,<br />
5<br />
Charite Campus Mitte, <strong>Rheumatology</strong>, Berlin, Germany, 6 Clinic<br />
Buch Rheumatologie, Berlin, Germany, 7 German Rheumatism<br />
Research Center, Berlin, Germany, 8 Pfizer- Wyeth, PA, 9 Private<br />
Practice, <strong>Rheumatology</strong>, Potsdam, Germany<br />
12:00 PM<br />
2272. A Prospective Inception Cohort Study <strong>of</strong> the Clinical<br />
Presentation and Response to Treatment <strong>of</strong> Undifferentiated<br />
Spondyloarthritis Versus Ankylosing Spondylitis and Psoriatic<br />
Arthritis.<br />
Jacqueline E. Paramarta 2 , Leen E. De Rycke 3 , Carmen A.<br />
Ambarus 3 , Paul P. Tak 1 and Dominique L. Baeten 2 , 1 Academic<br />
Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />
2<br />
Division <strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic<br />
Medical Center/University <strong>of</strong> Amsterdam, Amsterdam,<br />
The Netherlands, 3 Division <strong>of</strong> Clinical Immunology and<br />
<strong>Rheumatology</strong>, Academic Medical Center/University <strong>of</strong><br />
Amsterdam, Amsterdam, The Netherlands<br />
12:15 PM<br />
2273. Do Patients with Psoriatic Arthritis Who Present Early<br />
Fare Better Than Those Presenting Later in the Disease?<br />
Dafna D. Gladman 1 , Arane Thavaneswaran 2 and Vinod<br />
Chandran 2 , 1 Toronto Western Hospital, Toronto, ON, Canada,<br />
2<br />
University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto Western<br />
Hospital<br />
2010 Program Book 145<br />
thursday
thursday<br />
A311<br />
Systemic Lupus Erythematosus - Human Etiology and<br />
Pathogenesis: Etiology and Pathogenesis<br />
Moderators: Mariana J. Kaplan, MD; University <strong>of</strong> Michigan<br />
Medical Center; Ann Arbor, MI<br />
Andras Perl, MD, PhD; Upstate Medical University; Syracuse, NY<br />
11:00 AM<br />
Introductory Talk: IL-17 in Lupus Nephritis<br />
George C.Tsokos, MD; Harvard Medical School/Beth Israel<br />
Hospital; Boston, MA<br />
11:15 AM<br />
2274. Identification <strong>of</strong> cis-Regulatory Element Binding<br />
Differences in the C8orf13/BLK Promoter Region Linked with<br />
Risk <strong>of</strong> SLE.<br />
Rufei Lu 5 , Nicolas Dominguez 6 , Susan Macwana 5 , Celi Sun 5 ,<br />
Jennifer A. Kelly 5 , Kenneth M. Kaufman 5 , Carl D. Langefeld 11 ,<br />
Marta Alarcon-Riquielme for BIOLUPUS Network 5 , Sang-Cheol<br />
Bae 2 , Elizabeth E. Brown for PROFILE 9 , Gary S. Gilkeson 3 , Timothy<br />
B. Niewold 10 , Betty P. Tsao8, Nan Shen 7 , Kathy L. Moser 4 , John<br />
B. Harley 1 , Slegen, Carol Webb 5 , Judith A. James 5 , Swapan K.<br />
Nath 5 , Patrick M. Gaffney 5 and Joel M. Guthridge 5 , 1 Cincinnati<br />
Children’s Hospital Medical Center, 2 Hanyang University Hospital<br />
for Rheumatic Diseases, 3 Medical University <strong>of</strong> South Carolina,<br />
4<br />
Oklahoma Med Research Foundation, 5 Oklahoma Medical<br />
Research Foundation, 6 Oklahoma Medical Reserch Foundation,<br />
7<br />
Shanghai Ren Ji Hospital, 8 UCLA School <strong>of</strong> Medicine, 9 University<br />
<strong>of</strong> Alabama at Birmingham, 10 University <strong>of</strong> Chicago, 11 Wake<br />
Forest University Health Sciences<br />
11:30 AM<br />
2275. The HRES-1/RAB4 Lupus Susceptibility Gene Promotes<br />
Nitric Oxide Production in Human T Cells through Direct<br />
Interaction with Endothelial Nitric Oxide Synthase Interacting<br />
Protein.<br />
Tiffany N. Telarico 1 , Edward H. Doherty 1 , David R. Fernandez 1 ,<br />
Adam Bartos 1 , Stephanie Oess 2 , Werner Muller-Esterl 2 and<br />
Andras Perl 3 , 1 SUNY, 2 University <strong>of</strong> Frankfurt, 3 Upstate Medical<br />
Univ, Syracuse, NY<br />
11:45 AM<br />
2276. Transcriptional Inflammatory Mechanism in Murine<br />
Lupus Nephritis: An Insight into Human Disease.<br />
Tania C. Gonzalez Rivera 3 , Celine C. Berthier 3 , Viji Nair 3 ,<br />
Ramalingam Bethunaickan 1 , Matthias Kretzler 3 , Anne Davidson 2<br />
and ERCB Consortium, 1 Feinstein Institute, Manhasset, NY,<br />
2<br />
Feinstein Institute for Medical Research, Manhasset, NY,<br />
3<br />
University <strong>of</strong> Michigan, Ann Arbor, MI<br />
12:00 AM<br />
2277. SLE Serum Deposits C4d on Red Blood Cells, Decreases<br />
Red Blood Cell Membrane Deformability, and Promotes NO<br />
Production.<br />
Ionita C. Ghiran 1 , Ourania Kampagianni 1 , Mark L. Zeidel 1 , Sergey<br />
S. Shevkoplyas 2 , Jennie M. Burns 2 , George C. Tsokos 1 and<br />
Vasileios C. Kyttaris 1 , 1 Beth Israel Deaconess Medical Center,<br />
2<br />
Tulane University<br />
12:15 PM<br />
2278. What Are the Pathways by Which Interferon-alpha<br />
Decreases Vasculogenesis in Lupus?<br />
Seth G. Thacker 2 , Celine Berthier 2 , Deborah Mattinzoli 1 ,<br />
Maria-Pia Rastaldi 1 , Matthias Kretzler 2 and Mariana J. Kaplan 3 ,<br />
1<br />
Fondazione IRCCS Ospedale Maggiore Policlinico & Fondazione<br />
D’Amico per la Ricerca Sulle Malattie Renali, 2 University <strong>of</strong><br />
Michigan, 3 University <strong>of</strong> Michigan Medical Center, Ann Arbor, MI<br />
ARHP Concurrent Abstract Session<br />
11:00 AM - 12:30 PM<br />
B311<br />
Rheumatoid Arthritis: From Clinic to Home<br />
Moderator: Joyce P. Carlone, MN, RN, FNP-BC; Emory University;<br />
Atlanta, GA<br />
11:00 AM<br />
2279. The Nurse’s Role in Treatment and Management<br />
<strong>of</strong> Patients with Rheumatoid Arthritis: A Delphi-Based<br />
Recommendation on Patient Unmet Needs.<br />
Jane E. D. Cottrell 2 , Monique Jonas 1 and Leeanna M. Bulinckx 3 ,<br />
1<br />
Charité University Hospital, Berlin, Germany, 2 Mount Sinai<br />
Hospital, Toronto, ON, Canada, 3 PerCuro Clinical Research Ltd,<br />
Victoria, BC, Canada<br />
11:15 AM<br />
2280. Self-Efficacy and Follow-Up with Nursing, Medical or<br />
Shared Care for Outpatients with Rheumatoid Arthritis.<br />
Jette Primdahl 3 , Lis Wagner 2 and Kim Hørslev-Petersen 1 , 1 King<br />
Christian X’s Hospital for Rheumatic Diseases in Graasten and<br />
University <strong>of</strong> Southern Denmark, Graasten, Denmark, 2 Research<br />
Unit <strong>of</strong> Nursing, University <strong>of</strong> Southern Denmark, Odense,<br />
Denmark, 3 University <strong>of</strong> Southern Denmark, Sønderborg,<br />
Denmark<br />
11:30 AM<br />
2281. Future Expectations and Worst Case Scenarios <strong>of</strong> Patients<br />
with Rheumatoid Arthritis: A Focus Group Study in Patients.<br />
Laurien Buitinga 3 , Louise M. A. Braakman-Jansen 1 , Erik Taal 2 and<br />
Mart A. F. J. Van de Laar 4 , 1 University <strong>of</strong> Twente, Enschede, The<br />
Netherlands, 2 University <strong>of</strong> Twente, Enschede, The Netherlands,<br />
3<br />
University <strong>of</strong> Twente, 4 University <strong>of</strong> Twente; Medical Spectrum<br />
Twente, Enschede<br />
11:45 AM<br />
2282. Mapping Pathways through Care: Accounts <strong>of</strong> Help-<br />
Seeking in Early Rheumatoid Arthritis (RA).<br />
Anne Townsend 2 , Catherine L. Backman 3 , Paul Adam 1 , Susan<br />
M. Cox 4 , Linda C. Li 3 and Erahse Team, 1 Mary Pack Arthritis<br />
Centre, 2 Maurice Young Centre for Applied Ethics, University<br />
<strong>of</strong> British Columbia, Vancouver, BC, Canada, 3 University <strong>of</strong><br />
British Columbia, Vancouver, BC, Canada, 4 University <strong>of</strong> British<br />
Columbia<br />
12:00 PM<br />
2283. Home-Based Exercise Therapy in Patients with<br />
Rheumatoid Arthritis: A Systematic Review.<br />
Emalie J. Hurkmans 3 , Florus J. van der Giesen 2 , Thea P. M. Vliet<br />
Vlieland 1 , Jan W. Schoones 5 and Cornelia H. M. van den<br />
146<br />
2010 Program Book
Ende 4 , 1 Department <strong>of</strong> <strong>Rheumatology</strong> and Orthopaedics,<br />
Leiden University Medical Center, Leiden, The Netherlands,<br />
2<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Groene Hart Ziekenhuis,<br />
Gouda, The Netherlands, 3 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Leiden University Medical Center, Leiden, The Netherlands,<br />
4<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Sint Maartenskliniek, Nijmegen,<br />
The Netherlands, 5 Walaeus Library, LUMC, Leiden, The<br />
Netherlands, The Netherlands<br />
12:15 PM<br />
2284. An Interactive Website Reduces the Information Need<br />
Regarding the Accessibility <strong>of</strong> Health Care Services in RA<br />
Patients.<br />
Jorit J. L. Meesters 1 , Ingeborg G. de Boer 2 , Marta Fiocco 2 and<br />
Thea P. M. Vliet Vlieland 1 , 1 Leiden University Medical Center,<br />
Leiden, The Netherlands, 2 Leiden University Medical Center<br />
ARHP Concurrent Sessions<br />
11:00 AM - 12:30 PM<br />
B310<br />
Top 10 in ‘10: Top 10 Public Health Advances in the<br />
First 10 Years <strong>of</strong> the Centers for Disease Control and<br />
Prevention Arthritis Program C<br />
Moderator: Emily C. Somers, PhD, ScM; University <strong>of</strong> Michigan<br />
Health System; Ann Arbor, MI<br />
Speakers: Teresa J. Brady, PhD; Centesr for Disease Control;<br />
Atlanta, GA<br />
Charles G. Helmick, MD; Centers for Disease Control; Atlanta, GA<br />
Session Overview:<br />
Both health care reform and the <strong>American</strong> Recovery and<br />
Re-investment Act are emphasizing the importance <strong>of</strong> public<br />
health and prevention. The Centers for Disease Control and<br />
Prevention Arthritis Program, created in 1999 by a congressional<br />
appropriation, has spearheaded activating the public health<br />
system to respond to the challenge <strong>of</strong> arthritis as a public<br />
health problem in addition to a clinical problem. This focus on<br />
addressing arthritis as a public health problem has resulted in<br />
numerous advances in the last 10 years. This session is designed<br />
to provide attendees with an in depth review <strong>of</strong> the arthritisrelated<br />
advances in public health that have occurred since the<br />
creation <strong>of</strong> the program.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• describe a public health approach, and key elements <strong>of</strong> the<br />
public health approach to arthritis<br />
• list recent advances in arthritis related public health science<br />
• discuss recent advances in arthritis-related public health<br />
practice<br />
B309<br />
Total Shoulder Arthroplasty and Reverse Total<br />
Shoulder Arthroplasty: Surgery and Rehabilitation<br />
C<br />
Moderator: Jennifer L. Trizuto, MPT; Mills Health Center; San<br />
Mateo, CA<br />
Speakers: Victoria Gall, PT, MEd; Partners Healthcare; Hyde Park,<br />
MA<br />
Scott D. Pennington, MD; Peachtree Orthopaedic Clinic; Atlanta,<br />
GA<br />
Session Overview:<br />
Shoulder arthroplasty surgery changed in 2004 with the Food<br />
and Drug Administration approval <strong>of</strong> the reverse total shoulder<br />
arthroplasty. The procedure and rehabilitation are very<br />
complex and differs significantly from the traditional shoulder<br />
arthroplasty. Both <strong>of</strong> these procedures are being preformed<br />
outside <strong>of</strong> academic teaching facilities, so it is essential that<br />
therapists in all clinic settings who treat orthopedic patients be<br />
familiar with the protocols.<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• list the indications for a total shoulder arthroplasty and for an<br />
reverse total shoulder arthroplasty<br />
• explain the precautions for a total shoulder arthroplasty and<br />
an reverse total shoulder arthroplasty<br />
• use the protocols as guidelines when following the surgeon’s<br />
specific instructions<br />
Industry-Supported Post-<br />
Conference Symposia<br />
1:00 - 4:00 PM<br />
In 2010, there are two types <strong>of</strong> symposia <strong>of</strong>fered to attendees:<br />
CME-accredited and non-CME accredited. For CME-accredited<br />
symposia, the sponsoring organization is responsible for<br />
planning and providing CME credit. The non-CME accredited<br />
symposia have been planned and will be implemented in<br />
accordance with the requirements <strong>of</strong> the FDA and applicable<br />
standards <strong>of</strong> the PhRMA Code on Interactions with Healthcare<br />
Pr<strong>of</strong>essionals. Please visit the organization’s exhibit booth, the<br />
industry-supported symposia booth or see page 283 for more<br />
information.<br />
thursday<br />
2010 Program Book 147
ACR Poster Session A<br />
148<br />
Halls B1 & B2<br />
2010 Program Book<br />
MONDAY, NOVEMBER 8, 2010<br />
Antiphospholipid Syndrome<br />
1. Acquired Resistance to Activated Protein C Is a Feature <strong>of</strong> Both<br />
Systemic Lupus Erythematosus (SLE) and Antiphospholipid<br />
Syndrome (APS) and Is More Marked in Patients with SLE<br />
and APS. Denis Wahl 3 , Stéphane Zuily 4 , Agnès Brunette 2 ,<br />
Marie Prestat-Tilly 4 , Véronique Regnault 2 , Jean Devignes 1 and<br />
Thomas Lecompte 1 , 1 Biological Haematology Department,<br />
Nancy University Hospital, Vandoeuvre les Nancy, France,<br />
2<br />
INSERM U961, Nancy Université, Vandoeuvre les Nancy,<br />
France, 3 Vascular Medicine Unit, Vandoeuvre les Nancy, France,<br />
4<br />
Vascular Medicine Unit, Nancy University Hospital, Vandoeuvre<br />
les Nancy, France.<br />
2. AGTRL1 and PRKCH Are Genetic Risk Factors for<br />
Antiphospholipid Syndrome. Hisako Nakagawa 1 , Tetsuya<br />
Horita 2 , Toshio Odani 2 , Yuichiro Fujieda 2 , Masaru Kato 2 , Kotaro<br />
Otomo 2 , Yasuko Nakagawa 2 , Shinsuke Yasuda 2 , Tatsuya Atumi 2<br />
and Takao Koike 2 , 1 Department <strong>of</strong> Medicine II, Hokkaido<br />
University Graduate School <strong>of</strong> Medicine, Sapporo, Hokkaido,<br />
Japan, 2 Department <strong>of</strong> Medicine II, Hokkaido University<br />
Graduate School <strong>of</strong> Medicine.<br />
3. Anti-β2 Glycoprotein I Antibodies from Leprosy Patients Do<br />
Not Show Thrombogenic Effects in an In Vivo Animal Model.<br />
Ricardo Forastiero 2 , Marta Martinuzzo 2 , Mariano Vega-<br />
Ostertag 2 , Gabriela de Larranaga 2 and Silvia S. Pierangeli 1 , 1 Univ<br />
<strong>of</strong> TX Medical Branch, Galveston, TX, 2 Universidad Favaloro,<br />
Buenos Aires, Argentina.<br />
4. Antiphospholipid Antibodies in Children with Systemic<br />
Lupus Erythematosus – 18 Years <strong>of</strong> Clinical Experience<br />
from North India. Surjit Singh 2 , Jasmina Ahluwalia 1 , Shano<br />
Naseem 3 , Deepti Suri 2 and Amit Rawat 2 , 1 Department <strong>of</strong><br />
Hematology, Post Graduate Institute <strong>of</strong> Medical Education<br />
and Research, Chandigarh, India, 2 Division <strong>of</strong> Pediatric Allergy<br />
and Immunology, Advanced Pediatrics Centre, Post Graduate<br />
Institute <strong>of</strong> Medical Education and Research, Chandigarh, India,<br />
3<br />
Division <strong>of</strong> Pediatric Hematology, Advanced Pediatrics Centre,<br />
Post Graduate Institute <strong>of</strong> Medical Education and Research,<br />
Chandigarh, India.<br />
5. Antiphospholipid Score (aPL-S): A Comprehensive Predictive<br />
Marker <strong>of</strong> Developing Thrombosis in Autoimmune Diseases.<br />
Kotaro Otomo 1 , Tatsuya Atsumi 2 , Yuichiro Fujieda 3 , Masaru<br />
Kato 3 , Olga Amengual 3 , Tetsuya Horita 3 , Shinsuke Yasuda 3<br />
and Takao Koike 3 , 1 Hokkaido Graduate School <strong>of</strong> Medicine,<br />
Department <strong>of</strong> Medicine II, Sapporo, Hokkaido, Japan,<br />
2<br />
Hokkaido Graduate School <strong>of</strong> Medicine, Department <strong>of</strong><br />
Medicine II, Sapporo, Japan, 3 Hokkaido Graduate School <strong>of</strong><br />
Medicine, Department <strong>of</strong> Medicine II.<br />
6. Antiphospholipid Syndrome (APS) Clinical Research Task Force<br />
(CRTF) Report. Doruk Erkan 2 , Ronald Derksen 6 , Roger A. Levy 3 ,<br />
Samuel Machin 5 , Thomas Ortel 1 , Silvia S. Pierangeli 4 , Robert A.<br />
S. Roubey 7 , Michael D. Lockshin 2 and on Behalf <strong>of</strong> APS Clinical<br />
Research Task Force, 1 Duke University Health System, Durham,<br />
NC, 2 Hospital for Special Surgery, New York, New York, NY,<br />
3<br />
Univ Estado Do Rio de Janeiro, Rio de Janeiro, Brazil, 4 Univ <strong>of</strong><br />
TX Medical Branch, Galveston, TX, 5 University <strong>College</strong> London<br />
Hospitals, London, UK, 6 University Medical Centre, Utrecht,<br />
Netherlands, 7 University <strong>of</strong> North Carolina, Chapel Hill, NC.<br />
7. Decreased Fibrin Clot Porosity in Patients with Antifosfolipid<br />
Syndrome. Anna Vikerfors 2 , Aleksandra Antovic 1 , Elisabet<br />
Svenungsson 2 , Katarina Bremme 3 and Margareta Holmström 4 ,<br />
1<br />
Department <strong>of</strong> Clinical Sciences, Karolinska Institutet/Danderyd<br />
Hospital, Stockholm, Sweden, 2 Department <strong>of</strong> Medicine,<br />
<strong>Rheumatology</strong> Unit, Karolinska Institutet/Karolinska University<br />
Hospital, Stockholm, Sweden, 3 Department <strong>of</strong> Woman and<br />
Child Health, Division <strong>of</strong> Obstetrics and Gynaecology, Karolinska<br />
Institutet/Karolinska University Hospital, Stockholm, Sweden,<br />
4<br />
Hematology Division, Department <strong>of</strong> Medicine, Karolinska<br />
Institutet/Karolinska University Hospital, Stockholm, Sweden.<br />
8. Global Analyses <strong>of</strong> Antiphospholipid Antibodies That Impair<br />
Antithrombin Inactivation <strong>of</strong> Procoagulant Factors. Meifang<br />
Wu 2 , Jennifer M. Grossman 3 , John FitzGerald 2 , Bevra H. Hahn 4<br />
and Pojen P. Chen 1 , 1 UCLA Schl <strong>of</strong> Medicine, Los Angeles, CA,<br />
2<br />
UCLA School <strong>of</strong> Medicine, 3 University <strong>of</strong> California Los Angeles,<br />
Sherman Oaks, CA, 4 University <strong>of</strong> California Los Angeles School<br />
<strong>of</strong> Medicine, Los Angeles, CA.<br />
9. Influenza Vaccination Can Induce New Onset Anticardiolipins<br />
but Not β2-Glycoprotein-I Antibodies among Patients with<br />
Systemic Lupus Erythematosusβ. Evan Glenn Vista 3 , Sherry<br />
R. Crowe 3 , Amy B. Dedeke 3 , Jourdan R. Anderson 2 , Linda F.<br />
Thompson 3 , Gillian Air 4 and Judith A. James 1 , 1 Oklahoma Med<br />
Research Foundation, Oklahoma City, OK, 2 Oklahoma Medical<br />
Research Foundation, 3 Oklahoma Medical Research Foundation,<br />
Oklahoma City, OK, 4 University <strong>of</strong> Oklahoma Health Science<br />
Center, Oklahoma City, OK.<br />
10. Platelet Activation and Paradoxical Inhibition <strong>of</strong> ADP<br />
Induced Aggregation by Antiphospholipid Antibodies. Kenji<br />
Oku 4 , Tatsuya Atsumi 2 , Olga Amengual 3 , Masahiro Ieko 1 , Shin<br />
Furukawa 6 , Hirohiko Kitakawa 6 , Yuji Hori 6 , Kazuyoshi Nihei 6 ,<br />
Yuuichiro Fujieda 3 , Kotaro Otomo 5 , Masaru Kato 3 , Tetsuya<br />
Horita 3 , Shinsuke Yasuda 3 and Takao Koike 3 , 1 Health Sciences<br />
University <strong>of</strong> Hokkaido, 2 Hokkaido University Graduate School<br />
<strong>of</strong> Medicine Internal Medicine II, Sapporo, Japan, 3 Hokkaido<br />
University Graduate School <strong>of</strong> Medicine Internal Medicine II,<br />
4<br />
Hokkaido University Graduate School <strong>of</strong> Medicine Internal<br />
Medicine II, Kushiro Red Cross Hospital, Japan, 5 Hokkaido<br />
UniversityGraduate School <strong>of</strong> Medicine Internal Medicine II,<br />
6<br />
Kushiro Red Cross Hospital.<br />
11. Prevalence and Prognostic Significance <strong>of</strong> Thrombotic<br />
Microangiopathy in Rheumatologic Patients: Clinical and<br />
Immunological Associations. Spyros Aslanidis, Athina<br />
Pyrpasopoulou, Stella Douma, Areti Triantafyllou, Michail<br />
Doumas and Chrysanthos Zamboulis, 2nd Propedeutic Dept <strong>of</strong><br />
Internal Medicine, Hippokration Hospital, Thessaloniki, Greece.<br />
12. Prevalence <strong>of</strong> Antibodies to Prothrombin (PT) and<br />
Prothrombin/Phosphatidylserine (PS) in a Cohort <strong>of</strong> Lupus<br />
Anticoagulant (LAC) Positive Samples. R. Aguilar-Valenzuela 2 , J.<br />
Dlott 1 , U. Khan 2 , M. Belter 1 , E. Doan 2 , N. Gould 1 , A. Schleh 2 and<br />
S. Pierangeli 2 , 1 Quest Diagnostics, Chantilly, VA, 2 Univ <strong>of</strong> TX Med<br />
Branch, Galveston, TX.<br />
13. The Influence <strong>of</strong> Thrombovascular Events on the Quality<br />
<strong>of</strong> Life in APS and SLE Patients. Amaris K. Balitsky, Valentina<br />
Peeva, Jiandong Su, Erik Yeo, Carol Landolt-Marticorena, Dafna<br />
D. Gladman, Murray B. Urowitz and Paul R. Fortin, University<br />
<strong>of</strong> Toronto Antiphospholipid Clinic, Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Toronto Western Hospital.<br />
14. Utility <strong>of</strong> Anti-Phosphatidylserine/Prothrombin and IgA<br />
Antiphospholipid Assays in Antiphospholipid Syndrome.<br />
Ehtisham Akhter 3 , Walter L. Binder 2 , Zakera Shums 2 and<br />
Michelle A. Petri 1 , 1 Timonium, MD, 2 Inova Diagnostics Inc, San<br />
Diego, CA, 3 Johns Hopkins University, Baltimore, MD.
ACR Poster Session A<br />
Cytokines, Mediators, Gene Regulation I<br />
15. BAFF Expression Correlates with Idiopathic Inflammatory<br />
Myopathy Disease Activity Measures, Interferon Signature<br />
and Autoantibodies. Kelly T. McNallan 1 , Hatice Bilgic 3 , Cynthia<br />
S. Crowson 2 , Steven R. Ytterberg 2 , Shreyasee Amin 2 , Peterson<br />
J. Erik 3 , Emily C. Baechler 3 and Ann M. Reed 2 , 1 Mayo Clinic,<br />
Rochester, MN, 2 Mayo Clinic, 3 University <strong>of</strong> Minnesota.<br />
16. Blockade <strong>of</strong> TLR2 Prevents Spontaneous and Induced Cytokine<br />
Release from Rheumatoid Arthritis Ex Vivo Synovial Explant<br />
Cultures. Sinead Nic An Ultaigh 1 , Tajvur Saber 1 , Jerome<br />
Dellacasagrande 2 , Brian Keogh 2 , William McCormack 2 , Mary<br />
Reilly 2 , Luke O’ Neill 2 , Peter McGuirk 2 , Ursula Fearon 1 and<br />
Douglas J. Veale 1 , 1 Dublin Academic Medical Centre, Dublin,<br />
Ireland, 2 Opsona Therapeutics Ltd, Dublin, Ireland.<br />
17. CCL15/Leukotactin-1: A Novel Mediator <strong>of</strong> Rheumatoid<br />
Arthritis Fibroblast-Like Synoviocyte Migration Via CCR3 and<br />
MAP Kinases. Eric K. Owens 1 , Karolina Klosowska 2 , Michael<br />
V. Volin 2 , Brian Zanotti 2 and James M. Woods 2 , 1 Midwestern<br />
University, Downers Grove, IL, 2 Midwestern University.<br />
18. Chronic Exposure to IL-6 Amplifies Macrophage Response to<br />
Toll-Like Receptor (TLR) Ligands. Raffaele Strippoli 1 , Francesco<br />
Carvello 2 , Loredana De Pasquale 2 , Luisa Bracci-Laudiero 2 and<br />
Fabrizio de Benedetti 2 , 1 IRCCS Ospedale Pediatrico Bambino<br />
Gesu, Rome, Italy, 2 IRCCS Ospedale Pediatrico Bambino Gesu,<br />
Rome, Italy.<br />
19. CX3CR1 Deficient Mice Have Decreased Th17 and Antigen-<br />
Specific Humoral Responses in the Collagen Induced Arthritis<br />
(CIA) Model. Teresa K. Tarrant 2 , Peng Liu 3 , Rishi Rampersad 3 ,<br />
Denise Esserman 3 , Lisa Rothlein, Marcus W. McGinnis 3 , David J.<br />
Fitzhugh 3 , Dhavalkumar D. Patel 1 and Alan M. Fong 3 , 1 Novartis<br />
Pharma AG, Basel, Switzerland, 2 UNC School <strong>of</strong> Medicine,<br />
Chapel Hill, NC, 3 UNC School <strong>of</strong> Medicine.<br />
20. Cytokine Expression in Synovial Tissue <strong>of</strong> Psoriatic Arthritis<br />
and Its Relation to Lymphoid Neogenesis, Erosive Disease<br />
and Disease Activity: A Longitudinal Study. Raquel Celis 1 ,<br />
Julio Ramírez 1 , Raimon Sanmarti 1 , José L. Pablos 2 and Juan D.<br />
Cañete 1 , 1 Servicio Reumatología, Hospital Clinic and IDIBAPS,<br />
Barcelona, Spain, 2 Unidad de Investigación, Hospital 12 de<br />
Octubre, Madrid, Spain.<br />
21. DNA Hypomethylation Upregulates CXCL12 in Rheumatoid<br />
Arthritis Synovial Fibroblasts. Emmanuel Karouzakis 1 , Yvonne<br />
Rengel 1 , Astrid Jüngel 1 , Christoph Kolling 3 , Renate E. Gay 1 ,<br />
Beat A. Michel 1 , Paul P. Tak 2 , Steffen Gay 1 , Michel Neidhart 1<br />
and Caroline Ospelt 1 , 1 Center <strong>of</strong> Experimental <strong>Rheumatology</strong><br />
and Zurich Center <strong>of</strong> Integrative Human Physiology (ZIHP),<br />
University Hospital Zurich, 2 Department <strong>of</strong> Clinical Immunology<br />
and <strong>Rheumatology</strong>, University <strong>of</strong> Amsterdam, 3 Schulthess Clinic,<br />
Zürich.<br />
22. Downregulation <strong>of</strong> the Chemokine Receptor CX3CR1 in Active<br />
RA Associated with a Pro-Osteoclastognic Phenotype. Grainne<br />
Murphy 1 , John Ryan 1 , Harney Sinead 1 , Fergus Shanahan 1 ,<br />
Michael Molloy 1 and Noel Caplice 2 , 1 Cork University Hospital,<br />
Cork, Ireland, 2 University <strong>College</strong> Cork, Cork, Ireland.<br />
23. Downstream Targets <strong>of</strong> IL-17 in Rheumatoid Arthritis. Sarah<br />
R. Pickens 4 , Richard M. Pope 3 , Michael V. Volin 1 and Shiva<br />
Shahrara 2 , 1 Midwestern University, 2Northwestern Univ<br />
Feinberg, Chicago, IL, 3 Northwestern Univ Med School, Chicago,<br />
IL, 4 Northwestern University.<br />
24. Elevated BLyS Levels Are Associated with an Increase in<br />
Autoantibody Specificites and ANA Titer in Systemic Lupus<br />
Erythematosus. Lauren L. Ritterhouse 3 , Amanda R. Moyer 3 ,<br />
Virginia C. Roberts 2 , Amy B. Dedeke 2 , Sherry R. Crowe 3 , Gillian<br />
M. Air 4 , Linda F. Thompson 3 , Joel M. Guthridge 3 and Judith A.<br />
James 1 , 1 Oklahoma Med Research Foundation, Oklahoma City,<br />
OK, 2 Oklahoma Medical Research Foundation, Oklahoma City,<br />
OK, 3 Oklahoma Medical Research Foundation, 4 University <strong>of</strong><br />
Oklahoma Health Sciences Center.<br />
25. Elevated Levels <strong>of</strong> CXCL9 or CXCL10 in Sera <strong>of</strong> Patients with<br />
Early RA Predict Greater Difficulty in Achieving Remission<br />
during the First Year <strong>of</strong> Treatment. Gregory R. Emkey 5 ,<br />
Klemen Strle 6 , Christopher R. Antolini 3 , Deborah S. Collier 5 ,<br />
Margaret Seton 5 , Arezou Khosroshahi 5 , Mark Fisher 2 , Nancy D.<br />
Kim 4 , John H. Stone 1 , Andrew D. Luster 4 and Allen C. Steere 5 ,<br />
1<br />
Massachusetts General Hospital, Sudbury, MA, 2 Massachusetts<br />
General Hospital, Haddon Heights, NJ, 3 Massachusetts General<br />
Hospital, Denver, CO, 4 Massachusetts General Hospital,<br />
Charlestown, MA, 5 Massachusetts General Hospital, Boston,<br />
MA, 6Massachusetts General Hospital.<br />
26. Elevated Serum CX3CL1 Levels in Adult-Onset Still’s Disease:<br />
Potential Involvement in Hemophagocytic Syndrome. Tsuyoshi<br />
Kasama 1 , Kumiko Ohtsuka 2 , Michihito Sato 2 , Ryo Takahashi 2 ,<br />
Kuninobu Wakabayashi 2 and Takeo Isozaki 2 , 1 Showa University<br />
School <strong>of</strong> Med, Shinagawa-ku Tokyo, Japan, 2 Showa University<br />
School <strong>of</strong> Med.<br />
27. Gallic Acid Diminishes Cellular Proliferation and Pro-<br />
Inflammatory Gene Expressions in Fibroblast Like Synoviocytes<br />
from Patients with Rheumatoid Arthritis. Soo-Jin Chung 1 ,<br />
Tae-Yeon Kim 2 , Yong-Jin Kwon 2 , Yong-Beom Park 2 , Soo-Kon Lee 2<br />
and Min-Chan Park 3 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Internal Medicine, Yonsei University <strong>College</strong> <strong>of</strong> Medicine, Seoul,<br />
Republic <strong>of</strong> Korea, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Internal Medicine, Yonsei University <strong>College</strong> <strong>of</strong> Medicine, Seoul,<br />
South Korea, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Yonsei University<br />
<strong>College</strong> <strong>of</strong> Medicine, Seoul, Korea, Republic <strong>of</strong>.<br />
28. WITHDRAWN<br />
29. Interleukine 34 Is Expressed in the Synovial Tissue from OA<br />
and RA Patients. Celine Cozic 1 , Benoit Le G<strong>of</strong>f 1 , Anne Riet 1 ,<br />
Marie-Francoise Heymann 1 , Celine Charrier 1 , Regis Brion 1 ,<br />
Sophie Touchais 3 , Marguerite Chemel 4 , Dominique Heymann 1<br />
and Jean-Marie Berthelot 2 , 1 INSERM UMR S 957, 2 INSERM UMR<br />
S 957 and <strong>Rheumatology</strong> Unit, CHU Nantes, Nantes, France,<br />
3<br />
Orthopedic Surgery Unit, CHU Nantes, 4 <strong>Rheumatology</strong> Unit,<br />
CHU Nantes.<br />
30. Oncostatin M, Acting through Oncostatin M Receptor, Is a<br />
Potent Regulator <strong>of</strong> IL-6 and RANKL Expression in Mouse<br />
Synovial Fibroblasts. Benoit Le G<strong>of</strong>f 3 , Narelle M. McGregor 1 ,<br />
T. John Martin 2 , Evange Romas 1 , Natalie A. Sims 1 and Nicole<br />
C. Walsh 1 , 1 St Vincent’s Institute, Fitzroy, VIC, Australia, 2 St<br />
Vincent’s Institute, Fitzroy, Australia, 3 St Vincent’s Institute and<br />
INSERM, UMR-S 957, Fitzroy, VIC, Australia.<br />
31. Oral Bisphosphonates and Risk <strong>of</strong> Atypical Femur Fractures<br />
in a Population-Based Cohort: A Propensity Score-Matched<br />
Analysis. Seo Young Kim 2 , Sebastian Schneeweiss 3 , Jeffrey<br />
N. Katz 1 , Raisa Levin 4 and Daniel H. Solomon 2 , 1 Brigham and<br />
Women’s Hosp, Boston, MA, 2 Brigham and Women’s Hospital,<br />
Boston, MA, 3 Brigham and Women’s Hospital, Boston, 4 Brigham<br />
and Women’s Hospital.<br />
2010 Program Book 149
ACR Poster Session A<br />
150<br />
32. Selective Involvement <strong>of</strong> ERK and JNK MAP Kinases in the<br />
Synovial Tissue <strong>of</strong> Patients with Early Arthritis. Daphne<br />
de Launay, Marleen van de Sande, Gijs van de Sande,<br />
Carla Wijbrandts, Danielle Gerlag, Paul Peter Tak and Kris<br />
Reedquist, Academic Medical Center, University <strong>of</strong> Amsterdam,<br />
Amsterdam, The Netherlands.<br />
33. Serum Concentrations <strong>of</strong> Cytokines in the IL-23/IL-17A<br />
Pathway May Be Modulated by Polymorphisms in IL-23R. Lisa<br />
K. Stamp 1 , Jody Hazlett 2 , Tony Merriman 2 , John Highton 2 and<br />
Paul Hessian 2 , 1 University <strong>of</strong> Otago, Christchurch, New Zealand,<br />
2<br />
University <strong>of</strong> Otago.<br />
34. Synovitis in Rheumatoid Arthritis: Paradoxical Inverse<br />
Relationship between Kinase Phosphorylation Status and<br />
CXCL13, a Biomarker <strong>of</strong> Inflammation. Sanna Rosengren and<br />
David L. Boyle, UCSD School <strong>of</strong> Medicine, La Jolla, CA.<br />
35. The microRNA 18a Enhances IL-6 Signaling through Inhibition<br />
<strong>of</strong> PIAS3. Matthias Brock 2 , Michelle Trenkmann 1 , Renate E. Gay 3 ,<br />
Beat A. Michel 4 , Steffen Gay 5 , Rudolf Speich 6 and Lars C. Huber 6 ,<br />
1<br />
Center for Experimental <strong>Rheumatology</strong> and Zurich Center for<br />
Integrative Human Physiology (ZIHP), University Zurich, Zurich,<br />
Switzerland, 2 Center for Experimental <strong>Rheumatology</strong> and Zurich<br />
Center for Integrative Human Physiology (ZIHP), University<br />
Zurich, Zürich, Switzerland, 3 Rheum Clinic, Univ Hospital,<br />
Zurich, Switzerland, 4 University Hospital, Zurich, Switzerland,<br />
5<br />
University Hospital Zurich, Zurich, Switzerland, 6 Working Group<br />
for Pulmonary Hypertension, Department for Internal Medicine,<br />
University Hospital Zurich, Zurich, Switzerland.<br />
36. TL1A Expressed on the Rheumatoid Fibroblast-Like<br />
Synoviosytes Mediates Signalling Induced by DcR3. Masayasu<br />
Takahashi, Dept. <strong>of</strong> Orthopaedic Surgery, Kobe Univ. Graduate<br />
School <strong>of</strong> Medicine, Kobe, Japan.<br />
37. Visfatin/NAMPT-Mediated NGF Stimulation in Articular<br />
Chondrocytes: A Potential Link between Pain and Obesity-<br />
Induced Osteoarthritis. Sabrina Priam 2 , Emilie Pecchi 3 ,<br />
Marjolaine Gosset 3 , Xavier Houard 2 and Francis Berenbaum 1 ,<br />
1<br />
Faculty <strong>of</strong> Medicine P&M Curie, Paris, France, 2 UPMC, Paris,<br />
France, Metropolitan, 3 UPMC.<br />
38. Vitamin D Suppresses Th17 Cytokines Via Down Regulation<br />
<strong>of</strong> RORgammat and NFATC2 and by Differential Regulation<br />
<strong>of</strong> GATA3. Anne-Marie Mus 2 , Jan Piet van Hamburg 2 , Patrick<br />
Asmawidjaja 2 , Johanna M. W. Hazes 2 , Hans van Leeuwen 2 , Louis<br />
Boon 1 , Edgar Colin 2 and Erik Lubberts 2 , 1 Bioceros, 2 Erasmus MC,<br />
University Medical Center.<br />
39. XCL1/Lymphotactin Induces Rheumatoid Arthritis Fibroblast-<br />
Like Synoviocytes Migration through MAP Kinases. Karolina<br />
Klosowska and James M. Woods, Midwestern University,<br />
Downers Grove, IL.<br />
Education<br />
40. An Audit on Patients’ Knowledge <strong>of</strong> Methotrexate. Evin<br />
Sowden, Wajeed Hassan, Ann Gooden, Bridget Jepson,<br />
Tamsheela Kausor, Ifraz Shafait, John Brockbank, Robert Ley<br />
and Lee-Suan Teh, Royal Blackburn Hospital, Blackburn, United<br />
Kingdom.<br />
41. Educating Primary Care Providers on Rheumatoid Arthritis<br />
Translates to Changes in Practice and Referrals: Results from<br />
the RAPID Continuing Medical Education Program. Clifton<br />
Bingham 3 , Karen Costenbader 1 , Steven Bender 2 , Daniel Duch 2<br />
and Michael Weinblatt 1 , 1 Brigham and Women’s, 2 Curatio CME<br />
Institute, 3 Johns Hopkins, Baltimore, MD.<br />
2010 Program Book<br />
42. Information Sources for Rheumatoid Arthritis: More Than Just<br />
the Rheumatologist. Katie Garneau 1 , Maura Iversen 4 , Saira Jan 3 ,<br />
Hsun Tsao 1 , Daniel Hal Solomon 2 and Kavita Parmar 3 , 1 Brigham<br />
and Women’s Hospital, 2 Brigham and Womens Hospital, Boston,<br />
MA, 3 Horizon Blue Cross Blue Shield, 4 Northeastern University,<br />
Brigham and Women’s Hospital, Harvard Medical School,<br />
Boston, MA.<br />
43. Knee and Shoulder Cadaver Teaching Improves Internal<br />
Medicine Residents’ Self-Reported Anatomy, Exam and<br />
Injection Skills. Jessica Berman 2 , Michael H. Pillinger 3 , Bradley<br />
Jensen 2 , Jennifer Hammann 2 and Stephen A. Paget 1 , 1 Hospital<br />
for Special Surgery, New York, NY, 2 Hospital for Special Surgery,<br />
New York, NY, 3 NYU-Manhattan VA Med Hospital, New York, NY.<br />
44. Medical Student Education in the Electronic Age: A Web-Based<br />
Virtual Teaching Tool. Ernesto J. Rodriguez 1 , Abie Alias 1 , Aasim<br />
Rehman 1 , Vanessa Osting 1 , Tanisha Battle 2 , Lara Westphal 2 ,<br />
Ashley G. Sterrett 3 , Helen Bateman 3 , John D. Carter 1 and Joanne<br />
Valeriano-Marcet 3 , 1 University <strong>of</strong> South Florida, Tampa, FL,<br />
2<br />
University <strong>of</strong> South Florida, 3 USF/JAHVA, Tampa, FL.<br />
45. <strong>Rheumatology</strong> Fellowship Curricular Rotation in<br />
Musculoskeletal Ultrasound. Dimitrios A. Pappas 2 , Marzouq A.<br />
Qubti 2 , Clifton O. Bingham III 2 and Allan C. Gelber 1 , 1 Baltimore,<br />
MD, 2 Johns Hopkins University, Baltimore, MD.<br />
46. Team-Based Learning in <strong>Rheumatology</strong> Resident Education:<br />
Two-Year Results on Receptiveness and Attitudes <strong>of</strong> Residents<br />
towards Collaborative Learning and Teamwork. Karina<br />
Marianne D. Torralba 2 , Beatrice A. Boateng 1 , Ron Ben-Ari 4 and<br />
Francisco P. Quismorio 3 , 1 Arkansas Children’s Hospital-University<br />
<strong>of</strong> Arkansas for Medical Sciences, 2 University <strong>of</strong> Southern<br />
California-Los Angeles County Medical Center, Pasadena, CA,<br />
3<br />
University <strong>of</strong> Southern California-Los Angeles County Medical<br />
Center, Los Angeles, CA, 4 University <strong>of</strong> Southern California-Los<br />
Angeles County Medical Center.<br />
47. The First Pediatric <strong>Rheumatology</strong> Objective Structured Clinical<br />
Examination: Providing Clinical Skills Feedback for Fellows<br />
and Program Directors. Megan L. Curran 1 and David D. Sherry 2 ,<br />
1<br />
Children’s Memorial Hospital, Northwestern University’s<br />
Feinberg School <strong>of</strong> Medicine, Chicago, IL, 2 The Children’s<br />
Hospital <strong>of</strong> Philadelphia, Philadelphia, PA.<br />
48. Utilization <strong>of</strong> Ambulatory Medical Clinic for <strong>Rheumatology</strong><br />
Education. James M. Ross, Lehigh Valley Health Network,<br />
Macungie, PA.<br />
Epidemiology and Health Services Research: Inflammatory<br />
Arthritis<br />
49. A Novel Baseline Biomarker <strong>of</strong> Acute-Phase Serum Amyloid<br />
A (A-SAA) and Serum Interleukin–2 Receptor alpha (sIL-2Rα)<br />
Predicted Long-Term (18 to 35 Yrs) Mortality <strong>of</strong> Incident<br />
Rheumatoid Arthritis (RA) and Matched Non-RA Cohort<br />
Controls (CN). Alfonse T. Masi 2 , Jean C. Aldag 2 and Jean D. Sipe 1 ,<br />
1<br />
Center for Scientific Review, NIH, Bethesda, MD, 2 University <strong>of</strong><br />
Illinois <strong>College</strong> <strong>of</strong> Medicine at Peoria, Peoria, IL.<br />
50. A Prediction Score To Differentiate Rheumatoid Arthritis<br />
from Undifferentiated Arthritis in an Early Arthritis Cohort.<br />
Christian Waimann 2 , Fernando DalPra 2 , Jimena Hogrefe 2 ,<br />
Josefina Marcos 2 , Soledad Retamozo 2 , Francisco Caeiro 2 , Luciana<br />
Casalla 2 , Mariana Benegas 2 , Oscar Rillo 2 , Horacio Berman 2 ,<br />
Alberto Berman 2 , Rodrigo García Salinas 2 , Antonio Catalán<br />
Pellet 2 , Federico Ceccato 2 , Sergio Paira 2 , Juan Carlos Marcos 2 ,<br />
José Maldonado Cocco 2 , Luis Cattogio 2 , Enrique Soriano 2 and<br />
Gustavo Citera 1 , 1 CONAART, Buenos Aires, Argentina, 2 CONAART,<br />
Argentina.
ACR Poster Session A<br />
51. Association <strong>of</strong> Patient Cost-Cutting Behaviors with Clinical<br />
Outcomes, Health Status, and Lost Work Productivity in<br />
Individuals with Rheumatoid Arthritis. Susan C. Bolge 1 , Ahmad<br />
B. Naim 2 , Chureen Carter 2 , Marco DiBonaventura 3 and Mike<br />
Ingham 2 , 1 Centocor Ortho Biotech Services, LLC, Horsham, PA,<br />
2<br />
Centocor Ortho Biotech Services, LLC, 3 KantarHealth.<br />
52. Baseline Factors Related to Response to Conventional DMARD<br />
Treatments. Kimberly L. Sterling 1 , Gebra Cuyun Carter 1 , Susan<br />
Messing 6 , George Reed 5 , Rui Chen 6 , Kimberly Kaukeinen 6 , Xin<br />
Tu 6 , David R. Nelson 2 , Khaled Sarsour 3 , Ronald A. Cantrell 3 ,<br />
Carlos I. Alatorre 3 and Jeffrey Greenberg 4 , 1 Eli Lilly and Co,<br />
Indianapolis, IN, 2 Eli Lilly and Co, 3 Eli Lilly and Co, Indianapolis,<br />
IN, 4 New York University School <strong>of</strong> Medicine, New York, NY,<br />
5<br />
University <strong>of</strong> Massachusetts, Amherst, MA, 6 University <strong>of</strong><br />
Rochester, Rochester, NY.<br />
53. Cerebrovascular and Venous Thromboembolic Events Predict<br />
Mortality in Rheumatoid Arthritis. A. Kirstin Bacani 2 , Sherine E.<br />
Gabriel 2 , Cynthia S. Crowson 1 and Eric L. Matteson 2 , 1 Rochester,<br />
MN, 2 Mayo Clinic, Rochester, MN.<br />
54. Changes in Corticosteroid Use after DMARD Initiation in<br />
Patients with Rheumatoid Arthritis. Vivian K. Kawai 5 , Carlos<br />
Grijalva 6 , Patrick Arbogast 6 , Jeffrey R. Curtis 4 , Daniel Hal<br />
Solomon 1 , Elizabeth Delzell 3 , Rita Ouellet-Hellstrom 2 , Ed<br />
Mitchel 6 , C. Michael Stein 5 and Marie R. Griffin 6 , 1 Brigham and<br />
Womens Hospital, Boston, MA, 2 FDA, 3 University <strong>of</strong> Alabama,<br />
4<br />
University <strong>of</strong> Alabama - Brimingham, Birmingham, AL,<br />
5<br />
Vanderbilt University, Nashville, TN, 6 Vanderbilt University.<br />
55. Changes in EQ-5D and SF-6D during Rituximab Treatment<br />
– Results from the CERERRA Collaboration. Elisabeth Lie 5 ,<br />
Katerina Chatzidionysiou7, Evgeny Nasonov9, Galina Lukina9,<br />
Cem Gebay 12 , Karel Pavelka 2 , Dan Nordström 6 , Matija Tomsic 13 ,<br />
Merete L. Hetland 3 , Ulrik Tarp 1 , Piet L. C. M. van Riel 1 0, Juan J.<br />
Gomez-Reino 11 , Ronald Van Vollenhoven8 and Tore K. Kvien 5 ,<br />
1<br />
Aarhus University Hospital, Aarhus, Denmark, 2 Charles<br />
University, Prague, Czech Republic, 3 Copenhagen University<br />
Hospital at Glostrup/DANBIO Registry, Copenhagen, Denmark,<br />
4<br />
Diakonhjemmet Hospital, Oslo, Norway, 5 Diakonhjemmet<br />
Hospital, Oslo, Norway, 6 Helsinki University Central Hospital,<br />
Helsinki, Finland, 7 Karolinska University Hospital, Stockholm,<br />
Sweden, 8 Karolinska University Hospital, Stockholm, Sweden,<br />
9<br />
Moscow Institute <strong>of</strong> <strong>Rheumatology</strong>, Moscow, Russian<br />
Federation, 10 Radboud University Nijmegen Medical Centre,<br />
Nijmegen, The Netherlands, 11 University Hospital <strong>of</strong> Santiago,<br />
Santiago, Spain, 12 University Hospitals <strong>of</strong> Geneva/SCQM<br />
Registry, Geneva, Switzerland, 13 University Medical Center <strong>of</strong><br />
Ljubljana, Ljubljana, Slovenia.<br />
56. Comparison <strong>of</strong> the Efficacy <strong>of</strong> Tocilizumab and TNFα-Inhibitors<br />
on the DAS28 in “Real Life” Conditions in Rheumatoid Arthritis<br />
(RA) Patients after DMARD Failure. Jörg Kaufmann 2 , Eugen<br />
Feist 1 , Hagen Schmidt 3 , Anne-Eve Roske 4 and Adrian Kielhorn 4 ,<br />
1<br />
Campus Charité Mitte, Med. Klinik Abt. Rheumatologie u.<br />
Klin. Immunologie, Berlin, Germany, 2 Praxis für Innere Medizin<br />
und Rheumatologie, Ludwigsfelde, Germany, 3 Praxis für Innere<br />
Medizin und Rheumatologie, Berlin, Germany, 4 Roche Pharma<br />
AG, Grenzach-Whylen, Germany.<br />
57. Demyelinating Events in Seniors with Rheumatoid Arthritis<br />
(RA): A Population-Based Study. Jessica Widdifield 7 , Sasha R.<br />
Bernatsky 2 , J. Michael Paterson 1 , Nadia Gunraj 1 , Janet E. Pope 5 ,<br />
J. Carter Thorne 4 , Alfred A. Cividino 3 and Claire Bombardier 6 ,<br />
1<br />
Institute for Clinical Evaluative Science, 2 McGill UHC/RVH,<br />
Montreal, QC, Canada, 3 McMaster University, Hamilton, ON,<br />
Canada, 4 Southlake Regional Health Care, Newmarket, ON,<br />
Canada, 5 St Joseph Health Care London, London, ON, Canada,<br />
6<br />
University <strong>of</strong> Toronto, Toronto, ON, Canada, 7 University <strong>of</strong><br />
Toronto.<br />
58. Descriptive Epidemiology <strong>of</strong> Adult Rheumatoid Arthritis in<br />
an Insurance Claims Database. Martin M. Crane 1 , Maneesh<br />
Juneja 3 , Fayaz A. Aziz 3 , Regina H. Kurrasch 2 , Myron E. Chu 2 ,<br />
Emilia Quattrocchi 3 , Stephanie Manson 4 and David J. Chang 2 ,<br />
1<br />
GlaxoSmithKline R&D, Research Triangle, NC, 2 GlaxoSmithKline<br />
R&D, King <strong>of</strong> Prussia, PA, 3 GlaxoSmithKline R&D, 4 United<br />
Biosource.<br />
59. Different Factors Are Important for RA Patients and<br />
Rheumatologists Regarding DMARD Escalation. Laura van<br />
Hulst 2 , Wietske Kievit 1 , Piet van Riel 2 and Liana Fraenkel 3 ,<br />
1<br />
Radboud University Nijmegen Medical Centre, Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Nijmegen, The Netherlands, 2 Radboud University<br />
Nijmegen Medical Centre, Department <strong>of</strong> <strong>Rheumatology</strong>, 3 Yale<br />
University School <strong>of</strong> Medicine, Department <strong>of</strong> Medicine, VA<br />
Connecticut Healthcare System, Section <strong>of</strong> <strong>Rheumatology</strong>.<br />
60. DMARD Use for Rheumatoid Arthritis as Reported in the<br />
National Ambulatory Medical Care Survey, 1996-2007. Daniel<br />
Hal Solomon 4 , John Ayanian 3 , M. Alan Brookhart 6 , Sebastian<br />
Schneeweiss 2 , Tamara Shaykevich 2 , Edward H. Yelin 5 and Jeffrey<br />
N. Katz 1 , 1 Brigham & Womens Hosp, Boston, MA, 2 Brigham and<br />
Women’s Hospital, 3 Brigham and Women’s Hospital, Harvard<br />
Medical School, 4 Brigham and Womens Hospital, Boston, MA,<br />
5<br />
University <strong>of</strong> California, San Francisco, CA, 6 University <strong>of</strong> North<br />
Caroline.<br />
61. Early Life Socioeconomic Factors and Rheumatoid Arthritis<br />
(RA) in Adulthood. Christine G. Parks 2 , Aimee A. D’Aloisio 1 , Lisa<br />
A. DeRoo 1 , Huiber Kirstin 3 and Dale P. Sandler, 1 National Institute<br />
<strong>of</strong> Environmental Health Science, Research Triangle Park, NC,<br />
2<br />
National Institute <strong>of</strong> Environmental Health Science, Research<br />
Triangle Park, NC, 3 UNC, School <strong>of</strong> Public Health, Chapel Hil NC.<br />
62. Effect <strong>of</strong> Disease-Modifying Anti-Rheumatic Drug (DMARD)<br />
Exposure on Head and Neck Cancer in a National Cohort <strong>of</strong><br />
Veterans with Rheumatoid Arthritis. Christopher R. Phillips 2 ,<br />
Angelique L. Zeringue 3 , Jay R. McDonald 1 , Seth A. Eisen 3 , Liron<br />
Caplan 4 and Prabha Ranganathan 5 , 1 Division <strong>of</strong> Infectious<br />
Disease, St. Louis Veterans Affairs Medical Center, 2 Division<br />
<strong>of</strong> <strong>Rheumatology</strong>, Washington University School <strong>of</strong> Medicine,<br />
Paducah, KY, 3 St. Louis Veterans Affairs Medical Center, 4 Univ <strong>of</strong><br />
CO-Denver Med Sc, Aurora, CO, 5 Washington University School<br />
<strong>of</strong> Medicine, St. Louis, MO.<br />
63. Elaboration and Validation <strong>of</strong> a Questionnaire To Assess the<br />
Impact <strong>of</strong> Rheumatoid Arthritis (RA) on Sexuality, with Patient<br />
Involvement: QUALISEX. Laure Gossec 2 , Catherine Solano 4 ,<br />
Simon Paternotte 2 , Catherine Beauvais 3 , Christelle Sordet 6 ,<br />
Philippe Gaudin 1 and Aleth Perdriger 5 , 1 Grenoble University<br />
Hospital, France, 2 Paris Cochin University Hospital, France,<br />
3<br />
Paris Saint Antoine University Hospital, France, 4 Paris, France,<br />
5<br />
Rennes University Hospital, France, 6 Strasbourg University<br />
Hospital, France.<br />
64. Geographical Variation <strong>of</strong> Rheumatoid Arthritis in Stockholm<br />
County, Sweden. Henrik Källberg 4 , Veronica M. Vieira 2 , Jamie E.<br />
Hart 1 , Karen H. Costenbader 3 , Marie Holmqvist 5 , Lars Klareskog 6 ,<br />
Lars Alfredsson 5 and Elizabeth W. Karlson 3 , 1 Channing<br />
Laboratory, Department <strong>of</strong> Medicine, Brigham and Women’s<br />
Hospital and Harvard Medical School, Boston Massachusetts,<br />
Department <strong>of</strong> Epidemiology, Harvard School <strong>of</strong> Public Health,<br />
Boston Massachusetts, 2 Department <strong>of</strong> Environmental Health,<br />
Boston University School <strong>of</strong> Public Health, Boston, MA,<br />
3<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, Immunology and Allergy, Brigham<br />
and Women’s Hospital and Harvard Medical School, Boston<br />
Massachusetts, 4 Institute <strong>of</strong> Environmental Medicine, Karolinska<br />
Institutet, Stockholm, Sweden, 5 Institute <strong>of</strong> Environmental<br />
Medicine, Karolinska Institutet, Stockholm, Sweden,<br />
6<br />
<strong>Rheumatology</strong> Unit, Department <strong>of</strong> Medicine, Karolinska<br />
Institutet/Karolinska Hospital, Stockholm, Sweden.<br />
2010 Program Book 151
ACR Poster Session A<br />
65. H2607 – Country <strong>of</strong> Residence Affects the Ability <strong>of</strong> Patients<br />
with Rheumatoid Arthritis (RA) To Achieve a Favorable<br />
Employment Status. Ronald van Vollenhoven 2 , Mary Cifaldi 1 ,<br />
Annelies Boonen 4 , Sanjoy Roy 1 , Naijun Chen 1 and Vibeke<br />
Strand 3 , 1 Abbott Laboratories, Abbott Park, IL, 2 Karolinska<br />
University Hospital and Karolinska Institute, Stockholm,<br />
Sweden, 3 Stanford University, Palo Alto, CA, 4 University Hospital<br />
Maastricht, Maastricht, The Netherlands.<br />
66. HLA Class II Associations Differ in Indian (Asian) Patients<br />
Suffering from RA: Regional Population (Urban and Rural)<br />
Surveys Using COPCORD Bhigwan Model. Anuradha<br />
Venugopalan 2 , Arvind Chopra 3 and Renu Bharadwaj 1 , 1 BJ<br />
Medical <strong>College</strong>, Pune, India, 2 Center for Rheumatic Diseases,<br />
Pune, India, 3 Center for Rheumatic Diseases.<br />
67. Hospitalizations Following Heart Failure Diagnosis in<br />
Rheumatoid Arthritis Patients. Cynthia S. Crowson, John<br />
M. Davis III, Veronique L. Roger, Eric L. Matteson, Terry M.<br />
Therneau and Sherine E. Gabriel, Mayo Clinic, Rochester, MN.<br />
68. WITHDRAWN<br />
69. Importance <strong>of</strong> Changes in People/Patient Reported<br />
Outcomes in Rheumatoid Arthritis Patients Treated with<br />
Anti-TNF Therapies. The Example <strong>of</strong> the RAID (Rheumatoid<br />
Arthritis Impact Disease) Score after Etanercept Therapy.<br />
Maxime Dougados 2 , Mahaut Ripert 4 , Pascal Hilliquin 1 , Patrice<br />
Fardellone 5 , Olivier Brocq 3 and Isabelle Logeart 4 , 1 CH sud<br />
Francilien, Corbeil-Essonnes, France, 2 Hôpital Cochin and<br />
University <strong>of</strong> Paris, Paris, France, 3 Hopital Princesse Grace de<br />
Monaco, Monaco, 4 Pfizer France, la Défense, France, 5 University<br />
Hospital Amiens, Amiens, France.<br />
70. Inadequate Treatment <strong>of</strong> Rheumatoid Arthritis (RA). K.<br />
Andrew Crighton 3 , Elliot D. Rosenstein 4 , Jared S. Young 5 , Yukiko<br />
Kimura 2 and Victor S. Sloan 1 , 1 Celgene Corporation, Summit,<br />
NJ, 2 Hackensack Univ Medical Ctr, Hackensack, NJ, 3 Prudential<br />
Financial, Newark, NJ, 4 Saint Barnabas Medical Center,<br />
Livingston, Far Hills, NJ, 5 Thomson Reuters, Ann Arbor, MI.<br />
71. Increased Risk <strong>of</strong> Total Mortality with Anti-Cyclic Citrullinated<br />
Peptide (Anti-CCP) Positivity among Postmenopausal Women<br />
Reporting RA. Rachel H. Mackey 5 , Lewis H. Kuller 5 , Michael<br />
Holers 4 , Kevin Deane 4 , Brian Walitt 2 , Bill Robinson 3 , Yuefang<br />
Chang 5 , Charles Eaton 1 , Iulia Grillo 1 , Monica Bertoia 1 and Larry<br />
W. Moreland 5 , 1 Brown University, 2 Georgetown University,<br />
3<br />
Stanford University, 4 University <strong>of</strong> Colorado, 5 University <strong>of</strong><br />
Pittsburgh.<br />
72. Independent Impact <strong>of</strong> Statin Discontinuation on Mortality<br />
in Patients with Rheumatoid Arthritis: A Population-Based<br />
Study. Mary A. De Vera 1 , Hyon K. Choi 3 , Michal Abrahamowicz 2 ,<br />
Jacek Kopec 1 and Diane V. Lacaille 1 , 1 Arthritis Research Centre<br />
<strong>of</strong> Canada, Vancouver, BC, Canada, 2 McGill University, Montreal,<br />
QC, Canada, 3 Univ <strong>of</strong> British Columbia, Vancouver, BC, Canada.<br />
73. Joint Damage Progresses in DAS28 Remission and Is Driven<br />
by Residual Joint Swelling. Daniel Aletaha and Josef S. Smolen,<br />
Medical University <strong>of</strong> Vienna, Austria.<br />
74. Large Discrepancy between Expected and Observed Ratios <strong>of</strong><br />
Biologic Treated Rheumatoid Arthritis Patients Also Compliant<br />
on DMARDs. Denis Choquette 2 , Mark Arundine 1 and Oliver<br />
Thomas 1 , 1 Mississauga, ON, Canada, 2 Institut de Rhumatologie<br />
de Montréal, Montreal, QC, Canada.<br />
75. Leflunomide and the Risk <strong>of</strong> Hepatotoxicity: A Review <strong>of</strong> Post-<br />
Marketing Data. Jane L. Gilbert 1 , Kate Gelperin 2 , Joann Lee 2 ,<br />
Poonam Mishra 2 , Lauren Choi 2 , Allen Brinker 2 , David Graham 2 ,<br />
Robert Boucher 2 , Mark Avigan 2 and John Senior 2 , 1 FDA,<br />
Washington, DC, 2 FDA.<br />
76. Meta-Analysis and Biologics – Comparing Apples to Apples:<br />
An Example Using Radiographic Outcomes in Rheumatoid<br />
Arthritis. Mike Ingham 1 and Chureen Carter 2 , 1 Centocor Ortho<br />
Biotech Services, LLC, Horsham, PA, 2 Centocor Ortho Biotech<br />
Services, LLC.<br />
77. Multiple Serum Cytokines/Chemokines Are Associated<br />
with RA-Related Autoantibodies in First-Degree Relatives<br />
without Rheumatoid Arthritis (RA): Studies <strong>of</strong> the Etiology<br />
<strong>of</strong> Rheumatoid Arthritis (SERA). Jan M. Hughes-Austin 8 , Kevin<br />
D. Deane 9 , Lezlie Derber 8 , Jason R. Kolfenbach 10 , Michael<br />
Weisman 2 , Jane Buckner 12 , James R. O’Dell 6 , Ted R. Mikuls 11 ,<br />
Peter K. Gregersen 3 , Richard M. Keating 1 , William Robinson 4 ,<br />
V. Michael Holers 5 and Jill Norris 7 , 1 Oak Park, IL, 2 Cedars Sinai<br />
Medical Center, 3 N Shore Univ Hosp Rsch Ctr, Manhasset, NY,<br />
4<br />
Stanford Univ School <strong>of</strong> Med, Stanford, CA, 5 Univ <strong>of</strong> Colorado<br />
School <strong>of</strong> Med, Aurora, CO, 6 University <strong>of</strong> Nebraska Medical<br />
Center, Omaha, NE, 7 University <strong>of</strong> Colorado Denver, Aurora,<br />
CO, 8 University <strong>of</strong> Colorado Denver, 9 University <strong>of</strong> Colorado<br />
School <strong>of</strong> Med, Aurora, CO, 10 University <strong>of</strong> Colorado School <strong>of</strong><br />
Medicine, Aurora, CO, 11 University <strong>of</strong> Nebraska Medical Center,<br />
Omaha, NE, 12 Virginia Mason Research Center.<br />
78. Noncardiac Vascular Disease in Rheumatoid Arthritis (RA):<br />
Increase in Venous Thromboembolic Events? A. Kirstin Bacani,<br />
Sherine E. Gabriel, Cynthia S. Crowson and Eric L. Matteson,<br />
Mayo Clinic, Rochester, MN.<br />
79. Perception <strong>of</strong> RA Disease Activity by Patients and Physicians:<br />
Reasons for and Estimators <strong>of</strong> Discrepancies. Paul Studenic,<br />
Josef S. Smolen and Daniel Aletaha, Medical University <strong>of</strong><br />
Vienna, Austria.<br />
80. Permanent Working Disability Caused by Rheumatoid Arthritis<br />
Is Declining, Partly Due to Use <strong>of</strong> TNF-Inhibitors – Results<br />
from a Nationwide Finnish Register in 2000-2007. Vappu<br />
Rantalaiho 6 , Hannu Kautiainen 1 , Salme Järvenpää 3 , Lauri Virta 5 ,<br />
Timo Pohjolainen 4 , Markku Korpela 6 , Timo Möttönen 7 and Kari<br />
Puolakka 2 , 1 Jyväskylä Central Hospital, Finland, 2 Lappeenranta<br />
Central Hospital, Finland, 3 Medcare Foundation, Finland, 4 Orton<br />
Rehabilitation Unit, Finland, 5 Social Incurance Institution,<br />
Finland, 6 Tampere University Hospital, Finland, 7 Turku University<br />
Hospital, Finland.<br />
81. Prescription Patterns in Pregnant Women with Rheumatoid<br />
Arthritis. Bindee Kuriya 3 , Sonia Hernandez-Diaz 4 , Jun Liu 2 ,<br />
Gregory Daniel 5 and Daniel Hal Solomon 1 , 1 Brigham and<br />
Women’s Hospital, Boston, MA, 2 Brigham and Women’s<br />
Hospital, 3 Harvard School <strong>of</strong> Public Health, Brookline, MA,<br />
4<br />
Harvard School <strong>of</strong> Public Health, 5 HealthCore Inc., Wilmington,<br />
DE.<br />
82. Relative Importance <strong>of</strong> Patient’s Opinion and Physician’s<br />
Criteria <strong>of</strong> Disease Activity Versus Information <strong>of</strong> Disease<br />
Duration and Rheumatologist Type <strong>of</strong> Exercise for Treatment<br />
Decision in Rheumatoid Arthritis: DUO Study. Maxime<br />
Dougados 2 , Henri Nataf 1 , Ghislaine Steinberg 4 , Géraldine<br />
Martineau 4 , Stéphanie Rouanet 4 and Bruno Falissard 3 , 1 Centre<br />
Hospitalier François Quesnay, Mantes-La-Jolie, France, 2 Hospital<br />
Cochin, Paris, France, 3 INSERM U669, PSIGIAM, Paris, France,<br />
4<br />
Roche, Neuilly-sur-Seine, France.<br />
152<br />
2010 Program Book
ACR Poster Session A<br />
83. Respiratory Cause Mortality Was Greater in 54 Incident<br />
Rheumatoid Arthritis (RA) Patients Than 204 Community-<br />
Based, Non-RA Matched Cohort Controls (CN). Alfonse T. Masi<br />
and Jean C. Aldag, University <strong>of</strong> Illinois <strong>College</strong> <strong>of</strong> Medicine at<br />
Peoria, Peoria, IL.<br />
84. Rheumatoid Arthritis (RA) Is the Only One <strong>of</strong> 8 Diseases for<br />
Which a Patient History and Physical Examination (Versus<br />
Laboratory Tests and Ancillary Studies) Were Rated as Most<br />
Important for Clinical Decisions by >50% in a Physician Survey.<br />
Lauren McCollum 4 , Sangmo Park 4 , Tuulikki Sokka 2 , Hasan Yazici 1<br />
and Theodore Pincus 3 , 1 Cerrahpasa Medical Faculty, Istanbul,<br />
Turkey, 2 Jyvaskyla Central Hospital, Jyvaskyla, Finland, 3 New York<br />
University Hospital for Joint Disease, Hastings-on-Hudson, NY,<br />
4<br />
NYU Hospital for Joint Diseases.<br />
85. Similar Performance <strong>of</strong> New and Old Criteria for Rheumatoid<br />
Arthritis in an Early Arthritis Cohort in Amsterdam. Karin<br />
Britsemmer, Jennie Ursum and Dirkjan van Schaardenburg, Jan<br />
van Breemen Institute Amsterdam.<br />
86. WITHDRAWN<br />
87. The Impact <strong>of</strong> Health Beliefs on Therapeutic Adherence in<br />
Patients with Rheumatoid Arthritis (RA). Tara J. Rizvi 1 , John<br />
Gomez 1 , S<strong>of</strong>ia de Achaval 2 , Michael A. Kallen 2 , Vanessa L. Cox 2 ,<br />
Marsha N. Richardson 2 , Bernard Ng 1 , John D. Reveille 3 and<br />
Maria E. Suarez-Almazor 4 , 1 Baylor <strong>College</strong> <strong>of</strong> Medicine, Houston,<br />
TX, 2 The University <strong>of</strong> Texas M. D. Anderson Cancer Center,<br />
Houston, TX, 3 Univ Texas Health Sci Ctr, Houston, TX, 4 University<br />
<strong>of</strong> Texas, MD Anderson Cancer Center, Houston, TX.<br />
88. TNF and Natural Atheroprotective Antibodies Against<br />
Phosphorylcholine: Implications for Biologics in RA. S<strong>of</strong>ia<br />
Ajeganova, Roland Fiskesund, Ingiäld Hafström and Johan<br />
Frostegård, Karolinska Institutet, Sweden.<br />
89. TNF Therapy Reduces the Odds <strong>of</strong> Worsening Disability<br />
Trajectories in Rheumatoid Arthritis over at Least 2 Years –<br />
Data from the NDB-Portugal Cohort. S<strong>of</strong>ia Pedro 1 , Elizabeth<br />
Benito-Garcia 1 , Joana Vasconcelos 1 , Irina Chaves 1 , Rita<br />
Marques 1 , Andreia Rodrigues 1 , Kaleb Michaud 3 and Fred Wolfe 2 ,<br />
1<br />
Bioepi Clinical and Translational Research Center, Oeiras,<br />
Portugal, 2 National Databank for Rheumatic Diseases, Kansas,<br />
3<br />
University <strong>of</strong> Nebraska Medical Center, NE.<br />
90. TNF-alpha Blocking Therapy Lowers Cardiovascular Risk in<br />
Rheumatoid Arthritis. Ingrid M. Visman 1 , Alper M. van Sijl 3 ,<br />
Mike J. L. Peters 5 , Carlo J. J. van Dongen 1 , Ben A. C. Dijkmans 4<br />
and Michael T. Nurmohamed 2 , 1 Jan van Breemen Institute, 2 Jan<br />
van Breemen Institute and VU Medical Centre, Amsterdam,<br />
The Netherlands, 3 Jan van Breemen Institute and VU Medical<br />
Centre, 4 VU Medical Centre, Amsterdam, The Netherlands, 5 VU<br />
Medical Centre.<br />
91. Validation <strong>of</strong> the Work Performance Visual Analog Scale:<br />
Measuring Work and Household Productivity <strong>of</strong> Patients with<br />
Early, Aggressive Rheumatoid Arthritis. Dennis Revicki 2 , Sanjoy<br />
Roy 1 , Miriam Kimel 2 , Chris Thompson 2 and Mary Cifaldi 1 , 1 Abbott<br />
Laboratories, Abbott Park, IL, 2 United Biosource Corporation,<br />
Bethesda, MD.<br />
Fibromyalgia and S<strong>of</strong>t Tissue Disorders I<br />
92. Candidate Gene Studies <strong>of</strong> Fibromyalgia: A Systematic Review<br />
and Meta-Analysis. Young Ho Lee, Sung Jae Choi, Jong Dae Ji<br />
and Gwan Gyu Song, KUMC, Seoul, Korea, Republic <strong>of</strong>.<br />
93. Clinical Determinants <strong>of</strong> Physical Activity in Fibromyalgia<br />
Patients. Dennis Ang 1 , Anthony Kaleth 3 , Silvia Bigatti 2 , Steven<br />
Mazzuca 2 , Chandan Saha 2 and Robert Bandy 2 , 1 Indiana<br />
University, Indianapolis, IN, 2 Indiana University, 3 Indiana<br />
University-Purdue University Indianapolis.<br />
94. Development <strong>of</strong> Responder Definitions for Fibromyalgia<br />
Clinical Trials. Lesley M. Arnold 8 , Philip J. Mease 6 , David A.<br />
Williams 7 , Susan A. Martin 5 , Fujun Wang 2 , Birol Emir 4 , Chinglin<br />
Lai 3 and Rong Zablocki 1 , 1 Cypress Bioscience, Inc., 2 Eli Lilly<br />
and Company, 3 Jazz Pharmaceuticals, 4 Pfizer, Inc., 5 RTI-Health<br />
Solutions, 6 Seattle <strong>Rheumatology</strong> Associate, Seattle, WA, 7 Univ<br />
<strong>of</strong> MI Hlth System-Lobby M, Ann Arbor, MI, 8 University <strong>of</strong><br />
Cincinnati <strong>College</strong> <strong>of</strong> Medicine, Cincinnati, OH.<br />
95. Does Obesity in Patients with Fibromyalgia Modify Response<br />
to Tai Chi Therapy: Analysis <strong>of</strong> a Randomized Controlled Trial.<br />
Chenchen Wang 1 , Christopher H. Schmid 2 , Yoojin Lee 2 and<br />
Timothy McAlindon 1 , 1 Tufts Medical Center, Boston, MA, 2 Tufts<br />
Medical Center.<br />
96. Dorsal Root Ganglia/Sympathetic Ganglia Sodium Channels<br />
Gene Polymorphisms in Fibromyalgia. Gilberto Vargas-Alarcon,<br />
Edith Alvarez-Leon, Jose-Manuel Fragoso, Angelica Vargas, Aline<br />
Martinez, Maite Vallejo and Manuel Martinez-Lavin, National<br />
Institute <strong>of</strong> Cardiology, Mexico.<br />
97. Durability <strong>of</strong> Response in a 38-Week Open-Label Study <strong>of</strong><br />
Sodium Oxybate in Patients with Fibromyalgia. Michael<br />
Spaeth 5 , I. Jon Russell 7 , Serge Perrot 6 , Sarah Alvarez-Horine 3 ,<br />
Diane R. Guinta 1 , Y. Grace Wang 2 and Robert M. Bennett 4 , 1 Jazz<br />
Pharmaceuticals Inc., Palo Alto, CA, 2 Jazz Pharmaceuticals Inc.,<br />
3<br />
Jazz Pharmaceuticals, Inc., 4 Oregon Health and Science Univ,<br />
Portland, OR, 5 Rheumatologische Schwerpunktpraxis, 6 Service<br />
de Medecine Interne et Centre de la Douleur, Hôtel-Dieu,<br />
7<br />
University <strong>of</strong> Texas Health Science Center, San Antonio, TX.<br />
98. Effects <strong>of</strong> Milnacipran Added to Pregabalin on Cognition and<br />
Mental Clarity in Fibromyalgia Patients. Robert S. Katz 4 , Robert<br />
H. Palmer 2 , Yong Wang 3 and R. Michael Gendreau 1 , 1 Cypress<br />
Bioscience, Inc, San Diego, CA, 2 Forest Research Institute, Jersey<br />
City, NJ, 3 Forest Research Institute, 4 Rush University Medical<br />
Center, Chicago, IL.<br />
99. Fatigue in Fibromyalgia Patients: A Qualitative Study Exploring<br />
a Conceptual Framework. Philip J. Mease 4 , Lisa D’Ambrosio 3 ,<br />
Asha Hareendran 6 , Maureen Mohyde 2 , Robin Pokrzywinski 6 ,<br />
Kristin Seymour 5 and Steven Blum 1 , 1 Forest Research Institute,<br />
2<br />
Outcome Sciences, 3 Outcome Sciences and MIT AgeLab,<br />
4<br />
Seattle <strong>Rheumatology</strong> Associate, Seattle, WA, 5 Seattle<br />
<strong>Rheumatology</strong> Associates, 6 United BioSource Corporation.<br />
100. Fibromyalgia Criteria and Severity Scales for Clinical and<br />
Epidemiological Studies: A Modification <strong>of</strong> the ACR Preliminary<br />
Diagnostic Criteria for Fibromyalgia. Frederick Wolfe 2 , Daniel<br />
J. Clauw 7 , Mary Ann Fitzcharles 1 , Don L. Goldenberg 3 , Winfried<br />
Häuser 6 , Robert S. Katz 4 , Philip J. Mease 5 , Anthony S. Russell 8 ,<br />
I. Jon Russell 10 and John B. Winfield 9 , 1 Montreal West, QC,<br />
Canada, 2 National Data Bank for Rheumatic Diseases, Wichita,<br />
KS, 3 Newton-Wellesley Hosp, Newton, MA, 4 <strong>Rheumatology</strong><br />
Associates, Chicago, IL, 5 Seattle <strong>Rheumatology</strong> Associate,<br />
Seattle, WA, 6 Technische Universität München, Munich,<br />
Germany, 7 UM/Chronic Pain & Fatigue Res, Ann Arbor, MI,<br />
8<br />
University <strong>of</strong> Alberta, Edmonton, AB, Canada, 9 University <strong>of</strong><br />
North Carolina, Chapel Hill, NC, 10 University <strong>of</strong> Texas HSC, San<br />
Antonio, TX.<br />
2010 Program Book 153
ACR Poster Session A<br />
154<br />
101. Fibromyalgia Is Associated with a Disruption <strong>of</strong> Emotional<br />
Modulation <strong>of</strong> Pain, but Not Emotional Modulation <strong>of</strong> Spinal<br />
Nociception. Jennifer L. DelVentura 1 , Ellen L. Terry 2 , Emily J.<br />
Bartley 2 , Ashley Vincent 2 , Ewa Olech 3 and Jamie L. Rhudy 2 ,<br />
1<br />
The University <strong>of</strong> Tulsa, Tulsa, OK, 2 The University <strong>of</strong> Tulsa,<br />
3<br />
University <strong>of</strong> Oklahoma, Health Sciences Center.<br />
102. Fibromyalgia with and without Comorbid Positional Cervical<br />
Cord Compression (PC3): An Iron-Clad Difference. Patrick B.<br />
Wood 2 , Tobias Schmidt-Wilcke 3 and Andrew J. Holman 1 , 1 Pacific<br />
<strong>Rheumatology</strong> Assoc, Renton, WA, 2 Pacific <strong>Rheumatology</strong><br />
Associates, Renton, WA, 3 University <strong>of</strong> Michigan.<br />
103. Flt3-L Is a Novel Biomarker Increased in Cerebrospinal Fluid<br />
<strong>of</strong> Patients with Primary Fibromyalgia and Sjogren Syndrome.<br />
Jan L. Bjersing, Mats Dehlin, Henrik Zetterberg, Anette Larsson,<br />
Malin Erlandsson, Kaisa Mannerkorpi and Maria Bokarewa, Dept<br />
<strong>Rheumatology</strong>, Gothenburg University, Sweden.<br />
104. Hysterectomy Status and Fibromyalgia Symptom Severity.<br />
Mary O. Whipple, Ann Vincent, Terry H. Oh, Connie A. Luedtke<br />
and Tanya L. Hoskin, Mayo Clinic, Rochester, MN.<br />
105. Improvement in Multiple Dimensions <strong>of</strong> Fatigue in<br />
Fibromyalgia Patients Treated with Duloxetine. Lesley M.<br />
Arnold 2 , Fujun Wang 1 , Jonna Ahl 1 , Paula Gaynor 1 and Madelaine<br />
Wohlreich 1 , 1 Lilly USA LLC, Indianapolis, IN, 2 Women’s Health<br />
Research Program, Department <strong>of</strong> Psychiatry, University <strong>of</strong><br />
Cincinnati <strong>College</strong> <strong>of</strong> Medicine, Cincinnati, OH.<br />
106. Novel Treatment <strong>of</strong> Tendinopathies with a Sulfated<br />
Disaccharide <strong>of</strong> Hyaluronic Acid-Promising In Vitro Results.<br />
Anna Torrent 1 , Ramon Ruhí 1 , Carlos Aláez 1 , Constanze<br />
Buhrmann 2 and Mehdi Shakibaei 3 , 1 BIOIBERICA S.A., Palafolls,<br />
Barcelona, Spain, 2 Ludwig-Maximilians-University, Munich,<br />
Germany, 3 Ludwig-Maximilians-University Munich, Munich,<br />
Germany.<br />
107. Outcome for a Prospective Cohort <strong>of</strong> Fibromyalgia Patients<br />
Receiving Tailored Treatments in a Multidisciplinary Pain<br />
Center. Mary-Ann Fitzcharles, Pantelis Panopalis, Ann Gamsa,<br />
Mark Ware and Yoram Shir, McGill University.<br />
108. Predictors <strong>of</strong> Clinical Outcome in Fibromyalgia: Single Center<br />
Experience <strong>of</strong> a Brief Interdisciplinary Fibromyalgia Treatment<br />
Program. Terry H. Oh 1 , Tanya L. Hoskin 1 , Connie L. Luedtke 2 ,<br />
Toby N. Weingarten 2 , Ann Vincent 2 and Jeffrey M. Thompson 2 ,<br />
1<br />
Mayo Clinic, Rochester, MN, 2 Mayo Clinic.<br />
109. Should Rheumatologists Retain Ownership <strong>of</strong> Fibromyalgia?<br />
A Survey <strong>of</strong> Ontario Rheumatologists. Sassan Ghazan-Shahi,<br />
Tanveer E. Towheed and Wilma Hopman, Queen’s University,<br />
Kingston, ON, Canada.<br />
110. The Course <strong>of</strong> Fibromyalgia – A Long-Term Longitudinal Cohort<br />
Study. Brian Walitt 5 , Winfried Häuser 3 , Afton Hassett 4 , Robert S.<br />
Katz 2 and Frederick Wolfe 1 , 1 National Databank for Rheumatic<br />
Diseases, 2 Rush University, 3 Technische Universität München,<br />
4<br />
University <strong>of</strong> Michigan Medical School, 5 Washington Hospital<br />
Center, Washington, DC.<br />
111. The Development <strong>of</strong> Fibromyalgia: Examination <strong>of</strong> Rates<br />
and Predictors in Patients with Osteoarthritis (OA). Frederick<br />
Wolfe 1 and Winfried Häuser 2 , 1 National Data Bank for Rheumatic<br />
Diseases, Wichita, KS, 2 Technische Universität München,<br />
Munich, Germany.<br />
2010 Program Book<br />
112. The Development <strong>of</strong> Fibromyalgia: Examination <strong>of</strong> Rates<br />
and Predictors in Patients with Rheumatoid Arthritis (RA).<br />
Frederick Wolfe 1 , Winfried Häuser 3 , Afton L. Hassett 4 , Robert<br />
S. Katz 2 and Brian T. Walitt 5 , 1 National Data Bank for Rheumatic<br />
Diseases, Wichita, KS, 2 Rush University Medical Center, Chicago,<br />
IL, 3 Technische Universität München, 4 University <strong>of</strong> Michigan<br />
Medical School, 5 Washington Hospital Center, Washington, DC.<br />
113. The Effect <strong>of</strong> Duloxetine on Cognition in Patients with<br />
Fibromyalgia. Philip J. Mease 3 , Lesley Arnold 4 , Fujun Wang 1 ,<br />
Jonna Ahl 1 , Richard Mohs 1 , Paula Gaynor 1 and Madelaine<br />
Wohlreich 2 , 1 Eli Lilly and Company, 2 Lilly USA, LLC, 3 Seattle<br />
<strong>Rheumatology</strong> Associate, Seattle, WA, 4 Women’s Health<br />
Research Program, Department <strong>of</strong> Psychiatry, University <strong>of</strong><br />
Cincinnati <strong>College</strong> <strong>of</strong> Medicine, Cincinnati, OH.<br />
114. The Effectiveness <strong>of</strong> Botulinum Toxin Type-A and Prilocaine<br />
Injections in My<strong>of</strong>ascial Pain Syndrome. Mehmet Zeki Kiralp,<br />
Baki Ozdemir, Engin Cakar, Oguz Durmus, Levent Tekin and Umit<br />
Dincer, Gülhane Military Medical Academy, Haydarpasa Training<br />
Hospital, Department <strong>of</strong> Physical Medicine and Rehabilitation,<br />
Istanbul, Turkey.<br />
115. The Patient Specific Functional Scale Outperforms the<br />
Fibromyalgia Impact Questionnaire Physical Function Scale.<br />
Chad S. Boomershine 1 , Kim A. Edwards 2 , Jennifer Y. Hong 2 and<br />
Kenneth A. Wallston 2 , 1 Vanderbilt University, Nashville, TN,<br />
2<br />
Vanderbilt University.<br />
116. The Revised Version <strong>of</strong> the Fibromyalgia Impact Questionnaire:<br />
Association with Physical Function and Quality <strong>of</strong> Life. Seong-<br />
Rye Seo 1 , Sung-Ji Lee 3 , Tae-Jong Kim 3 , Yong-Wook Park 3 and<br />
Shin-Seok Lee 2 , 1 Chonnam Natl Univ Med School, Gwangju,<br />
Republic <strong>of</strong> Korea, 2 Chonnam Natl Univ Med School, Gwangju,<br />
Korea, Republic <strong>of</strong>, 3 Chonnam Natl Univ Med School.<br />
117. Treatment with FDA Approved Therapies in Patients with<br />
Fibromyalgia. Brian T. Walitt 3 , Robert S. Katz 2 and Frederick<br />
Wolfe 1 , 1 National Data Bank for Rheumatic Diseases, Wichita,<br />
KS, 2 <strong>Rheumatology</strong> Associates, Chicago, IL, 3 Washington Hospital<br />
Center, Washington, DC.<br />
Imaging <strong>of</strong> Rheumatic Disease I: X-ray, CT and MRI<br />
118. A Novel Tool for Fully Automatic Quantification <strong>of</strong> MRI<br />
Synovitis in Rheumatoid Arthritis Is More Sensitive to Change<br />
Than the Current Standard Semi-Quantitative Assessment.<br />
Michael A. Bowes 1 , Jane E. Freeston 4 , Edward J. Vital 4 , Graham<br />
Vincent 2 , Gwenael Guillard 2 , Paul Bird 5 , Paul Emery and Philip<br />
G. Conaghan 4 , 1 Imorphics Ltd, Manchester, United Kingdom,<br />
2<br />
Imorphics Ltd, 4 Section <strong>of</strong> Musculoskeletal Disease, University<br />
<strong>of</strong> Leeds, UK, 5 University <strong>of</strong> NSW, Sydney, Australia.<br />
119. Application <strong>of</strong> High-Resolution Peripheral Quantitative<br />
Computed Tomography (HR-pQCT) To Quantify Bony Damage<br />
in Rheumatoid Arthritis. Cheryl C. M. Barnabe 1 , Liam Martin 1 ,<br />
Steven K. Boyd 2 and Susan G. Barr 1 , 1 University <strong>of</strong> Calgary,<br />
Calgary, AB, Canada, 2 University <strong>of</strong> Calgary.<br />
120. Baseline CRP Predicts Early Improvement in Synovitis, Osteitis,<br />
and Erosion on MRI in RA Patients Treated with Tocilizumab:<br />
Results from the ACT-RAY MRI Substudy. Orrin M. Troum 6 ,<br />
Charles G. Peterfy 4 , Jeffrey L. Kaine 3 , Carol Chung 1 , Andrew<br />
Anisfeld 1 , Ewa Olech 2 and Philip G. Conaghan 5 , 1 Genentech,<br />
a Member <strong>of</strong> the Roche Group, South San Francisco, CA,<br />
2<br />
Oklahoma University Health Sciences Center, Oklahoma City,<br />
OK, 3 Sarasota Arthritis Research Center, Sarasota, FL, 4 Spire<br />
Sciences and Synarc, San Francisco, Kentfield, CA, 5 University<br />
<strong>of</strong> Leeds, Leeds, United Kingdom, 6 University <strong>of</strong> Southern<br />
California, Santa Monica, CA, Santa Monica, CA.
ACR Poster Session A<br />
121. Bone Density Measurement in Osteoarthritis Using Digital<br />
Radiographic Procedures. M. B. Kinds 2 , L. W. Bartels 1 , A. C. A.<br />
Marijnissen 3 , K. L. Vincken 1 , H. W.A.M. de Jong 1 , M. A. Viergever 1<br />
and F. P. J. G. Lafeber 3 , 1 Image Sciences Institute, University<br />
Medical Center Utrecht, The Netherlands, 2 <strong>Rheumatology</strong><br />
& Clinical Immunology, Image Sciences Institute, University<br />
Medical Utrecht, The Netherlands, Utrecht, The Netherlands,<br />
3<br />
<strong>Rheumatology</strong> & Clinical Immunology, University Medical<br />
Center Utrecht, The Netherlands.<br />
122. Bone Marrow Lesion (BML) Size in Osteoarthritic Knees<br />
Correlates with Extent <strong>of</strong> Cartilage Damage and Predicts<br />
Longitudinal Cartilage Loss. Jeffrey B. Driban 3 , Grace H. Lo 1 ,<br />
Ji Yeon Lee 2 , Robert J. Ward 3 , Eric Miller 5 and Timothy E.<br />
McAlindon 4 , 1 Tufts Medical Center, Houston, TX, 2 Tufts Medical<br />
Center, Brookline, MA, 3 Tufts Medical Center, Boston, MA, 4 Tufts<br />
Medical Center Box 406 , Boston, MA, 5 Tufts University.<br />
123. Decreased Incidence <strong>of</strong> Synovitis, Osteitis, and Erosion in Early<br />
RA Patients Treated with Adalimumab Plus Methotrexate<br />
Compared to Those with Methotrexate Alone: High-Field<br />
MRI Analysis from OPTIMA. Charles Peterfy 4 , Boulos Haraoui 5 ,<br />
Patrick Durez 3 , Kaushik Patra 2 and Hartmut Kupper 1 , 1 Abbott<br />
GmbH & Co. KG, Ludwigshafen, Germany, 2 Abbott Laboratories,<br />
Abbott Park, IL, 3 Cliniques Universitaires Saint-Luc, Université<br />
Catholique de Louvain, Brussels, Belgium, 4 Spire Sciences, San<br />
Francisco, CA, 5 University <strong>of</strong> Montreal Hospital Centre, Hopital<br />
Notre Dame, Montreal, QC, Canada.<br />
124. Detection <strong>of</strong> Radiographic Progression in Early Knee<br />
Osteoarthritis (CHECK): Sensitivity to Change <strong>of</strong> Knee Images<br />
Digital Analysis Compared to Altman Grading. M. B. Kinds 3 , S.<br />
M. A. Bierma-Zeinstra 1 , A. C. A. Marijnissen 5 , M. A. Viergever 2 , J.<br />
W. J. Bijlsma 5 , P. M. J. Welsing 4 and F. P. J. G. Lafeber 5 , 1 General<br />
Practice, Erasmus University Rotterdam, the Netherlands,<br />
2<br />
Image Sciences Institute, University Medical Center Utrecht,<br />
The Netherlands, 3 <strong>Rheumatology</strong> & Clinical Immunology,<br />
Image Sciences Institute, University Medical Center Utrecht,<br />
The Netherlands, 4 <strong>Rheumatology</strong> &Clinical Immunology,<br />
Julius Center for Health Sciences & Primary Care, University<br />
Medical Center Utrecht, The Netherlands, 5 <strong>Rheumatology</strong> &<br />
Clinical Immunology, University Medical Center Utrecht, The<br />
Netherlands.<br />
125. Discriminative Power <strong>of</strong> Different Combinations <strong>of</strong> Bones and<br />
Joints for Assessing Change in Rheumatoid Arthritis with MRI:<br />
Results Based on Pooled Data from Four Multisite Clinical<br />
Trials. Charles G. Peterfy 8 , Peter Countryman 7 , Julie DiCarlo 7 ,<br />
Annarita Gabriele 4 , Tim M. Shaw 3 , Andrew Anisfeld 5 , Wayne<br />
H. Tsuji 1 , Ewa Olech 6 and Norman B. Gaylis 2 , 1 Amgen, Seattle,<br />
WA, 2 Arthritis & Rheumatic Disease, Aventura, FL, 3 F H<strong>of</strong>fmann<br />
La-Roche, Ltd, Welwyn Gladen City Herts, United Kingdom,<br />
4<br />
F H<strong>of</strong>fmann La-Roche, Ltd, Italy, 5 Genentech, a Member <strong>of</strong><br />
the Roche Group, 6 Oklahoma Medical Research Foundation,<br />
Oklahoma City, OK, 7 Spire Sciences, LLC, San Francisco, CA,<br />
8<br />
Spire Sciences, LLC, Kentfield, CA.<br />
126. Giant Cell Arteritis and MRI Evaluation <strong>of</strong> the Cranial Arteries.<br />
Marie I. Clements-Baker 1 , Samir Patel 4 , Ryan Rebello 2 , George<br />
Ionnadis 5 and Nader Khalidi 3 , 1 St Joseph’s Healthcare Hamilton<br />
Ontario, Canada McMaster University, Hamilton, ON, Canada,<br />
2<br />
St Joseph’s Healthcare Hamilton, Mcmaster University,<br />
Hamilton, ON, Canada, 3 St. Joseph’s Healthcare Hamilton,<br />
McMaster University, Hamilton, ON, Canada, 4 St. Joseph’s<br />
Healthcare Hamilton, Mcmaster University, 5 St. Joseph’s<br />
Healthcare Hamilton. McMaster University.<br />
127. High-Field MRI and Powerdoppler Sonography –<br />
Supplementary Imaging Techniques in Assesing Disease<br />
Activity in Patients with Psoriasis Arthritis (PsA) and<br />
Rheumatoid Arthritis (RA) in Sustained Clinical Remission.<br />
Maria Hoehle, Rheumatologic Practice, Hamburg, Germany.<br />
128. Inflammatory Osteophyte Formation Is Different from<br />
Degenerative Osteophyte Formation. Stephanie Finzel,<br />
Christian Ernet, Christian Stach, Klaus Engelke, Matthias<br />
Englbrecht and Georg Schett, University <strong>of</strong> Erlangen-<br />
Nuremberg.<br />
129. Magnetic Resonance Elastography for the Evaluation <strong>of</strong> Liver<br />
Fibrosis in Patients with Rheumatoid Arthritis Receiving<br />
Methotrexate. Deana D. Hoganson 1 , Jun Chen 2 , Richard L.<br />
Ehman 2 , Jayant A. Talwalkar 2 , Clement J. Michet 1 , Meng Yin and<br />
Eric L. Matteson 1 , 1 Mayo Clinic, Rochester, MN, 2 Mayo Clinic.<br />
130. Magnetic Resonance Imaging (MRI) <strong>of</strong> the Spine May Be Useful<br />
in Patients with Non-Radiographic Axial Spondyloarthritis<br />
(NRASpA) without Active Sacroiliitis on MRI. Guillaume<br />
Direz 1 , Manuel Couchot 2 , Philippe Cotty 1 , Denis Mulleman 3 and<br />
Philippe M. Goupille 1 , 1 University Hospital, Tours, Tours, France,<br />
2<br />
University Hospital, Tours, Tours, France, 3 University Hospital,<br />
Tours, Tours, France.<br />
131. Malalignment <strong>of</strong> the Knee Is Associated with an Increased Risk<br />
for Incident and Enlarging Subchondral Bone Marrow Lesions<br />
in the More Loaded Compartments: The MOST Study. Daichi<br />
Hayashi 3 , Martin Englund 5 , Frank Roemer 4 , Jingbo Niu 1 , Leena<br />
Sharma 6 , Neil Segal 9 , Cora Lewis 8 , David T. Felson 2 , Michael<br />
C. Nevitt 7 and Ali Guermazi 4 , 1 Boston University, Boston, MA,<br />
2<br />
Boston University School <strong>of</strong> Medicine, Boston, MA, 3 Boston<br />
University School <strong>of</strong> Medicine, Boston, MA, 4 Boston University<br />
School <strong>of</strong> Medicine, 5 Lund University, Sweden, 6 Northwestern<br />
University, Chicago, IL, 7 UCSF, San Francisco, CA, 8 University <strong>of</strong><br />
Alabama at Birmingham, 9 University <strong>of</strong> Iowa.<br />
132. MRI and X-Ray Measured Changes in Joint Space Narrowing<br />
Are Closely Associated in Early RA Patients: A Pilot Study.<br />
Siri Lillegraven 2 , Pernille Bøyesen 2 , Mikkel Østergaard 3 ,<br />
Sølve Sesseng 2 , Tore K. Kvien 1 and Espen A. Haavardsholm 2 ,<br />
1<br />
Diakonhjemmet Hospital, Oslo, Norway, 2 Diakonhjemmet<br />
Hospital, Oslo, Norway, 3 Hvidovre University Hospital, Hvidovre,<br />
Denmark.<br />
133. MRI Bone Edema Is an Independent Predictor <strong>of</strong> Development<br />
<strong>of</strong> Rheumatoid Arthritis in Patients with Early Undifferentiated<br />
Arthritis. Anne Duer-Jensen 7 , Kim Hørslev-Petersen 10 , Merete<br />
L. Hetland 1 , Lene Bak 5 , Bo J. Ejbjerg 9 , Michael S. Hansen 6 , Julia<br />
S. Johansen 3 , Hanne M. Lindegaard 8 , Henrik Vinterberg 11 , Jakob<br />
M. Møller 4 and Mikkel Ostergaard 2 , 1 Copenhagen Univ Hosp<br />
Hvidovre and Glostrup, Hvidovre, Denmark, 2 Copenhagen<br />
University Hospitals at Hvidovre and Glostrup, Hvidovre,<br />
Denmark, 3 Dept <strong>of</strong> Oncology, Copenhagen University Hospital<br />
at Herlev, 4 Dept <strong>of</strong> Radiology, Copenhagen University Hospital<br />
at Herlev, 5 Dept <strong>of</strong> Radiology, Sygehus Lillebælt, Kolding, 6 Dept<br />
<strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University Hospital at Gent<strong>of</strong>te,<br />
7<br />
Dept <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University Hospital at<br />
Glostrup and Hvidovre, Denmark, 8 Dept <strong>of</strong> <strong>Rheumatology</strong>,<br />
Odense University Hospital, 9 Dept <strong>of</strong> <strong>Rheumatology</strong>, Slagelse<br />
Hospital, 10 King Christian Xth Hospital for Rheumatic Diseases,<br />
Gråsten, 11 <strong>Rheumatology</strong> Clinic, Amagerbrogade, Copenhagen.<br />
2010 Program Book 155
ACR Poster Session A<br />
156<br />
134. MRI Inflammation in the Sacroiliac Joints Is Associated with<br />
CTX-II and Changes in Systemic Inflammation during TNFα<br />
Inhibitor Therapy. Susanne Juhl Pedersen 8 , Inge Juul Sørensen 13 ,<br />
Robert Lambert 5 , Kay-Geert Hermann 17 , Patrick Garnero 18 ,<br />
Julia S. Johansen 1 , Ole Rintek Madsen 9 , Annette Hansen 15 ,<br />
Michael Sejer Hansen 10 , Gorm Thamsborg 9 , Lis Smedegaard<br />
Andersen 19 , Ole Majgaard 14 , Anne Gitte L<strong>of</strong>t 16 , Jon Erlendsson 11 ,<br />
Karsten Asmussen 7 , Anne Grethe Jurik 3 , Jakob Møller 4 , Maria<br />
Hasselquist 4 , Dorrit Mikkelsen 2 , Thomas Skjødt 6 and Mikkel<br />
Østergaard 12 , 1 Dep. <strong>of</strong> Internal Medicine, Herlev Hospital,<br />
Copenhagen, Denmark, 2 Dep. <strong>of</strong> Radiology, Aabenraa Hospital,<br />
Aabenraa, Denmark, 3 Dep. <strong>of</strong> Radiology, Aarhus University<br />
Hospitals, Aarhus, Denmark, 4 Dep. <strong>of</strong> Radiology, Herlev<br />
University Hospital, Copenhagen, Denmark, 5 Dep. <strong>of</strong> Radiology,<br />
University <strong>of</strong> Alberta, Canada, 6 Dep. <strong>of</strong> Radiology, Vejle<br />
Hospital, Vejle, Denmark, 7 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Bispebjerg<br />
Hospital, Copenhagen, Denmark, 8 Dep. <strong>of</strong> <strong>Rheumatology</strong>,<br />
Gent<strong>of</strong>te and Herlev Hospitals, Copenhagen, Denmark, 9 Dep.<br />
<strong>of</strong> <strong>Rheumatology</strong>, Gent<strong>of</strong>te Hospital, Copenhagen, Denmark,<br />
10<br />
Dep. <strong>of</strong> <strong>Rheumatology</strong>, Herlev Hospital, Copenhagen,<br />
Denmark, 11 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Horsens Hospital, Denmark,<br />
12<br />
Dep. <strong>of</strong> <strong>Rheumatology</strong>, Hvidovre and Glostrup Hospitals,<br />
Copenhagen, Denmark, 13 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Hvidovre<br />
and Glostrup Hospitals and DANBIO, Copenhagen, Denmark,<br />
14<br />
Dep. <strong>of</strong> <strong>Rheumatology</strong>, Hvidovre Hospital, Copenhagen,<br />
Denmark, 15 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Rigshospitalet, Copenhagen,<br />
Denmark, 16 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Vejle Hospital, Denmark,<br />
17<br />
Departments <strong>of</strong> Radiology, Charité University Hospital, Berlin,<br />
Germany, 18 INSERM Unit 664, Lyon, and Cisbio Bioassays<br />
Bagnols/Cèze, France, 19 Rheumatism Hospital, University <strong>of</strong><br />
Southern Denmark, Graasten, Denmark.<br />
135. Quantitative Characterization <strong>of</strong> Bone Marrow Edema in<br />
Patients with Rheumatoid Arthritis. Xiaojuan Li 1 , Daniel Kuo 2 ,<br />
Warapat Virayavanich 2 , Thomas M. Link 2 , Sarah B. Gratton 2 ,<br />
Jonathan Graf 2 and John Imboden 2 , 1 University <strong>of</strong> California,<br />
San Francisco, San Francisco, CA, 2 University <strong>of</strong> California, San<br />
Francisco.<br />
136. Quantitative In Vivo HR-pQCT Imaging <strong>of</strong> 3D Radiocarpal and<br />
Metacarpophalangeal Joint Space Distances in Rheumatoid<br />
Arthritis. Andrew J. Burghardt 2 , Christina Kurhanewicz 3 , John<br />
B. Imboden 1 , Sharmila Majumdar 3 , Thomas M. Link 3 and<br />
Xiaojuan Li 2 , 1 Department <strong>of</strong> Medicine, University <strong>of</strong> California,<br />
San Francisco and Division <strong>of</strong> <strong>Rheumatology</strong>, San Francisco<br />
General Hospital, 2 Musculoskeletal Quantitative Imaging<br />
Research Group, Department <strong>of</strong> Radiology and Biomedical<br />
Imaging, University <strong>of</strong> California, San Francisco, San Francisco,<br />
CA, 3 Musculoskeletal Quantitative Imaging Research Group,<br />
Department <strong>of</strong> Radiology and Biomedical Imaging, University <strong>of</strong><br />
California, San Francisco.<br />
137. Radiographic Severity <strong>of</strong> Knee Osteoarthritis Predicts<br />
Quantitative Bone Marrow Lesions on MRI. Svetlana<br />
Krasnokutsky 4 , Ravinder Regatte 2 , Jenny Bencardino 2 , Leon<br />
Rybak 2 , Ilana Belitskaya-Lévy 2 , Jonathan Samuels 1 , Mukundan<br />
Attur 3 and Steven B. Abramson 4 , 1 New York University Hospital<br />
for Joint Disease, New York, NY, 2 NYU Langone Medical Center,<br />
3<br />
NYU Langone Medical Center, NYU Hospital for Joint Diseases,<br />
4<br />
NYU Langone Medical Center, NYU Hospital for Joint Diseases,<br />
New York, NY.<br />
2010 Program Book<br />
138. REMISSION PLUS: Multicenter Evaluation <strong>of</strong> Low-Field MRI<br />
for Monitoring Treatment Response in Rheumatoid Arthritis<br />
Patients. Ben Ostendorf 8 , Sabine Kamp 8 , Birthe Koerbl 2 ,<br />
Dorothea Reichelt 1 , Klaus Strassburger 2 , Axel Scherer 1 , Sabine<br />
Blaschke 9 , Edmund Edelmann 6 , Ino Gao 7 , Gernot Keyßer 11 ,<br />
Hans-Martin Lorenz 5 , Ulf Müller-Ladner 10 , Hans-Georg Pott 3 ,<br />
Marisa Walther 4 and Matthias Schneider 8 , 1 Department <strong>of</strong><br />
Radiology, Heinrich-Heine-University Düsseldorf, Düsseldorf,<br />
NRW, Germany, 2 German Diabetes Center at the Heinrich-<br />
Heine-University Düsseldorf, Leibniz Center for Diabetes<br />
Research, Institute <strong>of</strong> Biometrics and Epidemiology, Düsseldorf,<br />
NRW, Germany, 3 <strong>Rheumatology</strong> Center, Hannover, Hannover,<br />
Germany, 4 <strong>Rheumatology</strong> Clinic, Berlin-Buch, Berlin, Germany,<br />
5<br />
<strong>Rheumatology</strong> Department, Heidelberg University Hospital,<br />
Heidelberg, Germany, 6 <strong>Rheumatology</strong> Office, Bad Aibling,<br />
Bad Aibling, Germany, 7 <strong>Rheumatology</strong> Office, Heidelberg,<br />
Heidelberg, Germany, 8 <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Endocrinology, Diabetology and <strong>Rheumatology</strong>, Rhine-Ruhr<br />
<strong>Rheumatology</strong> Center, Heinrich-Heine-University Düsseldorf,<br />
Düsseldorf, NRW, Germany, 9 <strong>Rheumatology</strong>, Göttingen<br />
University Hospital, Göttingen, Germany, 10 <strong>Rheumatology</strong>,<br />
Kerckh<strong>of</strong>f Clinic, Bad Nauheim, Germany, 11 <strong>Rheumatology</strong>,<br />
Martin Luther University, Halle-Wittenberg, Halle, Germany.<br />
139. Repair <strong>of</strong> Bone Erosions in Patients Treated with TNF<br />
Antagonists in the Real World. Kaoru Takase 2 , Kouji Kobayashi 3 ,<br />
Kayo Terauchi 3 , Toshiyuki Watanabe 3 , Reikou Watanabe 3 ,<br />
Maasa Hama 3 , Rhusuke Yoshimi 3 , Hiroshi Kobayashi 3 , Atsushi<br />
Ihata 3 , Atsuhisa Ueda 3 , Mitsuhiro Takeno 3 , Haruko Ideguchi 1 ,<br />
Shigeru Ohno 1 and Yoshiaki Ishigatsubo 2 , 1 Center for<br />
Rheumatic Diseases, Yokohama City University Medical Center,<br />
2<br />
Department <strong>of</strong> Internal Medicine and Clinical Immunology,<br />
Yokohama City University Graduate School <strong>of</strong> Medicine,<br />
Yokohama, Japan, 3 Department <strong>of</strong> Internal Medicine and Clinical<br />
Immunology, Yokohama City University Graduate School <strong>of</strong><br />
Medicine.<br />
140. Responsiveness to Change and Reliability <strong>of</strong> Radiographic<br />
Joint Space Width in Osteoarthritis <strong>of</strong> the Knee: A Systematic<br />
Review. William M. Reichmann 2 , Jean Francis Maillefert 4 , David<br />
J. Hunter 5 , Jeffrey N. Katz 1 , Philip G. Conaghan 3 and Elena<br />
Losina 2 , 1 Brigham & Womens Hosp, Boston, MA, 2 Brigham and<br />
Womens Hospital, Boston, MA, 3 Chapel Allerton Hospital, Leeds,<br />
United Kingdom, 4 Dijon University Hospital, Dijon, France,<br />
5<br />
University <strong>of</strong> Sydney, Boston, MA.<br />
141. Synovitis and Osteitis Is Very Frequent in Rheumatoid Arthritis<br />
(RA) Patients in Clinical Remission: Results from a MRI Study<br />
<strong>of</strong> 300 RA Patients in Clinical Remission or Low Disease Activity<br />
State. Frederique Gandjbakhch 5 , Philip G. Conaghan 12 , Bo<br />
Ejbjerg 2 , Espen Haavardsholm 3 , Violaine Foltz 6 , Andrew Brown 12 ,<br />
Uffe Moller Dohn 11 , Marissa Lassere 9 , Jane Freeston 12 , Pernille<br />
Bøyesen 3 , Paul Bird 4 , Bruno Fautrel 6 , Merete Lund Hetland 2 ,<br />
Paul Emery 1 , Pierre Bourgeois 6 , Kim Hørslev-Petersen 8 , Tore<br />
Kvien 3 , Fiona M. McQueen 10 and Mikkel Østergaard 7 , 1 Chapel<br />
Allerton Hospital, Leeds, United Kingdom, 2 Copenhagen<br />
University Hospitals at Hvidovre and Glostrup, Denmark,<br />
3<br />
Diakonhjemmet Hospital, University <strong>of</strong> Oslo, Oslo, Norway,<br />
4<br />
Division <strong>of</strong> Medicine, University <strong>of</strong> NSW, Sydney Australia,<br />
5<br />
Hôpital Pitié-Salpétrière, Université PARIS VI - UPMC, Paris,<br />
France, 6 Hôpital Pitié-Salpétrière, Université PARIS VI - UPMC,<br />
Paris, France, 7 Hvidovre University Hospital, Hvidovre, Denmark,<br />
8<br />
King Christian X’s Hospital for Rheumatic Diseases, University<br />
<strong>of</strong> Southern Denmark, 9 St. George Hospital, University <strong>of</strong> NSW,<br />
Sydney, Australia, 10 Univ <strong>of</strong> Auckland Sch <strong>of</strong> Med, Auckland,<br />
New Zealand, 11 University Hospitals at Hvidovre and Glostrup,<br />
Denmark, 12 University <strong>of</strong> Leeds, Leeds, UK.
ACR Poster Session A<br />
142. The Intra- and Inter-Reader Reliability <strong>of</strong> the Oslo Hand<br />
Osteoarthritis (HOA) Magnetic Resonance Imaging (MRI)<br />
Score. Ida Kristin Haugen 2 , Siri Lillegraven 2 , Barbara Slatkowsky-<br />
Christensen 2 , Espen Haavardsholm 2 , Sølve Sesseng 2 , Tore K.<br />
Kvien 1 , Desiree M. Van Der Heijde 3 and Pernille Bøyesen 2 ,<br />
1<br />
Diakonhjemmet Hospital, Oslo, Norway, 2 Diakonhjemmet<br />
Hospital, 3 Leiden University Medical Center, Meerssen, The<br />
Netherlands.<br />
143. Validity and Responsiveness to Change <strong>of</strong> Radiograph-Based<br />
Joint Space Narrowing Metric Measurement: A Systematic<br />
Review. Delphine Chu Miow Lin 6 , William M. Reichmann 2 , Laure<br />
Gossec 4 , Elena Losina 1 , Philip G. Conaghan 5 and Jean-Francis<br />
Maillefert 3 , 1 Department <strong>of</strong> Orthopaedic Surgery, Brigham and<br />
Women’s Hospital, Boston, MA, 2 Department <strong>of</strong> Orthopaedic<br />
Surgery, Brigham and Women’s Hospital, Boston, MA and<br />
3<br />
. Department <strong>of</strong> Biostatistics, Boston University School <strong>of</strong><br />
Public Health, Boston, MA, 3 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Dijon University Hospital, Dijon, F-21078, France, University<br />
<strong>of</strong> Burgundy, Dijon, F-21079, France, INSERM U887, Dijon,<br />
F-21079, France, 4 Paris Descartes University, Medicine Faculty;<br />
UPRES-EA 4058; APHP, <strong>Rheumatology</strong> B Department, Cochin<br />
Hospital, Paris France, 5 Section <strong>of</strong> Musculoskeletal Disease,<br />
University <strong>of</strong> Leeds & NIHR Leeds Musculoskeletal Biomedical<br />
Research Unit, Leeds, UK, 6 Tours Medicine Faculty; Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Tours University Hospital, Tours, France.<br />
Metabolic and Crystal Arthropathies - Therapeutics and Outcomes<br />
I<br />
144. A Single Cohort, Dose Escalation Phase 1 Study <strong>of</strong> Intravenous<br />
Infusion <strong>of</strong> Pegsiticase (Formerly Uricase-PEG 20), a Drug for<br />
Managing Hyperuricemia in Refractory Gout. Tony Fiorino 3 ,<br />
Alan J. Kivitz 1 , Patricia Pardo 5 , Rocelle Flores 2 , Zhihua Zhang 2 and<br />
John S. Bomalaski 4 , 1 Altoona Arthritis & Osteo Ctr, Duncansville,<br />
PA, 2 EnzymeRx, 3 EnzymeRx, Paramus, NJ, 4 EnzymeRx, Wayne,<br />
PA, 5 Miami Research Associates, Miami, FL.<br />
145. Canakinumab (ACZ885) Relieves Pain and Controls<br />
Inflammation Rapidly in Patients with Difficult-To-Treat Gouty<br />
Arthritis: Comparison with Triamcinolone Acetonide. A. So 6 ,<br />
M. De Meulemeester 4 , A. Pikhlak 2 , A. E. Yücel 1 , U. Arulmani 3 , D.<br />
Richard 3 , V. Murphy 3 , P. Sallstig 3 and N. Schlesinger 5 , 1 Baskent<br />
University, Ankara, Turkey, 2 Moscow State University <strong>of</strong><br />
Medicine and Dentistry, Moscow, Russian Federation, 3 Novartis<br />
Pharma AG, Basel, Switzerland, 4 Private Practice, Gozée,<br />
Belgium, 5 UMDNJ-Robert Wood Johnson Medical School, New<br />
Brunswick, NJ, 6 University <strong>of</strong> Lausanne, Lausanne, Switzerland.<br />
146. Change in Uric Acid Level Is Associated with Change in Patient<br />
Reported Outcomes in the Context <strong>of</strong> a Clinical Trial for<br />
Chronic Gout. Will Taylor 1 , Steve Hamburger 2 , Lisa K. Stamp 5 ,<br />
Zebulun D. Horowitz 3 and Nicola Dalbeth 4 , 1 Department <strong>of</strong><br />
Medicine, University <strong>of</strong> Otago Christchurch, New Zealand,<br />
2<br />
Savient Pharmaceuticals, Inc., E. Brunswick NJ, 3 Savient<br />
Pharmaceuticals, Inc., E. Brunswick NJ, Baskingridge, NJ,<br />
4<br />
Univ Auckland, Auckland, New Zealand, 5 University <strong>of</strong> Otago<br />
Christchurch, Christchurch, New Zealand.<br />
147. Chronologic Age, Renal Function, and Comorbid Conditions<br />
(Physiologic Age) <strong>of</strong> Patients with Gout Did Not Increase<br />
Likelihood <strong>of</strong> Adverse Events (AEs): AGREE Study Post Hoc<br />
Analyses. Daniel E. Furst 1 , Paul Maranian 1 , Matthew W. Davis 3 ,<br />
Suman Wason 3 , Dinesh Khanna 1 and Robert Terkeltaub 2 ,<br />
1<br />
University <strong>of</strong> California Los Angeles, Los Angeles, CA,<br />
2<br />
University <strong>of</strong> California San Diego, San Diego, CA, 3 URL Pharma,<br />
Inc, Philadelphia, PA.<br />
148. Colchicine Use Is Associated with Decreased Diagnosis <strong>of</strong><br />
Myocardial Infarction (MI) and Trend toward Reduction <strong>of</strong> All-<br />
Cause Mortality and C-Reactive Protein (CRP) Levels: Insights<br />
from the NY VA Gout Cohort. Aaron Lehmann 5 , Laura Schneck 5 ,<br />
Robert T. Keenan 2 , William O’Brien 6 , Daria B. Crittenden 6 , Kristen<br />
Lee 6 , Rekha Tadoori 6 , Jeffrey D. Greenberg 1 , Bruce N. Cronstein 3 ,<br />
Steven Sedlis 4 and Michael H. Pillinger 5 , 1 Millburn, NJ, 2 Duke<br />
University, Durham, NC, 3 New York Univ Med Ctr, New York, NY,<br />
4<br />
NYU Langone Medical Center, 5 NYU Langone Medical Center,<br />
NYU Hospital for Joint Diseases, New York, NY, 6 NYU Langone<br />
Medical Center, NYU Hospital for Joint Diseases.<br />
149. Effect <strong>of</strong> Multiple Doses <strong>of</strong> Febuxostat on the<br />
Pharmacokinetics <strong>of</strong> a Single Dose <strong>of</strong> Theophylline. Max Tsai,<br />
Jingtao Wu, Lhanoo Gunawardhana and Himanshu Naik, Takeda<br />
Global Research &Development Center, Inc., Deerfield, IL.<br />
150. Effects <strong>of</strong> a Purine Nucleoside Phosphorylase Inhibitor,<br />
BCX4208, on the Serum Uric Acid Concentrations in Patients<br />
with Gout. David Fitz-Patrick 2 , Waymon Drummond 4 , John<br />
Pappas 3 and Alan S. Hollister 1 , 1 BioCryst Pharmaceuticals,<br />
Inc., Durham, NC, 2 East-West Medical Research Institute,<br />
Honolulu, HI, 3 Kentucky Medical Research Center, Lexington, KY,<br />
4<br />
Renaissance Clinical Research, Dallas, TX.<br />
151. Efficacy and Tolerability <strong>of</strong> Celecoxib in the Treatment<br />
<strong>of</strong> Moderate to Extreme Pain Associated with Acute<br />
Gouty Arthritis: A Randomized Controlled Trial. H. Ralph<br />
Schumacher 4 , Manuela Berger 3 , Julie Li-Yu 5 , Fernando Perez-<br />
Ruiz 1 , Ruben Burgos Vargas 2 and Chunming (Mark) Li 3 , 1 Hospital<br />
de Cruces, Baracaldo, Spain, 2 Hospital General de México,<br />
México City, Mexico, 3 Pfizer Inc., New York, NY, 4 University <strong>of</strong><br />
Pennsylvania VA Medical Center, Philadelphia, PA, 5 University <strong>of</strong><br />
Santo Tomas Hospital, Manila, Philippines.<br />
152. Evaluation <strong>of</strong> Rilonacept for Prevention <strong>of</strong> Gout Flares during<br />
Initiation <strong>of</strong> Urate-Lowering Therapy: Results <strong>of</strong> a Phase 3,<br />
Randomized, Double-Blind, Placebo-Controlled Trial. Robert<br />
Terkeltaub 6 , H. Ralph Schumacher 5 , Kenneth G. Saag 4 , James<br />
Clower 7 , William Jennings 1 , Robert R. Evans 2 , Jian Wang 3 ,<br />
Shirletta King-Davis 3 and Steven P. Weinstein 2 , 1 Radiant<br />
Research, San Antonio, TX, 2 Regeneron Pharmaceuticals, Inc.,<br />
Tarrytown, NY, 3 Regeneron Pharmaceuticals, Inc., 4 University<br />
<strong>of</strong> Alabama-Birmingham, Birmingham, AL, 5 VA Medical Center<br />
and UPenn, Philadelphia, PA, 6 VA Medical Ctr, San Diego, CA,<br />
7<br />
Westside Center for Clinical Research, Jacksonville, FL.<br />
153. Evaluation <strong>of</strong> Rilonacept in Patients with Gouty Arthritis<br />
Experiencing an Acute Gout Attack. Robert Terkeltaub 6 , H.<br />
Ralph Schumacher 5 , Craig Curtis 1 , Neil Patterson 2 , Robert<br />
R. Evans 3 , Jian Wang 4 , Shirletta King-Davis 4 and Steven P.<br />
Weinstein 3 , 1 Compass Research, Orlando, FL, 2 Private Practice,<br />
Oviedo, FL, 3 Regeneron Pharmaceuticals, Inc., Tarrytown,<br />
NY, 4 Regeneron Pharmaceuticals, Inc., 5 VA Medical Center,<br />
Philadelphia, PA, 6 VA Medical Ctr, San Diego, CA.<br />
154. Febuxostat Versus Allopurinol in the Treatment <strong>of</strong> Gout<br />
in Subjects >65 Years <strong>of</strong> Age: A Subgroup Analysis <strong>of</strong> the<br />
CONFIRMS Trial. Eswar Krishnan 1 , Patricia A. MacDonald 2 ,<br />
Barbara Hunt 2 and Robert Jackson 2 , 1 Stanford University,<br />
Stanford, CA, 2 Takeda Global Research & Development Center,<br />
Inc., Lake Forest, IL.<br />
155. Healthcare Utilization and Productivity at Home and Work<br />
Place in Tophaceous vs. Non-Tophaceous Gout. Puja Khanna 3 ,<br />
Jay Persselin 1 , Ron Hays 2 , Daniel Furst 2 , Harold Paulus 2 , Paul<br />
Maranian 2 and Dinesh Khanna 2 , 1 Greater Los Angeles VA, 2 UCLA,<br />
3<br />
UCLA and Greater Los Angeles VA.<br />
2010 Program Book 157
ACR Poster Session A<br />
156. Patient Knowledge and Beliefs Concerning Gout and Its<br />
Treatment. Leslie R. Harrold 4 , Kathleen M. Mazor 2 , Daniel<br />
Peterson 3 , Cassandra Firneno 3 and Robert A. Yood 1 , 1 Fallon<br />
Clinic, Worcester, MA, 2 Meyers Primary Care Insitute/UMass<br />
Medical School, 3 Meyers Primary Care Institute, 4 UMass Medical<br />
Schl, Worcester, MA.<br />
157. Progressive Reduction in Tophus Burden with Pegloticase<br />
Therapy in Patients with Chronic Gout Refractory to<br />
Conventional Therapy. Herbert Baraf 1 , Sergio R. Gutierrez-<br />
Urena 4 , Janitzia Vazquez-Mellado 5 , Claudia Rehrig 6 , Faith<br />
Ottery 6 , John S. Sundy 2 and Robert A. Yood 3 , 1 Arthritis &<br />
Rheumatism Association, Wheaton, MD, 2 Duke University<br />
Medical Center, Durham, NC, 3 Fallon Clinic, Worcester, MA,<br />
4<br />
Hospital Civil de Guadelajara, Guadalajara, Mexico, 5 Hospital<br />
General de México, México City, 6 Savient Pharmaceuticals, Inc.<br />
158. Safety and Efficacy <strong>of</strong> Febuxostat (FEB) Treatment in Subjects<br />
with Gout and Severe Allopurinol (ALLO) Adverse Reactions.<br />
Saima Chohan and Michael A. Becker, University <strong>of</strong> Chicago,<br />
Chicago, IL.<br />
159. Serum Urate Levels Have an Impact on Renal Function in<br />
Patients with Gout Withdrawing Urate-Lowering Therapy<br />
(ULT). Fernando Perez-Ruiz 1 , Ana M. Herrero-Beites 2 and Miguel<br />
A. Gonzalez-Gay 3 , 1 Hospital de Cruces, Jopelana, Spain, 2 Hospital<br />
de Górliz, 3 Hospital Univesitario Marqués de Valdecilla.<br />
160. The Combination <strong>of</strong> Tranilast with Allopurinol Results in<br />
Enhanced Urate Lowering. John S. Sundy 4 , Michael M. Kitt 5 ,<br />
Sue G. Griffith 1 , Randall R. Stoltz 2 and Ronald Goldblum 3 ,<br />
1<br />
ClinPharma Resources, San Diego, CA, 2 Covance, Evansville,<br />
IN, 3 CPC Inc, Carlsbad, CA, 4 Duke University Medical Center,<br />
Durham, NC, 5 Nuon Therapeutics, Inc., San Mateo, CA.<br />
161. The Effect <strong>of</strong> Allopurinol on Renal Function in Patients with<br />
Hyperuricemia: A Case-Control Study. Aneesa Krishnamurthy 1 ,<br />
Deana M. Lazaro 5 , David R. Blumenthal 4 , Donald A. Gerber 2 and<br />
Peter L. Flom 3 , 1 SUNY Downstate Medical Center, Kew Garden<br />
Hills, NY, 2 SUNY Downstate Medical Center, Brooklyn, NY, 3 SUNY<br />
Downstate Medical Center, 4 VA New York Harbor Healthcare<br />
System, Short Hills, NJ, 5 VA New York Harbor Healthcare System<br />
and SUNY Downstate Medical Center, Brooklyn, NY.<br />
162. The Impact <strong>of</strong> Deficits in Gout Care on Hospitalizations.<br />
Prachaya Nitichaikulvatana 1 , Katherine Upchurch 2 and Leslie<br />
Harrold 2 , 1 University <strong>of</strong> Massachusetts Medical School,<br />
Worcester, 2 University <strong>of</strong> Massachusetts Medical School.<br />
163. The Safety and Efficacy <strong>of</strong> Anakinra in the Treatment <strong>of</strong><br />
Acute Gout in Hospitalized Patients. Michael Cho 1 , Pradipta<br />
Ghosh 3 , Gurpreet Hans 4 , Julia J. Rhiannon 2 , Gregory C. Gardner 1<br />
and Peter A. Simkin 1 , 1 University <strong>of</strong> Washington, Seattle,<br />
WA, 2 University <strong>of</strong> Washington, Seattle, WA, 3 University <strong>of</strong><br />
Washington, Lake Forest Park, WA, 4 University <strong>of</strong> Washington,<br />
Kirkland, WA.<br />
164. Tranilast Inhibits Urate Transport Mediated by URAT1 and<br />
GLUT9. Asim Mandal 3 , Daniel Emerling 1 , Tito Serafini 1 and David<br />
B. Mount 2 , 1 Nuon Therapeutics, Inc., San Mateo, CA 94403,<br />
2<br />
Renal Division, VA Boston Healthcare System and Brigham &<br />
Women’s Hospital, Harvard Medical School, Boston, MA, 3 Renal<br />
Division, VA Boston Healthcare System and Brigham & Women’s<br />
Hospital, Harvard Medical School, Boston, MA 02115.<br />
165. Urate-Lowering (UL) Efficacy and Safety <strong>of</strong> Febuxostat (FEB)<br />
and Allopurinol (ALLO) in Women with Gout, an Older Subset<br />
<strong>of</strong> Gout Subjects with Increased Comorbidity. Saima Chohan 3 ,<br />
Michael A. Becker 3 , Patricia A. MacDonald 1 , Solomon Chefo 2<br />
and Robert Jackson 2 , 1 Takeda Global R&D Inc, Lake Forest, IL,<br />
2<br />
Takeda Global Research & Development Center, Inc, Deerfield,<br />
IL, 3 University <strong>of</strong> Chicago, Chicago, IL.<br />
166. Use <strong>of</strong> Pegloticase in Chronic Gout Refractory to Conventional<br />
Therapy Is Associated with Significant Clinical Benefit: Tender<br />
Joint and Swollen Joint Counts and Patient Global Assessment<br />
(Health Assessment Questionnaire). David R. Mandel 3 , Herbert<br />
Baraf 1 , Claudia Rehrig 5 , Zebulun D. Horowitz 6 , Faith D. Ottery 4<br />
and Robert A. Yood 2 , 1 Arthritis & Rheumatism Association,<br />
Wheaton, MD, 2 Fallon Clinic, Worcester, MA, 3 Private<br />
Practive, Mayfield Village, OH, 4 Savient Pharmaceuticals, Inc,<br />
5<br />
Savient Pharmaceuticals, Inc., 6 Savient Pharmaceuticals, Inc.,<br />
Baskingridge, NJ.<br />
Orthopedics, Low Back Pain, and Rehabilitation<br />
167. A Specific Chemokine Expression Pattern Is Associated<br />
with Synovial Inflammation and Symptoms in Patients with<br />
Traumatic Knee Injury Undergoing Arthroscopic Meniscectomy.<br />
Carla R. Scanzello 7 , Brian McKeon 6 , Bryan H. Swaim 6 , Edward<br />
DiCarlo 5 , Eva Umoh 4 , Veero Kanda 8 , Anjali Nair 8 , David M. Lee 2 ,<br />
John C. Richmond 6 , Jeffrey N. Katz 1 , Mary K. Crow 3 and Steven<br />
R. Goldring 3 , 1 Brigham & Womens Hosp, Boston, MA, 2 Brigham<br />
and Womens Hospital, Boston, MA, 3 Hospital for Special<br />
Surgery, New York, NY, 4 Hospital for Special Surgery, New York<br />
NY, 5 Hosptial for Special Surgery, New York NY, 6 New England<br />
Baptist Hospital, Boston MA, 7 Rush University Medical Center,<br />
Chicago, IL, 8 Rush University Medical Center, Chicago IL.<br />
168. A Systematic Review and Meta-Analysis <strong>of</strong> the Impact <strong>of</strong><br />
Total Shoulder Arthroplasty on Health-Related Quality <strong>of</strong><br />
Life. Michael J. Carter 1 , Ted R. Mikuls 1 , Smita Nayak 2 , Edward V.<br />
Fehringer 1 and Kaleb D. Michaud 1 , 1 Univ <strong>of</strong> Nebraska Med Ctr,<br />
Omaha, NE, 2 University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />
169. Cane Use in Hip Osteoarthritis. Karen L. Perell-Gerson 1 ,<br />
Constance Heiney 4 , Nancy D. Harada 4 , Jennifer M. Yentes 2 ,<br />
Sulabha Masih 4 and Meika A. Fang 3 , 1 Georgia Gwinnett <strong>College</strong>,<br />
Lawrenceville, GA, 2 University <strong>of</strong> Nebraska at Omaha, 3 VA<br />
Greater Los Angeles Healthcare System, Los Angeles, CA, 4 VA<br />
Greater Los Angeles Healthcare System, Los Angeles, CA.<br />
170. Comorbid Subjective Health Complaints in Patients with<br />
Sciatica, a Prospective Study Including Comparison with<br />
the General Population. Lars Grøvle 2 , Anne J. Haugen 2 ,<br />
Camilla Ihlebaek 5 , Anne Keller 1 , Bård Natvig 4 , Jens I. Brox 6<br />
and Margreth Grotle 3 , 1 Department <strong>of</strong> Physical Medicine and<br />
Rehabilitation, Oslo University Hospital, Ullevaal, 2 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Østfold Hospital Trust, Fredrikstad, Norway,<br />
3<br />
FORMI (Communication Unit for Musculoskeletal Disorders),<br />
Oslo University Hospital, Ullevaal, 4 National Resource Centre<br />
for Rehabilitation in <strong>Rheumatology</strong>, Diakonhjemmet Hospital<br />
& Department <strong>of</strong> General Practice and Community Medicine,<br />
ASAM, University <strong>of</strong> Oslo, 5 Research Group <strong>of</strong> Nature, Health<br />
and Quality <strong>of</strong> Life, Norwegian University <strong>of</strong> Life Sciences,<br />
Aas, 6 Section for Back Surgery and Physical Medicine and<br />
Rehabilitation, Orthopaedic Department, Oslo University<br />
Hospital, Rikshospitalet.<br />
158<br />
2010 Program Book
ACR Poster Session A<br />
171. Early Progressive Rehabilitation Following Total Knee<br />
Arthroplasty Improves Outcomes. Michael J. Bade 2 , Tami<br />
Struessel 2 and Jennifer E. Stevens-Lapsley 1 , 1 University <strong>of</strong><br />
Colorado Denver, Aurora, CO, 2 University <strong>of</strong> Colorado Denver.<br />
172. Facet Joint Injections for Low Back Pain Improve Quality<br />
<strong>of</strong> Life. Cecilia Mercieca 2 , Stefania Chetcuti Zammit 2 , Josef<br />
Lauri 1 and Andrew Albert Borg 2 , 1 Department <strong>of</strong> Mathematics,<br />
University <strong>of</strong> Malta, Malta, 2 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Mater Dei Hospital, Msida, Malta.<br />
173. Fat Mass Is a Predictor <strong>of</strong> Disabling Foot Pain: A Cross-<br />
Sectional Study. Stephanie Tanamas 4 , Anita Wluka 4 , Patricia<br />
Berry 4 , Hylton Menz 2 , Boyd Strauss 4 , Miranda Davies-Tuck 4 ,<br />
Joseph Proietto 5 , John Dixon 1 , Graeme Jones 3 and Flavia<br />
Cicuttini 4 , 1 Baker IDI Heart and Diabetes Institute, 2 La Trobe<br />
University, 3 Menzies Research Institute, 4 Monash University,<br />
5<br />
University <strong>of</strong> Melbourne.<br />
174. Is There an Association between Living Situation and Pain<br />
Severity at the Time Patients Choose Total Hip Replacement?<br />
Yvonne C. Lee 1 , Huong T. Do 3 and Lisa A. Mandl 2 , 1 Brigham and<br />
Women’s Hospital, Boston, MA, 2 Hospital for Special Surgery,<br />
New York, NY, 3 Hospital for Special Surgery.<br />
175. OMERACT Responder Analysis <strong>of</strong> Patients Treated with<br />
Duloxetine for Chronic Low Back Pain. Vladimir Skljarevski 1 ,<br />
Matthew J. Bair 2 , Melissa J. Ossanna 1 , Eli Frakes 1 , Shuyu Zhang 1<br />
and Karla Alaka 1 , 1 Eli Lilly and Company, 2 Roudebush VA Medical<br />
Center.<br />
176. The Clinical Benefit <strong>of</strong> Joint Distraction in Treatment <strong>of</strong><br />
Advanced Ankle OA May Be Partly Explained by Subchondral<br />
Bone Changes. F. Intema 1 , T. P. Thomas 2 , D. D. Anderson 2 , J.<br />
Elkins 2 , S. C. Mastbergen 1 , F. P. J. G. Lafeber 1 , T. D. Brown 2 ,<br />
A. Amendola 2 and C. L. Saltzman 3 , 1 <strong>Rheumatology</strong> &Clinical<br />
Immunology, University Medical Center Utrecht, The<br />
Netherlands, 2 The University <strong>of</strong> Iowa, Iowa City, IA, 3 The<br />
University <strong>of</strong> Utah, Salt Lake City, UT.<br />
177. The Safety and Patient Acceptability <strong>of</strong> Suprascpular Nerve<br />
Block. E. Michael Shanahan 2 , Kieran Ross Shanahan 2 , Catherine<br />
Hill 1 , Malcolm Smith 2 and Michael John Ahern 2 , 1 Adelaide<br />
University, Adelaide, South Australia, Australia, 2 Flinders<br />
University, Adelaide, South Australia, Australia.<br />
178. Using the Patient Generated Index (PGI) To Measure<br />
Personalized Quality <strong>of</strong> Life (QoL) in Patients Undergoing Total<br />
Knee Arthroplasty (TKA). Maria A. Lopez-Olivo 2 , Michael A.<br />
Kallen 2 , Chong H. Pak 2 , Sherwin J. Siff 1 , Glenn C. Landon 1 , David<br />
Edelstein 1 , Kausha C. Robinson 2 and Maria E. Suarez-Almazor 3 ,<br />
1<br />
St. Luke’s Episcopal Health System, Houston, TX, 2 The University<br />
<strong>of</strong> Texas M.D. Anderson Cancer Center, Houston, TX, 3 University<br />
<strong>of</strong> Texas, MD Anderson Cancer Center, Houston, TX.<br />
Osteoarthritis - Clinical Aspects: Biomechanics, Function, and<br />
Imaging I<br />
179. Adiponectin but Not Leptin and Resistin, Is Associated with the<br />
Progression <strong>of</strong> Hand Osteoarthritis. Erlangga Yusuf 1 , Andreea<br />
Ioan-Facsinay 2 , Jessica Bijsterbosch 2 , Joanneke Kwekkeboom 2 ,<br />
P. Eline Slagboom 2 , Tom W. J. Huizinga 2 and Margreet<br />
Kloppenburg 2 , 1 LUMC, Leiden, The Netherlands, 2 LUMC, The<br />
Netherlands.<br />
180. Association <strong>of</strong> Knee, Ankle, and Midfoot Osteoarthritis and<br />
Physical Performance. Gary McDaniel 1 , Jordan B. Renner 2 ,<br />
Richard Sloane 1 and Virginia B. Kraus 1 , 1 Duke University Medical<br />
Center, Durham, NC, 2 University <strong>of</strong> North Carolina School <strong>of</strong><br />
Medicine.<br />
181. Associations between Composite Measures <strong>of</strong> Multi-<br />
Joint Osteoarthritis, Gait Speed, and Health Assessment<br />
Questionnaire Scores: The Johnston County Osteoarthritis<br />
Project. Amanda E. Nelson 6 , Robert F. DeVellis 5 , Jordan B.<br />
Renner 5 , Jama Purser 3 , Todd A. Schwartz 5 , Philip G. Conaghan 1 ,<br />
Virginia Byers Kraus 2 and Joanne M. Jordan 4 , 1 Chapel Allerton<br />
Hospital, Leeds, United Kingdom, 2 Duke Univ Med Ctr, Durham,<br />
Durham, NC, 3 Duke Univ Med Ctr, Durham, NC, 4 Thurston<br />
Arthritis Research Center, Univ <strong>of</strong> North Carolina, Chapel Hill,<br />
Chapel Hill, NC, 5 Thurston Arthritis Research Center, Univ <strong>of</strong><br />
North Carolina, Chapel Hill, NC, 6 UNC School <strong>of</strong> Medicine,<br />
Chapel Hill, NC.<br />
182. Associations between Radiographic Hand Osteoarthritis and<br />
Femorotibial Cartilage Thickness and Thinning in Subjects<br />
with Prevalent or at High Risk <strong>of</strong> Knee Osteoarthritis – Data<br />
from OAI. Ida Kristin Haugen 2 , Sebastian Cot<strong>of</strong>ana 5 , Martin<br />
Englund 3 , Tore K. Kvien 1 , Donatus Dreher 4 , Michael C. Nevitt 6 ,<br />
Nancy E. Lane 7 and Felix Eckstein 5 , 1 Diakonhjemmet Hospital,<br />
Oslo, Norway, 2 Diakonhjemmet Hospital, 3 Lund University,<br />
Boston University, Lund, Sweden, 4 Merck Serono SA, 5 Paracelsus<br />
Medical University, Chondrometrics GmbH, 6 UCSF, San<br />
Francisco, CA, 7 Univ <strong>of</strong> California at Davis, Hillsborough, CA.<br />
183. Change in Weight over 10 Years Is Associated with Bone<br />
Marrow Lesions in a Population-Based Cohort Study <strong>of</strong><br />
Adult Women. Sharon Brennan 1 , Flavia Cicuttini 1 , Julie Pasco 1 ,<br />
Margaret Henry 2 , Yuanyuan Wang 1 , Mark Kotowicz 2 , Ge<strong>of</strong>frey<br />
Nicholson 2 and Anita Wluka 1 , 1 Monash University, 2 University <strong>of</strong><br />
Melbourne.<br />
184. Comorbidity and Health Status in Early Osteoarthritis <strong>of</strong><br />
Hip and Knee; CHECK Cohort. J. Wesseling 2 , S. M. A. Bierma-<br />
Zeinstra 1 , J. Dekker 4 , K. J. Gorter 3 , J. W. J. Bijlsma 3 and on Behalf<br />
<strong>of</strong> the CHECK Group, 1 Erasmus University Medical Center<br />
Rotterdam, 2 <strong>Rheumatology</strong> & Clinical Immunology, University<br />
Medical Center Utrecht, Utrecht, The Netherlands, 3 University<br />
Medical Center Utrecht, 4 VU University Medical Center<br />
Amsterdam.<br />
185. Do Bony Enlargements Correlate with Radiological Findings<br />
in Hand Osteoarthritis (HOA)? Roshan Dhawale 3 , Niveditha<br />
Mohan 2 , Michael J. Hannon 4 and C. Kent Kwoh 1 , 1 Univ <strong>of</strong><br />
Pittsburgh, Pittsburgh, PA, 2 Univ <strong>of</strong> Pittsburgh Arth Inst,<br />
Pittsburgh, PA, 3 University <strong>of</strong> Pittsburgh, Pittsburgh, PA,<br />
4<br />
University <strong>of</strong> Pittsburgh.<br />
186. Frailty and 3-Year Mobility Outcome in Persons with or at<br />
Higher Risk for Knee Osteoarthritis. September Cahue 4 , Karen<br />
W. Hayes 2 , Jing Song 4 , Dorothy D. Dunlop 3 , Joan S. Chmiel 4 ,<br />
Marc C. Hochberg 5 , Carmelita J. Colbert 1 and Leena Sharma 3 ,<br />
1<br />
Northwestern University, LaGrange, IL, 2 Northwestern<br />
University, Downers Grove, IL, 3 Northwestern University,<br />
Chicago, IL, 4 Northwestern University, 5 University <strong>of</strong> Maryland,<br />
Baltimore, MD.<br />
187. Greater Burden <strong>of</strong> Disease in Erosive Hand Osteoarthritis.<br />
Mariko L. Ishimori 1 , Roy D. Altman 4 , Myles J. Cohen 2 , Jerome I.<br />
Rotter 2 and Michael H. Weisman 3 , 1 Cedars Sinai Medical Center,<br />
Los Angeles, CA, 2 Cedars-Sinai, 3 Cedars-Sinai Medical Center, Los<br />
Angeles, CA, 4 UCLA, Agua Dulce, CA.<br />
188. Image Processing and Machine Learning Methods Applied to<br />
MRI Trabecular Morphometry in Knee Osteoarthritis. Jason<br />
Nochlin 4 , Eric Miller 4 , Grace H. Lo 2 , Anna Tassinari 1 and Timothy<br />
E. McAlindon 3 , 1 Tufts Medical Center, Boston, MA, 2 Tufts<br />
Medical Center, Houston, TX, 3 Tufts Medical Center Box 406,<br />
Boston, MA, 4 Tufts University, Medford, MA.<br />
2010 Program Book 159
ACR Poster Session A<br />
189. Knee Confidence and Physical Function Outcome in Persons<br />
with Knee Osteoarthritis. Carmelita J. Colbert 1 , Jing Song 4 ,<br />
Dorothy D. Dunlop 3 , Joan S. Chmiel 4 , Karen W. Hayes 2 ,<br />
September Cahue 4 , Kirsten Moisio 4 , Alison H. Chang 3 and Leena<br />
Sharma 3 , 1 Northwestern University, LaGrange, IL, 2 Northwestern<br />
University, Downers Grove, IL, 3 Northwestern University,<br />
Chicago, IL, 4 Northwestern University.<br />
190. Lateral Compartment Unloading in People with Medial Knee<br />
Osteoarthritis. Deepak Kumar, Katherine S. Rudolph and Kurt<br />
Manal, University <strong>of</strong> Delaware, Newark, DE.<br />
191. Lower Extremity Muscle Function, Quality <strong>of</strong> Life and Physical<br />
Function Outcomes and Their Relation to Subsequent<br />
Knee Replacement in a 24 Month Period – Data from the<br />
Osteoarthritis Initiative (OAI). Bjoern Buehring 1 , Boris<br />
Bershadsky 2 and M. Elaine Husni 1 , 1 Cleveland Clinic, Cleveland,<br />
OH, 2 Cleveland Clinic.<br />
192. Morphological Changes in Articular Cartilage and Subchondral<br />
Bone in Tibi<strong>of</strong>emoral and Patell<strong>of</strong>emoral Joints Following<br />
Arthroscopic Partial Medial Meniscectomy. Yuanyuan Wang 2 ,<br />
Alasdair Dempsey 3 , David Lloyd 3 , Peter Mills 1 , Tim Wrigley 4 ,<br />
Kim Bennell 4 , Ben Metcalf 4 , Fahad Hanna 2 and Flavia Cicuttini 2 ,<br />
1<br />
Griffith University, 2 Monash University, 3 The University <strong>of</strong><br />
Western Australia, 4 University <strong>of</strong> Melbourne.<br />
193. MRI-Defined Risk Factors for Cartilage Loss over a 6 Months<br />
Period. Frank W. Roemer 1 , C. Kent Kwoh 2 , Michael J. Hannon 2 ,<br />
Stephanie M. Green 2 , John M. Jakicic 2 , Robert Boudreau 2 ,<br />
Michel D. Crema 1 and Ali Guermazi 1 , 1 Boston University,<br />
2<br />
University <strong>of</strong> Pittsburgh.<br />
194. Neuromuscular Responses to Perturbations during Walking<br />
in Knee Osteoarthritis: Influence <strong>of</strong> Instability, Strength,<br />
Proprioception and Stiffness. Deepak Kumar, Darcy Reisman,<br />
Charles B. Swanik and Katherine S. Rudolph, University <strong>of</strong><br />
Delaware, Newark, DE.<br />
195. Peri-Articular Bone Density Is Strongly Correlated with Static<br />
Alignment and Varus Thrust. Grace H. Lo 1 , William F. Harvey 2 ,<br />
Melanie Ripley 3 , Erica McAdams 3 , Melynn Nuite 2 and Timothy<br />
E. McAlindon 4 , 1 Baylor <strong>College</strong> <strong>of</strong> Medicine, Houston, TX, 2 Tufts<br />
Medical Center, Boston, MA, 3 Tufts Medical Center, 4 Tufts<br />
Medical Center Box 406 , Boston, MA.<br />
196. Prediction <strong>of</strong> Total Knee Replacement in a Two-Year Multi-<br />
Centre Clinical Trial in Knee Osteoarthritis: Results from a 4-6<br />
Year Observation. Jean-Pierre Raynauld 3 , Johanne Martel-<br />
Pelletier 1 , Marc Dorais 5 , François Abram 4 , Boulos Haraoui 2 , Denis<br />
Choquette 2 and Jean-Pierre Pelletier 6 , 1 CR-CHUM, Notre-Dame<br />
Hospital, Montreal, QC, Canada, 2 Osteoarthritis Research Unit,<br />
University <strong>of</strong> Montreal Hospital Research Centre (CRCHUM),<br />
Notre-Dame Hospital, Montreal, QC, Canada, 3 Osteoarthritis<br />
Research Unit, University <strong>of</strong> Montreal Hospital Research Centre<br />
(CRCHUM), Notre-Dame Hospital, 4 Research and Development,<br />
ArthroVision Inc., Montreal, 5 StatSciences Inc., Notre-Dame de<br />
l’Ile-Perrot, 6 University <strong>of</strong> Montreal Hospital Research Centre<br />
(CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada.<br />
197. Prevalence <strong>of</strong> MRI-Detected Joint Pathology <strong>of</strong> the Knee in a<br />
Population-Based Sample: Framingham Osteoarthritis Study.<br />
Jingbo Niu 3 , Yuqing Zhang 1 , Ali Guermazi 4 , Frank W. Roemer 4<br />
and David T. Felson 2 , 1 Boston Univ School <strong>of</strong> Medicine, Boston,<br />
MA, 2 Boston University School <strong>of</strong> Medicine, Boston, MA,<br />
3<br />
Boston University School <strong>of</strong> Medicine, Boston, MA, 4 Boston<br />
University School <strong>of</strong> Medicine.<br />
198. Relation <strong>of</strong> Hand Enthesophytes on Plain Radiographs with<br />
Findings <strong>of</strong> Knee Enthesopathy: Is Osteoarthritis a Generalized<br />
Enthesopathy? Nadia Gibson 1 , Mary M. Clancy 4 , Jingbo Niu 3 ,<br />
Peter Grayson 2 , Piran Aliabadi 6 , Ali Guermazi 2 and David T.<br />
Felson 5 , 1 Boston Medical Center, Boston, MA, 2 Boston Medical<br />
Center, 3 Boston University, Boston, MA, 4 Boston University<br />
Sch Med, Boston, MA, 5 Boston University School <strong>of</strong> Medicine,<br />
Boston, MA, 6 Brigham’s and Women Hospital.<br />
199. Responsiveness and Reliability <strong>of</strong> MRI in Osteoarthritis:<br />
Analytic Literature Review. David J. Hunter 5 , Weiya Zhang 1 ,<br />
Philip G. Conaghan 4 , Kelly Hirko, Leo Menashe, William M.<br />
Reichmann 2 and Elena Losina 3 , 1 United Kingdom, 2 Brigham and<br />
Womens Hosp, Boston, MA, 3 Brigham and Womens Hospital,<br />
Boston, MA, 4 Chapel Allerton Hospital, Leeds, United Kingdom,<br />
5<br />
University <strong>of</strong> Sydney, Sydney, NSW, Australia.<br />
200. `The Effects <strong>of</strong> Hip Muscle Training on Knee Joint Loading<br />
in Medial Knee Osteoarthritis. Julia Daher 1 , Joel A. Block 2 ,<br />
Markus Wimmer 1 , Dale R. Sumner 1 and Laura E. Thorp 3 , 1 Rush<br />
University Medical Center, 2 Rush University Medical Center,<br />
Chicago, IL, 3 Rush University Medical Center, Chicago, IL.<br />
201. The Relationship between Symptoms <strong>of</strong> Medial Tibi<strong>of</strong>emoral<br />
Osteoarthritis and Toe-Out Angle during Walking: The<br />
MOST Study. K. Douglas Gross 4 , Jingbo Niu 3 , Yuqing Zhang 1 ,<br />
Michael C. Nevitt 6 , Cora E. Lewis 5 , James Torner 7 and David T.<br />
Felson 2 , 1 Boston Univ School <strong>of</strong> Medicine, Boston, MA, 2 Boston<br />
University School <strong>of</strong> Medicine, Boston, MA, 3 Boston University<br />
School <strong>of</strong> Medicine, Boston, MA, 4 MGH Institute <strong>of</strong> Health<br />
Pr<strong>of</strong>essions, Boston, MA, 5 University <strong>of</strong> Alabama, Birmingham,<br />
Birmingham, AL, 6 University <strong>of</strong> California, San Francisco, San<br />
Francisco, CA, 7 University <strong>of</strong> Iowa, Iowa City.<br />
202. The Relationship between Varus and Valgus Thrust and<br />
Meniscal Damage in Persons with Knee Osteoarthritis. Alison<br />
H. Chang 4 , Ali Guermazi 1 , Frank Roemer 1 , Kirsten Moisio 5 , Jing<br />
Song 5 , Dorothy D. Dunlop 4 , Michael C. Nevitt 6 , Carmelita J.<br />
Colbert 2 , John A. Lynch 7 , Karen W. Hayes 3 and Leena Sharma 4 ,<br />
1<br />
Boston University, 2 Northwestern University, LaGrange, IL,<br />
3<br />
Northwestern University, Downers Grove, IL, 4 Northwestern<br />
University, Chicago, IL, 5 Northwestern University, 6 UCSF, San<br />
Francisco, CA, 7 UCSF.<br />
203. Thigh Muscle Quality Correlates with Function, Leg Strength,<br />
and Walking Speed, but Not with Alignment in Individuals with<br />
Obesity and Knee Osteoarthritis. Rachel W. Holt 3 , Richard F.<br />
Loeser 5 , Cralen Davis 4 , Claudine Legault 4 , Barb Nicklas 4 , Jeffrey<br />
Carr 4 , David J. Hunter 1 and Stephen P. Messier 2 , 1 New England<br />
Baptist Hospital, Boston, MA, 2 Wake Forest Univ, Winston-<br />
Salem, NC, 3 Wake Forest Univ., Winston Salem, NC, 4 Wake<br />
Forest Univ., 5 Wake Forest University, Winston-Salem, NC.<br />
204. Understanding the Individual Burden <strong>of</strong> Osteoarthritis:<br />
Development <strong>of</strong> a Conceptual Model. Lucy Busija 3 , Richard<br />
H. Osborne 2 and Rachelle Buchbinder 1 , 1 Cabrini Institute and<br />
Monash University, Malvern, Australia, 2 Deakin University,<br />
Melbourne, Australia, 3 University <strong>of</strong> Melbourne.<br />
205. Vibratory Sense Deficits in Radiographic Knee Osteoarthritis:<br />
The Multicenter Osteoarthritis Study (MOST). Najia Shakoor 4 ,<br />
Tuhina Neogi 1 , David T. Felson 3 , Jingbo Niu 2 , Laura Frey Law 7 ,<br />
Cora E. Lewis 6 and Michael C. Nevitt 5 , 1 Boston Univ Schl <strong>of</strong> Med,<br />
Boston, MA, 2 Boston University, Boston, MA, 3 Boston University<br />
School <strong>of</strong> Medicine, Boston, MA, 4 Rush-University Medical<br />
Center, Chicago, IL, 5 UCSF, San Francisco, CA, 6 University <strong>of</strong><br />
Alabama, 7 University <strong>of</strong> Iowa, Iowa City, IA.<br />
160<br />
2010 Program Book
ACR Poster Session A<br />
Pediatric <strong>Rheumatology</strong> - Clinical and Therapeutic Aspects: Juvenile<br />
Idiopathic Arthritis I<br />
206. A Critical Appraisal <strong>of</strong> Lumbar Spine DXA Bone Mineral<br />
Density in a Longitudinal Study <strong>of</strong> Children with JIA. Maureen<br />
G. Leffler 1 , Justine Shults 6 , Sogol Mostoufi-Moab 2 , Babette<br />
S. Zemel 7 , Sarah E. Dubner 5 , Mary B. Leonard 4 and Jon M.<br />
Burnham 3 , 1 AI duPont Hospital for Children, Thomas Jefferson<br />
University, 2 Children’s Hospital <strong>of</strong> Philadelphia, 3 Children’s<br />
Hospital <strong>of</strong> Philadelphia, University <strong>of</strong> Pennsylvania School <strong>of</strong><br />
Medicine, Center for Clinical Epidemiology and Biostatistics,<br />
Philadelphia, PA, 4 Children’s Hospital <strong>of</strong> Philadelphia, University<br />
<strong>of</strong> Pennsylvania School <strong>of</strong> Medicine, Center for Clinical<br />
Epidemiology and Biostatistics, 5 Seattle Children’s Hospital,<br />
University <strong>of</strong> Washington School <strong>of</strong> Medicine, 6 University<br />
<strong>of</strong> Pennsylvania School <strong>of</strong> Medicine, Center for Clinical<br />
Epidemiology and Biostatistics, 7 University <strong>of</strong> Pennsylvania<br />
School <strong>of</strong> Medicine, Children’s Hospital <strong>of</strong> Philadelphia.<br />
207. Adolescents with Juvenile Idiopathic Arthritis Currently<br />
Followed in a Tertiary Care Hospital Have a Better Psychosocial<br />
Well-Being Than Healthy Adolescents. Marta Bertamino 4 ,<br />
Giovanni Filocamo 5 , Sara Dalprà 4 , Elena Palmisani 4 , Nicoletta<br />
Solari 4 , Silvia Magni-Manzoni 1 , Benedetta Schiappapietra 4 ,<br />
Nicolino Ruperto 4 , Alberto Martini 3 and Angelo Ravelli 2 , 1 IRCCS<br />
Fondazione Policlinico San Matteo, Pavia, Italy, 2 IRCCS G. Gaslini<br />
and Università di Genova, Genova, Italy, 3 IRCCS G. Gaslini and<br />
Università di Genova, Genova, Italy, 4 IRCCS G. Gaslini, Genova,<br />
Italy, 5 Policlinico Sant’Orsola, Bologna, Italy.<br />
208. An International Consensus Survey <strong>of</strong> the Diagnostic Criteria<br />
for Macrophage Activation Syndrome in Systemic Juvenile<br />
Idiopathic Arthritis. Sergio Davì 4 , Alessandro Consolaro 4 ,<br />
Dinara Guseinova 4 , Angela Pistorio 4 , Alberto Martini 3 , Randy<br />
Q. Cron 1 and Angelo Ravelli 2 , 1 Children’s Hospital <strong>of</strong> Alabama<br />
and University <strong>of</strong> Alabama at Birmingham, Birmingham, AL,<br />
2<br />
IRCCS G. Gaslini and Università di Genova, Genova, Italy, 3 IRCCS<br />
G. Gaslini and Università di Genova, Genova, Italy, 4 IRCCS G.<br />
Gaslini, Genova, Italy.<br />
209. Anakinra as First-Line Disease Modifying Therapy in Systemic<br />
Juvenile Idiopathic Arthritis – Report <strong>of</strong> 46 Patients from an<br />
International Multicenter Series. Peter A. Nigrovic 4 , Melissa<br />
Mannion 14 , Andrew S. Zeft 15 , Egla C. Rabinovich 8 , Marion A.<br />
J. van Rossum 9 , Elisabetta Cortis 2 , Manuela Pardeo 2 , Paivi M.<br />
Miettunen 1 , Ginger L. Janow 5 , James D. Birmingham 10 , Aaron T.<br />
Eggebeen 10 , Erin M. Janssen 3 , Andrew I. Shulman 4 , Mary Beth<br />
F. Son 4 , Sandy D. Hong 13 , Karla B. Jones 11 , Norman T. Ilowite 7 ,<br />
Randy Q. Cron 6 and Gloria C. Higgins 12 , 1 Alberta Childrens<br />
Hospital, Calgary, AB, Canada, 2 Bambino Gesù Hospital, Rome,<br />
Italy, 3 Children’s Hospital Boston, Cambridge, MA, 4 Children’s<br />
Hospital Boston, Boston, MA, 5 Children’s Hospital Montefiore,<br />
New York, NY, 6 Children’s Hospital <strong>of</strong> Alabama, Birmingham,<br />
AL, 7 Children’s Hospital Montefiore, Bronx, NY, 8 Duke University<br />
Medical Center, Durham, NC, 9 Emma Children’s Hospital,<br />
Amsterdam, The Netherlands, 10 Michigan State Univ, Grand<br />
Rapids, MI, 11 Nationwide Children’s Hospital, Columbus, OH,<br />
12<br />
Nationwide Childrens Hosp, Columbus, OH, 13 U <strong>of</strong> Iowa<br />
Children’s Hosp, Iowa City, IA, 14 Univ <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, 15 University <strong>of</strong> Utah, Salt Lake City, UT.<br />
210. Antinuclear Antibody Positive Patients Should Be Grouped as<br />
a Separate Category in the Classification <strong>of</strong> Juvenile Idiopathic<br />
Arthritis. Angelo Ravelli 2 , Giulia C. Varnier 4 , Sheila K. Oliveira 5 ,<br />
Esteban Castell 4 , Olga Arguedas 4 , Alessandra Magnani 4 , Angela<br />
Pistorio 4 , Nicolino Ruperto 4 , Silvia Magni-Manzoni 1 , Bianca<br />
Lattanzi 4 , Roberta Galasso 4 and Alberto Martini 3 , 1 IRCCS<br />
Fondazione Policlinico San Matteo, Pavia, Italy, 2 IRCCS G. Gaslini<br />
and Università di Genova, Genova, Italy, 3 IRCCS G. Gaslini and<br />
Università di Genova, Genova, Italy, 4 IRCCS G. Gaslini, Genova,<br />
Italy, 5 Universidade Federal do Rio de Janeiro, Rio de Janeiro,<br />
Brazil.<br />
211. Are They Ready for Adult Care? An Assessment <strong>of</strong> Variables<br />
Affecting Patient Autonomy When Transitioning from<br />
Pediatric to Adult <strong>Rheumatology</strong>. Sharon E. Banks 3 , Catherine<br />
A. Bingham 1 and Brandt P. Groh 2 , 1 Hershey Medical Center,<br />
Zionsville, PA, 2 Hershey Medical Center, Hershey, PA, 3 Hershey<br />
Medical Center.<br />
212. Assessment <strong>of</strong> Activity in Children with Enthesitis Related<br />
Arthritis Using Bath Ankylosing Spondylitis Disease Activity<br />
Index (BASDAI). Marìa M. Katsicas 2 and Ricardo A. G. Russo 1 ,<br />
1<br />
Hospital de Pediatrìa Pr<strong>of</strong> Dr JP Garrahan, Buenos Aires,<br />
Argentina, 2 Hospital de Pediatrìa Pr<strong>of</strong> Dr JP Garrahan.<br />
213. Benefit <strong>of</strong> Intra-Articular Corticosteroid Injections by Oral<br />
and Maxill<strong>of</strong>acial Surgery Treating Temporomandibular Joint<br />
Arthritis in Children with Juvenile Idiopathic Arthritis. Tyler<br />
Sharpe 2 , Jennifer Good 2 , Timothy Beukelman 3 , Peter Waite 2 and<br />
Randy Q. Cron 1 , 1 Children’s Hospital <strong>of</strong> Alabama, Birmingham,<br />
AL, 2 Univ <strong>of</strong> Alabama-Birmingham, 3 University <strong>of</strong> Alabama-<br />
Birmingham, Birmingham, AL.<br />
214. Cancer Risk in Juvenile Idiopathic Arthritis. Sasha R. Bernatsky 1 ,<br />
Ann E. Clarke 5 , Kiem G. Oen 9 , Ciaran M. Duffy 4 , Alan M.<br />
Rosenberg 8 , Jeremy Labrecque 2 , Elizabeth M. Turnbull 3 ,<br />
Jennifer L. F. Lee 7 and Rosalind Ramsey-Goldman 6 , 1 McGill<br />
UHC/RVH, Montreal, QC, Canada, 2 McGill University, Canada,<br />
3<br />
McGill University Health Ctr, Montreal, QC, Canada, 4 Montreal<br />
Childrens Hospital, Montreal, QC, Canada, 5 Montreal General<br />
Hospital, Montreal, QC, Canada, 6 Northwestern University,<br />
Chicago, IL, 7 RI McGill Univ Health Ctr, Montreal, QC, Canada,<br />
8<br />
Royal Univ Hosp, Saskatoon, SK, Canada, 9 University <strong>of</strong><br />
Manitoba, Winnipeg, MB, Canada.<br />
215. Childhood Idiopathic Chondrolysis: A Form <strong>of</strong> Monoarthritis?<br />
Rafka Chaiban 1 and Robert P. Sundel 2 , 1 Children’s Hospital<br />
Boston, Boston, MA, 2 Childrens Hosp Medical Center, Boston,<br />
MA.<br />
216. Clinical Outcomes after Withdrawal <strong>of</strong> Anti-Tumor Necrosis<br />
Factor-Alpha Therapy in Juvenile Idiopathic Arthritis: A<br />
Twelve-Year Experience. Kevin W. Baszis 2 , Dana Toib 2 , Richard<br />
Brasington 1 , Allison King 3 , Jingnan Mao 3 , Andrew J. White 2 , Jane<br />
Garbutt 3 and Anthony R. French 2 , 1 Washington Univ Schl <strong>of</strong><br />
Med, St Louis, MO, 2 Washington University School <strong>of</strong> Medicine,<br />
Department <strong>of</strong> Pediatrics, St Louis, MO, 3 Washington University<br />
School <strong>of</strong> Medicine, Department <strong>of</strong> Pediatrics.<br />
217. Contribution <strong>of</strong> TNFalpha–308 and T676G TNF-RII<br />
Polymorphism on Response to Etanercept and Posibility To<br />
Discontinue Treatment. Jelena Vojinovic 1 , Gordana Susic 3 ,<br />
Jelena Basic 2 , Dragana Lazarevic 1 and Nemanja Damjanov 3 ,<br />
1<br />
Dept Ped <strong>Rheumatology</strong>, University Clinic Center Nis, Nis,<br />
Serbia, 2 Institute <strong>of</strong> Biochemestry Faculty <strong>of</strong> Medicine Nis, Nis,<br />
Serbia, 3 Institute <strong>of</strong> <strong>Rheumatology</strong> Belgrade, Belgrade, Serbia.<br />
2010 Program Book 161
ACR Poster Session A<br />
162<br />
218. Effectiveness <strong>of</strong> Dexamethasone Iontophoresis in<br />
Temporomandibular Joint (TMJ)-Arthritis in Juvenile Idiopathic<br />
Arthritis (JIA). Rina Mina 3 , Paula G. Melson 3 , Stephanie Powell 2 ,<br />
Claas H. Hinze 1 , Joshua Pendl 2 , Thomas B. Graham 5 and Hermine<br />
I. Brunner 4 , 1 Children’s National Medical Center, Rockville, MD,<br />
2<br />
Cincinnati Children’s Hosp Medical Ctr, 3 Cincinnati Children’s<br />
Hospital Medical Ctr, Cincinnati, OH, 4 Cincinnati Children’s Med<br />
Ctr, Cincinnati, OH, 5 Vanderbilt Children’s Hospital, Nashville,<br />
TN.<br />
219. Effectiveness <strong>of</strong> Etanercept in Juvenile Psoriatic Arthritis<br />
and in Children with Enthesitis Related Arthritis. Marieke H.<br />
Otten 3 , Femke H. M. Prince 4 , Marinka Twilt 7 , Nico M. Wulffraat 12 ,<br />
Rebecca ten Cate 7 , Esther P. A. H. Hoppenreijs 9 , Yvonne<br />
Koopman-Keemink 6 , Simone L. Gorter 10 , Wineke Armbrust 11 ,<br />
Koert M. Dolman 8 , Joost F. Swart 13 , Arnold P. Oranje 4 , Flora<br />
B. de Waard-van der Spek 2 , Marion A. J. van Rossum 1 and<br />
Lisette W. A. van Suijlekom-Smit 5 , 1 Academic Medical Centre<br />
Emma Children’s Hospital and Jan van Breemen Institute<br />
Amsterdam, 2 Erasmus MC Rotterdam, 3 Erasmus MC Sophia<br />
Children’s Hospital Rotterdam, Rotterdam, The Netherlands,<br />
4<br />
Erasmus MC Sophia Children’s Hospital Rotterdam, 5 Erasmus<br />
MC Sophia Children’s Hospital Rotterdam, The Netherlands,<br />
6<br />
Haga Ziekenhuis Juliana Children’s Hospital The Hague, 7 Leiden<br />
University Medical Centre, 8 St Lucas Andreas Hospital and<br />
Jan van Breemen Institute Amsterdam, 9 St Maartenskliniek<br />
Nijmegen, 10 University Hospital Maastricht, 11 University Medical<br />
Centre Groningen Beatrix Children’s Hospital, 12 Utrecht Medical<br />
Centre Wilhelmina Children’s Hospital, 13 VU Medical Centre and<br />
Jan van Breemen Institute Amsterdam.<br />
220. Efficacy and Safety <strong>of</strong> Oral and Parenteral Methotrexate<br />
Therapy in Children with Juvenile Idiopathic Arthritis. Gerd<br />
Horneff 2 , Gerd Ganser, Ivan Foeldvari 1 , Andreas Urban and<br />
Ariane Klein, 1 Hamburg, Germany, 2 Asklepios Clinic Sankt<br />
Augustin, Germany.<br />
221. Electronic Medical Record (EMR) Entries Can Provide a Source<br />
for Quality Improvement Projects for Juvenile Idiopathic<br />
Arthritis (JIA): Results <strong>of</strong> a Pilot Study. Michael L. Miller 2 , Jason<br />
Ruprecht 1 , George Lales, Sean McKenna and Frank Dupont,<br />
1<br />
Chicago, IL, 2 Childrens Memorial Hospital, Chicago, IL.<br />
222. Evaluation <strong>of</strong> the Role <strong>of</strong> Bone Mass Determinants in<br />
the Prediction <strong>of</strong> Bone Strength in Patients with Juvenile<br />
Idiopathic Arthritis (JIA): Bone Status Assessment Using<br />
pQCT, DXA and QUS. Fernanda Falcini 1 , Loredana Cavalli 2 ,<br />
Laura Masi 2 , Serena Capannini 1 , Giovanni D’Elia 4 , Valentina<br />
Denaro 1 , Marco Matucci Cerinic 1 , Stefano Stagi 3 and Maria Luisa<br />
Brandi 2 , 1 Department <strong>of</strong> BioMedicine, Section <strong>of</strong> <strong>Rheumatology</strong>,<br />
Transition Clinic, Florence, Italy, 2 Department <strong>of</strong> Internal<br />
Medicine, Endocrinology Unit, University <strong>of</strong> Florence, Florence,<br />
Italy, 3 Pediatric Unit, Villamarina Hospital, Piombino, Livorno,<br />
Italy, 4 Radiology Unit, AOC Careggi, Florence, Italy.<br />
223. Gut Inflammation in Pediatric Spondyloarthritis. Matthew<br />
Stoll 2 , Marilynn G. Punaro 3 and Molly Dempsey-Robertson 1 ,<br />
1<br />
Texas Scottish Rite Hospital for Children, 2 UT Southwestern<br />
Med Ctr, Dallas, TX, 3 UT Southwestern Medical Ctr, Dallas, TX.<br />
224. Immunogenicity and Short Term Safety <strong>of</strong> Pandemic Influenza<br />
Vaccine (Anti-H1n1) in Patients with Juvenile Idiopathic<br />
Arthritis. Nadia E. Aikawa 3 , Lucia M. A. Campos 5 , Clovis A. Silva 5 ,<br />
Vanessa R. Guissa 5 , Adriana M. Sallum 5 , Adriana A. Jesus 5 , Julio<br />
B. Moraes 4 , Cleonice Bueno 4 , Maria C. S. T. Timenetsky 1 , Alex R.<br />
Precioso 2 and Claudia Goldenstein-Schainberg 4 , 1 Adolpho Lutz<br />
Institute, University <strong>of</strong> Sao Paulo, 2 Butantan Institute, 3 Division<br />
<strong>of</strong> <strong>Rheumatology</strong>, Pediatric Reumatology Unit, Universidade<br />
de Sao Paulo, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Universidade de Sao<br />
Paulo, 5 Pediatric Reumatology Unit, Universidade de Sao Paulo.<br />
2010 Program Book<br />
225. Intra-rater Reliability <strong>of</strong> the Bath Ankylosing Spondylitis<br />
Disease Activity Index (BASDAI) and the Bath Ankylosing<br />
Spondylitis Functional Index (BASFI) in Children with<br />
Spondyloarthritis. Michelle Batthish 2 , Alisa Rachlis, Bertha<br />
Wong, Samantha Stevens, Michelle Anderson, Brian M.<br />
Feldman 1 , Ronald M. Laxer 1 , Joanne Marcuz, Margaret Reaume,<br />
Lynn Spiegel, Kristi Whitney-Mahoney and Shirley M. L. Tse 1 ,<br />
1<br />
Toronto, ON, Canada, 2 The Hospital for Sick Children, The<br />
University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />
226. Juvenile Idiopathic Arthritis (JIA) Classification: An Audit <strong>of</strong><br />
a Tertiary Paediatric <strong>Rheumatology</strong> Service’s Adherence to<br />
ILAR (Edmonton 2001) Classification Criteria. Angela J. Cox 2 ,<br />
Sern Chin Lim 1 , Roger C. Allen 3 , Jonathan D. Akikusa 1 and<br />
Jane Munro 1 , 1 Royal Children’s Hospital, Melbourne, Victoria,<br />
Australia, 2 Royal Children’s Hospital, Melbourne, Australia,<br />
3<br />
Royal Childrens Hospital, Melbourne, Australia.<br />
227. Long-Term Outcome <strong>of</strong> Patients with Juvenile Idiopathic<br />
Arthritis Treated with Etanercept – Results <strong>of</strong> the Biologic<br />
Register JuMBO. Kirsten Minden 3 , Martina Niewerth 4 , Angela<br />
E. Zink 2 , Eva Seipelt 6 , Ivan Foeldvari 5 , Hermann Girschick 7 and<br />
Gerd Horneff 1 , 1 Asklepios Kinderklinik St. Augustin GmbH,<br />
2<br />
German Arthritis Res Centre, Berlin, Germany, 3 German<br />
Rheumatism Research Center Berlin, a Leibnitz Institute,<br />
Berlin, Germany, 4 German Rheumatism Research Center Berlin,<br />
a Leibnitz Institute, 5 Hamburger Zentrum für Kinder- und<br />
Jugendrheumatologie am Klinikum Eilbek, Hamburg, Germany,<br />
6<br />
Immanuel Krankenhaus Berlin-Buch, Germany, 7 Scientific<br />
Advisory Board.<br />
228. Magnetic Resonance Imaging Findings <strong>of</strong> Temporomandibular<br />
Joint in Patients with Active and Inactive Juvenile Idiopathic<br />
Arthritis. Liete Zwir, Soraia Souza, Maria Teresa Terreri, Antônio<br />
Sérgio Guimarães, Artur Fernandes and Maria Odete Hilário,<br />
UNIFESP.<br />
229. Methotrexate and Leflunomide Combination Therapy Is a Safe<br />
and Effective Alternative to Methotrexate and Etanercept in<br />
JIA. Arturo Borzutzky 1 , Tamy Lagunas 2 , David Zurakowski 2 and<br />
Robert P. Sundel 3 , 1 Children’s Hospital Boston, Boston, MA,<br />
2<br />
Children’s Hospital Boston, 3 Childrens Hosp Medical Center,<br />
Boston, MA.<br />
230. Methotrexate Gives Protection Against the New Onset <strong>of</strong><br />
Uveitis in Combination with Etanercept. Data from the<br />
German Etanercept Registry. Ivan Foeldvari 1 , Nina Thome 2<br />
and Gerd Horneff 2 , 1 Hamburger Zentrum Fuer Kinder- und<br />
Jugendrheumatologie, Hamburg, Germany, 2 Kinder- und<br />
Jugendrheumatologie Asklepios Clinics, Sankt Augustin, Sant<br />
Augustin, Germany.<br />
231. Obesity and Disease Activity in Juvenile Idiopathic Arthritis.<br />
Christina F. Pelajo 1 , Jorge M. Lopez-Benitez 2 and Laurie C.<br />
Miller 2 , 1 Floating Hospital for Children at Tufts Medical Center,<br />
Boston, MA, 2 Floating Hospital for Children at Tufts Medical<br />
Center.<br />
232. Preliminary Definition <strong>of</strong> Remission and Minimal Disease<br />
Activity Cut-Points for the Juvenile Arthritis Disease Activity<br />
Score (JADAS). Alessandro Consolaro 3 , Giovanni Filocamo 4 ,<br />
Bianca Lattanzi 3 , Giulia C. Varnier 3 , Angela Pistorio 3 , Nicolino<br />
Ruperto 3 , Alberto Martini 2 and Angelo Ravelli 1 , 1 IRCCS G. Gaslini<br />
and Università di Genova, Genova, Italy, 2 IRCCS G. Gaslini and<br />
Università di Genova, Genova, Italy, 3 IRCCS G. Gaslini, Genova,<br />
Italy, 4 Policlinico Sant’Orsola, Bologna, Italy.
ACR Poster Session A<br />
233. Prevalence <strong>of</strong> Enthesitis in Pediatric Patients with Enthesitis-<br />
Related Arthritis. Pamela Weiss 2 , Andrew J. Klink 4 , Edward<br />
M. Behrens 1 , David D. Sherry 5 , Terri H. Finkel 3 , Mark Ramos 4 ,<br />
Robert Grundmeier 4 , Ron Keren 4 and Chris Feudtner 4 ,<br />
1<br />
Childrens Hospital <strong>of</strong> Phil, Philadelphia, PA, 2 The Children’s<br />
Hosp <strong>of</strong> Philadelphia, Philadelphia, PA, 3 The Children’s Hospital<br />
<strong>of</strong> Philadelphia, Philadelphia, PA, 4 The Children’s Hospital<br />
<strong>of</strong> Philadelphia, 5 The Children’s Hospital <strong>of</strong> Philadelphia,<br />
Philadelphia, PA.<br />
234. Prospective Study <strong>of</strong> Infliximab for Treatment <strong>of</strong> Pediatric<br />
Uveitis. Egla C. Rabinovich 4 , Janet Wootton 4 , Lawrence S.<br />
Zemel 3 , Lisa F. Imundo 2 , Jennifer E. Weiss 5 , Leslie S. Abramson 7 ,<br />
Mark F. Hoeltzel 1 , Deborah M. Levy 6 and David Wallace 4 ,<br />
1<br />
Children’s Mercy Hospital, Kansas City, MO, 2 Childrens Hospital<br />
<strong>of</strong> NY, New York, NY, 3 Connecticut Childrens Med Ctr, Hartford,<br />
CT, 4 Duke University Medical Center, Durham, NC, 5 Hackensack<br />
Univ Med Ctr, Hackensack, NJ, 6 The Hospital for Sick Children,<br />
Toronto, ON, Canada, 7 University <strong>of</strong> Vermont, Morrisville, VT.<br />
235. Safety and Efficacy <strong>of</strong> H1N1 Influenza Vaccination in Children<br />
with Chronic Inflammatory Rheumatic Diseases. Catherine<br />
F. Cortot 1 and Robert P. Sundel 2 , 1 Children’s Hospital Boston,<br />
Brookline, MA, 2 Childrens Hosp Medical Center, Boston, MA.<br />
236. Status <strong>of</strong> Vaccination Coverage in Children with Juvenile<br />
Idiopathic Arthritis (JIA) Followed at a Pediatric Tertiary-Care<br />
Center. Marie-Paule Morin 1 , Élise Fortin 3 , Caroline Quach 3 and<br />
Gaëlle Chédeville 2 , 1 The Montreal Children’s Hospital, Montreal,<br />
QC, Canada, 2 The Montreal Children’s Hospital, Montréal, QC,<br />
Canada, 3 The Montreal Children’s Hospital.<br />
237. The Clinical Feature <strong>of</strong> 2009-2010 Influenza Virus Infection<br />
during Tocilizumab Treatment for Systemic Onset Juvenile<br />
Idiopathic Arthritis. Toru Uchimura 1 , Tomoyuki Imagawa 1 ,<br />
Takuma Hara 1 , Masako Kikuchi 1 , Ryoki Hara 2 , Takako Miyamae 1 ,<br />
Masaaki Mori 1 , Akiyoshi Nariai 3 , Toshihiro Mitsuda 1 and<br />
Shumpei Yokota 1 , 1 Department <strong>of</strong> Pediatrics Yokohama City<br />
University, Yokohama, Japan, 2 Department <strong>of</strong> Pediatrics<br />
Yokohama City University, 3 Department <strong>of</strong> Pediatrics Yokohama<br />
Minami Kyosai Hospital, Yokohama, Japan.<br />
238. The Financial Burden <strong>of</strong> Juvenile Idiopathic Arthritis. Andrea<br />
Ens 2 , Bianca A. Lang 1 , Suzanne E. Ramsey 1 , Elizabeth Stringer 2<br />
and Adam M. Huber 1 , 1 IWK Health Ctr, Halifax, NS, Canada, 2 IWK<br />
Health Ctr.<br />
239. Usage <strong>of</strong> TNFα Inhibitors for the Treatment <strong>of</strong> Juvenile<br />
Idiopathic Arthritis: Data from a National U.S. Administrative<br />
Claims Database. Timothy Beukelman 3 , Fenglong Xie 1 and<br />
Jeffrey R. Curtis 2 , 1 Univ <strong>of</strong> Alabama at Birmingham, 2 University<br />
<strong>of</strong> Alabama - Brimingham, Birmingham, AL, 3 University <strong>of</strong><br />
Alabama-Birmingham, Birmingham, AL.<br />
240. Use <strong>of</strong> Abatacept for Childhood Refractory Vision-Threatening<br />
Uveitis. Gabriele Simonini 2 , De Libero Cinzia 1 , Roberto Caputo 1 ,<br />
Teresa Giani 2 , Laura Pascoli 2 , Ilaria Pagnini 2 and Rolando Cimaz 2 ,<br />
1<br />
Opthalmology Unit, A Meyer Children’s Hospital, Florence,<br />
Italy, 2 <strong>Rheumatology</strong> Unit Dpt <strong>of</strong> Pediatrics, A.Meyer Children’s<br />
Hospital-University <strong>of</strong> Florence, Italy.<br />
241. Use <strong>of</strong> TNFα Antagonists in the Treatment <strong>of</strong> Chronic Non-<br />
Bacterial Osteomyelitis (CNO). Sara Stern 2 , Katherine Marzan 2 ,<br />
Arturo Borzutzky 1 , Evan Steinberg 3 and Andreas Reiff 2 , 1 Boston<br />
Children’s Hospital, Boston, MA, 2 Childrens Hospital Los<br />
Angeles, Los Angeles, CA, 3 Kaiser-Permanente Sunset Hospital,<br />
Los Angeles, CA.<br />
Pediatric <strong>Rheumatology</strong> - Pathogenesis and Genetics: Bench to<br />
Bedside - The Science <strong>of</strong> Pediatric <strong>Rheumatology</strong><br />
242. A Pilot Study <strong>of</strong> Gene Expression (GE) Pr<strong>of</strong>iles in Juvenile<br />
Dermatomyositis (JDM) Responders and Non-Responders:<br />
Diagnostic and Follow-Up Muscle Biopsy (MBx) Data. Lauren<br />
M. Pachman 1 , Yi-Wen Chen 2 , Peter Hendrickson 1 , Sheela<br />
Shrestha 1 , Gabrielle Morgan 1 and Simone Sredni 1 , 1 Children’s<br />
Memorial Research Center, Chicago, IL, 2 Children’s National<br />
Medical Center.<br />
243. A Whole Blood Gene Expression Pr<strong>of</strong>ile <strong>of</strong> Untreated Children<br />
with Polyarticular JIA Enrolled in the TREAT Trial. Mark Barton<br />
Frank 3 , Kaiyu Jiang 2 , Yanmin Chen 2 , Melissa Bebak 3 , Carol A.<br />
Wallace 4 , Susan Thompson 1 and James N. Jarvis 2 , 1 Cincinnati<br />
Children’s Hospital Medical Center, 2 Dept. <strong>of</strong> Pediatrics, U <strong>of</strong> OK<br />
<strong>College</strong> <strong>of</strong> Medicine, 3 Oklahoma Medical Research Foundation,<br />
4<br />
Seattle Children’s Medical Center.<br />
244. Angiopoietin-Like 4 Is Expressed in Human Synovial Fibroblasts<br />
and Expression Is Increased in Response to TGFβ. Ndate Fall 2 ,<br />
Malinda Frederick 2 , Alexei A. Grom 1 and Sherry Thornton 3 ,<br />
1<br />
Childrens Hospital Medical Center, Cincinnati, OH, 2 Childrens<br />
Hosp Med Ctr, 3 Childrens Hospital Medical Center, Cincinnati,<br />
OH.<br />
245. Anti-CCP Antibodies Identify a Subset <strong>of</strong> RF-Negative Juvenile<br />
Idiopathic Arthritis. Anne E. Tebo 2 , Troy D. Jaskowski 1 , K. Wayne<br />
Davis 1 , April Vigus 6 , Bronte Clifford 4 , Andrew S. Zeft 5 , Bernadette<br />
McNally 5 , Harry R. Hill 2 , John F. Bohnsack 5 and Sampath<br />
Prahalad 3 , 1 ARUP Laboratories, 2 ARUP Laboratories, Univ Utah,<br />
3<br />
Emory Children’s Center, Atlanta, GA, 4 Nationwide Children’s<br />
Hospital, 5 University <strong>of</strong> Utah, Salt Lake City, UT, 6 University <strong>of</strong><br />
Utah.<br />
246. CD4+CD161+ Cells with Th1 or Th17/Th1 Pr<strong>of</strong>ile Accumulate in<br />
the Synovial Fluid <strong>of</strong> Patients with Juvenile Diopathic Arthritis<br />
and Correlate with Inflammation Parameters. Rolando Cimaz 1 ,<br />
L. Cosmi 2 , L. Maggi 2 , V. Santarlasci 2 , M. Capone 2 , F. Borriello 3 ,<br />
F. Frosali 2 , V. Querci 2 , G. Simonini 2 , G. Barra 3 , F. Liotta 2 , R. De<br />
Palma 3 , E. Maggi 2 , S. Romagnani 2 and F. Annunziato 2 , 1 University<br />
<strong>of</strong> Florence, Firenze, Italy, 2 University <strong>of</strong> Florence, 3 University <strong>of</strong><br />
Naples.<br />
247. Characterization <strong>of</strong> Granulocyte Transcriptome in Polyarticular<br />
Juvenile Idiopathic Arthritis (JIA). Mark Barton Frank 3 ,<br />
Kaiyu Jiang 1 , Yanmin Chen 1 , Jeanette Osban 3 , Pascal Gellert 2<br />
and James N. Jarvis 1 , 1 Dept <strong>of</strong> Pediatrics, U <strong>of</strong> OK <strong>College</strong> <strong>of</strong><br />
Medicine, 2 Max Planck-Institute for Heart and Lung Research,<br />
3<br />
Oklahoma Medical Research Foundation.<br />
248. CLARITY: ChiLdhood Arthritis Risk Factor Identification sTudY.<br />
Justine Ellis 1 , Jane Munro 2 , Anne-Louise Ponsonby 1 , Angela<br />
Pezic 1 , Betty Lim 1 , Raul Chavez 1 , William Siero 1 , Jonathan<br />
Akikusa 2 and Roger Allen 2 , 1 Murdoch Childrens Research<br />
Institute, Melbourne, Parkville, Victoria, Australia, 2 Royal<br />
Children’s Hospital, Melbourne, Parkville, Victoria, Australia.<br />
249. Costimulation Mediated Rescue <strong>of</strong> Superantigen Stimulated T<br />
Cells in Kawasaki Disease. Aaron Wong 2 and Rae S. M. Yeung 1 ,<br />
1<br />
Hospital for Sick Children, Toronto, ON, Canada, 2 The Hospital<br />
for Sick Children, Toronto, ON, Canada.<br />
250. Detection <strong>of</strong> Potentially Disease Associated Copy Number<br />
Variants in Children with Rheumatoid Arthritis. Sampath<br />
Prahalad 1 , Jennifer Gladys Mulle 2 , Anne Dodd 3 , Jennifer<br />
Prozonic 3 , Milton Brown 3 , Andrew S. Zeft 4 , John F. Bohnsack 4 ,<br />
Stephen T. Warren 3 , M. Katharine Rudd 3 and Christa L. Martin 3 ,<br />
1<br />
Emory Children’s Center, Atlanta, GA, 2 Emory University,<br />
Atlanta, GA, 3 Emory University, 4 University <strong>of</strong> Utah, Salt Lake<br />
City, UT.<br />
2010 Program Book 163
ACR Poster Session A<br />
251. Differences in Transcription Pr<strong>of</strong>iles in Juvenile Idiopathic<br />
Arthritis (JIA) Patients Who Achieved Remission Using<br />
Different Therapies. Mark Barton Frank 2 , Kaiyu Jiang 1 , Yanmin<br />
Chen 1 and James N. Jarvis 1 , 1 Dept <strong>of</strong> Pediatrics, U <strong>of</strong> OK <strong>College</strong><br />
<strong>of</strong> Med, 2 Oklahoma Medical Research Foundation.<br />
252. Disease Activity, Proteinuria, and Vitamin D Status in<br />
Children with Systemic Lupus Erythematosus and Juvenile<br />
Dermatomyositis. Angela B. Robinson 1 , Myrtle Thierry-Palmer 2 ,<br />
Keisha L. Gibson 3 and Egla C. Rabinovich 1 , 1 Duke University<br />
Medical Center, Durham, NC, 2 Morehouse School <strong>of</strong> Medicine,<br />
3<br />
University <strong>of</strong> North Carolina at Chapel Hill.<br />
253. Effect <strong>of</strong> Methotrexate and Genotype on RBC Folate<br />
Concentrations and Polyglutamate Distribution in JIA. Mara L.<br />
Becker 1 , Leon van Haandel 5 , Roger Gaedigk 3 , Bradley Thomas 3 ,<br />
Mark F. Hoeltzel 2 , Andrew Lasky 4 , John Stobaugh 5 and J. Steven<br />
Leeder 3 , 1 Children’s Mercy Hospital, Kansas City, MO, 2 Children’s<br />
Mercy Hospitals and Clinics, Kansas City, MO, 3 Children’s Mercy<br />
Hospitals and Clinics, 4 Childrens Mercy Hospitals and Clinics,<br />
Kansas City, MO, 5 University <strong>of</strong> Kansas.<br />
254. Genetic Variation Associated with Methotrexate Response in<br />
Juvenile Idiopathic Arthritis: Role <strong>of</strong> the Mitochondrial and<br />
Purine Synthesis Pathways. Mara L. Becker 1 , Roger Gaedigk 3 ,<br />
Bradley Thomas 3 , Andrew Lasky 4 , Mark F. Hoeltzel 2 , Hongying<br />
Dai 3 and J. Steven Leeder 3 , 1 Children’s Mercy Hospital, Kansas<br />
City, MO, 2 Children’s Mercy Hospitals and Clinics, Kansas City,<br />
MO, 3 Children’s Mercy Hospitals and Clinics, 4 Childrens Mercy<br />
Hospitals and Clinics, Kansas City, MO.<br />
255. Hierarchy <strong>of</strong> Risk Conferred by the HLA-DR Shared Epitope in<br />
Childhood Onset Rheumatoid Arthritis. Sampath Prahalad 3 ,<br />
Susan D. Thompson 2 , Karen Conneely 6 , Yunxuan Jiang 6 , Jennifer<br />
Prozonic 6 , Milton Brown 6 , Sheila Angeles-Han 5 , Larry B. Vogler 7 ,<br />
Christine W. Kennedy 4 , Carol A. Wallace 14 , Carol Wise 12 ,<br />
Marilynn G. Punaro 11 , Ann M. Reed 8 , Jane L. Park 10 , Elizabeth<br />
D. Mellins 9 , Andrew S. Zeft 13 , John F. Bohnsack 13 and David N.<br />
Glass 1 , 1 Childrens Hospital Med Ctr, Cincinnati, OH, 2 Cincinnati<br />
Childrens Hospital Med Ctr, Cincinnati, OH, 3 Emory Children’s<br />
Center, Atlanta, GA, 4 Emory Children’s Center, Decatur, GA,<br />
5<br />
Emory University, Atlanta, GA, 6 Emory University, 7 Emory<br />
University School <strong>of</strong> Medicine, Atlanta, GA, 8 Mayo Clinic,<br />
Rochester, MN, 9 Stanford University Med Ctr, Stanford, CA,<br />
10<br />
Stanford University Med Ctr, San Jose, CA, 11 Texas Scottish Rite<br />
Hospital for Children, Dallas, TX, 12 Texas Scottish Rite Hospital<br />
for Children, 13 University <strong>of</strong> Utah, Salt Lake City, UT, 14 University<br />
<strong>of</strong> Washington and Seattle Childerns’s Hospital, Seattle, WA.<br />
256. HLA Associations in Oligo- and Polyarticular RF (-) Juvenile<br />
Idiopathic Arthritis-Associated Uveitis. Sheila Angeles-<br />
Han 5 , Andrew S. Zeft 8 , John F. Bohnsack 8 , Bronte Clifford 7 ,<br />
Lori Ponder 1 , Jennifer Prozonic 3 , Milton Brown 3 , Christine W.<br />
Kennedy 4 , Larry B. Vogler 6 and Sampath Prahalad 2 , 1 Children’s<br />
Healthcare <strong>of</strong> Atlanta, 2 Emory Children’s Center, Atlanta, GA,<br />
3<br />
Emory Children’s Center, 4 Emory Children’s Center, Decatur,<br />
GA, 5 Emory University, Atlanta, GA, 6 Emory University School <strong>of</strong><br />
Medicine, Atlanta, GA, 7 Nationwide Children’s Hospital Research<br />
Institute, 8 University <strong>of</strong> Utah, Salt Lake City, UT.<br />
257. Hyaluronidase Mutation (HYAL1) Presenting as JIA, a<br />
Description <strong>of</strong> an Extended Family Provides New Information<br />
and Characterizes This Genetic Disorder That Causes<br />
Widespread Synovitis. Lisa F. Imundo 2 and Wendy Chung 1 ,<br />
1<br />
Columbia University, NY, NY, 2 Columbia University, New York,<br />
NY.<br />
258. Leukocyte Expression <strong>of</strong> Transcription Factor HNF4a, a<br />
Regulator <strong>of</strong> Gene Expression in Polyarticular Juvenile<br />
Idiopathic Arthritis. Kaiyu Jiang 1 , Yanmin Chen 1 , Mark Barton<br />
Frank 2 and James N. Jarvis 1 , 1 Dept <strong>of</strong> Pediatrics, U <strong>of</strong> OK <strong>College</strong><br />
<strong>of</strong> Medicine, 2 Oklahoma Medical Research Foundation.<br />
259. Low Serum Levels <strong>of</strong> NT-proCNP in Children with Poly-Articular<br />
Onset Juvenile Rheumatoid Arthritis. Fozia Khan 1 , Ann<br />
Pokelsek 2 , Lori Galla 2 , Mary Toth 2 and Hulya Bukulmez 3 , 1 Akron<br />
Children’s Hospital, NEOUCOM, Akron, OH and MetroHealth<br />
Medical Center, CWRU, Cleveland, OH, 2 Akron Children’s<br />
Hospital, NEOUCOM, OH, 3 MetroHealth Medical Center, CWRU,<br />
Cleveland, OH.<br />
260. Novel Founder Mutation in IL1RN Accounts for Deficiency<br />
<strong>of</strong> the IL-1 Receptor (DIRA) in Brazil. Adriana Almeida Jesus 4 ,<br />
Clovis Artur Almeida Silva 4 , Peter W. Kim 2 , Tuyet H. Pham 2 ,<br />
Débora Romeo Bertola 4 , Magda Carneiro-Sampaio 4 , Barbara<br />
Yang 2 , Deborah Stone 2 , Dawn Chapelle 2 , Nicole Plass 2 , Massimo<br />
Gadina 2 , John Sims 1 , Hatem El-Shanti 3 and Raphaela Goldbach-<br />
Mansky 2 , 1 Amgen Inc, Thousand Oaks, CA, 2 NIAMS/NIH,<br />
Bethesda, MD, 3 Shafallah Medical Genetics Center, Doha, Qatar,<br />
4<br />
Universidade de São Paulo, Sao Paulo, Brazil.<br />
261. Novel Mutations <strong>of</strong> Camptodactyly Arthropathy Coxa Vara<br />
Pericarditis (CACP) Syndrome: A Study on Ten Cases. Sara<br />
Ciullini Mannurita 7 , Marina Vignoli 7 , Lucia Bianchi 7 , Chiara<br />
Azzari 7 , Maurizio de Martino 7 , Angelo Ravelli 4 , Anuela Kondi 6 ,<br />
Valeria Gerloni 5 , Rebecca ten Kate 2 , Luciana Breda 3 , Eleonora<br />
Gambineri 7 and Fernanda Falcini 1 , 1 Department <strong>of</strong> BioMedicine,<br />
Section <strong>of</strong> <strong>Rheumatology</strong>, Transition Clinic, University <strong>of</strong><br />
Florence, 2 Department <strong>of</strong> Pediatrics, Leiden University Medical<br />
Centre, The Netherlands, 3 Department <strong>of</strong> Pediatrics, University<br />
<strong>of</strong> Chieti, Chieti, Italy, 4 Istituto di Ricovero e Cura a Carattere<br />
Scientifico G. Gaslini and Università degli Studi di Genoa,<br />
5<br />
Istituto G. Pini, Milan, Italy, 6 Pediatric Department, University<br />
Hospital Centre, Tirana, Albania, 7 University <strong>of</strong> Florence,<br />
Department <strong>of</strong> Sciences for Woman and Child’s Health.<br />
262. Plasma Osteopontin as a Marker for Damage in Pediatric<br />
Systemic Lupus Erythematosus. Ornella J. Rullo 2 , Jennifer M.<br />
P. Woo 2 , Alice D. C. H<strong>of</strong>tman 1 , Timothy B. Niewold 5 , Angela<br />
Presson 4 , Deborah K. McCurdy 2 and Betty P. Tsao 3 , 1 CHOC-<br />
Children’s, Orange, CA, 2 Mattel Children’s UCLA, Los Angeles,<br />
CA, 3 UCLA School <strong>of</strong> Medicine, Los Angeles, CA, 4 UCLA School <strong>of</strong><br />
Public Health, 5 University <strong>of</strong> Chicago, Chicago, IL.<br />
263. Predominance <strong>of</strong> Complement Components C1q and C4 Bound<br />
to Circulating Immune Complexes (CICs) in Juvenile Idiopathic<br />
Arthritis (JIA): Support for Classical Pathway Activation.<br />
Brooke E. Gilliam 1 , Melinda R. Reed 2 , Anil K. Chauhan 1 , Amanda<br />
Dehlendorf 2 and Terry L. Moore 2 , 1 Saint Louis University, St.<br />
Louis, MO, 2 Saint Louis University, St Louis, MO.<br />
264. Rheumatoid Arthritis Susceptibility Loci; PTPRC, PTPN2,<br />
IKZF3, c5orf30, BLK and CD247 Are Also Associated with<br />
Juvenile Idiopathic Arthritis. Anne Hinks 1 , Steve Eyre 2 , Paul<br />
Martin 2 , Edward Flynn 2 , Jon Packham 3 , Anne Barton 2 , Jane<br />
Worthington 2 and Wendy Thomson 2 , 1 Arthritis Research UK<br />
Epidemiology Unit, University <strong>of</strong> Manchester, Manchester,<br />
United Kingdom, 2 Arthritis Research UK Epidemiology Unit,<br />
University <strong>of</strong> Manchester, 3 Haywood Hospital, University <strong>of</strong><br />
North Staffordshire.<br />
265. Role <strong>of</strong> IL-1b in the Development <strong>of</strong> Human TH17 Cells: Lesson<br />
from Patients Carrying NLPR3 Gene Mutations. Denise Lasigliè,<br />
Elisabetta Traggiai, Federica Penco, Silvia Federici, Andrea<br />
Accogli, Antonella Buoncompagni, Alberto Martini and Marco<br />
Gattorno, G. Gaslini Institute, Genoa, Italy.<br />
164<br />
2010 Program Book
ACR Poster Session A<br />
266. Subtype Specific Genetic Associations for Juvenile Idiopathic<br />
Arthritis (JIA): ERAP1 with the Enthesitis Related Arthritis<br />
Subtype and IL23R with Juvenile Psoriatic Arthritis. Anne<br />
Hinks 1 , Paul Martin 2 , Edward Flynn 2 , Steve Eyre 2 , Jon Packham 3 ,<br />
Anne Barton 2 , Jane Worthington 2 and Wendy Thomson 2 ,<br />
1<br />
Arthritis Research UK Epidemiology Unit, University <strong>of</strong><br />
Manchester, Manchester, United Kingdom, 2 Arthritis Research<br />
UK Epidemiology Unit, University <strong>of</strong> Manchester, 3 Haywood<br />
Hospital, University Hospital <strong>of</strong> North Staffordshire.<br />
267. The Role <strong>of</strong> Platelets and CD40L in the Pathogenesis <strong>of</strong><br />
Kawasaki Disease. Parnian Arjmand 2 and Rae S. M. Yeung 1 ,<br />
1<br />
Hospital for Sick Children, Toronto, ON, Canada, 2 University <strong>of</strong><br />
Toronto, The Hospital for Sick Children, Toronto, ON, Canada.<br />
268. Urinary Biomarkers To Distinguish Class IV vs Class V Lupus<br />
Nephritis. Hermine Brunner 1 , Michael Bennett 2 , Lindsey Romick-<br />
Rosendale 5 , Michiko Suzuki 3 , Shannen L. Nelson 2 , Joshua Pendl 3 ,<br />
Adnan Kiani 4 , Lena Das 3 , Michelle Petri 4 , Kenneth Greis 6 , Pavel<br />
Shiyanov 7 , Michael Kennedy 5 and Prasad Devarajan 3 , 1 Cincinnati<br />
Child Hosp Med Ctr, Cincinnati, OH, 2 Cincinnati Children’s Med<br />
Ctr, Cincinnati, OH, 3 Cincinnati Children’s Med Ctr, 4 John Hopkins<br />
Med Ctr, 5 Miami University, Oxford, 6 University <strong>of</strong> Cincinnati,<br />
7<br />
WPAFB, Dayton.<br />
Rheumatoid Arthritis - Animal Models: Cytokines, Novel Therapeutics<br />
and Mechanisms <strong>of</strong> Action<br />
269. AC430, a Potent JAK2 Inhibitor, Provides Protection in Multiple<br />
Inflammatory and Autoimmune Disease Models. Barbara<br />
Belli 1 , Daniel Brigham 2 , Alan Dao 2 , Ron Nepomuceno 2 , Eduardo<br />
Setti 2 , Gary Liu 2 , Michael Hadd 2 , Shripad Bhagwat 2 , Wendell<br />
Wierenga 2 , Mark W. Holladay 2 and Robert C. Armstrong 2 , 1 Ambit<br />
Biosciences, San Diego, CA, 2 Ambit Biosciences.<br />
270. Anti-CXCL5 Therapy Ameliorates IL-17 Induced Arthritis.<br />
Sarah R. Pickens 4 , Michael V. Volin 1 , Arthur M. Mandelin 2<br />
and Shiva Shahrara 3 , 1 Midwestern University, 2 Northwester<br />
University, Chicago, IL, 3 Northwestern Univ Feinberg, Chicago,<br />
IL, 4 Northwestern University.<br />
271. Beneficial Effects <strong>of</strong> Systemic IFNβ Are Mediated by IL-1Ra:<br />
Implications for Rheumatoid Arthritis. Mary Corr 4 , David L.<br />
Boyle 3 , Lisa Ronacher 4 , Brian R. Lew 4 , Lisa G. M. van Baarsen 2 ,<br />
Paul P. Tak 1 and Gary S. Firestein 4 , 1 Academic Med Ctr/Univ <strong>of</strong><br />
Amsterdam, Amsterdam, The Netherlands, 2 Academic Medical<br />
Center, Amsterdam, The Netherlands, 3 UCSD Schl <strong>of</strong> Medicine,<br />
La Jolla, CA, 4 UCSD School <strong>of</strong> Medicine, La Jolla, CA.<br />
272. Combined Depletion <strong>of</strong> Interleukin-1 and Interleukin-6 Does<br />
Not Exceed Single Depletion <strong>of</strong> Interleukin-1 in TNF-Mediated<br />
Arthritis. Silvia Hayer, Birgit Niederreiter, Josef Smolen and Kurt<br />
Redlich, Medical University <strong>of</strong> Vienna, Department <strong>of</strong> Internal<br />
Medicine III, Division <strong>of</strong> <strong>Rheumatology</strong>, Vienna, Austria.<br />
273. Efficacy <strong>of</strong> the Selective CSF1R (Fms) Inhibitor PLX5622 in<br />
Mouse Models <strong>of</strong> Rheumatoid Arthritis. Gaston Habets,<br />
Jiazhong Zhang, Betsy Burton, Chao Zhang, Prabha Ibrahim,<br />
Bernice Wong, Marika Nespi, Wayne Spevak, Ben Powell, Brian<br />
West, Paul Lin, Gideon Bollag and Peter Hirth, Plexxikon.<br />
274. HMPL-011, a Small Molecule Compound, Modulates Pro-<br />
Inflammatory Cytokine Production, in Part, Via Potentiating<br />
IL-10 Production. Weihua Gu 2 , Weigang He 2 , Yan Qiu 2 , Zhenhao<br />
Zhou 2 , Xiaomin Dai 2 , Wuzhong Shen 2 , Xiaoning Yang 2 , Linfang<br />
Wang 2 , Yuan Zhou 2 , Yu Cai 2 , Edwin Lee 2 , Wei Deng 2 , Weiguo<br />
Su 1 and Haoran Zhao 1 , 1 Hutchison MediPharma Ltd, Shanghai,<br />
China, 2 Hutchison MediPharma Ltd.<br />
275. IL-1 Driven IL-22 Expression by TH17 Cells Aggravates<br />
Experimental Arthritis. Renoud J. Marijnissen 3 , Marije I.<br />
Koenders 3 , Mark H. T. Stappers 4 , Leo A. B. Joosten 1 , Ruben<br />
L. Smeets 2 , Cheryl Nickerson-Nutter 5 , Annemieke M. H.<br />
Boots 2 and Wim B. van den Berg 3 , 1 Department <strong>of</strong> Internal<br />
Medicine, RUNMC, Nijmegen, The Netherlands, 2 Department<br />
<strong>of</strong> Pharmacology, MSD, Oss, The Netherlands, 3 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, RUNMC, Nijmegen, The Netherlands,<br />
4<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, RUNMC, The Netherlands,<br />
5<br />
Inflammation, Pfizer, Cambridge, MA.<br />
276. IL-27 Is Increased by IL-17 from Synovial Macrophage and<br />
Bone Marrow-Derived Dendritic Cells in Collagen-Induced<br />
Arthritis. Seunghoon Baek 5 , Juin Kim 4 , Huashu Jin 4 , Seonghu<br />
Park 5 , Youngeun Park 5 , Joungwook Lee 1 , MIRA Cho 6 , Geuntae<br />
Kim 3 , Junhee Lee 2 and Sungil Kim 5 , 1 Busan St Mary Hospital,<br />
Korea, Republic <strong>of</strong>, 2 Choonhae Hospital, Korea, Republic <strong>of</strong>,<br />
3<br />
Kosin University Medical School, Korea, Republic <strong>of</strong>, 4 Pusan<br />
National University Hospital Research Institutes, Korea, Republic<br />
<strong>of</strong>, 5 Pusan National University Medical School, Korea, Republic<br />
<strong>of</strong>, 6 Pusan National University Medical Shool, Korea, Republic <strong>of</strong>.<br />
277. IL-32 Aggravated Synovial Inflammation and Bone Destruction,<br />
and Increased Synovial NK Cells in Experimental Arthritis<br />
Models. Geun-Tae Kim 2 , Ju-In Kim 4 , Hua-Shu Jin 4 , Seong-Hu<br />
Park 3 , Young-Eun Park 3 , Seung-Hoon Baek 3 , Joung-Wook Lee 1<br />
and Sung-Il Kim 3 , 1 Department <strong>of</strong> Internal Medicine, Busan<br />
St. Mary’s Medical Center, 2 Department <strong>of</strong> Internal Medicine,<br />
Kosin University, <strong>College</strong> <strong>of</strong> Medicine, Busan, Korea, Republic <strong>of</strong>,<br />
3<br />
Department <strong>of</strong> Internal Medicine, Pusan National University,<br />
School <strong>of</strong> Medicine, 4 Research Institute, Pusan National<br />
University.<br />
278. IL-7 Correlates with Severity <strong>of</strong> Proteoglycan-Induced Arthritis,<br />
and Arthritis Severity Is Diminished by IL-7 Neutralization.<br />
Sarita A. Y. Hartgring 3 , Cynthia R. Willis 1 , Kim M. G. van der<br />
Wurff-Jacobs 3 , Femke Broere 2 , Johannes W. J. Bijlsma 3 , Floris<br />
P. J. G. Lafeber 3 and Joel A. G. van Roon 3 , 1 Inflammation<br />
Dept. Amgen Inc, Seattle WA, 2 Inst. Infectious Diseases &<br />
Immunology, UU, Utrecht, The Netherlands, 3 <strong>Rheumatology</strong> &<br />
Clinical Immunology, University Medical Center Utrecht, The<br />
Netherlands.<br />
279. Immunomodulatory Properties <strong>of</strong> Novel CRAC Channel<br />
Inhibitors Exhibit Promising Potential in Rheumatoid Arthritis.<br />
Kanthikiran V. S. Varanasi, Meyyappan Muthuppalaniappan,<br />
Gayatriswaroop Merikapudi, Sridhar Veeraraghavan, Kasi V.<br />
Routhu, Srikant Viswanadha and Swaroop Vakkalanka, Incozen<br />
Therapeutics Pvt. Ltd..<br />
280. Inhibition <strong>of</strong> c-Fos/AP-1 Suppresses Passive Anti-Collagen<br />
Antibody-Induced Arthritis in Mice. Masaaki Mikami 4 , Yukihiko<br />
Aikawa 5 , Akira Hashiramoto 3 , Mari Yamamoto 5 , Hidetoshi<br />
Murao 5 , Hisaaki Chaki 5 , Hirokazu Narita 5 , Shuichi Hirono 1<br />
and Shunichi Shiozawa 2 , 1 Department <strong>of</strong> Pharmaceutical<br />
Sciences, School <strong>of</strong> Pharmacy, Kitasato University, Tokyo, Japan,<br />
2<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, Kobe University Graduate School<br />
<strong>of</strong> Health Sciences and Medicine/ The Center for Rheumatic<br />
Diseases, Kobe University Hospital, Kobe, Japan, 3 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Kobe University Graduate School <strong>of</strong> Health<br />
Sciences and Medicine/ The Center for Rheumatic Diseases,<br />
Kobe University Hospital, Kobe, Japan, 4 Research Laboratories,<br />
Toyama Chemical Co., Ltd., Toyama, Japan, 5 Research<br />
Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan.<br />
2010 Program Book 165
ACR Poster Session A<br />
281. Innovative Treatment <strong>of</strong> Experimental Arthritis and Inhibition<br />
<strong>of</strong> Human Osteoclasts Differentiation by Dendrimers. Myriam<br />
Hayder 2 , Mary Poupot 1 , Jean-Pierre Majoral 4 , Cédric Olivier<br />
Turrin 4 , Anne-Marie Caminade 4 , Alain Cantagrel 3 , Jean-Jacques<br />
Fournié 1 , Rémy Poupot 1 and Jean-Luc Davignon 3 , 1 INSERM U563,<br />
CPTP, IFR150, Toulouse, France, 2 JE2510, IFR150, Paul Sabatier<br />
University, Toulouse, France, 3 JE2510, IFR150, Paul Sabatier<br />
University, University Hospital Purpan, Toulouse, France,<br />
4<br />
Laboratoire de Chimie de Coordination, CNRS, Toulouse,<br />
France.<br />
282. IRF-1 Reduces TNFα-Induced-IL-18 Bioactivity in Rheumatoid<br />
Arthritis Synovial Fibroblasts by Induction <strong>of</strong> IL-18BPa.<br />
Hubert Marotte 1 , Adam J. Pinney 2 , Tatiana Fedorora 2 , Nalin<br />
Lalwani 2 , Pei-Suen Tsou 2 , Bradley J. Rabquer 2 and Alisa E.<br />
Koch 3 , 1 University <strong>of</strong> Michigan Medical School, Ann Arbor,<br />
MI, 2 University <strong>of</strong> Michigan Medical School, 3 Veteran’s<br />
Administration and University <strong>of</strong> Michigan.<br />
283. Liposomal Targeting <strong>of</strong> Glucocorticoids to the Synovial Lining<br />
during Experimental Arthritis Inhibits M1 Macrophage<br />
Activation in Favour <strong>of</strong> M2 Differentiation. Wouter H<strong>of</strong>kens 2 ,<br />
Gert Storm 3 , Wim B. Van Den Berg 1 and Peter van Lent 2 ,<br />
1<br />
Radboud Univ Nijmegen Med Cntr, Nijmegen, The Netherlands,<br />
2<br />
Radboud University Nijmegen Medical Center, 3 Utrecht<br />
University.<br />
284. Nanoparticles <strong>of</strong> LDE: A Potential Delivery Route for MTX<br />
in Sinovial Tissue <strong>of</strong> Antigen-Induced Arthritis. Suzana B.<br />
V. Mello 2 , Eloisa D. O. Bonfá 3 , Claudete J. Valduga 1 , Adriana<br />
Bugaralli 1 , Elaine R. Tavarez 1 and Raul Maranhão 1 , 1 Heart<br />
Institute (InCor), Faculdade de Medicina da Uiversidade de<br />
São Paulo, 2 Reumatology Division, Faculdade de Medicina da<br />
Unversidade de São Paulo, São Paulo, Brazil, 3 <strong>Rheumatology</strong><br />
Division, Faculdade de Medicina da Universidade de São Paulo.<br />
285. Novel Small Molecule Aminopyridizines Inhibit Rat<br />
Collagen-Induced Arthritis and Suppress Proinflammatory<br />
Cytokine Pathways. Soo-In Choi 2 , Lori D. Klaman 3 , Bruce<br />
Connop 3 , Aleksandra Pastrak 3 and Ernest Brahn 1 , 1 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, UCLA School <strong>of</strong> Medicine, Los Angeles, CA,<br />
2<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, UCLA School <strong>of</strong> Medicine and<br />
VA Greater Los Angeles Healthcare System, Los Angeles, CA,<br />
3<br />
Transition Therapeutics.<br />
286. PCI-45292, a Novel Btk Inhibitor with Optimized<br />
Pharmaceutical Properties, Demonstrates Potent Activities in<br />
Mouse Models <strong>of</strong> Arthritis. Betty Y. Chang 2 , Patricia Thiemann 1 ,<br />
Nadia Moore 3 , Michelle Francesco 3 , Min Mei Huang 3 , Chitra<br />
Mani 3 , Purvi Jejurkar 3 , Danielle Tonev 3 , Wei Chen 3 , Joseph J.<br />
Buggy 3 and David J. Loury 3 , 1 Pharmacyclics, 2 Pharmacyclics,<br />
Research, Sunnyvale, CA, 3 Pharmacylics.<br />
287. Recognition <strong>of</strong> IL-23 Dependent and Independent Stages<br />
during Autoimmune Collagen-Induced Arthritis. Ferry<br />
Cornelissen 2 , Patrick Asmawidjaja 2 , Anne-Marie Mus 2 , Odilia<br />
Corneth 2 , Kristine Kikly 1 and Erik Lubberts 2 , 1 Eli Lilly, 2 Erasmus<br />
MC, University Medical Center.<br />
288. RO2492, a Phosphoinositide-3-Kinase d Inhibitor, Shows<br />
Inhibitory Effects in a Variety <strong>of</strong> Human Cell Types and<br />
Suppresses Collagen-Induced Arthritis in Mice. Cheng Liao 4 ,<br />
Pei-Yuan Hsu 4 , Shu Jin 2 , Vaishali Patel 2 , Mattew C. Lucas 3 , Yong<br />
Nam Kim 3 , Joe Dalpoto 3 , Karim Dabbagh 3 , Emma Masteller 3 ,<br />
Brian R. Wong 1 , Satwant K. Narula 2 and Julie A. Demartino 3 ,<br />
1<br />
H<strong>of</strong>fma-La Roche Inc., San Francisco, CA, 2 H<strong>of</strong>fma-La Roche<br />
Inc., Nutley, NJ, 3 H<strong>of</strong>fma-La Roche Inc., 4 H<strong>of</strong>fmann-La Roche Inc.,<br />
Nutley, NJ.<br />
289. Selective Switch Pocket Kinase Inhibitors Suppress<br />
Autoimmune Inflammatory Models <strong>of</strong> Rheumatoid Arthritis.<br />
Soo-In Choi 3 , Scott C. Wise 1 , Daniel L. Flynn 1 , Zejin Zhu 3 and<br />
Ernest Brahn 2 , 1 Deciphera Pharmaceuticals, 2 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, UCLA School <strong>of</strong> Medicine, Los Angeles, CA,<br />
3<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, UCLA School <strong>of</strong> Medicine and VA<br />
Greater Los Angeles Healthcare System, Los Angeles, CA.<br />
290. The Effects <strong>of</strong> Low Dose Etanercept on Disease Control<br />
and Radiographic Progression in Moderate to Severe<br />
Rheumatoid Arthritis. Bernd Raffeiner 1 , Costantino Botsios 2 ,<br />
Paolo Sfriso 2 , Francesca Ometto 2 , Livio Bernardi 2 , Silvano<br />
Todesco 2 and Leonardo Punzi 2 , 1 University Hospital <strong>of</strong> Padova -<br />
<strong>Rheumatology</strong> Unit, Padova, Italy, 2 University Hospital <strong>of</strong> Padova<br />
- <strong>Rheumatology</strong> Unit (Italy).<br />
291. TNF Inhibitors Induce the Fibrosis in Deep Lining Layers <strong>of</strong> the<br />
Synovium with Degeneration <strong>of</strong> Synoviocytes in Rheumatoid<br />
Arthritis. Shunsei Hirohata 1 , Tetsuya Tomita 2 , Hideki Yoshikawa 3<br />
and Masahisa Kyogoku 4 , 1 Kitasato Univ School <strong>of</strong> Med,<br />
Kanagawa, Japan, 2 Osaka Univ Med School, Suita Osaka, Japan,<br />
3<br />
Osaka Univ Med School, 4 Tohoku Univ School <strong>of</strong> Med.<br />
292. TNFα-Induced Adipose-Related Protein (TIARP) Regulates<br />
Autoimmune Arthritis Via the Suppression <strong>of</strong> IL-6. Asuka<br />
Inoue 1 , Isao Matsumoto 2 , Yoko Tanaka-Watanabe 2 , Kayo<br />
Yamamoto 2 , Naoto Umeda 2 , Yuki Tanaka 2 and Takayuki Sumida 3 ,<br />
1<br />
Division <strong>of</strong> Clinical Immunology, Doctoral Program in Clinical<br />
Sciences, Graduate School <strong>of</strong> Comprehensive Human Sciences,<br />
University <strong>of</strong> Tsukuba/ JSPS Research Fellow, Tsukuba City,<br />
Ibaraki, Japan, 2 University <strong>of</strong> Tsukuba, 3 University <strong>of</strong> Tsukuba/<br />
Inst Clin Med, Tsukuba City, Japan.<br />
293. Tyrosin Kinases Are Essential Mediators in the Development<br />
<strong>of</strong> Antigen Induced Arthritis Regulating Formation <strong>of</strong><br />
Dendritic Cells and Antigen Presentation. Mats I. Dehlin 1 ,<br />
S<strong>of</strong>ia Andersson 2 , Malin Erlandsson 2 and Maria Bokarewa 2 ,<br />
1<br />
Department <strong>of</strong> <strong>Rheumatology</strong> and Inflammation Research,<br />
Sahlgrenska University Hospital, University <strong>of</strong> Göteborg,<br />
Gothenburg, Sweden, 2 Department <strong>of</strong> <strong>Rheumatology</strong> and<br />
Inflammation Research, Sahlgrenska University Hospital,<br />
University <strong>of</strong> Göteborg, Sweden.<br />
Rheumatoid Arthritis - Clinical Aspects: Drug Studies, Drug<br />
Safety, Disease Activity and Remission, Infections I<br />
294. A Decrease in Neutrophil Counts Following a Single Infusion<br />
<strong>of</strong> Tocilizumab Is Predictive <strong>of</strong> Low Disease Activity and<br />
Remission after 24 Weeks. Jasemine Saech 2 , Kathrin Kuhr 1 ,<br />
Matthias Laudes 1 , Olaf Schultz 1 , Thomas Rath 1 , Tobias Roehrs 1<br />
and Andrea Rubbert-Roth 1 , 1 University Clinic Cologne,<br />
2<br />
University Clinic <strong>of</strong> Cologne, Cologne.<br />
295. A Simplified Disease Activity Score (DAS): Validation in the<br />
BeSt Trial. Rosanne Koevoets 6 , Yvonne Goekoop-Ruyterman 2 ,<br />
Desiree M. Van Der Heijde 5 , K. H. Han 7 , H. K. Ronday 1 , T. W. J.<br />
Huizinga 6 , P. J. S. M Kerstens 3 , B. A. C. Dijkmans 8 and Cornelia<br />
F. Allaart 4 , 1 Haga Hospital, Den Hague, 2 Haga Hospital, Den<br />
Hague, The Netherlands, 3 JBI, Amsterdam, 4 Leiden Univ Med<br />
Ctr, Leiden, The Netherlands, 5 Leiden University Medical Center,<br />
Meerssen, The Netherlands, 6 Leiden University Medical Centre,<br />
Leiden, The Netherlands, 7 Maasstad Hospital, Rotterdam, 8 VU<br />
Medical Centre, Amsterdam, The Netherlands.<br />
296. Aiming To Reach Remission – Is It Worthwhile? Helga Radner 3 ,<br />
Josef S. Smolen 1 and Daniel Aletaha 2 , 1 Krankenhaus Lainz,<br />
Vienna, Austria, 2 Medical University <strong>of</strong> Vienna, Vienna, Austria,<br />
3<br />
Medical University Vienna, Vienna, Austria.<br />
166<br />
2010 Program Book
ACR Poster Session A<br />
297. Body Weight and Response to Biologics in RA and<br />
Spondyloarthritides. Obesity Reduces the Rate <strong>of</strong> Remission-<br />
Response. The GISEA Registry. Gianfranco Ferraccioli 2 ,<br />
Francesco Trotta 5 , Leonardo Punzi 11 , Clodoveo Ferri 10 ,<br />
Piercarlo Sarzi-Puttini 6 , Lisa Maria Bambara 4 , Giovanni<br />
Triolo 3 , Roberto Giacomelli 1 , Roberto Gerli 12 , Roberto Gorla 7 ,<br />
Angelo Marchesoni 13 , Walter Grassi 9 and G. Lapadula 8 ,<br />
1<br />
Department <strong>of</strong> Internal Medicine, University <strong>of</strong> L’Aquila,<br />
L’Aquila, Italy, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, UCSC, Rome,<br />
Italy, 3 <strong>Rheumatology</strong> Department, University <strong>of</strong> Palermo,<br />
Palermo, Italy, 4 <strong>Rheumatology</strong> Department, University <strong>of</strong><br />
Verona, Verona, Italy, 5 <strong>Rheumatology</strong> Division, University <strong>of</strong><br />
Ferrara, Ferrara, Italy, 6 <strong>Rheumatology</strong> Unit, L Sacco University,<br />
Milano, Italy, 7 <strong>Rheumatology</strong> Unit, Spedali Civili <strong>of</strong> Brescia,<br />
Brescia, Italy, 8 <strong>Rheumatology</strong> Unit, University <strong>of</strong> Bari, Bari,<br />
Italy, 9 <strong>Rheumatology</strong> Unit, University <strong>of</strong> Marche, Jesi, Italy,<br />
10<br />
<strong>Rheumatology</strong> Unit, University <strong>of</strong> Modena, Modena, Italy,<br />
11<br />
<strong>Rheumatology</strong> Unit, University <strong>of</strong> Padova, Padova, Italy,<br />
12<br />
<strong>Rheumatology</strong> Unit, University <strong>of</strong> Perugia, Perugia, Italy, 13 UOC<br />
DH <strong>of</strong> <strong>Rheumatology</strong>, G. Pini Orthopaedic Institute, Milano, Italy.<br />
298. Celecoxib, a Selective COX-2 Inhibitor Improved Upper<br />
Gastrointestinal (GI) Adverse Lesions in Patients with<br />
Rheumatoid Arthritis on Long-Term NSAID Therapy with<br />
Endoscopic Evaluation. Shigeyoshi Tsuji 1 , Hir<strong>of</strong>umi Miyoshi 2 ,<br />
Tetsuya Tomita 3 , Takanobu Nakase 2 , Masayuki Hamada 2 ,<br />
Takahiro Oomae 2 , Chikako Tsumoto 2 , Yoshimasa Hirata 2 ,<br />
Munetaka Iguchi 2 , Shoko Edogawa 2 , Hideo Kawai 2 and Hideki<br />
Yoshikawa 4 , 1 Hoshigaoka Kosei-Nenkin Hospital, Hirakata City,<br />
Osaka, Japan, 2 Hoshigaoka Kosei-Nenkin Hospital, 3 Osaka Univ<br />
Med School, Suita Osaka, Japan, 4 Osaka Univ Med School.<br />
299. Changes in Lipoproteins Associated with MTX, MTX +<br />
Etanercept, and Triple DMARD Therapy among Early RA<br />
Patients in the TEAR Trial. Jeffrey R. Curtis 6 , Christina Charles-<br />
Schoeman 2 , Shuo Yang 4 , Lang Chen 4 , Stacey C<strong>of</strong>ield 4 , George<br />
Howard 4 , Theresa M. McVie 4 , Larry W. Moreland 5 , James R.<br />
O’Dell 7 , Harold E. Paulus 1 , Monika Safford 4 and S. Louis Bridges 3 ,<br />
1<br />
Encino, CA, 2 UCLA, Santa Monica, CA, 3 Univ <strong>of</strong> Alabama-<br />
Birmingham, Birmingham, AL, 4 Univ <strong>of</strong> Alabama-Birmingham,<br />
5<br />
Univ <strong>of</strong> Pittsburgh Med Ctr, Pittsburgh, PA, 6 University <strong>of</strong><br />
Alabama - Brimingham, Birmingham, AL, 7 University <strong>of</strong> Nebraska<br />
Medical Center, Omaha, NE.<br />
300. DAS28 Level at Baseline Best Predicts Which Patients with New<br />
Onset Inflammatory Arthritis Will Ultimately Require Biologic<br />
Therapy. Vivian P. Bykerk 9 , Gilles Boire 6 , Boulos Haraoui 3 , Carol<br />
Hitchon 7 , Diane Ferland 2 , Carter Thorne 4 , Ed C. Keystone 8 ,<br />
Janet E. Pope 5 and CATCH Investogators 1 , 1 Canada, 2 Hopital<br />
Maisonneuve Rosement, Montreal, PQ, Canada, 3 Institut de<br />
Rhumatologie de Montreal, Montreal, PQ, Canada, 4 South<br />
Lake Regional Health Center, Newmarket, Newmarket, ON,<br />
Canada, 5 St Joseph Health Care London, London, ON, Canada,<br />
6<br />
Universite de Sherbrooke, Sherbrooke, PQ, Canada, 7 University<br />
<strong>of</strong> Manitoba, Winnipeg, MB, Canada, 8 University <strong>of</strong> Toronto,<br />
Toronto, ON, Canada, 9 University <strong>of</strong> Toronto, Boston, MA.<br />
301. Decreased Rate <strong>of</strong> Remission at 1 Year in Menopaused Women<br />
with Early Inflammatory Arthritis: The ESPOIR Cohort Study.<br />
Cédric Lukas 2 , Ihsane Hmamouchi 2 , Xavier Le Loet 3 , Bruno<br />
Fautrel 1 and Bernard Combe 2 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
La Pitie Salpetriere Hospital, Paris, France, 2 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Lapeyronie Hospital, Montpellier, France,<br />
3<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Rouen Hospital, Rouen, France.<br />
302. Demographic, Disease and Treatment Characteristics <strong>of</strong> the<br />
Rheumatoid Arthritis Population Enrolled in the AMORA Study<br />
(Applications for Methotrexate Optimization in Rheumatoid<br />
Arthritis) in Evaluating the Avise PGSM Test. Prashanth R.<br />
Sunkureddi 1 , Judith F. Gendreau 2 , Rong Zablocki 3 and Dawn<br />
Navis 3 , 1 Clear Lake <strong>Rheumatology</strong>, Nassau Bay, TX, 2 Cypress<br />
Bioscience, Inc, San Diego, CA, 3 Cypress Bioscience, Inc.<br />
303. Demonstration <strong>of</strong> the Structural Efficacy <strong>of</strong> Very Early DMARD<br />
Initiation in Early Inflammatory Arthritis in Clinical Practice:<br />
Results <strong>of</strong> a Propensity Analysis in the ESPOIR. Cédric Lukas 3 ,<br />
Bernard G. Combe 4 , Philippe Ravaud 1 , Jean Sibilia 2 , Robert<br />
Landewe 6 and Desiree M. Van Der Heijde 5 , 1 Department<br />
<strong>of</strong> Epidemiology and Biostatistics, Bichat Hospital, Paris,<br />
France, 2 Department <strong>of</strong> <strong>Rheumatology</strong>, Hautepierre Hospital,<br />
Strasbourg, France, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Lapeyronie<br />
Hospital, Montpellier, France, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Lapeyronie Hospital, Montpellier, France, 5 Leiden University<br />
Medical Center, Meerssen, The Netherlands, 6 Univ Hosp<br />
Maastricht, Maastricht, The Netherlands.<br />
304. Derivation <strong>of</strong> a Preliminary Administrative Claims-Based<br />
Algorithm To Identify Lack <strong>of</strong> Effectiveness <strong>of</strong> Rheumatoid<br />
Arthritis Medications. Jeffrey R. Curtis 7 , Shuo Yang 4 , John<br />
Baddley 1 , Grant W. Cannon 9 , Lang Chen 5 , Elizabeth Delzell 5 ,<br />
Nivedita M. Patkar 2 , Kenneth G. Saag 8 , Monika Safford 3 ,<br />
Jasvinder Singh 1 and Ted R. Mikuls 6 , 1 Birmingham VAMC/UAB,<br />
2<br />
Univ <strong>of</strong> AL at Birmingham, Birmingham, AL, 3 Univ <strong>of</strong> AL at<br />
Birmingham, 4 Univ <strong>of</strong> Alabama at Birmingham, 5 Univ <strong>of</strong> Alabama<br />
at Birmingham, Birmingham, 6 Univ <strong>of</strong> Nebraska Med Ctr,<br />
Omaha, NE, 7 University <strong>of</strong> Alabama - Brimingham, Birmingham,<br />
AL, 8 University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />
9<br />
University <strong>of</strong> Utah, Salt Lake City, UT.<br />
305. Differences in Disease Severity and Response to Biologic<br />
Agents in a Racially Diverse US-Based Cohort <strong>of</strong> Patients with<br />
Rheumatoid Arthritis (RA). George A. Karpouzas 2 , Rosalinda<br />
Moran 2 , Soha Dolatabadi 1 and Michael Weisman 1 , 1 Cedars Sinai,<br />
2<br />
Harbor-UCLA.<br />
306. Disease Activity in Patients with Early Rheumatoid Arthritis<br />
Receiving Stable Conventional DMARDs Significantly Influences<br />
the Timing <strong>of</strong> Achieving a Low Disease State and Remission<br />
at 3 Versus 6 Months. Pooneh Akhavan 3 , Vivian P. Bykerk 3 ,<br />
Ye Sun 4 , J. Hochman 7 , Janet E. Pope 10 , Janet E. Pope 10 , Carol<br />
A. Hitchon 11 , Gilles Boire 8 , Boulos Haraoui 2 , Diane S. Ferland 6 ,<br />
J. Carter Thorne 9 , Deborah A. Weber 5 , Ed C. Keystone 12 and<br />
All CATCH Investigators 1 , 1 Canada, 2 Institut de Rhumatologie,<br />
Montreal, QC, Canada, 3 Mount Sinai Hospital, University <strong>of</strong><br />
Toronto, Toronto, ON, Canada, 4 Mount Sinai Hospital, University<br />
<strong>of</strong> Toronto, Toronto, ON, Canada, 5 Mt Sinai Hosp, Toronto, ON,<br />
Canada, 6 <strong>Rheumatology</strong>, Hopital Maisonneuve, LaSalle, QC,<br />
Canada, 7 <strong>Rheumatology</strong>, University <strong>of</strong> Toronto, 8 Sherbrooke<br />
University, Sherbrooke, QC, Canada, 9 Southlake Regional Health<br />
Care, Newmarket, ON, Canada, 10 St Joseph Health Care London,<br />
London, ON, Canada, 11 University <strong>of</strong> Manitoba, Winnipeg, MB,<br />
Canada, 12 University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />
307. Does Sequence Matter When Switching from One Anti–Tumor<br />
Necrosis Factor Agent to Another? O. Baser 3 , S. Roy 1 , C.<br />
Akin 2 and M. A. Cifaldi 1 , 1 Abbott Laboratories, Abbott Park, IL,<br />
2<br />
Brigham and Women’s Hospital, Boston, MA, 3 University <strong>of</strong><br />
Michigan, Ann Arbor, MI.<br />
2010 Program Book 167
ACR Poster Session A<br />
168<br />
308. Durability <strong>of</strong> Clinical Remission in Rheumatoid Arthritis<br />
Based on Various Criteria. Femke H. M. Prince 2 , Vivian P.<br />
Bykerk 2 , Nancy A. Shadick 1 , Jing Cui 2 , Michele Frits 2 , Christine<br />
K. Iannaccone 2 , Michael E. Weinblatt 3 and Daniel Hal Solomon 3 ,<br />
1<br />
Brigham & Womens Hospital, Boston, MA, 2 Brigham and<br />
Women’s Hospital, Division <strong>of</strong> <strong>Rheumatology</strong>, Immunology and<br />
Allergy, BRASS, Boston, MA, 3 Brigham and Womens Hospital,<br />
Boston, MA.<br />
309. Effect <strong>of</strong> Anti-Tumor Necrosis Factor Alpha Therapy on<br />
Cardiovascular Events in Rheumatoid Arthritis: A Systematic<br />
Review and Meta-Analysis. Cheryl C. M. Barnabe 2 , Billie-Jean<br />
Martin 1 and William A. Ghali 2 , 1 Libin Cardiovascular Institute,<br />
2<br />
University <strong>of</strong> Calgary, Calgary, AB, Canada.<br />
310. Effect <strong>of</strong> Intensive Repletion and Maintenance Vitamin D<br />
Therapy in Rheumatoid Arthritis Patients. Uzma J. Haque 1 ,<br />
Kevin Fontaine 2 and Susan J. Bartlett 3 , 1 Johns Hopkins School <strong>of</strong><br />
Medicine, Lutherville, MD, 2 Johns Hopkins School <strong>of</strong> Medicine,<br />
3<br />
McGill University, Montreal, QC, Canada.<br />
311. Effectiveness <strong>of</strong> Initial Treatment Allocation Based on Expert<br />
Opinion for Prevention <strong>of</strong> Rapid Radiological Progression<br />
in a Daily Practice Early RA Cohort. Anne Durnez 2 , Geert<br />
Vanderschueren 1 , Luc Lateur 1 , Rene Westhovens 2 and Patrick<br />
Verschueren 2 , 1 University Hospital Leuven Radiology, Leuven,<br />
Belgium, 2 University Hospital Leuven <strong>Rheumatology</strong>, Leuven,<br />
Belgium.<br />
312. ESR, CRP, or RF Status at Presentation Is Only Marginally<br />
Predictive <strong>of</strong> Future Treatments with Methotrexate or Biologic<br />
Agents over 25 Years in Two Settings in the United States and<br />
in Finland. Tuulikki Sokka 1 , Hannu Kautiainen 2 and Theodore<br />
Pincus 3 , 1 Jyvaskyla Central Hospital, Jyvaskyla, Finland, 2 Medcare<br />
Oy, Annekoski, Finland, 3 New York University Hospital for Joint<br />
Disease, Hastings-on-Hudson, NY.<br />
313. Invasive Fungal Infections in Seniors with Rheumatoid<br />
Arthritis: A Population-Based Study from the Ontario Biologics<br />
Research Initiative. Jessica Widdifield 7 , Sasha R. Bernatsky 3 ,<br />
J. Michael Paterson 1 , Nadia Gunraj 2 , Janet E. Pope 6 , J. Carter<br />
Thorne 5 , Alfred A. Cividino 4 and Claire Bombardier 7 , 1 Institute<br />
for Clinical Evaluative Science, Canada, 2 Institute for Clinical<br />
Evaluative Science, 3 McGill UHC/RVH, Montreal, QC, Canada,<br />
4<br />
McMaster University, Hamilton, ON, Canada, 5 Southlake<br />
Regional Health Care, Newmarket, ON, Canada, 6 St Joseph<br />
Health Care London, London, ON, Canada, 7 University <strong>of</strong><br />
Toronto.<br />
314. Is DAS28 Remission Good Enough? Disease Activity and<br />
Functionality in Rheumatoid Arthritis, Results <strong>of</strong> the DREAM<br />
Remission Induction Cohort. Marloes Vermeer 3 , Ina H. Kuper 3 ,<br />
Monique Hoekstra 1 , Hein J. Bernelot Moens 4 , Piet L. C. M. van<br />
Riel 2 and Mart A. F. J. van de Laar 3 , 1 Isala Klinieken, Zwolle,<br />
The Netherlands, 2 Radboud University Nijmegen Medical<br />
Centre, Nijmegen, The Netherlands, 3 University <strong>of</strong> Twente<br />
and Medisch Spectrum Twente, Enschede, The Netherlands,<br />
4<br />
Ziekenhuisgroep Twente, Almelo/Hengelo, The Netherlands.<br />
315. Low Rate <strong>of</strong> Rheumatoid Arthritis Remission in Real Life: Might<br />
Predictive Factors Explain? Elodie Loppin 2 , Ronan Garlantezec 1<br />
and Elisabeth Solau-Gervais 2 , 1 Public Heatlh Department,<br />
University Hospital Brest, France, 2 <strong>Rheumatology</strong> Department<br />
University Hospital Poitiers, France.<br />
316. Lymphocytopenia and Infection Risk in Rheumatoid Arthritis:<br />
A Population Based Analysis. Deana D. Hoganson 2 , Eric L.<br />
Matteson 1 , Patrick D. Fitz-Gibbon 3 and Cynthia S. Crowson 3 ,<br />
1<br />
Mayo Clinic, Rochester, MN, 2 Mayo Clinic Rochester, Rochester,<br />
MN, 3 Mayo Clinic Rochester.<br />
2010 Program Book<br />
317. Measures <strong>of</strong> Disease Activity Provide Various Clinical Decisions<br />
in Individual Patients. P. H. P. de Jong 1 , J. M. W. Hazes 2 , J. J.<br />
Luime 2 and A. E. A. M. Weel 3 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
ErasmusMC, Rotterdam, The Netherlands, 2 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, ErasmusMC, Rotterdam, 3 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Maasstad Hospital, Rotterdam.<br />
318. Minocycline and Doxycycline Therapy in Community Patients<br />
with Rheumatoid Arthritis (RA): Incidence, Patient-Level<br />
Determinants <strong>of</strong> Use and Side Effects. Christopher J. Smith 2 ,<br />
Harlan R. Sayles 2 , Ted R. Mikuls 1 and Kaleb D. Michaud 1 , 1 Univ <strong>of</strong><br />
Nebraska Med Ctr, Omaha, NE, 2 University <strong>of</strong> Nebraska Med Ctr,<br />
Omaha, NE.<br />
319. Multi-Centre, Cross-Sectional, Observational Study <strong>of</strong> the<br />
Safety <strong>of</strong> Methotrexate and Leflunomide in Combination in<br />
the Treatment <strong>of</strong> Patients with Rheumatoid Arthritis The<br />
SMILE Study – Safety <strong>of</strong> Methotrexate In Combination with<br />
Leflunomide. Paul Bird 2 , Hedley Griffiths 1 and The Optimising<br />
Patient Outcomes in Australian RheumatoLogy [OPAL]<br />
Consortium, 1 Barwon <strong>Rheumatology</strong> Service, Victoria, Australia,<br />
2<br />
Combined <strong>Rheumatology</strong> Practice (CRP), University <strong>of</strong> NSW,<br />
Sydney, NSW, Australia.<br />
320. Multi-Centre, Observational Study Shows High Proportion <strong>of</strong><br />
Australian Rheumatoid Arthritis Patients Have Inadequate<br />
Disease Control. Ge<strong>of</strong>frey Littlejohn 2 and Kathleen E. Tymms 1 ,<br />
1<br />
Canberra <strong>Rheumatology</strong>, Canberra, ACT, Australia, 2 Monash<br />
Medical Centre, Clayton, Victoria, Australia.<br />
321. Multiple Courses <strong>of</strong> Rituximab Produce Sustained Efficacy<br />
in Patients with Rheumatoid Arthritis with an Inadequate<br />
Response to One or More TNF Inhibitors. Edward C. Keystone 6 ,<br />
Roy M. Fleischmann 5 , Paul Emery 2 , Maxime Dougados 3 , Sarah<br />
Williams 4 , Matthew D. Linnik 1 and Mark Reynard 4 , 1 Biogen<br />
Idec, San Diego, San Diego, CA, 2 Chapel Allerton Hospital,<br />
Leeds, United Kingdom, 3 Hospital Cochin, Paris, France, 4 Roche<br />
Products Ltd, Welwyn Garden City, UK, 5 University <strong>of</strong> Texas<br />
Southwestern Medical Center, Dallas, Dallas, TX, 6 University <strong>of</strong><br />
Toronto, Toronto, ON, Canada.<br />
322. National Trends in Drug Use, Health Status and Costs in Older<br />
<strong>American</strong>s with Rheumatoid Arthritis. Leslie R. Harrold 3 , Becky<br />
Briesacher 4 , Daniel Peterson 1 and Jerry H. Gurwitz 2 , 1 Meyers<br />
Primary Care Institute, 2 Meyers Primary Care Institute/UMass<br />
Medical School, 3 UMass Medical Schl, Worcester, MA, 4 UMass<br />
Medical School.<br />
323. Pandemic H1N1 Influenza Vaccination Responses in Rheumatid<br />
Arthritis and Systemic Lupus Erythematosus Patients: An<br />
Association with Serum IL17 and CXCL13 Level. Sung-Hoon<br />
Park 1 , Hwa-Jeong Lee 2 , Hyun-Hee Kwon 2 , Seong-Kyu Kim 2 and<br />
Jung-Yoon Choe 2 , 1 Catholic University <strong>of</strong> Daegu, School <strong>of</strong><br />
Medicine, Arthritis and Autoimmunity Research Center, Daegu,<br />
Korea, Republic <strong>of</strong>, 2 Catholic University <strong>of</strong> Daegu, School <strong>of</strong><br />
Medicine, Arthritis and Autoimmunity Research Center.<br />
324. Patient Preferences for Biologic Agents in Rheumatoid<br />
Arthritis: A Discrete Choice Experiment. David A. Navarta 2 ,<br />
Federico Augustovski 3 , Andrea Beratarrechea 3 , Vilma Irazola 3 ,<br />
Fernando Rubinstein 3 , Pablo Tesolin 3 , Juan M. Gonzalez 6 ,<br />
Veronica Lencina 4 , Marina Scolnik 2 , Christian Wainmann 5 ,<br />
Gustavo Citera 4 and Enrique R. Soriano 1 , 1 Hospital Italiano<br />
de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires,<br />
Capital Federal, Argentina, 2 Hospital Italiano de Buenos<br />
Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina,<br />
Argentina, 3 Institute for Clinical Effectiveness and Health Policy,<br />
Buenos Aires, Argentina, 4 Instituto Rehabilitacion Psic<strong>of</strong>isica,<br />
Buenos Aires, Argentina, 5 Instituto Rehabilitacion Psic<strong>of</strong>isica,<br />
Buenos Aires, Argentina, 6 RTI Health Solutions, NC.
ACR Poster Session A<br />
325. Patient Risk Perception <strong>of</strong> Teratogenicity <strong>of</strong> Disease Modifying<br />
Anti-Rheumatic Drugs. Eliza F. Chakravarty 3 , Megan E. Clowse 2 ,<br />
Karen H. Costenbader 1 , Christina Chambers 4 and Kaleb<br />
Michaud 5 , 1 Brigham and Womens Hospital, 2 Duke University,<br />
Durham, NC, 3 Stanford University, 4 University <strong>of</strong> California, San<br />
Diego, 5 University <strong>of</strong> Nebraska.<br />
326. Post-Treatment Changes in Serum C-Reactive Protein Levels<br />
and Clinical Response in Rheumatoid Arthritis. Paul Emery 8 ,<br />
Eric L. Matteson 6 , Mark C. Genovese 7 , Sarah Sague 1 , Elizabeth<br />
C. Hsia 3 , Mittie K. Doyle 4 , Hongtao Fan 2 , Michael Elash<strong>of</strong>f 5 and<br />
Mahboob U. Rahman 4 , 1 Centocor Research and Development,<br />
Inc., Malvern, PA, 2 Centocor Research and Development, Inc.,<br />
3<br />
Centocor Research and Development, Inc./Univ <strong>of</strong> Pennsylvania<br />
School <strong>of</strong> Medicine, Malvern, PA, 4 Centocor Research and<br />
Development, Inc./Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine,<br />
Malvern, PA, 5 Elash<strong>of</strong>f Consulting, 6 Mayo Clinic, Rochester, MN,<br />
7<br />
Stanford Universit, Sunnyvale, CA, 8 University Leeds, Leeds,<br />
United Kingdom.<br />
327. Practice Patterns <strong>of</strong> US Rheumatologists Related to<br />
Diagnosis and Assessment <strong>of</strong> Disease Activity as Well as<br />
Switching Biologic Therapies in Rheumatoid Arthritis. Marco<br />
DiBonaventura 2 , Sanjoy Roy 1 , Jochen Ertl 2 and Mary A. Cifaldi 1 ,<br />
1<br />
Abbott Laboratories, Abbott Park, IL, 2 Kantar Health, New York,<br />
NY.<br />
328. Predictors <strong>of</strong> Successful Cessation <strong>of</strong> TNF Blockers in Patients<br />
with RA. M. van den Broek 4 , N. B. Klarenbeek 5 , L. Dirven 5 , A.<br />
A. Schouffoer 1 , H. M. J. Hulsmans 2 , P. J. S. M Kerstens 3 , T. W.<br />
J. Huizinga 5 , B. A. C. Dijkmans 6 and C. F. Allaart 5 , 1 Groene Hart<br />
Hospital, Gouda, The Netherlands, 2 Haga Hospital, The Hague,<br />
The Netherlands, 3 Jan van Breemen Instituut, Amsterdam,<br />
The Netherlands, 4 LUMC, Leiden, The Netherlands, 5 LUMC,<br />
Leiden, The Netherlands, 6 VU Medical Centre, Amsterdam, The<br />
Netherlands.<br />
329. Prevalence <strong>of</strong> Reactivation <strong>of</strong> Hepatitis B Virus Replication<br />
in Rheumatoid Arthritis Patients. Dai Tanaka 2 , Yukitomo<br />
Urata 4 , Ryoko Uesato 3 , Kenji Kowatari 3 , Yoshihide Nakamura 1<br />
and Taisuke Nitobe 3 , 1 Department <strong>of</strong> Orthopaedic Surgery,<br />
Hirosaki University Graduate School <strong>of</strong> Medicine, 2 Department<br />
<strong>of</strong> Orthopaedic Surgery, Seihoku Chuo Hospital, Gosyogawara,<br />
Aomori, Japan, 3 Department <strong>of</strong> Orthopaedic Surgery, Seihoku<br />
Chuo Hospital, 4 Departments <strong>of</strong> <strong>Rheumatology</strong>, Seihoku Chuo<br />
Hospital, Gosyogawara, Japan.<br />
330. Primary Anti-TNF Failures Experience Better Clinical Responses<br />
but Similar Health Care Utilization to a Second Anti-TNF Agent<br />
Than Secondary Failures: Analysis <strong>of</strong> the Alberta Rheumatoid<br />
Arthritis Biologics Registry. Walter P. Maksymowych 2 , Arto<br />
Ohinmaa 1 , Liam Martin 3 , Anthony S. Russell 2 , Susan G. Barr 3 ,<br />
Dale Sholter 2 , Chris J. Penney 3 , Charles Yan 1 and Philip Jacobs 1 ,<br />
1<br />
Institute <strong>of</strong> Health Economics, Edmonton, AB, Canada,<br />
2<br />
University <strong>of</strong> Alberta, Edmonton, AB, Canada, 3 University <strong>of</strong><br />
Calgary, Calgary, AB, Canada.<br />
331. Rate <strong>of</strong> Remission in Clinical RA Patients by ACR/EULAR<br />
Criteria. Shadi H. Shahouri 3 , James D. Anderson 5 , Ruth E. Busch 2 ,<br />
Timothy S. Shaver 4 , Shirley Y. Wang 3 , David N. Weidensaul 1 ,<br />
Martin J. Bergman 6 , Kaleb D. Michaud 8 and Frederick Wolfe 7 ,<br />
1<br />
ARCKArthritis & Rheum Clinics KS, Wichita, KS, 2 Arthritis &<br />
Rheum Clinic, Wichita, KS, 3 Arthritis & Rheum Clinic <strong>of</strong> KS,<br />
Wichita, KS, 4 Arthritis & Rheum Clinics KS, Wichita, KS, 5 Arthritis<br />
& Rheum Clinics KS, Leawood, KS, 6 Arthritis and <strong>Rheumatology</strong>,<br />
Ridley Park, PA, 7 Natil Data Bank for Rheumatic, Wichita, KS,<br />
8<br />
Univ <strong>of</strong> Nebraska Med Ctr, Omaha, NE.<br />
332. Rituximab Alters the HDL Particle from a Pro-Inflammatory<br />
into an Anti-Inflammatory Property in Good Responding<br />
Rheumatoid Arthritis Patients. Hennie G. Raterman 2 , Han H.<br />
M. Levels 1 , Alexandre E. Voskuyl 2 , Willem F. Lems 2 , Ben A. C.<br />
Dijkmans 2 and Michael T. Nurmohamed 2 , 1 Academical Medical<br />
Center, The Netherlands, 2 VU University Medical Center,<br />
Amsterdam, The Netherlands.<br />
333. Rituximab-Reduced Immunoglobulin Free Light Chains in<br />
RA Correlate with Disease Suppression: A Novel Mechanism<br />
<strong>of</strong> Action <strong>of</strong> Rituximab. J. Tekstra 3 , T. Groot Kormelink 2 , R.<br />
Thurlings 1 , M. Boumans 1 , K. Vos 1 , P. P. Tak 1 , J. W. J. Bijlsma 3 , F.<br />
P. J. G. Lafeber 3 , F. A. Redegeld 2 and J. A. G. van Roon 3 , 1 Clinical<br />
Immunology & <strong>Rheumatology</strong>, Academic Medical Center/<br />
University <strong>of</strong> Amsterdam, The Netherlands, 2 Pharmacology and<br />
Pathophysiology, Utrecht Institute for Pharmaceutical Sciences,<br />
Fac. Science, Utrecht, the Netherlands, 3 <strong>Rheumatology</strong> &<br />
Clinical Immunology, University Medical Center Utrecht, The<br />
Netherlands.<br />
334. Seven Year Results <strong>of</strong> DAS Steered Treatment in the BeSt<br />
Study: Clinical and Radiological Outcomes. L. Dirven 5 , M. van<br />
den Broek 5 , N. B. Klarenbeek 5 , M. V. van Krugten 1 , P. A. H. M.<br />
van der Lubbe 2 , P. J. S. M. Kerstens 3 , T. W. J. Huizinga 5 , B. A. C.<br />
Dijkmans 6 and C. F. Allaart 4 , 1 Admiraal de Ruyter Hospital, 2 Haga<br />
Hospital, 3 Jan van Breemen Institute, 4 Leiden Univ Med Ctr,<br />
Leiden, The Netherlands, 5 Leiden University Medical Center, 6 VU<br />
Medical Centre, Amsterdam, The Netherlands.<br />
335. Surveillance <strong>of</strong> Surgical Site Infection in Patients with<br />
Rheumatoid Arthritis. Kengo Harigane 1 , Yuichi Mochida 2 ,<br />
Katsushi Ishii 2 , Naoya Taki 2 , Naoto Mitsugi 2 and Tomoyuki<br />
Saito 3 , 1 Yokohama City University Medical Center, Yokohama,<br />
Kanagawa, Japan, 2 Yokohama City University Medical Center,<br />
3<br />
Yokohama City University School <strong>of</strong> Medicine.<br />
336. Sustained Remission in Early RA: Results from SONORA Study.<br />
Claire Bombardier 3 , Pooneh Akhavan 2 , Maggie Chen 1 and<br />
Xiuying Li 1 , 1 University Health Network, 2 University <strong>of</strong> Toronto,<br />
University Health Network, 3 University <strong>of</strong> Toronto, University<br />
Health Network, Mount Sinai Hospital, Toronto, ON, Canada.<br />
337. Sustained Remission, a Realistic Target in Early Rheumatoid<br />
Arthritis Patients Treated with Conventional DMARDs. Irazú<br />
Contreras-Yáñez, Marina Rull-Gabayet and Virginia Pascual-<br />
Ramos, Instituto Nacional de Ciencias Médicas y Nutrición<br />
Salvador Zubirán, Ciudad de México, DF, Mexico.<br />
338. Switching Patterns for Biologic Drugs among Patients with<br />
Rheumatoid Arthritis Who Have Previously Failed at Least<br />
One Biologic Agent. Stephen Johnston 2 , Sarika Ogale 1 , Nicole<br />
Princic 3 , Bong-Chul Chu 3 and Tripthi Kamath 1 , 1 Genentech USA,<br />
Inc., 2 Thomson Reuters, Washington, DC, 3 Thomson Reuters.<br />
339. Systemic Immunosuppressives and the Risk <strong>of</strong> Diabetes in<br />
Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). Daniel<br />
Hal Solomon 3 , Elena M. Massarotti 1 , Raj Garg 2 , Claire Canning 2 ,<br />
Jun Liu 2 and Sebastian Schneeweiss 2 , 1 Brigham & Women’s<br />
Hospital, Boston, MA, 2 Brigham and Women’s Hospital,<br />
3<br />
Brigham and Womens Hospital, Boston, MA.<br />
340. The Belgian MIRA (MabThera in Rheumatoid Arthritis)<br />
Registry: Clues for the Optimization <strong>of</strong> Rituximab Treatment<br />
Strategies. Bert Vander Cruyssen 2 , Patrick Durez 1 , Rene<br />
Westhovens 5 , Ilse H<strong>of</strong>fman 3 , M. J. Kaiser 4 and Filip De Keyser,<br />
1<br />
Cliniques Universitaires Saint-Luc, Brussels, 2 Ghent University<br />
Hosptial, 3 GZA St-Augustinus Hospital Antwerp, Belgium,<br />
4<br />
University Hospital Liege, Liege, Belgium, 5 University Hospitals<br />
KULeuven, Leuven, Belgium.<br />
2010 Program Book 169
ACR Poster Session A<br />
341. The Incidence <strong>of</strong> Herpes Zoster in Seniors with Rheumatoid<br />
Arthritis. Jessica Widdifield 7 , Sasha R. Bernatsky 2 , J. Michael<br />
Paterson 1 , Nadia Gunraj 1 , Janet E. Pope 5 , J. Carter Thorne 4 ,<br />
Alfred A. Cividino 3 and Claire Bombardier 6 , 1 Institute for Clinical<br />
Evaluative Science, 2 McGill UHC/RVH, Montreal, QC, Canada,<br />
3<br />
McMaster University, Hamilton, ON, Canada, 4 Southlake<br />
Regional Health Care, Newmarket, ON, Canada, 5 St Joseph<br />
Health Care London, London, ON, Canada, 6 University <strong>of</strong><br />
Toronto, Toronto, ON, Canada, 7 University <strong>of</strong> Toronto.<br />
342. The Influence <strong>of</strong> Systemic Glucocorticoid Therapy upon the<br />
Risk <strong>of</strong> Non-Serious Infection in Patients with Rheumatoid<br />
Arthritis. William G. Dixon 3 , Abbas Kezouh 2 , Sasha R. Bernatsky 1<br />
and Samy Suissa 2 , 1 McGill UHC/RVH, Montreal, QC, Canada,<br />
2<br />
McGill University, 3 The University <strong>of</strong> Manchester, Manchester,<br />
United Kingdom.<br />
343. Three Months <strong>of</strong> Therapy with DMARDs Is an Inadequate<br />
Period <strong>of</strong> Time To Alter the Treatment in Patients with Early<br />
Rheumatoid Arthritis When Treating to a Target <strong>of</strong> Low Disease<br />
State or Remission. Results from Canadian Early ArThritis<br />
CoHort (CATCH). Pooneh Akhavan 4 , Vivian P. Bykerk 5 , Ye Sun 6 ,<br />
J. Hochman 12 , Janet E. Pope 9 , Carol A. Hitchon 1 , Gilles Boire 10 ,<br />
Boulos Haraoui 2 , Diane S. Ferland 7 , J. Carter Thorne 8 , Deborah<br />
A. Weber 5 , Ed C. Keystone 11 and CATCH Investogators 3 , 1 Arthritis<br />
Center, University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 2 Institut<br />
de Rhumatologie, Montreal, QC, Canada, 3 M, Canada, 4 Mount<br />
Sinai Hospital, University <strong>of</strong> Toronto, Toronto, ON, Canada, 5 Mt<br />
Sinai Hospital, Toronto, ON, Canada, 6 Mt Sinai Hospital, Toronto,<br />
ON, Canada, 7 <strong>Rheumatology</strong>, Hopital Maisonneuve, Rosement,<br />
University <strong>of</strong> Montreal, LaSalle, QC, Canada, 8 Southlake Regional<br />
Health Care, Newmarket, ON, Canada, 9 St Joseph Health Care<br />
London, London, ON, Canada, 10 Universite de Sherbrooke,<br />
Sherbrooke, QC, Canada, 11 University <strong>of</strong> Toronto, Toronto, ON,<br />
Canada, 12 University <strong>of</strong> Toronto, Toronto, ON.<br />
344. Treating to Target with TNFi in Active Established Rheumatoid<br />
Arthritis Results in Longer Drug Survival Than Routine Care<br />
with TNFi: Results from the Optimization <strong>of</strong> Humira RCT. Janet<br />
E. Pope 4 , J. Carter Thorne 3 , Boulos Haraoui 2 and John Sampalis 1 ,<br />
1<br />
Montreal, ON, Canada, 2 Institut de Rhumatologie, Montreal,<br />
QC, Canada, 3 Southlake Regional Health Care, Newmarket, ON,<br />
Canada, 4 St. Joseph’s Health Care, London, ON, Canada.<br />
345. Tumor Necrosis Factor-α Inhibitor Use Does Not Affect Lipid<br />
Pr<strong>of</strong>iles in Patients with Rheumatoid Arthritis. Stephanie J.<br />
Morris 1 , Jana L. Antohe 1 , Jennifer Sartorius 2 , H. Les Kirchner 2 ,<br />
Sorina Dancea 1 , Mary Chester Wasko 3 and Androniki Bili 1 ,<br />
1<br />
Geisinger Health System, Danville, PA, 2 Geisinger Health<br />
System, 3 Univ <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />
346. Urinary Tract Infections in Rheumatoid Arthritis. Colin C.<br />
Edgerton 1 , Kaleb D. Michaud 3 and Frederick Wolfe 2 , 1 Eisenhower<br />
Army Medical Center, Evans, GA, 2 Natilonal Data Bank for<br />
Rheumatic Disease, Wichita, KS, 3 Univ <strong>of</strong> Nebraska Med Ctr,<br />
Omaha, NE.<br />
347. Women with RA Achieve Remission Less Frequently Than Men,<br />
Using the CORRONA Database among 6668 Patients. Daniel E.<br />
Furst 5 , Veena Ranganath 4 , Joel M. Kremer 1 , James Louie 4 , Dinesh<br />
Khanna 4 , Lawrence Rasouliyan 2 and Jeffrey D. Greenberg 3 ,<br />
1<br />
Albany Medical <strong>College</strong>, 2 ICON, 3 NYU, 4 UCLA, 5 University <strong>of</strong><br />
California Los Angeles Medical School, Los Angeles, CA.<br />
Rheumatoid Arthritis - Human Etiology and Pathogenesis I<br />
348. A Novel Splicing Regulatory Mechanism in Generating a<br />
Truncated Human Death Receptor 3 (DR3) Gene Product That<br />
Contributes to the Pathogenesis <strong>of</strong> Rheumatoid Arthritis.<br />
Masaru Mizuhara 2 , Akira Hashiramoto 3 , Kohsuke Yoshida 1 and<br />
Shunichi Shiozawa 4 , 1 Department <strong>of</strong> Biophysics, Kobe University<br />
Graduate School <strong>of</strong> Health Science, Kobe, Hyogo, Japan,<br />
2<br />
Department <strong>of</strong> Biophysics, Kobe University Graduate School <strong>of</strong><br />
Health Science, Kobe, Japan, 3 Department <strong>of</strong> Biophysics, Kobe<br />
University Graduate School <strong>of</strong> Health Science/Department <strong>of</strong><br />
Medicine, Kobe University Graduate School <strong>of</strong> Medicine/The<br />
Center for Rheumatic Diseases, Kobe University Hospital, Kobe,<br />
Hyogo, Japan, 4 Department <strong>of</strong> Biophysics, Kobe University<br />
Graduate School <strong>of</strong> Health Science/Department <strong>of</strong> Medicine,<br />
Kobe University Graduate School <strong>of</strong> Medicine/The Center for<br />
Rheumatic Diseases, Kobe University Hospital, Kobe, Japan.<br />
349. BAFF Expression on the Surface <strong>of</strong> RA Synovial Fibroblasts<br />
(RASFib) Facilitates B Cell Responses to IL-15. Yolanda<br />
Garcia-Carmona, Marta Benito-Miguel, Alejandro Balsa, Emilio<br />
Martin-Mola and Maria Eugenia Miranda-Carus, Hospital La Paz,<br />
Madrid, Spain, Hospital La Paz, Madrid, Spain, Hospital La Paz,<br />
Madrid.<br />
350. Characterization <strong>of</strong> Fibrinogen-Specific CD4 T Cells Using<br />
Peptide-MHC Tetramers. Laura F. Su 1 and Mark M. Davis 2 ,<br />
1<br />
Stanford, Mountain View, CA, 2 Stanford.<br />
351. Defective ERK Signaling in Hematopoietic Progenitor Cells in<br />
Rheumatoid Arthritis. Ines Colmegna 2 , Sergei Pryschep 1 , Hisashi<br />
Oishi 3 , Jorg J. Goronzy 3 and Cornelia M. Weyand 3 , 1 Georgia<br />
Institute <strong>of</strong> Technology, 2 McGill University, Montreal, QC,<br />
Canada, 3 Stanford University.<br />
352. Human STEAP4 (Six-Transmembrane Epithelial Antigen<br />
<strong>of</strong> Prostate 4) Regulates Inflammatory Cytokines and the<br />
Proliferation <strong>of</strong> Fibroblast-Like Synoviocyte in Patients<br />
with RA. Yoko Tanaka, Isao Matsumoto, Naoto Umeda, Kayo<br />
Yamamoto, Yuki Tanaka, Asuka Inoue and Takayuki Sumida,<br />
University <strong>of</strong> Tsukuba.<br />
353. IL-15 Promotes Osteoclastogenesis Via Phospholipase D<br />
Signaling Pathway in Rheumatoid Arthritis. Ji-Min Kim 1 ,<br />
Mi-Kyung Park 2 , Mi-La Cho 2 , Yong-Geun Jung 1 , Su-Jin Moon 1 ,<br />
Seung-Ki Kwok 1 , Ji-Hyeon Ju 1 , Kyung-Su Park 1 , Ho-Youn Kim 1<br />
and Sung-Hwan Park 1 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, Department<br />
<strong>of</strong> Internal Medicine, Seoul St. Mary’s Hospital, The Catholic<br />
University <strong>of</strong> Korea, Seoul, Korea, Republic <strong>of</strong>, 2 Rheumatism<br />
Research Center, Catholic Research Institute <strong>of</strong> Medical Science,<br />
The Catholic University <strong>of</strong> Korea, Seoul, Korea, Republic <strong>of</strong>.<br />
354. IL-17A and IL-17F Contribute to the Progression <strong>of</strong> Rheumatoid<br />
Arthritis by Inducing a CXCR4-Dependent Invasive Phenotype<br />
in Synoviocytes. Arnaud Hot 2 , Saloua Zrioual 1 , Vanina Lenief 1<br />
and Pierre Miossec 1 , 1 Hospital Edouard Herriot, Lyon, Lyon,<br />
France, 2 Immunogenomics and Inflammation Research Unit<br />
and Department <strong>of</strong> Immunology and <strong>Rheumatology</strong>, Hospital<br />
Edouard Herriot, Lyon, France.<br />
355. In Rheumatoid Arthritis, Naïve B Cells Prevail in the Peripheral<br />
Blood, Whereas Memory B Cells Accumulate in the Joint<br />
Compartment, Express ZAP-70 and Characterize the Aggregate<br />
Pattern. Alessandro Michelutti 2 , Elisa Gremese 2 , Barbara<br />
Tolusso 2 , Francesca Morassi 1 , Rosalia Privitera 2 , Silvia Canestri 2 ,<br />
Giusy Peluso 2 , Silvia L. Bosello 2 and Gianfranco Ferraccioli 2 ,<br />
1<br />
Division <strong>of</strong> Histopathology, Catholic University <strong>of</strong> Sacred Heart,<br />
Rome, Italy, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Catholic University <strong>of</strong><br />
Sacred Heart, Rome, Italy.<br />
170<br />
2010 Program Book
ACR Poster Session A<br />
356. Influence <strong>of</strong> TNF-α, MMP-3, TIMP-3 and HLA Class II Genes<br />
Polymorphisms in the Rheumatoid Arthritis Articular<br />
Damage. Renata T. Alarcon 5 , Artur R. C. Fernandes 5 , Geraldo<br />
R. C. Pinheiro 3 , Magali J. G. Usnayo 3 , Luis C. M. Porto 4 , Juliana<br />
Cardoso-Oliveira 3 , Gustavo M. Fabricio-Silva 3 , Ieda M. M.<br />
Laurindo 1 , Manoel B. Bertolo 2 , Mario Yazbek 2 , Mariana G.<br />
Soares 5 , Neusa P. Silva 5 , Kaline M. C. Pereira 5 and Luis E. C.<br />
Andrade 5 , 1 Universidade de Sao Paulo, Sao Paulo, SP, Brazil,<br />
2<br />
Universidade Estadual de Campinas, Campinas, SP, Brazil,<br />
3<br />
Universidade Estadual do Rio de Janeiro, Rio de Janeiro, RJ,<br />
Brazil, 4 Universidade Estadual do Rio de Janeiro, Rio de Janeiro,<br />
RF, Brazil, 5 Universidade Federal de Sao Paulo - UNIFESP, Sao<br />
Paulo, SP, Brazil.<br />
357. Inhibition <strong>of</strong> the Recycling <strong>of</strong> Polyamines Restores DNA<br />
Methylation in Rheumatoid Arthritis Synovial Fibroblasts.<br />
Emmanuel Karouzakis 1 , Christoph Kolling 2 , Renate E. Gay 1 ,<br />
Beat A. Michel 1 , Steffen Gay 1 and Michel Neidhart 1 , 1 Center <strong>of</strong><br />
Experimental <strong>Rheumatology</strong> and Zurich Center <strong>of</strong> Integrative<br />
Human Physiology (ZIHP), University Hospital Zurich, 2 Schulthess<br />
Clinic, Zurich.<br />
358. Interleukin-6 Promotes Pathological Angiogenesis by<br />
Modulating Angiopoietin Expression in Rheumatoid Arthritis.<br />
Ken Kayakabe 1 , Takashi Kuroiwa 2 , Noriyuki Sakurai 2 , Hidekazu<br />
Ikeuchi 2 , Akito Maeshima 2 , Keiju Hiromura 2 and Yoshihisa<br />
Nojima 2 , 1 Department <strong>of</strong> Medicine and Clinical Science, Gunma<br />
University Graduate School <strong>of</strong> Medicine, Maebashi, Gunma,<br />
Japan, 2 Department <strong>of</strong> Medicine and Clinical Science, Gunma<br />
University Graduate School <strong>of</strong> Medicine.<br />
359. MicroRNA and mRNA Integrated Analysis in Rheumatoid<br />
Arthritis Synovial Macrophages. Jong Dae Ji 3 , Bit-Na-Ra Lee 5 ,<br />
Tae-Hwan Kim 5 , Jae-Bum Jun 5 , Dae-Hyun Yoo 5 , Kyung-Sun Na 2 ,<br />
Jin-Hyun Woo 4 , Sung Jae Choi 4 , Young Ho Lee 4 , Jeongwon Sohn 1<br />
and Gwan Gyu Song 4 , 1 Department <strong>of</strong> Biochemistry, <strong>College</strong> <strong>of</strong><br />
Medicine, Korea University, Seoul, Korea, 2 Kim’s Clinic, Seoul,<br />
Korea, 3 <strong>Rheumatology</strong>, <strong>College</strong> <strong>of</strong> Medicine, Korea University,<br />
Seoul, Korea, Republic <strong>of</strong>, 4 <strong>Rheumatology</strong>, <strong>College</strong> <strong>of</strong> Medicine,<br />
Korea University, Seoul, Korea, 5 The Hospital for Rheumatic<br />
Diseases, Hanyang University, Seoul, Korea.<br />
360. Mitochondrial Mutagenesis in Synovial Tissue Is Associated<br />
with In Vivo Hypoxia, Inflammation and Oxidative Damage.<br />
Monika Biniecka 2 , Edward Fox 1 , Chin T. Ng 2 , Len Harty 2 , Ursula<br />
Fearon 2 , Douglas J. Veale 2 and Jacintha O’Sullivan 2 , 1 Department<br />
<strong>of</strong> Pathology, University <strong>of</strong> Washington, Seattle, WA, 2 Translation<br />
Research Group, Dublin Academic Medical Centre, St. Vincent’s<br />
University Hospital, Dublin, Co. Dublin, Ireland.<br />
361. Nerve Fiber Repulsion by Semaphorins – More Redundancy<br />
Than Expected in the Rheumatoid Arthritis Joint. Susanne<br />
Klatt, Alexander Fassold and Rainer H. Straub, University<br />
Hospital Regensburg, Regensburg, Germany, University Hospital<br />
Regensburg, Regensburg, Germany.<br />
362. Phosphoinositide 3-Kinase Delta (PI3Kδ) Regulation and<br />
Function in RA. Beatrix Bartok 2 , David Boyle 2 , Christian Rommel 1<br />
and Gary S. Firestein 3 , 1 Intellikine, 2 UCSD, San Diego, 3 UCSD.<br />
363. Platelet Microparticle Proteome: Insight into Role <strong>of</strong><br />
Microparticles under Different Stimulatory Conditions. Roopa<br />
Shree Subbaiah 5 , K. C. Sekhar Rao 1 , Peter Nigrovic 2 , David Lee 4 ,<br />
Masaru Miyagi 1 , Eric Boilard 3 and Reuben Gobezie 6 , 1 Case<br />
Center for Proteomics and Bioinformatics, School <strong>of</strong> Medicine,<br />
Case Western Reserve University, Cleveland, OH, 2 Center for<br />
Adults with Pediatric Rheumatic Illness (CAPRI), Pediatric and<br />
Adult <strong>Rheumatology</strong>, Children’s Hospital Boston, Brigham and<br />
Women’s Hospital, Boston, MA, 3 Department <strong>of</strong> <strong>Rheumatology</strong><br />
and Immunology, CHUL, QC, Canada, 4 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Immunology and Allergy, Brigham & Women’s Hospital, Boston,<br />
MA, 5 The Department <strong>of</strong> Orthopaedic Surgery, Case Western<br />
Reserve University, School <strong>of</strong> Medicine, University Hospitals<br />
<strong>of</strong> Cleveland, Cleveland, OH, 6 The Department <strong>of</strong> Orthopaedic<br />
Surgery, Case Western Reserve University, School <strong>of</strong> Medicine,<br />
University Hospitals <strong>of</strong> Cleveland, Cleveland, OH.<br />
364. Post-Transcriptional Regulation <strong>of</strong> IL-6 Production by Zc3h12a<br />
in Fibroblast-Like Synovial Cells. Tomohiro Koga, Satoshi<br />
Yamasaki, Akitomo Okada, Shin-ya Kawashiri, Hideki Nakamura,<br />
Atsushi Kawakami and Katsumi Eguchi, Nagasaki University,<br />
Nagasaki, Japan, Nagasaki University, Nagasaki, Japan.<br />
365. Role <strong>of</strong> IL-17 in Pannus Formation and Osteoclastogenesis in<br />
Rheumatoid Arthritis. Hiroshi Ito 2 , Hidehiro Yamada 3 , Toshiko<br />
Nozaki Shibata 2 , Hir<strong>of</strong>umi Mitomi 2 , Kiyomi Matsuo 2 , So Nomoto 1<br />
and Shoichi Ozaki 4 , 1 Department <strong>of</strong> Orthopaedic Surgery and<br />
<strong>Rheumatology</strong>, Saiseikai Yokohama Tobu Hospital, 2 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine, St. Marianna<br />
University School <strong>of</strong> Medicine, Kawasaki, Japan, 3 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine, St. Marianna<br />
University School <strong>of</strong> Medicine, Kawasaki, Japan, 4 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, St. Marianna University School <strong>of</strong> Medicine,<br />
Kawasaki, Japan.<br />
366. Role <strong>of</strong> Raf Kinase Inhibitor Protein in Cytokines, Matrix<br />
Metalloproteinases Regulation and Invasiveness <strong>of</strong><br />
Rheumatoid Fibroblast-Like Synobiocytes. Joong Kyong Ahn 1 ,<br />
You Sun Lee 2 , Eun-Jung Park 3 , Ji-Won Hwang 3 , Ji-Min Oh 3 ,<br />
Jaejoon Lee 3 , Chan-Hong Jeon 4 , Eun-Mi Koh 3 and Hoon-Suk<br />
Cha 3 , 1 Kangbuk Samsung Hospital, Sungkyunkwan University<br />
School <strong>of</strong> Medicine, 2 Masan Samsung Hospital, Sungkyunkwan<br />
University School <strong>of</strong> Medicine, 3 Samsung Medical Center,<br />
Sungkyunkwan University School <strong>of</strong> Medicine, 4 Soonchunhyang<br />
University <strong>College</strong> <strong>of</strong> Medicine.<br />
367. Sublining CD79a+ B Cell Correlates with Joint Destruction in<br />
Rheumatoid Arthritis. Ying-qian Mo 2 , Lie Dai 1 , Dong-hui Zheng 3 ,<br />
Lang-jing Zhu 2 , Xiu-ning Wei 4 and Bai-yu Zhang 2 , 1 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Sun Yat-sen Memorial Hospital, Sun Yat-sen<br />
University, Guangzhou, China, 2 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Sun Yat-sen Memorial Hospital, Sun Yat-sen University,<br />
Guangzhou, China, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Sun Yat-sen<br />
Memorial Hospital, Sun Yat-sen University, Guangzhou, China,<br />
4<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Sun Yat-sen Memorial Hospital,<br />
Sun Yat-sen University, Guangzhou, China.<br />
368. SUMO-2/3 Regulates Apoptosis and MMP Expression in RA<br />
Fibroblast-Like Synoviocytes. Svetlana Frank 3 , Simon Strietholt 3 ,<br />
Christine Seyfert 2 , Thomas Pauly 1 , George Kollias 4 , Thomas<br />
Pap 5 and Marvin A. Peters 3 , 1 Department <strong>of</strong> Nephrology and<br />
<strong>Rheumatology</strong>, Heinrich-Heine University, 2 Department <strong>of</strong><br />
Orthopaedic Surgery, Zeisigwaldkliniken, Chemnitz, Germany,<br />
3<br />
Institute <strong>of</strong> Experimental Musculoskeletal Medicine, University<br />
<strong>of</strong> Muenster, Muenster, Germany, 4 Institute <strong>of</strong> Immunology,<br />
Biomedical Sciences Research Center, Vari, Greece, 5 University<br />
Hospital Münster, Münster, Germany.<br />
369. The 6-O Extracellular Endosulfatases as Novel Regulators <strong>of</strong><br />
Synovitis. Yoon Hoon Hong 1 , Shuhei Otsuki 1 , Shugeru Miyaki 1 ,<br />
Beatriz Caramez 2 , Noboru Taniguchi 1 and Martin Lotz 1 , 1 The<br />
Scripps Research Institute, La Jolla, CA, 2 The Scripps Research<br />
Institute, La Jolla, CA.<br />
2010 Program Book 171
ACR Poster Session A<br />
370. The Critical Role <strong>of</strong> STAT3 in the Th17 Differentiation <strong>of</strong> RA<br />
Synovial T Cells. Ji Hyeon Ju, Mi-La Cho, Ji Min Kim, Yong-Geun<br />
Jeong, Seung-Ki Kwok, Kyung Su Park, Sung-Hwan Park and Ho-<br />
Youn Kim, <strong>College</strong> <strong>of</strong> Medicine, The Catholic University <strong>of</strong> Korea.<br />
371. TNFα-Driven IL-32 Expression in Rheumatoid Arthritis Synovial<br />
Tissue Amplifies an Inflammatory Cascade. Bas Heinhuis 4 ,<br />
Marije I. Koenders 4 , Piet L. van Riel 2 , Charles A. Dinarello 3 ,<br />
Mihai G. Netea 1 , Wim B. van den Berg 4 and Leo A. B. Joosten 1 ,<br />
1<br />
Department <strong>of</strong> Medicine, Radboud University Nijmegen<br />
Medical Centre, Nijmegen the Netherlands, 2 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Radboud University Nijmegen Medical Centre,<br />
Nijmegen, The Netherlands, 3 Division <strong>of</strong> Infectious Diseases,<br />
University <strong>of</strong> Colorado Denver, Aurora, CO, 4 <strong>Rheumatology</strong><br />
Research & Advanced Therapeutics, Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Radboud University Nijmegen Medical Centre,<br />
Nijmegen the Netherlands.<br />
372. Underexpression <strong>of</strong> TIM-3 and Blunted Galectin-9-Induced<br />
Apoptosis <strong>of</strong> CD4+ T Cells in Rheumatoid Arthritis. Jaejoon<br />
Lee 4 , Ji-Min Oh 6 , Ji Won Hwang 6 , Eun-Jung Park 6 , Eun-Kyung<br />
Bae 3 , Joong Kyong Ahn 1 , Yoo Sun Lee 2 , Eun-Mi Koh 5 and<br />
Hoon-Suk Cha 4 , 1 Kangbook Samsung Hospital, Sungkyunkwan<br />
University School <strong>of</strong> Medicine, 2 Masan Samsung Hospital,<br />
Sungkyunkwan University School <strong>of</strong> Medicine, 3 Samsung<br />
Biomedical Research Institute, 4 Samsung Medical Center,<br />
Sungkyunkwan University School <strong>of</strong> Medicine, Seoul, Korea,<br />
Republic <strong>of</strong>, 5 Samsung Medical Center, Sungkyunkwan University<br />
School <strong>of</strong> Medicine, Seoul, Korea, Republic <strong>of</strong>, 6 Samsung<br />
Medical Center, Sungkyunkwan University School <strong>of</strong> Medicine.<br />
Rheumatoid Arthritis Treatment - Small Molecules, Biologics<br />
and Gene Therapy: Safety, Non-Biologic DMARDs, Switching<br />
Biologics I<br />
373. Appearance <strong>of</strong> Non-Rheumatoid Arthralgia after Tocilizumab<br />
Treatment in RA Patients with High Disease Activity. Osamu<br />
Saiki 2 and Hiroshi Uda 1 , 1 Sakai Onshinkai Hospital, Sakai, Japan,<br />
2<br />
Shiraishi Hospital, Imabari, Japan.<br />
374. Are Venous Thrombotic Events (VTE) Increased in Patients with<br />
Rheumatoid Arthritis (RA) Treated with Anti-TNF Therapy?<br />
Results from the British Society for <strong>Rheumatology</strong> Biologics<br />
Register (BSRBR). Rebecca Davies, James Galloway, Kath D.<br />
Watson, Mark Lunt, BSRBR Control Centre Consortium, Deborah<br />
P. M. Symmons, Kimme L. Hyrich and on Behalf <strong>of</strong> the British<br />
Society for <strong>Rheumatology</strong> Biologics Register, University <strong>of</strong><br />
Manchester.<br />
375. Assessment <strong>of</strong> Cardiovascular Markers after 24 Weeks <strong>of</strong><br />
Abatacept or Rituximab Therapy in Patients with Rheumatoid<br />
Arthritis. Sylvain Mathieu 3 , Gauthier Szymanski 1 , Jean-Jacques<br />
Dubost 2 , Natacha Mrozek 4 , Ge<strong>of</strong>froy Marceau 1 , Jean-Michel<br />
Ristori 4 and Martin Soubrier 4 , 1 Biochimie, CHU Gabriel<br />
Montpied, Clermont-Ferrand, France, 2 Humatologie, CHU<br />
Gabriel Montpied, Clermont-Ferrand, France, 3 Rhumatologie,<br />
CHU Gabriel Montpied, Clermont-Ferrand, France,<br />
4<br />
Rhumatologie, CHU Gabriel Montpied, Clermont-Ferrand,<br />
France.<br />
376. Before Beginning Anti-TNF, a Better Targeted Screening and<br />
a Twice Decrease Frequency <strong>of</strong> Latent Tuberculosis (TB) with<br />
IFN gamma Release Assays (IGRA) Compared with Tuberculin<br />
Skin Test. Results in 396 Patients from the ETAT Study. Xavier<br />
Mariette 3 , Gabriel Baron 3 , Frédéric Lioté 3 , Philippe Goupille 4 ,<br />
René-Marc Flipo 1 , Bernard Combe 2 , Florence Tubach 3 ,<br />
Dominique Emilie 3 , Dominique Salmon 3 , Marc Leman 3 , Guislaine<br />
Carcelain 3 and Philippe Ravaud 3 , 1 Lille University, 2 Montpellier<br />
University, 3 Paris University, 4 Tours University.<br />
377. Better Results Are Achieved with Switching Directly to<br />
Biologics Than Switching Via DMARD Combinations in RA<br />
Patients Who Have Failed Methotrexate as Their Initial<br />
DMARD: Real Life Data from NOR-DMARD. Elisabeth Lie 2 , Till<br />
Uhlig 2 , Knut Mikkelsen 3 , Synøve Kalstad 5 , Erik Rødevand 4 , Cecilie<br />
Kaufmann 1 and Tore K. Kvien 2 , 1 Buskerud Central Hospital,<br />
Norway, 2 Diakonhjemmet Hospital, Norway, 3 Lillehammer<br />
Hospital for Rheumatic Diseases, Lillehammer, Norway, 4 St.<br />
Olavs Hospital, Norway, 5 University Hospital <strong>of</strong> Northern<br />
Norway, Norway.<br />
378. Characterization <strong>of</strong> Laboratory Parameters in Long-Term<br />
Extension Studies <strong>of</strong> Tocilizumab in Rheumatoid Arthritis.<br />
William Rigby 3 , Daniel E. Furst 8 , Warren Rizzo 1 , Alexandra<br />
Balbir-Gurman 5 , Moshe Zilberstein 6 , Emma Vernon 7 , Joel M.<br />
Kremer 2 , Andrea Rubbert-Roth 9 and Ronald F. van Vollenhoven 4 ,<br />
1<br />
Advanced Arthritis Care, Scottsdale, AZ, 2 Albany Medical<br />
<strong>College</strong>, Albany, NY, 3 Dartmouth Medical School, Lebanon, NH,<br />
4<br />
Karolinska University Hospital, Stockholm, Sweden, 5 Rambam<br />
Health Care Campus, Haifa, Israel, 6 Roche, Nutley, NJ, 7 Roche,<br />
Welwyn, UK, 8 UCLA Medical Center, Los Angeles, CA, 9 University<br />
<strong>of</strong> Cologne, Cologne, Germany.<br />
379. Disease Activity, Calendar Year, and Physician Preference Are<br />
Associated with Switching <strong>of</strong> Biologic Agents for Reasons<br />
<strong>of</strong> Inadequate Efficacy. Jeffrey R. Curtis 3 , Ying Shan 4 , Joel M.<br />
Kremer 2 , Jeffrey D. Greenberg 1 and George Reed 4 , 1 Millburn,<br />
NJ, 2 The Center for <strong>Rheumatology</strong>, Albany, NY, 3 University<br />
<strong>of</strong> Alabama - Brimingham, Birmingham, AL, 4 University <strong>of</strong><br />
Massachusetts.<br />
380. Early Clinical Response to Treatment Predicts Long-Term<br />
Outcome in RA Patients: 5 Year Follow-Up Results <strong>of</strong> a MTX-<br />
Based Tight Control Strategy (CAMERA). M. F. Bakker 1 , J. W. G.<br />
Jacobs 1 , P. M. J. Welsing 1 , S. A. Vreugdenhil 4 , C. van Booma-<br />
Frankfort 2 , S. P. Linn-Rasker 3 , E. Ton 1 , F. P. J. G. Lafeber 1 and J. W.<br />
J. Bijlsma 1 , 1 <strong>Rheumatology</strong> & Clinical Immunology, University<br />
Medical Center Utrecht, The Netherlands, 2 <strong>Rheumatology</strong>,<br />
Diakonessenhuis Utrecht, The Netherlands, 3 <strong>Rheumatology</strong>,<br />
Meander Medical Center Amersfoort, The Netherlands,<br />
4<br />
<strong>Rheumatology</strong>, St. Antonius Hospital Nieuwegein, The<br />
Netherlands.<br />
381. Early Development <strong>of</strong> Antibodies Against Infliximab Predicts<br />
Withdrawal Due to Adverse Drug Reactions in Patients with<br />
Rheumatoid Arthritis. Sophine B. Krintel 2 , Veit Peter Grunert 4 ,<br />
Merete L. Hetland 1 , Julia S. Johansen 3 , Matthias Rothfuss 4<br />
and Ursula Klause 4 , 1 DANBIO Registry and Department <strong>of</strong><br />
<strong>Rheumatology</strong> at Copenhagen University Hospital, Hvidovre<br />
and Glostrup, Hvidovre, Denmark, 2 DANBIO Registry and<br />
Department <strong>of</strong> <strong>Rheumatology</strong> at Copenhagen University<br />
Hospital, Hvidovre and Glostrup and Department <strong>of</strong> Medicine<br />
at Copenhagen University Hospital, Herlev, Valby, Denmark,<br />
3<br />
Medicine and Oncology at Copenhagen University Hospital,<br />
Herlev, Denmark, 4 Roche Diagnostics GmbH, Penzberg,<br />
Penzberg, Germany.<br />
382. Effect <strong>of</strong> Switching Anti–Tumor Necrosis Factor Agents on<br />
Clinical Outcomes for Patients with Rheumatoid Arthritis.<br />
Amir Goran 2 , Sanjoy Roy 1 , Marco DiBonaventura 2 , Jochen Ertl 2<br />
and Mary Cifaldi 1 , 1 Abbott Laboratories, Abbott Park, IL, 2 Kantar<br />
Health, New York, NY.<br />
172<br />
2010 Program Book
ACR Poster Session A<br />
383. Efficacy and Safety <strong>of</strong> Ocrelizumab in Patients with Active<br />
Rheumatoid Arthritis Who Had an Inadequate Response to<br />
Methotrexate: Results from the Phase III STAGE Trial. William<br />
F. C. Rigby 2 , Hans Peter T. Tony 7 , Kurt R. Oelke 5 , Bernard G.<br />
Combe 8 , Andrew J. Laster 1 , Helen Travers 6 , Carlos A. Von<br />
Muhlen 4 , Elena Fisheleva 6 , Carmen Martin 6 and Wolfgang<br />
Dummer 3 , 1 Arthritis & Osteoporosis Consultants <strong>of</strong> the<br />
Carolinas, Charlotte, NC, 2 Dartmouth Medical School, Lebanon,<br />
NH, 3 Genentech Inc, San Francisco, CA, 4 Pontifical Catholic<br />
University <strong>of</strong> Rio Grande do Sul, Porto Alegre, Brazil, 5 Rheumatic<br />
Disease Center, Glendale, WI, 6 Roche, Welwyn Garden City,<br />
UK, 7 Universitätsklinikum Würzburg, Wuerzburg, Germany,<br />
8<br />
Université Montpellier, Montpellier, France.<br />
384. First Experiences with Pregnancies in RA Patients (pts)<br />
Receiving Tocilizumab (TCZ) Therapy. Andrea Rubbert-Roth 4 ,<br />
Philippe M. Goupille 1 , Shahrzad Moosavi 3 and Antony Hou 2 ,<br />
1<br />
Hopital Trousseau, Tours, France, 2 Inland <strong>Rheumatology</strong> Clinical<br />
Trials, Upland, CA, 3 Roche, Nutley, NJ, 4 University <strong>of</strong> Cologne,<br />
Cologne, Germany.<br />
385. Golimumab and Cardiovascular Disease Markers in<br />
Inflammatory Arthritides. Bruce Kirkham 3 , Mary C. Wasko 8 ,<br />
Joan M. Bathon 4 , Elizabeth C. Hsia 2 , Roy M. Fleischmann 6 , Mark<br />
C. Genovese 7 , Eric L. Matteson 5 , Hongjuan Liu 1 and Mahboob U.<br />
Rahman 2 , 1 Centocor Research and Development, Inc., 2 Centocor<br />
Research and Development, Inc./Univ. <strong>of</strong> Pennsylvania School<br />
<strong>of</strong> Medicine, Malvern, PA, 3 Guy’s and St. Thomas’ Hospital,<br />
London, United Kingdom, 4 Johns Hopkins Univ., School <strong>of</strong><br />
Medicine, Baltimore, MD, 5 Mayo Clinic, Rochester, MN,<br />
6<br />
<strong>Rheumatology</strong> Associates, Dallas, TX, 7 Stanford University,<br />
Sunnyvale, CA, 8 Univ. <strong>of</strong> Pittsburgh.<br />
386. Golimumab and Cardiovascular Disease: Carotid Artery<br />
Ultrasound Evaluation and Cardiovascular Adverse Events.<br />
Joan M. Bathon 5 , Mary Chester Wasko 7 , Bruce Kirkham 4 , Pierre-<br />
Jean Touboul 6 , Elizabeth C. Hsia 3 , Weichun Xu 2 , Jiandong Lu 1 and<br />
Mahboob U. Rahman 3 , 1 Centocor Research and Development,<br />
Inc., Malvern, PA, 2 Centocor Research and Development,<br />
Inc., 3 Centocor Research and Development, Inc./Univ. <strong>of</strong><br />
Pennsylvania School <strong>of</strong> Medicine, Malvern, PA, 4 Guy’s & St.<br />
Thomas’ Hospital, London, United Kingdom, 5 Johns Hopkins<br />
University, Baltimore, MD, 6 Paris-Diderot University, London,<br />
United Kingdom, 7 University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />
387. Hepatitis B Virus Reactivation in Rheumatoid Arthritis and<br />
Ankylosing Spondylitis Patients Using Anti-TNFα Agents: A<br />
Retrospective Analysis <strong>of</strong> 52 Cases with or without Anti-Viral<br />
Prophylaxis. Han Hee Ryu 5 , Eun Young Lee 5 , Kichul Shin 4 , In<br />
Ah Choi 5 , Chul Kim 5 , Yoon Jong Lee 5 , Bin Yoo 7 , Min-Chan Park 6 ,<br />
Yong-Beom Park 6 , Sang-Cheol Bae 1 , Wan Hee Yoo 3 , Sung Il<br />
Kim 2 , Jun Wan Kim 5 , Eun Bong Lee 5 and Yeong Wook Song 5 ,<br />
1<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Hanyang University Hospital for<br />
Rheumatic Diseases, Seoul, Korea, 2 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Department <strong>of</strong> Internal Medicine Pusan National University<br />
Hospital Institutes, Busan, Korea, 3 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Department <strong>of</strong> Internal Medicine, Chonbuk National University<br />
Medical School and Research Institute <strong>of</strong> Clinical Medicine,<br />
Jeonju, Korea, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Internal Medicine, Seoul National University Hospital, Seoul,<br />
Korea, Republic <strong>of</strong>, 5 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Internal Medicine, Seoul National University Hospital, Seoul,<br />
Korea, 6 Divsion <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />
Medicine, Yonsei University <strong>College</strong> <strong>of</strong> Medicine, Seoul, Korea,<br />
7<br />
Divsion or <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine,<br />
University <strong>of</strong> Ulsan, Asan Medical Center, Seoul, Korea.<br />
388. Individual Dose Response Relation for MTX: Prediction <strong>of</strong> the<br />
Optimally Effective Dose in Patients with Early Rheumatoid<br />
Arthritis. Paco M. J. Welsing 1 , Marije F. Bakker 2 and Johannes<br />
W. G. Jacobs 2 , 1 <strong>Rheumatology</strong> & Clinical Immunology and<br />
Julius Center for Health Sciences and Primary Care, University<br />
Medical Center Utrecht, The Netherlands, 2 <strong>Rheumatology</strong> &<br />
Clinical Immunology, University Medical Center Utrecht, The<br />
Netherlands.<br />
389. Long-Term Effect <strong>of</strong> Anti TNF-Alpha Therapies on Insulin<br />
Resistance, Body Composition and Adipokines in Rheumatoid<br />
Arthritis Patients. Esmeralda Delgado-Frias 3 , Vanesa Hernández-<br />
Hernández 2 , Iván Ferraz-Amaro 1 , Juan Carlos Quevedo 1 , Jose R.<br />
Muñiz, Maria T. Arce-Franco, Judith Lopez-Fernandez, Andres<br />
Franco-Maside and Federico Diaz-Gonzalez, 1 La Laguna, S/C<br />
Tenerife, Spain, 2 La Laguna, S/C Tenerfe, Spain, 3 Hospital<br />
Universitario de Canarias, Tenerife, La Laguna, S/C Tenerife,<br />
Spain.<br />
390. Long-Term Safety <strong>of</strong> Abatacept: Integrated Analysis <strong>of</strong><br />
Clinical Program Data <strong>of</strong> up to 7 Years <strong>of</strong> Treatment. Marc<br />
C. Hochberg 7 , Rene Westhovens 4 , Richard Aranda 2 , Sheila M.<br />
Kelly 2 , Nadar Khan 2 , Keqin Qi 2 , Ramesh Pappu 2 , Ingrid Delaet 2 ,<br />
Allison Luo 2 , Anne Torbeyns 3 , Larry W. Moreland 6 , Roger B.<br />
Cohen 5 , Sheila Gujrathi 2 and Michael E. Weinblatt 1 , 1 Brigham<br />
& Womens Hospital, Boston, MA, 2 Bristol-Myers Squibb,<br />
Princeton, NJ, 3 Bristol-Myers Squibb, Braine-l’Alleud, Belgium,<br />
4<br />
Catholic University <strong>of</strong> Leuven, Leuven, Belgium, 5 Fox Chase<br />
Cancer Center, Philadelphia, PA, 6 Univ <strong>of</strong> Pittsburgh Med Ctr,<br />
Pittsburgh, PA, 7 University <strong>of</strong> Maryland, Baltimore, MD.<br />
391. Long-Term Safety <strong>of</strong> Rituximab: Follow-Up <strong>of</strong> the Rheumatoid<br />
Arthritis Clinical Trials and Retreatment Population. Ronald<br />
van Vollenhoven 5 , Paul Emery 2 , Clifton O. Bingham 4 , Edward<br />
C. Keystone 9 , Roy M. Fleischmann 8 , Daniel E. Furst 7 , Katherine<br />
Macey 6 , Marianne Sweetser 1 , Patricia Lehane 6 , Pam Farmer 3<br />
and Simon G. Long 6 , 1 Biogen Idec Inc, 2 Chapel Allerton Hospital,<br />
Leeds, United Kingdom, 3 Genentech Inc, 4 Johns Hopkins<br />
University, Baltimore, MD, 5 Karolinska Institute, Stockholm,<br />
Sweden, 6 Roche Products Ltd, 7 University <strong>of</strong> California Los<br />
Angeles Medical School, Los Angeles, CA, 8 University <strong>of</strong> Texas<br />
Southwestern Medical Center, Dallas, TX, 9 University <strong>of</strong> Toronto,<br />
Toronto, ON, Canada.<br />
392. Low-Dose Glucocorticoid Chronotherapy <strong>of</strong> Rheumatoid<br />
Arthritis: 12 Week Efficacy and Safety <strong>of</strong> Modified-Release<br />
(MR) Prednisone. Frank Buttgereit 2 , Daksha P. Mehta 3 , John R.<br />
Kirwan 1 , Jacek Szechinski 7 , Maarten Boers 12 , Rieke Alten 10 , Jerzy<br />
Supronik 8 , István Szombati 9 , Ulrike Römer 4 , Stephan Witte 5 ,<br />
Amy Grahn 6 and Kenneth G. Saag 11 , 1 Bristol Royal Infirmary,<br />
Bristol, United Kingdom, 2 Charite University Med-Berlin,<br />
Berlin, Germany, 3 Ctr Arthritis & Osteoporosis, Elizabethtown,<br />
KY, 4 Horizon Pharma GmbH, Mannheim, Germany, 5 Horizon<br />
Pharma GmbH, Mannheim, Germany, 6 Horizon Pharma, Inc.,<br />
Northbrook, IL, 7 Med. University Dept. <strong>of</strong> <strong>Rheumatology</strong>,<br />
Wroclaw, Poland, 8 NZOZ Centrum Medyczne, Bialystok, Poland,<br />
9<br />
OEC, Budapest, Hungary, 10 Schlosspark-Klinik, UnivMed, Berlin,<br />
Germany, 11 University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />
12<br />
VU University Medical Center, Amsterdam, The Netherlands.<br />
393. Metanalysis on the Effect <strong>of</strong> TNF-Inhibitors on Lipid Pr<strong>of</strong>ile.<br />
Claire Immediato Daien 1 , Yohan Duny 3 , Thomas Barnetche 2<br />
and Jacques Morel 1 , 1 Département de Rhumatologie,<br />
Hôpital Lapeyronie, Montpellier, France, 2 Département de<br />
Rhumatologie, Hôpital Pellegrin, Bordeaux, France, 3 Institut<br />
Universitaire de Recherche Clinique, Service de Biostatistiques,<br />
Epidémiologie et Santé Publique, Montpellier, France.<br />
2010 Program Book 173
ACR Poster Session A<br />
174<br />
394. Methothrexate Directly Inhibits RANKL Expression and<br />
Osteoclasts Formation in Very Early Arthritis. Shankar Revu,<br />
Petra Neregård, Erik Afklint and Anca Irinel Catrina, Department<br />
<strong>of</strong> Medicine, <strong>Rheumatology</strong> Unit, Karolinska University Hopsital<br />
and Karolinska Institute, Stockholm, Sweden.<br />
395. Non-Infectious Pulmonary Complications <strong>of</strong> Biologic Agents<br />
for Rheumatic Diseases – A Systematic Literature Review.<br />
Andreas Hadjinicolaou 2 , Shweta Bhagat 1 and Andrew Ostor 1 ,<br />
1<br />
<strong>Rheumatology</strong> Research Unit, Addenbrooke’s Hospital,<br />
Cambridge, Cambridge, United Kingdom, 2 University <strong>of</strong><br />
Cambridge, United Kingdom.<br />
396. Parenteral MTX as an Initial Treatment Strategy for Early<br />
Rheumatoid Arthritis: Results from a Nationwide Cohort.<br />
Vivian P. Bykerk 2 , David S. Rowe 3 , Janet E. Pope 5 , CATCH<br />
Scientific Advisory Committee 1 , Ashley Bonner 1 and J. Carter<br />
Thorne 4 , 1 Canada, 2 Mt Sinai Hospital, Toronto, ON, Canada,<br />
3<br />
Saba University School <strong>of</strong> Medicine, Stouffville, ON, Canada,<br />
4<br />
Southlake Regional Health Care, Newmarket, ON, Canada, 5 St<br />
Joseph Health Care London, London, ON, Canada.<br />
397. Polymorphisms in the Folate Metabolism Gene MTHFR<br />
(C677T and A1298C) Are Not Associated with Methotrexate<br />
Adherence: Findings from the Veteran’s Affairs Rheumatoid<br />
Arthritis (VARA) Registry. Lisa A. Davis 2 , Grant W. Cannon 5 ,<br />
Roger Wolff 6 , Leah Haverhals 3 , Ted R. Mikuls 7 , Andreas M.<br />
Reimold 1 , Gail S. Kerr 8 , John S. Richards 8 , Dannette S. Johnson 4<br />
and Liron Caplan 2 , 1 Dallas VAMC, Dallas, TX, 2 Denver VAMC,<br />
Aurora, CO, 3 Denver VAMC, 4 Jackson VAMC, Jackson, MS, 5 Salt<br />
Lake City VAMC, Salt Lake City, UT, 6 Salt Lake City VAMC, 7 Univ<br />
<strong>of</strong> Nebraska Med Ctr, Omaha, NE, 8 Washington, D.C. VAMC,<br />
Washington, DC.<br />
398. Pooled Analysis <strong>of</strong> Observational Studies on Lymphoma<br />
Incidence among Rheumatoid Arthritis (RA) Patients Initiating<br />
Etanercept Therapy. Peter McCroskery 2 , Virgil C. Dias 2 , Scott<br />
Stryker 3 , Bojena Bitman 3 , Sean Z. Zhao 2 and Debra J. Zack 1 ,<br />
1<br />
Amgen Inc, Thousand Oaks, CA, 2 Amgen Inc., Thousand Oaks,<br />
CA, 3 Amgen Inc.<br />
399. Post-Marketing Surveillance Program <strong>of</strong> Tocilizumab for<br />
RA in Japan – Interim Analyses <strong>of</strong> 3,881 Patients. Takao<br />
Koike 2 , Masayoshi Harigai 8 , Shigeko Inokuma 3 , Naoki<br />
Ishiguro 6 , Junnosuke Ryu 7 , Tsutomu Takeuchi 5 , Syuji Takei 4 ,<br />
Yoshiya Tanaka 10 , Hisashi Yamanaka 9 and Kyoko Ito 1 , 1 Chugai<br />
Pharmaceutical Co.Ltd, 2 Hokkaido University, Japan, 3 Japanese<br />
Red Cross Medical Center, 4 Kagoshima University, Kagoshima<br />
City, Japan, 5 Keio University, Toyko, Japan, 6 Nagoya University,<br />
7<br />
Nihon University, 8 Tokyo Medical and Dental University, Tokyo,<br />
Japan, 9 Tokyo Womens Med Univ, Shinjuku-ku, Tokyo, Japan, 10 U<br />
Occupa & Environ Hlth, Kitakyushu, Japan.<br />
400. Predictive Risk Factors <strong>of</strong> Severe Infections in RA Patients<br />
Treated with Abatacept in Real Life: Results from the<br />
Orencia and Rheumatoid Arthritis (ORA) Registry. Jacques-<br />
Eric Gottenberg 11 , Philippe Ravaud 5 , Thomas Bardin 7 , Patrice<br />
Cacoub 6 , Aain Cantagrel 12 , Bernard Combe 9 , Maxime Dougados 3 ,<br />
René-Marc Flipo 8 , Bertrand Godeau 4 , Loic Guillevin 3 , Eric<br />
Hachulla 8 , Xavier Le Loët 10 , Thierry Schaeverbeke 2 , Jean<br />
Sibilia 11 , Gabriel Baron 5 and Xavier Mariette 1 , 1 Bicetre Hospital,<br />
2<br />
Bordeaux Hospital, 3 Cochin Hospital, 4 Henri Mondor Hospital,<br />
5<br />
Hotel Dieu Hospital, 6 La Pitié Hospital, 7 Lariboisière Hospital,<br />
8<br />
LIlle Hospital, 9 Montpellier Hospital, 10 Rouen Hospital,<br />
11<br />
Strasbourg Hospital, 12 Toulouse Hospital.<br />
401. Pregnancy Outcomes in Patients with Autoimmune Diseases<br />
Treated with Rituximab. Eliza F. Chakravarty 1 , Elaine Murray 2 ,<br />
Ariella Kelman 2 and Pamela Farmer 3 , 1 Mountain View, CA,<br />
2<br />
Genentech, South San Francisco, CA, 3 Genentech.<br />
2010 Program Book<br />
402. Pulmonary Function in Patients with Rheumatoid Arthritis<br />
Treated with Anti-TNF Biologic Agents. Andrew J. Odden 1 , Ann<br />
J. Impens 2 , Elena Schiopu 2 , Kevin Flaherty 1 and Kristine Phillips 2 ,<br />
1<br />
University <strong>of</strong> Michigan, 2 University <strong>of</strong> Michigan, Ann Arbor, MI.<br />
403. Rate <strong>of</strong> Serious Infections in RA Patients Who Subsequently<br />
Receive Other Biologic Therapies after Discontinuing<br />
Rituximab Treatment. Mark C. Genovese 8 , Ferdinand<br />
Breedveld 4 , Paul Emery 2 , Stanley B. Cohen 6 , Ed C. Keystone 9 ,<br />
Eric L. Matteson 5 , Laura Burke 7 , Akiko Chai 3 , William Reiss 3 ,<br />
Marianne Sweetser 1 and Tim Shaw 7 , 1 Biogen Idec, 2 Chapel<br />
Allerton Hospital, Leeds, United Kingdom, 3 Genentech, 4 Leiden<br />
Univ, 5 Mayo Clinic, Rochester, MN, 6 <strong>Rheumatology</strong> Associates,<br />
Dallas, TX, 7 Roche, 8 Stanford Univ, Sunnyvale, CA, 9 University <strong>of</strong><br />
Toronto, Toronto, ON, Canada.<br />
404. Rates <strong>of</strong> Tuberculosis and Nontuberculous Mycobacterial<br />
Disease among Rheumatoid Arthritis Patients Who Use<br />
Anti-Tumor Necrosis Factor alpha Therapy; from the SAfety<br />
<strong>of</strong> Biologic ThERapy (SABER) Study. K. L. Winthrop 2 , John<br />
Baddley 4 , Lang Chen 4 , Liyan Liu 1 , Carlos G. Grijalva 8 , Nivedita M.<br />
Patkar 3 , Fenlong Xie 4 , Elizabeth Delzell 4 , Timothy Beukelman 6 ,<br />
Lisa J. Herrinton 1 , Kenneth G. Saag 7 and Jeffrey R. Curtis 5 ,<br />
1<br />
Kaiser-Permanente, 2 OSHU, 3 Univ <strong>of</strong> AL at Birmingham,<br />
Birmingham, AL, 4 Univ <strong>of</strong> AL at Birmingham, 5 University<br />
<strong>of</strong> Alabama-Brimingham, Birmingham, AL, 6 University <strong>of</strong><br />
Alabama-Birmingham, Birmingham, AL, 7 University <strong>of</strong> Alabama-<br />
Birmingham, Birmingham, AL, 8 Vanderbilt.<br />
405. Real Life Analysis <strong>of</strong> the Romanian Experience in Switching<br />
from Anti-TNF Based Therapy to Rituximab. Ioan Ancuta 1 ,<br />
Catalin Codreanu 2 , Ruxandra Maria Ionescu 4 , Horatiu Bolosiu 5 ,<br />
Magda Parvu 3 and Lia Georgescu 6 , 1 ”Dr. I. Cantacuzino” Hospital,<br />
Bucharest, Romania, 2 ”Dr. I. Stoia” Center for Rheumatic<br />
Diseases, Bucharest, Romania, 3 ”N. Gh. Lupu” Clinical Hospital,<br />
Bucharest, Romania, 4 ”Sfanta Maria” Clinical Hospital,<br />
Bucharest, Romania, 5 <strong>Rheumatology</strong> Clinic, Cluj - Napoca,<br />
Romania, 6 <strong>Rheumatology</strong> Clinic, Tirgu-Mures, Targu - Mures,<br />
Romania.<br />
406. Real Life Treatment with Rituximab in TNF Blocker Non-<br />
Responders Is Superior to Treatment with a Second TNF<br />
Blocker. Joern Kekow 4 , Ulf Müller-Ladner 2 , Hendrik Schulze-<br />
Koops 1 , Ralf Link 3 , Steffen Breuer 3 and Monika Kobialko 3 ,<br />
1<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Munich, Germany,<br />
2<br />
Justus-Liebig University Giessen, Kerckh<strong>of</strong>f Clinic, Bad Nauheim,<br />
Germany, 3 Roche Pharma AG, Grenzach-Wyhlen, Germany,<br />
4<br />
Specialized Hospital for <strong>Rheumatology</strong> & Orthopaedics,<br />
Vogelsang-Gommern, Vogelsang-Gommern, Germany.<br />
407. Risk <strong>of</strong> Malignancies in Patients with Rheumatoid Arthritis<br />
Treated with Biologic Therapy: Meta-Analysis <strong>of</strong> Controlled<br />
Trials. Maria A. Lopez-Olivo 4 , Juan A. Martinez-Lopez 2 , Jean H.<br />
Tayar 7 , Jose Polo Cueto 5 , Eduardo N. Pollono 3 , M. Rosa Gonzales-<br />
Crespo 1 , Stephanie Fulton 6 and Maria E. Suarez-Almazor 7 ,<br />
1<br />
Hospital 12 de Octubre, 2 Spanish Society <strong>of</strong> <strong>Rheumatology</strong>,<br />
Spain, 3 Texas Tech University Health Science Center - Paul Foster<br />
School <strong>of</strong> Medicine, 4 The University <strong>of</strong> Texas M.D. Anderson<br />
Cancer Center, Houston, TX, 5 The University <strong>of</strong> Texas MD<br />
Anderson Cancer Center, 6 University <strong>of</strong> Texas, MD Anderson<br />
Cancer Center, Houston, TX, 7 UT M D Anderson Cancer Ctr,<br />
Houston, TX.<br />
408. Risk <strong>of</strong> Malignancy during Anti-TNF alfa Therapy in Patients<br />
with Rheumatoid Arthritis: Systematic Review and Meta-<br />
Analysis <strong>of</strong> Registries, Long-Term Extension Studies and<br />
Randomized Controlled Trials. Pierre Le Blay 3 , Gael Mouterde 4 ,<br />
Thomas Barnetche 1 and Bernard G. Combe 2 , 1 Bordeaux<br />
University Hospital, 2 Hopital Lapeyronie, Montpellier, France,<br />
3<br />
Hopital Lapeyronie, France, 4 Hopital Lapeyronie.
ACR Poster Session A<br />
409. Rituximab vs TNF-Inhibitor Cycling in Patients Who Previously<br />
Failed to TNF-Inhibitors: The MIRAR Study. Juan-Jesús Gómez-<br />
Reino 1 , Raimon Sanmartí 2 , Ana-Belen Romero 3 and Laura<br />
Monclus 3 , 1 Hospital Clínico Universitario / Xeral de Galicia,<br />
Santiago de Compostela, 2 Hospital Clinic, Barcelona, 3 Roche.<br />
410. Rituximab vs. Anti-TNF after Failure <strong>of</strong> Anti-TNF: An<br />
Observational Study. Katerina Chatzidionysiou 2 and Ronald<br />
Van Vollenhoven 1 , 1 Karolinska University Hospital, Stockholm,<br />
Sweden, 2 Karolinska University Hospital, Stockholm.<br />
411. Safety and Tolerability <strong>of</strong> Tocilizumab in Long-Term Extension<br />
Studies <strong>of</strong> Rheumatoid Arthritis. Mark C. Genovese 5 , Anthony<br />
Sebba 7 , Andrea Rubbert-Roth 6 , Juan J. Scali 1 , Moshe Zilberstein 3 ,<br />
Emma Vernon 4 and Ronald F. van Vollenhoven 2 , 1 Durand<br />
University Hospital, Buenos Aires, Argentina, 2 Karolinska<br />
University Hospital, Stockholm, Sweden, 3 Roche, Nutley, NJ,<br />
4<br />
Roche, Welwyn, UK, 5 Stanford University Medical Center, Palo<br />
Alto, Palo Alto, CA, 6 University <strong>of</strong> Cologne, Cologne, Germany,<br />
7<br />
University <strong>of</strong> South Florida, Palm Harbor, FL.<br />
412. Safety <strong>of</strong> Combination Therapies in Early RA: A Systematic<br />
Comparison between Combination DMARDs and TNF<br />
Inihibitors with Methotrexate. Margaret H. Y. Ma 2 , Andrew P.<br />
Cope 1 and David L. Scott 2 , 1 Surrey, United Kingdom, 2 Academic<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, King’s <strong>College</strong> London.<br />
413. Scleritis: A New Paradoxical Effect <strong>of</strong> Etanercept? A Series <strong>of</strong><br />
3 Cases and a Systematic Literature Review <strong>of</strong> Etanercept-<br />
Associated Inflammatory Eye Disease. Cécile Gaujoux-Viala 1 ,<br />
Cecilia Giampietro 2 , Thomas Gaujoux 3 , Hang-Korng Ea 4 ,<br />
Philippe Orcel 4 and Frédéric Lioté 4 , 1 Paris 6 – Pierre et Marie<br />
Curie University; <strong>Rheumatology</strong>, Pitié-Salpêtrière Hospital,<br />
Paris, France, 2 Paris 6 – Pierre et Marie Curie University;<br />
<strong>Rheumatology</strong>, Pitié-Salpêtrière Hospital, Paris, France<br />
2<br />
University <strong>of</strong> L’Aquila, L’Aquila, Italy, 3 Paris 7 University,<br />
Medicine Faculty; AP-HP, Lariboisière Hospital, Ophtalmology<br />
Department, Paris, France, 4 Paris Diderot University, School<br />
<strong>of</strong> Medicine; Lariboisière Hospital, AP-HP, <strong>Rheumatology</strong><br />
Department, Paris, France.<br />
414. Serious Infections with Ocrelizumab in Rheumatoid Arthritis:<br />
Pooled Results from Double-Blind Periods <strong>of</strong> the Ocrelizumab<br />
Phase III RA Program. Paul Emery 3 , William F. C. Rigby 5 , Paul P.<br />
Tak 1 , T. Dörner 4 , Ewa Olech 9 , Mark C. Genovese 11 , G. Ferraccioli 2 ,<br />
Emilio Martin-Mola 8 , Maxime Dougados 7 , Helen Travers 10 , E.<br />
Fisheleva 10 and Wolfgang Dummer 6 , 1 Academic Med Ctr/Univ<br />
<strong>of</strong> Amsterdam, Amsterdam, The Netherlands, 2 Catholic Univ,<br />
3<br />
Chapel Allerton Hospital, Leeds, United Kingdom, 4 Charité<br />
Univ Hospital, 5 Dartmouth-Hitchcock Med Ctr, Lebanon,<br />
NH, 6 Genentech, 7 Hospital Cochin, Paris, France, 8 Hospital<br />
Universitario La Paz, Madrid, Spain, 9 Oklahoma Medical<br />
Research Foundation, Oklahoma City, OK, 10 Roche, 11 Stanford<br />
Univ, Sunnyvale, CA.<br />
415. Subsequent Therapy <strong>of</strong> Patients with Biologic Response<br />
Modifiers after a Diagnosis <strong>of</strong> Coccidiomycosis Infection. Sara<br />
Taroumian 3 , Jeffrey R. Lisse 5 , Eric P. Gall 5 , Rafael G. Grau 5 , Neil<br />
M. Ampel 2 , Susan E. Hoover 4 , James Yanes 4 and Berchman Vaz 1 ,<br />
1<br />
Tucson, AZ, 2 Southern Arizona VA Health Care System, Tucson,<br />
AZ, 3 The University <strong>of</strong> Arizona Department <strong>of</strong> Internal Medicine,<br />
Tucson, AZ, 4 The University <strong>of</strong> Arizona Section <strong>of</strong> Infectious<br />
Diseases, Tucson, AZ, 5 The University <strong>of</strong> Arizona Section <strong>of</strong><br />
<strong>Rheumatology</strong>, Arizona Arthritis Center, Tucson, AZ.<br />
416. Switching Patients (pts) with Rheumatoid Arthritis (RA) from<br />
Intravenous (IV) to Subcutaneous (SC) Abatacept Is Well<br />
Tolerated and Sustains Previously Established Efficacy. Edward<br />
C. Keystone 9 , Joel M. Kremer 6 , Anthony S. Russell 7 , Jane H.<br />
Box 1 , Carlos Abud-Mendoza 5 , Mario Alberto Garza Elizondo 4 ,<br />
Allison Luo 2 , Richard Aranda 2 , Ingrid Delaet 2 , Rene Swanink 3 ,<br />
Sheila Gujrathi 2 and Michael E. Luggen 8 , 1 Box Arthritis and<br />
<strong>Rheumatology</strong> <strong>of</strong> the Carolinas, Charlotte, NC, 2 Bristol-Myers<br />
Squibb, Princeton, NJ, 3 Bristol-Myers Squibb, Braine-l’Alleud,<br />
Belgium, 4 Faculty <strong>of</strong> Medicine, Universidad Autónoma de Nuevo<br />
León, Monterrey, NL, Mexico, 5 Regional Unit <strong>of</strong> <strong>Rheumatology</strong>,<br />
Faculty <strong>of</strong> Medicine and Central Hospital, University <strong>of</strong> San Luis<br />
Potosí, San Luis Potosi, Mexico, 6 The Center for <strong>Rheumatology</strong>,<br />
Albany, NY, 7 University <strong>of</strong> Alberta, Edmonton, AB, Canada,<br />
8<br />
University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong> Medicine, Cincinnati, OH,<br />
9<br />
University <strong>of</strong> Toronto and Mount Sinai Hospital, Toronto, ON,<br />
Canada.<br />
417. The Effect on MTX Polyglutamate Concentration Pr<strong>of</strong>ile<br />
after Changing from Oral to Subcutaneous Methotrexate in<br />
Rheumatoid Arthritis. Lisa K. Stamp 4 , John L. O’Donnell 1 , Peter<br />
Chapman 3 , Mei Zhang 2 , Jill James 3 , Christopher Frampton 5 and<br />
Murray Barclay 5 , 1 Canterbury Health Laboratories, Christchurch,<br />
New Zealand, 2 Canterbury Health Laboratories, 3 Christchurch<br />
Hospital, 4 University <strong>of</strong> Otago, Christchurch, New Zealand,<br />
5<br />
University <strong>of</strong> Otago.<br />
418. TNF Switch after Failure <strong>of</strong> One or More TNF Inhibitors –<br />
Results <strong>of</strong> an Observational Study. Katerina Chatzidionysiou 2<br />
and Ronald Van Vollenhoven 1 , 1 Karolinska University Hospital,<br />
Stockholm, Sweden, 2 Karolinska University Hospital, Stockholm.<br />
419. TNF Therapy and the Risk <strong>of</strong> Serious Infection and Malignancy<br />
in Patients with Early Rheumatoid Arthritis: A Meta-Analysis<br />
<strong>of</strong> Randomized Controlled Trials. Andrew E. Thompson 2 , Janet<br />
E. Pope 1 and Scott W. Rieder 3 , 1 St Joseph Health Care London,<br />
London, ON, Canada, 2 University <strong>of</strong> Western Ontario, London,<br />
ON, Canada, 3 University <strong>of</strong> Western Ontario.<br />
420. Treatment with Infliximab Improves Clinical Response and<br />
Physical Function in Patients with Moderate or Severe<br />
Rheumatoid Arthritis Actively Switch from Etanercept or<br />
Adalimumab Therapy. Roy M. Fleischmann 8 , John A. Goldman 2 ,<br />
Marjatta Leirisalo-Repo 4 , Ellen I. Zanetakis 7 , Hisham S. El-Kadi 1 ,<br />
Herbert L. Kellner 6 , Rebecca Bolce 3 , Jim Wang 5 , Raphael<br />
Dehoratius 3 and Dennis Decktor 3 , 1 Arthritis and Osteoporosis<br />
Association, Freehold, NJ, 2 Atlanta Center for Clinical Research,<br />
3<br />
Centocor Ortho Biotech Services, LLC, 4 Helsinki University<br />
Central Hospital, Helsinki, Finland, 5 Johnson and Johnson<br />
Pharmaceutical Research and Development, LLC, 6 Medizinische<br />
Poliklinik/Munich University Hospital, Munchen, Germany,<br />
7<br />
Oklahoma Center for Arthritis Therapy, Tulsa, OK, 8 University <strong>of</strong><br />
Texas SW Medical Center, Dallas, TX.<br />
421. Varicella Zoster Virus (VZV) Infections Are Increased in<br />
Patients with Rheumatoid Arthritis (RA) Treated with Anti-TNF<br />
Therapy; Results from the British Society for <strong>Rheumatology</strong><br />
Biologics Register (BSRBR). James Galloway 1 , Alison Moseley 2 ,<br />
Lousie Mercer 2 , Will Dixon 2 , Bo Fu 2 , Andrew Ustianowski 2 ,<br />
Kath Watson 2 , Mark Lunt 2 , BSRBR Control Centre Consortium 2 ,<br />
Kimme Hyrich 2 , Deborah Symmons 2 and on Behalf <strong>of</strong> the British<br />
Society for <strong>Rheumatology</strong> Biologics Register 2 , 1 University <strong>of</strong><br />
Manchester, Manchester, United Kingdom, 2 University <strong>of</strong><br />
Manchester.<br />
2010 Program Book 175
ACR Poster Session A<br />
Systemic Lupus Erythematosus - Animal Models<br />
422. Altered microRNA Expression in the Murine Tri-Congenic<br />
B6.Sle123 Model. Barry Garchow 1 , Yiu Tak Leung 3 , Roberto<br />
Caricchio 2 and Marianthi Kiriakidou 1 , 1 Department <strong>of</strong> Medicine,<br />
University <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine, Philadelphia,<br />
PA, 2 Temple Univ Med Office Bldg, Philadelphia, PA, 3 Thomas<br />
Jefferson University Hospital, Philadelphia, PA.<br />
423. Amelioration <strong>of</strong> Lupus Nephritis by a Macromolecular Prodrug<br />
<strong>of</strong> Dexamethasone in NZB/W F1 Mice. Fang Yuan 2 , Richard K.<br />
Nelson 2 , Xin-ming Liu 2 , Karen A. Gould 2 and Dong Wang 1 , 1 Univ<br />
Nebraska Med Ctr, Omaha, NE, 2 University <strong>of</strong> Nebraska Medical<br />
Center.<br />
424. An Intrinsic B Cell Defect That Affects Toll-Like Receptor<br />
Signaling Supports Autoimmunity in New Zealand Black<br />
Chromosome 13 Congenic Mice. Christina Loh 2 , Evelyn Pau 3 ,<br />
Nan-Hua Chang 1 and Joan E. Wither 2 , 1 University Health<br />
Network, 2 University <strong>of</strong> Toronto, Toronto, ON, Canada,<br />
3<br />
University <strong>of</strong> Toronto.<br />
425. Breach <strong>of</strong> B Cell Tolerance in New Zealand Black Chromosome<br />
1 Congenic Mice. Nan-Hua Chang 1 , Evelyn Pau 3 , Christina Loh 3<br />
and Joan E. Wither 2 , 1 Toronto Western Research Institute,<br />
Toronto, ON, Canada, 2 University Health Network, Toronto, ON,<br />
Canada, 3 University <strong>of</strong> Toronto.<br />
426. Dysfunction <strong>of</strong> Hematopoietic Stem Cells in Lupus Mice. Haitao<br />
Niu 2 , Luokun Xie 3 , Laurence Marguerite Morel 4 , Betty Diamond 1<br />
and Yong-rui Zou 3 , 1 Feinstein Institute for Medical Research,<br />
Manhasset, NY, 2 The Feinstein Institute for Medical Research,<br />
Manhasset, NY, 3 The Feinstein Institute for Medical Research,<br />
4<br />
University <strong>of</strong> Florida.<br />
427. Engraftment <strong>of</strong> PBMC from SLEand ACL Donors into BALB-<br />
Rag2 -/- IL2Rgc - KO Mice: A Promising Model for Studying<br />
SLE. Danieli Andrade 1 , Milena Vukelic 2 , Patricia B. Redecha 1 ,<br />
Xiaoping Qing 1 , Giorgio Perino 3 , Jane E. Salmon 2 and Gloria C.<br />
Koo 4 , 1 Hospital for Special Surgery, NY, NY, 2 Hospital for Special<br />
Surgery, New York, NY, 3 Hospital for Special Surgery, NY, NY,<br />
4<br />
Hospital for Special Surgery, New York, NY.<br />
428. Enhancement <strong>of</strong> IL-17 and Interferon-gamma Inflammatory<br />
Pathways in IRF9-/- MRL/lpr Mice with Disrupted Type I<br />
Interferon Signaling. Alvina D. Chu 2 , Nicole H. Kattah 3 , Michael<br />
T. Wong 3 , Catherine Tadina 3 and Paul J. Utz 1 , 1 Stanford Univ Schl<br />
<strong>of</strong> Med, Stanford, CA, 2 Stanford University School <strong>of</strong> Medicine,<br />
Palo Alto, CA, 3 Stanford University School <strong>of</strong> Medicine.<br />
429. Epistatic Interactions between Lupus Susceptibility Loci on<br />
New Zealand Black Chromosomes 1 and 13 Lead to Marked<br />
Expansion <strong>of</strong> Dendritic Cell Populations but Have Little Effect<br />
on Autoimmunity. Yui Ho Cheung 2 , Evelyn Pau 2 and Joan E.<br />
Wither 1 , 1 University Health Network, Toronto, ON, Canada,<br />
2<br />
University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />
430. Hypercholesterolaemia and Autoimmunity Interact in a<br />
Mouse Model <strong>of</strong> Systemic Lupus Erythematosus To Enhance<br />
Both Atherosclerosis and Renal Inflammation, but by Distinct<br />
Mechanisms. Myles J. Lewis 2 , Talat H. Malik 2 , Liliane M. Fossati-<br />
Jimack 2 , Daniele Carassiti 2 , Terence H. Cook 2 , Dorian O. Haskard 1<br />
and Marina Botto 1 , 1 Imperial <strong>College</strong>, London, United Kingdom,<br />
2<br />
Imperial <strong>College</strong>.<br />
431. IL-17 Promotes Autoimmunity in Pristane-Induced Lupus.<br />
Elaine V. Lourenco, Chunlin Cai, Bevra H. Hahn and Antonio La<br />
Cava, UCLA.<br />
432. IL-21 Promotes Autoimmune Features in Chronic Graft Versus<br />
Host Disease by Enhancing T Follicular Helper Development<br />
and B Cell Response. Vinh Nguyen 3 , Irina G. Luzina 1 , Qing Chen 1 ,<br />
Horea Rus 1 and Violeta Rus 2 , 1 Baltimore, MD, 2 Univ <strong>of</strong> Maryland<br />
Schl <strong>of</strong> Med, Baltimore, MD, 3 University <strong>of</strong> Maryland School <strong>of</strong><br />
Medicine, Baltimore, MD.<br />
433. Interferon Regulatory Factor-5 (IRF-5) Is Critical for the<br />
Development <strong>of</strong> Lupus in MRL/lpr Mice. Yoshifumi Tada 3 , Seiji<br />
Kondo 4 , Shigehisa Aoki 2 , Syuichi Koarada 3 , Hisako Inoue 3 , Rie<br />
Suematsu 3 , Akihide Ohta 1 and Kohei Nagasawa 3 , 1 Department<br />
<strong>of</strong> Clinical Nursing, Saga University, Saga, Japan, 2 Department<br />
<strong>of</strong> Pathology, Saga University, Saga, Japan, 3 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Saga University, Saga, Japan, 4 National Hospital<br />
Organization Kyushu Medical Center, Fukuoka, Japan.<br />
434. Interferonα Causes SLE by Expanding CD3+ CD4- CD8- Double<br />
Negative T Cell (DN T Cell). Chieri Akiyama 1 , Eriko Honda 1 ,<br />
Akira Hashiramoto 2 , Dean W. Felsher 3 and Shunichi Shiozawa 2 ,<br />
1<br />
Department <strong>of</strong> Biophysics, Graduate School <strong>of</strong> Health<br />
Science, Kobe University, Kobe, Hyogo, Japan, 2 Department <strong>of</strong><br />
Biophysics, Graduate School <strong>of</strong> Health Science, Kobe University/<br />
Department <strong>of</strong> Medicine, Graduate School <strong>of</strong> Medicine, Kobe<br />
University/The Center for Rheumatic Disease, Kobe University<br />
Hospital, Kobe, Japan, 3 Stanford University, School <strong>of</strong> Medicine,<br />
Division <strong>of</strong> Oncology, Department <strong>of</strong> Medicine and Pathology,<br />
Stanford, CA.<br />
435. IRF4-Deficient Lupus-Prone MRL/lpr Mice Lack Serum Ig/<br />
Auto-Abs and Th17 Cells but Develop Non-Immune Complex-<br />
Mediated Diffuse Proliferative Glomerulonephritis and<br />
Dermatitis/Ear Necrosis. Hideharu Sekine 4 , Takeshi Machida 1 ,<br />
Eiji Suzuki 3 , Efrain Martinez Avila 3 , Phil Ruiz 5 , Christopher M.<br />
Reilly 6 and Gary S. Gilkeson 2 , 1 Fukushima Medical University,<br />
Fukushima, Japan, 2 Med Univ <strong>of</strong> South Carolina, Charleston, SC,<br />
3<br />
Medical University <strong>of</strong> South Carolina, Charleston, SC, 4 Medical<br />
University <strong>of</strong> South Carolina/Fukushima Medical University,<br />
Charleston, SC, 5 University <strong>of</strong> Miami, Miami, FL, 6 Virginia Tech,<br />
VA.<br />
436. Long-Term Anti-CD20 Treatment Reduces Antibody-Secreting<br />
Ells in NZB/W Lupus Mouse. Wensheng Wang 2 , Terasa Owen 2 ,<br />
Travis Ichikawa 2 and Jennifer H. Anolik 1 , 1 University <strong>of</strong> Rochester,<br />
Rochester, NY, 2 University <strong>of</strong> Rochester Medical Center,<br />
Rochester, NY.<br />
437. Mitochondrial Dysfunction in T Cells Precede Disease<br />
Development in Lupus-Prone Mice. Tiffany Telarico 4 , David R.<br />
Fernandez 4 , Ann F. H<strong>of</strong>bauer 2 , Gary S. Gilkeson 1 , Jim C. Oates 3<br />
and Andras Perl 5 , 1 Med Univ <strong>of</strong> South Carolina, Charleston, SC,<br />
2<br />
Medical University <strong>of</strong> South Carolina, 3 MUSC, Charleston, SC,<br />
4<br />
SUNY, 5 Upstate Medical Univ, Syracuse, NY.<br />
438. Molecular Mechanisms <strong>of</strong> Lupus Dyslipidemia in Mice.<br />
Nilamadhab Mishra 1 , Kailin Yan 3 and Qiang Cao 2 , 1 Wake Forest<br />
Univ Health Scienc, Winston-Salem, NC, 2 Wake Forest University<br />
Health Sciences, 3 Wake Forest University Unv Health Sciences.<br />
439. Nuclear Modifications during Apoptosis Are Required To<br />
Maintain Tolerance to Nuclear Antigens. Neelakshi R. Jog 1 ,<br />
Eline Luning-Prak 2 and Roberto Caricchio 1 , 1 Temple University,<br />
2<br />
University <strong>of</strong> Pennsylvania.<br />
440. PARP-1 Deficiency Leads to More Severe Glomerulonephritis<br />
and Increased Mortality in an Inducible Mouse Model <strong>of</strong> SLE.<br />
Maximilian F. Koenig 1 , Serena M. Bagnasco 1 , Janelle Montagne 1 ,<br />
Antony Rosen 2 and Thomas Grader-Beck 2 , 1 Johns Hopkins School<br />
<strong>of</strong> Medicine, 2 Johns Hopkins School <strong>of</strong> Medicine, Baltimore, MD.<br />
176<br />
2010 Program Book
ACR Poster Session A<br />
441. Recombinant Chaperonin 10 Suppresses Cutaneous Lupus and<br />
Lupus Nephritis in MRL-(Fas)lpr Mice. Onkar P. Kulkarni 3 , Mi<br />
Ryu 3 , Claudia Kantner 3 , Miklos Sardy 2 , Dean Naylor 1 , Richard<br />
Brown 1 , Daina Vanags 1 and Hans-Joachim Anders 3 , 1 CBio Ltd,<br />
Eight Mile Plains, Queensland, Australia, 2 Department <strong>of</strong><br />
Dermatology and Allergology, University <strong>of</strong> Munich, Munich,<br />
Germany, 3 Medizinische Poliklinik-Innenstadt, University <strong>of</strong><br />
Munich, Munich, Germany.<br />
442. TGF-β-Induced CD4+Foxp3+ Cells Suppress Lupus-Like<br />
Syndrome through Induction <strong>of</strong> Formation <strong>of</strong> Tolerogenic<br />
DC. Xiaohui Zhou 4 , Julie Wang 4 , David A. Horwitz 2 , Huimin<br />
Fan 3 , Hejian Zou 1 , Zhongmin Liu 3 and Song Guo Zheng 4 , 1 Fudan<br />
University Medical School, 2 LAC/USC Medical Center, Los<br />
Angeles, CA, 3 Tongji University Medical School, 4 University <strong>of</strong><br />
Southern California.<br />
443. Widespread Upregulation <strong>of</strong> mEPCR in Kidney, Spleen<br />
and Liver <strong>of</strong> a Nephritic NZM B/W F1: Implications to<br />
Microvascular Disease. Sherry Xu 1 and Robert M. Clancy 2 , 1 NYU<br />
School <strong>of</strong> Medicine, 2 Tisch Hospital 4 - 407 , New York, NY.<br />
Systemic Lupus Erythematosus - Clinical Aspects and Treatment I<br />
444. Anti C1q Antibodies in Patients with Systemic Lupus<br />
Erythematosus and Cutaneous Vasculitis: A Controlled Study.<br />
Shirish R. Sangle 1 , Loh Yet Lin 2 , Esther Sanchez 2 , Davies Rachel 2<br />
and David P. D’Cruz 2 , 1 St Thomas’ Hospital, London, United<br />
Kingdom, 2 St Thomas’ Hospital, United Kingdom.<br />
445. Antimalarials May Attenuate the Risk <strong>of</strong> Metabolic Syndrome<br />
in SLE: Results from an International Imception Cohort<br />
Registry. M. H. X. Ting 2 , R. P. Donn 3 , M. Lunt 3 , M. B. Urowitz 4 ,<br />
D. D. Gladman 1 , D. Ibanez 1 , C. Gordon 1 , S. C. Bae 1 , A. Clarke 1 ,<br />
S. Bernatsky 1 , J. Hanly 1 , D. Isenberg 1 , A. Rahman 1 , J. Sanchez-<br />
Guerrero 1 , J. Romero-Diaz 1 , P. R. Fortin 1 , D. Wallace 1 , E. Ginzler 1 ,<br />
A. Vasudevan 1 , J. Merrill 1 , G. S. Alarcon 1 , B. Fessler 1 , G. Sturfelt 1 ,<br />
O. Nived 1 , K. Steinsson 1 , M. Khamashta 1 , M. Petri 1 , S. Manzi 1 , M.<br />
Dooley 1 , R. Ramsey-Goldman 1 , C. Aranow 1 , R. Van Vollenhoven 1 ,<br />
M. Ramos 1 , T. Stoll 1 , K. Kalunian 1 , A. Zoma 1 , P. Maddison 1 and I.<br />
N. Bruce 3 , 1 Systemic Lupus International Collaborating Clinics,<br />
Toronto, ON, Canada, 2 The University <strong>of</strong> Manchester, Salford,<br />
Manchester, United Kingdom, 3 The University <strong>of</strong> Manchester,<br />
4<br />
Toronto Western Hospital, Toronto, ON, Canada.<br />
446. Arthritis in an Ethnically Diverse Systemic Lupus<br />
Erythematosus Population. Guada Respicio 1 , Clare Cleveland 1 ,<br />
Kim Taylor 1 and Lindsey A. Criswell 2 , 1 Rosalind Russell Medical<br />
Research Center for Arthritis, University <strong>of</strong> California, San<br />
Francisco, San Francisco, CA, 2 UCSF-Box 0500, San Francisco, CA.<br />
447. Association <strong>of</strong> Low-Dose Pulsed Intravenous<br />
Cyclophosphamide Therapy and Amenorrhea in 62 Patients<br />
with Systemic Lupus Erythematosus: A Case-Control Study.<br />
Sayumi Baba 1 , Yasuhiro Katsumata 4 , Yasushi Kawaguchi 2 , Kae<br />
Takagi 1 , Takahisa Gono 1 , Yuko Okamoto 1 , Yuko Ota 1 , Masako<br />
Hara 1 and Hisashi Yamanaka 3 , 1 Tokyo Women’s Medical<br />
University, Tokyo, Japan, 2 Tokyo Women’s Medical University,<br />
Tokyo, Japan, 3 Tokyo Women’s Medical University, Shinjuku-ku,<br />
Tokyo, Japan, 4 Tokyo Women’s Medical University.<br />
448. Atherosclerotic Vascular Events in a Multinational Inception<br />
Cohort <strong>of</strong> SLE: Description and Attribution over an 8 Year<br />
Period. Murray B. Urowitz 33 , Dafna D. Gladman 22 , Dominique<br />
Ibanez 32 , Caroline P. Gordon 29 , Sang-Cheol Bae 6 , Ann E.<br />
Clarke 15 , Sasha R. Bernatsky 15 , F. Jorge Sanchez-Guerrero 9 ,<br />
John G. Hanly 19 , David A. Isenberg 24 , Anisur Rahman 25 , Paul R.<br />
Fortin 33 , Daniel J. Wallace 1 , Ellen M. Ginzler 20 , Joan T. Merrill 18 ,<br />
Graciela S. Alarcón 28 , Barri J. Fessler 23 , Ian N. Bruce 13 , Gunnar<br />
K. Sturfelt 27 , Ola Nived 27 , Kristjan Steinsson 12 , Munther A.<br />
Khamashta 21 , Michelle A. Petri 2 , Rosalind Ramsey-Goldman 17 ,<br />
Susan Manzi 34 , Mary Anne Dooley 31 , Ronald V. Vollenhoven 11 ,<br />
Cynthia B. Aranow 4 , Thomas Stoll 10 , Manuel Ramos 7 , Kenneth<br />
C. Kalunian 26 , Asad A. Zoma 5 , Guillermo Ruiz-Irastorza 8 , Peter<br />
J. Maddison 16 , Diane L. Kamen 14 , S. Sam Lim 3 and Christine A.<br />
Peschken 30 , 1 West Hollywood, CA, 2 Timonium, MD, 3 Emory<br />
University, Atlanta, GA, 4 Feinstein Institute, Manhasset, NY,<br />
5<br />
Hairmyres Hospital, East Kilbride, United Kingdom, 6 Hanyang<br />
University Medical Center, Seoul, Korea, Republic <strong>of</strong>, 7 Hospital<br />
Clinico I Provincial, Spain, 8 Hospital de Cruces, Universidad<br />
del Pais Vasco, Spain, 9 Instituto Nacional Nutricion, Mexico<br />
City, DF, Mexico, 10 Kantonsspital Schaffhausen, Schaffhausen,<br />
Switzerland, 11 Karolinska University Hospital, Sweden,<br />
12<br />
Landspitalinn University Hospital, Iceland, 13 Manchester Royal<br />
Infirmary, Manchester, United Kingdom, 14 Medical University<br />
<strong>of</strong> South Carolina, Charleston, SC, 15 Montreal General Hospital,<br />
Montreal, QC, Canada, 16 North West Whales NHS Trust, Colwyn<br />
Bay, United Kingdom, 17 Northwestern University, Chicago, IL,<br />
18<br />
Oklahoma Med Research Foundation, Oklahoma City, OK,<br />
19<br />
Queen Elizabeth II Health Services Center, Halifax, NS, Canada,<br />
20<br />
SUNY-Downstate Medical Center, Brooklyn, NY, 21 The Rayne<br />
Institute, London, United Kingdom, 22 Toronto Western Hospital,<br />
Toronto, ON, Canada, 23 UAB <strong>Rheumatology</strong>, Birmingham, AL,<br />
24<br />
UCL Div <strong>of</strong> Medicine, London, United Kingdom, 25 UCL Div <strong>of</strong><br />
Medicine, United Kingdom, 26 UCSD School <strong>of</strong> Medicine, La Jolla,<br />
CA, 27 University Hospital Lund, Lund, Sweden, 28 University <strong>of</strong><br />
Alabama, Oakland, CA, 29 University <strong>of</strong> Birmingham, Birmingham,<br />
United Kingdom, 30 University <strong>of</strong> Manitoba, Winnipeg, MB,<br />
Canada, 31 University <strong>of</strong> North Carolina, Chapel Hill, NC,<br />
32<br />
University <strong>of</strong> Toronto Lupus Clinic, Toronto Western Hospital,<br />
33<br />
University <strong>of</strong> Toronto Lupus Clinic, Toronto Western Hospital,<br />
Toronto, ON, Canada, 34 West Penn Allegheny Health System,<br />
Pittsburgh, PA.<br />
449. Attention Deficit and Hyperactivity Disorder Scores Are<br />
Elevated and Associated with Disease Activity and Fatigue in<br />
Patients with Systemic Lupus Erythematosus. Ricardo J. Garcia,<br />
Lisa Francis, Maha Dawood, Irene Ramos, Stephen Faraone and<br />
Andras Perl, SUNY.<br />
450. Autoantibody Response to Adjuvant and Non-Adjuvant H1N1<br />
Vaccination in SLE. Murray B. Urowitz, Anoja Anton, Domonique<br />
Ibañez and Dafna D. Gladman, Toronto Western Hospital,<br />
Toronto, ON, Canada, Toronto Western Hospital, Toronto, ON,<br />
Canada.<br />
451. Belimumab, a BLyS-Specific Inhibitor, Reduced Corticosteroid<br />
Use in Patients with Active SLE: Results from the Phase 3<br />
BLISS-52 and -76 Studies. R. F. van Vollenhoven 9 , A. Gallacher 3 ,<br />
S. Navarra 11 , E. M. Ginzler 8 , M. A. Dooley 10 , R. Cervera 4 , E. K. Li 2 ,<br />
R. A. Levy 5 , R. Gúzman 7 , Z. J. Zhong 6 , S. Cooper 6 , L. Pineda 6 , D.<br />
Hough 6 , D. J. Wallace 1 and for the BLISS- 52 and - 76 Study Groups,<br />
1<br />
Cedars-Sinai/UCLA, Los Angeles, CA, 2 Chinese University <strong>of</strong><br />
Hong Kong, Hong Kong, China, 3 Hospital Británico de Buenos<br />
Aires, Argentina, 4 Hospital Clinic, Barcelona, Spain, 5 Hospital<br />
Universitário Pedro Ernesto, Rio de Janeiro, Brazil, 6 Human<br />
Genome Sciences, Inc, Rockville, MD, 7 SaludCoop, Bogotá,<br />
Colombia, 8 SUNY Downstate Medical Center, Brooklyn, NY, 9 The<br />
Karolinska Institute, Stockholm, Sweden, 10 University <strong>of</strong> North<br />
Carolina at Chapel Hill, Chapel Hill, NC, 11 University <strong>of</strong> Santo<br />
Tomas Hospital, Manila, Philippines.<br />
2010 Program Book 177
ACR Poster Session A<br />
452. Belimumab, a BLyS-Specific Inhibitor, Reduced Disease Activity,<br />
Flares, and Prednisone Use in Patients with Seropositive SLE:<br />
Combined Efficacy Results from the Phase 3 BLISS-52 and -76<br />
Studies. M. A. Petri 5 , R. A. Levy 3 , J. T. Merrill 7 , S. Navarra 10 , R.<br />
Cervera 2 , R. F. van Vollenhoven 8 , S. Manzi 11 , D. Gladman 9 , A.<br />
Gallacher 1 , L. Pineda 4 , Z. J. Zhong 4 , D. Hough 4 , W. Freimuth 4 ,<br />
R. A. Furie 6 and for the BLISS- 52 and - 76 Study Groups, 1 Hospital<br />
Británico de Buenos Aires, Argentina, 2 Hospital Clinic, Barcelona,<br />
Spain, 3 Hospital Universitário Pedro Ernesto, Rio de Janeiro,<br />
Brazil, 4 Human Genome Sciences, Inc, Rockville, MD, 5 Johns<br />
Hopkins University School <strong>of</strong> Medicine, Timonium, MD, 6 North<br />
Shore LIJ Health System, Lake Success, NY, 7 Oklahoma Medical<br />
Research Foundation, Oklahoma City, OK, 8 The Karolinska<br />
Institute, Stockholm, Sweden, 9 Toronto Western Hospital,<br />
Toronto, ON, Canada, 10 University <strong>of</strong> Santo Tomas Hospital,<br />
Manila, Philippines, 11 West Penn Allegheny Health System,<br />
Pittsburgh, PA.<br />
453. BILAG-Measured Improvement in Moderately and Severely<br />
Affected Body Systems in Patients with Systemic Lupus<br />
Erythematosus (SLE) by Epratuzumab: Results from EMBLEM,<br />
a Phase IIb Study. Kenneth C. Kalunian 5 , Daniel J. Wallace 1 ,<br />
Michelle A. Petri 2 , Frederic A. Houssiau 6 , Marilyn C. Pike 3 ,<br />
Brian Kilgallen 4 , Lexy Kelley 4 and Caroline P. Gordon 7 , 1 West<br />
Hollywood, CA, 2 Timonium, MD, 3 Massachusetts General<br />
Hospital, Harvard Medical School, Boston, MA, 4 UCB, Smyrna,<br />
GA, 5 UCSD School <strong>of</strong> Medicine, La Jolla, CA, 6 Universite<br />
Catholique Louvain, Brussels, Belgium, 7 University <strong>of</strong><br />
Birmingham, Birmingham, United Kingdom.<br />
454. Biologics Use in SLE in 7 Centers – Data from the International<br />
Registry for Biologics in SLE (IRBIS). Ronald Van Vollenhoven 4 ,<br />
Søren Jacobsen 9 , Daniel J. Wallace 1 , John G. Hanly 8 , Michelle<br />
A. Petri 2 , David A. Isenberg 10 , Ann E. Clarke 7 , Julia F. Simard 3 ,<br />
Christian A. Pineau 6 , Sasha R. Bernatsky 5 and for the SLICC<br />
Group, 1 West Hollywood, CA, 2 Timonium, MD, 3 Clinical<br />
Epidemiology Unit, Stockholm, Sweden, 4 Karolinska University<br />
Hospital, Stockholm, Sweden, 5 McGill UHC/RVH, Montreal, QC,<br />
Canada, 6 McGill Univ Health Center, Montreal, QC, Canada,<br />
7<br />
Montreal General Hospital, Montreal, QC, Canada, 8 Queen<br />
Elizabeth II Health Services Center, Halifax, NS, Canada,<br />
9<br />
Rigshospitalet - 4242 , Copenhagen, Denmark, 10 UCL Div <strong>of</strong><br />
Medicine, London, United Kingdom.<br />
455. Carotid Plaque Area Correlates Better Than Intima Media<br />
Thickness with Cardiovascular Risk Factors and Clinical<br />
Ischemic Heart Disease in Lupus Patients. Lihi Eder, Murray<br />
B. Urowitz, Dominique Ibanez and Dafna D. Gladman, Toronto<br />
Western Hospital, Toronto, ON, Canada.<br />
456. Circulating Pro-Angiogenic Cells Are Reduced in Patients<br />
with SLE Independent <strong>of</strong> the Presence <strong>of</strong> Coronary<br />
Artery Calcification. Joshua Baker 1 , Lifeng Zhang 2 , Sotonye<br />
Imadojemu 2 , Alexis Sharpe 2 , Sarita Patil 2 , Jonni Moore 2 ,<br />
Emile R. Mohler III 2 and Joan Marie Von Feldt 3 , 1 University <strong>of</strong><br />
Pennsylvania, Philadelphia, PA, 2 University <strong>of</strong> Pennsylvania,<br />
3<br />
University <strong>of</strong> Pennsylvania-Philadelphia, Veterans Affairs<br />
Medical Center, Philadelphia, PA.<br />
457. Effect <strong>of</strong> Belimumab, a B-Lymphocyte Stimulator–Specific<br />
Inhibitor, on Functional Antibodies to Pneumococcal, Tetanus,<br />
and Influenza Vaccines. W. W. Chatham 6 , D. J. Wallace 1 , W.<br />
Stohl 11 , K. Latinis 8 , S. Manzi 10 , J. McCune 9 , D. Tegzová 3 , J.<br />
McKay 5 , H. E. Avila-Armengol 4 , T. O. Utset 7 , Z. J. Zhong 2 , D.<br />
Hough 2 , W. Freimuth 2 , T. S. Migone 2 and for the BLISS- 76 Study<br />
Group, 1 Cedars-Sinai/UCLA, Los Angeles, CA, 2 Human Genome<br />
Sciences, Inc, Rockville, MD, 3 Institute <strong>of</strong> <strong>Rheumatology</strong> and<br />
Rheumatological Clinic, Prague, Czech Republic, 4 Instituto<br />
Jalisciense de Investigacion Clinica, Guadalajara, Mexico,<br />
5<br />
Oklahoma Center for Arthritis Therapy & Research, Tulsa, OK,<br />
6<br />
UAB Arthritis Clinical Intervention Program, Birmingham, AL,<br />
7<br />
University <strong>of</strong> Chicago, IL, 8 University <strong>of</strong> Kansas Medical Center,<br />
Kansas City, KS, 9 University <strong>of</strong> Michigan Health System, Ann<br />
Arbor, MI, 10 University <strong>of</strong> Pittsburgh School <strong>of</strong> Medicine, PA,<br />
11<br />
USC Keck School <strong>of</strong> Medicine, Los Angeles, CA.<br />
458. Effect <strong>of</strong> Systemic Lupus Erythematosus (SLE) on Pregnancy<br />
Outcome: An Analysis <strong>of</strong> 268 Pregnancies. Chi Chiu Mok and<br />
Ling Yin Ho, Tuen Mun Hospital.<br />
459. Effects <strong>of</strong> Disease Activity and Use <strong>of</strong> Antimalarials on the<br />
Risk <strong>of</strong> Coronary-Artery Calcifications in SLE Patients. Juanita<br />
Romero-Díaz 3 , Florencia Vargas-Worackova 1 , Eric Kimura-<br />
Hayama 2 , Carlos Aguilar-Salinas 3 and Jorge Sanchez-Guerrero 4 ,<br />
1<br />
Instituto Nacional ce Ciencias Medicas y Nutricion Salvador<br />
Zubiran, 2 Instituto Nacional de Cardiologia Ignacio Chavez,<br />
3<br />
Instituto Nacional de Ciencias Medicas y Nutricion Salvador<br />
Zubiran, 4 Instituto Nacional de Ciencias Medicas y Nutricion<br />
Salvador Zubiran, Mexico.<br />
460. Elevated Levels <strong>of</strong> Plasma Micro-Particles (PMPs) in Systemic<br />
Lupus Erythematosus (SLE) Are Associated with Higher Risk<br />
<strong>of</strong> Thrombosis. Aisha Lateef 3 , Laurence S. Magder 4 , Jayesh<br />
Jani 2 , Thomas S. Kickler 2 and Michelle A. Petri 1 , 1 Timonium, MD,<br />
2<br />
Johns Hopkins University, 3 National University Health System,<br />
Singapore, Singapore, 4 University <strong>of</strong> Maryland Medical School.<br />
461. Evaluation <strong>of</strong> Cardiac Function and Myocardial Damage in<br />
Women with Systemic Lupus Erythematosus (SLE) by Cardiac<br />
MRI. Mala S. Kaul 2 , Han Kim 2 , E. William St Clair 2 and Megan<br />
E. B. Clowse 1 , 1 Duke Univ Med, Durham, NC, 2 Duke University,<br />
Durham, NC.<br />
462. Fulvestrant (Faslodex) an Estrogen Selective Receptor Down<br />
Regulator in the Therapy <strong>of</strong> Female SLE Patients, One to Two<br />
Year Following Faslodex Study Termination Revealed Mild<br />
Reactivation <strong>of</strong> the Serologic Parameters and Disease Activity.<br />
Nabih I. Abdou 1 , Virginia Rider 3 and Cindy A. Greenwell 2 , 1 Center<br />
for Rheumatic Disease Allergy & Immunology, Kansas City, MO,<br />
2<br />
Center for Rheumatic Disease Allery & Immunology, Kansas<br />
City, MO, 3 University <strong>of</strong> Pittsburg, Pittsburg, KS.<br />
463. Hydroxychloroquine Can Interfere with Flow Cytometric<br />
Analysis <strong>of</strong> Blood Cells from Patients Taking This Medication.<br />
Louise Fraser 1 , Graham H. Mitchell 1 , Shirish Sangle 2 , Lee Meng<br />
Choong 2 , Richard Ellis 1 , Jo Spencer 1 and David P. D’Cruz 3 ,<br />
1<br />
Department <strong>of</strong> Immunobiology, King’s <strong>College</strong> London, 2 Lupus<br />
Research Unit, St Thomas’ Hospital, 3 St Thomas Hospital,<br />
London, United Kingdom.<br />
464. Immunogenicity <strong>of</strong> the Quadrivalent Recombinant HPV<br />
Vaccine in Female Systemic Lupus Erythematosus Patients<br />
Aged 9 to 26 Years. Arzu Soybilgic 2 , Karen Onel 1 , Tammy O.<br />
Utset 1 , Kenneth A. Alexander 1 and Linda Wagner-Weiner 1 , 1 Univ<br />
<strong>of</strong> Chicago, Chicago, IL, 2 University <strong>of</strong> Illinois at Chicago, Chicago,<br />
IL.<br />
178<br />
2010 Program Book
ACR Poster Session A<br />
465. Immunoglobulin Levels as Potential Predictors <strong>of</strong> Response to<br />
B-Cell Depletion (BCD). Sara C. Croca 1 and David A. Isenberg 2 ,<br />
1<br />
Hospital de Santa Maria, Department <strong>of</strong> Medicine 1 , Lisbon,<br />
Portugal, 2 UCL Div <strong>of</strong> Medicine, Room 331 , 3 rd Floor, London,<br />
United Kingdom.<br />
466. Influenza Humoral Immune Responses in Patients with<br />
Systemic Lupus Erythematosus. Evan Glenn Vista 3 , Sherry<br />
Crowe 2 , Linda Thompson 2 , Gillian Air 4 and Judith A. James 1 ,<br />
1<br />
Oklahoma Med Research Foundation, Oklahoma City, OK,<br />
2<br />
Oklahoma Medical Research Foundation, 3 Oklahoma Medical<br />
Research Foundation, Oklahoma City, OK, 4 University <strong>of</strong><br />
Oklahoma Health Science Center.<br />
467. Low-Dose Combination <strong>of</strong> Mycophenolate M<strong>of</strong>etil and<br />
Tacrolimus for Refractory Lupus Nephritis: An Open-Labeled<br />
Trial. Chi Chiu Mok, Chi Hung To, Pak To Chan, Ka Lung Yu and<br />
Ling Yin Ho, Tuen Mun Hospital.<br />
468. Lupus Disease Severity Is Not a Risk for Cervical Intraepithelial<br />
Neoplasia in SLE. J. Patricia Dhar 3 , Lucie Gregoire 3 , Wayne<br />
Lancaster 3 , Azadeh Stark 1 , Ann Schwartz 3 , Daniel Schultz 2 ,<br />
Lynnette Essenmacher 3 , Joel Ager 3 , Lisa Chiodo 3 , Mujitaba<br />
Husain 3 and Robert J. Sokol 3 , 1 Geisinger Health Systems,<br />
Danville, PA, 2 Hernry Ford Health Systems, Detroit, MI, 3 Wayne<br />
State University, Detroit, MI.<br />
469. Lupus Nephritis: Decrease in Proteinuria and Sustained<br />
Stabilization <strong>of</strong> Disease Activity in Patients under Prolonged<br />
Immunoadsorption (IAS). Georg H. Stummvoll 2 , Peter<br />
Biesenbach 1 , Sabine Schmaldienst 1 , Josef Smolen 3 and Kurt<br />
Derfler 1 , 1 Dept. <strong>of</strong> Nephrology, Medical University <strong>of</strong> Vienna,<br />
Austria, 2 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Medical University <strong>of</strong> Vienna,<br />
Vienna, Austria, 3 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Medical University <strong>of</strong><br />
Vienna, Austria.<br />
470. Peripheral Vascular Disease in Systemic Lupus Patients.<br />
Rayford June 3 , Robert C. Gilkeson 1 , Shweta Bhatt 4 and Lisabeth<br />
Scalzi 2 , 1 Case Western Reserve University, 2 Penn State Univ<br />
Hershey Medical, Hershey, PA, 3 Penn State Univ Hershey<br />
Medical, 4 University <strong>of</strong> Rochester.<br />
471. PiHDL and High Plasma Leptin Levels Are Predictors <strong>of</strong><br />
Longitudinal Progression <strong>of</strong> Subclincal Atherosclerosis in SLE.<br />
Maureen A. McMahon 5 , Jennifer M. Grossman 7 , Lori Sahakian 5 ,<br />
Brian Skaggs 5 , John D. FitzGerald 6 , Christina Charles-Schoeman 3 ,<br />
Alan H. Gorn 4 , Michael H. Weisman 2 , Daniel J. Wallace 1 and<br />
Bevra H. Hahn 8 , 1 West Hollywood, CA, 2 Cedars-Sinai Medical<br />
Center, Los Angeles, CA, 3 UCLA, Santa Monica, CA, 4 UCLA<br />
Medical Center, Los Angeles, CA, 5 UCLA School <strong>of</strong> Medicine,<br />
Los Angeles, CA, 6 UCLA School <strong>of</strong> Medicine Rehabilitation, Los<br />
Angeles, CA, 7 University <strong>of</strong> California Los Angeles, Sherman<br />
Oaks, CA, 8 University <strong>of</strong> California Los Angeles School <strong>of</strong><br />
Medicine, Los Angeles, CA.<br />
472. Positivity for Anti-RNP Antibody Is a Risk Factor for Adverse<br />
Effects by Trimethoprim-Sulphamethoxazole, a Prophylaxis<br />
Agent <strong>of</strong> P. jiroveci Pneumonia, in Patients with Collagen-<br />
Vasular Diseases. Reika Maezawa 1 , Kazuhiro Kurasawa 2 ,<br />
Satoko Arai 2 , Takayoshi Owada 2 and Takeshi Fukuda 2 , 1 Clinical<br />
Immunology, Dokkyo Medical University, Mibu, Tochigi, Japan,<br />
2<br />
Dokkyo Medical University, Mibu, Tochigi, Japan.<br />
473. Potential Risk Factors for Lupus Nephritis. Mehrnaz Hojjati 3 ,<br />
Semi Ayub 4 , Qi Wang 5 , Timothy W. Behrens 2 , Emily Gillespie 5<br />
and Michelle A. Petri 1 , 1 Timonium, MD, 2 Genentech Inc, South<br />
San Francisco, CA, 3 Univ <strong>of</strong> Minnesota, Minneapolis, MN, 4 Univ<br />
<strong>of</strong> Minnesota, Little Canada, MN, 5 Univ <strong>of</strong> Minnesota.<br />
474. Predictors <strong>of</strong> Rate <strong>of</strong> Progression in Organ Damage in SLE.<br />
Sneha Purvey 2 , Laurence S. Magder 3 , Hong Fang 2 and Michelle<br />
A. Petri 1 , 1 Timonium, MD, 2 Johns Hopkins University School <strong>of</strong><br />
Medicine, 3 University <strong>of</strong> Maryland School <strong>of</strong> Medicine.<br />
475. Pregnancy Outcomes among African <strong>American</strong> Patients with<br />
Systemic Lupus Erythematosus (SLE) Compared to Controls.<br />
April Barnado 1 , Lee Wheless 4 , Anna K. Meyer 4 , Gary S. Gilkeson 2<br />
and Diane L. Kamen 3 , 1 Duke University Medical Center, Durham,<br />
NC, 2 Med Univ <strong>of</strong> South Carolina, Charleston, SC, 3 Medical<br />
University <strong>of</strong> South Carolina, Charleston, SC, 4 Medical University<br />
<strong>of</strong> South Carolina.<br />
476. Prevalence and Persistence <strong>of</strong> Metabolic Syndrome in a<br />
Multicentre International Inception Cohort <strong>of</strong> Patients with<br />
SLE. Murray B. Urowitz 34 , Dafna D. Gladman 22 , Dominique<br />
Ibanez 33 , Ian N. Bruce 13 , Caroline P. Gordon 30 , Sang-Cheol Bae 6 ,<br />
Ann E. Clarke 15 , Sasha R. Bernatsky 15 , F. Jorge Sanchez-Guerrero 9 ,<br />
John G. Hanly 19 , David A. Isenberg 25 , Anisur Rahman 24 , Paul R.<br />
Fortin 27 , Daniel J. Wallace 1 , Ellen M. Ginzler 20 , Joan T. Merrill 18 ,<br />
Graciela S. Alarcón 29 , Barri J. Fessler 23 , Gunnar K. Sturfelt 28 , Ola<br />
Nived 28 , Kristjan Steinsson 12 , Munther A. Khamashta 21 , Michelle<br />
A. Petri 2 , Rosalind Ramsey-Goldman 17 , Susan Manzi 35 , Mary<br />
Anne Dooley 32 , Ronald V. Vollenhoven 11 , Cynthia B. Aranow 4 ,<br />
Thomas Stoll 10 , Manuel Ramos 7 , Kenneth C. Kalunian 26 , Asad<br />
A. Zoma 5 , Guillermo Ruiz-Irastorza 8 , Peter J. Maddison 16 , Diane<br />
L. Kamen 14 , S. Sam Lim 3 and Christine A. Peschken 31 , 1 West<br />
Hollywood, CA, 2 Timonium, MD, 3 Emory University, Atlanta,<br />
GA, 4 Feinstein Institute, Manhasset, NY, 5 Hairmyres Hospital,<br />
East Kilbride, United Kingdom, 6 Hanyang University Medical<br />
Center, Seoul, Korea, Republic <strong>of</strong>, 7 Hospital Clinico I Provincial,<br />
8<br />
Hospital de Cruces, Universidad del Pais Vasco, 9 Instituto<br />
Nacional Nutricion, Mexico City, DF, Mexico, 10 Kantonsspital<br />
Schaffhausen, Schaffhausen, Switzerland, 11 Karolinska University<br />
Hospital, 12 Landspitalinn University Hospital, 13 Manchester Royal<br />
Infirmary, Manchester, United Kingdom, 14 Medical University<br />
<strong>of</strong> South Carolina, Charleston, SC, 15 Montreal General Hospital,<br />
Montreal, QC, Canada, 16 North West Wales NHS Trust, Colwyn<br />
Bay, United Kingdom, 17 Northwestern University, Chicago, IL,<br />
18<br />
Oklahoma Med Research Foundation, Oklahoma City, OK,<br />
19<br />
Queen Elizabeth II Health Services Center, Halifax, NS, Canada,<br />
20<br />
SUNY-Downstate Medical Center, Brooklyn, NY, 21 The Rayne<br />
Institute, London, United Kingdom, 22 Toronto Western Hospital,<br />
Toronto, ON, Canada, 23 UAB <strong>Rheumatology</strong>, Birmingham, AL,<br />
24<br />
UCL Div <strong>of</strong> Medicine, 25 UCL Div <strong>of</strong> Medicine, London, United<br />
Kingdom, 26 UCSD School <strong>of</strong> Medicine, La Jolla, CA, 27 Univerity <strong>of</strong><br />
Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON,<br />
Canada, 28 University Hospital Lund, Lund, Sweden, 29 University<br />
<strong>of</strong> Alabama, Oakland, CA, 30 University <strong>of</strong> Birmingham,<br />
Birmingham, United Kingdom, 31 University <strong>of</strong> Manitoba,<br />
Winnipeg, MB, Canada, 32 University <strong>of</strong> North Carolina at Chapel<br />
Hill, Chapel Hill, NC, 33 University <strong>of</strong> Toronto Lupus Clinic, Toronto<br />
Western Hospital, 34 University <strong>of</strong> Toronto Lupus Clinic, Toronto<br />
Western Hospital, Toronto, ON, Canada, 35 West Penn Allegheny<br />
Health System, Pittsburgh, PA.<br />
477. Risk <strong>of</strong> Renal Flares and Decline in Renal Function in Patients<br />
with Active Lupus Nephritis Treated with Mycophenolate<br />
M<strong>of</strong>etil (MMF). Chi Chiu Mok 2 , King Yee Ying 1 , Cheuk Wan Yim 3<br />
and Woon Leung Ng 3 , 1 Princess Margaret Hospital, 2 Tuen Mun<br />
Hospital, 3 United Christian Hospital.<br />
2010 Program Book 179
ACR Poster Session A<br />
180<br />
478. Safety and Efficacy <strong>of</strong> a Pandemic 2009 Influenza A (H1N1)<br />
Monovalent, Unadjuvanted Vaccine in Systemic Lupus<br />
Erythematosus Patients. Alexis Mathian 3 , Herve Devilliers 2 ,<br />
Anne Krivine 1 , Nathalie Costedoat-Chalumeau 3 , Julien Haroche 3 ,<br />
Du Boutin-Le Thi Huong 3 , Bertrand Wechsler 3 , Baptiste Hervier 3 ,<br />
Makoto Miyara 3 , Nathalie Morel 3 , Jean-Charles Piette 3 , Brigitte<br />
Autran 3 , Flore Rozenberg 1 and Zahir Amoura 3 , 1 Hôpital Cochin,<br />
2<br />
Hôpital Dijon, 3 Hôpital Pitié Salpêtrière.<br />
479. Serum Osteoprotegrin (OPG) in Systemic Lupus<br />
Erythematosus. Adnan N. Kiani 2 , Pal Aukrust 3 , Thor Ueland 3 ,<br />
Laurence S. Magder 4 , Hollan Ivana 3 and Michelle A. Petri 1 ,<br />
1<br />
Timonium, MD, 2 Johns Hopkins University School <strong>of</strong> Medicine,<br />
Baltimore, MD, 3 Oslo University Hospital, 4 University <strong>of</strong><br />
Maryland.<br />
480. Steroid Free Remission in Systemic Lupus Erythematosus.<br />
Akiko Suda 3 , Haruko Ideguchi 1 , Shigeru Ohno 1 , Mitsuhiro<br />
Takeno 2 , Shohei Nagaoka 4 and Yoshiaki Ishigatsubo 5 , 1 Center for<br />
Rheumatic Disease, Yokohama City University Medical Center,<br />
2<br />
Department <strong>of</strong> Internal Medicine and Clinical Immunology,<br />
Yokohama City University Graduate School <strong>of</strong> Medicine,<br />
3<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Yokohama Minami Kyosai<br />
Hospital, Yokohama, Japan, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Yokohama Minami Kyosai Hospital, 5 Yokohama City Grad Sch <strong>of</strong><br />
Med, Yokohama, Japan.<br />
481. The Novel Pandemic Influenza A (H1N1) 2009 Vaccine: Low<br />
Rate <strong>of</strong> Seroconversion after Vaccination in Systemic Lupus<br />
Erythematosus. Eduardo F. Borba 4 , Carla G. S. Saad 5 , Ana Luisa<br />
G. Calich 5 , Sandra G. Pasoto 5 , Vilma S. T. Viana 5 , Maria do Carmo<br />
S. T. Timenetsky 2 , Alexander R. Precioso 3 and Eloisa Bonfa 1 ,<br />
1<br />
Faculdade de Medicina da Universidade de São Paulo, Sao<br />
Paulo, Brazil, 2 Instituto Adolpho Lutz, Brazil, 3 Instituto Butantan,<br />
Brazil, 4 <strong>Rheumatology</strong> Division, Faculdade de Medicina da<br />
Universidade de São Paulo, Sao Paulo, Brazil, 5 <strong>Rheumatology</strong><br />
Division, Faculdade de Medicina da Universidade de São Paulo,<br />
Brazil.<br />
482. The Presence <strong>of</strong> Renal Platelet Microthrombosis in Patients<br />
with Lupus Nephritis Correlates with the Degree <strong>of</strong><br />
Macrophagic Infiltration. Elena Gonzalo 4 , María Paz Martinez-<br />
Vidal 2 , Begoña Santiago 4 , Natalia Redondo 4 , Estibaliz Loza 1 ,<br />
José Luis Pablos 3 and María Galindo 3 , 1 Fundación Española de<br />
Reumatología, Sociedad Española de Reumatología, Madrid,<br />
Spain, 2 Servicio de Reumatología, Hospital 12 de Octubre,<br />
Madrid, Madrid, Spain, 3 Unidad de Investigación y Servicio de<br />
Reumatología, Hospital 12 de Octubre, Madrid, Madrid, Spain,<br />
4<br />
Unidad de Investigación, Hospital 12 de Octubre, Madrid,<br />
Madrid, Spain.<br />
483. The Relationship between N Terminal Pro Brain Natriuretic<br />
Peptide (NT-proBNP) and Atherosclerosis in SLE Patients. Diana<br />
Goldenberg 2 , Emily Miller 2 , Naveed Sattar 3 , Paul Welsh 4 , Mary<br />
Roman 5 and Jane E. Salmon 1 , 1 Hospital for Special Surgery, New<br />
York, NY, 2 Hospital for Special Surgery, New York, NY, 3 University<br />
<strong>of</strong> Glasgow, Glasgow, United Kingdom, 4 University <strong>of</strong> Glasgow,<br />
5<br />
Weill Cornell Medical <strong>College</strong>, New York, NY.<br />
484. Underuse <strong>of</strong> Hydroxychloroquine among Patients with<br />
Systemic Lupus Erythematosus. Aimee O. Hersh 2 , Daniel J.<br />
Shapiro 3 , Edward H. Yelin 4 and Gabriela Schmajuk 1 , 1 Stanford<br />
University, Palo Alto, CA, 2 UCSF, San Francisco, CA, 3 UCSF,<br />
4<br />
University <strong>of</strong> California, San Francisco, CA.<br />
485. Vitamin D Deficiency in Systemic Lupus Erythematosus (SLE) Is<br />
Not Associated with Coronary Artery Calcium (CAC) or Carotid<br />
Plaque. Adnan N. Kiani 2 , Laurence S. Magder 3 and Michelle A.<br />
Petri 1 , 1 Timonium, MD, 2 Johns Hopkins University, School <strong>of</strong><br />
Medicine, Baltimore, 3 University <strong>of</strong> Maryland.<br />
2010 Program Book<br />
Systemic Lupus Erythematosus - Human Etiology and Pathogenesis:<br />
Genetics and Mechanisms<br />
486. 9G4 Autoantibodies Dominate the Anti-Apoptotic Cell<br />
Autoimmune Response in SLE. Scott A. Jenks 1 , Elise Palmer 2 ,<br />
Elides Marin 2 and Ignacio Sanz 1 , 1 Univ <strong>of</strong> Rochester, Rochester,<br />
NY, 2 Univ <strong>of</strong> Rochester.<br />
487. ASF/SF2, a Protein Involved in Multiple RNA and microRNA<br />
Processing Pathways, Is a Novel Autoantigen in SLE. Amit<br />
Golding 6 , Ehtisham Akhter 4 , Tonie Hines 3 , Felipe Andrade 4 ,<br />
Ranjan Sen 5 , Livia Casciola-Rosen 2 , Antony Rosen 7 and Michelle<br />
A. Petri 1 , 1 Timonium, MD, 2 John Hopkins University, Baltimore,<br />
MD, 3 John Hopkins University, 4 Johns Hopkins University School<br />
<strong>of</strong> Medicine, Baltimore, MD, 5 NIA/National Institues <strong>of</strong> Health,<br />
6<br />
NIAID/National Institutes <strong>of</strong> Health, Bethesda, MD, 7 The Johns<br />
Hopkins University, Baltimore, MD.<br />
488. Association <strong>of</strong> adam33 Polymorphisms with Systemic Lupus<br />
Erythematosus. Seung-Cheol Shim, Mi-Kyoung Lim and Dong-<br />
Hyuk Sheen, Eulji University, Daejeon, Korea, Republic <strong>of</strong>.<br />
489. Binding <strong>of</strong> Apoptotic Fetal Cardiocytes by Anti-Ro/La<br />
Antibodies Stimulates uPA/uPAR-Dependent Activation<br />
<strong>of</strong> TGFbeta and Potentiates Fibrosis. Paraskevi Briassouli 2 ,<br />
Daniel Rifkin 1 , Jill P. Buyon 1 and Robert M. Clancy 1 , 1 New York<br />
University School <strong>of</strong> Medicine, 2 New York University Medical<br />
Center, New York, NY.<br />
490. Binding Target for C-Reactive Protein Is Released from<br />
Secondary Necrotic Cells. Christina Janko 1 , Christine Schorn 1 ,<br />
Luis Munoz 1 , Manfred Rauh 3 , Kirsten Lauber 2 , Georg Schett 1<br />
and Martin Herrmann 1 , 1 Department <strong>of</strong> Internal Medicine 3<br />
and Institute for Clinical Immunology, University <strong>of</strong> Erlangen-<br />
Nuremberg, Erlangen, Germany, 2 Department <strong>of</strong> Internal<br />
Medicine I, University <strong>of</strong> Tuebingen, Tuebingen, Germany,<br />
3<br />
Department <strong>of</strong> Paediatrics and Adolescent Medicine, University<br />
<strong>of</strong> Erlangen-Nuremberg, Erlangen, Germany.<br />
491. C1q and Complement Proteins Induce a Non-Caspase-<br />
Dependent, Non –Necrotic, Cell Death, That Protects from<br />
Autoimmunity. Mizhir Atallah, Amir Grau and Dror Mevorach,<br />
Hadassah-Hebrew University.<br />
492. Characterisation <strong>of</strong> Ex Vivo Leukocyte Rolling and Adhesion<br />
Responses in SLE. Eric F. Morand 1 , Qiang Cheng 2 , Alberta<br />
Hoi 2 and Michael J. Hickey 2 , 1 Monash University, Melbourne,<br />
Australia, 2 Monash University.<br />
493. Inhibition <strong>of</strong> Cytosolic Nucleic Acid Receptor Pathways Using<br />
the Small Molecule IKKε/TBK1 Kinase Inhibitor MPI-0485520.<br />
Burt Richards, Ju-Fen Zhu, Nathan Seager, Monica Cronin, Harry<br />
Austin, Thomas Douce, Daniel Cimbora, Ryan Holcomb, Daniel<br />
Wettstein and Paul Bartel, Myrexis, Inc., Salt Lake City, UT.<br />
494. Inhibition <strong>of</strong> Interferon-Alpha by Sialylated IgG in Response<br />
to TLR7 and TLR9 Activation Is Mediated by a Soluble Factor<br />
Produced by Monocytes. Alice E. Wiedeman 2 , Deanna M.<br />
Santer 2 , Fabian Käsermann 1 , Sylvia Miescher 1 and Keith B.<br />
Elkon 2 , 1 CSL Behring, 2 University <strong>of</strong> Washington.<br />
495. IRF5 SLE-Risk Haplotype Is Strongly Enriched in Anti-Ro Positive<br />
Mothers <strong>of</strong> Neonatal Lupus Patients with Diverse Diagnoses.<br />
Timothy B. Niewold 2 , Silvia N. Kariuki 2 , Beverly S. Franek 2 , Jill P.<br />
Buyon 1 and Robert M. Clancy 1 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, New<br />
York University School <strong>of</strong> Medicine, 2 Section <strong>of</strong> <strong>Rheumatology</strong><br />
and Gwen Knapp Center for Lupus and Immunology Research,<br />
University <strong>of</strong> Chicago.
ACR Poster Session A<br />
496. IRF8 Allele Associated with Susceptibility to Multiple<br />
Sclerosis Is Associated with Serum Interferon Alpha and<br />
Serologic Pr<strong>of</strong>ile in Systemic Lupus Erythematosus. Beverly<br />
S. Franek 2 , Silvia N. Kariuki 2 , Jasmine Arrington 2 , Rachel A.<br />
Mikolaitis 3 , Meenakshi Jolly 3 , Tammy O. Utset 2 , Dimitrios T.<br />
Boumpas 1 , George Goulielmos 1 and Timothy B. Niewold 2 ,<br />
1<br />
Internal Medicine and <strong>Rheumatology</strong>, Clinical Immunology and<br />
Allergy, University <strong>of</strong> Crete Medical School, Heraklion, Greece,<br />
2<br />
Section <strong>of</strong> <strong>Rheumatology</strong> and Gwen Knapp Center for Lupus<br />
and Immunology Research, University <strong>of</strong> Chicago, 3 Section <strong>of</strong><br />
<strong>Rheumatology</strong>, Rush University Medical Center.<br />
497. Leptin Promotes T Cell Autoimmunity through Modulation <strong>of</strong><br />
the PKB/Akt/mTOR Pathway in Systemic Lupus Erythematosus<br />
(SLE) Patients. Elaine V. Lourenco, Bevra H. Hahn, Noriko Iikuni,<br />
Sarah J. Kim, Maida Wong, Ram P. Singh, Jennifer Grossman and<br />
Antonio La Cava, UCLA.<br />
498. Low C4A Gene Copy Number in Systemic Lupus<br />
Erythematosus. Kaline M. C. Pereira 4 , Atila G. A. Faria 4 , Eloisa<br />
S. Moreira 1 , Viviane C. Santos 3 , Marcelle Grecco 3 , Neusa P.<br />
Silva 3 and Luis Eduardo C. Andrade 2 , 1 Hospital Sirio Libanes,<br />
Brazil, 2 Universidade Federal de São Paulo, Sao Paulo,<br />
Brazil, 3 Universidade Federal de Sao Paulo - UNIFESP, Brazil,<br />
4<br />
Universidade Federal de Sao Paulo - UNIFESP, Sao Paulo, SP,<br />
Brazil.<br />
499. Lupus Immune Complex Gene Expression Arrays Reveal<br />
Divergent Pro- and Anti-Inflammatory Pathways Induced<br />
Depending on the Presence <strong>of</strong> Plasmacytoid Dendritic Cells<br />
and C1q. Deanna M. Santer and Keith B. Elkon, University <strong>of</strong><br />
Washington, Seattle, WA.<br />
500. Meta-Analysis <strong>of</strong> Autoimmune Variants Shared between<br />
Systemic Lupus Erythematosus (SLE) and 16 Other Diseases<br />
Identifies Novel SLE Loci. Paula S. Ramos 3 , Patrick M. Gaffney 1 ,<br />
Lindsey A. Criswell 12 , Mary E. Comeau 3 , Adrienne H. Williams 3 ,<br />
Robert R. Graham 8 , Sharon A. Chung 10 , Raphael Zidovetzki 5 ,<br />
Jennifer A. Kelly 2 , Kenneth M. Kaufman 2 , Chaim O. Jacob 9 ,<br />
Robert P. Kimberly 4 , Betty P. Tsao 11 , Marta E. Alarcon-Riquelme 6 ,<br />
Timothy J. Vyse 7 , John B. Harley 13 , Kathy L. Moser 1 , Carl D.<br />
Langefeld 3 and SLEGEN Consortium, 1 Arthritis and Immunology<br />
Program, Oklahoma Medical Research Foundation, Oklahoma<br />
City, OK, 2 Arthritis and Immunology Program, Oklahoma Medical<br />
Research Foundation, 3 Dept Biostatistical Sciences, Wake<br />
Forest University Health Sciences, 4 Dept Medicine, University<br />
<strong>of</strong> Alabama at Birmingham, Birmingham, AL, 5 Dept <strong>of</strong> Cell<br />
Biology and Neuroscience, University <strong>of</strong> California, Riverside,<br />
6<br />
Dept <strong>of</strong> Genetics and Pathology, Uppsala University, Uppsala,<br />
Sweden, 7 Faculty <strong>of</strong> Medicine, Imperial <strong>College</strong>, London, UK,<br />
8<br />
Immunology Biomarkers Group, Genentech, 9 Keck School <strong>of</strong><br />
Medicine, University <strong>of</strong> Southern California, Los Angeles, Los<br />
Angeles, CA, 10 Rosalind Russell Medical Research Center for<br />
Arthritis, University <strong>of</strong> California, San Francisco, San Francisco,<br />
CA, 11 UCLA School <strong>of</strong> Medicine, Los Angeles, CA, 12 UCSF-Box<br />
0500, San Francisco, CA, 13 Univ <strong>of</strong> OK Hlth Sci Ctr, Oklahoma<br />
City, OK.<br />
501. MicroRNA miR-146a, Type I Interferon, and Race in Systemic<br />
Lupus Erythematosus. Paul R. Dominguez 1 , Minoru Satoh 2 ,<br />
Angela R. Ceribelli 1 , Eric S. Sobel 2 , Yi Li 2 , Westley H. Reeves 2 and<br />
Edward K. .L Chan 2 , 1 Department <strong>of</strong> Oral Biology, University <strong>of</strong><br />
Florida, Gainesville, FL, 2 University <strong>of</strong> Florida, Gainesville, FL.<br />
502. Multiple Independent Major Histocompatibility Complex<br />
Associations with Nephritis and Autoantibody Production in<br />
Systemic Lupus Erythematosus. Sharon A. Chung 7 , Kimberly<br />
E. Taylor 7 , Suzanne L. May 10 , Patricia P. Ramsay 9 , Hong L.<br />
Quach 9 , Julie A. Lane 2 , Joanne Nititham 8 , Janelle A. Noble 2 ,<br />
Diana L. Quach 9 , Jennifer A. Kelly 5 , Kathy L. Moser 4 , Timothy<br />
W. Behrens 3 , Michael F. Seldin 11 , John B. Harley 1 , Patrick M.<br />
Gaffney 4 , Lisa F. Barcellos 9 and Lindsey A. Criswell 6 , 1 Children’s<br />
Hospital Cincinnati Medical Center, Cincinnati, OH, 2 Children’s<br />
Hospital Oakland Research Institute, Oakland, CA, 3 Genentech,<br />
Inc., South San Francisco, CA, 4 Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK, 5 Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK, 6 Rosalind Russell Medical<br />
Research Center for Arthritis, University <strong>of</strong> California, San<br />
Francisco, San Francisco, CA, 7 Rosalind Russell Medical Research<br />
Center for Arthritis, University <strong>of</strong> California, San Francisco,<br />
8<br />
Rosalind Russell Medical Research Center for Arthritis,<br />
University <strong>of</strong> California, San Francisco, CA, 9 University <strong>of</strong><br />
California, Berkeley, CA, 10 University <strong>of</strong> California, Berkely, CA,<br />
11<br />
University <strong>of</strong> California, Davis, CA.<br />
503. NK Cells Regulate the IFN-α Production by Plasmacytoid<br />
Dendritic Cells Via Soluble Factors and Cell-Cell Contact. Niklas<br />
Hagberg 2 , Ol<strong>of</strong> Berggren 2 , Gunnar V. Alm 1 , Maija-Leena Eloranta 2<br />
and Lars Rönnblom 2 , 1 Department <strong>of</strong> Biomedical Sciences and<br />
Veterinary Public Health, Swedish University <strong>of</strong> Agricultural<br />
Sciences, Uppsala, Sweden, 2 Department <strong>of</strong> Medical Sciences,<br />
Uppsala University, Uppsala, Sweden.<br />
504. Novel Fc gamma Receptor 3B Gene (FCGR3B) Allele Variants<br />
and Polymorphism Distribution in Brazilian Systemic Lupus<br />
Erythematosus Patients and Blood Bank Donors. Viviane<br />
C. Santos 2 , Marcelle Grecco 2 , Kaline M. C. Pereira 2 , Luis E. C.<br />
Andrade 2 and Neusa P. Silva 1 , 1 Universidade Federal de São<br />
Paulo, São Paulo, Brazil, 2 Universidade Federal de São Paulo,<br />
Brazil.<br />
505. Numerical and Functional Deficiencies <strong>of</strong> Natural Killer T Cells<br />
in Systemic Lupus Erythematosus: Their Dysfunction Related<br />
to Up-Regulation <strong>of</strong> Cbl-b. Young-Nan Cho 2 , Sung-Ji Lee 3 ,<br />
Seong-Rye Seo 3 , Seung-Jung Kee 1 , Tae-Jong Kim 3 , Shin-Seok Lee 3<br />
and Yong-Wook Park 2 , 1 Department <strong>of</strong> Laboratory Medicine,<br />
Chonnam National University Medical School and Hospita,<br />
2<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Chonnam National University<br />
Medical School and Hospital, Gwangju, Republic <strong>of</strong> Korea,<br />
3<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Chonnam National University<br />
Medical School and Hospital.<br />
506. Paucity <strong>of</strong> PD-L1 Expression on Monocytes during Active<br />
Systemic Lupus Erythematosus Is Regulated by IL-10, TNF-α<br />
and TGF-β. Anne M. Stevens 3 , Jing-Ni Ou 1 and Alice Wiedeman 2 ,<br />
1<br />
Center for Immunity and Immunotherapies, Seattle Children’s<br />
Research Institute, Seattle, WA, 2 Department <strong>of</strong> Immunology,<br />
University <strong>of</strong> Washington, Seattle, WA, 3 Pediatrics, U. <strong>of</strong><br />
Washington, Seattle, WA.<br />
507. RFX1 Regulates CD70 and CD11a Expression by Recruiting<br />
the Histone Methyltransferase SUV39H1 in Lupus T Cells.<br />
Ming Zhao, Xiaoyan Wu, Fei Gao, Qing Zhang, Heng Yin and<br />
Qianjin Lu, Second Xiangya Hospital, Central South University,<br />
Changsha, China.<br />
2010 Program Book 181
ACR Poster Session A<br />
508. The HLA Haplotype DQA1+, DQB1+, DR4- Identifies Lupus<br />
Patients in Whom Anti-dsDNA Titers Correlate with<br />
Disease Activity. Mikhail Olferiev 1 , Kyriakos A. Kirou 1 , Dorthe<br />
Lundsgaard 4 , Klaus S. Frederiksen 3 , Jan Fleckner 2 and Mary<br />
K. Crow 1 , 1 Hospital for Special Surgery, New York, NY, 2 Novo<br />
Nordisk, 3 Novo Nordisk, Denmark, 4 Novo Nordisk, Copenghagen,<br />
Denmark.<br />
509. The Integrity <strong>of</strong> Double Strand Break Repair in Pediatric<br />
Systemic Lupus Erythematosus Cells. Robert C. Davies 2 , Kelly<br />
Pettijohn 2 , Francesca Fike 2 , Jiexi Wang 2 , Shareef A. Nahas 2 ,<br />
Richard A. Gatti 3 and Deborah K. McCurdy 1 , 1 Mattel Children’s<br />
UCLA-<strong>Rheumatology</strong>, Los Angeles, CA, 2 UCLA-Pathology<br />
and Laboratory Medicine, 3 UCLA-Pathology and Laboratory<br />
Medicine; Human Genetics.<br />
510. The Lupus Africa to US Gradient Revisited – Genetic Versus<br />
Environmental Factors in Lupus. Gary S. Gilkeson 1 , Diane L.<br />
Kamen 4 , Natasha M. Ruth 3 , Anna Meyer 2 and Darrius Maggi 5 ,<br />
1<br />
Med Univ <strong>of</strong> South Carolina, Charleston, SC, 2 MUSC, 3 MUSC,<br />
Charleston, SC, 4 MUSC PO Box 250637 , Charleston, SC, 5 West Africa<br />
Fistula Foundation.<br />
511. The Variant <strong>of</strong> MHC Class I Polypeptide-Related Sequence<br />
(MICA) Is a Genetic Risk Factor for SLE Independent <strong>of</strong> HLA-<br />
DRB1 and Modulates the Behavior <strong>of</strong> NK Cell Via NKG2D<br />
Receptor. Kohsuke Yoshida 1 , Koichiro Komai 2 , Kazuko Shiozawa 7 ,<br />
Aya Mashida 2 , Takahiko Horiuchi 6 , Yuki Tanaka 4 , Masato<br />
Nose 5 , Akira Hashiramoto 3 and Shunichi Shiozawa 3 , 1 Dept. <strong>of</strong><br />
Biophysics, Kobe Univ. Graduate School <strong>of</strong> Health Sciences,<br />
Kobe, Hyogo, Japan, 2 Dept. <strong>of</strong> Biophysics, Kobe Univ. Graduate<br />
School <strong>of</strong> Health Sciences, Kobe, Japan, 3 Dept. <strong>of</strong> Biophysics,<br />
Kobe Univ. Graduate School <strong>of</strong> Health Sciences/ Department<br />
<strong>of</strong> Medicine, Kobe University Graduate School <strong>of</strong> Medicine/<br />
The Center for Rheumatic Diseases, Kobe University Hosp.,<br />
Kobe, Japan, 4 Dept. <strong>of</strong> Clinical Immunology, <strong>Rheumatology</strong>,<br />
and Infectious Diseases, Kyushu Univ., Fukuoka, Japan, 5 Dept.<br />
<strong>of</strong> Pathogenomics, Ehime Univ. Graduate School <strong>of</strong> Medicine,<br />
Ehime, Japan, 6 Div. <strong>of</strong> Genome Analysis, Medicine Institute<br />
<strong>of</strong> Bioregulation, Kyushu Univ., Fukuoka, Japan, 7 Rheumatic<br />
Diseases Center, Konan-Kakogawa Hosp., Kakogawa, Japan.<br />
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects<br />
and Treatment I<br />
512. Acute Anterior Uveitis in Ankylosing Spondylitis: Clinical<br />
Characteristics and Impact <strong>of</strong> Biologic Therapy. Nai Lee<br />
Lui 1 , Finbar (Barry) D. O’Shea 3 , Hua Shen 2 , Richard J. Cook 2<br />
and Robert D. Inman 4 , 1 Department <strong>of</strong> <strong>Rheumatology</strong><br />
and Immunology, Singapore General Hospital, Singapore,<br />
2<br />
Department <strong>of</strong> Statistics and Actuarial Science, University <strong>of</strong><br />
Waterloo, Canada, 3 St James’s Hospital, Dublin, Ireland, 4 Toronto<br />
Western Hospital, Toronto, ON, Canada.<br />
513. Ankylosing Spondylitis: High Frequency <strong>of</strong> Varicocele<br />
Associated with Teratozoospermia. Lucia A. Nukumizu 5 , Carla<br />
G. S. Saad 5 , Breno P. de Almeida 5 , Jozélio F. Carvalho 5 , Marcello<br />
Cocuzza 2 , Celio R. Goncalves 5 , Osmar Saito 1 , Eloisa Bonfa 3 and<br />
Clovis A. A. Silva 4 , 1 Department <strong>of</strong> Radiology - Faculdade de<br />
Medicina da Universidade de São Paulo, Brazil, 2 Department <strong>of</strong><br />
Urology - Faculdade de Medicina da Universidade de São Paulo,<br />
Brazil, 3 Faculdade de Medicina da Universidade de São Paulo,<br />
Sao Paulo, Brazil, 4 Pediatric Reumatology Unit, Faculdade de<br />
Medicina da Universidade de São Paulo, Brazil, 5 <strong>Rheumatology</strong><br />
Division - Faculdade de Medicina da Universidade de São Paulo,<br />
Brazil.<br />
514. Application <strong>of</strong> Composite Disease Activity Scores in Psoriatic<br />
Arthritis to the PRESTA Dataset. Oliver M. FitzGerald 3 , Philip<br />
Helliwell 5 , Aizad Mumtaz 4 , Laure Coates 5 , Ronald Pedersen 2 and<br />
Charles T. Molta 1 , 1 Pfizer, Inc., Paoli, PA, 2 Pfizer, Inc., <strong>College</strong>ville,<br />
PA, 3 University <strong>College</strong> Dublin, Ranelagh Dublin, Ireland,<br />
4<br />
University <strong>College</strong> Dublin, Dublin, Ireland, 5 University <strong>of</strong> Leeds,<br />
Leeds, United Kingdom.<br />
515. Association <strong>of</strong> BMI and Psoriatic Arthritis Disease Activity.<br />
Elena Eberle 2 , Eric Knight 2 , Donald A. Raddatz 2 , Susan<br />
Messing 5 , George Reed 4 , Jeffrey D. Greenberg 1 and Joel M.<br />
Kremer 3 , 1 Millburn, NJ, 2 Bassett Healthcare, Cooperstown,<br />
NY, 3 The Center for <strong>Rheumatology</strong>, Albany, NY, 4 University <strong>of</strong><br />
Massachusetts, Worchester, MA, 5 University <strong>of</strong> Rochester,<br />
Rochester, NY.<br />
516. Can We Discontinue Anti-TNF Therapy in Patients with<br />
Ankylosing Spondylitis and Remission? A Systematic Literature<br />
Review. Miguel A. Abad 3 , Ana M. Ortiz 2 , Estibaliz Loza 1 , Juan<br />
A. Martinez Lopez 1 , Maria P. Rosario 1 and Loreto Carmona 1 ,<br />
1<br />
Fundación Española de Reumatología, Madrid, Spain,<br />
2<br />
Hospital Universitario de la Princesa, Madrid, Spain, Spain,<br />
3<br />
<strong>Rheumatology</strong> Unit, Hospital Virgen del Puerto, Plasencia,<br />
Spain, Spain.<br />
517. Clinical and Demographic Characterization <strong>of</strong> a Colombian<br />
Cohort <strong>of</strong> Patients with Diagnosis <strong>of</strong> Spondylarthritis. Wilson<br />
A. Bautista 1 , John Londoño 3 , Marlon Porras 3 and Rafael R. Valle 2 ,<br />
1<br />
Military Hospital, Division <strong>of</strong> <strong>Rheumatology</strong>, Bogota, Colombia,<br />
2<br />
Military Hospital, Division <strong>of</strong> <strong>Rheumatology</strong>, Bogota, Colombia,<br />
3<br />
Military Hospital, Division <strong>of</strong> <strong>Rheumatology</strong>, Bogota, Colombia.<br />
518. Comparison <strong>of</strong> ASAS Partial Remission and Low ASDAS as<br />
Indicators <strong>of</strong> Remission-Like States in Ankylosing Spondylitis.<br />
Desiree van der Heijde 4 , Joachim Sieper 3 , Steve Brown 2 ,<br />
Frederic Lavie 1 and Aileen Pangan 2 , 1 Abbott Laboratories,<br />
Rungis, France, 2 Abbott Laboratories, Abbott Park, IL, 3 Charité<br />
Universitätsmedizin Berlin, Berlin, Germany, 4 Leiden University<br />
Medical Center, Leiden, The Netherlands.<br />
519. Complex Assessment <strong>of</strong> Subclinical Vascular Disease<br />
Associated with Ankylosing Spondylitis. Nóra Bodnár 3 , György<br />
Kerekes 2 , Zoltan Szekanecz 1 , Ildiko Seres 4 , György Paragh 4 , Pál<br />
Soltész 2 , Gabriella Szücs 3 and Sándor Szántó 3 , 1 University <strong>of</strong><br />
Debrecen Med Ctr, Debrecen, Hungary, 2 University <strong>of</strong> Debrecen<br />
Medical and Health Sciences Center, Department <strong>of</strong> Medicine,<br />
3<br />
University <strong>of</strong> Debrecen Medical and Health Sciences Center,<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, 4 University <strong>of</strong> Debrecen Medical<br />
and Health Sciences Center, First Department <strong>of</strong> Medicine.<br />
520. Correlates <strong>of</strong> Physical Function in Axial Spondylarthropathy:<br />
Fear <strong>of</strong> Movement as an Independent Contributor. Thijs<br />
Swinnen 3 , Johan Vlaeyen 4 , Wim Dankaerts 1 , Rene Westhovens 5<br />
and Kurt de Vlam 2 , 1 Department <strong>of</strong> Rehabilitation Sciences,<br />
Catholic University <strong>of</strong> Leuven, Leuven, Belgium, 2 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, University Hospitals Leuven, Sint Martens<br />
Leerne, Belgium, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, University<br />
Hospitals Leuven, Department <strong>of</strong> Rehabilitation Sciences,<br />
Catholic University <strong>of</strong> Leuven, Leuven, Belgium, 4 Research<br />
Group on Health Psychology, Catholic University <strong>of</strong> Leuven,<br />
Department <strong>of</strong> Clinical Psychological Science, Maastricht<br />
University, Leuven, Belgium, 5 University Hospitals Leuven,<br />
Department <strong>of</strong> Rehabilitation Sciences, Catholic University <strong>of</strong><br />
Leuven, Leuven, Belgium.<br />
182<br />
2010 Program Book
ACR Poster Session A<br />
521. DC-STAMP (Dendritic Cell-Specific Transmembrane protein),<br />
a Potential Biomarker To Predict the Risk <strong>of</strong> Psoriasis Patients<br />
in Developing Psoriatic Arthritis. Yahui Grace Chiu 1 , Sutha<br />
Shanmugarajah 3 , Ben Panepento 1 , Lihi Eder 2 , Vinod Chandran 2 ,<br />
Dafna Gladman 2 , Sharon Moorehead 1 , Rick Barrett 1 and<br />
Christopher T. Ritchlin 1 , 1 AIR Unit, University <strong>of</strong> Rochester,<br />
Rochester, NY, 2 UHN-Toronto Western Hospital, Toronto, ON,<br />
Canada, 3 UHN-Toronto Western Hospital, Toronoto, ON, Canada.<br />
522. Development and Validation <strong>of</strong> a Questionnaire for Evaluation<br />
<strong>of</strong> Spondyloarthritis Related Manifestations in the First Degree<br />
Relatives <strong>of</strong> Patients with Ankylosing Spondylitis. Roozbeh<br />
Sharif 4 , John D. Reveille 6 , Michael H. Weisman 1 , Michael M.<br />
Ward 2 , Laura A. Diekman 4 , Mamatha Hanumanthaiah 5 and<br />
Shervin Assassi 3 , 1 Cedars-Sinai Medical Center, Los Angeles, CA,<br />
2<br />
NIH, NIAMS, IRP, Bethesda, MD, 3 Univ <strong>of</strong> Texas Health Science,<br />
Houston, TX, 4 Univ <strong>of</strong> Texas Health Science Center Houston,<br />
Houston, TX, 5 Univ <strong>of</strong> Texas Health Science Center Houston,<br />
6<br />
Univ Texas Health Sci Ctr, Houston, TX.<br />
523. Differences in Body Mass Index among Individuals with<br />
Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and the<br />
General Population. Vidula M. Bhole 1 , Hyon K. Choi 5 , Lindsay<br />
C. Burns 1 , Cristián Vera Kellet 2 , Diane V. Lacaille 1 , Dafna D.<br />
Gladman 3 and Jan P. Dutz 4 , 1 Arthritis Research Centre <strong>of</strong> Canada,<br />
Vancouver, BC, Canada, 2 Department <strong>of</strong> Dermatology, Pontificia<br />
Universidad Católica de Chile, Santiago, 3 Toronto Western<br />
Hospital, Toronto, ON, Canada, 4 Univ <strong>of</strong> BC, Vancouver, BC,<br />
Canada, 5 Univ <strong>of</strong> British Columbia, Vancouver, BC, Canada.<br />
524. Disease Activity Assessment by ASDAS Doesn’t Predict<br />
Sacroiliac Inflammation with MRI in Axial SpA. Sibel Z. Aydin 2 ,<br />
Alex Bennett 1 , Paul Emery 2 , Dennis McGonagle 2 and Helena<br />
Marzo-Ortega 2 , 1 Defence Medical Rehabilitation Centre, Headley<br />
Court, Epsom, Surrey, 2 Section <strong>of</strong> Musculoskeletal Diseases, The<br />
Leeds Institute <strong>of</strong> Molecular Medicine. University <strong>of</strong> Leeds, UK.<br />
525. Estimation <strong>of</strong> Optimal Cutt-Off Point <strong>of</strong> Ankylosing Spondylitis<br />
Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis<br />
Disease Activity Index (BASDAI) and Mini-BASDAI. Ruxandra<br />
Schiotis 7 , Eliza Muñoz Gomariz 3 , Juan Mulero 5 , Xavier Juanola 4 ,<br />
Janitzia Vazquez-Mellado 1 , Percival D. Sampaio-Barros 2 and<br />
Eduardo Collantes 6 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>, General<br />
Hospital <strong>of</strong> México, México City, 2 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
University <strong>of</strong> São Paulo, 3 Instituto Maimónides de Investigación<br />
Biomédica /Hospital Universitario Reina S<strong>of</strong>ia, Cordoba,<br />
Spain, 4 <strong>Rheumatology</strong> Department, H. U. Bellvitge, Barcelona,<br />
5<br />
<strong>Rheumatology</strong> Department, Hospital Puerta de Hierro<br />
Majadahonda. Madrid, Spain, 6 <strong>Rheumatology</strong> Department,<br />
Hospital Reina S<strong>of</strong>ía. Córdoba, Spain, 7 University <strong>of</strong> Medicine<br />
and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.<br />
526. Evaluation <strong>of</strong> the New ASAS Instrument To Assess Disease<br />
Activity, the ASDAS, in Patients with Ankylosing Spondylitis<br />
Treated with TNF Blockers over 8 Years. Xen<strong>of</strong>on Baraliakos 4 ,<br />
Claudia Fritz 2 , Joachim Listing 2 , Joachim Sieper 1 and Juergen<br />
Braun 3 , 1 Charite Campus Benjamin Frankl, Berlin, Germany,<br />
2<br />
German Rheumatism Research Center, 3 Rheumazentrum<br />
Ruhrgebiet, Herne, Germany, 4 Rheumazentrum Ruhrgebiet<br />
Herne.<br />
527. Evolution <strong>of</strong> Familial Spondyloarthritis (SPA) without<br />
Radiographic Sacroiliitis over Time: Results <strong>of</strong> a Prospective<br />
Follow Up Study. Nadine Zeboulon-Ktorza 3 , Roula Said-<br />
Nahal 1 , Maria-Antonietta D’Agostino 3 and Maxime Breban 2 ,<br />
1<br />
Hôpital Ambroise Paré, Assistance Publique Hôpitaux de<br />
Paris, Boulogne-Billancourt, France, 2 Hôpital Ambroise Paré,<br />
Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt,<br />
France; INSERM Unité 1016 ; Université Versailles Saint Quentin<br />
en Yvelines, F- 78000 , Versailles, France, 3 Hôpital Ambroise Paré,<br />
Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt,<br />
France; Université Versailles Saint Quentin en Yvelines, F- 78000 ,<br />
Versailles, France.<br />
528. Frequency <strong>of</strong> Iridocyclitis at Onset in a Large Series <strong>of</strong> Patients<br />
with Early Psoriatic Arthritis. Fabrizio Cantini 2 , Carlotta<br />
Nannini 2 , Emanuele Cassarà 2 , Olga Kaloudi 2 , Massimo Susini 1<br />
and Laura Niccoli 2 , 1 Ophthalmology Unit, Hospital <strong>of</strong> Prato,<br />
Prato, Tuscany, Italy, 2 <strong>Rheumatology</strong> Unit, Hospital <strong>of</strong> Prato,<br />
Prato, Tuscany, Italy.<br />
529. Hip Involvement Concerns 18% <strong>of</strong> Spondyloarthritis Patients,<br />
Is Often Bilateral and Total Joint Replacement Leads to Good<br />
Functional Results in These Patients. Vincent Burki, Simon<br />
Paternotte, Muriel Elhai, Isabelle Fabreguet, Eugenie Koumakis,<br />
Magali Meyer, Judith Payet, Fanny Roure, Laure Gossec and<br />
Maxime Dougados, Paris Descartes University, Cochin Hospital,<br />
Paris, France.<br />
530. HLA-Cw*06 Allele Increases the Duration <strong>of</strong> Time between<br />
the Onset <strong>of</strong> Psoriasis and Psoriatic Arthritis. Lihi Eder 2 ,<br />
Vinod Chandran 2 , Fawnda Pellett 2 , Sutha Shanmugarajah 2 ,<br />
Hua Shen 3 , Richard Cook 3 and Dafna D. Gladman 1 , 1 Toronto<br />
Western Hospital, Toronto, ON, Canada, 2 University <strong>of</strong> Toronto<br />
Psoriatic Arthritis Clinic, Toronto Western Hospital, 3 University<br />
<strong>of</strong> Waterloo.<br />
531. Hypertension and Diabetes Significantly Enhance the Risk<br />
for Cardiovascular Disease in Patients with Psoriasic Arthritis<br />
(PsA). Maria Helena Sampaio Favarato 1 , Carla Gonçalves Saad 2 ,<br />
Célio Roberto Gonçalves 2 , Percival Degrava Sampaio-Barros 2 and<br />
Claudia Goldenstein-Schainberg 2 , 1 <strong>Rheumatology</strong>, HC-FMUSP,<br />
São Paulo, Brazil, 2 <strong>Rheumatology</strong>, HC-FMUSP.<br />
532. Identification <strong>of</strong> the Clinical Features That Can Distinguish<br />
between Psoriatic Polyenthesitis and Fibromyalgia. Antonio<br />
Marchesoni 6 , Valentina Varisco 6 , Fabiola Atzeni 7 , Antonio<br />
Spadaro 3 , Ennio Lubrano 5 , Salvatore D’Angelo 10 , Alberto Cauli 4 ,<br />
Carlo Salvarani 8 , Giuseppe Provenzano 2 , Raffaele Scarpa 9 ,<br />
Daniela Melchiorre 1 , Piercarlo Sarzi Puttini 7 , Ignazio Olivieri 10 ,<br />
Mariangela Atteno 9 , Monica Montepane 3 , Gabriele De Marco 6 ,<br />
Laura Rotunno 6 and Maria Manara 6 , 1 AOUC University <strong>of</strong><br />
Florence, Italy, 2 CTO Hospital, Palermo, Italy, 3 Department <strong>of</strong><br />
Clinical and Medical Therapy, Sapienza-University <strong>of</strong> Rome,<br />
Italy, 4 Department <strong>of</strong> Medical Sciences, University <strong>of</strong> Cagliari,<br />
Italy, 5 Fondazione Maugeri, IRCCS, Telese Terme, Italy, 6 G.Pini<br />
Orthopedic Institute, Milan, Italy, 7 L. Sacco University Hospital,<br />
Milan, Italy, 8 Reggio Emilia Hospital, Italy, 9 <strong>Rheumatology</strong><br />
Research Unit, University Federico II Naples, Italy, 10 San Carlo<br />
Hospital <strong>of</strong> Potenza, Italy.<br />
2010 Program Book 183
ACR Poster Session A<br />
184<br />
533. Impact <strong>of</strong> Environmental Factors on Disease Activity in<br />
Spondyloarthritis (SPA): Results <strong>of</strong> the Prospective Co-Env<br />
Cohort. Nadine Zeboulon-Ktorza 9 , Pierre-Yves Boelle 6 , Roula<br />
Said-Nahal 1 , Maria Antonietta D’Agostino 7 , Jean-Francois Vibert 6 ,<br />
Emmanuelle Durand 1 , Homa Madrakian 1 , Odile Launay 3 , Alfred<br />
Mahr 2 , Antoine Flahault 4 , Thomas Hanslik 8 and Maxime Breban 5 ,<br />
1<br />
Assistance Publique Hôpitaux de Paris, Hôpital Ambroise<br />
Paré, F-92100, Boulogne Billancourt, France, 2 Assistance<br />
Publique Hôpitaux de Paris, Hôpital Cochin, F-75014, Paris,<br />
France, 3 Assistance Publique Hôpitaux de Paris, Hôpital Cochin,<br />
F-75014, Paris, France; Universite Paris Descartes, Faculte<br />
de Médecine; INSERM (Institut National de la Santé et de la<br />
Recherche Medicale, 4 EHESP School <strong>of</strong> Public Health, F-35200,<br />
Rennes, France, 5 Hôpital Ambroise Paré, Assistance Publique<br />
Hôpitaux de Paris, Boulogne-Billancourt, France, INSERM Unité<br />
1016, Université Versailles Saint Quentin en Yvelines, F-78000,<br />
Versailles, France, 6 INSERM, UMR S 707, F-75012, Paris, France;<br />
UPMC Université Paris 06, UMR S707, F-75012, Paris, France;<br />
APHP Hopital Saint Antoine F-75 012 Paris France, 7 Université<br />
Versailles Saint Quentin en Yvelines, F-78000, Versailles, France;<br />
Assistance Publique Hôpitaux de Paris, Hôpital Ambroise<br />
Paré, F-92100, Boulogne Billancourt, France;, 8 Universite<br />
Versailles Saint Quentin en Yvelines, F-78000, Versailles, France;<br />
Assistance Publique Hopitaux de Paris, Hopital Ambroise Pare,<br />
F-92100, Boulogne Billancourt, France; INSERM, UMR S707,<br />
F-75012, Paris, France; UPMC Universite Paris , 9 UNIVERSITY <strong>of</strong><br />
Versailles Saint Quentin en Yvelines, F-78000, Versailles, France;<br />
APHP Hopital Ambroise Paré F-92100 Boulogne Billancourt,<br />
France; Inserm UMR-S 707 F-75012, Paris, France.<br />
534. Increased Risk <strong>of</strong> Cardiovascular Disease in Patients with<br />
Active Ankylosing Spondylitis. Inger J. Berg, Anne G. Semb,<br />
Hanne Dagfinrud, Camilla Fongen, Sella A. Provan and Tore<br />
K. Kvien, Dep <strong>of</strong> <strong>Rheumatology</strong>, Diakonhjemmet Hospital,<br />
Increased Risk <strong>of</strong> Gastrointestinal Complications among Persons<br />
with Ankylosing Spondylitis: A Population-Based Study from<br />
Québec, Canada. Adrian R. Levy 3 , Shelagh M. Szabo 3 , Walter<br />
P. Maksymowych 4 , Sumati Rao 1 , Diane V. Lacaille 2 and Mary<br />
Cifaldi 1 , 1 Abbott, 2 Arthritis Research Ctr Canada, Vancouver, BC,<br />
Canada, 3 Oxford Outcomes, 4 University <strong>of</strong> Alberta, Edmonton,<br />
AB, Canada.<br />
536. Inflammation in an Individual Joint Predicts Damage to That<br />
Joint in Psoriatic Arthritis. Vinod Chandran 3 , Lynne Creswell 1 ,<br />
Vernon T. Farewell 1 and Dafna D. Gladman 2 , 1 MRC Biostatistics<br />
Unit, Cambridge, UK, 2 Toronto Western Hospital, Toronto, ON,<br />
Canada, 3 University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto<br />
Western Hospital.<br />
537. Inflammatory Bowel Disease Markers in the Stool <strong>of</strong> Patients<br />
with Ankylosing Spondylitis Compared to Healthy Controls.<br />
Franziska Matzkies 1 , Dermot McGovern 2 , Stephen Targan 2 and<br />
Michael H. Weisman 3 , 1 Cedars Sinai, San Bruno, CA, 2 Cedars<br />
Sinai, Los Angeles, CA, 3 Cedars-Sinai Medical Center, Los<br />
Angeles, CA.<br />
538. Influence <strong>of</strong> Fc-Gamma Receptor IIA (CD32) and IIIA (CD16)<br />
Polymorphisms on the EULAR Response to Anti-Tumor<br />
Necrosis Factor-alpha Therapy in Psoriatic Arthritis: A<br />
Longitudinal Study with 2 Years Follow-Up. Julio Ramirez 7 ,<br />
José Luis Fernández-Sueiro 6 , Raquel López-Mejías 1 , Carlos<br />
Montilla 5 , Belen Suarez 2 , Raimon Sanmartí 4 , Concepción Moll 3 ,<br />
Francisco Blanco 6 , Francisco Lozano 1 and Juan D. Cañete 3 ,<br />
1<br />
Servicio de Inmunología, Hospital Clínic y Universidad de<br />
Barcelona, Barcelona, Spain, 2 Servicio de Inmunología, Hospital<br />
Clínic y Universidad de Barcelona, Barcelona, Spain, 3 Servicio<br />
de Reumatología, Hospital Clínic e IDIBAPS, Barcelona, Spain,<br />
4<br />
Servicio de Reumatología, Hospital Clinic e IDIBAPS, Barcelona,<br />
2010 Program Book<br />
Spain, 5 Servicio de Reumatología, Hospital Clinico de Salamanca,<br />
Salamanca, Spain, 6 Servicio de Reumatología, Hospital Juan<br />
Canalejo, La Coruña, Spain, 7 Servicio Reumatología, Hospital<br />
Clinic e IDIBAPS, Barcelona, Spain.<br />
539. Intestinal Microsporidiosis: High Risk in Rheumatic<br />
Diseases Patients under Anti-TNF Therapy Combined with<br />
Methotrexate. Nadia E. Aikawa 3 , Aline O. Twardowsky 5 ,<br />
Jozelio Carvalho 5 , Clovis Silva 4 , Ivan Silva 2 , Ana Medeiros 5 ,<br />
Carla Gonçalves 5 , Julio Moraes 5 and Eloisa Bonfa 1 , 1 Faculdade<br />
Medicina, Sao Paulo, Brazil, 2 <strong>Rheumatology</strong> Division<br />
(CEDMAC) and Infectology Division, Faculdade de Medicina da<br />
Universidade de Sao Paulo, 3 <strong>Rheumatology</strong> Division (CEDMAC)<br />
and Pediatric <strong>Rheumatology</strong> Unit, Faculdade de Medicina da<br />
Universidade de Sao Paulo, Sao Paulo, Brazil, 4 <strong>Rheumatology</strong><br />
Division (CEDMAC) and Pediatric <strong>Rheumatology</strong> Unit, Faculdade<br />
de Medicina da Universidade de Sao Paulo, 5 <strong>Rheumatology</strong><br />
Division (CEDMAC), Faculdade de Medicina da Universidade de<br />
Sao Paulo.<br />
540. Involvement <strong>of</strong> the Anterior Chest Wall in Patients with<br />
Spondyloarthritis: Relationships between Clinical Symptoms<br />
and Imaging Features. Roberta Ramonda 2 , Alessandro Lo<br />
Nigro 2 , Mariagrazia Lorenzin 2 , Valentina Modesti 2 , Federico<br />
Angelini 1 , Carla Campana 2 , Paola Frallonardo 2 and Leonardo<br />
Punzi 2 , 1 Radiology Unit, University <strong>of</strong> Padova, 2 <strong>Rheumatology</strong><br />
Unit, University <strong>of</strong> Padova.<br />
541. Long Term Pr<strong>of</strong>ile <strong>of</strong> Cytokine, Metalloproteinase and Cartilage<br />
Biomarkers in Psoriatic Arthritis Patients Treated with Biologic<br />
Therapy. Jose Luis Fernandez-Sueiro, J. C. Fernández-Lopez, N.<br />
Oreiro-Villar, S. Pertega-Diaz, J. A. Pinto and FJ Blanco, Complejo<br />
Hospitalario Universitario La Coruña, La Coruña, Spain.<br />
542. Myocardial Infarction and Cardiovascular Risk Pr<strong>of</strong>ile in<br />
Ankylosing Spondylitis. A Systematic Review and Meta-<br />
Analysis. Sylvain Mathieu 3 , Laure Gossec 2 , Maxime Dougados 1<br />
and Martin Soubrier 3 , 1 Hospital Cochin, Paris, France,<br />
2<br />
Rhumatologie B, Hôpital Cochin, Paris, France, Paris, France,<br />
3<br />
Rhumatologie, CHU Gabriel Montpied, Clermont-Ferrand,<br />
France.<br />
543. National Survey <strong>of</strong> Patients with Psoriatic Arthritis in Spain:<br />
Disease Activity, Pharmacological Therapy and Impact on<br />
Quality <strong>of</strong> Life. Juan D. Cañete 1 , Julio Ramírez 2 and Rosario<br />
Rodríguez 3 , 1 Arthritis Unit, <strong>Rheumatology</strong> Dpt. Hospital Clinic<br />
and IDIBAPS, Barcelona, Spain, 2 IDIBAPS, Barcelona, Spain,<br />
3<br />
Medical Dept, San<strong>of</strong>i-Aventis Spain, Barcelona, Spain.<br />
544. Performance <strong>of</strong> Different Criteria Sets for Inflammatory Back<br />
Pain in Patients with Axial Spondyloarthritis with and without<br />
Radiographic Sacroiliitis. Dilek Solmaz 3 , Servet Akar 3 , Ozgul<br />
Gunduz 3 , Feride Yuksel 1 , Gercek Can 3 , Vedat Gerdan 3 , Yesim<br />
Akkoc 2 , Merih Birlik 3 , Fatos Onen 3 and Nurullah Akkoc 3 , 1 Internal<br />
Medicine, Dokuz Eylul University Faculty <strong>of</strong> Medicine, 2 Physical<br />
Therapy and Rehabilitation, Ege University Faculty <strong>of</strong> Medicine,<br />
3<br />
<strong>Rheumatology</strong>, Dokuz Eylul University Faculty <strong>of</strong> Medicine,<br />
Izmir, Turkey.<br />
545. Pregnancy in Ankylosing Spondylitis Is Associated with<br />
Fluctuation in Back Pain but Return to Baseline Postpartum:<br />
A Case Control Study. Nai Lee Lui 1 , Adele Carty 4 , Nigil Haroon 3 ,<br />
Sutha Shanmugarajah 4 , Hua Shen 2 , Richard J. Cook 2 , Dafna D.<br />
Gladman 5 and Robert D. Inman 6 , 1 Department <strong>of</strong> <strong>Rheumatology</strong><br />
and Immunology, Singapore General Hospital, Singapore,<br />
2<br />
Department <strong>of</strong> Statistics and Actuarial Science, University <strong>of</strong><br />
Waterloo, Canada, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Toronto Western<br />
Hospital, Toronto, ON, Canada, 4 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Toronto Western Hospital, Toronto, Canada, 5 Toronto Western<br />
Hospital, Toronto, ON, Canada, 6 Toronto Western Hospital,<br />
Toronto, ON, Canada.
ACR Poster Session A<br />
546. Prevalence and Characteristics <strong>of</strong> Uveitis in US Veterans<br />
with Seroneagative Spondyloarthropathy. Hashem Monshie-<br />
Vahabzadeh 4 , Saloomeh Vahadat 4 , J. Steuart S. Richards 4 ,<br />
Andreas Reimold 1 , Jessica Walsh 2 and Gail S. Kerr 3 , 1 Dallas<br />
VA Medical Center, Dallas, TX, 2 Salt Lake City VA Medical<br />
Center, Salt Lake City, UT, 3 VA Medical Center Washington<br />
DC, Washington, DC, 4 VA Medical Center Washington, DC,<br />
Washington, DC.<br />
547. Prevalence <strong>of</strong> Metabolic Syndrome in Patients with<br />
Seronegative Spondyloarthritis. Marwin Gutierrez 1 , Andrea<br />
Becciolini 1 , Emilio Filippucci 1 , Fausto Salaffi 1 , Rossella De<br />
Angelis 1 , Bernd Raffeiner 4 , Marco Canzoni 2 , Viviana Ravagnani 3 ,<br />
Chiara Bertolazzi 1 , Maria L. Sorgi 2 , Domenico Biasi 3 , Leonardo<br />
Punzi 4 and Walter Grassi 1 , 1 Clinica Reumatologica, Università<br />
Politecnica delle Marche, Jesi, Ancona, Italy, 2 Dipartimento<br />
di Clinica e Terapia Medica, Sapienza Università di Roma,<br />
Italy, 3 Unità Semplice di Reumatologia, Università degli<br />
Studi di Verona, Italy, 4 UOC Reumatologia, Clinica Medica e<br />
Sperimentale, Politecnico Universitario, Padova, Italy.<br />
548. Prospective Serum Levels Assessment <strong>of</strong> DKK-1 and SOST in<br />
Patients with Ankylosing Spondylitis and Treated with Anti-<br />
TNFa Treatments. Corinne Miceli-Richard 1 , Stéphanie Malbos 1 ,<br />
Stephan Pavy 1 , Sami Kolta 3 , Karine Briot 3 , Jérémie Sellam 5 ,<br />
Xavier Mariette 2 , Christian Roux 3 and Maxime Dougados 4 ,<br />
1<br />
Bicêtre Hospital, Université Paris XI Sud, 2 Bicetre Hospital/Paris<br />
Univ, Le Kremlin Bicetre, France, 3 Cochin Hospital, Université<br />
Paris-Descartes, 4 Hospital Cochin, Paris, France, 5 Saint-Antoine<br />
Hospital, Paris.<br />
549. Radiographic Progression Is Influenced by ERAP1<br />
Polymorphisms with Gender and Age Being C<strong>of</strong>actors. Nigil<br />
Haroon 2 , Walter P. Maksymowych 4 , Proton Rahman 1 , Florence<br />
W. Tsui 3 and Robert D. Inman 2 , 1 St Claires Mercy Hospital, St<br />
Johns, NL, Canada, 2 Toronto Western Hospital, Toronto, ON,<br />
Canada, 3 Toronto Western Research Institute and University <strong>of</strong><br />
Toornto, 4 University <strong>of</strong> Alberta, Edmonton, AB, Canada.<br />
550. Recently Diagnosed Ankylosing Spondylitis: Gender<br />
Differences and Factors Related to Delay in the Diagnosis.<br />
The North Israeli Study <strong>of</strong> ANkylosing Spondylitis (NISAN).<br />
Gleb Slobodin 1 , Iris Reychan 7 , Nina Avshovich 5 , Alexandra<br />
Balbir-Gurman 6 , Nina Boulman 2 , Mona Elias 3 , Joy Feld 3 , Reuven<br />
Mader 4 , Doron Markovitz 6 , Doron Rimar 2 , Itzhak Rosner 2 ,<br />
Michael Rozenbaum 2 , Devy Zisman 3 and Majed Odeh 2 , 1 Bnai<br />
Zion Medical Center, Haifa, Israel, 2 Bnai Zion Medical Center,<br />
3<br />
Carmel Medical Center, 4 Haemek Medical Center, Afula, Israel,<br />
5<br />
Hillel Yaffe Mecial Center, 6 Rambam Medical Center, 7 Technion.<br />
551. The ECHOSPA MRI Module for Diagnosis <strong>of</strong> Early<br />
Spondyloarthritis (SpA): Preliminary Validation and<br />
Assessment <strong>of</strong> Diagnostic Utility. Walter P. Maksymowych 4 ,<br />
Damien Loeuille 2 , Alexandra Desvignes-Engelbert 2 , Olivia Judet 3 ,<br />
Isabelle Chary-Valckenaere 2 , Robert Lambert 4 , Maxime A.<br />
Breban 1 and Maria-Antonietta D’Agostino 3 , 1 Courbevoie, France,<br />
2<br />
Faculté de Médecine de Nancy, Vandoeuvre les Nancy, France,<br />
3<br />
Université Versailles Saint Quentin en Yvelines, Boulogne-<br />
Billancourt, France, 4 University <strong>of</strong> Alberta, Edmonton, AB,<br />
Canada.<br />
552. The New ASAS Classification Criteria for Axial and Peripheral<br />
Spondylarthritis: Valid in the Latin <strong>American</strong> Patients,<br />
but…. John D. Londono 1 , Marlon B. Porras 2 , Enrique Calvo 4 ,<br />
Pedro Santos 3 , Wilson Bautista 3 , Consuelo Romero-Sánchez 3 ,<br />
Mabel Avila 3 , Ana María Santos 3 and Rafael Valle-Oñate 3 ,<br />
1<br />
Spondylarthropathies Group / <strong>Rheumatology</strong> Division, Hospital<br />
Militar Central / Universidad de La Sabana, Chía, Cundinamarca,<br />
Colombia, 2 Spondylarthropathies Group / <strong>Rheumatology</strong><br />
Division, Hospital Militar Central / Universidad de La Sabana,<br />
Bogotá, Cundinamarca, Colombia, 3 Spondylarthropathies Group<br />
/ <strong>Rheumatology</strong> Division, Hospital Militar Central / Universidad<br />
de La Sabana, Bogotá, Colombia, 4 Universidad Nacional de<br />
Colombia, Bogotá, Colombia.<br />
553. The New ASAS Criteria for Axial SpA Does Not Predict the<br />
Development <strong>of</strong> mNYC AS at 8 Years in a Cohort <strong>of</strong> Very Early<br />
IBP Patients. Sibel Z. Aydin 2 , Alex Bennett 1 , Paul Emery 2 , Dennis<br />
McGonagle 2 and Helena Marzo-Ortega 2 , 1 Defence Medical<br />
Rehabilitation Centre, Headley Court, Epsom, Surrey, United<br />
Kingdom, 2 Section <strong>of</strong> Musculoskeletal Diseases, The Leeds<br />
Institute <strong>of</strong> Molecular Medicine. University <strong>of</strong> Leeds, Leeds,<br />
United Kingdom.<br />
554. The Prevalence <strong>of</strong> Cardiovascular Risk Factors in Patients with<br />
Early Psoriatic Arthritis. Majed M. Khraishi 3 , Rana Aslanov 1<br />
and Don MacDonald 2 , 1 Memorial University <strong>of</strong> Newfoundland,<br />
2<br />
Newfoundland and Labrador Centre for Health Information,<br />
3<br />
Nexus Clinical Research, St Johns, NL, Canada.<br />
555. Time to Diagnosis <strong>of</strong> Ankylosing Spondylitis in an Irish Cohort<br />
and the Effect on Work Disability. Catherine Sullivan 2 and Oliver<br />
M. FitzGerald 1 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>, St Vincents<br />
University Hospital, Ranelagh Dublin, Ireland, 2 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, St Vincents University Hospital, Elm Park, Dublin<br />
4<br />
, Ireland.<br />
556. Urolithiasis in Ankylosing Spondylitis – Are Stone Formers<br />
Also Bone Formers? Nai Lee Lui 1 , Adele Carty 5 , Nigil Haroon 3 ,<br />
Hua Shen 2 , Richard Cook 2 and Robert D. Inman 4 , 1 Department<br />
<strong>of</strong> <strong>Rheumatology</strong> and Immunology, Singapore General Hospital,<br />
Singapore, 2 Department <strong>of</strong> Statistics and Actuarial Science,<br />
University <strong>of</strong> Waterloo, Canada, 3 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Toronto Western Hospital, Toronto, ON, Canada, 4 Toronto<br />
Western Hospital, Toronto, ON, Canada, 5 Toronto Western<br />
Hospital.<br />
557. Validation <strong>of</strong> the Patient Acceptable Work State (PAWS):<br />
Establishing Thresholds for Major Work Transition in<br />
Ankylosing Spondylitis. Walter P. Maksymowych 3 , Sumati Rao 1 ,<br />
Annelies Boonen 2 , Naijun Chen 1 and Mary Cifaldi 1 , 1 Abbott<br />
Laboratories, Abbott Park, IL, 2 University Hospital Maastricht,<br />
Maastricht, Netherlands, 3 University <strong>of</strong> Alberta, Edmonton, AB.<br />
558. Variation during Different Decades <strong>of</strong> Diagnostic and<br />
Therapeutic Delay in Patients <strong>of</strong> Ankylosing Spondylitis (AS).<br />
Giuliana Salvadorini 2 , Francesca Bandinelli 2 , Andrea Delle<br />
Sedie 1 , Lucrezia Riente 1 , Antonio Candelieri 3 , Sergio Generini 2 ,<br />
Nicola Possemato 1 , Stefano Bombardieri 1 and Marco Matucci<br />
Cerinic 2 , 1 Department <strong>Rheumatology</strong> <strong>of</strong> University <strong>of</strong> Pisa, Pisa,<br />
Italy, 2 Division <strong>of</strong> <strong>Rheumatology</strong> AOUC, University <strong>of</strong> Florence,<br />
Department <strong>of</strong> Biomedicine, DENOThe Centre, Florence, Italy,<br />
3<br />
Laboratory <strong>of</strong> Decision Engineering for Health Care Delivery,<br />
Department <strong>of</strong> Electronics, Informatics and Systems, University<br />
<strong>of</strong> Cosenza, Italy.<br />
2010 Program Book 185
ACR Poster Session A<br />
559. Week 12 Response Is a Better Predictor Than Baseline<br />
Disease Characteristics <strong>of</strong> Long-Term Remission in Ankylosing<br />
Spondylitis. Joachim Sieper 3 , Desiree van der Heijde 4 ,<br />
Steve Brown 2 , Frederic Lavie 1 and Aileen Pangan 2 , 1 Abbott<br />
Laboratories, Rungis, France, 2 Abbott Laboratories, Abbott Park,<br />
IL, 3 Charité Universitätsmedizin Berlin, Berlin, Germany, 4 Leiden<br />
University Medical Center, Leiden, The Netherlands.<br />
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical<br />
Aspects and Therapeutics I<br />
560. A Multi-Center, Open-Label, Pro<strong>of</strong> <strong>of</strong> Concept Study <strong>of</strong><br />
Imatinib Mesylate Demonstrates No Benefit for the Treatment<br />
<strong>of</strong> Fibrosis in Patients with Early, Diffuse Systemic Sclerosis.<br />
Oliver Distler 8 , Jorg H. W. Distler 9 , John Varga 4 , Christopher<br />
P. Denton 7 , Robert A. Lafyatis 1 , Fredrick M. Wigley 3 , Georg<br />
Schett 2 , Marco Matucci-Cerinic 10 , Timothy M. Wright 5 , Arthur<br />
P. Bertolino 6 and Peter Gergely, Jr 6 , 1 Boston University School<br />
<strong>of</strong> Medicine, Arlington, MA, 2 Friedrich Alexander Univ,<br />
Erlangen, Germany, 3 Johns Hopkins University, Baltimore, MD,<br />
4<br />
Northwestern Univ Feinberg School, Chicago, IL, 5 Novartis<br />
Institutes for Biomedical Research, Cambridge, MA, 6 Novartis<br />
Institutes for Biomedical Research, 7 Royal Free Hospital,<br />
London, United Kingdom, 8 University Hospital Zurich, Zurich,<br />
Switzerland, 9 University <strong>of</strong> Erlangen, Erlangen, Germany,<br />
10<br />
University <strong>of</strong> Florence, Firenze, Italy.<br />
561. Baseline Differences in the “Borderline” Pulmonary<br />
Hypertension vs. “Normal” Hemodynamics: PHAROS Registry.<br />
Dinesh Khanna 4 , Rajeev Saggar 4 , Daniel Furst 4 , Lorinda Chung 3 ,<br />
James Seibold 5 , Tracy Frech 7 , ELENA Schiopu 6 , Rajan Saggar 4 ,<br />
Marcy Bolster 2 , Virginia Steen 1 and PHAROS Investigators,<br />
1<br />
Georgetown University, 2 MUSC, 3 Stanford, 4 UCLA, 5 Univ <strong>of</strong><br />
Connecticut, 6 Univ <strong>of</strong> Michigan, 7 Univ <strong>of</strong> Utah.<br />
562. Cigarette Smoking Is Not a Risk Factor for Systemic Sclerosis.<br />
Prateek Chaudhary 3 , Xing Chen 6 , Shervin Assassi 3 , Olga Gorlova 7 ,<br />
Hilda Draeger 5 , Emilio Gonzalez 8 , Terry McNearney 1 , Marilyn<br />
Perry 3 , Jason Anderson 4 and Maureen D. Mayes 2 , 1 Indianapolis,<br />
IN, 2 University <strong>of</strong> Texas Health Science Center at Houston,<br />
Houston, TX, 3 University <strong>of</strong> Texas Health Science Center<br />
Houston, Houston, TX, 4 University <strong>of</strong> Texas Health Science<br />
Center Houston, 5 University <strong>of</strong> Texas Health Science Center San<br />
Antonio, San Antonio, TX, 6 University <strong>of</strong> Texas MD Anderson<br />
Cancer Center, Houston, TX, 7 University <strong>of</strong> Texas MD Anderson<br />
Health Science Center, Houston, TX, 8 University <strong>of</strong> Texas Medical<br />
Branch at Galveston, Galveston, TX.<br />
563. Clinical Characteristics <strong>of</strong> Systemic Sclerosis Sine Scleroderma<br />
Associated Interstitial Lung Disease. Rohit Aggarwal 3 , Mary<br />
Lucas 2 , Noreen Fertig 2 and Thomas A. Medsger 1 , 1 Univ <strong>of</strong><br />
Pittsburgh, Pittsburgh, PA, 2 University <strong>of</strong> Pittsburgh, 3 University<br />
<strong>of</strong> Pittsburgh Medical Center, Pittsburgh, PA.<br />
564. Clinical Predictive Factors on Response to Oral Monotherapy in<br />
Patients with Systemic Sclerosis-Associated Pulmonary Arterial<br />
Hypertension. Yih Chang Lin, Soumya Chatterjee, Meng Xu,<br />
Raed Dweik and Joseph Parambil, Cleveland Clinic.<br />
565. Combined Analysis <strong>of</strong> Outcomes <strong>of</strong> Sitaxentan Treatment<br />
<strong>of</strong> Pulmonary Arterial Hypertension (PAH) Associated with<br />
Systemic Sclerosis (Scleroderma). James R. Seibold 5 , Marco<br />
Matucci-Cerinic 6 , Michael Louie 3 , Stephen Watt 3 , Simon A. Teal 4 ,<br />
Xuexuan Liu 1 , Lie-Ju Hwang 3 and David Langleben 2 , 1 Aerotek,<br />
Houston, TX, 2 Cardiology, Montreal Jewish Hospital, Montreal,<br />
Canada, 3 Pfizer Inc, New York, NY, 4 Pfizer Ltd, Tadworth, Surrey,<br />
UK, 5 <strong>Rheumatology</strong>, University <strong>of</strong> Connecticut, Farmington,<br />
Farmington, CT, 6 University <strong>of</strong> Florence, Firenze, Italy.<br />
566. Comparative Analysis <strong>of</strong> Change in Modified Rodnan Skin<br />
Score in Patients with Diffuse Systemic Sclerosis Receiving<br />
Imatinib Mesylate Suggests Similar Disease Course to Matched<br />
Patients Receiving Standard Therapy. Christopher P. Denton 9 ,<br />
Svetlana I. Nihtyanova 2 , John Varga 5 , Oliver Distler 10 , Fredrick M.<br />
Wigley 4 , Robert A. Lafyatis 1 , Jorg H. W. Distler 11 , Georg Schett 3 ,<br />
Marco Matucci-Cerinic 12 , Timothy M. Wright 6 , Monica Costa<br />
Antunes 8 , Amy Racine 8 , Arthur P. Bertolino 7 and Peter Gergely,<br />
Jr 7 , 1 Boston University School <strong>of</strong> Medicine, Arlington, MA,<br />
2<br />
Center for <strong>Rheumatology</strong> and Connective Tissue Diseases, UCL<br />
Medical School, London, United Kingdom, 3 Friedrich Alexander<br />
Univ, Erlangen, Germany, 4 Johns Hopkins University, Baltimore,<br />
MD, 5 Northwestern Univ Feinberg School, Chicago, IL, 6 Novartis<br />
Institutes for Biomedical Research, Cambridge, MA, 7 Novartis<br />
Institutes for Biomedical Research, 8 Novartis Pharma, 9 Royal<br />
Free Hospital, London, United Kingdom, 10 University Hospital<br />
Zurich, Zurich, Switzerland, 11 University <strong>of</strong> Erlangen, Erlangen,<br />
Germany, 12 University <strong>of</strong> Florence, Firenze, Italy.<br />
567. Comparison <strong>of</strong> Estimated Pulmonary Artery Systolic<br />
Pressure by Echocardiography (PASPECHO) and Right Heart<br />
Catheterization (PASPRHC) in Patients with Systemic Sclerosis<br />
(Scleroderma, SSc). Elena Schiopu 3 , Ann J. Impens 3 , Melvyn<br />
Rubenfire 2 , Fazleomar Mahmood 3 and Kristine Phillips 1 ,<br />
1<br />
University <strong>of</strong> Michigan, Ann Arbor, MI, 2 University <strong>of</strong> Michigan,<br />
Division <strong>of</strong> Cardiology, Ann Arbor, MI, 3 University <strong>of</strong> Michigan,<br />
Scleroderma Program, Ann Arbor, MI.<br />
568. Determination <strong>of</strong> the Accurate Incidence <strong>of</strong> Pulmonary Arterial<br />
Hypertension in Patients with Systemic Sclerosis, Mixed<br />
Connective Tissue Disease and Systemic Lupus Erythematosus<br />
by Prospective Study for 3-Years. Sumiaki Tanaka 1 , Kenta<br />
Hoshi 4 , Junichi Tanaka 4 , Tatsuhiko Wada 4 , Toshimichi Matsui 4 ,<br />
Tatsuo Nagai 4 , Jun Okada 2 and Shunsei Hirohata 3 , 1 Drexel<br />
University <strong>College</strong> <strong>of</strong> MedicineDepartment <strong>of</strong> <strong>Rheumatology</strong><br />
and Infectious Diseases, Kitasato University School <strong>of</strong> Medicine,<br />
Sagamihara, Kanagawa, Japan, 2 Drexel University <strong>College</strong><br />
<strong>of</strong> MedicineDepartment <strong>of</strong> <strong>Rheumatology</strong> and Infectious<br />
Diseases, Kitasato University School <strong>of</strong> Medicine, Sagamihara,<br />
Japan, 3 Drexel University <strong>College</strong> <strong>of</strong> MedicineDepartment <strong>of</strong><br />
<strong>Rheumatology</strong> and Infectious Diseases, Kitasato University<br />
School <strong>of</strong> Medicine, Kanagawa, Japan, 4 Drexel University <strong>College</strong><br />
<strong>of</strong> MedicineDepartment <strong>of</strong> <strong>Rheumatology</strong> and Infectious<br />
Diseases, Kitasato University School <strong>of</strong> Medicine.<br />
569. Difficulty Using World Health Organization Criteria To<br />
Categorize Pulmonary Hypertension in Patients with<br />
Systemic Sclerosis. Jessica K. Gordon 3 , Mardi Gomberg-<br />
Maitland 5 , Barbara M. Segal 2 , Robyn T. Domsic 6 , Ami A.<br />
Shah 4 , Laura K. Hummers 4 , Virginia D. Steen 1 , Evelyn Horn 7<br />
and PHAROS Investigators, 1 Georgetown University Medical<br />
Center, Washington, DC, 2 Hennepin County Medical Center,<br />
Minneapolis, MN, 3 Hospital for Special Surgery, New York,<br />
NY, 4 Johns Hopkins University, Baltimore, MD, 5 University <strong>of</strong><br />
Chicago, 6 University <strong>of</strong> Pittsburgh, Pittsburgh, PA, 7 Weill-Cornell<br />
Medical <strong>College</strong>.<br />
570. Dyspnea in Scleroderma Patients from the PHAROS Registry:<br />
A Major Contributor to Disability. Lorinda Chung 2 , Hubert<br />
Chen 3 , Dinesh Khanna 5 , Ann J. Impens 4 , Virginia D. Steen 1 and<br />
PHAROS Investigators, 1 Georgetown University Medical Center,<br />
Washington, DC, 2 Stanford Univ Medical Center, Palo Alto,<br />
CA, 3 UCSF, 4 Univ <strong>of</strong> Michigan Lobby M 2500, Ann Arbor, MI,<br />
5<br />
University <strong>of</strong> California Los Angeles, Los Angeles, CA.<br />
186<br />
2010 Program Book
ACR Poster Session A<br />
571. Epidemiology <strong>of</strong> Systemic Sclerosis in the Afro-Caribbean<br />
Population <strong>of</strong> Martinique, FWI: A Population-Based Study.<br />
Christophe Deligny, Vincent Goeb, Marie Elise Truchetet,<br />
Valentine Kahn, Veronique Dehlinger, Patrick Numéric, Christian<br />
Derancourt, Georges Jean Baptiste and Serge Arfi, CHU de Fort<br />
de France, Fort de France, Martinique.<br />
572. European Scleroderma Study Group (ESCSG) Activity Index<br />
Is Correlated to Quality <strong>of</strong> Life Measures Both at Admission<br />
and Overtime. Gabriele Valentini 2 , Michele Iudici 3 , Giuseppina<br />
Abignano 3 , Serena Vettori 1 and Giovanna Cuomo 3 , 1 Italy,<br />
2<br />
<strong>Rheumatology</strong> Unit - Second University <strong>of</strong> Naples, Napoli, Italy,<br />
3<br />
<strong>Rheumatology</strong> Unit- Second University <strong>of</strong> Naples, Italy.<br />
573. Evaluation <strong>of</strong> an Imatinib Response Gene Signature in Patients<br />
with Systemic Sclerosis. Lorinda Chung 3 , Pedro Ruiz 5 , Tammara<br />
Wood 1 , Stanford Shoor 2 , William Robinson 4 , Michael Whitfield 1 ,<br />
Howard Chang 5 and David Fiorentino 5 , 1 Dartmouth Medical<br />
School, 2 Kaiser Permanente <strong>of</strong> Northern California, 3 Stanford<br />
Univ Medical Center, Palo Alto, CA, 4 Stanford Univ School <strong>of</strong><br />
Med, Stanford, CA, 5 Stanford University School <strong>of</strong> Medicine.<br />
574. Evaluation <strong>of</strong> the Effect <strong>of</strong> Ambrisentan on Digital<br />
Microvascular Flow in Patients with Systemic Sclerosis Using<br />
Laser Doppler Perfusion Imaging. Nilanjana Bose 2 , James F.<br />
Bena 2 , Charles M. Trunick 3 , Debora J. Bork 2 , Geetha Krishnan 2 ,<br />
John Petrich 2 and Soumya Chatterjee 1 , 1 Cleveland Clinic,<br />
Richmond Heights, OH, 2 Cleveland Clinic, Cleveland, OH,<br />
3<br />
Cleveland Clinic.<br />
575. Identification <strong>of</strong> New Autoantibody Specificities in Different<br />
Subsets <strong>of</strong> Systemic Sclerosis Patients. Guillaume Bussone 3 ,<br />
Hanadi Dib 4 , Mathieu C. Tamby 1 , Cédric Broussard 5 , Loïc<br />
Guillevin 2 and Luc Mouthon 2 , 1 Université Paris Descartes,<br />
Institut Cochin, INSERM U1016, CNRS (UMR 8104), Paris,<br />
France, 2 Universite Paris Descartes, Faculte de Medecine,<br />
Pole de Medecine Interne et Centre de Reference Pour les<br />
Vascularites Necrosantes et la Sclerodermie Systemique, Hopital<br />
Cochin, Assistance Publique-Hopitaux de Paris, Paris, 3 Universite<br />
Paris Descartes, Institut Cochin, INSERM U1016, CNRS (UMR<br />
8104), Paris, France, 4 Universite Paris Descartes, Institut Cochin,<br />
INSERM U1016, CNRS (UMR 8104), Paris, France, 5 Universite<br />
Paris Descartes, Institut Cochin, INSERM U1016, CNRS (UMR<br />
8104), Plate-forme Proteomique Paris 5 , Paris.<br />
576. Intravenous Immunoglobulin (IVIg) in the Treatment <strong>of</strong><br />
Systemic Sclerosis (SSc) Associated Myopathy. Arnaud Dzeing-<br />
Ella 7 , Alice Bérezné 7 , Brigitte Ranque 4 , François-Jérôme Authier 1 ,<br />
Yannick Allanore 5 , Jean Cabane 3 , Eric Hachulla 2 , Loïc Guillevin 7<br />
and Luc Mouthon 6 , 1 Service d’Histologie, Hôpital Henri-<br />
Mondor, Creteil, France, 2 Service de Medecine Interne, Hôpital<br />
Claude-Huriez, Lille, 3 Service de Medecine Interne, Hôpital<br />
Saint-Antoine, Paris, France, 4 Service de Medecine Interne,<br />
HEGP, Paris, France, 5 Service de Rhumatologie A, Hôpital Cochin,<br />
Paris, France, 6 Universite Paris Descartes, Faculte de Medecine,<br />
Pole de Medecine Interne et Centre de Reference Pour les<br />
Vascularites Necrosantes et la Sclerodermie Systemique, Hopital<br />
Cochin, Assistance Publique-Hopitaux de Paris, Paris, France,<br />
7<br />
Universite Paris Descartes, Faculte de Medecine, Pole de<br />
Medecine Interne et Centre de Reference Pour les Vascularites<br />
Necrosantes et la Sclerodermie Systemique, Hopital Cochin,<br />
Assistance Publique-Hopitaux de Paris, Paris.<br />
577. Modeling Smoking in Systemic Sclerosis: A Comparison <strong>of</strong><br />
Different Statistical Approaches. Marie Hudson 3 , Ernest Lo 2 ,<br />
Russell Steele 3 and Murray Baron 1 , 1 Jewish General Hospital,<br />
Montreal, QC, Canada, 2 Lady Davis Institute, Jewish General<br />
Hospital, 3 McGill University.<br />
578. Nailfold Microangiopathy and Pheripheral Blood Perfusion<br />
Correlate with Internal Organ Involvement in Sistemic<br />
Sclerosis. Alberto Sulli 1 , Carmela Ferrone 2 , Carmen Pizzorni 2 ,<br />
Elisa Alessandri 2 , Francesca Ravera 2 , Giuseppe Zampogna 2 ,<br />
Bruno Seriolo 2 and Maurizio Cutolo 1 , 1 Research Laboratory and<br />
Academic Unit <strong>of</strong> Clinical <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />
Medicine, University <strong>of</strong> Genova, Genova, Italy, 2 Research<br />
Laboratory and Academic Unit <strong>of</strong> Clinical <strong>Rheumatology</strong>,<br />
Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Genova,<br />
Genova, Italy.<br />
579. Oral N-acetylcysteine in the Treatment <strong>of</strong> Raynaud’s<br />
Phenomenon Secondary to Systemic Sclerosis: A Randomized,<br />
Double-Blind, Placebo-Controlled Clinical Trial. Marcelo<br />
José Uchoa Correa 2 , Henrique A. Mariz 3 , Luis Eduardo Coelho<br />
Andrade 3 and Cristiane Kayser 1 , 1 Universidade Federal de São<br />
Palo, Brazil, 2 Universidade Federal de São Paulo, São Paulo,<br />
Brazil, 3 Universidade Federal de São Paulo, Brazil.<br />
580. Outcomes <strong>of</strong> Barrett’s Esophagus Related to Systemic Sclerosis:<br />
A 3-Year EULAR/EUSTAR Prospective Follow-Up Study.<br />
Julien Wipff 11 , Romain Coriat 9 , Michela Masciocchi 5 , Paola<br />
Caramaschi 2 , Chris T. Derk 7 , Eric Hachulla 8 , Valeria Riccieri 12 , Luc<br />
Mouthon 10 , Dorota Krasowska 1 , L. P. Ananyeva 6 , Andre Kahan 3 ,<br />
Marco Matucci-Cerinic 13 , Stanislas Chaussade 9 and Yannick<br />
Allanore 4 , 1 Department <strong>of</strong> Dermatology, Medical University <strong>of</strong><br />
Lublin, Lublin, 2 Department <strong>of</strong> Medicine, Verona University,<br />
Verona, 3 Hopital Cochin, Paris, France, 4 Hopitaux de Paris<br />
Cochin, Paris, France, 5 Immunological Clinic, Mangiagalli Regina<br />
Elena Fundation, Milan, 6 Institute <strong>of</strong> <strong>Rheumatology</strong>, Russian<br />
Academy <strong>of</strong> Medical Science, Moscow, 7 Jefferson Medical<br />
<strong>College</strong>, Philadelphia, PA, 8 National Scleroderma Centre, Lille<br />
Cedex, France, 9 Paris Descartes University, Gastroenterology<br />
Dpt, Cochin Hospital, 10 Paris Descartes University, Internal<br />
Medicine Dpt, Cochin Hospital, 11 Paris Descartes University,<br />
<strong>Rheumatology</strong> A Dpt, Cochin Hospital, 12 Sapienza University<br />
<strong>of</strong> Rome, Medical Clinic and Therapy Department, Rome,<br />
13<br />
University <strong>of</strong> Florence, Firenze, Italy.<br />
581. WITHDRAWN<br />
582. Preclinical Evaluation <strong>of</strong> Cardiac Involvement in Systemic<br />
Sclerosis Patients by Speckle Tracking Strain Analysis. Anne<br />
A. Schouffoer 3 , Kai H. Yiu 1 , Maarten K. Ninaber 2 , Jan Stolk 2 ,<br />
Thea P. M. Vliet-Vlieland 3 , Eduard R. Holman 1 , Tom W. J.<br />
Huizinga 3 , Jeroen J. Bax 1 , Nina Ajmone Marsan 1 and Annemie<br />
J. M. Schuerwegh 4 , 1 Department <strong>of</strong> Cardiology, Leiden, The<br />
Netherlands, 2 Department <strong>of</strong> Pulmonology, Leiden, The<br />
Netherlands, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden, The<br />
Netherlands, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden University<br />
Medical Center, Leiden, The Netherlands.<br />
583. Preliminary Composite Response Index for Raynaud’s<br />
Phenomenon. Dinesh Khanna 2 , Paul Maranian 2 , Daniel Furst 2 ,<br />
James Seibold 3 , Marco Matucci Cerinic 4 , Jeff Gregory 1 and<br />
Harold Paulus 2 , 1 MediQuest, 2 UCLA, 3 Univ <strong>of</strong> Conneticut, 4 Univ<br />
<strong>of</strong> Florence.<br />
584. Prevalence <strong>of</strong> Coronary Heart Disease in a Cohort <strong>of</strong> Australian<br />
Scleroderma Patients. Gene-Siew Ngian 2 , Joanne Sahhar 7 , Jill<br />
Byron 14 , Susanna Proudman 9 , Catherine Hill 8 , Janet Roddy 11 ,<br />
Peter Youssef 12 , Kathleen Tymms 1 , Leslie Schrieber 10 , Wendy<br />
Stevens 14 , Jane Zochling 6 , Peter Nash 15 , Allan Sturgess 13 , Gabor<br />
Major 5 , Ian Wicks 3 and Sharon Van Doornum 4 , 1 Canberra<br />
<strong>Rheumatology</strong>, Australia, 2 Department <strong>of</strong> Medicine (RMH/<br />
WH), University <strong>of</strong> Melbourne, Melbourne, Victoria, Australia,<br />
3<br />
Department <strong>of</strong> Medicine (RMH/WH), University <strong>of</strong> Melbourne,<br />
Melbourne, Australia, 4 Department <strong>of</strong> Medicine (RMH/WH),<br />
2010 Program Book 187
ACR Poster Session A<br />
University <strong>of</strong> Melbourne, 5 John Hunter Hospital, Newcastle,<br />
Australia, 6 Menzies Research Institute, University <strong>of</strong> Tasmania,<br />
Hobart, Australia, 7 Monash Medical Centre, Melbourne,<br />
Australia, 8 Queen Elizabeth Hospital, Adelaide, Australia,<br />
9<br />
Royal Adelaide Hospital, Adelaide, Australia, 10 Royal North<br />
Shore Hospital, Sydney, Australia, 11 Royal Perth Hospital, Perth,<br />
Australia, 12 Royal Prince Alfred Hospital, Sydney, Australia, 13 St<br />
George Hospital, Sydney, Australia, 14 St Vincent’s Hospital,<br />
Melbourne, Australia, 15 Sunshine Coast <strong>Rheumatology</strong>,<br />
Australia.<br />
585. Pulmonary Artery Diameter Is Associated with Pulmonary<br />
Hypertension in Patients with Systemic Sclerosis (SSc).<br />
Elena Schiopu 4 , Ann J. Impens 4 , Barry H. Gross 3 , Fazleomar<br />
Mahmood 4 , James R. Seibold 1 and Kristine Phillips 2 , 1 University<br />
<strong>of</strong> Connecticut Health Center, Farmington, CT, 2 University <strong>of</strong><br />
Michigan, Ann Arbor, MI, 3 University <strong>of</strong> Michigan, Department<br />
<strong>of</strong> Radiology, Ann Arbor, MI, 4 University <strong>of</strong> Michigan,<br />
Scleroderma Program, Ann Arbor, MI.<br />
586. Pulmonary Hypertension Assessment and Recognition <strong>of</strong><br />
Outcomes in Scleroderma (PHAROS): Comparison <strong>of</strong> Outcomes<br />
in Subtypes <strong>of</strong> Pulmonary Hypertension. Robyn T. Domsic 6 ,<br />
Lorinda Chung 3 , Mardi Gomnberg-Maitland 4 , Jessica K. Gordon 2 ,<br />
Barbara M. Segal 5 , Virginia D. Steen 1 and PHAROS Investigators,<br />
1<br />
Gerogetown University Medical Center, Washington, DC,<br />
2<br />
Hospital for Special Surgery, New York, NY, 3 Stanford University<br />
Medical Center, Palo Alto, CA, 4 University <strong>of</strong> Chicago Medical<br />
Center, Chicago, IL, 5 University <strong>of</strong> Minnesota, Minneapolis, MN,<br />
6<br />
University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />
587. Pulmonary Hypertension by Age <strong>of</strong> Scleroderma Onset and<br />
Subtype. Rebecca L. Manno 2 , Fredrick M. Wigley 1 and Laura K.<br />
Hummers 2 , 1 Johns Hopkins University, Baltimore, MD, 2 Johns<br />
Hopkins University, Baltimore, MD.<br />
588. Reproducibility <strong>of</strong> Semi-Automated Quantitative Nailfold<br />
Capillaroscopy Measurements in Patients with Systemic<br />
Sclerosis. Andrea K. Murray 4 , Tonia L. Moore 4 , Andy Vail 1 ,<br />
Joanne Manning 2 and Ariane L. Herrick 3 , 1 <strong>Rheumatology</strong><br />
Directorate, HealthMethodology Research Group, Manchester<br />
Academic Health ScienceCentre, The University <strong>of</strong><br />
Manchester, Salford Royal Hospital, Salford, UK, 2 Salford Royal<br />
NHSFoundation Trust, Salford, 3 The University <strong>of</strong> Manchester,<br />
Manchester Academic Health Science Centre, Manchester,<br />
Salford Royal Hospital, Salford, Greater Manchester, United<br />
Kingdom, 4 The University <strong>of</strong> Manchester, Manchester Academic<br />
Health Science Centre, Manchester, Salford Royal Hospital, UK.<br />
589. Risk Associated with African <strong>American</strong> Race in Relation<br />
to Prevalence <strong>of</strong> Cardinal Organ System Manifestations in<br />
Scleroderma. Elizabeth N. Le 3 , Rebecca L. Manno 3 , Laura K.<br />
Hummers 3 , Fredrick M. Wigley 2 and Allan C. Gelber 1 , 1 Baltimore,<br />
MD, 2 Johns Hopkins University, Baltimore, MD, 3 Johns Hopkins<br />
University, Baltimore, MD.<br />
590. Role <strong>of</strong> N-Terminal Pro-BNP in Detecting Clinically-Significant<br />
Cardiac Involvement in Systemic Sclerosis Patients. Cecilia<br />
Chighizola 3 , Benjamin Schreiber 2 , Pier Luigi Meroni 3 , Gerry<br />
Coghlan 1 , Christopher P. Denton 4 and Voon Ong 1 , 1 Center for<br />
<strong>Rheumatology</strong> and Connective Tissue Diseases, UCL Medical<br />
School, Royal Free Hospital, London, United Kingdom, 2 Center<br />
for <strong>Rheumatology</strong> and Connective Tissue Diseases, UCL Medical<br />
School, Royal Free Hospital, London, 3 <strong>Rheumatology</strong> Division,<br />
Department <strong>of</strong> Internal Medicine, Istituto G. Pini, University<br />
<strong>of</strong> Milan, Milan, Italy, 4 Royal Free Hospital, London, United<br />
Kingdom.<br />
591. Scleroderma Autoantibodies and Disease Subtype Predict<br />
Pulmonary Hypertension Classification in the PHAROS<br />
Registry. Monique E. Hinchcliff 5 , Aryeh Fischer 4 , Nadera Sweiss 6 ,<br />
Maureen Mayes 7 , Marcy Bolster 3 , Virginia Steen 1 and PHAROS<br />
Investigators 2 , 1 Georgetown University, 2 Gerogetwon University,<br />
3<br />
Medical University <strong>of</strong> South Carolina, 4 National Jewish Health,<br />
5<br />
Northwestern University, 6 University <strong>of</strong> Chicago, 7 University <strong>of</strong><br />
Texas-Houston Medical School.<br />
592. Scleroderma Lung Disease: Effect <strong>of</strong> Co-Existent Pulmonary<br />
Hypertension on Progression <strong>of</strong> Interstitial Lung Disease.<br />
Anupama Shahane, Joseph Parambil, Meng Xu and Soumya<br />
Chatterjee, Cleveland Clinic.<br />
593. Sildenafil Increases Vasodilation in Systemic Sclerosis: An<br />
Interim Analysis from a Single Centre Pilot Study. Silvia<br />
Bellando-Randone, Irene Miniati, Serena Guiducci, Maria Letizia<br />
Conforti, Jelena Blagojevic, Ginevra Fiori, Francesca Bartoli,<br />
Francesca Nacci and Marco Matucci-Cerinic, Department <strong>of</strong><br />
Biomedicine Section <strong>of</strong> <strong>Rheumatology</strong> University <strong>of</strong> Florence,<br />
Italy.<br />
594. Subclinical Atherosclerosis Is Increased in Systemic Sclerosis<br />
— A Case-Control Study. Karen M. Au 1 , Maureen A. McMahon 1 ,<br />
Daniel E. Furst 3 , Bevra H. Hahn 4 , Nagesh Ragavendra 1 , Amber<br />
Bechtel 1 , Lori Sahakian 1 and Dinesh Khanna 2 , 1 UCLA School <strong>of</strong><br />
Medicine, Los Angeles, CA, 2 University <strong>of</strong> California Los Angeles,<br />
Los Angeles, CA, 3 University <strong>of</strong> California Los Angeles Medical<br />
School, Los Angeles, CA, 4 University <strong>of</strong> California Los Angeles<br />
School <strong>of</strong> Medicine, Los Angeles, CA.<br />
595. Symptom Burden, Quality <strong>of</strong> Life and Attitudes toward<br />
Palliative Care in Patients with Pulmonary Hypertension with<br />
and without Systemic Sclerosis. Nicole M. Orzechowski 1 , Keith<br />
M. Swetz 2 , Tait D. Shanafelt 3 , Jeff A. Sloan 3 , Paul J. Novotny 3 ,<br />
Robert P. Frantz 3 and Michael D. McGoon 3 , 1 Dartmouth<br />
Hitchcock Med Center, Lebanon, NH, 2 Mayo Clinic, Rochester,<br />
MN, 3 Mayo Clinic.<br />
596. The Degree <strong>of</strong> Skin Involvement Predicts Distinct Interstitial<br />
Lung Disease Outcomes in Systemic Sclerosis. Tricia R. Cottrell,<br />
Fredrick Wigley, Robert Wise and Francesco Boin, Johns Hopkins<br />
University, Baltimore, MD.<br />
597. The Effect <strong>of</strong> Gastric Acid Suppression with Esomeprazole<br />
on Treprostinil Diethanolamine Pharmacokinetics in Healthy<br />
Volunteers. Kristan Rollins 2 , Susan Walker 2 , Jennifer Kates 2 ,<br />
Kevin Laliberte 2 and Allison Lim 1 , 1 United Therapetutics,<br />
Research Triangle Park, NC, 2 United Therapeutics.<br />
598. The Pulmonary Arterial Hypertension Quality Enhancement<br />
Research Initiative (PAH-QuERI): Comparing Baseline<br />
Characteristics, Management and Survival in Patients with<br />
Idiopathic PAH (IPAH) to Patients with Systemic Sclerosis<br />
Related PAH (SSc-PAH). Philip J. Clements 2 , Amparo Casanova 1 ,<br />
Tan Mary 1 , Channick Richard 4 , Valerie McLaughlin 6 , Ron Oudiz 2 ,<br />
Lew Rubin 5 , Tapson Victor 3 and Langer Anatoly 1 , 1 Canadian<br />
Heart Research Center, 2 David Geffen School <strong>of</strong> Medicine<br />
at UCLA, 3 Duke University Medical Center, Durham, NC,<br />
4<br />
Massachusetts General Hospital, 5 University <strong>of</strong> California at San<br />
Diego, 6 University <strong>of</strong> Michigan Health System.<br />
188<br />
2010 Program Book
ACR Poster Session A<br />
599. Validation <strong>of</strong> 6 Minute Walking Distance in Patients with<br />
Pulmonary Arterial Hypertension Associated with Systemic<br />
Sclerosis. Dörte Huscher 11 , Nicholas Roubinis 17 , Jerome<br />
Avouac 18 , Frank Behrens 10 , Christopher P. Denton 1 , Daniel E.<br />
Furst 8 , Ivan Foeldvari 14 , Marc Humbert 19 , Otylia Kowal-Bielecka 4 ,<br />
Marco Matucci-Cerinic 3 , Peter Nash 6 , Christian F. Opitz 2 ,<br />
David Pittrow 13 , Lewis J. Rubin 7 , James R. Seibold 9 , Marius M.<br />
Hoeper 12 , Mark F. Morris 15 , Simon A. Teal 16 and Oliver Distler 5 ,<br />
1<br />
Centre for <strong>Rheumatology</strong>, Royal Free Campus, University<br />
<strong>College</strong> Medical School, London, United Kingdom, 2 Department<br />
<strong>of</strong> Internal Medicine, DRK-Kliniken Berlin Köpenick, Berlin,<br />
Germany, 3 Department <strong>of</strong> Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Denothe Center, University <strong>of</strong> Florence, Italy, 4 Department <strong>of</strong><br />
<strong>Rheumatology</strong> and Internal Medicine, Medical University <strong>of</strong><br />
Bialystok, Poland, 5 Department <strong>of</strong> <strong>Rheumatology</strong>, University<br />
Hospital Zurich, Zurich, Switzerland, 6 Dept. <strong>of</strong> Medicine,<br />
University <strong>of</strong> Queensland, Queensland, Australia, 7 Division<br />
<strong>of</strong> Pulmonary and Critical Care Medicine, University <strong>of</strong><br />
California, San Diego School <strong>of</strong> Medicine, La Jolla, 8 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Department <strong>of</strong> Medicine, David Geffen School<br />
at UCLA, Los Angeles, CA, 9 Division <strong>of</strong> <strong>Rheumatology</strong>, University<br />
<strong>of</strong> Connecticut, Farmington, CT, 10 Division <strong>of</strong> <strong>Rheumatology</strong>/<br />
ZAFES, J.W. Goethe University, Frankfurt, Germany, 11 German<br />
Rheumatism Research Centre, Berlin, Germany, 12 Hannover<br />
Medical School, Department <strong>of</strong> Pneumology, Hannover,<br />
Germany, 13 Institute for Clinical Pharmacology, Medical<br />
Faculty, Technical University, Dresden, Germany, 14 Pediatric<br />
<strong>Rheumatology</strong> Clinic, General Hospital Eilbek, Germany, 15 Pfizer<br />
Ltd, Sandwich, UK, 16 Pfizer Ltd, Tadworth, UK, 17 Quanticate Ltd,<br />
Hitchin, UK, 18 <strong>Rheumatology</strong> A Department, RDU, Paris, France,<br />
19<br />
Service de Pneumologie et Reanimation Respiratoire, Centre<br />
des Maladies Vasculaires Pulmonaires, Hopital Antoine-Beclere,<br />
Université Paris-Sud, Clamart, France.<br />
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis<br />
and Animal Models I<br />
600. Adenosine A 2 A Receptor Occupancy Promotes Dermal Fibrosis<br />
by Modulating FLI 1 and CTGF Expression. Hailing Liu 3 , Edwin<br />
Chan 2 , Patricia Fernández 2 and Bruce N. Cronstein 1 , 1 New York<br />
Univ Med Ctr, New York, NY, 2 NYU School <strong>of</strong> Medicine, 3 NYU<br />
School <strong>of</strong> Medicine, New York, NY.<br />
601. Adipocyte-Targeted Wnt Activation Results in Spontaneous<br />
Dermal Fibrosis and Subcutaneous Lipoatrophy. Jun Wei 3 ,<br />
Denisa S. Melichian 2 , Kazuhiro Kumora 2 , Ormond Macdougald 4<br />
and John Varga 1 , 1 Northwestern Univ Feinberg School, Chicago,<br />
IL, 2 Northwestern University Feinberg School <strong>of</strong> Medicine,<br />
3<br />
Northwestern University Feinberg School <strong>of</strong> Medicine, Chicago,<br />
IL, 4 University <strong>of</strong> Michigan.<br />
602. Cadherin 11 Promotes Pulmonary Fibrosis through Production<br />
<strong>of</strong> TGF β and the Regulation <strong>of</strong> Epithelial to Mesenchymal<br />
Transition. Daniel J. Schneider 1 , Minghua Wu 4 , Thuy T. Le 2 ,<br />
Seo-Hee Cho 3 , Michael B. Brenner 5 , Michael R. Blackburn 2<br />
and Sandeep K. Agarwal 4 , 1 Department <strong>of</strong> Biochemistry and<br />
Molecular Biology, University <strong>of</strong> Texas Health Science Center,<br />
Houston, TX, 2 Department <strong>of</strong> Biochemistry and Molecular<br />
Biology, University <strong>of</strong> Texas Health Science Center, 3 Department<br />
<strong>of</strong> Pediatrics, Pediatric Research Center, University <strong>of</strong> Texas<br />
Health Science Center, 4 Division <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />
Immunogenetics, The University <strong>of</strong> Texas-Houston Medical<br />
School, Houston, TX, 5 Division <strong>of</strong> <strong>Rheumatology</strong>, Immunology<br />
and Allergy, Brigham and Women’s Hospital and Harvard<br />
Medical School.<br />
603. Cadherin-11 in Systemic Sclerosis and Its Role in Dermal<br />
Fibrosis. Minghua Wu 3 , Michael B. Brenner 1 , Maureen D.<br />
Mayes 4 , Frank C. Arnett 5 , Filemon K. Tan 6 and Sandeep K.<br />
Agarwal 2 , 1 Brigham & Womens Hospital, Boston, MA, 2 Division<br />
<strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunogenetics, University <strong>of</strong><br />
Texas Health Science Center at Houston, Houston, TX, 3 Division<br />
<strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunogenetics, University <strong>of</strong><br />
Texas Health Science Center at Houston (UTHSC-H), Houston,<br />
TX, 4 University <strong>of</strong> Texas-Houston, Houston, TX, 5 UT Medical<br />
School, Houston, TX, 6 UT-Houston Med School, Houston, TX.<br />
604. Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor,<br />
Represses Fibrotic Changes in a Murine Model <strong>of</strong> Pulmonary<br />
Fibrosis. Galina Bogatkevich 3 , Anna Ludwicka-Bradley 3 , Paul J.<br />
Nietert 4 , Joanne van Ryn 1 and Richard M. Silver 2 , 1 Boehringer<br />
Ingelheim, 2 Medical University <strong>of</strong> South Carolina, Charleston,<br />
SC, 3 Medical University <strong>of</strong> South Carolina, Charleston, SC,<br />
4<br />
Medical University <strong>of</strong> South Carolina.<br />
605. Endothelial Dysfunction and Abnormal Collagen V Deposition<br />
in Pulmonary Vasculature <strong>of</strong> Experimental Systemic Sclerosis<br />
Model. Roberta G. Marangoni 2 , Edwin R. Parra 1 , Ana Paula P.<br />
Velosa 3 , Walcy R. Teodoro 3 , Vera L. Capelozzi 1 and Natalino H.<br />
Yoshinari 3 , 1 Pathology Department, Faculdade de Medicina da<br />
Universidade de São Paulo, 2 <strong>Rheumatology</strong> Division, Faculdade<br />
de Medicina da Universidade de São Paulo, São Paulo, SP,<br />
Brazil, 3 <strong>Rheumatology</strong> Division, Faculdade de Medicina da<br />
Universidade de São Paulo.<br />
606. Genetic Deletion or Pharmacologic Antagonism <strong>of</strong> LPA1<br />
Ameliorates Dermal Fibrosis in a Mouse Model <strong>of</strong> Systemic<br />
Sclerosis. Flavia V. Castelino 3 , Jon Seiders 1 , Gretchen Bain 1 ,<br />
Chris King 1 , James Swaney 1 , Dan Lorrain 1 , Jerold Chun 5 , Andrew<br />
D. Luster 2 and Andrew M. Tager 4 , 1 Amira Pharmaceuticals,<br />
2<br />
Massachusetts General Hospital, Charlestown, MA,<br />
3<br />
Massachusetts General Hospital, Boston, MA, 4 Massuchusetts<br />
General Hospital, 5 Scripps Research Institute.<br />
607. Inactivation <strong>of</strong> the Transcription Factor STAT4 Prevents<br />
Inflammation-Driven Fibrosis in Systemic Sclerosis Animal<br />
Models. Jerome Avouac 3 , Barbara G. Fürnrohr 2 , Michal Tomcik 4 ,<br />
Katrin Palumbo 2 , Pawel Zerr 2 , Angelika Horn 2 , Clara Dees 2 ,<br />
Alfiya Akhmetshina 2 , Christian Beyer 2 , Oliver Distler 1 , Georg<br />
Schett 5 , Yannick Allanore 6 and Jorg H. W. Distler 7 , 1 Center <strong>of</strong><br />
Experimental <strong>Rheumatology</strong> and Zurich Center <strong>of</strong> Integrative<br />
Human Physiology, University Hospital Zurich, Zurich,<br />
Switzerland, 2 Department <strong>of</strong> Internal Medicine III and Institute<br />
for Clinical Immunology, University <strong>of</strong> Erlangen-Nuremberg,<br />
Erlangen, Germany, 3 Department <strong>of</strong> Internal Medicine III<br />
and Institute for Clinical Immunology, University <strong>of</strong> Erlangen-<br />
Nuremberg, Erlangen, Germany, Paris Descartes University,<br />
<strong>Rheumatology</strong> A Department, Cochin Hospital, and INSERM<br />
U781, Necker Hospital, Paris, Fr, 4 Department <strong>of</strong> Internal<br />
Medicine III, University <strong>of</strong> Erlangen-Nuremberg, Erlangen,<br />
Germany and Institute <strong>of</strong> <strong>Rheumatology</strong> and Connective<br />
Tissue Research Laboratory, Department <strong>of</strong> <strong>Rheumatology</strong> <strong>of</strong><br />
the First Faculty <strong>of</strong> Medicine, Charles University i, 5 Friedrich<br />
Alexander Univ, Erlangen, Germany, 6 Paris Descartes University,<br />
<strong>Rheumatology</strong> A Department, Cochin Hospital, and INSERM<br />
U781, Necker Hospital, Paris, France, 7 University <strong>of</strong> Erlangen,<br />
Erlangen, Germany.<br />
608. Induction <strong>of</strong> Peripheral Tissue Ischemia and Anti-Endothelial<br />
Antibodies after B Cell Adoptive Transfer from RNP-Immunized<br />
Mice. YunJuan Zang 3 , Irina Fernandez 3 , Maite Chavez 3 , Laisel<br />
Martinez 1 and Eric L. Greidinger 2 , 1 Miami VA Medical Center,<br />
2<br />
Miami VA Medical Center and University <strong>of</strong> Miami Miller School<br />
<strong>of</strong> Medicine, Miami, FL, 3 University <strong>of</strong> Miami Miller School <strong>of</strong><br />
Medicine.<br />
2010 Program Book 189
ACR Poster Session A<br />
609. Mice Lacking the Receptor-Like Protein Tyrosine Phosphatase<br />
CD148 Are Protected from Bleomycin-Induced Pulmonary<br />
Fibrosis. Tamiko R. Katsumoto 1 , Kevin K. Kim 2 , Alexis N.<br />
Brumwell 2 , John X. Nguyen 2 , Jing W. Zhu 2 , Mark R. Looney 2 ,<br />
Harold A. Chapman 2 and Arthur Weiss 2 , 1 UCSF, South San<br />
Francisco, CA, 2 UCSF.<br />
610. Noggin +/LacZ Heterozygous Mice Have Reduced Pulmonary<br />
Fibrosis in the Bleomycin Induced Model. Ellen de Langhe 2 ,<br />
Vanessa De Vooght 2 , Frank P. Luyten 1 and Rik Lories 1 , 1 KU<br />
Leuven, Leuven, Belgium, 2 KU Leuven.<br />
611. Nr4a1 Ameliorates the Pro-Fibrotic Effects <strong>of</strong> TGFβ in Systemic<br />
Sclerosis (SSc) and Might Be an Interesting Target for Anti-<br />
Fibrotic Therapies. Katrin Palumbo 1 , Alfiya Akhmetshina 1 ,<br />
Pawel Zerr 1 , Michal Tomcik 1 , Angelika Horn 1 , Clara Dees 1 , Oliver<br />
Distler 3 , Georg Schett 2 and Jorg H. W. Distler 4 , 1 Department<br />
<strong>of</strong> Internal Medicine III and Institute for Clinical Immunology,<br />
University <strong>of</strong> Erlangen-Nuremberg, Erlangen, Germany,<br />
2<br />
Friedrich Alexander Univ, Erlangen, Germany, 3 University<br />
Hospital Zurich, Zurich, Switzerland, 4 University <strong>of</strong> Erlangen,<br />
Erlangen, Germany.<br />
612. Osteopontin in Systemic Sclerosis and Its Role in Dermal<br />
Fibrosis. Minghua Wu 2 , Daniel J. Schneider 1 , Maureen D.<br />
Mayes 3 , Shervin Assassi 2 , Frank C. Arnett 4 , Filemon K. Tan 5 ,<br />
Michael R. Blackburn 1 and Sandeep K. Agarwal 2 , 1 Department<br />
<strong>of</strong> Biochemistry and Molecular Biology, UTHSC-H, Houston,<br />
TX, 2 Division <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunogenetics,<br />
University <strong>of</strong> Texas Health Science Center at Houston, Houston,<br />
TX, 3 University <strong>of</strong> Texas-Houston, Houston, TX, 4 UT Medical<br />
School, Houston, TX, 5 UT-Houston Med School, Houston, TX.<br />
613. Relevance <strong>of</strong> Epithelial Phenotypic Switching in the<br />
Pathogenesis <strong>of</strong> Systemic Sclerosis. Xu Shiwen 1 , S. Sonnylal 3 ,<br />
A. Tam 2 , R. Stratton 2 , A. Leask 2 , C. P. Denton 2 , J. Norman 2<br />
and D. Abraham 2 , 1 <strong>Rheumatology</strong>, London, United Kingdom,<br />
2<br />
<strong>Rheumatology</strong>,, United Kingdom, 3 UT M. D. Anderson Cancer,<br />
Houston, TX.<br />
614. S100A4 as a Novel Mediator <strong>of</strong> TGF-β Driven Dermal Fibrosis<br />
in Systemic Sclerosis. Michal Tomcik 4 , Pawel Zerr 2 , Katrin<br />
Palumbo 2 , Barbara G. Fürnrohr 2 , Jerome Avouac 3 , Angelika<br />
Horn 2 , Clara Dees 2 , Alfiya Akhmetshina 2 , Christian Beyer 2 ,<br />
Radim Becvar 7 , Oliver Distler 1 , Mariam Grigorian 6 , Ladislav<br />
Senolt 7 , Georg Schett 5 and Jorg H. W. Distler 8 , 1 Center <strong>of</strong><br />
Experimental <strong>Rheumatology</strong> and Zurich Center <strong>of</strong> Integrative<br />
Human Physiology, University Hospital Zurich, Switzerland,<br />
2<br />
Department <strong>of</strong> Internal Medicine III and Institute for<br />
Clinical Immunology, University <strong>of</strong> Erlangen-Nuremberg,<br />
Erlangen, Germany, 3 Department <strong>of</strong> Internal Medicine III<br />
and Institute for Clinical Immunology, University <strong>of</strong> Erlangen-<br />
Nuremberg, Erlangen, Germany and Paris Descartes University,<br />
<strong>Rheumatology</strong> A Department Cochin Hospital, Paris, France,<br />
4<br />
Department <strong>of</strong> Internal Medicine III, University <strong>of</strong> Erlangen-<br />
Nuremberg, Erlangen, Germany and Institute <strong>of</strong> <strong>Rheumatology</strong><br />
and Connective Tissue Research Laboratory, Department<br />
<strong>of</strong> <strong>Rheumatology</strong> <strong>of</strong> the First Faculty <strong>of</strong> Medicine, Charles<br />
University i, 5 Friedrich Alexander Univ, Erlangen, Germany,<br />
6<br />
Institute <strong>of</strong> Cancer Biology, Danish Cancer Society, Copenhagen,<br />
Denmark, 7 Institute <strong>of</strong> <strong>Rheumatology</strong> and Connective Tissue<br />
Research Laboratory, Department <strong>of</strong> <strong>Rheumatology</strong> <strong>of</strong> the<br />
First Faculty <strong>of</strong> Medicine, Charles University in Prague, Czech<br />
Republic, 8 University <strong>of</strong> Erlangen, Erlangen, Germany.<br />
615. The Synthetic Cannabinoid Ajulemic Acid Targets<br />
Scleroderma Fibrosis. Estrella Garcia Gonzalez 3 , Enrico Selvi 2 ,<br />
Balistreri Epifania 3 , Alfiya Akhmetshina 1 , Sauro Lorenzini 3 ,<br />
Kathrin Palumbo 1 , Mauro Galeazzi 3 and Jorg W. H. Distler 1 ,<br />
1<br />
Departement <strong>of</strong> Internal Medicine III and Institute for Clinical<br />
Immunology -Friedrich-Alexander University-Erlangen-Germany,<br />
2<br />
<strong>Rheumatology</strong> Unit - Departement <strong>of</strong> Clinical Medicine and<br />
Immunological Sciences-University <strong>of</strong> Siena, Siena, Italy,<br />
3<br />
<strong>Rheumatology</strong> Unit - Departement <strong>of</strong> Clinical Medicine and<br />
Immunological Sciences-University <strong>of</strong> Siena- Italy.<br />
616. The Transcription Factor AP-1 Mediates the Pro-Fibrotic Effects<br />
<strong>of</strong> TGFβ and Contributes to the Development <strong>of</strong> Experimental<br />
Dermal Fibrosis. Jerome Avouac 3 , Katrin Palumbo 2 , Michal<br />
Tomcik 4 , Pawel Zerr 2 , Clara Dees 2 , Angelika Horn 2 , Alfiya<br />
Akhmetshina 2 , Christian Beyer 2 , Shunichi Shiozawa 5 , Oliver<br />
Distler 1 , Georg Schett 6 , Yannick Allanore 7 and Jorg H. W. Distler 8 ,<br />
1<br />
Center <strong>of</strong> Experimental <strong>Rheumatology</strong> and Zurich Center <strong>of</strong><br />
Integrative Human Physiology, University Hospital Zurich, Zurich,<br />
Switzerland, 2 Department <strong>of</strong> Internal Medicine III and Institute<br />
for Clinical Immunology, University <strong>of</strong> Erlangen-Nuremberg,<br />
Erlangen, Germany, 3 Department <strong>of</strong> Internal Medicine III<br />
and Institute for Clinical Immunology, University <strong>of</strong> Erlangen-<br />
Nuremberg, Erlangen, Germany, Paris Descartes University,<br />
<strong>Rheumatology</strong> A Department, Cochin Hospital and INSERM U 781 ,<br />
Necker Hospital, Paris, Fra, 4 Department <strong>of</strong> Internal Medicine<br />
III, University <strong>of</strong> Erlangen-Nuremberg, Erlangen, Germany and<br />
Institute <strong>of</strong> <strong>Rheumatology</strong> and Connective Tissue Research<br />
Laboratory, Department <strong>of</strong> <strong>Rheumatology</strong> <strong>of</strong> the First Faculty<br />
<strong>of</strong> Medicine, Charles University i, 5 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Department <strong>of</strong> Medicine, Kobe University Graduate School <strong>of</strong><br />
Medicine, Kobe University Hospital, Kobe, Japan, 6 Friedrich<br />
Alexander Univ, Erlangen, Germany, 7 Paris Descartes University,<br />
<strong>Rheumatology</strong> A Department, Cochin Hospital and INSERM<br />
U781, Necker Hospital, Paris, France, 8 University <strong>of</strong> Erlangen,<br />
Erlangen, Germany.<br />
617. The Triterpenoid CDDO Abrogates Canonical TGF-beta<br />
Signaling and Fibrotic Responses in Normal and Scleroderma<br />
Fibroblasts by Stabilizing the Anti-Oxidant Nuclear Factor-<br />
Like 2 (Nrf2). Kazuhiro Komura 2 , Jun Wei 2 , Gabriel Lord 2 and<br />
John Varga 1 , 1 Northwestern Univ Feinberg School, Chicago, IL,<br />
2<br />
Northwestern University Feinberg School <strong>of</strong> Medicine.<br />
618. Urantide Prevents and Alleviates Monocrotaline Induced<br />
Pulmonary Arterial Hypertension in Wistar Rats. Yifang<br />
Mei 1 , Hong Jin 3 , Hao Wang 2 , Wei Tian 2 , Yanping Zhao 2 and<br />
Zhiyi Zhang 2 , 1 The First Affiliated Hospital <strong>of</strong> Harbin Medical<br />
University, Harbin, Heilongjiang, China, 2 The First Affiliated<br />
Hospital <strong>of</strong> Harbin Medical University, Harbin, China, 3 The<br />
First Affiliated Hospital <strong>of</strong> Shantou University Medical <strong>College</strong>,<br />
Shantou, China.<br />
619. Visfatin/NAMPT in Interstitial Pneumonia <strong>of</strong> Patients with<br />
Systemic Sclerosis and Scleroderma Mice Model Induced<br />
by Bleomycin. Hirahito Endo 2 , Tatsuhiro Yamamoto 1 , Kaichi<br />
Kaneko 3 , Yoshie Kusunoki 3 , Natsuko Kusunoki 3 and Shinichi<br />
Kawai 3 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />
Medicine, Toho University School <strong>of</strong> Medicine, Ohmori-nishi,<br />
Ohta-ku, Japan, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Internal Medicine, Toho University School <strong>of</strong> Medicine, Ohmorinishi,<br />
Oh-taku, Japan, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Internal Medicine, Toho University School <strong>of</strong> Medicine.<br />
190<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
Halls B1 & B2<br />
TUESDAY, NOVEMBER 9, 2010<br />
B-Cell Biology and Targets in Autoimmune Disease<br />
733. A Systems Biology Approach to Understanding SLE Complexity.<br />
John Jung 5 , Jennifer Hossler 5 , Youqun Huang 5 , Elise Palmer 5 ,<br />
Elides Marin 5 , Tracy Sanford 5 , Ehtisham Akhter 2 , Michelle A.<br />
Petri 1 , Alex Rosenberg 5 , Jennifer H. Anolik 3 , Chungwen Wei 5 and<br />
Ignacio Sanz 4 , 1 Timonium, MD, 2 John Hopkin University School<br />
<strong>of</strong> Medicine, Baltimore, MD, 3 University <strong>of</strong> Rochester, Rochester,<br />
NY, 4 University <strong>of</strong> Rochester Medical Center, Rochester, NY,<br />
5<br />
University <strong>of</strong> Rochester Medical Center, Rochester, NY.<br />
734. Antibodies from Antibody-Secreting Cells Following<br />
Vaccination in Patients with Systemic Lupus Erythematosus<br />
Are Autoreactive and Polyspecific. Kenneth A. Smith 2 , Lori<br />
Garman 3 , Jennifer Morris 3 , Linda Thompson 3 , Patrick C. Wilson 4<br />
and Judith A. James 1 , 1 Oklahoma Medical Research Foundation,<br />
Oklahoma City, OK, 2 Oklahoma Medical Research Foundation,<br />
Fort Wayne, IN, 3 Oklahoma Medical Research Foundation,<br />
4<br />
University <strong>of</strong> Chicago.<br />
735. Antibodies to CCP Versus the Unmodified Arginine-Containing<br />
Peptide (CAP) as a Serological Marker To Differentiate SLE<br />
from RA. Jason Chan 2 , Rufus Burlingame 1 , Angela Ceribelli 2 ,<br />
Eric S. Sobel 3 , Yi Li 3 , Westley H. Reeves 3 , Edward K. .L Chan 3 and<br />
Minoru Satoh 3 , 1 INOVA Diagnostics, Inc., 2 University <strong>of</strong> Florida,<br />
3<br />
University <strong>of</strong> Florida, Gainesville, FL.<br />
736. Apoptotic Cell Bodies and Blebs Stimulate Self Reactive B-Cells<br />
Via Engagement <strong>of</strong> the BCR and Endosomal Toll-Like Receptors.<br />
John McCahan 2 , Nathanial Green 1 and Ann Marshak-Rothstein 3 ,<br />
1<br />
Boston University, Boston, MA, 2 <strong>Rheumatology</strong> Section, Boston<br />
University, 3 The University <strong>of</strong> Massachusetts Medical School,<br />
Worcester MA.<br />
737. B Cell-Dependent Regulation (Breg) <strong>of</strong> T-Cell Proliferation Is<br />
Deficient in Systemic Lupus Erythematosus (SLE). Jacques-<br />
Olivier Pers, Sébastien Lemoine, Ahsen Morva, Christophe Jamin<br />
and Pierre Youinou, Brest University.<br />
738. B Cells Modify Regulatory T Cells in Healthy Individuals but<br />
Not in Patients with Systemic Lupus Erythematosus. Mark<br />
N. Lazarus, Hardeep S. Kalsi, David A. Isenberg and Michael R.<br />
Ehrenstein, UCL Div <strong>of</strong> Medicine, London, United Kingdom.<br />
739. BAFF Binding Receptors (BBR) Related To Relapse after<br />
Rituximab in Patients with Reumatoid Arthritis (RA).<br />
Inmaculada De la Torre 1 , Lara Valor 1 , Rita Moura 2 , Maria J.<br />
Leandro 3 , Jonathan C. W. Edwards 3 and Geraldine Cambridge 3 ,<br />
1<br />
Hospital Gregorio Maranon, Madrid, Spain, 2 Instituto de<br />
Biologia Molecular, Lisboa, Portugal, 3 University <strong>College</strong> London,<br />
London, UK.<br />
740. Cellular and Serological Changes Following B Cell Repopulation<br />
after Rituximab Therapy Suggest Antibody-Independent Roles<br />
for B Cells in Systemic Lupus Erythematosus. Mark N. Lazarus,<br />
Andrew Fester, Tabitha Turner-Stokes, David A. Isenberg and<br />
Michael R. Ehrenstein, UCL Div <strong>of</strong> Medicine, London, United<br />
Kingdom.<br />
741. Elevated Serum BAFF Correlates with Loss <strong>of</strong> Mature B Cells<br />
and Promotes B Cell Recovery in Mice after B Cell Depletion<br />
Treatment. Yue Wang 2 , Sandra Gallagher 1 , Isharat Yusuf 1 , Bahija<br />
Jallal 1 , Anthony Coyle 1 and Ronald Herbst 1 , 1 MedImmune LLC,<br />
2<br />
MedImmune LLC, Gaithersburg, MD.<br />
742. Elimination <strong>of</strong> Autoantibody Producing Plasma Cells Using<br />
CXCR4 Antagonist AMD3100. Jason Weinstein 4 , Yuan Xu 1 ,<br />
Matthew Delano 3 , Yi Li 2 , Lijun Yang 1 , Eric S. Sobel 2 , Lyle<br />
Moldawer 1 and Westley H. Reeves 2 , 1 University <strong>of</strong> Florida,<br />
2<br />
University <strong>of</strong> Florida, Gainesville, FL, 3 Universsity <strong>of</strong> Florida,<br />
4<br />
Yale University.<br />
743. Expression <strong>of</strong> the Idiotope 9G4 on Autoantibodies and B Cells<br />
from Patients with Rheumatoid Arthritis (RA): Description <strong>of</strong><br />
a New B Cell Phenotype. Inmaculada De la Torre 1 , Rita Moura 2 ,<br />
Maria J. Leandro 3 , Jonathan C. W. Edwards 3 and Geraldine<br />
Cambridge 3 , 1 Hospital Gregorio Maranon, Madrid, Spain,<br />
2<br />
Instituto de Biologia Molecular, Lisbon, Portugal, 3 University<br />
<strong>College</strong> London, London, UK.<br />
744. Expression <strong>of</strong> ZAP-70 in B-Cell Is a Feature <strong>of</strong> Peripheral<br />
Blood Repopulation after Rituximab Therapy in Rheumatoid<br />
Arthritis. Francesca Faustini, Barbara Tolusso, Giusy Peluso, Elisa<br />
Gremese, Silvia Canestri, Graziella D’Antona, Antonella Laria<br />
and Gianfranco Ferraccioli, Division <strong>of</strong> <strong>Rheumatology</strong>, Catholic<br />
University <strong>of</strong> the Sacred Heart, Rome, Italy.<br />
745. In Vivo Effects <strong>of</strong> Tocilizumab on Peripheral B Cells in Patients<br />
with Rheumatoid Arthritis. Petra Roll 2 , Khalid Muhammad 2 ,<br />
Mathias Schumann 2 , Stefan Kleinert 2 , Thomas Dörner 1 and<br />
Hans-Peter Tony 2 , 1 <strong>Rheumatology</strong> and Clinical Immunology<br />
Charite Universitätsmedizin Berlin and DRFZ Berlin, Berlin,<br />
Germany, 2 <strong>Rheumatology</strong>/Clinical Immunology, University <strong>of</strong><br />
Würzburg, Würzburg, Germany.<br />
746. Predominant Suppression <strong>of</strong> Plasmablasts by<br />
Cyclophosphamide in Patients with Systemic Lupus<br />
Erythematosus: A Possible Therapeutic Mechanism. Yuko<br />
Okamoto 1 , Yasuhiro Katsumata 5 , Yasushi Kawaguchi 2 , Manabu<br />
Kawamoto 5 , Sayumi Baba 5 , Kae Takagi 5 , Takahisa Gono 5 , Yuko<br />
Ota 5 , Masako Hara 4 and Hisashi Yamanaka 3 , 1 Tokyo Women’s<br />
Medical University, Tokyo, Japan, 2 Tokyo Women’s Medical<br />
University, Tokyo, Japan, 3 Tokyo Women’s Medical University,<br />
Shinjuku-ku, Tokyo, Japan, 4 Tokyo Women’s Medical University,<br />
Kamakura Kanagawa, Japan, 5 Tokyo Women’s Medical<br />
University.<br />
747. Progesterone Receptors Regulate Humoral Immunity. Alan<br />
Wong, Chang Li, Ed Clark and Grant Hughes, University <strong>of</strong><br />
Washington.<br />
748. SLAP Deficiency Alters Both Central and Peripheral B Cell<br />
Tolerance Leading to Decreased Autoantibody Production. Lisa<br />
K. Peterson 2 , Laura A. Shaw 2 , Luke F. Pennington 1 and Leonard L.<br />
Dragone 2 , 1 Denver, CO, 2 National Jewish Health, Denver, CO.<br />
749. SLE Anti-CD45/B220 9G4 Autoantibodies Induce Attenuated<br />
BCR Signaling: Implication for Disease Pathogenesis. Scott A.<br />
Jenks 2 , Anna E. Schroeder 1 and Ignacio Sanz 2 , 1 Duke University,<br />
Durham, NC, 2 Univ <strong>of</strong> Rochester, Rochester, NY.<br />
750. Specific Histone Deacetylase (HDAC2) Inhibition in B Cells May<br />
Protect Lupus. Nilamadhab Mishra 1 , Kristen Delany 3 and Issac<br />
Snowhite 2 , 1 Wake Forest Univ Health Scienc, Winston-Salem,<br />
NC, 2 Wake Forest Univ Health Science, 3 Wake Forest Univ Health<br />
Sciences.<br />
751. The Effects <strong>of</strong> the Anti-CD22 Monoclonal Antibody<br />
Epratuzumab on B-Cell Surface Proteins. Anthony Shock 1 , Derek<br />
Brown 2 , Kenneth Crook 2 and Timothy Bourne 2 , 1 UCB, Slough,<br />
Berkshire, Slough, United Kingdom, 2 UCB, Slough, Berkshire, UK.<br />
2010 Program Book 191
ACR Poster Session B<br />
752. The Effects <strong>of</strong> the Anti-CD22 Monoclonal Antibody<br />
Epratuzumab on Peripheral Blood B Cells and Immune<br />
Responses In Vivo, and Immunoglobulin Production In Vitro.<br />
Anthony Shock 1 , Derek Brown 2 , Kenneth Crook 2 , Stevan Shaw 2 ,<br />
Timothy Bourne 2 , Roland Foulkes 2 and Ge<strong>of</strong>frey Rose 2 , 1 UCB,<br />
Slough, Berkshire, Slough, United Kingdom, 2 UCB, Slough,<br />
Berkshire, UK.<br />
753. TNF Blockade Impairs the Induction <strong>of</strong> T-Cell Dependent<br />
Antibody Responses. Gabriela Franco Salinas 1 , Leen De Rycke 2 ,<br />
Sophie Brouard 4 , Vojislav Jovanovic 4 , Frederique Moizant 4 ,<br />
Tineke Cantaert 2 , Mirjam van der Burg 3 , Barbara Barendregt 3 ,<br />
Paul Peter Tak 2 , Jean-Paul Soulillou 4 and Dominique Baeten 2 ,<br />
1<br />
Academisch Medisch Centrum, University <strong>of</strong> Amsterdam,<br />
Amsterdam, Noord Holland, The Netherlands, 2 Academisch<br />
Medisch Centrum, University <strong>of</strong> Amsterdam, Amsterdam, The<br />
Netherlands, 3 Immunology, Erasmus Medical Center, Rotterdam,<br />
Netherlands, 4 Institut de Transplantation et Recherche en<br />
Transplantation, INSERM U 643 , Nantes, France.<br />
Epidemiology and Health Services Research: MSK, CTD and SLE<br />
754. A Systematic Literature Review <strong>of</strong> the Direct Costs <strong>of</strong><br />
Systemic Lupus Erythematosus (SLE) in the United States<br />
(US). Katherine A. Slawsky 1 , Ancilla Fernandes 2 , Susan Manzi 3 ,<br />
Lauren Fusfeld 1 and Thomas F. Goss 1 , 1 Boston Healthcare<br />
Associates, Inc., Boston MA and Washington DC, 2 MedImmune<br />
LLC, Gaithersburg, MD, 3 West Penn Allegheny Health System,<br />
Pittsburgh, PA.<br />
755. A Systematic Review To Appraise the Quality <strong>of</strong> Cost-<br />
Effectiveness Studies <strong>of</strong> Biologic Agents for the Treatment<br />
<strong>of</strong> Rheumatoid Arthritis. Maria A. Lopez-Olivo 1 , Yomei Shaw 2<br />
and Maria E. Suarez-Almazor 3 , 1 The University <strong>of</strong> Texas M.D.<br />
Anderson Cancer Center, Houston, TX, 2 The University <strong>of</strong><br />
Texas M.D. Anderson Cancer Center, 3 University <strong>of</strong> Texas, MD<br />
Anderson Cancer Center, Houston, TX.<br />
756. Agreement between Tuberculin Skin Test and Interferon-Assay<br />
in Korean Patients with Rheumatoid Arthritis and Ankylosing<br />
Spondylitis before Initiation <strong>of</strong> Anti-Tumor Necrosis Factor<br />
Therapy. Yong-Geun Jeong 1 , Ji-Min Kim 3 , Su-Jin Moon 3 , Seung-Ki<br />
Kwok 3 , Ji-Hyeon Ju 3 , Kyung-Su Park 3 , Sung-Hwan Park 2 and Ho-<br />
Youn Kim 1 , 1 Seoul St. Mary’s Hospital, The Catholic University <strong>of</strong><br />
Korea, Seoul, Republic <strong>of</strong> Korea, 2 Seoul St. Mary’s Hospital, The<br />
Catholic University <strong>of</strong> Korea, Seoul, Korea, Republic <strong>of</strong>, 3 Seoul St.<br />
Mary’s Hospital, The Catholic University <strong>of</strong> Korea, Seoul, South<br />
Korea.<br />
757. Assessing Systemic Lupus Erythematosus Disease Severity and<br />
Disease Flares: Development <strong>of</strong> a Claims-Based Algorithm.<br />
Cindy P. Garris 2 , Priti M. Jhingran 2 , Nicole M. Engel-Nitz 4 , Aylin<br />
A. Riedel 5 , George Goldberg 4 , Damon L. Bass 1 and Gregory J.<br />
Dennis 3 , 1 GlaxoSmithKline, King <strong>of</strong> Prussia, PA, 2 GlaxoSmithKline,<br />
Research Triangle Park, NC, 3 Human Genome Sciences,<br />
Rockville, MD, 4 i 3 Innovus, Eden Prarie, MN, 5 i 3 Innovus, Eden<br />
Prarie, NC.<br />
758. Colonization and Infection by Staphylococcus Aureus among<br />
Those Using Biologic Therapy. Cara Varley 1 , Atul A. Deodhar 1 ,<br />
Benjamin Ehst 1 , Antony Bakke 1 , Andrew Blauvelt 1 , Robert Vega 2<br />
and Kevin Winthrop 1 , 1 Oregon Health & Science University,<br />
Portland, OR, 2 Oregon State Public Health Laboratory, Hillsboro,<br />
OR.<br />
759. Comprehensive Health Economic Assessment <strong>of</strong> Sequenced<br />
Treatment with Biologics in Moderate-to-Severe Rheumatoid<br />
Arthritis: Analysis Based on ACR50 and ACR70 Responses.<br />
Erkki J. O. Soini 1 , Taru A. Hallinen 1 , Markku J. Kauppi 3 , Ville<br />
Vihervaara 4 and Kari Puolakka 2 , 1 ESiOR Oy, Kuopio, Finland,<br />
2<br />
Lappeenranta Central Hospital, Lappeenranta, Finland,<br />
3<br />
Päijät-Häme Central Hospital, Lahti, Finland, 4 Roche Oy, Espoo,<br />
Finland.<br />
760. Correlations between 3 Work-Related Patient-Reported<br />
Outcome Instruments for Patients with Ankylosing Spondylitis.<br />
Annelies Boonen 2 , Walter P. Maksymowych 3 , Sumati Rao 1 ,<br />
Naijun Chen 1 and Mary Cifaldi 1 , 1 Abbott Laboratories,<br />
Abbott Park, IL, 2 University Hospital Maastricht, Maastricht,<br />
Netherlands, 3 University <strong>of</strong> Alberta, Edmonton, AB.<br />
761. Costs for Health Care, Prescribed Drugs, and Sick Leave Differ<br />
for Patients with Different Types <strong>of</strong> Spondylarthropathy. Ann<br />
B. I. Bremander 1 , Aleksandra Turkiewicz 2 , Martin Englund 2 ,<br />
Emma Haglund 3 , Gisela Kobelt 2 , Ingemar F. Petersson 2 and<br />
Britta Strömbeck 2 , 1 Musculoskeletal Research Center, Dept. <strong>of</strong><br />
Orthopedics, Clinical Sciences, Lund University, Lund, Research<br />
and Development Cente at Spenshult Hospital for Rheumatic<br />
Diseases, Oskarstrom, Sweden, 2 Musculoskeletal Research<br />
Center, Dept. <strong>of</strong> Orthopedics, Clinical Sciences, Lund University,<br />
Lund, Sweden, 3 Musculoskeletal Research Center, Dept. <strong>of</strong><br />
Orthopedics, Clinical Sciences, Lund University, Lund, Sweden,<br />
Research and Development Cente at Spenshult Hospital for<br />
Rheumatic Diseases, Halmstad, Sweden.<br />
762. Dietary Intake <strong>of</strong> Vitamin D during Adolescence and Risk <strong>of</strong><br />
Adult Onset Systemic Lupus Erythematosus and Rheumatoid<br />
Arthritis. Linda T. Hiraki 3 , Karen H. Costenbader 1 , Kassandra<br />
Munger 4 and Elizabeth W. Karlson 2 , 1 Brigham & Women, Boston,<br />
MA, 2 Brigham and Womens Hospital, Boston, MA, 3 Harvard<br />
School <strong>of</strong> Public Health, Boston, MA, 4 Harvard School <strong>of</strong> Public<br />
Health.<br />
763. Direct and Indirect Costs <strong>of</strong> Spondlyoarthritis Patients Preand<br />
Post-Diagnosis. Noam Kirson 2 , Howard Birnbaum 2 , Sumati<br />
Rao 1 , Elyse Swallow 2 , Tracy Waldman 2 , Elias Dayoub 2 and Mary<br />
Cifaldi 1 , 1 Abbott Laboratories, Abbott Park, IL, 2 Analysis Group,<br />
Inc., Boston, MA.<br />
764. Distinguishing Levels <strong>of</strong> Disease Flare in Patients with Systemic<br />
Lupus Erythematosus Using Administrative Claims Data.<br />
Nicole Engel-Nitz 5 , James Burke 5 , Cindy P. Garris 3 , Priti Jhingran 1 ,<br />
Damon L. Bass 2 and Gregory J. Dennis 4 , 1 GlaxoSmithKline,<br />
2<br />
GlaxoSmithKline, King <strong>of</strong> Prussia, PA, 3 GlaxoSmithKline, RTP, NC,<br />
4<br />
Human Genome Sciences, 5 i 3 Innovus.<br />
765. Does Cigarette Smoking Affect Disease Phenotype in Systemic<br />
Lupus Erythematosus. Meenakshi Jolly 2 , Rachel A. Mikolaitis 4 ,<br />
Joel A. Block 4 and Michelle Petri 1 , 1 John Hopkins University,<br />
2<br />
Rush University Medical Center, Chicago, IL, 3 Rush University<br />
Medical Center, Chicago, IL, 4 Rush University Medical Center.<br />
766. Early and Persistent Clinical Remission Reduces Long-Term<br />
Disability in Inflammatory Polyarthritis: Results from the<br />
Norfolk Arthritis Register. Carlo Alberto Scirè 2 , Suzanne M.<br />
Verstappen 1 , Hoda Mjriafari 1 , Diane Bunn 3 , Mark Lunt 1 , Ian<br />
Bruce 1 , Carlomaurizio Montecucco 2 and Deborah P. Symmons 4 ,<br />
1<br />
Arthritis Research UK Epidemiology Unit, Stopford Building,<br />
The University <strong>of</strong> Manchester, Manchester, United Kingdom,<br />
2<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, IRCCS Policlinico San Matteo<br />
Foundation, University <strong>of</strong> Pavia, Pavia, Italy, 3 Norfolk Arthritis<br />
Register, Norfolk and Norwich University Hospital, Norwich,<br />
United Kingdom., 4 Univ <strong>of</strong> Manchester, Manchester, United<br />
Kingdom.<br />
192<br />
2010 Program Book
ACR Poster Session B<br />
767. Economic Evaluation <strong>of</strong> Rituximab Versus Alternative Anti-<br />
Tumor Necrosis Factor (TNF) Therapy after Failure <strong>of</strong> Anti-TNF<br />
for Treatment <strong>of</strong> Rheumatoid Arthritis in Mexico. Fernando<br />
Carlos 2 and Patricia Clark 1 , 1 Hospital Infantil Federico Gómez<br />
México, Mexico City, Mexico, 2 R A C Salud Consultores, S.A. de<br />
C.V..<br />
768. High Level <strong>of</strong> Disease Activity in Chronic Inflammatory<br />
Rheumatisms Increases the Rate <strong>of</strong> Indeterminate Interferon-<br />
Gamma-Release Assay Results for Latent Tuberculosis<br />
Infection Detection. Félicie Costantino 2 , Gilbert Faure 1 , Marcelo<br />
De Carvalho 1 , Anne-Christine Rat 2 , Hervé Dintinger 2 , Damien<br />
Loeuille 2 and Isabelle Chary-Valckenaere 2 , 1 Immunology<br />
(EA RHEM4369) Department, Nancy University Hospital,<br />
Vandoeuvre-lès-Nancy, France, 2 <strong>Rheumatology</strong> department,<br />
Nancy University Hospital, Vandoeuvre-lès-Nancy, France.<br />
769. Improving Health-Related Quality <strong>of</strong> Life in Patients with<br />
Systemic Lupus Erythematosus (SLE): The Role <strong>of</strong> Disease<br />
Control, Steroid Reduction and Smoking Cessation. Mark J.<br />
Harrison 5 , Nicola Dale 1 , Sahena Haque 2 , Joanna Shelmerdine 6 ,<br />
Lee-Suan Teh 4 , Yasmeen Ahmad 3 and Ian N. Bruce 1 , 1 Arthritis<br />
Research UK Epidemiology Unit, The University <strong>of</strong> Manchester,<br />
Manchester, United Kingdom, 2 Arthritis Research UK<br />
Epidemiology Unit, The University <strong>of</strong> Manchester, Manchester,<br />
United Kingdom, 3 Betsi Cadwaladr University Health Board-<br />
West, <strong>Rheumatology</strong>, Llandudno, United Kingdom, 4 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Royal Blackburn Hospital, Blackburn, United<br />
Kingdom, 5 Health Sciences Research Group, The University<br />
<strong>of</strong> Manchester, Manchester, UK, 6 The Kellgren Centre for<br />
<strong>Rheumatology</strong>, Central Manchester Foundation Trust,<br />
Manchester, UK.<br />
770. Increase in Direct and Decrease in Indirect Costs <strong>of</strong><br />
Rheumatoid Arthritis in Germany between 2002 and 2008.<br />
Dörte Huscher 2 , Katja Thiele 2 , Andrea Pfaefflin 2 , Sascha<br />
Bisch<strong>of</strong>f 2 , Rieke Alten 4 , Ulrich von Hinueber 3 , Matthias K.<br />
Schneider 5 and Angela Zink 1 , 1 German Rheumatism Research<br />
Centre and Charité University Hospital, Berlin, Germany,<br />
2<br />
German Rheumatism Research Centre, Berlin, Germany,<br />
3<br />
Hildesheim, Germany, 4 Schlosspark-Klinik KG, Department<br />
<strong>of</strong> Internal Medicine II, <strong>Rheumatology</strong>, Clinical Immunology<br />
Osteology, Berlin, Germany, 5 University Hospital Düsseldorf,<br />
Duesseldorf, Germany.<br />
771. Increased Risk <strong>of</strong> Valvular and Nonvalvular Cardiovascular<br />
Disease in Younger Individuals with Ankylosing Spondylitis: A<br />
Population-Based Study. Adrian R. Levy 3 , Shelagh M. Szabo 3 ,<br />
Sumati Rao 1 , Diane V. Lacaille 2 , Mary Cifaldi 1 and Walter P.<br />
Maksymowych 4 , 1 Abbott, 2 Arthritis Research Ctr Canada,<br />
Vancouver, BC, Canada, 3 Oxford Outcomes, 4 University <strong>of</strong><br />
Alberta, Edmonton, AB, Canada.<br />
772. Is There an Advantage for a Lupus Specific Quality <strong>of</strong> Life<br />
Measure over SF-36? Zahi Touma 2 , Dafna D. Gladman 3 ,<br />
Dominique Ibanez 2 and Murray B. Urowitz 1 , 1 The Toronto<br />
Western Hospital, Toronto, ON, Canada, 2 Toronto Western<br />
Hospital, Toronto, ON, Canada, 3 Toronto Western Hospital,<br />
Toronto, ON, Canada.<br />
773. Life Expectancy, Standardized Mortality Ratios and Causes <strong>of</strong><br />
Deaths <strong>of</strong> Six Rheumatic Diseases in Hong Kong, China. Chi<br />
Chiu Mok 1 , Raymond C. L. Kwok 2 , Ling Yin Ho 1 , Pak To Chan 1 and<br />
Paul S. F. Yip 2 , 1 Tuen Mun Hospital, 2 University <strong>of</strong> Hong Kong.<br />
774. Lower Body Mass Index Is Associated with an Increased Risk <strong>of</strong><br />
Giant Cell Arteritis. Karin Jakobsson 3 , Lennart T. H. Jacobsson 2 ,<br />
Kenneth J. Warrington 1 , Eric L. Matteson 1 , Kimberly P. Liang 5 ,<br />
Olle Melander 4 and Carl Turesson 3 , 1 Mayo Clinic, Rochester,<br />
MN, 2 Skåne University Hospital, Malmo, Sweden, 3 Skåne<br />
University Hospital, Malmö, Sweden, 4 Skåne University Hospital,<br />
5<br />
University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />
775. Obstetrical and Neonatal Outcomes in Rheumatic Disease.<br />
Cheryl C. M. Barnabe, Peter Faris and Hude Quan, University <strong>of</strong><br />
Calgary, Calgary, AB, Canada.<br />
776. Patient Perceptions and Access to Resources Influence Patient<br />
Decisions To Attend <strong>Rheumatology</strong> Appointments. Valerie<br />
Milne 2 , Robin Kearns 1 and Andrew A. Harrison 3 , 1 University <strong>of</strong><br />
Auckland, New Zealand, New Zealand, 2 University <strong>of</strong> Otago,<br />
Wellington, Wellington, New Zealand, 3 University <strong>of</strong> Otago,<br />
Wellington, New Zealand, New Zealand.<br />
777. Patient-Reported Outcome Measures in Patients with<br />
Polymyalgia Rheumatica (PMR): Results from an International,<br />
Prospective, Multi-Centre Study. ACR – EULAR Study Group<br />
for Development <strong>of</strong> Classification Criteria for PMR. Bhaskar<br />
Dasgupta 16 , Marco A. Cimmino 10 , Hilal Maradit-Kremers 3 ,<br />
Wolfgang A. Schmidt 19 , Schirmer Michael 5 , Carlo Salvarani 11 ,<br />
Peter Mandl 20 , Artur Bachta 4 , Maria C. Cid 17 , Haner Direskeneli 13 ,<br />
Pierluigi Macchioni 11 , Peter V. Balint 1 , Christina Duftner 9 ,<br />
Christian Dejaco 14 , Hanna Slott-Jensen 18 , Zsuzsa Schmidt 20 ,<br />
Gyula Poór 20 , Annamaria Iagnocco 24 , Victor Martínez-Taboada 28 ,<br />
Elizabeth Nordborg 26 , Nicolò Pipitone 11 , Pierre Duhaut 27 , Carlotta<br />
Nannini 25 , Georgina Espígol-Frigolé 2 , Sibel Z. Aydin 13 , Khalid<br />
Ahmed 15 , Raashid Luqmani 21 , Brian Hazelman 12 , Colin Pease 22 ,<br />
Richard J. Wakefield 22 , Neil Gonter 23 , Ralph Marcus 23 , Clement<br />
J. Michet 7 , Mehrdad Mazlumzadeh 8 , Andy Abril 6 , Cynthia S.<br />
Crowson 3 and Eric L. Matteson 7 , 13 rd <strong>Rheumatology</strong> Department,<br />
National Institute <strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy,<br />
Budapest, 2 Center for Diagnosis Imaging, Hospital Clínic,<br />
Montserrat del Amo, Barcelona, Spain, 3 Department <strong>of</strong> Health<br />
Sciences Research, Mayo Clinic, Rochester, MN, 4 Department<br />
<strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, WIM CSK MON,<br />
Warszawa, Poland, 5 Department <strong>of</strong> Internal Medicine I, Medical<br />
University Innsbruck, Innsbruck, Austria, 6 Department <strong>of</strong><br />
Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic,<br />
Jacksonville, FL, 7 Department <strong>of</strong> Internal Medicine, Division<br />
<strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic, Rochester, MN, 8 Department<br />
<strong>of</strong> Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic,<br />
Scottsdale, AZ, 9 Department <strong>of</strong> Internal Medicine, General<br />
Hospital <strong>of</strong> the Elisabethinen, Klagenfurt, Austria, 10 Department<br />
<strong>of</strong> Internal Medicine, University <strong>of</strong> Genova, Genova, Italy,<br />
11<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Arcispedale S. Maria<br />
Nuova, Reggio Emilia, Italy, 12 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Cambridge University, Cambridge, UK, 13 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Marmara University Medical School, Istanbul,<br />
Turkey, 14 Department <strong>of</strong> <strong>Rheumatology</strong>, Medical University,<br />
Graz, Graz, Austria, 15 Department <strong>of</strong> <strong>Rheumatology</strong>, Princess<br />
Alexandra Hospital, Harlow, United Kingdom, 16 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Southend University Hospital, Essex, United<br />
Kingdom, 17 Department <strong>of</strong> Systemic Autoimmune Hospital<br />
Clinic Provincial, Barcelona, Spain, 18 Gent<strong>of</strong>te Hospital,<br />
<strong>Rheumatology</strong> Division, Hellerup, Denmark, 19 Immanuel<br />
Krankenhaus Berlin: Medical Center for <strong>Rheumatology</strong><br />
Berlin-Buch Berlin, Berlin, Germany, 20 National Institute<br />
<strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy, Budapest, Hungary,<br />
21<br />
Nuffield Department <strong>of</strong> Orthopaedics, <strong>Rheumatology</strong> and<br />
Musculoskeletal Sciences, Oxford University, Oxford, UK,<br />
22<br />
<strong>Rheumatology</strong> and Rehabilitation Research Unit, University <strong>of</strong><br />
Leeds, Leeds, UK, 23 <strong>Rheumatology</strong> Associates <strong>of</strong> North Jersey,<br />
Teaneck, NJ, 24 <strong>Rheumatology</strong> Unit, Clinica e Terapia Medica<br />
Department, Sapienza Università di Roma, Policlinico Umberto<br />
I, Rome, Italy, 25 <strong>Rheumatology</strong> Unit, Ospedale Misericordia e<br />
Dolce, Prato, Italy, 26 Sahlgren University Hospital, Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Göteborg, Sweden, 27 Service de Medecine<br />
Interne, Amiens, France, 28 Servicio de Reumatología, Hospital<br />
Universitario Marques de Valdecilla, Facultad de Medicina,<br />
Universidad de Cantabria, Santander, Spain.<br />
2010 Program Book 193
ACR/ARHP Poster Session B<br />
778. Psychometric Properties <strong>of</strong> a Self-Administered Early<br />
Inflammatory Arthritis Detection Tool. Mary J. Bell 3 , Joel P.<br />
Scarf 2 and Ruben Tavares 1 , 1 McMaster University, Hamilton, ON,<br />
Canada, 2 Sunnybrook Health Science Ctr, Toronto, ON, Canada,<br />
3<br />
Sunnybrook Health Sciences Ctr, Toronto, ON, Canada.<br />
779. Reproductive History and Functional Outcome in Women<br />
with Recent-Onset Inflammatory Polyarthritis. Elizabeth M.<br />
Camacho 1 , Mark Lunt 1 , Tracey M. Farragher 1 , Mark Harrison 1 ,<br />
Suzanne M. Verstappen 1 , Diane K. Bunn 2 and Deborah P.<br />
Symmons 3 , 1 Arthritis Research UK Epidemiology Unit, Stopford<br />
Building, The University <strong>of</strong> Manchester, Manchester, United<br />
Kingdom, 2 Norfolk Arthritis Register, School <strong>of</strong> Medicine Health<br />
Policiy & Practice, University <strong>of</strong> East Anglia, Norwich UK, 3 Univ<br />
<strong>of</strong> Manchester, Manchester, United Kingdom.<br />
780. Rheumatic Diseases among Oklahoma Tribal Populations.<br />
Jasmine R. Gaddy 8 , Amy B. Dedeke 4 , Wendy Klein 3 , Fabio<br />
Mota 2 , Tina Cooper 2 , M. Sohail Khan 1 , Virginia Roberts 5 , Jeremy<br />
Levin 5 , Scott Stewart 5 , Rebecca Stormont 6 and Judith A. James 7 ,<br />
1<br />
Cherokee Nation, 2 Chickasaw Nation, 3 Oklahom Research<br />
Foundation, OKC, OK, 4 Oklahoma Medical Research Foundation,<br />
OKC, OK, 5 Oklahoma Medical Research Foundation, 6 University<br />
<strong>of</strong> Oklahoma HSC, 7 University <strong>of</strong> Oklahoma HSC, Oklahoma<br />
Medical Research Foundation, OKC, OK, 8 University <strong>of</strong> Oklahoma<br />
HSC, Oklahoma Medical Research Foundation, Veteran’s Affairs<br />
Medical Center, OKC, OK.<br />
781. Rheumatoid Arthritis (RA) Impact on Work and RA-Related<br />
Indirect Costs during the First Three Years after RA Diagnosis.<br />
An Economic Analysis from the ESPOIR Cohort. Sabrina<br />
Dadoun 6 , Sandy Lucier 2 , Marie De Rosa 2 , Alain Saraux 3 , Francis<br />
Berenbaum 4 , Isabelle Durand-Zaleski 2 , Francis Guillemin 1 , Karine<br />
Chevreul 7 and Bruno Fautrel 5 , 1 Nancy, France, 2 Paris, France,<br />
3<br />
CHU de la Cavale Blanche, Brest Cedex, France, 4 Faculty <strong>of</strong><br />
Medicine P&M Curie, Paris, France, 5 Pitie Salpetriere Hospital,<br />
Paris, France, 6 Pitie Salpetriere Hospital, Paris, France, 7 URC Eco,<br />
Paris, France.<br />
782. Screening for Latent Tuberculosis Infection (LTBI) –<br />
Performance <strong>of</strong> Tuberculous Skin Test and Interferon-gamma<br />
Release Assays (IGRA) under Real Life Conditions. Stefan<br />
Kleinert 7 , Hans Peter T. Tony 7 , Klaus Krueger 6 , Jacqueline<br />
Detert 1 , Frank Mielke 4 , Gerd R. Burmester 2 , Roland Diel 3 ,<br />
Martin Feuchtenberger 8 and Christian Kneitz 5 , 1 Charité -<br />
Universitätsmedizin Berlin, Dep. <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />
Immunology, CC 12 , 2 Charité Berlin, 3 Department <strong>of</strong> Pneumology,<br />
Medical School (MHH) Hannover, 4 Gemeinschaftspraxis Innere<br />
Medizin, Dres. Mielke, Berlin, 5 Klinik für Innere Medizin II<br />
(Klinische Immunologie und Rheumatologie, Klinikum Südstadt<br />
Rostock), 6 Praxiszentrum St.Bonifatius München, 7 <strong>Rheumatology</strong><br />
/ Clinical Immunology, Med. Klinik 2 , University <strong>of</strong> Wuerzburg,<br />
Wuerzburg, Germany, 8 <strong>Rheumatology</strong> / Clinical Immunology,<br />
Med. Klinik 2 , University <strong>of</strong> Wuerzburg.<br />
783. Seasonal Variation in Vitamin D Levels in Patients with<br />
Psoriatic Arthritis from Northern and Southern Latitudes<br />
and Its Association with Clinical Outcomes. Zahi Touma 5 ,<br />
Lihi Eder 4 , Devy Zisman 1 , Joy Field 1 , Vinod Chandran 5 , Cheryl<br />
Rosen 5 , Hua Shen 2 , Richard Cook 2 and Dafna D. Gladman 3 , 1 ”Lin”<br />
Medical Centre, Clalit Health Service, Carmel Medical Centre,<br />
Haifa, Israel, 2 Division <strong>of</strong> Biostatistics, University <strong>of</strong> Waterloo,<br />
Waterloo, ON, Canada, 3 Toronto Western Hospital, Toronto, ON,<br />
Canada, 4 University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto<br />
Western Hospital, Torotn, ON, Canada, 5 University <strong>of</strong> Toronto<br />
Psoriatic Arthritis Clinic, Toronto Western Hospital, Toronto, ON,<br />
Canada.<br />
784. Sedentarity Is an Independent Cardiovascular Risk Factor in<br />
Rheumatologic Patients. Marco Antivalle 1 , Cecilia Imperio 2 ,<br />
Michele Battellino 2 , Alessandra Mutti 2 , Maria Chiara Ditto 2 ,<br />
Alberto Batticciotto 2 , Fabiola Atzeni 2 and Piercarlo Sarzi-Puttini 2 ,<br />
1<br />
<strong>Rheumatology</strong> Unit, L. Sacco University Hospital Milano,<br />
MIlano, Italy, 2 <strong>Rheumatology</strong> Unit, L. Sacco University Hospital<br />
Milano, Italy.<br />
785. Sex Differences in Pain Level and Location in Inflammatory<br />
Arthritis: A Systematic Review and Meta-Analysis. Cheryl C.<br />
M. Barnabe 2 , Louis Bessette, Cathy Flanagan, Sharon LeClercq 3<br />
and Vivian P. Bykerk 1 , 1 Mt Sinai Hospital, Toronto, ON, Canada,<br />
2<br />
University <strong>of</strong> Calgary, Calgary, AB, Canada, 3 University <strong>of</strong><br />
Calgary.<br />
786. Sleep Disturbances in Adults with Arthritis: Prevalence,<br />
Mediators, and Subgroups at Greatest Risk. Grant H. Louie 2 ,<br />
Maria G. Tektonidou 1 , Alberto J. Caban-Martinez 4 and Michael<br />
M. Ward 3 , 1 National University Health System, Singapore,<br />
Athens, Greece, 2 NIH, Bethesda, MD, 3 NIH, NIAMS, IRP,<br />
Bethesda, MD, 4 University <strong>of</strong> Miami Miller School <strong>of</strong> Medicine,<br />
Miami, FL.<br />
787. The Comparative Responsiveness <strong>of</strong> the EQ-5D and SF-6D<br />
to Change in Patients with Early Arthritis: Results from the<br />
ESPOIR Cohort. Cécile Gaujoux-Viala 1 , Anne-Christine Rat 2 ,<br />
Francis Guillemin 2 , René-Marc Flipo 5 , Patrice Fardellone 4 , Pierre<br />
Bourgeois 3 and Bruno Fautrel 3 , 1 1INSERM, CIC-EC CIE6 2CHU<br />
Nancy, Epidemiologie et Evaluation Cliniques 3 Nancy-University,<br />
Metz University, Paris Descartes University, EA 4360 Apemac<br />
4<br />
Paris 6 – Pierre et Marie Curie University; <strong>Rheumatology</strong>, Pitie-<br />
Salpêtriere Hospital, 2 1INSERM, CIC-EC CIE 6 , Nancy, France 2 CHU<br />
Nancy, Epidemiologie et Evaluation Cliniques, Nancy, France<br />
3<br />
Nancy-University, Paul Verlaine Metz University, Paris Descartes<br />
University, EA 4360 Apemac, Nancy, France, 3 Paris 6 – Pierre<br />
et Marie Curie University; <strong>Rheumatology</strong>, Pitié-Salpêtrière<br />
Hospital, Paris, France, 4 <strong>Rheumatology</strong>, Amiens University,<br />
France, 5 <strong>Rheumatology</strong>, Lille University 2, France.<br />
788. The Economic Burden <strong>of</strong> Uveitis. S. E. Kirbach, O. A. Hayes and<br />
M. A. Cifaldi, Abbott Laboratories.<br />
789. The Effect <strong>of</strong> Health Insurance and Physician Specialty on<br />
Quality <strong>of</strong> Care for SLE. Edward H. Yelin 6 , Jinoos Yazdany 6 , Laura<br />
Trupin 6 , Chris Tonner 6 , Gabriela Schmajuk 3 , Patricia P. Katz 5 ,<br />
Lindsey A. Criswell 4 , Laura J. Julian 6 , Joann Z. Gillis 2 and Pantelis<br />
Panopalis 1 , 1 McGill University, Montreal, QC, Canada, 2 National<br />
Jewish Medical Center, Denver, CO, 3 Stanford University, Palo<br />
Alto, CA, 4 UCSF-Box 0500, San Francisco, CA, 5 Univ <strong>of</strong> CA San<br />
Francisco, San Francisco, CA, 6 University <strong>of</strong> California, San<br />
Francisco, San Francisco, CA.<br />
790. The Georgia Lupus Registry: Health Care Utilization Rises<br />
during the Transition from Pediatric to Adult Systemic Lupus<br />
Erythematosus (SLE) Care. S. Sam Lim 3 , Gaobin Bao 1 , Larry B.<br />
Vogler 4 and Cristina M. Drenkard 2 , 1 Emory University, 2 Emory<br />
University, Atlanta, GA, 3 Emory University, Atlanta, GA, 4 Emory<br />
University School <strong>of</strong> Medicine, Atlanta, GA.<br />
791. The Impact <strong>of</strong> RA Diagnoses on Cost Related Medication<br />
Nonadherence in Older Patients: 2004-2007. Leslie R. Harrold 3 ,<br />
Becky A. Briesacher 4 , Daniel Peterson 2 , Jeanne Madden 1 , Jerry<br />
H. Gurwitz 2 and Stephen B. Soumerai 1 , 1 Harvard Medical School,<br />
Boston, MA, 2 Meyers Primary Care Institute, Worcester, MA,<br />
3<br />
UMass Medical Schl, Worcester, MA, 4 UMass Medical School,<br />
Worcester, MA.<br />
194<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
792. The Influence <strong>of</strong> Immunosuppressive Therapy and Underlying<br />
Diseases on Vaccine Responses to Influenza A H1N1/09<br />
Vaccines in Inflammatory Rheumatic Diseases. Cem Gabay,<br />
Sara Meier, Danielle Gascon, Karin Posfay-Barbe, Christophe<br />
Combesure, M. Bel, Laurent Kaiser, Pierre-Andre Guerne and<br />
Claire-Anne Siegrist, Univ Hosp <strong>of</strong> Geneva, Geneva, Switzerland.<br />
793. The Risk <strong>of</strong> Myocardial Infarction among Patients with<br />
Psoriatic Arthritis. Thorvardur J. Love 1 , Daniel Hal Solomon 3 and<br />
Elizabeth W. Karlson 2 , 1 Brigham and Women’s Hospital, Boston,<br />
MA, 2 Brigham and Womens Hosp, Boston, MA, 3 Brigham and<br />
Womens Hospital, Boston, MA.<br />
794. Validation <strong>of</strong> a Self-Administered Inflammatory Arthritis<br />
Detection Tool for <strong>Rheumatology</strong> Triage. Mary J. Bell 6 , George<br />
A. Wells 7 , Vivian P. Bykerk 3 , Peter Tugwell 1 , Ruben Tavares 2 ,<br />
Francis Guillimen 4 and Joel Scarf 5 , 1 Institute <strong>of</strong> Population Hlth,<br />
Ottawa, ON, Canada, 2 MaMaster University, 3 Mt Sinai Hospital,<br />
Toronto, ON, Canada, 4 Nancy University, 5 Sunnybrook Health<br />
Sciences Ctr, 6 Sunnybrook Health Sciences Ctr, Toronto, ON,<br />
Canada, 7 Univ <strong>of</strong> Ottawa Faculty <strong>of</strong> Med, Ottawa, ON, Canada.<br />
795. Validation <strong>of</strong> the SF-6D Utility Measure in Patients with<br />
Systemic Lupus Erythematosus (SLE). Mark J. Harrison 5 , Nicola<br />
Dale 1 , Sahena Haque 2 , Joanna Shelmerdine 6 , Lee-Suan Teh 4 ,<br />
Yasmeen Ahmad 3 and Ian N. Bruce 1 , 1 Arthritis Research UK<br />
Epidemiology Unit, The University <strong>of</strong> Manchester, Manchester,<br />
United Kingdom, 2 Arthritis Research UK Epidemiology Unit,<br />
The University <strong>of</strong> Manchester, Manchester, United Kingdom,<br />
3<br />
Betsi Cadwaladr University Health Board-West, <strong>Rheumatology</strong>,<br />
Llandudno, United Kingdom, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Royal Blackburn Hospital, Blackburn, United Kingdom, 5 Health<br />
Sciences Research Group, The University <strong>of</strong> Manchester,<br />
Manchester, UK, 6 The Kellgren Centre for <strong>Rheumatology</strong>, Central<br />
Manchester Foundation Trust, Manchester, UK.<br />
796. Working Status in Patients with Early Inflammatory<br />
Polyarthritis: Results from the Norfolk Arthritis Register<br />
(NOAR). S. M. M. Verstappen 1 , M. Lunt 1 , T. Marshall 2 , D.<br />
K. Bunn 2 , J. Chipping 2 and D. P. M. Symmons 1 , 1 Arthritis<br />
Research UK Epidemiology Unit, The University <strong>of</strong> Manchester,<br />
Manchester, United Kingdom, 2 Norfolk Arthritis Register, Norfolk<br />
and Norwich University Hospital, Norwich, United Kingdom,<br />
United Kingdom.<br />
Fibromyalgia and S<strong>of</strong>t Tissue Disorders II<br />
797. A Randomized Attention-Controlled Study <strong>of</strong> Motivational<br />
Interviewing To Encourage Exercise in Fibromyalgia: Week<br />
12 Interim Analysis. Dennis C. Ang 3 , Anthony S. Kaleth 1 , Sylvia<br />
M. Bigatti 2 , Steven A. Mazzuca 3 , Chandan K. Saha 2 and Robert<br />
W. Bandy 2 , 1 Indiana Univ Purdue Univ Indianapolis, 2 Indiana<br />
University, 3 Indiana University, Indianapolis, IN.<br />
798. Correlation between Bone Mineral Density and Urine<br />
Carboxyl Terminal <strong>of</strong> Collagen Type (CTX) in Premenopausal<br />
Fibromyalgia Patients. Alaa Alsalawy 3 , Mohammed M. Kamel 2<br />
and Ibrahim Eweis 1 , 1 AlAzhar University, Cairo, Egypt, 2 ALAzhar<br />
University, Alkhobar, Saudi Arabia, 3 Tanta University, Tanta,<br />
Egypt.<br />
799. Cyclobenzaprine (CBP) Is a Potent Antagonist <strong>of</strong> Serotonin<br />
Receptor 2a (5-HT2a) and α-2 Adrenergic Receptors:<br />
Mechanistic Implications for Promoting Restorative Sleep in<br />
Fibromyalgia Syndrome (FMS). Herbert W. Harris 1 and Seth<br />
Lederman 2 , 1 Krele Pharmaceuticals, Saddle Brook, NJ, 2 Krele<br />
Pharmaceuticals, New York, NY.<br />
800. Developing an Improved PROMIS Fatigue Short-Form for<br />
Use in Patients with Fibromyalgia. Stephen Schilling 5 , Steven<br />
I. Blum 1 , Stavros Tourkodimitris 2 , Andy Stankus 3 and David A.<br />
Williams 4 , 1 Forest Research Institute, Jersey City, NJ, 2 Forest<br />
Research Institute, 3 KantarHealth, 4 Univ <strong>of</strong> MI Hlth System-<br />
Lobby M, Ann Arbor, MI, 5 University <strong>of</strong> Michigan.<br />
801. Evaluation <strong>of</strong> Drug-Drug Interactions <strong>of</strong> Sodium Oxybate:<br />
Results from Pharmacokinetic/Pharmacodynamic Studies with<br />
Duloxetine, Lorazepam, and Tramadol. Mark Eller, Whitney<br />
Halladay and Annette Madrid, Jazz Pharmaceuticals, Inc..<br />
802. Fibromyalgia Patients with High Global Disease Severity,<br />
Depression, Anxiety or Cognitive Dysfunction Are Likely<br />
To Benefit from Cognitive Behavioral Therapy. Chad S.<br />
Boomershine 1 , Cara L. Hammonds 1 , Jennifer Y. Hong 2 and<br />
Kenneth A. Wallston 2 , 1 Vanderbilt University, Nashville, TN,<br />
2<br />
Vanderbilt University.<br />
803. Identifying Fibromyalgia Subgroups Using Cluster Analysis:<br />
Relationships with Clinical Variables. Shin-Seok Lee 3 , Seong-Ho<br />
Kim 6 , Seong-Su Nah 11 , Ji Hyun Lee 8 , Seong-Kyu Kim 2 , Yeon-Ah<br />
Lee 10 , Seung-Jae Hong 10 , Hyun-Sook Kim 4 , Hye-Soon Lee 5 , Hyoun<br />
Ah Kim 1 , Chung-Il Joung 7 and Sang-Hyon Kim 9 , 1 Ajou University<br />
Hospital, Ajou University School <strong>of</strong> Medicine, 2 Catholic<br />
University <strong>of</strong> Daegu, School <strong>of</strong> Medicine, 3 Chonnam Natl Univ<br />
Med School, Gwangju, Korea, Republic <strong>of</strong>, 4 <strong>College</strong> <strong>of</strong> Medicine,<br />
Chosun University, 5 Hanyang University <strong>College</strong> <strong>of</strong> Medicine,<br />
6<br />
Inje University Haeundae Paik Hospital, 7 Konyang University<br />
Medical School, 8 Maryknoll Medical Center, 9 School <strong>of</strong><br />
Medicine, Keimyung University, 10 School <strong>of</strong> Medicine, Kyung Hee<br />
University, 11 Soonchunhyang University, <strong>College</strong> <strong>of</strong> Medicine.<br />
804. Lack <strong>of</strong> Detection <strong>of</strong> Xenotropic Murine Leukemia Virus-<br />
Related Virus (XMRV) in Patients with Fibromyalgia. Jorge<br />
J. Gonzalez Martin 1 , Gabriel Herrero-Beaumont 2 and Rafael<br />
Delgado 3 , 1 Reumatología, IIS-Fundación Jiménez Díaz, 28040,<br />
2<br />
Reumatología, IIS-Fundación Jimenez Díaz, 28040, 3 Servicio de<br />
Microbiología, Imas 12 , Hospital Universitario 12 de Octubre.<br />
805. Milnacipran Improves Pain and Global Status Independent<br />
<strong>of</strong> Changes in Depressive Symptoms in Patients with<br />
Fibromyalgia. Lesley M. Arnold 5 , R. Michael Gendreau 1 , Judy<br />
Gendreau 2 , Allan Spera 3 and Wei Chen 4 , 1 Cypress Bioscience,<br />
Inc., San Diego, CA, 2 Cypress Bioscience, Inc., 3 Forest Research<br />
Institute, Jersey City, NJ, 4 Forest Research Institute, 5 University<br />
<strong>of</strong> Cincinnati, Cincinnati, OH.<br />
806. Milnacipran Reduces the Overall Severity <strong>of</strong> Fibromyalgia<br />
Symptoms in Patients with Fibromyalgia. Robert H. Palmer 2 ,<br />
Robert M. Bennett 4 , Yong Wang 3 and R. Michael Gendreau 1 ,<br />
1<br />
Cypress Bioscience, Inc., San Diego, CA, 2 Forest Research<br />
Institute, Jersey City, NJ, 3 Forest Research Institute, 4 Oregon<br />
Health & Science Univ, Portland, OR.<br />
807. National Fibromyalgia Association Survey on Children with<br />
Fibromyalgia: Preliminary Results. Sanjida Ali 1 and Rae Marie<br />
Gleason 2 , 1 Forest Research Institute, Jersey City, NJ, 2 National<br />
Fibromyalgia Association.<br />
808. Nocturnal Heart Rate Variability Parameters. A Potential<br />
Fibromyalgia Biomarker. Claudia Lerma, Aline Martinez, Natllely<br />
Ruiz, Angelica Vargas, Oscar Infante and Manuel Martinez-Lavin,<br />
National Institute <strong>of</strong> Cardiology, Mexico.<br />
809. Orthostatic Stress Reverses Sympathetic but Not<br />
Parasympathetic Abnormalities <strong>of</strong> Fibromyalgia Patients.<br />
Florence Luong 2 , Donald D. Price 2 , Michael E. Robinson 2<br />
and Roland Staud 1 , 1 Univ <strong>of</strong> Florida JHMHC, Gainesville, FL,<br />
2<br />
University <strong>of</strong> Florida.<br />
2010 Program Book 195
ACR/ARHP Poster Session B<br />
810. Over-Reporting Is a Central Determinant <strong>of</strong> Pain and Symptom<br />
Reporting in Fibromyalgia. Frederick Wolfe, National Data Bank<br />
for Rheumatic Diseases, Wichita, KS.<br />
811. Proteomic Mass Spectra Classification in Fibromyalgic Patients.<br />
Camillo Giacomelli 3 , Laura Bazzichi 3 , Federica Ciregia 2 , Chiara<br />
Baldini 3 , Francesca Sernissi 2 , Pasquale Pepe 1 , Laura Giusti 2 ,<br />
Antonio Lucacchini 2 and Stefano Bombardieri 3 , 1 Department<br />
<strong>of</strong> Clinical Pharmacology, University <strong>of</strong> Pisa, Pisa, Italy,<br />
2<br />
Department <strong>of</strong> Psychiatry, Neurobiology, Pharmacology and<br />
Biotechnology. University <strong>of</strong> Pisa, Pisa, Italy, 3 <strong>Rheumatology</strong><br />
Unit. Department <strong>of</strong> Internal Medicine. University <strong>of</strong> Pisa, Pisa,<br />
Italy.<br />
812. Sexual Dysfunction in Female Fibromyalgia Patients. Jacob N.<br />
Ablin 4 , Inna Gurevitz 3 , Hagit Cohen 1 and Dan Buskila 2 , 1 Ben-<br />
Gurion University <strong>of</strong> the Negev, Beer Sheva, Israel, 2 Soroka<br />
Medical Center, Beer Sheva, Israel, 3 Soroka Medical Center, Beer<br />
- Sheva, Israel, 4 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.<br />
813. Simplifying Fibromyalgia Assessment: The VASFIQ Brief<br />
Symptom Scale. Chad S. Boomershine, Gergana Zlateva,<br />
Yi Wang, Ed Whalen and Birol Emir, Vanderbilt University,<br />
Nashville, TN.<br />
814. Sodium Oxybate Improves Pain, Function, and PGIC in Patients<br />
with Fibromyalgia: A Pooled Analysis <strong>of</strong> 2 Pivotal Clinical<br />
Trials. I. Jon Russell 5 , Robert M. Bennett 3 , Cayetano Alegre 1 ,<br />
John B. Winfield 4 , Chinglin Lai 2 , Y. Grace Wang 2 and Beverly<br />
Benson 2 , 1 Hospital de la Vall d’Hebron, Alella, Spain, 2 Jazz<br />
Pharmaceuticals, Inc., 3 Oregon Health & Science University,<br />
Portland, OR, 4 University <strong>of</strong> North Carolina, Chapel Hill, NC,<br />
5<br />
University <strong>of</strong> Texas Health Science Center, San Antonio, TX.<br />
815. Sodium Oxybate Improves Sleep and Fatigue in Patients with<br />
Fibromyalgia: Pooled Analysis from 2 Pivotal Clinical Trials.<br />
Stuart L. Silverman 3 , Andrew J. Holman 4 , Beverly Benson 1 , Sarah<br />
Alvarez-Horine 1 , Y. Grace Wang 1 and Piercarlo Sarzi-Puttini 2 ,<br />
1<br />
Jazz Pharmaceuticals, Inc., 2 L. Sacco University Hospital, Milano,<br />
Italy, 3 Osteoporosis Medical Center, Beverly Hills, CA, 4 Pacific<br />
<strong>Rheumatology</strong> Associates, Inc., Renton, WA.<br />
816. SPECT Imaging <strong>of</strong> the Brain: Regional Cerebral Blood<br />
Flow before and after Treatment <strong>of</strong> Patients with Primary<br />
Fibromyalgia. Manal Osman 3 , Osama Hajji 3 , Ola Abdul Nasser 3 ,<br />
Ahmad Khodair 2 and Nashwa Al Sarraf 1 , 1 Internal Medicine<br />
Department, Faculty <strong>of</strong> Medicine, Cairo University, Cairo,<br />
Egypt, 2 Radiology Department, Faculty <strong>of</strong> Medicine, Ain Shams<br />
University, Cairo, Egypt, 3 <strong>Rheumatology</strong> and Rehabilitation<br />
Department, Faculty <strong>of</strong> Medicine, Ain Shams University, Cairo,<br />
Egypt.<br />
817. The Prevalence <strong>of</strong> Fibromyalgia in Patients with Chronic<br />
Hepatitis C Infection. Ausaf Mohammad 1 , John J. Carey 4 , Eoin<br />
R. Storan 2 , Margaret Scarry 2 , Mary B. Keane 2 , Angela Moore 2 ,<br />
Ann Lyons 2 , Maureen O’ Grady 2 , Catriona Minihan 2 and John M.<br />
Lee 3 , 1 Department <strong>of</strong> Hepatology and <strong>Rheumatology</strong>, Galway<br />
University Hospital, Ireland, 2 Galway University Hospital,<br />
3<br />
Hepatology Galway University Hospital, 4 <strong>Rheumatology</strong> Merlin<br />
Park University Hospital.<br />
818. The Prevalence <strong>of</strong> Fibromyalgia in Patients with Hereditary<br />
Hemochromatosis. Ausaf Mohammad 1 , John J. Carey 4 , Eoin R.<br />
Storan 2 , Margaret Scarry 2 , Mary B. Keane 2 , Angela Moore 2 , Ann<br />
Lyons 2 , Maureen O’ Grady 2 , Catriona Minihan 2 and John M.<br />
Lee 3 , 1 Department <strong>of</strong> Hepatology and <strong>Rheumatology</strong> Galway<br />
University Hospital, Ireland, 2 Galway University Hospital,<br />
3<br />
Hepatology Galway University Hospital, 4 <strong>Rheumatology</strong> Merlin<br />
Park University Hospital.<br />
819. Use <strong>of</strong> Path Analysis To Evaluate the Effects <strong>of</strong> Sodium Oxybate<br />
on Pain Reduction in Patients with Fibromyalgia. Fowzia<br />
Ibrahim 2 , Chinglin Lai 1 and Ernest Choy 3 , 1 Jazz Pharmaceuticals,<br />
Inc., 2 King’s <strong>College</strong> London, 3 Kings <strong>College</strong> Hospital, London,<br />
United Kingdom.<br />
820. Very Low Dosage (VLD) Bedtime Cyclobenzaprine (CBP)<br />
Reduces Cyclic Alternating Pattern (CAP) Rate Indices <strong>of</strong><br />
EEG Sleep Instability and Improves Pre-Sleep Fatigue in<br />
Fibromyalgia Syndrome (FMS). Harvey Mold<strong>of</strong>sky 1 , Herbert W.<br />
Harris 2 , Tad Archambault 4 , Terence Kwong 1 and Seth Lederman 3 ,<br />
1<br />
Centre for Sleep & Chronobiology, Toronto, ON, Canada, 2 Krele<br />
Pharmaceuticals, Saddle Brook, NJ, 3 Krele Pharmaceuticals, New<br />
York, NY, 4 VirtuStat Ltd, North Wales, PA.<br />
821. Vibrotactile Analgesia Is Not Abnormal in Fibromyalgia<br />
Patients. Casey T. Goldman 2 , Donald D. Price 2 , Michael<br />
E. Robinson 2 and Roland Staud 1 , 1 Univ <strong>of</strong> Florida JHMHC,<br />
Gainesville, FL, 2 University <strong>of</strong> Florida.<br />
Genetics, Genomics and Proteomics in the Rheumatic Diseases<br />
822. A Putative Functional Variant within the Ubiquitin-Associated<br />
Domain-Containing Protein 2 Gene (UBAC2) Is Associated<br />
with Increased Risk <strong>of</strong> Behcet’s Disease. Amr H. Sawalha 7 ,<br />
Travis Hughes 6 , Ajay Nadig 6 , Vuslat Yilmaz 2 , Kenan Aksu 1 ,<br />
Gokhan Keser 1 , Ayse Cefle 3 , Ayten Yazici 3 , Andac Ergen 5 , Haner<br />
Direskeneli 4 and Güher Saruhan-Direskeneli 2 , 1 Ege University,<br />
2<br />
Istanbul University, 3 Kocaeli University, 4 Marmara University,<br />
Istanbul, Turkey, 5 Okmeydani Research and Education Hospital,<br />
6<br />
OMRF, 7 University <strong>of</strong> Oklahoma, OMRF, VAMC, Oklahoma City,<br />
OK.<br />
823. A Role for PACE4 in Pain in Mice and Humans: Pain Phenotype<br />
<strong>of</strong> a PACE4 Null Mutant and Genetic Association with<br />
Knee Osteoarthritis Pain. Anne-Marie M. Malfait 6 , Albert B.<br />
Seymour 5 , Ana M. Valdes 4 , Linda S. Wood 5 , Kathryn Durham 5 ,<br />
Micky Tortorella 3 , Nigel K. Arden 8 , Frances L. Vaughn 7 , Paul<br />
E. Leaverton 7 , Deborah J. Hart 4 , Robert E. Sorge 1 , Susana<br />
G. Sotocinal 2 , Ara Schorscher-Petcu 1 and Jeffrey S. Mogil 1 ,<br />
1<br />
Dept <strong>of</strong> Psychology and Alan Edwards Centre for Research<br />
on Pain, McGill University, Montreal, QC, Canada, 2 Dept <strong>of</strong><br />
Psychology and Alan Edwards Centre for Research on Pain,<br />
McGill University, 3 Guangzhou Institute <strong>of</strong> Biomedical Health,<br />
Guangzhou, China, 4 King’s <strong>College</strong> London, London, United<br />
Kingdom, 5 Pfizer Global Research and Development, Cambridge,<br />
MA, 6 Rush University Medical Center, Chicago, IL, 7 The Arthritis<br />
Research Institute <strong>of</strong> America, Clearwater, FL, 8 University <strong>of</strong><br />
Oxford, Oxford, United Kingdom.<br />
824. Analysis <strong>of</strong> the Influence <strong>of</strong> PTPN22 Gene Polymorphisms in<br />
Systemic Sclerosis. Lina Marcela Diaz-Gallo 7 , Pravitt Gourh 27 ,<br />
Jasper Broen 4 , Carmen Simeón 16 , Vicent Fonollosa 16 , Norberto<br />
Ortego-Centeno 13 , M. C. Vonk 4 , Marieke Coenen 5 , Gabriela<br />
Riemekasten 2 , Nicolas Hunzelmann 1 , Roger Hesselstrand 3 ,<br />
Filemon K. Tan 26 , Sandeep K. Agarwal 26 , John D. Reveille 26 ,<br />
Shervin Assassi 26 , Francisco J. García-Hernandez 17 , Patricia<br />
Carreira 18 , Maria Teresa Camps 12 , Antomio Fernandez-Nebro 19 ,<br />
Paloma Garcia de la Peña 23 , R. Rios 13 , T. Nearney 30 , D. Hilda 28 ,<br />
Miguel Angel González-Gay 22 , Paolo Airo 25 , Lorenzo Beretta 8 ,<br />
Raffaella Scorza 8 , Ariane Herrick 10 , Jane Worthington 9 , Ana<br />
Pros 21 , Inmaculada Gómez-Gracia 24 , Luis Trapiella 15 , Gerard<br />
Espinosa 14 , Ivan Castellvi 20 , Torsten Witte 6 , Filip De Keyser 29 ,<br />
Marie Vanthuyne 11 , Maureen D. Mayes 26 , Timothy R. D.J.<br />
Radstake 4 , Frank C. Arnett 26 , Javier Martin 7 and Blanca Rueda 7 ,<br />
1<br />
Department <strong>of</strong> Dermatology, University <strong>of</strong> Cologne, Germany,<br />
2<br />
Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Charité<br />
196<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
University Hospital, Berlin, 3 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Lund University Hospital, Lund, Sweden, 4 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Radboud University Nijmegen Medical Centre,<br />
Nijmegen, The Netherlands, 5 Department<strong>of</strong> Human Genetics,<br />
Radboud University Nijmegen Medical Centre, Nijmegen,<br />
The Netherlands, 6 Hannover Medical School, Hannover,<br />
Germany, 7 Instituto de Parasitología y Biomedicina Lopez-<br />
Neyra CSIC, Granada, Spain, 8 Referral Center for Systemic<br />
Autoimmune Diseases, University <strong>of</strong> Milan, Milan, Italy,<br />
9<br />
Rheumatic Diseases Centre, University <strong>of</strong> Manchester, Salford<br />
Royal NHS Foundatin Trust, UK, 10 Rheumatic Diseases Centre,<br />
University <strong>of</strong> Manchester, Salford Royal NHS Foundation Trust,<br />
UK, 11 <strong>Rheumatology</strong> Department, Universite Catholique de<br />
Louvain, 12 Servicio de Medicina Interna, Hospital Carlos Haya,<br />
Málaga, Spain, 13 Servicio de Medicina Interna, Hospital Clinico<br />
Universitario, Granada, Spain, 14 Servicio de Medicina Interna,<br />
Hospital Clinico, Barcelona, Spain, 15 Servicio de Medicina<br />
Interna, Hospital Universitario Central de Asturias, Oviedo,<br />
Spain, 16 Servicio de Medicina Interna, Hospital Valle de Hebron,<br />
Barcelona, Spain, 17 Servicio de Medicina Interna. Hospital Virgen<br />
del Rocio, Sevilla, Spain, 18 Servicio de Reumatología, Hospital 12<br />
de Octubre, Madrid, Spain, 19 Servicio de Reumatología, Hospital<br />
Carlos Haya, Málaga, Spain, 20 Servicio de Reumatología, Hospital<br />
de Sant Pau, Barcelona, Spain, 21 Servicio de Reumatología,<br />
Hospital del Mar, Barcelona, Spain, 22 Servicio de Reumatología,<br />
Hospital Marques de Valdecillas, Santander, Spain, 23 Servicio de<br />
Reumatología, Hospital Ramon y Cajal, Madrid, Spain, 24 Servicio<br />
de Reumatología. Hospital Reina S<strong>of</strong>ía, Córdoba, Spain,<br />
25<br />
Servizio di Reumatologia ed Immunologia Clinica Spedali Civili,<br />
Brescia, Italy, 26 The University <strong>of</strong> Texas Health Science Center<br />
at Houston Medical School, Department <strong>of</strong> Internal Medicine,<br />
Division <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunogenetics,<br />
27<br />
The University <strong>of</strong> Texas Health Science Center at Houston<br />
Medical School, Department <strong>of</strong> Internal Medicine, Division <strong>of</strong><br />
<strong>Rheumatology</strong> and Clinical Immunogenetics., 28 The University<br />
<strong>of</strong> Texas Health Science Center at San Antonio, San Antonio, TX,<br />
29<br />
University <strong>of</strong> Ghent, Belgium, 30 University <strong>of</strong> Texas Medical<br />
Branch at Galveston, Galveston, TX.<br />
825. BLK Is Expressed in Human Peripheral T Cells and Thymocytes<br />
and Regulates CD4+ T Cell Numbers in Cord Blood. Kim R.<br />
Simpfendorfer 1 , Lina Olsson 2 , Nataly Manjarraz-Orduno 2 ,<br />
Houman Khalili 2 , Annette T. Lee 2 and Peter K. Gregersen 1 ,<br />
1<br />
Feinstein Institute for Medical Research, Manhasset, NY,<br />
2<br />
Feinstein Institute for Medical Research.<br />
826. Epigenetic Studies Characteristic <strong>of</strong> Muscle Biopsies (MBx)<br />
from Untreated Children with Juvenile Myositis (JM). Lauren<br />
M. Pachman, Min Wang, Hehuang Xie, Peter Hendrickson,<br />
Sheela Shrestha and Gabrielle Morgan, Children’s Memorial<br />
Research Center, Chicago, IL.<br />
827. Functional Change <strong>of</strong> 5-Aminoimidazole-4-Carboxamide<br />
Ribonucleotide Formyltransferase in Dermal Fibroblasts from<br />
Methotrexate-Sensitive and Resistant Mice. Xin You 2 , Bruce N.<br />
Cronstein 2 , Adrienne Williams 2 and Thierry Dervieux 1 , 1 Cypress<br />
Pharmaceuticals, 2 NYU.<br />
828. Functional Polymorphisms in the Inhibitory FCGR2B Associate<br />
with Efficacy <strong>of</strong> IVIG Treatment Response among Patients<br />
with Kawasaki Disease. Sadeep Shrestha 2 , Howard W. Wiener 1 ,<br />
Aditi Shendre 1 , Richard A. Kaslow 1 , Aaron K. Olson 3 , Mary Beth<br />
Lee 3 , Jeffrey C. Edberg 4 and Michael Portman 3 , 1 Department<br />
<strong>of</strong> Epidemiology, University <strong>of</strong> Alabama at Birmingham,<br />
2<br />
Department <strong>of</strong> Epidemiology, University <strong>of</strong> Alabama at<br />
Birmingham, Birmingham, AL, 3 Department <strong>of</strong> Pediatrics,<br />
University <strong>of</strong> Washington, Seattle Children’s Hospital, 4 Division<br />
<strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Medicine, University <strong>of</strong> Alabama at Birmingham.<br />
829. Functional Variants in the Pre-B Cell Colony Enhancing Factor<br />
Gene Are Associated with Systemic Sclerosis Susceptibility<br />
and the Clinical Hallmark Pulmonary Arterial Hypertension.<br />
Jasper Broen 9 , Pravitt Gourh 7 , Madelon Vonk 9 , Lorenzo Beretta 10 ,<br />
Blanca Rueda 8 , Lenny Geurts-van Bon 9 , Christel Brouwer 9 ,<br />
Roger Hesselstrand 5 , Ariane Herrick 11 , Jane Worthington 11 ,<br />
Nico Hunzelmann 2 , Chris Denton 1 , Carmen Fonseca 1 , Gabriela<br />
Riemekasten 6 , Hans Kiener 4 , Raffaella Scorza 10 , C. Simeon 14 ,<br />
N. Ortego-Centeno 13 , M. Gonzalez-Gay 12 , Paolo Airo’ 15 ,<br />
Marieke Coenen 3 , Maureen Mayes 7 , Diego Kyburz 16 , Frank<br />
Arnett 7 , Javier Martin 8 and Timothy Radstake 9 , 1 Centre for<br />
<strong>Rheumatology</strong>, Royal Free and University <strong>College</strong> Medical<br />
School, London, United Kingdom, 2 Department <strong>of</strong> Dermatology,<br />
University <strong>of</strong> Cologne, Germany, 3 Department <strong>of</strong> Human<br />
Genetics, Radboud University Nijmegen Medical Center, The<br />
Netherlands, 4 Department <strong>of</strong> Internal Medicine, Division <strong>of</strong><br />
<strong>Rheumatology</strong>, University <strong>of</strong> Vienna, Austria, 5 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Lund University Hospital, S- 221 85 Lund, Sweden,<br />
6<br />
Dept <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Charité<br />
University Hospital and German Rheumatism Research Centre,<br />
a Leibniz Institute, 7 Division <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />
Immunogenetics, Department <strong>of</strong> Internal Medicine, University<br />
<strong>of</strong> Texas Health Science Center at Houston (UTHSC-H), Houston,<br />
TX, 8 Instituto de Parasitología y Biomedicina, CSIC, Granada,<br />
Spain, 9 Radboud University Medical Center, Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Nijmegen, The Netherlands, 10 Referral Center<br />
for Systemic Autoimmune Diseases, University <strong>of</strong> Milan, Italy,<br />
11<br />
Rheumatic Diseases Centre, University <strong>of</strong> Manchester, Salford<br />
Royal NHS Foundation Trust, UK, 12 Servicio de Medicina Interna,<br />
Hospital Clinico Universitario, Granada, Spain., 13 Servicio de<br />
Medicina Interna, Hospital Universitario Central de Asturias,<br />
Oviedo, Spain., 14 Servicio de Medinina Interna, Hospital Valle<br />
de Hebron, Barcelona, Spain, 15 Servizio di Reumatologia ed<br />
Immunologia Clinica, Spedali Civili, Brescia, Italia., 16 University<br />
Hospital Zurich Div. <strong>of</strong> <strong>Rheumatology</strong> Zurich, Switzerland..<br />
830. Gene Expression Pr<strong>of</strong>ile at the Initial Phase <strong>of</strong> Collagen-<br />
Induced Arthritis in the Synovium, Peripheral Blood and<br />
Thymus. Seung-Cheol Shim 2 , Mi-Kyung Lim 1 and Dong-Hyuk<br />
Sheen 1 , 1 Eulji University, Daejeon, Korea, Republic <strong>of</strong>, 2 Eulji<br />
University, Daeejon, Korea, Republic <strong>of</strong>.<br />
831. Genetic Variants Associated with Susceptibility to Knee<br />
Osteoarthritis: The Johnston County Osteoarthritis Project.<br />
Xiaodong Wu 3 , Venkateswarlu Kondragunta 4 , Jordan B. Renner 2 ,<br />
Gordon W. Duff 5 , Kenneth S. Kornman 4 and Joanne M. Jordan 1 ,<br />
1<br />
Chapel Hill, NC, 2 Department <strong>of</strong> Radiology and Thurston<br />
Arthritis Research Center, University <strong>of</strong> North Carolina at Chapel<br />
Hill, 3 Interleukin Genetics, Inc., Waltham, MA, 4 Interleukin<br />
Genetics, Inc., 5 School <strong>of</strong> Medicine, University <strong>of</strong> Sheffield.<br />
832. HLA-DRB1*04 Is a Novel Fetal Susceptibility Allele in<br />
Congenital Heart Block. Therese Östberg 2 , Stina Salomonsson 2 ,<br />
Bo Ding 4 , Håkan Eliasson 4 , Lars Alfredsson 4 , Lars Klareskog 5 ,<br />
Anders Hamsten 2 , Tomas Olsson 4 , Leonid Padyukov 2 , Tomas<br />
Axelsson 6 , Swedish Congenital Heart Block Study Group 7 , Fredrik<br />
Gadler 2 , Anders Jonzon 6 , Sven-Erik Sonesson 3 , Ingrid Kockum 4<br />
and Marie Wahren-Herlenius 1 , 1 Department <strong>of</strong> Medicine,<br />
Karolinska Institutet, Stockholm, 2 Department <strong>of</strong> Medicine,<br />
Karolinska Institutet, 3 Department <strong>of</strong> Women and Child Health,<br />
Karolinska Instituet, 4 Karolinska Institutet, 5 Karolinska University<br />
Hospital, Stockholm, Sweden, 6 Uppsala University, 7 www.<br />
combinesweden.se.<br />
2010 Program Book 197
ACR/ARHP Poster Session B<br />
833. IL13 Is a Risk Locus for Psoriatic Arthritis but Not Psoriasis<br />
Vulgaris. John Bowes 1 , Pauline Ho 2 , Salma Salah 1 , Richard<br />
B. Warren 5 , Eleanor Korendowych 7 , Neil McHugh 7 , Oliver<br />
FitzGerald 4 , Jonathon Packham 3 , Ann W. Morgan 6 , Christopher<br />
E. M. Griffiths 5 , Ian N. Bruce 2 , Jane Worthington 1 and<br />
Anne Barton 2 , 1 Arthritis Research UK Epidemiology Unit,<br />
The University <strong>of</strong> Manchester, UK, 2 Arthritis Research UK<br />
Epidemiology Unit, The University <strong>of</strong> Manchester, UK; The<br />
Kellgren Centre for <strong>Rheumatology</strong>, Manchester, UK, 3 Arthritis<br />
Research UK, National Primary Care Centre, Keele University<br />
UK, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, University <strong>College</strong> Dublin,<br />
Ireland, 5 Dermatological Sciences, The University <strong>of</strong> Manchester,<br />
UK., 6 NIHR-Leeds Musculoskeletal Biomedical Research Unit,<br />
University <strong>of</strong> Leeds, UK, 7 Royal National Hospital for Rheumatic<br />
Diseases.<br />
834. Major Differences among Proteomes <strong>of</strong> Macro-Vascular and<br />
Micro-Vascular Endothelial Cells: 2D-DIGE Approach. Hanadi<br />
Dib 1 , Philippe Chafey 3 , Guilhem Clary 3 , Morgane Le Gall 3 ,<br />
Cedric Broussard 4 , Luc Camoin 4 , Christian Federici 3 , Veronique<br />
Witko-Sarsat 3 , Mathieu C. Tamby 3 and Luc Mouthon 2 , 1 INSERM<br />
1016, Cochin Institute, Paris Descartes University, Paris, France,<br />
2<br />
INSERM 1016, Cochin Institute, Paris Descartes University,<br />
Paris, France, 3 INSERM 1016, Cochin Institute, Paris, France,<br />
4<br />
Proteomics Platform <strong>of</strong> Paris Descartes, Paris, France.<br />
835. mtDNA Haplogroups Define Two Phenotypes <strong>of</strong> Osteoarthritis<br />
(OA). Ignacio Rego-Pérez 4 , Mercedes Fernández-Moreno 5 , M.<br />
Deberg 1 , Sonia Pértega 3 , Carlos Fernández-López 5 , Natividad<br />
Oreiro 5 , Manuel Acasuso 2 , Victoria Bonome-González 2 , Y.<br />
Henrotin 1 and Francisco J. Blanco 5 , 1 Bone and Cartilage<br />
Res. Unit. Univ. <strong>of</strong> Liege, Liege, Belgium, 2 Centro de Salud<br />
Matogrande - SERGAS, A Coruña, Spain, 3 Epidemiology Unit.<br />
INIBIC-Complejo Hosp. Univ. A Coruna, A Coruna, Spain,<br />
4<br />
Osteoarticular and Aging Res. Lab. <strong>Rheumatology</strong> Div, INIBIC-<br />
Complejo Hosp, Univ. A Coruña, Coruña, Spain, 5 Osteoarticular<br />
and Aging Res. Lab. <strong>Rheumatology</strong> Div, INIBIC-Complejo Hosp,<br />
Univ. A Coruña, A Coruña, Spain.<br />
836. Neurotransmitter Receptor Gene Polymorphisms Are<br />
Associated with Widespread Pain: Findings from the First<br />
Genome-Wide Association Study <strong>of</strong> Musculoskeletal Pain. Kate<br />
L. Holliday 3 , Tuhina Neogi 2 , David Felson 2 , Ke Wang 1 , Wendy<br />
Thomson 4 and John McBeth 4 , 1 Boston Univerity School <strong>of</strong> Public<br />
Health, 2 Boston University School <strong>of</strong> Medicine, 3 University<br />
<strong>of</strong> Manchester, Manchester, United Kingdom, 4 University <strong>of</strong><br />
Manchester.<br />
837. Pathogenesis <strong>of</strong> Idiopathic Recurrent Pericarditis and Role <strong>of</strong><br />
the TNFRSF1A Gene Mutations. Luca Cantarini, Orso Maria<br />
Lucherini, Maria Giuseppina Brizi and Mauro Galeazzi, Unit <strong>of</strong><br />
<strong>Rheumatology</strong>, University <strong>of</strong> Siena, Siena, Italy.<br />
838. Radiographic Kellgren-Lawrence (KL) Grade 1 Is Genetically<br />
Distinct from KL 0: Implications for Genetic Studies <strong>of</strong> Knee<br />
Osteoarthritis (OA). Venkateswarlu Kondragunta 3 , Xiaodong<br />
Wu 3 , Jordan B. Renner 2 , Gordon W. Duff 4 , Kenneth S. Kornman 3<br />
and Joanne M. Jordan 1 , 1 Chapel Hill, NC, 2 Department <strong>of</strong><br />
Radiology and Thurston Arthritis Research Center, University <strong>of</strong><br />
North Carolina at Chapel Hill, 3 Interleukin Genetics, Inc., 4 School<br />
<strong>of</strong> Medicine, University <strong>of</strong> Sheffield.<br />
839. Salivary Proteomic Pr<strong>of</strong>ile in Behçet’s Disease. Rosaria<br />
Talarico, Chiara Baldini, Laura Giusti, Ylenia Da Valle, Camillo<br />
Giacomelli, Elena Donadio, Francesca Sernissi, Anna d’Ascanio,<br />
Laura Bazzichi, Antonio Lucacchini and Stefano Bombardieri,<br />
<strong>Rheumatology</strong> Unit, Department <strong>of</strong> Internal Medicine,<br />
University <strong>of</strong> Pisa, Pisa, Italy.<br />
840. Study <strong>of</strong> the Chondrogenic Differentiation Process by<br />
Metabolic Labeling <strong>of</strong> Mesenchymal Stem Cells. Beatriz Rocha 1 ,<br />
Valentina Calamia 2 , Patricia Fernández-Puente 2 , Jesús Mateos 2 ,<br />
Cristina Ruiz-Romero 2 and Francisco J. Blanco 2 , 1 Osteoarticular<br />
and Aging Research Lab, Proteomics Unit, Nodo Asociado<br />
de ProteoRed. INIBIC-Complejo Hospitalario Universitario A<br />
Coruña, A Coruña, Coruña, Spain, 2 Osteoarticular and Aging<br />
Research Lab, Proteomics Unit, Nodo Asociado de ProteoRed.<br />
INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruña,<br />
Spain.<br />
841. The FAAH Gene Is Involved in Risk <strong>of</strong> Symptomatic<br />
Osteoarthritis <strong>of</strong> the Knee and in Pain in Osteoarthritis. Ana<br />
M. Valdes 1 , Anne-Marie Malfait 3 , Sally Doherty 5 , Rosalina Das 4 ,<br />
Margaret Wheeler 5 , Deborah Hart 2 , Tim D. Spector 2 , Cyrus<br />
Cooper 6 , Michael Doherty 5 and Nigel K. Arden 6 , 1 King’s <strong>College</strong><br />
London, London, United Kingdom, 2 King’s <strong>College</strong> London, 3 Rush<br />
University Medical Center, Chicago, IL, 4 Rush University Medical<br />
Center, 5 University <strong>of</strong> Nottingham, United Kingdom, 6 University<br />
<strong>of</strong> Southampton - University <strong>of</strong> Oxford, United Kingdom.<br />
842. The Pr<strong>of</strong>ile <strong>of</strong> miRNA Expression during the Differentiation <strong>of</strong><br />
Murine Osteoclast. Inhye E. Ahn 1 , Ji Hyeon Ju 2 and Jin Sil Park 3 ,<br />
1<br />
Department <strong>of</strong> Internal Medicine, The Methodist Hospital,<br />
Houston, TX, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />
Medicine, Catholic University <strong>of</strong> Korea, Seoul, Korea, Republic<br />
<strong>of</strong>, 3 <strong>Rheumatology</strong> Research Center, Catholic University <strong>of</strong><br />
Korea, Seoul, Korea, Republic <strong>of</strong>.<br />
843. Towards Allele-Specific Dynamic Proteomics: Measuring<br />
Protein Synthesis and Turnover Using Heavy Water Labelling<br />
and Peptide Mass Spectrometry. Michael J. Deery 1 , Alessandra<br />
De Riva 2 , Claudia Prevosto 2 , Sarah McDonald 2 and Robert<br />
Busch 2 , 1 Centre for Proteomics, University <strong>of</strong> Cambridge, 2 Dept<br />
<strong>of</strong> Medicine, University <strong>of</strong> Cambridge.<br />
Innate Immunity and Rheumatic Disease<br />
844. β2 Integrins Control the Pro-Inflammatory Phenotype <strong>of</strong> Type<br />
1 Macrophages and Dendritic Cells. Kim C. M. Santegoets 2 ,<br />
Mark H. Wenink 2 , Richard Huijbens 2 , Lenny van Bon 2 , Alessandra<br />
Cambi 2 , Piet L. Van Riel 3 , Wim B. Van Den Berg 1 and Timothy R.<br />
D. J. Radstake 2 , 1 Radboud Univ Nijmegen Med Cntr, Nijmegen,<br />
The Netherlands, 2 Radboud University Nijmegen Medical<br />
Center, 3 University Hosp Nijmegen, Nijmegen, The Netherlands.<br />
845. “Alarmins”S100A8 and A9 Are Expressed in Synovium <strong>of</strong><br />
Early OA Patients and Regulate Synovial Activation and<br />
Joint Destruction during Experimental Osteoarthritis. Peter<br />
van Lent 1 , Arjen Blom 1 , Rik Schelbergen 1 , Annet Sloetjes 1 ,<br />
Thomas Vogl 2 , Johannes Roth 2 and Wim van den Berg 1 , 1 Dep<br />
<strong>of</strong> <strong>Rheumatology</strong> University Hospital Nijmegen Medical<br />
Centre, Nijmegen, Gelderland, The Netherlands, 2 Institute <strong>of</strong><br />
Immunology Muenster, Muenster, Germany.<br />
846. Altered T Cell Signaling in Systemic Lupus Erythematosus (SLE):<br />
A Role for FcγRIII and Immune Complexes (ICs). Anil Chauhan 1 ,<br />
John P. Atkinson 3 and Terry L. Moore 2 , 1 Saint Louis University,<br />
Saint Louis, MO, 2 St Louis University, St Louis, MO, 3 Washington<br />
University School <strong>of</strong> Medicine, St Louis, MO.<br />
847. C5aR Is Expressed by Macrophages and Dendritic Cells in<br />
Close Proximity to T-Cells in Synovial Tissue from Patients<br />
with Rheumatoid Arthritis. Ditte Tornehave 1 and Lars<br />
Hornum 2 , 1 Histology, Biopharmaceuticals Research Unit,<br />
Novo Nordisk A/S, Måløv, Denmark, 2 Immunopharmacology,<br />
Biopharmaceuticals Research Unit, Novo Nordisk A/S, Måløv,<br />
Måløv, Denmark.<br />
198<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
848. Cellular Immunity in Rheumatoid Arthritis Patients Not<br />
Responding to Synthetic DMARDs. Andra Balanescu 3 , Ionela<br />
Victoria Neagoe 5 , Florian Berghea 3 , Carolina Negrei 2 , Magda<br />
Parvu 1 , Ruxandra Ionescu 4 , Denisa Predeteanu 4 , Violeta<br />
Bojinca 4 , Vasile Preoteasa 6 and Gina Manda 6 , 1 Colentina Clinical<br />
Hospital, Bucharest, Romaia, 2 Department <strong>of</strong> Toxicology,<br />
University <strong>of</strong> Medicine and Pharmacy Carol Davila, Bucharest,<br />
Romania, 3 Research Center <strong>of</strong> Rheumatic Diseases, Sf. Maria<br />
Hospital, University <strong>of</strong> Medicine and Pharmacy Carol Davila,<br />
Bucharest, Romania, 4 Research Center <strong>of</strong> Rheumatic Diseases,<br />
Sf. Maria Hospital, University <strong>of</strong> Medicine and Pharmacy Carol<br />
Davila, Bucharest, Romania, 5 Victor Babes National Institute <strong>of</strong><br />
Pathology, Bucharest, Romania, 6 Victor Babes National Institute<br />
<strong>of</strong> Pathology, Bucharest, Romania.<br />
849. Comprehensive Flow Cytometric Pr<strong>of</strong>iling <strong>of</strong> Peripheral<br />
Blood Dendritic Cells in Rheumatoid and Psoriatic Arthritis<br />
Patients. James Kobie 6 , Ben Panepento 6 , Jyh-Chiang E. Wang 6 ,<br />
Grace Chiu 6 , Darren Tabechian 8 , Allen P. Anandarajah 2 , Richard<br />
J. Looney 3 , Ralf G. Thiele 5 , Jennifer H. Anolik 1 , Ignacio Sanz 4 ,<br />
Sally Quataert 6 , Alex Rosenberg 6 and Christopher T. Ritchlin 7 ,<br />
1<br />
University <strong>of</strong> Rochester, Rochester, NY, 2 Univ <strong>of</strong> Rochester<br />
Med Ctr, Rochester, NY, 3 University <strong>of</strong> Rochester, Rochester, NY,<br />
4<br />
University <strong>of</strong> Rochester, Rochester, NY, 5 University <strong>of</strong> Rochester,<br />
Rochester, NY, 6 University <strong>of</strong> Rochester, 7 University <strong>of</strong> Rochester<br />
Medical Center, Rochester, NY, 8 University <strong>of</strong> Rochester School<br />
<strong>of</strong> Medicine, Rochester, NY.<br />
850. C-Reactive Protein Inhibition <strong>of</strong> the Response to Type I<br />
Interferon (IFN). Carolyn Mold 2 , Daniel Goldberg 1 , Carol Morris 1<br />
and Terry Du Clos 1 , 1 University <strong>of</strong> New Mexico, 2 University <strong>of</strong><br />
New Mexico, Albuquerque, NM.<br />
851. Endosomal Trafficking <strong>of</strong> Antigen in Antigen Cross-Presentation<br />
and the Cause <strong>of</strong> Lupus Tissue Injuries. Mai Takimoto 1 , Ken<br />
Tsumiyama 1 and Shunichi Shiozawa 2 , 1 Department <strong>of</strong> Biophysics,<br />
Kobe University Graduate School <strong>of</strong> Health Sciences, Kobe,<br />
Japan, 2 Department <strong>of</strong> Biophysics, Kobe University Graduate<br />
School <strong>of</strong> Health Sciences/Department <strong>of</strong> Medicine, Kobe<br />
University Graduate School <strong>of</strong> Medicine/The Center for<br />
Rheumatic Diseases, Kobe University Hospital, Kobe, Japan.<br />
852. Exposure to U1-RNP Components Induces Bone Marrow-<br />
Derived Dendritic Cell Trafficking to the Lung. Luis Sorell 4 ,<br />
YunJuan Zang 4 , Irina Fernandez 4 , Laisel Martinez 1 , Maria<br />
Carpintero 3 and Eric L. Greidinger 2 , 1 Miami VA Medical Center,<br />
2<br />
Miami VA Medical Center and University <strong>of</strong> Miami Miller School<br />
<strong>of</strong> Medicine, Miami, FL, 3 University <strong>of</strong> Miami Miller School<br />
<strong>of</strong> Medicine, Pembroke Pines, FL, 4 University <strong>of</strong> Miami Miller<br />
School <strong>of</strong> Medicine.<br />
853. Fas Expression in Myeloid Cells Is Required To Prevent<br />
Systemic Autoimmunity. Carla M. Cuda 1 , Hemant Agrawal 1 ,<br />
Evan Weber 2 , G. Kenneth Haines 3 and Harris R. Perlman 1 ,<br />
1<br />
Northwestern University, Chicago, IL, 2 Northwestern University,<br />
3<br />
Yale University.<br />
854. FLIP: The Novel Regulator <strong>of</strong> Macrophage Differentiation<br />
and Granulocyte Homeostasis. Qi Quan Huang 2 , Harris R.<br />
Perlman 2 , Zan Huang 3 , Robert Birkett 3 , John D. Crispino 3 and<br />
Richard M. Pope 1 , 1 Northwestern Univ Med School, Chicago, IL,<br />
2<br />
Northwestern University, Chicago, IL, 3 Northwestern University.<br />
855. IкB Kinase (IKK)ε: Bridging Innate and Adaptive Immunity in<br />
Collagen-Induced Arthritis (CIA). Deepa Hammaker 2 , Katharyn<br />
Topolewski 3 , David L. Boyle 1 and Gary S. Firestein 1 , 1 UCSD School<br />
<strong>of</strong> Medicine, La Jolla, CA, 2 Univ <strong>of</strong> California San Diego, La Jolla,<br />
CA, 3 University <strong>of</strong> California, San Diego.<br />
856. IMO-3100, a Toll-Like Receptor (TLR) Antagonist, Suppresses<br />
TLR7- and TLR9-Mediated Immune Responses in Non-<br />
Human Primates. Lakshmi Bhagat 2 , Jimmy X. Tang 2 , Tim<br />
Sullivan 2 , Ekambar R. Kandimalla 1 and Sudhir Agrawal 2 , 1 Idera<br />
Pharmaceuticals, Inc, Cambridge, MA, 2 Idera Pharmaceuticals,<br />
Inc.<br />
857. Involvement <strong>of</strong> Toll-Like Receptor 2 in Pristane-Induced Lupus.<br />
Vilma Urbonaviciute 3 , Silke Frey 2 , Carsten Kirschning 1 , Georg<br />
Schett 2 and Reinhard E. Voll 2 , 1 Essen, Germany, 2 Erlangen,<br />
Germany, 3 Department Internal Medicine 3 , University Hospital<br />
Erlangen, University <strong>of</strong> Erlangen-Nuremberg, Erlangen,<br />
Germany.<br />
858. Mir-19b Regulates TLR2 Expression in Rheumatoid Arthritis<br />
Fibroblast-Like Synoviocytes. Lucas Philippe 3 , Guillaume<br />
Suffert 1 , Ghada Alsaleh 3 , Arnaud Theulin 3 , Jacques Eric<br />
Gottenberg 3 , Jean Sibilia 3 , Sebastien Pfeffer 2 and Dominique<br />
Wachsmann 3 , 1 Architecture et Réactivité de l’ARN, Université<br />
de Strasbourg, Institut de Biologie Moléculaire et Cellulaire<br />
du CNRS, Strasbourg, France, Metropolitan, 2 Architecture<br />
et Reactivite de l’ARN, Universite de Strasbourg, Institut de<br />
Biologie Moleculaire et Cellulaire du CNRS, Strasbourg, France,<br />
Metropolitan, 3 Laboratoire de Physiopathologie des Arthrites,<br />
EA4438, Faculté de Pharmacie, 74 Route du Rhin, Illkirch-<br />
Graffenstaden, France, Metropolitan.<br />
859. Myeloid but Not Lymphoid Bim Expression Is Required<br />
Suppress SLE-Like Disease. Hemant Agrawal 1 , Evan Weber 1 ,<br />
Alexander Misharin 1 , Carla M. Cuda 1 , G. Kenneth Haines 2 ,<br />
Rosalind Ramsey-Goldman 1 and Harris Perlman 1 , 1 Dept Med/Div<br />
<strong>Rheumatology</strong>, Northwestern University, 2 Yale University.<br />
860. Natural Killer (NK) Cells Resident in Normal Human Skin Are<br />
Distinct from Blood and Lung NK Cells. Ahmed Gehad 1 , Sandra<br />
King 1 and Robert Fuhlbrigge 2 , 1 Brigham and Women’s Hospital,<br />
2<br />
Children’s Hospital- Boston, Boston, MA.<br />
861. p21 Suppression <strong>of</strong> Inflammatory Arthritis Requires the PCNA<br />
Domain and Inhibition <strong>of</strong> p38. Angelica K. Gierut 1 , Melissa<br />
Mavers 3 , Carla M. Cuda 2 , Alexander Misharin 2 , Evan Weber 2<br />
and Harris R. Perlman 1 , 1 Northwestern University, Chicago, IL,<br />
2<br />
Northwestern University, 3 St. Louis University.<br />
862. Peripheral Blood Mononuclear Cells and Plasmacytoid<br />
Dendritic Cells from Healthy Human Females Exhibit Altered<br />
TLR7-Mediated Immune Responses Compared to Males.<br />
Melissa Precopio 1 , Dong Yu 2 , Ekambar R. Kandimalla 2 and<br />
Sudhir Agrawal 2 , 1 Idera Pharmaceuticals, Cambridge, MA, 2 Idera<br />
Pharmaceuticals.<br />
863. Post-Translational Control Mechanisms Regulate Dendritic Cell<br />
Activation <strong>of</strong> T Cell Responses. Dana Orange 1 , Jak Fak 2 , Nathalie<br />
Blachere 2 and Robert Darnell 2 , 1 The Hospital for Special Surgery,<br />
2<br />
The Rockefeller University.<br />
864. Reduced T-Cell-Dependent Humoral Immune Response in<br />
Microsomal Prostaglandin E Synthase-1 Null Mice. Rahul G.<br />
Matnani 2 , Fumiaki Kojima 2 , Jerold G. Woodward 2 and Leslie J.<br />
Cr<strong>of</strong>ford 1 , 1 Univ <strong>of</strong> KY, Lexington, KY, 2 Univ <strong>of</strong> KY.<br />
865. Regulation <strong>of</strong> VLA-4 in SLE Monocytes. Homaira Rahimi 1<br />
and Kathleen E. Sullivan 2 , 1 Children’s Hosp Philadelphia,<br />
Philadelphia, PA, 2 Childrens Hosp <strong>of</strong> Philadelphia, Philadelphia,<br />
PA.<br />
866. The Cholinergic Anti-Inflammatory Pathway as a Modulator<br />
<strong>of</strong> Immune Complex-Induced Acute Inflammation. Milena<br />
Vukelic 2 , Gloria Koo 2 and Jane E. Salmon 1 , 1 Hospital for Special<br />
Surgery, New York, NY, 2 Hospital for Special Surgery, New York,<br />
NY.<br />
2010 Program Book 199
ACR/ARHP Poster Session B<br />
200<br />
867. The Help <strong>of</strong> Autoantibody-Inducing CD4+ T Cell and Antigen<br />
Cross-Presentation Are Required for the Full-Maturation<br />
<strong>of</strong> Cytotoxic T Lymphocyte and Subsequent Lupus Kidney<br />
Disease. Yumi Miyazaki 1 , Ken Tsumiyama 1 and Shunichi<br />
Shiozawa 2 , 1 Department <strong>of</strong> Biophysics, Kobe University<br />
Graduate School <strong>of</strong> Health Science, Kobe, Japan, 2 Department <strong>of</strong><br />
Biophysics, Kobe University Graduate School <strong>of</strong> Health Science/<br />
Department <strong>of</strong> Medicine, Kobe University Graduate School <strong>of</strong><br />
Medicine/The Center for Rheumatic Diseases, Kobe University<br />
Hospital, Kobe, Japan.<br />
868. Unique Role <strong>of</strong> the FcγRI (CD64) Cytoplasmic Domain in<br />
Mediating Phosphorylation Dependent Lipid Raft Localization.<br />
Andrew G. Gibson 3 , Xinrui Li 3 , Jeffrey C. Edberg 2 and Robert<br />
P. Kimberly 1 , 1 Univ Alabama at Birmingham, Birmingham,<br />
AL, 2 University <strong>of</strong> Alabama at Birmingham, Birmingham, AL,<br />
3<br />
University <strong>of</strong> Alabama at Birmingham.<br />
Metabolic and Crystal Arthropathies - Pathogenesis, Epidemiology,<br />
and Clinical Manifestations II<br />
869. A Prospective Study <strong>of</strong> Correlates <strong>of</strong> Axial Gout. Rukmini<br />
M. Konatalapalli 4 , Elena Lumezanu 3 , James Jelinek 3 , Mark<br />
Murphey 1 , Elizabeth Carter 2 and Arthur Weinstein 3 , 1 Armed<br />
Force Institute, 2 Medstar Health Research Institute, 3 Washington<br />
Hospital Center, 4 Washington Hospital Center, DC.<br />
870. Acute Gout Results in Increased Plasma Myeloperoxidase: A<br />
Potential Mechanism for Increase Cardiovascular Risk? Lisa K.<br />
Stamp 1 , Irada Khalilova 2 and Tony Kettle 2 , 1 University <strong>of</strong> Otago,<br />
Christchurch, New Zealand, 2 University <strong>of</strong> Otago.<br />
871. A-SAA Induces Cytokine Production and Matrix<br />
Metalloproteinase Activity in Adipose and RA Synovial Tissue.<br />
Jennifer McCormick, Ronan M. Mullan, Mary Connolly, Chin<br />
Teck Ng, Ursula Fearon and Douglas J. Veale, Dublin Academic<br />
Medical Centre, Dublin, Ireland.<br />
872. Association <strong>of</strong> Vitamin K and Chondrocalcinosis <strong>of</strong> the Knee:<br />
The MOST and Framingham Osteoarthritis Studies. Devyani<br />
Misra 3 , Sarah L. Booth 8 , Micheal LaValley 3 , Irina Toltsykh 6 ,<br />
Micheal Nevitt 6 , C. Elizabeth Lewis 5 , James Torner 7 , Piran<br />
Aliabadi 4 , David T. Felson 2 and Tuhina Neogi 1 , 1 Boston Univ Schl<br />
<strong>of</strong> Med, Boston, MA, 2 Boston University School <strong>of</strong> Medicine,<br />
Boston, MA, 3 BUSM, Boston, MA, 4 BWH, Harvard University,<br />
Boston, MA, 5 UAB, Birmingham, AL, 6 UCSF, San Francisco, CA,<br />
7<br />
U-Iowa, Iowa City, IA, 8 USDA HNRCA, Tufts University, Boston,<br />
MA.<br />
873. Calcium Pyrophosphate Crystal Arthritis (CPPA) Is a Frequent<br />
Cause <strong>of</strong> “Refractory Gout”. Fernando Perez-Ruiz 1 , Ana M.<br />
Herrero-Beites 3 , Alberto Alonso-Ruiz 2 and Marcelo Calabozo 2 ,<br />
1<br />
Hospital de Cruces, Jopelana, Spain, 2 Hospital de Cruces,<br />
3<br />
Hospital de Górliz.<br />
874. Clinical and Genetic Subtypes <strong>of</strong> Hyperuricemia in a Renal<br />
Transplant Cohort. Gabriela Hernandez-Molina, Julio Granados,<br />
Adriana Torres, Antonio Cachafeiro-Vilar and Marina Rull-<br />
Gabayet, Instituto Nacional de Ciencias Medicas y Nutricion,<br />
Mexico City, Mexico.<br />
875. Diffuse Calcium-Containing Crystal Deposits in Human<br />
Osteoarthritic Articular Cartilage: Not Limited to the Medial<br />
Compartment. Christelle Nguyen 4 , Hang-Korng Ea 4 , Didier<br />
Hannouche 2 , Michel Daudon 3 , Dominique Bazin 1 and Frédéric<br />
Lioté 4 , 1 Laboratoire de Physique des Solides; Paris Sud<br />
University; Orsay; France, 2 Orthopaedic Surgery Department;<br />
Lariboisière Hospital; Paris Diderot University; Assistance<br />
Publique-Hôpitaux de Paris (AP-HP), Paris, 3 Service de Biochimie<br />
A; Necker Hospital; Paris Sud University; AP-HP; Paris, 4 UMR-S<br />
606, INSERM & Paris Diderot University; PRES Sorbonne Paris-<br />
Cite; Lariboisiere Hospital; Paris; France.<br />
2010 Program Book<br />
876. Factors Associated with an Acute Attack <strong>of</strong> Chronic Gout<br />
without Hyperuricemia. MinWook So 1 , SeungGeun Lee 3 ,<br />
YongGil Kim 3 , ChangKeun Lee 3 , HeeBom Moon 3 , Jiseon Oh 4 and<br />
Bin Yoo 2 , 1 ASAN Medical Ctr, Seoul, Korea, Republic <strong>of</strong>, 2 ASAN<br />
Medical Ctr, Seoul, Korea, Republic <strong>of</strong>, 3 ASAN Medical Ctr, 4 Ulsan<br />
University.<br />
877. Hyperuricemia and Gout: Nature Versus Nurture. Eswar<br />
Krishnan 3 , Christina N. Lessov-Schlaggar 4 , James F. Fries 2 , Ruth<br />
Krasnow 1 and Gary E. Swan 1 , 1 SRI International, 2 Stanford Univ<br />
Medical Ctr, Palo Alto, CA, 3 Stanford University, Palo Alto, CA,<br />
4<br />
WUSTL.<br />
878. Hyperuricemia as a Risk Factor for Hypertension among Young<br />
Adults without Metabolic Syndrome. Eswar Krishnan 1 , Bhavik<br />
Pandya 2 , Ali Hariri 3 and Omar Dabbous 2 , 1 Stanford University<br />
School <strong>of</strong> Medicine, Stanford, CA, 2 Takeda Pharmaceuticals<br />
International, Inc, Deerfield, IL, 3 Takeda Pharmaceuticals North<br />
America, Inc, Deerfield, IL.<br />
879. Individuals in the US General Population with Gout and<br />
Hyperuricemia Have Significantly Higher Comorbidities: The<br />
National Health and Nutrition Examination Survey (NHANES)<br />
2007-2008. Bhavik Pandya 2 , Yanyan Zhu 1 and Hyon Choi 1 ,<br />
1<br />
Boston University <strong>of</strong> School <strong>of</strong> Medicine, Boston, MA, 2 Takeda<br />
Pharmaceuticals International, Inc, Deerfield, IL.<br />
880. Low Prevalence <strong>of</strong> Coexistent Gout and Rheumatoid Arthritis<br />
in a Population <strong>of</strong> Veterans. Armine Tumyan 1 , Kara H. Prescott 2<br />
and Andreas M. Reimold 1 , 1 Dallas VA Medical Center and Univ <strong>of</strong><br />
TX Southwestern Med Ctr, Dallas, TX, 2 Dallas VA Medical Center<br />
and Univ <strong>of</strong> TX Southwestern Med Ctr, Cross Roads, TX.<br />
881. Monosodium Urate Monohydrate Crystals Inhibit Osteoblast<br />
Viability and Differentiation: Implications for Development <strong>of</strong><br />
Bone Erosion in Chronic Gout. Ashika Chhana 2 , Karen Callon 2 ,<br />
Bregina Pool 2 , Dorit Naot 2 , Fiona M. McQueen 2 , Jillian Cornish 2<br />
and Nicola Dalbeth 1 , 1 Univ Auckland, Auckland, New Zealand,<br />
2<br />
University <strong>of</strong> Auckland, Auckland, New Zealand.<br />
882. Number <strong>of</strong> Flares Are Associated with Both Gastrointestinal<br />
and Vascular Complications in Patients with Gout. Another<br />
Issue for Early Intervention. Fernando Perez-Ruiz 1 , Ana M.<br />
Herrero-Beites 2 and Miguel A. Gonzalez-Gay 3 , 1 Hospital de<br />
Cruces, Spain, 2 Hospital de Górliz, Spain, 3 Hospital Universitario<br />
Marqués de Valdecilla, Spain.<br />
883. Patients with Gout May Have a Decreased Risk <strong>of</strong> Colonic<br />
Polyps Relative to Patients with Osteoarthritis (OA): Insights<br />
from the NY VA Gout Database. Aaron Lehmann 3 , Laura<br />
Schneck 4 , Robert T. Keenan 1 , William O’Brien 2 , Daria Crittenden 2 ,<br />
Kristen Lee 2 , Rekha Tadoori, Fritz Francois 2 and Michael H.<br />
Pillinger 4 , 1 Duke University, Durham, NC, 2 NYU Langone Medical<br />
Center, 3 NYU Langone Medical Center, Flushing, NY, 4 NYU<br />
Langone Medical Center, New York, NY.<br />
884. P-Homocysteine Levels Are Independently Correlated to<br />
S-Urate but Not to Urate Lowering Treatment. Results <strong>of</strong> an<br />
Observational Study <strong>of</strong> 112 Patients with Gout. Ole Slot, Dept.<br />
<strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University Hospital, Glostrup,<br />
Denmark.<br />
885. Rates <strong>of</strong> Meniscal Tearing Seen on Arthroscopy <strong>of</strong> Patients<br />
with Chondrocalcinosis. William Chun 1 , Humaira Hussain 3 ,<br />
Vincent J. Zarro 1 , Carolyn R. O’Connor 1 and Angel E. Checa 2 ,<br />
1<br />
Drexel University <strong>College</strong> <strong>of</strong> Medicine, Philadelphia, PA,<br />
2<br />
Drexel University <strong>College</strong> <strong>of</strong> Medicine, Cherry Hill, NJ, 3 Drexel<br />
University <strong>College</strong> <strong>of</strong> Medicine.
ACR/ARHP Poster Session B<br />
886. Screening for Hereditary Hemochromatosis in the<br />
<strong>Rheumatology</strong> Practice. Gunther Neeck 1 , Helge Wernitzsch 2 ,<br />
Andreas Klüter 2 , Martin Schulz 2 and Helmut Dotzlaw 2 , 1 Center<br />
for <strong>Rheumatology</strong> at Hospital Bad Doberan, Hohenfelde,<br />
Germany, 2 Center for <strong>Rheumatology</strong> at Hospital Bad Doberan,<br />
Germany.<br />
887. Synovial Extracellular Matrix Remodeling in Experimental<br />
Model <strong>of</strong> Diabetes. Sandra Aparecida Atayde 1 , Priscila Cristina<br />
Andrade 2 , Sérgio Catanozi 2 , Edna Regina Nakandakare 2 , Marisa<br />
Passarelli 2 , Ana Paula Pereira Velosa 2 , Vera Luiza Capelozzi 2 ,<br />
Edwin Roger Parra 2 , Natalino Hajime Yoshinari 2 and Walcy<br />
Rosolia Teodoro 2 , 1 University <strong>of</strong> São Paulo, São Paulo, Brazil,<br />
2<br />
University <strong>of</strong> São Paulo.<br />
888. The GOSPEL 1000 Study. Features <strong>of</strong> the Metabolic Syndrome<br />
in 1003 French Patients with Gout. Frédéric P. Lioté 7 , Hang-<br />
Korng Ea 2 , Pascal Guggenbuhl 1 , Alain Saraux 6 , Charles Lambert,<br />
Sabine Lanz 4 , Pierre Chiarelli 3 and Sylvie Lancrenon 5 , 1 Rennes,<br />
France, 2 Paris, France, 3 Courbevoie, France, 4 Chatou, France,<br />
5<br />
Bourg-la-Reine, France, 6 CHU de la Cavale Blanche, Brest Cedex,<br />
France, 7 Hopital Lariboisiere, Paris, France.<br />
889. Ultrasound Detects More Erosions in Gout Than Conventional<br />
Radiography. Ralf G. Thiele 2 and Naomi Schlesinger 1 , 1 UMDNJ/<br />
RWJMS, 2 University <strong>of</strong> Rochester, Rochester, NY.<br />
Miscellaneous Rheumatic and Inflammatory Diseases I<br />
890. A Comprehensive Tuberculosis Screening Program in Patients<br />
with Inflammatory Arthritis Treated with Golimumab, a<br />
Human Anti-TNF Antibody, in Phase 3 Clinical Trials. Elizabeth<br />
C. Hsia 4 , John J. Cush 1 , Eric L. Matteson 5 , Anna Beutler 2 ,<br />
Mittie K. Doyle 4 , Benjamin L. Hsu 3 and Mahboob U. Rahman 4 ,<br />
1<br />
Baylor Research Institute, Dallas, TX, 2 Centocor Research and<br />
Development, Inc., <strong>College</strong>ville, PA, 3 Centocor Research and<br />
Development, Inc./Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine,<br />
Wynnewood, PA, 4 Centocor Research and Development, Inc./<br />
Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine, Malvern, PA, 5 Mayo<br />
Clinic, Rochester, MN.<br />
891. Anakinra in Adult Onset Stills Disease (AOSD). Clinically<br />
Beneficial Results in an Open, Randomized, Multicenter Study.<br />
Dan C. Nordström 3 , Ann Knight 11 , Reijo Luukkainen 8 , Ronald<br />
V. Vollenhoven 5 , Vappu Rantalaiho 9 , Anna Karjalainen 7 , Johan<br />
Brun 2 , Anne Proven 6 , Lotta Ljung 10 , Hannu Kautiainen 1 and<br />
Tom Pettersson 4 , 1 Central Finland Central Hospital, Finland,<br />
2<br />
Haukeland University Hospital, Norway, 3 Helsinki Univerity<br />
Central Hospital, Finland, 4 Helsinki University Central Hospital,<br />
Finland, 5 Karolinska Hospital, Sweden, 6 Martina Hansens<br />
Hospital, Norway, 7 Oulu University Hospital, Finland, 8 Rauma<br />
Hospital, Finland, 9 Tampere University Hospital, Finland, 10 Umeå<br />
University Hospital, Sweden, 11 Uppsala University Hospital,<br />
Sweden.<br />
892. Anti-Double Stranded DNA and Other Autoantibodies Are<br />
Common in Alaska Native Autoimmune Hepatitis Patients.<br />
Elizabeth D. Ferucci 1 , Kathy J. Hurlburt 1 , Stephen Livingston 1 ,<br />
Julia Plotnik 1 , James Gove 1 , Brian J. McMahon 1 and Judith A.<br />
James 2 , 1 Alaska Native Tribal Health Consortium, 2 Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK.<br />
893. Anti-U1C Autoantibody Specifically Interferes with the U1RNP-<br />
Mediated Splicing <strong>of</strong> Angiopoietin-1 (Ang1) Gene and Induces<br />
Functionally Defective Ang-1/ins Variant in the Patients with<br />
MCTD. Yuka Kosugi 1 , Koichiro Komai 1 , Shogo Funaki 1 , Aya<br />
Mashida 1 , Kazuko Shiozawa 3 , Akira Hashiramoto 2 and Shunichi<br />
Shiozawa 2 , 1 Dep. <strong>of</strong> Biophysics, Graduate School <strong>of</strong> Health<br />
Sciences, Kobe Univ., Kobe, Japan, 2 Dep. <strong>of</strong> Biophysics, Graduate<br />
School <strong>of</strong> Health Sciences, Kobe Univ./Dep. <strong>of</strong> Medicine,<br />
Graduate School <strong>of</strong> Medicine, Kobe Univ./The Center for<br />
Rheumatic Diseases, Kobe Univ., Hosp., Kobe, Japan, 3 Rheumatic<br />
Diseases Center, Konan Kakogawa Hosp., Kakogawa, Japan.<br />
894. Autoimmune Phenomena in Muckle-Wells Syndrome (MWS).<br />
Katharina Gramlich 1 , Reinhild Klein 4 , Sandra Hansmann 3 ,<br />
Susanne M. Benseler 5 and Jasmin B. Kuemmerle-Deschner 2 ,<br />
1<br />
Division <strong>of</strong> Pediatric <strong>Rheumatology</strong>, Department <strong>of</strong> Pediatrics,<br />
University Hospital Tübingen, Tuebingen, Germany, 2 Division <strong>of</strong><br />
Pediatric <strong>Rheumatology</strong>, Department <strong>of</strong> Pediatrics, University<br />
Hospital Tübingen, Tuebingen, Germany, 3 Division <strong>of</strong> Pediatric<br />
<strong>Rheumatology</strong>, Department <strong>of</strong> Pediatrics, University Hospital<br />
Tübingen, Germany, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Internal Medicine, University Hospital Tübingen, 5 The Hospital<br />
for Sick Children, Toronto, ON, Canada.<br />
895. Canakinumab (ILARIS®) Provides Rapid Response and<br />
Sustained Remission in Cryopyrin-Associated Periodic<br />
Syndrome (CAPS) Patients across All Severity Phenotypes.<br />
H. J. Lachmann 12 , J. B. Kuemmerle-Deschner 6 , E. Hachulla 3 , R.<br />
Cartwright 1 , I. Kone-Paut 4 , J. Hoyer 2 , P. Quartier 11 , J. Smith 14 ,<br />
M. Gattorno 5 , K. Leslie 10 , J. Braun 9 , A. Widmer 7 , N. Patel 8 , R.<br />
Preiss 8 and P. N. Hawkins 13 , 1 Allergy Center at Brookstone,<br />
Columbus, GA, 2 Department <strong>of</strong> Internal Medicine and<br />
Nephrology, Universitaetsklinikum Giessen und Marburg<br />
GmbH, Marburg, Germany, 3 Hôpital Claude Huriez CHRU, Lille<br />
Cedex, France, 4 Hôpital Kremlin Bicetre, CEREMAI, Le Kremlin<br />
Bicetre, France, 5 Istituto Giannina Gaslini, Genova, Italy,<br />
6<br />
Klinik fuer Kinder-und Jugendmedizin, Universitaetsklinikum,<br />
Tuebingen, Germany, 7 Novartis Pharma AG, Basel, Switzerland,<br />
8<br />
Novartis Pharmaceuticals Corporation, East Hanover, NJ,<br />
9<br />
Rheumazentrum Ruhrgebiet, Herne, Germany, 10 UCSF School<br />
<strong>of</strong> Medicine, San Francisco, CA, 11 Unit’e d’Immunologie,<br />
Hematologie et Rhumatologie Pediatrique, Hopital Necker-<br />
Enfants Malades, Paris, France, 12 University <strong>College</strong> London<br />
Medical School, London, United Kingdom, 13 University <strong>College</strong><br />
London Medical School, London, United Kingdom, 14 University<br />
<strong>of</strong> Wisconsin Hospital and Clinics, Madison, WI.<br />
896. Celecoxib Analogue Lacking COX-2-Inhibitory Activity Inhibits<br />
Arthritis by Supressing IL-23 and Inflammatory Cytokines.<br />
Asako Chiba 2 , Ryohsuke Tajima 2 , Miho Mizuno 2 , Chiharu Tomi 2 ,<br />
Iraide Alloza 3 , Takashi Yamamura 2 , Koen Vandenbroeck 3 and<br />
Sachiko Miyake 1 , 1 Department <strong>of</strong> Immunology, National Institute<br />
<strong>of</strong> Neuroscience, NCNP, Kodaira Tokyo, Japan, 2 Department<br />
<strong>of</strong> Immunology, National Institute <strong>of</strong> Neuroscience, NCNP,<br />
3<br />
Neurogenomiks Laboratory, Ikerbasque and Universidad Del<br />
País Vasco (UPV/EHU), Parque Tecnológico de Bizkaia.<br />
897. Comprehensive Analyses <strong>of</strong> MEFV, TNFRSF1A, MVK, and<br />
CIAS1 Mutations in 63 Patients with Clinically Periodic Fever<br />
Syndrome in Japan. Sayuri Kataoka 2 , Manabu Kawamoto 1 ,<br />
Yasushi Kawaguchi 3 , Takahisa Gono 1 , Masanori Hanaoka 1 , Hisae<br />
Ichida 1 , Yasuhiro Katsumata 1 , Yuko Okamoto 4 , Yuko Ota 2 , Ikuko<br />
Masuda 1 and Hisashi Yamanaka 1 , 1 Tokyo Women’s Medical<br />
University, 2 Tokyo Women’s Medical University, Japan, 3 Tokyo<br />
Women’s Medical University, 4 Tokyo Womens Med Univ.<br />
2010 Program Book 201
ACR/ARHP Poster Session B<br />
898. Defining the Aromatase Inhibitor Musculoskeletal Syndrome:<br />
A Prospective Trial. Ora Singer 1 , Alana B. Levine 1 , Tessa Cigler 3 ,<br />
Anne B. Moore 2 , Huong T. Do 1 and Lisa A. Mandl 1 , 1 Hospital for<br />
Special Surgery, New York, NY, 2 NY Presbyterian - Weill Cornell<br />
Medical Center, New York, NY, 3 NY Presbyterian-Weill Cornell<br />
Medical Center, New York, NY.<br />
899. Hearing Loss in Muckle-Wells-Syndrome. Assen Koitschev 1 ,<br />
Katharina Gramlich 3 , Sandra Hansmann 3 , Susanne M.<br />
Benseler 5 , Stefan Plontke 2 , Christiane Koitschev 2 , Ina<br />
Koetter 4 and Jasmin Kuemmerle-Deschner 3 , 1 Department <strong>of</strong><br />
Otorhinolaryngology, Klinikum Stuttgart, Germany, 2 Department<br />
<strong>of</strong> Otorhinolaryngology, University Hospital Tübingen,<br />
Germany, 3 Division <strong>of</strong> Pediatric <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Pediatrics, University Hospital Tübingen, Germany, 4 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine, University<br />
Hospital Tübingen, Tuebingen, Germany, 5 The Hospital for Sick<br />
Children, Toronto, ON, Canada.<br />
900. Hearing Loss in Muckle-Wells-Syndrome – Effects <strong>of</strong> IL-1<br />
Inhibition. Assen Koitschev 1 , Katharina Gramlich 3 , Sandra<br />
Hansmann 3 , Susanne Benseler 4 , Stefan Plontke 2 , Christiane<br />
Koitschev 2 , Ina Koetter 6 , Ralph Preiss 5 and Jasmin Kuemmerle-<br />
Deschner 3 , 1 Department <strong>of</strong> Otorhinolaryngology, Klinikum<br />
Stuttgart, Germany, 2 Department <strong>of</strong> Otorhinolaryngology,<br />
University Hospital Tübingen, Germany, 3 Division <strong>of</strong> Pediatric<br />
<strong>Rheumatology</strong>, Department <strong>of</strong> Pediatrics, University Hospital<br />
Tübingen, Germany, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Department<br />
<strong>of</strong> Pediatrics, The Hospital for Sick Children, Toronto, Canada,<br />
5<br />
Novartis Pharmaceuticals Corporation, East Hanover, NJ,<br />
6<br />
University Hospital, Tuebingen, Germany.<br />
901. Inflammatory Arthritis Associated with Isolated Anti-CBir1<br />
Antibodies: Part <strong>of</strong> the Spectrum <strong>of</strong> “Seronegative” Arthritis?<br />
Melissa A. Peda 1 and Stanford L. Peng 2 , 1 Benaroya Research<br />
Institute, 2 Benaroya Research Institute and Virginia Mason<br />
Medical Center, Seattle, WA.<br />
902. Long Term Treatment with Anakinra in Patients with Adult-<br />
Onset Still Disease. Giampietro Cecilia 1 , Ridene Meriem 2 ,<br />
Fautrel Bruno 3 , Bourgeois Pierre 3 and CRI, 1 University <strong>of</strong> L’Aquila,<br />
L’Aquila, Italy, 2 University <strong>of</strong> Tunis, Tunis, Tunisia, 3 University<br />
Paris 6 – Pierre et Marie Curie University; <strong>Rheumatology</strong>, Pitie-<br />
Salpêtriere Hospital, Paris, France.<br />
903. Lymph Node and Bone Marrow Expression <strong>of</strong> Macrophage<br />
Migration Inhibitory Factor and IL18 in Adult-Onset Still’s<br />
Disease. Sung-Hoon Park 1 , Hwa-Jeong Lee 2 , Seong-Kyu Kim 2<br />
and Jung-Yoon Choe 2 , 1 Catholic University <strong>of</strong> Daegu, School <strong>of</strong><br />
Medicine, Arthritis and Autoimmunity Research Center, Daegu,<br />
Korea, Republic <strong>of</strong>, 2 Catholic University <strong>of</strong> Daegu, School <strong>of</strong><br />
Medicine, Arthritis and Autoimmunity Research Center.<br />
904. New Onset <strong>of</strong> Uveitis under Anti TNF Therapy. A Nationwide<br />
Series. Daniel Wendling, Julien Paccou, René-Marc Flipo,<br />
Emmanuelle Dernis, Guillaume Direz, Veronique Ferrazzi,<br />
Séverine Guillaume, Jean-Michel Ristori and Club Rhumatismes<br />
et Inflammation (CRI), <strong>Rheumatology</strong>, University Hospital,<br />
Besançon, Besançon, France.<br />
905. Preliminary Scores for the Evaluation <strong>of</strong> Disease Activity in<br />
Familial Mediterranean Fever, Mevalonate Kinase Deficiency,<br />
TNF-Receptor Associated Periodic Syndrome and Cryopyrin-<br />
Associated Diseases: Results from the AIDAI Consensus<br />
Conference. Maryam Piram 1 , Joost Frenkel 11 , Marco Gattorno 13 ,<br />
Seza Ozen 15 , Helen Lachmann 16 , Rafaela Goldbach-Mansky 17 ,<br />
Anna Simon 3 , Veronique Hentgen 10 , Benedicte Neven 7 , Katia<br />
Stankovic-stojanovic 18 , Jasmin Kuemmerle-Deschner 14 , Hal<br />
H<strong>of</strong>fman 8 , Sylvia Stojanov 4 , Agnes Duquesne 6 , Pascal Pillet 9 ,<br />
Alberto Martini 12 , Jacques Pouchot 5 and Isabelle Kone-Paut 2 ,<br />
1<br />
CEREMAI, Pediatric <strong>Rheumatology</strong>, Bicêtre Hospital, Paris<br />
University <strong>of</strong> Medicine, Le Kremlin Bicêtre, France, 2 CEREMAI,<br />
Pediatric <strong>Rheumatology</strong>, Bicêtre Hospital, Paris University <strong>of</strong><br />
Medicine, Le Krelmlin Bicêtre, France, 3 Department <strong>of</strong> General<br />
Internal Medicine, Radboud University Nijmegen Medical<br />
Centre, Nijmegen, The Netherlands, 4 Department <strong>of</strong> Infectious<br />
Diseases and Immunology, University Children’s Hospital,<br />
Munich, Germany, 5 Department <strong>of</strong> Internal Medicine, European<br />
Georges Pompidou Hospital, Paris-Descartes University,<br />
6<br />
Department <strong>of</strong> Nephrology and Pediatric <strong>Rheumatology</strong>,<br />
Hôpital Femme Mere Enfant, Hospices Civils de Lyon, Lyon,<br />
France, 7 Department <strong>of</strong> Pediatric Immuno-Hematology and<br />
Pediatric <strong>Rheumatology</strong>, Necker-Enfants Malades Hospital,<br />
Paris, 8 Department <strong>of</strong> Pediatrics and Medicine, University <strong>of</strong><br />
California at San Diego, Rady Children’s Hospital <strong>of</strong> San Diego,<br />
9<br />
Department <strong>of</strong> Pediatrics, Children’s Hospital <strong>of</strong> Bordeaux,<br />
France, 10 Department <strong>of</strong> Pediatrics, National Reference Center<br />
for Auto-inflammatory Disorders, Versailles-Le Chesnay<br />
Hospital, France, 11 Department <strong>of</strong> Pediatrics, University Medical<br />
Center Utrecht, Utrecht, The Netherlands, 12 Department <strong>of</strong><br />
Pediatrics, University Medical Center Utrecht, Utrtecht, The<br />
Netherlands; 3 UO Pediatria II and Department <strong>of</strong> Pediatrics, “G.<br />
Gaslini” Institute and University <strong>of</strong> Genoa, Italy, 13 Department<br />
<strong>of</strong> Pediatrics, University Medical Center Utrecht; 3 UO Pediatria<br />
II and Department <strong>of</strong> Pediatrics, “G. Gaslini” Institute and<br />
University <strong>of</strong> Genoa, Genoa, Italy, 14 Division <strong>of</strong> Pediatric<br />
<strong>Rheumatology</strong>, Department <strong>of</strong> Pediatrics, University Hospital<br />
Tübingen, Germany, 15 Hacettepe University Faculty <strong>of</strong> Medicine,<br />
Ankara, Turkey, 16 National Amyloidosis Centre, University<br />
<strong>College</strong> London Medical School, London, UK, 17 National Institute<br />
<strong>of</strong> Arthritis Musculoskeletal and Skin Disease, NIH, Bethesda,<br />
MD, 18 National Reference Center for Inflammatory Amyloidosis<br />
and Familial Mediterranean Fever, Department <strong>of</strong> Internal<br />
Medicine, Tenon University Hospital, Université Pierre et Marie<br />
Curie Paris 6 , Paris, France.<br />
906. Prevalence and Clinical Significance <strong>of</strong> Cry<strong>of</strong>ibrinogenemia<br />
in Patients with Renal Disorders. Benjamin Terrier, Hassan<br />
Izzedine, Lucile Musset, David Saadoun and Patrice Cacoub,<br />
Pitié-Salpétrière.<br />
907. Pseudo-Hypertrophic Osteoarthropathy in Lung Transplant<br />
Recipients on Long Term Voriconazole Therapy. Rajan Saggar 1 ,<br />
Tisha Wang 3 , Rajeev Saggar 3 and Roy D. Altman 2 , 1 UCLA, Los<br />
Angeles, CA, 2 UCLA, Agua Dulce, CA, 3 UCLA.<br />
908. QuantiFERON®-TB Gold In-Tube Test Versus Tuberculin Skin<br />
Test across RA, PsA, and AS Patients Prior to Treatment with<br />
Golimumab, a Human Anti-TNF Antibody. Elizabeth C. Hsia 5 ,<br />
Neil Schluger 6 , John J. Cush 1 , Richard E. Chaisson 7 , Eric L.<br />
Matteson 8 , Anna Beutler 3 , Mittie K. Doyle 2 , Benjamin L. Hsu 4<br />
and Mahboob U. Rahman 5 , 1 Baylor Research Institute, Dallas,<br />
TX, 2 Centocor Research and Development, Inc., Malvern,<br />
PA, 3 Centocor Research and Development, Inc., <strong>College</strong>ville,<br />
PA, 4 Centocor Research and Development, Inc./Univ. <strong>of</strong><br />
Pennsylvania School <strong>of</strong> Medicine, Wynnewood, PA, 5 Centocor<br />
Research and Development, Inc./Univ. <strong>of</strong> Pennsylvania School<br />
<strong>of</strong> Medicine, Malvern, PA, 6 Columbia University <strong>College</strong> <strong>of</strong><br />
Physicians & Surgeons, 7 Johns Hopkins University, 8 Mayo Clinic,<br />
Rochester, MN.<br />
202<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
909. Regulatory T-Cells in Familial Mediterranean Fever (FMF).<br />
Doron Rimar 2 , Itzhak Rosner 3 , Gleb Slobodin 3 , Nina Boulman 3 ,<br />
Aharon Kessel 1 , Elias Touby 1 and Michael Rozenbaum 3 ,<br />
1<br />
Immunology Unit, Bnai-Zion Medical Center, Haifa, Israel,<br />
2<br />
<strong>Rheumatology</strong> Unit, Bnai-Zion Medical Center, Haifa, Israel,<br />
3<br />
<strong>Rheumatology</strong> Unit, Bnai-Zion Medical Center, Haifa, Israel.<br />
910. Safety <strong>of</strong> Arthrocentesis in Patients on Chronic Warfarin<br />
Therapy with Therapeutic INR. Imdad Ahmed 2 and Elie<br />
Gertner 1 , 1 Regions Hospital, St Paul, MN, 2 Regions Hospital.<br />
911. Standardization <strong>of</strong> Antinuclear Antibody Assessment on<br />
HEp-2 Cells by Automated Interpretation. Karl Egerer 1 , Dirk<br />
Roggenbuck 4 , Rico Hiemann 6 , Max-Georg Weyer 5 , Barbara<br />
Lehmann 3 , Eugen Feist 3 and Gerd R. Burmester 2 , 1 Charite -<br />
University Medicine, Berlin, Germany, 2 Charite - University<br />
Medicine, Berlin, Germany, 3 Charite - University Medicine,<br />
4<br />
Medipan GmbH, Berlin Dahlewitz, Germany, 5 Medizinisches<br />
Versorgungszentrum für Laboratoriumsmedizin, Mikrobiologie,<br />
Virologie und Infektionsepidemiologie, Hygiene und<br />
Umweltmedizin, 6 University <strong>of</strong> Applied Science Lausitz.<br />
912. The CIRAS Study: A Case Control Study To Define the Clinical,<br />
Immunologic and Radiographic Features <strong>of</strong> the Aromatase<br />
Inhibitor Arthralgia Syndrome. Victoria K. Shanmugam 3 , James<br />
McCloskey 1 , Elizabeth Elston 4 , Sandra J. Allison 2 , Claudine<br />
Isaacs 5 and Jennifer Eng-Wong 5 , 1 Department <strong>of</strong> Internal<br />
Medicine, Georgetown University Medical Center, Washington,<br />
DC, 2 Department <strong>of</strong> Radiology, Georgetown University<br />
Medical Center, Washington, DC, 3 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Immunology and Allergy, Georgetown University Medical<br />
Center, Washington, DC, 4 Georgetown University, 5 Lombardi<br />
Cancer Center, Georgetown University Medical Center,<br />
Washington, DC.<br />
Muscle Biology, Myositis and Myopathies: New Developments in<br />
the Diagnosis, Pathogenesis and Treatment <strong>of</strong> Myositis<br />
913. A Negative Anti-Nuclear Antibody Does Not Indicate<br />
Autoantibody Negativity. Rohit Aggarwal 2 , Noreen Fertig 2 ,<br />
Dana P. Ascherman 3 , Elaine A. Cassidy 1 and Chester V. Oddis 2 ,<br />
1<br />
Children’s Hospital Pittsburg, Pittsburgh, PA, 2 University <strong>of</strong><br />
Pittsburgh, Pittsburgh, PA, 3 University <strong>of</strong> Pittsburgh, Pittsburgh,<br />
PA.<br />
914. A Novel Form <strong>of</strong> an Autosomal Dominant Vacuolar Hereditary<br />
Myopathy. Christine Castro 5 , Ivona Aksentijevich 6 , Elaine<br />
Remmers 6 , Elisabeth Rushing 1 , Simona Bianconi 3 , Marjan<br />
Huizing 4 , Mildred Wilson 6 , Thomas Markello 2 , Daniel Kastner 6<br />
and Mark Gourley 6 , 1 Armed Forces Institute <strong>of</strong> Pathology,<br />
2<br />
National Institues <strong>of</strong> Health/National Human Genome Research<br />
Institute/Medical Genetics Branch, 3 National Institutes <strong>of</strong><br />
Health, 4 National Institutes <strong>of</strong> Health, National Human Genome<br />
Research Institute, Medical Genetics Branch, 5 National Institutes<br />
<strong>of</strong> Health, National Institute <strong>of</strong> Arthritis and Musculoskeletal<br />
and Skin Diseases, Bethesda, MD, 6 National Institutes <strong>of</strong> Health,<br />
National Institute <strong>of</strong> Arthritis and Musculoskeletal and Skin<br />
Diseases.<br />
915. Anti-SRP Auto-Antibody Titers Correlate with Serum Creatine<br />
Kinase in Necrotising Myopathy. Olivier Benveniste 1 , Laurent<br />
Drouot 3 , Fabienne Jouen 3 , Serge Herson 2 , Jean-Luc Charuel 2 ,<br />
Coralie Bloch 2 , Anthony Behin 2 , Zahir Amoura 2 , Isabelle Marie 4 ,<br />
Bruno Eymard 2 , Danièle Gilbert 3 , François Tron 3 , Lucile Musset 2<br />
and Olivier Boyer 3 , 1 Assistance Publique - Hôpitaux de Paris,<br />
Hôpital Pitié-Salpêtrière, Paris, France, 2 Assistance Publique -<br />
Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, France, 3 Inserm,<br />
U905, Rouen University, France, 4 Rouen University Hospital,<br />
Department <strong>of</strong> Internal Medicine, France.<br />
916. Clinical Manifestation and Prognostic Factor in Anti-Melanoma<br />
Differentiation-Associated Gene 5 Antibody-Associated<br />
Interstitial Lung Disease as a Complication <strong>of</strong> Dermatomyositis.<br />
Takahisa Gono 5 , Yasushi Kawaguchi 3 , Takashi Satoh 2 , Masataka<br />
Kuwana 1 , Yasuhiro Katsumata 5 , Kae Takagi 5 , Ikuko Masuda 3 ,<br />
Sayumi Baba 5 , Masanori Hanaoka 5 , Yuko Okamoto 5 , Yuko Ota 5 ,<br />
Sayuri Kataoka 5 and Hisashi Yamanaka 4 , 1 Keio University School,<br />
Tokyo, Japan, 2 Keio University School, 3 Tokyo Women’s Medical<br />
University, Tokyo, Japan, 4 Tokyo Women’s Medical University,<br />
Shinjuku-ku, Tokyo, Japan, 5 Tokyo Women’s Medical University.<br />
917. Efficacy and Tolerance <strong>of</strong> Rituximab in Refractory Idiopathic<br />
Inflammatory Myopathy. Data <strong>of</strong> the AIR Registry. Marion<br />
Couderc 3 , Jacques E. Gottenberg 12 , Xavier Mariette 2 , Eric<br />
Hachulla 9 , Jean Sibilia 11 , Olivier Fain 6 , Arnaud Hot 8 , Maxime<br />
Dougados 5 , Liana E. Euller-Ziegler 7 , Pierre Bourgeois 10 ,<br />
Claire Larroche 10 , Anne Tournadre 3 , Zahir Amoura 10 , Bernard<br />
Mazieres 14 , P. Arlet 13 , Michel De Bandt 1 , Thierry Schaeverbeke 4<br />
and Martin Soubrier 3 , 1 Aulnay Hospital, Carrieres Sur Seine,<br />
France, 2 Bicetre Hospital/Paris Univ, Le Kremlin Bicetre, France,<br />
3<br />
Clermont-Ferrand Hospital, 4 Groupe Hospitalier Pellegrin,<br />
Bordeaux, France, 5 Hospital Cochin, Paris, France, 6 Jean Verdier<br />
Hospital, Paris University, 7 L’Archet Hospital (University),<br />
Nice, France, 8 Lyon Hospital, 9 National Scleroderma Centre,<br />
Lille Cedex, France, 10 Paris Hospital, 11 Strasbourg Hospital,<br />
Strasbourg, France, 12 Strasbourg Hospitals, Strasbourg, France,<br />
13<br />
Toulouse Hopsital, 14 Toulouse Hospital.<br />
918. Efficacy <strong>of</strong> Allogeneic Mesenchymal Stem Cells Transplantation<br />
in Patients with Drug-Resistant Polymyositis and<br />
Dermatomyositis. Lingyun Sun 1 , Dandan Wang 2 , Huayong<br />
Zhang 2 , Jun Liang 2 and Xuebing Feng 2 , 1 Department <strong>of</strong><br />
<strong>Rheumatology</strong> and Immunology, The Affiliated Drum Tower<br />
Hospital <strong>of</strong> Nanjing University Medical School, Nanjing, Jiangsu,<br />
China, 2 Department <strong>of</strong> <strong>Rheumatology</strong> and Immunology, The<br />
Affiliated Drum Tower Hospital <strong>of</strong> Nanjing University Medical<br />
School.<br />
919. ESR and CRP Do Not Correlate with Extent <strong>of</strong> Muscle Injury<br />
but Their Elevation Is Associated with Pulmonary Involvement<br />
in Idiopathic Inflammatory Myopathy. Jin Kyun Park 4 , Michael<br />
George 2 , Sonye K. Dan<strong>of</strong>f 3 , Marzouq A. Qubti 4 , Allan C. Gelber 1<br />
and Lisa Christopher-Stine 5 , 1 Baltimore, MD, 2 Department <strong>of</strong><br />
Medicine, University <strong>of</strong> Pennsylvania, 3 Division <strong>of</strong> Pulmonary<br />
and Critical Care Medicine, Johns Hopkins University School <strong>of</strong><br />
Medicine, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Medicine,<br />
Johns Hopkins University School <strong>of</strong> Medicine, Baltimore, MD,<br />
5<br />
Johns Hopkins University, Baltimore, MD.<br />
920. Evaluation <strong>of</strong> Reliability, Validity, and Responsiveness <strong>of</strong> the<br />
CDASI and CAT-BM. Renato Goreshi 8 , Joyce Okawa 8 , Matt<br />
Rose 8 , Rui Feng 1 , Lela Lee 6 , Christopher Hansen 10 , Carolyn<br />
Bangert 9 , Kari Connolly 5 , Mark Davis 2 , Jeff Callen 7 , Nicole Fett 8 ,<br />
Steven Fakharzadeh 4 , Jennie Clarke 3 and Victoria Werth 8 ,<br />
1<br />
Center for Clinical Epidemiology and Biostatistics, University<br />
<strong>of</strong> Pennsylvania, 2 Mayo Clinic- Rochester, 3 Penn State Hershey,<br />
School <strong>of</strong> Medicine, 4 Philadelphia VA Medical Center, 5 University<br />
<strong>of</strong> California-San Francisco, School <strong>of</strong> Medicine, 6 University <strong>of</strong><br />
Colorado, School <strong>of</strong> Medicine, 7 University <strong>of</strong> Louisville, School<br />
<strong>of</strong> Medicine, 8 University <strong>of</strong> Pennsylvania, School <strong>of</strong> Medicine,<br />
9<br />
University <strong>of</strong> Texas, School <strong>of</strong> Medicine, 10 University <strong>of</strong> Utah,<br />
School <strong>of</strong> Medicine.<br />
2010 Program Book 203
ACR/ARHP Poster Session B<br />
921. Fasciitis Is a Common Lesion <strong>of</strong> Dermatomyositis<br />
Demonstrable Early after Disease Onset by En Bloc Biopsy<br />
Combined with Magnetic Resonance Imaging. Ken Yoshida 2 ,<br />
Daitaro Kurosaka 2 , Kensuke Joh 1 , Eigo Takahashi 2 , Kenichiro<br />
Hirai 2 , Kentaro Noda 2 , Taro Ukichi 2 , Kazuhiro Furuya 2 , Maimi<br />
Yanagimachi 2 , Isamu Kingetsu 2 and Akio Yamada 2 , 1 Division<br />
<strong>of</strong> Pathology, Sendai Shakai Hoken Hospital, 2 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine, Jikei<br />
University School <strong>of</strong> Medicine, Tokyo, Japan.<br />
922. Immunosuppressive Treatments Do Not Alter Natural History<br />
<strong>of</strong> Sporadic Inclusion Body Myositis: The Paris/Oxford Study<br />
on 136 Patients. Benveniste Olivier 2 , Guiguet Marguerite 5 , Jane<br />
Freebody 4 , Serge Herson 2 , Odile Dubourg 3 , Waney Squier 4 ,<br />
Pascal Laforet 1 , Isabel Leite 4 , Bruno Eymard 1 and David Hilton-<br />
Jones 4 , 1 Assistance Publique - Hôpitaux de Paris, Hôpital Pitié-<br />
Salpêtrière, Institut de Myologie, France, 2 Assistance Publique<br />
- Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Interne,<br />
France, 3 Assistance Publique - Hôpitaux de Paris, Hôpital<br />
Pitié-Salpêtrière, Neuropathologie, France, 4 Department <strong>of</strong><br />
Neurology, West Wing, John Radcliffe Hospital, Oxford, United<br />
Kingdom, 5 INSERM – UPMC UMR S 943, Biostatistique, Paris,<br />
France.<br />
923. Interleukin-18 Is a Key Mediator in Dermatomyositis:<br />
Contribution to Development <strong>of</strong> Interstitial Lung Disease.<br />
Takahisa Gono 2 , Yasushi Kawaguchi 1 , Tomoko Sugiura 2 , Kae<br />
Takagi 2 , Ikuko Masuda 1 , Hisae Ichida 2 , Yasuhiro Katsumata 2 ,<br />
Akiko Tochimoto 2 , Sayumi Baba 2 , Masanori Hanaoka 2 , Yuko<br />
Okamoto 2 , Yuko Ota 2 , Sayuri Kataoka 2 and Hisashi Yamanaka 3 ,<br />
1<br />
Tokyo Women’s Medical University, Tokyo, Japan, 2 Tokyo<br />
Women’s Medical University, 3 Tokyo Womens Med Univ,<br />
Shinjuku-ku, Tokyo, Japan.<br />
924. KL-6: A Serological Biomarker for Interstitial Lung Disease<br />
and Pulmonary Function in Patients with Polymyositis and<br />
Dermatomyositis. Sevim Barbasso Helmers 3 , Maryam Fathi 1 and<br />
Ingrid E. Lundberg 2 , 1 Department <strong>of</strong> Respiratory Medicine and<br />
Allergy, Karolinska Institutet, Stockholm, Sweden, 2 Karolinska<br />
Institutet, Stockholm, Sweden, 3 <strong>Rheumatology</strong> Unit, Dpt. <strong>of</strong><br />
Medicine, Karolinska University Hospital, Solna, Karolinska<br />
Institutet, Stockholm, Sweden.<br />
925. Longitudinal Assessment <strong>of</strong> Activity and Damage in a<br />
Synthetase Positive Cohort. Elaine A. Cassidy 1 , Rohit Aggarwal 3 ,<br />
Noreen Fertig 4 , Dana P. Ascherman 3 and Chester V. Oddis 2 ,<br />
1<br />
Children’s Hospital Pittsburgh Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Pittsburgh, PA, 2 University <strong>of</strong> Pittsburgh, Pittsburgh, PA,<br />
3<br />
University <strong>of</strong> Pittsburgh School <strong>of</strong> Medicine Division <strong>of</strong><br />
<strong>Rheumatology</strong> and Clinical Immunology, Pittsburgh, PA,<br />
4<br />
University <strong>of</strong> Pittsburgh School <strong>of</strong> Medicine Division <strong>of</strong><br />
<strong>Rheumatology</strong> and Clinical Immunology.<br />
926. Longitudinally Followed Serum Levels <strong>of</strong> B-Cell Activating<br />
Factor <strong>of</strong> the TNF Family Correlate with Disease Activity in<br />
Anti-Jo-1 Positive Patients with Myositis. Olga Krystufkova 1 ,<br />
Marta Mitterwald-Modra 2 , Herman Mann 2 , Louise Ekholm 5 ,<br />
Hana Hulejova 2 , Ingrid E. Lundberg 4 and Jiri Vencovsky 3 ,<br />
1<br />
Institute <strong>of</strong> <strong>Rheumatology</strong>, Prague, Czech Republic, 2 Institute<br />
<strong>of</strong> <strong>Rheumatology</strong>, 3 Institute <strong>of</strong> <strong>Rheumatology</strong> and Dept <strong>of</strong><br />
<strong>Rheumatology</strong> <strong>of</strong> the 1 st Faculty <strong>of</strong> Medicine, Charles University,<br />
Prague, Prague, Czech Republic, 4 Karolinska Institutet,<br />
Stockholm, Sweden, 5 Karolinska Institutet, Sweden.<br />
927. MHC Classes I and II Expressions in Membrane and<br />
Cytoplasm <strong>of</strong> Muscle Fibers in Untreated Juvenile and Adult<br />
Dermatomyositis. Adriana Maluf Elias Sallum, Samuel Katsuyuki<br />
Shinjo, Mary Souza Carvalho, Clóvis Artur Almeida da Silva,<br />
Maurício Levy-Neto and Suely Kazue Nagahashi Marie, Hospital<br />
das Clínicas da Faculdade de Medicina da Universidade de São<br />
Paulo, São Paulo, Brazil.<br />
928. MicroRNA Expression in Juvenile Dermatomyositis (JDM):<br />
Clues to Disease Pathogenesis and Chronicity. Simone Sredni,<br />
Peter Hendrickson, Sheela Shrestha and Lauren M. Pachman,<br />
Children’s Memorial Research Center, Chicago, IL.<br />
929. Non-Jo-1 Anti-Synthetase Autoantibodies Are Not Specific<br />
for Myositis and Are Associated with Poor Survival. Elaine A.<br />
Cassidy 1 , Rohit Aggarwal 3 , Noreen Fertig 3 , Mary Lucas 3 , Dana<br />
P. Ascherman 3 and Chester V. Oddis 2 , 1 Children’s Hospital <strong>of</strong><br />
Pittsburgh Division <strong>of</strong> <strong>Rheumatology</strong>, Pittsburgh, PA, 2 University<br />
<strong>of</strong> Pittsburgh, Pittsburgh, PA, 3 University <strong>of</strong> Pittsburgh School <strong>of</strong><br />
Medicine Division <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology,<br />
Pittsburgh, PA.<br />
930. Predictors <strong>of</strong> Survival in Patients with Anti-Synthetase<br />
Autoantibodies. Rohit Aggarwal 5 , Elaine A. Cassidy 1 , Noreen<br />
Fertig 4 , Mary Lucas 4 , Dana P. Ascherman 2 and Chester V. Oddis 3 ,<br />
1<br />
Children’s Hospital Pittsburg, Pittsburgh, PA, 2 University <strong>of</strong><br />
Pittsburgh, Pittsburgh, PA, 3 University <strong>of</strong> Pittsburgh, Pittsburgh,<br />
PA, 4 University <strong>of</strong> Pittsburgh, 5 University <strong>of</strong> Pittsburgh Medical<br />
Center, Pittsburgh, PA.<br />
931. Pulmonary Manifestations <strong>of</strong> Polymyositis and Long-Term<br />
Outcomes – A Retrospective Study. Catherine Bakewell 1 , James<br />
Hotaling 1 , Michael Huck 3 , Dale Wilson 3 , Jennifer Hayes 1 , Carolyn<br />
Spada 1 , Gurpreet Rawat 1 and Ganesh Raghu 2 , 1 University<br />
<strong>of</strong> Washington Medical Center, Seattle, WA, 2 University <strong>of</strong><br />
Washington Medical Center, Seattle, 3 University <strong>of</strong> Washington<br />
School <strong>of</strong> Medicine, Seattle, WA.<br />
932. Skin Ulcer Is a Prognostic Factor <strong>of</strong> Respiratory Failure in<br />
Interstitial Lung Disease in Patients with Polymyositis or<br />
Dermatomyositis. Kazuyoshi Ishigaki 3 , Yasunobu Takizawa 4 ,<br />
Junko Maruyama 4 , Ran Nakashima 1 , Tsuneyo Mimori 2 and<br />
Keigo Setoguchi 4 , 1 Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />
Immunology, Kyoto University Graduate School <strong>of</strong> Medicine,<br />
Japan, 2 Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology,<br />
Kyoto University Graduate School <strong>of</strong> Medicine, Japan 3 Tokyo<br />
Metropolitan Komagome Hospital, Bunkyo-ku, Tokyo, Japan,<br />
4<br />
Tokyo Metropolitan Komagome Hospital.<br />
933. The Anti-Oxidant Function <strong>of</strong> High Density Lipoprotein<br />
and Paraoxanase-1 Are Abnormal in Patients with<br />
Dermatomyositis. Christina Charles-Schoeman 2 , Yuen Yin<br />
Lee 3 , John D. FitzGerald 4 , Veena K. Ranganath 1 and Srinivasa T.<br />
Reddy 3 , 1 UCLA School <strong>of</strong> Med Rehab 32-59, Los Angeles, CA,<br />
2<br />
UCLA School <strong>of</strong> Medicine, Los Angeles, CA, 3 UCLA School <strong>of</strong><br />
Medicine, 4 UCLA School <strong>of</strong> Medicine Rehabilitation, Los Angeles,<br />
CA.<br />
934. The Interferon Signature in Myositis Is Associated with RNA-<br />
Binding Protein Autoantibodies. Hatice Bilgic 4 , Joseph Wilson 4 ,<br />
Thearith Koeuth 4 , Kelly T. McNallan 2 , Steven R. Ytterberg 1 , Erik<br />
J. Peterson 3 , Ann M. Reed 1 and Emily C. Baechler 4 , 1 Mayo Clinic,<br />
Rochester, MN, 2 Mayo Clinic, <strong>Rheumatology</strong>, Rochester, MN,<br />
3<br />
University <strong>of</strong> Minnesota Department <strong>of</strong> Medicine, Minneapolis,<br />
MN, 4 University <strong>of</strong> Minnesota Department <strong>of</strong> Medicine,<br />
Minneapolis, MN.<br />
204<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
935. The Role <strong>of</strong> Innate Immunity in a Model <strong>of</strong> HRS-Induced<br />
Myositis. Makoto Soejima 4 , Eun Ha Kang 1 , Yasuhiro Katsumata 2 ,<br />
Xinyan Gu 3 , Paula Clemens 3 and Dana Ascherman 3 , 1 Seoul<br />
National University <strong>College</strong> <strong>of</strong> Medicine, 2 Tokyo Women’s<br />
Medical University, 3 University <strong>of</strong> Pittsburgh, 4 University <strong>of</strong><br />
Pittsburgh, Pittsburgh, PA.<br />
Osteoarthritis - Clinical Aspects: Pain and Treatment II<br />
936. 13-Week Efficacy and Safety Evaluation <strong>of</strong> Naproxcinod, a<br />
Cyclooxygenase Inhibiting Nitric Oxide Donator (CINOD), in<br />
Patients with Osteoarthritis <strong>of</strong> the Hip. Christoph Baerwald 3 ,<br />
Hayet Frayssinet 1 , Thierry Ferreira 1 , Brigitte Duquesroix 1 and<br />
Thomas Schnitzer 2 , 1 NicOx, SA, 2 Northwestern University,<br />
3<br />
Universitätsklinikum Leipzig.<br />
937. A Fixed-Dose Combination <strong>of</strong> Naproxen and Esomeprazole<br />
Magnesium (VIMOVO) Has Comparable Efficacy and<br />
Tolerability to Celecoxib in Patients with Osteoarthritis (OA)<br />
<strong>of</strong> the Knee: Results from Two Randomized, Controlled Trials.<br />
Marc C. Hochberg 4 , Byron Cryer 5 , John G. Fort 3 , Clara Hwang 1 ,<br />
Ola Svensson 2 and Mark B. Sostek 1 , 1 AstraZeneca, Wilmington,<br />
DE, 2 AstraZeneca, Sodertalje, Sweden, 3 POZEN, Inc, Chapel Hill,<br />
NC, 4 University <strong>of</strong> Maryland, Baltimore, MD, 5 University <strong>of</strong> Texas<br />
Southwestern Medical Center, Dallas, TX.<br />
938. Chondroitin Sulfate Treatment Is Effective at Reducing<br />
Cartilage Loss in the Tibi<strong>of</strong>emoral Compartment in Knee<br />
OA as Assessed by Magnetic Resonance Imaging (MRI).<br />
Jean-Pierre Pelletier 8 , Lukas M. Wildi 5 , Jean-Pierre Raynauld 5 ,<br />
André Beaulieu 3 , Louis Bessette 4 , Frédéric Morin 1 , François<br />
Abram 6 , Marc Dorais 7 and Johanne Martel-Pelletier 2 , 1 Centre<br />
de Recherche Musculo-squelettique, Trois-Rivières, 2 CR-CHUM,<br />
Notre-Dame Hospital, Montreal, QC, Canada, 3 Faculty <strong>of</strong><br />
Medicine, University <strong>of</strong> Laval, QC, 4 Groupe de Recherche en<br />
Rhumatologie et Maladies Osseuses, Sainte-Foy, 5 Osteoarthritis<br />
Research Unit, University <strong>of</strong> Montreal Hospital Research Centre<br />
(CRCHUM), Notre-Dame Hospital, 6 Research and Development,<br />
ArthroVision Inc., Montreal, 7 StatSciences Inc., Notre-Dame de<br />
l’Ile-Perrot, 8 University <strong>of</strong> Montreal Hospital Research Centre<br />
(CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada.<br />
939. Chronic Pain Associated with Obesity in the Elderly Is in Part<br />
Explained by the Presence <strong>of</strong> Osteoarthritis. Irene Blanco 2 ,<br />
Richard B. Lipton 2 , Chaim Putterman 1 and Carol A. Derby 2 ,<br />
1<br />
Albert Einstein <strong>College</strong> <strong>of</strong> Med, Bronx, NY, 2 Albert Einstein<br />
<strong>College</strong> <strong>of</strong> Medicine, Bronx, NY.<br />
940. Clinical Evaluation <strong>of</strong> Chondroitin 4&6 Sulfate (Condrosulf®) in<br />
the Treatment <strong>of</strong> Symptomatic Hand Osteoarthritis. A 6-Month<br />
Randomized Double-Blind, Placebo Controlled Study. Cem<br />
Gabay, Carole Medinger, Danielle Gascon and Axel Finckh, Univ<br />
Hosp <strong>of</strong> Geneva, Geneva, Switzerland.<br />
941. Controversies in the Use <strong>of</strong> Acupuncture for Osteoarthritis<br />
(OA). A Systematic Review <strong>of</strong> the Quality and Treatment<br />
Features <strong>of</strong> Randomized Clinical Trials (RCT). Maria F.<br />
Marengo 2 , Christian A. Waimann 2 , Maria A. Lopez-Olivo 2 , Carol<br />
Looney 1 and Maria E. Suarez-Almazor 3 , 1 The University <strong>of</strong> Texas<br />
M. D. Anderson Cancer Center, 2 The University <strong>of</strong> Texas M. D.<br />
Anderson Cancer Center, Houston, TX, 3 University <strong>of</strong> Texas, MD<br />
Anderson Cancer Center, Houston, TX.<br />
942. Disease Modifying Activity <strong>of</strong> Celecoxib on Articular Cartilage<br />
in Osteoarthritis? – A Randomized Clinical Trial. T. N. de Boer 2 ,<br />
S. C. Mastbergen 2 , A. M. Huisman 3 , A. A. Polak 1 , J. W. J. Bijlsma 2<br />
and F. P. J. G. Lafeber 2 , 1 Orthopedics, Sint Franciscus Gasthuis<br />
Rotterdam, Rotterdam, The Netherlands, 2 <strong>Rheumatology</strong><br />
& Clinical Immunology, University Medical Center Utrecht,<br />
Utrecht, The Netherlands, 3 <strong>Rheumatology</strong>, Sint Franciscus<br />
Gasthuis Rotterdam, Rotterdam, The Netherlands.<br />
943. Effects <strong>of</strong> Intraarticular (IA) Corticosteroid Injections on Bone<br />
Markers and Endogenous Cortisol in Patients with Knee<br />
Osteoarthritis (OA), a Pilot Study. Aruna Baratham 3 , Barbara<br />
P. Lukert 1 and Herbert B. Lindsley 2 , 1 Kansas City, KS, 2 Kansas<br />
University Med Ctr, Kansas City, KS, 3 KU Medical Ctr, Kansas City,<br />
KS.<br />
944. Efficacy and Safety <strong>of</strong> the Lidocaine Patch 5% (Lidoderm®)<br />
When Used as Adjunct Treatment in Patients with<br />
Osteoarthritis <strong>of</strong> the Knee. Alan Kivitz 1 , Ernest A. Kopecky 3 ,<br />
Yusong Chen 2 , Steve Xiang 2 , Matthew Wieman 2 and Errol M.<br />
Gould 2 , 1 Altoona Center for Clinical Research, Duncansville,<br />
PA, 2 Endo Pharmaceuticals Inc., Chadds Ford, PA, 3 Endo<br />
Pharmaceuticals Inc.<br />
945. Efficacy, Safety and Tolerability <strong>of</strong> HZT-501, Including<br />
Users <strong>of</strong> Low-Dose Aspirin, a Single-Tablet Combination <strong>of</strong><br />
Ibupr<strong>of</strong>en-Famotidine: Results <strong>of</strong> Two Phase 3 Trials. Michael<br />
E. Weinblatt 2 , Mark C. Genovese 5 , Alan J. Kivitz 1 , Alfonso E.<br />
Bello 4 , Amy Grahn 3 , Jeffrey W. Sherman 3 and Michael H. Schiff 6 ,<br />
1<br />
Altoona Arthritis & Osteo Ctr, Duncansville, PA, 2 Brigham<br />
& Womens Hospital, Boston, MA, 3 Horizon Pharma, Inc.,<br />
Northbrook, IL, 4 Illinois Bone & Joint Inst, Glenview, IL, 5 Stanford<br />
University, Stanford, Sunnyvale, CA, 6 University <strong>of</strong> Colorado,<br />
Denver, Greenwood Village, CO.<br />
946. Long Term Safety <strong>of</strong> an NSAID with Built-in Gastroprotection<br />
for Treatment <strong>of</strong> Pain and Inflammation Related to OA and<br />
RA: Results from a One Year Safety Trial <strong>of</strong> a Single-Tablet<br />
Combination <strong>of</strong> Ibupr<strong>of</strong>en-Famotidine vs. Ibupr<strong>of</strong>en Alone.<br />
Michael H. Schiff 6 , Mark C. Genovese 5 , Alan J. Kivitz 1 , Alfonso<br />
E. Bello 4 , Jeffrey W. Sherman 3 , Amy Grahn 3 and Michael E.<br />
Weinblatt 2 , 1 Altoona Arthritis & Osteo Ctr, Duncansville, PA,<br />
2<br />
Brigham & Womens Hospital, Boston, MA, 3 Horizon Pharma,<br />
Inc., Northbrook, IL, 4 Illinois Bone & Joint Inst, Glenview, IL,<br />
5<br />
Stanford University, Stanford, Sunnyvale, CA, 6 University <strong>of</strong><br />
Colorado, Denver, Greenwood Village, CO.<br />
947. Modified Bent Knee Approach for Highly Accurate Injection<br />
<strong>of</strong> the Knee. Suzanne Delea 1 , Wilmer L. Sibbitt 3 , Philip<br />
Band, Natalia Chavez-Chiang 2 , Hillary Norton 2 and Arthur D.<br />
Bankhurst 4 , 1 University <strong>of</strong> New Mexico, Albuquerque, NM,<br />
2<br />
University <strong>of</strong> New Mexico, 3 University <strong>of</strong> New Mexico HSC,<br />
Albuquerque, NM, 4 University <strong>of</strong> NM Med Ctr, Albuquerque,<br />
NM.<br />
948. OARSI-OMERACT Virtual Joint Replacement in Disease<br />
Modifying Osteoarthritis Drug (DMOAD) Randomized Clinical<br />
Trials (RCTs) for Knee and Hip Osteoarthritis (OA): Selection<br />
<strong>of</strong> Optimal Thresholds for Symptomatic Severity. Rebecca L.<br />
Manno 5 , Clifton O. Bingham 6 , Simon Paternotte 1 , Philippe Coste,<br />
Giampaolo Giacovelli 9 , Lucio C. Rovati 8 , Kenneth D. Brandt 7 ,<br />
Steven A. Mazzuca 4 , Daniel O. Clegg 10 , Helen Shi, Eleonora<br />
Tajana Messi 3 , Arturo Lanzarotti 3 and Maxime Dougados 2 , 1 AP-<br />
HP Cochin Hospital, René Descartes University, Paris, France,<br />
2<br />
Hospital Cochin, Paris, France, 3 IBSA Institut Biochimique SA,<br />
4<br />
Indiana Univ Schl <strong>of</strong> Medicine, Indianapolis, IN, 5 Johns Hopkins<br />
University, Baltimore, MD, 6 Johns Hopkins University, Baltimore,<br />
MD, 7 Kansas Univ Medical Center, Fairway, KS, 8 Rottapharm,<br />
Monza Milan, Italy, 9 Rottapharm, 10 University <strong>of</strong> Utah Med Ctr,<br />
Salt Lake City, UT.<br />
949. Pain Sensitivity and Biomarkers <strong>of</strong> Systemic Inflammation<br />
in Osteoarthritis. Yvonne C. Lee 2 , Bing Lu 1 , Joan M. Bathon 4 ,<br />
Jennifer A. Haythornwaite 5 , Michael T. Smith 5 , Gayle G. Page 5<br />
and Robert R. Edwards 3 , 1 Brigham and Women’s Hospital,<br />
Foxboro, MA, 2 Brigham and Women’s Hospital, Boston, MA,<br />
3<br />
Brigham and Womens Hospital, Chestnut Hill, MA, 4 Johns<br />
Hopkins University, Baltimore, MD, 5 Johns Hopkins University.<br />
2010 Program Book 205
ACR/ARHP Poster Session B<br />
950. Patient Global Impression <strong>of</strong> Change Results from a 1-Year<br />
Open-Label Extension Study <strong>of</strong> Tapentadol Extended<br />
Release in Patients with Chronic Osteoarthritis or Low Back<br />
Pain. Bettyanne McCann 2 , Robert Lange 1 , Bertil Wagner 2 ,<br />
Achim Steup 1 , Bernd Lange 1 and Mila Etrolpolski 2 , 1 Global<br />
Development, Grünenthal GmbH, Aachen, Germany, 2 Johnson<br />
& Johnson Pharmaceutical Research & Development, L.L.C.,<br />
Raritan, NJ.<br />
951. Racial/Ethnic Differences in Pain Sensation in Subjects with<br />
or at Risk <strong>of</strong> Knee Osteoarthritis: Analysis <strong>of</strong> the Multicenter<br />
Osteoarthritis (MOST) Study. Jasvinder Singh 1 , Tuhina Neogi 2 ,<br />
David T. Felson 3 , James Torner 7 , Kristin Baker 4 , Michael C.<br />
Nevitt 5 , Irina Tolstykh 5 and Cora E. Lewis 6 , 1 Birmigham VA<br />
Medical Center and University <strong>of</strong> Alabama, Minneapolis, MN,<br />
2<br />
Boston Univ Schl <strong>of</strong> Med, Boston, MA, 3 Boston University<br />
School <strong>of</strong> Medicine, Boston, MA, 4 Boston University School <strong>of</strong><br />
Medicine, 5 UCSF, San Francisco, CA, 6 University <strong>of</strong> Alabama,<br />
7<br />
University <strong>of</strong> Iowa.<br />
952. The Importance <strong>of</strong> Methodological Quality for the Association<br />
between Radiographic and Clinical Features <strong>of</strong> Hip and<br />
Knee Osteoarthritis: A Systematic Review. M. B. Kinds 2 , E. P.<br />
Vignon 5 , J. W. J. Bijlsma 4 , M. A. Viergever 1 , A. C. A. Marijnissen 4 ,<br />
F. P. J. G. Lafeber 4 and P. M. J. Welsing 3 , 1 Image Sciences<br />
Institute, University Medical Center Utrecht, The Netherlands,<br />
2<br />
<strong>Rheumatology</strong> & Clinical Immunology, Image Sciences<br />
Institute, University Medical Center Utrecht, The Netherlands,<br />
3<br />
<strong>Rheumatology</strong> & Clinical Immunology, Julius Center for Health<br />
Sciences & Primary Care, University Medical Center Utrecht, The<br />
Netherlands, 4 <strong>Rheumatology</strong> & Clinical Immunology, University<br />
Medical Center Utrecht, The Netherlands, 5 <strong>Rheumatology</strong>,<br />
University Hospital Lyon-Sud Pierre-Benite, France.<br />
953. Time to Onset <strong>of</strong> Gastrointestinal Adverse Events <strong>of</strong><br />
Naproxcinod vs. Naproxen and Placebo in Patients with<br />
Osteoarthritis. Byron Cryer 2 , Angel Lanas 1 , Rosanna Fleming 4 ,<br />
Fabrizio Dolphi 3 , Diana Aguirre 3 and Brigitte Duquesroix 3 ,<br />
1<br />
Aragon Health Sciences Institute, University <strong>of</strong> Zaragoza,<br />
2<br />
Department <strong>of</strong> Veterans Affairs Medical Center, 3 NicOx SA,<br />
4<br />
NicOx, Inc.<br />
954. Topical Dicl<strong>of</strong>enac Solution (PENNSAID®) Compared with Oral<br />
Dicl<strong>of</strong>enac in Osteoarthritis <strong>of</strong> the Knee: Pooled Analysis from<br />
2 Controlled Clinical Trials. Sanford H. Roth 1 and Philip Fuller 2 ,<br />
1<br />
Arizona Research and Education, Arthritis Research Laboratory,<br />
Arizona State University, Phoenix, AZ, 2 Covidien.<br />
955. Topical Dicl<strong>of</strong>enac Solution with the Absorption Enhancer<br />
Dimethyl Sulfoxide (PENNSAID®) for the Treatment <strong>of</strong><br />
Osteoarthritis <strong>of</strong> the Knee: Integrated Summary <strong>of</strong> Safety.<br />
Sanford H. Roth 1 and Philip Fuller 2 , 1 Arizona Research and<br />
Education, Arthritis Research Laboratory, Arizona State<br />
University, Phoenix, AZ, 2 Covidien.<br />
Osteoporosis and Metabolic Bone Disease: Clinical Aspects and<br />
Pathogenesis<br />
956. Adenosine A2A Antagonist ZM241385 Increases Osteoblast<br />
Differentiation and Function In Vitro. Louisa Ziglar 2 and Bruce<br />
N. Cronstein 1 , 1 New York Univ Med Ctr, New York, NY, 2 NYU<br />
Medical Center, New York, NY.<br />
957. Algorithm for Using a Bone Formation Marker PINP To<br />
Monitor the Response to Teriparatide (TPTD) in Patients with<br />
Glucocorticoid-Induced Osteoporosis (GIO). Nancy E. Lane 2 ,<br />
Kyoungah See 1 , Margaret Warner 1 and John H. Krege 1 , 1 Eli Lilly,<br />
Indianapolis, IN, 2 Univ <strong>of</strong> California at Davis, Hillsborough, CA.<br />
958. Anti-Hypertensive Therapy and Bone Mineral Density: Analysis<br />
in a Population-Based U.S. Sample. Mitsuyo Kinjo 3 , Soko<br />
Setoguchi 1 and Daniel Hal Solomon 2 , 1 Brigham and Women’s<br />
Hospital, 2 Brigham and Womens Hospital, Boston, MA,<br />
3<br />
Okinawa Chubu Hospital, Japan.<br />
959. Bone Density Following Long-Duration Spaceflight and<br />
Recovery. Shreyasee Amin 1 , Sara Achenbach 1 , Elizabeth<br />
Atkinson 1 , L. Joseph Melton 1 , Sundeep Khosla 1 and Jean<br />
Sibonga 2 , 1 Mayo Clinic, 2 NASA-Johnson Space Center.<br />
960. Bone Geometry Parameters among Black and White Women<br />
with SLE. Jimmy D. Alele 2 , Diane L. Kamen 2 , Kelly J. Hunt 2 , Gary<br />
S. Gilkeson 1 and Rosalind Ramsey-Goldman 3 , 1 Med Univ <strong>of</strong><br />
South Carolina, Charleston, SC, 2 Medical University <strong>of</strong> South<br />
Carolina, Charleston, SC, 3 Northwestern University, Chicago, IL.<br />
961. Cardiovascular Disease Is Associated with Increased Bone Loss<br />
and Fracture Risk: A Systematic Review <strong>of</strong> the Association<br />
between Cardiovascular Disease and Osteoporosis. Debby den<br />
Uyl 2 , Mike T. Nurmohamed 1 , Lilian H. D. van Tuyl 2 , Hennie G.<br />
Raterman 2 and Willem F. Lems 2 , 1 Department <strong>Rheumatology</strong>/<br />
Jan van Breemen Institute, Amsterdam, The Netherlands,<br />
2<br />
Department <strong>Rheumatology</strong>/VU University Medical Centre,<br />
Amsterdam, The Netherlands.<br />
962. Cholecalciferol High Dose Supplementation Should Be<br />
Preferred in Rheumatic Patients Independently to the<br />
Presence <strong>of</strong> an Autoimmune Disease. Mattia Bellan 3 , Pier<br />
Paolo Sainaghi 1 and Mario Pirisi 2 , 1 Immuno-<strong>Rheumatology</strong><br />
Outpatient Unit, DMCS, “A. Avogadro” University and IRCAD<br />
(Interdisciplinary Reseach Center <strong>of</strong> Autoimmune Diseases),<br />
Novara, Novara, Italy, 2 Immuno-<strong>Rheumatology</strong> Outpatient Unit,<br />
DMCS, “A. Avogadro” University and IRCAD (Interdisciplinary<br />
Reseach Center <strong>of</strong> Autoimmune Diseases), Novara, Italy,<br />
3<br />
Immuno-<strong>Rheumatology</strong> Outpatient Unit, DMCS, “A. Avogadro”<br />
University, Novara, Italy.<br />
963. Differences in the Observed Rate <strong>of</strong> Hip Fracture in Male and<br />
Female Patients Diagnosed with Osteoarthritis or Ankylosing<br />
Spondylitis Compared with the Expected Based on the<br />
General Population Seeking Health Care. Martin Englund 2 ,<br />
Jonas Franklin 3 and Ingemar F. Petersson 1 , 1 Lund University<br />
Hosp, Lund, Sweden, 2 Musculoskeletal Sciences, Department<br />
<strong>of</strong> Orthopedics, Clinical Sciences Lund, Lund University, Lund,<br />
Sweden, 3 University Hospital, Akureyri, Iceland.<br />
964. Effect <strong>of</strong> Oral Ibandronate on Bone Microarchitecture in<br />
Women with Osteopenia – A Randomized Placebo-Controlled<br />
Trial. Roland Chapurlat 2 , Michel Laroche 4 , Thierry Thomas 1 ,<br />
Stéphanie Rouanet 5 , Pierre D. Delmas 2 and Marie-Christine de<br />
Vernejoul 3 , 1 CHU St Etienne, Saint Etienne, France, 2 INSERM<br />
U831, Université de Lyon, Hôpital E Herriot, Lyon, France,<br />
3<br />
Lariboisière Hospital, Paris, France, 4 Pôle Institut Locomoteur<br />
Hôpital Purpan, Toulouse, France, 5 Roche France, Neuilly,<br />
France.<br />
965. Effects <strong>of</strong> Glucocorticoid on Osteocyte Autophagy In Vivo. Wei<br />
Yao 1 , Junjing Jia 1 , Weiwei Dai 1 , Min Guan 1 , Lynda Bonewald 3 and<br />
Nancy E. Lane 2 , 1 UC Davis Medical Center, 2 Univ <strong>of</strong> California at<br />
Davis, Hillsborough, CA, 3 Univ. <strong>of</strong> Missouri at Kansas City, School<br />
<strong>of</strong> Dentistry, Dept. <strong>of</strong> Oral Biology, Kansas City, MO.<br />
966. Fracture Epidemiology among a Cohort <strong>of</strong> HIV-Infected Adults<br />
in the UK: An Epidemiologic Study. Karen Walker-Bone 1 ,<br />
Reshad Malik 2 , Martin Fisher 2 , Yvonne Gilleece 2 and Amanda<br />
Samarawickrama 2 , 1 Brighton& Sussex Medical School, Brighton,<br />
East Sussex, United Kingdom, 2 Brighton & Sussex University<br />
Hospitals NHS Trust.<br />
206<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
967. Fracture Incidence, Quality <strong>of</strong> Life and Back Pain in Women<br />
with Osteoporosis and Concomitant Glucocorticoid Use<br />
Treated with Teriparatide: 36 Month Results from the<br />
European Forsteo Observational Study (EFOS). Willem Lems 9 ,<br />
Bente Langdahl 6 , Osten Ljunggren 7 , Annabel Barrett 2 , Dimitrios<br />
Karras 8 , James Bernard Walsh 4 , Astrid Fahrleitner-Pammer 3 ,<br />
Gerald Rajzbaum 5 , Clare Barker 2 , Franz Jakob 1 and Fernando<br />
Marin 2 , 1 Julius-Maximilians-Univ, Würzburg, Germany, 2 Lilly<br />
Research Ctr., Windlesham, UK, 3 Med Univ, Graz, Austria, 4 St<br />
James’s Hosp Trinity <strong>College</strong>, Dublin, Ireland, 5 St Joseph Hosp,<br />
Paris, France, 6 Univ Hosp, århus, Denmark, 7 Univ Hosp, Uppsala,<br />
Sweden, 8 Veterans Admin Hosp, Athens, Greece, 9 VU Univ Hosp,<br />
Amsterdam, Netherlands.<br />
968. Fracture Risk Assessment and Osteoporosis Treatment<br />
Disparities in 4027 Japanese Patients with Rheumatoid<br />
Arthritis. Takefumi Furuya 2 , Takayuki Hosoi 1 , Eisuke Inoue 3 ,<br />
Atuo Taniguchi 3 , Shigeki Momohara 3 and Hisashi Yamanaka 4 ,<br />
1<br />
Department <strong>of</strong> Clinical Research and Development,<br />
National Center for Geriatrics and Gerontology, 2 Institute <strong>of</strong><br />
<strong>Rheumatology</strong>, Tokyo Women’s Medical University, Tokyo,<br />
Japan, 3 Institute <strong>of</strong> <strong>Rheumatology</strong>, Tokyo Women’s Medical<br />
University, 4 Tokyo Women’s Medical University, Shinjuku-ku,<br />
Tokyo, Japan.<br />
969. Health Care Utilization Following a Fracture: Global<br />
Longitudinal Study <strong>of</strong> Osteoporosis in Women (GLOW).<br />
George Ioannidis 3 , Jonathan D. Adachi 2 , Laura Pickard 3 , Roland<br />
Chapurlat 4 , Kenneth G. Saag 5 , Stuart L. Silverman 1 , Julie Flahive 6<br />
and Stephen Gehlbach 6 , 1 Cedars-Sinai Medical Center, University<br />
<strong>of</strong> California Los Angeles, Beverly Hills, CA, 2 McMaster<br />
University, Hamilton, ON, Canada, 3 McMaster University,<br />
4<br />
Universite de Lyon, 5 University <strong>of</strong> Alabama-Birmingham,<br />
Birmingham, AL, 6 University <strong>of</strong> Massachusetts.<br />
970. High Adherence with Bisphosphonate Therapy in US Veterans<br />
with Rheumatoid Arthritis. J. Steuart Richards 10 , Grant W.<br />
Cannon 9 , Candace L. Hayden 8 , Richard L. Amdur 11 , Ted R.<br />
Mikuls 6 , Andreas Reimold 2 , Liron Caplan 3 , Dannette S. Johnson 5 ,<br />
Pascale Schwab 7 , Deana Lazaro 1 , Bogdan N. Cherascu 4 and Gail<br />
S. Kerr 11 , 1 Brooklyn NY VA Medical Center, New York, NY, 2 Dallas<br />
TX VA Medical Center, Dallas, TX, 3 Denver CO VA Medical Center,<br />
Denver, CO, 4 Iowa City IA VA Medical Center, Iowa City, 5 Jackson<br />
MS VA Medical Center, Jackson, MS, 6 Omaha NE VA Medical<br />
Center, Omaha, NE, 7 Portland OR VA Medical Center, Portland,<br />
OR, 8 Salt Lake City UT VA Medical Center, Salt Lake City, UT, 9 Salt<br />
Lake City VA Medical Center, Salt Lake City, UT, 10 Washington<br />
DC VA Medical Cener, Washington, DC, 11 Washington DC VA<br />
Medical Center, Washington, DC.<br />
971. Impact <strong>of</strong> Incident Clinical Vertebral Fractures on Back Pain<br />
Outcomes in Postmenopausal Women Who Participated in the<br />
FREEDOM Trial. Michael C. Nevitt 11 , Stuart L. Silverman 3 , Hema<br />
Viswanathan 1 , Yu-Ching Yang 1 , Andrea Wang 1 , Steven Boonen 2 ,<br />
Sergio Ragi-Eis 4 , Patrice Fardellone 9 , Andreas Grauer 1 , Nigel<br />
Gilchrist 5 , Paul Lips 12 , Santiago Palacios 8 , Karel Pavelka 6 , Dennis<br />
Revicki 10 , James Simon 13 , David Macarios 1 and Ethel Siris 7 ,<br />
1<br />
Amgen Inc., Thousand Oaks, CA, 2 Bone Research Unit, Leuven<br />
University, Leuven, Belgium, 3 Cedars-Sinai Medical Center,<br />
University <strong>of</strong> California Los Angeles, Beverly Hills, CA, 4 CEDOES<br />
Diagnóstico e Pesquisa, Vitória (ES), Brazil, 5 CGM Research<br />
Trust and Canterbury District Health Board, Christchurch, New<br />
Zealand, 6 Charles University, Prague, Czech Republic, 7 Columbia<br />
University Medical Center, New York, NY, 8 Palacios Institute <strong>of</strong><br />
Woman’s Health, Madrid, Spain, 9 Service de Rhumatologie,<br />
Hôpital Nord, INSERM ERI 12, Amiens, France, 10 United<br />
BioSource Corporation, Bethesda, MD, 11 University <strong>of</strong> California<br />
San Francisco, San Francisco, CA, 12 VU University Medical<br />
Center, Amsterdam, The Netherlands, 13 Women’s Health &<br />
Research Consultants®, Washington, DC.<br />
972. Incidence <strong>of</strong> Low Energy Hip Fracture in Southern Norway<br />
Significantly Lower Than Reported from the Capital <strong>of</strong> Norway<br />
(Oslo). Andreas Diamantopoulos 1 , Gudrun Rohde 2 , Irene<br />
Johnsrud 1 , Inger Marie Skoie 1 , Villy Johnsen 1 , Marc C. Hochberg 3<br />
and Glenn Haugeberg 1 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Soerlandet Hospital SSHF, Kristiansand, Norway, 2 Faculty <strong>of</strong><br />
Health and Sport, University <strong>of</strong> Agder, Kristiansand, Norway,<br />
3<br />
University <strong>of</strong> Maryland, Baltimore, MD.<br />
973. Increases in Macrophage Inhibitory Factor Correlate with<br />
Increases in Bone Mineral Density in Glucocorticoid-Treated<br />
Patients with RA. Jos Nicolaas Hoes 1 , Marlies C. Van der Goes 2 ,<br />
Johannes W. G. Jacobs 2 , Johannes W. J. Bijlsma 2 and Joel A. G.<br />
Van Roon 2 , 1 University Medical Center Utrecht, Department<br />
<strong>of</strong> <strong>Rheumatology</strong> & Clinical Immunology, Utrecht, The<br />
Netherlands, 2 University Medical Center Utrecht, Department <strong>of</strong><br />
<strong>Rheumatology</strong> & Clinical Immunology.<br />
974. Low Bone Mineral Density in Depoprovera Users – An Under<br />
Recognised Health Issue. Mani Nallasivan 1 and Tim Gillott 2 ,<br />
1<br />
Diana Princess <strong>of</strong> Wales Hospital, Northern Lincolnshire and<br />
Goole Hospitals NHS Trust, Hull, Yorkshire, United Kingdom,<br />
2<br />
Diana Princess <strong>of</strong> Wales Hospital, Northern Lincolnshire and<br />
Goole Hospitals NHS Trust, Grimsby, Northeast Lincolnshire,<br />
United Kingdom.<br />
975. National Registry <strong>of</strong> Paget Disease <strong>of</strong> Bone. Estibaliz Loza, Nuria<br />
Guañabens, Maria Jesus Garcia de Yebenes, Antonio Morales,<br />
Javier Del Pino, Antonio Torrijos, Jesus Garrido, Jesus Tornero,<br />
Jorge Malouf, Jordi Carbonell and Manuel Rodriguez, Spanish<br />
Society <strong>of</strong> <strong>Rheumatology</strong>.<br />
976. Prevalence <strong>of</strong> Osteoporosis and Osteoporotic Fractures:<br />
A Population Based Survey Including Vertebral Fracture<br />
Assessment by Morphometry (VFA). Liana E. Euller-Ziegler 1 ,<br />
Christian H. Roux 1 , Veronique Breuil 1 , Virginie Dasilva 1 , Christine<br />
Albert-Sabonnadiere 1 , Christian Grisot 1 , Philippe Flory 1 , Yacine<br />
Allam 1 , Hasna Chami 1 , Gerard Ziegler 1 and Pascal Staccini 2 ,<br />
1<br />
L’Archet Hospital, University <strong>of</strong> Nice, Nice, France, 2 Labstic<br />
Santé, University <strong>of</strong> Nice, Nice, France.<br />
977. Proactively Contacting Men with Prostate Cancer Treated<br />
with Anti-Androgen Medications Improves the Evaluation and<br />
Treatment <strong>of</strong> Osteoporosis. Brian P. Oppermann 1 , Thomas M.<br />
Harrington 2 and William Ayoub 3 , 1 Geisinger Medical Center,<br />
Danville, PA, 2 Geisinger Medical Center, Danville PA, 3 Geisinger<br />
Medical Group, Scenary Park PA.<br />
978. Quality Assurance Study <strong>of</strong> the Use <strong>of</strong> Preventative Therapies<br />
in Glucocorticord Induced Osteoporosis (GIOP) in Early<br />
Inflammatory Arthritis (EIA): Results from the CATCH Cohort.<br />
Emily McKeown 10 , Vivian P. Bykerk 5 , Faye Deleon 4 , J. Carter<br />
Thorne 6 , Carol A. Hitchon 8 , Gilles Boire 2 , Boulos Haraoui 3 ,<br />
Diane S. Ferland 1 , Ed C. Keystone 9 and Janet E. Pope 7 , 1 LaSalle,<br />
QC, Canada, 2 CHUS - Sherbrooke University, Sherbrooke, QC,<br />
Canada, 3 Institut de Rhumatologie, Montreal, QC, Canada,<br />
4<br />
McMaster University, Hamilton, ON, Canada, 5 Mt Sinai<br />
Hospital, Toronto, ON, Canada, 6 Southlake Regional Health<br />
Care, Newmarket, ON, Canada, 7 St Joseph Health Care London,<br />
London, ON, Canada, 8 University <strong>of</strong> Manitoba, Winnipeg,<br />
MB, Canada, 9 University <strong>of</strong> Toronto, Toronto, ON, Canada,<br />
10<br />
University <strong>of</strong> Western Ontario, London, ON, Canada.<br />
979. Relationships between Changes in Bone Mineral Density or<br />
Bone Turnover Markers and Vertebral Fractures Incidence<br />
in Patients Treated with Bazedoxifene. Olivier Bruyere 2 ,<br />
Johann Detilleux 3 , Arkadi Chines 1 and Jean Y. Reginster 2 , 1 Pfizer,<br />
2<br />
University <strong>of</strong> Liege, Liege, Belgium, 3 University <strong>of</strong> Liege.<br />
2010 Program Book 207
ACR Poster Session B<br />
208<br />
980. The Direct Assessment <strong>of</strong> Nonvertebral Fractures in<br />
Community Experience (DANCE) Study: 2-Year Nonvertebral<br />
Fragility Fracture Results. Stuart L. Silverman 2 , Paul Miller 4 ,<br />
Anthony I. Sebba 1 , Michael Weitz 3 , Xiaohai Wan 5 , Kathleen<br />
Taylor 5 , Valerie Ruff 5 and Kelly D. Krohn 6 , 1 Arthritis Associates,<br />
Palm Harbor, FL, 2 Cedars-Sinai Medical Center, University <strong>of</strong><br />
California Los Angeles, Beverly Hills, CA, 3 Center Arthritis and<br />
<strong>Rheumatology</strong>, South Miami, FL, 4 Colorado Center for Bone<br />
Research, Lakewood, CO, 5 Eli Lilly and Company and/or One <strong>of</strong><br />
Its Subsidiaries, Indianapolis, IN, 6 Lilly USA, LLC, Indianapolis, IN.<br />
981. The Effects <strong>of</strong> Biologics on Bone Metabolism <strong>of</strong> Patients with<br />
Rheumatoid Arthritis. Tadashi Okano, Masahiro Tada, Shigeyuki<br />
Wakitani, Hiroaki Nakamura and Tatsuya Koike, Osaka City Univ<br />
Med School, Osaka, Japan.<br />
982. The Effects <strong>of</strong> Denosumab (DMAb) on Bone Mineral Density<br />
(BMD), Fracture and Safety Outcomes by Level <strong>of</strong> Renal<br />
Function. Sophie A. Jamal 8 , Peter R. Ebeling 7 , Osten Ljunggren 9 ,<br />
Catherine Stehman-Breen 1 , Steven R. Cummings 5 , Michael R.<br />
McClung 4 , Stefan Goemaere 3 , Edward Franek 2 , Yu-Ching Yang 1 ,<br />
Ogo I. Egbuna 1 and Paul Miller 6 , 1 Amgen Inc., Thousand Oaks,<br />
CA, 2 Central Clinical Hospital, Warsaw, Poland, 3 Ghent University<br />
Hospital, Belgium, 4 Oregon Osteoporosis Center, Portland, OR,<br />
5<br />
San Francisco Coordinating Center, CPMC Research Institute<br />
and University <strong>of</strong> California, San Francisco, San Francisco, CA,<br />
6<br />
University <strong>of</strong> Colorado Health Sciences Center, CO, 7 University<br />
<strong>of</strong> Melbourne, Melbourne, Australia, 8 University <strong>of</strong> Toronto,<br />
Toronto, ON, Canada, 9 Uppsala University Hospital, Sweden.<br />
983. The Serum Level <strong>of</strong> Undercarboxylated Osteocalcin (ucOC)<br />
in Patients with Rheumatoid Arthritis – A High Dose<br />
<strong>of</strong> Predonisolone Decrease the Serum Level <strong>of</strong> ucOC.<br />
Yoshitada Sakai 2 , Akira Hashiramoto 4 , Teppei Hashimoto 4 ,<br />
Yoshiko Kawasaki 4 , Chihiro Tanaka 4 , Shunichi Shiozawa 3 and<br />
Masahiro Kurosaka 1 , 1 Department <strong>of</strong> Orthopaedic Surgery,<br />
Kobe University Graduate School <strong>of</strong> Medicine, 2 The Center <strong>of</strong><br />
Rheumatic Diseases, Kobe University Hospital, Kobe, Hyogo,<br />
Japan, 3 The Center <strong>of</strong> Rheumatic Diseases, Kobe University<br />
Hospital, Kobe, Japan, 4 The Center <strong>of</strong> Rheumatic Diseases, Kobe<br />
University Hospital.<br />
Quality Measures and Innovation in Practice Management and<br />
Care Delivery<br />
984. “Early Arthritis: Early Act”. A Community-Based Knowledge<br />
Transfer Program To Improve Ability <strong>of</strong> General Practitionner<br />
to Rapidly Detect and Refer to the Rheumatologist Patients<br />
with Early Arthritis. Bruno Fautrel 3 , Patrick Froger 1 , Cecile<br />
Gaujoux-Viala 2 and Eric Leutenegger, 1 Lyon, France, 2 Paris,<br />
France, 3 Pitie Salpetriere Hospital, Paris, France.<br />
985. A Checklist <strong>of</strong> 10 Measures, 6 from a Patient Questionnaire<br />
& 4 Physician Global Scores, Requiring
ACR Poster Session B<br />
993. Early Experience with the <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />
(ACR) <strong>Rheumatology</strong> Clinical Registry (RCR). Salahuddin<br />
Kazi 2 , Elizabeth A. Tindall 3 , Kristen McNiff 1 and Itara Barnes 1 ,<br />
1<br />
<strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong>, Atlanta, GA, 2 Arthritis<br />
Consultation Center, Dallas, TX, 3 Oregon Health & Science<br />
University, West Linn, OR.<br />
994. Evaluating Adherence to Quality Indicators in Prevention<br />
<strong>of</strong> Glucocorticoid Induced Osteoporosis in Patients at the<br />
Veterans Affairs in Lexington. Magdalena Winiarska 1 , Joseph<br />
Conigliaro 2 , Heather Bush 2 , Lucia Hardi 1 , Elnaz N Tabrizi 1 and<br />
Leslie J. Cr<strong>of</strong>ford 3 , 1 Univ <strong>of</strong> Kentucky, Lexington, KY, 2 Univ <strong>of</strong><br />
Kentucky, 3 Univ <strong>of</strong> KY, Lexington, KY.<br />
995. Formal Joint Counts Are Performed at More Than 50% <strong>of</strong> Visits<br />
<strong>of</strong> Patients with Rheumatoid Arthritis in Usual Care outside<br />
<strong>of</strong> Clinical Research, by 64% <strong>of</strong> European Rheumatologists<br />
in 2010 Compared to 44% in 2003. Theodore Pincus 2 , Ed C.<br />
Keystone 4 , Marc de Longueville 3 and Sophie Costello 1 , 1 Costello<br />
Medical Consulting, 2 New York University Hospital for Joint<br />
Disease, Hastings-on-Hudson, NY, 3 UCB Pharma, 4 University <strong>of</strong><br />
Toronto, Toronto, ON, Canada.<br />
996. Frequency <strong>of</strong> PAP Smears among Lupus Patients – A Patient<br />
Report Survey. Eileen J. Lydon and H. Michael Belmont,<br />
NYUHJD, New York, NY.<br />
997. Impact <strong>of</strong> a Screening Protocol with Added Thoracic CT and<br />
Quantiferon on Prophylactic Treatment <strong>of</strong> Latent Tuberculosis<br />
in Anti-TNFa Candidate Patients. Nathalie Saidenberg-<br />
Kermanac’h 3 , Luca Semerano 4 , Jean-Marc Naccache 1 , Michel<br />
Brauner 2 , Géraldine Falgarone 4 , Dominique Dumont-Fischer 4 ,<br />
Xavier Guillot 4 and Marie-Christophe Boissier 4 , 1 Department<br />
<strong>of</strong> Pneumology, Avicenne Hospital (AP-HP), Bobigny, France,<br />
2<br />
Department <strong>of</strong> Radiology, Avicenne Hospital (AP-HP), Bobigny,<br />
France, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Avicenne Hospital (AP-<br />
HP), Bobigny, Bobigny, France, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Avicenne Hospital (AP-HP), Bobigny, France, EA 4222 , Paris- 13<br />
University, France.<br />
998. Implementation <strong>of</strong> an Electronic Interface for Medical Record<br />
Documentation in an Academic Pediatric <strong>Rheumatology</strong><br />
Outpatient Clinic. Jennifer M. P. Woo 2 , Miriam F. Parsa 2 , Gil<br />
Amarilyo 2 , Nasim Afsarmanesh 1 , Kerry T. Gallagher 2 , Ornella<br />
J. Rullo 2 and Deborah K. McCurdy 2 , 1 Division <strong>of</strong> Internal<br />
Medicine and Neurosurgery-Medicine; Hospital Medicine and<br />
Neurosurgical Clinical Quality Programs, UCLA, Los Angeles, CA,<br />
2<br />
Division <strong>of</strong> Pediatric <strong>Rheumatology</strong>, UCLA, Los Angeles, CA.<br />
999. Inpatient HiROC (High Risk Osteoporosis Clinic): Improving<br />
Osteoporosis Care Post Fracture. Gwynne L. Maloney-Saxon 2 ,<br />
Thomas P. Olenginski 3 , Cynthia K. Matzko 2 , Haiyan Sun 1 , Karen<br />
Mackiewicz 4 and Eric D. Newman 2 , 1 Center for Health Research,<br />
Danville, PA, 2 Geisinger Medical Center, Danville, PA, 3 Geisinger<br />
Medical Center, Danville, PA, 4 Geisinger Medical Center,<br />
Davnille, PA.<br />
1000. Lipid and C-Reactive Protein Screening Thresholds and CVD<br />
Risk in a Community Lupus Cohort. Christie M. Bartels 4 , Kevin<br />
Buhr 5 , Jerry Goldberg 2 , Carolyn Bell 3 and Robert Greenlee 1 ,<br />
1<br />
Marshfield Clinic Research Foundation, 2 Marshfield Clinic<br />
<strong>Rheumatology</strong>, 3 Univ <strong>of</strong> Wisconsin School <strong>of</strong> Medicine and<br />
Public Health, Dept <strong>of</strong> Medicine, <strong>Rheumatology</strong>, 4 Univ <strong>of</strong><br />
Wisconsin School <strong>of</strong> Medicine and Public Health, Dept <strong>of</strong><br />
Medicine, <strong>Rheumatology</strong>, Madison, WI, 5 University <strong>of</strong> Wisconsin<br />
Department <strong>of</strong> Biostatistics.<br />
1001. Measuring the Impact <strong>of</strong> Patient Educational Materials about<br />
Medications in Meeting Patient Needs: Development and<br />
Validation <strong>of</strong> the Medication Education Impact Questionnaire<br />
(MeiQ). Sabina Ciciriello 3 , Rachelle Buchbinder 1 , Ian Wicks 4<br />
and Richard H. Osborne 2 , 1 Cabrini Medical Center, Malvern,<br />
Australia, 2 Deakin University, Melbourne, Australia, 3 Royal<br />
Melbourne Hospital, Melbourne, Victoria, Australia, 4 Royal<br />
Melbourne Hospital, Melbourne, Australia.<br />
1002. Multispecialty Unit for Infusion Therapy: Patient, Nursing and<br />
Provider Satisfaction. Barbara E. Ostrov, Kristine Reynolds and<br />
Lisabeth V. Scalzi, Penn State Hershey, Hershey, PA.<br />
1003. Rheumatoid Arthritis (RA) Disease Activity Assessment and<br />
Treatment Decisions in <strong>Rheumatology</strong> Practice. J. Timothy<br />
Harrington 6 , Leslie R. Harrold 4 , George Reed 5 , Hong Chang 3 , Joel<br />
M. Kremer 2 and Jeffrey D. Greenberg 1 , 1 Millburn, NJ, 2 The Center<br />
for <strong>Rheumatology</strong>, Albany, NY, 3 Tufts Medical School, 4 UMass<br />
Medical Schl, Worcester, MA, 5 UMass Medical Schl, 6 University<br />
<strong>of</strong> Wisconsin, Madison, WI.<br />
1004. Scleroderma QuERI: Reduced Utility <strong>of</strong> Echocardiography in<br />
Pulmonary Hypertension Screening in the Community. James<br />
R. Seibold 6 , Amparo Casanova 1 , Mary Tan 1 , Daniel E. Furst 5 ,<br />
Nicholas Hill 4 , Vallerie V. McLaughlin 7 , Richard M. Silver 3 , Virginia<br />
D. Steen 2 and Anatoly Langer 1 , 1 Canadian Heart Research<br />
Centre, 2 Georgetown University Medical Center, Washington,<br />
DC, 3 Medical University <strong>of</strong> South Carolina, Charleston, SC, 4 Tufts<br />
Medical Center, 5 University <strong>of</strong> California Los Angeles Medical<br />
School, Los Angeles, CA, 6 University <strong>of</strong> Connecticut Health<br />
Center, Farmington, CT, 7 University <strong>of</strong> Michigan.<br />
1005. Secondary Fracture Prevention in Home Health Care: Initial<br />
Results from a Group Randomized Trial. Meredith L. Kilgore 2 ,<br />
Jeffrey R. Curtis 4 , Ryan C. Outman 5 , Julie Locher 1 , Jeroan Allison 3<br />
and Kenneth G. Saag 5 , 1 Univ <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, 2 Univ <strong>of</strong> Alabama at Birmingham, 3 Univ<br />
<strong>of</strong> Massachusetts, Worcester, MA, 4 University <strong>of</strong> Alabama<br />
- Brimingham, Birmingham, AL, 5 University <strong>of</strong> Alabama-<br />
Birmingham, Birmingham, AL.<br />
1006. Self-Scheduling <strong>of</strong> DXA Scans To Improve Osteoporosis<br />
Screening in Women. Amy H. Warriner 2 , Ryan C. Outman 5 ,<br />
Kenneth G. Saag 5 , Sarah L. Morgan 1 , Elizabeth Kitchin 3 and<br />
Jeffrey R. Curtis 4 , 1 U <strong>of</strong> Alabama in Birm, Birmingham, AL, 2 Univ<br />
<strong>of</strong> Alabama at Birmingham, 3 Univ <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, 4 University <strong>of</strong> Alabama - Brimingham,<br />
Birmingham, AL, 5 University <strong>of</strong> Alabama-Birmingham,<br />
Birmingham, AL.<br />
1007. Spanning Generations: Appointment Reminder Preferences<br />
among Outpatient <strong>Rheumatology</strong> Patients. Carl Gauthier 3 ,<br />
William E. Davis 2 and Robert J. Quinet 1 , 1 Ochsner Med Ctr-New<br />
Orleans, New Orleans, LA, 2 Ochsner Med-Ctr-New Orleans, New<br />
Orleans, LA, 3 Ochsner Med-Ctr-New Orleans, Hammond, LA.<br />
1008. Survey <strong>of</strong> Teen Transition Needs among Pediatric<br />
Rheumatologists in the United States and Canada: Barriers,<br />
Services and Opportunities. Tova Ronis 3 , Stacy P. Ardoin 2 ,<br />
Patience H. White 1 and Peter Chira 3 , 1 Arthritis Foundation,<br />
Bethesda, MD, 2 Ohio State University, Columbus, OH, 3 Stanford<br />
University, Palo Alto, CA.<br />
1009. Testing Patient Knowledge about Methotrexate: Development<br />
and Validation <strong>of</strong> the Methotrexate in Rheumatoid Arthritis<br />
Knowledge Test (MiRAK). Sabina Ciciriello 3 , Ian Wicks 4 , Richard<br />
H. Osborne 2 and Rachelle Buchbinder 1 , 1 Cabrini Medical Center,<br />
Malvern, Australia, 2 Deakin University, Melbourne, Australia,<br />
3<br />
Royal Melbourne Hospital, Melbourne, Victoria, Australia,<br />
4<br />
Royal Melbourne Hospital, Melbourne, Australia.<br />
2010 Program Book 209
ACR/ARHP Poster Session B<br />
210<br />
1010. The Impact <strong>of</strong> the ACR Treatment Recommendations on<br />
Physician Prescribing in a U.S. Cohort <strong>of</strong> Rheumatoid Arthritis<br />
Patients. Leslie R. Harrold 3 , Jeffrey D. Greenberg 1 , Jeffrey R.<br />
Curtis 5 , Daniel E. Furst 6 , Mary Jane Bentley 4 , Ying Shan 4 , George<br />
Reed and J. Timothy Harrington 7 , 1 Millburn, NJ, 3 UMass Medical<br />
Schl, Worcester, MA, 4 Umass Medical School, 5 University<br />
<strong>of</strong> Alabama - Brimingham, Birmingham, AL, 6 University <strong>of</strong><br />
California Los Angeles Medical School, Los Angeles, CA,<br />
7<br />
University <strong>of</strong> Wisconsin, Madison, WI.<br />
1011. The Preliminary Testing <strong>of</strong> a Core Set To Monitor SLE Patients<br />
in Routine Clinical Practice. Marta Mosca 6 , Chiara Tani 6 ,<br />
Federico Quaglierini 6 , Katia Goehner 5 , Joao Matos Costa 2 , Oskar<br />
Psenak 3 , Magdalena Szmyrka-Kaczmarek 7 , Jan Sznajd 4 , Nuntana<br />
Kasitanon 1 and Stefano Bombardieri 6 , 1 Chiang Mai, University,<br />
Thailand, 2 Hospital de Santarem, Portugal, 3 Saltzbugr University,<br />
Austria, 4 University Hospital, Krakow, Poland, 5 University<br />
Hospital, Zurich, Switzerland, 6 University <strong>of</strong> Pisa, Italy, 7 Wroclaw<br />
University, Poland.<br />
1012. The Use <strong>of</strong> Electronic Health Record To Improve Tuberculosis<br />
Screening in Pediatric <strong>Rheumatology</strong> Patients Receiving<br />
Biologic Response Modifiers. David W. Moser 4 , Elaine Haddix 5 ,<br />
Mary Beth Burns 5 , James Brown 3 , Anna Carmela P. Sagcal-<br />
Gironella 4 , Thomas A. Griffin 1 , Hermine Brunner 2 and Esi M.<br />
Morgan DeWitt 6 , 1 Childrens Hospital Med Ctr, Cincinnati, OH,<br />
2<br />
Cincinnati Child Hosp Med Ctr, Cincinnati, OH, 3 Cincinnati<br />
Children’s Hospital, 4 Cincinnati Children’s Hospital Medical<br />
Center, Cincinnati, OH, 5 Cincinnati Children’s Hospital Medical<br />
Center, 6 Cincinnati Children’s Hospital, Cincinnati, OH.<br />
1013. Treating Rheumatoid Arthritis to Target: Multinational<br />
Recommendations Assessment Questionnaire. Boulos<br />
Haraoui 13 , Josef S. Smolen 18 , Daniel Aletaha 21 , Ferdinand<br />
C. Breedveld 4 , Maarten de Wit 25 , Maxime Dougados 8 , Paul<br />
Emery 2 , Allan Gib<strong>of</strong>sky 9 , Desiree M. Van Der Heijde 19 , Gerd R.<br />
Burmester 3 , Mario Cardiel-Rios 7 , Catalin Codreanu 1 , Patrick<br />
Durez 23 , Joao Eurico Fonseca 11 , Winfried B. Graninger 20 , Verdat<br />
Hamuryudan 12 , Maria Jose Jannaut-Pena, Jochen Kalden 14 , Tore<br />
K. Kvien 5 , Ieda Laurindo 6 , Carlomaurizio Montecucco 16 , Jose A.<br />
Pereira Da Silva 24 , Guyla Poor 22 , Pedro Ivan Santos Moreno 10 ,<br />
Ewa Stanislawska-Biernat 15 , Tsutomu Takeuchi 17 and and the<br />
Treat to Target Taskforce, 1 Center <strong>of</strong> Rheumatic Diseases,<br />
Bucharest, Romania, 2 Chapel Allerton Hospital, Leeds, United<br />
Kingdom, 3 Charite - University Medicine, Berlin, Germany,<br />
4<br />
Dept. <strong>of</strong> <strong>Rheumatology</strong>, Leiden University, Medical Centre,<br />
Leiden, The Netherlands, 5 Diakonhjemmet Hospital, Oslo,<br />
Norway, 6 Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Sao Paolo,<br />
Brazil, 7 Facultad de Ciencias Medicas y Bioplogicas Dr. Ignacio<br />
Chavez UMSNH, Morelia, Michoacan, Mexico, 8 Hospital Cochin,<br />
Paris, France, 9 Hospital for Special Surgery, New York, NY,<br />
10<br />
Hospital Militar Central, Bogota, Colombia, 11 Hospital Santa<br />
Maria, Lisboa, Portugal, 12 Instanbul University, Cerrahpasa<br />
Medical School, Istanbul, Turkey, 13 Institut de Rhumatologie,<br />
Montreal, QC, Canada, 14 Institute for Clinical Immunology,<br />
Erlangen, Germany, 15 Institute <strong>of</strong> <strong>Rheumatology</strong>, Warszawa,<br />
Poland, 16 IRCCS Policlinico S Matteo, Pavia, Italy, 17 Keio<br />
University, Toyko, Japan, 18 Krankenhaus Lainz, Vienna, Austria,<br />
19<br />
Leiden University Medical Center, Meerssen, The Netherlands,<br />
20<br />
Medical University <strong>of</strong> Graz, Graz, Austria, 21 Medical University<br />
<strong>of</strong> Vienna, Vienna, Austria, 22 National Institute <strong>of</strong> <strong>Rheumatology</strong><br />
and Physiotherapy, Budapest, Hungary, 23 Universite Catholique<br />
de Louvain, Brussels, Belgium, 24 University <strong>of</strong> Coimbra, Protuga,<br />
Algés, Portugal, 25 VU Medical Centre, Department <strong>of</strong> Medical<br />
Humanities, Amsterdam, The Netherlands.<br />
2010 Program Book<br />
1014. Using an Electronic Data Capture System To Measure<br />
Outcomes in Patients on Biologic DMARD Therapy: The<br />
<strong>Rheumatology</strong> Health Tracker (RHT). Sita A. Narayanan 1 , Jeffrey<br />
R. Lisse 2 , Alexis A. Alvarez 4 , Catherine Lo, Rafael G. Grau 3 , Eric P.<br />
Gall 2 and Oscar Furet 4 , 1 Univ <strong>of</strong> Arizona, Tucson, AZ, 2 Univ <strong>of</strong> AZ<br />
Arthritis Ctr, Tucson, AZ, 3 Univ <strong>of</strong> AZ Arthritis Ctr, Indianapolis,<br />
IN, 4 Univ <strong>of</strong> AZ Arthritis Ctr.<br />
Rheumatoid Arthritis - Clinical Aspects: Clinical Features, Disease<br />
Risk Factors, Bone in RA, CVD II<br />
1015. Anti-Cyclic Citrullinated Peptide Antibodies in Rheumatoid<br />
Arthritis Patients with Lymphoma. Eva Baecklund 10 , Karin<br />
Ekström Smedby 3 , Carin Backlin 5 , Johan Rönnelid 2 , Erik Åhlin 2 ,<br />
Rene Toes 6 , Johan Askling 4 , Ephraim Hochberg 1 , Mandakolathur<br />
Murali 7 , Lars Klareskog 8 , Tom Huizinga 9 , Fred Hochberg 1 and<br />
Jonathan Kay 11 , 1 Cancer Center, Massachusetts General Hospital,<br />
Boston, 2 Clinical Immunology, Uppsala University, 3 Epidemiology<br />
Unit, Karolinska Institutet at Karolinska University Hospital,<br />
Stockholm, 4 Epidemiology, <strong>Rheumatology</strong>, Karolinska Institutet<br />
at Karolinska University Hospital, Stockholm, 5 Genetics and<br />
Pathology, Uppsala University, 6 Immunology, Leiden University<br />
Medical Center, 7 Immunology, Massachusetts General<br />
Hospital, Boston, 8 Karolinska University Hospital, Stockholm,<br />
Sweden, 9 <strong>Rheumatology</strong>, Leiden University Medical Center,<br />
10<br />
<strong>Rheumatology</strong>, Medical Sciences, Uppsala University, Uppsala,<br />
Sweden, 11 UMass Memorial Medical Center, Worcester, MA.<br />
1016. Assessment <strong>of</strong> Cardiovascular Risk in Rheumatoid Arthritis.<br />
Impact <strong>of</strong> the New EULAR Recommendations. Montserrat<br />
Robustillo, Carmen Gomez-Vaquero, Javier Narváez, Jesus<br />
Rodriguez-Moreno, Paula Estrada, Laura López-Vives and<br />
Joan M. Nolla, <strong>Rheumatology</strong> Service. Hospital Universitari de<br />
Bellvitge.<br />
1017. Association between Serum Osteoprotegerin Levels and<br />
Carotid Atherosclerotic Plaque in Patients with Rheumatoid<br />
Arthritis. Yu Asanuma, Yuki Shimada and Toshihide Mimura,<br />
Department <strong>of</strong> <strong>Rheumatology</strong> and Applied Immunology, Faculty<br />
<strong>of</strong> Medicine, Saitama Medical University.<br />
1018. Body Composition Trends in Patients with Rheumatoid<br />
Arthritis: Associations with Disease Characteristics and<br />
Inflammatory Markers. Henry R. Kramer 1 , Joan M. Bathon 1<br />
and Jon T. Giles 2 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, Johns Hopkins<br />
University, Baltimore, MD, 2 Johns Hopkins Univ, Baltimore, MD.<br />
1019. Cardiovascular Risk Estimates in Rheumatoid Arthritis in<br />
the Netherlands. Inger L. Meek 3 , Harald E. Vonkeman 2 and<br />
Mart A. F. J. van de Laar 1 , 1 Enschede, The The Netherlands,<br />
2<br />
Enschede, The Netherlands, 3 <strong>Rheumatology</strong> Centre Twente,<br />
University Twente & Medisch Spectrum Twente, Enschede, The<br />
Netherlands.<br />
1020. Circulating Immune Complexes in Patients with Severe<br />
Extra-Articular Rheumatoid Arthritis Induce Tumour Necrosis<br />
Factor Production by Peripheral Blood Mononuclear Cells.<br />
Carl Turesson 1 , Linda Mathsson 3 , Lennart Jacobsson 1 , Gunnar<br />
Sturfelt 2 and Johan Rönnelid 3 , 1 Skåne University Hospital,<br />
Malmö, Sweden, 2 Skåne University Hospital, Lund, Sweden,<br />
3<br />
Uppsala University Hospital, Uppsala, Sweden.<br />
1021. Clinical and Laboratory Risk Factors <strong>of</strong> Cardiovascular<br />
Disease (CVD) in a Cohort <strong>of</strong> Greek Patients with Early<br />
Rheumatoid Arthritis (RA). Nikolaos Papadopoulos 3 , Georgios<br />
Tsiaousis 2 , Marios Katsounaros 1 , Dimitrios Baltzis 3 and Vasiliki<br />
Galanopoulou 3 , 1 B’ Internal Medicine Clinic, Papanikolaou<br />
General Hospital, Thessaloniki, Greece, 2 Cardiologist, Kastoria,<br />
Greece, 3 <strong>Rheumatology</strong> Unit, Papageorgiou General Hospital,<br />
Thessaloniki, Thessaloniki, Greece.
ACR/ARHP Poster Session B<br />
1022. Computed Tomographic Densitometry (CTD) for the Evaluation<br />
<strong>of</strong> Interstitial Lung Fibrosis in Rheumatoid Arthritis (RA).<br />
Dimitrios A. Pappas 3 , Jon T. Giles 4 , Ge<strong>of</strong>frey Connors 2 , Noah<br />
Lechtzin 2 , Joan M. Bathon 3 and Sonye Dan<strong>of</strong>f 1 , 1 Division<br />
<strong>of</strong> Pulmonary and Critical Care, Johns Hopkins University,<br />
Baltimore, MD, 2 Division <strong>of</strong> Pulmonary and Critical Care, Johns<br />
Hopkins University, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Johns Hopkins<br />
University, Baltimore, MD, 4 Johns Hopkins Univ, Baltimore, MD.<br />
1023. Cystatin C, Renal Function and Atherosclerosis in Rheumatoid<br />
Arthritis. Ratchaya Lertnawapan 2 , Aihua Bian 2 , Yong Hee Rho 2 ,<br />
Vivian Kawai 2 , Paolo Raggi 1 , Annette Oeser 2 , Joseph Solus 2 ,<br />
Tebeb Gebretsadik 2 , Ayumi Shintani 2 and Charles Michael Stein 2 ,<br />
1<br />
Emory University, Atlanta, GA, 2 Vanderbilt University, Nashville,<br />
Nashville, TN.<br />
1024. Depressive Symptoms and Perceived Communication around<br />
Shared Decision Making among Patients with Rheumatoid<br />
Arthritis. Jennifer L. Barton 1 , Laura Trupin 2 , Mary E.<br />
Margaretten 1 , Laura J. Julian 5 , Jonathan D. Graf 1 , John Imboden 2 ,<br />
Edward H. Yelin 4 and Dean Schillinger 3 , 1 UCSF, San Francisco, CA,<br />
2<br />
UCSF, 3 UCSF, Center for Vulnerable Populations at San Francisco<br />
General Hospital, 4 University <strong>of</strong> California, San Francisco, CA,<br />
5<br />
University <strong>of</strong> California San Francisco, San Francisco, CA.<br />
1025. Differences in the Autonomic Reactivity Pattern upon<br />
Various Stressors in Patients with Rheumatoid Arthritis. Olga<br />
Malysheva 2 , Petra Baum 2 , Anke Voitzsch 1 and Christoph G. O.<br />
Baerwald 2 , 1 University Hopital, Leipzig, Germany, 2 University<br />
Hospital, Leipzig, Germany.<br />
1026. Disease Specific Cardiovascular Risk Factors in Patients with<br />
Rheumatic Diseases. Stefan Kleinert 2 , Margret Breunig 1 , Hans<br />
Peter T. Tony 3 , Martin Feuchtenberger 4 , Stefanie Bouma 1 ,<br />
Angermann E. Christiane 1 , Georg Ertl 1 and Stefan Stoerk 1 ,<br />
1<br />
Department <strong>of</strong> Cardiology, Med. Klinik 1 , University <strong>of</strong><br />
Wuerzburg, 2 <strong>Rheumatology</strong> / Clinical Immunology, Med. Klinik 2 ,<br />
University <strong>of</strong> Wuerzburg, Wuerzburg, Germany, 3 <strong>Rheumatology</strong><br />
/ Clinical Immunology, Med. Klinik 2 , University <strong>of</strong> Wuerzburg,<br />
Wuerzburg, Germany, 4 <strong>Rheumatology</strong> / Clinical Immunology,<br />
Med. Klinik 2 , University <strong>of</strong> Wuerzburg.<br />
1027. Do Men and Women Cope Differently with Disease Impact <strong>of</strong><br />
Rheumatoid Arthritis, and If So, Why? Matthias Englbrecht 2 ,<br />
Laure Gossec 1 , Anita DeLongis 3 , Tore K. Kvien 4 , Marieke<br />
Scholte-Voshaar 6 , Tuulikki Sokka 5 and Schett Georg 2 , 1 APHP,<br />
<strong>Rheumatology</strong> B Department, Paris Descartes University,<br />
Medicine Faculty, Paris, France, 2 Department <strong>of</strong> Internal<br />
Medicine 3 , University <strong>of</strong> Erlangen-Nuremberg, Erlangen,<br />
Germany, 3 Department <strong>of</strong> Psychology, University <strong>of</strong> British<br />
Columbia, Vancouver, Canada, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Diakonhjemmet Hospital, Oslo, Norway, 5 Jyvaskyla Central<br />
Hospital, Jyvaskyla, Finland, 6 <strong>Rheumatology</strong>, VU University<br />
Medical Center and Jan van Breemen Institute, Amsterdam,<br />
Netherlands.<br />
1028. Effects <strong>of</strong> HMG-CoA Reductase Inhibitor on Progression <strong>of</strong><br />
Carotid Intima-Media Thickness and Arterial Stiffness in<br />
Rheumatoid Arthritis – A Randomized Controlled Trial. Lai-<br />
Shan Tam 3 , Edmund K. Li 2 , Qing Shang 3 , Brian Tomlinson 3 , Vivian<br />
W. Lee 3 , Kenneth K. Lee 3 , Martin Li 3 , Woon-Pang Kuan 1 , Tena K.<br />
Li 3 , Lorraine Tseung 3 , Gabriel Yip 3 , Ben Freedman 4 and Cheuk-<br />
Man Yu 3 , 1 Hospital Selayang, Malaysia, 2 The Chinese University<br />
<strong>of</strong> Hong Kong, Hong Kong, China, 3 The Chinese University <strong>of</strong><br />
Hong Kong, 4 University <strong>of</strong> Sydney.<br />
1029. Elevated Prevalence <strong>of</strong> Hypothyroidism in Female<br />
Inflammatory Arthritis Patients in Primary Care Amplifies<br />
the Prevalence <strong>of</strong> Cardiovascular Disease. Hennie G.<br />
Raterman 2 , Mark M. J. Nielen 1 , Mike J. L. Peters 2 , Robert A.<br />
Verheij 1 , Francois G. Schellevis 1 and Michael T. Nurmohamed 2 ,<br />
1<br />
Netherlands Institute for Health Services Research (NIVEL),<br />
Utrecht, The Netherlands, 2 VU University Medical Center,<br />
Amsterdam, The Netherlands.<br />
1030. Elevations in ApoC-III Containing Apolipoprotein Complexes<br />
Predict Coronary Atherosclerosis Progression in Rheumatoid<br />
Arthritis Patients. Joan M. Bathon 3 , Michael Centola 4 , Jon T.<br />
Giles 2 , Nicholas Knowlton 5 , Joshua Wages 5 , Adam J. Payne 5 , Guy<br />
Cavet 1 and Petar Alaupovic 5 , 1 Crescendo Biosciences, Inc., South<br />
San Francisco, CA, 2 Johns Hopkins Univ, Baltimore, MD, 3 Johns<br />
Hopkins Univ Ste, Baltimore, MD, 4 Oklahoma Med Research<br />
Foundation, Oklahoma City, OK, 5 Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK.<br />
1031. Factors Associated with Upper and Lower Gastrointestinal<br />
Perforation in a Cohort <strong>of</strong> Patients with Rheumatoid Arthritis.<br />
Jeffrey R. Curtis 5 , Angel Lanas 4 , Winifred Werther 2 , Ani John 2 ,<br />
David A. Johnson 1 and Kathy L. Schulman 3 , 1 Eastern Virginia<br />
Medical School, Norfolk, VA, 2 Genentech, a Member <strong>of</strong> the<br />
Roche Group, South San Francisco, CA, 3 Outcomes Research<br />
Solutions, Inc. Bolton, MA, 4 Universidad de Zaragoza, Zaragoza,<br />
Spain, 5 University <strong>of</strong> Alabama at Birmingham, Birmingham, AL.<br />
1032. Fatigue in Inflammatory Arthritis: Clinical Characteristics, and<br />
Contributory Factors Following 6-Months <strong>of</strong> Anti-TNF Therapy.<br />
Patricia Minnock 1 , Barry Bresnihan 3 , Gabrielle McKee 2 , Oliver<br />
FitzGerald 3 and Douglas Veale 3 , 1 <strong>Rheumatology</strong> Rehabilitation,<br />
Our Lady’s Hospice and Care Services, Dublin, Dublin, Ireland,<br />
2<br />
School <strong>of</strong> Nursing & Midwifery, Trinity <strong>College</strong> Dublin, Dublin,<br />
Ireland, 3 St Vincent’s University Hospital, Dublin, Dublin, Ireland.<br />
1033. Favorable Changes in the Lipid Pr<strong>of</strong>ile in the First Year <strong>of</strong> Early<br />
Arthritis. Karin Britsemmer 1 , Dirkjan van Schaardenburg 1 ,<br />
Willem F. Lems 2 and Michael T. Nurmohamed 1 , 1 Jan van<br />
Breemen Institute Amsterdam, 2 VU University Medical Center<br />
Amsterdam.<br />
1034. Free Fatty Acids Are Associated with Insulin Resistance but<br />
Not Coronary Artery Atherosclerosis in Rheumatoid Arthritis.<br />
Michelle J. Ormseth 2 , Larry Swift 4 , Sergio Fazio 4 , MacRae F.<br />
Linton 4 , Cecilia P. Chung 3 , Paolo Raggi 1 , Young-Hee Rho 2 , Joseph<br />
Solus 4 , Annette M. Oeser 5 , Aihua Bian 4 , Tebeb Gebretsadik 4 ,<br />
Ayumi Shintani 4 and C. Michael Stein 4 , 1 Emory University,<br />
2<br />
Vanderbilt University, Nashville, TN, 3 Vanderbilt University,<br />
Baltimore, MD, 4 Vanderbilt University, 5 VUMC 23rd Ave South<br />
Pierce, Nashville, TN.<br />
1035. Gene-Environment Interaction Determines Interstitial<br />
Lung Disease in Rheumatoid Arthritis. Jose Felix Restrepo 2 ,<br />
Inmaculada del Rincon 4 , Ricardo Zuniga 3 , Samvel Pogosian 4 and<br />
Agustin Escalante 1 , 1 Univ <strong>of</strong> Texas HSC San Antonio, San Antonio,<br />
TX, 2 Univ <strong>of</strong> Texas HSC, San Antonio, San Antonio, TX, 3 University<br />
<strong>of</strong> Texas HSC, San Antonio, TX, 4 UTHSCSA, San Antonio, TX.<br />
1036. Glucocorticoid Use Is Not Associated with an Increased Risk<br />
<strong>of</strong> Cerebrovascular Accidents in Patients with Rheumatoid<br />
Arthritis. A Population-Based Study. Antonio Avina-Zubieta 1 ,<br />
Michal Abrahamowicz 2 , Hyon K. Choi 4 , M. Mushfiqur Rahman 1 ,<br />
Marie-Pierre Sylvestre 3 , John Esdaile 1 and Diane V. Lacaille 1 ,<br />
1<br />
Arthritis Res Centre <strong>of</strong> Canada, Vancouver, BC, Canada,<br />
2<br />
Department <strong>of</strong> Epidemiology and Biostatistics, McGill<br />
University, Montreal, QC, Canada, 3 Samuel Lunenfeld Research<br />
Institute, 4 Univ <strong>of</strong> British Columbia, Vancouver, BC, Canada.<br />
2010 Program Book 211
ACR/ARHP Poster Session B<br />
212<br />
1037. Heptavalent Conjugate Pneumococcal Vaccine (Prevenarâ)<br />
Elicits Similar Antibody Responses as 23-Valent Polysaccharide<br />
Vaccine (PPV) in Adult Patients with Established Arthritis.<br />
Meliha C. Kapetanovic 1 , Carmen Roseman 2 , Göran Jönsson 1 ,<br />
Lennart Truedsson 3 , Tore Saxne 1 and Pierre Geborek 1 , 1 Dept<br />
<strong>of</strong> Clinical Sciences Lund, Section <strong>of</strong> Infectious Diseases, Lund<br />
University, Lund, Sweden, 2 Dept <strong>of</strong> Clinical Sciences Lund,<br />
Section <strong>of</strong> <strong>Rheumatology</strong>, Lund University, Lund, Sweden, 3 Dept<br />
<strong>of</strong> Laboratory Medicine, Section <strong>of</strong> Microbiology, Immunology<br />
and Glycobiology, Lund University, Lund, Sweden.<br />
1038. Higher Prevalence <strong>of</strong> Coexisting Papillary Thyroid Cancer<br />
as Well as Autoimmune Thyroid Diseases in Patients with<br />
Rheumatoid Arthritis. Yeon-Ah Lee 3 , Sang-Hoon Lee 1 , Ran<br />
Song 2 , Kyoung Min Son, Hyung-In Yang and Seung-Jae Hong 4 ,<br />
1<br />
Seoul, Korea, Republic <strong>of</strong>, 2 Korea, Republic <strong>of</strong>, 3 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine, School <strong>of</strong><br />
Medicine, KyungHee University, Seoul, Korea, Republic <strong>of</strong>,<br />
4<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine,<br />
School <strong>of</strong> Medicine, KyungHee University.<br />
1039. Hospital-Based Surgical Procedures and the Risk <strong>of</strong><br />
Perioperative Cardiovascular Events: A Comparison Study<br />
<strong>of</strong> Rheumatoid Arthritis and Diabetes Mellitus Using the<br />
National Inpatient Sample <strong>of</strong> the Healthcare Cost and<br />
Utilization Project. Ali Yazdanyar 2 , Mary C. Wasko 3 , Kevin L.<br />
Kraemer 3 and Michael M. Ward 1 , 1 National Institute <strong>of</strong> Arthritis<br />
and Musculoskeletal and Skin Diseases, 2 St Luke’s Hospital,<br />
Bethlehem, PA, 3 University <strong>of</strong> Pittsburgh.<br />
1040. Hypogonadism in Males with Rheumatoid Arthritis. Dannette<br />
S. Johnson and Robert W. McMurray, G.V. (Sonny) Montgomery<br />
VA and University <strong>of</strong> Mississippi Medical Center, Jackson, MS.<br />
1041. Il-17 as a Novel Predictor <strong>of</strong> Vascular Damage in Rheumatoid<br />
Arthritis. Wendy Marder 2 , Shokoufeh Khalatbari 3 , James D.<br />
Myles 3 , Rita P. Hench 2 , Susan Lustig 1 , Robert D. Brook 1 and<br />
Mariana J. Kaplan 2 , 1 Division <strong>of</strong> Cardiology, University <strong>of</strong><br />
Michigan, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Michigan,<br />
Ann Arbor, MI, 3 Michigan Institute for Clinical and Health<br />
Research, Ann Arbor, MI.<br />
1042. Incidence <strong>of</strong> Progressive Interstitial Pneumonia in Patients<br />
with Rheumatoid Arthritis. Yuko Takahashi, Hiroyuki Yamashita,<br />
Yo Ueda, Yuji Yoshida, Hiroshi Kaneko and Akio Mimori, Division<br />
<strong>of</strong> Rheumatic Diseases, National Center for Global Health and<br />
Medicine, Shinjyuku-ku, Tokyo, Japan.<br />
1043. Infertility in Women with RA and Pregnancy Loss in Women<br />
with SLE Contribute to Smaller Than Desired Family<br />
Size. Megan E. B. Clowse 3 , Eliza F. Chakravarty 1 , Karen H.<br />
Costenbader 2 , Christine D. Chambers 5 and Kaleb D. Michaud 4 ,<br />
1<br />
Mountain View, CA, 2 Brigham & Women, Boston, MA, 3 Duke<br />
Univ Med, Durham, NC, 4 Univ <strong>of</strong> Nebraska Med Ctr, Omaha, NE,<br />
5<br />
University <strong>of</strong> California, San Diego.<br />
1044. Interstitial Lung Disease in Rheumatoid Arthritis: Effect on<br />
Physical Function, Disability, Mental Health and Survival over<br />
a 10-Year Period. Inmaculada Del Rincon 2 , Jose Felix Restrepo 3 ,<br />
Mrisa Sahai 2 , Daniel F. Battafarano 1 , L. Ricardo Zuniga-Montes 2<br />
and Agustin Escalante 2 , 1 Brooke Army Medical Ctr, San Antonio,<br />
TX, 2 UTHSCSA, San Antonio, TX, 3 UTHSCSA, Bogota, Colombia.<br />
1045. Lower Extremity Ulcers in Rheumatoid Arthritis. David M.<br />
DeMaria 2 , Christopher E. Attinger 1 and Victoria K. Shanmugam 2 ,<br />
1<br />
Center for Wound Healing, Georgetown University Medical<br />
Center, Washington, DC, 2 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Immunology and Allergy, Georgetown University Medical<br />
Center, Washington, DC.<br />
2010 Program Book<br />
1046. Lower Prevalence and Severity <strong>of</strong> “Vulnerable” Coronary<br />
Plaque in a-TNF-Exposed Asymptomatic Patients with<br />
Rheumatoid Arthritis (RA). George A. Karpouzas 1 , Naser<br />
Ahmadi 2 , Tae-Young Choi 2 , Fereshteh Hajsadeghi 2 , Silvia Munoz 2<br />
and Mathew Bud<strong>of</strong>f 2 , 1 Harbor-UCLA, Long Beach, CA, 2 Harbor-<br />
UCLA.<br />
1047. Measuring Therapeutic Adherence in Rheumatoid Arthritis<br />
(RA) Using a Medication Event Monitoring System (MEMS®).<br />
Christian A. Waimann, Maria F. Marengo, S<strong>of</strong>ia de Achaval,<br />
Vanessa L. Cox, Araceli Garcia Gonzalez, Marsha N. Richardson<br />
and Maria E. Suarez-Almazor, The University <strong>of</strong> Texas MD<br />
Anderson Cancer Center, Houston, TX.<br />
1048. Polyautoimmunity and Autoimmune Aggregation in<br />
Rheumatoid Arthritis. Adriana Rojas-Villarraga 1 , Ricardo A.<br />
Cifuentes 3 , Diana Botello-Corzo 3 , Antonio Iglesias-Gamarra 4 ,<br />
Ruben D. Mantilla 5 and Juan-Manuel Anaya 2 , 1 Center for<br />
Autoimmune Diseases Research (CREA), Universidad del<br />
Rosario, 2 CREA, Universidad del Rosario, Bogota, Colombia,<br />
3<br />
CREA, Universidad del Rosario, 4 <strong>Rheumatology</strong> Unit,<br />
Universidad Nacional, 5 Riesgo de Fractura-CAYRE IPS.<br />
1049. Prediction <strong>of</strong> 10-Year Cardiovascular and All-Cause Mortality<br />
in Rheumatoid Arthritis Using the Ankle-Brachial Index.<br />
Carlos Ramirez 3 , Agustin Escalante 2 , Mrisa Sahai 3 , Daniel F.<br />
Battafarano 1 , Samvel Pogosian 3 and Inmaculada Del Rincon 2 ,<br />
1<br />
Brooke Army Medical Ctr, San Antonio, TX, 2 UTHSCSA, San<br />
Antonio, TX, 3 UTHSCSA.<br />
1050. Prevalence and Predictors <strong>of</strong> Pain in Rheumatoid Arthritis<br />
Patients in DAS28 Remission. Yvonne C. Lee 1 , Jing Cui 3 , Bing<br />
Lu 2 , Michelle Frits 3 , Christine K. Iannaccone 3 , Nancy A. Shadick 4 ,<br />
Michael E. Weinblatt 4 and Daniel Hal Solomon 4 , 1 Brigham &<br />
Womens Hospital, Boston, MA, 2 Brigham and Women’s Hospital,<br />
Foxboro, MA, 3 Brigham and Women’s Hospital, Boston, MA,<br />
4<br />
Brigham and Womens Hospital, Boston, MA.<br />
1051. Rheumatoid Arthritis Patients in Clinical Remission Manifest<br />
Persistent Joint Inflammation on Histology and Imaging. Allen<br />
P. Anandarajah 1 , Ralf G. Thiele 2 , Johnny Monu 4 , Gwy-Suk Seo 3 ,<br />
Aqiba Bokhari 3 and Christopher T. Ritchlin 5 , 1 Univ <strong>of</strong> Rochester<br />
Med Ctr, Rochester, NY, 2 University <strong>of</strong> Rochester, Rochester,<br />
NY, 3 University <strong>of</strong> Rochester, 4 University <strong>of</strong> Rochester Med Ctr,<br />
5<br />
University <strong>of</strong> Rochester Medical Center, Rochester, NY.<br />
1052. Rheumatoid Arthritis Patients Receive Less Frequent Acute<br />
Reperfusion and Secondary Prevention after Myocardial<br />
Infarction. Sharon Van Doornum 4 , Caroline Brand 3 , Vijaya<br />
Sundararajan 1 , Andrew Ajani 3 and Ian Wicks 2 , 1 Monash<br />
University, 2 Royal Melbourne Hospital, Melbourne, Australia,<br />
3<br />
Royal Melbourne Hospital, 4 University <strong>of</strong> Melbourne, Victoria,<br />
Australia.<br />
1053. Risk Factors for Coronary Heart Diseases in Japanese Patients<br />
with Rheumatoid Arthritis: From a Large Observational<br />
Study, IORRA. Eiichi Tanaka 1 , Eisuke Inoue 3 , Toru Yamada 3 ,<br />
Ayako Nakajima 3 , Atsuo Taniguchi 3 , Shigeki Momohara 3 and<br />
Hisashi Yamanaka 2 , 1 Institute <strong>of</strong> <strong>Rheumatology</strong>, Tokyo Women’s<br />
Medical University, Tokyo, Japan, 2 Institute <strong>of</strong> <strong>Rheumatology</strong>,<br />
Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan,<br />
3<br />
Institute <strong>of</strong> <strong>Rheumatology</strong>, Tokyo Women’s Medical University.<br />
1054. Risk <strong>of</strong> Acute Coronary Syndromes in Relation to TNF-<br />
Inhibition in Early Rheumatoid Arthritis. Lotta Ljung 5 , Julia<br />
F. Simard 3 , Lennart T. H. Jacobsson 4 , Solbritt M. Rantapaa-<br />
Dahlqvist 1 and Johan Askling 2 , 1 Umea, Sweden, 2 Clinical<br />
Epidemiology Unit, 3 Clinical Epidemiology Unit, Stockholm,<br />
Sweden, 4 Malmo University Hospital, Malmo, Sweden, 5 Umea<br />
University Hospital.
ACR/ARHP Poster Session B<br />
1055. Sonographic Guidance and the Injection <strong>of</strong> the Rheumatoid<br />
Joint. Courtney R. Johnson 4 , Natalia Chavez Chiang 1 , Suzanne<br />
Delea 1 , Hilliary Norton, Wilmer L. Sibbitt 2 and Arthur D.<br />
Bankhurst 3 , 1 Albuquerque, NM, 2 University <strong>of</strong> New Mexico HSC,<br />
Albuquerque, NM, 3 University <strong>of</strong> NM Med Ctr, Albuquerque,<br />
NM, 4 UNM Carrie Tingley Hospital, Albuquerque, NM.<br />
1056. Statin Discontinuation and Risk <strong>of</strong> Acute Myocardial Infarction<br />
in Rheumatoid Arthritis: A Population-Based Study. Mary A.<br />
De Vera 1 , Hyon K. Choi 5 , Michal Abrahamowicz 3 , Jacek Kopec 1 ,<br />
Maria Victoria Goycochea-Robles 4 and Diane V. Lacaille 2 ,<br />
1<br />
Arthritis Research Centre <strong>of</strong> Canada, Vancouver, BC, Canada,<br />
2<br />
Arthritis Research Ctr Canada, Vancouver, BC, Canada, 3 McGill<br />
University, Montreal, QC, Canada, 4 Research Unit <strong>of</strong> Clinical<br />
Epidemiology, Hospital Regional 1 IMSS, Mexico City, Mexico,<br />
5<br />
Univ <strong>of</strong> British Columbia, Vancouver, BC, Canada.<br />
1057. Stroke in Rheumatoid Arthritis: (When) Is There an Increased<br />
Risk? Marie E. Holmqvist 1 , Lennart T. H. Jacobsson 3 , Lars<br />
Alfredsson 1 and Johan Askling 2 , 1 Karolinska Institutet,<br />
2<br />
Karolinska University Hospital, 3 Malmö University Hospital.<br />
1058. Subclinical Atherosclerosis in Patients with Rheumatoid<br />
Arthritis Is Associated with Decreased Activity <strong>of</strong> Lecithin<br />
Cholesterol Acyl: Transferase, a High Density Lipoprotein<br />
(HDL)-Associated Protein Involved in Reverse Cholesterol<br />
Transport. Christina Charles-Schoeman 2 , Yuen Yin Lee 3 , Sogol<br />
Amjadi 3 , John D. FitzGerald 4 , Veena K. Ranganath 2 , Mihaela<br />
Taylor 3 , Maureen A. McMahon 2 , Harold E. Paulus 1 and Srinivasa<br />
T. Reddy 3 , 1 Encino, CA, 2 UCLA School <strong>of</strong> Medicine, Los Angeles,<br />
CA, 3 UCLA School <strong>of</strong> Medicine, 4 UCLA School <strong>of</strong> Medicine<br />
Rehabilitation, Los Angeles, CA.<br />
1059. Symptomatic Heart Failure, NT-proBNP Levels, and Diastolic<br />
Dysfunction in RA-Patients with and without Anti-TNFa<br />
Therapy. A Prospective Consecutive Cohort Study. Michael<br />
Gottwald 1 , Denio Ridjab 2 , Stephanie Glocke 1 , Kathrin Behring 1 ,<br />
Robert Lange 3 , Christian Butter 1 and Michael Zaenker 1 , 1 EFKH<br />
and Heart Center Brandenburg, Bernau, Germany, 2 EFKH and<br />
Heart Center Brandenburg, Bernau, Germany, 3 Hospitalverbund<br />
and Rheumazentrum Nord-Brandenburg.<br />
1060. The Clinical Features <strong>of</strong> 13 Women with Microchimerism<br />
in Rheumatoid Nodules. Christopher J. Atkins 4 , William F. N.<br />
Chan 1 , David Naismith 6 , Nicholas van der Westhuizen 6 , Janet<br />
Woo 3 , Valerie Cortez 5 and J. Lee Nelson 2 , 1 Fred Hutchinson<br />
Cancer Research Center, 2 Fred Hutchinson Cancer Research<br />
Center and University <strong>of</strong> Washington, 3 University <strong>of</strong> British<br />
Columbia, 4 University <strong>of</strong> Victoria, Victoria, BC, Canada,<br />
5<br />
University <strong>of</strong> Washington, 6 Vancouver Island Health Authority.<br />
1061. The Clinical Implication <strong>of</strong> Anti-Cyclic Citrullinated Peptide<br />
Antibody in Late Onset Rheumatoid Arthritis. Se Jin Jung 3 ,<br />
Yoon Kang 3 , You-Jung Ha 3 , Kwang-Hoon Lee 3 , Sang Won Lee 3 ,<br />
Min-Chan Park 1 , Soo Kon Lee 2 and Yong-Beom Park, 1 Gangnam<br />
Severance Hospital, Seoul, Korea, Republic <strong>of</strong>, 2 Yonsei Univ<br />
<strong>College</strong> <strong>of</strong> Med, Seoul, Korea, Republic <strong>of</strong>, 3 Yonsei Univ <strong>College</strong><br />
<strong>of</strong> Med.<br />
1062. The Effect <strong>of</strong> Calcium and Vitamin D Supplementation on the<br />
Incidence <strong>of</strong> Rheumatoid Arthritis in the Women’s Health<br />
Initiative Randomized Study. Marius Racovan 10 , Brian Walitt 10 ,<br />
Christopher Collins 10 , Mary Pettinger 2 , Christine Parks 4 , James<br />
Shikany 6 , Jean Wactawski-Wende 8 , JoAnn E. Manson 1 , Larry<br />
Moreland 9 , Nicole Wright 7 , Rebecca Jackson 5 and Barbara V.<br />
Howard 3 , 1 Brigham and Women’s Hospital, Harvard Medical<br />
School, 2 Fred Hutchinson Cancer Research Center, 3 MedStar<br />
Research Institute, 4 National Institute <strong>of</strong> Enviromental Health<br />
Sciences, 5 Ohio State University, 6 University <strong>of</strong> Alabama,<br />
7<br />
University <strong>of</strong> Arizona, 8 University <strong>of</strong> Buffalo, 9 University <strong>of</strong><br />
Pittsburgh, 10 Washington Hospital Center.<br />
1063. The Impact <strong>of</strong> Rheumatoid Arthritis (RA) on Women: Focus<br />
on Pain, Productivity and Relationships. Vibeke Strand 2 , Paul<br />
Emery 1 , Scott Fleming 4 and Catherine Griffin 3 , 1 Chapel Allerton<br />
Hospital, Leeds, United Kingdom, 2 Division <strong>of</strong> Immunology and<br />
<strong>Rheumatology</strong>, Stanford University School <strong>of</strong> Medicine, Palo<br />
Alto, CA, 3 Echo Research, London, UK, 4 UCB, Slough, UK.<br />
1064. There Are No Differences in Lipids between RA Patients and<br />
Their Siblings, Despite Higher Incidence <strong>of</strong> CHD in RA. Namita<br />
Kumar, Nicola J. Marshall, David J. Walker and Philip N. Platt,<br />
University Hospital <strong>of</strong> North Durham.<br />
1065. Thigh Fat and Muscle in Rheumatoid Arthritis: Associations<br />
with Disease Features and Physical Functioning. Henry R.<br />
Kramer 1 , Kevin R. Fontaine 1 , Joan M. Bathon 1 and Jon T. Giles 2 ,<br />
1<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, Johns Hopkins University, Baltimore,<br />
MD, 2 Johns Hopkins Univ, Baltimore, MD.<br />
1066. TNF Inhibitors and the Risk <strong>of</strong> Fracture in Rheumatoid<br />
Arthritis. Daniel Hal Solomon 3 , Seo Young Kim 1 , Jun Liu 2 , Claire<br />
Canning 2 and Sebastian Schneeweiss 2 , 1 Brigham and Women’s<br />
Hospital, Boston, MA, 2 Brigham and Women’s Hospital,<br />
3<br />
Brigham and Womens Hospital, Boston, MA.<br />
1067. Traditional and Novel Risk Markers for Atherosclerosis but<br />
Not Clinical Measures <strong>of</strong> Inflammatory Disease Are Associated<br />
with Atheromatous Plaque Presence in Early Inflammatory<br />
Polyarthritis-Results from the Norfolk Arthritis Register<br />
(NOAR). Hoda Mirjafari 3 , Suzanne M. M. Verstappen 2 , Diane<br />
Bunn 6 , Helena Edlin 5 , Valentine Charlton-Menys 4 , Philip<br />
Pemberton 5 , Tarnya Marshall 6 , Paddy Wilson 6 , Mark Lunt 2 ,<br />
Deborah P. Symmons 7 and Ian N. Bruce 1 , 1 Arthritis Research<br />
UK Epidemiology Unit, Stopford Building, The University <strong>of</strong><br />
Manchester, Manchester, United Kingdom, 2 Arthritis Research<br />
UK Epidemiology Unit, Stopford Building, The University <strong>of</strong><br />
Manchester, 3 Arthritis Research UK Epidemiology Unit, The<br />
University <strong>of</strong> Manchester, 4 Cardiovascular Research Group,<br />
The University <strong>of</strong> Manchester, 5 Manchester Royal Infirmary,<br />
6<br />
Norfolk and Norwich University Hospital, 7 Univ <strong>of</strong> Manchester,<br />
Manchester, United Kingdom.<br />
1068. Unaffected First-Degree Relatives <strong>of</strong> RA Patients Exhibit a High<br />
Prevalence <strong>of</strong> Joint Symptoms That Is Not Explained by the<br />
Presence <strong>of</strong> RA Autoantibodies: Studies in a Predisposed North<br />
<strong>American</strong> Native Population. Irene Smolik 3 , Qier Tan 3 , Xikui<br />
Wang 3 , Donna Hart 3 , Marianna Newkirk 1 , Charles N. Bernstein 3 ,<br />
David B. Robinson 3 and Hani S. El-Gabalawy 2 , 1 McGill University,<br />
2<br />
University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 3 University <strong>of</strong><br />
Manitoba.<br />
Rheumatoid Arthritis - Human Etiology and Pathogenesis II<br />
1069. ‘Shared’ T-Cell Clones Identified in Lymph Nodes and Synovial<br />
Tissue <strong>of</strong> Early Rheumatoid Arthritis Patients Using a Novel<br />
High Throughput Sequencing Technology. Paul L. Klarenbeek 4 ,<br />
Marjolein J. de Hair 4 , Stefano Alivernini 4 , Marleen G. van de<br />
Sande 4 , Marieke E. Doorenspleet 4 , Barbera D. van Schaik 3 ,<br />
Ferco H. Berger 2 , Rebecca E. Esveldt 4 , Antoine H. van Kampen 3 ,<br />
Danielle M. Gerlag 4 , Frank Baas 5 , Paul P. Tak 1 and Niek de<br />
Vries 4 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam,<br />
The Netherlands, 2 Dept <strong>of</strong> Radiology, Academic Medical<br />
Center-University <strong>of</strong> Amsterdam, 3 Dept. <strong>of</strong> Clin. Epidemiology,<br />
Biostatistics and Bioinformatics, Academic Medical Center-<br />
University <strong>of</strong> Amsterdam, 4 Div <strong>of</strong> Clin Immunology &<br />
<strong>Rheumatology</strong>, Academic Medical Center-University <strong>of</strong><br />
Amsterdam, Amsterdam, The Netherlands, 5 Lab. For Genome<br />
Analysis, Academic Medical Center-University <strong>of</strong> Amsterdam.<br />
2010 Program Book 213
ACR Poster Session B<br />
214<br />
1070. Anticitrullinated Peptide Antibodies (ACPAS) in the Sera<br />
<strong>of</strong> Heavy Smokers without Arthritis. A Differential Role <strong>of</strong><br />
Associated Pulmonary Disease? Virginia Ruiz-Esquide 3 , María<br />
José Gómara 4 , Víctor Peinado 1 , José Alfredo Gómez Puerta 3 ,<br />
María Victoria Hernández 2 , Joan A. Barberà 1 , Julio Ramírez 3 ,<br />
Juan de Dios Cañete 3 , Isabel Haro 4 and Raimon Sanmartí 3 ,<br />
1<br />
Pneumology Service, Hospital Clínic <strong>of</strong> Barcelona, Barcelona,<br />
Spain, 2 <strong>Rheumatology</strong> Service, Hospital Clínic <strong>of</strong> Barcelona,<br />
Barcelona, Spain, 3 <strong>Rheumatology</strong> Service. Hospital Clínic <strong>of</strong><br />
Barcelona, Barcelona, Spain, 4 Unit <strong>of</strong> Synthesis and Biomedical<br />
Applications <strong>of</strong> Peptides, IQAC-CSIC, Barcelona, Spain.<br />
1071. Anti-Citrullinated Protein Antibodies (ACPA) in Unaffected<br />
Siblings <strong>of</strong> ACPA-Positive Rheumatoid Arthritis Patients. Lillian<br />
Barra 1 , Elizabeth Wilson 1 , Matthias Scinocca 1 , Kelly Summers 1 ,<br />
Ewa Cairns 2 and David A. Bell 2 , 1 The University <strong>of</strong> Western<br />
Ontario, 2 The University <strong>of</strong> Western Ontario, London, ON,<br />
Canada.<br />
1072. Atherogenic Properties <strong>of</strong> Rheumatoid Arthritis Plasma:<br />
Effect on Cholesterol Transport Genes. Allison B. Reiss 1 ,<br />
Iryna Voloshyna 1 , Michael Littlefield 1 , Elise Belilos 1 , Kristina<br />
Belostocki 2 , Lois A. Bonetti 1 , Gary C. Rosenblum 1 and Steven E.<br />
Carsons 1 , 1 Winthrop University Hospital, Mineola, NY, 2 Winthrop<br />
University Hospital, Jamaica, NY.<br />
1073. Circulating Cytokines Influence the Fetal Growth in Pregnant<br />
Women with Rheumatoid Arthritis. Florentien D. O. de<br />
Steenwinkel 2 , Johanna M. W. Hazes 1 , Yaël A. de Man 1 , Anita C.<br />
S. Hokken 2 , Yolanda B. de Rijke 2 and Radboud J. E. M. Dolhain 1 ,<br />
1<br />
Erasmus Medical Center, Rotterdam, The Netherlands,<br />
2<br />
Erasmus Medical Center/Sophia Children’s Hospital, Rotterdam,<br />
The Netherlands.<br />
1074. Citrullination and Peptidylarginine Deiminase (PAD) Expression<br />
Is Detected in the Oral Mucosa and Periodontium in the<br />
Absence <strong>of</strong> Rheumatoid Arthritis. Clifton O. Bingham 1 , Mark A.<br />
Reynolds 3 , Jon Giles 2 , Felipe Andrade 2 , Joan M. Bathon 2 , Karen<br />
Fox-Talbot 2 and Marc K. Halushka 2 , 1 Johns Hopkins, Baltimore,<br />
MD, 2 Johns Hopkins, 3 University <strong>of</strong> Maryland Dental School.<br />
1075. Common Genetic Background for Rheumatoid Arthritis and<br />
Systemic Lupus Erythematosus. Gisela Orozco, Steve Eyre, Anne<br />
Hinks, Wendy Thomson, Jane Worthington and Anne Barton,<br />
Arthritis Research Campaign Epidemiology Unit, The University<br />
<strong>of</strong> Manchester.<br />
1076. Confirmation <strong>of</strong> the Especial Interaction <strong>of</strong> Autoimmunity<br />
Against Citrullinated α-Enolase with Genotypes Predisposing<br />
to Rheumatoid Arthritis. Antonio Gonzalez 1 , Ariana Montes 2 ,<br />
Rebeca Dieguez-Gonzalez 2 , Manuel Calaza 2 , Eva Perez-Pampin 2 ,<br />
Antonio Mera 2 and Juan J. Gomez-Reino 2 , 1 Hospital Clinico<br />
Universitario de Santiago, Santiago de Compostela, A Coruña,<br />
Spain, 2 Hospital Clinico Universitario de Santiago.<br />
1077. C-Reactive Protein (CRP) Single Nucleotide Polymorphisms<br />
(SNPs) Are Associated with Radiographic Damage and Plasma<br />
CRP Levels in African <strong>American</strong>s (AAs) with Early Rheumatoid<br />
Arthritis (RA). Maria I. Danila 6 , Lang Chen 5 , Desiree M. Van<br />
Der Heijde 2 , Doyt L. Conn 1 , Beth L. Jonas 7 , Leigh F. Callahan 8 ,<br />
Edwin A. Smith 3 , Richard Brasington 10 , Larry W. Moreland 9 , S.<br />
Louis Bridges 6 and Laura B. Hughes 4 , 1 Emory Univ Schl <strong>of</strong> Med,<br />
Atlanta, GA, 2 Leiden University Medical Center, Meerssen, The<br />
Netherlands, 3 Med Univ <strong>of</strong> South Carolina, Charleston, SC, 4 Univ<br />
<strong>of</strong> Alabama Birmingham, Birmingham, AL, 5 Univ <strong>of</strong> Alabama-<br />
Birmingham, 6 Univ <strong>of</strong> Alabama-Birmingham, Birmingham,<br />
AL, 7 Univ <strong>of</strong> N Carolina-Chapel Hill, Chapel Hill, NC, 8 Univ <strong>of</strong><br />
North Carolina, Chapel Hill, NC, 9 Univ <strong>of</strong> Pittsburgh Med Ctr,<br />
Pittsburgh, PA, 10 Washington Univ Schl <strong>of</strong> Med, St Louis, MO.<br />
2010 Program Book<br />
1078. Differential Association <strong>of</strong> IL23R Genetic Variants with Anti-<br />
CCP Positive and Negative Rheumatoid Arthritis Patients.<br />
Antonio Gonzalez 6 , Aida Ferreiro 5 , Eva Perez-Pampin 5 , Manuel<br />
Calaza 5 , Francisco J. Lopez-Longo 13 , Jose Luis Marenco 12 ,<br />
Francisco J. Blanco 9 , Rafael Caliz 14 , Javier Narvaez 10 , Federico<br />
Navarro 15 , Juan Cañete 3 , Arturo R. de la Serna 8 , Isidoro<br />
Gonzalez-Alvarez 11 , Gabriel Herrero-Beaumont 1 , Jose Luis<br />
Pablos 2 , Alejandro Balsa 7 , Benjamin Fernandez-Gutierrez 4<br />
and Juan J. Gomez-Reino 5 , 1 Fundacion Jimenez Diaz. Madrid,<br />
2<br />
Hospital 12 de Octubre, Madrid, 3 Hospital Clinic. Barcelona,<br />
4<br />
Hospital Clinico San Carlos, Madrid, 5 Hospital Clinico<br />
Universitario de Santiago, 6 Hospital Clinico Universitario de<br />
Santiago, Santiago de Compostela, Spain, 7 Hospital La Paz .<br />
Madrid, 8 Hospital Santa Creu e San Pau. Barcelona, 9 Hospital<br />
Universitario A Coruña, 10 Hospital Universitario de Bellvitge.<br />
Barcelona, 11 Hospital Universitario de la Princesa, 12 Hospital<br />
Universitario de Valme. Sevilla, 13 Hospital Universitario Gregorio<br />
Marañon, Madrid, 14 Hospital Universitario Virgen de las Nieves,<br />
Granada, 15 Hospital Universitario Virgen Macarena, Sevilla.<br />
1079. DNA Damage, T Cell Lymphopenia and Immunosenescence in<br />
Rheumatoid Arthritis. Lan Shao 1 , Hiroshi Fujii 2 , Jorg J. Goronzy 1<br />
and Cornelia M. Weyand 1 , 1 Stanford University School <strong>of</strong><br />
Medicine, Stanford, CA, 2 Tohoku University School <strong>of</strong> Medicine,<br />
Sendai, Japan.<br />
1080. Do Patients with Rheumatoid Arthritis Exhibit Differential<br />
Cellular Responses to Implant Wear Debris and Do the Implant<br />
Failure Mechanisms Differ from Non-RA Patients? Anant<br />
Vasudevan 5 , Edward F. DiCarlo 3 , Timothy Wright 2 , Dan Chen 2 ,<br />
Steven R. Goldring 1 and Lisa A. Mandl 4 , 1 Chief Scientific Officer,<br />
Hospital for Special Surgery, 2 Department <strong>of</strong> Biomechanics,<br />
Hospital for Special Surgery, 3 Department <strong>of</strong> Pathology and<br />
Laboratory Medicine, Hospital for Special Surgery, 4 Hospital for<br />
Special Surgery, New York, NY, 5 Yale School <strong>of</strong> Medicine, New<br />
York, NY.<br />
1081. Dual Roles <strong>of</strong> Heme Oxygenase-1 on Rheumatoid Arthritis:<br />
Anti-Inflammation Versus Angiogenesis. Kaoru Takase 2 , Shigeru<br />
Ohno 1 , Mitsuhiro Takeno 3 and Yoshiaki Ishigatsubo 4 , 1 Center for<br />
Rheumatic Diseases, Yokohama City University Medical Center,<br />
2<br />
Department <strong>of</strong> Internal Medicine and Clinical Immunology,<br />
Yokohama City University Graduate School <strong>of</strong> Medicine, Japan,<br />
3<br />
Department <strong>of</strong> Internal Medicine and Clinical Immunology,<br />
Yokohama City University Graduate School <strong>of</strong> Medicine, Japan<br />
4<br />
Yokohama City Grad Sch <strong>of</strong> Med, Yokohama, Japan.<br />
1082. Epstein Barr Virus Serologies and Future Risk <strong>of</strong> Rheumatoid<br />
Arthritis among Women. Barbara L. Goldstein 2 , Lori B. Chibnik 2 ,<br />
Elizabeth W. Karlson 2 and Karen H. Costenbader 1 , 1 Brigham &<br />
Women, Boston, MA, 2 Brigham and Women’s Hospital, Boston,<br />
MA.<br />
1083. Expanded Cytokine/Chemokine Testing Improves Prediction<br />
<strong>of</strong> Time to Future Diagnosis <strong>of</strong> Seropositive Rheumatoid<br />
Arthritis (RA) in an Age-Dependent Manner. Kevin D. Deane 8 ,<br />
Colin I. O’Donnell 2 , Lezlie A. Derber 3 , Jess D. Edison 10 , William<br />
R. Gilliland 1 , Wolfgang Hueber 4 , Jeremy Sokolove 6 , Piyanka E.<br />
Chandra 7 , Jill Norris 9 , William Robinson 5 and V. Michael Holers 8 ,<br />
1<br />
Department <strong>of</strong> Medicine, <strong>Rheumatology</strong> Section, Walter<br />
Reed Army Medical Center, Washington, DC, 2 Department <strong>of</strong><br />
Preventive Medicine and Biometrics, University <strong>of</strong> Colorado<br />
Denver, Denver, CO, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong><br />
Colorado School <strong>of</strong> Medicine, Aurora, CO, 4 Novartis Institutes<br />
for BioMedical Research, Basel, Switzerland, 5 Stanford Univ<br />
School <strong>of</strong> Med, Stanford, CA, 6 Stanford University School <strong>of</strong><br />
Medicine, Palo Alto, Mountain View, CA, 7 Stanford University<br />
School <strong>of</strong> Medicine, Palo Alto, CA, 8 Univ <strong>of</strong> Colorado School <strong>of</strong><br />
Med, Aurora, CO, 9 University <strong>of</strong> Colorado Denver, Aurora, CO,<br />
10<br />
Walter Reed Army Med Ctr, Washington, DC.
ACR Poster Session B<br />
1084. Gene Expression Pr<strong>of</strong>iling in Rheumatoid Arthritis Patients<br />
Following B Cell Depletion with Rituximab Reveals Changes in<br />
Type I IFN Activity Related to Clinical Responsiveness. Saskia<br />
Vosslamber 1 , Hennie G. Raterman 2 , Tineke C. T. M. van der<br />
PouwKraan 2 , Micheal T. Nurmohamed 2 , Willem F. Lems 2 , Ben A.<br />
C. Dijkmans 2 , Alexandre E. Voskuyl 2 and Cornelis L. Verweij 2 , 1 VU<br />
University Medical Center, Amsterdam, The Netherlands, 2 VU<br />
University Medical Center.<br />
1085. Heterogeneity in the Bone Marrow B Cell Compartment:<br />
Implications for Pathogenesis <strong>of</strong> Human RA. Arumugam<br />
Palanichamy, Chris Cistrone, Jennifer Hossler, Chungwen Wei,<br />
James Kobie, Inaki Sanz and Jennifer Anolik, University <strong>of</strong><br />
Rochester Medical Center.<br />
1086. High Level <strong>of</strong> Serum Matrix Metalloproteinase-3 Could Be<br />
Implicated in the Pathogenesis <strong>of</strong> Rheumatoid Interstitial<br />
Lung Disease. Yoshinobu Koyama 3 , Kosuke Tsuruno 1 , Toshiyuki<br />
Ota 2 and Kenji Fujii 1 , 1 Center for Rheumatic Diseases, Iizuka<br />
Hospital, 2 Department <strong>of</strong> Laboratory and Transfusion Medicine,<br />
University <strong>of</strong> Occupational and Environmental Health, 3 Iizuka<br />
Hospital, Iizuka, Japan.<br />
1087. Identification <strong>of</strong> Genes Associated with Erosion in Cohorts<br />
<strong>of</strong> Patients with Early Arthritis. Amir Kadi 5 , Brigitte Izac 5 ,<br />
Jean-Philippe Jais 3 , Thierry Lequerre 4 , Olivier Vittecoq 4 , Xavier<br />
Le Loet 4 , Philippe Dieude 1 , Corinne Miceli 3 , Maxime Breban 2<br />
and Gilles Chiocchia 5 , 1 AP-HP, Paris, France, 2 AP-HP, Boulogne-<br />
Billancourt, France, 3 AP-HP, 4 CHU Rouen, 5 Inserm U1016 / CNRS<br />
UMR8104, Paris, France.<br />
1088. In Early RA, Serum Increase <strong>of</strong> IL-21 Is Associated with<br />
Serum Level <strong>of</strong> IL-6, Autoantibody Secretion, Markers <strong>of</strong><br />
B-Cell Activation, and Radiographic Progression. Jacques-Eric<br />
Gottenberg 4 , Pascale Roux-Lombard 2 , Alain Cantagrel 5 , Alain<br />
Saraux 1 , Cedric Lukas 3 , Jean-Michel Dayer 2 and Xavier Mariette,<br />
1<br />
Brest Hospital, 2 Geneva Hospital, 3 Montpellier Hospital,<br />
4<br />
Strasbourg Hospital, 5 Toulouse Hospital.<br />
1089. Strong Activation <strong>of</strong> Dopamine Pathway in Synovial Tissue<br />
from Rheumatoid Arthritis Patients: New Target <strong>of</strong> Pathology?<br />
Silvia Capellino 1 , Christine Wolff 2 , Franca Marino 3 , Alessandra<br />
Luini 3 , Marco Cosentino 3 and Rainer H. Straub 1 , 1 University<br />
Hospital Regensburg, Dept. <strong>of</strong> Internal Medicine I, Regensburg,<br />
Germany, 2 University Hospital Regensburg, Dept. <strong>of</strong> Internal<br />
Medicine I, Regensburg, Germany, 3 University <strong>of</strong> Insubria,<br />
Varese, Italy.<br />
1090. T-Cell Subsets Dys-Regulation and Cytokines Are Predictive<br />
<strong>of</strong> RA Pathogenesis in an ACPA-Positive Background. Richard<br />
Cuthbert 2 , Rekha Parmar 2 , Jackie Nam 2 , Edith Villeneuve 2 , Diane<br />
Corscadden 2 , Karen Henshaw 2 , Paul Emery 1 and Frederique<br />
Ponchel 2 , 1 Chapel Allerton Hospital, Leeds, United Kingdom,<br />
2<br />
University <strong>of</strong> Leeds.<br />
1091. The Development <strong>of</strong> the ACPA Repertoire Prior to the Onset<br />
<strong>of</strong> Clinical RA. Lotte A. van de Stadt 4 , Margret de Koning 2 , Rob<br />
J. van de Stadt 1 , Gertjan Wolbink 2 , B. A. C. Dijkmans 5 , Dörte<br />
Hamann 3 and Dirkjan van Schaardenburg 2 , 1 Jan van Breemen<br />
Institiute, 2 Jan van Breemen Institute, 3 Sanquin Diagnostics,<br />
4<br />
Sanquin Research, 5 VU Medical Centre, Amsterdam, The<br />
Netherlands.<br />
1092. The Differential Effect <strong>of</strong> HLA-DRB1 *0901 Allele from Shared<br />
Epitope on the Development <strong>of</strong> Rheumatoid Arthritis. So-<br />
Young Bang 1 , Hye-Soon Lee 1 , Ji-Seon Lee 1 , Eun-Mi Kim 1 , Kyung<br />
Wha Lee 2 and Sang-Cheol Bae 1 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Hanyang University Hospital for Rheumatic Diseases, Korea,<br />
Republic <strong>of</strong>, 2 Hallym Institute for Genome Application, Hallym<br />
University Sacred Heart Hospital, Anyang, Korea, Republic <strong>of</strong>.<br />
1093. The Smoking-Induced Heat Shock Protein DNAjC6 Is<br />
Downregulated in Rheumatoid Arthritis. Caroline Ospelt 1 ,<br />
Joanna Stanczyk 2 , Christoph Kolling 3 , Renate E. Gay 1 and Steffen<br />
Gay 4 , 1 Center <strong>of</strong> Experimental <strong>Rheumatology</strong> and Center <strong>of</strong><br />
Integrative Human Physiology, Zurich, Switzerland, 2 Center <strong>of</strong><br />
Experimental <strong>Rheumatology</strong> and Center <strong>of</strong> Integrative Human<br />
Physiology, Zurich, Switzerland, 3 Schulthess Clinic Zurich,<br />
Switzerland, 4 University Hospital Zurich, Zurich, Switzerland.<br />
1094. Variability <strong>of</strong> Anti-CCP Kit Testing in Cohorts with and without<br />
RA. Kevin D. Deane 7 , Kristen Demoruelle 10 , Mark Parish 4 ,<br />
Whitney Hilton 4 , Lauren Harrington 4 , Lezlie Derber 4 , Jason R.<br />
Kolfenbach 6 , Jan M. Hughes-Austin 4 , Michael H. Weisman 3 ,<br />
Ted R. Mikuls 14 , James R. O’Dell 8 , Richard M. Keating 1 , Peter K.<br />
Gregersen 5 , Jane Buckner 2 , Irene Smolik 13 , Donna Hart 13 , Charles<br />
N. Bernstein 13 , David B. Robinson 12 , Jill Norris 9 , V. Michael<br />
Holers 7 and Hani S. El-Gabalawy 11 , 1 Oak Park, IL, 2 Benaroya<br />
Research Institute at Virginia Mason, Seattle, WA, 3 Cedars-Sinai<br />
Medical Center, Los Angeles, CA, 4 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
University <strong>of</strong> Colorado School <strong>of</strong> Medicine, Aurora, CO, 5 N<br />
Shore Univ Hosp Rsch Ctr, Manhasset, NY, 6 Univ <strong>of</strong> CO Schl <strong>of</strong><br />
Med, Aurora, CO, 7 Univ <strong>of</strong> Colorado School <strong>of</strong> Med, Aurora, CO,<br />
8<br />
University <strong>of</strong> Nebraska Medical Center, Omaha, NE, 9 University<br />
<strong>of</strong> Colorado Denver, Aurora, CO, 10 University <strong>of</strong> Colorado School<br />
<strong>of</strong> Medicine, 11 University <strong>of</strong> Manitoba, Winnipeg, MB, Canada,<br />
12<br />
University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 13 University <strong>of</strong><br />
Manitoba, 14 University <strong>of</strong> Nebraska Medical Center, Omaha, NE.<br />
Rheumatoid Arthritis Treatment - Small Molecules, Biologics<br />
and Gene Therapy: Predicting and Measuring Outcomes, Novel<br />
Compounds II<br />
1095. A Phase IIa, Randomized, Double-Blind, Placebo-Controlled<br />
Clinical Study <strong>of</strong> Apilimod Mesylate, an Oral IL-12/IL-23<br />
Inhibitor, in Patients with Active Rheumatoid Arthritis. Sarah<br />
Krausz 3 , Maartje J. H. Boumans 3 , Daniëlle M. Gerlag 3 , Joelle<br />
Lufkin 4 , Arno W. R. van Kuijk 2 , Alian A. B. Bakker 3 , Maarten de<br />
Boer 3 , Beatrijs M. Lodde 3 , Kris A. Reedquist 3 , Eric W. Jacobson 4 ,<br />
Michael O’Meara 4 and Paul P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong><br />
Amsterdam, Amsterdam, The Netherlands, 2 Academic Medical<br />
Center/University <strong>of</strong> Amsterdam, 3 Academic Medical Center-<br />
University <strong>of</strong> Amsterdam, 4 Synta Pharmaceuticals Corp.<br />
1096. ALD518 (BMS945429), a High-Affinity Anti-Interleukin-6<br />
Monoclonal Antibody, Provides Improvements in Health-<br />
Related Quality <strong>of</strong> Life (HRQoL) in Patients with Rheumatoid<br />
Arthritis (RA) and an Inadequate Response to Methotrexate.<br />
Vibeke Strand 3 , Levan Shalamberidze 6 , Aleksandar Dimic 4 ,<br />
Jeffrey Smith 1 , Robin Mukherjee 2 and Philip Mease 5 , 1 Alder<br />
Biopharmaceuticals Inc., Bothell, WA, 2 Bristol-Myers Squibb,<br />
Princeton, NJ, 3 Division <strong>of</strong> Immunology/<strong>Rheumatology</strong>, Stanford<br />
University, Palo Alto, CA, 4 Institute <strong>of</strong> Rehabilitation and<br />
Treatment, Niska Banja, Serbia, 5 Swedish Medical Center and<br />
University <strong>of</strong> Washington, Seattle, WA, 6 V. Tsitlanadze Scientific<br />
Practical Centre <strong>of</strong> <strong>Rheumatology</strong>, Tbilisi, Georgia.<br />
1097. Assessment <strong>of</strong> Inflammation and Damage by MRI in<br />
Established RA Patients with Methotrexate Inadequate<br />
Response Receiving Golimumab: Results <strong>of</strong> the GO-FORWARD<br />
Trial. Philip G. Conaghan 3 , Paul Emery 4 , Mikkel Østergaard 5 ,<br />
Ed C. Keystone 8 , Mark C. Genovese 7 , Lars Klareskog 6 , Weichun<br />
Xu 1 , Elizabeth C. Hsia 2 and Mahboob U. Rahman 2 , 1 Centocor<br />
Research and Development, Inc., 2 Centocor Research and<br />
Development, Inc./Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine,<br />
Malvern, PA, 3 Chapel Allerton Hospital, Leeds, United Kingdom,<br />
4<br />
Chapel Allerton Hospital, Leeds, United Kingdom, 5 Copenhagen<br />
University Hospital at Glostrup and Hvidovre, 6 Karolinska<br />
University Hospital, Stockholm, Sweden, 7 Stanford University,<br />
Sunnyvale, CA, 8 University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />
2010 Program Book 215
ACR/ARHP Poster Session B<br />
1098. Biomarkers Predictors <strong>of</strong> Good EULAR Response to B Cell<br />
Depletion Therapy (BCDT) in Seropositive Rheumatoid Arthritis<br />
Patients. Gianfranco Ferraccioli 3 , Barbara Tolusso 3 , Francesca<br />
Bobbio Pallavicini 4 , Elisa Gremese 3 , Viviana Ravagnani 1 , Maurizio<br />
Benucci 5 , Edoardo Podesta’ 2 , Fabiola Atzeni 6 , Giusy Peluso 3 ,<br />
G. Biasi 1 , Mariangela Manfredi 5 , Piercarlo Sarzi Puttini 6 , Bruno<br />
Lagana’ 2 and Carlomaurizio Montecucco 4 , 1 Department <strong>of</strong><br />
Clinical and Experimental Medicine, Section <strong>of</strong> <strong>Rheumatology</strong> &<br />
Internal Medicine, University <strong>of</strong> Verona, Verona, Italy, 2 Division<br />
<strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, S. Andrea University<br />
Hospital, “Sapienza” University <strong>of</strong> Rome, II School <strong>of</strong> Medicine,<br />
Rome, Italy, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Catholic University<br />
<strong>of</strong> the Sacred Heart, Rome, Italy, 4 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
University <strong>of</strong> Pavia, IRCCS S. Matteo Foundation, Pavia, Italy,<br />
5<br />
<strong>Rheumatology</strong> Unit, Department <strong>of</strong> Internal Medicine,<br />
Ospedale di S. Giovanni di Dio, Florence, Italy, 6 <strong>Rheumatology</strong><br />
Unit, University Hospital L. Sacco, Milan, Italy.<br />
1099. Candidate Gene Analysis in US Veteran Rheumatoid Arthritis<br />
Patients with Clinical Improvement during Treatment with<br />
Anti-Tumor Necrosis Factor Agents in the Veterans Affairs<br />
Rheumatoid Arthritis (VARA) Registry. Grant W. Cannon 5 ,<br />
Roger K. Wolff 5 , Jian Ying 8 , Candace L. Hayden 6 , Brian C. Sauer 6 ,<br />
Jeffrey R. Curtis 7 , Dannette S. Johnson 3 , Gail S. Kerr 9 , J. Steuart<br />
Richards 10 , Liron Caplan 2 , Andreas Reimold 1 and Ted R. Mikuls 4 ,<br />
1<br />
Dallas VA and University <strong>of</strong> Texas Southwestern, 2 Denver<br />
VA and University <strong>of</strong> Colorado, 3 Jackson VA and University <strong>of</strong><br />
Mississippi, 4 Omaha VA and University <strong>of</strong> Nebraska, 5 Salt Lake<br />
City VA and University <strong>of</strong> Utah, Salt Lake City, UT, 6 Salt Lake City<br />
VA and University <strong>of</strong> Utah, 7 University <strong>of</strong> Alabama, 8 University<br />
<strong>of</strong> Utah, 9 Washington DC VA and Georgetown and Howard<br />
Universities, 10 Washington DC VA and Georgetown University.<br />
1100. CCR1 Antagonist CCX354-C in Phase 2 Clinical Development<br />
for Rheumatoid Arthritis. Daniel J. Dairaghi, Vittorio Marchesin,<br />
Daniel A. Johnson, Shichang Miao, Lisa C. Seitz, Yu Wang,<br />
Penglie Zhang, Jay P. Powers, Bert Ho, Pirow J. Bekker, Juan C.<br />
Jaen and Thomas J. Schall, ChemoCentryx.<br />
1101. Change in CRP at 12 Weeks Predicts the Risk <strong>of</strong> Rapid<br />
Radiographic Progression at 2 Years in Methotrexate-Treated<br />
Patients with Early Rheumatoid Arthritis. Boulos Haraoui 4 ,<br />
Paul Emery 3 , Neelufar Mozaffarian 1 , Benoit Guerette 2 ,<br />
Hartmut Kupper 2 , Kaushik Patra 2 and Ed C. Keystone 5 , 1 Abbott<br />
Laboratories, Abbott Park, IL, 2 Abbott Laboratories, 3 Chapel<br />
Allerton Hospital, Leeds, United Kingdom, 4 Institut de<br />
Rhumatologie, Montreal, QC, Canada, 5 University <strong>of</strong> Toronto,<br />
Toronto, ON, Canada.<br />
1102. Clinical and Radiographic Implications <strong>of</strong> Time to Treatment<br />
Response in Patients with Early Rheumatoid Arthritis. Ed<br />
C. Keystone 7 , Michael E. Weinblatt 4 , Boulos Haraoui 5 , Benoit<br />
Guerette 2 , Neelufar Mozaffarian 1 , Kaushik Patra 3 and Arthur<br />
Kavanaugh 6 , 1 Abbott Laboratories, Abbott Park, IL, 2 Abbott<br />
Laboratories, France, 3 Abbott Laboratories, 4 Brigham &Womens<br />
Hospital, Boston, MA, 5 Institut de Rhumatologie, Montreal,<br />
QC, Canada, 6 University <strong>of</strong> California-San Diego, La Jolla, CA,<br />
7<br />
University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />
1103. Composite Remission Using Clinical, Structural, and Functional<br />
Criteria in Patients with Rheumatoid Arthritis (RA) Treated<br />
with Etanercept. Mark C. Genovese 4 , Andrew S. Koenig 3 , Grace<br />
S. Park 1 and Scott W. Baumgartner 2 , 1 Amgen Inc., Thousand<br />
Oaks, CA, 2 Amgen, Inc., Thousand Oaks, CA, 3 Pfizer Inc., Blue<br />
Bell, PA, 4 Stanford University, Sunnyvale, CA.<br />
1104. DAS-Driven Therapy Versus Routine Care in Patients with<br />
Recent-Onset Active Rheumatoid Arthritis: Data from the<br />
GUEPAR Trial and ESPOIR Cohort. Martin Soubrier 1 , Cédric<br />
Lukas 2 , Jean Sibilia 3 , Bruno Fautrel 5 , Laure Gossec 4 , Simon<br />
Patternotte 4 and Maxime Dougados 4 , 1 CHU Clermont-Ferrand,<br />
Sevice de Rhumatologie, F-63003, Clermont-Ferrand, Puy-dedôme,<br />
France, 2 CHU Montpellier, Service de Rhumatologie,<br />
F-34295 Montpellier, France, 3 CHU Strasbourg, Service de<br />
Rhumatologie, Strasbourg, France, 4 Hôpital Cochin, Service de<br />
Rhumatologie, F-75014, Paris, France, 5 Hôpital Pitié-Salpétrière,<br />
Service de Rhumatologie, F-75013, Paris, France.<br />
1105. Differential Serum Glycosylation Changes in Rheumatoid and<br />
Psoriatic Arthritis – In Response to Anti-TNF Therapy. Azita<br />
Alavi 1 , Oliver M. FitzGerald 3 , Emily S. Collins 4 , Owen Fraser 2 ,<br />
Edward Tarelli 1 , Chin Teck Ng 4 , Barry Bresnihan 5 , Douglas J.<br />
Veale 4 and John S. Axford 1 , 1 St. Georges University <strong>of</strong> London,<br />
London, United Kingdom, 2 St. Georges University <strong>of</strong> London,<br />
London, United Kingdom, 3 St. Vincent’s University Hospital,<br />
Dublin, Ranelagh Dublin, Ireland, 4 St. Vincent’s University<br />
Hospital, Dublin, Dublin, Ireland, 5 St. Vincent’s University<br />
Hospital, Dublin, Co. Dublin, Ireland.<br />
1106. Double-Blind, Randomized, Controlled, Placebo-Included, Pilot<br />
Study Comparing Classical Ayurvedic Medicine, Methotrexate,<br />
and Their Combination in RA. Daniel E. Furst 3 , Manorama<br />
M. Venkatraman 4 , Mary McGann 1 , P. Ram Manohar 1 , Cathryn<br />
Booth-LaForce 4 , Dinesh Khanna 2 , K. G. Raveendran 1 , Reshmi<br />
Sarin 1 , Anita Mahapatra 1 , Jidesh Gopinath 1 and P. R. Krishna<br />
Kumar 1 , 1 The Ayurvedic Trust, 2 UCLA, 3 University <strong>of</strong> California<br />
Los Angeles Medical School, Los Angeles, CA, 4 University <strong>of</strong><br />
Washington.<br />
1107. HM-A42, a Novel Inhibitor <strong>of</strong> IKKβ Kinase Reverses Clinical<br />
and Histological Disease Parameters in Multiple Autoimmune<br />
Disease Models. Yu Cai 1 , Xinrong Wang 1 , Ping Ren 1 , Changwu<br />
Lu 1 , Jianlin He 1 , Xiaoming Dai 3 , Qianqian Dong 1 , Jun Yu 3 , Lei<br />
Fang 2 , Xiaoning Yang 1 , Lei Jiang 3 , Jia Li 1 , Weifang Xue 1 , Pingmin<br />
Tang 1 , Jian Wang 1 , Fang Yin 3 , Yongjuan Yu 3 , Jingshui Li 3 , Yang Sai 3 ,<br />
James Yan 3 , Jianguo Ji 3 , Weiguo Qing 3 , Weiguo Su 3 and Haoran<br />
Zhao 1 , 1 Hutchison MediPharma Ltd, Shanghai, China, 2 Hutchison<br />
MediPharma Ltd, Shanghai, China, 3 Hutchison MediPharma Ltd.<br />
1108. Impact <strong>of</strong> Genetic Interactions on Response to Adalimumab<br />
Plus Methotrexate Versus Methotrexate Alone: Six Month<br />
Results <strong>of</strong> the OPTIMA Trial. Alla Skapenko 3 , Kaushik Patra 2 ,<br />
Hartmut Kupper 1 and Hendrik Schulze-Koops 3 , 1 Abbott GmbH &<br />
Co. KG, Ludwigshafen, Germany, 2 Abbott Laboratories, Abbott<br />
Park, IL, 3 University <strong>of</strong> Munich, Munich, Germany.<br />
1109. Improved Disease Control in Response to Tocilizumab Therapy<br />
Is Accompanied by Decreased Platelet Reactivity in Patients<br />
with Rheumatoid Arthritis. Paul A. MacMullan 3 , Anne M.<br />
Madigan 1 , Paola Bagaglia 2 , Dermot Kenny 3 and Geraldine M.<br />
McCarthy 1 , 1 Mater Misericordiae Univ. Hosp, Dublin, Ireland,<br />
2<br />
Mater Misericordiae Univ. Hosp, Dublin, Ireland, 3 RCSI, Dublin,<br />
Ireland.<br />
1110. In Patients with Early Inflammatory Polyarthritis, ACPA<br />
Positivity and Inefficacy <strong>of</strong> the First DMARD Are Associated<br />
with the Need To Start a Biologic Later on: Results from the<br />
Norfolk Arthritis Register (NOAR). S. M. M. Verstappen 1 ,<br />
M. Lunt 1 , D. K. Bunn 2 , D. G. I. Scott 2 and D. P. M. Symmons 1 ,<br />
1<br />
Arthritis Research UK Epidemiology Unit, The University <strong>of</strong><br />
Manchester, Manchester, United Kingdom, 2 Norfolk Arthritis<br />
Register, Norfolk and Norwich University Hospital, Norwich,<br />
United Kingdom, United Kingdom.<br />
216<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
1111. Increasing Chance <strong>of</strong> Remission in Patients with Rheumatiod<br />
Arthritis. Anja Strangfeld 1 , Maria Eveslage 3 , Martin Aringer 4 ,<br />
Rainer Dockhorn 5 , Matthias Schneider 6 , Joachim Listing 3<br />
and Angela Zink 2 , 1 German Rheumatism Research Center,<br />
Berlin, Germany, 2 German Rheumatism Research Center and<br />
Charité University Medicine Berlin, 3 German Rheumatism<br />
Research Center, Berlin, 4 Rheumatologist, Dresden, Germany,<br />
5<br />
Rheumatologist, Weener, Weener, Germany, 6 Scientific<br />
Advisory Board, Düsseldorf.<br />
1112. Influence <strong>of</strong> ESR on EULAR Response Rates in Patients Treated<br />
with Tocilizumab. Results from the German Biologics Register<br />
RABBIT. Anja Strangfeld 1 , Maria Eveslage 1 , Joachim Listing 1 ,<br />
Peter Herzer 5 , Anke Liebhaber 4 , Brigitte Krummel-Lorenz 3<br />
and Angela Zink 2 , 1 German Rheumatism Research Center,<br />
Berlin, Germany, 2 German Rheumatism Research Center and<br />
Charité Berlin, Berlin, Germany, 3 Rheumatologist Frankfurt/M,<br />
Frankfurt, Germany, 4 Rheumatologist Halle/S, Halle/Saale,<br />
Germany, 5 Scientific Advisory Board, Munich, Munich, Germany.<br />
1113. Joint Space Narrowing Has a Stronger Impact on Physical<br />
Function Than Joint Erosion: Results from 8-Year Longitudinal<br />
Analyses. Desiree M. Van Der Heijde 2 , Robert Landewe 3 , Benoit<br />
Guerette 1 , Sanjoy Roy 1 , Kaushik Patra 1 and Ed C. Keystone 4 ,<br />
1<br />
Abbott Laboratories, 2 Leiden University Medical Center,<br />
Meerssen, The Netherlands, 3 Univ Hosp Maastricht, Maastricht,<br />
The Netherlands, 4 University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />
1114. Magnetic Resonance Imaging Assessments <strong>of</strong> Patients with<br />
RA and Their Association with Clinical and Radiographic<br />
Outcomes. Paul Emery 3 , Desiree M. Van Der Heijde 6 , Mikkel<br />
Østergaard 5 , Philip G. Conaghan 4 , Mark C. Genovese 7 , Ed<br />
C. Keystone 9 , Roy M. Fleischmann 8 , Weichun Xu 1 , Stephen<br />
Xu 1 , Elizabeth C. Hsia 2 and Mahboob U. Rahman 2 , 1 Centocor<br />
Research and Development, Inc., 2 Centocor Research and<br />
Development, Inc./Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine,<br />
Malvern, PA, 3 Chapel Allerton Hospital, Leeds, United Kingdom,<br />
4<br />
Chapel Allerton Hospital, Leeds, United Kingdom, 5 Copenhagen<br />
University Hospital at Glostrup and Hvidovre, 6 Leiden University<br />
Medical Center, Meerssen, The Netherlands, 7 Stanford<br />
University, Sunnyvale, CA, 8 University <strong>of</strong> Texas SW Medical<br />
Center, Dallas, TX, 9 University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />
1115. Optimal Dose Prediction by Pharmacokinetic and Biomarker<br />
Response <strong>of</strong> Subcutaneous Tocilizumab Treatment – A<br />
Phase I/II Study Evaluating the Safety, Pharmacokinetics<br />
and Clinical Response in Patients with Rheumatoid Arthritis.<br />
Shuji Ohta 8 , Tomomi Tsuru 5 , Kimio Terao 2 , Seiji Mogi 7 , Midori<br />
Suzaki 4 , Hitoshi Nakashima 3 , Eisuke Shono 6 , Eriko Tarumi 1 and<br />
Masato Imai 6 , 1 Chugai Clinical Research Center Co., Ltd, 2 Chugai<br />
Pharmaceutical Co., Ltd., Tokyo, Japan, 3 Fukuoka University,<br />
4<br />
Med Co LTA PS Clinic, 5 Med Co LTA PS Clinic, Fukuoka, Japan,<br />
6<br />
Shono Rheumatism Clinic, 7 Taga General Hospital, Hitachi, Ltd,<br />
Japan 8 Taga General Hospital, Hitachi, Ltd, Japan.<br />
1116. Preclinical Development <strong>of</strong> Autologous, Autoantigen-Loaded<br />
Dendritic Cells Modified with Bay11-7082 for Tolerizing<br />
Immunotherapy in Anti-Citrullinated Peptide Antibody Positive<br />
Rheumatoid Arthritis Patients Bearing the HLA-DR Shared<br />
Epitope. Sakoontalla Ramnoruth 2 , Marion Brunck 2 , Claire Hyde 2 ,<br />
Shayna Street 2 , Ge<strong>of</strong>frey Strutton 1 , Christelle Capini 2 , Sebastien<br />
Bertin-Maghit 2 , Brendan O’Sullivan 2 and Ranjeny Thomas 2 ,<br />
1<br />
Queensland Health Pathology, 2 University <strong>of</strong> Queensland<br />
Diamantina Institute.<br />
1117. Prediction <strong>of</strong> One-Year Response to Etanercept and<br />
Methotrexate in Rheumatoid Arthritis Patients in TEMPO.<br />
Jeffrey R. Curtis 4 , Shuo Yang 7 , Lang Chen 6 , Grace S. Park 1 ,<br />
Bojena Bitman 2 , Brian C. Wang 3 , Iris Navarro-Millan 5 and<br />
Arthur Kavanaugh 8 , 1 Amgen Inc., Thousand Oaks, CA, 2 Amgen<br />
Inc., South San Francisco, CA, 3 KForce Clinical Research, South<br />
San Francisco, CA, 4 University <strong>of</strong> Alabama - Brimingham,<br />
Birmingham, AL, 5 University <strong>of</strong> Alabama at Birmingham,<br />
Vestavia, AL, 6 University <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, 7 University <strong>of</strong> Alabama at Birmingham,<br />
8<br />
University <strong>of</strong> California-San Diego, La Jolla, CA.<br />
1118. Predictors <strong>of</strong> Response to Rituximab in Patients with Active<br />
Rheumatoid Arthritis and Inadequate Response to Anti-TNF<br />
Agents or Traditional DMARD. Javier Narvaez 4 , Cesar Díaz<br />
Torné 2 , Jose Miguel Ruiz 3 , Maria Victoria Hernández 1 , Vicens<br />
Torrente 2 , Sergio Ros 3 , Cesar Díaz López 2 , Arturo Rodriguez<br />
de la Serna 2 , Raimon Sanmartí 1 and Joan Miquel Nolla 4 ,<br />
1<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Clinic, Barcelona, Spain,<br />
2<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital de la Santa Creu i Sant<br />
Pau, Barcelona, Spain, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital<br />
de Viladecans, Barcelona, Spain, 4 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Hospital Universitario de Bellvitge, Barcelona, Spain.<br />
1119. Pro<strong>of</strong> <strong>of</strong> Concept Study for a Potent p38 MAPK Dual Action<br />
Inhibitor BMS-582949 in Subjects with RA Receiving<br />
Concomitant Methotrexate. Mark C. Genovese 6 , Ling Gao 3 , Jie<br />
Yin 3 , Stefani Smith 3 , Michael E. Weinblatt 1 , Josef S. Smolen 5 ,<br />
Xiaoning Wang 3 , Gary Schieven 3 , Juan A. Garcia-Meijide 4 , Robert<br />
Latek 3 , Richard Pasternak 3 , Sanjeev Kaul 3 , Amit Roy 3 , Ralph<br />
Raymond 3 , Ulrich Thienel 3 and Jingsong Wang 2 , 1 Brigham &<br />
Womens Hospital, Boston, MA, 2 Bristol-Myers Squibb, Wayne,<br />
PA, 3 Bristol-Myers Squibb, 4 Hospital Clínico Universitario de<br />
Santiago, Santiago de Compostela, Spain, 5 Krankenhaus Lainz,<br />
Vienna, Austria, 6 Stanford University, Sunnyvale, CA.<br />
1120. Radiographic Progression Correlates Well with Patient-<br />
Reported RAPID3 Disease Activity Levels in Methotrexate<br />
(MTX)-Naive Patients with Early Rheumatoid Arthritis (RA):<br />
Insights from the AGREE Study. Edward C. Keystone 3 , Rene<br />
Westhovens 4 , Diane Moniz Reed 1 , Allison Covucci 1 and Alvin<br />
F. Wells 2 , 1 Bristol-Myers Squibb, Princeton, NJ, 2 Rheum &<br />
Immunotherapy Center, Oak Creek, WI, 3 University <strong>of</strong> Toronto,<br />
Toronto, ON, Canada, 4 UZ Gasthuisburg, Leuven, Leuven,<br />
Belgium.<br />
1121. REGN88/SAR153191, a Fully-Human Interleukin-6 Receptor<br />
Monoclonal Antibody, Reduces Acute Phase Reactants in<br />
Patients with Rheumatoid Arthritis: Preliminary Observations<br />
from Phase 1 Studies. Allen R. Radin 1 , Scott J. Mellis 1 , Martine<br />
Jasson 3 , Douglas Nadler 2 , Pavel Belomestnov 2 , Richard Wu 2 ,<br />
Stephanie Biedermann 2 , Damir Skific 2 and Jennifer Hamilton 2 ,<br />
1<br />
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2 Regeneron<br />
Pharmaceuticals, Inc., 3 San<strong>of</strong>i-aventis, SA.<br />
1122. Results from a Phase I Study <strong>of</strong> MLTA3698A, a Novel Anti-<br />
Lymphotoxin-a Monoclonal Antibody: Safety, Tolerability and<br />
Biologic Activity in Patients with Active Rheumatoid Arthritis.<br />
Brinda Emu 2 , Diana Luca 3 , Carolyn Offutt 3 , Jane Grogan 3 , John<br />
Davis 3 , Bernadette Rojkovich 1 , Marna Williams 3 , Meina Tang 3<br />
and June Lee 3 , 1 Budai Irgalmasrendi, 2 Genentech, Inc., South San<br />
Francisco, CA, 3 Genentech, Inc..<br />
2010 Program Book 217
ACR Poster Session B<br />
1123. Safety <strong>of</strong> a Novel Modified-Release (MR) Prednisone<br />
Formulation: Results <strong>of</strong> the “Circadian Administration <strong>of</strong><br />
Prednisone in Rheumatoid Arthritis” (CAPRA) Studies. Frank<br />
Buttgereit 1 , Jacek Szechinski 5 , Gisela Döring 6 , Stephan Witte 2 ,<br />
Christine Knauer 3 , Amy Grahn 4 , Kenneth G. Saag 8 and Rieke<br />
Alten 7 , 1 Charite University Med-Berlin, Berlin, Germany,<br />
2<br />
Horizon Pharma GmbH, Mannheim, Germany, 3 Horizon<br />
Pharma GmbH, Mannheim, Germany, 4 Horizon Pharma, Inc.,<br />
Northbrook, IL, 5 Med. Uni. Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Wroclaw, Poland, 6 Merck KGaA, 7 Schlosspark-Klinik, UnivMed,<br />
Berlin, Germany, 8 University <strong>of</strong> Alabama-Birmingham,<br />
Birmingham, AL.<br />
1124. Safety, Pharmacokinetics and Pharmacodynamics <strong>of</strong> ALD518<br />
(BMS-945429), a High-Affinity Monoclonal Antibody Directed<br />
Against Interleukin-6 (IL-6) Administered by Subcutaneous<br />
Injection: A Phase I Trial. Sepehr Shakib 2 , Barbara Francis 1 and<br />
Jeffrey Smith 1 , 1 Alder Biopharmaceuticals Inc., Bothell, WA,<br />
2<br />
Royal Adelaide Hospital, Adelaide, Australia.<br />
1125. Selective Activation <strong>of</strong> Naturally Occurring Regulatory T Cells<br />
(Tregs) by the Monoclonal Antibody (mAb) BT-061. Markers<br />
<strong>of</strong> Clinical Activity and Early Phase II Results in Patients<br />
with Rheumatoid Arthritis (RA). Anatoliy Rudnev 1 , Sukanya<br />
Ragavan 6 , Christina Trollmo 6 , Vivianne Malmstroem 6 , Christian<br />
Becker 5 , Helmut Jonuleit 5 , Vibeke Strand 7 , Silke Aigner 1 , Niklas<br />
Czeloth 1 , Benjamin Daelken 1 , Andre Engling 1 , Helga Koch 1 ,<br />
Gabriele Niemann 1 , Frank Osterroth 1 , Christoph Uherek 1 ,<br />
Andrea Wartenberg-Demand 1 , Olga Ershova 4 , Tatiana Sotnikova 2<br />
and Alexander Orlov-Morozov 3 , 1 Biotest AG, Dreieich, Germany,<br />
2<br />
Botkin Clinical Hospital, Moscow, Russian Federation, 3 City<br />
Clinical Hospital Nr. 23 n.a. Medsantrud, Moscow, Russian<br />
Federation, 4 Clinical Hospital for Emergency Medical Care,<br />
Yaroslavl, Russian Federation, 5 Johannes-Gutenberg University,<br />
Mainz, Germany, 6 Karolinska Institute, Stockholm, Sweden,<br />
7<br />
Stanford University, Portola Valley, CA.<br />
1126. Serum Cytokine Pr<strong>of</strong>ile Predicts Response to Rituximab<br />
Therapy in Rheumatoid Arthritis. Edward M. Vital 4 , Richard J.<br />
Cuthbert 4 , Shouvik Dass 1 , Rekha Parmar 4 , Andrew C. Rawstron 3 ,<br />
Frederique C. Ponchel 1 and Paul Emery 2 , 1 Leeds, West Yorkshire,<br />
United Kingdom, 2 Chapel Allerton Hospital, Leeds, United<br />
Kingdom, 3 Leeds Teaching Hospitals NHS Trust, Leeds, West<br />
Yorkshire, United Kingdom, 4 University <strong>of</strong> Leeds, Leeds, West<br />
Yorkshire, United Kingdom.<br />
1127. Serum Markers Associated with Structural Damage in<br />
Methotrexate Naïve Rheumatoid Arthritis Patients Treated<br />
with MTX in Combination with Placebo or Golimumab, a<br />
Human Anti-TNFa Monoclonal Antibody. Carrie Wagner 2 ,<br />
Dion Chen 1 , Hongtao Fan 1 , Sudha Visvanathan 5 , Elizabeth C.<br />
Hsia 3 , Paul Emery 4 , Roy M. Fleischmann 6 , Michael Mack 1 and<br />
Mahboob U. Rahman 3 , 1 Centocor Research and Development,<br />
Inc., 2 Centocor Research and Development, Inc., Malvern,<br />
PA, 3 Centocor Research and Development, Inc./Univ. <strong>of</strong><br />
Pennsylvania School <strong>of</strong> Medicine, Malvern, PA, 4 Chapel<br />
Allerton Hospital, Leeds, United Kingdom, 5 H<strong>of</strong>fmann La Roche,<br />
6<br />
University <strong>of</strong> Texas SW Medical Center, Dallas, TX.<br />
1128. Targeting Potassium Channels for the Treatment <strong>of</strong><br />
Rheumatoid Arthritis. Xueyou Hu 2 , Teresina Laragione 4 , Liang<br />
Sun 2 , Shyny Koshy 2 , Karlie R. Jones 2 , Frank T. Horrigan 2 , Percio<br />
S. Gulko 3 and Christine Beeton 1 , 1 Baylor <strong>College</strong> <strong>of</strong> Medicine,<br />
Houston, TX, 2 Baylor <strong>College</strong> <strong>of</strong> Medicine, 3 Feinstein Institute<br />
for Medical Research, Manhasset, NY, 4 Feinstein Institute for<br />
Medical Research.<br />
1129. Tasocitinib (CP-690,550), an Orally Available Selective Janus<br />
Kinase Inhibitor, Exhibits Sustained Safety and Efficacy in the<br />
Treatment <strong>of</strong> Rheumatoid Arthritis over 24 Months. Carol A.<br />
Connell, Richard Riese, Susan Wood, John Bradley and Samuel<br />
H. Zwillich, Pfizer Inc.<br />
1130. The Bacterial Effector Protein YopM Reduces Bone Destruction<br />
in Rheumatoid Arthritis (RA). Jessica Bertrand 1 , Christian<br />
Rüter 3 , Julia Scharnert 3 , Alexander Schmidt 3 and Thomas Pap 2 ,<br />
1<br />
Institute for Experimental Musculoskeletal Medicine, Münster,<br />
Germany, 2 Institute for Experimental Musculoskeletal Medicine,<br />
3<br />
Institute for Infectiology ZMBE.<br />
1131. The Effects <strong>of</strong> Manzamine A on Rheumatoid Arthritis<br />
Synoviocyte Cytokine Secretion. Kyle Chong 1 , Karolina<br />
Klosowska 1 and James M. Woods 2 , 1 Midwestern University,<br />
Downers Grove, IL, 2 Midwestern University.<br />
1132. The Hawthorne Effect, Sponsored Trials, and the<br />
Overestimation <strong>of</strong> Treatment Effectiveness. Frederick Wolfe 1<br />
and Kaleb D. Michaud 2 , 1 National Data Bank for Rheumatic<br />
Diseases, Wichita, KS, 2 Univ <strong>of</strong> Nebraska Med Ctr, Omaha, NE.<br />
1133. The Relationship <strong>of</strong> Serum Cytokine Levels with Disease<br />
Activity Parameters and Ultrasonographic Findings in RA<br />
Patients before and after Treatment with TNF Antagonists.<br />
Nevsun Inanc 2 , Atilla Bulur 2 , Meryem Can 2 , Onder Ergonul 1 ,<br />
Pamir Atagunduz 2 , Sule Yavuz 2 and Haner Direskeneli 2 ,<br />
1<br />
Marmara University Medical School, Department <strong>of</strong> Infectious<br />
Diseases, 2 Marmara University Medical School, Division <strong>of</strong><br />
<strong>Rheumatology</strong>.<br />
1134. Therapeutic Potential <strong>of</strong> Human Umbilical Cord Mesenchymal<br />
Stem Cells in the Treatment <strong>of</strong> Rheumatoid Arthritis. Yanying<br />
Liu, Rong Mu, Shiyao Wang and Zhanguo Li, Peking University<br />
People’s Hospital.<br />
1135. TRA-8 (CS-1008), a Novel Anti-Arthritic Biologic Agent That<br />
Targets Macrophages with Low Toxicity. Jun Li 1 , Hui-Chen Hsu 2 ,<br />
PingAr Yang 2 , Qi Wu 2 and John D. Mountz 1 , 1 Division <strong>of</strong> Clinical<br />
Immunology and <strong>Rheumatology</strong>, Department <strong>of</strong> Medicine,<br />
University <strong>of</strong> Alabama at Birmingham, Birmingham, AL, 2 Division<br />
<strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Medicine, University <strong>of</strong> Alabama at Birmingham, Birmingham,<br />
AL.<br />
1136. Treat-To-Target for the Management <strong>of</strong> Rheumatoid Arthritis:<br />
A Validation Using Patient Reported Outcomes Data from<br />
Two Phase III Clinical Trials <strong>of</strong> Golimumab. Ed C. Keystone 6 ,<br />
Roy M. Fleischmann 4 , Chenglong Han 3 , Paul Emery 2 , Mark C.<br />
Genovese 5 , Timothy Gathany 3 , Elizabeth C. Hsia 1 and Mahboob<br />
U. Rahman 1 , 1 Centocor Research and Development, Inc./Univ. <strong>of</strong><br />
Pennsylvania School <strong>of</strong> Medicine, Malvern, PA, 2 Chapel Allerton<br />
Hospital, Leeds, United Kingdom, 3 Johnson and Johnson<br />
Pharmaceutical Services, LLC, 4 <strong>Rheumatology</strong> Associates, Dallas,<br />
TX, 5 Stanford University, Sunnyvale, CA, 6 University <strong>of</strong> Toronto,<br />
Toronto, ON, Canada.<br />
1137. WITHDRAWN<br />
1138. Validation <strong>of</strong> an Algorithm Using Genome-Wide SNP Analysis<br />
for Prediction <strong>of</strong> Responders, Non-Responders, and Adverse<br />
Events <strong>of</strong> Tocilizumab-Treated RA Patients Using Two<br />
Population Samples from Multiple Medical Cohorts. Tsukasa<br />
Matsubara 5 , Satoru Koyano 10 , Keiko Funahashi 10 , Takafumi<br />
Hagiwara 6 , Takako Miura 5 , Kosuke Okuda 5 , Akira Sagawa 11 ,<br />
Takeo Sakurai 2 , Hiroaki Matsuno 7 , Tomomaro Izumihara 3 , Eisuke<br />
Shono 12 , Kou Katayama 4 , Toyomitsu Tsuchida 13 , Mitsuhiro<br />
Iwahashi 1 , Tomomi Tsuru 9 and Motohiro Oribe 8 , 1 Higashi-<br />
218<br />
2010 Program Book
ACR Poster Session B<br />
hiroshima Memorial Hospital, Higashihiroshima, Japan, 2 Inoue<br />
Hospital, Takasaki, Japan, 3 Izumihara Rheumatic and Medical<br />
Clinic, Kagoshima, Japan, 4 Katayama Orthopedic Reumatology<br />
Clonic, Asahikawa, Japan, 5 Matsubara Mayflower Hospital,<br />
Kato, Japan, 6 Matsubara Mayflower Hospital, Kato, Japan,<br />
7<br />
Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 8 Oribe<br />
Rheumatism and Internal Medicine Clinic, Oita, Japan, 9 PS Clinic,<br />
Fukuoka, Japan, 10 Research Institute <strong>of</strong> Joint Diseases, Kobe,<br />
Japan, 11 Sagawa Akira <strong>Rheumatology</strong> Clinic, Sapporo, Japan,<br />
12<br />
Shono <strong>Rheumatology</strong> Clinic, Fukuoka, Japan, 13 Tsuchida Clinic,<br />
Chiba, Japan.<br />
Systemic Lupus Erythematosus - Clinical Aspects and Treatment II<br />
1139. 1α,25-Dihydroxyvitamin D3 Suppresses Differentiation,<br />
Maturation and Activation <strong>of</strong> Dendritic Cells from Patients<br />
with Systemic Lupus Erythematosus. Hai Jing Wu, Chak Sing<br />
Lau and Mo Yin Mok, The University <strong>of</strong> Hong Kong, Queen Mary<br />
Hospital, Hong Kong.<br />
1140. 30-Year Follow-Up <strong>of</strong> Lupus Nephritis in a Single Clinic –<br />
Outcome, Serology and Ethnicity. Sara C. Croca 2 , Teresa<br />
Rodrigues 1 and David A. Isenberg 3 , 1 Faculdade de Medicina<br />
de Lisboa, Laboratory <strong>of</strong> Biomathematics, Lisboa, Portugal,<br />
2<br />
Hospital de Santa Maria, Department <strong>of</strong> Medicine 1 , Lisboa,<br />
Portugal, 3 UCL Div <strong>of</strong> Medicine, London, United Kingdom.<br />
1141. A Flow Cytometric Receptor Occupancy Assay Demonstrates<br />
Dose-Dependent Blockade <strong>of</strong> B7RP-1 by AMG 557 on<br />
Circulating B Cells from SLE Subjects. Barbara A. Sullivan 1 ,<br />
Cherie L. Green 2 , Ming Zhang 1 , Christina Abbott 1 , Shelley<br />
Belouski 1 , John Thomas 1 , Kevin Gorski 1 , Gerald Siu 3 , James B.<br />
Chung 1 and John Ferbas 1 , 1 Amgen, Thousand Oaks, CA, United<br />
Kingdom, 2 Amgen, Thousand Oaks, CA, 3 GlaxoSmithKline,<br />
Stevenage, United Kingdom.<br />
1142. A Longitudinal Study <strong>of</strong> the Prolongation <strong>of</strong> the Corrected QT<br />
Interval in Anti-Ro/SSA Positive Adults with Systemic Lupus<br />
Erythematosus. Josiane Bourré-Tessier 3 , Thao Huynh 5 , Ann E.<br />
Clarke 4 , Sasha R. Bernatsky 1 , Lawrence Joseph 3 , Patrick Belisle 3<br />
and Christian A. Pineau 2 , 1 McGill UHC/RVH, Montreal, QC,<br />
Canada, 2 McGill Univ Health Center, Montreal, QC, Canada,<br />
3<br />
McGill University, 4 Montreal General Hospital, Montreal, QC,<br />
Canada, 5 Montreal General Hospital.<br />
1143. Allogeneic Mesenchymal Stem Cells Transplantation in Severe<br />
and Refractory Systemic Lupus Erythematosus. Lingyun Sun 1 ,<br />
Dandan Wang 1 , Huayong Zhang 1 , Jun Liang 1 , Xuebing Feng 1 and<br />
Yayi Hou 2 , 1 Department <strong>of</strong> <strong>Rheumatology</strong> and Immunology, The<br />
Affiliated Drum Tower Hospital <strong>of</strong> Nanjing University Medical<br />
School, 2 Immunology Laboratory, Nanjing University Medical<br />
School.<br />
1144. Analysis <strong>of</strong> the Use <strong>of</strong> Rituximab in the Treatment <strong>of</strong> Lupus<br />
Nephritis. Sara C. Croca 1 and David A. Isenberg 2 , 1 Hospital de<br />
Santa Maria, Department <strong>of</strong> Medicine 1 , Lisbon, Portugal, 2 UCL<br />
Div <strong>of</strong> Medicine, London, United Kingdom.<br />
1145. Anti-Mullerian Hormone in Systemic Lupus Erythematodes<br />
– Is Fertility Affected? Joerg C. Henes 1 , Melanie Henes 4 ,<br />
Tanja Fehm 4 , Diethelm Wallwiener 4 , Lothar Kanz 2 , Ina<br />
Koetter 2 and Barbara Lawrenz 3 , 1 Department for Internal<br />
Medicine II; University Hospital Tuebingen, Tuebingen,<br />
Germany, 2 Department for Internal Medicine II; University<br />
Hospital Tuebingen, Germany, 3 Department <strong>of</strong> Gynecology<br />
and Obstetrics; University Hospital <strong>of</strong> Tuebingen, Germany,<br />
4<br />
Department <strong>of</strong> Gynecology and Obstetrics; University Hospital<br />
Tuebingen, Germany.<br />
1146. Belimumab, a BLyS-Specific Inhibitor, Significantly Reduced<br />
Autoantibodies, Normalized Low Complement, and Reduced<br />
Selected B-Cell Populations in Patients with Seropositive<br />
Systemic Lupus Erythematosus (SLE): The Phase 3 BLISS<br />
Studies. W. Stohl 12 , F. Hiepe 1 , M. Thomas 8 , M. A. Scheinberg 2 ,<br />
A. E. Clarke 9 , C. Aranow 10 , R. Jimenez 4 , F. Wellborne 5 , C. Abud-<br />
Mendoza 3 , D. Hough 6 , L. Pineda 7 , T. S. Migone 7 , W. Freimuth 7 , W.<br />
W. Chatham 11 and on Behalf <strong>of</strong> the BLISS- 52 and - 76 Study Groups,<br />
1<br />
Charité Universitätsmedizin, Berlin, Germany, 2 Hospital Abreu<br />
Sodré Pesquisa Clínica, Sao Paulo, SP, Brazil, 3 Hospital Central<br />
y Facultad de Medicina, San Luis Potosi, Mexico, 4 Hospital G.<br />
Fricke, Vina del Mar, Vina del Mar, Chile, 5 Houston Institute<br />
for Clinical Research, Houston, TX, 6 Human Genome Sciences,<br />
Inc, Rockville, MD, 7 Human Genome Sciences, Inc, Rockville,<br />
Rockville, MD, 8 Kerala Institute <strong>of</strong> Medical Sciences, Trivandrum,<br />
India, 9 McGill University Health Centre, The Montreal General<br />
Hospital, Montreal, QC, Canada, 10 The Feinstein Institute for<br />
Medical Research, Manhasset, Manhasset, NY, 11 UAB Arthritis<br />
Clinical Intervention Program, Birmingham, AL, 12 USC Keck<br />
School <strong>of</strong> Medicine, Los Angeles, CA.<br />
1147. Comparison <strong>of</strong> Serum Free Light Chains, Interferon and<br />
Interleukins as Biomarkers <strong>of</strong> Disease Activity in Systemic<br />
Lupus Erythematosus (SLE). Serene Francis 4 , Rohit Aggarwal 6 ,<br />
Rachel Mikolaitis 4 , Timothy B. Niewold 5 , Susanna Chubinskaya 4 ,<br />
Joel A. Block 1 , Winston Sequeira 2 and Meenakshi Jolly 3 , 1 Rush<br />
University Medical Center, Chicago, IL, 2 Rush University Medical<br />
Center, Chicago, IL, 3 Rush University Medical Center, Section<br />
<strong>of</strong> <strong>Rheumatology</strong>, Chicago, IL, 4 Rush University Medical Center,<br />
Section <strong>of</strong> <strong>Rheumatology</strong>, 5 University <strong>of</strong> Chicago, Section <strong>of</strong><br />
<strong>Rheumatology</strong>, Chicago, IL, 6 University <strong>of</strong> Pittsburgh Medical<br />
Center.<br />
1148. Coronary Calcification in SLE: Comparison with Multi-Ethnic<br />
Study <strong>of</strong> Atherosclerosis (MESA). Adnan N. Kiani 3 , Wendy Post 4 ,<br />
Moyses Szklo 2 , Joan M. Bathon 4 , Laurence S. Magder 6 , Russell<br />
Tracy 8 , Pamela Schreiner 7 , Daniel O’Leary 5 and Michelle A.<br />
Petri 1 , 1 Timonium, MD, 2 Johns Hopkins University, Department<br />
<strong>of</strong> Epidemiology, 3 Johns Hopkins University, School <strong>of</strong> Medicine,<br />
Baltimore, MD, 4 Johns Hopkins University, School <strong>of</strong> Medicine,<br />
5<br />
Tufts University, 6 University <strong>of</strong> Maryland, 7 University <strong>of</strong><br />
Minnesota, 8 University <strong>of</strong> Vermont.<br />
1149. Decrease in Complement (C3) Levels during Systemic Lupus<br />
Erythematosus Pregnancy Is Associated with Higher Rates <strong>of</strong><br />
Pre-Eclampsia. Aisha Lateef 2 , Laurence S. Magder 3 and Michelle<br />
A. Petri 1 , 1 Johns Hopkins Lupus Center, School <strong>of</strong> Medicine,<br />
Johns Hopkins University, Timonium, MD, 2 National University<br />
Health System, Singapore, Singapore, 3 University <strong>of</strong> Maryland<br />
Medical School, Baltimore, MD.<br />
1150. Dendritic Cells and Regulatory T CD4+CD25Bright in Pregnant<br />
Patients with Systemic Lupus Erythematosus. Luis J. Jara 1 ,<br />
Griselda Teresa Romero-Sánchez 1 , Laura A. Montiel-Cervantes 1 ,<br />
Gabriela Medina 1 , Polita Cruz-Cruz 2 , Jorge Vela-Ojeda 1 , Rafael<br />
Arias-Flores 1 , Olga Vera-Lastra 1 and Miguel A. Saavedra Salinas 1 ,<br />
1<br />
Hospital de Especialidades Centro Medico La Raza, IMSS,<br />
Mexico City, DF, Mexico, 2 Hospital de Gineco-Obstetricia No. 3 ,<br />
Centro Medico La Raza, IMSS, Mexico City, DF, Mexico.<br />
1151. Distinctions in the ISN/RPS 2003 Subclasses <strong>of</strong> Class IV Lupus<br />
Nephritis. Suhail Hameed 2 , Kun Chen 2 , Surya Seshan 3 and<br />
Michael D. Lockshin 1 , 1 Hosp for Spec Surgery, Cornell, New York,<br />
NY, 2 Hospital for Special Surgery, Cornell, New York, NY, 3 Weill<br />
Cornell Medical Center.<br />
2010 Program Book 219
ACR/ARHP Poster Session B<br />
220<br />
1152. Does Smoking Influence Disease Manifestations and Disease<br />
Severity in Systemic Lupus Erythematosus? Nayef Al Ghanim 2 ,<br />
Aqeel Ghanem 2 , Ebrahim Nahar 1 , John M. Esdaile 2 and Diane<br />
Lacaille 2 , 1 Mubarak Al Kabeer Hospital, Vancouver, BC, Canada,<br />
2<br />
University <strong>of</strong> British Columbia, Vancouver, BC, Canada.<br />
1153. Early Treatment with Rituximab (RTX) in Newly Diagnosed<br />
Systemic Lupus Erythematosus (SLE) Patients: A Steroid<br />
Sparing Regimen. Amara N. Ezeonyeji 2 and David A. Isenberg 1 ,<br />
1<br />
UCL Div <strong>of</strong> Medicine, Room 331, 3 rd Floor, London, United<br />
Kingdom, 2 University <strong>College</strong> London Hospital NHS Trust,<br />
London, United Kingdom.<br />
1154. Evidence <strong>of</strong> Peripheral B Cell Depletion in Subjects with<br />
Controlled Systemic Lupus Erythematosus (SLE) Following<br />
Subcutaneous Administration <strong>of</strong> SBI-087. Roy M. Fleischmann 3 ,<br />
Stanley B. Cohen 7 , Patricia Pardo 4 , Marianne L. Shaw 1 , Megan E.<br />
B. Clowse 2 , Kyri Dunussi-Joannopoulos 6 , Indranil Bhattacharya 6 ,<br />
Sudhakar T. Sridharan 5 , Annette Diehl 6 and Ian Gourley 6 ,<br />
1<br />
Altoona Center for Clinical Research, Duncansville, PA, 2 Duke<br />
University, Durham, NC, 3 Metroplex Clinical Research Center,<br />
Dallas, TX, 4 Miami Research Associates, 5 Pfizer Inc, <strong>College</strong>ville,<br />
PA, 6 Pfizer Inc, 7 <strong>Rheumatology</strong> Associates, Dallas, TX.<br />
1155. Fibroblast Growth Factor (FGF23) Serum Levels in Juvenile<br />
Onset Systemic Lupus Erythematosus (JSLE): A Potential<br />
Link with Renal Involvement. Fernanda Falcini 1 , Laura Masi 2 ,<br />
Serena Capannini 1 , Francesco Franceschelli 2 , Gigliola Leoncini 2 ,<br />
Valentina Denaro 1 , La Torre Francesco 3 , Giuseppina Calcagno 3 ,<br />
Marco Matucci Cerinic 1 and Maria Luisa Brandi 2 , 1 Dpt <strong>of</strong><br />
BioMedicine, <strong>Rheumatology</strong> Section, Transition Unit, University<br />
<strong>of</strong> Florence, 2 Dpt <strong>of</strong> Internal Medicine, Metabolic Bone Diseases<br />
Unit, University <strong>of</strong> Florence, Florence, 3 Dpt <strong>of</strong> Paediatrics,<br />
<strong>Rheumatology</strong> Unit, University <strong>of</strong> Messina, Messina, Italy.<br />
1156. Fracture Risk Assessment and Prevalence <strong>of</strong> Low Bone Mass in<br />
Canadian Females Living with Systemic Lupus Erythematosus<br />
(SLE). Jennifer J. Lee 6 , Angela M. Cheung 6 , Ellie Aghdassi 6 ,<br />
Stacey Morrison 6 , Valentina Peeva 6 , Carolyn Neville 1 , Sarah<br />
Hewitt 4 , Janet E. Pope 3 , Deborah DaCosta 2 and Paul R. Fortin 5 ,<br />
1<br />
McGill University, Montreal, QC, Canada, 2 McGill University, 3 St<br />
Joseph Health Care London, London, ON, Canada, 4 St. Joseph’s<br />
Health Care, 5 University Health Network, Toronto, ON, Canada,<br />
6<br />
University Health Network.<br />
1157. Immunosuppression in the Treatment <strong>of</strong> Systemic Lupus<br />
Erythematosus Associated Pulmonary Arterial Hypertension:<br />
Improvement in Functional and Exercise Capacity. Judith<br />
Ashouri 2 , Yon Sung 2 , Roham Zamanian 2 and Lorinda Chung 1 ,<br />
1<br />
Stanford Univ Medical Center, Palo Alto, CA, 2 Stanford<br />
University School <strong>of</strong> Medicine.<br />
1158. Immunosuppressive Drugs for Systemic Lupus in the Michigan<br />
Lupus Cohort: Increased Requirement for Cyclophosphamide<br />
and Mycophenolate M<strong>of</strong>etil in Men. Emily E. Lewis 3 , Emily<br />
Crooks 4 , Zhichao Sun 4 , Patricia C. Cagnoli 3 , Tania Gonzalez-<br />
Rivera 4 , Mariana J. Kaplan 3 , Wendy Marder 2 , Panduranga Rao 4 ,<br />
Emily C. Somers 1 and W. Joseph McCune 3 , 1 U <strong>of</strong> Michigan Health<br />
System, Ann Arbor, MI, 2 Univ <strong>of</strong> Michigan, Ann Arbor, MI,<br />
3<br />
University <strong>of</strong> Michigan, Ann Arbor, MI, 4 University <strong>of</strong> Michigan.<br />
1159. Increased Recruitment <strong>of</strong> Brain Activation within the<br />
Hippocampus in SLE Patients as Shown by Functional MRI<br />
May Be a Compensatory Mechanism To Cope with Memory<br />
Impairment. Daphna Paran 3 , Ifat Glikmann-Johnston 2 ,<br />
Talma Hendler 2 , Irena Litinsky 3 , Eli Vakil 1 , Dan Caspi 3 and<br />
Irit Shapira-Lichter 2 , 1 Department <strong>of</strong> Psychology and Gonda<br />
Multidisciplinary Brain Research Center, Bar-Ilan University,<br />
2<br />
Functional Brain Center, Wohl Institute for Advanced Imaging,<br />
Tel-Aviv Sourasky Medical Center, 3 <strong>Rheumatology</strong> Department,<br />
Tel-Aviv Soursky Medical Center.<br />
2010 Program Book<br />
1160. Inhibition <strong>of</strong> Complement Activation by Heparins but Not<br />
Fondaparinux on Alternative, Mannose/Mannan Binding<br />
Lectin (MBL) and Classical Pathways in Active SLE with Low C3/<br />
C4. Andrea A. Ramirez 1 , Ankur A. Kamdar 2 and Barry L. Myones 1 ,<br />
1<br />
Baylor <strong>College</strong> <strong>of</strong> Medicine/Texas Children’s Hospital, Houston,<br />
TX, 2 University <strong>of</strong> Texas Medical School at Houston, Houston, TX.<br />
1161. Long-Term Outcome <strong>of</strong> Autologous Hematopoietic Stem<br />
Cell Transplantation (AutoHSCT) Using Lymphoablative<br />
Conditioning in Treatment-Resistant Systemic Lupus<br />
Erythematosus. Gabor G. Illei 11 , Sarfaraz A. Hasni 7 , Nikolay P.<br />
Nikolov 1 , Francis Hakim 2 , Susan Leitman 2 , James Balow 9 , Howard<br />
Austin 4 , Juan Gea-Banacloche 2 , Unsong Oh 10 , Jeanie Odom 2 ,<br />
Donna Hardwick 8 , Claude Sportes 2 , Ronald Gress 2 , Steven<br />
Pavletic 2 , Cheryl Yarboro 6 , Paolo Muraro 5 and Peter Lipsky 3 ,<br />
1<br />
Bldg. 22 , Room 3335, HFD-570, Silver Spring, MD, 2 National<br />
Cancer Institute, 3 National Institue <strong>of</strong> Arthritis, Musculoskelatal<br />
and Skin Diseases, 4 National Institue <strong>of</strong> Dibetes, Digestive and<br />
Kidney DIseases, 5 National Institue <strong>of</strong> Neurological Diseases and<br />
Stroke, 6 National Institute <strong>of</strong> Arthritis, Musculoskelatal and Skin<br />
Diseases, 7 National Institute <strong>of</strong> Arthritis, Musculoskelatal and<br />
Skin Diseases, Bethesda, MD, 8 National Institute <strong>of</strong> Arthritis,<br />
Musculoskeletal and Skin Diseases, 9 National Institute <strong>of</strong><br />
Diabetes, Digestive and Kidney Diseases, 10 National Institute<br />
<strong>of</strong> Neurological Disroders and Stroke, 11 NIDCR, NIH #10 1N114,<br />
Bethesda, MD.<br />
1162. Microembolic Signals Detected by Transcranial Doppler<br />
Ultrasound Corresponds to Persistence <strong>of</strong> Foramen Ovale<br />
in Neuropsychiatric Lupus with Brain MRI Abnormalities.<br />
Melissa Padovan 2 , Alessandra Bortoluzzi 2 , Cristiano Azzini 1 ,<br />
Alessandro De Vito 1 , Maria Rosaria Tola 1 , Francesco Trotta 3<br />
and Marcello Govoni 3 , 1 Neurology Unit, Department <strong>of</strong><br />
Neurosciences, Azienda Ospedaliero-Universitaria Sant’Anna,<br />
Ferrara, Italy, 2 <strong>Rheumatology</strong> Unit, Department <strong>of</strong> Clinical and<br />
Experimental Medicine, University <strong>of</strong> Ferrara and Azienda<br />
Ospedaliero-Universitaria Sant’Anna - Ferrara, Ferrara, FE, Italy,<br />
3<br />
<strong>Rheumatology</strong> Unit, Department <strong>of</strong> Clinical and Experimental<br />
Medicine, University <strong>of</strong> Ferrara and Azienda Ospedaliero-<br />
Universitaria Sant’Anna – Ferrara, Italy.<br />
1163. Multivariate Analysis <strong>of</strong> Vitamin D Insufficiency and Deficiency<br />
in SLE: The SOLD (Systemic Lupus Associates <strong>of</strong> Low Vitamin<br />
D) Project. Caroline D’Souza 2 , Kayode Jibril Bello 2 , Hong Fang 2 ,<br />
Laurence Magder 3 and Michelle A. Petri 1 , 1 Timonium, MD,<br />
2<br />
Johns Hopkins University, 3 University <strong>of</strong> Maryland.<br />
1164. Network Analysis <strong>of</strong> Associations between Serum Interferon<br />
Alpha, Serology, and Clinical Features in Systemic Lupus<br />
Erythematosus in a Large Multi-Ancestral Cohort. Corinna E.<br />
Weckerle 6 , Beverly S. Franek 7 , Jennifer Kelly 2 , Marissa Kumabe 7 ,<br />
Rachel Mikolaitis 5 , Stephanie Green 7 , Gail R. Bruner 3 , Tammy O.<br />
Utset 6 , Meenakshi Jolly 4 , Judith A. James 1 , John B. Harley 8 and<br />
Timothy B. Niewold 9 , 1 Oklahoma Med Research Foundation,<br />
Oklahoma City, OK, 2 Oklahoma Medical Research Foundation,<br />
3<br />
Oklahoma Medical Rsrch, Oklahoma City, OK, 4 Rush University<br />
Med Ctr, Chicago, IL, 5 Rush University Med Ctr, 6 Univ <strong>of</strong> Chicago<br />
Med Ctr, Chicago, IL, 7 Univ <strong>of</strong> Chicago Med Ctr, 8 Univ <strong>of</strong> OK Hlth<br />
Sci Ctr, Oklahoma City, OK, 9 University <strong>of</strong> Chicago, Chicago, IL.<br />
1165. Peripheral Neuropathy in Patients with Systemic Lupus<br />
Erythematosus. Brandusa Florica 2 , Jiandong Su 1 , Ellie Aghdassi 1 ,<br />
Dafna D. Gladman 1 , Murray B. Urowitz 1 and Paul R. Fortin 1 ,<br />
1<br />
University Health Network, 2 University <strong>of</strong> Toronto, Toronto, ON,<br />
Canada.
ACR/ARHP Poster Session B<br />
1166. Predictors <strong>of</strong> Mortality in Diffuse Alveolar Haemorrhage<br />
(DAH) Associated with Systemic Lupus Erythematosus. Marco<br />
U. Martínez-Martínez 2 , Eufrates Hernández-Núñez 3 , Enrique<br />
Cuevas-Orta 3 , Ricardo Moreno-Valdés 3 , Martin Saldaña-Barnad 3 ,<br />
Martin Magaña-Aquino 3 , Juan C. Rizo-Rodríguez 2 and Carlos<br />
Abud-Mendoza 1 , 1 <strong>Rheumatology</strong> Unit, Hospital Central and<br />
Faculty <strong>of</strong> Medicine, University <strong>of</strong> San Luis Potosí, San Luis<br />
Potosi, Mexico, 2 <strong>Rheumatology</strong> Unit, Hospital Central and<br />
Faculty <strong>of</strong> Medicine, University <strong>of</strong> San Luis Potosí, México,<br />
3<br />
<strong>Rheumatology</strong> Unit, Hospital Central and Faculty <strong>of</strong> Medicine,<br />
University <strong>of</strong> San Luis Potosí, Mexico.<br />
1167. Prefrontal Lobe Volume Could Reveal Working Memory<br />
Function in Patients with System Lupus Erythematosus. Yongfei<br />
Fang 2 , Haitao Lii 1 , Qinghua Zou 3 and Yun Lin 1 , 1 Department<br />
<strong>of</strong> Radiology, Southwest Hospital, Third Military Medical<br />
University, Chongqing, China, 2 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Southwest Hospital, Third Military Medical University,<br />
Chongqing, China, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Southwest<br />
Hospital, Third Military Medical University, Chongqing, China.<br />
1168. Preliminary Results: Baseline Nutritional Vitamin D Level<br />
Does Not Predict Progression <strong>of</strong> Subclinical Atherosclerosis<br />
in Women with SLE. Apinya Lertratanakul 2 , Peggy Wu 2 , Alan<br />
R. Dyer 2 , Craig Langman 1 , William Pearce 2 , Kim Sutton-Tyrrell 4 ,<br />
George Kondos 3 , Daniel Edmundowicz 4 , James Carr 2 and<br />
Rosalind Ramsey-Goldman 2 , 1 Childrens Memorial Hospital,<br />
Chicago, IL, 2 Northwestern University, Chicago, IL, 3 University <strong>of</strong><br />
Illinois, Chicago, IL, 4 University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />
1169. Progression <strong>of</strong> Carotid Atherosclerosis and Its Determinants<br />
in Lupus Patients. Rosa Weiss Telles 3 , Cristina Costa Duarte<br />
Lanna 3 , Tulio Pinho Navarro 3 , Adriano Jose Souza 1 , Rodrigo<br />
Citton Padilha Reis 4 , Fabiana Lemos Sousa 2 , Luciana Andrade<br />
Rodrigues 3 and Antonio Luiz Ribeiro 3 , 1 Clinica Radiologica<br />
CONRAD, Brazil, 2 Hospital das Clinicas, Universidade Federal de<br />
Minas Gerais, Brazil, 3 School <strong>of</strong> Medicine, Universidade Federal<br />
de Minas Gerais , Brazil, 4 Statistics Department, Universidade<br />
Federal de Minas Gerais, Brazil.<br />
1170. Regional Brain Diffusion Abnormalities in Systemic Lupus<br />
Erythematosus. Simone Appenzeller 3 , Leticia Rittner 4 , Gabriel<br />
Leonard 1 , Martin Vielleux 2 , Bruce Pike 1 and Ann Clarke 1 , 1 McGill<br />
University, Canada, 2 McGill University, Canada 3 State University<br />
<strong>of</strong> Campinas, Brazil, 4 State University <strong>of</strong> Campinas, Brazil.<br />
1171. Renal Biopsy in Systemic Lupus Erithematosus Patients with<br />
Low Levels <strong>of</strong> Proteinuria. Esther Rodriguez, Julio Sánchez, Eva<br />
Salgado, Isabel Mateo, María Galindo and Patricia E. Carreira,<br />
<strong>Rheumatology</strong> Department, Hospital 12 de Octubre, Madrid,<br />
Spain.<br />
1172. Safety Pr<strong>of</strong>ile <strong>of</strong> Belimumab, a BLyS-Specific Inhibitor, in<br />
Patients with Active Systemic Lupus Erythematosus (SLE):<br />
Pooled Data from Phase 2 and 3 Studies. D. J. Wallace 1 , S.<br />
Navarra 12 , A. Gallacher 2 , R. Gúzman 10 , M. Thomas 7 , R. A. Furie 8 ,<br />
O. Zamani 9 , R. A. Levy 4 , R. van Vollenhoven 11 , S. Cooper 6 , Z.<br />
J. Zhong 5 , W. Freimuth 6 , L. Pineda 6 , R. Cervera 3 and for the<br />
BLISS-52 and -76 and LBSL02/99 Study Groups, 1 Cedars-Sinai/<br />
UCLA, Los Angeles, CA, 2 Hospital Británico de Buenos Aires,<br />
Buenos Aires, Argentina, 3 Hospital Clinic, Barcelona, Spain,<br />
4<br />
Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil,<br />
5<br />
Human Genome Sciences, Inc, Rockville, MD, 6 Human Genome<br />
Sciences, Inc, Rockville, Rockville, MD, 7 Kerala Institute <strong>of</strong><br />
Medical Sciences, Kerala, India, 8 North Shore LIJ Health System,<br />
Lake Success, NY, 9 Rheumazentrum Favoriten, Wien, Wien,<br />
Austria, 10 SaludCoop, Bogotá, Colombia, Bogotá, Colombia,<br />
11<br />
The Karolinska Institute, Stockholm, Sweden, 12 University <strong>of</strong><br />
Santo Tomas Hospital, Manila, Manila, Philippines.<br />
1173. Second Renal Biopsy in Proliferative Lupus Nephritis. Alberto<br />
Allievi 2 , Ana Malvar Perrin 2 , Bruno Lococo 2 , Mariac Cristina<br />
Basta 2 , Paola Pirruccio 2 , Sebastian Andres Muñoz 2 , Alejandra<br />
Quevedo 2 , Bernarda Fazzini 2 , Valeria Alberton 2 and Alejandro<br />
Iotti 1 , 1 Hospital Britanico, Ciudad Autonoma de Buenos Aires,<br />
Buenos Aires, Argentina, 2 Hospital Juan A Fernandez, Ciudad<br />
Autonoma de Buenos Aires, Buenos Aires, Argentina.<br />
1174. Seroprevalence <strong>of</strong> NMO-IgG (Anti-Aquaporin 4 Antibodies)<br />
in Patients with Neuropsychiatric Systemic Lupus<br />
Erythematosus. Jakub Zavada 4 , Petra Nytrova 1 , Klaus-Peter<br />
Wandinger 2 , Svobodova Radka 4 , Ivana Putova 4 , Dana Tegzova 4<br />
and Jiri Vencovsky 3 , 1 Department <strong>of</strong> Neurology, First Faculty<br />
<strong>of</strong> Medicine, Charles University in Prague and General<br />
University Hospital in Prague, Czech Republic, 2 Institute <strong>of</strong><br />
Experimental Immunology, Euroimmun, Lübeck, Germany,<br />
3<br />
Institute <strong>of</strong> <strong>Rheumatology</strong>, Prague, Czech Republic, 4 Institute <strong>of</strong><br />
<strong>Rheumatology</strong> and First Faculty <strong>of</strong> Medicine, Charles University<br />
in Prague, Czech Republic.<br />
1175. Serum Free Light Chains and Disease Activity in Systemic<br />
Lupus Erythematosus. Meenakshi Jolly 1 , Rohit Aggarwal 4 ,<br />
Rachel Mikolaitis 3 , Joel A. Block 2 and Winston Sequeira 1 , 1 Rush<br />
University Medical Center, Chicago, IL, 2 Rush University Medical<br />
Center, Chicago, IL, 3 Rush University Medical Center, 4 University<br />
<strong>of</strong> Pittsburgh Medical Center, Pittsburgh, PA.<br />
1176. Shrinking Lung Syndrome Is Associated with Pleuritis. David<br />
Allen 3 , Zoheir Bshouty 3 , Mellissa Moyen 3 , David B. Robinson 3 ,<br />
Christine A. Peschken 1 , Carol A. Hitchon 3 , Hani S. El-Gabalawy 2<br />
and Shikha Mittoo 1 , 1 Univ <strong>of</strong> Manitoba, Winnipeg, MB, Canada,<br />
2<br />
University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 3 University <strong>of</strong><br />
Manitoba, Winnipeg, MB, Canada.<br />
1177. The Metabolic Syndrome in Systemic Lupus Erythematosus:<br />
More Than the Sum <strong>of</strong> Its Parts? Ben Parker 3 , Yasmeen Ahmad 4 ,<br />
Joanna Shelmerdine 1 , Sahena Haque 2 and Ian N. Bruce 1 ,<br />
1<br />
Manchester, United Kingdom, 2 Manchester, United Kingdom,<br />
3<br />
Arthritis Research UK Epidemiology Unit, University <strong>of</strong><br />
Manchester, Manchester, United Kingdom, 4 Manchester Royal<br />
Infirmary, Manchester, United Kingdom.<br />
1178. The Prevalence <strong>of</strong> Liver Abnormalities in Patients with<br />
Systemic Lupus Erythematosus. Darryl Huang 2 , Ellie Aghdassi 2 ,<br />
Jiandong Su 2 and Paul R. Fortin 1 , 1 Toronto Western Hospital,<br />
Toronto, ON, Canada, 2 University Health Network, Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Toronto, ON, Canada.<br />
1179. Undertreatment <strong>of</strong> Active Disease May Increase Mortality in<br />
Lupus Patients with End Stage Renal Disease. Anna R. Broder 2<br />
and Chaim Putterman 1 , 1 Albert Einstein <strong>College</strong> <strong>of</strong> Med, Bronx,<br />
NY, 2 Montefiore Medical Ctr, Bronx, NY.<br />
1180. Vitamin D Levels Are Positively Associated with Complement<br />
among Patients with SLE. Michelle A. Petri 1 , Kayode Jibril Bello 2 ,<br />
Hong Fang 2 and Laurence Magder 3 , 1 Timonium, MD, 2 Johns<br />
Hopkins University School <strong>of</strong> Medicine, 3 University <strong>of</strong> Maryland<br />
School <strong>of</strong> Medicine.<br />
Systemic Lupus Erythematosus - Human Etiology and Pathogenesis:<br />
Cardiovascular Disease and Clinical<br />
1181. Acute Flares <strong>of</strong> Neuropsychiatric Systemic Lupus<br />
Erythematosus (NPSLE) Are Sometimes Associated with Spikes<br />
<strong>of</strong> Interferon-alpha Activity in the CSF. Elisabet Svenungsson 2 ,<br />
Clio P. Mavragani 1 , Liisa Hopia 3 , Mohsen Khademi 3 , Anna<br />
Laveskog 2 , Mary K. Crow 1 and Magnus Andersson 2 , 1 Hospital for<br />
Special Surgery, New York, NY, 2 Karolinska Institutet, Stockholm,<br />
Sweden, 3 Karolinska Institutet, Sweden.<br />
2010 Program Book 221
ACR/ARHP Poster Session B<br />
1182. Allogeneic Mesenchymal Stem Cells Inhibited OAZ Expression<br />
in Patients with Systemic Lupus Erythematosus. Xuebing Feng 1 ,<br />
Rongliang Li 2 , Jing Huang 2 , Dandan Wang 2 , Xiaolei Ma 2 , Betty<br />
P. Tsao 3 and Lingyun Sun 2 , 1 Affiliated Drum Tower Hospital <strong>of</strong><br />
Nanjing University Medical School, Nanjing, China, 2 Affiliated<br />
Drum Tower Hospital <strong>of</strong> Nanjing University Medical School,<br />
3<br />
UCLA School <strong>of</strong> Medicine, Los Angeles, CA.<br />
1183. Analysis <strong>of</strong> Vascular Endothelium from Female Systemic Lupus<br />
Erythematosus (SLE) Patients Identifies an Interferon Signature<br />
That Correlates with Disease Activity. Diana Goldenberg 3 ,<br />
Mikhail Olferiev 3 , Duygu Onat 1 , Danieli Andrade 3 , Mary K. Crow 3 ,<br />
Paolo C. Colombo 1 and Jane E. Salmon 2 , 1 Columbia University<br />
<strong>College</strong> <strong>of</strong> Physicians and Surgeons, New York, NY, 2 Hospital for<br />
Special Surgery, New York, NY, 3 Hospital for Special Surgery, New<br />
York, NY.<br />
1184. Anti-C1q Antibodies Are Associated with Global Activity <strong>of</strong><br />
Systemic Lupus Erythematosus, but Not Specifically with<br />
Nephritis. Yuko Okamoto 1 , Yasuhiro Katsumata 5 , Yasushi<br />
Kawaguchi 2 , Kohei Miyake 5 , Manabu Kawamoto 5 , Kae Takagi 5 ,<br />
Takahisa Gono 5 , Sayumi Baba 5 , Yuko Ota 5 , Masako Hara 4 and<br />
Hisashi Yamanaka 3 , 1 Tokyo Women’s Medical University, Tokyo,<br />
Japan, 2 Tokyo Women’s Medical University, Tokyo, Japan, 3 Tokyo<br />
Women’s Medical University, Shinjuku-ku, Tokyo, Japan, 4 Tokyo<br />
Women’s Medical University, Kamakura Kanagawa, Japan,<br />
5<br />
Tokyo Women’s Medical University.<br />
1185. Biomarkers <strong>of</strong> Oxidative Stress, mTOR Activation, and Treg<br />
Depletion Correlate with Disease Activity in Patients with<br />
Systemic Lupus Erythematosus. Zhiwei Lai 1 , Adam Bartos 1 ,<br />
Tiffany Tekarico 1 , Robert Hanczko 1 , Gabriella Miklossy 1 , Brandon<br />
Clair 1 , John Jimah 1 , Lisa Francis 1 , Hajra Tily 1 , Ricardo Garcia 1 ,<br />
Maha Dawood 1 , David R. Fernandez 1 , Paul E. Phillips 2 , Ioana<br />
Coman 1 and Andras Perl 3 , 1 SUNY, 2 SUNY-Upstate Medical Univ,<br />
Syracuse, NY, 3 Upstate Medical Univ, Syracuse, NY.<br />
1186. CD138 RNA Can Be Detected in the Circulation <strong>of</strong> Patients with<br />
Systemic Lupus and Correlated to Other Factors Suggestive <strong>of</strong><br />
Plasma Cell Activation. Ming Chen 3 , Joy G. Hutcheson 2 , Stan<br />
Kamp 2 , Danny Walker 2 and Joan T. Merrill 1 , 1 Oklahoma Med<br />
Research Foundation, Oklahoma City, OK, 2 OMRF, Oklahoma<br />
City, OK, 3 OMRF, Allen, TX.<br />
1187. Characterisation <strong>of</strong> Lipid Order in Lymphocyte Subsets from<br />
Patients with Systemic Lupus Erythematosus (SLE). Laura<br />
Miguel 2 , Chrissie Lim 2 , David A. Isenberg 1 and Elizabeth C. Jury 2 ,<br />
1<br />
UCL Div <strong>of</strong> Medicine, London, United Kingdom, 2 University<br />
<strong>College</strong> London, London, United Kingdom.<br />
1188. Correlates <strong>of</strong> ANA Positivity in Healthy Individuals. David R.<br />
Karp 2 , Quan-Zhen Li 2 , Valerie K. Branch 2 , Jiexia Quan 3 and Nancy<br />
J. Olsen 1 , 1 Univ <strong>of</strong> TX Southwestern Med Ctr, Dallas, TX, 2 UT<br />
Southwestern Med Ctr, Dallas, TX, 3 UT Southwestern Med Ctr.,<br />
Dallas, TX.<br />
1189. Dysfunctional, Pro-Inflammatory High Density Lipoproteins<br />
Directly Influence Monocyte PDGFRβ Transcript Levels,<br />
TNFα Secretion, and Chemotaxis. Brian J. Skaggs 1 , Bevra H.<br />
Hahn 4 , Lori Sahakian 2 , Jennifer M. Grossman 3 and Maureen<br />
A. McMahon 1 , 1 UCLA School <strong>of</strong> Medicine, Los Angeles, CA,<br />
2<br />
UCLA School <strong>of</strong> Medicine, 3 University <strong>of</strong> California Los Angeles,<br />
Sherman Oaks, CA, 4 University <strong>of</strong> California Los Angeles School<br />
<strong>of</strong> Medicine, Los Angeles, CA.<br />
1190. Dysregulation <strong>of</strong> the Microvascular as Assessed by Expression<br />
<strong>of</strong> Protective and Injury Associated Markers Is Reflected in<br />
the Non-Lesional Non-Sunexposed Skin <strong>of</strong> Patients with Lupus<br />
Nephritis. Peter M. Izmirly 1 , Shane Meehan 2 , Sherry X. Xu 2 ,<br />
Anca D. Askanase 1 , Joan T. Merrill 3 , Jill P. Buyon 1 and Robert M.<br />
Clancy 4 , 1 NYU School <strong>of</strong> Medicine, New York, NY, 2 NYU School<br />
<strong>of</strong> Medicine, 3 Oklahoma Med Research Foundation, Oklahoma<br />
City, OK, 4 Tisch Hospital 4-407, New York, NY.<br />
1191. Evidence <strong>of</strong> N-methyl-D-aspartate Receptor (NMDAR)<br />
Expression on Primary Human Endothelial Cells. Cagri Yildirim-<br />
Toruner 3 , Paola Mina-Osario 2 and Betty Diamond 1 , 1 Feinstein<br />
Institute for Medical Research, Manhasset, NY, 2 Feinstein<br />
Institute for Medical Research, 3 Morgan Stanley Children’s<br />
Hospital <strong>of</strong> NewYork- Presbyterian Columbia University Medical<br />
Center, Feinstein Institute for Medical Research, New York, NY.<br />
1192. Expession <strong>of</strong> B Cell Subsets in SLE Pregnancy: Correlation<br />
with Preterm Birth. Megan E. B. Clowse 1 , Sara Sparks 2 , Sallie<br />
Allgood 2 , Mark Lanasa 2 and David S. Pisetsky 3 , 1 Duke Univ Med,<br />
Durham, NC, 2 Duke University, Durham, NC, 3 Duke University<br />
Medical Ctr, Durham, NC.<br />
1193. Increased Male Fetal Loss and Fewer Male Siblings in a Cohort<br />
<strong>of</strong> Systemic Lupus Erythematosus Families. Rachna Aggarwal 1<br />
and Robert H. Sc<strong>of</strong>ield 2 , 1 OUHSC, 2 OUHSC, OMRF, VA.<br />
1194. Low Levels <strong>of</strong> Atheroprotective Natural IgM Antibodies Against<br />
Phosphorylcholine and Increased Prevalence <strong>of</strong> Vulnerable<br />
Atherosclerotic Plaques in Patients with SLE. Cristina Anania 2 ,<br />
Thomas Gustafsson 2 , Xiang Hua 2 , Jun Su 2 , Mikael Heimbürger 1 ,<br />
Tomas Jogestrand 2 and Johan Frostegård 2 , 1 Abbot, 2 Karolinska<br />
Institutet.<br />
1195. Presence <strong>of</strong> HMGB1 (High Mobility Group Box 1) and<br />
Antibodies to HMGB1 in Systemic Lupus Erythematosus (SLE).<br />
Deena Abdulahad, Johanna Westra, Pieter Limburg, Cees<br />
Kallenberg and Marc Bijl, UMCG.<br />
1196. Reversal <strong>of</strong> CD3+/CD4+/CD25+/Foxp3+ Treg Depletion in<br />
Active SLE Patients with Rapamycin. Zhiwei Lai 1 , Tiffany N.<br />
Telarico 1 , Adam Bartos 1 , Gabriella Miklossy 1 , Robert Hanczko 1 ,<br />
John Jimah 1 , Brandon Clair 1 , Lisa Francis 1 , Hajra Tily 1 , Ricardo<br />
Garcia 1 , Paul E. Phillips 2 , Irene Ramos 1 and Andras Perl 3 , 1 SUNY,<br />
2<br />
SUNY-Upstate Medical Univ, Syracuse, NY, 3 Upstate Medical<br />
Univ, Syracuse, NY.<br />
1197. Strong Viral Associations among Filipinos with Systemic Lupus<br />
Erythematosus. Evan Glenn Vista 6 , Michael H. Weisman 3 ,<br />
Mariko L. Ishimori 1 , Jourdan Anderson 5 , Robelle Tanangunan 8 ,<br />
Noga Gal 2 , John B. Harley 7 , Guthridge Joel 5 , Sandra Navarra 8<br />
and Judith A. James 4 , 1 Cedars Sinai Medical Center, Los Angeles,<br />
CA, 2 Cedars-Sinai, 3 Cedars-Sinai Medical Center, Los Angeles,<br />
CA, 4 Oklahoma Med Research Foundation, Oklahoma City, OK,<br />
5<br />
Oklahoma Medical Research Foundation, 6 Oklahoma Medical<br />
Research Foundation, Oklahoma City, OK, 7 Univ <strong>of</strong> OK Hlth Sci<br />
Ctr, Oklahoma City, OK, 8 University <strong>of</strong> Santo Tomas Hospital.<br />
1198. TNFα Expression in Peripheral Blood Mononuclear Cells<br />
<strong>of</strong> Cutaneous Lupus & Dermatomyositis Patients. Adam S.<br />
Nabatian 2 , Maria Wysocka 4 , Muhammad M. Bashir 1 and Victoria<br />
P. Werth 3 , 1 Philadelphia VAMC, University <strong>of</strong> Pennsylvania,<br />
2<br />
UMDNJ-Robert Wood Johnson Medical School, Philadelphia<br />
VAMC, University <strong>of</strong> Pennsylvania, 3 University <strong>of</strong> Pennsylvania,<br />
Philadelphia, PA, 4 University <strong>of</strong> Pennsylvania.<br />
222<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
1199. Type I IFN Signature in Pregnant Patients with Lupus. Danieli<br />
Andrade 3 , Gloria C. Koo 3 , Patricia Redecha 3 , Kyriakos A. Kirou 3 ,<br />
Mimi Kim 1 , Mary K. Crow 3 and Jane E. Salmon 2 , 1 Albert Einstein<br />
<strong>College</strong> <strong>of</strong> Medicine, New York, NY, 2 Hospital for Special Surgery,<br />
New York, NY, 3 Hospital for Special Surgery, New York, NY.<br />
1200. Vitamin D and Vascular Stiffness in Patients with Systemic<br />
Lupus Erythematosus. John A. Reynolds 3 , Sahena Haque 4 ,<br />
Jacqueline L. Berry 4 , Lee-Suan Teh 2 , Pauline Ho 1 , Rachel<br />
Gorodkin 1 and Ian N. Bruce 4 , 1 Central Manchester University<br />
Hospitals NHS Foundation Trust, 2 East Lancashire Hospitals NHS<br />
Trust, 3 University <strong>of</strong> Manchester, Manchester, United Kingdom,<br />
4<br />
University <strong>of</strong> Manchester.<br />
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical<br />
Aspects and Therapeutics II<br />
1201. A Pilot Study To Evaluate Digital Perfusion in Scleroderma<br />
Patients Treated with Oral Treprostinil. Ami A. Shah 2 , Laura<br />
K. Hummers 2 , Kristan D. Rollins 4 , Susan Walker 4 , Mike Wade 4 ,<br />
Cynthia Anderson 3 , Robert Wise 3 , Francesco Boin 2 and Fredrick<br />
M. Wigley 1 , 1 Johns Hopkins University, Baltimore, MD, 2 Johns<br />
Hopkins University, Baltimore, MD, 3 Johns Hopkins University,<br />
4<br />
United Therapeutics.<br />
1202. An Analysis <strong>of</strong> Agreement <strong>of</strong> Guidelines for Management<br />
in SSc from a Large Database (CSRG: Canadian Scleroderma<br />
Research Group). Janet E. Pope 3 , Sarah Harding 4 , Sarit Khimdas 4 ,<br />
Ash Bonner 2 , Murray Baron 1 and The CSRG, 1 Jewish General<br />
Hospital, Montreal, QC, Canada, 2 McMaster University, 3 St<br />
Joseph Health Care London, London, ON, Canada, 4 University <strong>of</strong><br />
Western Ontario.<br />
1203. Are SSc Experts Doing What They Should Do? An Analysis <strong>of</strong><br />
Practice Variability in Large SSc Centers within the Canadian<br />
Scleroderma Research Group (CSRG) Shows Practice<br />
Differences. Sarah Harding 4 , Sarit Khimdas 4 , A. Bonner 2 , Murray<br />
Baron 1 and Janet E. Pope 3 , 1 Jewish General Hospital, Montreal,<br />
QC, Canada, 2 McMaster University, 3 St Joseph Health Care<br />
London, London, ON, Canada, 4 University <strong>of</strong> Western Ontario.<br />
1204. Assessing Health Status in Patients with Systemic Sclerosis:<br />
Construct Validity <strong>of</strong> the Karn<strong>of</strong>sky Performance Status Score.<br />
Christelle Nguyen 2 , Alice Bérezné 2 , François Rannou 3 , Caroline<br />
Mestre-Stanislas 2 , Sandrine Morell-Dubois 1 , Loïc Guillevin 2 ,<br />
Serge Poiraudeau 3 and Luc Mouthon 2 , 1 Universite Lille 2 ; Service<br />
de Medecine Interne; Centre de Reference Pour la Sclerodermie<br />
Systemique; Hopital Claude Huriez; Lille; France, 2 Universite<br />
Paris Descartes; Faculte de Medecine Paris Descartes; Pole de<br />
Medecine Interne, Centre de Reference Pour les Vascularites<br />
Necrosantes et la Sclerodermie Systemique; Hopital Cochin;<br />
Assistance Publique-Hopitaux de Paris (AP-HP); 3 Universite<br />
Paris Descartes; Faculte de Medecine Paris Descartes; Service<br />
de Medecine Physique et Readaptation; Hopital Cochin; AP-HP;<br />
Inserm, Institut Federatif de Recherche sur le Handicap, Paris.<br />
1205. Association <strong>of</strong> Gastrointestinal Involvement and Depressive<br />
Symptoms in Patients with Systemic Sclerosis. Vijay Bodukam 1 ,<br />
Ron D. Hays 2 , Paul Maranian 2 , Daniel E. Furst 2 , James R.<br />
Seibold 3 , Ann Impens 4 , Maureen D. Mayes 5 , Philip J. Clements 2<br />
and Dinesh Khanna 2 , 1 Interfaith Medical Center, Brooklyn,<br />
Los Angeles, CA, 2 UCLA, 3 Univ <strong>of</strong> Connecticut, 4 University <strong>of</strong><br />
MIchigan, 5 University <strong>of</strong> Texas Houston.<br />
1206. Bone Mineral Density and Body Composition in Systemic<br />
Sclerosis: A Case-Control Study. Chi Chiu Mok, Ling Yin Ho, Chi<br />
Hung To and Kwok Man Ma, Tuen Mun Hospital.<br />
1207. Clinical Significance <strong>of</strong> Defined ANCA Positivity in Systemic<br />
Sclerosis. Emma C. Derrett-Smith 2 , Svetlana Nihtyanova 2 ,<br />
Jennifer Parker 1 , Christopher Bunn 1 , Aine Burns 1 , Mark A.<br />
Little 1 and Christopher P. Denton 3 , 1 Centre for Immunology,<br />
Royal Free Campus, UCL Medical School, London, 2 Centre for<br />
<strong>Rheumatology</strong> and Connective Tissue Diseases, Royal Free<br />
Campus, UCL Medical School, London, 3 Royal Free Hospital,<br />
London, United Kingdom.<br />
1208. Cognitive Impairment in Systemic Sclerosis. Neslihan Yilmaz 2 ,<br />
Aynur Mollahasanoglu 1 , Meryem Can 2 , Müge Koçak 1 , Nese<br />
Tuncer 1 , Nevsun Inanç 2 and Sule Yavuz 2 , 1 Marmara University,<br />
Faculty <strong>of</strong> Medicine, Neurology Department, Istanbul, Turkey,<br />
2<br />
Marmara University, Faculty <strong>of</strong> Medicine, <strong>Rheumatology</strong><br />
Department, Istanbul, Turkey.<br />
1209. Coronary Artery Calcification in Systemic Sclerosis: There<br />
Was No Difference between SSc and Healthy Control Groups.<br />
Young-Eun Park 2 , Seong-Hu Park 2 , Seung-Hoon Baek 2 , Jun-<br />
Hee Lee 2 , Joung-Wook Lee 2 , Geun-Tae Kim 2 , Yeon-Ju Jeong 3 ,<br />
Su-Yeon Choi 4 , Wan-Hee Yoo 1 and Sung-Il Kim 2 , 1 Chonbuk<br />
National University Medical School, Jeonju, Jeonbuk, South<br />
Korea, 2 Department <strong>of</strong> Internal Medicine, School <strong>of</strong> Medicine,<br />
Pusan National University, Busan, South Korea, 3 Department<br />
<strong>of</strong> Radiology, School <strong>of</strong> Medicine, Pusan National University,<br />
Busan, South Korea, 4 Seoul National University Hospital<br />
Healthcare System Gangnam Center, Seoul, South Korea.<br />
1210. CXCL4, a Novel Marker for Systemic Sclerosis That Clearly<br />
Correlates with the Clinical Hallmarks and Pathological Events.<br />
Timothy Ruben Radstake 3 , Lenny van Bon 2 , Jasper Broen 2 ,<br />
Romy Beatriz-Christmann 1 , Alsya Affandi 1 , Madelon Vonk 2 ,<br />
Mike York 1 , Cindy Collins 1 , Mark Wenink 2 , Roger Hesselstrand 7 ,<br />
Dirk Wuttge 7 , Sandeep Agarwal 6 , John Reveille 6 , Joost Drenth 2 ,<br />
Jaqueline de Graaf 2 , Martin Den Heijer 2 , Cees Kallenberg 5 , Marc<br />
Bijl 4 , Wim van den Berg 2 , Joosten Leo 2 , Waander van Heerde 2 ,<br />
Piet van Riel 2 and Robert Lafyatis 1 , 1 Boston Medical Center,<br />
2<br />
Radboud University Nijmegen Medical Center, 3 Radboud<br />
University Nijmegen Medical Center / Boston Medical Center,<br />
Nijmegen, The Netherlands, 4 University Hospital Groninge,<br />
5<br />
University Hospital Groningen, 6 University Hospital Houston,<br />
TX, 7 University Hospital Lund, Sweden.<br />
1211. Determinants <strong>of</strong> Work Disability in Patients with Systemic<br />
Sclerosis: A Longitudinal Study <strong>of</strong> the GENISOS Cohort.<br />
Roozbeh Sharif 2 , Maureen D. Mayes 8 , Perry M. Nicassio 1 ,<br />
Emilio B. Gonzalez 6 , Hilda T. Draeger 5 , Terry A. McNearney 7 ,<br />
Deepthi K. Nair 3 , John D. Reveille 4 , Frank C. Arnett 9 and Shervin<br />
Assassi 2 , 1 Department <strong>of</strong> Psychiatry, University <strong>of</strong> California, Los<br />
Angeles, CA, 2 Division <strong>of</strong> <strong>Rheumatology</strong> and Immunogenetics,<br />
University <strong>of</strong> Texas Health Science Center at Houston, Houston,<br />
TX, 3 Division <strong>of</strong> <strong>Rheumatology</strong> and Immunogenetics, University<br />
<strong>of</strong> Texas Health Science Center at Houston, Houston, TX, 4 Univ<br />
Texas Health Sci Ctr, Houston, TX, 5 University <strong>of</strong> Texas Health<br />
Science Center at San Antonio, San Antonio, TX, 6 University <strong>of</strong><br />
Texas Medical Branch at Galveston, Galveston, TX, 7 University<br />
<strong>of</strong> Texas Medical Branch at Galveston, TX, 8 University <strong>of</strong> Texas-<br />
Houston, Houston, TX, 9 UT Medical School, Houston, TX.<br />
1212. Developing a Disease Activity and Therapeutic Response Index<br />
in Connective Tissue Disease Related Interstitial Lung Disease<br />
(CTD-ILD): Rationale, Aims, Design and Results from Tier 0,<br />
the Pre-Delphi Exercise. Lesley Ann Saketkoo 4 , Dörte Huscher 2 ,<br />
Dinesh Khanna 12 , Paul F. Dellaripa 1 , Kevin Flaherty 15 , Eric L.<br />
Matteson 5 , Chester V. Oddis 16 , Kristine Phillips 14 , David Pittrow 3 ,<br />
Athol Wells 8 , Christopher P. Denton 9 , Oliver Distler 11 , Otylia M.<br />
Kowal-Bielecka 6 , Vibeke Strand 10 , Kevin K. Brown 7 and James R.<br />
2010 Program Book 223
ACR/ARHP Poster Session B<br />
Seibold 13 , 1 Brigham & Womens Hospital, Boston, MA, 2 German<br />
Rheumatism Research Centre - Berlin, Berlin, Germany,<br />
3<br />
Institute <strong>of</strong> Clinical Pharmacology, Medical Faculty, University<br />
<strong>of</strong> Dresden, Dresden, Germany, 4 Louisiana State University<br />
Health Sciences Center - New Orleans, New Orleans, LA,<br />
5<br />
Mayo Clinic, Rochester, MN, 6 Medical University <strong>of</strong> Bialystok,<br />
Bialystok, Poland, 7 National Jewish Health, Denver, CO, 8 Royal<br />
Brompton Hospital and National Heart and Lung Institute,<br />
London, United Kingdom, 9 Royal Free Hospital, London, United<br />
Kingdom, 10 Stanford University; Palo Alto, Portola Valley, CA,<br />
11<br />
University Hospital Zurich, Zurich, Switzerland, 12 University<br />
<strong>of</strong> California Los Angeles, Los Angeles, CA, 13 University <strong>of</strong><br />
Connecticut Health Center, Farmington, CT, 14 University <strong>of</strong><br />
Michigan, Ann Arbor, MI, 15 University <strong>of</strong> Michigan, Ann Arbor,<br />
16<br />
University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />
1213. Development <strong>of</strong> a Limited Scleroderma Cutaneous Activity and<br />
Damage Index. Lorinda Chung 1 , Daniel E. Furst 5 , Paul Maranian 3 ,<br />
Kait Arefiev 2 , Jeffrey Zwerner 2 , Dinesh Khanna 4 , Victoria P.<br />
Werth 6 and David Fiorentino 2 , 1 Stanford Univ Medical Center,<br />
Palo Alto, CA, 2 Stanford Univ Medical Center, 3 UCLA Medical<br />
School, 4 University <strong>of</strong> California Los Angeles, Los Angeles,<br />
CA, 5 University <strong>of</strong> California Los Angeles Medical School, Los<br />
Angeles, CA, 6 University <strong>of</strong> Pennsylvania, Philadelphia, PA.<br />
1214. Effect <strong>of</strong> Selective and Dual Endothelin Receptor Antagonists<br />
(ERAs) on SSc and Control Endothelial Cells Apoptosis.<br />
Yongqing Wang, Omar R. Kahaly and Bashar Kahaleh, University<br />
<strong>of</strong> Toledo, Toledo, OH.<br />
1215. Findings in Ocular Examination <strong>of</strong> Patients with Systemic<br />
Sclerosis. Niki Tsifetaki 3 , Charalampos Papagoras 3 , Contantinos<br />
A. Paschides 1 and Alexandros A. Drosos 2 , 1 Department <strong>of</strong><br />
Ophthalmology, Medical School, University <strong>of</strong> Ioannina,<br />
Ioannina, Greece, 2 Ioannina Medical School, Ioannina, Greece,<br />
3<br />
<strong>Rheumatology</strong> Clinic, Department <strong>of</strong> Internal Medicine,<br />
Medical School, University <strong>of</strong> Ioannina, Ioannina, Greece.<br />
1216. Genetic and Clinical Correlates <strong>of</strong> Anti-Fibrillarin (U3-RNP)<br />
Auto-Antibodies in African <strong>American</strong>s with Systemic Sclerosis.<br />
Roozbeh Sharif 2 , Marvin J. Fritzler 4 , John D. Reveille 3 , Shervin<br />
Assassi 1 , Maureen D. Mayes 5 and Frank C. Arnett 6 , 1 Univ <strong>of</strong><br />
Texas Health Science, Houston, TX, 2 Univ <strong>of</strong> Texas Health<br />
Science Center at Houston, Houston, TX, 3 Univ Texas Health Sci<br />
Ctr, Houston, TX, 4 University <strong>of</strong> Calgary, Calgary, AB, Canada,<br />
5<br />
University <strong>of</strong> Texas-Houston, Houston, TX, 6 UT Medical School,<br />
Houston, TX.<br />
1217. Impact <strong>of</strong> Systemic Sclerosis on Occupational and Pr<strong>of</strong>essional<br />
Activity with Attention to Patients with Digital Ulcers. Alice<br />
Berezne 3 , Raphaele Seror 2 , Sandrine Morell-Dubois 1 , Christelle<br />
Nguyen 4 , Eric Hachulla 1 , Loic Guillevin 4 and Luc Mouthon 4 ,<br />
1<br />
Service de Medecine Interne, Centre de Reference Pour la<br />
Sclerodermie Systemique, Hôpital Claude Huriez, Universite<br />
Lille 2 , Lille, France, Metropolitan, 2 Université Paris Descartes,<br />
Faculté de Médicine, Pôle de Médecine Interne, Centre de<br />
Reference Pour les Vascularites Necrosantes et la Sclerodermie<br />
Systemique, Hôpital Cochin, Assistance Publique-Hopitau,<br />
3<br />
Universite Paris Descartes, Faculte de Medicine, Pôle de<br />
Medecine Interne, Centre de Reference Pour les Vascularites<br />
Necrosantes et la Sclerodermie Systemique, Hôpital Cochin,<br />
Assistance Publique-Hôpitaux de Paris, Paris, Fra, 4 Universite<br />
Paris Descartes, Faculte de Medicine, Pole de Medecine Interne,<br />
Centre de Reference Pour les Vascularites Necrosantes et la<br />
Sclerodermie Systemique, Hopital Cochin, Assistance Publique-<br />
Hopitaux de Paris (AP-HP), Paris, France, Metro.<br />
1218. Is Surfactant D or CC-Chemokine Ligand 18 Biomarkers<br />
for Interstitial Lung Disease in Systemic Sclerosis? Shervin<br />
Assassi 2 , Julio Charles 3 , Frank C. Arnett 7 , Roozbeh Sharif 2 ,<br />
Robert E. Lasky 3 , Emilio B. Gonzalez 5 , Hilda T. Draeger 4 , Terry<br />
A. McNearney 1 , Sandeep K. Agarwal 2 , Ramana V. Gutala 3 , Rosa<br />
M. Estrada-Y-Martin 3 and Maureen D. Mayes 6 , 1 Eli Lilly and<br />
Co, Indianapolis, IN, 2 Univ <strong>of</strong> Texas Health Science Center at<br />
Houston, Houston, TX, 3 Univ <strong>of</strong> Texas Health Science Center at<br />
Houston, 4 Univ <strong>of</strong> Texas Health Science Center at San Antonio,<br />
San Antonio, TX, 5 Univ <strong>of</strong> Texas Medical Branch Galveston,<br />
Galveston, TX, 6 University <strong>of</strong> Texas-Houston, Houston, TX, 7 UT<br />
Medical School, Houston, TX.<br />
1219. Longitudinal Fatigue Severity Scale Scores Correlate with<br />
Modifiable Psychosocial Variables in Early Systemic Sclerosis.<br />
Astrud Lorraine Leyva 3 , Shervin Assassi 1 , Maureen D. Mayes 6 ,<br />
Deepthi K. Nair 1 , Michael Fischbach 2 , Roozbeh Sharif 1 , John D.<br />
Reveille 5 , Emilio B. Gonzalez 3 and Terry A. McNearney 4 , 1 Univ<br />
<strong>of</strong> Texas Health Science Center Houston, Houston, TX, 2 Univ <strong>of</strong><br />
Texas Health Science Center San Antonio, San Antonio, TX, 3 Univ<br />
<strong>of</strong> Texas Medical Branch, Galveston, TX, 4 Univ <strong>of</strong> Texas Medical<br />
Branch; Currently at Eli Lilly and Co, Indianapolis, IN, 5 Univ<br />
Texas Health Sci Ctr, Houston, TX, 6 University <strong>of</strong> Texas-Houston,<br />
Houston, TX.<br />
1220. Loss <strong>of</strong> Microvascular Response to Central Nervous Impulses<br />
to Finger Pulp in Systemic Sclerosis. Tone Kristin Bergersen 2 ,<br />
Anna-Maria H<strong>of</strong>fmann-Vold 1 , Oivind Midtvet 2 , Jan Tore Gran 2 ,<br />
Cato Mork 2 and Karin Toska 3 , 1 Oslo University Hospital, Oslo,<br />
PO Box 4950 Nydalen, Norway, 2 Oslo University Hospital, Oslo,<br />
Norway, 3 University <strong>of</strong> Oslo, PO Box 1103 Blindern, Norway.<br />
1221. Lower Education as a Proxy for Socioeconomic Status Is? Not<br />
Associated with Poor Outcomes in Systemic Sclerosis (SSc):<br />
Data from a Large SSc Cohort (Canadian Scleroderma Research<br />
Group). Samah Mansour 4 , Ashley Bonner 2 , Murray Baron 1 , Janet<br />
E. Pope 3 and The CSRG, 1 Jewish General Hospital, Montreal, QC,<br />
Canada, 2 McMaster University, 3 St Joseph Health Care London,<br />
London, ON, Canada, 4 University <strong>of</strong> Western Ontario.<br />
1222. Open Label Trial <strong>of</strong> Oral Treprostinil in Patients with Systemic<br />
Sclerosis and History <strong>of</strong> Digital Ulcers: Multiple Dose<br />
Pharmacokinetics and Tolerability. Elena Schiopu 6 , Laura K.<br />
Hummers 2 , Ami A. Shah 2 , Susan Walker 4 , Kristine Phillips 6 ,<br />
James R. Seibold 5 , Fredrick M. Wigley 1 and Kristan Rollins 3 ,<br />
1<br />
Johns Hopkins University, Baltimore, MD, 2 Johns Hopkins<br />
University, Baltimore, MD, 3 United Therapeutics, RTP, NC,<br />
4<br />
United Therapeutics, 5 University <strong>of</strong> Conneticut, Farmington, CT,<br />
6<br />
University <strong>of</strong> Michigan, Ann Arbor, MI.<br />
1223. Outcomes in a Newly Diagnosed Population <strong>of</strong> Connective<br />
Tissue Disease-Associated Pulmonary Arterial Hypertension<br />
Patients from the REVEAL Registry. Lorinda Chung 4 , Lori<br />
Parsons 1 , Paul M. Hassoun 2 , Michael McGoon 3 , David Badesch 6 ,<br />
Dave P. Miller 1 , Mark R. Nicolls 5 and Roham T. Zamanian 5 ,<br />
1<br />
ICON Clinical Research, 2 Johns Hopkins University, 3 Mayo<br />
Clinic, 4 Stanford Univ Medical Center, Palo Alto, CA, 5 Stanford<br />
University, 6 University <strong>of</strong> Colorado.<br />
1224. Patients with Systemic Sclerosis and Anti-Centromere<br />
Antibodies Are Affected with Accelerated Atherosclerosis.<br />
Annica Nordin 2 , Lena Björnådal 3 , Kerstin Jensen-Urstad 1<br />
and Elisabet Svenungsson 4 , 1 Dept. <strong>of</strong> Clinical Physiology,<br />
Södersjukhuset, Karolinska Institutet, Sweden, 2 Dept. <strong>of</strong><br />
Medicine, <strong>Rheumatology</strong> Unit, Karolinska Institutet, Stockholm,<br />
Sweden, 3 Dept. <strong>of</strong> Medicine, <strong>Rheumatology</strong> Unit, Karolinska<br />
Institutet, Sweden, Sweden, 4 Dept. <strong>of</strong> Medicine, <strong>Rheumatology</strong><br />
Unit, Karolinska Institutet, Sweden.<br />
224<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
1225. Physician Opinion <strong>of</strong> Variables That Differentiate Disease<br />
Activity and Damage in Systemic Sclerosis. Geneviève Gyger,<br />
Ernest Lo, Marie Hudson, Canadian Scleroderma Research<br />
Group and Murray Baron, McGill, Canada.<br />
1226. Plasma Endogenous Met- and Leu-Enkephalin Levels Are<br />
Decreased and Associated with Clinical and Laboratory<br />
Parameters in Early Systemic Sclerosis. Terry A. McNearney 4 ,<br />
Kathleen A. Sluka 2 , Chul W. Ahn 5 , John D. Reveille 6 , Michael<br />
Fischbach 1 and Maureen D. Mayes 3 , 1 Univ Texas Hlth Sci Ctr<br />
at San Antonio, San Antonio, TX, 2 University <strong>of</strong> Iowa Medical<br />
Center, Iowa City, IA, 3 University <strong>of</strong> Texas -Houston Health<br />
Sciences Center, Houston, TX, 4 University <strong>of</strong> Texas Medical<br />
Branch, Galveston, TX, 5 University <strong>of</strong> Texas Southwestern<br />
Medical Center, Dallas, TX, 6 University <strong>of</strong> Texas-Houston Health<br />
Sciences Center, Houston, TX.<br />
1227. Predictors <strong>of</strong> Interstitial Lung Disease in Early Systemic<br />
Sclerosis: A Prospective Longitudinal Study. Shervin Assassi 2 ,<br />
Roozbeh Sharif 2 , Robert E. Lasky 3 , Terry A. McNearney 1 , Rosa<br />
Estrada Y Martin 3 , Hilda T. Draeger 4 , Deepthi K. Nair 3 , Marvin<br />
J. Fritzler 6 , John D. Reveille 5 , Frank C. Arnett 8 and Maureen D.<br />
Mayes 7 , 1 Eli Lilly and Co, Indianapolis, IN, 2 Univ <strong>of</strong> Texas Health<br />
Science Houston, Houston, TX, 3 Univ <strong>of</strong> Texas Health Science<br />
Houston, 4 Univ <strong>of</strong> Texas Health Science San Antonio, San<br />
Antonio, TX, 5 Univ Texas Health Sci Ctr, Houston, TX, 6 University<br />
<strong>of</strong> Calgary, Calgary, AB, Canada, 7 University <strong>of</strong> Texas-Houston,<br />
Houston, TX, 8 UT Medical School, Houston, TX.<br />
1228. Prevalence and Correlates <strong>of</strong> Sleep Disturbance in Systemic<br />
Sclerosis — Results from the UCLA Scleroderma Quality <strong>of</strong> Life<br />
Study. Tracy M. Frech 1 , Ron D. Hays 2 , Paul Maranian 3 , Philip J.<br />
Clements 6 , Daniel E. Furst 5 and Dinesh Khanna 4 , 1 Department<br />
<strong>of</strong> Internal Medicine, University <strong>of</strong> Utah, Salt Lake City, UT,<br />
2<br />
Division <strong>of</strong> General Internal Medicine, David Geffen School <strong>of</strong><br />
Medicine, Los Angeles, CA, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, David<br />
Geffen School <strong>of</strong> Medicine, Los Angeles, CA, 4 University <strong>of</strong><br />
California Los Angeles, Los Angeles, CA, 5 University <strong>of</strong> California<br />
Los Angeles Medical School, Los Angeles, CA, 6 University <strong>of</strong><br />
California Los Angeles School <strong>of</strong> Medicine, Los Angeles, CA.<br />
1229. Prevalence <strong>of</strong> Associated Autoimmune Diseases in a Spanish<br />
Population with Systemic Sclerosis. Esther Francisca Vicente 2 ,<br />
María Jesús García-Arias 2 , Rosario García-Vicuña 2 , Alicia<br />
Humbría 2 , Juan Pedro López-Bote 2 and Santos Castañeda 1 ,<br />
1<br />
<strong>Rheumatology</strong> Department, Hospital Universitario de<br />
La Princesa, IIS Princesa, Madrid, Spain, 2 <strong>Rheumatology</strong><br />
Department, Hospital Universitario de La Princesa, IIS Princesa.<br />
1230. Serum Chemokine and Cytokine Levels as Indicators <strong>of</strong> Disease<br />
Activity in Patients with Systemic Sclerosis. Minoru Hasegawa,<br />
Manabu Fujimoto, Kazuhiko Takehara and Shinichi Sato,<br />
Kanazawa University.<br />
1231. Severe Pulmonary Fibrosis Is Uncommon in Scleroderma<br />
Patients with RNA Polymerase 3 Antibody. Virginia D. Steen 1 ,<br />
Robyn T. Domsic 2 and Thomas Medsger 2 , 1 Georgetown<br />
University, Washington, DC, 2 University <strong>of</strong> Pittsburgh.<br />
1232. Survival in Pulmonary Hypertension Associated with<br />
Scleroderma-Spectrum Disease: A Single Center Experience.<br />
Dinesh Khanna, Rajeev Saggar, Daniel Furst, Paul Maranian,<br />
Philip Clements and Rajan Saggar, UCLA.<br />
1233. Systemic Sclerosis Is an Independent Predictive Factor to<br />
Coronary Atherosclerosis. Mo Yin Mok, Chak Sing Lau, Sonny<br />
Chiu, Annette Tso, Ka Fung Mak, Woon Sing Wong, Pek Lan<br />
Khong and Karen S. L. Lam, The University <strong>of</strong> Hong Kong, Queen<br />
Mary Hospital, Hong Kong.<br />
1234. The Psychological Impact <strong>of</strong> Systemic Sclerosis-Related<br />
Telangiectases. Holly Ennis 3 , Helen L. Richards 1 , Claire Cassidy 3<br />
and Ariane L. Herrick 2 , 1 Mercy University Hospital, Cork, Co.<br />
Cork, Ireland, 2 Rheumatic Diseases Centre, Trust Salford, United<br />
Kingdom, 3 University <strong>of</strong> Manchester, Manchester, United<br />
Kingdom.<br />
1235. The Use <strong>of</strong> Calcium-Channel Blockers May Prevent the<br />
Development <strong>of</strong> Scleroderma Renal Crisis. Gaia Montanelli,<br />
Lorenzo Beretta, Alessandro Santaniello and Raffaella Scorza,<br />
Referral Center for Systemic Autoimmune Diseases.<br />
1236. Time <strong>of</strong> Transition through Different Patterns <strong>of</strong> Nailfold<br />
Microangiopathy in Systemic Sclerosis. Alberto Sulli 1 , Carmen<br />
Pizzorni 2 , Francesca Ravera 2 , Elisa Alessandri 2 , Giuseppe<br />
Zampogna 2 , Bruno Seriolo 2 and Maurizio Cutolo 1 , 1 Research<br />
Laboratory and Academic Unit <strong>of</strong> Clinical <strong>Rheumatology</strong>,<br />
Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Genova,<br />
Genova, Italy, 2 Research Laboratory and Academic Unit <strong>of</strong><br />
Clinical <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine,<br />
University <strong>of</strong> Genova, Genova, Italy.<br />
1237. Ultrasonographic Assessment <strong>of</strong> Hand Joint and Tendon<br />
Involvement in 30 Patients with Systemic Sclerosis. Emmanuel<br />
Chatelus, Hélène Chifflot, Viriginie Clavert, Christelle<br />
Sordet, Jacques-Eric Gottenberg and Jean Sibilia, Hospital <strong>of</strong><br />
Hautepierre, Strasbourg, France.<br />
1238. Vaccination Against Influenza in Patients with Scleroderma.<br />
Irena Litinsky 3 , Alexandra Balbir 2 , Devy Zisman 4 , Michal<br />
Mandelboim 1 , Ella Mendelson 1 , Marina Anouk 3 , Ilana Kaufman 3 ,<br />
Daphna Paran 3 and Ori Elkayam 3 , 1 Central Virology Laboratory,<br />
Sheba Medical Center, 2 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Rambam Health Care Campus Background, 3 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Tel Aviv Medical Center, 4 <strong>Rheumatology</strong> Service,<br />
Carmel Medical Center.<br />
1239. Wound Fluid <strong>of</strong> Skin Ulcers in Systemic Sclerosis: Cellular and<br />
Cytokines’ Pr<strong>of</strong>ile Helps To Define Healers Versus Non Healers<br />
Characteristics. Stefano Alivernini 1 , Barbara Tolusso 2 , Mariarita<br />
Gigante 2 , Annunziata Capacci 2 , Francesca Faustini 2 , Silvia<br />
Laura Bosello 2 , Maria De Santis 2 and Gianfranco Ferraccioli 1 ,<br />
1<br />
<strong>Rheumatology</strong> Division, Catholic University <strong>of</strong> the Sacred Heart,<br />
Rome, Rome, Italy, 2 <strong>Rheumatology</strong> Division, Catholic University<br />
<strong>of</strong> the Sacred Heart, Rome, Italy, Italy.<br />
T Cell Biology and Targets in Autoimmune Disease<br />
1240. A Novel Role for the Jak-Stat Pathway in Rheumatoid Arthritis:<br />
Inhibition <strong>of</strong> TNF-Induced T Cell Attracting Chemokine<br />
Synthesis in Fibroblast-Like Synoviocytes (FLS) by Tasocitinib.<br />
Sanna Rosengren 2 , Gary S. Firestein 2 and David L. Boyle 1 , 1 UCSD<br />
Schl <strong>of</strong> Medicine, La Jolla, CA, 2 UCSD School <strong>of</strong> Medicine, La<br />
Jolla, CA.<br />
1241. A Th17 Immune Response Can Be Amplified by Human Th9<br />
Cells. Andreas Ramming 1 , Hendrik Schulze-Koops 2 and Alla<br />
Skapenko 2 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Munich,<br />
Munich, Bavaria, Germany, 2 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
University <strong>of</strong> Munich, Munich, Germany.<br />
1242. Addition <strong>of</strong> Retinoic Acid and TGF-beta Accelerate the<br />
Maturation Naive CD8+ Cells into CD8+CD25+FOXP3+<br />
Regulatory Cells. J. Dixon Gray 1 , Stephanie Q. Pan 2 and David<br />
A. Horwitz 1 , 1 University <strong>of</strong> Southern California, Los Angeles, CA,<br />
2<br />
University <strong>of</strong> Southern California.<br />
2010 Program Book 225
ACR/ARHP Poster Session B<br />
1243 An Assessment <strong>of</strong> the Thromboembolic Potential <strong>of</strong> CDP7657,<br />
a Monovalent Fab’ PEG Anti-CD40L Antibody, in Rhesus<br />
Macaques. Ian Wakefield 2 , Olivier Harari 2 , David Hutto 1 , Linda<br />
Burkly 1 , Janine Ferrant 1 , Fred Taylor 1 , Martyn Robinson 2 ,<br />
Anthony Shock 2 , Timothy Bourne 2 and Christopher Peters 2 ,<br />
1<br />
Biogen Idec, 2 UCB.<br />
1244. Blockade <strong>of</strong> CD40L with a Monovalent Fab’ PEG Monoclonal<br />
Antibody Inhibits Disease in the Murine Collagen-Induced<br />
Arthritis Model. Alexander Vugler 2 , Daniel Sutton 2 , Diane<br />
Marshall 2 , Stevan Shaw 2 , Linda Burkly 1 , Janine Ferrant 1 , Ellen<br />
Garber 1 and Anthony Shock 2 , 1 Biogen Idec, 2 UCB.<br />
1245. CDP7657, a Monovalent Fab’ PEG Anti-CD40L Antibody,<br />
Inhibits Immune Responses in Both HuSCID Mice and Non-<br />
Human Primates. Ian Wakefield 2 , Christopher Peters 2 , Linda<br />
Burkly 1 , Ellen Garber 1 , Janine Ferrant 1 , Fred Taylor 1 , Lihe Su 1 ,<br />
Yen-Ming Hsu 1 , Martyn Robinson 2 , Timothy Bourne 2 , Roger<br />
Palframan 2 , Lisa Berry 2 , Olivier Harari 2 and Anthony Shock 2 ,<br />
1<br />
Biogen Idec, 2 UCB.<br />
1246. Characterization <strong>of</strong> Human Follicular Helper T Cells. Sang Taek<br />
Kim 3 , Jin-Young Choi 4 , Begona Lainez 4 , Leah DiPlacido 1 , Vivian E.<br />
Vlamakis 2 and Joseph E. Craft 4 , 1 Department <strong>of</strong> Immunobiology,<br />
Yale University School <strong>of</strong> Medicine, New Haven, CT, 2 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, University <strong>of</strong> Washington School <strong>of</strong> Medicine,<br />
Bothell, WA, 3 Section <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />
Medicine, Yale University School <strong>of</strong> Medicine, Orange, CT,<br />
4<br />
Section <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine,<br />
Yale University School <strong>of</strong> Medicine, New Haven, CT.<br />
1247. Chronic Inflammatory Responses in Rheumatoid Arthritis:<br />
The Vicious Circle Might Be Related to Interaction <strong>of</strong> Th17<br />
Cells with FLS or Mesenchymal Stem Cells. Assia Eljaafari 1 ,<br />
Marie-Laure Tartelin 1 and Pierre Miossec 2 , 1 HCL and UCBL, Lyon,<br />
France, 2 HCL and UCBL, France.<br />
1248. Circulating FOXP3+ CTLA-4+ CD25+ Regulatory T Cells in<br />
Human Infants Counteract the Maturation and Homing<br />
Receptor Switch <strong>of</strong> CD4+ T Cells at 18 and 36 Months <strong>of</strong><br />
Age. Hardis Rabe 2 , Anna-Carin Lundell 2 , Kerstin Andersson 2 ,<br />
Ingegerd Adlerberth 1 , Agnes E. Wold 1 and Anna Rudin 3 , 1 Dept <strong>of</strong><br />
Clinical Bacteriology, 2 Dept <strong>of</strong> <strong>Rheumatology</strong> and Inflammation<br />
Research, 3 Dept <strong>of</strong> <strong>Rheumatology</strong> and Inflammation Research,<br />
The Sahlgrenska Academy at University <strong>of</strong> Gothenburg,<br />
Gothenburg, Sweden.<br />
1249. Critical Role <strong>of</strong> IL-21 in Modulating Th17 Responses and<br />
Regulatory T Cells in Behçet Disease. Guillaume Geri 1 , Benjamin<br />
Terrier 1 , Michelle Rosenzwajg 1 , Bertrand Wechsler 2 , Du Le<br />
Boutin 1 , Bahram Bodaghi 1 , Tu-Ahn Tran 1 , Nathalie Costedoat-<br />
Chalumeau 2 , Lucile Musset 1 , David Klatzman 1 , Patrice Cacoub 1<br />
and David Saadoun 1 , 1 Pitié-Salpetrière Hospital, Paris, France,<br />
2<br />
Pitie-Salpetriére Hospital, Paris, France.<br />
1250. CXCL13 Signals through CXCR5 To Upregulate Nuclear CXCR5<br />
and Bcl-6 and Promote the Development <strong>of</strong> Follicular T Helper<br />
Cells in Autoimmune BXD2 Mice. Yanna Ding 3 , Hui-Chen Hsu 1<br />
and John D. Mountz 2 , 1 Department <strong>of</strong> Medicine, The University<br />
<strong>of</strong> Alabama at Birmingham, 2 Department <strong>of</strong> Medicine, The<br />
University <strong>of</strong> Alabama at Birmingham; Birmingham VA Medical<br />
Center, 3 Department <strong>of</strong> Pathology, The Univerisity <strong>of</strong> Alabama at<br />
Birmingham.<br />
1251. Decreasing Fli1 Levels in Lupus T Cells Has Effects on Serum<br />
Immunoglobulin Levels and T Cell Infiltration in the Kidney.<br />
Erin Morris 1 , Maria I. Harrell 1 , John Svenson 1 , Laura Tonks 1 , John<br />
Zhang 3 and Tamara K. Nowling 2 , 1 MUSC, 2 Ralph Johnson VAMC/<br />
MUSC, Charleston, SC, 3 Ralph Johnson VAMC/MUSC.<br />
1252. Dendritic Cells and Continued Smoking in Rheumatoid<br />
Arthritis. Marina Kazantseva 3 , John Highton 1 , Lisa K. Stamp 4<br />
and Paul A. Hessian 2 , 1 Univ <strong>of</strong> Otago Med Sch, Dunedin,<br />
New Zealand, 2 University <strong>of</strong> Otago, Dunedin, New Zealand,<br />
3<br />
University <strong>of</strong> Otago, Dundein, New Zealand, 4 University <strong>of</strong><br />
Otago, Christchurch, New Zealand.<br />
1253. DNA Methylation Affects Gene Expression in CD4+CD28- T<br />
Cells through microRNAs. Dipak R. Patel, Anura Hewagama,<br />
Sushma Yarlagadda and Bruce C. Richardson, University <strong>of</strong><br />
Michigan, Ann Arbor, MI.<br />
1254. Dys-Regulation <strong>of</strong> T-Cell Subsets and Cytokines Is Associated<br />
with the Development <strong>of</strong> Inflammatory Symptoms in ACPA-<br />
Positive Asymptomatic Individual. Richard J. Cuthbert 2 , Rekha<br />
Parmar 2 , Jackie Nam 2 , Edith Villeneuve 2 , Diane Corscadden 2 ,<br />
Karen Henshaw 2 , Paul Emery 1 and Frederique Ponchel 2 , 1 Chapel<br />
Allerton Hospital, Leeds, United Kingdom, 2 University <strong>of</strong> Leeds,<br />
Leeds, UK.<br />
1255. Expression <strong>of</strong> K2P5.1 Potassium Channels on CD4+ T<br />
Lymphocytes Correlates with Disease Activity in Rheumatoid<br />
Arthritis Patients. Martin Feuchtenberger 2 , Stefan Bittner 3 ,<br />
Nicole Bobak 3 , Alexander M. Herrmann 3 , Kerstin Goebel 3 , Stefan<br />
Kleinert 3 , Heinz Wiendl 1 , Hans-Peter Tony 3 and Sven G. Meuth 3 ,<br />
1<br />
University <strong>of</strong> Muenster, 2 University <strong>of</strong> Wuerzburg, Wuerzburg,<br />
Germany, 3 University <strong>of</strong> Wuerzburg.<br />
1256. Foxp3+ CD4+ Tregs Prevent Arthritis by Promoting Clonal<br />
Anergy Induction in Self Ag-Specific CD4+ T Cells. Ryan<br />
Martinez 2 , Na Zhang 2 , Sara Nandiwada 2 , Stephanie Thomas 2 ,<br />
Bryce Binstadt 2 and Daniel L. Mueller 1 , 1 University <strong>of</strong> Minnesota<br />
Medical School, Minneapolis, MN, 2 University <strong>of</strong> Minnesota<br />
Medical School.<br />
1257. Gender and Sex Hormones Influence CD4+ Regulatory T Cells<br />
and Their Expression <strong>of</strong> FoxP3 in Healthy People and in SLE.<br />
Ravi K. Dinesh 1 , Bevra H. Hahn 2 and Ram P. Singh 1 , 1 David Geffen<br />
Schl <strong>of</strong> Med/UCLA, Los Angeles, CA, 2 University <strong>of</strong> California Los<br />
Angeles School <strong>of</strong> Medicine, Los Angeles, CA.<br />
1258. Identification <strong>of</strong> a Pathological TCR <strong>of</strong> Autoantibody-Inducing<br />
CD4+ T Cell That Induces Autoantibodies and Lupus-Like<br />
Immune Tissue Injury. Kohsuke Yoshida 1 , Ken Tsumiyama 2 and<br />
Shunichi Shiozawa 3 , 1 Department <strong>of</strong> Biophysics, Kobe University<br />
Graduate School <strong>of</strong> Health Sciences, Kobe, Hyogo, Japan,<br />
2<br />
Department <strong>of</strong> Biophysics, Kobe University Graduate School <strong>of</strong><br />
Health Sciences, Kobe, Japan, 3 Department <strong>of</strong> Biophysics, Kobe<br />
University Graduate School <strong>of</strong> Health Sciences/Department <strong>of</strong><br />
Medicine, Kobe University Graduate School <strong>of</strong> Medicine/The<br />
Center for Rheumatic Diseases, Kobe University Hospital, Kobe,<br />
Japan.<br />
1259. IL-23 Suppresses IL-22 Levels and AHR Expression in Human<br />
CCR6+ Memory T Cells. Ferry Cornelissen, Jan Piet van<br />
Hamburg, Nadine Davelaar, Patrick Asmawidjaja, Anne-Marie<br />
Mus and Erik Lubberts, Erasmus MC, University Medical Center.<br />
1260. IL-23-Mediated RORγt Pathway Is Associated with Thymic<br />
Negative Selection <strong>of</strong> Autoreactive T Cells. Hao Li 2 , Hui-Chen<br />
Hsu 2 , Qi Wu 2 , PingAr Yang 2 , Jun Li 2 and John D. Mountz 1 , 1 Univ<br />
Alabama at Birmingham, Birmingham, AL, 2 Univ Alabama at<br />
Birmingham.<br />
1261. Immune Regulation by Peripheral Suppressor T Cells Induced<br />
upon Homotypic T Cell Interaction. Katja Thuemmler 1 , Leipe<br />
Jan 1 , Andreas Ramming 1 , Hendrik Schulze-Koops 2 and Alla<br />
Skapenko 1 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, LMU Munich, Munich,<br />
Germany, 2 LMU Munich, Munich, Germany.<br />
226<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
1262. Late Complement Complex in T Cell Function and Cell Death.<br />
Anil Chauhan 1 , John P. Atkinson 3 and Terry L. Moore 2 , 1 Saint<br />
Louis University, 2 St Louis University, St Louis, MO, 3 Washington<br />
University School <strong>of</strong> Medicine, St Louis, MO.<br />
1263. Linking Power Doppler Ultrasound with Th17 Cells in the RA<br />
Joint. Nicola J. Gullick 1 , Hayley G. Evans 2 , Leigh Church 3 , David<br />
Jayaraj 2 , Andrew Filer 3 , Bruce W. Kirkham 4 and Leonie S. Taams 2 ,<br />
1<br />
CMCBI, King’s <strong>College</strong> London, London, United Kingdom,<br />
2<br />
CMCBI, King’s <strong>College</strong> London, 3 <strong>Rheumatology</strong> Research Group,<br />
University <strong>of</strong> Birmingham, 4 <strong>Rheumatology</strong>, Guy’s& St Thomas’<br />
NHS Foundation Trust.<br />
1264. NKT Cell Is Required for the Break <strong>of</strong> T Cell Anergy, Inducing<br />
Autoantibody, and Generation <strong>of</strong> Autoantibody-Inducing CD4+<br />
T Cell That Causes Systemic Autoimmunity. Yuko Fujita 1 , Ken<br />
Tsumiyama 2 and Shunichi Shiozawa 3 , 1 Depertment <strong>of</strong> Biophysics,<br />
Kobe University Graduate School <strong>of</strong> Health Science, Kobe,<br />
Japan, 2 Depertment <strong>of</strong> Biophysics, Kobe University Graduate<br />
School <strong>of</strong> Health Science, Kobe, Japan, 3 Depertment <strong>of</strong><br />
Biophysics, Kobe University Graduate School <strong>of</strong> Health Science/<br />
Depertment <strong>of</strong> Medicine, Kobe University Graduate School <strong>of</strong><br />
Medicine/ The Center for Rheumatic Diseases, Kobe University<br />
Hospital, Kobe, Japan.<br />
1265. Peroxisome Proliferator-Activated Receptor α and γ Agonists<br />
Together with TGF-β Convert Human CD4+CD25- T Cells into<br />
Functional Foxp3+ Regulatory T Cells. Hitoshi Hasegawa 1 ,<br />
Jin Lei 2 , Takuya Matsumoto 2 and Masaki Yasukawa 2 , 1 Ehime<br />
University Graduate School <strong>of</strong> Medicine, Toon, Ehime, Japan,<br />
2<br />
Ehime University Graduate School <strong>of</strong> Medicine.<br />
1266. Phenotype and Functional Stability <strong>of</strong> TGF-β-Induced<br />
CD4+Foxp3+ Regulatory T Cells in Steady and Inflammatory<br />
States. NIng Kong 3 , Julie Wang 3 , David Brand 4 , Hejian Zou 1 ,<br />
Xuezhong Yu 2 and Song Guo Zheng 3 , 1 Fudan University Medical<br />
School, 2 H. Lee M<strong>of</strong>fitt Cancer Center and Research Institute,<br />
3<br />
USC Keck School <strong>of</strong> Medicine, 4 VA Medical Center, Memphis.<br />
1267. Plasmacytoid Dendritic Cells Control Peripheral Treg<br />
Conversion to the RNA-Binding Nuclear Self Antigen La/SS-B.<br />
A. Darise Farris 1 , Christina Lawrence 2 and Zi-jian Pan 2 , 1 Arthritis<br />
and Immunology Program, Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK, 2 Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK.<br />
1268. Protective Human CD4+CD25+FOXP3+ Regulatory T Cells<br />
Generated Ex-Vivo with IL-2, Retinoic Acid and TGF-bets Are<br />
Resistant to Pro-Inflammitory Cytokines. Xiaohui Zhou 1 , Chin<br />
Lan 1 , Juhua Wang 1 , Song-guo Zheng 1 and David A. Horwitz 2 ,<br />
1<br />
University <strong>of</strong> Southern California, 2 University <strong>of</strong> Southern<br />
California, Los Angeles, CA.<br />
1269. RANKL Expression in Human T-Lymphocytes Requires<br />
Cooperative Signaling through the T-Cell Receptor and<br />
Adhesion Molecule CD2. Bohdan P. Harvey and Zehra<br />
Kaymakcalan, Abbott Laboratories, Worcester, MA.<br />
1270. Regulation <strong>of</strong> Human T Cell Activation and Effector Functions<br />
by Kv1.3 and KCa3.1 Channels. Gang Chen 1 , Vaishali Patel 1 ,<br />
Rothschild Soto 2 , Chen Shiow-Ling 2 , Sandip Panicker 2 , Philip<br />
A. Nunn 2 and Julie A. DeMartino 2 , 1 Inflammation Discovery,<br />
H<strong>of</strong>fmann-La Roche, Inc., Nutley, NJ, 2 Inflammation Discovery,<br />
H<strong>of</strong>fmann-La Roche, Inc..<br />
1271. Role for IL-23 in Differentiation <strong>of</strong> Human Th17 Cells. Hiroshi<br />
Kato 1 , Laura Cooney 2 , Judith Endres 2 and David A. Fox 3 ,<br />
1<br />
University <strong>of</strong> Michigan, Northville, MI, 2 University <strong>of</strong> Michigan,<br />
Ann Arbor, MI, 3 University <strong>of</strong> Michigan Medical Center, Ann<br />
Arbor, MI.<br />
1272. Self-Organized Criticality Theory for the Cause <strong>of</strong><br />
Autoimmunity. Ken Tsumiyama 1 , Yumi Miyazaki 1 and Shunichi<br />
Shiozawa 2 , 1 Department <strong>of</strong> Biophysics, Kobe University<br />
Graduate School <strong>of</strong> Health Science, Kobe, Japan, 2 Department <strong>of</strong><br />
Biophysics, Kobe University Graduate School <strong>of</strong> Health Science/<br />
Department <strong>of</strong> Medicine, Kobe University Graduate School <strong>of</strong><br />
Medicine/The Center for Rheumatic Diseases, Kobe University<br />
Hospital, Kobe, Japan.<br />
1273. SGN-70: Phase 1a Study <strong>of</strong> a Novel Humanized Antibody<br />
Targeting CD70 for the Treatment <strong>of</strong> Autoimmune Diseases.<br />
Jonathan G. Drachman 2 , Julie A. McEarchern 2 , Che-Leung Law 2 ,<br />
Luis Lopez-Lazaro 1 , Gabriele Fabian 1 and Michael Seiberling 1 ,<br />
1<br />
Covance Clinical Research Unit AG, Basel, Switzerland, 2 Seattle<br />
Genetics, Inc., Bothell, WA.<br />
1274. Vitamin D Suppresses the Pathogenic Behavior <strong>of</strong> Primary<br />
Th17 Cells from Patients with Early RA in Synovial Fibroblast<br />
Activation. Jan Piet van Hamburg 3 , Patrick Asmawidjaja 3 , Anne-<br />
Marie Mus 3 , Mieke Hazes 2 , Hans van Leeuwen 1 , Edgar Colin 2<br />
and Erik Lubberts 4 , 1 Department <strong>of</strong> Internal Medicine, Erasmus<br />
MC, University Medical Center Rotterdam, 2 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Erasmus MC, University Medical Center<br />
Rotterdam, 3 Departments <strong>of</strong> <strong>Rheumatology</strong> and Immunology,<br />
Erasmus MC, University Medical Center Rotterdam, 4 Erasmus<br />
MC, Rotterdam, ZH, The Netherlands.<br />
Large-Vessel Vasculitis and Behçet’s Disease I<br />
1275. 18F-Fluorodeoxyglucose Positron Emission Tomography<br />
Scanning (FDG-PET/CT) in Evaluation <strong>of</strong> Disease Activity<br />
in Takaysu Arteritis. Øyvind Palm 3 , Birgir Gudbrandsson 2 ,<br />
Torhild Garen 2 , Kjersti Johnsrud 1 and Jan Tore Gran 2 , 1 Section<br />
for Nuclear Medicine, OUS, Rikshospitalet, 2 Section for<br />
<strong>Rheumatology</strong>, OUS, Rikshospitalet, 3 Section for <strong>Rheumatology</strong>,<br />
OUS, Rikshospitalet, Oslo, Norway.<br />
1276. A Double-Blind Placebo Controlled Trial <strong>of</strong> Infliximab<br />
in Patients with Corticosteroid-Dependent Polymyalgia<br />
Rheumatica. Victor M. Martinez-Taboada 11 , Francisco Javier<br />
López-Longo 10 , Rosario García de Vicuña 8 , Jordi Gratacos 5 ,<br />
Georgina Espígol-Frigolé 2 , Julio Medina 6 , Javier Narváez 3 , Rosa<br />
Roselló 7 , Luis Carreño 9 , Iñigo Rua-Figueroa 4 and María Cintia<br />
Cid 1 , 1 Hospital Clinic, Barcelona, Spain, 2 Hospital Clinic, Spain,<br />
3<br />
Hospital de Bellvitge, Barcelona, Spain, 4 Hospital Doctor Negrín,<br />
Spain, 5 Hospital Parc Taulí, Barcelona, Spain, 6 Hospital Río<br />
Carrión, Palencia, Spain, 7 Hospital San Jorge de Huesca, Spain,<br />
8<br />
Hospital Universitario de la Princesa, Madrid, Spain, 9 Hospital<br />
Universitario Gregorio Maranón, Madrid, Spain, 10 Hospital<br />
Universitario Gregorio Maranón, Spain, 11 Hospital Universitario<br />
Marqués de Valdecilla, Santander, Spain.<br />
1277. Adverse Outcomes <strong>of</strong> Glucocorticoid Therapy among Patients<br />
with Giant Cell Arteritis. Laura López Vives, Javier Narvaez,<br />
Paula Estrada, Carmen Gómez Vaquero and Joan Miquel<br />
Nolla, Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Universitario de<br />
Bellvitge, Barcelona, Spain.<br />
1278. Alemtuzumab (CAMPATH-1H) as Remission Induction Therapy<br />
in Behcet’s Disease. Rona M. Smith 1 , Yok W. Chow 2 and David<br />
R. W. Jayne 1 , 1 Addenbrooke’s Hospital, Cambridge, United<br />
Kingdom, 2 Hospital Pantai Ayer Keroh Melaka, Malaysia.<br />
1279. Ankylosing Spondylitis Associated with Takayasu Arteritis.<br />
Süleyman Yildirim, Gülen Hatemi, Sebahattin Yurdakul, Izzet<br />
Fresko and Huri Ozdogan, Istanbul University, Cerrahpasa<br />
Medical School, <strong>Rheumatology</strong>.<br />
2010 Program Book 227
ACR/ARHP Poster Session B<br />
1280. Association <strong>of</strong> VEGF, NOS2, IL6, CCL2 and IL1RN<br />
Polymorphisms and Haplotypes with Susceptibility to Giant<br />
Cell Arteritis. A Simultaneous Study <strong>of</strong> 130 Potentially<br />
Functional SNPs in 14 Candiadte Genes. Anna Enjuanes 4 ,<br />
Yolanda Benavente 8 , Jose Hernandez-Rodriguez 6 , Carme<br />
Queralt 6 , Jordi Yagüe 1 , Pedro Jares 5 , Silvia de Sanjose 7 , Elias<br />
Campo 3 and Maria C. Cid 2 , 1 Department <strong>of</strong> Immunology,<br />
Barcelona, Spain, 2 Department<strong>of</strong> Systemic Autoimmune<br />
Diseases, Hospital Clinic, Barcelona, Spain, 3 Hematopathology<br />
Section, Department <strong>of</strong> Anatomic Pathology, Barcelona, Spain,<br />
4<br />
Hematopathology Section, Department <strong>of</strong> Anatomic Pathology,<br />
Hospital Clinic, Barcelona, Spain, 5 Hematopatholoy Section,<br />
Department <strong>of</strong> Anatomic Pathology, Barcelona, Spain, 6 Systemic<br />
Autoimmune Diseases, Barcelona, Spain, 7 Unit <strong>of</strong> Infection<br />
and Cancer, Cancer Epidemiology Research, Catalan Institute<br />
<strong>of</strong> Oncology, Barcelona, Spain, 8 Unit <strong>of</strong> Infection and Cancer.<br />
Cancer Epidemiology Research. Catalan Institute <strong>of</strong> Oncology.<br />
1281. Behcet’s Disease and the Major Histocompatibility Complex:<br />
Looking beyond HLA-B51. Michael J. Ombrello 2 , Yohei Kirino 2 ,<br />
Fulya Cosan 1 , Ahmet Gul 1 , Daniel L. Kastner 2 and Elaine<br />
F. Remmers 2 , 1 Istanbul Faculty <strong>of</strong> Medicine, Department<br />
<strong>of</strong> Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Istanbul<br />
University, Istanbul, Turkey, 2 Laboratory <strong>of</strong> Clinical Investigation,<br />
NIAMS, NIH, Bethesda, MD.<br />
1282. Circulating Adipokine, Ghrelin and Acylated Ghrelin Levels<br />
in Patients with Takayasu’s Arteritis. Hatice Yilmaz 1 , Vedat<br />
Gerdan 3 , Didem Kozaci 4 , Servet Akar 3 , Gercek Can 3 , Aytac Gulcu 2 ,<br />
Volkan Cakir 2 , Yigit Goktay 2 , Merih Birlik 3 , Nurullah Akkoc 3 and<br />
Fatos Onen 3 , 1 Internal Medicine, Dokuz Eylul University Faculty<br />
<strong>of</strong> Medicine, Izmir, Turkey, 2 Radiology, Dokuz Eylul University<br />
Faculty <strong>of</strong> Medicine, Izmir, Turkey, 3 <strong>Rheumatology</strong>, Dokuz<br />
Eylul University Faculty <strong>of</strong> Medicine, Izmir, Turkey, 4 Science,<br />
Technology Research and Aplication Center, Aydin, Turkey.<br />
1283. Circulating Endothelial Cells and Endothelial Progenitor Cells in<br />
Takayasu Arteritis. Serkan Dogan 2 , Dilek Solmaz 4 , Ozden Piskin 1 ,<br />
Servet Akar 4 , Aytac Gulcu 3 , Faize Yuksel 1 , Volkan Cakir 3 , Gercek<br />
Can 4 , Yigit Goktay 3 , Merih Birlik 4 , Nurullah Akkoc 4 and Fatos<br />
Onen 4 , 1 Hematology, Dokuz Eylul University Faculty <strong>of</strong> Medicine,<br />
Izmir, Turkey, 2 Internal Medicine, Dokuz Eylul University Faculty<br />
<strong>of</strong> Medicine, Izmir, Turkey, 3 Radiology, Dokuz Eylul University<br />
Faculty <strong>of</strong> Medicine, Izmir, Turkey, 4 <strong>Rheumatology</strong>, Dokuz Eylul<br />
University Faculty <strong>of</strong> Medicine, Izmir, Turkey.<br />
1284. Clinical Characteristics, Treatment and Ethnic/Racial<br />
Differences in the Manifestations <strong>of</strong> 518 Behcet’s Syndrome<br />
Patients in the United States. Yusuf Yazici, Maria T. Filopoulos,<br />
Elizabeth Schimmel, Andy McCraken and Christopher<br />
Swearingen, NYU Hospital for Joint Diseases.<br />
1285. Clinical Features <strong>of</strong> Behçet’s Disease with Vascular<br />
Involvement. Hirotoshi Kikuchi 2 , Kurumi Asako 1 , Maki<br />
Takayama 1 , Hajime Kono 1 , Shunsei Hirohata 4 and Yasuo Ono 3 ,<br />
1<br />
Department <strong>of</strong> Internal Medicine, Teikyo University School<br />
<strong>of</strong> Medicine, 2 Department <strong>of</strong> Microbiology and Immunology,<br />
Teikyo University School <strong>of</strong> Medicine, Itabashi-ku, Tokyo,<br />
Japan, 3 Department <strong>of</strong> Microbiology and Immunology, Teikyo<br />
University School <strong>of</strong> Medicine, 4 Department <strong>of</strong> <strong>Rheumatology</strong><br />
and Infectious Disease, Kitasato University School <strong>of</strong> Medicine,<br />
Kanagawa, Japan.<br />
1286. Clinical Spectrum, Angiographic Findings and Outcome in<br />
Takayasu Arteritis, Using the Disease Extent Index for Takayasu<br />
Arteritis (DEI.TAK). Sivakumar M. Rajappa, Cerebrovascular and<br />
Vasculitis Research Foundation, Chennai, Tamilnadu, India.<br />
1287. Cluster Analysis <strong>of</strong> Vascular Involvement in Takayasu Arteritis:<br />
Extension <strong>of</strong> the Lesions Is Contiguous in the Aorta and<br />
Symmetric in Paired Arterial Beds. Laurent Arnaud 1 , Julien<br />
Haroche 1 , Dan Toledano 2 , Patrice Cacoub 1 , Nathalie Costedoat-<br />
Chalumeau 1 , Du Le Thi Huong-Boutin 1 , Philippe Cluzel 2 and<br />
Zahir Amoura 1 , 1 Department <strong>of</strong> Internal Medicine, Groupe<br />
Hospitalier Pitié-Salpêtriere, UPMC Univ Paris 6 , AP-HP, 47-83 bd<br />
de l’Hôpital, Paris, France, 2 Department <strong>of</strong> Radiology, Groupe<br />
Hospitalier Pitié-Salpêtrière, UPMC Univ Paris 6 , AP-HP, 47-83 bd<br />
de l’Hôpital, 75013, Paris, France..<br />
1288. Colchicine Does Not Decrease the Need for<br />
Immunosuppressive Use at Long Term in Behçet’s Syndrome.<br />
Vedat Hamuryudan 3 , Gülen Hatemi 3 , Sebahattin Yurdakul 3 , Cem<br />
Mat 1 , Koray Tascilar 3 , Yilmaz Ozyazgan 2 , Emire Seyahi 3 , Serdal<br />
Ugurlu 3 and Hasan Yazici 3 , 1 Istanbul University, Cerrahpasa<br />
Medical School, Dermatology, 2 Istanbul University, Cerrahpasa<br />
Medical School, Ophthalmology, 3 Istanbul University,<br />
Cerrahpasa Medical School, <strong>Rheumatology</strong>.<br />
1289. Diagnostic Value <strong>of</strong> Pathergy Phenomenon in Behcet’s Disease.<br />
Fereydoun Davatchi, Cheyda Chams-Davatchi, Farhad Shahram,<br />
Bahar Sadeghi Abdollahi, Abdolhadi Nadji, Massoomeh<br />
Akhlaghi, Tahereh Faezi and Roghieh Larimi, <strong>Rheumatology</strong><br />
Research Center, Tehran University <strong>of</strong> Medical Sciences, Tehran,<br />
Islamic Republic <strong>of</strong> Iran.<br />
1290. Disease Activity Assessment in Large Vessel Vasculitis. Luca<br />
Magnani 1 , Annibale Versari 1 , Diana Salvo 1 , Massimiliano Casali 1 ,<br />
Giuseppe Germanò 1 , Riccardo Meliconi 3 , Lia Pulsatelli 2 , Debora<br />
Formisano 1 , Gianluigi Bajocchi 1 , Nicolò Pipitone 1 , Luigi Boiardi 1<br />
and Carlo Salvarani 1 , 1 Arcispedale S Maria Nuova, Reggio<br />
Emilia, Italy, 2 Istituti Ortopedici Rizzoli, Bologna, Bologna, Italy,<br />
3<br />
University <strong>of</strong> Bologna, Bologna, Italy.<br />
1291. Disease Assessment in Takayasu’s Arteritis: Data from a<br />
Literature Search and a Survey <strong>of</strong> Expert Opinion. Haner<br />
Direskeneli 3 , Sibel Z. Aydin 3 , Peter A. Merkel 2 and Turkish<br />
Takayasu Study Group 1 , 1 Istanbul, Turkey, 2 Boston University<br />
School <strong>of</strong> Medicine, West Newton, MA, 3 Marmara University,<br />
School <strong>of</strong> Medicine, Istanbul, Turkey.<br />
1292. Effect <strong>of</strong> Glucocorticoids on Gelatinase (MMP-2 and MMP-<br />
9) Expression in Giant-Cell Arteritis (GCA) Using an Ex-Vivo<br />
Temporal Artery Culture Model. Marc Corbera-Bellalta, Ana<br />
García-Martínez, Ester Planas-Rigol, Ester Lozano, Marta<br />
Segarra, Georgina Espígol-Frigolé, José Hernández-Rodríguez,<br />
Itziar Tavera and Maria C. Cid, Department <strong>of</strong> Systemic<br />
Autoimmune Diseases. Hospital Clínic. University <strong>of</strong> Barcelona,<br />
IDIBAPS, Barcelona, Spain.<br />
1293. Efficacy <strong>of</strong> Cerebrospinal Fluid Testing and Magnetic<br />
Resonance Imaging for Diagnosis <strong>of</strong> Neuro-Behcet’s Disease:<br />
A Multicenter Retrospective Analysis. Shunsei Hirohata 3 ,<br />
Hirotoshi Kikuchi 5 , Tetsuji Sawada 6 , Hiroko Nagafuchi 4 , Masataka<br />
Kuwana 2 , Mitsuhiro Takeno 1 and Yoshiaki Ishigatsubo 7 ,<br />
1<br />
Department <strong>of</strong> Internal Medicine and Clinical Immunology,<br />
Yokohama City University Graduate School <strong>of</strong> Medicine, 2 Keio<br />
University School <strong>of</strong> Med, Tokyo, Japan, 3 Kitasato Univ School <strong>of</strong><br />
Med, Kanagawa, Japan, 4 St Marianna University School <strong>of</strong> Med,<br />
5<br />
Teikyo Univ School <strong>of</strong> Med, 6 Tokyo Medical University, Shinjuku<br />
Tokyo, Japan, 7 Yokohama City Grad Sch <strong>of</strong> Med, Yokohama,<br />
Japan.<br />
228<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
1294. Endothelin-1 (ET-1) Induces Collagen Type I and Type III<br />
Production by Temporal Artery-Derived Myointimal Cells.<br />
A Mechanism Potentially Leading to Intimal Hyperplasia in<br />
Giant-Cell Arteritis (GCA). Ester Planas-Rigol, Marc Corbera-<br />
Bellalta, Ester Lozano, Montserrat Butjosa, Sergio Prieto-<br />
González, José Hernández-Rodríguez, Marta Segarra and Maria<br />
C. Cid, Department <strong>of</strong> Systemic Autoimmune Diseases. Hospital<br />
Clínic. University <strong>of</strong> Barcelona, IDIBAPS, Barcelona, Spain.<br />
1295. Expansion <strong>of</strong> Peripheral Blood Plasma Blasts Reflects<br />
Disturbances <strong>of</strong> B Cell Homeostasis in Patients with Takayasu<br />
Arteritis and Success <strong>of</strong> B Cell Depletion Therapy. Bimba F.<br />
Hoyer 3 , Imtiaz M. Mumtaz 3 , Udo Schneider 2 , Rolf Keitzer 1 , Gerd-<br />
Rüdiger Burmester 2 , Andreas Radbruch 5 and Falk Hiepe 4 , 1 Dep.<br />
Pediatric <strong>Rheumatology</strong>, Charité Universityhospital Berlin, 2 Dep.<br />
<strong>Rheumatology</strong> and Clin. Immunology, Charité Universityhospital<br />
Berlin, 3 Dep. <strong>Rheumatology</strong> and Clin. Immunology, Charité<br />
Universityhospital Berlin and German Rheumatism Reserach<br />
Center Berlin, Berlin, Germany, 4 Dep. <strong>Rheumatology</strong> and Clin.<br />
Immunology, Charité Universityhospital Berlin and German<br />
Rheumatism Reserach Center Berlin, 5 German Rheumatism<br />
Reserach Center Berlin.<br />
1296. Expression and Function <strong>of</strong> Toll Like Receptors in Peripheral<br />
Blood Mononuclear Cells <strong>of</strong> Patients with Polymyalgia<br />
Rheumatica and Giant Cell Arteritis. Lorena Alvarez-Rodriguez 4 ,<br />
Marcos Lopez-Hoyos 4 , Cristina Mata 1 , Ana Fontalba 4 , Jaime<br />
Calvo-Alen 1 , Maria Jose Marin 4 , Jose Luis Fernandez-Luna 4 , Jesus<br />
Agüero-Balbin 4 , Maitane Aranzamendi-Zaldunbide 4 , Ricardo<br />
Blanco 4 , Ignacio Villa 2 , Orlando Pompei 4 , Marien Peiro 4 , Teresa<br />
Ruiz 1 and Victor M. Martinez-Taboada 3 , 1 Hospital de Sierrallana,<br />
Spain, 2 Hospital de Sierrallana, 3 Hospital Universitario Marques<br />
de Valdecilla, Santander, Spain, 4 Hospital Universitario Marques<br />
de Valdecilla.<br />
1297. Extracellular HMGB1 Is Increased in Patients with Behcet’s<br />
Disease with Intestinal Involvement. Joong Kyong Ahn 2 ,<br />
You Sun Lee 3 , Eun-Jung Park 4 , Ji-Won Hwang 4 , Ji-Min Oh 4 ,<br />
Jaejoon Lee 4 , Chan-Hong Jeon 1 , Eun-Mi Koh 4 and Hoon-Suk<br />
Cha 4 , 1 Bucheon Hospital, Soonchunhyang University <strong>College</strong><br />
<strong>of</strong> Medicine, 2 Kangbuk Samsung Hospital, Sungkyunkwan<br />
University School <strong>of</strong> Medicine, 3 Masan Samsung Hospital,<br />
Sungkyunkwan University School <strong>of</strong> Medicine, 4 Samsung<br />
Medical Center, Sungkyunkwan University School <strong>of</strong> Medicine.<br />
1298. Eye Involvement in Behcet’s Syndrome Patients in a North<br />
<strong>American</strong> Cohort. Johannes Nowatzky 3 , Maria T. Filopoulos 4 ,<br />
Christopher Swearingen 1 and Yusuf Yazici 2 , 1 Biostatistics UAMS<br />
Pediatrics, 2 Hospital for Joint Diseases, Hastings on Hudson, NY,<br />
3<br />
NYU Hospital for Joint Diseases, Brooklyn, NY, 4 NYU Hospital for<br />
Joint Diseases.<br />
1299. Glucocorticoid Therapy in Giant Cell Arteritis: Duration and<br />
Predictors for Long-Lasting Remission. Paula Estrada, Javier<br />
Narvaez, Laura Lopez Vives, Carmen Gomez Vaquero and<br />
Joan Miquel Nolla, Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital<br />
Universitario de Bellvitge, Barcelona, Spain.<br />
1300. Infliximab Therapy Is Beneficial for Intestinal Behcet’s Disease<br />
in Japan. Reikou Watanabe, Mitsuhiro Takeno and Yoshiaki<br />
Ishigatsubo, Department <strong>of</strong> Internal Medicine and Clinical<br />
Immunology, Yokohama City Graduate School <strong>of</strong> Medicine.<br />
1301. Influence <strong>of</strong> CD40 rs1883832 Polymorphism in the<br />
Susceptibility to and Clinical Manifestations <strong>of</strong> Biopsy-<br />
Proven Giant Cell Arteritis. Luis Rodríguez-Rodríguez 8 , Santos<br />
Castañeda 4 , Tomás R. Vazquez-Rodriguez 7 , Inmaculada C.<br />
Morado 3 , Beatriz Marí-Alfonso 1 , Carmen Gómez-Vaquero 5 , Jose<br />
A. Miranda-Filloy 7 , Javier Narvaez 5 , Norberto Ortego-Centeno 2 ,<br />
Ricardo Blanco 6 , Benjamín Fernández-Gutiérrez 3 , Javier<br />
Martín 9 and Miguel A. Gonzalez-Gay 6 , 1 Department <strong>of</strong> Internal<br />
Medicine, Corporació Sanitaria Parc Taulí, Instituto Universitario<br />
Parc Taulí, UAB, Sabadell, Barcelona, Spain, 2 Department <strong>of</strong><br />
Internal Medicine, Hospital Clínico San Cecílio, Granada, Spain,<br />
3<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Clinico San Carlos,<br />
Madrid, Spain, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital de<br />
la Princesa, Madrid, Spain, 5 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Hospital Universitario de Bellvitge-IDIBELL, L’Hospitalet de<br />
Llobregat, Barcelona, Spain, 6 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Hospital Universitario Marqués de Valdecilla, IFIMAB, Santander,<br />
Spain, 7 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Xeral-Calde,<br />
Lugo, Spain, 8 Instituto de Parasitología y Biomedicina López-<br />
Neyra, C.S.I.C., Granada, and Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Hospital Clinico San Carlos, Madrid, Spain, 9 Instituto de<br />
Parasitología y Biomedicina López-Neyra, C.S.I.C., Granada,<br />
Spain.<br />
1302. Large-Vessel Involvement in Newly-Diagnosed Giant<br />
Cell Arteritis: A Case-Control Study Using Color-Doppler<br />
Sonography. Alessandra Ghinoi 1 , Luigi Boiardi 1 , Nicolò Pipitone 1 ,<br />
Giovanna Restuccia 1 , Alberto Nicolini 1 , Mauro Silingardi 1 ,<br />
Giuseppe Germanò 1 , Gianluigi Bajocchi 1 , Ilaria Chiarolanza 1 ,<br />
Luca Magnani 2 , Pierluigi Macchioni 1 , Andrea Caruso 1 and Carlo<br />
Salvarani 1 , 1 Arcispedale S Maria Nuova, Reggio Emilia, Italy,<br />
2<br />
Arcispedale S Maria Nuova, Reggia Emilia, Italy.<br />
1303. New Disease Activity Indices in the Management <strong>of</strong> Behcet’s<br />
Disease: A Comparative Study <strong>of</strong> Patients from Turkey and the<br />
USA. Gonca Mumcu, Yusuf Yazici, Nevsun Inanc, Tulin Ergun,<br />
Maria Filopoulos and Haner Direskeneli, Faculty <strong>of</strong> Health<br />
Sciences, Department <strong>of</strong> Health Informatics and Technologies,<br />
Marmara School <strong>of</strong> Medicine.<br />
1304. Normal Sedimentation Rate and C-Reactive Protein at<br />
Diagnosis in Biopsy-Proven Giant Cell Arteritis. Tanaz A.<br />
Kermani, Cynthia S. Crowson, Steven R. Ytterberg, Gene G.<br />
Hunder and Kenneth J. Warrington, Mayo Clinic, Rochester, MN.<br />
1305. Pediatric Behçet’s Disease, PED-BD: An International Cohort<br />
Study <strong>of</strong> 110 Patients. One-Year Follow-Up Data. Isabelle<br />
Koné-Paut 11 , Martha Darce Bello 11 , Farahd Shahram 15 , Marco<br />
Gattorno 7 , Rolando Cimaz 10 , Seza Ôzen 2 , Michael H<strong>of</strong>er 14 ,<br />
Ilknur Tugal-Tuktun 5 , Samir Assaad-Khalil 3 , Jasmin Kümmerle-<br />
Deschner 16 , Saida Benamour 4 , Soulaymane Al Mayouf 8 ,<br />
Christine Pajot 13 , Jordi Anton 9 , Albert Faye 12 , Susan Nielsen 6 ,<br />
Alexia Letierce 1 and Tu-Anh Tran 11 , 1 Bicêtre University Hospital,<br />
Clinical Research Unit, Le Kremlin-Bicêtre, France, 2 Hacettepe<br />
University, Department <strong>of</strong> Pediatrics, Ankara, Turkey, 3 Hospital<br />
Alexandria Hospital, Alexandria, Egypt, 4 IBN Rochid University<br />
Hospital, Casablanca, Morocco, 5 Istanbul University -<br />
Ophtalmology, Istambul, Turkey, 6 Pediatric Clinic, Blegdamsvej,<br />
Copenhagen, Denmark, 7 Pediatric <strong>Rheumatology</strong> G. Gaslini<br />
Scientific Institut, Genoa, Italy, 8 Pediatric <strong>Rheumatology</strong> King<br />
Fayçal Hospital, Riyadh, Saudi Arabia, 9 Pediatric <strong>Rheumatology</strong><br />
Unit, Sant Joan de Déu University Hospital, Esplugues de<br />
Llobregat, Spain, 10 Pediatric <strong>Rheumatology</strong>, A. Meyer Institut<br />
Florence, Florence, Italy, 11 Pediatric <strong>Rheumatology</strong>, Bicêtre<br />
University Hospital, Le Kremlin-Bicêtre, France, 12 Pediatric<br />
<strong>Rheumatology</strong>, Robert Debré University Hospital, Paris, France,<br />
13<br />
Pediatric <strong>Rheumatology</strong>, Toulouse University Hospital,<br />
Toulouse, France, 14 Pediatric <strong>Rheumatology</strong>, Vaudois University<br />
Hospital, Lausanne, Switzerland, 15 <strong>Rheumatology</strong> Research<br />
Center, Shariati Hospital, Tehran, Islamic Republic <strong>of</strong> Iran,<br />
16<br />
Rhumatology, Childrens Hospital, University <strong>of</strong> Tuebingen,<br />
Tübingen, Germany.<br />
2010 Program Book 229
ACR/ARHP Poster Session B<br />
1306. Plasma Fibrinogen Is More Specific Than Either ESR or CRP<br />
for Confirmation <strong>of</strong> Response to Treatment in Patients with<br />
Active Polymyalgia Rheumatica. Eoghan M. McCarthy 2 , Paul A.<br />
MacMullan 4 , Shibeb Al-Mudhaffer 4 , Anne Madigan 4 , Suzanne<br />
Donnelly 4 , Conor J. McCarthy 3 , Eamonn S. Molloy 5 and Geraldine<br />
M. McCarthy 1 , 1 Mater Misericordiae Univ. Hosp, Dublin,<br />
Ireland, 2 Mater Misericordiae University Hospital, Dublin,<br />
Ireland, 3 Mater Misericordiae University Hospital, Dublin,<br />
Ireland, 4 Mater Misericordiae University Hospital, 5 St Vincent’s<br />
University Hospital, Dublin, Ireland.<br />
1307. Prevalence <strong>of</strong> Behçet’s Disease in Southern Sweden. Aladdin<br />
Mohammad 1 , Thomas Mandl 3 , Gunnar K. Sturfelt 2 and Mårten<br />
Segelmark 2 , 1 Helsingborg Hospital, Helsingborg, Sweden, 2 Skåne<br />
University Hospital, Lund, Lund, Sweden, 3 Skåne University<br />
Hospital, Malmö, Malmö, Sweden.<br />
1308. Safe, Rapid-Onset, and Sustained Biological Activity <strong>of</strong> IL-1β<br />
Regulating Antibody XOMA 052 in Resistant Uveitis <strong>of</strong> Behçet’s<br />
Disease: Results <strong>of</strong> a Pilot Trial. Ahmet Gül 2 , Bahar Artim-<br />
Esen 2 , Alan M. Solinger 4 , Linda Giustino 4 , Charles Dinarello 3 and<br />
Ilknur M. Tugal-Tutkun 1 , 1 Istanbul, Turkey, 2 Istanbul University,<br />
Istanbul, Turkey, 3 University <strong>of</strong> Colorado, Aurora, CO, 4 XOMA<br />
(US) LLC, Berkeley, CA.<br />
1309. Serum Hepcidin Is Elevated in Patients with Giant Cell Arteritis<br />
and Is Inversely Associated with Serum Iron Levels. Curry L.<br />
Koening 2 , Jose Hernandez-Rodriguez 1 , Marc Corbera-Bellalta 1 ,<br />
Maria C. Cid 1 , Bradley Katz 3 and Ivana De Domenico 3 , 1 University<br />
<strong>of</strong> Barcelona, 2 University <strong>of</strong> Utah, Salt Lake City, UT, 3 University<br />
<strong>of</strong> Utah.<br />
1310. Severe and Opportunistic Infections during Giant Cell Arteritis<br />
Course: A Case-Control Study. Javier Narvaez 3 , Laura López<br />
Vives 1 , Paula Estrada 2 , Nuria del Castillo 4 , Montserrat Robustillo 4<br />
and Joan Miquel Nolla 4 , 1 Daprtment <strong>of</strong> <strong>Rheumatology</strong>, Hospital<br />
Universitario de Bellvitge, Barcelona, Spain, 2 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Barcelona, Spain, 3 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Hospital Universitario de Bellvitge, Barcelona,<br />
Spain, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Universitario<br />
de Bellvitge, Barcelona, Spain, Spain, 5 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Hospital Universitario de Bellvitge, Barcelona,<br />
Spain.<br />
1311. Significance <strong>of</strong> “Healed Arteritis” (HA) on Temporal Artery<br />
Biopsy. Rahul Sehgal, Elise Belilos, Matthew Geller, Lorna<br />
Ogden, Steven E. Carsons and George K. Turi, Winthrop<br />
University Hospital, Mineola, NY.<br />
1312. Some Manifestations Disappear Earlier Than Others in<br />
Behcet’s Syndrome (BS). Sevgi F. Sacli 2 , Emire Seyahi 4 , Yilmaz<br />
Ozyazgan 3 , Cem Mat 1 and Hasan Yazici 4 , 1 Cerrahpasa Medical<br />
Faculty, Dermatology Department, Turkey, 2 Cerrahpasa Medical<br />
Faculty, Internal Medicine Department, Turkey, 3 Cerrahpasa<br />
Medical Faculty, Ophthalmology Department, Turkey,<br />
4<br />
Cerrahpasa Medical Faculty, <strong>Rheumatology</strong> Department,<br />
Turkey.<br />
1313. Takayasu’s Arteritis Is Associated with HLA-B*52, but Not with<br />
B*51, in Turkey. Turkish Takayasu Study Group, Turkey.<br />
1314. Treatment with Angiotensin Converting Enzyme Inhibitors<br />
(ACEI) or Angiotensin II Receptor Antagonists (ARA) Is<br />
Associated with Higher Frequency <strong>of</strong> Ischemic Complications<br />
but Better Response to Therapy in Patients with Giant-Cell<br />
Arteritis (GCA). Marco A. Alba 3 , Ana Garcia-Martinez 1 , Georgina<br />
Espigol-Frigole 3 , Itziar Tavera 2 , Montserrat Butjosa 3 , Sergio<br />
Prieto-Gonzalez 5 , Jose Hernandez-Rodriguez 4 and Maria C. Cid 2 ,<br />
1<br />
Emergency Department, Hospital Clinic, Barcelona, Spain,<br />
2<br />
Systemic Autoimmune Diseases, Hospital Clinic, Barcelona,<br />
Spain, 3 Systemic Autoimmune Diseases. Hospital Clinic,<br />
Barcelona, Spain, 4 Systemic Autoimmune Diseases. Hospital<br />
Clininc, Barcelona, Spain, 5 Systemic Autoimmune Diseases.<br />
Hospital Clinic, Barcelona, Spain.<br />
1315. Use <strong>of</strong> Peri-Operative Glucocorticoids and Post-Operative<br />
Complications in Patients with Takayasu’s Arteritis Undergoing<br />
Vascular Surgical Procedures. Bijal A. Jayakar 1 , Gary S. H<strong>of</strong>fman 3<br />
and Carol A. Langford 2 , 1 Cleveland Clinic, Cleveland, OH,<br />
2<br />
Cleveland Clinic Foundation, Cleveland, OH, 3 Cleveland Clinic<br />
Foundation, Pepper Pike, OH.<br />
ARHP Poster Session B: Osteoporosis<br />
1316. Application <strong>of</strong> the Generalizability Theory for Determining<br />
Inter-Rater and Inter-Trial Reliability <strong>of</strong> Spine Curvature<br />
Measures in Postmenopausal Women with Osteoporosis <strong>of</strong> the<br />
Spine Using the Flexicurve Ruler and the Digital Inclinometer.<br />
Norma J. MacIntyre 1 , Lisa Bennett 2 , Alison Bonnyman 2 and Paul<br />
W. Stratford 2 , 1 McMaster University, Hamilton, ON, Canada,<br />
2<br />
McMaster University.<br />
1317. Baseline Serum Interleukin-6 (IL-6), Tumor Necrosis Factor-α<br />
(TNF-α) and C-Reactive Protein (CRP) Do Not Predict<br />
Subsequent Hip Bone Loss in Men or Women: The Framingham<br />
Osteoporosis Study. Robert R. McLean 3 , Xiaochun Zhang 4 , Joao<br />
D. T. Fontes 2 , James B. Meigs 7 , L. Adrienne Cupples 1 , Douglas<br />
P. Kiel 5 and Marian T. Hannan 6 , 1 Boston University School <strong>of</strong><br />
Public Health, 2 Framingham Heart Study and Boston University,<br />
3<br />
Hebrew Senior Life, Boston, MA, 4 Hebrew SeniorLife, 5 Hebrew<br />
SeniorLife and Harvard Medical School, 6 Hebrew SL & Harvard<br />
Med Sch, Boston, MA, 7 Massachusetts General Hospital.<br />
1318. Development <strong>of</strong> a Motivational Interviewing Protocol for<br />
Clinical Application in Osteoporosis. Maura D. Iversen 3 , Laura<br />
Rekedal 1 and Daniel Hal Solomon 2 , 1 Boston, MA, 2 Brigham<br />
and Womens Hospital, Boston, MA, 3 Northeastern University,<br />
Boston, MA.<br />
1319. Type <strong>of</strong> Activity Pacing Instruction Affects Physical Activity<br />
Variability in Adults with Symptomatic Knee or Hip<br />
Osteoarthritis. Susan L. Murphy 2 , Dylan M. Smith 1 and Angela<br />
K. Lyden, 1 StonyBrook University, 2 University <strong>of</strong> Michigan, Ann<br />
Arbor, MI.<br />
ARHP Poster Session B: Behavioral Science<br />
1320. A Prospective, Longitudinal Cohort Study Evaluating<br />
Psychosocial Risk and Protective Factors for Post Lyme Disease<br />
Syndrome. Afton L. Hassett 6 , Terry Shlimbaum 2 , Diane C.<br />
Radvanski 4 , David J. Herman 1 , Ronald Nahass 1 , Steven Buyske 3<br />
and Leonard H. Sigal 5 , 1 ID CARE, 2 Phillips-Barber Family Health<br />
Center, 3 Rutgers University, 4 UMDNJ-Robert Wood Johnson<br />
Medical School, Union City, NJ, 5 UMDNJ-Robert Wood Johnson<br />
Medical School, 6 University <strong>of</strong> Michigan Medical School, Ann<br />
Arbor, MI.<br />
230<br />
2010 Program Book
ACR/ARHP Poster Session B<br />
1321. Changing Shoes: Metaphorical Descriptions <strong>of</strong> Rheumatoid<br />
Arthritis and Identity. Catherine L. Backman 1 , Anne Townsend 2<br />
and Linda C. Li 1 , 1 University <strong>of</strong> British Columbia, Vancouver, BC,<br />
Canada, 2 W. Maurice Young Centre for Applied Ethics, University<br />
<strong>of</strong> British Columbia.<br />
1322. Emotional Response to Serial Doppler Echocardiography<br />
Examinations as a Screening Method To Detect Developing<br />
Congenital Heart Block in SSA/Ro Positive Pregnancy. Joanna<br />
Tingström 2 , Mia Barimani 1 , Sven-Erik Sonesson 1 , Marie Wahren-<br />
Herlenius 2 and Elisabet M. B. Welin Henriksson 3 , 1 Karolinska<br />
Institutet, Stockholm, Sweden, 2 Karolinska Institutet CMM,<br />
Stockholm, Sweden, 3 Karolinska Institutet Rheum, Stockholm,<br />
Sweden.<br />
1323. Psychological Factors but Not Clinical Markers <strong>of</strong> Disease<br />
Activity Predict Adherence among Rheumatoid Arthritis<br />
(RA) Patients Receiving DMARDs and Adalimumab (ADA):<br />
Results from the British Society for <strong>Rheumatology</strong> Biologics<br />
Register (BSRBR). C. Morgan 1 , J. McBeth 2 , L. Cordingley 2 , K. D.<br />
Watson 2 , BSRBR Control Centre Consortium, K. L. Hyrich 2 , D. P.<br />
M. Symmons 2 , I. N. Bruce 2 and on Behalf <strong>of</strong> the BSR Biologics<br />
Register, 1 The University <strong>of</strong> Manchester, Manchester, United<br />
Kingdom, 2 The University <strong>of</strong> Manchester.<br />
1324. Spousal Social Support and Well-Being among Persons with<br />
Rheumatoid Arthritis: Is Support in the Eye <strong>of</strong> the Beholder?<br />
Allen J. Lehman 1 , Anita DeLongis 3 , Daniel D. Pratt 3 , John B.<br />
Collins 3 and John M. Esdaile 2 , 1 Arthritis Research Centre <strong>of</strong><br />
Canada; Simon Fraser University, Vancouver, BC, Canada,<br />
2<br />
Arthritis Research Centre <strong>of</strong> Canada; University <strong>of</strong> British<br />
Columbia, Vancouver, BC, Canada, 3 University <strong>of</strong> British<br />
Columbia, Canada.<br />
1325. Sustained Reduction in Fatigue Impact in Rheumatoid<br />
Arthritis: RCT <strong>of</strong> Cognitive Behavioural Therapy. Sarah E.<br />
Hewlett 5 , Nicholas Ambler 2 , Bev Knops 2 , Alena Cliss 1 , Celia<br />
Almeida 6 , Denise Pope 3 , Alison Hammond 4 , Annette Swinkels 6 ,<br />
Karen Kitchen 3 and Jon Pollock 6 , 1 Frenchay Hospital, Bristol UK,<br />
2<br />
Frenchay Hospital, Bristol, UK, 3 University Hospitals Bristol, UK,<br />
4<br />
University <strong>of</strong> Salford, Matlock Derbyshire, United Kingdom,<br />
5<br />
University <strong>of</strong> the West <strong>of</strong> England, Bristol, United Kingdom,<br />
6<br />
University <strong>of</strong> the West <strong>of</strong> England, Bristol UK.<br />
1326. The Effect <strong>of</strong> Social Support from Physicians and Partners<br />
on the Health-Related Quality <strong>of</strong> Life <strong>of</strong> Vasculitis Patients<br />
in Relapse and Remission. Delesha M. Carpenter 2 , Jessica<br />
A. Kadis 2 , Robert F. DeVellis 2 , Susan L. Hogan 3 and Joanne M.<br />
Jordan 1 , 1 Chapel Hill, NC, 2 UNC, Chapel Hill, NC, 3 UNC.<br />
ARHP Poster Session B: Foot<br />
1327. Foot Pain in Relation to the Foot Biomechanical Measures <strong>of</strong><br />
Plantar Peak Pressures and Pressure Time Intergral. Virginia<br />
A. Casey 3 , Andrew M. Galica 3 , Alyssa B. Dufour 1 , Robert R.<br />
McLean 1 and Marian T. Hannan 2 , 1 Hebrew Senior Life, Boston,<br />
MA, 2 Hebrew SL & Harvard Med Sch, Boston, MA, 3 IFAR Hebrew<br />
SeniorLife, Boston, MA.<br />
1328. Hallux Valgus and Foot Bimechanics: Relation between<br />
Structure and Function. Andrew M. Galica 5 , Alyssa B. Dufour 1 ,<br />
Marian T. Hannan 2 , Virginia A. Casey 5 , Jocelyn C. Frey 4 , Mark W.<br />
Lenh<strong>of</strong>f 4 and Howard J. Hillstrom 3 , 1 Hebrew Senior Life, Boston,<br />
MA, 2 Hebrew SL & Harvard Med Sch, Boston, MA, 3 Hospital<br />
Special Surgery, New York, NY, 4 Hospital Special Surgery, New<br />
York, NY, 5 Institute for Aging Research.<br />
1329. Hallux Valgus and Pes Cavus Are Highly Heritable in Older Men<br />
and Women: The Framingham Foot Study. Marian T. Hannan 4 ,<br />
Yi-Hsiang Hsu 3 , L. Adrienne Cupples 2 and Joanne M. Jordan 1 ,<br />
1<br />
Chapel Hill, NC, 2 BUSPH, Boston, MA, 3 Hebrew SeniorLife, HSPH<br />
and Harvard Medical School, Boston, MA, 4 Hebrew SL & Harvard<br />
Med Sch, Boston, MA.<br />
1330. Racial Differences in Foot Disorders: The Johnston County<br />
Osteoarthritis Project. Yvonne M. Golightly 2 , Marian T. Hannan 1 ,<br />
Alyssa B. Dufour 1 and Joanne M. Jordan 2 , 1 Institute for Aging<br />
Research, Hebrew Senior Life, 2 University <strong>of</strong> North Carolina at<br />
Chapel Hill.<br />
1331. Risk Factors for Hallux Valgus (HV) in a Population-Based Study<br />
<strong>of</strong> Older Adults: The Framingham Foot Study. Alyssa B. Dufour 4 ,<br />
Virginia A. Casey 5 , Andrew M. Galica 5 , David R. Gagnon 1 ,<br />
Howard J. Hillstrom 3 and Marian T. Hannan 2 , 1 Boston University<br />
School <strong>of</strong> Public Health, Boston, MA, 2 Hebrew SL & Harvard<br />
Med Sch, Boston, MA, 3 Hospital Special Surgery, New York,<br />
NY, 4 Institute for Aging Research, Hebrew SeniorLife & Boston<br />
University School <strong>of</strong> Public Health, Boston, MA, 5 Institute for<br />
Aging Research, Hebrew SeniorLife, Boston, MA.<br />
ARHP Poster Session B: Patient Education/Support<br />
1332. A Model <strong>of</strong> Quality Patient-Health Care Provider<br />
Communication. Elizabeth Salt 1 and Graham Rowles 2 ,<br />
1<br />
University <strong>of</strong> Kentucky, Lexington, KY, 2 University <strong>of</strong> Kentucky.<br />
1333. Comparison <strong>of</strong> Physician- and Nurse Prescriber-Led Dose<br />
Adjustment <strong>of</strong> DMARD Therapy in RA. Grainne Murphy, Mary<br />
Daly, John Ryan, Fergus Shanahan, Sinead Harney and Molloy<br />
Michael, Cork University Hospital.<br />
1334. Developing an Interactive Health Communication Application<br />
within <strong>Rheumatology</strong>: What Do Patients Want? Rosalie van der<br />
Vaart 2 , Constance H. C. Drossaert 2 , Erik Taal 1 and Mart A. F. J.<br />
van de Laar 2 , 1 Arthritis Centre Twente, Institute for Behavioural<br />
Research, University <strong>of</strong> Twente & Medisch Spectrum Twente,<br />
Enschede, The Netherlands, 2 Arthritis Centre Twente, Institute<br />
for Behavioural Research, University <strong>of</strong> Twente & Medisch<br />
Spectrum Twente.<br />
1335. Does an RA Peer Support Program Impact Disease Outcomes?<br />
Melanie Zibit 3 , Jing Cui 4 , Christine K. Iannaccone 2 , Nancy A.<br />
Shadick 1 , Michael E. Weinblatt 1 , Meghan Courtney 3 , Margo<br />
Hanlan 3 , Husen Tsao 3 and Anne Fossel 3 , 1 Brigham & Womens<br />
Hospital, Boston, MA, 2 Brigham and Woemens Hospital, Boston,<br />
MA, 3 Brigham and Women’s Hospital, Boston, MA, 4 Brigham and<br />
Womens Hospital, Boston, MA.<br />
1336. Educational Needs Assessment among Patients with<br />
Rheumatic Diseases in Kenya. Ines Colmegna 1 , Susan J.<br />
Bartlett 1 , Sharon Kodhek 2 , Omondi G. Oyoo 3 and International<br />
League <strong>of</strong> Associations for <strong>Rheumatology</strong> East Africa Initiative,<br />
1<br />
McGill University, Montreal, QC, Canada, 2 Nairobi SLE Support<br />
Group, Nairobi, Kenya, 3 University <strong>of</strong> Nairobi, Nairobi, Kenya.<br />
1337. Phone Administration Compared to Self-Administration on<br />
Paper <strong>of</strong> the Main Instruments Used To Evaluate Ankylosing<br />
Spondylitis Patients. Rafael Ariza-Ariza, Blanca Hernández-<br />
Cruz, Victoria Navarro-Compán and Federico Navarro-Sarabia,<br />
Hospital Virgen Macarena, Sevilla, Spain.<br />
2010 Program Book 231
ACR/ARHP Poster Session B<br />
1338. <strong>Rheumatology</strong> Health Pr<strong>of</strong>essionals’ Care: Current and Future<br />
Tasks and Education. Emalie J. Hurkmans 3 , Rinie Geenen 1 , John<br />
Verhoef 4 and Thea P. M. Vliet Vlieland 2 , 1 Clinical and Health<br />
Psychology, Utrecht University & University Medical Center,<br />
Utrecht, The Netherlands, 2 Department <strong>of</strong> <strong>Rheumatology</strong> and<br />
Orthopaedics, Leiden University Medical Center, Leiden, The<br />
Netherlands, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden University<br />
Medical Center, Leiden, The Netherlands, 4 Faculty <strong>of</strong> Health,<br />
University <strong>of</strong> Applied Sciences, Leiden, The Netherlands.<br />
ARHP Poster Session B: Pediatrics<br />
1339. Accuracy <strong>of</strong> the Early Detection <strong>of</strong> Juvenile Idiopathic Arthritis<br />
Questionnaire – A Multicenter Study. Claudio A. Len 7 , Luciana<br />
T. P. Paulo 7 , Maria Teresa R. A. Terreri 7 , Silvana B. Sacchetti 3 ,<br />
Virginia P. L. Ferriani 5 , Clovis A. A. Silva 4 , Cássia M. P. Barbosa 1 ,<br />
Simone Lotufo 2 and Roberto Marini 6 , 1 Hospital Darcy Vargas, São<br />
Paulo, Brazil, 2 Hospital Menino Jesus, São Paulo, Brazil, 3 Santa<br />
Casa de São Paulo, São Paulo, Brazil, 4 Universidade de São<br />
Paulo, São Paulo, Brazil, 5 Universidade de São Paulo, Ribeirão<br />
Preto, São Paulo, Brazil, 6 Universidade Estadual de Campinas,<br />
São Paulo, Brazil, 7 Universidade Federal de São Paulo, São Paulo,<br />
Brazil.<br />
1340. Engaging Youth in a Web Based Transition Intervention:<br />
Usability and Feasibility <strong>of</strong> Rheumtogrow.org. Peter Scal, Ann<br />
Garwick and Keith Horvath, University <strong>of</strong> Minnesota.<br />
1341. FEAR (False ELISA Associated Rheumatic) Syndrome in<br />
Children. Donald P. Goldsmith 1 , Carolann Martucci 3 and Svetlana<br />
Lvovich 2 , 1 St Christopher Hosp Children/Drexel University<br />
<strong>College</strong> <strong>of</strong> Medicine, Philadelphia, PA, 2 St Christopher’s Hosp<br />
Children/Drexel University <strong>College</strong> <strong>of</strong> Medicine, Philadelphia,<br />
PA, 3 St Christopher’S Hospital for Children, Philadelphia, PA.<br />
1342. Physiotherapy Management <strong>of</strong> Children with Hypermobility:<br />
A Review <strong>of</strong> an Out-Patient Self Management Exercise<br />
Programme. Susan M. Maillard 1 , David Adkins 2 , Elaine Haggart 2<br />
and Swati Bhagat 2 , 1 Great Ormond Street Hospital, London,<br />
Maidenhead, United Kingdom, 2 Great Ormond Street Hospital,<br />
London, London, United Kingdom.<br />
1343. Stress in Adolescents with Idiopathic Musculoskeletal Pain.<br />
Juliana Molina 2 , Flavia H. Santos 1 , Maria Sylvia Vitalle 2 , Maria<br />
Odete E. Hilário 2 , Maria Teresa R. A. Terreri 2 , Simone G. L. Silva 2<br />
and Claudio A. Len 2 , 1 Universidade Estadual de São Paulo, Assis,<br />
São Paulo, Brazil, 2 Universidade Federal de São Paulo, São Paulo,<br />
Brazil.<br />
1344. To Explore the Use <strong>of</strong> the PedsQL Subjective Questionnaire<br />
To Assess Levels <strong>of</strong> Fatigue in Children with Juvenile<br />
Dermatomyositis. Susan M. Maillard 1 , Amy Todd 2 , Kiran<br />
Nistala 3 , Clarissa Pilkington 2 and Abdul Hassan 2 , 1 Great Ormond<br />
Street Hospital, London, Maidenhead, United Kingdom, 2 Great<br />
Ormond Street Hospital, London, 3 Institute <strong>of</strong> Child Health,<br />
London.<br />
1345. Utilizing Social Media To Reach Young Arthritis Patients.<br />
Jane S. Brandenstein 1 , Emily Cope 3 , Allison J. Kerr 2 , Ashley M.<br />
Boynes 2 , Carol D. Popp 2 and Lori Knapp 2 , 1 Freedom, PA, 2 W Pa<br />
Arthritis Foundation, Pittsburgh, PA, 3 WPa Arthritis Foundation,<br />
Pittsburgh, PA.<br />
232<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
Halls B1 & B2<br />
WEDNESDAY, NOVEMBER 10, 2010<br />
Biology and Pathology <strong>of</strong> Bone and Joint: Osteoarthritis-Cartilage<br />
Degradation and Skeletal Turnover<br />
1466. A Novel Serum Biomarker <strong>of</strong> Cartilage Destruction, Measured<br />
in OA and RA Patients, Is Significantly Associated with<br />
Kellgren-Lawrence Score. Anne C. Bay-Jensen 1 , Erik B. Dam 3 ,<br />
Inger Byrjalsen 2 , Tanja Schubert 4 , Phillip Vergnaud 4 , Per Qvist 1<br />
and Morten A. Karsdal 1 , 1 Cartilage Biology and Biomarkers,<br />
Denmark, 2 CCBR-Synarc, Denmark, 3 Nordic Bioscience Imaging,<br />
Denmark, 4 Synarc-Lyon, France.<br />
1467. A Small Molecule c-Fos/AP-1 Inhibitor T-5224 Inhibits<br />
Osteoclastogenesis and Bone Resorption. Hidetoshi Murao 3 ,<br />
Yukihiko Aikawa 4 , Akira Hashiramoto 1 , Tetsuya Yamamoto 4 ,<br />
Hisaaki Chaki 4 , Hirokazu Narita 4 , Shuichi Hirono 2 and Shunichi<br />
Shiozawa 1 , 1 Department <strong>of</strong> Biophysics, Kobe University <strong>of</strong><br />
Graduate School <strong>of</strong> Health Sciences/The Center for Rheumatic<br />
Diseases, Kobe University Hospital, Kobe, Japan, 2 Department<br />
<strong>of</strong> Pharmaceutical Sciences, School <strong>of</strong> Pharmacy, Kitasato<br />
University, Tokyo, Japan, 3 Research Laboratories, Toyama<br />
Chemical Co., Ltd, Toyama, Japan, 4 Research Laboratories,<br />
Toyama Chemical Co., Ltd, Toyama, Japan.<br />
1468. Activation <strong>of</strong> Wnt and Bone Morphogenetic Protein Signalling<br />
Pathways in the Articular Cartilage in Frzb-/- Mice. Liesbet<br />
Lodewyckx 1 , Jeroen Eyckmans 3 , Frank P. Luyten 2 and Rik Lories 1 ,<br />
1<br />
KU Leuven, Leuven, Belgium, 2 KU Leuven, Leuven, Belgium, 3 KU<br />
Leuven.<br />
1469. Adenosine A1 Receptors Regulates RANKL-Induced Osteoclast<br />
Formation Via Regulation <strong>of</strong> c-fos and NFATc1 Expression.<br />
Wenjie He 2 , Tuere Wilder 2 and Bruce N. Cronstein 1 , 1 New York<br />
Univ Med Ctr, New York, NY, 2 NYU School <strong>of</strong> Medicine.<br />
1470. Adenosine A2A Receptor Agonists: Can They Prevent/<br />
Treat Joint Prosthesis Loosening? Aranzazu Mediero 1 , Sally<br />
R. Frenkel 2 , Tuere Wilder 1 , Igor Immerman 3 , Scott Hadley 3 ,<br />
R. Damani Howell 3 , Maya Hawly 4 , Elie Sellam 4 and Bruce N.<br />
Cronstein 5 , 1 Department <strong>of</strong> Medicine, NYU Langone Medical<br />
Center, New York, NY, 2 Department <strong>of</strong> Orthopaedic Surgery,<br />
NYU Hospital for Joint Diseases, New York, NY, 3 Department <strong>of</strong><br />
Orthopaedic Surgery, NYU Hospital for Joint Diseases, 4 Institut<br />
Supérieur des BioSciences de Paris, France, 5 New York Univ Med<br />
Ctr, New York, NY.<br />
1471. Adenosine A2A Receptor Ligation Inhibits Osteoclast<br />
Formation. Aranzazu Mediero 1 , Firas M. Kara 1 , Maya Hawly 2 ,<br />
Elie Sellam 2 and Bruce N. Cronstein 3 , 1 Department <strong>of</strong> Medicine,<br />
NYU School <strong>of</strong> Medicine, New York, NY, 2 Institut Supérieur des<br />
Biosciences de Paris, Creteil, Ile de France, France, 3 New York<br />
Univ Med Ctr, New York, NY.<br />
1472. Alarmins S100A8 and S100A9 Skew Human Chondrocytes<br />
towards a Cartilage Breakdown Phenotype. Rik F. P.<br />
Schelbergen 4 , Peter L. van Lent 5 , Arjen B. Blom 5 , Annet Sloetjes 5 ,<br />
Thomas Vogl 2 , Johannes Roth 1 and Wim B. Van Den Berg 3 ,<br />
1<br />
Children’s Hospital Eastern Ontario, Ottawa, ON, Canada,<br />
2<br />
Institute <strong>of</strong> Immunology, Muenster, 3 Radboud Univ Nijmegen<br />
Med Cntr, Nijmegen, The Netherlands, 4 Radboud University<br />
Nijmegen Medical Centre, Nijmegen, The Netherlands,<br />
5<br />
Radboud University Nijmegen Medical Centre.<br />
1473. Analysis <strong>of</strong> Secretome from Mesenchymal Stem Cells from<br />
Human Umbilical Cord Strome during the Chondrogenesis.<br />
María C. Arufe 1 , Alexandre De la Fuente 2 , Jesús Mateos 4 ,<br />
Patricia Fernández-Puente 4 , Esther Rendal 4 , Silvia Díaz 2 ,<br />
Isaac Fuentes 2 , Francisco J. De Toro 2 and Francisco J. Blanco 3 ,<br />
1<br />
INIBIC-Universidad de A Coruna, A Coruna, Osteoarticular<br />
and Aging Research Laboratory, Proteomics Unit-Associated<br />
Node to ProteoRed-Biomedical Research Center (INIBIC),<br />
Hospital Universitario A Coruna, La Coruna, Coruña, Spain,<br />
2<br />
INIBIC-Universidad de A Coruna, A Coruna, Spain, 3 INIBIC-<br />
Universidad de A Coruna, A Coruna, Spain. Osteoarticular and<br />
Aging Research Laboratory, Proteomics Unit-Associated Node<br />
to ProteoRed-Biomedical Research Center (INIBIC). Hospital<br />
Universitario A Coruna, La Coruna, Spain, 4 Osteoarticular and<br />
Aging Research Laboratory, Proteomics Unit-Associated Node<br />
to ProteoRed-Biomedical Research Center (INIBIC), Hospital<br />
Universitario A Coruña. La Coruña, Spain.<br />
1474. Biochemical Markers <strong>of</strong> Bone Balance (CTX-I/Osteocalcin)<br />
Improve with Tocilizumab Treatment in a Population <strong>of</strong> RA<br />
Patients with an Inadequate Response to Anti-TNF Therapy.<br />
Morten Karsdal 2 , Thasia G. Woodworth 3 , Andy Kenwright 4 ,<br />
Inger Byrjalsesn 1 , Adam Platt 4 and Georg Schett 5 , 1 CCBR Synarc,<br />
Ballerup, Denmark, 2 Nordic Bioscience, Herlev, Herlev, Denmark,<br />
3<br />
Roche Products Ltd., Welwyn, Welwyn Garden City, United<br />
Kingdom, 4 Roche, Welwyn, United Kingdom, 5 University <strong>of</strong><br />
Erlangen-Nuremberg, Erlangen, Germany.<br />
1475. Chondrogenic Differentiation <strong>of</strong> Bone Marrow Mesenchymal<br />
Stem Cells Grown on Type I Collagen and Heparan Sulfate<br />
Scaffolds. Silvia Díaz-Prado 4 , Emma Muiños 3 , C. G. Trejo-<br />
Iriarte 1 , D. Lozano 2 , N. García-Honduvilla 1 , Isaac Fuentes 3 ,<br />
Francisco J. De Toro 3 , P. Esbrit 2 , Julia Buján 1 and Francisco J.<br />
Blanco 3 , 1 Department <strong>of</strong> Medical Specialties. University <strong>of</strong><br />
Alcalá de Henares, Madrid, Spain, 2 Laboratory <strong>of</strong> Bone and<br />
Mineral Metabolism. Fundación Jiménez Díaz (Capio Group).<br />
Madrid, Spain, 3 Osteoarticular and Aging Res. Lab. CIBER-BBN,<br />
<strong>Rheumatology</strong> Div, INIBIC-Complejo Hosp, Univ. A Coruña, A<br />
Coruña, SPAIN, 4 Osteoarticular and Aging Res. Lab. CIBER-BBN.<br />
<strong>Rheumatology</strong> Div. INIBIC-Complejo Hosp. Univ. A Coruña,<br />
Coruña, Spain.<br />
1476. CXCR1/2 Signalling Is Required but Is Not Sufficient To<br />
Maintain the Phenotypic Stability <strong>of</strong> Human Articular<br />
Chondrocytes. Joanna C. Sherwood 1 , Pramod Achan 2 , Giovanna<br />
Nalesso 2 , Costantino Pitzalis 2 and Francesco Dell’Accio 2 , 1 Barts<br />
and The London School <strong>of</strong> Medicine and Dentistry, Queen Mary<br />
University <strong>of</strong> London, London, United Kingdom, 2 Barts and<br />
The London School <strong>of</strong> Medicine and Dentistry, Queen Mary<br />
University <strong>of</strong> London.<br />
1477. Effects <strong>of</strong> NSAIDs and the Cyclooxygenase-Inhibiting Nitric<br />
Oxide Donator (CINOD) NCX 429 on Human Chondrocytes and<br />
Cartilage from OA Patients. Manlio Bolla 1 , Serena Viappiani 2 ,<br />
Mandar Dave 4 , Jyoti Patel 4 , Steven B. Abramson 3 and Mukundan<br />
Attur 3 , 1 NicOx Research, Sophia Antipolis, France, 2 NicOx<br />
Research, 3 NYU Hospital for Joint Diseases, New York, NY, 4 NYU<br />
Hospital for Joint Diseases.<br />
1478. Endogeneous TIMP3 Induce Death Receptor Ligand-<br />
Independent Apoptosis in Mesenchymal Cells. Christina<br />
Wunrau 2 , Doreen Wendholt 3 , Noreen Pundt 3 , Thomas Pap 1 and<br />
Berno Dankbar 3 , 1 IEMM, University Hospital Muenster, Münster,<br />
Germany, 2 Institute <strong>of</strong> Experimental Musculoskeletal Medicine-<br />
IEMM, University Hospital Muenster, Münster, Germany,<br />
3<br />
Institute <strong>of</strong> Experimental Musculoskeletal Medicine-IEMM,<br />
University Hospital Muenster, Muenster, Germany.<br />
2010 Program Book 233
ACR/ARHP Poster Session C<br />
1479. Endogenous Joint Repair after Damage in the Red-Spotted<br />
Newt. Matthias Geyer 1 , Thilo Borchardt 2 , Carina Schreiyaeck 1 ,<br />
Ulf Müller-Ladner 1 and Robert Dinser 1 , 1 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Justus Liebig University Giessen, Kerckh<strong>of</strong>f-<br />
Klinik, Bad Nauheim, 2 Max Planck Institute for Heart and Lung<br />
Research, Bad Nauheim.<br />
1480. Experimental Osteoarthritis in Rats Is Attenuated by Treatment<br />
with a Selective Inhibitor <strong>of</strong> Sphingosine Kinase 2. Leo R.<br />
Fitzpatrick 3 , Cecelia Green 1 , Lynn W. Maines 1 and Charles<br />
D. Smith 2 , 1 Apogee Biotechnology Corporation, 2 Apogee<br />
Biotechnology Corporation and Medical University <strong>of</strong> South<br />
Carolina, 3 Penn State <strong>College</strong> <strong>of</strong> Medicine, Hummelstown, PA.<br />
1481. Expression <strong>of</strong> MMP-13 and ADAMTS-5 Is Mediated Via Nuclear<br />
Orphan Receptor NR4A3 Signalling in Human Chondrocytes.<br />
Martin H. Stradner 2 , Hannes Angerer 3 , Daniela Krusch 1 ,<br />
Florentine C. Fürst 3 , Marie-Luise Kremser 3 , Daniela Setznagl 3 and<br />
Winfried B. Graninger 3 , 1 Karl-Franzens University Graz, 2 Medical<br />
University Graz, Graz, Austria, 3 Medical University Graz.<br />
1482. Histamine Contributes to Inflammatory Joint Disease by<br />
Regulating the Expression <strong>of</strong> RANKL and OPG through<br />
Altered NR4A Activity in Human Chondrocyte Cells. Viviana<br />
Marzaioli 2 , Jason P. McMorrow 2 , Alice McEvoy 1 and Evelyn P.<br />
Murphy 2 , 1 Dublin Institute <strong>of</strong> Technology, Kevin Street, Dublin,<br />
Ireland, 2 UCD Veterinary Sciences Centre and Conway Insitute<br />
for Biomolecular and Biomedical Research, Human Amniotic<br />
Membrane as Scaffold for Human Articular Cartilage Repair.<br />
Emma Muiños-López 4 , Silvia M. Díaz-Prado 3 , Tamara Hermida-<br />
Gómez 2 , Esther Rendal-Vázquez 1 , Isaac Fuentes-Boquete 3 ,<br />
María C. Arufe-Gonda 3 , Francisco J. De Toro 3 and Francisco J.<br />
Blanco 2 , 1 Cryobiology Unit. Complejo Hosp. Univ. A Coruña, A<br />
Coruña, Spain, 2 Osteoarticular and Aging Res. Lab. CIBER-BBN,<br />
<strong>Rheumatology</strong> Div, INIBIC-Complejo Hosp, Univ. A Coruña, A<br />
Coruña, SPAIN, 3 Osteoarticular and Aging Res. Lab. CIBER-BBN,<br />
<strong>Rheumatology</strong> Div. INIBIC-Complejo Hosp, Univ. A Coruña, A<br />
Coruña, SPAIN. INIBIC-University <strong>of</strong> A Coruña, A Coruña, SPAIN,<br />
4<br />
Osteoarticular and Aging Res. Lab. CIBER-BBN. <strong>Rheumatology</strong><br />
Div. INIBIC-Complejo Hosp. Univ. A Coruña, Coruña, Spain.<br />
1484. Increased Expression <strong>of</strong> Arthritic Marker Genes in the Cartilage<br />
<strong>of</strong> SirT1 Null Mice. Odile H. Gabay 2 , Eun Jin Lee 2 , Richard<br />
Booth 2 , Viktoria Gagarina 2 , Mona Dvir-Ginzberg 1 and David J.<br />
Hall 2 , 1 Hebrew University, Jerusalem, Israel, 2 NIH, Bethesda, MD.<br />
1485. Increasing Osteoclastic Bone Loss Inspite <strong>of</strong> Fewer Osteoclast<br />
Precursors during Chronic Autoimmune SKG-Arthrtitis<br />
Evaluated by 3D Stereological Estimators. Kresten K. Keller 3 ,<br />
Kristian Stengaard-Pedersen 2 , Frederik Dagnæs-Hansen 5 , Jens<br />
R. Nyengaard 6 , Shimon Sakaguchi 1 and Ellen-Margrethe Hauge 4 ,<br />
1<br />
Department <strong>of</strong> Experimental Pathology, Institute for Frontier<br />
Medical Science, Kyoto University, 2 Dept. <strong>of</strong> <strong>Rheumatology</strong>,<br />
Aarhus University Hospital, Aarhus, Denmark, 3 Dept. <strong>of</strong><br />
<strong>Rheumatology</strong>, Aarhus University Hospital, Århus, Denmark,<br />
4<br />
Dept. <strong>of</strong> <strong>Rheumatology</strong>, Aarhus University Hospital, Denmark,<br />
5<br />
Institut <strong>of</strong> Medical Microbiology and Immunology, Aarhus<br />
University, Denmark, 6 Stereology and Electron Microscopy<br />
Research Laboratory, Aarhus University, Denmark.<br />
1486. Influence <strong>of</strong> NPP1 on Osteoarthritis (OA)-Associated Cartilage<br />
Calcification. Jessica Bertrand 3 , Martin Fürst 5 , Wolfgang Rüther 1 ,<br />
Frank Rutsch 2 , Yvonne Nitschke 2 and Thomas Pap 4 , 1 Centre for<br />
Orthopaedics and Trauma Surgery, 2 Department <strong>of</strong> Pedriatrics,<br />
3<br />
Insitute for Experimental Musculoskeletal Medicine, Münster,<br />
Germany, 4 Insitute for Experimental Musculoskeletal Medicine,<br />
5<br />
MedBaltic.<br />
1487. Inhibitory кBα Is a Direct Bone Morphogenetic Protein Target<br />
Gene and an Essential Mediator <strong>of</strong> Anti-Catabolic Effects <strong>of</strong><br />
BMPs. Olexandr Korchynskyi 3 , Paul-Peter Tak 3 , Alisa E. Koch 2 ,<br />
Peter ten Dijke 1 and Dhavalkumar D. Patel 4 , 1 Department<br />
<strong>of</strong> Molecular Cell Biology, Leiden University Medical Cente,<br />
Leiden, The Netherlands, 2 Department <strong>of</strong> Veteran’s Affairs<br />
and the University <strong>of</strong> Michigan, Ann Arbor, MI, 3 Division <strong>of</strong><br />
Clinical Immunology & <strong>Rheumatology</strong>, Academic Medical<br />
Center, University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />
4<br />
Thurston Arthritis Research Center, University <strong>of</strong> North Carolina<br />
at Chapel Hill, Chapel Hill, NC.<br />
1488. Interleukin-10 Regulates Bone Metabolism by Suppressing<br />
Osteoclastogenesis In Vivo. Seungwoo Han 4 , Younkwan<br />
Jung 3 , Eunsoo Kim 2 and Gunwoo Kim 1 , 1 CIHR Group in Skeletal<br />
Development and Remodeling, Department <strong>of</strong> Physiology and<br />
Pharmacology, University <strong>of</strong> Western Ontario, London, ON,<br />
Canada, 2 Dongsan Medical Center, Keimyung University, Daegu,<br />
Korea, Republic <strong>of</strong>, 3 Laboratory for Arthritis and Bone Biology,<br />
Fatima Research Institute, Korea, Republic <strong>of</strong>, 4 Laboratory<br />
for Arthritis and Bone Biology, Fatima Research Institute,<br />
Department <strong>of</strong> Internal Medicine, Daegu Fatima Hospital,<br />
Daegu, Korea, Republic <strong>of</strong>.<br />
1489. Interleukin-1-Induced Cyclooxygenase-2 and Inducible Nitric<br />
Oxide Synthase Expression in Human OA Chondrocytes Is<br />
Associated with Histone H3K4 Methylation. Fatima Ezzahra<br />
El-Mansouri 3 , Nadir Chabane 3 , Nadia Zayed 3 , Johanne Martel-<br />
Pelletier 2 , Jean-Pierre Pelletier 1 and Hassan Fahmi 3 , 1 CHUM<br />
- Notre-Dame Hospital, Montreal, QC, Canada, 2 CR-CHUM,<br />
Notre-Dame Hospital, Montreal, QC, Canada, 3 Osteoarthritis<br />
Research Unit, University <strong>of</strong> Montreal Hospital Research Centre<br />
(CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada.<br />
1490. miR-7 and miR-130b Are Differentially Regulated during<br />
Mesenchymal Stem Cell Commitment. Glyn Palmer 4 , Laura S.<br />
Danielson 2 , Mukundan Attur 3 , Steven B. Abramson 1 and Eva<br />
Hernando 2 , 1 Hospital for Joint Dis/NYU, New York, NY, 2 NYU-<br />
Department <strong>of</strong> Pathology, 3 NYU-Hospital for Joint Diseases,<br />
4<br />
NYU-Hospital for Joint Diseases, New York, NY.<br />
1491. MMP-3 and DKK-1 Levels in Juvenile Idiopathic Arthritis.<br />
Matthew L. Stoll 2 , Michelle L. Christadoss 2 , Marilynn G. Punaro 2<br />
and Nancy J. Olsen 1 , 1 Penn State Hershey Medical Center,<br />
Hershey, PA, 2 UT Southwestern Med Ctr, Dallas, TX.<br />
1492. Modeling Osteoclast Precursor Master Fusogens and<br />
Mononuclear OCP Donors with Raw Cell Line Clones. Yawen<br />
Ju, Masahiko Takahata, K<strong>of</strong>i Mensah, Grace Chiu, Christopher<br />
T. Ritchlin, Lianping Xing and Edward M. Schwarz, University <strong>of</strong><br />
Rochester.<br />
1493. Multi-Targeted Kinase Inhibitor PKC412 Diminishes<br />
Osteoclastogenesis and Counteracts Osteoclast Mediated<br />
Bone Resorption In Vitro. Despoina Sykoutri 1 , Silvia Hayer 3 ,<br />
Josef S. Smolen 4 and Kurt Redlich 2 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Department <strong>of</strong> Internal Medicine III, Medical University <strong>of</strong><br />
Vienna, Vienna, Austria, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Department<br />
<strong>of</strong> Internal Medicine III, Medical University <strong>of</strong> Vienna, Vienna,<br />
Austria, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />
Medicine III, Medical University <strong>of</strong> Vienna, 4 Krankenhaus Lainz,<br />
Vienna, Austria.<br />
1494. Potential Role <strong>of</strong> the LKB1-AMPK and CaMKKb-AMPK<br />
Pathways in Controlling the Progression <strong>of</strong> OA. Robert<br />
Terkeltaub 3 , Bing Yang 4 , Martin K. Lotz 1 and Ru L. Bryan 2 ,<br />
1<br />
Scripps Rsch Inst, La Jolla, CA, 2 UCSD/VAMC, San Diego, CA, 3 VA<br />
Medical Ctr, San Diego, CA, 4 VA Medical Ctr.<br />
234<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
1495. S100A8 Enhances Osteoclastic Bone Resorption in<br />
Experimental Antigen-Induced Arthritis. Lilyanne C. Grevers 3 ,<br />
Teun J. de Vries 1 , Vincent Everts 1 , Annet W. Sloetjes 3 , Thomas<br />
Vogl 2 , Johannes Roth 2 , Wim B. van den Berg 3 and Peter L. van<br />
Lent 3 , 1 Department <strong>of</strong> Oral Cell Biology, ACTA, UVA and VU<br />
University Amsterdam, Amsterdam, The Netherlands, 2 Institute<br />
<strong>of</strong> Experimental Dermatology, University <strong>of</strong> Münster, Muenster,<br />
Germany, 3 Radboud University Nijmegen, Medical Centre,<br />
Nijmegen, The Netherlands.<br />
1496. Serum Biomarkers Predict Progressive Structural Damage in<br />
the BeSt Study. Yijing Shen 1 , Linda Dirven 4 , Guy Cavet 1 , Michael<br />
Centola 5 , B. A. C. Dijkmans 2 , Lyndal K. Hesterberg 1 , Thomas<br />
Huizinga 4 , Willem F. Lems 6 and Cornelia F. Allaart 3 , 1 Crescendo<br />
Bioscience, Inc., 2 JBI, Amsterdam, The Netherlands, 3 Leiden Univ<br />
Med Ctr, Leiden, The Netherlands, 4 Leiden University Medical<br />
Center, 5 Oklahoma Med Research Foundation, Oklahoma City,<br />
OK, 6 VU University Medical Center.<br />
1497. Strontium Ranelate Inhibits Key Factors Affecting Bone<br />
Remodelling in Human Osteoarthritic Subchondral Bone<br />
Osteoblasts. Johanne Martel-Pelletier 2 , Steeve Kwan Tat 3 ,<br />
Anne-Christine Goulet 3 , Judith Caron 1 , Daniel Lajeunesse 4 and<br />
Jean-Pierre Pelletier 4 , 1 ArthroLab Inc., Montreal, 2 CR-CHUM,<br />
Notre-Dame Hospital, Montreal, QC, Canada, 3 Osteoarthritis<br />
Research Unit, University <strong>of</strong> Montreal Hospital Research Centre<br />
(CRCHUM), Notre-Dame Hospital, 4 University <strong>of</strong> Montreal<br />
Hospital Research Centre (CRCHUM), Notre-Dame Hospital,<br />
Montreal, QC, Canada.<br />
1498. Study <strong>of</strong> Chondrogenic Potential <strong>of</strong> Subpopulations <strong>of</strong> Cells<br />
Expressing Mesenchymal Stem Cell Markers Derived from<br />
Human Synovial Membranes. María C. Arufe 4 , Alexandre De la<br />
Fuente 3 , Silvia Diaz 2 , Isaac Fuentes 2 , Francisco J. de Toro 1 and<br />
Francisco J. Blanco 5 , 1 Dpto. Medicine, Area <strong>of</strong> Anatomy and<br />
Human Embryology, Campus Oza s/n. Fac. <strong>of</strong> Health Science,<br />
University <strong>of</strong> A Coruna, CIBER-BBN, Instituto de Salud Carlos<br />
III, Spain, 2 Osteoarticular and Aging Research Lab. Cellular<br />
Therapy Unit, INIBIC- CHUAC, A Coruña, Dpto. Medicine, Area<br />
<strong>of</strong> Anatomy and Human Embryology, Campus Oza s/n. Fac. <strong>of</strong><br />
Health Science, University <strong>of</strong> A Coruna, CIBER-BBN, Instituto<br />
de Salud C, 3 Osteoarticular and Aging Research Lab. Cellular<br />
Therapy Unit, INIBIC- CHUAC, A Coruña, Spain, CIBER-BBN,<br />
Instituto de Salud Carlos III, Spain, 4 Osteoarticular and Aging<br />
Research Lab. Cellular Therapy Unit. INIBIC- CHUAC, A Coruna,<br />
Dpto. Medicine, Area <strong>of</strong> Anatomy and Human Embryology,<br />
Campus Oza s/n. Fac. <strong>of</strong> Health Science, University <strong>of</strong> A Coruna,<br />
CIBER-BBN, Instituto de Salud Carlos , 5 Osteoarticular and Aging<br />
Research Lab. Cellular Therapy Unit., INIBIC- CHUAC, A Coruña.<br />
Cathedra BIOIBERICA <strong>of</strong> Cell Therapy University <strong>of</strong> A Coruna, A<br />
Coruña, SPAIN, CIBER-BBN, Instituto de Salud Carlos III, Spain.<br />
1499. TGF-β-Induced CD4+CD25+Foxp3+ Regulatory T Cells Suppress<br />
Bone Erosion in Collagen-Induced Arthritis through Restraining<br />
the Osteoclastogenesis. NIng Kong 3 , Ziyan Yang 2 , Julie Wang 3 ,<br />
Ryan Park 3 , Grant Dagliyan 3 , Peter S. Conti 3 , Hejian Zou 1 and<br />
Song Guo Zheng 3 , 1 Fudan University Medical School, 2 UCLA<br />
Department <strong>of</strong> Biomed, 3 USC Keck School <strong>of</strong> Medicine.<br />
1500. The Calcitonin Receptor Is Localized to Specific Phenotypes <strong>of</strong><br />
Cartilage Chondrocytes In Situ. Pingping Chen-An, Yadong Li,<br />
Bodil C. Sondergaard, Toni Silvestra-Segovia, Per Qvist, Morten<br />
A. Karsdal and Anne C. Bay-Jensen, Cartilage Biology and<br />
Biomarkers, Denmark.<br />
1501. The Enhanced Expression <strong>of</strong> Suppressor <strong>of</strong> Cytokine Signaling<br />
(SOCS)-3 in Human Pathological Chondrocytes Impairs the<br />
TLR4 and IGF-1 Signaling in These Cells. Fons A. J. van de Loo,<br />
Miranda B. Bennink, Onno J. Arntz, Henk M. van Beuningen,<br />
Peter M. van der Kraan, Sharon S. Veenbergen and Wim B. van<br />
den Berg, Department <strong>of</strong> <strong>Rheumatology</strong>, Radboud University<br />
Nijmegen Medical Centre, Nijmegen, The Netherlands.<br />
1502. The HCO3-/Cl- Anion Exchanger SLC4A2 Regulates pH and<br />
Actin Organization within Osteoclasts. Fabienne Coury 1 ,<br />
Andrew K. Stewart 3 , Sebastien Stephens 2 , Lynn Neff 2 , William<br />
C. Horne 2 , Seth L. Alper 3 , Roland Baron 2 and Antonios O.<br />
Aliprantis 1 , 1 Department <strong>of</strong> Immunology and Infectious<br />
Diseases, Harvard School <strong>of</strong> Public Health, and Department <strong>of</strong><br />
Medicine, Harvard Medical School, Boston, MA, 2 Department <strong>of</strong><br />
Oral Medicine Infection and Immunity, Harvard Dental School,<br />
3<br />
Division <strong>of</strong> Nephrology, Beth Israel Deaconess Medical Center.<br />
1503. WNT3A Signals Simultaneously through Multiple Pathways<br />
in Human Articular Chondrocytes, Resulting in Distinct<br />
Outcomes. Giovanna Nalesso 2 , Costantino Pitzalis 1 and<br />
Francesco Dell’Accio 2 , 1 William Harvey Research Institute, Barts<br />
and the London Queen Mary School <strong>of</strong> Medicine and Dentistry,<br />
Bromley Kent, United Kingdom, 2 William Harvey Research<br />
Institute, Barts and the London Queen Mary School <strong>of</strong> Medicine<br />
and Dentistry.<br />
Cell-Cell Adhesion, Cell Trafficking and Angiogenesis<br />
1504. A Novel Role for Inducible Fucosyltransferase2 as a Regulator<br />
<strong>of</strong> Angiogenesis. Mohammad A. Amin 1 , Jeffrey H. Ruth 2 , Peisuen<br />
Tsou 2 , Phillip L. Campbell 2 , Hubert Marotte 2 , SolHee Lee 2 ,<br />
Sivakumar Nallasivam 2 , Steven E. Domino 2 and Alisa E. Koch 3 ,<br />
1<br />
University <strong>of</strong> Michigan, Ann Arbor, MI, 2 University <strong>of</strong> Michigan,<br />
3<br />
Unversity <strong>of</strong> Michigan, Ann Arbor, MI.<br />
1505. CD86 Is Involved in the Intercellullar Contacts between IL15<br />
Activated Natural Killer Cells and THP-1 Cells That Result in<br />
TNF Production. Amalia Lamana, Belen Diaz-Sanchez, Ana M.<br />
Ortiz, Santos Castañeda, Rosario Garcia-Vicuña and Isidoro<br />
Gonzalez-Alvaro, <strong>Rheumatology</strong> Department. HU La Princesa. IIS<br />
Princesa, Madrid, Spain.<br />
1506. Characterization <strong>of</strong> CCR7 and Its Ligands CCL19 and CCL21<br />
in Rheumatoid Arthritis. Sarah R. Pickens 5 , Michael V. Volin 1 ,<br />
Richard M. Pope 4 , Arthur M. Mandelin 2 and Shiva Shahrara 3 ,<br />
1<br />
Midwestern University, 2 Northwester University, Chicago, IL,<br />
3<br />
Northwestern Univ Feinberg, Chicago, IL, 4 Northwestern Univ<br />
Med School, Chicago, IL, 5 Northwestern University, Chicago, IL.<br />
1507. Chemerin Levels Are Increased in Rheumatoid Arthritis<br />
Patients Who Smoke, Correlate with Disease Activity, and<br />
Decrease after Adalimumab Treatment. Marieke Herenius 2 ,<br />
Cristina Lebre 3 , Ana Oliveira 3 , Carla Wijbrandts 3 , Daniëlle Gerlag 3<br />
and Paul P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam,<br />
Amsterdam, The Netherlands, 2 Division <strong>of</strong> Clinical Immunology<br />
and <strong>Rheumatology</strong>, Academic Medical Center, University <strong>of</strong><br />
Amsterdam, Amsterdam, Utrecht, The Netherlands, 3 Division<br />
<strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic Medical<br />
Center, University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands.<br />
1508. Contribution <strong>of</strong> NR4A2 Gene Expression in Modulation<br />
<strong>of</strong> Thrombospondin-1 in Human Joint Disease. Jason P.<br />
McMorrow 3 , Ursula Fearon 3 , Douglas J. Veale 1 , Oliver M.<br />
FitzGerald 2 and Evelyn P. Murphy 3 , 1 St Vincents Univ Hospital,<br />
Dublin, Ireland, 2 University <strong>College</strong> Dublin, Ranelagh Dublin,<br />
Ireland, 3 University <strong>College</strong> Dublin, Dublin, Ireland.<br />
2010 Program Book 235
ACR/ARHP Poster Session C<br />
1509. Role <strong>of</strong> the Metalloproteinase ADAM-8 in the Regulation <strong>of</strong><br />
the Inflammatory Response. PSGL-1 Shedding by ADAM-8<br />
in Human Neutrophils. Maria Jesus Dominguez-Luis 4 , Ana<br />
Urzainqui-Mayayo 1 , Ada Maria Herrera-Garcia 4 , Ana Diaz-<br />
Martin 5 , Maria Teresa Arce-Franco 5 , Faustino Mollinedo 2 ,<br />
Francisco Sanchez-Madrid 1 and Federico Diaz-Gonzalez 3 ,<br />
1<br />
Immunology Service, Hospital de La Princesa, Madrid, Spain,<br />
2<br />
Instituto Superior del Cancer, Salamanca, Spain, 3 <strong>Rheumatology</strong><br />
Service, Hospital Universitario de Canarias, La Laguna, Tenerife,<br />
Spain, 4 <strong>Rheumatology</strong> Service, Hospital Universitario de<br />
Canarias, La Laguna, Spain, 5 <strong>Rheumatology</strong> Service, Hospital<br />
Universitario de Canarias, Spain.<br />
Cytokines, Mediators, Gene Regulation II<br />
1510. In Vitro Hypoxia-Induced Mitochondrial Genome Mutagenesis<br />
and Dysfunction. Monika Biniecka 2 , Edward Fox 1 , Chin T.<br />
Ng 2 , Wei Gao 2 , Ursula Fearon 2 , Douglas Veale 2 and Jacintha<br />
O’Sullivan 2 , 1 Department <strong>of</strong> Pathology, University <strong>of</strong><br />
Washington, Seattle, WA, 2 Translation Research Group, Dublin<br />
Academic Medical Centre, St. Vincent’s University Hospital,<br />
Dublin, Co. Dublin, Ireland.<br />
1511. Allograft Inflammatory Factor-1 Facilitates the Migration<br />
<strong>of</strong> Fibroblasts and Has a Correlation with the Pathogensis<br />
<strong>of</strong> Skin Fibrosis in a Murine Model <strong>of</strong> a Murine Model <strong>of</strong><br />
Sclerodermatous GVHD. Aihiro Yamamoto 1 , Eishi Ashihara 2 ,<br />
Yoko Nakagawa 2 , Hiroshi Obayashi 3 , Takahiro Seno 1 , Masatoshi<br />
Kadoya 1 , Masahide Hamaguchi 1 , Hidetaka Ishino 1 , Masataka<br />
Kohno 1 , Taira Maekawa 2 and Yutaka Kawahito 1 , 1 Department<br />
<strong>of</strong> Inflammation and Immunology, Graduate School <strong>of</strong> Medical<br />
Science, Kyoto Prefectural University <strong>of</strong> Medicine, 2 Department<br />
<strong>of</strong> Transfusion Medicine and Cell Therapy, Kyoto University<br />
Hospital, 3 Institute <strong>of</strong> Bio-Response Informatics.<br />
1512. Bach1 Regulates Heme Oxygenase-1 Expression <strong>of</strong> Human<br />
Monocytes in Response to LPS: Implication in Behcet’s<br />
Disease. Mitsuhiro Takeno, Takuya Miyazaki, Yohei Kirino, Sei<br />
Samukawa, Maasa Hama and Yoshiaki Ishigatsubo, Yokohama<br />
City University Graduate School <strong>of</strong> Medicine.<br />
1513. BMS-582949 Is a Dual Action p38 Kinase Inhibitor Well Suited<br />
To Avoid Resistance Mechanisms That Increase p38 Activation<br />
in Cells. Gary Schieven 1 , Rosemary Zhang 2 , Sidney Pitt 2 , Ding-<br />
Ren Shen 2 , Jian Cao 2 , John Sack 2 , Arthur Doweyko 2 and Petra<br />
Ross-MacDonald 2 , 1 Bristol-Myers Squibb, Princeton, NJ, 2 Bristol-<br />
Myers Squibb.<br />
1514. Both Insulin Receptor and Nampt Activity Are Implicated<br />
in Visfatin/Nampt Induced PGE2 Synthesis in Articular<br />
Chondrocytes. Marjolaine Gosset 4 , Francis Berenbaum 2 ,<br />
Colette Salvat 4 , Alain Sautet 1 , Martin Holzenberger 3 and Claire<br />
Jacques 4 , 1 Faculty <strong>of</strong> Medicine P&M Curie, Paris, France, 2 Faculty<br />
<strong>of</strong> Medicine P&M Curie, UR 4 Paris Universitas, Paris, France,<br />
3<br />
Inserm U 893 , Paris, France, 4 UR 4 Paris Universitas, Paris, France.<br />
1515. Comparison <strong>of</strong> IL-17F and IL-17A Effects and Signaling in<br />
Human Rheumatoid Arthritis Synoviocytes. Arnaud Hot,<br />
Saloua Zrioual, Anne Tournadre, Vanina Lenief and Pierre<br />
Miossec, Immunogenomics and Inflammation Research Unit<br />
and Department <strong>of</strong> Immunology and <strong>Rheumatology</strong>, Hospital<br />
Edouard Herriot, Lyon, France.<br />
1516. Down-Regulation <strong>of</strong> Pyrin Promotes Up-Regulation <strong>of</strong> the<br />
Anti-Apoptotic Gene, BCL2, Via the Signal Transducer, gp130,<br />
and Leads to the Activation <strong>of</strong> the PI3K/Akt Pathway. Geryl M.<br />
Wood 4 , James Balow, Jr 3 , Hong-Wei Sun 2 , Ivona Aksentijevich 3 ,<br />
Jae Jin-Chae 3 , Nitza Shoham 1 and Daniel L. Kastner 3 , 1 Allergy<br />
Immunology Laboratory, Meir Hospital, Kfar-Saba, Israel,<br />
2<br />
Biodata Mining and Discovery, Office <strong>of</strong> Science and<br />
Technology, National Institutes <strong>of</strong> Health, NIAMS, 3 Laboratory<br />
<strong>of</strong> Clinical Investigation, National Institutes <strong>of</strong> Health, NIAMS,<br />
4<br />
Laboratory <strong>of</strong> Clinical Investigation, National Institutes <strong>of</strong><br />
Health, NIAMS, Bethesda, MD.<br />
1517. Effect <strong>of</strong> the PEG Component <strong>of</strong> Certolizumab Pegol on Calcium<br />
Flux in Cellular Systems. Gianluca Fossati 2 and Andrew Nesbitt 1 ,<br />
1<br />
New Medicines, UCB, Slough, Berkshire, United Kingdom, 2 New<br />
Medicines, UCB, Slough, UK.<br />
1518. Expression <strong>of</strong> the Wnt Inhibitor sFRP-1 in Synovial Fibroblasts<br />
Is Regulated by the Histone Methyltransferase EZH2. Michelle<br />
Trenkmann 1 , Matthias Brock 3 , Renate E. Gay 2 , Christoph Kolling 5 ,<br />
Rudolf Speich 4 , Beat A. Michel 2 , Steffen Gay 2 and Lars C. Huber 3 ,<br />
1<br />
Center <strong>of</strong> Experimental <strong>Rheumatology</strong>, University Hospital<br />
Zurich/Zurich Center <strong>of</strong> Integrative Human Physiology (ZIHP),<br />
Zurich, Switzerland, 2 Center <strong>of</strong> Experimental <strong>Rheumatology</strong>,<br />
University Hospital Zurich/Zurich Center <strong>of</strong> Integrative Human<br />
Physiology (ZIHP), Switzerland, 3 Center <strong>of</strong> Experimental<br />
<strong>Rheumatology</strong>, University Hospital Zurich/Zurich Center <strong>of</strong><br />
Integrative Human Physiology (ZIHP), Switzerland/Department<br />
<strong>of</strong> Internal Medicine, University Hospital, Zurich, Switzerland,<br />
4<br />
Department <strong>of</strong> Internal Medicine, University Hospital Zurich,<br />
Switzerland, 5 Schulthess Clinic, Zurich, Switzerland.<br />
1519. Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) Levels Are Elevated<br />
in Arthritis: Role <strong>of</strong> Flt3L in Regulating Monocyte Migratory<br />
Pattern in RA. Inês Ramos 2 , Ana Oliveira 3 , Geurt Schilders 3 ,<br />
Saïda Aarrass 3 , Cristina Lebre 3 and Paul P. Tak 1 , 1 Academic Med<br />
Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands, 2 Division<br />
<strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic Medical<br />
Center/University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />
3<br />
Division <strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic<br />
Medical Center/University <strong>of</strong> Amsterdam, Amsterdam, The<br />
Netherlands.<br />
1520. Functional Expression <strong>of</strong> CD13/Aminopeptidase N by RA<br />
Synovial Cells In Vitro and In Vivo. Rachel Morgan, Judith<br />
Endres and David A. Fox, University <strong>of</strong> Michigan.<br />
1521. Gottron’s Papules Exhibit Accumulation <strong>of</strong> CD44 Variant 7<br />
(CD44v7) and Its Binding Partner Osteopontin: A Unique<br />
Molecular Signature. Jessica Kim 1 and Victoria P. Werth 2 , 1 New<br />
York University School <strong>of</strong> Medicine, 2 University <strong>of</strong> Pennsylvania,<br />
Philadelphia, PA.<br />
1522. Identification <strong>of</strong> the NR4A Family <strong>of</strong> Orphan Nuclear Receptors<br />
as Mediators <strong>of</strong> Adenosine A2A Receptor Activation. Jason P.<br />
McMorrow 2 , Evelyn P. Murphy 2 and Bruce N. Cronstein 1 , 1 New<br />
York Univ Med Ctr, New York, NY, 2 University <strong>College</strong> Dublin,<br />
Dublin, Ireland.<br />
1523. Increased Expression <strong>of</strong> Acid Sensing Ion Channel (ASIC)<br />
Mediated by ERK/MAPK Pathway in Mouse Anti-Type II<br />
Collagen Antibody-Induced Arthritis. Juyoun Kim 2 , Keon Uk<br />
Park 2 , Jinyeong Chae 3 , Hyun-OK Kim 1 and Sang-Hyon Kim 2 ,<br />
1<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, <strong>College</strong> <strong>of</strong> Medicine and<br />
Institute <strong>of</strong> Health Science, Jinju, Korea, Republic <strong>of</strong>, 2 Keimyung<br />
University Dongsan Medical Center, Daegu, Kungsang Province,<br />
Korea, Republic <strong>of</strong>, 3 Keimyung University Dongsan Medical<br />
Center, Daegu, Kungsang, Korea, Republic <strong>of</strong>.<br />
236<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
1524. Increased Levels <strong>of</strong> Soluble Programmed Death 1 (sPD-1) and<br />
Its Soluble Ligand (sPD-L1) in Early Rheumatoid Arthritis Are<br />
Associated with Disease Activity and Progression. Stinne R.<br />
Greisen 4 , Tue K. Rasmussen 5 , Kristian Stengaard-Pedersen 1 ,<br />
Merete L. Hetland 2 , Kim Hørslev-Petersen 6 , Malene Hvid 4 and<br />
Bent Deleuran 3 , 1 Arhus University Hospital, Aarhus, Denmark,<br />
2<br />
Copenhagen Univ Hosp Hvidovre, Hvidovre, Denmark, 3 Institute<br />
<strong>of</strong> Medical Microbiology and Immunology, University <strong>of</strong> Aarhus<br />
and 2 Department <strong>of</strong> <strong>Rheumatology</strong> Aarhus University Hospital,<br />
8000 Aarhus C, Denmark, 4 Institute <strong>of</strong> Medical Microbiology and<br />
Immunology, University <strong>of</strong> Aarhus, 8000 Aarhus C, Denmark,<br />
5<br />
Institute <strong>of</strong> Medical Microbiology and Immunology, University<br />
<strong>of</strong> Aarhus, 8000 Aarhus C, Denmark and Department <strong>of</strong><br />
Dermato-Venerology, Aarhus University Hospital, 8000 Aarhus<br />
C, Denmark, 6 King Christian X Hospital for Rheumatic Disease,<br />
University <strong>of</strong> Southern Denmark, Graasten, Denmark.<br />
1525. Lack <strong>of</strong> IL-17RA Signaling Prevents Autoimmune Inflammation<br />
<strong>of</strong> the Joint and Give Rise to a Th2-Like Phenotype in Collagen-<br />
Induced Arthritis. Anne-Marie Mus, Odilia Corneth, Patrick<br />
Asmawidjaja and Erik Lubberts, Erasmus MC, University Medical<br />
Center.<br />
1526. Lower Expression <strong>of</strong> Fli-1 Leads to Decreased Inflammatory<br />
Cell Infiltration in the Kidneys from NZM2410 Mice. Sarah<br />
Williams 4 , Emmanuel Reyes-Cortes 2 , Eva Karam 3 , Eiji Suzuki 3 ,<br />
Gary S. Gilkeson 1 and John Zhang 5 , 1 Med Univ <strong>of</strong> South<br />
Carolina, Charleston, SC, 2 Medical University <strong>of</strong> South Carolina,<br />
Charleston, SC, 3 Medical University <strong>of</strong> South Carolina, 4 Ralph H.<br />
Johnson VA Medical Center, Charleston, SC, 5 Ralph H. Johnson<br />
VA Medical Center and Medical University <strong>of</strong> South Carolina,<br />
Charleston, SC.<br />
1527. Mechanisms and Clinical Relevance <strong>of</strong> TRAIL-Triggered<br />
Responses in Synovial Fibroblasts <strong>of</strong> Rheumatoid Arthritis<br />
Patients. Rachel Audo 4 , Flavia Calmon Hamaty 5 , Dominique<br />
Baeten 1 , Bernard G. Combe 2 , Michael Hahne 4 and Jacques<br />
Morel 3 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam,<br />
The Netherlands, 2 Department <strong>of</strong> <strong>Rheumatology</strong>. Teaching<br />
Hospital <strong>of</strong> Lapeyronie, Montpellier, France, 3 Department <strong>of</strong><br />
<strong>Rheumatology</strong>. Teaching Hospital <strong>of</strong> Lapeyronie, Montpellier,<br />
France, 4 IGMM, UMR5535, CNRS, Montpellier, Montpellier,<br />
France, 5 IGMM, UMR5535, CNRS, Montpellier.<br />
1528. Pro-Inflammatory Activity <strong>of</strong> SIRT1 in Monocytes. Fabienne<br />
Niederer 1 , Caroline Ospelt 1 , Fabia Brentano 1 , Beat A. Michel 2 ,<br />
Christoph Kolling 4 , Michael O. Hottiger 3 , Renate E. Gay 2 , Steffen<br />
Gay 2 and Diego Kyburz 2 , 1 Center <strong>of</strong> Experimental <strong>Rheumatology</strong>,<br />
University Hospital Zurich and Zurich Center <strong>of</strong> Integrative<br />
Human Physiology (ZIHP), Zurich, Switzerland, 2 Center <strong>of</strong><br />
Experimental <strong>Rheumatology</strong>, University Hospital Zurich<br />
and Zurich Center <strong>of</strong> Integrative Human Physiology (ZIHP),<br />
Switzerland, 3 Institute <strong>of</strong> Veterinary Biochemistry and Molecular<br />
Biology, University Zurich, Switzerland, 4 Schulthess Clinic,<br />
Zurich, Switzerland.<br />
1529. Ras GTPase Homologues Make Redundant Contributions to RA<br />
FLS Activation and Broad Silencing <strong>of</strong> Ras Proteins Decreases<br />
Inflammation and Joint Destruction in Experimental Arthritis.<br />
Daphne de Launay 1 , Jeroen Vreijling 1 , Joana Abreu 1 , Aleksander<br />
Grabiec 1 , Marjolein van Maanen 2 , Marjolein Sanders 2 , Margriet<br />
Vervoordeldonk 2 , Henrik Oerum 3 , Kees Fluiter 1 , Paul Peter Tak 1<br />
and Kris Reedquist 1 , 1 Academic Medical Center, University <strong>of</strong><br />
Amsterdam, Amsterdam, The Netherlands, 2 Academic Medical<br />
Center, University <strong>of</strong> Amsterdam, The Netherlands, 3 Santaris<br />
Pharma A/S, Horsholm, Denmark.<br />
1530. Resveratrol Inhibits TNF-α-Induced MMP-9 Expression through<br />
a mTOR Independent Pathway. Xiaoxia Zhu 2 , Jianhua Qiu 1 and<br />
Hejian Zou 2 , 1 Department <strong>of</strong> Neurology, Massachusetts General<br />
Hospital, Harvard Medical School, Boston, MA, 2 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Huashan Hospital, Fudan University, Shanghai,<br />
China.<br />
1531. Role <strong>of</strong> Dipeptidyl Peptidase I (Cathepsin C) in the Maturation<br />
<strong>of</strong> IL-1β In Vivo. Hajime Kono 1 , Zubin Patel 2 , Tamiko Yanagida 1 ,<br />
Maki Takayama 1 and Kennth Rock 2 , 1 Teikyo University School <strong>of</strong><br />
Medicine, 2 University <strong>of</strong> Massachusetts Medical School.<br />
1532. The Expression <strong>of</strong> the Anti-Apoptotic Transcription Factor<br />
NFkappaB-P65 Is Markedly Diminished in Chondrocytes <strong>of</strong><br />
Murine Osteoarthritic Cartilage and in a Subset <strong>of</strong> Human<br />
Osteoarthritic Cartilage Samples. Fons A. J. van de Loo, Onno<br />
J. Arntz, Miranda B. Bennink, Esmeralda Blaney-Davidson, Peter<br />
M. van der Kraan and Wim B. van den Berg, Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Radboud University Nijmegen Medical Centre,<br />
Nijmegen, The Netherlands.<br />
1533. TLR2 Mediates Acute Serum Amyloid A Induced Pro-<br />
Inflammatory Effects in Rheumatoid Arthritis. Mary Connolly 3 ,<br />
Ashwini Maratha 1 , Sinead Nic an Ultaigh 3 , Sinead Miggin 2 ,<br />
Ursula Fearon 3 and Douglas J. Veale 3 , 1 Institute <strong>of</strong> Immunology,<br />
National University <strong>of</strong> Ireland Maynooth, Maynooth, Ireland,<br />
2<br />
Institute <strong>of</strong> Immunology, National University <strong>of</strong> Ireland<br />
Maynooth, 3 Translational Research Group, Dublin Academic<br />
Medical Centre, St. Vincents University Hospital., Ireland.<br />
1534. TNF-a and Chemerin Cross-Talk in Rheumatoid Arthritis. M. C.<br />
Lebre 2 , M. I. Ramos 2 , C. H<strong>of</strong>stra 3 , H. van Eenennaam 3 , S. Aarrass 2<br />
and Paul P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam,<br />
Amsterdam, The Netherlands, 2 Division <strong>of</strong> Clinical Immunology&<br />
<strong>Rheumatology</strong>, Academic Medical Center/University <strong>of</strong><br />
Amsterdam, Amsterdam, The Netherlands, 3 Merck Research<br />
Laboratories, Oss, The Netherlands.<br />
1535. Toll-Like Receptor 4 Signalling Is Specifically TAK1-Independent<br />
in Synovial Fibroblasts. Fons A. J. van de Loo 1 , Ben T. van den<br />
Brand 1 , Shahla Abdollahi-Roodsaz 1 , Onno J. Arntz 1 , Michael<br />
Kracht 2 , Jeroen Geurts 1 and Wim B. van den Berg 1 , 1 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Radboud University Nijmegen Medical Centre,<br />
Nijmegen, The Netherlands, 2 Rudolf-Buchheim-Institute <strong>of</strong><br />
Pharmacology, University <strong>of</strong> Giessen, Hannover, Germany.<br />
1536. Tyrosine Kinase Inhibitors Reduce NMDA Receptor NR1<br />
Expression, Nuclear Translocation and Thermal Hyperalgesia/<br />
CentralSensitization in a Rat Arthritis Model. Terry A.<br />
McNearney 5 , Ying Lu 5 , Zaiming Ye 2 , Liping Zhang 3 , Giulio<br />
Taglialatela 5 , Todd Pappas 1 , Wen-Ru Zhang 5 and Karin N.<br />
Westlund 4 , 1 Asuragen, Inc, Austin, TX, 2 MD Anderson Medical<br />
Center, Houston, TX, 3 University <strong>of</strong> Kentucky, Lexington, TX,<br />
4<br />
University <strong>of</strong> Kentucky, Lexington, KY, 5 University <strong>of</strong> Texas<br />
Medical Branch, Galveston, TX.<br />
Epidemiology and Health Services Research: OP/OA<br />
1537. An Evaluation <strong>of</strong> Prescription Insurance Coverage<br />
Inconsistencies – Prior Authorization Does Not Mean Approval.<br />
Dawn C. Crate 2 and Daniel A. Albert 1 , 1 Dartmouth-Hitchcock<br />
Med Ctr, Lebanon, NH, 2 Dartmouth-Hitchcock Medical Center.<br />
2010 Program Book 237
ACR/ARHP Poster Session C<br />
1538. Arthritis Prevalence and Access to Care in Indigenous People:<br />
Results <strong>of</strong> a Population-Based Study. Allen J. Lehman 1 ,<br />
Matthew H. Liang 3 , Linda Li 2 , John M. Esdaile 2 , Catherine L.<br />
Backman 5 , Phyllis Jorgensen 4 , Kim Roberts 4 , Linda Lavender 4<br />
and Diane Lacaille 2 , 1 Arthritis Research Centre <strong>of</strong> Canada,<br />
Vancouver, BC, Canada, 2 Arthritis Research Centre <strong>of</strong> Canada;<br />
University <strong>of</strong> British Columbia, 3 Harvard, Boston, MA, 4 Kwakiutl<br />
District Council Health Centre, 5 University <strong>of</strong> British Columbia,<br />
Vancouver, BC, Canada.<br />
1539. Aspirin vs. Low Molecular Weight Heparin for Prophylaxis<br />
Against Venous Thromboembolism after Total Knee or<br />
Hip Replacement in Lower Risk Individuals: A Cost-Utility<br />
Analysis. John T. Schousboe 1 and Gregory A. Brown 2 , 1 Park<br />
Nicollet Institute, Minneapolis, St Louis Park, MN, 2 Park Nicollet<br />
Institute, Minneapolis, MN.<br />
1540. Assessment <strong>of</strong> the Incremental Cost <strong>of</strong> Osteoporosis-Related<br />
Fractures among Women in a Large U.S. Managed Care<br />
Population. Hema Viswanathan 1 , Jeffrey White 6 , Sally W. Wade 5 ,<br />
Jingbo Yu 3 , Jeffrey R. Curtis 4 , Bradley Stolshek 2 , Claire Merinar 2 ,<br />
Joel Kallich 2 , Akhila Balasubramanian 2 and John Adams 2 ,<br />
1<br />
Amgen Inc., Thousand Oaks, CA, 2 Amgen Inc., 3 HealthCore, Inc.,<br />
4<br />
University <strong>of</strong> Alabama - Brimingham, Birmingham, AL, 5 Wade<br />
Outcomes Research and Consulting, 6 WellPoint, Inc..<br />
1541. Bending the Cost Curve in Early RA: Sick Leave and Disability<br />
Pension before and after Initiation <strong>of</strong> Biologics or DMARD<br />
Combination Therapy. Martin Neovius 1 , Julia F. Simard 1 ,<br />
Johan Askling 2 and ARTIS Study Group 3 , 1 Karolinska Institute,<br />
Stockholm, Sweden, 2 Karolinska Institute, 3 Sweden.<br />
1542. Differences in Clinical and Economic Pr<strong>of</strong>iles <strong>of</strong> Rheumatoid<br />
Arthritis Patients Using Frequently Dosed Subcutaneous<br />
or Less Frequently Dosed Intravenous Biologic Therapy.<br />
Chureen T. Carter 1 , O. Tunceli 3 , Susan C. Bolge 2 , Leigh Denny 2 ,<br />
C. Fang 3 and Joseph Singer 3 , 1 Centocor Ortho Biotech Services,<br />
LLC, Horsham, PA, 2 Centocor Ortho Biotech Services, LLC,<br />
3<br />
HealthCore, Inc..<br />
1543. DXA Screening and Use <strong>of</strong> Osteoporosis Medications in Two<br />
Large Regional Healthcare Systems. Amy Warriner 5 , Ryan C.<br />
Outman 4 , Jeffrey R. Curtis 5 , Adrian Feldstein 1 , Harry Glauber 3 ,<br />
Junling Ren 2 , Douglas Roblin 2 , Ana Rosales 1 , Robert Unitan 3<br />
and Kenneth G. Saag 7 , 1 Kaiser Permanente Center for Health<br />
Research, Portland, OR, 2 Kaiser Permanente Center for Health<br />
Research, Atlanta, GA, 3 Kaiser Permanente Northwest, 4 Univ <strong>of</strong><br />
Alabama at Birmingham, Birmingham, AL, 5 Univ <strong>of</strong> Alabama at<br />
Birmingham, Birmingham.<br />
1544. Erectile Dysfunction Is Associated with Gout in the Campaign<br />
Against Cancer and Heart Disease (CLUE II). Janet W. Maynard,<br />
Mara A. McAdams, Alan N. Baer, Judith H<strong>of</strong>fman-Bolton, Allan<br />
C. Gelber and Josef Coresh, Johns Hopkins.<br />
1545. Floor and Ceiling Effects and Choice <strong>of</strong> Physical Function<br />
Instruments. Eswar Krishnan 3 , Bharathi Lingala 4 , Bonnie Bruce 1<br />
and James F. Fries 2 , 1 Stanford Dept <strong>of</strong> Medicine, Palo Alto, CA,<br />
2<br />
Stanford Univ Medical Ctr, Palo Alto, CA, 3 Stanford University,<br />
Palo Alto, CA, 4 Stanford University.<br />
1546. Fragility Fractures in Brazilian Community-Dwelling Elderly:<br />
Prevalence and Risk Factors. Jaqueline B. Lopes, Camille P.<br />
Figueiredo, Liliam Takayama, Valeria F. Caparbo and Rosa M.<br />
R. Pereira, <strong>Rheumatology</strong> Division, Faculdade de Medicina da<br />
Universidade de São Paulo.<br />
1547. Higher Serum Urate Levels Correlate with Increased<br />
Prevalence <strong>of</strong> Comorbidities in the US General Population:<br />
NHANES 1999-2008. Yanyan Zhu 1 , Bhavik Pandya 2 and Hyon<br />
Choi 1 , 1 Boston University <strong>of</strong> School <strong>of</strong> Medicine, Boston, MA,<br />
2<br />
Takeda Pharmaceuticals International, Inc, Deerfield, IL.<br />
1548. How Large Are the Productivity Losses in Contemporary<br />
Patients with RA, and How Soon in Relation to Diagnosis Do<br />
They Develop? A Six-Year Nationwide Cohort Study. Martin<br />
Neovius 1 , Julia F. Simard 1 , Johan Askling 2 and ARTIS Study<br />
Group 3 , 1 Karolinska Institute, Stockholm, Sweden, 2 Karolinska<br />
Institute, 3 Sweden.<br />
1549. Incidental Capture <strong>of</strong> Chikungunya Associated Chronic<br />
Rheumatism along with Other Rheumatic Musculoskeletal<br />
Disorders in a Rural Community in South India: A BJD India<br />
WHO COPCORD (Community Oriented Program for Control <strong>of</strong><br />
Rheumatic Diseases) Project. Ashish J. Mathew 3 , Vinay Goyal 2 ,<br />
Elizabeth George 2 , Dany Varughese 2 , Jacob Antony 2 and Arvind<br />
Chopra 1 , 1 BJD India Co-ordinator, Pune, India, 2 The Trivandrum<br />
COPCORD Study Group, 3 The Trivandrum COPCORD Study<br />
Group, Medical <strong>College</strong> Hospital and Health Action by People,<br />
Trivandrum, India.<br />
1550. Mortality Outcomes amongst Patients with Rheumatiod<br />
Arthritis with and without Joint Surgery: A Comparative Study.<br />
Courtney A. Shourt 1 , Cynthia S. Crowson 2 , Sherine E. Gabriel 3<br />
and Eric L. Matteson 4 , 1 Department <strong>of</strong> Medicine, Mayo Clinic<br />
<strong>College</strong> <strong>of</strong> Medicine, 2 Division <strong>of</strong> Biostatistics, Department <strong>of</strong><br />
Health Sciences Research, Mayo Clinic <strong>College</strong> <strong>of</strong> Medicine,<br />
3<br />
Division <strong>of</strong> Epidemiology, Department <strong>of</strong> Health Science<br />
Research, and Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic <strong>College</strong><br />
<strong>of</strong> Medicine, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic <strong>College</strong> <strong>of</strong><br />
Medicine.<br />
1551. Oral Tobacco Use Is Significantly Associated with Rheumatic<br />
Musculoskeletal (RMSK) Pain: Result <strong>of</strong> a WHO ILAR COPCORD<br />
(Community Oriented Program for Control <strong>of</strong> Rheumatic<br />
Diseases) Rural Population Study in India. Arvind Chopra 1 ,<br />
Sarika Chaturvedi 4 , Manjit Saluja 2 , Vaijayanti Lagoo Joshi 2 and<br />
Sanjiv Sarmukadam 3 , 1 Center for Rheumatic Diseases, Pune,<br />
India, 2 Center for Rheumatic Diseases, 3 Center for Rheumatic<br />
Diseses, 4 FRCH, Pune, India.<br />
1552. Osteoporosis Medication Adherence and Fracture Risk among<br />
Women in a Large U.S. Health Plan. Hema Viswanathan 1 , Sally<br />
W. Wade 5 , Jeffrey R. Curtis 4 , Jingbo Yu 3 , Jeffrey White 6 , Bradley<br />
Stolshek 2 , Claire Merinar 2 , Akhila Balasubramanian 2 , Joel Kallich 2<br />
and John Adams 2 , 1 Amgen Inc., Thousand Oaks, CA, 2 Amgen Inc.,<br />
3<br />
HealthCore, Inc., 4 University <strong>of</strong> Alabama at Birmingham, 5 Wade<br />
Outcomes Research and Consulting, 6 WellPoint, Inc..<br />
1553. Patient Age, Ethnicity and Wait Times Determine the<br />
Likelihood <strong>of</strong> Non-Attendance at a First Specialist<br />
<strong>Rheumatology</strong> Assessment. Valerie Milne 2 , Robin Kearns 1 and<br />
Andrew A. Harrison 2 , 1 University <strong>of</strong> Auckland, New Zealand,<br />
New Zealand, 2 University <strong>of</strong> Otago, Wellington, New Zealand,<br />
New Zealand.<br />
1554. Predictors <strong>of</strong> Vitamin D Deficiency among Veterans. Joshua<br />
Baker 3 , Alexis Ogdie 3 , Li yun Zhang 2 , Jan Dinella 4 , H. Ralph<br />
Schumacher 5 and Sally W. Pullman-Mooar 1 , 1 Philadelphia, PA,<br />
2<br />
Second Hospital <strong>of</strong> Shanxi Medical University, China, 3 University<br />
<strong>of</strong> Pennsylvania, Philadelphia, PA, 4 University <strong>of</strong> Pennsylvania,<br />
5<br />
VA Medical Center - 151K, Philadelphia, PA.<br />
238<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
1555. Projecting the Effects <strong>of</strong> a 5-Point Reduction in Body Mass<br />
Index on Knee or Hip Osteoarthritis and Health-Related Quality<br />
<strong>of</strong> Life in a Closed Population to 2031: A Microsimulation<br />
Study. Eric C. Sayre 1 , Jacek A. Kopec 4 , Behnam Sharif 4 , William<br />
M. Flanagan 3 , Philippe Fines 3 , Mushfiqur Rahman 5 , Michal<br />
Abrahamowicz 2 , David Buckeridge 2 , Sam Harper 2 , John Lynch 7 ,<br />
Douglas Manuel 6 , Jillian Oderkirk 3 and Michael Wolfson 6 ,<br />
1<br />
Arthritis Research Centre <strong>of</strong> Canada, Vancouver, BC, Canada,<br />
2<br />
McGill University, Canada, 3 Statistics Canada, Canada,<br />
4<br />
University <strong>of</strong> British Columbia, Canada, 5 University <strong>of</strong> British<br />
Columbia, Canada 6 University <strong>of</strong> Ottawa, Canada, 7 University <strong>of</strong><br />
South Australia, Canada.<br />
1556. Racial Differences in Gout Risk and Uric Acid Levels in Both<br />
Men and Women in the Atherosclerosis Risk in Communities<br />
(ARIC) Study. Janet W. Maynard, Mara A. McAdams, Alan N.<br />
Baer, Allan C. Gelber and Josef Coresh, Johns Hopkins.<br />
1557. Racial/Ethnic and Sex Differences in Somatosensory<br />
Abnormalities in Subjects with or at High Risk <strong>of</strong> Knee<br />
Osteoarthritis: Preliminary Analysis <strong>of</strong> the Multicenter<br />
Osteoarthritis (MOST) Study. Jasvinder Singh 2 , Niu Jingbo 5 ,<br />
Laura Freylaw 9 , Joachim Scholz 6 , Lars Arendt-Nielsen 1 , Cora E.<br />
Lewis 8 , Clifford Woolf 6 , Larry Bradley 8 , David T. Felson 4 , Michael<br />
C. Nevitt 7 , Irina Tolstykh 7 and Tuhina Neogi 3 , 1 Aalborg University,<br />
Aalborg, Denmark, 2 Birmingham VA Medical Center and<br />
University <strong>of</strong> Alabama, Birmingham, Minneapolis, MN, 3 Boston<br />
Univ Schl <strong>of</strong> Med, Boston, MA, 4 Boston University School <strong>of</strong><br />
Medicine, Boston, MA, 5 Boston University School <strong>of</strong> Medicine,<br />
6<br />
Childrens Hospital and Harvard School <strong>of</strong> Medicine, 7 UCSF, San<br />
Francisco, CA, 8 University <strong>of</strong> Alabama, Birmingham, 9 University<br />
<strong>of</strong> Iowa.<br />
1558. Relationship between Physical Activity and Health-Related<br />
Utility in Knee Osteoarthritis Patients. Larry Manheim 2 ,<br />
Jing Song 2 , Rowland W. Chang 1 and Dorothy D. Dunlop 3 ,<br />
1<br />
Northwestern Univ, Chicago, IL, 2 Northwestern University,<br />
3<br />
Northwestern University Medical School, Chicago, IL.<br />
1559. Reporting <strong>of</strong> the Recruitment Process in Randomized Clinical<br />
Trials <strong>of</strong> Biological Agents for the Treatment <strong>of</strong> Rheumatoid<br />
Arthritis. Ismail Simsek and Yusuf Yazici, NYU Hospital for Joint<br />
Diseases.<br />
1560. Rheumatologists Practise Evidence Based Medicine, an<br />
Observational Study. Stephen Hall 1 , Adam Moreton 4 , Kathryn<br />
A. Gibson 2 , Barry A. Kane 2 , Vivek Thakkar 2 , J. Hanrahan 1 ,<br />
Evange Romas 1 , Timothy Godfrey 1 , Marie Feletar 1 , Alexander<br />
Stockman 1 , Jennifer Harmer 1 , Rani Axtens 1 , Peter Ryan 1 , Andrew<br />
Gibson 1 , Christopher Mack 1 , Robert J. Moots 3 and Geraldine<br />
Hassett 2 , 1 Department <strong>of</strong> Medicine, Cabrini Health, Melbourne,<br />
Australia, 2 <strong>Rheumatology</strong> Department, Liverpool Hospital,<br />
Sydney Australia, 3 School <strong>of</strong> Clinical Sciences, University<br />
<strong>of</strong> Liverpool, Liverpool United Kingdom, Liverpool, United<br />
Kingdom, 4 School <strong>of</strong> Clinical Sciences, University <strong>of</strong> Liverpool,<br />
Liverpool United Kingdom.<br />
1561. Screening and Treatment <strong>of</strong> Glucocorticoid Induced<br />
Osteoporosis in a Large U.S. National Pharmacy Database.<br />
Ryan C. Outman 2 , Nathan J. Markward 1 , Mona Khalid 1 , Ronald<br />
E. Aubert 1 , Jeffrey R. Curtis 2 , Robert S. Epstein 1 , Felix W. Frueh 1 ,<br />
Eric J. Stanek 1 , Amy Steinkellner 1 , Amy H. Warriner 2 and Kenneth<br />
G. Saag 2 , 1 Medco Health Solutions, Inc., 2 Univ <strong>of</strong> Alabama at<br />
Birmingham, Birmingham, AL.<br />
1562. Self-Management Strategies in Overweight/Obese Canadians<br />
with Arthritis. Sasha R. Bernatsky 1 , Corneliu Rusu 2 , Siobahn<br />
O’Donnell 2 , Gillian A. Hawker 5 , Crystal Mackay 4 , Louise McRae 2 ,<br />
Mayilee Canizar 4 and Elizabeth M. Badley 3 , 1 McGill UHC/RVH,<br />
Montreal, QC, Canada, 2 PHAC, 3 University <strong>of</strong> Toronto, Toronto,<br />
ON, Canada, 4 University <strong>of</strong> Toronto, 5 Women’s <strong>College</strong> Hospital,<br />
Toronto, ON, Canada.<br />
1563. State-Specific ICF Disability Pr<strong>of</strong>iles among US Adults with<br />
Arthritis. Jennifer M. Hootman 3 , Kristina A. Theis 1 , Julie Bolen 2<br />
and Charles G. Helmick 1 , 1 CDC, Atlanta, GA, 2 CDC, 3 Centers for<br />
Disease Control, Kennesaw, GA.<br />
1564. Statistical Methods Analyzing Count Data with Excessive<br />
Zeros in Arthritis Research. Bin Zhang 3 , Jingbo Niu 5 , Yanyan<br />
Zhu 6 , Tuhina Neogi 2 , Ling Xu 1 , David T. Felson 7 , Michael P.<br />
LaValley 8 and Yuqing Zhang 4 , 1 Beijing, China, 2 Boston Univ Schl<br />
<strong>of</strong> Med, Boston, MA, 3 Boston Univ Schl <strong>of</strong> Medicine, Boston,<br />
MA, 4 Boston Univ School <strong>of</strong> Medicine, Boston, MA, 5 Boston<br />
University, Boston, MA, 6 Boston University, 7 Boston University<br />
School <strong>of</strong> Medicine, Boston, MA, 8 BU School <strong>of</strong> Public Health,<br />
Boston, MA.<br />
1565. The Association <strong>of</strong> Race with Gout: A Broadly Representative<br />
Inpatient Survey. Allan C. Gelber 1 , Janet W. Maynard 2 and<br />
Carlton Haywood, Jr 2 , 1 Baltimore, MD, 2 Johns Hopkins<br />
University, Baltimore, MD.<br />
1566. The Clinical and Economic Burden <strong>of</strong> Corticosteroid Adverse<br />
Events (AEs): A Systematic Literature Review. Evelyn F. Sarnes 2<br />
and Maria E. Watson 1 , 1 GlaxoSmithKline, Research Triangle Park,<br />
NC, 2 Xcenda, Palm Harbor, FL.<br />
1567. The Cost-Effectiveness <strong>of</strong> Corticosteroid Injection <strong>of</strong> the Carpal<br />
Tunnel. Suzanne L. DeLea 1 , Janet L. Poole 1 , Natalia Chavez-<br />
Chiang 2 , Wilmer L. Sibbitt 3 and Arthur D. Bankhurst 4 , 1 University<br />
<strong>of</strong> New Mexico, Albuquerque, NM, 2 University <strong>of</strong> New Mexico,<br />
3<br />
University <strong>of</strong> New Mexico HSC, Albuquerque, NM, 4 University<br />
<strong>of</strong> NM Med Ctr, Albuquerque, NM.<br />
1568. The Prevalence and Characteristics <strong>of</strong> Fluorosis Causing<br />
Skeletal Deformities in Rural Tanzania. Helen G. Jarvis 2 , Peta<br />
S. Heslop 2 , John Kissima 1 and Richard Walker 3 , 1 Hai District<br />
Hospital, Kilimanjaro Region, Tanzania, East Africa, 2 Newcastle<br />
upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United<br />
Kingdom, 3 Northumbria Healthcare NHS Foundation Trust, Tyne<br />
& Wear, United Kingdom.<br />
1569. Thiazide and Loop Diuretics Are Associated with Incident<br />
Gout in the Atherosclerosis Risk in Communities (ARIC) Study.<br />
Mara A. McAdams 4 , Janet W. Maynard 2 , Allan C. Gelber 1 , Alan<br />
N. Baer 3 and Josef Coresh 4 , 1 Baltimore, MD, 2 Johns Hopkins<br />
Univ, Baltimore, MD, 3 Johns Hopkins University, Baltimore, MD,<br />
4<br />
Johns Hopkins, Bloomberg School <strong>of</strong> Public Health.<br />
1570. Trends in Orthopedic Surgery Utilization among Patients<br />
with Rheumatoid Arthritis: A Focus on Surgery Type and<br />
Gender. Courtney A. Shourt 1 , Cynthia S. Crowson 2 , Sherine<br />
E. Gabriel 3 and Eric L. Matteson 4 , 1 Department <strong>of</strong> Medicine,<br />
Mayo Clinic <strong>College</strong> <strong>of</strong> Medicine, 2 Division <strong>of</strong> Biostatistics,<br />
Department <strong>of</strong> Health Science Research, Mayo Clinic <strong>College</strong><br />
<strong>of</strong> Medicine, 3 Division <strong>of</strong> Epidemiology, Department <strong>of</strong> Health<br />
Science Research, and Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic<br />
<strong>College</strong> <strong>of</strong> Medicine, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, and Division <strong>of</strong><br />
Epidemiology, Mayo Clinic <strong>College</strong> <strong>of</strong> Medicine.<br />
2010 Program Book 239
ACR/ARHP Poster Session C<br />
240<br />
1571. Understanding Billing Data: A Survey <strong>of</strong> Billing Process<br />
and Codes Used by Family Physicians for Rheumatological<br />
Conditions. Diane Lacaille, Jack Chang and Pamela Rogers,<br />
Arthritis Research Centre <strong>of</strong> Canada, Vancouver, BC, Canada.<br />
1572. Urate-Lowering Therapy in Chronic Gout Results in Clinically<br />
Important Improvements in Health-Related Quality <strong>of</strong> Life—<br />
SF-36 Is Responsive to Change in Chronic Gout. Puja Khanna 2 ,<br />
Fernando Perez-Ruiz 1 , Paul Maranian 2 and Dinesh Khanna 2 ,<br />
1<br />
Hospital de Cruces, 2 UCLA.<br />
1573. Validation <strong>of</strong> Diagnostic Codes for Subtrochanteric, Diaphyseal,<br />
and Typical Hip Fractures Using Administrative Claims Data.<br />
Pongthorn Narongroeknawin, Nivedita M. Patkar, Bita Shakoory,<br />
Archana Jain, Jeffrey R. Curtis, Elizabeth Delzell, Philip H. Lander,<br />
Robert Lopez-Ben, Michael J. Pitt, Monika M. Safford, David A.<br />
Volgas and Kenneth G. Saag, Univ <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL.<br />
1574. Vitamin C Supplementation and Serum Uric Acid: A Meta-<br />
Analysis <strong>of</strong> Randomized Controlled Trials. Stephen P. Juraschek,<br />
Edgar R. Miller and Allan C. Gelber, Johns Hopkins Medical<br />
Institutions, Baltimore, MD.<br />
1575. What Kinds <strong>of</strong> Advice Do Health Food Store Employees and<br />
Pharmacists Provide to Consumers with Acute Low Back Pain?<br />
Jaya K. Rao 2 , Dio Kavalieratos 1 , Mary Roth 1 , Morris Weinberger 1<br />
and Timothy Carey 1 , 1 Chapel Hill, NC, 2 UNC Eshelman School <strong>of</strong><br />
Pharmacy, Chapel Hill, NC.<br />
1576. Who Falls? A Decade <strong>of</strong> Experience at a Musculoskeletal<br />
Specialty Hospital. Lisa A. Mandl 1 , Michael Parks 2 , Patricia<br />
Quinlan 2 , Tina Bailey 2 , Jacklyn Katz 2 and Steven Magid 2 ,<br />
1<br />
Hospital for Special Surgery, New York, NY, 2 Hospital for Special<br />
Surgery.<br />
Genetics, Genomics and Proteomics: Rheumatoid Arthritis and<br />
SLE<br />
1577. BLK Confers a Risk for Renal Involvement in Japanese Patients<br />
with Systemic Lupus Erythematosus. Kenichi Shimane 2 , Yuta<br />
Kochi 5 , Ryo Yamada 5 , Yukinori Okada 1 , Akari Suzuki 5 , Keiko<br />
Myouzen 5 , Tetsuya Horita 3 , Tomonori Ishii 7 , Michito Hirakata 4 ,<br />
Hir<strong>of</strong>umi Amano 6 , Michiaki Kubo 1 , Yusuke Nakamura 1 , Naoyuki<br />
Kamatani 1 and Kazuhiko Yamamoto 8 , 1 CGM, RIKEN, Yokohama,<br />
Japan, 2 Department <strong>of</strong> Allergy and <strong>Rheumatology</strong>, Graduate<br />
School <strong>of</strong> Medicine, the University <strong>of</strong> Tokyo, Tokyo, Japan,<br />
3<br />
Hokkaido University Graduate School <strong>of</strong> Medicine, Sapporo,<br />
Japan, 4 Keio University School <strong>of</strong> Medicine, Tokyo, Japan,<br />
5<br />
Laboratory for Autoimmune Diseases, Center for Genomic<br />
Medicine, Institute <strong>of</strong> Physical Chemical Research (CGM, RIKEN),<br />
Tokyo, Japan, 6 School <strong>of</strong> Medicine, Juntendo University, Tokyo,<br />
Japan, 7 Tohoku University Graduate School <strong>of</strong> Medicine, Sendai,<br />
Japan, 8 Univ Tokyo Gr Schl <strong>of</strong> Med, Tokyo, Japan.<br />
1578. A Comprehensive Replication Study and Functional Analysis<br />
<strong>of</strong> SLE Associated Variants in BLK, ATG5, PXK and SCUBE1.<br />
Angelica M. Delgado-Vega 6 , Sergey Kozyrev 6 , Johan Frostegård 4 ,<br />
Lennart Truedsson 5 , Bernardo A. Pons-Estel 8 , Sandra D’Alfonso 11 ,<br />
Torsten Witte 1 , Bernard Lauwerys 9 , Emoke Endreffy 12 , László<br />
Kovács 12 , Carlos Vasconcelos 2 , Berta Martins da Silva 10 , Javier<br />
Martin 3 and Marta E. Alarcón-Riquelme 7 , 1 Hannover Medical<br />
School, Germany, 2 Hosp Santo Antonio and ICBAS, Porto,<br />
Portugal, 3 Inst d Biomedicina y Parasitología López-Neyra,<br />
Granada, Spain, 4 Karolinska University Hosp at Huddinge,<br />
Stockholm, Sweden, 5 Lund U, Sweden, 6 Rudbeck Laboratory,<br />
Uppsala U, Sweden, 7 Rudbeck Laboratory, Uppsala U, Sweden.<br />
OMRF, OK. Andalucian Center f Genomics and Oncological<br />
Research Pfizer-University <strong>of</strong> Granada-Junta de Andalucia,<br />
Spain, 8 Sanatorio Parque, Rosario, Argentina, 9 U Catholique d<br />
Louvain, Bruxells, Belgium, 10 U do Porto, Porto, Portugal, 11 U<br />
Eastern Piedmont, Novara, Italy, 12 U <strong>of</strong> Szeged, Hungary.<br />
2010 Program Book<br />
1579. A High-Density Genome-Wide Association Study by the<br />
Sjögren’s Genetics Network (SGENE) Identifies Both Novel<br />
Susceptibility Loci for Primary Sjögren’s Syndrome and<br />
Overlapping Effects with Other Autoimmune Disorders.<br />
Christopher J. Lessard 3 , Indra Adrianto 1 , Kenneth Kaufman 1 ,<br />
Roland Jonsson 14 , Gabor Illei 10 , Maureen Rischmueller 12 , Gunnel<br />
Nordmark 16 , Xavier Mariette 13 , Corrine Miceli-Richard 13 , Marie<br />
Wahren-Herlenius 9 , Torsten Witte 6 , Michael Brennan 4 , Roald<br />
Omdal 14 , Fai Ng 11 , Nelson Rhodus 15 , Barbara Segal 7 , R. Hal<br />
Sc<strong>of</strong>ield 2 , Ben Rybicki for ACCESS 8 , Courtney G. Montgomery 1 ,<br />
Juan-Manuel Anaya 5 , John B. Harley 17 and Kathy L. Moser 2 ,<br />
1<br />
Arthritis and Immunology Research Program, Oklahoma<br />
Medical Research Foundation, 2 Arthritis and Immunology<br />
Research Program, Oklahoma Medical Research Foundation<br />
and Department <strong>of</strong> Pathology, University <strong>of</strong> Oklahoma Health<br />
Sciences Center, 3 Arthritis and Immunology Research Program,<br />
Oklahoma Medical Research Foundation and Department <strong>of</strong><br />
Pathology, University <strong>of</strong> Oklahoma Health Sciences Center,<br />
Oklahoma City, OK, 4 Carolinas Medical Center, 5 Center for<br />
Autoimmune Diseases Research (CREA), Universidad del<br />
Rosario, Bogota, Columbia, 6 Hannover Medical School,<br />
Germany, 7 Hennepin County Medical Center, Minneapolis,<br />
8<br />
Henry Ford Health System, 9 Karolinska Institute, Sweden,<br />
10<br />
National Institute <strong>of</strong> Dental and Crani<strong>of</strong>acial Research, NIH,<br />
11<br />
Newcastle University, England, 12 The Queen Elizabeth Hospital<br />
and Health Service, Australia, 13 Universite Paris-Sud, 14 University<br />
<strong>of</strong> Bergen, Norway, 15 University <strong>of</strong> Minnesota, 16 Uppsala<br />
University Hospital, Sweden, 17 US Department <strong>of</strong> Veterans<br />
Affairs Medical Center, Department <strong>of</strong> Medicine, University <strong>of</strong><br />
Oklahoma Health Sciences Center, and Cincinnati Children’s<br />
Hospital Medical Center.<br />
1580. An Immune Signature Based on Ex Vivo Responsiveness <strong>of</strong><br />
Peripheral Blood Cells Is Associated with Radiographic Joint<br />
Damage in Rheumatoid Arthritis. John M. Davis III, Keith L.<br />
Knutson, Michael A. Strausbauch, Cynthia S. Crowson, Terry M.<br />
Therneau, Eric L. Matteson and Sherine E. Gabriel, Mayo Clinic,<br />
Rochester, MN.<br />
1581. An Immune Signature Based on the Ex Vivo Responsiveness<br />
<strong>of</strong> Peripheral Blood Cells for Monitoring Disease Activity<br />
in Rheumatoid Arthritis. John M. Davis III, Keith L. Knutson,<br />
Michael A. Strausbauch, Cynthia S. Crowson, Terry M. Therneau,<br />
Eric L. Matteson and Sherine E. Gabriel, Mayo Clinic, Rochester,<br />
MN.<br />
1582. Analysis <strong>of</strong> the Association <strong>of</strong> CDA (Cytidin Deaminase)<br />
(K27Q), TNF-α (-308G>A) and PTPN22 R620W Genetic<br />
Polymorphisms with Auto-Antibody Seropositive RA and the<br />
Response to B Cell Depletion. Barbara Tolusso 3 , Fabio Di Pietro 7 ,<br />
Francesca Bobbio Pallavicini 4 , Viviana Ravagnani 1 , Maurizio<br />
Benucci 5 , Edoardo Podesta’ 2 , Fabiola Atzeni 6 , Valerio Napolioni 7 ,<br />
F. Carpi 7 , Giusy Peluso 3 , Francesca Faustini 3 , Elisa Gremese 3 ,<br />
G. Biasi 1 , Mariangela Manfredi 5 , Pier Carlo Sarzi Puttini 6 ,<br />
Bruno Lagana’ 2 , Carlomaurizio Montecucco 4 and Gianfranco<br />
Ferraccioli 3 , 1 Department <strong>of</strong> Clinical and Experimental Medicine,<br />
Section <strong>of</strong> <strong>Rheumatology</strong> & Internal Medicine, University <strong>of</strong><br />
Verona, Verona, Italy, 2 Division <strong>of</strong> Clinical Immunology and<br />
<strong>Rheumatology</strong>, S. Andrea University Hospital, “Sapienza”<br />
University <strong>of</strong> Rome, II School <strong>of</strong> Medicine, Rome, Italy, 3 Division<br />
<strong>of</strong> <strong>Rheumatology</strong>, Catholic University <strong>of</strong> the Sacred Heart,<br />
Rome, Italy, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Pavia,<br />
IRCCS S. Matteo Foundation, Pavia, Italy, 5 <strong>Rheumatology</strong> Unit,<br />
Department <strong>of</strong> Internal Medicine, Ospedale di S. Giovanni di<br />
Dio, Florence, Italy, 6 <strong>Rheumatology</strong> Unit, University Hospital L.<br />
Sacco, Milan, Italy, 7 School <strong>of</strong> Biosciences and Biotechnology,<br />
University <strong>of</strong> Camerino, Camerino (MC), Italy.
ACR/ARHP Poster Session C<br />
1583. Association <strong>of</strong> PPP2CA Polymorphisms with SLE Susceptibility<br />
in Multiple Ethnic Groups. Wenfeng Tan 15 , Jian Zhao 15 , Yun<br />
Deng 15 , Kenneth M. Kaufman 2 , Jennifer A. Kelly 1 , Sang-Cheol<br />
Bae 5 , Deh-Ming Chang 9 , Yeong Wook Song 13 , Chack-Yung<br />
Yu 14 , Robert P. Kimberly 11 , Marta E. Alarcón-Riquelme 12 ,<br />
John B. Harley 4 , Chaim O. Jacob 17 , Timothy J. Vyse 6 , Timothy<br />
B. Niewold 16 , Patrick M. Gaffney 10 , Kathy L. Moser 10 , Judith<br />
A. James 10 , Gary S. Gilkeson 7 , Diane L. Kamen 8 , Jennifer M.<br />
Grossman 15 , Bevra H. Hahn 15 , George C. Tsokos 3 and Betty P.<br />
Tsao 15 , 1 Arthritis and Immunology Program, Oklahoma Medical<br />
Research Foundation, 2 Arthritis and Immunology Program,<br />
Oklahoma Medical Research Foundation and US Department <strong>of</strong><br />
Veterans Affairs Medical Center, 3 Beth Israel Deaconess Medical<br />
Center, Harvard Medical School, 4 Cincinnati Children’s Hospital<br />
Medical Center and US Department <strong>of</strong> Veterans Affairs Medical<br />
Center, 5 Hanyang University, Korean, 6 Imperial <strong>College</strong> London,<br />
Hammersmith Hospital, London, UK, 7 Medical University <strong>of</strong><br />
South Carolina, 8 Medical University <strong>of</strong> South Carolina,, 9 National<br />
Defense Medical Center, Taipei, Taiwan, 10 Oklahoma Medical<br />
Research Foundation, 11 On Behalf <strong>of</strong> PROFILE Investigators,<br />
University <strong>of</strong> Alabama, 12 On Behalf <strong>of</strong> the BIOLUPUS and GENLES<br />
Networks, Uppsala University, Sweden, Center for Genomics<br />
and Oncological Research, Granada, Spain, Oklahoma Medical<br />
Research Foundation, 13 Seoul National University, Seoul, Korea,<br />
14<br />
The Ohio State University, 15 University <strong>of</strong> California, Los<br />
Angeles, CA, 16 University <strong>of</strong> Chicago, 17 University <strong>of</strong> Southern<br />
California.<br />
1584. Association <strong>of</strong> Variants in the TLR7-TLR8 Region with Systemic<br />
Lupus Erythematosus in Non-Asian Populations. Yun Deng 8 ,<br />
Jian Zhao 8 , Wenfeng Tan 8 , Kenneth M. Kaufman 2 , Elizabeth E.<br />
Brown 7 , Jeffrey C. Edberg 7 , Diane L. Kamen 6 , Gary S. Gilkeson 10 ,<br />
Chaim O. Jacob 10 , Robert H. Sc<strong>of</strong>ield 2 , Robert P. Kimberly on<br />
behalf <strong>of</strong> PROFILE Investigators 7 , Carl D. Langefeld 12 , Jennifer A.<br />
Kelly 1 , Marta E. Alarcón-Riquelme on Behalf <strong>of</strong> the BIOLUPUS<br />
and GENLES Networks 3 , John B. Harley 4 , Timothy J. Vyse 5 , Barry<br />
I. Freedman 11 , Patrick M. Gaffney 2 , Kathy L. Moser 2 , Judith<br />
A. James 2 , Timothy B. Niewold 9 , Jennifer M. Grossman 8 , Rita<br />
M. Cantor 8 , Bevra H. Hahn 8 and Betty P. Tsao 8 , 1 Arthritis and<br />
Immunology Program, Oklahoma Medical Research Foundation,<br />
Oklahoma City, OK, 2 Arthritis and Immunology Program,<br />
Oklahoma Medical Research Foundation, Oklahoma City, OK;<br />
University <strong>of</strong> Oklahoma Health Sciences Center, Oklahoma<br />
City, OK; US Department <strong>of</strong> Veterans Affairs Medical Center,<br />
Oklahoma City, OK, 3 Center for Genomics and Oncological<br />
Research, Granada, Spain, 4 Cincinnati Children’s Hospital<br />
Medical Center and US Department <strong>of</strong> Veterans Affairs Medical<br />
Center, Cincinnati, OH, 5 Imperial <strong>College</strong> London, Hammersmith<br />
Hospital, London, United Kingdom, 6 Medical University <strong>of</strong> South<br />
Carolina, Charleston, SC, 7 University <strong>of</strong> Alabama, Birmingham,<br />
AL, 8 University <strong>of</strong> California, Los Angeles, CA, 9 University <strong>of</strong><br />
Chicago, Chicago, IL, 10 University <strong>of</strong> Southern California, Los<br />
Angeles, CA, 11 Wake Forest University Baptist Medical Center,<br />
NC, 12 Wake Forest University Health Sciences, NC.<br />
1585. Association <strong>of</strong> Variants in the TNFAIP3 Region with Systemic<br />
Lupus Erythematosus in a Multi-Ethnic Study. Indra Adrianto 5 ,<br />
Christopher J. Lessard 8 , Kenneth M. Kaufman 9 , Juan-Manuel<br />
Anaya 12 , Marta E. Alarcón-Riquelme on Behalf <strong>of</strong> the BIOLUPUS<br />
and GENLES Networks 6 , Sang-Cheol Bae 1 , Elizabeth E. Brown<br />
for PROFILE 13 , Barry I. Freedman 18 , Gary S. Gilkeson 4 , Chaim<br />
O. Jacob 16 , Judith A. James 8 , Robert P. Kimberly 13 , Javier<br />
Martin 3 , Joan T. Merrill 8 , Timothy B. Niewold 15 , So-Yeon Park 1 ,<br />
Bernardo A. Pons-Estel 10 , Betty P. Tsao 14 , Timothy J. Vyse 2 , Carl<br />
D. Langefeld 19 , Mary B. Humphrey 11 , John B. Harley 17 , Kathy L.<br />
Moser 8 , Courtney G. Montgomery 7 and Patrick M. Gaffney 7 ,<br />
1<br />
Hanyang University, Seoul, Republic <strong>of</strong> Korea, 2 Imperial <strong>College</strong><br />
London, 3 Instituto de Parasitologia y Biomedicina López-<br />
Neyra, CSIC, Granada, Spain, 4 Medical University <strong>of</strong> South<br />
Carolina, 5 Oklahoma Medical Research Foundation, Oklahoma<br />
City, OK, 6 Oklahoma Medical Research Foundation; Center<br />
<strong>of</strong> Genomics and Oncological Research (GENyO), Granada,<br />
Spain, 7 Oklahoma Medical Research Foundation; Co-Senior<br />
Authors, 8 Oklahoma Medical Research Foundation; The<br />
University <strong>of</strong> Oklahoma Health Sciences Center, 9 Oklahoma<br />
Medical Research Foundation; The University <strong>of</strong> Oklahoma<br />
Health Sciences Center; Oklahoma City VA Medical Center,<br />
10<br />
Sanatorio Parque, Rosario, Argentina, 11 The University <strong>of</strong><br />
Oklahoma Health Sciences Center, 12 Universidad del Rosario,<br />
Colombia, 13 University <strong>of</strong> Alabama at Birmingham, 14 University<br />
<strong>of</strong> California, Los Angeles, 15 University <strong>of</strong> Chicago, 16 University <strong>of</strong><br />
Southern California Keck School <strong>of</strong> Medicine, 17 US Department<br />
<strong>of</strong> Veterans Affairs Medical Center; Cincinnati Children’s Hospital<br />
Medical Center, 18 Wake Forest University Baptist Medical Center,<br />
19<br />
Wake Forest University Health Sciences.<br />
1586. Association <strong>of</strong> Variants in the NF-kB Regulatory Pathway Loci<br />
with Systemic Lupus Erythematosus in Multiple Populations.<br />
Graham Wiley 6 , Indra Adrianto 8 , Jennifer A. Kelly 5 , Kenneth M.<br />
Kaufman 11 , Juan-Manuel Anaya 13 , Marta E. Alarcón-Riquelme<br />
on Behalf <strong>of</strong> the BIOLUPUS and GENLES Networks 7 , Sang-Cheol<br />
Bae 1 , So-Young Bang 1 , Elizabeth E. Brown for PROFILE 14 , Barry<br />
I. Freedman 19 , Gary S. Gilkeson 4 , Chaim O. Jacob 17 , Judith A.<br />
James 10 , Robert P. Kimberly 14 , Javier Martin 3 , Joan T. Merrill 10 ,<br />
Timothy B. Niewold 16 , Bernardo A. Pons-Estel 12 , Betty P. Tsao 15 ,<br />
Timothy J. Vyse 2 , Carl D. Langefeld 20 , John B. Harley 18 , Kathy L.<br />
Moser 10 , Courtney G. Montgomery 9 and Patrick M. Gaffney 9 ,<br />
1<br />
Hanyang University, Seoul, Republic <strong>of</strong> Korea, 2 Imperial <strong>College</strong><br />
London, 3 Instituto de Parasitologia y Biomedicina López-Neyra,<br />
CSIC, Granada, Spain, 4 Medical University <strong>of</strong> South Carolina,<br />
5<br />
Oklahoma Medical Research Foundation, 6 Oklahoma Medical<br />
Research Foundation, Oklahoma City, OK, 7 Oklahoma Medical<br />
Research Foundation; Center <strong>of</strong> Genomics and Oncological<br />
Research (GENyO), Granada, Spain, 8 Oklahoma Medical<br />
Research Foundation; Co-First Authors, 9 Oklahoma Medical<br />
Research Foundation; Co-Senior Authors, 10 Oklahoma Medical<br />
Research Foundation; The University <strong>of</strong> Oklahoma Health<br />
Sciences Center, 11 Oklahoma Medical Research Foundation;<br />
The University <strong>of</strong> Oklahoma Health Sciences Center; Oklahoma<br />
City VA Medical Center, 12 Sanatorio Parque, Rosario, Argentina,<br />
13<br />
Universidad del Rosario, Colombia, 14 University <strong>of</strong> Alabama at<br />
Birmingham, 15 University <strong>of</strong> California, Los Angeles, 16 University<br />
<strong>of</strong> Chicago, 17 University <strong>of</strong> Southern California Keck School <strong>of</strong><br />
Medicine, 18 US Department <strong>of</strong> Veterans Affairs Medical Center;<br />
Cincinnati Children’s Hospital Medical Center, 19 Wake Forest<br />
University Baptist Medical Center, 20 Wake Forest University<br />
Health Sciences.<br />
1587. Association Study <strong>of</strong> the ILAK1 Gene with Susceptibility to<br />
Systemic Lupus Erythematosus and Systemic Sclerosis. Yuko<br />
Ota 3 , Yasushi Kawaguchi 1 , Manabu Kawamoto 2 , Kae Takagi 2 ,<br />
Akiko Tochimoto 2 , Yasuhiro Katsumata 2 , Takahisa Gono 2 ,<br />
Sayumi Baba 2 , Yuko Okamoto 2 and Hisashi Yamanaka 4 , 1 Tokyo<br />
Women’s Medical Univ, Tokyo, Japan, 2 Tokyo Women’s Medical<br />
Univ, 3 Tokyo Women’s Medical University, Tokyo, Japan, 4 Tokyo<br />
Womens Med Univ, Shinjuku-ku, Tokyo, Japan.<br />
1588. Combining Genetic and Environmental Risk Factors To Model<br />
RA Susceptibility. Lori B. Chibnik 3 , Bo Ding 7 , Brendan T. Keenan 4 ,<br />
Katherine P. Liao 2 , Karen H. Costenbader 1 , Lars Klareskog 6 , Lars<br />
Alfredsson 7 and Elizabeth W. Karlson 5 , 1 Brigham & Women,<br />
Boston, MA, 2 Brigham & Women’s Hosp, Boston, MA, 3 Brigham<br />
and Women’s Hospital, Boston, MA, 4 Brigham and Women’s<br />
Hospital, 5 Brigham and Womens Hosp, Boston, MA, 6 Karolinska<br />
University Hospital, Stockholm, Sweden, 7 Karolinska University<br />
Hospital.<br />
2010 Program Book 241
ACR/ARHP Poster Session C<br />
1589. Contribution <strong>of</strong> VpreB1 Gene Copy Number Variation to the<br />
Risk <strong>of</strong> Rheumatoid Arthritis. Seung-Cheol Shim 2 , Mi-Kyoung<br />
Lim 2 , Dong-Hyuk Sheen 2 and Yeun-Jun Chung 1 , 1 Catholic<br />
University, Seoul, Korea, Republic <strong>of</strong>, 2 Eulji University, Daejeon,<br />
Korea, Republic <strong>of</strong>.<br />
1590. Early Disease Onset Is Predicted by a Higher Genetic Risk<br />
for Lupus and Is Associated with a More Severe Phenotype<br />
in Lupus Patients. Ryan Webb 3 , Jennifer A. Kelly 3 , Emily C.<br />
Somers 7 , Travis Hughes 3 , Kenneth M. Kaufman 4 , Elena Sanchez 3 ,<br />
Swapan K. Nath 3 , Gail Bruner 3 , Marta E. Alarcon-Riquelme 5 ,<br />
Gary S. Gilkeson 2 , Diane L. Kamen 2 , Bruce C. Richardson 6 ,<br />
John B. Harley 1 and Amr H. Sawalha 8 , 1 Cincinnati Children’s<br />
Hospital Medical Center, VAMC, Oklahoma City, OK, 2 Med<br />
Univ <strong>of</strong> South Carolina, Charleston, SC, 3 Oklahoma Medical<br />
Research Foundation, 4 Oklahoma Medical Research Foundation,<br />
University <strong>of</strong> Oklahoma, US Department <strong>of</strong> Veterans Affairs<br />
Medical Center, 5 Oklahoma Medical Research Foundation,<br />
Uppsala University, Uppsala, Sweden, 6 University <strong>of</strong> Michigan,<br />
Ann Arbor, MI, 7 University <strong>of</strong> Michigan, 8 University <strong>of</strong> Oklahoma,<br />
US Department <strong>of</strong> Veterans Affairs Medical Center, Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK.<br />
1591. Ethnic Specific Genetic Associations within the FCRL Gene<br />
Cluster in SLE. Nickolas M. Pajewski 15 , Carl D. Langefeld 23 ,<br />
Kenneth M. Kaufman 11 , Adrienne Williams 23 , Mary Comeau 23 ,<br />
Graciela S. Alarcon 2 , Michelle A. Petri 1 , Rosalind Ramsey-<br />
Goldman 7 , John D. Reveille 18 , Luis M. Vila 17 , Marta E. Alarcon-<br />
Riquelme on Behalf <strong>of</strong> the BIOLUPUS and GENLES Networks 10 ,<br />
Juan-Manuel Anaya 19 , Sang-Cheol Bae 3 , Susan A. Boackle 21 ,<br />
Lindsey A. Criswell 14 , Barry I. Freedman 23 , Patrick M. Gaffney 9 ,<br />
Gary S. Gilkeson 5 , Peter K. Gregersen 6 , John B. Harley 16 , Chaim<br />
O. Jacob 22 , Judith A. James 9 , Joan T. Merrill 9 , Kathy L. Moser 9 ,<br />
Timothy B. Niewold 20 , Robert Hal Sc<strong>of</strong>ield 8 , Anne M. Stevens 12 ,<br />
Betty P. Tsao 13 , Timothy J. Vyse 4 , Elizabeth E. Brown 15 , Robert P.<br />
Kimberly 15 and Jeffrey C. Edberg 15 , 1 Timonium, MD, 2 Oakland,<br />
CA, 3 Hanyang Univ Medical Center, Seoul, Korea, Republic<br />
<strong>of</strong>, 4 Imperial <strong>College</strong> London, 5 Med Univ <strong>of</strong> South Carolina,<br />
Charleston, SC, 6 N Shore Univ Hosp Rsch Ctr, Manhasset, NY,<br />
7<br />
Northwestern University, Chicago, IL, 8 Oklahoma Med Res<br />
Foundation, Oklahoma City, OK, 9 Oklahoma Med Research<br />
Foundation, Oklahoma City, OK, 10 Oklahoma Medical Research<br />
Foundation, Uppsala, Sweden, 11 Oklahoma Medical Research<br />
Foundation; The University <strong>of</strong> Oklahoma Health Sciences<br />
Center; Oklahoma City VA Medical Center, 12 Pediatrics, U.<br />
<strong>of</strong> Washington, Seattle, WA, 13 UCLA School <strong>of</strong> Medicine,<br />
Los Angeles, CA, 14 UCSF-Box 0500, San Francisco, CA, 15 Univ<br />
Alabama Birmingham, 16 Univ <strong>of</strong> OK Hlth Sci Ctr, Oklahoma<br />
City, OK, 17 Univ <strong>of</strong> PuertoRico Schl <strong>of</strong> Med, San Juan, PR, 18 Univ<br />
Texas Health Sci Ctr, Houston, TX, 19 Universidad del Rosario,<br />
Colombia, 20 University <strong>of</strong> Chicago, Chicago, IL, 21 University <strong>of</strong><br />
Colorado-Denver SOM, Aurora, CO, 22 USC School <strong>of</strong> Medicine,<br />
Los Angeles, CA, 23 Wake Forest University Health Sciences.<br />
1592. European Genetic Ancestry Protects Against the Development<br />
<strong>of</strong> Renal Disease in Systemic Lupus Erythematosus. Ilana B.<br />
Richman 7 , Kimberly E. Taylor 7 , Sharon A. Chung 6 , Laura Trupin 7 ,<br />
Michelle A. Petri 4 , Edward H. Yelin 6 , Robert R. Graham 3 , Annette<br />
T. Lee 1 , Timothy W. Behrens 2 , Peter K. Gregersen 5 , Michael<br />
F. Seldin 9 and Lindsey A. Criswell 8 , 1 Feinstein Insititute Med<br />
Rsch, Manhasset, NY, 2 Genentech Inc, South San Francisco,<br />
CA, 3 Immunology Biomarkers Group, Genentech, South San<br />
Francisco, 4 Johns Hopkins University School <strong>of</strong> Medicine,<br />
Timonium, MD, 5 N Shore Univ Hosp Rsch Ctr, Manhasset, NY,<br />
6<br />
Rosalind Russell Medical Research Center for Arthritis, Division<br />
<strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> California, San Francisco, San<br />
Francisco, CA, 7 Rosalind Russell Medical Research Center for<br />
Arthritis, Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> California, San<br />
Francisco, 8 UCSF-Box 0500, San Francisco, CA, 9 University <strong>of</strong><br />
California, Davis.<br />
1593. Fine Mapping and Expression Studies Point to KIF5A as the<br />
Gene Responsible for Association <strong>of</strong> the 12q13 Locus with<br />
Rheumatoid Arthritis. Annie McClure, Steve Eyre, Wendy<br />
Thomson, Jane Worthington and Anne Barton, The University <strong>of</strong><br />
Manchester, Manchester, United Kingdom.<br />
1594. Fine Mapping and Trans-Ethnicity Genotyping in IL2/IL21<br />
Establish the Genetic Association between IL21 and Systemic<br />
Lupus Erythematosus. Travis Hughes 7 , Xana Kim 7 , Jennifer<br />
A. Kelley 7 , Kenneth M. Kaufman 9 , Carl D. Langefeld 17 , Julie<br />
Ziegler 17 , Robert P. Kimberly 10 , Jeffrey C. Edberg 15 , Rosalind<br />
Ramsey-Goldman 5 , Michelle A. Petri 1 , John D. Reveille 14 , Javier<br />
Martin 3 , Elizabeth E. Brown 11 , Luis M. Vila 13 , Judith A. James 6 ,<br />
Gary S. Gilkeson 4 , Kathy L. Moser 6 , Patrick M. Gaffney 6 , Joan T.<br />
Merrill 6 , Timothy J. Vyse 2 , Marta E. Alarcon-Riquelme 8 , Swapan<br />
K. Nath 7 , John B. Harley 12 and Amr H. Sawalha 16 , 1 Timonium,<br />
MD, 2 Imperial <strong>College</strong>, <strong>Rheumatology</strong> Section, Hammersmith<br />
Hospital, 3 Instituto de Parasitología y Biomedicina López-<br />
Neyra, Consejo Superior de Investigaciones Científicas,<br />
4<br />
Med Univ <strong>of</strong> South Carolina, Charleston, SC, 5 Northwestern<br />
University, Chicago, IL, 6 Oklahoma Med Research Foundation,<br />
Oklahoma City, OK, 7 OMRF, 8 OMRF, Center for Genomics and<br />
Oncological Research Pfizer, University <strong>of</strong> Granada, Junta de<br />
Andalucia, Uppsala, Sweden, 9 OMRF, OUHSC, VAMC, 10 Univ<br />
Alabama at Birmingham, Birmingham, AL, 11 Univ Alabama at<br />
Birmingham, 12 Univ <strong>of</strong> OK Hlth Sci Ctr, Oklahoma City, OK, 13 Univ<br />
<strong>of</strong> PuertoRico Schl <strong>of</strong> Med, San Juan, PR, 14 Univ Texas Health<br />
Sci Ctr, Houston, TX, 15 University <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, 16 University <strong>of</strong> Oklahoma Health Sciences<br />
Center, OMRF, VAMC, Oklahoma City, OK, 17 Wake Forest<br />
University Health Sciences.<br />
1595. Fine Mapping <strong>of</strong> NMNAT2 for Association with SLE<br />
Susceptibility: A Multiethnic Case-Control Study. Jian Zhao 13 ,<br />
Carl D. Langefeld 16 , Kenneth M. Kaufman 2 , Jennifer A. Kelly 1 ,<br />
Patrick M. Gaffney 1 , Kathy L. Moser 1 , Marta E. Alarcón-Riquelme<br />
on Behalf <strong>of</strong> the BIOLUPUS and GENLES Networks 3 , Timothy J.<br />
Vyse 5 , Chaim O. Jacob 14 , Robert P. Kimberly 15 , Jeffrey C. Edberg 15 ,<br />
Elizabeth E. Brown on Behalf <strong>of</strong> PROFILE investigators 11 ,<br />
Lindsey A. Criswell 7 , John B. Harley 4 , Deh-Ming Chang 6 , Yeong<br />
Wook Song 9 , Chack-Yung Yu 10 , Bernardo Pons-Estel 8 , Jennifer<br />
M. Grossman 12 , Rita M. Cantor 12 , Bevra H. Hahn 12 and Betty<br />
P. Tsao 12 , 1 Arthritis and Immunology Program, Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK, 2 Arthritis<br />
and Immunology Program, Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK; US Department <strong>of</strong> Veterans<br />
Affairs Medical Center, Oklahoma City, OK, 3 Center for Genomics<br />
and Oncological Research, Granada, Spain, 4 Cincinnati Children’s<br />
Hospital Medical Center and US Department <strong>of</strong> Veterans Affairs<br />
Medical Center, Cincinnati, OH, 5 Imperial <strong>College</strong> London,<br />
Hammersmith Hospital, London, United Kingdom, 6 National<br />
Defense Medical Center, Taipei, Taiwan, 7 Rosalind Russell<br />
Medical Research Center for Arthritis, University <strong>of</strong> California,<br />
San Francisco, CA, 8 Sanatorio Parque, Rosario, Argentina, 9 Seoul<br />
National University, Seoul, Korea, 10 The Ohio State University,<br />
Columbus, OH, 11 University <strong>of</strong> Alabama, Birmingham, AL,<br />
12<br />
University <strong>of</strong> California, 13 University <strong>of</strong> California, Los Angeles,<br />
CA, 14 University <strong>of</strong> Southern California, Los Angeles, CA, 15 US<br />
Department <strong>of</strong> Veterans Affairs Medical Center, Oklahoma City,<br />
OK, 16 Wake Forest University Health Sciences, NC.<br />
242<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
1596. Gene-Interactions Influence Methotrexate Efficacy in<br />
Rheumatoid Arthritis: Analysis <strong>of</strong> 62 SNPs Panel in a<br />
Monocentric Cohort <strong>of</strong> Rheumatoid Arthritis Affected Patients.<br />
Thomas Barnetche 1 , Caroline Rooryck-Thambo 4 , Christophe<br />
Hubert 3 , Christophe Richez 2 , Benoit Arveiler 4 and Thierry<br />
Schaeverbeke 2 , 1 Bordeaux University Hospital, <strong>Rheumatology</strong><br />
Department, Bordeaux, France, 2 Bordeaux University Hospital,<br />
<strong>Rheumatology</strong> Department, 3 Genomics-Transcriptomics Facility,<br />
Bordeaux, 4 Human Genetics Laboratory EA4137, University<br />
Victor Segalen Bordeaux 2 .<br />
1597. Genome-Wide Association Study for Rheumatoid Arthritis in<br />
the Korean Population Points to Population-Specific Candidate<br />
Loci as Well as Overlap with European Susceptibility Loci.<br />
Jan Freudenberg 2 , Hye-Soon Lee 4 , H. D. Shin 7 , B. D. Han 5 , Y. M.<br />
Kang 6 , S. C. Shim 1 , Y. K. Sung 4 , CB Choi 4 , Annette Lee 3 , Peter K.<br />
Gregersen 2 and S. C. Bae 4 , 1 Eulji University Hospital, 2 Feinstein<br />
Institute for Medical Research, Manhasset, NY, 3 Feinstein<br />
Institute for Medical Research, 4 Hanyang University Hospital<br />
for Rheumatic Diseases, 5 Korea National Institute <strong>of</strong> Health,<br />
6<br />
Kyungpook National University School <strong>of</strong> Medicine, 7 Sogang<br />
University.<br />
1598. Genome-Wide Copy-Number-Variation Study in Chinese Han<br />
Population Identifies Deletion <strong>of</strong> LCE3C_LCE3B as Susceptibility<br />
Factor for Rheumatoid Arthritis. Xiaolan Lu 2 , Jianping Guo 3 ,<br />
Ru Li 3 , Xia Liu 3 , Zuowei Wu 4 , Jinxia Shi 3 , Xinyu Wu 3 , Yingni<br />
Li 3 , Yi Zhao 3 , Chun Li 3 , Sisi Pan 3 , Lei Zhu 3 , Jing He 3 , Xu Liu 3 ,<br />
Wenjun Chen 1 , Baoli Zhu 4 and Zhanguo Li 3 , 1 Beijing Institute<br />
<strong>of</strong> Genomics, Chinese Academy <strong>of</strong> Sciences, 2 Department <strong>of</strong><br />
<strong>Rheumatology</strong> and Immunology, People’s Hospital Peking<br />
University, Beijing, China, 3 Department <strong>of</strong> <strong>Rheumatology</strong> and<br />
Immunology, People’s Hospital Peking University, 4 Institute <strong>of</strong><br />
Microbiology, Chinese Academy <strong>of</strong> Sciences.<br />
1599. Genome-Wide Pathway Analysis Identifies Oxidative Stress<br />
Related Gene MSRA as Rheumatoid Arthritis Susceptibility<br />
Locus. Jose Ezequiel Martin 5 , Behrooz Z. Alizadeh 10 , Miguel<br />
A. Gonzalez-Gay 4 , Alejandro Balsa 2 , Dora Pascual-Salcedo 2 ,<br />
Benjamín Fernández-Gutiérrez 1 , Enrique Raya 3 , Lude Franke 9 ,<br />
Ruben Van’t Slot 11 , Marieke J. H. Coenen 7 , Piet van Riel 8 , T. R.<br />
D. J. Radstake 8 , B. P. C. Koeleman 11 and Javier Martin 6 , 1 Hospital<br />
Clinico San Carlos, Dept. <strong>of</strong> <strong>Rheumatology</strong>, Spain, 2 Hospital<br />
La Paz, Madrid, Dept. <strong>of</strong> <strong>Rheumatology</strong>, Spain, 3 Hospital<br />
Universitario Clinico San Cecilio, Dept. <strong>of</strong> <strong>Rheumatology</strong>, Spain,<br />
4<br />
Hospital Xeral-Calde, Dept. <strong>of</strong> <strong>Rheumatology</strong>, Lugo, Spain,<br />
Spain, 5 Instituto de Parasitologia y Biomedicina Lopez-Neyra,<br />
CSIC, Armilla, Granada, Spain, 6 Instituto de Parasitologia y<br />
Biomedicina Lopez-Neyra, CSIC, Spain, 7 Radboud University<br />
Nijmegen Medical Center, Department <strong>of</strong> Human Genetics,<br />
The Netherlands, 8 Radboud University Nijmegen Medical<br />
Center, Department <strong>of</strong> <strong>Rheumatology</strong>, The Netherlands,<br />
9<br />
University Medical Center Groningen, Dept. Human Genetic,<br />
The Netherlands, 10 University Medical Centre Groningen, Dept.<br />
<strong>of</strong> Epidemiology, 11 University Medical Centre Utrecht, Dept.<br />
Medical Genetics, The Netherlands.<br />
1600. Identification <strong>of</strong> Genetic Markers <strong>of</strong> Rheumatoid Arthritis<br />
Severity by Genome-Wide Association Studies. Sebastien<br />
Viatte 1 , Darren Plant 2 , John Bowes 2 , Deborah Symmons 2 ,<br />
Jane Worthington 2 and Anne Barton 1 , 1 Arthritis Research UK<br />
Epidemiology Unit, The University <strong>of</strong> Manchester, Manchester,<br />
United Kingdom, 2 Arthritis Research UK Epidemiology Unit, The<br />
University <strong>of</strong> Manchester.<br />
1601. Identification <strong>of</strong> KIAA Proteins in Immune Complex Proteome<br />
from Juvenile Idiopathic Arthritis and Systemic Lupus<br />
Erythematosus. Anil Chauhan 2 , Brooke Gilliam 2 , Catherine P.<br />
Riley 1 , Jiri Adamec 1 and Terry L. Moore 3 , 1 Purdue University,<br />
2<br />
Saint Louis University, 3 St Louis University, St Louis, MO.<br />
1602. Major Histocompatibility Complex Associations with<br />
Thrombosis and Antiphospholipid Antibody Production<br />
in Systemic Lupus Erythematosus. Rachel Kaiser 4 , Sharon<br />
A. Chung 4 , Kimberly E. Taylor 5 , Suzanne L. May 2 , Patricia P.<br />
Ramsay 2 , Hong L. Quach 2 , Diana L. Quach 2 , Julie A. Lane 1 , Janelle<br />
A. Noble 1 , Michael F. Seldin 3 , Lisa Barcellos 2 and Lindsey A.<br />
Criswell 6 , 1 Children’s Hospital Oakland Research Institute, 2 UC<br />
Berkeley, 3 UC Davis, 4 UCSF, San Francisco, CA, 5 UCSF, 6 UCSF-Box<br />
0500, San Francisco, CA.<br />
1603. MMEL1 and CDK6 Are Associated with ACPA Positive and RF<br />
Positive Rheumatoid Arthritis. Marthe Thoresen Mæhlen 1 ,<br />
Tore K. Kvien 3 , Till Uhlig 2 and Benedicte A. Lie 4 , 11 .Dept.<br />
<strong>of</strong> <strong>Rheumatology</strong>, Diakonhjemmet Hospital, 2 . Institute <strong>of</strong><br />
Immunology, Oslo University Hospital, Oslo, Oslo, Norway,<br />
2<br />
Dept. <strong>of</strong> <strong>Rheumatology</strong>, Diakonhjemmet Hospital, Oslo,<br />
Norway, 3 Diakonhjemmet Hospital, Oslo, Norway, 4 Institute <strong>of</strong><br />
Immunology, Oslo University Hospital, Oslo, Norway.<br />
1604. Multiple Expanded B-Cell Clones Are Already Present in Early<br />
Rheumatoid Arthritis: Results <strong>of</strong> a Comparison between<br />
Early and Longstanding Disease Using High Throughput<br />
Sequencing Technology. Marieke E. Doorenspleet 2 , Stefano<br />
Alivernini 2 , Marjolein J. de Hair 2 , Paul L. Klarenbeek 2 , Marieke<br />
M. Herenius 2 , Marleen G. van de Sande 2 , Barbera D. van<br />
Schaik 1 , Rebecca E. Esveldt 2 , Antoine H. van Kampen 1 , Danielle<br />
M. Gerlag 2 , Frank Baas 3 , Paul P. Tak 2 and Niek de Vries 2 , 1 Dept.<br />
<strong>of</strong> Clinical Epidemiology, Biostatistics and Bioinformatics<br />
Academic Medical Center-University <strong>of</strong> Amsterdam, 2 Div.<br />
Clinical Immunology and <strong>Rheumatology</strong> Academic Medical<br />
Center-University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />
3<br />
Laboratory for Genome Analysis Academic Medical Center-<br />
University <strong>of</strong> Amsterdam.<br />
1605. New HLA-DRB1 Classifications in Association with Rheumatoid<br />
Arthritis for Global Application: Beyond the Conventional<br />
Shared Epitope Hypothesis. So-Young Bang 1 , Hye-Soon Lee 1 , Ji-<br />
Seon Lee 1 , Eun-Mi Kim 1 , Kyung Wha Lee 2 and Sang-Cheol Bae 1 ,<br />
1<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Hanyang University Hospital<br />
for Rheumatic Disease, Korea, Republic <strong>of</strong>, 2 Hallym Institute for<br />
Genome Application, Hallym University Sacred Heart Hospital,<br />
Korea, Republic <strong>of</strong>.<br />
1606. Pre Analytical Effects <strong>of</strong> Serum Collection and Handling<br />
in Quantitative Immunoassays for Rheumatoid Arthritis.<br />
Ferhan Qureshi 3 , William Manning 3 , Scott Eastman 3 , Wayne<br />
Hu 3 , Michael Centola 6 , Mary Turner 7 , Craig W. Carson 5 , Ana A.<br />
Kumar 4 , Linda A. Zacharias 2 , Claire Alexander 3 , Doug Haney 3 ,<br />
Guy Cavet 3 and Lyndal K. Hesterberg 1 , 1 Crescendo Bioscience,<br />
Inc., South San Francisco, CA, 2 Crescendo Bioscience, Inc.,<br />
Edmond, OK, 3 Crescendo Bioscience, Inc., 4 OK Arthritis Center,<br />
Edmond, OK, 5 Oklahoma Arthritis Ctr, Edmond, OK, 6 Oklahoma<br />
Med Research Foundation, Oklahoma City, OK, 7 Oklahoma<br />
Medical Research Foundation.<br />
1607. Serum TNFα and IL-6 Concentrations in Systemic Lupus<br />
Erythematosus, Rheumatoid Arthritis and Controls Are<br />
Associated with Polymorphisms in PTPN2, IRF5, INFG, and<br />
NOD2. Joseph F. Solus 3 , Young Hee Rho 3 , Annette M. Oeser 4 ,<br />
Cecilia P. Chung 2 , Chun Li 3 , Jeffrey R. Smith 3 and C. Michael<br />
Stein 1 , 1 Vanderbilt University Medical Center, Nashville,<br />
TN, 2 Vanderbilt University Medical Center, Baltimore, MD,<br />
3<br />
Vanderbilt University Medical Center, 4 VUMC 23rd Ave South<br />
Pierce, Nashville, TN.<br />
2010 Program Book 243
ACR/ARHP Poster Session C<br />
244<br />
1608. SLE-Associated Genetic Variants Influence Gene Expression<br />
in Patients. Hatice Bilgic 4 , Thearith Koeuth 5 , Joseph C. Wilson 5 ,<br />
Ward Ortmann 1 , Michelle Petri 2 , Peter Gregersen 3 , Timothy<br />
Behrens 1 and Emily C. Baechler 5 , 1 Genentech, Inc., 2 Johns<br />
Hopkins School <strong>of</strong> Medicine, 3 The Feinstein Institute for<br />
Medical Research, 4 University <strong>of</strong> Minnesota, MN, 5 University <strong>of</strong><br />
Minnesota.<br />
1609. Stratification <strong>of</strong> Rheumatoid Arthritis Patients into Disease<br />
Subtypes with Clinical Implications. Glynn Dennis, Cecile<br />
Holweg, Jason Hackney, Houston Glibert, Wei Yu Lin, Lauri Diehl,<br />
Judith Endres, David Fox, Mike Townsend and Flavius Martin,<br />
Genentech.<br />
1610. The Associations between RA Genetic Risk Alleles and<br />
Seropositive but Non-Erosive Rheumatoid Arthritis. Katherine<br />
P. Liao, Jing Cui, Michael E. Weinblatt, Christine Iannaccone,<br />
Nancy Shadick, Robert M. Plenge, Daniel H. Solomon and<br />
Elizabeth W. Karlson, Brigham and Women’s Hospital, Boston,<br />
MA.<br />
1611. TNIP2 Is Associated with Joint Destruction in Patients with<br />
Rheumatoid Arthritis. Taku Suzuki 2 , Katsunori Ikari 2 , Koichiro<br />
Yano 2 , Yoshiaki Toyama 1 , Atsuo Taniguchi 2 , Hisashi Yamanaka 2<br />
and Shigeki Momohara 2 , 1 Department <strong>of</strong> Orthopaedic Surgery,<br />
Keio University, 2 Institute <strong>of</strong> <strong>Rheumatology</strong>, Tokyo Woman’s<br />
Medical University, Japan.<br />
1612. Trait-Stratified Genome-Wide Association Study Identifies<br />
Novel and Diverse Genetic Associations with Serologic and<br />
Cytokine Phenotypes in Systemic Lupus Erythematosus.<br />
Silvia N. Kariuki 4 , Beverly S. Franek 4 , Akaash A. Kumar 4 ,<br />
Jasmine Arrington 4 , Racheal A. Mikolaitis 2 , Tammy O. Utset 4 ,<br />
Meenakshi Jolly 2 , Mary K. Crow 1 , Andrew D. Skol 3 and Timothy<br />
B. Niewold 4 , 1 Hospital for Special Surgery, Mary Kirkland Center<br />
for Lupus Research, New York, NY, 2 Rush University, Section<br />
<strong>of</strong> <strong>Rheumatology</strong>, Chicago, IL, 3 University <strong>of</strong> Chicago Pritzker<br />
School <strong>of</strong> Medicine, Section <strong>of</strong> Genetic Medicine, Chicago, IL,<br />
4<br />
University <strong>of</strong> Chicago Pritzker School <strong>of</strong> Medicine, Section<br />
<strong>of</strong> <strong>Rheumatology</strong> and Gwen Knapp Center for Lupus and<br />
Immunology Research, Chicago, IL.<br />
Imaging <strong>of</strong> Rheumatic Disease II: Ultrasound, PET, Capillary<br />
Microscopy and Molecular Imaging<br />
1613. 18FPEG-Folate: A New Potential Macrophage PET Tracer for<br />
Imaging <strong>of</strong> Arthritis. Conny J. van der Laken 3 , Inge de Greeuw 2 ,<br />
Yoony Y. J. Gent 4 , Karin Weijers 4 , Alexandre E. Voskuyl 4 , Gerrit<br />
Jansen 4 , Ben A. C. Dijkmans 4 , Adriaan A. Lammertsma 2 , Phil<br />
S. Low 1 , Sumith Kularatne 1 , Albert D. Windhorst 2 and Carla F.<br />
M. Molth<strong>of</strong>f 2 , 1 Dept. <strong>of</strong> Chemistry, Purdue University, 2 Dept.<br />
<strong>of</strong> Nuclear Medicine & PET Research, VU Medical Center,<br />
Amsterdam, 3 Dept. <strong>of</strong> <strong>Rheumatology</strong>, VU Medical Center,<br />
Amsterdam, The Netherlands, 4 Dept. <strong>of</strong> <strong>Rheumatology</strong>, VU<br />
Medical Center.<br />
1614. Asymptomatic Hyperuricemia: Ultrasonographic Findings.<br />
Carla Solano 3 , Pedro José Rodríguez-Henríquez 4 , Fritz H<strong>of</strong>mann 4 ,<br />
Araceli Bernal 4 , Norma Marín-Arriaga 4 , Alberto Gabriel<br />
López-Reyes 4 , Luis Guirado 1 , Angelica Vargas-Guerrero 1 , Luis<br />
Amezcua-Guerra 1 , Marwin Gutierréz 5 , Cristina Hernández-Díaz 4 ,<br />
Manuel Martínez-Lavín 1 and Carlos Pineda 2 , 1 Instituto Nacional<br />
de Cardiología, Mexico, 2 Instituto Nacional de Rehab, Mexico<br />
City, Mexico, 3 Instituto Nacional de Rehabilitación, El Salvador,<br />
4<br />
Instituto Nacional de Rehabilitación, Mexico, 5 Universitá<br />
Politecnicá delle Marche Ospedale “A Murri”, Italy.<br />
2010 Program Book<br />
1615. Capillary Microscopy – A Cross-Sectional Study in the<br />
Population. Oliver Sander 1 , Moritz Schroeder 3 , Benedikt<br />
Ostendorf 1 , Jutta Richter 1 , Matthias Reppel 3 , Hasan Acar 2 ,<br />
Martina Blumenroth 4 and Matthias K. Schneider 1 , 1 Dept.<br />
<strong>Rheumatology</strong>, Heinrich-Heine University, Duesseldorf,<br />
Germany, 2 Dept. <strong>Rheumatology</strong>, Heinrich-Heine University,<br />
3<br />
Heinrich-Heine University Duesseldorf, 4 Rheumazentrum Rhein-<br />
Ruhr.<br />
1616. Concordance between Ultrasound Readers Determining<br />
Presence <strong>of</strong> Monosodium Urate Crystal Deposition in Knee<br />
and Toe Joints. Rennie N. G. Howard 2 , Michael H. Pillinger 2 ,<br />
Soterios Gyftopoulos 2 , Ralf G. Thiele 4 , Christopher Swearingen 3<br />
and Jonathan Samuels 1 , 1 New York University Hospital for<br />
Joint Disease, New York, NY, 2 NYU Langone Medical Center,<br />
NYU Hospital for Joint Diseases, New York, NY, 3 University <strong>of</strong><br />
Arkansas for Medical Sciences, Little Rock, AR, 4 University <strong>of</strong><br />
Rochester, Rochester, NY.<br />
1617. Demonstrating Musculoskeletal Ultrasound Competency in a<br />
Valid and Reliable Way. Eugene Y. Kissin 4 , Jingbo Niu 5 , Ralf G.<br />
Thiele 11 , Midori Jane Nishio 1 , Jay B. Higgs 13 , Janak R. Goyal 10 ,<br />
Daniel G. Malone 12 , David A. Bong 2 , Amy M. Evangelisto 3 ,<br />
Wolfgang A. Schmidt 7 , Peter Balint 8 , Carlos Pineda 6 and Gurjit<br />
S. Kaeley 9 , 1 Lafayette, CA, 2 Bruce, WI, 3 Arthritis Rheumatic &<br />
Back Disease Association, Philadelphia, PA, 4 Boston University,<br />
Boston, MA, 5 Boston University, Boston, MA, 6 Institutu<br />
Nacional de Rehab, Mexico City, Mexico, 7 Medical Center for<br />
<strong>Rheumatology</strong> Berlin-Buch, Berlin, Germany, 8 National Institute<br />
<strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy, Budapest, Hungary,<br />
9<br />
University <strong>of</strong> Florida <strong>College</strong> <strong>of</strong> Medicine, Ponte Vedra Beach,<br />
FL, 10 University <strong>of</strong> Medicine and Dentistry <strong>of</strong> New Jersey, Robert<br />
Wood Johnson Medical School, Perth Amboy, NJ, 11 University <strong>of</strong><br />
Rochester, Rochester, NY, 12 University <strong>of</strong> Wisconsin, Madison,<br />
WI, 13 Wilford Hall Medical Center/Brooke Army Medical Center,<br />
San Antonio, TX.<br />
1618. Effect <strong>of</strong> Musculoskeletal Ultrasound (MSKUS) Examination on<br />
Therapeutic Decision Making in Inflammatory Arthritis. Arnold<br />
Ceponis 2 , John J. Cush 1 and Arthur Kavanaugh 3 , 1 Baylor Research<br />
Institute, Dallas, TX, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Allergy and<br />
Immunology, University <strong>of</strong> California San Diego, San Diego, CA,<br />
3<br />
University <strong>of</strong> California-San Diego, La Jolla, CA.<br />
1619. Enthesopathy Detected by 18-Fluorodeoxyglucose Positron<br />
Emission Tomography in Patients with Polymyalgia<br />
Rheumatica. Hiroyuki Yamashita 2 , Kazuo Kubota 1 , Yuko<br />
Takahashi 3 , Hiroshi Kaneko 3 and Akio Mimori 3 , 1 Department<br />
<strong>of</strong> Radiology, National Center for Global Health and Medicine,<br />
2<br />
Division <strong>of</strong> Rheumatic Diseases, National Center for Global<br />
Health and Medicine, Shinjuku-ku, Tokyo-to, Japan, 3 Division<br />
<strong>of</strong> Rheumatic Diseases, National Center for Global Health and<br />
Medicine.<br />
1620. Erosive Osteoarthritis Is Not Associated with Invading<br />
Synovial Tissue: An Ultrasound Study. Ralf G. Thiele 1 , Laura<br />
A. Paxton 3 , Bethany A. Marston 2 , Darren Tabechian 4 and<br />
Allen P. Anandarajah 1 , 1 University <strong>of</strong> Rochester, Rochester, NY,<br />
2<br />
University <strong>of</strong> Rochester, Rochester, NY, 3 University <strong>of</strong> Rochester,<br />
North Chili, NY, 4 University <strong>of</strong> Rochester School <strong>of</strong> Medicine,<br />
Rochester, NY.<br />
1621. Evaluation <strong>of</strong> the 7-Joint Ultrasound Score (US7) by Detailed<br />
Joint Region-Analysis <strong>of</strong> an Arthritis Patient Cohort over One<br />
Year. Sarah Ohrndorf 3 , Beatrice Halbauer 3 , Lydia Naumann 3 ,<br />
Ekkehart Dietz 2 , Gerd R. Burmester 1 and Marina Backhaus 4 ,<br />
1<br />
Charite - University Medicine, Berlin, Germany, 2 Department<br />
<strong>of</strong> Medical Statistics Charité, Berlin, Germany, 3 Department <strong>of</strong><br />
<strong>Rheumatology</strong> and Clinical Immunology, University Hospital<br />
Charité, Berlin, Germany, 4 University Medicine Berlin: Campus<br />
Charité Mitte, Berlin, Germany.
ACR/ARHP Poster Session C<br />
1622. Fluorescence Imaging <strong>of</strong> Articular Proteinase Activities and<br />
Osteoblast Activity Showed Treatment Response to Anti-<br />
Interleukin-1 Antibodies in a Mouse Model <strong>of</strong> Collagen-<br />
Induced Arthritis. Fons A. J. van de Loo, Eline Vermeij, Onno J.<br />
Arntz, Marije Koenders and Wim B. van den Berg, Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Radboud University Nijmegen Medical Centre,<br />
Nijmegen, The Netherlands.<br />
1623. High Reliability <strong>of</strong> Nailfold Videocapillaroscopy – An Outcome<br />
Measure for Systemic Sclerosis-Related Microvsacular<br />
Disease? Herman H<strong>of</strong>stee 4 , Erik Serné 4 , Chris Roberts 2 , Roger<br />
Hesselstrand 1 , Agneta Scheja 1 , Tonia Moore 3 , Marie Wildt 1 ,<br />
Joanne Manning 2 , Anton Vonk Noordegraaf 4 , Alexandre Voskuyl 4<br />
and Ariane Herrick 2 , 1 Lund University, Sweden, 2 The University<br />
<strong>of</strong> Manchester, United Kingdom, 3 The University <strong>of</strong> Manchester,<br />
United Kingdom 4 VU University Medical Center, Amsterdam,<br />
The Netherlands.<br />
1624. Hypodermal Compressibility as a Diagnostic Test for<br />
Eosinophilic Fasciitis. Eugene Y. Kissin 1 , Michael R. York 2 and<br />
Robert W. Simms 3 , 1 Boston University, Boston, MA, 2 Boston<br />
University Medical Ctr, Boston, MA, 3 Boston University School <strong>of</strong><br />
Medicine, Boston, MA.<br />
1625. Novel PET/MR Fusion Imaging and Quantification <strong>of</strong> Knee<br />
Synovitis in Rheumatoid Arthritis. John T. Ryan 4 , C. T. Ng 1 ,<br />
Aisling Kennedy 2 , Robert G. Gibney 1 , Oliver Fitzgerald 1 , Patrick C.<br />
Brennan 5 , Eric Heffernan 1 , Jonathan McNulty 3 , Louise Rainford 3 ,<br />
Ursula Fearon 1 and Douglas Veale 1 , 1 Dublin Academic Medical<br />
Centre, Dublin, Ireland, 2 Dublin Academic Medical Centre,<br />
3<br />
University <strong>College</strong> Dublin, 4 University <strong>of</strong> Sydney, Lidcombe,<br />
NSW, Australia, 5 University <strong>of</strong> Sydney.<br />
1626. Outcomes and Cost-Effectiveness <strong>of</strong> Carpal Tunnel Injections<br />
Using Sonographic Needle Guidance. Natalia R. Chavez-Chiang 2 ,<br />
Suzanne Delea 1 , Wilmer L. Sibbitt 3 , Arthur D. Bankhurst 4 and<br />
Hillary Norton 2 , 1 University <strong>of</strong> New Mexico, Albuquerque, NM,<br />
2<br />
University <strong>of</strong> New Mexico, 3 University <strong>of</strong> New Mexico HSC,<br />
Albuquerque, NM, 4 University <strong>of</strong> NM Med Ctr, Albuquerque,<br />
NM.<br />
1627. WITHDRAWN<br />
1628. Potential Use <strong>of</strong> Matrix Metalloproteinase-13 Fluorogenic<br />
Probe for Imaging Osteoarthritis Development In Vivo. Sung<br />
Jae Choi 2 , Young Ho Lee 2 , Jong Dae Ji 2 and Gwan Gyu Song 1 ,<br />
1<br />
Korea Univ <strong>College</strong> <strong>of</strong> Med, Seoul, Korea, Republic <strong>of</strong>, 2 Korea<br />
Univ <strong>College</strong> <strong>of</strong> Medicine, Korea, Republic <strong>of</strong>.<br />
1629. Psychometric Properties <strong>of</strong> Synovitis Assessed in Rheumatoid<br />
Arthritis: Improved Intraobserver Reliability <strong>of</strong> Ultrasound vs.<br />
Clinical Evaluation in an Ancillary Study <strong>of</strong> the “Etanercept<br />
Versus DMARDs” Randomized, Prospective, Multicentre Study.<br />
Peter Mandl 5 , Peter V. Balint 5 , Yves Brault 4 , Marina Backhaus 9 ,<br />
Maria Antonietta D’Agostino 7 , Walter Grassi 1 , Desiree M. Van<br />
Der Heijde 3 , Eugenio De Miguel 8 , Richard J. Wakefield 6 , Isabelle<br />
Logeart 4 and Maxime Dougados 2 , 1 Clinica Reumatologica,<br />
Università Politecnica delle Marche, Jesi, Ancona, Italy,<br />
2<br />
Hospital Cochin, Paris, France, 3 Leiden University Medical<br />
Center, Meerssen, The Netherlands, 4 Pfizer, La Défense, Paris,<br />
France, 5 <strong>Rheumatology</strong> Department III, National Institute <strong>of</strong><br />
<strong>Rheumatology</strong> and Physiotherapy, Budapest, Pest, Hungary,<br />
6<br />
<strong>Rheumatology</strong> Department, University <strong>of</strong> Leeds, Chapel<br />
Allerton Hospital, Leeds, United Kingdom, 7 <strong>Rheumatology</strong><br />
Department, Versailles-Saint Quentin en Yvelines University;<br />
APHP, Ambroise-Paré Hospital, Boulogne-Billancourt, France,<br />
8<br />
<strong>Rheumatology</strong> Unit, La Paz University Hospital, Madrid, Spain,<br />
Spain, 9 University Medicine Berlin: Campus Charité Mitte,<br />
Berlin, Germany.<br />
1630. Sensitivity and Specificity <strong>of</strong> the Physical Examination<br />
Compared to Ultrasound in Identifying Knee and Ankle<br />
Arthritis in JIA. Ginger L. Janow 3 , Vikash Panghaal 2 , Terry L.<br />
Levin 2 and Norman T. Ilowite 1 , 1 Children’s Hospital Montefiore,<br />
Bronx, NY, 2 Department <strong>of</strong> Radiology, Montefiore Medical<br />
Center, 3 Division <strong>of</strong> Pediatric <strong>Rheumatology</strong>, Children’s Hospital<br />
Montefiore, New York, NY.<br />
1631. The Comparison <strong>of</strong> Ultrasound & Physical Findings (CUSP)<br />
Remission Study – Ultrasound Remission Is Attained in Only<br />
20% <strong>of</strong> Patients on Anti-TNF Therapy. Joanne M. Kitchen 1 ,<br />
Bernadette M. Lynch 3 , Oliver M. FitzGerald 2 , Douglas J. Veale 3<br />
and David Kane 1 , 1 Adelaide and Meath Hospital, Dublin,<br />
Ireland, 2 St Vincents Univ Hospital, Ranelagh Dublin, Ireland, 3 St<br />
Vincents Univ Hospital, Dublin, Ireland.<br />
1632. The Power Doppler Ultrasonography Score from 24<br />
Synovial Sites or 6 Simplified Synovial Sites, Including the<br />
Metacarpophalangeal (MCP) Joints, Reflects Well the Clinical<br />
Disease Activity and Serum Biomarkers in Patients with<br />
Rheumatoid Arthritis. Atsushi Kawakami 1 , Shin-ya Kawashiri 1 ,<br />
Naoki Iwamoto 1 , Mami Tamai 1 , Hideki Nakamura 1 , Junko Kita 1 ,<br />
Akitomo Okada 1 , Tomohiro Koga 1 , Satoshi Yamasaki 1 , Tomoki<br />
Origuchi 1 and Katsumi Eguchi 2 , 1 Nagasaki University, Nagasaki,<br />
Japan, 2 Sasebo City General Hospital, Sasebo, Nagasaki, Japan.<br />
1633. The Role <strong>of</strong> Ultrasound in B Mode and Power Doppler<br />
Sonography in the Diagnosis <strong>of</strong> Enthesitis in Children.<br />
Dana Toib 1 , Anthony R. French 1 , Nirvikar Dahiya 2 , William<br />
D. Middleton 2 , Richard Brasington 1 and Andrew J. White 1 ,<br />
1<br />
Washington Univ Schl <strong>of</strong> Med, St Louis, MO, 2 Washington Univ<br />
Schl <strong>of</strong> Med.<br />
1634. Ultrasound Bone Erosions – Their Morphological Basis<br />
Obtained by High-Resolution Micro-Computed Tomography<br />
Imaging. Stephanie Finzel 2 , Sarah Ohrndorf 1 , Matthias<br />
Englbrecht 2 , Christian M. Stach 2 , Janin Messerschmidt 1 , Georg<br />
Schett 3 and Marina Backhaus 4 , 1 Charite University Hospital,<br />
Berlin, Germany, 2 Department <strong>of</strong> Internal Medicine 3 , University<br />
<strong>of</strong> Erlangen-Nuremberg, Erlangen, Germany, 3 Friedrich<br />
Alexander Univ, Erlangen, Germany, 4 University Medicine Berlin:<br />
Campus Charité Mitte, Berlin, Germany.<br />
1635. Ultrasound Lung Comets. Validity, Reproducibility and<br />
Feasibility <strong>of</strong> a Simplified Assessment <strong>of</strong> Pulmonary Interstitial<br />
Fibrosis in Connective Tissue Disorders. Marwin Gutierrez 1 ,<br />
Fausto Salaffi 1 , Marina Carotti 3 , Marika Tardella 1 , Chiara<br />
Bertolazzi 1 , Elisabetta Bichisecchi 3 , Mara Giorgi 3 , Alarico Ariani 1 ,<br />
Carlos Pineda 2 , Emilio Filippucci 1 and Walter Grassi 1 , 1 Clinica<br />
Reumatologica, Università Politecnica delle Marche, Jesi,<br />
Ancona, Italy, 2 Instituto Nacional de Rehabilitacion, Mexico<br />
City, Mexico, 3 S.O.D Radiologia Clinica, Dipartimento di Scienze<br />
Radiologiche, Ospedale Riuniti, Ancona.<br />
1636. Use <strong>of</strong> Musculoskeletal Ultrasound in Diagnosis <strong>of</strong> Early<br />
Inflammatory Arthritis: Are Limited Joint Surveys Adequate?<br />
Paramvir Sidhu, Jeffrey Lisse, Rafael Grau, Eric P. Gall and Mihra<br />
Taljanovic, University <strong>of</strong> Arizona, Tucson, AZ.<br />
1637. Utility <strong>of</strong> Ultrasound in the Diagnostic Assessment <strong>of</strong><br />
Shoulder Pain in Polymyalgia Rheumatica: Results from an<br />
International, Prospective, Multi-Center Longitudinal Study.<br />
ACR–EULAR Study Group for Development <strong>of</strong> Classification<br />
Criteria for PMR. Wolfgang A. Schmidt 17 , Marco A. Cimmino 9 ,<br />
Peter Mandl 18 , Peter V. Balint 1 , Annamaria Iagnocco 22 , Richard J.<br />
Wakefield 20 , Michael Schirmer 4 , Carlo Salvarani 10 , Artur Bachta 16 ,<br />
Maria C. Cid 15 , Christina Duftner 8 , Christian Dejaco 12 , Georgina<br />
Espígol-Frigolé 2 , Pierluigi Macchioni 10 , Zsuzsa Schmidt 18 ,<br />
Novák P. Kaposi 19 , Gyula Poór 18 , Elizabeth Nordborg 23 , Haner<br />
2010 Program Book 245
ACR/ARHP Poster Session C<br />
Direskeneli 11 , Sibel Z. Aydin 11 , Colin Pease 20 , Khalid Ahmed 13 ,<br />
Mehrdad Mazlumzadeh 7 , Andy Abril 5 , Neil Gonter 21 , Hilal<br />
Maradit-Kremers 3 , Cynthia S. Crowson 3 , Bhaskar Dasgupta 14<br />
and Eric L. Matteson 6 , 13 rd <strong>Rheumatology</strong> Department, National<br />
Institute <strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy, Budapest,<br />
2<br />
Center for Diagnosis Imaging, Hospital Clínic, Montserrat<br />
del Amo, Barcelona, Spain, 3 Department <strong>of</strong> Health Sciences<br />
Research, Mayo Clinic, Rochester, MN, 4 Department <strong>of</strong> Internal<br />
Medicine I, Medical University Innsbruck, Innsbruck, Austria,<br />
5<br />
Department <strong>of</strong> Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Mayo Clinic, Jacksonville, FL, 6 Department <strong>of</strong> Internal Medicine,<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic, Rochester, MN,<br />
7<br />
Department <strong>of</strong> Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Mayo Clinic, Scottsdale, AZ, 8 Department <strong>of</strong> Internal Medicine,<br />
General Hospital <strong>of</strong> the Elisabethinen, Klagenfurt, Austria,<br />
9<br />
Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Genova,<br />
Genova, Italy, 10 Department <strong>of</strong> <strong>Rheumatology</strong>, Arcispedale<br />
S. Maria Nuova, Reggio Emilia, Italy, 11 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Marmara University Medical School, Istanbul,<br />
Turkey, 12 Department <strong>of</strong> <strong>Rheumatology</strong>, Medical University,<br />
Graz, Graz, Austria, 13 Department <strong>of</strong> <strong>Rheumatology</strong>, Princess<br />
Alexandra Hospital, Harlow, United Kingdom, 14 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Southend University Hospital, Essex,<br />
United Kingdom, 15 Department <strong>of</strong> Systemic Autoimmune<br />
Hospital Clinic Provincial, Barcelona, Spain, 16 Deptartment<br />
<strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, WIM CSK MON,<br />
Warszawa, Poland, 17 Immanuel Krankenhaus Berlin: Medical<br />
Center for <strong>Rheumatology</strong> Berlin-Buch Berlin, Berlin, Germany,<br />
18<br />
National Institute <strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy,<br />
Budapest, Hungary, 19 Radiology Department, National Institute<br />
<strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy, Budapest, Hungary,<br />
20<br />
<strong>Rheumatology</strong> and Rehabilitation Research Unit, University <strong>of</strong><br />
Leeds, Leeds, UK, 21 <strong>Rheumatology</strong> Associates <strong>of</strong> North Jersey,<br />
Teaneck, NJ, 22 <strong>Rheumatology</strong> Unit, Clinica e Terapia Medica<br />
Department, Sapienza Università di Roma, Policlinico Umberto<br />
I, Rome, Italy, 23 Sahlgren University Hospital, Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Göteborg, Sweden.<br />
Infection-Related Rheumatic Disease<br />
1638. A Comparison <strong>of</strong> the Presentation, Synovial Fluid Analysis, and<br />
Treatment Course in Children and Adults with Lyme Arthritis.<br />
Brian E. Daikh 4 , Fred Emerson 3 , F. Lee Lucas 2 , Robert Smith 1 and<br />
Carol McCarthy 1 , 1 Maine Medical Center, 2 Maine Medical Center<br />
Research Institute, 3 Maine Medical Partners, 4 <strong>Rheumatology</strong><br />
Associates PC, Portland, ME.<br />
1639. Autoantibodies to a Novel Cytoplasmic Rod/Ring Structure<br />
Target CTP/GTP Synthetic Pathway in HCV Infection after<br />
Interferon/Ribavirin Therapy. Wendy C. Carcamo 2 , Angela<br />
Ceribelli 3 , Jason Y. F Chan 3 , Westley H. Reeves 2 , Giovanni Covini,<br />
Carlos A. Von Muhlen 1 , Liu Chen 3 , Minoru Satoh 2 and Edward<br />
K. .L Chan 2 , 1 Metanalysis, Porto Alegre, Brazil, 2 University <strong>of</strong><br />
Florida, Gainesville, FL, 3 University <strong>of</strong> Florida.<br />
1640. Chloroquine (CQN) Is Not Superior to Meloxicam (MCAM) in<br />
the Treatment <strong>of</strong> Early Persistent ‘Musculoskeletal Pain and<br />
Polyarthralgias’ (MSK-P) Following Chikungunya (CHIKV): A<br />
Non Commercial Investigator Initiated Community Based<br />
Controlled Drug Study. Arvind Chopra 2 , Manjit Saluja 3 and<br />
Anuradha Venugopalan 1 , 1 Center for Rheuamatic Diseases,<br />
2<br />
Center for Rheumatic Diseases, Pune, India, 3 Center for<br />
Rheumatic Diseases.<br />
1641. Clinical Features <strong>of</strong> Acute Human Parvovirus B19 in Adults:<br />
What We Could Learn from It? Hideto Oshikawa 1 , Makiko<br />
Yamamoto 2 , Akira Jibatake 2 , Kiyoharu Muranaka 2 , Kazuki<br />
Yoshida 2 , Masako Utsunomiya 2 , Tatsuo Kobayashi 2 , Mitsumasa<br />
Kishimoto 3 and Kazuo Matsui 2 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Kameda Medical Center, Kamogawa City, Chiba, Japan,<br />
2<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Kameda Medical Center, 3 St<br />
Luke’s International Hospital, Japan.<br />
1642. Cytokines in Chikungunya (CHIKV): Storm in a Teacup or Winds<br />
before the Storm. Arvind Chopra 2 and Anuradha Venugopalan 1 ,<br />
1<br />
Center for Rheumatic Disease, Pune, India, 2 Center for<br />
Rheumatic Diseases, Pune, India.<br />
1643. Geographic Distribution <strong>of</strong> Endemic Fungal Infections among<br />
Older <strong>American</strong>s. John W. Baddley 3 , Kevin L. Winthrop 1 ,<br />
Nivedita M. Patkar 3 , Elizabeth Delzell 4 , Fenglong Xie 4 ,<br />
Lang Chen 4 and Jeffrey R. Curtis 2 , 1 Oregon Health Sciences<br />
University, 2 University <strong>of</strong> Alabama - Brimingham, Birmingham,<br />
AL, 3 University <strong>of</strong> Alabama at Birmingham, Birmingham, AL,<br />
4<br />
University <strong>of</strong> Alabama at Birmingham, Birmingham, AL.<br />
1644. Identification <strong>of</strong> Borrelia Burgdorferi in Brazil: The Etiologic<br />
Agent <strong>of</strong> Brazilian Lyme Disease-Like Syndrome (Baggio-<br />
Yoshinari Syndrome). Elenice Mantovani, Roberta G.<br />
Marangoni, Giancarla Gauditano, Virgínia L. N. Bonoldi and<br />
Natalino H. Yoshinari, <strong>Rheumatology</strong> Division, Faculdade de<br />
Medicina da Universidade de São Paulo.<br />
1645. Prevalence, Impact and Risk Factors for Musculoskeletal Pain<br />
among HIV Infected Adults: An Epidemiologic Study. Karen<br />
Walker-Bone 1 , Edwina Lawson 2 , Duncan Churchill 2 , Yvonne<br />
Gilleece 2 , Martin Fisher 2 and Caroline Sabin 3 , 1 Brighton &Sussex<br />
Medical School, Brighton, United Kingdom, 2 Brighton &Sussex<br />
University Hospitals NHS Trust, 3 University <strong>College</strong>, London.<br />
1646. Surrogate Markers <strong>of</strong> B-Cell Non-Hodgkin Lymphoma in<br />
Patients with Hepatitis C Virus-Related Cryoglobulinemia<br />
Vasculitis. Guillaume Geri 2 , Benjamin Terrier 2 , Oren Semoun 1 ,<br />
David Saadoun 2 , Damien Sène 2 , Hélène Merle-Beral 2 , Frédéric<br />
Charlotte 2 , Lucile Musset 2 , Mathieu Resche-Rigon 1 and Patrice<br />
Cacoub 2 , 1 INSERM URMS 717, Paris 7 , Paris, France, 2 Pitié-<br />
Salpetrière Hospital, Paris, France.<br />
1647. The Diagnosis <strong>of</strong> Reactive Arthritis in the Real World and<br />
Factors That Might Contribute to Its Under/Misdiagnosis.<br />
Jenny Lin 2 , Anjali G. Shetty 2 and John D. Carter 1 , 1 Univ <strong>of</strong> South<br />
Florida, Tampa, FL, 2 University <strong>of</strong> South Florida.<br />
1648. The Infectious Risk <strong>of</strong> the Lower Respiratory Tract Is Increased<br />
in Patients with Rheumatic Diseases Treated by Biologic<br />
DMARDs, in Particular in Case <strong>of</strong> Pre-Existing Colonisation.<br />
Guillaume Geri, Sabrina Dadoun, Simon Paternotte, Maxime<br />
Dougados and Laure Gossec, Cochin Hospital, Paris, France.<br />
1649. Usefulness <strong>of</strong> Procalcitonin Measurement in Differentiating<br />
between Activity <strong>of</strong> Systemic Autoimmune Disease and<br />
Bacterial Infection. Olga Sleglova 3 , Helena Dejmkova 4 , Jana<br />
Uhrova 2 and Jaromir Belacek 1 , 1 Department <strong>of</strong> Biostatistics, 1 .<br />
Medical Faculty, Charles University, Prague, Czech Republic,<br />
2<br />
Institute <strong>of</strong> Clinical Biochemistry, Prague, Czech Republic, Czech<br />
Republic, 3 Institute <strong>of</strong> <strong>Rheumatology</strong>, Prague, Czech Republic,<br />
4<br />
Institute <strong>of</strong> <strong>Rheumatology</strong>, Prague, Czech Republic.<br />
246<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
Miscellaneous Rheumatic and Inflammatory Diseases II<br />
1650. Adalimumab Therapy in 18 Patients with Severe Hidradenitis<br />
Suppurativa. Orlando Pompei Fernández 5 , Ricardo Blanco<br />
Alonso 5 , Ignacio Villa 4 , Marcos Gonzalez López 2 , Hector<br />
Fernández LLaca 1 , M. Del Carmen González-Vela 3 , Mario Agudo<br />
Bilbao 6 , Cristina Martinez Dubois 6 , Victor M. Martinez-Taboada 7 ,<br />
M. Enriqueta Peiro Callizo 5 , Jose Luis Peña Salgredo 5 , Alfonso<br />
Fernando Corrales Martinez 5 and Miguel Angel Gonzalez-Gay<br />
Mantecon 5 , 1 Department <strong>of</strong> Dermatology, Hospital Universitario<br />
Marqués de Valdecilla, Santander, Cantabria, 2 Department<br />
<strong>of</strong> Inmunology, Hospital de Liencres, Santander, Cantabria,<br />
3<br />
Department <strong>of</strong> Pathology, Hospital Universitario Marqués de<br />
Valdecilla, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Sierrallana,<br />
5<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Universitario Marqués<br />
de Valdecilla, Santander, Cantabria, Spain, 6 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Hospital Universitario Marqués de Valdecilla,<br />
Santander, Cantabria, 7 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital<br />
Universitario Marqués de Valdecilla, Santander, Spain.<br />
1651. Association <strong>of</strong> Langerhans Cell Histiocytosis with Erdheim-<br />
Chester Disease: How Close Monocyte/Macrophage and<br />
Dendritic Cell Lineages Are? Baptiste Hervier, Frrederic<br />
Charlotte, Olivier Hermine, Antoine Neel, Nicole Brousse,<br />
Aude Rigolet, Christian De gennes, Eric Hachulla, Xavier Girerd,<br />
Antoine Dupuy, Zahir Amoura and Julien Haroche, CHU Pitié<br />
Salpetrière, APHP, Paris, France, French Reference Center for<br />
Lupus.<br />
1652. Blinded Multi-Rater Evaluation <strong>of</strong> Diagnosis and Candidate<br />
Classification Criteria for Polymyalgia Rheumatica (PMR).<br />
ACR – EULAR Study Group for Development <strong>of</strong> Classification<br />
Criteria for PMR. Eric L. Matteson 5 , Marco A. Cimmino 7 , Hilal<br />
Maradit-Kremers 1 , Carlo Salvarani 8 , Michael Schirmer 3 , Wolfgang<br />
A. Schmidt 13 , Maria C. Cid 12 , Christian Dejaco 10 , Pierre Duhaut 20 ,<br />
Zsuzsa Schmidt 14 , Annamaria Iagnocco 18 , Artur Bachta 2 , Carlotta<br />
Nannini 19 , Fabrizio Cantini 19 , Victor Martínez-Taboada 21 ,<br />
Haner Direskeneli 9 , Sibel Z. Aydin 9 , Raashid Luqmani 15 , Colin<br />
Pease 16 , Mehrdad Mazlumzadeh 6 , Kenneth Calamia 4 , Clement<br />
J. Michet 5 , Andy Abril 4 , Neil Gonter 17 , Cynthia S. Crowson 1 ,<br />
Rickey Carter 1 and Bhaskar Dasgupta 11 , 1 Department <strong>of</strong> Health<br />
Sciences Research, Mayo Clinic, Rochester, MN, 2 Department<br />
<strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, WIM CSK MON,<br />
Warszawa, Poland, 3 Department <strong>of</strong> Internal Medicine I, Medical<br />
University Innsbruck, Innsbruck, Austria, 4 Department <strong>of</strong><br />
Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic,<br />
Jacksonville, FL, 5 Department <strong>of</strong> Internal Medicine, Division<br />
<strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic, Rochester, MN, 6 Department<br />
<strong>of</strong> Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic,<br />
Scottsdale, AZ, 7 Department <strong>of</strong> Internal Medicine, University<br />
<strong>of</strong> Genova, Genova, Italy, 8 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Arcispedale S. Maria Nuova, Reggio Emilia, Italy, 9 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Marmara University Medical School, Istanbul,<br />
Turkey, 10 Department <strong>of</strong> <strong>Rheumatology</strong>, Medical University,<br />
Graz, Graz, Austria, 11 Department <strong>of</strong> <strong>Rheumatology</strong>, Southend<br />
University Hospital, Essex, United Kingdom, 12 Department <strong>of</strong><br />
Systemic Autoimmune Hospital Clinic Provincial, Barcelona,<br />
Spain, 13 Immanuel Krankenhaus Berlin: Medical Center for<br />
<strong>Rheumatology</strong> Berlin-Buch Berlin, Berlin, Germany, 14 National<br />
Institute <strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy, Budapest,<br />
Hungary, 15 Nuffield Department <strong>of</strong> Orthopaedics, <strong>Rheumatology</strong><br />
and Musculoskeletal Sciences, Oxford University, Oxford, UK,<br />
16<br />
<strong>Rheumatology</strong> and Rehabilitation Research Unit, University <strong>of</strong><br />
Leeds, Leeds, UK, 17 <strong>Rheumatology</strong> Associates <strong>of</strong> North Jersey,<br />
Teaneck, NJ, 18 <strong>Rheumatology</strong> Unit, Clinica e Terapia Medica<br />
Department, Sapienza Università di Roma, Policlinico Umberto<br />
I, Rome, Italy, 19 <strong>Rheumatology</strong> Unit, Ospedale Misericordia<br />
e Dolce, Prato, Italy, 20 Service de Medecine Interne, Amiens,<br />
France, 21 Servicio de Reumatología, Hospital Universitario<br />
Marques de Valdecilla, Facultad de Medicina, Universidad de<br />
Cantabria, Santander, Spain.<br />
1653. Bone Events in Type 1 Gaucher Disease before and during<br />
Treatment. Jerome Stirnemann 2 , Djazia Heraoui 1 , Corine<br />
Vincent 3 , Olivier Fain 2 , Bruno Fantin 1 , France Mentre 3 and Nadia<br />
Belmatoug 1 , 1 APHP - Referral Center <strong>of</strong> Lysosomal Diseases<br />
(RCLD), Clichy, France, 2 APHP - Referral Center <strong>of</strong> Lysosomal<br />
Diseases (RCLD), Bondy, France, 3 INSERM, Paris, France.<br />
1654. Development <strong>of</strong> Classification Criteria for Polymyalgia<br />
Rheumatica (PMR): Results from an International, Prospective,<br />
Multi-Center Longitudinal Study ACR – EULAR Study Group<br />
for Development <strong>of</strong> Classification Criteria for PMR. Bhaskar<br />
Dasgupta 16 , Marco A. Cimmino 10 , Hilal Maradit-Kremers 3 ,<br />
Wolfgang A. Schmidt 19 , Michael Schirmer 5 , Carlo Salvarani 5 ,<br />
Peter Mandl 20 , Artur Bachta 4 , Maria Cid 17 , Haner Direskeneli 13 ,<br />
Pierluigi Macchioni 11 , Peter V. Balint 1 , Christina Duftner 9 ,<br />
Christian Dejaco 14 , Hanna Slott Jensen 18 , Zsuza Schmidt 20 , Gyula<br />
Poór 20 , Annamaria Iagnocco 24 , Victor Martínez-Taboada 28 ,<br />
Elizabeth Nordborg 26 , Carlotta Nannini 25 , Pierre Duhaut 27 , Nicolò<br />
Pipitone 11 , Georgina Espígol-Frigolé 2 , Sibel Z. Aydin 13 , Khalid<br />
Ahmed 15 , Raashid Luqmani 21 , Brian Hazelman 12 , Colin Pease 22 ,<br />
Richard J. Wakefield 22 , Neil Gonter 23 , Ralph Marcus 23 , Clement<br />
J. Michet 7 , Mehrdad Mazlumzadeh 8 , Andy Abril 6 , Cynthia S.<br />
Crowson 3 and Eric L. Matteson 7 , 13 rd <strong>Rheumatology</strong> Department,<br />
National Institute <strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy,<br />
Budapest, 2 Center for Diagnosis Imaging, Hospital Clínic,<br />
Montserrat del Amo, Barcelona, Spain, 3 Department <strong>of</strong> Health<br />
Sciences Research, Mayo Clinic, Rochester, MN, 4 Department<br />
<strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, WIM CSK MON,<br />
Warszawa, Poland, 5 Department <strong>of</strong> Internal Medicine I, Medical<br />
University Innsbruck, Innsbruck, Austria, 6 Department <strong>of</strong><br />
Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic,<br />
Jacksonville, FL, 7 Department <strong>of</strong> Internal Medicine, Division<br />
<strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic, Rochester, MN, 8 Department<br />
<strong>of</strong> Internal Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Mayo Clinic,<br />
Scottsdale, AZ, 9 Department <strong>of</strong> Internal Medicine, General<br />
Hospital <strong>of</strong> the Elisabethinen, Klagenfurt, Austria, 10 Department<br />
<strong>of</strong> Internal Medicine, University <strong>of</strong> Genova, Genova, Italy,<br />
11<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Arcispedale S. Maria<br />
Nuova, Reggio Emilia, Italy, 12 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Cambridge University, Cambridge, UK, 13 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Marmara University Medical School, Istanbul,<br />
Turkey, 14 Department <strong>of</strong> <strong>Rheumatology</strong>, Medical University,<br />
Graz, Graz, Austria, 15 Department <strong>of</strong> <strong>Rheumatology</strong>, Princess<br />
Alexandra Hospital, Harlow, United Kingdom, 16 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Southend University Hospital, Essex, United<br />
Kingdom, 17 Department <strong>of</strong> Systemic Autoimmune Hospital<br />
Clinic Provincial, Barcelona, Spain, 18 Gent<strong>of</strong>te Hospital,<br />
<strong>Rheumatology</strong> Division, Hellerup, Denmark, 19 Immanuel<br />
Krankenhaus Berlin: Medical Center for <strong>Rheumatology</strong><br />
Berlin-Buch Berlin, Berlin, Germany, 20 National Institute<br />
<strong>of</strong> <strong>Rheumatology</strong> and Physiotherapy, Budapest, Hungary,<br />
21<br />
Nuffield Department <strong>of</strong> Orthopaedics, <strong>Rheumatology</strong> and<br />
Musculoskeletal Sciences, Oxford University, Oxford, UK,<br />
22<br />
<strong>Rheumatology</strong> and Rehabilitation Research Unit, University <strong>of</strong><br />
Leeds, Leeds, UK, 23 <strong>Rheumatology</strong> Associates <strong>of</strong> North Jersey,<br />
Teaneck, NJ, 24 <strong>Rheumatology</strong> Unit, Clinica e Terapia Medica<br />
Department, Sapienza Università di Roma, Policlinico Umberto<br />
I, Rome, Italy, 25 <strong>Rheumatology</strong> Unit, Ospedale Misericordia e<br />
Dolce, Prato, Italy, 26 Sahlgren University Hospital, Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Göteborg, Sweden, 27 Service de Medecine<br />
Interne, Amiens, France, 28 Servicio de Reumatología, Hospital<br />
Universitario Marques de Valdecilla, Facultad de Medicina,<br />
Universidad de Cantabria, Santander, Spain.<br />
2010 Program Book 247
ACR/ARHP Poster Session C<br />
248<br />
1655. Different Diagnostic Criteria in the Diagnosis <strong>of</strong> Polymyalgia<br />
Rheumatica. Samy Zakout and John R. Kirwan, University <strong>of</strong><br />
Bristol, Bristol, United Kingdom.<br />
1656. Diseases Associated with Positive NOD2/CARD15 Gene<br />
Mutations: Blau’s Syndrome Versus an Intermediate Subset<br />
<strong>of</strong> Blau’s Syndrome and Crohn’s Disease. Qingping Yao 4 , Lan<br />
Zhou 3 , Philip Cusumano 2 and Le-Chu Su 1 , 1 The Department<br />
<strong>of</strong> Gastroenterology, Cleveland Clinic, Cleveland, OH, 2 The<br />
Department <strong>of</strong> Internal Medicine, Cleveland Clinic, Cleveland,<br />
OH, 3 The Department <strong>of</strong> Neurology, Cleveland Clinic, Cleveland,<br />
OH, 4 The Department <strong>of</strong> Rheumatic and Immunologic Diseases,<br />
Cleveland Clinic, Cleveland, OH.<br />
1657. Efficacy and Safety <strong>of</strong> Thalidomide on Mucocutaneous<br />
Symptoms: A Systematic Review and Meta-Analysis. Juan A.<br />
Martinez Lopez 3 , Estibaliz Loza 3 , Jesús Maese 3 , Maria Rosario<br />
Rodriguez Moreno 2 , Maria Piedad Rosario Lozano 3 and Loreto<br />
Carmona 1 , 1 Fundación Española Reumatol, Madrid, Spain,<br />
2<br />
Hospital Virgen de las Nieves, Granada, Spain, 3 Sociedad<br />
Española de Reumatología, Madrid, Spain.<br />
1658. Efficacy <strong>of</strong> High Doses <strong>of</strong> Interferon-a-2a (IFNa) in Erdheim-<br />
Chester Disease. Baptiste Hervier, Laurent Arnaud, Bertrand<br />
Wechsler, Zahir Amoura and Julien Haroche, CHU Pitié-<br />
Salpétrière, APHP, Paris France, French Reference Center for<br />
Lupus &Autoimmune Diseases.<br />
1659. Endothelial Anti-Inflammatory Effect <strong>of</strong> alpha2 Adrenergic<br />
Agonists. Ada Herrera 2 , M. Jesús Domínguez 2 , M. Teresa Arce 2 ,<br />
A. Diaz 2 , Manuel Feria 1 and Federico Diaz 2 , 1 Medical School,<br />
Spain, 2 <strong>Rheumatology</strong> Service, Hospital Universitario de<br />
Canarias, Spain.<br />
1660. Erdheim-Chester Disease: Prospective Follow-Up <strong>of</strong> a Single-<br />
Center Cohort <strong>of</strong> 48 Patients Reveals Improved Survival in<br />
Patients Treated with Interferon-alpha. Laurent Arnaud,<br />
Julien Haroche, Baptiste Hervier, Bertrand Wechsler, Nathalie<br />
Costedoat-Chalumeau, Patrice Cacoub, David Saadoun and Zahir<br />
Amoura, Department <strong>of</strong> Internal Medicine, Groupe Hospitalier<br />
Pitié-Salpêtriere, UPMC Univ Paris 6 , AP-HP, 47-83 bd de<br />
l’Hôpital, Paris, France.<br />
1661. Expression <strong>of</strong> Type 1 Interferon Related Proteins and<br />
Plasmacytoid Dendritic Cells in the Lesional Skin <strong>of</strong> Morphea<br />
Patients. Mehran Ghoreishi 1 , Cristián Vera Kellet 2 and Jan Peter<br />
Dutz 1 , 1 Department <strong>of</strong> Dermatology and Skin Science, University<br />
<strong>of</strong> British Columbia, Vancouver, BC, Canada, 2 Department <strong>of</strong><br />
Dermatology, Pontificia Universidad Católica de Chile, Santiago,<br />
Vancouver, BC, Canada.<br />
1662. Idiopathic Retroperitoneal Fibrosis: Clinical Findings in 185<br />
Patients. Tanaz A. Kermani 1 , Cynthia S. Crowson 2 and Harvinder<br />
S. Luthra 1 , 1 Mayo Clinic, Rochester, MN, 2 Mayo Clinic.<br />
1663. IL-1 Blockade for Schnitzler’s Syndrome. Rona M. Smith 1 , Helen<br />
J. Lachmann 2 and David R. W. Jayne 1 , 1 Addenbrooke’s Hospital,<br />
Cambridge, United Kingdom, 2 UK National Amyloidosis Centre,<br />
London.<br />
1664. IL-18 Binding Protein (IL-18BP) Dramatically Improves Liver<br />
Histological Lesions in an Animal Model <strong>of</strong> Macrophage<br />
Activation Syndrome (MAS). Laura Chiossone 3 , Sandra<br />
Audonnet 3 , Karin Mazodier 2 , Marc Dalod 3 , Catherine Farnarier 1 ,<br />
Daniela Novick 5 , Charles A. Dinarello 4 , Eric Vivier 3 and Gilles<br />
Kaplanski 2 , 1 Assiatnce Publique-Hôpitaux de Marseille,<br />
Marseille, France, 2 Assistance Publique-Hôpitaux de Marseille,<br />
Marseille, France, 3 CIML, Marseille, France, 4 University <strong>of</strong><br />
Colorado Health Science, Denver, CO, 5 Weizmann Institute <strong>of</strong><br />
Science, Rehovot, Israel.<br />
2010 Program Book<br />
1665. Is Pamidronate Useful as Very Effective Therapeutic<br />
Intervention in Midtarsal Arthropathy? Mani Nallasivan 2 and<br />
Tim Tait 1 , 1 Diana Princess <strong>of</strong> Wales Hospital Grimsby, Grimsby,<br />
Lincolnshire, United Kingdom, 2 Diana Princess <strong>of</strong> Wales Hospital,<br />
Grimsby, Northern Lincolnshire and Goole Hospital NHS Trust,<br />
Hull, Yorkshire, United Kingdom.<br />
1666. Nonalcoholic Steatohepatitis as a Complication <strong>of</strong> Collagen<br />
Disease. Kae Takagi, Yasushi Kawaguchi, Yuko Ota, Akiko<br />
Tochimoto, Chikako Fukazawa, Takahisa Gono, Yasuhiro<br />
Katsumata, Masako Hara and Hisashi Yamanaka, Tokyo Women’s<br />
Medical University, Tokyo, Japan.<br />
1667. Prevalence <strong>of</strong> Atherosclerotic Risk Factors and the Metabolic<br />
Syndrome in Patients with Chronic Inflammatory Arthritis. Chi<br />
Chiu Mok 2 , Tin Choi Ko 1 , Ling Yin Ho 2 , Ka Lung Yu 2 , Pak To Chan 2<br />
and Chi Hung To 2 , 1 Chinese University Hong Kong, 2 Tuen Mun<br />
Hospital.<br />
1668. Renal Dysfunction Is Associated with Increased Mortality in<br />
Adults with Macrophage Activation Syndrome. Bita Shakoory 3 ,<br />
W. Winn Chatham 3 , Graciela S. Alarcon 1 and Randy Q. Cron 2 ,<br />
1<br />
Oakland, CA, 2 Children’s Hospital <strong>of</strong> Alabama, Birmingham, AL,<br />
3<br />
Univ <strong>of</strong> Alabama-Birmingham, Birmingham, AL.<br />
1669. Retrospective Analysis <strong>of</strong> Relapsing Polychondritis in the US<br />
Department <strong>of</strong> Defense Population. Stephanie D. Mathew,<br />
Daniel F. Battafarano and Michael J. Morris, San Antonio Military<br />
Medical Consortium, Fort Sam Houston, TX.<br />
1670. Retrospective Case Series <strong>of</strong> Single Center Experience <strong>of</strong><br />
Methotrexate and Mycophenolate M<strong>of</strong>etil Monotherapy<br />
for Patients with Non Infectious Posterior, Intermediate and<br />
Panuveitis. Mariam Khan 1 , Careen Lowder 1 and Rula Hajj-Ali 2 ,<br />
1<br />
Cleveland Clinic Foundation, Cleveland, OH, 2 Clevelnad Clinic,<br />
Cleveland, OH.<br />
1671. Rituximab Therapy Is an Effective Approach in Treatment <strong>of</strong><br />
IgG4-Related Systemic Disease. Arezou Khosroshahi 3 , Donald B.<br />
Bloch 2 , Vikram Deshpande 4 and John H. Stone 1 , 1 Massachusetts<br />
General Hospital, Sudbury, MA, 2 Massachusetts General<br />
Hospital, Newton, MA, 3 Massachusetts General Hospital,<br />
Boston, MA, 4 Massachusetts General Hospital.<br />
Pediatric <strong>Rheumatology</strong> - Clinical and Therapeutic Aspects: Pediatric<br />
Rheumatic Diseases II<br />
1672. Anti-CADM-140/MDA5 Antibody Predicts Complication<br />
<strong>of</strong> Interstitial Lung Disease in Japanese Cases <strong>of</strong> Juvenile<br />
Dermatomyositis. Ichiro Kobayashi 1 , Yuka Okura 1 , Yasuhiro<br />
Yamazaki 1 , Shunichiro Takezaki 1 , Masafumi Yamada 1 , Masataka<br />
Kuwana 2 and Tadashi Ariga 1 , 1 Department <strong>of</strong> Pediatrics,<br />
Hokkaido University Graduate School <strong>of</strong> Medicine, Sapporo,<br />
Japan, 2 Keio University School <strong>of</strong> Med, Tokyo, Japan.<br />
1673. Characterization at Diagnosis <strong>of</strong> Children with Microscopic<br />
Polyangiitis (MPA) Defined Uniquely among Patients with<br />
ANCA-Associated Vasculitis (AAV) in a Registry for Children<br />
with Vasculitis (ARChiVe). David A. Cabral 2 , America G.<br />
Uribe 2 , Leslie S. Abramson 37 , Matthew D. Adams 5 , Susanne<br />
M. Benseler 31 , Sarah S. C. Campillo 20 , Peter Chira 30 , B. Anne<br />
Eberhard 28 , Kaleo C. Ede 24 , Aimee O. Hersh 33 , Gloria C. Higgins 21 ,<br />
Adam Huber 15 , Lisa F. Imundo 10 , Rita S. Jerath 11 , Susan Kim 8 ,<br />
Daniel J. Kingsbury 17 , Marisa S. Klein-Gitelman 12 , Suzanne C. Li 16 ,<br />
Daniel J. Lovell 9 , Thomas G. Mason 19 , Deborah K. McCurdy 18 ,<br />
Renee F. Modica 34 , Lakshmi N. Moorthy 27 , Eyal Muscal 1 ,<br />
Kabita Nanda 25 , Lorien A. Nassi 32 , Kathleen M. O’Neil 22 , Egla<br />
C. Rabinovich 14 , Andreas O. Reiff 7 , Margalit E. Rosenkranz 6 ,<br />
Kenneth N. Schikler 35 , Anne M. Stevens 23 , Mary B. Toth 4 , Linda<br />
Wagner-Weiner 13 , Dawn M. Wahezi 3 , Andrew J. White 29 , Amy
ACR/ARHP Poster Session C<br />
L. Woodward 26 , Andrew S. Zeft 36 and ARChiVe Investigators<br />
<strong>of</strong> CARRA, 1 Baylor <strong>College</strong> <strong>of</strong> Medicine, Houston, TX, 2 BC<br />
Children’s Hospital, Vancouver, BC, Canada, 3 Children’s Hospital<br />
at Montefiore, Bronx, NY, 4 Children’s Hospital Med Ctr, Akron,<br />
OH, 5 Children’s Hospital <strong>of</strong> Michigan, Huntington Woods, MI,<br />
6<br />
Children’s Hospital <strong>of</strong> Pittsburgh, Pittsburgh, PA, 7 Childrens<br />
Hosp LA MS 60 , Los Angeles, CA, 8 Childrens Hospital Boston,<br />
Boston, MA, 9 Childrens Hospital Medical Center, Cincinnati,<br />
OH, 10 Childrens Hospital <strong>of</strong> NY, New York, NY, 11 Childrens Med<br />
Ctr Med Schl GA, Augusta, GA, 12 Childrens Mem Hosp/NW<br />
Univ, Chicago, IL, 13 Corner Children’s Hospital, Chicago, IL,<br />
14<br />
Duke University Medical Center, Durham, NC, 15 IWK Health<br />
Centre, Halifax, NS, Canada, 16 Joseph M Sanzari Children’s<br />
Hospital, Short Hills, NJ, 17 Legacy Emanuel Children’s Hosp,<br />
Portland, OR, 18 Mattel Children’s UCLA, Los Angeles, CA,<br />
19<br />
Mayo Clinic Rochester, Rochester, MN, 20 Montreal Children’s<br />
Hospital, Montreal, QC, Canada, 21 Nationwide Childrens Hosp,<br />
Columbus, OH, 22 OU Health Science Center, Oklahoma City, OK,<br />
23<br />
Pediatrics, U. <strong>of</strong> Washington, Seattle, WA, 24 Phoenix Children’s<br />
Hospital, Phoenix, AZ, 25 Rainbow Babies and Children’s<br />
Hospital, Beachwood, OH, 26 Riley Children’s Hospital, Nashville,<br />
TN, 27 Robert Wood Johnson Medical School, Metuchen,<br />
NJ, 28 Schneider Children’s Hospital, New Hyde Park, NY, 29 St<br />
Louis Childrens Hosp, St Louis, MO, 30 Stanford Univ Schl <strong>of</strong><br />
Med, Stanford, CA, 31 The Hospital for Sick Children, Toronto,<br />
ON, Canada, 32 TX Scottish Rite Hosp, Dallas, TX, 33 UCSF, San<br />
Francisco, CA, 34 University <strong>of</strong> Florida, Orlando, FL, 35 University <strong>of</strong><br />
Louisville SOM, Louisville, KY, 36 University <strong>of</strong> Utah, Salt Lake City,<br />
UT, 37 University <strong>of</strong> Vermont, Morrisville, VT.<br />
1674. Clinical and Serological Factors Associated with Lupus Serositis<br />
in Children: Results from the 1000 Canadian Faces Multiethnic<br />
Cohort. America G. Uribe 1 , Jaime Guzman 1 , Ross E. Petty 3 , Lori<br />
B. Tucker 2 , Laura Musyj 1 , Earl D. Silverman 4 , Gaelle Chedeville 7 ,<br />
Adam Huber 5 , Suzanne E. Ramsey 6 and Christine A. Peschken 8 ,<br />
1<br />
BC Children’s Hospital, 2 BC Childrens Hospital, Vancouver, BC,<br />
Canada, 3 BCs Childrens Hosptial, Vancouver, BC, Canada, 4 Hosp<br />
for Sick Children, Toronto, ON, Canada, 5 IWK Health Centre,<br />
Halifax, NS, Canada, 6 IWK Health Ctr, Halifax, NS, Canada,<br />
7<br />
Montreal Children’s Hospital, 8 Univ <strong>of</strong> Manitoba, Winnipeg,<br />
MB, Canada.<br />
1675. Cogan Syndrome: A Rare but Severe Vasculitis in Pediatric<br />
Age. Ilaria Pagnini 3 , Maria Elisabetta Zannin 4 , Marianna Sari 2 ,<br />
Gabriele Simonini 1 , Rolando Cimaz 6 and Francesco Zulian 5 ,<br />
1<br />
Anna Meyer Children’s Hospital, Florence, Italy, 2 Department<br />
<strong>of</strong> Medical and Surgical Specialties, Section <strong>of</strong> Otolaryngology,<br />
University <strong>of</strong> Padua, Italy, 3 Department <strong>of</strong> Pediatrics, University<br />
<strong>of</strong> Florence, Italy, 4 Department <strong>of</strong> Pediatrics, University <strong>of</strong><br />
Padua, Italy, 5 Universita Di Padova, Padova, Italy, 6 University <strong>of</strong><br />
Firenze, Firenze, Italy.<br />
1676. Decreased Vitamin D Levels in Children and Adolescents<br />
with Systemic Lupus Erythematosus. Octavio Augusto Bedin<br />
Peracchi 1 , Regina Viviane Munekata 2 , Maria Teresa Ramos<br />
Ascensão Terreri 2 , Roseli Oselka Sacardo Sarni 2 , Marise Lazaretti 2<br />
and Maria Odete Esteves Hilario 2 , 1 Universidade Federal de São<br />
Paulo, São Paulo, Brazil, 2 Universidade Federal de São Paulo,<br />
Brazil.<br />
1677. Does Atorvastatin Reduce Progression <strong>of</strong> Carotid Intimal<br />
Medial Thickening (CIMT) in Childhood SLE? Results from the<br />
Atherosclerosis Prevention in Pediatric Lupus (APPLE) Trial: A<br />
Multicenter, Randomized, Double-Blind Placebo-Controlled<br />
Study. Laura E. Schanberg 3 , Christy I. Sandborg 4 , Huiman X.<br />
Barnhart 3 , Stacy P. Ardoin 2 , Eric Yow 3 , Gregory W. Evans 5 , Kelly<br />
L. Mieszkalski 3 , Normal T. Ilowite 2 , Anne Eberhard 2 , Lisa F.<br />
Imundo 1 , Yukiko Kimura 2 , Emily Von Scheven 2 , Earl Silverman 2 ,<br />
Suzanne L. Bowyer 2 , Lynn Punaro 2 , Nora G. Singer 2 , David D.<br />
Sherry 2 , Deborah McCurdy 2 , Marisa Klein-Gittelman 2 , Carol<br />
A. Wallace 2 , Richard Silver 2 , Linda Wagner-Weiner 2 , Gloria C.<br />
Higgins 2 , Hermine I. Brunner 2 , Lawrence Jung 2 , Jennifer B. Soep 2 ,<br />
Ann Reed 2 , Charles Tegler 6 and APPLE Investigators 2 , 1 Childhood<br />
Arthitis and <strong>Rheumatology</strong> Research Alliance, New York, NY,<br />
2<br />
Childhood Arthritis and <strong>Rheumatology</strong> Research Alliance,<br />
CARRA, 3 Duke Univ Medical Center, Durham, NC, 4 Stanford<br />
Medical Center, Stanford, CA, 5 Wake Forest Univ, 6 Wake Forest<br />
University.<br />
1678. Environmental Factors Preceding Illness Onset Differ<br />
in Phenotypes <strong>of</strong> the Juvenile Idiopathic Inflammatory<br />
Myopathies. Lisa G. Rider 11 , Lan Wu 12 , Gulnara Mamyrova 4 ,<br />
David D. Sherry 13 , Maria D. Perez 9 , Carol A. Wallace 14 , Lisa F.<br />
Imundo 6 , Catherine A. Bingham 3 , Lawrence S. Zemel 1 , Carol B.<br />
Lindsley 8 , Rafael F. Rivas-Chacon 7 , Patience H. White 11 , Robert<br />
Rennebohm 12 , Michael Henrickson 10 , Ira N. Targ<strong>of</strong>f 5 , Frederick<br />
W. Miller 2 and Childhood Myositis Heterogeneity Study<br />
Group 12 , 1 Connecticut Childrens Med Ctr, Hartford, CT, 2 National<br />
Institute <strong>of</strong> Environmental Health Sciences, NIH, Kennsington,<br />
MD, 3 NIEHS, NIH, Zionsville, PA, 4 NIEHS, NIH, Washington, DC,<br />
5<br />
NIEHS, NIH, Oklahoma City, OK, 6 NIEHS, NIH, New York, NY,<br />
7<br />
NIEHS, NIH, Miami, FL, 8 NIEHS, NIH, Kansas City, KS, 9 NIEHS,<br />
NIH, Houston, TX, 10 NIEHS, NIH, Cincinnati, OH, 11 NIEHS, NIH,<br />
Bethesda, MD, 12 NIEHS, NIH, 13 The Children’s Hospital <strong>of</strong><br />
Philadelphia, Philadelphia, PA, 14 University <strong>of</strong> Washington and<br />
Seattle Childerns’s Hospital, Seattle, WA.<br />
1679. High Prevalence <strong>of</strong> Inflammatory Myositis in Patients with<br />
Pediatric Systemic Lupus Erythematosus in a Southeastern<br />
US State. Jessica L. Record 3 , Timothy Beukelman 2 and Randy<br />
Q. Cron 1 , 1 Children’s Hospital <strong>of</strong> Alabama, Birmingham,<br />
AL, 2 University <strong>of</strong> Alabama-Birmingham, Birmingham, AL,<br />
3<br />
University <strong>of</strong> Alabama-Birmingham, Birmingham, AL.<br />
1680. Infliximab for the Treatment <strong>of</strong> Intravenous Immunoglobulin<br />
Resistant Kawasaki Disease in Chinese Children. F. Q. Wu 1 ,<br />
X. M. Hu 2 , Y. L. Zhang 2 and L. P. Yang 2 , 1 Capital Institute <strong>of</strong><br />
Pediatrics, Beijing, China, 2 Capital Institute <strong>of</strong> Pediatrics.<br />
1681. Juvenile Fibromyalgia: Responsiveness <strong>of</strong> Tools, Greatest Areas<br />
<strong>of</strong> Impairment, and Impact <strong>of</strong> an Aerobic Exercise Program.<br />
Nadia J. C. Luca 2 , Brian M. Feldman 3 , Larisa Tshantshapanyan 4 ,<br />
Lusine Abrahamyan 4 , Samantha Stephens 4 , Nicolette Bradley 4 ,<br />
Jane Schneiderman 4 , Virginia Wright 1 and Shirley M. L. Tse 3 ,<br />
1<br />
Bloorview Kids Rehab, Bloorview Research Institute, 2 Hospital<br />
for Sick Children, Toronto, ON, Canada, 3 The Hospital for Sick<br />
Children, Toronto, ON, Canada, 4 The Hospital for Sick Children.<br />
1682. Juvenile Localized Scleroderma <strong>of</strong> the Face: A Neuro-<br />
Cutaneous Disease? Francesco Zulian 2 , Mattia Parolin 3 , Fabio<br />
Vittadello 3 , Milena Calderone 3 , Giorgia Martini 3 and Susanne<br />
Ullman 1 , 1 Bispebjerg Hospital, Copenhagen, Denmark,<br />
2<br />
University <strong>of</strong> Padua, Padova, Italy, 3 University <strong>of</strong> Padua.<br />
1683. Localized Scleroderma Therapy: When Would Be a Good Time<br />
To Stop? Thaschawee Arkachaisri 1 and Kathryn S. Torok 2 , 1 KK<br />
Women’s and Children’s Hosp, Singapore, Singapore, 2 Univ <strong>of</strong><br />
Pittsburgh Med Ctr, Pittsburgh, PA.<br />
1684. Longitudinal Study on Growth Failure and Height Deflection<br />
in Juvenile Systemic Lupus Erythematosus (JSLE): The Result<br />
<strong>of</strong> a Prospective Multicentre PRINTO Study. Marite Rygg 3 ,<br />
Angela Pistorio 3 , Angelo Ravelli 3 , Mohamad Maghnie 3 , Natascia<br />
Di Iorgi 3 , Erkan Demirkaya 3 , Srdjan Pasic 3 , Huri Ozdogan 3 ,<br />
Brigitte Bader-Meunier 3 , Carlos Henrique M. Da Silva 3 , Liora<br />
Harel 3 , Maria Rosa Roldan Molina 3 , Helena Canhao 3 , Johannes<br />
Roth 3 , Carine Wouters 3 , Judith Barash 3 , Rym Hajri Ben Ammar 3 ,<br />
Christina Dracou 3 , Sylvie Gandon-Laloum 3 , Alberto Martini 2 and<br />
Nicolino Ruperto 1 , 1 IRCCS G. Gaslini/Università degli Studi di<br />
Genova, Genova, Italy, 2 IRCCS G. Gaslini/Università degli Studi di<br />
Genova, 3 PRINTO.<br />
2010 Program Book 249
ACR/ARHP Poster Session C<br />
250<br />
1685. Long-Term Follow Up <strong>of</strong> Hyper IgD Syndrome: A National<br />
Multicentre Study. Silvia Federici 8 , Alberto Tommasini 6 ,<br />
Antonella Meini 7 , Giuseppina Calcagno 5 , Francesco Zulian 2 ,<br />
Rita Consolini 3 , Martina Finetti 8 , Luciana Breda 1 , Roberta<br />
Caorsi 8 , Romina Gallizzi 5 , Maria Alessio 4 , Alberto Martini 8 and<br />
Marco Gattorno 8 , 1 Clinica Pediatrica, Divisione Reumatologia<br />
Pediatrica, Ospedale Policlinico di Chieti, 2 Dipartimento A.I.<br />
di Pediatria, Università di Padova, 3 Dipartimento di Medicina<br />
della Procreazione e dell’Eta’ Evolutiva, Università di Pisa,<br />
Italy, 4 Dipartimento di Pediatria, Università Federico II, Napoli,<br />
Italy, 5 Dipartimento di Scienze Pediatriche, AOU “G. Martino”,<br />
Messina, 6 IRCCS Burlo Gar<strong>of</strong>olo, Trieste, 7 Unità di Immunologia e<br />
Reumatologia Pediatrica, Spedali Civili, Brescia, 8 UO Pediatria II<br />
Istituto G. Gaslini, Genova, Italy.<br />
1686. Measuring Changes in Calcifications in Juvenile<br />
Dermatomyositis (JDM) Using Single Slice Computerized<br />
Tomography (CT). Maria F. Ibarra 5 , Cynthia Rigsby 3 , Gabrielle<br />
Morgan 2 , Deli Wang 1 and Lauren M. Pachman 4 , 1 Children’s<br />
Memorial Research Center’s Biostatistics Core, Chicago, IL,<br />
2<br />
Clinical Immunology, Children’s Memorial Research Center<br />
(CMRC), Chicago, IL, 3 Division <strong>of</strong> Radiology, Children’s Memorial<br />
Hospital (CMH), Feinberg School <strong>of</strong> Medicine, Northwestern<br />
University, Chicago, IL, 4 Division <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />
Immunology, Children’s Memorial Research Center (CMRC),<br />
Feinberg School <strong>of</strong> Medicine, Northwestern University, Chicago,<br />
IL, 5 Division <strong>of</strong> <strong>Rheumatology</strong>, Children’s Memorial Hospital<br />
(CMH), Feinberg School <strong>of</strong> Medicine, Northwestern University,<br />
Chicago, IL.<br />
1687. Odontostomatologic Involvement in Juvenile Localized<br />
Scleroderma <strong>of</strong> the Face. Sabina Trainito 5 , Troels Herlin 4 ,<br />
Thomas Klit Pedersen 3 , Giorgia Martini, Chiara Scibetta 2 ,<br />
Giuseppe Fioretti, Vittorio Favero, Stefano Puggina 6 , Lorenzo<br />
Favero and Francesco Zulian 1 , 1 Padova, Italy, 2 Department<br />
<strong>of</strong> Dentistry, Gnatology Unit, University <strong>of</strong> Padova, Italy,<br />
3<br />
Department <strong>of</strong> Orthodontics and Radiology, University <strong>of</strong><br />
Aarhus, Denmark, 4 Department <strong>of</strong> Pediatrics, <strong>Rheumatology</strong><br />
Unit, University <strong>of</strong> Aarhus, Denmark, 5 Department <strong>of</strong> Pediatrics,<br />
<strong>Rheumatology</strong> Unit, University <strong>of</strong> Padova, Padova, Italy,<br />
6<br />
Radiology Institute, University <strong>of</strong> Padova, Italy.<br />
1688. Preliminary Criteria for Global Disease Flares in Juvenile<br />
Systemic Lupus Erythematosus (jSLE). Rina Mina 8 , Michael<br />
Beresford 12 , B. Anne Eberhard 13 , Edward H. Giannini 3 , Deborah<br />
M. Levy 15 , Clarissa Pilkington 10 , Marilynn G. Punaro 14 , Angelo<br />
Ravelli 11 , Andreas O. Reiff 2 , Claudia Saad-Magalhaes 16 , Laura E.<br />
Schanberg 9 , Lori B. Tucker 1 , Marisa S. Klein-Gitelman 4 , Shannen<br />
L. Nelson 6 , Jamie Eaton 5 , Jun Ying 17 and Hermine I. Brunner 7 ,<br />
1<br />
BC Childrens Hospital, Vancouver, BC, Canada, 2 Childrens Hosp<br />
LA MS 60 , Los Angeles, CA, 3 Childrens Hosp Med Ctr, Cincinnati,<br />
OH, 4 Childrens Mem Hosp/NW Univ, Chicago, IL, 5 Cincinnati<br />
Children’s Hospital, 6 Cincinnati Children’s Hospital, Cincinnati,<br />
OH, 7 Cincinnati Children’s Hospital Medical Ctr, Cincinnati,<br />
OH, 8 Cincinnati Children’s Med Ctr, Cincinnati, OH, 9 Duke Univ<br />
Medical Center, Durham, NC, 10 Great Ormond Street and<br />
University <strong>College</strong> London Hospitals, 11 IRCCS G Gaslini, 12 Royal<br />
Liverpool Children’s Hospital, 13 Schneider Children’s Hospital,<br />
New Hyde Park, NY, 14 Texas Scottish Rite Hospital for Children,<br />
Dallas, TX, 15 The Hospital for Sick Children, Toronto, ON, Canada,<br />
16<br />
UNESP, 17 University <strong>of</strong> Cincinnati.<br />
2010 Program Book<br />
1689. Preliminary Findings <strong>of</strong> Functional Magnetic Resonance<br />
Imaging (fMRI) Assessments <strong>of</strong> Specific Cognitive Domains<br />
in Childhood-Onset Systemic Lupus Erythematosus (cSLE)<br />
Patients and Best-Friend Controls. Blair Dina 3 , Aimee Baker 4 ,<br />
Anna Carmela Sagcal-Gironella 4 , Marisa Klein-Gitelman 3 , Frank<br />
Zelko 5 , Dean Beebe 1 , Darren Gitelman 6 , Mark DiFrancesco 2 and<br />
Hermine Brunner 4 , 1 CCHMC Division <strong>of</strong> Behavioral Medicine and<br />
Child Psychology, 2 CCHMC Neuroimaging Research Consortium,<br />
3<br />
Children’s Memorial Hospital (CMH) Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
4<br />
Cincinnati Children’s Hospital Medical Center (CCHMC), Division<br />
<strong>of</strong> <strong>Rheumatology</strong>, 5 CMH Division <strong>of</strong> Child and Adolescent<br />
Psychiatry, 6 Northwestern University, Feinberg School <strong>of</strong><br />
Medicine.<br />
1690. Pre-Pubertal Onset Systemic Lupus Erythematosus in Girls:<br />
Clinical and Serologic Manifestations Differ from Post-Pubertal<br />
Onset SLE. Kathleen M. O’Neil 4 , Lauren M. Kickingbird 7 , Andrew<br />
S. Zeft 8 , Hermine Brunner 2 , Marilynn G. Punaro 5 , Barry L.<br />
Myones 1 , Suzanne C. Li 3 and Tracey Wright 6 , 1 Baylor <strong>College</strong><br />
<strong>of</strong> Medicine, Houston, TX, 2 Cincinnati Child Hosp Med Ctr,<br />
Cincinnati, OH, 3 Hackensack University Medical Center, Short<br />
Hills, NJ, 4 OU Health Science Center, Oklahoma City, OK, 5 Texas<br />
Scottish Rite Hospital, Dallas, TX, 6 Univ <strong>of</strong> TX Southwestern,<br />
Dallas, TX, 7 University <strong>of</strong> Oklahoma Health Sciences Center,<br />
Oklahoma City, OK, 8 University <strong>of</strong> Utah, Salt Lake City, UT.<br />
1691. Relative Performance <strong>of</strong> Two Validated Classification Systems<br />
for Wegener’s Granulomatosis among Patients with ANCA-<br />
Associated Vasculitis (AAV) in a Registry for Children with<br />
Vasculitis: e-entry (ARChiVe). America G. Uribe 3 , David A.<br />
Cabral 3 , Kimberly Morishita 2 , Leslie S. Abramson 38 , Matthew<br />
D. Adams 6 , Kevin W. Baszis 30 , Susanne M. Benseler 32 , Sarah<br />
S. C. Campillo 22 , Peter Chira 31 , B. Anne Eberhard 29 , Kaleo C.<br />
Ede 26 , Aimee O. Hersh 34 , Gloria C. Higgins 23 , Lisa F. Imundo 10 ,<br />
Rita S. Jerath 12 , Susan Kim 8 , Daniel J. Kingsbury 18 , Marisa S.<br />
Klein-Gitelman 13 , Suzanne C. Li 17 , Daniel J. Lovell 9 , Thomas G.<br />
Mason 20 , Deborah K. McCurdy 19 , Renee F. Modica 35 , Lakshmi N.<br />
Moorthy 28 , Eyal Muscal 1 , Lorien A. Nassi 33 , Kathleen M. O’Neil 24 ,<br />
Egla C. Rabinovich 15 , Suzanne E. Ramsey 16 , Andreas O. Reiff 7 ,<br />
Margalit E. Rosenkranz 11 , Kenneth N. Schikler 36 , Nora G. Singer 21 ,<br />
Anne M. Stevens 25 , Mary B. Toth 5 , Linda Wagner-Weiner 14 , Dawn<br />
M. Wahezi 4 , Amy L. Woodward 27 , Andrew S. Zeft 37 and ARChiVe<br />
Investigators <strong>of</strong> CARRA, 1 Baylor <strong>College</strong> <strong>of</strong> Medicine, Houston,<br />
TX, 2 BC Children’s Hospital, 3 BC Children’s Hospital, Vancouver,<br />
BC, Canada, 4 Children’s Hospital at Montefiore, Bronx, NY,<br />
5<br />
Children’s Hospital Med Ctr, Akron, OH, 6 Children’s Hospital<br />
<strong>of</strong> Michigan, Huntington Woods, MI, 7 Childrens Hosp LA MS 60 ,<br />
Los Angeles, CA, 8 Childrens Hospital Boston, Boston, MA,<br />
9<br />
Childrens Hospital Medical Center, Cincinnati, OH, 10 Childrens<br />
Hospital <strong>of</strong> NY, New York, NY, 11 Childrens Hospital <strong>of</strong> Pittsburgh,<br />
Pittsburgh, PA, 12 Childrens Med Ctr Med Schl GA, Augusta, GA,<br />
13<br />
Childrens Mem Hosp/NW Univ, Chicago, IL, 14 Corner Children’s<br />
Hospital, Chicago, IL, 15 Duke University Medical Center, Durham,<br />
NC, 16 IWK Health Ctr, Halifax, NS, Canada, 17 Joseph M Sanzari<br />
Children’s Hospital, Short Hills, NJ, 18 Legacy Emanuel Children’s<br />
Hosp, Portland, OR, 19 Mattel Children’s UCLA, Los Angeles, CA,<br />
20<br />
Mayo Clinic Rochester, Rochester, MN, 21 MetroHealth Medical<br />
Center, Cleveland, OH, 22 Montreal Children’s Hospital, Montreal,<br />
QC, Canada, 23 Nationwide Childrens Hosp, Columbus, OH, 24 OU<br />
Health Science Center, Oklahoma City, OK, 25 Pediatrics, U. <strong>of</strong><br />
Washington, Seattle, WA, 26 Phoenix Children’s Hospital, Phoenix,<br />
AZ, 27 Riley Children’s Hospital, Nashville, TN, 28 Robert Wood<br />
Johnson Medical School, Metuchen, NJ, 29 Schneider Children’s<br />
Hospital, New Hyde Park, NY, 30 St. Louis Children’s Hospital,<br />
St Louis, MO, 31 Stanford Univ Schl <strong>of</strong> Med, Stanford, CA, 32 The<br />
Hospital for Sick Children, Toronto, ON, Canada, 33 TX Scottish<br />
Rite Hosp, Dallas, TX, 34 UCSF, San Francisco, CA, 35 University <strong>of</strong><br />
Florida, Orlando, FL, 36 University <strong>of</strong> Louisville SOM, Louisville, KY,<br />
37<br />
University <strong>of</strong> Utah, Salt Lake City, UT, 38 University <strong>of</strong> Vermont,<br />
Morrisville, VT.
ACR/ARHP Poster Session C<br />
1692. Resistance to Annexin A5 Anticoagulant Activity in<br />
Children with Rheumatic Disease Correlates with Persistent<br />
Antiphospholipid Antibodies and Thrombosis. Dawn M.<br />
Wahezi 4 , Jacob H. Rand 2 , Swapnil Rajpathak 3 and Norman<br />
T. Ilowite 1 , 1 Children’s Hospital Montefiore, Bronx, NY,<br />
2<br />
Department <strong>of</strong> Pathology, Hematology Laboratories,<br />
Montefiore Medical Center, Bronx, NY, 3 Departments <strong>of</strong><br />
Medicine, Epidemiology and Population Health, Albert Einstein<br />
<strong>College</strong> <strong>of</strong> Medicine, 4 Division <strong>of</strong> Pediatric <strong>Rheumatology</strong>,<br />
Children’s Hospital at Montefiore, Bronx, NY.<br />
1693. Safety and Efficiency <strong>of</strong> Rituximab in Juvenile<br />
Dermatomyositis: A Series <strong>of</strong> Eight Cases from the French AIR<br />
Registry. Brigitte Bader-Meunier 3 , Helene Decaluwe 5 , Pierre<br />
Quartier 3 , Albert Faye 4 , Vincent Guigonis 1 , Anne Pagnier 2 ,<br />
Christine Barnerias 3 , Jacques E. Gottenberg 6 and Christine<br />
Bodemer 3 , 1 Dupuytren Hospital, 2 Grenoble Hospital, 3 Necker<br />
Hospital, 4 Robert Debre Hospital, 5 Sainte Justine Hospital,<br />
6<br />
Strasbourg Hospitals, Strasbourg, France.<br />
1694. Safety and Immunogenicity <strong>of</strong> Influenza Vaccine (FluVac) in<br />
Patients with Juvenile Systemic Lupus Erythematosus (JSLE).<br />
Luciana M. de Carvalho 2 , Rodrigo V. D. Silvestre 1 , Wyller A.<br />
Mello 1 and Virginia P. L. Ferriani 2 , 1 Evandro Chagas Institute<br />
(WHO National Influenza Center), Ananindeua, Brazil, 2 School<br />
<strong>of</strong> Medicine <strong>of</strong> Ribeirão Preto, University <strong>of</strong> São Paulo, Ribeirão<br />
Preto, Brazil.<br />
1695. Serum Tumor Necrosis Factor alfa (TNFα) Is Associated with<br />
Disease Activity in Juvenil Systemic Lupus Erythematosus<br />
(jSLE). Mariana Postal, Karina Pereira, Karina Peliçari, Barbara<br />
Longhi, Roberto Marini, Lilian T. L. Costallat and Simone<br />
Appenzeller, State University <strong>of</strong> Campinas.<br />
1696. Study <strong>of</strong> the Growth and Body Mass Index (BMI) <strong>of</strong> 86<br />
Children with Familial Mediterranean Fever (FMF): Results <strong>of</strong><br />
the French Referral Centre for Auto-Inflammatory Diseases<br />
(CeReMAI). Aurelie Klein 1 , Alexia Letierce 1 , Anuela Kondi 1 ,<br />
Veronique Hentgen 2 , Isabelle Kone-Paut 1 and Severine<br />
Guillaume-Czitrom 1 , 1 Bicetre University Hospital, Le Kremlin<br />
Bicetre, France, 2 Versailles Hospital, Versailles, France.<br />
1697. The Disease Presentation and Outcome in Juvenile Behcet’s<br />
Syndrome. Emire Seyahi 3 , Huri Ozdogan 3 , Yilmaz Ozyazgan 2 ,<br />
Serdal Ugurlu 3 , Yesim Ozguler 1 , Gulen Hatemi 3 , Hasan Yazici 3<br />
and Sebahattin Yurdakul 3 , 1 Cerrahpasa Medical Faculty,<br />
Internal Medicine Department, 2 Cerrahpasa Medical Faculty,<br />
Ophtalmology Department, 3 Cerrahpasa Medical Faculty,<br />
<strong>Rheumatology</strong> Department.<br />
1698. The Role <strong>of</strong> Montelukast in the Management <strong>of</strong><br />
Hyperimmunoglobulinemia D with Periodic Fever Syndrome<br />
(HIDS). Donald P. Goldsmith 2 , Karyl S. Barron 1 , Anne Jones 1 ,<br />
Dawn Chapelle 1 , Beverly Barham 1 , Robert Lembo 1 , Eric Hanson 1 ,<br />
Amanda Ombrello 1 , Deborah Stone 1 and Daniel L. Kastner 3 ,<br />
1<br />
National Institutes <strong>of</strong> Health, Bethesda, MD, 2 National<br />
Institutes <strong>of</strong> Health, Drexel University <strong>College</strong> <strong>of</strong> Medicine,<br />
Philadelphia, PA, 3 NIAMS, NIH, Bethesda, MD.<br />
1699. The Use <strong>of</strong> Lenalidomide for Cutaneous Manifestations <strong>of</strong> SLE.<br />
Eveline Wu, Laura E. Schanberg, Heather VanMater and Egla C.<br />
Rabinovich, Duke University Medical Center, Durham, NC.<br />
1700. Therapeutic Approaches for the Treatment <strong>of</strong> Active Juvenile<br />
Dermatomyositis: An International Multicenter Study. Rachana<br />
Hasija 3 , Angela Pistorio 3 , Angelo Ravelli 3 , Erkan Demirkaya 3 , Raju<br />
Khubchandani 3 , Dinara Guseinova 3 , Clara Malattia 3 , Carmen<br />
De Cunto 3 , Tomas Brent Graham 3 , Kathleen Haines 3 , Christian<br />
Huemer 3 , Yukiko Kimura 3 , Harald Mangge 3 , Silvana Martino 3 ,<br />
Carlo Minetti 3 , Ellen Berit Nordal 3 , Pierre Philippet 3 , Manuel<br />
Salgado 3 , Alberto Martini 2 and Nicolino Ruperto 1 , 1 IRCCS G.<br />
Gaslini/Università degli Studi di Genova, Genova, Italy, 2 IRCCS G.<br />
Gaslini/Università degli Studi di Genova, 3 PRINTO.<br />
1701. Towards Defining Clinical Remission in Juvenile Systemic Lupus<br />
Erythematosus (jSLE). Rina Mina 5 , Laura E. Schanberg 6 , B. Anne<br />
Eberhard 14 , Marisa S. Klein-Gitelman 3 , Gloria C. Higgins 12 , Karen<br />
Onel 17 , Nora G. Singer 11 , Kathleen M. O’Neil 13 , Lori B. Tucker 1 ,<br />
Lisa F. Imundo 2 , Emily Von Scheven 16 , Shannen L. Nelson 4 , Frank<br />
Dressler 10 , Ruben Cuttica 7 , Claudia Saad Magalhães 15 , Angelo<br />
Ravelli 9 , Alberto Martini 8 and Hermine I. Brunner 5 , 1 BC Childrens<br />
Hospital, Vancouver, BC, Canada, 2 Childrens Hospital <strong>of</strong> NY, New<br />
York, NY, 3 Childrens Mem Hosp/NW Univ, Chicago, IL, 4 Cincinnati<br />
Children’s Hospital, Cincinnati, OH, 5 Cincinnati Children’s Med<br />
Ctr, Cincinnati, OH, 6 Duke Univ Medical Center, Durham, NC,<br />
7<br />
Hospital General de Ninos Pedro de Elizalde, Buenos Aires,<br />
Argentina, 8 IRCCS G Gaslini, Genova, Italy, 9 IRCCS G Gaslini,<br />
10<br />
Medizinische Hochschule, Hannover, Germany, 11 MetroHealth<br />
Medical Center, Cleveland, OH, 12 Nationwide Childrens Hosp,<br />
Columbus, OH, 13 OU Health Science Center, Oklahoma City, OK,<br />
14<br />
Schneider Children’s Hospital, New Hyde Park, NY, 15 UNESP,<br />
16<br />
Univ <strong>of</strong> Calif San Francisco, San Francisco, CA, 17 Univ <strong>of</strong><br />
Chicago, Chicago, IL.<br />
1702. Towards the Development <strong>of</strong> Standardized Treatment<br />
Protocols for Proliferative Nephritis in Juvenile Systemic Lupus<br />
Erythematosus (jSLE). Rina Mina 6 , Hermine Brunner 5 , B. Anne<br />
Eberhard 12 , Marilynn G. Punaro 14 , Stacy P. Ardoin 10 , Marisa S.<br />
Klein-Gitelman 4 , Joyce J. Hsu 13 , Lakshmi N. Moorthy 11 , Linda<br />
Wagner-Weiner 8 , Eyal Muscal 1 , Suhas M. Radhakrishna 2 , Jenny<br />
Palter 9 , Laura Schanberg 7 , Carol A. Wallace 16 , Norman T. Ilowite 3 ,<br />
Emily Von Scheven 15 and for the CARRA Lupus Disease-Specific<br />
Group, 1 Baylor <strong>College</strong> <strong>of</strong> Medicine, Houston, TX, 2 Children’s<br />
Hospital Los Angeles, Los Angeles, CA, 3 Children’s Hospital<br />
Montefiore, Bronx, NY, 4 Childrens Mem Hosp/NW Univ, Chicago,<br />
IL, 5 Cincinnati Child Hosp Med Ctr, Cincinnati, OH, 6 Cincinnati<br />
Children’s Med Ctr, Cincinnati, OH, 7 Duke Medical Center,<br />
Durham, NC, 8 La Rabida Children’s Hospital, Chicago, IL, 9 Lupus<br />
Foundation, 10 Ohio State University, Columbus, OH, 11 Robert<br />
W Johnson University, Metuchen, NJ, 12 Schneider Children’s<br />
Hospital, New Hyde Park, NY, 13 Stanford University, Stanford,<br />
CA, 14 Texas Scottish Rite Hospital for Children, Dallas, TX,<br />
15<br />
Univ <strong>of</strong> Calif San Francisco, San Francisco, CA, 16 University <strong>of</strong><br />
Washington and Seattle Childerns’s Hospital, Seattle, WA.<br />
1703. Trends in Incidence and Drug Therapy <strong>of</strong> Complex Regional<br />
Pain Syndrome in Children’s Hospitals across the U.S. Cara<br />
M. H<strong>of</strong>fart 1 , Pamela F. Weiss 2 , Andrew J. Klink 2 , D. D. Sherry 2<br />
and Chris Feudtner 2 , 1 The Children’s Hospital <strong>of</strong> Philadelphia,<br />
Philadelphia, PA, 2 The Children’s Hospital <strong>of</strong> Philadelphia.<br />
1704. Update on the Juvenile Systemic Sclerosis Inception Cohort.<br />
Ivan Foeldvari 2 , Angela Wierk 1 , Claudie Len 8 , Maria Martha<br />
Katsicas 4 , Avcin Tadey 6 , Till Kallinich 7 , Isabelll Kone-Paut 9 , Kirsten<br />
Minden 7 , Luc Mouthon 10 , Juergen Brunner 5 and Yuoef Uziel 3 ,<br />
1<br />
Hamburger Zentrum Für Kinder- und Jugenrheumatologie,<br />
Hamburg, Germany, 2 Hamburger Zentrum Fuer Kinder- und<br />
Jugendrheumatologie, Hamburg, Germany, 3 Universitiy<br />
Childrens Hospital, Israel, 4 Universitiy Childrens Hosptial, Brazil,<br />
5<br />
Universitiy Childrens Hosptial, Austria, 6 University Childrens<br />
Hospital, Slovenia, 7 University Childrens Hospital, Germany,<br />
8<br />
University Childrens Hospital, Brazil, 9 University Childrens<br />
Hosptial, France, 10 University Hospital, France.<br />
1705. Validation <strong>of</strong> Birmingham Vasculitis Activity Score in Childhood<br />
Vasculitis. Erkan Demirkaya 1 , Seza Ozen 3 , Angela Pistorio 3 ,<br />
Angelo Ravelli 3 , Rachana Hasija 3 , Raju Khubchandani 3 , Salvatore<br />
Scarpato 3 , Michel Fischbach 3 , Nicolae Iagaru 3 , Srdjan Pasic 3 , Esra<br />
Baskin 3 , Frank Dressler 3 , Marion A. J. van Rossum 3 , Julia García-<br />
Consuegra 3 , Maria Teresa Apaz 3 , Maka Ioseliani 3 , Henryka<br />
Mazur-Zielinska 3 , Alberto Martini 2 , Roberta Galasso 3 , Nicolino<br />
Ruperto 2 and Pavla Dolezalova 3 , 1 IRCCS G. Gaslini, Genova, Italy,<br />
2<br />
IRCCS G. Gaslini/Università degli Studi di Genova, 3 PRINTO.<br />
2010 Program Book 251
ACR/ARHP Poster Session C<br />
1706. Validation <strong>of</strong> the Newly Developed Pediatric Criteria for<br />
the Diagnosis <strong>of</strong> Familiar Mediterranean Fever in a Large<br />
Pediatric Cohort <strong>of</strong> Western European Children with Periodic<br />
Fever. Silvia Federici 7 , Giuseppina Calcagno 5 , Martina Finetti 7 ,<br />
Antonella Meini 6 , Agata Vitale 5 , Marco Cattalini 6 , Roberta<br />
Caorsi 7 , Francesco Zulian 1 , Alberto Tommasini 3 , Maurizia Baldi 2 ,<br />
Joost Frenkel 8 , Isabella Ceccherini 4 , Alberto Martini 7 and Marco<br />
Gattorno 7 , 1 Dipartimento A.I. di Pediatria, University <strong>of</strong> Padua,<br />
2<br />
Dipartmento di Genetica Umana, Ospedale Galliera, Genoa,<br />
3<br />
IRCCS Burlo Gar<strong>of</strong>olo, Trieste, 4 Lab Genetica Molecolare Istituto<br />
G. Gaslini, Genoa, Italy, 5 Sezione di Reumatologia Pediatrica,<br />
Dipartimento di Scienze Pediatriche, AOU “G. Martino”,<br />
Messina, 6 Unità di Immunologia e Reumatologia Pediatrica,<br />
Spedali Civili, Brescia, 7 UO Pediatria II Istituto G. Gaslini, Genoa,<br />
Italy, 8 Wilhelmina Children’s Hospital, Utrecht, The Netherlands.<br />
Rheumatoid Arthritis - Animal Models: Pathogenesis, Novel<br />
Targets and Technology<br />
1707. (22-52)adrenomedullin Shifts Cytokine Balance from Th1 to<br />
Th2, Reduces IL-17A Expressions and Modulates Treg Cells in<br />
Collagen-Induced Arthritis. Marie-Dominique Ah Kioon 5 , Carine<br />
Asensio 5 , Korng Ea 5 , Sandrine Rullé 1 , Géraldine Falgarone 1 ,<br />
Corinne Collet 4 , Jean-Marie Launay 3 and Frederic P. Liote 2 ,<br />
1<br />
EA 4222, Paris 13 University, Bobigny, France, Metropolitan,<br />
2<br />
Hopital Lariboisiere, Paris, France, 3 Paris 5 University, Paris,<br />
France, Metropolitan, 4 Paris 5 University, Bobigny, France,<br />
Metropolitan, 5 UMR-S606 Inserm, Paris Diderot University,<br />
Paris, France, Metropolitan.<br />
1708. A New Humanized Mouse Model for Experimental Erosive<br />
Arthritis: A Possible Role <strong>of</strong> Epstein-Barr Virus (EBV) for<br />
Experimental Erosive Arthritis That Resembles Rheumatoid<br />
Arthritis (RA). Yoshikazu Kuwana 5 , Masami Takei 5 , Misako<br />
Yajima 3 , Hirotake Inomata 6 , Masaaki Shiozaki 7 , Natsumi Ikumi 7 ,<br />
Takamasa Nozaki 7 , Hidetaka Shiraiwa 7 , Noboru Kitamura 7 ,<br />
Shigemasa Sawada 7 , Hiroyuki Masuda 7 , Naoki Yamamoto 3 ,<br />
Norio Shimizu 4 , Mamoru Ito 1 , Ken-ichi Imadome 2 and Shigeyoshi<br />
Fujiwara 2 , 1 Central Institute for Experimental Animals, Kawasaki,<br />
Japan, 2 Department <strong>of</strong> Infectious Diseases, National Research<br />
Institute for Child Health and Development, Tokyo, Japan,<br />
3<br />
Department <strong>of</strong> Microbiology, Yong Loo Lin School <strong>of</strong> Medicine,<br />
National University <strong>of</strong> Singapore, Singapore, 4 Department<br />
<strong>of</strong> Virology, Division <strong>of</strong> Medical Science, Medical Research<br />
Institute, Tokyo Medical and Dental University, Tokyo, Japan,<br />
5<br />
Division <strong>of</strong> Hematology and <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Medicine, Nihon University School <strong>of</strong> Medicine, Itabashi Tokyo,<br />
Japan, 6 Division <strong>of</strong> Hematology and <strong>Rheumatology</strong>, Department<br />
<strong>of</strong> Medicine, Nihon University School <strong>of</strong> Medicine, Itabashi<br />
Tokyo, Japan, 7 Division <strong>of</strong> Hematology and <strong>Rheumatology</strong>,<br />
Department <strong>of</strong> Medicine, Nihon University School <strong>of</strong> Medicine,<br />
Tokyo, Japan.<br />
1709. ASC Plays a Role in the Priming Phase <strong>of</strong> the Immune Response<br />
to Type II Collagen in Collagen-Induced Arthritis. Hideshi<br />
Yamazaki 1 , Michiko Takeoka 1 , Masato Kitazawa 1 , Takashi Ehara 2 ,<br />
Naoki Itano 1 , Hiroyuki Kato 2 and Shun’ichiro Taniguchi 1 , 1 Shinshu<br />
University Graduate School <strong>of</strong> Medicine, Matsumoto, Japan,<br />
2<br />
Shinshu University School <strong>of</strong> Medicine, Matsumoto, Japan.<br />
1710. Asymmetric Arthritic Flare in the Knees <strong>of</strong> TNF-Tg Mice<br />
Is Mediated by Expansion <strong>of</strong> CD23+/CD21hi B Cells and<br />
Ipsilateral Collapse <strong>of</strong> Lymph Nodes in Series. Jie Li, Igor Kuzin,<br />
Christopher Ritchlin, Ignacio Sanz, Andrea Bottaro, Lianping Xing<br />
and Edward Schwarz, University <strong>of</strong> Rochester.<br />
1711. CD44 Involvement in Arthritis: The Role <strong>of</strong> cd44-Splice<br />
Variants in Development <strong>of</strong> Collagen-Induced Arthritis in<br />
Mice. Celia Menckeberg 3 , Marjolein van Maanen 4 , Ronald<br />
van der Neut 2 , Steven T. Pals 2 , Margriet Vervoordeldonk 3<br />
and Paul P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam,<br />
Amsterdam, The Netherlands, 2 Department <strong>of</strong> Pathology,<br />
Amsterdam, The Netherlands, 3 Division <strong>of</strong> Clinical Immunology<br />
and <strong>Rheumatology</strong>, Amsterdam, The Netherlands, 4 Division <strong>of</strong><br />
Clinical Immunoly, Amsterdam, The Netherlands.<br />
1712. Counter-Regulatory Role <strong>of</strong> Interferon Regulatory Factor 7<br />
in Serum Transfer K/BxN Inflammatory Arthritis. Susan E.<br />
Sweeney 1 and Trevor B. Kimbler 2 , 1 University <strong>of</strong> California San<br />
Diego, La Jolla, CA, 2 University <strong>of</strong> California San Diego.<br />
1713. Dectin-1 and NOD2 Mediate Zymosan-Induced Arthritis in<br />
Mice. Holly L. Rosenzweig 1 , Jenna S. Clowers 4 , Gabriel Nunez 3 ,<br />
James T. Rosenbaum 2 and Michael P. Davey 5 , 1 Oregon Health &<br />
Science University/VA Medical Ctr, Portland, OR, 2 Oregon Health<br />
Science Univ, Portland, OR, 3 University <strong>of</strong> Michigan Medical<br />
School, Ann Arbor, MI, 4 VA Medical Ctr, 5 VA Medical Ctr/Oregon<br />
Health &Science University, Portland, OR.<br />
1714. Dendritic Cell-Based Immunotherapy Combined with Low-<br />
Dose Methothrexate Is Effective in the Treatment <strong>of</strong> Advanced<br />
Collagen-Induced Arthritis in Mice. Mi-Sun Kang 4 , Jung-Wook<br />
Lee 4 , Hyun-Soo Lee 4 , Chan-Bum Choi 1 , Hye-Soon Lee 3 , Sang-<br />
Cheol Bae 2 and Yong-Soo Bae 5 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Hanyang University Hospital for Rheumatic Diseases, Seoul,<br />
Republic <strong>of</strong> Korea, 2 Department <strong>of</strong> <strong>Rheumatology</strong>, Hanyang<br />
University Hospital for Rheumatic Diseases, Seoul, Korea,<br />
Republic <strong>of</strong>, 3 Department <strong>of</strong> <strong>Rheumatology</strong>, Hanyang University<br />
Hospital for Rheumatic Diseases, 4 Research Institute for DC<br />
Immunotherapy, CreaGene Inc., 5 Research Institute for DC<br />
Immunotherapy, CreaGene Inc., Department <strong>of</strong> Biological<br />
Science, Sungkyunkwan University.<br />
1715. Histone Deacetylase Inhibitor (HDAi) Ameliorates Chronic<br />
Arthritis in SKG Mice by Altering Conventional Dendritic Cells<br />
(cDCs) Phenotype into Tolerogenic DCs. Kenta Misaki 2 , Akio<br />
Morinobu 2 , Jun Saegusa 2 , Yoshiaki Miyamoto 2 , Shinpei Kasagi 2<br />
and Shunichi Kumagai 1 , 1 Clinical Immunology and Pathology,<br />
Kobe University, Kobe, Japan, 2 Clinical Immunology and<br />
Pathology, Kobe University, Japan.<br />
1716. IDO Expressed CD11c+CD11b+ Dendritic Cells Enhance the<br />
Differentiation <strong>of</strong> Ag Inducible CD4+CD25+ Regulatory T Cells<br />
in Induction <strong>of</strong> Oral Tolerance under the Inflammatory State.<br />
Min Jung Park 2 , Yong-Geun Jung 2 , Su-Jin Moon 2 , Ji-Min Kim 2 ,<br />
Seung-Ki Kwok 2 , Ji-Hyeon Ju 2 , Kyung-Su Park 2 , Hyun Sil Park 2 ,<br />
Mi-La Cho 2 , Sung-Hwan Park 2 and Ho-Youn Kim 1 , 1 Kang Nam St<br />
Marys Hospital, Seoul, Korea, Republic <strong>of</strong>, 2 Kang Nam St Marys<br />
Hospital.<br />
1717. Immunisation with Citrullinated Human and Porphyromonas<br />
Gingivalis Enolase Induces Rapid Onset Arthritis in HLA DR4<br />
Transgenic Mice. Andrew J. Kinloch 2 , William Brintnell 5 , David<br />
Yue 5 , Lillian Barra 5 , Natalia Wegner 1 , Karin Lundberg 1 , David A.<br />
Bell 3 , Ewa Cairns 4 and Patrick J. Venables 1 , 1 Imperial <strong>College</strong><br />
London, 2 Imperial <strong>College</strong> London, London, United Kingdom,<br />
3<br />
SJHC, London, ON, Canada, 4 Univ Western Ontario, London,<br />
ON, Canada, 5 University <strong>of</strong> Western Ontario.<br />
1718. JNK1 Deficiency Limits Macrophage Mediated Antigen Induced<br />
Arthritis. Monica Guma 1 , Gary S. Firestein 2 , Michael Karin and<br />
Mary Corr 2 , 1 UCSD, 2 UCSD School <strong>of</strong> Medicine, La Jolla, CA.<br />
252<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
1719. Loss <strong>of</strong> Integrin alpha2beta1 Suppresses Joint Inflammation<br />
and Cartilage Destruction in Mouse Models <strong>of</strong> Rheumatoid<br />
Arthritis. Marvin A. Peters 4 , Doreen Wendholt 6 , Simon<br />
Strietholt 6 , Svetlana Frank 6 , Adelheid Korb 5 , Leo A. B. Joosten 2 ,<br />
Wim B. Van Den Berg 8 , George Kollias 7 , Elena Neumann 3 , Beate<br />
Eckes 1 , Ulf Muller-Ladner 9 and Thomas Pap 10 , 1 Department <strong>of</strong><br />
Dermatology, University <strong>of</strong> Cologne, 2 Department <strong>of</strong> General<br />
Internal Medicine, Radboud University Nijmegen Medical<br />
Centre, 3 Department <strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>,<br />
Justus-Liebig-University Giessen, Kerckh<strong>of</strong>f Clinic, Bad Nauheim,<br />
Germany, 4 Department <strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>,<br />
Justus-Liebig-University Giessen, Kerckh<strong>of</strong>f Clinic; Institute<br />
<strong>of</strong> Experimental Musculoskeletal Medicine, University <strong>of</strong><br />
Muenster, Bad Nauheim, Germany, 5 Department <strong>of</strong> Internal<br />
Medicine D, University <strong>of</strong> Muenster, 6 Institute <strong>of</strong> Experimental<br />
Musculoskeletal Medicine, University <strong>of</strong> Muenster, Muenster,<br />
Germany, 7 Institute <strong>of</strong> Immunology, Biomedical Sciences<br />
Research Center, 8 Radboud Univ Nijmegen Med Cntr, Nijmegen,<br />
The Netherlands, 9 Univ.Giessen/Kerckh<strong>of</strong>f-Clinic, Bad Nauheim,<br />
Germany, 10 University Hospital Münster, Münster, Germany.<br />
1720. Lung Inflammation and Pulmonary Function Alterations in<br />
Collagen-Induced Arthritis and in the Absence <strong>of</strong> Interferongamma<br />
Signaling. Evelien Schurgers 1 , Freya Mertens 2 , Jeroen<br />
Vanoirbeek 3 , Tania Mitera 2 , Stéphanie Put 2 , Benoit Nemery 3 and<br />
Patrick Matthys 2 , 1 Laboratory <strong>of</strong> Immunobiology, Rega Institute,<br />
Katholieke Universiteit Leuven, Leuven, Belgium, 2 Laboratory <strong>of</strong><br />
Immunobiology, Rega Institute, Katholieke Universiteit Leuven,<br />
Leuven, Belgium, 3 Research Unit <strong>of</strong> Lung Toxicology (Laboratory<br />
<strong>of</strong> Pneumology), Katholieke Universiteit Leuven, Leuven,<br />
Belgium.<br />
1721. Macrophage Migration Inhibitory Factor Plays an Important<br />
Role in Inflammatory Arthritis. Mohammad A. Amin 2 , Jeffrey<br />
H. Ruth 2 , Bradley J. Rabquer 2 , Phillip L. Campbell 2 , Solhee Lee 2 ,<br />
John R. David 1 and Alisa E. Koch 3 , 1 Harvard School <strong>of</strong> Public<br />
Health, 2 University <strong>of</strong> Michigan, 3 VA Medical Service and<br />
University <strong>of</strong> Michigan Medical School, Ann Arbor, MI.<br />
1722. Matrix Components Influence the Aggressive Behavior <strong>of</strong><br />
Rheumatoid Arthritis Synovial Fibroblasts. Stephanie Lefevre 2 ,<br />
Birgit Zimmermann 3 , Matthias Geyer 3 , Angela Lehr 5 , Henning<br />
Stürz 4 , Jürgen Steinmeyer 1 , Stefan Rehart 5 , Ulf Müller-Ladner 3<br />
and Elena Neumann 3 , 1 Dept Experimental Orthopedics,<br />
Justus-Liebig-University Giessen, 2 Dept Internal Medicine and<br />
<strong>Rheumatology</strong>, Justus-Liebig University Giessen, Bad Nauheim,<br />
Germany, 3 Dept Internal Medicine and <strong>Rheumatology</strong>, Justus-<br />
Liebig University Giessen, 4 Dept Orthopedics and Orthopedic<br />
Surgery, Justus-Liebig-University Giessen, 5 Dept Orthopedics<br />
and Trauma Surgery, Markus-Hospital, Frankfurt.<br />
1723. Monocytes Are Required for Progression but Not for Initiation<br />
<strong>of</strong> Arthritis in Mouse Model <strong>of</strong> Autoantibody-Mediated<br />
Arthritis. Alexander Misharin 1 , Evan Weber 1 and Harris R.<br />
Perlman 2 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, Northwestern University,<br />
Chicago, IL, 2 Northwestern University, Chicago, IL.<br />
1724. Overexpression <strong>of</strong> RORγt Attenuated Collagen Induced<br />
Arthritis (CIA). Zhaojin Yao 2 , Yuya Kondo 2 , Masahiro Tahara 2 ,<br />
Satoru Takahashi 1 , Isao Matsumoto 2 and Takayuki Sumida 3 ,<br />
1<br />
Department <strong>of</strong> Anatomy and Embryology, Biomolecular, and<br />
Integrated Medical Sciences, Graduate School <strong>of</strong> Comprehensive<br />
Human Sciences, University <strong>of</strong> Tsukuba, 2 Division <strong>of</strong> Clinical<br />
Immunology, Major <strong>of</strong> Advanced Biochemical Applications,<br />
Graduate School <strong>of</strong> Comprehensive Human Science, University<br />
<strong>of</strong> Tsukuba, Ibaraki, Japan, 3 Univ <strong>of</strong> Tsukuba/Inst Clin Med,<br />
Tsukuba City, Japan.<br />
1725. Paradoxical Decrease in Collagen Induced Arthritis Severity in<br />
Gadd45β Deficient Mice. Yubin Luo 2 , David L. Boyle 1 and Gary S.<br />
Firestein 1 , 1 UCSD School <strong>of</strong> Medicine, La Jolla, CA, 2 UCSD School<br />
<strong>of</strong> Medicine.<br />
1726. Protection from Collagen-Induced Arthritis in a CX3CR1-<br />
Deficient Mouse Strain. Grainne Murphy 1 , Arun Kumar 2 , Fergus<br />
Shanahan 1 , Sinead Harney 1 , Michael Molloy 1 and Noel Caplice 2 ,<br />
1<br />
Cork University Hospital, Cork, Ireland, 2 University <strong>College</strong> Cork,<br />
Cork, Ireland.<br />
1727. Role <strong>of</strong> the Central Nervous System (CNS) in Peripheral<br />
Inflammation: Sympathetic Innervation <strong>of</strong> the Spleen<br />
Regulates Inflammatory Arthritis. David L. Boyle 1 , Meghan<br />
Edgar 2 , Linda Sorkin 2 and Gary S. Firestein 1 , 1 UCSD School <strong>of</strong><br />
Medicine, La Jolla, CA, 2 UCSD School <strong>of</strong> Medicine.<br />
1728. SapC-DOPS Agents in Imaging Arthritis. Sherry Thornton 1 ,<br />
Malinda Pinkerton 2 , Monica DeLay 2 , Tristan Bourdeau 2 , Rachel<br />
Mason 2 , Zhengtao Chu 2 , Matthew Flick 2 and Xiaoyang Qi 1 ,<br />
1<br />
Cincinnati Children’s Research Foundation, Cincinnati, OH,<br />
2<br />
Cincinnati Children’s Research Foundation.<br />
1729. Systemic, Lentiviral Gene Delivery <strong>of</strong> the Stress Protein<br />
BiP (Binding Immunoglobulin Protein) Improves Clinical,<br />
Histological and Immunological Parameters <strong>of</strong> Collagen-<br />
Induced Arthritis Via Suppression <strong>of</strong> IL-17. Adrian M. Shields 2 ,<br />
Paul H. Wooley 3 , Rana Alyahya 2 , Gabriel S. Panayi 1 , Stephen J.<br />
Thompson 2 and Valerie M. Corrigall 2 , 1 King’s <strong>College</strong> London,<br />
London, United Kingdom, 2 King’s <strong>College</strong> London, 3 Via Christi<br />
Reg Medical Ctr, Wichita, KS.<br />
1730. Targets <strong>of</strong> Innate and Adaptive Immunity in a Humanized<br />
Arthritis Model: Research Value <strong>of</strong> the RA Synovium SCID<br />
Mouse Model. Marije I. Koenders 3 , Shahla Abdollahi-Roodsaz 4 ,<br />
Renoud J. Marijnissen 4 , Franco E. Di Padova 2 , John Dulos 1 ,<br />
Annemieke M. H. Boots 1 and Wim B. van den Berg 4 , 1 MSD,<br />
Oss, The Netherlands, 2 Novartis Pharma AG, Switzerland,<br />
3<br />
Radboud University Nijmegen Medical Centre, Nijmegen, The<br />
Netherlands, 4 Radboud University Nijmegen Medical Centre,<br />
The Netherlands.<br />
1731. The Role for TIM-2 in Collagen-Induced Arthritis. Toshio<br />
Kawamoto 2 , Hisaya Akiba 1 , Yoshiyuki Abe 2 , Shinji Morimoto 2 ,<br />
Ken Yamaji 2 , Naoto Tamura 2 and Yoshinari Takasaki 2 ,<br />
1<br />
Department <strong>of</strong> Immunology, Juntendo University School <strong>of</strong><br />
Medicine, 2 Department <strong>of</strong> <strong>Rheumatology</strong>, Juntendo University<br />
School <strong>of</strong> Medicine.<br />
1732. The TNF-Ligand APRIL Can Control CIA by Regulating Antibody-<br />
Production and Stimulating Anti-Inflammatory IL-10 Producing<br />
B Cells. Leticia Fernandez 5 , Cecilia Rocha 5 , Carla Carvalho-Pinto 6 ,<br />
Jan Paul Medema 2 , Bernard G. Combe 3 , Dominique Baeten 1 ,<br />
Jacques Morel 4 and Michael Hahne 5 , 1 Academic Med Ctr/<br />
Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands, 2 Academic<br />
Medical Center, University <strong>of</strong> Amsterdam, 3 Hopital Lapeyronie,<br />
Montpellier, France, 4 Hopital Lapeyronie, 5 Institut de Génétique<br />
Moléculaire de Montpellier, 6 Universidade Federal Fluminense/<br />
UFF, Niteroi.<br />
1733. Towards Personalized Arthritis Gene Therapy: Screening <strong>of</strong><br />
Computationally-Designed Promoters in an In Vivo Mouse<br />
Model and in Human Synovial Fibroblasts. Fons A. J. van de<br />
Loo, Eline Vermeij, Onno J. Arntz, Miranda B. Bennink, Jeroen<br />
Geurts and Wim B. van den Berg, Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Radboud University Nijmegen Medial Centre, Nijmegen, The<br />
Netherlands.<br />
2010 Program Book 253
ACR/ARHP Poster Session C<br />
Rheumatoid Arthritis - Clinical Aspects: Classification, Biomarkers,<br />
Predictors <strong>of</strong> Response, Disease Activity, Severity III<br />
1734. A Longitudinal Trivariate Model <strong>of</strong> Disease Activity Score,<br />
Physical Function and Radiographic Damage: Results from<br />
SONORA Study. Maggie Chen 1 , Xiuying Li 1 , Pooneh Akhavan 2<br />
and Claire Bombardier 3 , 1 University Health Network, 2 University<br />
<strong>of</strong> Toronto, University Health Network, 3 University <strong>of</strong> Toronto,<br />
University Health Network, Mount Sinai Hospital, Toronto, ON,<br />
Canada.<br />
1735. A Randomized Controlled Trial <strong>of</strong> Rheumatologist Education<br />
Impacting on Systematic Measurements and Treatment<br />
Decisions in Rheumatoid Arthritis (RA): Results <strong>of</strong> the Metrix<br />
Study. Janet E. Pope 3 , J. Carter Thorne 2 , Alfred A. Cividino 1<br />
and Kurt Lucas, 1 McMaster University, Hamilton, ON, Canada,<br />
2<br />
Southlake Regional Health Care, Newmarket, ON, Canada, 3 St<br />
Joseph Health Care London, London, ON, Canada.<br />
1736. A Simple Fatigue Severity Scale Predicts Poor Health<br />
Outcomes, Frailty and Death in the Long-Term Follow-Up <strong>of</strong><br />
Patients with Rheumatoid Arthritis. Gisela Westh<strong>of</strong>f and Angela<br />
Zink, German Rheumatism Research Centre Berlin, Berlin,<br />
Germany.<br />
1737. Age, Sex, RF Antibodies, Baseline HAQ and DAS28 Score – But<br />
Not the Type <strong>of</strong> Initial Treatment – Are Predictive <strong>of</strong> Clinical<br />
Remission at 1 Year in Early Inflammatory Arthritis. Bindee<br />
Kuriya 9 , Boulos Haraoui 4 , Gilles Boire 2 , Carol A. Hitchon 7 , Janet<br />
E. Pope 6 , J. Carter Thorne 5 , Diane S. Ferland 3 , Ed C. Keystone 8<br />
and Vivian P. Bykerk 1 , 1 Brigham and Women’s Hospital, Toronto,<br />
ON, Canada, 2 CHUS - Sherbrooke University, Sherbrooke, QC,<br />
Canada, 3 Hospital Maisonneuve Rosemount, LaSalle, QC,<br />
Canada, 4 Institut de Rhumatologie, Montreal, QC, Canada,<br />
5<br />
Southlake Regional Health Care, Newmarket, ON, Canada, 6 St<br />
Joseph Health Care London, London, ON, Canada, 7 University<br />
<strong>of</strong> Manitoba, Winnipeg, MB, Canada, 8 University <strong>of</strong> Toronto,<br />
Toronto, ON, Canada, 9 University <strong>of</strong> Toronto, Brookline, MA.<br />
1738. Algorithm Using Genome-Wide SNP Analysis for Prediction<br />
<strong>of</strong> Progression <strong>of</strong> Joint Destruction in RA Patients from<br />
Multiple Medical Cohorts. Tsukasa Matsubara 4 , Satoru Koyano 7 ,<br />
Yoshitada Sakai 1 , Keiko Funahashi 7 , Takafumi Hagiwara 5 , Takako<br />
Miura 4 , Kosuke Okuda 4 , Akira Sagawa 8 , Takeo Sakurai 2 , Hiroaki<br />
Matsuno 6 , Tomomaro Izumihara 3 and Eisuke Shono 9 , 1 Himeji<br />
Dokkyo University, Himeji, Japan, 2 Inoue Hospital, Takasaki,<br />
Japan, 3 Izumihara Rheumatic and Medical Clinic, Kagoshima,<br />
Japan, 4 Matsubara Mayflower Hospital, Kato, Japan, 5 Matsubara<br />
Mayflower Hospital, Kato, Japan, 6 Matsuno Clinic for Rheumatic<br />
Diseases, Toyama, Japan, 7 Research Institute <strong>of</strong> Joint Diseases,<br />
Kobe, Japan, 8 Sagawa Akira <strong>Rheumatology</strong> Clinic, Sapporo,<br />
Japan, 9 Shono <strong>Rheumatology</strong> Clinic, Fukuoka, Japan.<br />
1739. An Algorithm Using Genome-Wide SNP Analysis for Prediction<br />
<strong>of</strong> Interstitial Pneumonia in RA Patients. Takeshi Nakamura 3 ,<br />
Satoru Koyano 5 , Keiko Funahashi 5 , Takafumi Hagiwara 3 , Takako<br />
Miura 3 , Kosuke Okuda 3 , Akira Sagawa 6 , Takeo Sakurai 1 , Hiroaki<br />
Matsuno 4 , Tomomaro Izumihara 2 , Eisuke Shono 7 and Tsukasa<br />
Matsubara 3 , 1 Inoue Hospital, Takasaki, Japan, 2 Izumihara<br />
Rheumatic and Medical Clinic, Kagoshima, Japan, 3 Matsubara<br />
Mayflower Hospital, Kato, Japan, 4 Matsuno Clinic for Rheumatic<br />
Diseases, Toyama, Japan, 5 Research Institute <strong>of</strong> Joint Diseases,<br />
Kobe, Japan, 6 Sagawa Akira <strong>Rheumatology</strong> Clinic, Sapporo,<br />
Japan, 7 Shono <strong>Rheumatology</strong> Clinic, Fukuoka, Japan.<br />
1740. Anti-Citrullinated Protein Antibodies Are Detected in a<br />
Significant Proportion <strong>of</strong> Patients with Anti-CCP-Negative,<br />
Early RA: Implications for Improved RA Diagnosis and Guided<br />
Therapy. Reuven Bromberg 3 , Jeremy Sokolove 2 , Piyanka<br />
Chandra 3 , Aarat Patel 8 , Stacy C<strong>of</strong>ield 7 , Theresa McVie 5 , S. Louis<br />
Bridges 4 , Larry W. Moreland 6 and William Robinson 1 , 1 Stanford<br />
Univ School <strong>of</strong> Med, Stanford, CA, 2 Stanford University,<br />
Mountain View, CA, 3 Stanford University, 4 Univ <strong>of</strong> Alabama-<br />
Birmingham, Birmingham, AL, 5 Univ <strong>of</strong> Alabama-Birmingham,<br />
6<br />
Univ <strong>of</strong> Pittsburgh Med Ctr, Pittsburgh, PA, 7 University <strong>of</strong><br />
Alabama-Birmingham, 8 University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />
1741. Anti-Cyclic Citrullinated Peptide Antibodies: Beyond<br />
Rheumatoid Arthritis. Dolors Grados, Melania Martinez-<br />
Morillo, Susana Holgado, Sonia Mínguez, Anna Moltó, Beatriz<br />
Tejera, Lourdes Mateo, Xavier Tena, Anna Marín, Iñaki Salvador,<br />
Eva Martínez-Caceres, Estíbaliz Ruiz and Alejandro Olivé,<br />
Hospital Universitari Germans Trias i Pujol.<br />
1742. Assessment <strong>of</strong> Nontraditional Prognostic Markers in Patients<br />
with Rheumatoid Arthritis. Bozena Targonska-Stepniak and<br />
Maria Majdan, Department <strong>of</strong> <strong>Rheumatology</strong> and Connective<br />
Tissue Diseases, Medical University <strong>of</strong> Lublin, Lublin, Poland.<br />
1743. Baseline ADAMTS5 Expression Could Sort the Prediction<br />
<strong>of</strong> Response to Infliximab or Adalimumab in Patients with<br />
Rheumatoid Arthritis. Kensei Tsuzaka 1 , Yuka Itami 2 , Naoshi<br />
Shinozaki 2 and Tetsuo Morishita 2 , 1 Tokyo Dental <strong>College</strong><br />
Ichikawa General Hospital, Ichikawa, Chiba, Japan, 2 Tokyo Dental<br />
<strong>College</strong> Ichikawa General Hospital, Ichikawa, Chiba, JAPAN.<br />
1744. Classification <strong>of</strong> Rheumatoid Arthritis – Comparison <strong>of</strong> the<br />
1987 ACR and 2010 ACR/EULAR Criteria. M. P. M. van der<br />
Linden, R. Knevel, T. W. J. Huizinga and A. H. M. van der Helmvan<br />
Mil, Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden University<br />
Medical Center, Leiden, The Netherlands.<br />
1745. Clinical Utility and Validity <strong>of</strong> Self Assessed Joint Involvement<br />
in Rheumatoid Arthritis (RA) Patients with Low Active Disease.<br />
Helga Radner 4 , Tanja Alexandra Stamm 3 , Johannes Grisar 2 , Josef<br />
S. Smolen 1 and Daniel Aletaha 3 , 1 Krankenhaus Lainz, Vienna,<br />
Austria, 2 Medical Universitiy Vienna, 3 Medical University <strong>of</strong><br />
Vienna, Vienna, Austria, 4 Medical Universty Vienna, Vienna,<br />
Austria.<br />
1746. Comparing the Validity <strong>of</strong> the EuroQol-5D, Short Form-6D and<br />
the Well-Being Preference-Based Scores Using the Mean Short<br />
Form-36 Health Dimension Scores in Patients with Rheumatoid<br />
Arthritis and in Healthy Controls. Fausto Salaffi 1 , Marina<br />
Carotti 2 , Stefania Gasparini 1 , Alessandro Ciapetti 1 and Walter<br />
Grassi 1 , 1 Department <strong>of</strong> Molecular Pathology and Innovative<br />
Therapies, Division <strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Ancona<br />
(Politecnica delle Marche), Italy, 2 Department <strong>of</strong> Radiology,<br />
University <strong>of</strong> Ancona (Politecnica delle Marche), Italy.<br />
1747. Computer Assisted Patient Reported (PR) Versus Physician<br />
Generated (PG) Joint Count (JC) and DAS28 Scores for<br />
Rheumatoid Arthritis (RA) Patients. Norman B. Gaylis 2 , Jeffrey<br />
Scott 3 , Sue North 3 , Marty True 3 , Guss Savl<strong>of</strong>f 1 and Barry V.<br />
Fortner 3 , 1 Arthritis &Rheumatic Disease Specialties, 2 Arthritis &<br />
Rheumatic Disease Specialties, Aventura, FL, 3 P4 Healthcare.<br />
1748. Concurrent Depressive or Anxiety Disorders Significantly<br />
Worsen the Health-Related Quality <strong>of</strong> Life <strong>of</strong> Patients with<br />
Rheumatoid Arthritis. Eugenia Y. C. Lok 1 , Chi Chiu Mok 2 , Fuk Chi<br />
Cheung 1 and Chi Wai Cheng 1 , 1 Castle Peak Hospital, 2 Tuen Mun<br />
Hospital.<br />
254<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
1749. Construct Validity and Reliability <strong>of</strong> the Quick Disability <strong>of</strong><br />
the Arm, Shoulder and Hand Questionnaire in Rheumatoid<br />
Arthritis Based on IORRA Cohort Study. Asami Tokita 1 , Takuji<br />
Iwamoto 2 , Ryo Hiroshima 2 , Yu Sakuma 2 , Koichiro Yano 2 ,<br />
Kosei Kawakami 2 , Katsunori Ikari 2 , Atsuo Taniguchi 2 , Hisashi<br />
Yamanaka 2 and Shigeki Momohara 2 , 1 Institute <strong>of</strong> <strong>Rheumatology</strong>,<br />
Tokyo Women’s Medical University, Kawada-cho, Shinjukuku,<br />
Tokyo, Japan, 2 Institute <strong>of</strong> <strong>Rheumatology</strong>, Tokyo Women’s<br />
Medical University, Japan.<br />
1750. Contribution <strong>of</strong> the Rheumatoid Arthritis Impact <strong>of</strong> Disease<br />
(RAID) on Disease Activity in Rheumatoid Arthritis (RA). Till<br />
Uhlig 1 , Turid Heiberg 3 , Cathrine Austad 2 and Tore K. Kvien 1 ,<br />
1<br />
Diakonhjemmet Hospital, Oslo, Norway, 2 Diakonhjemmet<br />
Hospital, Oslo, Norway, 3 Oslo University Hospital, Oslo, Norway.<br />
1751. CXCL2 as a Potential Biomarker <strong>of</strong> Disease Activity in<br />
Rheumatoid Arthritis. Kichul Shin 2 , Ji Ah Park 3 , Jun Wan<br />
Kim 3 , Hong Hee Kim 1 , Eun Bong Lee 3 and Yeong Wook Song 3 ,<br />
1<br />
Department <strong>of</strong> Cell and Developmental Biology, BK 21 and DRI,<br />
Seoul National University School <strong>of</strong> Dentistry, Seoul, Korea,<br />
2<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine,<br />
Seoul National University Hospital, Seoul, Korea, Republic <strong>of</strong>,<br />
3<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine,<br />
Seoul National University Hospital, Seoul, Korea.<br />
1752. Development by the STPR Group <strong>of</strong> the Flare Instument, a<br />
New Tool To Identify Flare in Rheumatoid Arthritis (RA) in<br />
Clinical Practice. Jean-Marie Berthelot 4 , Michel De Bandt 2 ,<br />
Jacques Morel 1 , Arnaud Constantin 3 , Philippe Gaudin 3 , Xavier Le<br />
Loët 3 , Jean-Francis Maillefert 3 , Olivier Meyer, Thao Pham, Alain<br />
Saraux, Elisabeth Solau-Gervais, Daniel Wendling, Elisabeth<br />
Spitz, Bruno Fautrel and Francis Guillemin, 1 Montpellier, France,<br />
2<br />
Aulnay Sous Bois, France, 3 France, 4 <strong>Rheumatology</strong> Unit CHU<br />
Nantes, Nantes, France.<br />
1753. Development <strong>of</strong> a Multi-Biomarker Test for Rheumatoid<br />
Arthritis (RA) Disease Activity (Vectra DA). Marije F. Bakker 8 ,<br />
Yijing Shen 3 , Johannes W. J. Bijlsma 7 , Johannes W. G. Jacobs 8 ,<br />
Floris P. J. G. Lafeber 8 , Guy Cavet 3 , Michael Centola 4 , Doug<br />
Haney 3 , Lyndal K. Hesterberg 3 , David Chern<strong>of</strong>f 3 , John Carulli 1 ,<br />
Nancy A. Shadick 2 , Michael E. Weinblatt 2 , Max I. Hamburger 6 ,<br />
Roy M. Fleischmann 5 , Jeffrey R. Curtis 9 and Ed C. Keystone 10 ,<br />
1<br />
Biogen Idec, 2 Brigham & Womens Hospital, Boston, MA,<br />
3<br />
Crescendo Bioscience, Inc., 4 Oklahoma Med Research<br />
Foundation, Oklahoma City, OK, 5 <strong>Rheumatology</strong> Associates,<br />
Dallas, TX, 6 <strong>Rheumatology</strong> Associates <strong>of</strong> LI, Dix Hills, NY,<br />
7<br />
University Medical Ctr Utrecht, Utrecht, The Netherlands,<br />
8<br />
University Medical Ctr Utrecht, 9 University <strong>of</strong> Alabama -<br />
Brimingham, Birmingham, AL, 10 University <strong>of</strong> Toronto, Toronto,<br />
ON, Canada.<br />
1754. Evaluation <strong>of</strong> Patients with Rheumatoid Arthritis in Clinical<br />
Remission with 12 Joints Ultrasonography. Preliminary Results.<br />
José M. Senabre 1 , José C. Rosas 2 , Carlos Santos-Ramírez 2 ,<br />
Gregorio Santos-Soler 2 , Xavier Barber 3 , Nuria Llahí 2 , Catalina<br />
Cano 2 and Rosa Riestra 2 , 1 Hospital Marina Baixa, Villajoyosa,<br />
Alicante, Spain, 2 Hospital Marina Baixa, 3 University Miguel<br />
Hernández.<br />
1755. Feasibility <strong>of</strong> Online Registration <strong>of</strong> Physical Functioning by<br />
RA Patients in the Out Patient Clinic. Rosanne Koevoets 3 , N. A.<br />
de Glas 3 , I. Speyer 1 , A. A. Schouffour 3 , T. W. J. Huizinga 3 , Thea<br />
P. M. Vliet Vlieland 2 and Cornelia F. Allaart 2 , 1 Bronovo Hospital,<br />
The Hague, 2 Leiden University Medical Centre, Leiden, The<br />
Netherlands, 3 Leiden University Medical Centre, Leiden, The<br />
Netherlands.<br />
1756. Identification <strong>of</strong> a Novel Marker <strong>of</strong> Radiological Damage in RA.<br />
A. Kleszcz, M. Teare, D. Moore, J. Worthington, A. Barton and G.<br />
Wilson, The University <strong>of</strong> Sheffield.<br />
1757. Improvement <strong>of</strong> Serological Rheumatoid Arthritis Diagnostics<br />
by Autoantibody Pr<strong>of</strong>iling. Karsten Conrad 2 , Dirk Roggenbuck 1<br />
and Kirsten Lüthke 3 , 1 Generic Assays GmbH, Dahlewitz,<br />
Germany, Germany, 2 Institute <strong>of</strong> Immunology, Medical<br />
Faculty <strong>of</strong> the Technical University <strong>of</strong> Dresden, Germany,<br />
3<br />
Rheumatological Practice, Dresden, Germany, Germany.<br />
1758. In Patients with Rheumatoid Arthritis Who Are in a Low<br />
Disease Activity State or Remission, Does Lack <strong>of</strong> Fatigue<br />
Relate to Better Function and Damage Scores. George A.<br />
Wells 2 , Tracy Li 1 and Maarten Boers 3 , 1 Bristol-Myers Squibb,<br />
Princeton, NJ, 2 Univ <strong>of</strong> Ottawa Faculty <strong>of</strong> Med, Ottawa, ON,<br />
Canada, 3 VU University Medical Center, Amsterdam, The<br />
Netherlands.<br />
1759. Is Exclusion <strong>of</strong> Joints <strong>of</strong> the Feet in a Disease Activity Index<br />
like DAS28 a Clinical Problem When Assessing the Individual<br />
RA Patient? M. F. Bakker 2 , J. W. G. Jacobs 2 , P. M. J. Welsing 1 , F.<br />
P. J. G. Lafeber 2 and J. W. J. Bijlsma 2 , 1 <strong>Rheumatology</strong> & Clinical<br />
Immunology, Julius Center for Health Sciences and Primary<br />
Care, University Medical Center Utrecht, The Netherlands,<br />
2<br />
<strong>Rheumatology</strong> & Clinical Immunology, University Medical<br />
Center Utrecht, The Netherlands.<br />
1760. Level <strong>of</strong> Agreement <strong>of</strong> 1987 ACR and 2010 ACR/EULAR<br />
Classification Criteria: An Analysis Based on the ESPOIR Cohort<br />
Data. Bruno Fautrel 3 , Nathalie Rincheval 4 , Bernard G. Combe 1 ,<br />
Maxime Dougados 2 and ESPOIR Scientific Committee, 1 Hopital<br />
Lapeyronie, Montpellier, France, 2 Hospital Cochin, Paris, France,<br />
3<br />
Pitie Salpetriere Hospital, Paris, France, 4 UIRC Montpellier.<br />
1761. Levels <strong>of</strong> Soluble CD163 Is Associated with Disease Activity<br />
and Radiographic Progression in Early Rheumatoid Arthritis.<br />
Stinne R. Greisen 6 , Malene Hvid 4 , Kristian Stengaard-Pedersen 1 ,<br />
Merete L. Hetland 2 , Kim Hørslev-Petersen 7 , Holger J. Møller 3 and<br />
Bent Deleuran 5 , 1 Arhus University Hospital, Aarhus, Denmark,<br />
2<br />
Copenhagen Univ Hosp Hvidovre, Hvidovre, Denmark,<br />
3<br />
Department <strong>of</strong> Clinical Biochemistry, Aarhus University<br />
Hospital, Denmark, 4 Institute <strong>of</strong> Medical Microbiology and<br />
Immunology, University <strong>of</strong> Aarhus and Department <strong>of</strong> Dermatovenerology<br />
Aarhus University Hospital, Denmark,, 5 Institute <strong>of</strong><br />
Medical Microbiology and Immunology, University <strong>of</strong> Aarhus,<br />
and Aarhus University Hospital, Denmark, 6 Institute <strong>of</strong> Medical<br />
Microbiology and Immunology, University <strong>of</strong> Aarhus, Denmark,<br />
7<br />
King Christian X Hospital for Rheumatic Disease, University <strong>of</strong><br />
Southern Denmark.<br />
1762. Liver Injury in Patients with Rheumatic Diseases and<br />
Inflammatory Syndrom: A Case-Control Prospective Analysis<br />
Using Biomarkers (FibroTest, ActiTest and SteatoTest). Cécile<br />
Gaujoux-Viala 2 , Mathilde Benhamou 2 , Mona Munteanu 1 ,<br />
Yen Ngo 1 , Djamila Messous 1 , Françoise Imbert-Bismut 1 , Vlad<br />
Ratziu 1 , Pierre Bourgeois 2 , Thierry Poynard 1 , Bruno Fautrel 2 and<br />
SAFE-T DILI- GHPS Study Group, 1 Paris 6 – Pierre et Marie Curie<br />
University; Hepatology, Pitié-Salpêtrière Hospital, Paris, France,<br />
2<br />
Paris 6 – Pierre et Marie Curie University; <strong>Rheumatology</strong>, Pitié-<br />
Salpêtrière Hospital, Paris, France.<br />
1763. New 2010 ACR-EULAR Rheumatoid Arthritis Classification<br />
Criteria Are Highly Sensitive in Patients with Early Rheumatoid<br />
Arthritis. Sarang Chitale 2 , Nicola J. Goodson 2 , David W.<br />
Sharpley 2 , Robert N. Thompson 1 , Robert J. Moots 2 and Cristina<br />
Estrach 2 , 1 Academic <strong>Rheumatology</strong> Department, University<br />
Hospital Aintree, Liverpool, Merseyside, United Kingdom,<br />
2<br />
Academic <strong>Rheumatology</strong> Department, University <strong>of</strong> Liverpool,<br />
Liverpool, Merseyside, United Kingdom.<br />
2010 Program Book 255
ACR/ARHP Poster Session C<br />
256<br />
1764. Novel Multiplex Technology for Diagnostic Characterization <strong>of</strong><br />
Rheumatoid Arthritis. Piyanka E. Chandra 4 , Jeremy Sokolove 3 ,<br />
Berthold G. Hipp 1 , Heike Eberl 1 , Ursula Klause 1 and William<br />
Robinson 2 , 1 Roche Diagnostics, 2 Stanford Univ School <strong>of</strong> Med,<br />
Stanford, CA, 3 Stanford University, Mountain View, CA, 4 Stanford<br />
University.<br />
1765. Patient Questionnaire Scores for Physical Function and Pain<br />
Are More Likely Than Erythrocyte Sedimentation Rate (ESR) To<br />
Document a Quantitative Abnormality in New Patients with<br />
Rheumatoid Arthritis (RA). Theodore Pincus 1 and Christopher<br />
J. Swearingen 2 , 1 New York University Hospital for Joint Disease,<br />
Hastings-on-Hudson, NY, 2 University <strong>of</strong> Arkansas for Medical<br />
Sciences, Little Rock, AR.<br />
1766. Preliminary Rheumatoid Arthritis (RA) Flare Assessment for<br />
Randomized Clinical Trials (RCTs): An Outcome Measures in<br />
<strong>Rheumatology</strong> (OMERACT) Data-Driven, Patient-Centered,<br />
and Consensus-Based Initiative. Clifton O. Bingham 3 , Ernest<br />
Choy 4 , Rieke Alten 6 , Maarten Boers 11 , Peter Brooks 9 , Vivian<br />
Bykerk 1 , Robin Christensen 5 , Dan Furst 8 , Sarah Hewlett 10 , Amye<br />
Leong 2 , James May, Christ<strong>of</strong> Pohl 6 , Tessa Sanderson 10 , Vibeke<br />
Strand 7 and Thasia Woodworth, 1 Brigham and Women’s,<br />
2<br />
Healthy Motivation, 3 Johns Hopkins University, Baltimore, MD,<br />
4<br />
King’s <strong>College</strong>, 5 Parker Institute: Musculoskeletal Statistics Unit<br />
Copenhagen University Hospital, 6 Schlosspark Klinik University<br />
Charite, 7 Stanford University, 8 UCLA, 9 University <strong>of</strong> Queensland,<br />
10<br />
University <strong>of</strong> the West <strong>of</strong> England, 11 Vu University Medical<br />
Center.<br />
1767. Preliminary Validation for the Short Version <strong>of</strong> the Valued<br />
Life Activities Questionnaire (S-VLA). Afton L. Hassett 5 , Diane<br />
C. Radvanski 3 , Anagha Nadkarni 1 , Steven Buyske 2 , Sam A.<br />
Schiff 3 , Moti L. Tiku 3 and Patricia P. Katz 4 , 1 Bristol-Myers Squibb<br />
Co, Princeton, NJ, 2 Rutgers University, New Brunswick, NJ,<br />
3<br />
UMDNJ-Robert Wood Johnson Medical School, New Brunswick,<br />
NJ, 4 University <strong>of</strong> California, San Francisco, CA, 5 University <strong>of</strong><br />
Michigan Medical School, Ann Arbor, MI.<br />
1768. Presence and Predictors <strong>of</strong> Poor Functional Outcomes in<br />
US Hispanics with Rheumatoid Arthritis (RA). George A.<br />
Karpouzas 4 , Soha Dolatabadi 1 , Rosalinda C. Moran 3 , Perry<br />
Nicassio 5 and Michael H. Weisman 2 , 1 Cedars Sinai, Los Angeles,<br />
CA, 2 Cedars-Sinai Medical Center, Los Angeles, CA, 3 Harbor<br />
UCLA, Carson, CA, 4 Harbor-UCLA, Long Beach, CA, 5 UCLA.<br />
1769. Progression Patterns <strong>of</strong> Radiographic Damage: Results from<br />
SONORA Study. Maggie Chen 1 , Xiuying Li 1 , Pooneh Akhavan 2<br />
and Claire Bombardier 3 , 1 University Health Network, 2 University<br />
<strong>of</strong> Toronto, University Health Network, 3 University <strong>of</strong> Toronto,<br />
University Health Network, Mount Sinai Hospital, Toronto, ON,<br />
Canada.<br />
1770. Quantification <strong>of</strong> Periarticular Osteopenia in Rheumatoid<br />
Arthritis. Inhye E. Ahn 3 , Ji Hyeon Ju 1 , Kwi Young Kang 2 ,<br />
Seung-Ki Kwok 1 , Kyung-su Park 1 , Sung-Hwan Park 1 and Ho-<br />
Youn Kim 1 , 1 Department <strong>of</strong> Internal Medicine, Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Catholic University <strong>of</strong> Korea, Seoul, Korea,<br />
Republic <strong>of</strong>, 2 Department <strong>of</strong> Internal Medicine, Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Chungbuk University, Cheongju, Korea, Republic<br />
<strong>of</strong>, 3 Department <strong>of</strong> Internal Medicine, The Methodist Hospital,<br />
Houston, TX.<br />
1771. Radiological Progression in Very Early Rheumatoid Arthritis,<br />
Results <strong>of</strong> the DREAM Remission Induction Cohort. Marloes<br />
Vermeer 3 , Ina H. Kuper 3 , Monique Hoekstra 1 , Hein J. Bernelot<br />
Moens 4 , Piet L. C. M. van Riel 2 and Mart A. F. J. van de Laar 3 ,<br />
1<br />
Isala Klinieken, Zwolle, The Netherlands, 2 Radboud University<br />
Nijmegen Medical Centre, Nijmegen, The Netherlands,<br />
3<br />
University <strong>of</strong> Twente and Medisch Spectrum Twente, Enschede,<br />
The Netherlands, 4 Ziekenhuisgroep Twente, Almelo/Hengelo,<br />
The Netherlands.<br />
2010 Program Book<br />
1772. Retinal Vascular Caliber Is Altered in Patients with Rheumatoid<br />
Arthritis: A Biomarker <strong>of</strong> Disease Activity and Cardiovascular<br />
Risk? Sharon Van Doornum 3 , Gemma Strickland 2 , Ryo Kawasaki 3 ,<br />
Jing Xie 3 , Lauren Hodgson 3 , Ian Wicks 1 and Tien Wong 3 , 1 Royal<br />
Melbourne Hospital, Melbourne, Australia, 2 Royal Melbourne<br />
Hospital, 3 University <strong>of</strong> Melbourne.<br />
1773. Serum Undercarboxylated Osteocalcin Levels in Patients with<br />
Rheumatoid Arthritis. Kuninobu Wakabayashi, Kumiko Otsuka,<br />
Michihito Sato, Ryo Takahashi, Tsuyoshi Odai, Takeo Isozaki,<br />
Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Division<br />
<strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Medicine, Showa University<br />
School <strong>of</strong> Medicine, Tokyo, Japan.<br />
1774. The 2010 ACR/EULAR Criteria for Rheumatoid Arthritis<br />
Perform Well in Prediction <strong>of</strong> Clinical RA Diagnosis at 6 Months<br />
in Very Early Arthritis Patients: Longitudinal Data from the<br />
NOR-VEAC Cohort. Maria D. Mjaavatten 3 , Desiree M. Van Der<br />
Heijde 8 , Till Uhlig 5 , Anne J. Haugen 1 , Halvor Nygaard 6 , Olav<br />
Bjørneboe 9 , Nils G. Arvidson 7 , Hans C. Gulseth 2 and Tore K.<br />
Kvien 4 , 1 Østfold Hospital, Moss, Norway, 2 Betanien Hospital,<br />
Skien, Norway, 3 Diakonhjemmet Hospital, Oslo, Norway,<br />
4<br />
Diakonhjemmet Hospital, Oslo, Norway, 5 Diakonhjemmet<br />
Hospital, Oslo, Norway, 6 Hospital for Rheumatic Diseases,<br />
Lillehammer, Norway, 7 Innlandet Hospital, Kongsvinger, Norway,<br />
8<br />
Leiden University Medical Center, Meerssen, The Netherlands,<br />
9<br />
Martina Hansen’s Hospital, Sandvika, Norway.<br />
1775. The ACR/EULAR 2010 Criteria as Well as Other Predictive<br />
Algorithms for Rheumatoid Arthritis Show Good Diagnostic<br />
Performance. Celina Alves 2 , Jolanda Luime 1 , Jendé van Zeben 4 ,<br />
Margriet Huisman 4 , Angelique Weel 3 , Pieternella Barendregt 3<br />
and Johanna Hazes 1 , 1 Erasmus MC, 2 Erasmus MC, Rotterdam,<br />
The Netherlands, 3 Maasstad Ziekenhuis, 4 Sint Franciscus<br />
Gasthuis.<br />
1776. The Diagnostic Performance <strong>of</strong> the ACR/EULAR 2010 Criteria<br />
If One <strong>of</strong> Its Parameters Is Not Available. Results from the<br />
Rotterdam Early Arthritis CoHort (REACH). Celina Alves 2 ,<br />
Jolanda Luime 1 , Jendé van Zeben 4 , Margriet Huisman 4 ,<br />
Angelique Weel 3 , Pieternella Barendregt 3 and Johanna Hazes 1 ,<br />
1<br />
Erasmus MC, 2 Erasmus MC, Rotterdam, The Netherlands,<br />
3<br />
Maasstad Ziekenhuis, 4 Sint Franciscus Gasthuis.<br />
1777. The Performance <strong>of</strong> the Hospital Anxiety and Depression<br />
Scale for Screening <strong>of</strong> Depressive and Anxiety Disorders in<br />
Patients with Rheumatoid Arthritis (RA). Eugenia Y. C. Lok 1 , Chi<br />
Chiu Mok 2 , Fuk Chi Cheung 1 and Chi Wai Cheng 1 , 1 Castle Peak<br />
Hospital, 2 Tuen Mun Hospital.<br />
1778. The Role <strong>of</strong> Objective Measures vs. Patient Reported<br />
Outcomes (PROs) as a Reflection <strong>of</strong> Flares in Patients with<br />
RA: Results from the Brigham RA Sequential Study (BRASS).<br />
Vivian Bykerk 1 , Daniel Hal Solomon 5 , Clifton O. Bingham 6 ,<br />
Michelle Frits 3 , Christine Iannaccone 4 , Michael E. Weinblatt 5 and<br />
Nancy A. Shadick 5 , 1 Brigham &Women’s Hospital, Boston, MA,<br />
2<br />
Brigham and Women’s Hospital, Jamaica Plain, MA, 3 Brigham<br />
and Women’s Hospital, Boston, MA, 4 Brigham and Women’s<br />
Hospital, MA, 5 Brigham and Womens Hospital, Boston, MA,<br />
6<br />
Johns Hopkins University, Baltimore, MD.<br />
1779. Total MRI Inflammatory Score Correlates with Disease Activity<br />
Measures after Aggressive Treatment <strong>of</strong> Rheumatoid Arthritis.<br />
Veena K. Ranganath 3 , David A. Elash<strong>of</strong>f 4 , Paul Maranian 4 , Kambiz<br />
Motamedi 4 , Espen Haavardsholm 2 , Fiona M. McQueen 5 , Theresa<br />
McVie 7 , Stacey S. C<strong>of</strong>ield 7 , Larry W. Moreland 6 , Weiling Chen 4<br />
and Harold E. Paulus 1 , 1 Encino, CA, 2 Diakonhjemmet Hospital,<br />
3<br />
UCLA, Los Angeles, CA, 4 UCLA, 5 Univ <strong>of</strong> Auckland Sch <strong>of</strong> Med,<br />
Auckland, New Zealand, 6 Univ <strong>of</strong> Pittsburgh Med Ctr, Pittsburgh,<br />
PA, 7 University <strong>of</strong> Birmingham.
ACR/ARHP Poster Session C<br />
1780. Towards a Data-Driven Evaluation <strong>of</strong> the 2010 ACR/EULAR<br />
Criteria for Rheumatoid Arthritis: Is It Sensible To Look at<br />
Levels <strong>of</strong> Rheumatoid Factor? M. P. M. van der Linden 4 , M.<br />
R. Batstra 1 , L. E. Bakker-Jonges 1 , J. Detert 2 , H. Bastian 2 , H. U.<br />
Scherer 2 , G. R. Burmester 2 , M. D. Mjaavatten 3 , T. K. Kvien 3 , R. E.<br />
M. Toes 4 , T. W. J. Huizinga 4 and A. H. M. van der Helm-van Mil 4 ,<br />
1<br />
Department <strong>of</strong> Medical Laboratories, Reinier de Graaf Group,<br />
Delft, The Netherlands, on Behalf <strong>of</strong> SKML-HIM (WGHAS),<br />
2<br />
Department <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology, Charité<br />
University Medicine Berlin, Berlin, Germany, 3 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Diakonhjemmet Hospital, Oslo, Norway,<br />
4<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden University Medical<br />
Center, Leiden, The Netherlands.<br />
1781. Ultrasound Evaluation Reveals the Reason for High Interrater<br />
Variability in Joints <strong>of</strong> the 66/68 Joint Count. Matthias<br />
Nikolaus Witt 2 , Monika Ronneberger 1 , Amelie Schnez 3 , Ruediger<br />
Laubender 4 , Matthias Engelbrecht 1 , Arthur Kavanaugh 6 , Hendrik<br />
Schulze-Koops 5 and Mathias Grunke 3 , 1 Department <strong>of</strong> Internal<br />
Medicine 3 , University <strong>of</strong> Erlangen-Nuremberg, Erlangen,<br />
Germany, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Ludwig-Maximilians-<br />
University, Munich, Germany, 3 Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
Ludwig-Maximilians-University, Munich, Germany, 4 Institute <strong>of</strong><br />
Medical Informatics, Biometry and Epidemiology (IBE), Ludwig-<br />
Maximilians-University, Munich, Germany, 5 Ludwig-Maximilians-<br />
University, Munich, Germany, 6 University <strong>of</strong> California-San<br />
Diego, La Jolla, CA.<br />
1782. Validation <strong>of</strong> a Multi-Biomarker Test for Rheumatoid Arthritis<br />
(RA) Disease Activity (Vectra DA) in a Multi-Cohort Study.<br />
Jeffrey R. Curtis 9 , Doug Haney 3 , Annette H. M. van der Helm 5 ,<br />
Yijing Shen 3 , Rachel Knevel 5 , Guy Cavet 3 , Linda Dirven 5 ,<br />
Cornelia F. Allaart 4 , Thomas W. J. Huizinga 5 , Michael Centola 6 ,<br />
Lyndal K. Hesterberg 3 , David Chern<strong>of</strong>f 3 , John Carulli 1 , Nancy<br />
A. Shadick 2 , Michael E. Weinblatt 2 , Max I. Hamburger 8 , Roy<br />
M. Fleischmann 7 and Ed C. Keystone 10 , 1 Biogen Idec, 2 Brigham<br />
&Womens Hospital, Boston, MA, 3 Crescendo Bioscience, Inc.,<br />
4<br />
Leiden Univ Med Ctr, Leiden, The Netherlands, 5 Leiden Univ<br />
Med Ctr, 6 Oklahoma Med Research Foundation, Oklahoma<br />
City, OK, 7 <strong>Rheumatology</strong> Associates, Dallas, TX, 8 <strong>Rheumatology</strong><br />
Associates <strong>of</strong> LI, Dix Hills, NY, 9 University <strong>of</strong> Alabama -<br />
Brimingham, Birmingham, AL, 10 University <strong>of</strong> Toronto, Toronto,<br />
ON, Canada.<br />
1783. Validation <strong>of</strong> New Classification Criteria for Rheumatoid<br />
Arthritis in Japanese Population. Hisanori Shimizu 1 , Hiromichi<br />
Tamaki 3 , Eishi Uechi 3 , Mitsumasa Kishimoto 2 , Ken-ichi<br />
Yamaguchi 3 and Masato Okada 1 , 1 St. Luke’s International<br />
Hospital, Tokyo, Japan, 2 St. Luke’s International Hospital, Chuoku,<br />
Tokyo, Japan, 3 St. Luke’s International Hospital.<br />
1784. Validity <strong>of</strong> Clinical Associations <strong>of</strong> Biomarkers in Translational<br />
Research Studies: The Case <strong>of</strong> Systemic Autoimmune Diseases.<br />
Maria Tektonidou 2 and Michael Ward 1 , 1 National Institute <strong>of</strong><br />
Arthritis and Musculoskeletal and Skin Diseases, 2 National<br />
University <strong>of</strong> Athens.<br />
1785. Validity <strong>of</strong> the Revised ACR/EULAR Classification Criteria for<br />
Rheumatoid Arthritis: Predicting Persistent Arthritis and Joint<br />
Erosions after 2 Years in Patients with Early Undifferentiated<br />
Arthritis. Jaap Fransen 3 , Mieke Hazes 2 and Henk Visser 1 , 1 Alysis<br />
Hospital, Arnhem, The Netherlands, 2 Erasmus Medical Centre,<br />
Rotterdam, The Netherlands, 3 Radboud University Nijmegen<br />
Medical Centre, Nijmegen, The Netherlands.<br />
1786. Vitamin D Levels Do Not Correlate with Disease Activity,<br />
Erosions, or Inflammatory Markers in Patients with Active<br />
Rheumatoid Arthritis. Joshua Baker 2 , Daniel G. Baker 1 , Gary<br />
Toedter, Justine Shults and Mary B. Leonard, 1 Centocor Inc,<br />
Malvern, PA, 2 University <strong>of</strong> Pennsylvania, Philadelphia, PA.<br />
1787. Work Disability in Early Rheumatoid Arthritis: Prognostic<br />
Factors after Two Years <strong>of</strong> Follow-Up. Fausto Salaffi 1 ,<br />
Gianfranco Ferraccioli 3 , Marina Carotti 2 , Alessandro Ciapetti 1 ,<br />
Stefania Gasparini 1 and Walter Grassi 1 , 1 Department <strong>of</strong><br />
Molecular Pathology and Innovative Therapies, Division<br />
<strong>of</strong> <strong>Rheumatology</strong>, University <strong>of</strong> Ancona (Politecnica delle<br />
Marche), Italy, 2 Department <strong>of</strong> Radiology, University <strong>of</strong> Ancona<br />
(Politecnica delle Marche), Italy, 3 School <strong>of</strong> Medicine, Catholic<br />
University <strong>of</strong> the Sacred Heart, Rome, Italy.<br />
Rheumatoid Arthritis Treatment - Small Molecules, Biologics and<br />
Gene Therapy: Biologic DMARDs III<br />
1788. A Study To Evaluate the Effectiveness and Safety <strong>of</strong> the<br />
Interleukin-6 (IL-6) Receptor Antagonist Tocilizumab (TCZ) after<br />
4 and 24 Weeks in Patients with Active Rheumatoid Arthritis<br />
(RA) – Final Effectiveness Results <strong>of</strong> the TAMARA Study. Eugen<br />
Feist 1 , Andrea Rubbert-Roth 2 , Jürgen Braun 6 , Jörg Kaufmann 4 ,<br />
Herbert L. Kellner 7 , Reiner Kurthen 3 , Jürgen Wollenhaupt 5 and<br />
Gerd R. Burmester 1 , 1 Campus Charité Mitte, Med. Klinik Abt.<br />
Rheumatologie u. Klin. Immunologie, Berlin, Germany, 2 Klinik I<br />
für Innere Medizin, Uniklinik Cologne, Cologne, Germany, 3 Praxis<br />
für Innere Medizin und Rheumatologie, Aachen, Germany,<br />
4<br />
Praxis für Innere Medizin und Rheumatologie, Ludwigsfelde,<br />
Germany, 5 Rheumatologikum Hamburg, Schön-Klinik Hamburg-<br />
Eilbeck, Hamburg, Germany, 6 Rheumazentrum Ruhrgebiet, St.<br />
Josefs-Krankenhaus, Herne, Germany, 7 Schwerpunktpraxis fuer<br />
Rheumatologie und Gastroenterologie, Munich, Germany.<br />
1789. Age at Onset and Comorbidities Correlate with the Health<br />
Assessment Questionnaire and Clinical Disease Activity Index<br />
(CDAI) Responses to Etanercept in Rheumatoid Arthritis<br />
Patients. Man R. Shim 6 , Harold E. Paulus 1 , Sandeep Chaudhari 3 ,<br />
JingYaun Feng 2 , David A. Elash<strong>of</strong>f 4 and Veena K. Ranganath 5 ,<br />
1<br />
Encino, CA, 2 Amgen, 3 Kforce Clinical Research/Amgen, 4 UCLA,<br />
5<br />
UCLA School <strong>of</strong> Med Rehab 32-59, Los Angeles, CA, 6 UCLA/ VA<br />
Greater Los Angeles Healthcare System, Los Angeles, CA.<br />
1790. Assessment <strong>of</strong> Real Life Efficacy <strong>of</strong> Rituximab in Rheumatoid<br />
Arthritis: Predicting Factors <strong>of</strong> the Therapeutic Maintenance<br />
and Demonstration <strong>of</strong> a Corticosteroid Sparing Effect in<br />
the AutoImmunity and Rituximab Registry. Jacques-Eric<br />
Gottenberg 10 , Philippe Ravaud 4 , Thomas Bardin 6 , Patrice<br />
Cacoub 5 , Alain Cantagrel 11 , Bernard Combe 8 , Maxime<br />
Dougados 2 , René-Marc Flipo 7 , Bertrand Godeau 3 , Loic Guillevin 2 ,<br />
Eric Hachulla 7 , Xavier Le Loët 9 , Thierry Schaeverbeke 1 , Jean<br />
Sibilia 10 , Gabriel Baron 4 and Xavier Mariette, 1 Bordeaux<br />
Hospital, 2 Cochin Hospital, 3 Henri Mondor Hospital, 4 Hotel Dieu<br />
Hospital, 5 La Pitié Hospital, 6 Lariboisière Hospital, 7 Lille Hospital,<br />
8<br />
Montpellier Hospital, 9 Rouen Hospital, 10 Strasbourg Hospital,<br />
11<br />
Toulouse Hospital.<br />
1791. Clinical and Functional Improvements in Early RA Following<br />
Treatment with Adalimumab Plus Methotrexate Compared<br />
with Methotrexate Monotherapy: 26-Week Results <strong>of</strong> the<br />
OPTIMA Trial. Arthur Kavanaugh 5 , Roy Fleischmann 6 , Paul<br />
Emery 3 , Benoit Guérette 1 , Laura Redden 2 , Kaushik Patra 2 and<br />
Josef S. Smolen 4 , 1 Abbott Laboratories, Rungis, France, 2 Abbott<br />
Laboratories, Abbott Park, IL, 3 Leeds Teaching Hospital, Leeds,<br />
United Kingdom, 4 Medical University <strong>of</strong> Vienna and Hietzing<br />
Hospital, Vienna, Austria, 5 University <strong>of</strong> California San Diego,<br />
La Jolla, CA, 6 University <strong>of</strong> Texas Southwestern Medical Center,<br />
Dallas, TX.<br />
2010 Program Book 257
ACR/ARHP Poster Session C<br />
258<br />
1792. Clinical Response during Sequential Anti-Tumor Necrosis<br />
Factor Therapy in US Veterans Enrolled in the Veterans<br />
Affairs Rheumatoid Arthritis (VARA) Registry. Grant W.<br />
Cannon 4 , Brian C. Sauer 5 , Candace L. Hayden 5 , Liron Caplan 2 ,<br />
Gail S. Kerr 7 , J. Steuart Richards 8 , Dannette S. Johnson 3 , Ted R.<br />
Mikuls 6 and Andreas M. Reimold 1 , 1 Dallas VA and University<br />
<strong>of</strong> Texas Southwestern, Dallas, TX, 2 Denver VA and University<br />
<strong>of</strong> Colorado, Aurora, CO, 3 Jackson VA and University <strong>of</strong><br />
Mississippi, Jackson, MS, 4 Salt Lake City VA and University <strong>of</strong><br />
Utah, Salt Lake City, UT, 5 Salt Lake City VA and University <strong>of</strong><br />
Utah, 6 Univ <strong>of</strong> Nebraska Med Ctr, Omaha, NE, 7 Washington VA<br />
and Georgetown and Howard Universities, Washington, DC,<br />
8<br />
Washington VA and Georgetown University, Washington, DC.<br />
1793. Clinical, Structural and Functional Remission in the Treatment<br />
<strong>of</strong> Rheumatoid Arthritis with Tocilizumab in Daily Clinical<br />
Practice – REACTION-2 Study. Tsutomu Takeuchi 2 , Yoshiya<br />
Tanaka 5 , Kouichi Amano 1 , Eri Sato 4 , Masao Nawata 6 , Hayato<br />
Nagasawa 1 , Daisuke Hoshi 4 , Masayoshi Saito 6 , Syunsuke<br />
Fukuyo 6 , Kentarou Hanami 6 , Hideto Kameda 3 , Takahiko<br />
Kurasawa 1 and Hisashi Yamanaka 4 , 1 Division <strong>of</strong> <strong>Rheumatology</strong><br />
and Clinical Immunology, Department <strong>of</strong> Internal Medicine,<br />
Saitama Medical Center, Saitama Medical University, Saitama,<br />
Japan, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, School <strong>of</strong> Medicine, Keio<br />
University, Tokyo, Japan, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, School<br />
<strong>of</strong> Medicine, Keio University, Tokyo, Japan, 4 Institute <strong>of</strong><br />
<strong>Rheumatology</strong>, Tokyo Women’s Medical University, Tokyo,<br />
Japan, 5 The First Department <strong>of</strong> Internal Medicine, School <strong>of</strong><br />
Medicine, University <strong>of</strong> Occupational &Environmental Health,<br />
Kitakyusyu, Japan, 6 The First Department <strong>of</strong> Internal Medicine,<br />
School <strong>of</strong> Medicine, University <strong>of</strong> Occupational &Environmental<br />
Health, Kitakyushu, Japan.<br />
1794. Comparable Persistency and Effectiveness <strong>of</strong> Abatacept<br />
Versus Anti-TNF Agents in the Treatment <strong>of</strong> Biologic-Naïve<br />
Rheumatoid Arthritis Patients Using the CORRONA Registry.<br />
Leslie Harrold 3 , George Reed 3 , Lisa C. Rosenblatt 1 , Monica<br />
Mody 1 , Diane Moniz Reed 1 and Jeffrey Greenberg 2 , 1 Bristol-<br />
Myers Squibb, Princeton, NJ, 2 NYU Hospital <strong>of</strong> Joint Diseases,<br />
New York, NY, 3 University <strong>of</strong> Massachusetts Medical School,<br />
Worcester, MA.<br />
1795. Comparative Effectiveness <strong>of</strong> Biological Treatment Options<br />
Following Tumor Necrosis Factor α Inhibitor Failure in<br />
Rheumatoid Arthritis: Systematic Review and Indirect Pairwise<br />
Meta-Analysis. Monika Schoels 1 , John B. Wong 2 , Daniel Aletaha 3<br />
and Josef S. Smolen 4 , 1 2nd Department <strong>of</strong> Internal Medicine,<br />
Hietzing Hospital, Vienna, Austria; Div. <strong>of</strong> Clinical Decision<br />
Making, Informatics and Telemedicine, Tufts University School<br />
<strong>of</strong> Medicine, Boston, MA, 2 Div. <strong>of</strong> Clinical Decision Making,<br />
Informatics and Telemedicine, Tufts University School <strong>of</strong><br />
Medicine, Boston, MA, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, Department<br />
<strong>of</strong> Medicine 3 , Medical University <strong>of</strong> Vienna, Austria, 4 Division <strong>of</strong><br />
<strong>Rheumatology</strong>, Department <strong>of</strong> Medicine 3 , Medical University <strong>of</strong><br />
Vienna, Austria; 2nd Department <strong>of</strong> Internal Medicine, Hietzing<br />
Hospital, Vienna, Austria.<br />
1796. Comparative Effectiveness <strong>of</strong> Rituximab in Combination with<br />
Either Methotrexate or Leflunomide in the Treatment <strong>of</strong><br />
Rheumatoid Arthritis. Javier Narvaez 4 , César Díaz Torné 2 , José<br />
Miguel Ruiz 3 , Maria Victoria Hernández 1 , Vicens Torrente 2 and<br />
Sergio Ros 3 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Clinic,<br />
Barcelona, Spain, 2 Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital<br />
de la Santa Creu i Sant Pau, Barcelona, Spain, 3 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Hospital de Viladecans, Barcelona, Spain,<br />
4<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, Hospital Universitario de<br />
Bellvitge, Barcelona, Spain.<br />
2010 Program Book<br />
1797. Comparison <strong>of</strong> Tocilizumab and Infliximab Treatment for RA<br />
for a Duration <strong>of</strong> 12 Weeks, Based on MMP-3: Preliminary<br />
Report. Isamu Yokoe 1 , Hitomi Kobayashi 2 , Hiroshi Sato 2 and<br />
Shinya Nishio 2 , 1 Itabashi Chuo Medical Center, Tokyo, Japan,<br />
2<br />
Itabashi Chuo Medical Center.<br />
1798. CTLA-4-Ig Fusion Protein (Abatacept) Modulate Inflammatory<br />
Activity <strong>of</strong> Cultured Synovial Macrophages from Rheumatoid<br />
Arthritis Patients. Maurizio E. Cutolo 6 , Stefano Soldano 3 ,<br />
Paola Montagna 3 , Alberto Sulli 3 , Bruno Seriolo 3 , Barbara<br />
Villaggio 4 , Pier Franco Triolo 5 , Paolo Clerico 5 , Lamberto Felli 1 ,<br />
Luigi Molfetta 2 and Renata Brizzolara 3 , 1 Academic Orthopedic<br />
Department, University <strong>of</strong> Genova, Italy, 2 Orthopedic Unit, San<br />
Martino Hospital, Genova, Italy, 3 Research Laboratories and<br />
Academic Unit <strong>of</strong> Clinical <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />
Medicine, University <strong>of</strong> Genova, Italy, 4 Research Laboratory <strong>of</strong><br />
Nephrology, Department <strong>of</strong> Internal Medicine - University <strong>of</strong><br />
Genova, Italy, 5 Rheumatoid Arthritis Unit – Orthopedic Surgery<br />
Department. CTO Hospital, Turin, Italy, 6 University <strong>of</strong> Genova,<br />
Genova, Italy.<br />
1799. Dosing <strong>of</strong> Anti-Tumor Necrosis Factor Biologics (Anti-TNFs)<br />
for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) in<br />
Clinical Practice in the United States. J. Timothy Harrington 5 ,<br />
Dimitrios A. Pappas 2 , Susan Messing 4 , Xin Tu 4 , Rui Chen 4 ,<br />
Kimberly Kaukeinen 4 , Timothy Pietras 4 , Jeffrey D. Greenberg 1<br />
and Joel M. Kremer 3 , 1 Millburn, NJ, 2 Johns Hopkins University,<br />
Baltimore, MD, 3 The Center for <strong>Rheumatology</strong>, Albany,<br />
NY, 4 University <strong>of</strong> Rochester Medical Center, 5 University <strong>of</strong><br />
Wisconsin, Madison, WI.<br />
1800. Drug Free REmission after Cessation <strong>of</strong> Tocilizumab (Actemra)<br />
Monotherapy (DREAM Study). Norihiro Nishimoto, Wakayama<br />
Medical University, Ibaraki-City, Japan.<br />
1801. Effect <strong>of</strong> Rituximab Treatment on Il-15 and T Cell<br />
Subpopulations in Rheumatoid Arthritis Patients. Cesar Diaz-<br />
Torne 1 , Maria A. Ortiz 1 , Carme Geli 1 , Josep M. Llobet 1 , Elisabeth<br />
Cantó 1 , Elena Perez 1 , Hector Corominas 2 , Candido Juarez 1 , Cesar<br />
R. Diaz-Lopez 1 and Silvia Vidal 1 , 1 Hospital de la Santa Creu i Sant<br />
Pau, 2 Hospital Moises Broggi.<br />
1802. Effectiveness <strong>of</strong> Different DMARD Co-Therapies in Rituximab-<br />
Treated Rheumatoid Arthritis (RA) Patients – Results <strong>of</strong> a<br />
One-Year Follow Up Study from the CERRERA Collaboration.<br />
Cem Gabay 12 , Katerina Chatzidionysou 11 , Elisabeth Lie 5 , Galina<br />
Lukina 9 , Merete L. Hetland 2 , Ulrik Tarp 3 , Piet L. Van Riel 14 ,<br />
Dan Nordström 6 , Juan J. Gomez-Reino 7 , Karel Pavelka 1 , Matija<br />
Tomsic 13 , Evgeny L. Nasonov 8 , Tore K. Kvien 4 and Ronald<br />
Van Vollenhoven 10 , 1 Charles Univ, Prague, Czech Republic,<br />
2<br />
Copenhagen Univ Hosp Hvidovre, Hvidovre, Denmark,<br />
3<br />
Copenhagen Univ Hosp Hvidovre, 4 Diakonhjemmet Hospital,<br />
Oslo, Norway, 5 Diakonhjemmet Hospital, Oslo, Norway, 6 Helsinki<br />
Univ Hosp, Helsinki, Finland, 7 Hospital Clinico Universitario,<br />
Santiago, Spain, 8 Institue <strong>of</strong> <strong>Rheumatology</strong>, Moscow,<br />
Russian Federation, 9 Institute <strong>of</strong> <strong>Rheumatology</strong>, Moscow,<br />
Russia, 10 Karolinska University Hospital, Stockholm, Sweden,<br />
11<br />
Karolinska, Stockholm, Sweden, Sweden, 12 Univ Hosp <strong>of</strong><br />
Geneva, Geneva, Switzerland, 13 Univ Medical Center, Ljubljana,<br />
Ljubljana, Slovenia, 14 University Hosp Nijmegen, Nijmegen, The<br />
Netherlands.<br />
1803. Effects <strong>of</strong> Anti-TNF Agents on the Lung Function <strong>of</strong> Patients<br />
with Rheumatoid Arthritis: A Prospective Study. Meryem Can 1 ,<br />
Sait Karakurt 3 , Atilla Bulur 1 , Pamir Atagündüz 1 , Sule Yavuz 2 ,<br />
Haner Direskeneli 2 and Nevsun Inanç 2 , 1 Marmara University<br />
Medical School, Division <strong>of</strong> <strong>Rheumatology</strong>, Istanbul, Turkey,<br />
2<br />
Marmara University Medical School, Division <strong>of</strong> <strong>Rheumatology</strong>,<br />
3<br />
Marmara University Medical SchoolDepartment <strong>of</strong> Pulmonary<br />
and Critical Care, Istanbul, Turkey.
ACR/ARHP Poster Session C<br />
1804. Effects <strong>of</strong> Subcutaneous and Intravenous Golimumab on<br />
Markers <strong>of</strong> Inflammation in Patients with Rheumatoid<br />
Arthritis. Mittie K. Doyle 4 , Mahboob U. Rahman 4 , Bart<br />
Frederick 2 , Charles A. Birbara 6 , Dick de Vries 1 , Gary Toedter 3 ,<br />
Xiaoying Wu 3 , Dion Chen 2 , Mark Westerman 5 and Daniel E.<br />
Furst 7 , 1 Centocor B.V., Leiden, The Netherlands, 2 Centocor<br />
Research and Development, Inc., Malvern, PA, 3 Centocor<br />
Research and Development, Inc., 4 Centocor Research and<br />
Development, Inc./Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine,<br />
Malvern, PA, 5 Intrinsic Life Sciences, 6 Univ. <strong>of</strong> Massachusetts City<br />
Campus, Worcester, MA, 7 University <strong>of</strong> California Los Angeles<br />
Medical School, Los Angeles, CA.<br />
1805. Efficacy and Safety <strong>of</strong> Certolizumab Pegol in a Clinically<br />
Representative Population <strong>of</strong> Patients (Pts) with Active<br />
Rheumatoid Arthritis (RA): Results <strong>of</strong> the REALISTIC Phase<br />
IIIb Randomized Controlled Study. Michael Weinblatt 2 , Roy<br />
Fleischmann 8 , Paul Emery 3 , Niti Goel 11 , Clifton O. Bingham 5 ,<br />
Janet Pope 9 , Elena Massarotti 1 , Ronald van Vollenhoven 6 ,<br />
Thomas W. J. Huizinga 7 , Benjamin Duncan 10 and Maxime<br />
Dougados 4 , 1 Brigham and Women’s Hospital, Boston, MA,<br />
2<br />
Brigham and Women’s Hospital, 3 Chapel Allerton Hospital,<br />
Leeds, United Kingdom, 4 Hospital Cochin, Paris, France, 5 Johns<br />
Hopkins University, Baltimore, MD, 6 Karolinska Institute,<br />
Stockholm, Sweden, 7 Leiden University Medical Centre, Leiden,<br />
The Netherlands, 8 MCRC, University <strong>of</strong> Texas, Dallas, TX, 9 St.<br />
Joseph’s Health Care, University <strong>of</strong> Western Ontario, London,<br />
ON, Canada, 10 UCB, Raleigh, NC, 11 UCB, Smyrna, GA.<br />
1806. Efficacy and Safety <strong>of</strong> Certolizumab Pegol Plus Methotrexate<br />
in Patients with Rheumatoid Arthritis (RA): 3-Year Data<br />
from the RAPID 2 Study. Josef S. Smolen 4 , Ronald F. van<br />
Vollenhoven 1 , Arthur Kavanaugh 8 , Niti Goel 7 , Andreas<br />
Fichtner 6 , Vibeke Strand 3 , Jiri Vencovsky 5 and Desiree van der<br />
Heijde 2 , 1 Department <strong>of</strong> <strong>Rheumatology</strong>, Karolinska Institute,<br />
Stockholm, Sweden, 2 Department <strong>of</strong> <strong>Rheumatology</strong>, Leiden<br />
University Medical Center, Leiden University Medical Center,<br />
Leiden, Meerssen, The Netherlands, 3 Division <strong>of</strong> Immunology<br />
and <strong>Rheumatology</strong>, Stanford University School <strong>of</strong> Medicine,<br />
Palo Alto, CA, 4 Division <strong>of</strong> <strong>Rheumatology</strong>, Medical University<br />
<strong>of</strong> Vienna and Hietzing Hospital, Vienna, Austria, 5 Institute<br />
<strong>of</strong> <strong>Rheumatology</strong>, Prague, Czech Republic, 6 UCB, Monheim,<br />
Germany, 7 UCB, Smyma, GA, 8 University <strong>of</strong> California-San Diego,<br />
La Jolla, CA.<br />
1807. Efficacy and Safety <strong>of</strong> Rituximab Treatment in Clinical<br />
Practice: Data from the CERERRA Collaboration. Katerina<br />
Chatzidionysiou 10 , Elisabeth Lie 5 , Galina Lukina 8 , Merete L.<br />
Hetland 3 , Ulrik Tarp 2 , Cem Gabay 12 , Piet L. Van Riel 14 , Dan C.<br />
Nordström 11 , Juan J. Gomez-Reino 6 , Karel Pavelka 1 , Matija<br />
Tomsic 13 , Evgeny L. Nasonov 7 , Tore K. Kvien 4 and Ronald Van<br />
Vollenhoven 9 , 1 Charles Univ, Prague, 2 DANBIO, Univ Hosp,<br />
Copenhagen, Denmark, 3 DANBIO, Univ Hosp, Copenhagen,<br />
Denmark, 4 Diakonhjemmet Hospital, Oslo, Norway,<br />
5<br />
Diakonhjemmet Hospital, Oslo, Norway, 6 Hospital Clinico<br />
Universitario, Santiago, Spain, 7 Institue <strong>of</strong> <strong>Rheumatology</strong>,<br />
Moscow, Russian Federation, 8 Institute <strong>of</strong> <strong>Rheumatology</strong>,<br />
Moscow, 9 Karolinska University Hospital, Stockholm, Sweden,<br />
10<br />
Karolinska University Hospital, Stockholm, 11 ROB-FIN Univ<br />
Hosp, Helsinki, 12 Univ Hosp <strong>of</strong> Geneva, Geneva, Switzerland,<br />
13<br />
Univ Med Center, Ljubljana, 14 University Hosp Nijmegen,<br />
Nijmegen, The Netherlands.<br />
1808. Efficacy and Safety <strong>of</strong> Tocilizumab in Patients with Moderate<br />
to Severe Active RA and a Previous Inadequate Response<br />
to DMARDs: The ROSE Study. Yusuf Yazici 3 , Jeffrey R. Curtis 6 ,<br />
Akgun Ince 4 , Herbert Baraf 5 , Raymond L. Malamet 1 , Carol Y.<br />
Chung 2 and Arthur Kavanaugh 7 , 1 Genentech, a Member <strong>of</strong><br />
the Roche Group, South San Francisco, South San Francisco,<br />
CA, 2 Genentech, a Member <strong>of</strong> the Roche Group, South San<br />
Francisco, CA, 3 NYU Hospital for Joint Diseases, New York,<br />
NY, 4 St. Louis University School <strong>of</strong> Medicine, St. Louis, MO,<br />
5<br />
The Center for <strong>Rheumatology</strong> and Bone Research, Wheaton,<br />
Wheaton, MD, 6 University <strong>of</strong> Alabama at Birmingham,<br />
Birmingham, AL, 7 University <strong>of</strong> California at San Diego, La Jolla,<br />
CA.<br />
1809. Efficacy <strong>of</strong> Abatacept and Tocilizumab in Rheumatoid<br />
Arthritis Patients Treated in Clinical Practice. Results from<br />
the Nationwide Danish DANBIO Registry. Henrik C. Leffers 4 ,<br />
Mikkel Ostergaard 4 , Bente Glintborg 7 , Niels Steen Krogh 10 , Heidi<br />
Foged 6 , Ulrik Tarp 1 , Tove Lorenzen 9 , Annette Hansen 3 , Michael<br />
S. Hansen 2 , Martin S. Jacobsen 8 and Merete L. Hetland 5 , 1 Aarhus<br />
University Hospital, Denmark, 2 Copenhagen University Hospital<br />
Gent<strong>of</strong>te, Denmark, 3 DANBIO Registry, and Copenhagen<br />
University Hospital Gent<strong>of</strong>te, Denmark, 4 DANBIO Registry,<br />
and Copenhagen University Hospital, Hvidovre and Glostrup,<br />
Hvidovre, Denmark, 5 DANBIO Registry, and Copenhagen<br />
University Hospital, Hvidovre and Glostrup, Denmark,<br />
6<br />
Frederiksberg Hospital, Denmark, 7 Holbæk Hospital, Denmark,<br />
8<br />
Randers Hospital, Denmark, 9 Vejle Hospital, Denmark, 10 Zitelab<br />
Aps, Denmark.<br />
1810. Efficacy <strong>of</strong> Rituximab on Pulmonary Rheumatoid Nodules:<br />
Data <strong>of</strong> 10 Patients from the French AIR/PR Registry. Baptiste<br />
Glace 7 , Jacques E. Gottenberg 13 , Xavier Mariette 1 , Antoine<br />
Roche 5 , Jean-Marie Berthelot 11 , Maxime Dougados 3 , Eric<br />
Toussirot 6 , Thao Pham 9 , Yannick Allanore 2 , Damien Loeuille 10 ,<br />
Liana E. Euller-Ziegler 4 , Thierry Lequerré 12 and Martin Soubrier 8 ,<br />
1<br />
Bicetre Hospital/Paris Univ, Le Kremlin Bicetre, France,<br />
2<br />
Hopitaux de Paris Cochin, Paris, France, 3 Hospital Cochin,<br />
Paris, France, 4 L’Archet Hospital (University), Nice, France,<br />
5<br />
Radiology Department, CHU Clermont-Ferrand, 6 <strong>Rheumatology</strong><br />
Department, CHU Besançon, 7 <strong>Rheumatology</strong> Department,<br />
CHU Clermont-Ferrand, 8 <strong>Rheumatology</strong> Department, CHU<br />
Clermont-Ferrand, 9 <strong>Rheumatology</strong> Department, CHU Marseille,<br />
10<br />
<strong>Rheumatology</strong> Department, CHU Nancy, 11 <strong>Rheumatology</strong><br />
Department, CHU Nantes, 12 <strong>Rheumatology</strong> Department, CHU<br />
Rouen, 13 Strasbourg Hospitals, Strasbourg, France.<br />
1811. Etanar® Therapy in Real-Life Patients with Rheumatoid<br />
Arthritis. Federico Rondon 11 , Alain Bautista 4 , Juan Carlos<br />
Salazar 1 , Nohemí Casas 9 , Pedro Santos 9 , Francisco Vargas 6 , Javier<br />
Márquez 2 , Fredy Pumarejo 8 , Fernando Fernández 3 , Andrés<br />
Fernández 5 , Rossana Mejía 1 , Oscar Ruiz 1 , Alberto Torrenegra 3 ,<br />
Jose Bernardo Martínez 7 and Rubén Darío Mantilla 10 , 1 CIREI,<br />
Bogota, 2 Hospital Pablo Tobon Uribe, Medellin, 3 <strong>Rheumatology</strong>,<br />
Barranquilla, 4 <strong>Rheumatology</strong>, Cucuta, 5 <strong>Rheumatology</strong>,<br />
Ibague, 6 <strong>Rheumatology</strong>, Medellin, 7 <strong>Rheumatology</strong>, Monteria,<br />
8<br />
<strong>Rheumatology</strong>, Valledupar, 9 Riesgo de Fractura-CAYRE IPS,<br />
Bogota, 10 Riesgo de Fractura-CAYRE IPS, Bogota, Colombia,<br />
11<br />
Universidad Nacional, Bogota.<br />
2010 Program Book 259
ACR/ARHP Poster Session C<br />
1812. Etanercept (ETN) Plus Methotrexate (MTX) Combination<br />
Therapy Resulted in a Better Radiographic Outcome Than<br />
ETN Monotherapy Even in Patients with Active Rheumatoid<br />
Arthritis Despite MTX Treatment: 104-Week Results from<br />
the JESMR Study. Hideto Kameda 2 , Katsuaki Kanbe 7 , Eri Sato 7 ,<br />
Yukitaka Ueki 5 , Kazuyoshi Saitoh 8 , Shouhei Nagaoka 9 , Toshihiko<br />
Hidaka 10 , Tatsuya Atsumi 1 , Michishi Tsukano 4 , Tsuyoshi Kasama 6 ,<br />
Shunichi Shiozawa 3 , Yoshiya Tanaka 8 , Hisashi Yamanaka 7 and<br />
Tsutomu Takeuchi 2 , 1 Hokkaido University Graduate School<br />
<strong>of</strong> Medicine, 2 Keio University, 3 Kobe University Hospital,<br />
4<br />
Kumamoto Orthopaedic Hospital, 5 Sasebo Chuo Hospital,<br />
6<br />
Showa University School <strong>of</strong> Medicine, 7 Tokyo Women’s Medical<br />
University Medical Center, 8 University <strong>of</strong> Occupational and<br />
Environmental Health, 9 Yokohama Minami Kyosai Hospital,<br />
10<br />
Zenjinkai Shimin-No-Mori-Hospital.<br />
1813. Etanercept Normalizes Systemic Bone Metabolism in<br />
Rheumatoid Arthritis Patients. Won Park 2 , Mie Jin Lim 1 , Seong<br />
Ryul Kwon 1 , Ji Yeol Yoon 1 , Chang Gi Moon 1 and Go Eun Ju 1 , 1 Inha<br />
University Hospital, Incheon, Republic <strong>of</strong> Korea, 2 Inha University<br />
Hospital, Choong-Gu Incheon, Korea, Republic <strong>of</strong>.<br />
1814. Golimumab, a Human Anti-TNFα Monoclonal Antibody<br />
Administered Subcutaneously Every Four Weeks as<br />
Monotherapy in Patients with Active Rheumatoid Arthritis<br />
Despite DMARD Therapy: 24-Week Results <strong>of</strong> Clinical and<br />
Radiographic Assessments. Tsutomu Takeuchi 5 , Masayoshi<br />
Harigai 8 , Yoshiya Tanaka 10 , Hisashi Yamanaka 9 , Naoki Ishiguro 7 ,<br />
Kazuhiko Yamamoto 11 , Takuya Oba 4 , Mahboob U. Rahman 1 ,<br />
Toru Yoshinari 6 , Nobuyuki Miyasaka 2 and Takao Koike 3 ,<br />
1<br />
Centocor Research and Development, Inc., Malvern, PA,<br />
2<br />
Graduate School <strong>of</strong> Medical and Dental Sciences, Tokyo, Japan,<br />
3<br />
Hokkaido University Graduate School <strong>of</strong> Medicine, 4 Janssen<br />
Pharmaceutical K.K., 5 Keio University, Toyko, Japan, 6 Mitsubishi<br />
Tanabe Pharma Corporation, 7 Nagoya University, 8 Tokyo Medical<br />
and Dental University, Tokyo, Japan, 9 Tokyo Womens Med Univ,<br />
Shinjuku-ku, Tokyo, Japan, 10 University <strong>of</strong> Occupational and<br />
Environmental Health, Kitakyushu, Japan, 11 University <strong>of</strong> Tokyo<br />
Graduate School <strong>of</strong> Medicine, Tokyo, Japan.<br />
1815. Golimumab, a Human Anti-TNFα Monoclonal Antibody<br />
Administered Subcutaneously Every Four Weeks in Patients<br />
with Active Rheumatoid Arthritis Despite Methotrexate<br />
Therapy: 24-Week Results <strong>of</strong> Clinical and Radiographic<br />
Assessments. Yoshiya Tanaka 10 , Masayoshi Harigai 8 ,<br />
Tsutomu Takeuchi 4 , Hisashi Yamanaka 9 , Naoki Ishiguro 6 ,<br />
Kazuhiko Yamamoto 7 , Takuya Oba 3 , Mahboob U. Rahman 1 ,<br />
Toru Yoshinari 5 , Nobuyuki Miyasaka 8 and Takao Koike 2 ,<br />
1<br />
Centocor Research and Development, Inc., Malvern, PA,<br />
2<br />
Hokkaido University Graduate School <strong>of</strong> Medicine, 3 Janssen<br />
Pharmaceutical K.K., 4 Keio University, Toyko, Japan, 5 Mitsubishi<br />
Tanabe Pharma Corporation, 6 Nagoya University, 7 The University<br />
<strong>of</strong> Tokyo, 8 Tokyo Medical and Dental University, Tokyo, Japan,<br />
9<br />
Tokyo Womens Medical University, Shinjuku-ku, Tokyo,<br />
Japan, 10 University <strong>of</strong> Occupational and Environmental Health,<br />
Kitakyushu, Japan.<br />
1816. Impact <strong>of</strong> Abatacept on Circulating Dendritic Cells and<br />
Regulatory T Cells in Rheumatoid Arthritis Patients with<br />
Inadequate Response or Intolerance to TNF-alpha Blockers.<br />
Emilie Shipley 1 , Christophe Richez 1 , Thomas Barnetche 2 , Cécile<br />
Contin-Bordes 2 , Patrick Blanco 2 and Thierry Schaeverbeke 1 ,<br />
1<br />
Hôpital Pellegrin, Bordeaux, France, Metropolitan, 2 Hôpital<br />
Pellegrin, France, Metropolitan.<br />
1817. Impact <strong>of</strong> Abatacept on Synovitis and Structural Damage in<br />
Methotrexate (MTX)-Inadequate Responders with Active<br />
Rheumatoid Arthritis (RA): A Randomized, Controlled<br />
Magnetic Resonance Imaging (MRI) Exploratory Study. Philip<br />
G. Conaghan 9 , Patrick Durez 8 , Rieke Alten 6 , Gerd Burmester 4 ,<br />
Paul P. Tak 1 , Lars Klareskog 5 , Corine Gaillez 2 , Manuela Le Bars 2 ,<br />
Xianhuang Zhou 3 and Charles Peterfy 7 , 1 Academic Medical<br />
Center/University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />
2<br />
Bristol-Myers Squibb, Rueil-Malmaison, France, 3 Bristol-Myers<br />
Squibb, Princeton, NJ, 4 Charité-Universitatsmedizin, Berlin,<br />
Germany, 5 Karolinska University Hospital, Stockholm, Sweden,<br />
6<br />
Schlosspark-Klinik, University Medicine Berlin, Germany,<br />
7<br />
Spire Science LCC, San Francisco, CA, 8 Université Catholique de<br />
Louvain, Brussels, Belgium, 9 University <strong>of</strong> Leeds, Leeds, UK.<br />
1818. Key Pharmacological Parameters Support Monthly Dosing<br />
for Golimumab. Mahboob U. Rahman 2 , Ann Cai 1 , Eilyn Lacy 1 ,<br />
Jonathan Kay 4 , Ed C. Keystone 5 , Eric L. Matteson 3 , Chuanpu<br />
Hu 1 , Honghui Zhou 1 and Dave Shealy 1 , 1 Centocor Research and<br />
Development, Inc., 2 Centocor Research and Development,<br />
Inc./Univ. <strong>of</strong> Pennsylvania School <strong>of</strong> Medicine, Malvern, PA,<br />
3<br />
Mayo Clinic, Rochester, MN, 4 UMass Memorial Medical Center,<br />
Worcester, MA, 5 University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />
1819. LITHE: Tocilizumab (TCZ) Inhibits Radiographic Progression<br />
and Improves Physical Function in Rheumatoid Arthritis (RA)<br />
Patients (pts) at 3 Years with Maintenance <strong>of</strong> Clinical Efficacy<br />
over Time. Joel M. Kremer 1 , Daniel E. Furst 6 , Ruben Burgos-<br />
Vargas 3 , Jean Dudler 2 , Christopher M. Mela 5 , Emma Vernon 5<br />
and Roy M. Fleischmann 4 , 1 Albany Medical <strong>College</strong>, Albany,<br />
NY, 2 Hôpital Orthopédique, Epalinges, Switzerland, 3 Hospital<br />
General de México and Universidad Nacional Autónoma de<br />
México, Mexico City, México, Mexico, 4 Metroplex Clinical<br />
Research Center, Dallas, TX, 5 Roche, Welwyn, United Kingdom,<br />
6<br />
UCLA Medical Center, Los Angeles, CA.<br />
1820. Long-Term Efficacy <strong>of</strong> Tocilizumab (TCZ) in Patients (Pts) with<br />
Rheumatoid Arthritis (RA) Treated up to 3.7 Years. Majed<br />
Khraishi 3 , Rieke Alten 8 , Juan J. Gomez-Reino 2 , Warren Rizzo 1 ,<br />
Joy Schechtman 6 , Andre Kahan 4 , Emma Vernon 5 , Monet Taylor 5<br />
and Josef Smolen 7 , 1 Advanced Arthritis Care, Scottsdale, AZ,<br />
2<br />
Hospital Clínico U. de Santiago, Santiago, Spain, 3 Memorial<br />
University <strong>of</strong> Newfoundland, St. John’s, NL, Canada, 4 Paris<br />
Descartes University, Paris, France, 5 Roche, Welwyn, UK,<br />
6<br />
SunValley Arthritis Center, Peoria, AZ, 7 University Clinic for<br />
Internal Medicine, Vienna, Austria, 8 University <strong>of</strong> Berlin, Berlin,<br />
Germany.<br />
1821. Mechanism <strong>of</strong> Inhibition <strong>of</strong> Joint Destruction by Rituximab<br />
in Rheumatoid Arthritis. Maria J. H. Boumans 2 , Rogier<br />
M. Thurlings 3 , Koen Vos 4 , Danielle M. Gerlag 3 and Paul P.<br />
Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam,<br />
The Netherlands, 2 Academic Medical Center/University <strong>of</strong><br />
Amsterdam, Amsterdam, Noord-Holland, The Netherlands,<br />
3<br />
Academic Medical Center/University <strong>of</strong> Amsterdam, 4 Academic<br />
Medical Center/University <strong>of</strong> Amsterdam/Jan van Breemen<br />
Institute.<br />
1822. Monocyte Migration to the Synovium in Rheumatoid Arthritis<br />
Patients Treated with Adalimumab. Marieke Herenius 3 , Rogier<br />
Thurlings 4 , Carla Wijbrandts 4 , Roel<strong>of</strong> Bennink 5 , Serge Dohmen 6 ,<br />
Carlijn Voermans 6 , Diana Wouters 2 , Elena Izmailova 7 , Daniëlle<br />
Gerlag 4 , Berthe van Eck-Smit 5 and Paul P. Tak 1 , 1 Academic<br />
Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />
2<br />
Department <strong>of</strong> Immunopathology, Sanquin Research,<br />
Amsterdam, Noord Holland, The Netherlands, Division <strong>of</strong> Clinical<br />
260<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
Immunology and <strong>Rheumatology</strong>, Academic Medical Center<br />
/ University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />
4<br />
Division <strong>of</strong> Clinical Immunology and <strong>Rheumatology</strong>, Academic<br />
Medical Center, University <strong>of</strong> Amsterdam, Amsterdam, The<br />
Netherlands, 5 Division <strong>of</strong> Nuclear Medicine, Academic Medical<br />
Center, University <strong>of</strong> Amsterdam, Amsterdam, The Netherlands,<br />
6<br />
Landsteiner Laboratory, Department <strong>of</strong> Experimental<br />
Immunohematology, Sanquin Research, Amsterdam, The<br />
Netherlands, 7 Millennium Pharmaceuticals, Inc, Department <strong>of</strong><br />
Research and Development, Cambridge, MA.<br />
1823. Multiple Regression Analysis on the Clinical Parameters<br />
Associating with Clinical, Structural and Functional Remission<br />
at 52 Weeks in RA Patients Treated with Anti-IL-6 Receptor<br />
Antibody, Tocilizumab – REACTION-2 Study. Tsutomu Takeuchi 2 ,<br />
Yoshiya Tanaka 5 , Kouichi Amano 1 , Eri Sato 4 , Masao Nawata 5 ,<br />
Hayato Nagasawa 1 , Daisuke Hoshi 4 , Kazuyoshi Saito 5 , Syunsuke<br />
Fukuyo 5 , Kentarou Hanami 5 , Takahiko Kurasawa 1 , Hideto<br />
Kameda 3 and Hisashi Yamanaka 4 , 1 Division <strong>of</strong> <strong>Rheumatology</strong> and<br />
Clinical Immunology, Department <strong>of</strong> Internal Medicine, Saitama<br />
Medical Center, Saitama Medical University, Saitama, Japan,<br />
2<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, School <strong>of</strong> Medicine, Keio University,<br />
Tokyo, Japan, 3 Division <strong>of</strong> <strong>Rheumatology</strong>, School <strong>of</strong> Medicine,<br />
Keio University, Tokyo, Japan, 4 Institute <strong>of</strong> <strong>Rheumatology</strong>,<br />
Tokyo Women’s Medical University, Tokyo, Japan, 5 The<br />
First Department <strong>of</strong> Internal Medicine, School <strong>of</strong> Medicine,<br />
University <strong>of</strong> Occupational &Environmental Health, Kitakyushu,<br />
Japan.<br />
1824. Outcome <strong>of</strong> Interstitial Lung Disease (ILD) after Administration<br />
<strong>of</strong> Biologics in Patients with Pre-Existing ILD in RA. Shinji<br />
Motojima 1 , Tamao Nakashita 1 , Akira Inoue 1 , Kei-ichi Inoue 1<br />
and Natsuki Fujio 2 , 1 Department <strong>of</strong> <strong>Rheumatology</strong> and Allergy,<br />
Kameda Medical Center, Kamogawa, Chiba, Japan, 2 Department<br />
<strong>of</strong> <strong>Rheumatology</strong> and Allergy, Kameda Medical Center, Japan.<br />
1825. Patients Not Responding to Etanercept Obtain Lower Trough<br />
Etanercept Concentrations Compared to Responding Patients.<br />
Anna Jamnitski 1 , Michael T. Nurmohamed 1 , Margreet M. Hart 2 ,<br />
Ben A. Dijkmans 3 , Lucien Aarden 2 and Gerrit Jan Wolbink 1 , 1 Jan<br />
van Breemen Institute, 2 Sanquin Research, 3 VU Medical Center.<br />
1826. Prevalence and Persistence <strong>of</strong> Low Infliximab Serum Trough<br />
Levels in RA Patients with Low Disease Activity in Daily Clinical<br />
Practice. Aatke van der Maas 3 , Alfons A. Den Broeder 4 , Gert-Jan<br />
Wolbink 1 , Frank H. J. van den Hoogen 4 , Piet L. C. M. van Riel 5<br />
and Bart J. F. van den Bemt 2 , 1 Department <strong>of</strong> Immunopathology,<br />
Sanquin Research, Amsterdam, The Netherlands, 2 Department<br />
<strong>of</strong> Pharmacy, St. Maartenskliniek, Nijmegen, The Netherlands,<br />
3<br />
Department <strong>of</strong> <strong>Rheumatology</strong>, St. Maartenskliniek, Nijmegen,<br />
The Netherlands, 4 Department <strong>of</strong> <strong>Rheumatology</strong>, St.<br />
Maartenskliniek, Nijmegen, The Netherlands, 5 Department <strong>of</strong><br />
<strong>Rheumatology</strong>, St. Radboud UMCN, Nijmegen, The Netherlands.<br />
1827. Regulatory T Cells from Patients with Rheumatoid Arthritis<br />
Are Not Affected by Adalimumab and Etanercept. Thierry<br />
Lequerré 3 , Céline Blache 2 , Stéphanie Beuteux 2 , Arnaud<br />
Roucheux 1 , Ingrid Dedreux 1 , Serge Jacquot 1 , Xavier Le<br />
Loët 4 , Olivier Boyer 1 and Olivier Vittecoq 4 , 1 Department <strong>of</strong><br />
Immunology, Inserm905, Rouen University Hospital, University<br />
<strong>of</strong> Rouen, 2 Inserm905, University <strong>of</strong> Rouen, 3 <strong>Rheumatology</strong><br />
Department, Inserm905, Rouen University Hospital, University<br />
<strong>of</strong> Rouen, Rouen, France, 4 <strong>Rheumatology</strong> Department,<br />
Inserm905, Rouen University Hospital, University <strong>of</strong> Rouen.<br />
1828. Relationship between Rituximab Serum Levels and Progression<br />
<strong>of</strong> Structural Damage in Rheumatoid Arthritis Patients. Maria<br />
J. H. Boumans 2 , Y. K. O. Teng 6 , Rogier M. Thurlings 3 , Koen Vos 4 ,<br />
Steven O. Stapel 7 , Gertjan Wolbink 5 , Janneke Tekstra 8 and Paul<br />
P. Tak 1 , 1 Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam,<br />
The Netherlands, 2 Academic Medical Center/University <strong>of</strong><br />
Amsterdam, Amsterdam, Noord-Holland, The Netherlands,<br />
3<br />
Academic Medical Center/University <strong>of</strong> Amsterdam, 4 Academic<br />
Medical Center/University <strong>of</strong> Amsterdam/Jan van Breemen<br />
Institute, 5 Jan van Breemen Institute, Sanquin Research,<br />
Amsterdam, 6 Leiden University Medical Center, 7 Sanquin<br />
Research, Amsterdam, 8 University Medical Centre, Utrecht.<br />
1829. Response, Remission, and Flare during Early Treatment<br />
<strong>of</strong> Rheumatoid Arthritis with Infliximab. Ronald F. Van<br />
Vollenhoven 2 , Dimitrios Boumpas 10 , Rene Westhovens 9 ,<br />
Marek Brzosko 7 , Karin E. Svensson 8 , Olav Bjorneboe 3 , Cees<br />
Meeuwisse 5 , Shankar Srinivasan 4 , Nathan Vastesaeger 6 and<br />
Philippe Gaudin 1 , 1 CHU Hôpital Sud, Echirolles Cedex, France,<br />
2<br />
Karolinska University Hospital, Stockholm, Sweden, 3 Martina<br />
Hansens Hospital, Gjettum, Norway, 4 Merck and Company, Inc,<br />
Kenilworth, NJ, 5 MSD, Oss, The Netherlands, 6 MSD, Brussels,<br />
Belgium, 7 Pomeranian Medical University, Szczecin, Poland,<br />
8<br />
Skövde Hospital, Skövde, Sweden, 9 University Hosp KU Leuven,<br />
Leuven, Belgium, 10 University Hospital <strong>of</strong> Heraklion, Heraklion<br />
Crete, Greece.<br />
1830. Rituximab (RTX) Is More Effective in Active Sero-Positive RA<br />
Than Sero-Negative RA. Abdul Khan 3 , Taher Mahmud 4 , Tony<br />
Hammond 1 , Mike Batley 2 and Alison Leak 5 , 1 Maidstone General<br />
Hospital Hermitage Lane Maidstone Kent, Maidstone, Kent,<br />
United Kingdom, 2 Maidstone General Hospital Maidstone Kent,<br />
Maidstone, Kent, United Kingdom, 3 Maidstone General Hospital,<br />
Maidstone, Kent, Maidstone, Kent, United Kingdom, 4 Pembury<br />
Hospital, Pembury, Kent, United Kingdom, 5 Queen Elizabeth<br />
Queen Mother Hospital, Margate, Kent, United Kingdom.<br />
1831. Safety and Efficacy <strong>of</strong> IL-1 Trap in Resistant Adult Onset Still’s<br />
Disease: 24 Month Follow-Up <strong>of</strong> Open Label Treatment and<br />
Biomarkers <strong>of</strong> Response. Cailin Henderson, Mildred Wilson,<br />
Tuyet-Hang Pham, Gregory Dolan, Adriana Gobbo, Christopher<br />
Snyder, Elizabeth Joyal and Raphaela Goldbach-Mansky, NIAMS<br />
/ NIH.<br />
1832. Safety, Efficacy, and Sustained Improvements in Household<br />
Productivity and Daily Activities with Certolizumab Pegol (CZP)<br />
Monotherapy over 2 Years in Patients with Active Rheumatoid<br />
Arthritis (RA). Roy M. Fleischmann 4 , Ernest Choy 3 , Ronald van<br />
Vollenhoven 2 , Niti Goel 6 , Oana Purcaru 5 , Kristel Luijtens 5 and<br />
Vibeke Strand 1 , 1 Division <strong>of</strong> Immunology and <strong>Rheumatology</strong>,<br />
Stanford University School <strong>of</strong> Medicine, Palo Alto, CA,<br />
2<br />
Karolinska Institute, Stockholm, Sweden, 3 Kings <strong>College</strong><br />
Hospital, London, United Kingdom, 4 MCRC, University <strong>of</strong> Texas,<br />
Dallas, TX, 5 UCB, Brussels, Belgium, 6 UCB, Smyrna, GA.<br />
1833. Statins Inhibit the Anti-Rheumatic Effects <strong>of</strong> Rituximab in<br />
Rheumatoid Arthritis – Results from the Dutch Rheumatoid<br />
Arthritis Monitoring (DREAM) Registry. Elke Arts 4 , Tim L.<br />
Jansen 2 , Alfons Den Broeder 6 , Harald E. Vonkeman 3 , Ellen<br />
Dutmer 1 , Mart A. F. J. Van de Laar 3 , Piet L. C. M. Van Riel 5 and<br />
Jaap Fransen 5 , 1 Gelderse Vallei Hospital Ede, 2 Medical Centre<br />
Leeuwarden, 3 Medisch Spectrum Twente &University <strong>of</strong> Twente,<br />
4<br />
Radboud University Nijmegen Medical Centre, Nijmegen, The<br />
Netherlands, 5 Radboud University Nijmegen Medical Centre,<br />
6<br />
Sint Maartenskliniek.<br />
2010 Program Book 261
ACR/ARHP Poster Session C<br />
262<br />
1834. Subcutaneous (SC) Abatacept Is Well-Tolerated, Demonstrates<br />
Clinical Efficacy and Is Associated with Low Immunogenicity<br />
Following Withdrawal and Re-Introduction: Phase III<br />
Evaluation in Rheumatoid Arthritis (RA) Patients Responding<br />
to Abatacept. Jeffrey L. Kaine 6 , Ge<strong>of</strong>frey S. Gladstein 5 , Ingrid<br />
Strusberg 4 , Manuel Robles 2 , Ramesh Pappu 1 , Ingrid Delaet 1 ,<br />
Miranda Pans 1 and Charles L. Ludivico 3 , 1 Bristol-Myers Squibb<br />
Co, Princeton, NJ, 2 Centro Médico Toluca, Metepec, Mexico,<br />
3<br />
East Penn <strong>Rheumatology</strong> Associates, East Stroudsburg,<br />
Philadelphia, PA, 4 Instituto Reumatológico, Strusberg, Cordoba,<br />
Argentina, 5 New England Research Associates, Trumbull, CT,<br />
6<br />
Sarasota Arthritis Center, Sarasota, FL.<br />
1835. Subcutaneous Golimumab Sustains Effects <strong>of</strong> Intravenous<br />
Golimumab in Patients with Active Rheumatoid Arthritis:<br />
Results <strong>of</strong> the GO-LIVE Long Term Extension. Joel M. Kremer 4 ,<br />
Peter Taylor 3 , Alan Mendelsohn 2 , Daniel G. Baker 1 , Lilianne<br />
Kim 2 and Christopher T. Ritchlin 5 , 1 Centocor Research and<br />
Development, Inc., Malvern, PA, 2 Centocor Research and<br />
Development, Inc., 3 Imperial <strong>College</strong> <strong>of</strong> London, 4 The Center<br />
for <strong>Rheumatology</strong>, Albany, NY, 5 University <strong>of</strong> Rochester Medical<br />
Center, Rochester, NY.<br />
1836. Sustained and Clinically Meaningful Improvements in Both<br />
Day- and Night-Time Aspects <strong>of</strong> HRQoL Are Observed with<br />
Abatacept Treatment in Patients with Rheumatoid Arthritis<br />
(RA) and Previous Inadequate Response to MTX: 5-Year Data<br />
from the AIM Trial. Joel Kremer 2 , Anthony S. Russell 3 , Rene<br />
Westhovens 5 , Julie Teng 1 , Lisa Rosenblatt 1 and Paul Emery 4 ,<br />
1<br />
Bristol-Myers Squibb, Princeton, NJ, 2 Center for <strong>Rheumatology</strong>,<br />
Albany Medical <strong>College</strong>, Albany, NY, 3 University <strong>of</strong> Alberta<br />
Hospital, Edmonton, AB, Canada, 4 University <strong>of</strong> Leeds, Leeds,<br />
United Kingdom, 5 UZ Gasthuisberg, Leuven, Belgium.<br />
1837. Sustained and Clinically Meaningful Improvements in Physical<br />
Function and Fatigue and Reductions in Activity Limitation<br />
Are Observed in MTX-Naïve Patients with Early Rheumatoid<br />
Arthritis (RA) Treated with Abatacept over 2 Years <strong>of</strong> the<br />
AGREE Trial. Rene Westhovens 5 , Jurgen Wollenhaupt 4 , Boulos<br />
Haraoui 2 , Jean-Claude Becker 1 , Allison Covucci 1 , Lisa Rosenblatt 1<br />
and Joan Bathon 3 , 1 Bristol-Myers Squibb, NJ, 2 Institut de<br />
Rumatologie de Montreal, Montreal, QC, Canada, 3 John Hopkins<br />
University School <strong>of</strong> Medicine, Baltimore, MD, 4 Klinikum Eilbek,<br />
Hamburg, Germany, 5 UZ Gasthuisburg, Leuven, Belgium.<br />
1838. TNF-alpha Antagonist Therapy Leads to an Expansion <strong>of</strong> IL-17<br />
Expressing CD4+ T Cells Both In Vitro and In Vivo. Hayley<br />
G. Evans 2 , Nicola J. Gullick 3 , Bruce W. Kirkham 1 and Leonie<br />
S. Taams 3 , 1 Guy’s &St Thomas’ NHS Foundation Trust, 2 Kings<br />
<strong>College</strong> London, London, United Kingdom, 3 Kings <strong>College</strong><br />
London.<br />
1839. Tocilizumab Monotherapy Improves Arterial Stiffness<br />
Compared with Other Biologics Monotherapy in Rheumatoid<br />
Arthritis. Kensuke Kume 1 , Kanzo Amano 1 , Susumu Yamada 1 and<br />
Hiroyuki Ohta 2 , 1 Hiroshima Clinic, Hiroshima, Japan, 2 IGL School,<br />
Hiroshima, Japan.<br />
1840. Tocilizumab Treatment in Patients with Rheumatoid Arthritis<br />
and an Inadequate Response to DMARDs and/or TNF<br />
Inhibitors: ACT-SURE Preliminary Results. Vivian P. Bykerk 7 ,<br />
Jose Álvaro-Gracia 3 , Jose Andres Roman Ivorra 4 , Michael T.<br />
Nurmohamed 6 , Karel Pavelka 5 , Corrado Bernasconi 8 , Andrea<br />
Stancati 8 , Jean Sibilia 2 and Andrew Östör and the ACT-SURE<br />
Study Group 1 , 1 Addenbrookes Hospital, Cambridge, United<br />
Kingdom, 2 Hautepierre Service de Rhumatologie, Strasbourg,<br />
France, 3 Hospital Universitario de La Princesa, IIS Princesa,<br />
Madrid, Spain, 4 Hospital Universitario Dr. Peset, Valencia, Spain,<br />
5<br />
Institute <strong>of</strong> <strong>Rheumatology</strong>, Prague, Czech Republic, 6 Jan van<br />
Breemen Institute, Amsterdam, The Netherlands, 7 Mount Sinai<br />
Hospital, Toronto, ON, Canada, 8 Roche, Basel, Switzerland.<br />
2010 Program Book<br />
1841. Treatment with TNF-Inhibitors Reduces Radiographic Joint<br />
Destruction in Rheumatoid Arthritis Patients Treated in Clinical<br />
Practice. Lykke M. Ørnbjerg 1 , Mikkel Østergaard 1 , Pernille<br />
Bøyesen 12 , Anja Thormann 1 , Ulrik Tarp 6 , Wolfgang Böhme 13 ,<br />
Ditte Dencker 13 , Hanne Lindegaard 15 , Uta Poulsen 14 , Anette<br />
Hansen 2 , Vibeke Ringsdal 5 , Anette Schlemmer 5 , Niels Graudal 10 ,<br />
Anne R. Andersen 16 , Jakob Espesen 4 , Gina Kollerup 7 , Torben G.<br />
Christensen 11 , Randi Pelck 3 , Bente Glintborg 3 , Ole R. Madsen 2 ,<br />
Dorte V. Jensen 8 , Ole Majgaard 9 and Merete L. Hetland 1 ,<br />
1<br />
DANBIO Registry and Depts. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen<br />
University Hospitals at Hvidovre and Glostrup, Denmark,<br />
2<br />
Dept. <strong>of</strong> Internal Medicine and <strong>Rheumatology</strong>, Gent<strong>of</strong>te<br />
University Hospital, Denmark, 3 Dept. <strong>of</strong> Internal Medicine,<br />
Copenhagen University Hospital at Holbæk, Denmark, 4 Dept.<br />
<strong>of</strong> Internal Medicine, Hospital Lillebaelt at Vejle, Denmark,<br />
5<br />
Dept. <strong>of</strong> <strong>Rheumatology</strong>, århus University Hospital at ålborg,<br />
Denmark, 6 Dept. <strong>of</strong> <strong>Rheumatology</strong>, århus University Hospital,<br />
Denmark, 7 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University<br />
Hospital at Frederiksberg, Denmark, 8 Dept. <strong>of</strong> <strong>Rheumatology</strong>,<br />
Copenhagen University Hospital at Hørsholm, Denmark, 9 Dept.<br />
<strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University Hospital at Næstved,<br />
Denmark, 10 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen University<br />
Hospital at Rigshospitalet, Denmark, 11 Dept. <strong>of</strong> <strong>Rheumatology</strong>,<br />
Copenhagen University Hospital at Slagelse, Denmark, 12 Dept. <strong>of</strong><br />
<strong>Rheumatology</strong>, Diakonhjemmet Hospital, Oslo, Norway, 13 Dept.<br />
<strong>of</strong> <strong>Rheumatology</strong>, Hospital <strong>of</strong> South West Jutland at Esbjerg,<br />
Denmark, 14 Dept. <strong>of</strong> <strong>Rheumatology</strong>, King Christian Xth Hospital,<br />
Gråsten, Denmark, 15 Dept. <strong>of</strong> <strong>Rheumatology</strong>, Odense University<br />
Hospital, Denmark, 16 Depts. <strong>of</strong> <strong>Rheumatology</strong>, Copenhagen<br />
University Hospitals at Hvidovre and Glostrup, Denmark.<br />
Systemic Lupus Erythematosus - Clinical Aspects and Treatment-<br />
Epidemiology and Health Services III<br />
1842. Accumulation <strong>of</strong> Traditional Risk Factors for Coronary Heart<br />
Disease in Patients with Systemic Lupus Erythematosus. Rosa<br />
W. Telles 2 , Cristina C. D. Lanna 2 , Fabricia F. Simil 1 , Luana G.<br />
Machado 1 , Fabiana L. Sousa 1 , Luciana A. Rodrigues 2 and Antonio<br />
L. Ribeiro 3 , 1 Hospital das Clinicas, 2 School <strong>of</strong> Medicine, 3 School<br />
<strong>of</strong> Medicine-Universidade Federal de Minas Gerias-Brazil.<br />
1843. Analysis <strong>of</strong> the Level <strong>of</strong> Agreement between Different<br />
Measures <strong>of</strong> Disease Flare in an Exploratory Study <strong>of</strong><br />
Abatacept in Systemic Lupus Erythematosus (SLE). Caroline<br />
Gordon 3 , Jean-Claude Becker 1 , Sheila Kelly 1 , Yun Peng 2 ,<br />
Michael Kinaszczuk 1 and Joan T. Merrill 4 , 1 Bristol-Myers Squibb,<br />
Princeton, NJ, 2 Bristol-Myers Squibb, Pennington, NJ, 3 University<br />
<strong>of</strong> Birmingham, Birmingham, United Kingdom, 4 University <strong>of</strong><br />
Oklahoma, Oklahoma City, OK.<br />
1844. Anti-NR2A Antibody as a Predictor for Neuropsychiatric<br />
Systemic Lupus Erythematosus. Masanori Hanaoka 3 ,<br />
Takahisa Gono 3 , Yasushi Kawaguchi 1 , Hirotaka Kaneko 2 , Katsuji<br />
Nishimura 2 , Yasuhiro Katsumata 2 , Yuko Okamoto 2 , Sayumi<br />
Baba 2 , Sayuri Kataoka 2 and Hisashi Yamanaka 4 , 1 Tokyo Women’s<br />
Medical Univ, Tokyo, Japan, 2 Tokyo Women’s Medical Univ,<br />
3<br />
Tokyo Women’s Medical University, 4 Tokyo Womens Med Univ,<br />
Shinjuku-ku, Tokyo, Japan.<br />
1845. Assessing the ANA Test as a Screening Tool: Utility or Futility?<br />
Aryeh M. Abeles and Micha Abeles, University <strong>of</strong> Connecticut<br />
Health Center.<br />
1846. Atherosclerosis in SLE: A Cross Sectional Study <strong>of</strong> 223 Patients<br />
with 223 Individually Matched Population Controls. Johanna<br />
T. Gustafsson 2 , Kerstin Urstad Jensen 1 , Marie Herlitz-Lindberg 1 ,<br />
Sonia Möller 4 , Susanne Petterson 3 , Iva Gunnarsson 2 and<br />
Elisabet Svenungsson 2 , 1 Department <strong>of</strong> Clinical Physiology,<br />
Södersjukhuset, Karolinska Institute, Stockholm, Sweden,
ACR/ARHP Poster Session C<br />
2<br />
Department <strong>of</strong> Medicine Solna, Karolinska Institute.<br />
<strong>Rheumatology</strong> Unit, Karolinska University Hospital, Stockholm,<br />
Sweden, 3 Department <strong>of</strong> Neurobiology, Care Sciences and<br />
Society (NVS), Division <strong>of</strong> Nursing, Karolinska Institutet,<br />
<strong>Rheumatology</strong> Unit, Karolinska University Hospital, Stockholm,<br />
Sweden, 4 <strong>Rheumatology</strong> Unit, Karolinska University Hospital,<br />
Stockholm, Sweden.<br />
1847. Autoantibodies Predate the Onset <strong>of</strong> Systemic Lupus<br />
Erythematosus. Solbritt Rantapää-Dahlqvist 2 , Catharina<br />
Eriksson 1 , Heidi Kokkonen 1 , Martin Johansson 1 , Göran Hallmans 1<br />
and Göran Wadell 1 , 1 Umeå, Sweden, 2 <strong>Rheumatology</strong>, Umeå,<br />
Sweden.<br />
1848. Belimumab, a BLyS-Specific Inhibitor, Improved Fatigue and<br />
SF-36 Physical and Mental Component Summary Scores in<br />
Patients with SLE: BLISS-76 and -52 Studies. V. Strand 8 , R.<br />
A. Levy 3 , R. Cervera 2 , M. A. Petri 6 , H. Rudge 1 , L. Pineda 5 , W.<br />
Freimuth 5 , Z. J. Zhong 4 , A. E. Clarke 7 and for the BLISS- 76 and<br />
- 52 Study Group, 1 GlaxoSmithKline, Uxbridge, Uxbridge, UK,<br />
2<br />
Hospital Clinic, Barcelona, Spain, 3 Hospital Universitário Pedro<br />
Ernesto, Rio de Janeiro, Brazil, 4 Human Genome Sciences,<br />
Inc, Rockville, MD, 5 Human Genome Sciences, Inc, Rockville,<br />
Rockville, MD, 6 Johns Hopkins University School <strong>of</strong> Medicine,<br />
Timonium, MD, 7 McGill University Health Centre, Montreal, QC,<br />
Canada, 8 Stanford University, Palo Alto, Portola Valley, CA.<br />
1849. Causes and Predictors <strong>of</strong> Death in 181 Brazilian Patients with<br />
Systemic Lupus. Rosa W. Telles 2 , Cristina C. D. Lanna 2 , Rodrigo<br />
C. P. Reis 4 , Fabiana L. Sousa 1 , Luciana A. Rodrigues 2 and Antonio<br />
L. Ribeiro 3 , 1 Hospital das Clinicas, 2 School <strong>of</strong> Medicine, 3 School<br />
<strong>of</strong> Medicine-Universidade Federal de Minas Gerais-Brazil,<br />
4<br />
Statistics Department.<br />
1850. Cigarette Smoking and Cutaneous Damage in Patients with<br />
Systemic Lupus Erythematosus. Josiane Bourré-Tessier 5 ,<br />
Christine A. Peschken 13 , Lawrence Joseph 5 , Patrick Belisle 5 ,<br />
Ann E. Clarke 7 , Sasha R. Bernatsky 3 , Marie Hudson 6 , Carol A.<br />
Hitchon 14 , Shikha Mittoo 13 , Janet E. Pope 8 , Paul R. Fortin 11 , C.<br />
Douglas Smith 10 , Hector Arbillaga 2 , Dafna D. Gladman 12 , Murray<br />
B. Urowitz 9 , Michel Zummer 1 , CANIOS 1000 Canadian Faces <strong>of</strong><br />
Lupus Investigators 15 and Christian A. Pineau 4 , 1 Ch Maisonneuve-<br />
Rosemont, Montreal, QC, Canada, 2 Chinook Regional Hospital,<br />
3<br />
McGill UHC/RVH, Montreal, QC, Canada, 4 McGill Univ Health<br />
Center, Montreal, QC, Canada, 5 McGill University, 6 McGill<br />
University and Jewish General Hospital, 7 Montreal General<br />
Hospital, Montreal, QC, Canada, 8 St Joseph Health Care London,<br />
London, ON, Canada, 9 The Toronto Western Hospital, Toronto,<br />
ON, Canada, 10 TOH Riverside Campus, Ottawa, ON, Canada,<br />
11<br />
Toronto Western Hospital, Toronto, ON, Canada, 12 Toronto<br />
Western Hospital, Toronto, ON, Canada, 13 Univ <strong>of</strong> Manitoba,<br />
Winnipeg, MB, Canada, 14 University <strong>of</strong> Manitoba, Winnipeg,<br />
MB, Canada, 15 Various Sites.<br />
1851. Clinical and Serologic Characteristics <strong>of</strong> Filipino Multiplex<br />
Systemic Lupus Erythematosus (SLE). Helmar F. Soldevilla and<br />
Sandra V. Navarra, University <strong>of</strong> Santo Tomas, Philippines.<br />
1852. CNS Lupus: The Prevalence and Antibodies Depend on the<br />
Definition. Results from the 1000 Faces <strong>of</strong> Lupus Cohort. Alan<br />
Borowoy 3 , Christine A. Peschken 2 and Janet E. Pope 1 , 1 St Joseph<br />
Health Care London, London, ON, Canada, 2 Univ <strong>of</strong> Manitoba,<br />
Winnipeg, MB, Canada, 3 University <strong>of</strong> Western Ontario, London,<br />
ON, Canada.<br />
1853. Cognitive Disfunction in Young Patients within the Early-<br />
Years If the Disease. An Inception-Cohort Study. Ali Duarte-<br />
Garcia 2 , Sandra Juárez-Arellano, Juanita Romero-Diaz, Hilda<br />
Fragoso-Loyo and Jorge Sánchez-Guerrero 1 , 1 Insituto Nacional<br />
de Ciencias Medicas y Nutricion Salvador Zubiran, México,<br />
2<br />
Instituto Nacional de Nutricion Salvador Zubiran.<br />
1854. Cognitive Dysfunction in Patients with SLE: A Prospective<br />
Study. Andres Piatti 2 , Tara Adhikari 2 and Michael Luggen 1 ,<br />
1<br />
University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong> Medicine, Cincinnati, OH,<br />
2<br />
University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong> Medicine.<br />
1855. Cognitive Dysfunction in Systemic Lupus Erythematosus:<br />
Development <strong>of</strong> a Screening Tool. Tara Adhikari 2 , Andres<br />
Piatti 2 and Michael Luggen 1 , 1 University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong><br />
Medicine, Cincinnati, OH, 2 University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong><br />
Medicine.<br />
1856. Determinants <strong>of</strong> Treatment Adherence in Patients with<br />
Systemic Lupus Erythematosus (SLE). Shazia A. Beg 1 , S<strong>of</strong>ia<br />
de Achaval 2 , Michael A. Kallen 2 , Vanessa L. Cox 2 , Marsha N.<br />
Richardson 2 , John D. Reveille 3 and Maria E. Suarez-Almazor 4 ,<br />
1<br />
Baylor <strong>College</strong> <strong>of</strong> Medicine, Houston, TX, 2 The University <strong>of</strong><br />
Texas M. D. Anderson Cancer Center, Houston, TX, 3 Univ Texas<br />
Health Sci Ctr, Houston, TX, 4 University <strong>of</strong> Texas, MD Anderson<br />
Cancer Center, Houston, TX.<br />
1857. Discordance between Self-Report and Physician-<br />
Assessed Disease Activity in Patients with Systemic Lupus<br />
Erythematosus (SLE): Implications for Clinical Trial Design and<br />
Clinical Care. Anca D. Askanase 3 , Isabel Castrejón 4 , Jill P. Buyon 5 ,<br />
Yusuf Yazici 1 and Theodore Pincus 2 , 1 Hospital for Joint Diseases,<br />
Hastings on Hudson, NY, 2 New York University Hospital for<br />
Joint Disease, Hastings-on-Hudson, NY, 3 NYU Hospital for Joint<br />
Diseases, New York, NY, 4 NYU Hospital for Joint Diseases, 5 NYU<br />
School <strong>of</strong> Medicine, New York, NY.<br />
1858. Ethnicity Affects the Frequency <strong>of</strong> CNS Manifestations <strong>of</strong> SLE.<br />
Maryna Shayuk 2 , Hong Fang 2 and Michelle A. Petri 1 , 1 Timonium,<br />
MD, 2 Johns Hopkins University.<br />
1859. Five Year Follow-Up Study <strong>of</strong> Bone Mineral Density in Patients<br />
with Systemic Lupus Erythematosus: The Influence <strong>of</strong><br />
Corticosteroid Treatment. Anna M. Schilder, Jonathan Jacobs,<br />
Lindy-Anne Korswagen, Ben A. C. Dijkmans, Willem F. Lems,<br />
Alexandre E. Voskuyl and Irene E. M. Bultink, VU University<br />
Medical Center, Amsterdam, The Netherlands.<br />
1860. High Prevalence <strong>of</strong> Fetal Loss and Pregnancy Complications<br />
in African-<strong>American</strong> Lupus Patients: A Retrospective Case-<br />
Control Study. Kirk C. Eddleman 2 and Vikas Majithia 1 , 1 University<br />
<strong>of</strong> Mississippi Medical Center, Jackson, MS, 2 University <strong>of</strong><br />
Mississippi Medical Center.<br />
1861. Hyperuricemia Is a Predictor <strong>of</strong> Subclinical CVD in SLE Patients<br />
but Not Controls. Joseph L. Enama 2 , Robert Gilkeson 1 and<br />
Lisabeth Scalzi 2 , 1 Case Western Reserve University, 2 Penn State<br />
Univ Hershey, Hershey, PA.<br />
1862. Identifying Modifiable Risk Factors for Depression in Systemic<br />
Lupus Erythematosus. David Karol 2 , Lisa G. Criscione-Schreiber 2<br />
and Megan E. B. Clowse 1 , 1 Duke Univ Med, Durham, NC, 2 Duke<br />
University, Durham, NC.<br />
1863. In Systemic Lupus Erythematosus (SLE) Patients, Patient<br />
Reported Outcomes and Physician Assessment <strong>of</strong> Disease<br />
Activity Are Poorly Correlated: Implications for Outcome<br />
Measures in SLE. Magaly Villafradez Diaz 1 , Ashwini Shadakshari,<br />
Andy McCracken, Christopher Swearingen, Daniel Ricciardi and<br />
Yusuf Yazici 2 , 1 Long Island <strong>College</strong> Hospital, 2 NYU Hospital for<br />
Joint Diseases.<br />
1864. Incidence and Predictors <strong>of</strong> Hospitalization in Systemic Lupus<br />
Erythematosus (SLE): Results from a Large Contemporary<br />
Multi-Ethnic Cohort. June Lee 3 , Janet E. Pope 1 , Christine A.<br />
Peschken 2 and The 1000 Faces <strong>of</strong> Lupus, 1 St Joseph Health Care<br />
London, London, ON, Canada, 2 Univ <strong>of</strong> Manitoba, Winnipeg,<br />
MB, Canada, 3 University <strong>of</strong> Western Ontario, London, ON,<br />
Canada.<br />
2010 Program Book 263
ACR/ARHP Poster Session C<br />
1865. Measuring Therapeutic Adherence in Systemic Lupus<br />
Erythematosus (SLE) Using the Medication Event Monitoring<br />
System (MEMS®). Maria F. Marengo, Christian A. Waimann,<br />
S<strong>of</strong>ia de Achaval, Vanessa L. Cox, Araceli Garcia Gonzalez,<br />
Marsha N. Richardson and Maria E. Suarez-Almazor, The<br />
University <strong>of</strong> Texas M. D. Anderson Cancer Center, Houston, TX.<br />
1866. Mycophenolate M<strong>of</strong>etil (MMF): Physician Prescribing<br />
Practices. Seema Malani 1 and Ellen M. Ginzler 2 , 1 SUNY<br />
Downstate Medical Center, Brooklyn, NY, 2 SUNY-Downstate<br />
Medical Center, Brooklyn, NY.<br />
1867. Novel Cardiovascular Risk Prediction Models in Patients with<br />
Systemic Lupus Erythematosus. Vivian K. Kawai 2 , Annette<br />
M. Oeser 4 , Joseph Solus 3 , Young H. Rho 3 , Paolo Raggi 1 , Aihua<br />
Bian 3 , Tebeb Gebretsadik 3 , Ayumi Shintani 3 and C. Michael<br />
Stein 2 , 1 Emory University, 2 Vanderbilt University, Nashville, TN,<br />
3<br />
Vanderbilt University, 4 VUMC 23 rd Ave South Pierce, Nashville,<br />
TN.<br />
1868. Optimal Frequency <strong>of</strong> Visits for SLE Patients To Capture Disease<br />
Activity over Time. Dominique Ibañez 3 , Dafna D. Gladman 2 and<br />
Murray B. Urowitz 1 , 1 The Toronto Western Hospital, Toronto,<br />
ON, Canada, 2 Toronto Western Hospital, Toronto, ON, Canada,<br />
3<br />
University <strong>of</strong> Toronto Lupus Clinic, Toronto Western Hospital,<br />
Toronto, ON, Canada.<br />
1869. Optimal Frequency <strong>of</strong> Visits To Capture Disease Activity over<br />
Time in SLE Patients with Varying Levels <strong>of</strong> Disease Activity.<br />
Dominique Ibanez 2 , Murray B. Urowitz 3 and Dafna D. Gladman 1 ,<br />
1<br />
Toronto Western Hospital, Toronto, ON, Canada, 2 University <strong>of</strong><br />
Toronto Lupus Clinic, Toronto Western Hospital, 3 University <strong>of</strong><br />
Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON,<br />
Canada.<br />
1870. Performance <strong>of</strong> Anti-Nucleosome, Anti-C1q and Anti-dsDNA<br />
Antibodies for the Diagnosis <strong>of</strong> Concurrent Disease Activity <strong>of</strong><br />
Systemic Lupus Erythematosus. Chi Chiu Mok, Ling Yin Ho, Hoi<br />
Wah Leung and Lap Gate Wong, Tuen Mun Hospital.<br />
1871. Predictive Value <strong>of</strong> High Levels <strong>of</strong> Antinuclear Antibodies in<br />
People without Other Feature <strong>of</strong> Autoinmunity. A Prospective<br />
Study. Ignacio Villa-Blanco 4 , Marcos Lopez-Hoyos 1 , Ana Ruibal 2<br />
and Jaime Calvo-Alen 3 , 1 Hospital “Marques de Valdecilla”,<br />
2<br />
Hospital “Txagorritxu”, 3 Hospital Sierrallana, Torrelavega, Spain,<br />
4<br />
Hospital Sierrallana, Spain.<br />
1872. Preliminary Comparison <strong>of</strong> Health-Related Quality <strong>of</strong> Life<br />
in Children with Lupus across Different Continents. Lakshmi<br />
Nandini Moorthy 14 , Claudia Saad-Magalhães 1 , Juliana Oliveira<br />
Sato 1 , Claudio A. Len 10 , Maria O. Hilário 10 , Flavio Sztajnbok 9 ,<br />
Rozana Gasparello de Almeida 9 , Feng Qi Wu 2 , Xiaolan L. Huang 2 ,<br />
Fernanda Falcini 13 , Donato Rigante 11 , Rolando Cimaz 12 , Jordi<br />
Antón Lopez 8 , Consuelo Modesto 7 , Rubén J. Cuttica 5 , Lisette W.<br />
A. van Suijlekom-Smit 3 , Marieke H. Otten 3 , Maria J. Baratelli 14 ,<br />
Margaret G. E. Peterson 6 , Afton L. Hassett 15 and Thomas J. A.<br />
Lehman 4 , 1 Botucatu Medical School - São Paulo State University,<br />
Brazil, 2 Capital Institute <strong>of</strong> Pediatrics, China, 3 Erasmus MC,<br />
Sophia Childrens Hospital, The Netherlands, 4 Hosp for Special<br />
Surgery, New York, NY, 5 Hospital de Pediatría Pedro de Elizalde,<br />
Argentina, 6 Hospital for Special Surgery, 7 Hospital Infantil<br />
Valle de Hebron, Spain, 8 Hospital Sant Joan de Déu, Spain,<br />
9<br />
Universidade do Estado do Rio de Janeiro, Brazil, 10 Universidade<br />
Federal de São Paulo, Brazil, 11 Università Cattolica Sacro Cuore,<br />
Italy, 12 University <strong>of</strong> Firenze, Firenze, Italy, 13 University <strong>of</strong><br />
Florence, Florence, Italy, 14 University <strong>of</strong> Medicine and Dentistry<br />
<strong>of</strong> NJ - Robert Wood Johnson Medical School, New Brunswick,<br />
NJ, 15 University <strong>of</strong> Michigan Medical School, Ann Arbor, MI.<br />
1873. Prevalence and Risk Factors <strong>of</strong> Glucocorticoid-Induced<br />
Diabetes Mellitus in Patients with Systemic Lupus<br />
Erythematosus. You Jung Ha 1 , Kwang-Hoon Lee 2 , Se-jin Jung 1 ,<br />
Yoon Kang 1 , Min-Chan Park 3 , Sang-Won Lee 1 , Soo Kon Lee 1 and<br />
Yong-Beom Park 1 , 1 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Internal Medicine, Yonsei University <strong>College</strong> <strong>of</strong> Medicine, Seoul,<br />
Korea, Republic <strong>of</strong>, 2 Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Internal Medicine, Yonsei University <strong>College</strong> <strong>of</strong> Medicine, Seoul,<br />
Korea, Republic <strong>of</strong>, 3 Gangnam Severance Hospital, Seoul, Korea,<br />
Republic <strong>of</strong>.<br />
1874. Prolonged Serologically Active Clinically Quiescent (SACQ)<br />
Systemic Lupus Erythematosus (SLE): Novel Predictors <strong>of</strong><br />
Flare? Amanda Steiman 1 , Murray B. Urowitz 2 , Joan E. Wither 4 ,<br />
Dominique Ibañez 1 , Timothy Li 3 and Dafna D. Gladman 1 ,<br />
1<br />
Toronto Western Hospital, Toronto, ON, Canada, 2 Toronto<br />
Western Hospital, Toronto, ON, Canada, 3 Toronto Western<br />
Hospital, 4 University Health Network, Toronto, ON, Canada.<br />
1875. Racial Disparities in Treatment Preferences among Lupus<br />
Patients. Ernest R. Vina, Christopher M. Masi, Stephanie L.<br />
Green and Tammy O. Utset, University <strong>of</strong> Chicago Medical<br />
Center, Chicago, IL.<br />
1876. Risk Factors Associated with the Presence <strong>of</strong> Pneumonia in<br />
Patients with Lupus Erythematosus (SLE): A Nested Case-<br />
Control Study. Iñigo Rúa-Figueroa 1 , Francisco J. Nóvoa 2 , Celia<br />
Erausquin 2 , Miguel Garcia-Bello 2 , Felipe Rodríguez de Castro 2 ,<br />
Juan C. Quevedo 2 , Isabel García-Laorden 2 , Carlos Rodriguez-<br />
Gallego 2 , Felix Francisco 2 and Carlos Rodriguez-Lozano 2 ,<br />
1<br />
Hospital Dr Negrin, Las Palmas GC, Spain, 2 Hospital Dr Negrin.<br />
1877. SLE and Atherosclerotic Risk Factors by Ethnicity and<br />
Geographic Distribution at Inception in a International Cohort<br />
<strong>of</strong> SLE. Murray B. Urowitz 33 , Dafna D. Gladman 22 , Dominique<br />
Ibanez 32 , Caroline P. Gordon 29 , Sang-Cheol Bae 6 , Ann E. Clarke 15 ,<br />
Sasha R. Bernatsky 15 , F. Jorge Sanchez-Guerrero 9 , John G.<br />
Hanly 19 , David A. Isenberg 24 , Anisur Rahman 25 , Paul R. Fortin 33 ,<br />
Daniel J. Wallace 1 , Ellen M. Ginzler 20 , Joan T. Merrill 18 , Graciela S.<br />
Alarcón 28 , Barri J. Fessler 23 , Ian N. Bruce 13 , Gunnar K. Sturfelt 27 ,<br />
Ola Nived 27 , Kristjan Steinsson 12 , Munther A. Khamashta 21 ,<br />
Michelle A. Petri 2 , Rosalind Ramsey-Goldman 17 , Susan Manzi 34 ,<br />
Mary Anne Dooley 31 , Ronald V. Vollenhoven 11 , Cynthia B.<br />
Aranow 4 , Thomas Stoll 10 , Manuel Ramos 7 , Kenneth C. Kalunian 26 ,<br />
Asad A. Zoma 5 , Guillermo Ruiz-Irastorza 8 , Peter J. Maddison 16 ,<br />
Diane L. Kamen 14 , S. Sam Lim 3 and Christine A. Peschken 30 , 1 West<br />
Hollywood, CA, 2 Timonium, MD, 3 Emory University, Atlanta,<br />
GA, 4 Feinstein Institute, Manhasset, NY, 5 Hairmyres Hospital,<br />
East Kilbride, United Kingdom, 6 Hanyang University Medical<br />
Center, Seoul, Korea, Republic <strong>of</strong>, 7 Hospital Clinico I Provincial,<br />
8<br />
Hospital de Cruces, Universidad del Pais Vasco, 9 Instituto<br />
Nacional Nutricion, Mexico City, DF, Mexico, 10 Kantansspital<br />
Schaffhausen, Schaffhausen, Switzerland, 11 Karolinska University<br />
Hospital, 12 Landspitalinn University Hospital, 13 Manchester Royal<br />
Infirmary, Manchester, United Kingdom, 14 Medical University<br />
<strong>of</strong> South Carolina, Charleston, SC, 15 Montreal General Hospital,<br />
Montreal, QC, Canada, 16 North West Wales NHS Trust, Colwyn<br />
Bay, United Kingdom, 17 Northwestern University, Chicago, IL,<br />
18<br />
Oklahoma Medical Research Foundation, Oklahoma City, OK,<br />
19<br />
Queen Elizabeth II Health Services Center, Halifax, NS, Canada,<br />
20<br />
SUNY-Downstate Medical Center, Brooklyn, NY, 21 The Rayne<br />
Institute, London, United Kingdom, 22 Toronto Western Hospital,<br />
Toronto, ON, Canada, 23 UAB <strong>Rheumatology</strong>, Birmingham, AL,<br />
24<br />
UCL Div <strong>of</strong> Medicine, London, United Kingdom, 25 UCL Div <strong>of</strong><br />
Medicine, 26 UCSD School <strong>of</strong> Medicine, La Jolla, CA, 27 University<br />
Hospital Lund, Lund, Sweden, 28 University <strong>of</strong> Alabama, Oakland,<br />
264<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
CA, 29 University <strong>of</strong> Birmingham, Birmingham, United Kingdom,<br />
30<br />
University <strong>of</strong> Manitoba, Winnipeg, MB, Canada, 31 University<br />
<strong>of</strong> North Carolina at Chapel Hill, Chapel Hill, NC, 32 University <strong>of</strong><br />
Toronto Lupus Clinic, Toronto Western Hospital, 33 University <strong>of</strong><br />
Toronto Lupus Clinic, Toronto Western Hospital, Toronto, ON,<br />
Canada, 34 West Penn Allegheny Health System, Pittsburgh, PA.<br />
1878. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-<br />
2K) Responder Index (SRI)-50: A Valid Index for Measuring<br />
Improvement in Disease Activity. Zahi Touma 2 , Dafna D.<br />
Gladman 1 , Dominique Ibañez 2 and Murray B. Urowitz 2 , 1 Toronto<br />
Western Hospital, Toronto, ON, Canada, 2 University <strong>of</strong> Toronto<br />
Lupus Clinic, Toronto Western Hospital, Toronto, ON, Canada.<br />
1879. The Relative Importance <strong>of</strong> Current Versus Past Use <strong>of</strong><br />
Medication in Excess Rates <strong>of</strong> Adverse Cardiovascular Events<br />
among Patients with SLE. Michelle A. Petri 1 and Laurence<br />
S. Magder 2 , 1 Timonium, MD, 2 Department <strong>of</strong> Epidemiology<br />
and Preventive Medicine, University <strong>of</strong> Maryland School <strong>of</strong><br />
Medicine, Baltimore, MD.<br />
1880. Validation <strong>of</strong> CLASI Scale with Lupus Disease Activity, Damage,<br />
Body Image and Quality <strong>of</strong> Life. Meenakshi Jolly 1 , Rachel A.<br />
Mikolaitis 3 , Thomas F. Cash 2 and Joel A. Block 2 , 1 Rush University<br />
Medical Center, Chicago, IL, 2 Rush University Medical Center,<br />
Chicago, IL, 3 Rush University Medical Center.<br />
1881. Validity <strong>of</strong> the ACR Criteria and SLICC Proposed Criteria for the<br />
Diagnosis and Classification <strong>of</strong> Systemic Lupus Erythematosus.<br />
Felipe Rodriguez-García 2 , Karina Santana- de Anda 2 , Ali Duarte-<br />
García 1 , Virginia Pascual-Ramos 2 , Gabriela Hernández-Medina 2 ,<br />
Tatiana Rodríguez-Reyna 2 and Jorge Sanchez-Guerrero 3 ,<br />
1<br />
Instituto Nacional ce Ciencias Medicas y Nutricion Salvador<br />
Zubiran, 2 Instituto Nacional de Ciencias Medicas y Nutricion<br />
Salvador Zubiran, 3 Instituto Nacional de Ciencias Medicas y<br />
Nutricion Salvador Zubiran, Mexico.<br />
1882. Work Disability, Lost Productivity and Associated Risk Factors<br />
in Patients Diagnosed with Systemic Lupus Erythematosus<br />
(SLE). Tammy O. Utset 5 , Barbara M. Segal 6 , Laura Trupin 4 , Sarika<br />
Ogale 1 , Ellen Herberich 2 and Kenneth C. Kalunian 3 , 1 Genentech,<br />
2<br />
Harris Interactive, 3 UCSD School <strong>of</strong> Medicine, La Jolla, CA,<br />
4<br />
University <strong>of</strong> California, San Francisco, 5 University <strong>of</strong> Chicago,<br />
Chicago, IL, 6 University <strong>of</strong> Minnesota, Minneapolis, MN.<br />
Sjögren’s Syndrome<br />
1883. Activation <strong>of</strong> Innate Immunity and Sjögren’s Syndrome<br />
Development. Seshagiri Rao Nandula 1 , Yogesh M. Scindia 2 ,<br />
Harini Bagavant 1 and Umesh S. Deshmukh 2 , 1 University <strong>of</strong><br />
Virginia, Charlottesville, VA, 2 University <strong>of</strong> Virginia.<br />
1884. Anticentromere Antibodies (ACA)-Positive Systemic Sclerosis<br />
(SSc) Patients with Sjögren’s Syndrome: A Distintict Subset at<br />
High Risk <strong>of</strong> Lymphoma. Chiara Baldini, Sara Grossi, Alessandra<br />
Della Rossa, Nicoletta Luciano, Marica Doveri, Antonio<br />
Gaetano Tavoni and Stefano Bombardieri, <strong>Rheumatology</strong> Unit,<br />
Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Pisa, Italy.<br />
1885. Association between Lymphotoxin Alpha Genetic Variants<br />
and Primary Sjögren’s Syndrome in Scandinavian Samples.<br />
Anne Isine Bolstad 1 , Stephanie Le Hellard 2 , Gudlaug Thora<br />
Kristjansdottir 4 , Gunnel Nordmark 4 , Lilian Vasaitis 8 , Marika<br />
Kvarnström 6 , Christopher Sjöwall 13 , Svein Joar Auglænd<br />
Johnsen 9 , Per Eriksson 12 , Roald Omdal 10 , Johan G. Brun 5 , Marie<br />
Wahren-Helenius 6 , Elke Theander 7 , Ann-Christine Syvänen 3 ,<br />
Lars Rönnblom 4 and Roland Jonsson 11 , 1 Department <strong>of</strong><br />
Clinical Dentistry-Periodontics, University <strong>of</strong> Bergen, Bergen,<br />
Norway, 2 Department <strong>of</strong> Clinical Medicine, University <strong>of</strong><br />
Bergen, Center <strong>of</strong> Medical Genetics and Molecular Medicine,<br />
Haukeland University Hospital, Bergen, Norway, 3 Department<br />
<strong>of</strong> Medical Sciences, Molecular Medicine, Uppsala University,<br />
Uppsala, Sweden, 4 Department <strong>of</strong> Medical Sciences, Section<br />
<strong>of</strong> <strong>Rheumatology</strong>, Uppsala University, Uppsala, Sweden,<br />
5<br />
Department <strong>of</strong> Medicine, Section <strong>of</strong> <strong>Rheumatology</strong>, University<br />
<strong>of</strong> Bergen, Bergen, Norway, 6 Karolinska Institutet, Stockholm,<br />
Sweden, 7 Malmö University Hospital, Malmö, Sweden, 8 Section<br />
<strong>of</strong> <strong>Rheumatology</strong>, Uppsala University, Uppsala, Sweden,<br />
9<br />
Stavanger University Hospital, Stavanger, Norway, 10 Stavanger<br />
University Hospital, Stavanger, Norway 11 The Gade Institute,<br />
University <strong>of</strong> Bergen, Bergen, Norway, 12 University Hospital<br />
Linköping, Sweden, Linköping, Sweden, 13 University Hospital,<br />
Linköping, Linköping, Sweden.<br />
1886. B-Cell Pr<strong>of</strong>iling Using Multi-Color Flow Cytometry as Biomarker<br />
<strong>of</strong> Disease Progression in Primary Sjogren’s Syndrome<br />
(pSS). Mustimbo Roberts 2 , Craig Maguire 3 , Alex Rosenberg 3 ,<br />
Andreea Coca 2 , Jennifer H. Anolik 1 and Iñaki Sanz 2 , 1 University<br />
<strong>of</strong> Rochester, Rochester, NY, 2 University <strong>of</strong> Rochester Medical<br />
Center, Rochester, NY, 3 University <strong>of</strong> Rochester Medical Center.<br />
1887. Best Scintigraphic Measures <strong>of</strong> Parotid Gland Dysfunction in<br />
Sjogren’s Syndrome. Anthony Keyes 4 , Julius Birnbaum 2 , John<br />
Petronis 1 and Alan N. Baer 3 , 1 Johns Holins University School <strong>of</strong><br />
Medicine, 2 Johns Hopkins University, Baltimore, MD, 3 Johns<br />
Hopkins University, Baltimore, MD, 4 Johns Hopkins University<br />
School <strong>of</strong> Medicine.<br />
1888. Clinical and Immunological Pr<strong>of</strong>ile <strong>of</strong> Patients with Primary<br />
Sjogren Syndrome Who Developed B-Cell Lymphoma. Analysis<br />
<strong>of</strong> 1010 Spanish Patients (The GEMESS Cohort). Manuel<br />
Ramos-Casals 3 , Roser Solans 11 , Jose Rosas 6 , Maria Teresa<br />
Camps 2 , Antonio Gil 9 , Javier Del-Pino 10 , Carmen Hidalgo 12 ,<br />
Jaime Calvo 4 , Maria Luisa Mico 8 , Roberto Perez-Alvarez 7 , Rafael<br />
Belenguer 1 and Lucio Pallares 5 , 1 Hospital 9 d’Octubre, València,<br />
Spain, 2 Hospital Carlos Haya, Malaga, Spain, 3 Hospital Clinic,<br />
Barcelona, Spain, 4 Hospital de Sierrallana, Torrelavega, Spain,<br />
5<br />
Hospital de Son Dureta, Palma de Mallorca, Spain, 6 Hospital<br />
de Vilajoyosa, Alicante, Spain, 7 Hospital do Meixoeiro, Vigo,<br />
Spain, 8 Hospital La Fe, Valencia, Spain, 9 Hospital La Paz, Madrid,<br />
Spain, 10 Hospital Universitario de Salamanca, Salamanca, Spain,<br />
11<br />
Hospital Vall d’Hebron, Barcelona, Spain, 12 Hospital Virgen de<br />
las Nieves, Granada, Spain.<br />
1889. Clonal Analysis <strong>of</strong> Ig-Expressing Cells in Salivary Glands<br />
<strong>of</strong> Primary Sjögren’s Syndrome Patients after Anti-CD20<br />
Treatment. Nishath Hamza 3 , Hendrika Bootsma 4 , Rodney<br />
P. E. Pollard 2 , Jiska M. Meijer 2 , Fred K. L. Spijkervet 2 , Arjan<br />
Vissink 2 , Hans G. M. Burgerh<strong>of</strong> 5 , Frans G. M. Kroese 1 , Cees G.<br />
M. Kallenberg 4 and Nicolaas A. Bos 1 , 1 Dept. <strong>of</strong> Cell Biology,<br />
Immunology Section, University Medical Center Groningen,<br />
University <strong>of</strong> Groningen, Groningen, The Netherlands,<br />
2<br />
Dept. <strong>of</strong> Oral and Maxill<strong>of</strong>acial Surgery, University Medical<br />
Center Groningen, University <strong>of</strong> Groningen, Groningen, The<br />
Netherlands, 3 Dept. <strong>of</strong> <strong>Rheumatology</strong> and Clinical Immunology<br />
& Dept. <strong>of</strong> Cell Biology, Immunology Section, University<br />
Medical Center Groningen, University <strong>of</strong> Groningen, Groningen,<br />
The Netherlands, 4 Dept. <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />
Immunology, University Medical Center Groningen, University<br />
<strong>of</strong> Groningen, Groningen, The Netherlands, 5 University Medical<br />
Center Groningen, University <strong>of</strong> Groningen, Groningen, The<br />
Netherlands.<br />
2010 Program Book 265
ACR/ARHP Poster Session C<br />
1890. Correlation <strong>of</strong> Serum BAFF and Markers <strong>of</strong> B-Cell Activation<br />
with Systemic Involvement Assessed by the EULAR Sjögren’s<br />
Syndrome Disease Activity Index: Results from the ASSESS<br />
Prospective Cohort. Jacques-Eric Gottenberg 16 , Raphaele<br />
Seror 2 , Joelle Benessiano 3 , Karine Inamo 2 , Philippe Dieude 3 ,<br />
Jean-Jacques Dubost 5 , Anne-Laure Fauchais 11 , Eric Hachulla 10 ,<br />
Claire Larroche 1 , Veronique Le Guern 6 , Jacques Morel 12 , Aleth<br />
Perdriger 14 , Xavier Puéchal 9 , Stéphanie Rist 13 , Alain Saraux 4 ,<br />
Damien Sene 7 , Jean Sibilia 16 , Olivier Vittecoq 15 , Charles<br />
Zarnitsky 8 , Philippe Ravaud 3 and Xavier Mariette 2 , 1 Avicenne<br />
Hospital, 2 Bicetre Hospital, 3 Bichat Hospital, 4 Brest Hospital,<br />
5<br />
Clermont-Ferrand Hospital, 6 Cochin Hospital, 7 La Pitié Hospital,<br />
8<br />
Le Havre Hospital, 9 Le Mans Hospital, 10 Lille Hospital, 11 Limoges<br />
Hospital, 12 Montpellier Hospital, 13 Orleans Hospital, 14 Rennes<br />
Hospital, 15 Rouen Hospital, 16 Strasbourg Hospital.<br />
1891. Detection <strong>of</strong> HTLV-1 p19 Protein in Labial Salivary Glands<br />
from Patients with Sjögren’s Syndrome: A Distinct Clinical<br />
Subgroup? Sung-Ji Lee 1 , Seong-Rye Seo 1 , Tae-Jong Kim 1 , Yong-<br />
Wook Park 1 and Shin-Seok Lee 2 , 1 Chonnam National University<br />
Medical School, 2 Chonnam Natl Univ Med School, Gwangju,<br />
Korea, Republic <strong>of</strong>.<br />
1892. Effect <strong>of</strong> Rituximab Treatment on BAFF Levels in Patients with<br />
Primary Sjögren’s Syndrome: A Placebo-Controlled Clinical<br />
Trial. Rodney Pollard 2 , Wayel Abdulahad 2 , Jiska Meijer 2 , Frans<br />
Kroese 2 , Fred Spijkervet 2 , Cees Kallenberg 1 , Arjan Vissink 2 and<br />
Hendrika Bootsma 2 , 1 Univer Med Center Groningen, Groningen,<br />
The Netherlands, 2 Univer Med Center Groningen.<br />
1893. Efficacy <strong>of</strong> Rituximab in Primary Sjogren’s Syndrome with<br />
Peripheral Nervous System Involvement: Results from the<br />
French AIR Registry. Arsene Mekinian 6 , Eric Hachulla 9 , Claire<br />
Larroche 2 , Jean Leone 11 , Bruno Gomberg 7 , Mohamed Hamidou 8 ,<br />
Alain G. Cantagrel 5 , Christian Marcelli 4 , Stephanie Rist 10 , Maxime<br />
A. Breban 1 , Olivier Fain 6 , Jacques E. Gottenberg 12 and Xavier<br />
Mariette 3 , 1 Courbevoie, France, 2 Avicenne Hospital, 3 Bicetre<br />
Hospital/Paris Univ, Le Kremlin Bicetre, France, 4 Caen Hospital,<br />
5<br />
Hopital Purpan, Toulouse, France, 6 Jean Verdier Hospital, 7 La<br />
Rochelle Hospital, 8 Nantes Hospital, 9 National Scleroderma<br />
Centre, Lille Cedex, France, 10 Orleans Hospital, 11 Reims Hospital,<br />
12<br />
Strasbourg Hospitals, Strasbourg, France.<br />
1894. Efficacy <strong>of</strong> Rituximab in Primary Sjogren’s Syndrome with<br />
Central Nervous System Involvement: Results from the<br />
French AIR Registry. Arsene Mekinian 4 , Claire Larroche 1 , Eric<br />
Hachulla 7 , Bruno Gomberg 6 , Claire Blanchard-Delaunay 8 , Alain<br />
G. Cantagrel 3 , Olivier Fain 5 , Jean Sibilia 9 , Jacques E. Gottenberg 10<br />
and Xavier Mariette 2 , 1 Avicenne Hospital, 2 Bicetre Hospital/Paris<br />
Univ, Le Kremlin Bicetre, France, 3 Hopital Purpan, Toulouse,<br />
France, 4 Jean Verdier Hospital, 5 Jean Verdier Hospital, 6 La<br />
Rochelle Hospital, 7 National Scleroderma Centre, Lille Cedex,<br />
France, 8 Niort Hospital, 9 Strasbourg Hospital, 10 Strasbourg<br />
Hospitals, Strasbourg, France.<br />
1895. Epitope Mapping <strong>of</strong> the Autoantigen Aquaporin-4 Reveals<br />
Linear Epitopes Located in the Intracellular Region <strong>of</strong> the<br />
Molecule. Eleni I. Kabylafka 1 , John G. Routsias 1 , Haralampos<br />
Alexopoulos 1 and Athanasios G. Tzioufas 2 , 1 Department <strong>of</strong><br />
Pathophysiology, Medical School <strong>of</strong> Athens, Athens, Greece,<br />
2<br />
Medical School-Univ <strong>of</strong> Athens, Athens, Greece.<br />
1896. EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI):<br />
Development <strong>of</strong> a Consensus Patient Index for Primary<br />
Sjögren’s Syndrome. Raphaèle Seror 5 , Philippe Ravaud 13 , Xavier<br />
Mariette 4 , Hendrika Bootsma 18 , Elke Theander 9 , Arne Hansen 3 ,<br />
Manel Ramos-Casals 1 , Thomas Dörner 3 , Stefano Bombardieri 20 ,<br />
Eric Hachulla 11 , Johan G. Brun 17 , Aike A. Kruize 19 , Sonja<br />
Praprotnik 14 , Matija Tomsic 14 , Jacques E. Gottenberg 12 , Valerie<br />
Devauchelle 6 , Salvatore Devita 16 , Cristina Vollenweider 8 , Thomas<br />
Mandl 9 , Athanasios G. Tzioufas 10 , Steven E. Carsons 22 , Alain<br />
Saraux 7 , Nurhan Sutcliffe 2 , Claudio Vitali 21 , Simon J. Bowman 15<br />
and The EULAR Sjögren’s Task Force, 1 ”Josep Font”, Hospital<br />
Barcelona, 2 Barts &The Royal London Hospital, 3 Berlin Charité,<br />
University Hospital, 4 Bicetre Hospital/Paris Univ, Le Kremlin<br />
Bicetre, France, 5 Bicetre Hospital/Paris Univ, Le Kremlin Bicetre,<br />
France, 6 CHU de la Cavale Blanche, 7 CHU de la Cavale Blanche,<br />
Brest Cedex, France, 8 German Hospital, Buenos-Aires, 9 Malmö<br />
University Hospital, 10 Medical School-Univ <strong>of</strong> Athens, Athens,<br />
Greece, 11 National Scleroderma Centre, Lille Cedex, France,<br />
12<br />
Strasbourg Hospitals, Strasbourg, France, 13 Université Paris<br />
Descartes, 14 University Clinical Centre <strong>of</strong> Ljubljana, 15 University<br />
Hospital Birmingham NHS Foundation, 16 University Hospital <strong>of</strong><br />
Udine, 17 University Hospital, Bergen, 18 University Medical Center<br />
Groningen, 19 University Medical Center Utrecht, 20 University <strong>of</strong><br />
Pisa, 21 Villamarina Hospital, 22 Winthrop Univ Hospital, Mineola,<br />
NY.<br />
1897. Evolution <strong>of</strong> Autoimmune Minor Salivary Gland (MSG) Lesions<br />
in Sjögren’s Syndrome (SS). Efstathia K. Kapsogeorgou 3 ,<br />
Maria I. Christodoulou 4 , Demosthenes B. Panagiotakos 2 ,<br />
Spyros Paikos 1 and Haralampos M. Moutsopoulos 4 , 1 Dental<br />
Department, “Laikon” General Hospital <strong>of</strong> Athens, Athens,<br />
Greece, 2 Dietetics and Nutrition Dept, Harokopio University <strong>of</strong><br />
Athens, 3 Pathophysiology Dept, School <strong>of</strong> Medicine, National<br />
University <strong>of</strong> Athens, Athens, Attica, Greece, 4 Pathophysiology<br />
Dept, School <strong>of</strong> Medicine, National University <strong>of</strong> Athens, Athens,<br />
Greece.<br />
1898. Extra-Glandular Manifestations <strong>of</strong> Primary Sjögren’s<br />
Syndrome in the SICCA International Sjögren’s Syndrome<br />
Registry. Arundathi S. Malladi 12 , Kenneth E. Sack 8 , Stephen<br />
Shiboski 10 , Caroline Shiboski 10 , Alan N. Baer 2 , Pekka Helin 7 , Bruce<br />
Kirkham 4 , Hisanori Umehara 3 , Frederick B. Vivino 6 , Cristina<br />
F. Vollenweider 1 , Yan Zhao 5 , John Greenspan 10 , Troy Daniels 9<br />
and Lindsey A. Criswell 11 , 1 German Hospital, Buenos Aires,<br />
Argentina, 2 Johns Hopkins University, Baltimore, MD, 3 Kanazawa<br />
Medical University, Ishikawa, Japan, 4 King’s <strong>College</strong> London, UK,<br />
5<br />
Peking Union Medical <strong>College</strong> Hospital, Beijing, China, 6 Penn<br />
Presbyt Med Ctr, Philadelphia, PA, 7 Rigshospitalet, Copenhagen,<br />
Denmark, 8 UCSF, Tiburon, CA, 9 UCSF, San Francisco, CA, 10 UCSF,<br />
11<br />
UCSF-Box 0500, San Francisco, CA, 12 University <strong>of</strong> California at<br />
San Francisco (UCSF), San Francisco, CA.<br />
1899. Germinal Center (GC) Formation in Salivary Gland Biopsies at<br />
Diagnosis <strong>of</strong> Primary Sjögren’s Syndrome (pSS) Is a New and<br />
Strong Predictor <strong>of</strong> Non-Hodgkin’s Lymphoma (NHL) during<br />
Follow-Up. Elke Theander 4 , Lilian Vasaitis 3 , Eva Baecklund 5 ,<br />
Gunnel Nordmark 5 , Gunnar Warfvinge 4 , Rolf Liedholm 4 , Karl<br />
Brokstad 1 , Roland Jonsson 1 and Malin V. Jonsson 2 , 1 University <strong>of</strong><br />
Bergen, Bergen, Norway, 2 University <strong>of</strong> Bergen, Bergen, Norway,<br />
3<br />
University <strong>of</strong> Lund, Uppsala, Sweden, 4 University <strong>of</strong> Lund,<br />
Malmö, Sweden, 5 University <strong>of</strong> Uppsala, Uppsala, Sweden.<br />
266<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
1900. IL-7 Receptor Effector T Cells Are Increased in the Inflamed<br />
Salivary Glands <strong>of</strong> pSS Patients and Correlate with<br />
Inflammatory Markers. A. Bikker, A. A. Kruize, M. J. G. Wenting,<br />
J. W. J. Bijlsma, F. P. J. G. Lafeber and J. A. G. van Roon,<br />
<strong>Rheumatology</strong> &Clinical Immunology, University Medical Center<br />
Utrecht, The Netherlands.<br />
1901. Immunization with Ro60 Peptide Leads to Sjögren’s Like<br />
Syndrome in Mice with Appropriate Genetic Background.<br />
Biji T. Kurien 1 , Sima Asfa 3 , Anil D’souza 3 , Yaser Dorri 3 , Skyler P.<br />
Dillon 3 , Sherry Hubbel 3 , Ali W. Khalili 2 , Olga Yelios<strong>of</strong>, Yun Jong<br />
Lee, Shannon Maier 3 and R. Hal Sc<strong>of</strong>ield 3 , 1 Oklahoma Medical<br />
Research Foundation, 2 University <strong>of</strong> Oklahoma, 3 University <strong>of</strong><br />
Oklahoma Health Sciences Center.<br />
1902. Impaired Gastric Emptying in Primary Sjögren’s Syndrome.<br />
Oskar Hammar, Bodil Ohlsson, Per Wollmer and Thomas Mandl,<br />
Skåne University Hospital Malmö, Malmö, Sweden.<br />
1903. Increased Numbers <strong>of</strong> IL-7Rα-CD25+FoxP3+ T Cells in pSS<br />
Patients Do Not Prevent Th1 and Th17 Induction by IL-7. A.<br />
Bikker, F. M. Moret, A. A. Kruize, J. W. J. Bijlsma, F. P. J. G. Lafeber<br />
and J. A. G. van Roon, <strong>Rheumatology</strong> & Clinical Immunology,<br />
University Medical Center Utrecht, The Netherlands.<br />
1904. Interferon Type I Signature in Monocytes in Primary Sjögren’s<br />
Syndrome. Zana Brkic 1 , Cornelia G. van Helden-Meeuwsen 1 ,<br />
Joop van der Merwe 1 , Hemmo A. Drexhage 1 and Marjan A.<br />
Versnel 2 , 1 Dept Immunology, Rotterdam, The Netherlands, 2 Dept<br />
Immunology, Erasmus MC, Rotterdam, The Netherlands.<br />
1905. Is Retreatment with Rituximab in Patients with Primary<br />
Sjögren’s Syndrome Safe and Effective? Petra M. Meiners,<br />
Arjan Vissink, Jiska M. Meijer, Fred K. .L Spijkervet, Cees G. M.<br />
Kallenberg and Hendrika Bootsma, University Medical Center<br />
Groningen, Groningen, The Netherlands.<br />
1906. Molecular and Cellular Evolution <strong>of</strong> Functional Tertiary<br />
Lymphoid Structures in Salivary Glands <strong>of</strong> NOD Mice. Elisa<br />
Astorri 3 , Michele Bombardieri 3 , Elisa Corsiero 3 , Francesca<br />
Barone 1 , Gordon Proctor 2 and Costantino Pitzalis 3 , 1 Birmingham<br />
University, Birmingham, United Kingdom, 2 King’s <strong>College</strong>,<br />
London, London, United Kingdom, 3 Queen Mary University<br />
London, London, United Kingdom.<br />
1907. New Classification Criteria for Childhood Sjögren’s Syndrome.<br />
Naoto Yokogawa 8 , Scott M. Lieberman 1 , Sharon M. Bout-<br />
Tabaku 3 , Faizan Alawi 7 , Juan P. Palazzo 6 , Martha Guttenberg 2 ,<br />
David D. Sherry 5 and Frederick B. Vivino 4 , 1 Children’s Hosp <strong>of</strong><br />
Philadelphia, Philadelphia, PA, 2 Children’s Hosp <strong>of</strong> Philadelphia,<br />
3<br />
Nationwide Children’s Hospital, Columbus, OH, 4 Penn<br />
Presbyt Med Ctr, Philadelphia, PA, 5 The Children’s Hospital <strong>of</strong><br />
Philadelphia, Philadelphia, PA, 6 Thomas Jefferson Univ., 7 Univ. <strong>of</strong><br />
Pennsylvania, 8 Univ. <strong>of</strong> Pennsylvania / Tokyo Metropolitan Tama<br />
Medical Center.<br />
1908. New Insights in Sjögren Syndrome Associated Peripheral<br />
Neuropathies: The Small Fibre Neuropathy and Its Clinical,<br />
Immunological and Neurophysiological Features from a<br />
Moncentre Cohort <strong>of</strong> 24 Patients. Damien Sène 2 , Jean-Pascal<br />
Lefaucheur 1 , Julien Haroche 2 , David Saadoun 2 , Baptiste Hervier 2 ,<br />
Jean-Charles Piette 2 , Zahir Amoura 2 and Patrice Cacoub 2 , 1 Henri-<br />
Mondor Hospital, 2 Pitié-Salpêtrière Hospital.<br />
1909. Novel Lupus Susceptible Gene Polymorphisms in Patients with<br />
Sjögren’s Syndrome in Japanese Population. Tetsuya Horita 1 ,<br />
Hisako Nakagawa 1 , Takashi Kurita 1 , Toshio Odani 1 , Yuichiro<br />
Fujieda 1 , Kotaro Otomo 2 , Masaru Kato 1 , Shinsuke Yasuda 1 ,<br />
Tatsuya Atsumi 1 and Takao Koike 1 , 1 Medicine II, Hokkaido<br />
University, Sapporo, Hokkaido, Japan, 2 Medicine II, Hokkaido<br />
University.<br />
1910. Patients’ Complaints Depend on Systemic Status in Patient<br />
with Primary Sjögren ‘s Syndrome: Concordant Results from<br />
2 Independant Cohorts. Raphaèle Seror 3 , Philippe Ravaud 23 ,<br />
Simon J. Bowman 24 , Hendrika Boostma 25 , Manel Ramos-Casals 17 ,<br />
Elke Theander 18 , Thomas Doerner 1 , Eric Hachulla 20 , Jacques E.<br />
Gottenberg 22 , Athanasios G. Tzioufas 19 , Alain Saraux 7 , Veronique<br />
Le Guern 16 , Stephanie Rist 10 , Claire Larroche 14 , Anne Laure<br />
Fauchais 8 , Aleth Pedriger 12 , Jacques Morel 9 , Jean Sibilia 21 ,<br />
Jean-Jacques Dubost 6 , Olivier Vittecoq 13 , Philippe Dieudé 15 ,<br />
Xavier Puechal 5 , Damien Sene 11 , Charles Zarnitsky 4 , Claudio<br />
Vitali 26 and Xavier Mariette 2 , 1 Berlin Charite University Hospital,<br />
2<br />
Bicetre Hospital/Paris Univ, Le Kremlin Bicetre, France, 3 Bicetre<br />
Hospital/Paris Univ, Le Kremlin Bicetre, France, 4 CH du Havre,<br />
5<br />
CH du Mans, 6 CHU Clermont-Ferrand, 7 CHU de la Cavale<br />
Blanche, Brest Cedex, France, 8 CHU Limoges, 9 CHU Montpellier,<br />
10<br />
CHU Orléans, 11 CHU Pitié Salpetriere, 12 CHU Rennes, 13 CHU<br />
Rouen, 14 Hopital Avicenne, 15 Hopital Bichat, 16 Hopital Cochin,<br />
17<br />
Josep Font Hospital, Barcelona, 18 Malmö University Hospital,<br />
19<br />
Medical School-Univ <strong>of</strong> Athens, Athens, Greece, 20 National<br />
Scleroderma Centre, Lille Cedex, France, 21 Strasbourg Hospitals,<br />
22<br />
Strasbourg Hospitals, Strasbourg, France, 23 Universite<br />
Paris-Rene Descartes, 24 University Hospital Birmingham NHS<br />
Foundation Trust, 25 University Medical Center Groningen,<br />
26<br />
Villamarina Hospital Pimobino.<br />
1911. Primary Sjögren’s Syndrome-Associated Non Ataxic<br />
Sensory Neuropathies and Sensorimotor Neuropathies Are<br />
Characterized by Distinctive Immunological Pr<strong>of</strong>iles. Damien<br />
Sène 2 , Moez Jallouli 2 , Jean-Pascal Lefaucheur 1 , David Saadoun 2 ,<br />
Thierry Maisonobe 2 , Julien Haroche 2 , Marie-Claude Diemert 2 ,<br />
Lucile Musset 2 , Jean-Charles Piette 2 , Zahir Amoura 2 and Patrice<br />
Cacoub 2 , 1 Henri-Mondor Hospital, 2 Pitie-Salpetriére Hospital.<br />
1912. Prognosis <strong>of</strong> Non-Hodgkin Lymphomas in Primary Sjogren’s<br />
Syndrome. Michael Voulgarelis, Panayiotis D. Ziakas, Aristea<br />
Papageorgiou, Athanasios G. Tzioufas and Haralampos M.<br />
Moutsopoulos, Dept <strong>of</strong> Pathophysiology, Medical School,<br />
University <strong>of</strong> Athens, Greece.<br />
1913. Risk <strong>of</strong> Non-Hodgkin’s Lymphoma in Primary Sjögren’s<br />
Syndrome. Svein J A. Johnsen 3 , Johan G. Brun 1 , Tom B.<br />
Johannesen 2 , Lasse Gøransson 3 , Karstein Haldorsen 1 , Roland<br />
Jonsson 4 and Roald Omdal 3 , 1 Haukeland University Hospital,<br />
2<br />
Norwegian Cancer Registry, 3 Stavanger University Hospital,<br />
4<br />
University <strong>of</strong> Bergen.<br />
1914. The FMS-Like Tyrosine Kinase3-Ligand (FL) Is a Marker for<br />
Lymphoma in Primary Sjögren’s Syndrome (SS). Jacques-Olivier<br />
Pers 1 , Gabriel J. Tobon 1 , Jacques E. Gottenberg 7 , Raphaèle<br />
Seror 4 , Valérie Devauchelle 2 , Jacques Morel 5 , Stéphanie Rist 6 ,<br />
Alain Saraux 3 and Pierre Youinou 1 , 1 Brest University, Brest,<br />
France, 2 Brest University, 3 CHU de la Cavale Blanche, Brest<br />
Cedex, France, 4 Le Kremlin Bicetre Hospital, 5 Montpellier<br />
University, 6 Orleans Hospital, 7 Strasbourg Hospitals, Strasbourg,<br />
France.<br />
1915. The Role <strong>of</strong> Immunostaining Against the Panaxonal Protein<br />
PGP 9.5 in the Evaluation <strong>of</strong> Sjogren’s Sensory Neuropathies,<br />
and the Increased Frequency <strong>of</strong> Male Sex and Seronegativity<br />
to Anti-La/SS-B Autoantibody with Peripheral Neuropathies.<br />
Julius Birnbaum, Alan N. Baer and Michael Polydefkis, Johns<br />
Hopkins University, Baltimore, MD.<br />
1916. The Temporal Appearance <strong>of</strong> Symptoms and Signs in Primary<br />
Sjögren’s Syndrome. Chiara Baldini, Nicoletta Luciano, Pasquale<br />
Pepe, Rosaria Talarico, Sara Grossi, Antonio Gaetano Tavoni<br />
and Stefano Bombardieri, <strong>Rheumatology</strong> Unit, Department <strong>of</strong><br />
Internal Medicine, University <strong>of</strong> Pisa, Italy.<br />
2010 Program Book 267
ACR/ARHP Poster Session C<br />
1917. Vaccination <strong>of</strong> Patients with Primary Sjogren’s Syndrome<br />
Induces IL-7 and Skewed B Cell Maturation with Increased<br />
Levels <strong>of</strong> Plasmablasts Resulting in Higher Titers <strong>of</strong> Vaccine-<br />
Specific IgG Antibodies. Susanna R. Brauner 2 , Marika<br />
Kvarnstrom 2 , Sabrina Goergen 2 , Karl A. Brokstad 3 , Christina<br />
Trollmo 2 , Lars Klareskog 1 , Roland Jonsson 3 , Vivianne Malmstrom 2<br />
and Marie Wahren-Herlenius 2 , 1 Karolinska University Hospital,<br />
Stockholm, Sweden, 2 Reumatology Unit, Karolinska Institutet,<br />
Stockholm, Sweden, 3 University <strong>of</strong> Bergen, Bergen, Norway.<br />
1918. Validation <strong>of</strong> microRNAs as Biomarkers <strong>of</strong> Salivary Gland<br />
Inflammation in Sjögren’s Syndrome. Seyed M. Emamian 1 , Ilias<br />
Alevizos 1 and Gabor G. Illei 2 , 1 NIDCR, 2 NIDCR, NIH #10 1N114,<br />
Bethesda, MD.<br />
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects<br />
and Treatment II<br />
1919. Abatacept (ABA) in the Treatment <strong>of</strong> Psoriatic Arthritis (PsA):<br />
12-Month Results <strong>of</strong> a Phase II Study. Philip J. Mease 8 , Mark C.<br />
Genovese 9 , Ge<strong>of</strong>frey S. Gladstein 3 , Alan J. Kivitz 2 , Christopher<br />
T. Ritchlin 11 , Paul P. Tak 1 , Jurgen Wollenhaupt 7 , Jean-Claude P.<br />
Becker 4 , Sheila M. Kelly 6 , Yun Peng 5 and Dafna D. Gladman 10 ,<br />
1<br />
Academic Med Ctr/Univ <strong>of</strong> Amsterdam, Amsterdam, The<br />
Netherlands, 2 Altoona Arthritis & Osteo Ctr, Duncansville, PA,<br />
3<br />
Arthritis Int Med Assoc LLC, Trumbull, CT, 4 Bristol-Myers Squibb,<br />
Princeton, NJ, 5 Bristol-Myers Squibb, Pennington, NJ, 6 Bristol-<br />
Myers Squibb, Doylestown, PA, 7 Schoen Klinik, Hamburg,<br />
Germany, 8 Seattle <strong>Rheumatology</strong> Associate, Seattle, WA,<br />
9<br />
Stanford University, Sunnyvale, CA, 10 Toronto Western Hospital,<br />
Toronto, ON, Canada, 11 University <strong>of</strong> Rochester Medical Center,<br />
Rochester, NY.<br />
1920. Agreement between Total Joint Count and DAS 28 Joint Count<br />
in Psoriatic Arthritis. Jose Luis Fernandez-Sueiro 1 , Eugenia<br />
Gonzalez Diaz de Rabago 1 , J. Pinto-Tasende 1 , Sonia Pertega-<br />
Diaz 1 , J. C. Fernandez-Lopez 1 , N. Oreiro-Villar 1 , F. Galdo 1 and<br />
Francisco J. Blanco 2 , 1 Complejo Hospitalario Universitario La<br />
Coruña, La Coruña, Spain, 2 Complejo Hospitalario Universitario<br />
La Coruña, A Coruna, Spain.<br />
1921. An Initial Diagnosis <strong>of</strong> Lumbar Disc Herniation Is Associated<br />
with a Late Refferral to the Rheumatologist and a Delay in<br />
the Diagnosis <strong>of</strong> Ankylosing Spondylitis. Servet Akar 1 , Vedat<br />
Gerdan 1 , Dilek Solmaz 1 , Mehmet Sayarlioglu 4 , Mehmet Akif<br />
Ozturk 2 , Ahmet Mesut Onat 3 , Bünyamin Kisacik 3 , Mehmet<br />
Emin Tezcan 2 , Merih Birlik 1 , Fatos Onen 1 and Nurullah Akkoc 1 ,<br />
1<br />
<strong>Rheumatology</strong>, Dokuz Eylul Univerisity Faculty <strong>of</strong> Medicine,<br />
Izmir, Turkey, 2 <strong>Rheumatology</strong>, Gazi University, Ankara, Turkey,<br />
3<br />
<strong>Rheumatology</strong>, Gaziantep University Faculty <strong>of</strong> Medcine,<br />
Gaziantep, Turkey, 4 <strong>Rheumatology</strong>, KahramanMaras Sutcu Imam<br />
University Faculty <strong>of</strong> Medicine, KahramanMaras, Turkey.<br />
1922. Ankylosing Spondylitis Disease Activity Score (ASDAS):<br />
Defining Cut-Off Values for Disease Activity States and<br />
Improvement Scores. Pedro Machado 1 , Robert Landewe 7 ,<br />
Elisabeth Lie 3 , Tore K. Kvien 2 , Juergen Braun 6 , Daniel G. Baker 5<br />
and Desiree M. Van Der Heijde 4 , 1 Coimbra University Hospital,<br />
Coimbra, Portugal; Leiden University Medical Center, Leiden,<br />
The Netherlands, 2 Diakonhjemmet Hospital, Oslo, Oslo, Norway,<br />
3<br />
Diakonhjemmet Hospital, Oslo, Norway, 4 Leiden University<br />
Medical Center, Meerssen, The Netherlands, 5 Research and<br />
Development, Centocor Inc, Malvern, PA, 6 Rheumazentrum<br />
Ruhrgebiet, Herne, Germany, 7 Univ Hosp Maastricht,<br />
Maastricht, The Netherlands.<br />
1923. Ankylosing Spondylitis Patient Organisations – Are There<br />
Benefits <strong>of</strong> Membership? In-Ho Song 1 , Cornelia Brenneis 1 ,<br />
Ludwig Hammel 2 , Ernst Feldtkeller 2 , Joachim Listing 3 , Joachim<br />
Sieper 1 and Martin Rudwaleit 1 , 1 Charite Campus Benjamin-<br />
Franklin, Medical Clinic I, <strong>Rheumatology</strong>, Berlin, Germany,<br />
2<br />
German Ankylosing Spondylitis Society (DVMB), Schweinfurt,<br />
Germany, 3 German Rheumatism Research Center, Berlin,<br />
Germany.<br />
1924. Anterior Chest Wall Pain in Spondyloarthritis Is a Frequent<br />
Manifestation, Appearing Early in the Disease Course, Which<br />
May Respond to NSAIDs. Muriel Elhai 1 , Simon Paternotte 1 ,<br />
Fanny Roure 1 , Eugénie Koumakis 1 , Judith Payet 1 , Vincent Burki 1 ,<br />
Isabelle Fabreguet 1 , Magali Meyer 1 , Maxime Dougados 2 and<br />
Laure Gossec 1 , 1 Cochin Hospital and Paris Descartes University,<br />
Paris, France, 2 Hospital Cochin, Paris, France.<br />
1925. Assessment <strong>of</strong> Efficacy and Safety <strong>of</strong> Pamidronate in<br />
Undifferentiated Spondyloarthropathy (uSpA): A Placebo<br />
Control Trial in a Tertiary Level Centre. Rathindra N. Sarkar 1 ,<br />
Sibaji Phaujdar 2 , Sattik Siddhanta 2 , Siwalik Banerjee 2 , Dibeyendu<br />
De 2 , Kuntal Bhattacharyya 2 and H. K. Pal 2 , 1 Calcutta Medical<br />
<strong>College</strong>, Kolkata, West Bengal, India, 2 Calcutta Medical <strong>College</strong>,<br />
Kolkata.<br />
1926. Can Clinical Phenotype Identify Early Psoriatic Arthritis in an<br />
Early Arthritis Cohort? Laura C. Coates 3 , Philip G. Conaghan 3 ,<br />
Paul Emery 3 , Michael J. Green 4 , Gamal Ibrahim 1 , Helen MakIver 1<br />
and Philip S. Helliwell 2 , 1 Bradford Hospitals NHS Trust, UK,<br />
Bradford, United Kingdom, 2 LIMM, Section <strong>of</strong> Musculoskeletal<br />
Disease, University <strong>of</strong> Leeds, Leeds, UK, 3 LIMM, Section <strong>of</strong><br />
Musculoskeletal Disease, University <strong>of</strong> Leeds, UK, 4 York Hospital<br />
NHS Trust, York, UK.<br />
1927. Clinical Improvement with Etanercept Versus Sulfasalazine<br />
Treatment in Patients with Ankylosing Spondylitis:<br />
Comparative Performance <strong>of</strong> Various Efficacy Measurements<br />
(ASCEND). Desiree M. Van Der Heijde 2 , Juergen Braun 7 , Maxime<br />
Dougados 1 , Annette Szumski 4 , Ronald Pedersen 6 , Bonnie<br />
Vlahos 3 , Bruce Freundlich 4 and Andrew S. Koenig 5 , 1 Hospital<br />
Cochin, Paris, France, 2 Leiden University Medical Center,<br />
Meerssen, The Netherlands, 3 Pfizer, Inc., Pottstown, PA, 4 Pfizer,<br />
Inc., <strong>College</strong>ville, PA, 5 Pfizer, Inc., Blue Bell, PA, 6 Prizer, Inc.,<br />
<strong>College</strong>ville, PA, 7 Rheumazentrum Ruhrgebiet, Herne, Germany.<br />
1928. Comparison <strong>of</strong> Comorbid Disease Burden in Psoriasis and<br />
Psoriatic Arthritis (PsA). Janice Husted 1 , Arane Thavaneswaran 4 ,<br />
Vinod Chandran 4 , Lihi Eder 4 , Sutha Shanmugarajah 4 , Cheryl<br />
F. Rosen 2 and Dafna D. Gladman 3 , 1 Department <strong>of</strong> Health<br />
Studies & Gerentology, University <strong>of</strong> Waterloo, 2 Division <strong>of</strong><br />
Dermatology, Toronto Western Hospital, 3 Toronto Western<br />
Hospital, Toronto, ON, Canada, 4 University <strong>of</strong> Toronto Psoriatic<br />
Arthritis Clinic.<br />
1929. Continued Efficacy <strong>of</strong> Infliximab in the Treatment <strong>of</strong> HLA<br />
B27 Positive Very Early Ankylosing Spondylitis Following Its<br />
Discontinuation; Clinical and Imaging Results <strong>of</strong> the 40 Week<br />
Follow-Up Study <strong>of</strong> a Three Month, Randomised, Placebo-<br />
Controlled Trial. Nick Barkham 3 , Helen Keen 4 , Laura Coates 4 ,<br />
Phil O’connor 2 , Elizabeth Hensor 4 , Dennis McGonagle 4 , Helena<br />
Marzo-Ortega 4 and Paul Emery 1 , 1 Chapel Allerton Hospital,<br />
Leeds, United Kingdom, 2 Leeda University, 3 Leeds University,<br />
Leeds, Yorkshire, United Kingdom, 4 Leeds University.<br />
268<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
1930. Correlation <strong>of</strong> Disease Activity, but Not Radiographic<br />
Progression, with Functional Outcomes in Adalimumab-<br />
Treated Patients with Active Psoriatic Arthritis. Arthur<br />
Kavanaugh 4 , Philip Mease 3 , Michele Olds 2 and Frederic Lavie 1 ,<br />
1<br />
Abbott Laboratories, Rungis, France, 2 Abbott Laboratories,<br />
Abbott Park, IL, 3 Swedish Medical Center and University <strong>of</strong><br />
Washington, Seattle, WA, 4 University <strong>of</strong> California San Diego, La<br />
Jolla, CA.<br />
1931. CT Scan Facilitates the Diagnosis <strong>of</strong> Sacroiliitis in Patients with<br />
Suspected Spondyloarthritis, and without Proven Sacroiliitis<br />
on Pelvic X-Ray – Results <strong>of</strong> the ECHOSPA Cohort. Valérie<br />
Devauchelle-Pensec 1 , Maria-Antonietta d’Agostino 8 , Julien<br />
Marion 1 , Sandrine Jousse-Joulin 2 , Marie Lapierre 1 , Daniele<br />
Colin 1 , Isabelle Chary-Valkenaere 6 , Christian Marcelli 3 , Damien<br />
Loeuille 7 , Philippe Aegerter 8 , Sandrine Guis 5 , Philippe Gaudin 4 ,<br />
Maxime Bréban 8 and Alain Saraux 1 , 1 CHU Brest, 2 CHU Brest,<br />
3<br />
CHU Caen, France, 4 CHU Grenoble, 5 CHU Marseille, France,<br />
6<br />
CHU Nancy, 7 CHU Nancy, 8 Hopital Ambroise Paré, France.<br />
1932. Dactylitis in Psoriatic Arthritis (PsA): Prevalence and<br />
Response to Therapy in the Biologic Era. Olga Ziouzina 2 , Arane<br />
Thavaneswaran 2 , Vinod Chandran 2 and Dafna D. Gladman 1 ,<br />
1<br />
Toronto Western Hospital, Toronto, ON, Canada, 2 University <strong>of</strong><br />
Toronto Psoriatic Arthritis Clinic.<br />
1933. Decreased Recurrence Rate <strong>of</strong> Anterior Uveitis in Ankylosing<br />
Spondylitis Treated with Adalimumab – An Interim Analysis.<br />
Irene E. van der Horst-Bruinsma 2 , J. Christiaan van Denderen 1 ,<br />
Ingrid Visman, Maria S. A. Suttorp-Schulten, Ben A. C.<br />
Dijkmans and Michael T. Nurmohamed, 1 Amsterdam, NH, The<br />
Netherlands, 2 VU University Medical Centre, Amsterdam, NH,<br />
The Netherlands.<br />
1934. Direct Imaging Evidence That Adalimumab Induces Resolution<br />
<strong>of</strong> Inflammatory Lesions in AS Patients at Sites <strong>of</strong> Complete<br />
Spinal Ankylosis. Walter P. Maksymowych, Nathalie Morency<br />
and Robert G. W. Lambert, University <strong>of</strong> Alberta, Edmonton, AB,<br />
Canada.<br />
1935. Disconnect between Radiographic Progression and Clinical<br />
Outcomes in Psoriatic Arthritis Patients Treated with<br />
Adalimumab. Philip Mease 3 , Christopher Ritchlin 4 , Michele<br />
Olds 2 and Frederic Lavie 1 , 1 Abbott Laboratories, Rungis, France,<br />
2<br />
Abbott Laboratories, Abbott Park, IL, 3 Swedish Medical Center<br />
and University <strong>of</strong> Washington, Seattle, WA, 4 University <strong>of</strong><br />
Rochester School <strong>of</strong> Medicine and Dentistry, Rochester, NY.<br />
1936. Environmental Risk Factors for Psoriatic Arthritis among<br />
Patients with Psoriasis – A Case-Control Study. Lihi Eder 3 ,<br />
Tamryn Loo 3 , Vinod Chandran 3 , Gideon Kalman-Lamb 3 , Sutha<br />
Shanmugarajah 3 , Richard Cook 1 and Dafna D. Gladman 2 ,<br />
1<br />
Department <strong>of</strong> Statistics and Actuarial Science, University <strong>of</strong><br />
Waterloo, Waterloo, ON, Canada, 2 Toronto Western Hospital,<br />
Toronto, ON, Canada, 3 University <strong>of</strong> Toronto Psoriatic Arthritis<br />
Clinic, Toronto Western Hospital, Toronto, ON, Canada.<br />
1937. Estimate <strong>of</strong> the Prevalence <strong>of</strong> Psoriatic Arthritis and<br />
Improvement with Etanercept Treatment in Moderate-to-<br />
Severe Plaque Psoriasis: PASE Results from the PRISTINE<br />
Trial. M. Elaine Husni 2 , Abrar A. Qureshi 1 , Deborah Robertson 4 ,<br />
Ronald Pedersen 4 , Bruce Freundlich 4 and Charles T. Molta 3 ,<br />
1<br />
Brigham and Women’s Hospital, Boston, MA, 2 Cleveland Clinic<br />
Foundation, Cleveland, OH, 3 Pfizer, Inc., Paoli, PA, 4 Pfizer, Inc.,<br />
<strong>College</strong>ville, PA.<br />
1938. Evaluation <strong>of</strong> the New Akylosing Spondylitis Disease Activity<br />
Score (ASDAS) To Assess Disease Activity in Patient with<br />
Active Non-Radiographic Axial Spondyloarthritis Treated<br />
with Adalimumab and Retreated after Interruption <strong>of</strong><br />
Therapy and Flare. Hildrun Haibel 3 , Frank Heldmann 2 , Joachim<br />
Listing 4 , Hartmut Kupper 1 , Jürgen Braun 2 and Joachim Sieper 3 ,<br />
1<br />
Abbott GmbH & Co. KG, Ludwigshafen, Germany, 2 Centre <strong>of</strong><br />
<strong>Rheumatology</strong> Ruhrgebiet, Herne, Germany, 3 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Charité CBF, Berlin, Germany, 4 German<br />
Rheumatism Research Centre, Berlin, Germany.<br />
1939. High Prevalence <strong>of</strong> Psoriatic Arthritis in a Psoriasis Patients<br />
Cohort. Majed M. Khraishi 2 , Trevor Newhook 1 , Ian Landells 3 ,<br />
Jonathan Mong 3 and Kassem Aboushehde, 1 Nexus Clinical<br />
Research, St. Johns, NL, Canada, 2 Nexus Clinical Research, St<br />
Johns, NL, Canada, 3 Nexus Clinical Research.<br />
1940. Improved Health-Related Quality <strong>of</strong> Life (HRQOL) with<br />
Apremilast (APR) Treatment in Psoriatic Arthritis (PsA):<br />
Results from a Phase 2 Randomized Controlled Study. Vibeke<br />
Strand 3 , Adele Vessey 1 , Angela Hu 2 and Victor S. Sloan 2 , 1 Celgene<br />
Corporation, Richlandtown, PA, 2 Celgene Corporation, Basking<br />
Ridge, NJ, 3 Stanford University, Portola Valley, CA.<br />
1941. Incidence <strong>of</strong> Tuberculosis in Korean Patients with Ankylosing<br />
Spondylitis Treated with Tumor Necrosis Factor Blockers. Eun-<br />
Mi Kim 2 , Chan-Bum Choi 2 , Yoon-Kyoung Sung 2 , Wan-Sik Uhm 2 ,<br />
Jae-Bum Jun 2 , Tae-Hwan Kim 2 , Sang-Cheol Bae 1 and Dae-Hyun<br />
Yoo 1 , 1 Hanyang University Hospital for Rheumatic Diseases,<br />
Seoul, Korea, Republic <strong>of</strong>, 2 Hanyang University Hospital for<br />
Rheumatic Diseases.<br />
1942. Long-Term Drug Survival <strong>of</strong> Anti-TNF Therapy in Ankylosing<br />
Spondylitis. Qiang Li 1 , Michelle Y. Seah 2 , John A. Burgess 3 ,<br />
Shyamali Dharmage 3 , Belinda J. Martin 1 , Russell Buchanan 1<br />
and Lionel Schachna 1 , 1 Austin Health, Melbourne, Australia,<br />
2<br />
Austin Health, Melbourne, Australia, 3 University <strong>of</strong> Melbourne,<br />
Melbourne, Australia.<br />
1943. Long-Term Radiographic Outcome in Psoriatic Arthritis Patients<br />
Treated with Golimumab: 104 Week Results from the GO-<br />
REVEAL Study. Arthur Kavanaugh 7 , Desiree M. Van Der Heijde 4 ,<br />
Dafna D. Gladman 6 , Philip J. Mease 5 , Iain B. McInnes 8 , Gerald<br />
G. Krueger 9 , Weichun Xu 3 , Neil Goldstein 2 and Anna Beutler 1 ,<br />
1<br />
Centocor Research and Development, Inc, <strong>College</strong>ville, PA,<br />
2<br />
Centocor Research and Development, Inc, 3 Centocor Research<br />
and Development, Inc., 4 Leiden University Medical Center,<br />
Meerssen, The Netherlands, 5 Seattle <strong>Rheumatology</strong> Associate,<br />
Seattle, WA, 6 Toronto Western Hospital, Toronto, ON, Canada,<br />
7<br />
University <strong>of</strong> California-San Diego, La Jolla, CA, 8 University <strong>of</strong><br />
Glasgow, Glasgow, United Kingdom, 9 University <strong>of</strong> Utah Health<br />
Sciences Center.<br />
1944. Low Doses <strong>of</strong> Etanercept Can Be Effective in Ankylosing<br />
Spondylitis Patients Who Achieve Remission <strong>of</strong> the Disease.<br />
Victoria Navarro Compán, Rafael Ariza Ariza, Carmen Vargas<br />
Lebrón, Blanca Hernández Cruz, Virginia Moreira Navarrete<br />
and Federico Navarro Sarabia, Hospital Universitario Virgen<br />
Macarena.<br />
1945. Methotrexate Does Not Influence Infliximab Pharmacokinetics<br />
and Concentration-Effect Relationship in Ankylosing<br />
Spondylitis. Emilie Ducourau 2 , David Ternant 2 , Francine<br />
Lauféron 2 , Denis Mulleman 2 , Daniel Wendling 1 , Gilles Paintaud 2<br />
and Philippe Goupille 2 , 1 Universite de Franche-Comte,<br />
Besançon, France, 2 Universite François Rabelais de Tours, Tours,<br />
France.<br />
2010 Program Book 269
ACR/ARHP Poster Session C<br />
1946. Nonsteroidal Anti-Inflammatory (NSAIDs) Drug-Sparing Effect<br />
and Sustained Clinical Improvement <strong>of</strong> Etanercept in Advanced<br />
Ankylosing Spondylitis. Results <strong>of</strong> an Open Label Extension<br />
Following a Randomized Double Blind Placebo-Controlled<br />
Study (SPINE). Maxime Dougados 2 , Jürgen Braun 5 , Sandor<br />
Szanto 6 , Bernard Combe 1 , Pal Geher 4 , Veronique Leblanc 3 and<br />
Isabelle Logeart 3 , 1 Lapeyronie Hospital, Montpellier, France,<br />
2<br />
Paris-Descartes Univ, Cochin Hospital, Paris, France, 3 Pfizer<br />
France, Paris La Défense, France, 4 Polyclinic <strong>of</strong> the Hospitaller<br />
Brothers <strong>of</strong> St. John <strong>of</strong> God, Budapest, Hungary, 5 Ruhrgebiet<br />
Univ, Herne, Germany, 6 Univ <strong>of</strong> Debrecen, Debrecen, Hungary.<br />
1947. Periarticular Bone Changes in Psoriatic and Rheumatoid<br />
Arthritis Patients Following Anti-TNF-alpha Therapy. Agnes<br />
Szentpetery 2 , Phil Gallagher 2 , Susan Van der Kamp 2 , Malachi<br />
J. McKenna 1 , Douglas J. Veale 2 and Oliver FitzGerald 2 , 1 St.<br />
Vincent’s University Hospital, Department <strong>of</strong> Endocrinology,<br />
Dublin, Ireland, 2 St. Vincent’s University Hospital, Department <strong>of</strong><br />
<strong>Rheumatology</strong>, Dublin, Ireland.<br />
1948. Prediction <strong>of</strong> Early Response to Anti-TNF Therapy and<br />
Disease Activity State Using the Ankylosing Spondylitis<br />
Disease Activity Score (ASDAS). Nathan Vastesaeger 5 , Yanxin<br />
Wang 6 , Robert D. Inman 9 , Atul A. Deodhar 7 , Benjamin L. Hsu 1 ,<br />
Mahboob U. Rahman 2 , B. A. C. Dijkmans 11 , Juergen Braun 8 ,<br />
Piet P. Geusens 10 , Joachim Sieper 3 and Desiree M. Van Der<br />
Heijde 4 , 1 Centocor Research and Development, Inc./Univ. <strong>of</strong><br />
Pennsylvania School <strong>of</strong> Medicine, Wynnewood, PA, 2 Centocor<br />
Research and Development, Inc./Univ. <strong>of</strong> Pennsylvania School<br />
<strong>of</strong> Medicine, Malvern, PA, 3 Charite Campus Benjamin Frankl,<br />
Berlin, Germany, 4 Leiden University Medical Center, Meerssen,<br />
The Netherlands, 5 Merck and Co., Inc., Whitehouse Station,<br />
NJ, 6 Merck and Co., Inc., 7 Oregon Health Sciences University,<br />
Portland, OR, 8 Rheumazentrum Ruhrgebiet, Herne, Germany,<br />
9<br />
Toronto Western Hospital, Toronto, ON, Canada, 10 University<br />
Hasselt, Genk, Belgium, 11 VU Medical Centre, Amsterdam, The<br />
Netherlands.<br />
1949. Predictors <strong>of</strong> Radiographic Progression in Adalimumab-Treated<br />
Patients with Ankylosing Spondylitis. Walter Maksymowych 5 ,<br />
Desiree van der Heijde 3 , Robert Landewe 4 , Aileen Pangan 2 ,<br />
Steve Brown 2 and Frederic Lavie 1 , 1 Abbott Laboratories, Rungis,<br />
France, 2 Abbott Laboratories, Abbott Park, IL, 3 Leiden University<br />
Medical Center, Leiden, The Netherlands, 4 Maastricht University<br />
Medical Center, Maastricht, The Netherlands, 5 University <strong>of</strong><br />
Alberta, Alberta, BC, Canada.<br />
1950. Prevalence <strong>of</strong> Psoriatic Arthritis in Thai Psoriasis at<br />
Ramathibodi Hospital. Bodin Butthum 4 , Suphaneewan<br />
Jaovisidha 1 , Pintip Ngamjanyaporn 3 , Surachai Nithiketkul 2 and<br />
Suchela Janwityanujit 2 , 1 Department <strong>of</strong> Radiology Faculty <strong>of</strong><br />
Medicine, Ramathibodi Hospital, Mahidol University, 2 Division<br />
<strong>of</strong> Allergy Immunology and <strong>Rheumatology</strong>, Department <strong>of</strong><br />
Medicine Faculty <strong>of</strong> Medicine, Ramathibodi Hospital, Mahidol<br />
University, Bangkok, Thailand, 3 Division <strong>of</strong> Allergy Immunology<br />
and <strong>Rheumatology</strong>, Department <strong>of</strong> Medicine Faculty <strong>of</strong><br />
Medicine, Ramathibodi Hospital, Mahidol University, 4 Naresuan<br />
University, Department <strong>of</strong> Medicine, Phitsanulok, Thailand.<br />
1951. Psoriatic Arthritis and Onycholysis – Results from a Study <strong>of</strong><br />
1116 Patients with Psoriasis, and Follow-Up <strong>of</strong> Those with<br />
Psoriatic Arthritis over 1-6 Years. Thorvardur J. Love 2 , Johann<br />
E. Gudjonsson 4 , Helgi Valdimarsson 1 and Bjorn Gudbjornsson 3 ,<br />
1<br />
Landspitali University Hospital, 2 Landspitali University Hospital,<br />
Boston, MA, 3 Landspitali University Hospital, Center for<br />
<strong>Rheumatology</strong> Research, 4 University <strong>of</strong> Michigan, Department<br />
<strong>of</strong> Dermatology.<br />
1952. Psoriatic Arthritis: Oligoarticular or Polyarticular Presentation?<br />
Carlotta Nannini 1 , Laura Niccoli 2 , Emanuele Cassarà 2 , Olga<br />
Kaloudi 2 and Fabrizio Cantini 2 , 1 <strong>Rheumatology</strong> Unit, Hospital <strong>of</strong><br />
Prato, Prato, Italy, 2 <strong>Rheumatology</strong> Unit, Hospital <strong>of</strong> Prato, Italy.<br />
1953. Radiographic Progression Is Associated with Resolution <strong>of</strong><br />
Systemic Inflammation in Patients with Axial Spondyloarthritis<br />
Treated with TNFα Inhibitors. Susanne Juhl Pedersen 8 , Inge<br />
Juul Sørensen 13 , Kay-Geert Hermann 4 , Patrick Garnero 17 ,<br />
Julia S. Johansen 1 , Ole Rintek Madsen 9 , Annette Hansen 15 ,<br />
Michael Sejer Hansen 10 , Gorm Thamsborg 9 , Lis Smedegaard<br />
Andersen 18 , Ole Majgaard 14 , Anne Gitte L<strong>of</strong>t 16 , Jon Erlendsson 11 ,<br />
Karsten Asmussen 7 , Anne Grethe Jurik 3 , Jakob Møller 5 , Maria<br />
Hasselquist 5 , Dorrit Mikkelsen 2 , Thomas Skjødt 6 and Mikkel<br />
Østergaard 12 , 1 Dep. <strong>of</strong> Internal Medicine, Herlev Hospital,<br />
Copenhagen, Denmark, 2 Dep. <strong>of</strong> Radiology, Aabenraa Hospital,<br />
Aabenraa, Denmark, 3 Dep. <strong>of</strong> Radiology, Aarhus University<br />
Hospitals, Aarhus, Denmark, 4 Dep. <strong>of</strong> Radiology, Charité<br />
University Hospital, Berlin, Germany, 5 Dep. <strong>of</strong> Radiology, Herlev<br />
University Hospital, Copenhagen, Denmark, 6 Dep. <strong>of</strong> Radiology,<br />
Vejle Hospital, Vejle, Denmark, 7 Dep. <strong>of</strong> <strong>Rheumatology</strong>,<br />
Bispebjerg Hospital, Copenhagen, Denmark, 8 Dep. <strong>of</strong><br />
<strong>Rheumatology</strong>, Gent<strong>of</strong>te and Herlev Hospitals, Copenhagen,<br />
Denmark, 9 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Gent<strong>of</strong>te Hospital,<br />
Copenhagen, Denmark, 10 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Herlev<br />
Hospital, Copenhagen, Denmark, 11 Dep. <strong>of</strong> <strong>Rheumatology</strong>,<br />
Horsens Hospital, Denmark, 12 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Hvidovre<br />
and Glostrup Hospitals, Copenhagen, Denmark, 13 Dep. <strong>of</strong><br />
<strong>Rheumatology</strong>, Hvidovre and Glostrup Hospitals and DANBIO,<br />
Copenhagen, Denmark, 14 Dep. <strong>of</strong> <strong>Rheumatology</strong>, Hvidovre<br />
Hospital, Copenhagen, Denmark, 15 Dep. <strong>of</strong> <strong>Rheumatology</strong>,<br />
Rigshospitalet, Copenhagen, Denmark, 16 Dep. <strong>of</strong> <strong>Rheumatology</strong>,<br />
Vejle Hospital, Denmark, 17 INSERM Unit 664, Lyon, and Cisbio<br />
Bioassays Bagnols/Cèze, France, 18 Rheumatism Hospital,<br />
University <strong>of</strong> Southern Denmark, Graasten, Denmark.<br />
1954. Reliability <strong>of</strong> Radiographic Scoring Methods in Axial Psoriatic<br />
Arthritis. Vinod Chandran 3 , Bradley Biagioni 3 , Richard Cook 1 ,<br />
Lihi Eder 3 , Anupam Wakhlu 3 , Michael Li 3 , Hua Shen 1 and Dafna<br />
D. Gladman 2 , 1 Department <strong>of</strong> Statistics and Actuarial Science,<br />
University <strong>of</strong> Waterloo, 2 Toronto Western Hospital, Toronto, ON,<br />
Canada, 3 University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto<br />
Western Hospital.<br />
1955. Rituximab in Psoriatic Arthritis Provides Modest Clinical<br />
Improvement and Reduces Expression <strong>of</strong> Inflammatory<br />
Biomarkers in Skin Lesions. Philip Mease 2 , Arthur Kavanaugh 3 ,<br />
Mark Genovese 1 , Chris Ritchlin 4 , Sanna Rosengren 3 , Alex<br />
Quistberg 5 and David Boyle 3 , 1 Stanford Univ, 2 Swedish Medical<br />
Ctr, Univ. <strong>of</strong> Washington, 3 U <strong>of</strong> Calif San Diego, 4 Univ. <strong>of</strong><br />
Rochester, 5 Univ. <strong>of</strong> Washington.<br />
1956. Smoking Is Negatively Associated with Development <strong>of</strong><br />
Psoriatic Arthritis among Psoriasis Patients. Lihi Eder 3 , Sutha<br />
Shanmugarajah 3 , Arane Thavaneswaran 3 , Vinod Chandran 3 ,<br />
Richard Cook 1 and Dafna D. Gladman 2 , 1 Department <strong>of</strong><br />
Biostatistics and Actuarial Science, University <strong>of</strong> Waterloo,<br />
Waterloo, ON, Canada, 2 Toronto Western Hospital, Toronto, ON,<br />
Canada, 3 University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto<br />
Western Hospital, Toronto, ON, Canada.<br />
1957. The Dimorphic Vertebral Corner Inflammatory Lesion (CIL):<br />
A Magnetic Resonance Imaging Biomarker Associated with<br />
New Bone Formation in Patients with Ankylosing Spondylitis.<br />
Walter P. Maksymowych, Nathalie Morency and Robert G. W.<br />
Lambert, University <strong>of</strong> Alberta, Edmonton, AB, Canada.<br />
270<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
1958. The Impact <strong>of</strong> Anti-TNF Therapy on Erosive Structural Changes<br />
in the Spine <strong>of</strong> Patients with Ankylosing Spondylitis. Xen<strong>of</strong>on<br />
Baraliakos 4 , Joachim Listing 2 , Martin Rudwaleit, Joachim<br />
Sieper 1 and Juergen Braun 3 , 1 Charite Campus Benjamin<br />
Frankl, Berlin, Germany, 2 German Rheumatism Research<br />
Center, 3 Rheumazentrum Ruhrgebiet, Herne, Germany,<br />
4<br />
Rheumazentrum Ruhrgebiet Herne.<br />
1959. TNF Blocking Agents Promote Resolution <strong>of</strong> Vertebral Erosions<br />
in Patients with Spondyloarthritis. Walter P. Maksymowych 2 ,<br />
Praveena Chiowchanwisawakit 1 and Robert Lambert 2 , 1 Mahidol<br />
University, Bangkok, Thailand, 2 University <strong>of</strong> Alberta, Edmonton,<br />
AB, Canada.<br />
1960. TNF Switching in PsA Patients. Eliza F. Chakravarty 1 , George<br />
Reed 5 , Dennis Decktor 3 , Susan Bolge 3 , Rebecca Bolce 3 , Michael<br />
Ingham 3 , Raphael J. DeHoratius 2 , Ying Shan 5 and Mark C.<br />
Genovese 4 , 1 Mountain View, CA, 2 Centocor Ortho-Biotech,<br />
Horsham, PA, 3 Centocor Ortho-Biotech, 4 Stanford University,<br />
Sunnyvale, CA, 5 University <strong>of</strong> Massachusetts Medical School.<br />
1961. Treatment <strong>of</strong> Active Ankylosing Spondylitis with Abatacept –<br />
An Open Label 24-Week Study. In-Ho Song 2 , Frank Heldmann 1 ,<br />
Martin Rudwaleit 3 , Hildrun Haibel 2 , Anja Weiss 4 , Jurgen<br />
Braun 1 and Joachim Sieper 2 , 1 Centre <strong>of</strong> <strong>Rheumatology</strong>, Herne,<br />
Germany, 2 Charite Campus Benjamin-Franklin, Medical Clinic<br />
I, <strong>Rheumatology</strong>, Berlin, Germany, 3 Charite Campus Benjamin-<br />
Franklin, Medical Clinic I, <strong>Rheumatology</strong>, Berlin, Germany,<br />
4<br />
German Rheumatism Research Center, Berlin, Germany.<br />
1962. Ultrasound (US) and X Rays (XR) Entheseal, Synovial and<br />
Sacroiliac Abnormalities in Early Psoriatic Arthritis (ePsA).<br />
Francesca Bandinelli 5 , Diletta Bonciani 3 , Francesca Prignano 3 ,<br />
Leonardo Giovannini 6 , Giuliana Salvadorini 6 , Ledio Collaku 1 ,<br />
Antonio Candelieri 4 , Francesca Bartoli 6 , Torello Lotti 2 and<br />
Marco Matucci Cerinic 6 , 1 Department <strong>of</strong> Internal Medicine <strong>of</strong><br />
University <strong>of</strong> Tirana, Faculty <strong>of</strong> Medicine, Albania, 2 Dermatology<br />
Unit, University <strong>of</strong> Florence, Italy, 3 Dermatology Unit, University<br />
<strong>of</strong> Florence, Italy, 4 Laboratory <strong>of</strong> Decision Engineering for<br />
Health Care Delivery, Department <strong>of</strong> Electronics, Informatics<br />
and Systems, University <strong>of</strong> Cosenza Italy, 5 <strong>Rheumatology</strong><br />
Division, University <strong>of</strong> Florence, Department <strong>of</strong> Biomedicine,<br />
Florence, Italy, 6 <strong>Rheumatology</strong> Division, University <strong>of</strong> Florence,<br />
Department <strong>of</strong> Biomedicine, Florence, Italy.<br />
1963. Validation <strong>of</strong> the ASAS Definition <strong>of</strong> a Positive MRI in a Cohort<br />
<strong>of</strong> Patients with Early SpA Followed for Eight Years. Helena<br />
Marzo-Ortega 2 , Alexander N. Bennett 2 , Dennis McGonagle 2 , Paul<br />
Emery 2 and Walter P. Maksymowych 1 , 1 University <strong>of</strong> Alberta,<br />
2<br />
University <strong>of</strong> Leeds, United Kingdom.<br />
1964. Which Clinical Variables Predict Radiographic Progression<br />
in Spondyloarthritis? An Analysis <strong>of</strong> the Spondyloarthritis<br />
Research Consortium <strong>of</strong> Canada (SPARCC) Cohort. Walter P.<br />
Maksymowych 4 , Nigil Haroon 6 , Nathalie Morency 5 , Richard<br />
Cook 7 , Hua Shen 7 , Proton Rahman 1 , Dafna D. Gladman 2 and<br />
Robert D. Inman 3 , 1 Memorial University Newfoundland, St.<br />
Johns, NL, Canada, 2 Toronto Western Hospital, Toronto, ON,<br />
Canada, 3 Toronto Western Hospital, Toronto, ON, Canada,<br />
4<br />
University <strong>of</strong> Alberta, Edmonton, AB, Canada, 5 University <strong>of</strong><br />
Alberta, Edmonton, Canada, 6 University <strong>of</strong> Toronto, Toronto,<br />
Canada, 7 University <strong>of</strong> Waterloo.<br />
Spondylarthritis and Psoriatic Arthritis - Pathogenesis, Etiology,<br />
and Animal Models<br />
1965. Ankylosing Spondylitis Macrophages Produce Greater IL-23 in<br />
Response to Lipopolysaccharide without Significant Unfolded<br />
Protein Response Induction. Ling Zeng, Mary Lindstrom and<br />
Judith Smith, University <strong>of</strong> Wisconsin.<br />
1966. Association between Killer-Cell Immunoglobulin-Like Receptor<br />
(KIR) Gene Polymorphisms and Psoriatic Arthritis (PsA). Vinod<br />
Chandran 2 , Fawnda Pellett 2 , Renise Ayearst 2 , Remy Pollock 2 and<br />
Dafna D. Gladman 1 , 1 Toronto Western Hospital, Toronto, ON,<br />
Canada, 2 University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto<br />
Western Hospital.<br />
1967. Decreased TH17 Cells in the Peripheral Blood <strong>of</strong> Patients with<br />
Early Spondyloarthritis (ESpA). María Belén Bautista-Caro 2 ,<br />
Irene Arroyo-Villa 2 , Concepcion Castillo-Gallego 2 , Eugenio de<br />
Miguel-Mendieta 2 , Emilio Martín-Mola 2 and María Eugenia<br />
Miranda-Carus 1 , 1 Hospital La Paz, Madrid, Spain, 2 Hospital La<br />
Paz.<br />
1968. Distinctive Patterns <strong>of</strong> Gene Expression Post-Infliximab<br />
Therapy in Psoriasis, Rheumatoid and Psoriatic Arthritis.<br />
Christopher T. Ritchlin 3 , Yahui Grace Chiu 2 , Alexander<br />
Rosenberg 2 , Darren Tabechian 2 , Sharon Moorehead 2 , Rick<br />
Barrett 2 , Hangtao Fan 1 , Fred Baribaud 1 , H. Liu 1 , Nancy<br />
Peffer 1 , David Shealy 1 and Edward S. Schwarz 2 , 1 Centocor<br />
R&D, 2 University <strong>of</strong> Rochester Medical Center, 3 University <strong>of</strong><br />
Rochester Medical Center, Rochester, NY.<br />
1969. Endoplasmic Reticulum Aminopeptidase (ERAP) Deficiency<br />
Alters IL-17 Production and Host Response Following Yersinia<br />
Gastrointestinal Infection in B27-Transgenic Mice. Robert D.<br />
Inman 1 and Fei Zhu 2 , 1 Toronto Western Hospital, Toronto, ON,<br />
Canada, 2 University <strong>of</strong> Toronto, Toronto, ON, Canada.<br />
1970. Evaluation <strong>of</strong> T Helper 17 Axis in Ankylosing Spondylitis. Ali<br />
Taylan, Ismail Sari, Didem Kozaci, Arif Yuksel, Safak Bilge, Yasar<br />
Yildiz, Gulten Sop, ISIL Coker, Necati Gunay and Nurullah AKKOC,<br />
Izmir Tepecik Training and Research Hospital, Department <strong>of</strong><br />
Internal Medicine, Izmir, Turkey.<br />
1971. Functional Significance <strong>of</strong> mTor in FLS Proliferation and Its Role<br />
in the Pathogenesis <strong>of</strong> Psoriatic Arthritis. Siba P. Raychaudhuri 2 ,<br />
Ankit Saxena 1 and Smriti K. Raychaudhuri 3 , 1 UC Davis, 2 UC Davis/<br />
VAMC Sacramento, Davis, CA, 3 UC Davis/VAMC Sacramento.<br />
1972. Genetic Studies <strong>of</strong> Ankylosing Spondylitis in Korean Confirm<br />
Associations with ERAP1 and 2p15 Reported in Caucasian<br />
Cases. So-Young Bang 5 , Tae-Hwan Kim 5 , Bitnara Lee 5 , Eunji<br />
Kwon 5 , Sang Hyun Choi 6 , Ki Soo Lee 1 , Seung Cheol Shim 2 , Angela<br />
Pope 8 , Proton Rahman 3 , John D. Reveille 7 and Robert D. Inman 4 ,<br />
1<br />
Cornell University, Republic <strong>of</strong> Korea, 2 Eulji University, Republic<br />
<strong>of</strong> Korea, 3 FRCPC, Memorial University <strong>of</strong> Newfoundland,<br />
4<br />
FRCPC, Toronto Western Hospital, University <strong>of</strong> Toronto,<br />
5<br />
Hanyang University Hospital for Rheumatic Diseases, Republic<br />
<strong>of</strong> Korea, 6 Korean Minjok Leadership Academy, Republic <strong>of</strong><br />
Korea, 7 <strong>Rheumatology</strong> and Clinical Immunogenetics, University<br />
<strong>of</strong> Texas Health Science Center at Houston, 8 Senior Scientist,<br />
Newfound Genomics.<br />
1973. HD6: A Novel Antibody That Recognises Cell Surface HLA-B27<br />
Homodimers. Kirsty McHugh 3 , Sravan K. Payeli 1 , Simon<br />
Kollnberger 2 , Markus Thiel 1 , Jacqueline Shaw 2 , Sascha Kleber 1 ,<br />
Andreas Wadle 1 , Christoph Renner 1 and Paul Bowness 2 ,<br />
1<br />
Department <strong>of</strong> Oncology, University <strong>of</strong> Zurich, 2 MRC Human<br />
Immunology Unit, Weatherall Institute <strong>of</strong> Molecular Medicine,<br />
Oxford, 3 MRC Human Immunology Unit, Weatherall Institute <strong>of</strong><br />
Molecular Medicine, Oxford, Oxfordshire, United Kingdom.<br />
2010 Program Book 271
ACR/ARHP Poster Session C<br />
1974. HLA- B*27 and Cw*06 Are Risk Alleles for Psoriatic Arthritis<br />
among Psoriasis Patients. Lihi Eder 2 , Fawnda Pellett 2 , Vinod<br />
Chandran 2 , Sutha Shanmugarajah 2 and Dafna D. Gladman 1 ,<br />
1<br />
Toronto Western Hospital, Toronto, ON, Canada, 2 Toronto<br />
Western Hospital, Centre for Prognosis Studies in the Rheumatic<br />
Diseases, Toronto, ON, Canada.<br />
1975. HLA-Bw4 Alleles and HLA-C Alleles That Have High Cell-Surface<br />
Expression Are Associated with Susceptibility to Psoriatic<br />
Arthritis (PsA). Vinod Chandran 3 , Fawnda Pellett 2 , Renise<br />
Ayearst 2 , Remy Pollock 3 and Dafna D. Gladman 1 , 1 Toronto<br />
Western Hospital, Toronto, ON, Canada, 2 University <strong>of</strong> Toronto<br />
Psoriatic Arthritis Clinic, Toronto Western Hospital, Toronto, ON,<br />
Canada, 3 University <strong>of</strong> Toronto Psoriatic Arthritis Clinic, Toronto<br />
Western Hospital.<br />
1976. IL-17 Receptor and Its Functional Significance in Psoriatic<br />
Arthritis. Siba P. Raychaudhuri 2 , Ankit Saxena 1 and Smriti K.<br />
Raychaudhuri 1 , 1 UC Davis, 2 UC Davis/VAMC Sacramento, Davis,<br />
CA.<br />
1977. Increase <strong>of</strong> CD5+ ‘Innate’ B Lymphocytes with Regulatory<br />
Capacities in Spondyloarthritis. Tineke Cantaert, Gabriela<br />
FrancoSalinas, Jacky Paramarta, Yvonne Tiersma, Christine<br />
Teitsma, Paul P. Tak and Dominique Baeten, Academic Medical<br />
Center/University <strong>of</strong> Amsterdam.<br />
1978. Increased Expression <strong>of</strong> Carbonic Anhydrase I in the Synovium<br />
<strong>of</strong> Patients with Ankylosing Spondylitis. Xiaotian Chang 2 , Yan<br />
Zhao, Xinfeng Yan and Yunzhong Zhang 1 , 1 China, 2 Shandong<br />
Acedemy <strong>of</strong> Medicinal Sciences, China.<br />
1979. MICA*016 Allele Differentiates Skin and Joint Manifestations<br />
<strong>of</strong> Psoriatic Disease. Vinod Chandran 3 , Remy Pollock 3 , Jessica<br />
Barrett 1 , Lihi Eder 3 , Fawnda Pellett 3 , Christopher Yao 3 , Marsel<br />
Lino 3 , Sutha Shanmugarajah 3 , Vernon Farewell 1 and Dafna D.<br />
Gladman 2 , 1 MRC Biostatistics Unit, University <strong>of</strong> Cambridge<br />
Institute <strong>of</strong> Public Health, Cambridge, UK, 2 Toronto Western<br />
Hospital, Toronto, ON, Canada, 3 University <strong>of</strong> Toronto Psoriatic<br />
Arthritis Clinic, Toronto Western Hospital.<br />
1980. Peripheral Joint Ankylosis in the Spontaneous Model <strong>of</strong><br />
Arthritis in DBA/1 Mice Is Associated with a Locus on<br />
Chromosome 3 That Contains the BMP Receptor Type 1b. Rik<br />
Lories 2 , Inge Derese 3 , Shea Carter 3 , Kirsten Braem 3 , Ana Valdes 1<br />
and Frank P. Luyten 2 , 1 King’s <strong>College</strong>, 2 KU Leuven, Leuven,<br />
Belgium, 3 KU Leuven.<br />
1981. Phenotypic, Functional and Transcriptomic Analysis <strong>of</strong><br />
Monocyte-Derived Dendritic Cells from SpA Patients Revealed<br />
Their Hypo-Stimulatory Capacity and Specific Molecular<br />
Response to LPS Compared to Healthy Controls. Maxime<br />
Breban 1 , Nelly Bonilla 2 , Badredine Mohand Oumoussa 2 , Alice<br />
Talpin 2 , Henri-Jean Garchon 2 and Gilles Chiocchia 2 , 1 AP-HP,<br />
2<br />
Inserm.<br />
1982. Plasma Cytokine Pr<strong>of</strong>les in Ankylosing Spondylitis. Brock E.<br />
Harper 4 , Michael H. Weisman 1 , Pravitt Gourh 5 , Shervin Assassi 4 ,<br />
Laura A. Diekman 4 , Michael M. Ward 2 , John D. Reveille 3 and<br />
Sandeep K. Agarwal 4 , 1 Cedars-Sinai Medical Center, Los Angeles,<br />
CA, 2 NIH, NIAMS, IRP, Bethesda, MD, 3 Univ Texas Health Sci Ctr,<br />
Houston, TX, 4 Univ. <strong>of</strong> Texas Health Science Center Houston,<br />
Houston, TX, 5 Univ. <strong>of</strong> Texas Health Science Center Houston.<br />
1983. Stromal Cell Derived Mediators <strong>of</strong> Bone Remodeling<br />
in Psoriatic Arthritis: Implications for Disordered<br />
Osteoclastogenesis and Bone Erosion. Nicola Dalbeth 1 , Bregina<br />
Pool, Timothy Smith, Karon Callon, Maria Lobo, William J. Taylor,<br />
Peter B. Jones, Jillian Cornish and Fiona M. McQueen 2 , 1 Univ<br />
Auckland, Auckland, New Zealand, 2 Univ <strong>of</strong> Auckland Sch <strong>of</strong><br />
Med, Auckland, New Zealand.<br />
1984. The Association <strong>of</strong> IL-13 Polymorphism with Psoriatic Arthritis<br />
among Psoriasis Patients. Lihi Eder 2 , Vinod Chandran 2 , Fawnda<br />
Pellett 2 , Remy Pollock 2 , Sutha Shanmugarajah 2 and Dafna D.<br />
Gladman 1 , 1 Toronto Western Hospital, Toronto, ON, Canada,<br />
2<br />
Toronto Western Hospital, Centre for Prognosis Studies in the<br />
Rheumatic Diseases, Toronto, ON, Canada.<br />
1985. The Relationship <strong>of</strong> Biomarkers and Radiographic Progression<br />
in Patients with Ankylosing Spondylitis. X. Baraliakos 5 , R.<br />
Landewe 4 , D. Van Der Heijde 3 , J. Listing 2 , D. Baker 1 , H. Benjamin 1<br />
and J. Braun 6 , 1 Centocor Inc, R&D, 2 German Rheumatism<br />
Research Center, 3 LeidenUniversity Medical Center, Meerssen,<br />
The Netherlands, 4 Maastricht University Medical Center,<br />
Maastricht, The Netherlands, 5 Rheumazentrum Ruhrgebiet<br />
Herne, 6 Rheumazentrum Ruhrgebiet, Herne, Herne, Germany.<br />
1986. Whole Blood Transcriptional Pr<strong>of</strong>iling in Ankylosing Spondylitis<br />
Identifies Novel Putative Candidate Genes for Both the<br />
Inflammatory and Tissue-Destructive Aspects <strong>of</strong> the Disease.<br />
Fernando Manuel Pimentel-Santos 2 , Dario Ligeiro 3 , Mafalda<br />
Matos 10 , Ana F. Mourão 2 , José Costa 4 , Helena Santos 9 , Elsa<br />
Sousa 1 , Anabela Barcelos 7 , Fátima Godinho 6 , João E. Fonseca 1 ,<br />
Henrique Gueds-Pinto 8 , Jaime C. Branco 2 , Matthew A. Brown 5<br />
and Gethin Thomas 5 , 1 (IMM), Faculdade de Medicina da<br />
Universidade de Lisboa, Lisboa, Portugal, 2 CEDOC, Faculdade<br />
de Ciências Médicas da Universidade Nova de Lisboa, Lisboa,<br />
Portugal, 3 Centro de Histocompatibilidade do Sul, Lisboa,<br />
Portugal, 4 Centro Hospitalar do Alto Minho (CHAM), Hospital<br />
de Ponte de Lima, Ponte de Lima, 5 Diamantina Institute<br />
for Cancer, Immunology and Metabolic Medicine, Princess<br />
Alexandra Hospital, University <strong>of</strong> Queensland, Brisbane,<br />
Australia, 6 Hospital Garcia de Orta, Almada, Portugal, 7 Hospital<br />
Infante D. Pedro, Aveiro, Portugal, 8 Instituto de Biotecnologia<br />
e Bioengenharia, Centro de Genética e Biotecnologia, da<br />
Universidade de Trás-os-Montes e Alto Douro (IBB / CGB –<br />
UTAD), Vila Real, Portugal, 9 Instituto Português de Reumatologia<br />
(IPR), Lisboa, Portugal, 10 UTAD, Universidade de Tás-os-Montes e<br />
Alto Douro, Vila Real, Portugal.<br />
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis<br />
and Genetics II<br />
1987. Association <strong>of</strong> the Functional CD226 307Ser Variant with<br />
Systemic Sclerosis (SSc): Evidence for the Contribution <strong>of</strong><br />
Co-Stimulation Pathways in the SSc Pathogenesis. Philippe<br />
Dieudé 10 , Mickaël Guedj 6 , Marie-Elise Truchetet 4 , Gabriela<br />
Riemekasten 3 , Marco Matucci-Cerinic 2 , Inga Melchers 1 , Eric<br />
Hachulla 8 , Paolo Airo 7 , Carlo Chizzolini 5 , Catherine Boileau 11 ,<br />
Yannick Allanore 9 and and the GENESYS Consortium, 1 Clinical<br />
Research Unit for <strong>Rheumatology</strong>, University Medical Center,<br />
Freiburg, Germany, 2 Department <strong>of</strong> Biomedicine, Section <strong>of</strong><br />
<strong>Rheumatology</strong>, Florence, Italy, 3 Department <strong>of</strong> <strong>Rheumatology</strong><br />
and Clinical Immunology, Charité University Hospital, Berlin,<br />
Germany, 4 Immunology and Allergy, Geneva University Hospital<br />
and School <strong>of</strong> Medicine, Geneva, Switzerland, 5 Immunology<br />
and Allergy, Geneva University Hospital and School <strong>of</strong> Medicine,<br />
Geneva, Switzerland, 6 Laboratoire Statistique et Génome, UMR<br />
CNRS-8071 / INRA-1152 / Université d’Evry Val d’Essonne,<br />
France, 7 <strong>Rheumatology</strong> and Clinical Immunology, Spedali<br />
Civili, Brescia, Italy, 8 Université Lille II, Médecine Interne, Lille,<br />
France, 9 Université Paris Descartes, Service de Rhumatologie<br />
A, Hôpital Cochin, Paris, France, 10 Université Paris Diderot,<br />
Service de Rhumatologie, Hôpital Bichat Claude Bernard, APHP,<br />
Paris, France, 11 Université Versailles Saint Quentin Yvelines,<br />
Laboratoire de Biochimie Hormonale et Génétique, Hôpital<br />
Ambroise Paré, AP-HP, Boulogne, France.<br />
272<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
1988. Characterization <strong>of</strong> Single Histone Deacetylase Is<strong>of</strong>orms<br />
in Endothelial Cells Derived from Progenitors in Systemic<br />
Sclerosis. Hossein Hemmatazad 1 , Britta Maurer 1 , Beat A.<br />
Michel 1 , Renate E. Gay 1 , Gay Steffen 1 , Jèrome Avouac 2 , Oliver<br />
Distler 1 , Yannick Allanore 2 and Astrid Jüngel 1 , 1 Center <strong>of</strong><br />
Experimental <strong>Rheumatology</strong>, University Hospital and Zurich<br />
Center <strong>of</strong> Integrative Human Physiology (ZIHP), Zurich,<br />
Switzerland, 2 Department <strong>of</strong> <strong>Rheumatology</strong> A, Cochin Hospital,<br />
Universitè Paris Descartes, INSERM U781, Paris, France.<br />
1989. Circulating T Cell Polarization Is Associated with Respiratory<br />
Decline in Scleroderma Patients with Active Interstitial Lung<br />
Disease. Francesco Boin 1 , Fredrick Wigley 2 , Robert Wise 2 and<br />
Antony Rosen 2 , 1 Johns Hopkins University, Baltimore, MD,<br />
2<br />
Johns Hopkins University.<br />
1990. Does Treatment with Imatinib Modify Gene Expression in the<br />
Skin and Peripheral Blood Mononuclear Cells <strong>of</strong> Patient with<br />
Systemic Sclerosis? Jessica K. Gordon 1 , Robert Spiera 2 , Jamie<br />
N. Mersten 1 , Horatio F. Wildman 4 , Ziad Taimeh 3 , Neil Hackett 4 ,<br />
Sasa Vukelic 3 , Kyriakos A. Kirou 1 and Mary K. Crow 1 , 1 Hospital for<br />
Special Surgery, New York, NY, 2 Hospital for Special Surgery, New<br />
York, NY, 3 Hospital for Special Surgery, 4 Weill-Cornell Medical<br />
<strong>College</strong>.<br />
1991. Enhanced Expression <strong>of</strong> Ephrins and Thrombospondins in<br />
the Dermis <strong>of</strong> Patients with Early Diffuse Systemic Sclerosis:<br />
Potential Contribution to Perturbed Angiogenesis and Fibrosis.<br />
Jerome Avouac 6 , Maud Clemessy 2 , Jorg H. W. Distler 8 , Jean<br />
Marie Gasc 2 , Barbara Ruiz 1 , Marie Cecile Vacher-Lavenu 3 ,<br />
Julien Wipff 6 , Andre Kahan 4 , Catherine Boileau 7 , Pierre Corvol 2<br />
and Yannick Allanore 5 , 1 INSERM U781, Necker Hospital, Paris,<br />
France, 2 INSERM U833 and Collège de France, Paris, France,<br />
3<br />
Paris Descartes University, Pathophysiology Department,<br />
Cochin Hospital, Paris, France, 4 Paris Descartes University,<br />
<strong>Rheumatology</strong> A Department, Cochin Hospital, APHP,<br />
Paris, France, 5 Paris Descartes University, <strong>Rheumatology</strong> A<br />
Department, Cochin Hospital, APHP, Paris and INSERM U781,<br />
Necker Hospital, Paris, France, 6 Paris Descartes University,<br />
<strong>Rheumatology</strong> A Department, Cochin Hospital, APHP, Paris<br />
and INSERM U781, Necker Hospital, Paris, France, 7 U.V.S.Q<br />
University, Biochemistry, Hormonology and Molecular Genetics<br />
Department, Ambroise Paré Hospital, AP-HP, Boulogne, France,<br />
8<br />
University <strong>of</strong> Erlangen, Erlangen, Germany.<br />
1992. Enhanced IL-17A and IL-22 Production by Peripheral Blood<br />
Mononuclear Cells Distinguish Systemic Sclerosis from Healthy<br />
Individuals. Nicolò C. Brembilla 1 , Marie-Elise Truchetet 2 ,<br />
Elisa Montanari 1 , Yannick Allanore 3 and Carlo Chizzolini 1 ,<br />
1<br />
Immunology & Allergy, Geneva University Hospital, Geneva,<br />
Switzerland, 2 Immunology Allergy, Geneva University Hospital,<br />
Geneva, Switzerland, 3 <strong>Rheumatology</strong>, Cochin Hospital, Paris,<br />
Paris, France.<br />
1993. Gd Compounds Signaling through Toll-Like Receptors 4<br />
and 7 in Normal Human Macrophages: Establishment <strong>of</strong><br />
a Proinflammatory Phenotype and Implications for the<br />
Pathogenesis <strong>of</strong> Nephrogenic Systemic Fibrosis. Peter J.<br />
Wermuth 1 and Sergio A. Jimenez 2 , 1 Jefferson Institute <strong>of</strong><br />
Molecular Medicine and Division <strong>of</strong> Connective Tissue Diseases,<br />
Thomas Jefferson University, Philadelphia, PA, 2 Thomas<br />
Jefferson Univ, Philadelphia, PA.<br />
1994. Genome-Wide Association Study in Systemic Sclerosis. Yannick<br />
Allanore 5 , Mohammad Saad 2 , Philippe Dieudé 4 , Catherine<br />
Boileau 1 , Maria Martinez 3 and GENESYS Consortium, 1 Biochimie<br />
A. Paré Hospital, Université VSQ, Boulogne, France, 2 INSERM<br />
U563 Université Paul Sabatier, Toulouse, France, 3 NSERM U563<br />
Université Paul Sabatier, Toulouse, France, 4 Rhumatologie,<br />
Inserm u699, Bichat, Paris Diderot Universite, France,<br />
5<br />
Université Paris Descarte, Rhumatologie A, INSERM U781,<br />
Paris, Paris, France.<br />
1995. High Resolution Magnetic Resonance Imaging for the<br />
Assessment <strong>of</strong> Dermal Fibrosis in a Pre-Clinical Model <strong>of</strong><br />
Scleroderma. Helen Jones 1 , Emma Derrett-Smith 1 , Chris P.<br />
Denton 1 , David Abraham 1 , George Bou-Gharios 2 and Po-Wah<br />
So 3 , 1 Centre for <strong>Rheumatology</strong>, UCL Medical School, 2 Kennedy<br />
Institute <strong>of</strong> <strong>Rheumatology</strong>, Imperial <strong>College</strong> London, 3 Pre-clinical<br />
Imaging Unit, Institute <strong>of</strong> Psychiatry, King’s <strong>College</strong> London.<br />
1996. IL-6 Overexpression in Early dcSSc Associates with Poor Clinical<br />
Outcome and May Drive Fibrotic Response. Korsa Khan 1 ,<br />
Shiwen Xu 1 , Christopher P. Denton 2 and Voon Ong 1 , 1 Center for<br />
<strong>Rheumatology</strong> and Connective Tissue Diseases, UCL Medical<br />
School, Royal Free Hospital, London, United Kingdom, 2 Royal<br />
Free Hospital, London, United Kingdom.<br />
1997. Imatinib Mesylate and Rottlerin Abrogate Transforming<br />
Growth Factor-β Induction <strong>of</strong> Endothelial-to-Mesenchymal<br />
Transition in Primary Lung Endothelial Cells. Zhaodong Li and<br />
Sergio A. Jimenez, Jefferson Institute <strong>of</strong> Molecular Medicine,<br />
Thomas Jefferson Univ, Philadelphia, PA.<br />
1998. In Systemic Sclerosis, Cooperation between B-Cells and Skin<br />
Fibroblasts Promotes Fibrogenic Cytokines and Collagen<br />
Production. Antoine Francois 3 , Dominique Wachsmann 3 , Jean<br />
Sibilia 1 and Jacques E. Gottenberg 2 , 1 Strasbourg Hospitals,<br />
Illkirch Graffenstaden, France, 2 Strasbourg Hospitals, Strasbourg,<br />
France, 3 Universite de Strasbourg, Illkirch Graffenstaden, France.<br />
1999. Inhibition <strong>of</strong> Glycogen Synthase Kinase (GSK)-3β<br />
Downregulates Collagen I Gene Expression in Normal and<br />
Scleroderma Fibroblasts and Abrogates the Pr<strong>of</strong>ibrotic Effects<br />
<strong>of</strong> Transforming Growth Factor β (TGF-β). Jolanta Fertala and<br />
Sergio A. Jimenez, Jefferson Institute <strong>of</strong> Molecular Medicine,<br />
Thomas Jefferson University, Philadelphia, PA.<br />
2000. Insights into the Pathogenesis <strong>of</strong> Systemic Sclerosis<br />
Vasculopathy Based on Gene Expression Pr<strong>of</strong>ile <strong>of</strong> Endothelial<br />
Cells Issued from Progenitors. Jerome Avouac 5 , Nicolas<br />
Cagnard 1 , Jorg H. W. Distler 6 , Yoland Schoindre 2 , Barbara Ruiz 2 ,<br />
Catherine Boileau 2 , Gilles Chiocchia 3 and Yannick Allanore 4 ,<br />
1<br />
INSERM U567, Cochin Hospital, APHP, Paris, France, 2 INSERM<br />
U781, Necker Hospital, Paris, France, 3 NSERM U567, Cochin<br />
Hospital, APHP, Paris, France, 4 Paris Descartes University,<br />
<strong>Rheumatology</strong> A Department, Cochin Hospital, APHP, Paris and<br />
INSERM U781, Necker Hospital, Paris, France, 5 Paris Descartes<br />
University, <strong>Rheumatology</strong> ADdepartment, Cochin Hospital,<br />
APHP, Paris and INSERM U781, Necker Hospital, 6 University <strong>of</strong><br />
Erlangen, Erlangen, Germany.<br />
2001. PDGF Receptor as Therapeutic and Diagnostic Target in<br />
Systemic Sclerosis. Gianluca Moroncini 4 , Antonella Grieco 5 ,<br />
Chiara Paolini 5 , Giulia Nacci 3 , Massimiliano Cuccioloni 2 , Matteo<br />
Mozzicafreddo 2 , Cecilia Tonnini 5 , Katarzyna Pozniak 5 , Silvia<br />
Svegliati 5 , Mauro Angeletti 2 , Enrico Avvedimento 1 , Ada Funaro 3<br />
and Armando Gabrielli 5 , 1 Dipartimento di Biologia e Patologia<br />
Molecolare e Cellulare, Università Federico II, Napoli, Italy,<br />
2<br />
Dipartimento di Biologia Molecolare, Cellulare e Animale,<br />
Università di Camerino, Italy, 3 Dipartimento di Genetica, Biologia<br />
e Biochimica, Università di Torino, Italy, 4 Dipartimento di Scienze<br />
Mediche e Chirurgiche, Clinica Medica, Università Politecnica<br />
delle Marche, Ancona, Italy, 5 Dipartimento di Scienze Mediche e<br />
Chirurgiche, Clinica Medica, Università Politecnica delle Marche,<br />
Ancona, Italy.<br />
2002. Proteomic Analysis <strong>of</strong> Systemic Sclerosis Serum Identifies the<br />
Toll-Like Receptor Agonists S100A8/A9 as a Novel Possible<br />
Pathogenic Marker. Lenny van Bon 3 , Arnoud Lo<strong>of</strong> 3 , Helmut<br />
Wittkowski 1 , Waander van Heerde 3 , Madelon Vonk 3 , Johannes<br />
Roth 1 , Wim B. Van Den Berg 2 , Peter van Lent 3 and Timothy<br />
Radstake 3 , 1 Interdisciplinary Centre for Clinical Research<br />
University <strong>of</strong> Muenster, 2 Radboud Univ Nijmegen Med Cntr,<br />
Nijmegen, The Netherlands, 3 Radboud University Medical<br />
Centre Nijmegen, The Netherlands.<br />
2010 Program Book 273
ACR/ARHP Poster Session C<br />
274<br />
2003. Role <strong>of</strong> Agonistic Autoantibodies Directed to the Angiotensin<br />
II Type 1 and the Endothelin-1 Type A Receptors in Systemic<br />
Sclerosis. Angela Kill 2 , Jeannine Günther 2 , Mike Oliver Becker 1 ,<br />
Gerd-Rüdiger Burmester 1 and Gabriela Riemekasten 1 , 1 Charité<br />
Berlin, Berlin, Germany, 2 Charité/DRFZ, Berlin, Germany.<br />
2004. Skewed X-Chromosomal Inactivation Impacts T Regulatory Cell<br />
Function in Systemic Sclerosis. Jasper Broen 4 , Ingrid Wolvers-<br />
Tettero 2 , Lenny Geurts-van Bon 4 , Madelon Vonk 4 , Marieke<br />
Coenen 3 , Robert A. Lafyatis 1 , Timothy Radstake 4 and Anton<br />
Langerak 2 , 1 Boston University School <strong>of</strong> Medicine, Arlington,<br />
MA, 2 Department <strong>of</strong> Immunology, Erasmus MC, University<br />
Medical Center, Rotterdam, The Netherlands, 3 Radboud<br />
University Medical Center, Dept. <strong>of</strong> Human Genetics, Nijmegen,<br />
Netherlands, 4 Radboud University Medical Center, Dept. <strong>of</strong><br />
<strong>Rheumatology</strong>, Nijmegen, Netherlands.<br />
2005. Structural and Vasomotor Dysfunction in the Thoracic and<br />
Pulmonary Vessels <strong>of</strong> the Tight-Skin 1 (Tsk-1/+) Mouse: Role <strong>of</strong><br />
Endogenous Nitric Oxide. Audrey Dooley 1 , Emma C. Derrett-<br />
Smith 1 , Xu Shiwen 1 , Nelson N. Orie 2 , Korsa Khan 1 , Christopher<br />
P. Denton 4 , Lucie Clapp 2 , Richard Bruckdorfer 3 and David<br />
Abraham 5 , 1 Center for <strong>Rheumatology</strong> and Connective Tissue<br />
Diseases, UCL Medical School, London, United Kingdom, 2 Centre<br />
for Pharmacology, UCL Medical School, Rayne Institute, London,<br />
United Kingdom, 3 Institute <strong>of</strong> Structural and Molecular Biology,<br />
UCL Medical School, London, United Kingdom, 4 Royal Free<br />
Hospital, London, United Kingdom, 5 University <strong>College</strong> London,<br />
London, United Kingdom.<br />
2006. Th1 and Th17 Cytokine Signatures in Early Pediatric Localized<br />
Scleroderma. Kathryn S. Torok 3 , Thaschawee Arkachaisri 1 ,<br />
Thomas A. Medsger 2 and Carol A. Feghali-Bostwick 4 , 1 KK<br />
Women’s and Children’s Hosp, Singapore, Singapore, 2 Univ<br />
<strong>of</strong> Pittsburgh, Pittsburgh, PA, 3 Univ <strong>of</strong> Pittsburgh Med Ctr,<br />
Pittsburgh, PA, 4 University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />
2007. The Effect <strong>of</strong> Oxidative Stress on Protein Tyrosine Phosphatase<br />
1B in Scleroderma Fibroblasts. Pei-Suen Tsou 5 , Nadin N. Talia 6 ,<br />
Sonsoles Piera 2 , Sergio A. Jimenez 1 , James R. Seibold 3 , Kristine<br />
Phillips 4 and Alisa E. Koch 7 , 1 Thomas Jefferson Univ, Philadelphia,<br />
PA, 2 Thomas Jefferson University, Philadelphia, PA, 3 University<br />
<strong>of</strong> Connecticut Health Center, Farmington, CT, 4 University <strong>of</strong><br />
Michigan, Ann Arbor, MI, 5 University <strong>of</strong> Michigan Medical<br />
School, Ann Arbor, MI, 6 University <strong>of</strong> Michigan Medical School,<br />
7<br />
Unversity <strong>of</strong> Michigan, Ann Arbor, MI.<br />
2008. The Wnt Signalling Inhibitor Gene, WIF1, Expression Is<br />
Downregulated in Fibroblasts Derived from Systemic Sclerosis<br />
Patients by a Persistent Oxidative Stress. Silvia Svegliati 2 ,<br />
Giusi Marrone 3 , Antonella Grieco 2 , Tatiana Spadoni 2 , Lucia<br />
De Gennaro 2 , Gianluca Moroncini 2 , Enrico Avvedimento 1 and<br />
Armando Gabrielli 2 , 1 Dipartimento di Biologia e Patologia<br />
Cellulare e Molecolare, Università Federico II, Napoli, Italy,<br />
2<br />
Dipartimento di Scienze Mediche e Chirurgiche, Università<br />
Politecnica delle Marche, Ancona, Italy, 3 Oncogenomic Center,<br />
NOGEC, CEINGE, Italy.<br />
Vasculitis II<br />
2009. Alveolar Hemorrhage (AH) in ANCA-Associated Vasculitis:<br />
Characteristics and Prognostic Factors in 65 Patients. Alex<br />
M. Kostianovsky 2 , Thomas Hauser 2 , Christian Pagnoux 2 , Pascal<br />
Cohen 2 , Eric Daugas 3 , Luc Mouthon 2 , Jean-Francois Cordier 4<br />
and Loic P. Guillevin 1 , 1 Hopital Cochin-Paris Univ, Paris, France,<br />
2<br />
Internal Medicine, Hopital Cochin, APHP, Universite Paris<br />
Descartes, Paris, France, 3 Nephrology, Assistance Publique de<br />
Paris, Paris, France, 4 Pulmonology, Hopsice Civils de Lyon, Lyon,<br />
France.<br />
2010 Program Book<br />
2010. Baseline Characteristics <strong>of</strong> Patients with Non-Infectious<br />
Mixed Cryoglobulinemia Vasculitis: Results from the French<br />
Nationwide CryoVas Survey. Benjamin Terrier 8 , Isabelle<br />
Marie 9 , Adeline Lacraz 2 , David Launay 5 , Emmanuelle Plaisier 11 ,<br />
Jean-Emmanuel Kahn 10 , Luc de Saint-Martin 3 , Fabrice Bonnet 2 ,<br />
Guillaume Le Guenno 4 , Elisabeth Diot 12 , Patricia Rullier 6 ,<br />
Raphaële Seror 1 , Estabaliz Lazaro 2 , Olivier Hermine 7 , Jean-<br />
Marc Léger 8 , Patricia Senet 11 , Xavier Mariette 1 and Patrice<br />
Cacoub 8 , 1 Bicêtre, 2 Bordeaux, 3 Brest, 4 Clermont-Ferrand, 5 Lille,<br />
6<br />
Montpellier, 7 Necker, 8 Pitié-Salpéterière, 9 Rouen, 10 Suresnes,<br />
11<br />
Tenon, 12 Tours.<br />
2011. Baseline Characteristics <strong>of</strong> Patients with Type I Monoclonal<br />
Cryoglobulinemia Vasculitis: Results from the French<br />
Nationwide CryoVas Survey. Benjamin Terrier 8 , Isabelle Marie 9 ,<br />
Jean-Emmanuel Kahn 10 , Guillaume Le Guenno 4 , Alexandre<br />
Karras 5 , Adeline Lacraz 2 , Olivier Hermine 7 , Luc de Saint-Martin 3 ,<br />
Elisabeth Diot 12 , Philippe Modiano 6 , Véronique Leblond 8 ,<br />
Patricia Senet 11 , Jean-Marc Léger 8 , Emmanuelle Plaisier 11 ,<br />
Xavier Mariette 1 , David Saadoun 8 and Patrice Cacoub 8 , 1 Bicêtre,<br />
2<br />
Bordeaux, 3 Brest, 4 Clermont-Ferrand, 5 HEGP, 6 Lille, 7 Necker,<br />
8<br />
Pitié-Salpéterière, 9 Rouen, 10 Suresnes, 11 Tenon, 12 Tours.<br />
2012. Circulating Markers <strong>of</strong> Vascular Injury in ANCA-Associated<br />
Vasculitis. Paul A. Monach 1 , Ronald D. Snyder, Ulrich Specks,<br />
John H. Stone 8 , David Cuthbertson, Linna Ding, Fernando C.<br />
Fervenza, Barri J. Fessler 10 , Gary S. H<strong>of</strong>fman 4 , David Ikle, Cees<br />
G. M. Kallenberg 11 , Carol A. Langford 3 , Mark Mueller, Philip<br />
Seo 7 , E. William St Clair 5 , Robert Spiera 6 , Nadia Tchao, Steven<br />
R. Ytterberg 9 and Peter A. Merkel 2 , 1 Boston University, Boston,<br />
MA, 2 Boston University School <strong>of</strong> Medicine, West Newton,<br />
MA, 3 Cleveland Clinic Foundation, Cleveland, OH, 4 Cleveland<br />
Clinic Foundation, Pepper Pike, OH, 5 Duke University Medical<br />
Center, Durham, NC, 6 Hospital for Special Surgery, New York,<br />
NY, 7 Johns Hopkins Bayview Medical Center, Baltimore, MD,<br />
8<br />
Massachusetts General Hospital, Sudbury, MA, 9 Mayo Clinic,<br />
Rochester, MN, 10 UAB <strong>Rheumatology</strong>, Birmingham, AL, 11 Univer<br />
Med Center Groningen, Groningen, The Netherlands.<br />
2013. Clinical and Autoimmune Manifestations <strong>of</strong> Levamisole-<br />
Adulterated Cocaine Abuse. Korey R. Ullrich 3 , Sterling G. West 4 ,<br />
Whitney High 5 , Robert J. Koval 3 , Erin Koval 5 , Srinivas Bapoje 2<br />
and Joel M. Hirsh 1 , 1 Denver Health Hospital Authority, Louisville,<br />
CO, 2 Denver Health Hospital Authority, 3 University <strong>of</strong> Colorado-<br />
Denver Medical School, Denver, CO, 4 University <strong>of</strong> Colorado-<br />
Denver Medical School, Aurora, CO, 5 University <strong>of</strong> Colorado-<br />
Denver Medical School.<br />
2014. Cluster Analysis and Clinical Phenotypes <strong>of</strong> ANCA-Associated<br />
Vasculitis. Alfred Mahr 3 , Sandrine Katsahian 1 , Loïc Guillevin 4 ,<br />
E. Christiaan Hagen 5 , Peter Höglund 2 , Peter A. Merkel 9 ,<br />
Christian Pagnoux 4 , Niels Rasmussen 8 , Kerstin Westman 6 and<br />
David Jayne 7 , 1 Clinical Epidemiology and Biostatistics, Hospital<br />
Saint-Louis, Paris, France, 2 Clinical Pharmacology, Department<br />
<strong>of</strong> Laboratory Medicine, Lund University, Lund, Sweden,<br />
3<br />
Internal Medicine, Hospital Cochin, Paris, Paris, France,<br />
4<br />
Internal Medicine, Hospital Cochin, Paris, France, 5 Internal<br />
Medicine, Meander Medical Center, Amersfoort, Netherlands,<br />
6<br />
Nephrology and Transplantation, Skane University Hospital<br />
Malmö, Lund University, Sweden, 7 Nephrology, Addenbrooke’s<br />
Hospital, Cambridge, United Kingdom, 8 Otolaryngology,<br />
Rigshospitalet, Copenhagen, Denmark, 9 <strong>Rheumatology</strong> and<br />
Clinical Epidemiology Unit, Boston University School <strong>of</strong><br />
Medicine, Boston, MA.
ACR/ARHP Poster Session C<br />
2015. CpG Stimulation <strong>of</strong> Neutrophils; a Possible Role for Bacterial<br />
DNA in Neutrophil-Mediated Pathogenesis <strong>of</strong> ANCA-<br />
Associated Vasculitis? Henko Tadema 2 , Cees G. M. Kallenberg 2 ,<br />
Sandra E. Thamerl 2 , Nikola Lepse 2 , Coen A. Stegeman 1 and<br />
Peter Heeringa 3 , 1 University Medical Center Groningen, Dept<br />
<strong>of</strong> Nephrology, Groningen, The Netherlands, 2 University<br />
Medical Center Groningen, Dept <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />
Immunology, Groningen, The Netherlands, 3 University Medical<br />
Center Groningen, Dept Pathology and Medical Biology,<br />
Groningen, The Netherlands.<br />
2016. CXCL16 Antagonist Ameliorates the Progression <strong>of</strong> Vasculitis<br />
in McH5/lpr Mice. Hitoshi Hasegawa 1 , Jin Lei 2 , Takuya<br />
Matsumoto 2 , Masaki Yasukawa 2 , Tatsuhiko Miyazaki 2 and<br />
Masato Nose 2 , 1 Ehime University Graduate School <strong>of</strong> Medicine,<br />
Toon, Ehime, Japan, 2 Ehime University Graduate School <strong>of</strong><br />
Medicine.<br />
2017. Describing the Performance <strong>of</strong> the Birmingham Vasculitis<br />
Activity Score (BVAS) at Diagnosis for Children with ANCA-<br />
Associated Vasculitis (AAV) in A Registry for Children with<br />
Vasculitis (ARChiVe). Kimberly A. Morishita 2 , America Uribe 2 ,<br />
Jaime Guzman 2 , Leslie S. Abramson 37 , Matthew D. Adams 8 ,<br />
Susanne M. Benseler 31 , Elizabeth B. Brooks 4 , Sarah S. C.<br />
Campillo 22 , Peter Chira 30 , B. Anne Eberhard 28 , Kaleo C. Ede 26 ,<br />
Aimee O. Hersh 33 , Gloria C. Higgins 23 , Adam Huber 18 , Lisa F.<br />
Imundo 13 , Rita S. Jerath 14 , Susan Kim 11 , Daniel J. Kingsbury 19 ,<br />
Marisa S. Klein-Gitelman 15 , Suzanne C. Li 7 , Daniel J. Lovell 12 ,<br />
Thomas G. Mason 21 , Deborah K. McCurdy 20 , Renee F. Modica 34 ,<br />
Lakshmi N. Moorthy 27 , Eyal Muscal 1 , Lorien A. Nassi 32 , Kathleen<br />
M. O’Neil 24 , Egla C. Rabinovich 17 , Andreas O. Reiff 10 , Margalit E.<br />
Rosenkranz 9 , Kenneth N. Schikler 35 , Anne M. Stevens 25 , Mary<br />
B. Toth 6 , Linda Wagner-Weiner 16 , Dawn M. Wahezi 5 , Andrew<br />
J. White 29 , Amy L. Woodward 38 , Andrew S. Zeft 36 , David A.<br />
Cabral 3 and ARChiVe Investigators <strong>of</strong> CARRA, 1 Baylor <strong>College</strong> <strong>of</strong><br />
Medicine, Houston, TX, 2 BC Children’s Hospital, 3 BC Children’s<br />
Hospital, Vancouver, BC, Canada, 4 Case Western, Beachwood,<br />
OH, 5 Children’s Hospital at Montefiore, Bronx, NY, 6 Children’s<br />
Hospital Med Ctr, Akron, OH, 7 Children’s Hospital <strong>of</strong> Boston,<br />
Short Hills, NJ, 8 Children’s Hospital <strong>of</strong> Michigan, Huntington<br />
Woods, MI, 9 Children’s Hospital <strong>of</strong> Pittsburg, Pittsburgh,<br />
PA, 10 Childrens Hosp LA MS60, Los Angeles, CA, 11 Childrens<br />
Hospital Boston, Boston, MA, 12 Childrens Hospital Medical<br />
Center, Cincinnati, OH, 13 Childrens Hospital <strong>of</strong> NY, New York,<br />
NY, 14 Childrens Med Ctr Med Schl GA, Augusta, GA, 15 Childrens<br />
Mem Hosp/NW Univ, Chicago, IL, 16 Corner Children’s Hospital,<br />
Chicago, IL, 17 Duke University Medical Center, Durham, NC,<br />
18<br />
IWK Health Centre, Halifax, NS, Canada, 19 Legacy Emanuel<br />
Children’s Hosp, Portland, OR, 20 Mattel Children’s UCLA, Los<br />
Angeles, CA, 21 Mayo Clinic Rochester, Rochester, MN, 22 Montreal<br />
Children’s Hospital, Montreal, QC, Canada, 23 Nationwide<br />
Childrens Hosp, Columbus, OH, 24 OU Health Science Center,<br />
Oklahoma City, OK, 25 Pediatrics, U. <strong>of</strong> Washington, Seattle,<br />
WA, 26 Phoenix Children’s Hospital, Phoenix, AZ, 27 Robert Wood<br />
Johnson Medical School, Metuchen, NJ, 28 Schneider Children’s<br />
Hospital, New Hyde Park, NY, 29 St Louis Childrens Hosp, St<br />
Louis, MO, 30 Stanford Univ Schl <strong>of</strong> Med, Stanford, CA, 31 The<br />
Hospital for Sick Children, Toronto, ON, Canada, 32 TX Scottish<br />
Rite Hosp, Dallas, TX, 33 UCSF, San Francisco, CA, 34 University <strong>of</strong><br />
Florida, Orlando, FL, 35 University <strong>of</strong> Louisville SOM, Louisville, KY,<br />
36<br />
University <strong>of</strong> Utah, Salt Lake City, UT, 37 University <strong>of</strong> Vermont,<br />
Morrisville, VT, 38 Vanderbilt Univ. School <strong>of</strong> Medicine, Nashville,<br />
TN.<br />
2018. Differences between PR3 and MPO-ANCA Associated Vasculitis<br />
– Population Based Study from Southern Sweden. Aladdin<br />
Mohammad 1 and Mårten Segelmark 2 , 1 Helsingborg Hospital,<br />
Helsingborg, Sweden, 2 Skåne University Hospital.<br />
2019. Early Predictors <strong>of</strong> Neurological Long-Term Deficits in Children<br />
with Primary CNS Vasculitis. Gordon S. Soon, Ivanna Yau,<br />
Gabrielle Deveber, Derek Armstrong, Pascal Tyrrell, Jeffrey<br />
Templeton, Suzanne Laughlin and Susanne M. Benseler, The<br />
Hospital for Sick Children.<br />
2020. Effects <strong>of</strong> Imatinib Mesylate on Pulmonary Vascular<br />
Remodeling <strong>of</strong> Allergic Vasculitis in Murine Mode. Nobuhito<br />
Sasaki 2 , Kohei Yamauchi 2 and Takashi Sawai 1 , 1 Department<br />
<strong>of</strong> Pathology, Iwate Medical University School <strong>of</strong> Medicine,<br />
Morioka, Iwate, Japan, 2 Division <strong>of</strong> Pulmonary Medicine, Allergy<br />
and <strong>Rheumatology</strong>, Department <strong>of</strong> Internal Medicine, Iwate<br />
Medical University School <strong>of</strong> Medicine, Morioka, Iwate, Japan.<br />
2021. Endothelial Lineage Impairment and Increased PR3 Expression<br />
on Peripheral Cells <strong>of</strong> Endothelial Phenotype in Wegener´s<br />
Granulomatosis. Susann Patschan, Daniel Patschan, Elvira<br />
Henze, Johannes Wessels, Sabine Blaschke and Gerhard<br />
Anton Müller, Department <strong>of</strong> Nephrology and <strong>Rheumatology</strong>,<br />
University Hospital Göttingen.<br />
2022. Epidemiology <strong>of</strong> Lupus Nephritis (LN) and ANCA Associated<br />
Nephritis (AAN) – Comparison Study from a Defined<br />
Population. Aladdin Mohammad 1 , Christina Ståhl-Hallengren 3 ,<br />
Ola Nived 3 , Gunnar K. Sturfelt 3 , Anders Bengtsson 3 and Mårten<br />
Segelmark 2 , 1 Helsingborg Hospital, Helsingborg, Sweden, 2 Skåne<br />
University Hospital, Lund, Sweden, 3 Skåne University Hospital,<br />
Lund, Lund, Sweden.<br />
2023. Expression <strong>of</strong> Toll-Like Receptors 2, 4 and 9 by Peripheral Blood<br />
Leukocytes in Patients with ANCA-Associated Vasculitis. Henko<br />
Tadema 3 , Wayel H. Abdulahad 3 , Coen A. Stegeman 1 , Cees G.<br />
M. Kallenberg 3 and Peter Heeringa 2 , 1 University Medical Center<br />
Groningen, Dept <strong>of</strong> Nephrology, Groningen, The Netherlands,<br />
2<br />
University Medical Center Groningen, Dept <strong>of</strong> Pathology and<br />
Medical Biology, Groningen, The Netherlands, 3 University<br />
Medical Center Groningen, Dept <strong>of</strong> <strong>Rheumatology</strong> and Clinical<br />
Immunology, Groningen, The Netherlands.<br />
2024. Hepatitis C Virus-Associated Polyarteritis Nodosa. David<br />
Saadoun, Benjamin Terrier, Damien Sene, Thierry Maisonobe,<br />
Lucile Musset, Zahir Amoura, Mathieu Resche Rigon and Patrice<br />
Cacoub, Pitie Salpetriere Hospital.<br />
2025. IL-25: A Cytokine Linking Eosinophils and Adaptative Immunity<br />
in Churg-Strauss Syndrome. Benjamin Terrier 1 , Ivan Bieche 2 ,<br />
Thierry Maisonobe 1 , Ingrid Laurendeau 2 , Michele Rosenzwajg 1 ,<br />
Marie-Claude Diemert 1 , Lucile Musset 1 , Michel Vidaud 2 , Damien<br />
Sène 1 , Nathalie Costedoat-Chalumeau 1 , Du Le Thi Huong 1 ,<br />
Zahir Amoura 1 , David Klatzmann 1 , Patrice Cacoub 1 and David<br />
Saadoun 1 , 1 Pitié-Salpétrière, 2 UMR745 INSERM.<br />
2026. Incidence and Predictors <strong>of</strong> Urotoxic Adverse Events in<br />
Cyclophosphamide-Treated Patients with Systemic Necrotizing<br />
Vasculitides. Guillaume Le Guenno 3 , Alfred Mahr 2 , Christian<br />
Pagnoux 3 , Robin Dhote 1 and Loïc Guillevin 3 , 1 Internal Medicine,<br />
Hospital Avicenne, Bobigny, France, 2 Internal Medicine, Hospital<br />
Cochin, Paris, France, 3 Internal Medicine, Hospital Cochin, Paris,<br />
France.<br />
2010 Program Book 275
ACR/ARHP Poster Session C<br />
2027. Inflammatory Aortitis: Diagnostic Performance <strong>of</strong> Aorta Wall<br />
Thickness CT-scan Measuring. Maia Forgues 8 , Jacques Giron 12 ,<br />
Anne Hitzel 11 , Anne Julian 11 , Pierre Payoux 11 , Daniel Adoue 10 ,<br />
Frédéric Degraeve 2 , Serge Madaule 1 , Laurent Prudhomme 3 ,<br />
Yann Leveneur 4 , Francis Gaches 6 , Xavier Delbrel 5 , Leonardo<br />
Astudillo 9 , Bruno Marchou 7 , Philippe Arlet 10 and Laurent Sailler 8 ,<br />
1<br />
CHG, Albi, France, 2 CHG, Auch, France, 3 CHG, Castres, France,<br />
4<br />
CHG, Lannemezan, France, 5 CHG, Pau, France, 6 Hôpital J<br />
Ducuing, Toulouse, France, 7 Hôpital Purpan, Infectious Diseases<br />
Department, Université de Toulouse, 8 Hôpital Purpan, Internal<br />
Medicine Department, Université de Toulouse, Toulouse,<br />
France, 9 Hôpital Purpan, Internal Medicine Department,<br />
Université de Toulouse, Toulouse, 10 Hôpital Purpan, Internal<br />
Medicine Department, Université de Toulouse, 11 Hôpital Purpan,<br />
Nuclear Medicine Department, Université de Toulouse, 12 Hôpital<br />
Purpan, Radiology Department, Université de Toulouse.<br />
2028. Interleukin-32 and Its Autoantibody Are Elevated in Patients<br />
with Wegener’s Granulomatosis and Correlated with<br />
Treatment Response. Suyoung Bae 3 , Yong-Gil Kim 2 , Siyoung<br />
Lee 4 , MinWook So 2 , Chang-Keun Lee 2 , Bin Yoo 1 , Yong-Beom<br />
Park 5 and Soohyun Kim 3 , 1 ASAN Medical Ctr, Seoul, Korea,<br />
Republic <strong>of</strong>, 2 ASAN Medical Ctr, 3 Konkuk University, Seoul, Korea,<br />
Republic <strong>of</strong>, 4 Konkuk University, 5 Yonsei University.<br />
2029. Investigation <strong>of</strong> the Effect <strong>of</strong> Histone Deacetylase 2 Function<br />
on Wegener’s Granulomatosis. Dai Takagi 1 , Yuji Nakamaru 2 ,<br />
Shigeru Akazawa 2 and Satoshi Fukuda 2 , 1 Department <strong>of</strong><br />
Otolaryngology and Head &Neck Surgery Hokkaido University<br />
Graduate School <strong>of</strong> Medicine, Sapporo, Hokkaido, Japan,<br />
2<br />
Department <strong>of</strong> Otolaryngology and Head &Neck Surgery<br />
Hokkaido University Graduate School <strong>of</strong> Medicine.<br />
2030. Low 25-OH Vitamin D Serum Levels Correlate with Extra-<br />
Hepatic Manifestations in Chronic Hepatitis C Virus Infection.<br />
Benjamin Terrier 2 , Jean-Claude Souberbielle 1 , David Saadoun 3 ,<br />
Guillaume Geri 3 , Yoland Schoindre 3 , Damien Sène 3 , Lucile<br />
Musset 3 and Patrice Cacoub 4 , 1 Necker, 2 Pitié-Salpéterière, Paris,<br />
France, 3 Pitié-Salpéterière, 4 Pitié-Salpétrière.<br />
2031. Patulous Eustachian Tube: A Novel Form <strong>of</strong> Damage in<br />
Wegener’s Granulomatosis. Philip Seo 1 and Howard W. Francis 2 ,<br />
1<br />
Johns Hopkins Bayview Medical Center, Baltimore, MD, 2 Johns<br />
Hopkins University.<br />
2032. Phase 1 Clinical Safety, Pharmacokinetic and<br />
Pharmacodynamic Evaluation <strong>of</strong> the Novel C5aR Antagonist<br />
CCX168, a Potential Therapeutic for ANCA-Vasculitis. Daniel<br />
J. Dairaghi, Juan C. Jaen, Kara Deshayes, Daniel A. Johnson,<br />
Manmohan R. Leleti, Shichang Miao, Jay P. Powers, Lisa C. Seitz,<br />
Yu Wang, Thomas J. Schall and Pirow J. Bekker, ChemoCentryx.<br />
2033. Predictors <strong>of</strong> Outcome in Juvenile Polyarteritis Nodosa: A<br />
Multicenter Study. Fernanda Falcini 1 , Francesco La Torre 7 ,<br />
Giorgia Martini 7 , Fabio Vittadello 7 , Antonella Boncompagni 10 ,<br />
Fabrizia Corona 6 , Maria Alessio 3 , Elisabetta Cortis 2 , Silvia<br />
Magni-Manzoni 8 , Giuseppina Calcagno 5 , Luciana Breda 4 , Matilde<br />
Beltramelli 6 , Manuela Pardeo 9 , Serena Capannini 1 , Marco<br />
Matucci Cerinic 1 and Francesco Zulian 7 , 1 Dpt <strong>of</strong> BioMedicine,<br />
Division <strong>of</strong> <strong>Rheumatology</strong>, Transition Unit, University <strong>of</strong><br />
Florence, 2 Dpt <strong>of</strong> Medicine, Division <strong>of</strong> <strong>Rheumatology</strong>, Ospedale<br />
Pediatrico, 3 Dpt <strong>of</strong> Pediatrics, <strong>Rheumatology</strong> Unit, Ospedale<br />
Federico II, 4 Dpt <strong>of</strong> Pediatrics, University <strong>of</strong> Chieti, Chieti, 5 Dpt <strong>of</strong><br />
Pediatrics, University <strong>of</strong> Messina, 6 Dpt <strong>of</strong> Pediatrics, University<br />
<strong>of</strong> Milan, 7 Dpt <strong>of</strong> Pediatrics, University <strong>of</strong> Padua, 8 San Matteo<br />
Hospital, Pavia, 9 Scientific Institute Bambino Gesu, Rome,<br />
10<br />
Scientific Institute G. Gaslini, Genoa.<br />
2034. Pregnancies in Systemic Necrotizing Vasculitides: Report on<br />
12 Women and Their 20 Pregnancies. Christian Pagnoux 3 ,<br />
Véronique Le Guern, François G<strong>of</strong>finet 1 , Elisabeth Diot, Nicolas<br />
Limal, Emmanuelle Pannier, Ursula Warzocha, Vassilis Tsatsaris,<br />
Robin Dhote, Alexandre Karras, Pascal Cohen, Richard Damade,<br />
Luc Mouthon and Loic P. Guillevin 2 , 1 Gynecology and Obstetrics,<br />
2<br />
Hopital Cochin-Paris Univ, Paris, France, 3 Hopital Cochin-Paris<br />
Universite Descartes, APHP, Paris, France.<br />
2035. Pregnancy Related Morbidity and Mortality in Patients with<br />
Systemic Vasculitis – A Single Centre Controlled Study. Shirish<br />
R. Sangle 1 , Periklis Vounotrypidis 2 , Ahlem Chaib 2 , Veronica<br />
Salas-Manzanedo 2 , Annette I. Briley 1 , Simon Angel 1 , Andrew<br />
Shennan 1 , Munther A. Khamashta 1 and David P. D’Cruz 1 , 1 St<br />
Thomas’ Hospital, London, United Kingdom, 2 St Thomas’<br />
Hospital.<br />
2036. Preliminary Classification Criteria for the Cryoglobulinemic<br />
Syndrome. Salvatore De Vita 18 , Franca Soldano 3 , Miriam Isola 3 ,<br />
Giuseppe Monti 12 , Armando Gabrielli 14 , Athanasios Tzioufas 7 ,<br />
Clodoveo Ferri 20 , Gianfranco Ferraccioli 19 , Luca Quartuccio 17 ,<br />
Laura Corazza 17 , Ginevra De Marchi 17 , Manuel Ramos-Casals 16 ,<br />
Michael Voulgarelis 5 , Marco Lenzi 4 , Francesco Saccardo 12 ,<br />
Paolo Fraticelli 14 , Maria Teresa Mascia 20 , Domenico Sansonno 23 ,<br />
Patrice Cacoub 2 , Matja Tomsic 8 , Antonio Tavoni 21 , Maurizio<br />
Pietrogrande 11 , Anna Linda Zignego 1 , Salvatore Scarpato 22 ,<br />
Cesare Mazzaro 6 , Paolo Pioltelli 13 , Serge Steinfeld 9 , Peter<br />
Lamprecht 10 , Stefano Bombardieri 21 and Massimo Galli 15 , 1 Center<br />
for Systemic Manifestations <strong>of</strong> Hepatitis Viruses (MaSVE),<br />
Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Florence,<br />
Florence, Italy, 2 Centre de Références Maladies Auto-Immunes,<br />
Service de Médecine Interne II, Hôpital Pitié-Salpêtrière, Paris,<br />
France, 3 Chair <strong>of</strong> Statistics, University <strong>of</strong> Udine, 4 Department<br />
<strong>of</strong> Clinical Medicine, University <strong>of</strong> Bologna, S. Orsola-Malpighi<br />
Hospital, Bologna, Italy, 5 Department <strong>of</strong> Hematology, Medical<br />
School, University <strong>of</strong> Athens, Greece, 6 Department <strong>of</strong> Internal<br />
Medicine, Pordenone General Hospital, Pordenone, Italy,<br />
7<br />
Department <strong>of</strong> Pathophysiology, Medical School <strong>of</strong> Athens,<br />
Athens, Greece, 8 Department <strong>of</strong> <strong>Rheumatology</strong>, University<br />
Medical Centre, Ljubljana, Slovenia, 9 Erasme University<br />
Hospital, Department <strong>of</strong> <strong>Rheumatology</strong>, Brussels, Belgium,<br />
10<br />
Institute <strong>of</strong> Immunology, University <strong>of</strong> Kiel, Kiel, Germany,<br />
11<br />
Internal Medicine Unit, Policlinico San Marco, Bergamo, Italy,<br />
12<br />
Internal Medicine Unit, Saronno Hospital, Azienda Ospedaliera<br />
di Busto Arsizio, Saronno, VA, Italy, 13 Internal Medicine,<br />
Donizetti Hospital, Monza, Italy, 14 Internal Medicine, Università<br />
Politecnica delle Marche, Ancona, Italy, 15 Istituto di Malattie<br />
Infettive e Tropicali, Università di Milano c/o Ospedale L. Sacco,<br />
Milan, Italy, 16 Laboratorio de Enfermedades Autoinmunes Josep<br />
Font, IDIBAPS, Hospital Clínic, Barcelona, Spain, 17 <strong>Rheumatology</strong><br />
Clinic, AOU SMM, University <strong>of</strong> Udine, 18 <strong>Rheumatology</strong> Clinic,<br />
AOU SMM, University <strong>of</strong> Udine, Udine, Italy, 19 <strong>Rheumatology</strong><br />
Division, Catholic University <strong>of</strong> the Sacred Heart, School <strong>of</strong><br />
Medicine, Rome, Italy, 20 <strong>Rheumatology</strong> Unit, Department <strong>of</strong><br />
Internal Medicine, University <strong>of</strong> Modena, Italy, 21 <strong>Rheumatology</strong><br />
Unit, Department <strong>of</strong> Internal Medicine, University <strong>of</strong> Pisa,<br />
Pisa, Italy, 22 <strong>Rheumatology</strong> Unit, M. Scarlato Hospital, Scafati,<br />
Salerno, Italy, 23 Section <strong>of</strong> Internal Medicine and Clinical<br />
Oncology, Department <strong>of</strong> Biomedical Sciences and Human<br />
Oncology, University <strong>of</strong> Bari, Medical School, Bari, Italy.<br />
2037. Primary Central Nervous System Vasculitis Presenting with<br />
Intracranial Hemorrhage. Carlo Salvarani 1 , Robert D. Brown,<br />
Jr 3 , Kenneth T. Calamia 2 , Teresa J. H. Christianson 3 , John Huston<br />
III 3 , James F. Meschia 2 , Caterina Giannini 3 and Gene G. Hunder 3 ,<br />
1<br />
Hospital <strong>of</strong> Reggio Emilia, Italy, 2 Mayo Clinic, Jacksonville, FL,<br />
3<br />
Mayo Clinic, Rochester, MN.<br />
276<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
2038. Primary Central Nervous System Vasculitis: Analysis <strong>of</strong> 131<br />
Patients. Carlo Salvarani 1 , Robert D. Brown, Jr 3 , Kenneth T.<br />
Calamia 2 , Teresa J. H. Christianson 3 , John Huston III 3 , James F.<br />
Meschia 2 , Caterina Giannini 3 and Gene G. Hunder 3 , 1 Hospital <strong>of</strong><br />
Reggio Emilia, Reggio Emilia, Italy, 2 Mayo Clinic, Jacksonville, FL,<br />
3<br />
Mayo Clinic, Rochester, MN.<br />
2039. Prognostic Factors in Hepatitis C Virus Patients with Systemic<br />
Vasculitis. Benjamin Terrier 1 , Oren Semoun 2 , David Saadoun 1 ,<br />
Damien Sène 1 , Matthieu Resche-Rigon 2 and Patrice Cacoub 1 ,<br />
1<br />
Pitié-Salpéterière, 2 Saint-Louis.<br />
2040. Risk Factors for Aortitis among Patients with Pathological<br />
Examination after Resection <strong>of</strong> the Thoracic Aorta in Denmark<br />
1997-2009: A 12-Year Nationwide Population-Based Cross-<br />
Sectional Study. Jean Schmidt 1 , Kaare Sunesen 2 , Jette Kornum 2 ,<br />
Pierre Duhaut 1 and Reimar Thomsen 2 , 1 Amiens University<br />
Hospital and RECIF, Amiens, France, 2 Department <strong>of</strong> Clinical<br />
Epidemiology, Aarhus University Hospital, Aalborg, Denmark.<br />
2041. Rituximab Maintenance Therapy for Relapsed Wegener’s<br />
Granulomatosis and Microscopic Polyangiitis. Claire Roubaud-<br />
Baudron 3 , Christian Pagnoux 3 , Julien Le Guen 3 , Mathilde de<br />
Menthon 3 , Sandra Camps 1 , Jessie Aouizerate 3 , Véronique Le<br />
Guern 3 , Pascal Cohen 3 , Luc Mouthon 3 and Loic P. Guillevin 2 ,<br />
1<br />
Department <strong>of</strong> Pharmacy, Hopital COchin, APHP, Universite<br />
Paris Descartes, 2 Hopital Cochin-Paris Univ, Paris, France,<br />
3<br />
Internal Medicine, Hopital Cochin, APHP, Universite Paris<br />
Descartes, France.<br />
2042. Safety and Efficacy <strong>of</strong> Rituximab in Non-Viral Cryoglobulinemia<br />
Vasculitis: Prospective Data from the French AIR Registry.<br />
Benjamin Terrier 15 , David Launay 6 , Gilles Kaplanski 10 ,<br />
Arnaud Hot 9 , Claire Larroche 1 , Pascal Cathebras 12 , Bernard<br />
Combe 11 , Jean-Pierre Jaureguiberry 14 , Olivier Meyer 3 , Thierry<br />
Schaeverbeke 8 , Alexandre Somogyi 5 , Leila Tricot 13 , Thierry<br />
Zenone 4 , Philippe Ravaud 3 , Jacques-Eric Gottenberg 7 , Xavier<br />
Mariette 2 and Patrice Cacoub 15 , 1 Avicenne, 2 Bicêtre, 3 Bichat, 4 CH<br />
Valence, 5 CHI Saint-Germain, 6 CHRU Lille, 7 CHRU Strasbourg,<br />
8<br />
CHU Bordeaux, 9 CHU LYon, 10 CHU Marseille, 11 CHU Montpellier,<br />
12<br />
CHU St Etienne, 13 CMC Foch, 14 HIA Toulon, 15 Pitié-Salpétrière.<br />
2043. Seasonal- (SFV) and H1N1-Flu Virus (HFV) Vaccination for<br />
Patients with Autoimmune Diseases (AID): The Prospective<br />
MAIVAX Trial on 174 Patients. Alex Kostianovsky 2 , Michele<br />
Goulet 2 , Jean Francois Alves 2 , Veronique Le Guern 2 , Christian<br />
Pagnoux 2 , Pascal Cohen 2 , Alice Berezne 2 , Anne Krivine 2 , Luc<br />
Mouthon 2 , Odile Launay 2 and Loic P. Guillevin 1 , 1 Hopital Cochin-<br />
Paris Univ, Paris, France, 2 Internal Medicine, Hopital Cochin,<br />
APHP, Universite Paris Descartes, Paris, France.<br />
2044. Small-Vessel Vasculitis Surrounding an Uninflamed Temporal<br />
Artery: A Population-Based Italian Study. Giovanna Restuccia,<br />
Luigi Boiardi, Alberto Cavazza, Luca Magnani, Maria Grazia<br />
Catanoso, Gianluigi Bajocchi, Fulvia Rossi, Pierluigi Macchioni,<br />
Ilaria Chiarolanza, Andrea Caruso, Nicolò Pipitone and Carlo<br />
Salvarani, Arcispedale S Maria Nuova, Reggio Emilia, Italy.<br />
2045. |Systemic Necrotizing Vasculitides in the Elderly: Baseline Data<br />
on the 101 Patients >65 Years Old Enrolled in the CORTAGE<br />
Multicenter Trial. Christian Pagnoux 8 , Florence Rollot 9 , Thomas<br />
Quemeneur 7 , Jacques Ninet 4 , Elisabeth Diot 3 , Xavier Kyndt 7 ,<br />
Benoît de Wazières 12 , Jean-Luc Reny 2 , Xavier J. Puechal 1 ,<br />
Pierre-Yves Leberruyer 13 , Olivier Lidove 11 , Pascal Godmer 10 ,<br />
Aimé Albath-Sadiki 14 , Severine Poignant 14 , Pascal Cohen 8 , Luc<br />
Mouthon 8 , Loic P. Guillevin 6 and The FVSG 5 , 1 Centre Hospitalier<br />
Du Mans, Le Mans, France, 2 CH Béziers - Narbonne, 3 CHRU<br />
TOurs, Medecine Interne, 4 CHU de Lyon - Hôpitale Edouard<br />
Herriot, Médecine Interne-Pathologie Vasculaire, 5 France,<br />
6<br />
Hopital Cochin-Paris Univ, Paris, France, 7 Internal Medicine,<br />
CH Valenciennes, 8 Internal Medicine, Hopital Cochin, APHP,<br />
Universite Paris Descartes, 9 Internal Medicine, Hopital Cochin,<br />
APHP, Universite Paris Descartes, 10 Medecine Interne, Centre<br />
Hospitalier Bretagne-Atlantique, BP 70555 56017 VANNES,<br />
11<br />
Medecine Interne, CHU Bichat, Paris Diderot, 12 Medecine<br />
Interne, CHU de Nimes, 13 Service de Medecine Interne. CHU<br />
Robert Debré. Avenue du Général Koenig. 51092 REIMS, 14 URC<br />
Cochin Tarnier, Paris Descartes.<br />
2046. Systemic Vasculitis in Patients with Hepatitis C Virus Infection<br />
with and without Detectable Mixed Cryoglobulinemia:<br />
Towards a Unique Entity. Benjamin Terrier 1 , Damien Sène 1 ,<br />
Agnès Dechartres 2 , David Saadoun 1 , Lucile Musset 1 , Matthieu<br />
Resche-Rigon 2 , Thierry Maisonobe 1 and Patrice Cacoub 1 , 1 Pitié-<br />
Salpéterière, 2 Saint-Louis.<br />
2047. The Correlation between Circulating Microparticles and<br />
Platelet Aggregation and Disease Activity in Wegener<br />
Granulomatosis. Rula Hajj-Ali 3 , Roy Silverstein 1 , Gary H<strong>of</strong>fman 1 ,<br />
Li Zhang 1 , Peter Imrey 1 and Carol A. Langford 2 , 1 Cleveland Clinic,<br />
2<br />
Cleveland Clinic Foundation, Cleveland, OH, 3 Clevelnad Clinic,<br />
Cleveland, OH.<br />
2048. The Human C5a Receptor (hC5aR) Antagonist CCX168<br />
Effectively Ameliorates a Model <strong>of</strong> ANCA Glomerulonephritis<br />
(GN) in hC5aR Knock-in Mice. Hong Xiao 2 , J. C. Jennette 3 , D.<br />
J. Dairaghi 1 , L. Ertl 1 , T. Baumgart 1 , S. Miao 1 , J. P. Powers 1 , L. C.<br />
Seitz 1 , Y. Wang 1 , P. Hu 3 , R. J. Falk 3 , T. J. Schall 1 and J. C. Jaen 1 ,<br />
1<br />
ChemoCentryx, 2 University <strong>of</strong> North Carolina, Chapel Hill, NC,<br />
3<br />
University <strong>of</strong> North Carolina.<br />
2049. The Relationship between Disease Status in Wegener’s<br />
Granulomatosis with the Development <strong>of</strong> Subclinical<br />
Atherosclerosis. Rula Hajj-Ali 5 , Roy Silverstein 2 , Douglas Joseph 1 ,<br />
Peter Imrey 2 , Gary S. H<strong>of</strong>fman 4 , Li Zhang 2 and Carol A. Langford 3 ,<br />
1<br />
Cleevland Clinic, 2 Cleveland Clinic, 3 Cleveland Clinic Foundation,<br />
Cleveland, OH, 4 Cleveland Clinic Foundation, Pepper Pike, OH,<br />
5<br />
Clevelnad Clinic, Cleveland, OH.<br />
Epidemiology and Health Services Research<br />
2089. Increased Fracture Rates among Female Osteoporosis<br />
Patients Taking Oral Bisphosphonates and Proton Pump<br />
Inhibitors Concurrently. Neetu Agashivala 1 and Wing Chan 2 ,<br />
1<br />
Novartis Pharmaceuctical Corp, East Hanover, NJ, 2 Novartis<br />
Pharmaceuctical Corp<br />
ARHP Poster Session C: Physical Exercise<br />
2050. ‘Specialized Generalists’: How Do Rehabilitation Therapists<br />
Practice in Rural Areas? Robin K. Roots, Linda C. Li, Lesley<br />
Bainbridge and Helen Brown, University <strong>of</strong> British Columbia,<br />
Vancouver, BC, Canada.<br />
2051. An Update <strong>of</strong> the Dutch Physical Therapy Guideline on<br />
Hip and Knee Osteoarthritis (HKOA). Wilfred F. H. Peter 5 ,<br />
Mariette J. Jansen 1 , Emalie J. Hurkmans 6 , Hans Bloo 12 , Leatitia<br />
M. M. C. J. Dekker-Bakker 11 , Roelien G. Dilling 10 , Wim K. H. A.<br />
Hilberdink 10 , Clarinda Kersten-Smit 3 , Mariette de Rooij 8 , Cindy<br />
Veenh<strong>of</strong> 9 , Eric M. Vermeulen 2 , Ineke de Vos 7 , Jan W. Schoones 13<br />
and Thea P. M. Vliet Vlieland 4 , 1 Centre for Evidence Based<br />
Physiotherapy (CEBP), University <strong>of</strong> Maastricht, Maastricht,<br />
The Netherlands, 2 Department <strong>of</strong> Physical Therapy, LUMC,<br />
Leiden, The Netherlands, 3 Department <strong>of</strong> Physical Therapy, St.<br />
Maartenskliniek, Nijmegen, The Netherlands, 4 Department<br />
<strong>of</strong> <strong>Rheumatology</strong>, Leiden University Medical Center (LUMC),<br />
2010 Program Book 277
ACR/ARHP Poster Session C<br />
Leiden, The Netherlands, Dept <strong>of</strong> Orthopaedics, Leiden,<br />
University Medical Center, 5 Department <strong>of</strong> <strong>Rheumatology</strong>,<br />
Leiden University Medical Center (LUMC); Jan van Breemen<br />
Instituut, Centre for <strong>Rheumatology</strong> and Rehabilitation,<br />
Amsterdam, Leiden, The Netherlands, 6 Dept <strong>of</strong> <strong>Rheumatology</strong>,<br />
Leiden, University Medical Center, 7 Exercise Therapy Private<br />
Practice, Leiden, The Netherlands, 8 Jan van Breemen Instituut,<br />
Centre for <strong>Rheumatology</strong> and Rehabilitation, Amsterdam,<br />
The Netherlands, 9 Netherlands Institute for Health Services<br />
Research, Utrecht, The Netherlands, 10 Paramedical Center<br />
for <strong>Rheumatology</strong> and Rehabilitation, Groningen, The<br />
Netherlands, 11 Physical Therapy Private Practice, Amstelveen,<br />
The Netherlands, 12 Veenendaal en Roessingh Research<br />
&Development, Enschede, The Netherlands, 13 Walaeus Library,<br />
Leiden University Medical Center, Leiden, The Netherlands.<br />
2052. Clinical Measures Associated with Self-Reported Knee<br />
Instability in Knee Osteoarthritis (KOA). G. Kelley Fitzgerald,<br />
Sara R. Piva and Stephen R. Wisniewski, University <strong>of</strong> Pittsburgh.<br />
2053. Describing the Pattern <strong>of</strong> Outpatient Physical Therapy<br />
Utilization Following Total Knee Replacement (TKR). Carol<br />
A. Oatis 1 , Jessica M. DiRusso 1 , Mindy J. Hoover 1 , Katherine K.<br />
Johnston 1 , Monika Kasinova 1 and Patricia D. Franklin 2 , 1 Arcadia<br />
University, Glenside, PA, 2 Univ <strong>of</strong> MA Med Schl, Worcester, MA.<br />
2054. Describing the Pattern <strong>of</strong> Physical Therapy Intervention<br />
Following Total Knee Replacement (TKR). Jessica M. DiRusso 1 ,<br />
Mindy J. Hoover 1 , Katherine K. Johnston 1 , Monika Kasinova 1 ,<br />
Patricia D. Franklin 2 and Carol A. Oatis 1 , 1 Arcadia University,<br />
Glenside, PA, 2 Univ <strong>of</strong> MA Med Schl, Worcester, MA.<br />
2055. Factors Associated with the Use <strong>of</strong> Physical Therapy by People<br />
with Hip and Knee Osteoarthritis. Renata T. B. Jorge 1 , Eric C.<br />
Sayre 4 , Jacek Kopec 2 , Jolanda Cibere 2 , John M. Esdaile 2 , Sherry<br />
Bar 3 and Linda C. Li 2 , 1 Arthritis Research Centre <strong>of</strong> Canada,<br />
Vancouver, BC, Canada, 2 Arthritis Research Centre <strong>of</strong> Canada,<br />
3<br />
BC Ministry <strong>of</strong> Health Services, 4 University <strong>of</strong> British Columbia.<br />
2056. Impaired Knee Frontal Plane Neuro-Muscular Stabilization<br />
in Persons with Knee Osteoarthritis (KOA): A Biomechanical<br />
Study. Alison H. Chang 1 , Song Joo Lee 1 , Yupeng Ren 4 , Heng Zhao 3<br />
and Li-Qun Zhang 2 , 1 Northwestern University, 2 Northwestern<br />
University; Rehabilitation Institute <strong>of</strong> Chicago, 3 Rehabilitation<br />
Institute <strong>of</strong> Chicago, 4 Rehabilitation Institute <strong>of</strong> Chiicago.<br />
2057. Physical Activity Level and Poor Disability Pr<strong>of</strong>ile: A<br />
Population-Based Study <strong>of</strong> US Adults with Arthritis. Jennifer M.<br />
Hootman 2 and David Brown 1 , 1 CDC, 2 Centers for Disease Control,<br />
Kennesaw, GA.<br />
2058. The Association <strong>of</strong> Arm and Back Pain with Incidence <strong>of</strong> Slow<br />
Walking in Persons with Knee Osteoarthritis: The MOST Study.<br />
Daniel White 1 , Yuqing Zhang 2 , Jingbo Niu 2 , Michael Nevitt 3 , C.<br />
Elizabeth Lewis 4 , James Torner 5 and Tuhina Neogi 2 , 1 Boston<br />
University, Boston, MA, 2 Boston University, 3 University California<br />
San Francisco, 4 University <strong>of</strong> Alabama, 5 University <strong>of</strong> Iowa.<br />
2059. The Effect <strong>of</strong> an Exercise Program in Gait Asymmetry in<br />
Patients after Total Knee Arthroplasty. Francisco J. Maia Neto 3 ,<br />
Gustavo J. M. Almeida 2 , G. Kelley Fitzgerald 1 and Sara R. Piva 3 ,<br />
1<br />
Univ <strong>of</strong> Pittsburgh, Pittsburgh, PA, 2 University <strong>of</strong> Pittsburgh,<br />
3<br />
University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />
2060. The Effectiveness <strong>of</strong> Thoracic Spine Manipulation on Pain<br />
and Disability in Patients with Neck Pain: A Pilot Randomized<br />
Clinical Trial. Samannaaz Shamsuddin Khoja, Daniel Daliman<br />
and Piva Regina Sara, University <strong>of</strong> Pittsburgh, Pittsburgh, PA.<br />
2061. Validity <strong>of</strong> Portable Devices To Assess Physical Activity in<br />
Patients with Total Knee Arthroplasty. Gustavo J. M. Almeida 1 ,<br />
Kelly S. Brower 2 , Derya Celik 2 , Hua-Chen Chang 2 and Sara R.<br />
Piva 1 , 1 University <strong>of</strong> Pittsburgh, Pittsburgh, PA, 2 University <strong>of</strong><br />
Pittsburgh.<br />
ARHP Poster Session C: Research Methods<br />
2062. A Meta-Analytic Assessment <strong>of</strong> the Effects <strong>of</strong> Stanford’s Small<br />
Group English Version <strong>of</strong> the Arthritis Self Management<br />
Program. Teresa J. Brady 1 , Benita J. O’Colmain 3 , Brandy S.<br />
Mobley 4 , Michael C. Greenberg 4 and Louise Murphy 2 , 1 Center<br />
for Disease Control, Atlanta, GA, 2 Centers for Disease Control<br />
and Prevention, 3 ICF Macro, Calverton, MD, 4 ICF Macro.<br />
2063. Development <strong>of</strong> the UK-Evaluation <strong>of</strong> Daily Activity<br />
Questionnaire (UK-EDAQ): Phase 2. Alison Hammond 3 , Rachel<br />
E. Gill 3 , Sarah Tyson 3 , Ulla Nordenskiold 1 and Alan Tennant 2 ,<br />
1<br />
Sahlgrenska Academy, Goteborg, Sweden, 2 University <strong>of</strong> Leeds,<br />
Leeds, Yorkshire, United Kingdom, 3 University <strong>of</strong> Salford, Salford,<br />
Greater Manchester, United Kingdom.<br />
2064. Factors Associated with Attrition in a Longitudinal Rheumatoid<br />
Arthritis (RA) Registry. Christine K. Iannaccone 2 , Anne Fossel 2 ,<br />
Hsun Tsao 2 , Jing Cui 2 , Michael E. Weinblatt 1 and Nancy A.<br />
Shadick 1 , 1 Brigham & Womens Hospital, Boston, MA, 2 Brigham<br />
and Women’s Hospital, Boston, MA.<br />
2065. Measuring Fatigue in Patients with Inflammatory Arthritis<br />
in Clinical Practice: Single Dimension and Multidimensional<br />
Scale Comparison. Patricia Minnock 1 , Barry Bresnihan 2 , McKee<br />
Gabrielle 3 , Oliver FitzGerald 2 and Douglas Veale 2 , 1 <strong>Rheumatology</strong><br />
Rehabilitation, Our Lady’s Hospice and Care Services, Dublin,<br />
Ireland, 2 St Vincent’s University Hospital, Dublin, Ireland, 3 Trinity<br />
<strong>College</strong> Dublin, Dublin, Ireland.<br />
2066. One Monthly Patient Reported Disability, Disease Activity<br />
and Fatigue Shows More Fluctuation Then Expected Based on<br />
the 3-Monthly Clinical Evaluation by DAS-28. Margot Walter,<br />
Siti Haslinda Binti Mohd Din, Mieke Hazes and Jolanda Luime,<br />
ErasmusMC.<br />
2067. Secular Trend <strong>of</strong> Adhesive Capsulitis over 13 Years: A United<br />
Kingdom General Population Cohort. Daniel K. White 1 , Hyon<br />
K. Choi 4 , Christine Peloquin 3 , Yanyan Zhu 2 and Yuqing Zhang 2 ,<br />
1<br />
Boston Univ School <strong>of</strong> Med, Boston, MA, 2 Boston Univ School<br />
<strong>of</strong> Medicine, Boston, MA, 3 Boston Univ School <strong>of</strong> Medicine,<br />
4<br />
Univ <strong>of</strong> British Columbia, Vancouver, BC, Canada.<br />
2068. The <strong>American</strong> Myositis Activities Pr<strong>of</strong>ile – A Valid Disease-<br />
Specific Activity/Participation Measure. Helene Alexanderson 1 ,<br />
Ann M. Reed 2 and Steven R. Ytterberg 2 , 1 Department <strong>of</strong><br />
Medicine, Karolinska Institutet, Department <strong>of</strong> Physical Therapy,<br />
Karolinska University Hospital, Solna, Stockholm, Sweden,<br />
2<br />
<strong>Rheumatology</strong> Division, Mayo Clinic, Rochester, MN.<br />
ARHP Poster Session C: Quality <strong>of</strong> Life<br />
2069. Arthritis Hurts… Your Resume: State-Specific Arthritis-<br />
Attributable Work Limitation and Employment among<br />
Working-Age (18-64) Adults. Kristina Theis 3 , Jennifer M.<br />
Hootman 2 and Charles G. Helmick 1 , 1 CDC, Atlanta, GA, 2 Centers<br />
for Disease Control, Kennesaw, GA, 3 Centers for Disease Control<br />
and Prevention.<br />
278<br />
2010 Program Book
ACR/ARHP Poster Session C<br />
2070. Assessement <strong>of</strong> Physical and Mental Health Related Quality<br />
<strong>of</strong> Life, Disease Activity and Damage, Mental Health Status,<br />
and Cognitive Impairment in Chilean Women with Systemic<br />
Lupus Erythematosus. Carla Henríquez 1 , Patricia Flores 2 , Babul<br />
Marcela 3 , Jorge Calderón 3 and Loreto Massardo 3 , 1 Pontificia<br />
Universidad Católica de Chile, Santiago, Chile, 2 Pontificia<br />
Universidad Católica de Chile, Santiago, 3 Pontificia Universidad<br />
Católica de Chile.<br />
2071. Change in Physical Activity on Sleep Quality in Persons with<br />
Arthritis. Jennifer Lias 2 , Leigh F. Callahan 1 and Jack H. Shreffler 2 ,<br />
1<br />
Univ <strong>of</strong> North Carolina, Chapel Hill, NC, 2 University <strong>of</strong> North<br />
Carolina, Chapel Hill.<br />
2072. Depression Rates Reported by Scleroderma (SSc) Patients<br />
Using Online Subject Recruitment and Questionnaire<br />
Completion. Feasibility <strong>of</strong> Data Collection Method and<br />
Comparison <strong>of</strong> Reported Depression Rates. Evelyn Rajan 1 ,<br />
Meagan Cr<strong>of</strong>oot 3 , Jibran Fateh 3 and Ann J. Impens 2 , 1 Briarcliff<br />
High School, 2 University <strong>of</strong> Michigan, Ann Arbor, MI, 3 University<br />
<strong>of</strong> Michigan.<br />
2073. Effects <strong>of</strong> Tadalafil on Sexual Activity and Quality <strong>of</strong> Sexual<br />
Functioning in Female Scleroderma (SSc) Patients. Ann J.<br />
Impens 2 , Elena Schiopu 2 , Kristine Phillips 2 and James R. Seibold 1 ,<br />
1<br />
University <strong>of</strong> Connecticut Health Center, Farmington, CT,<br />
2<br />
University <strong>of</strong> Michigan, Ann Arbor, MI.<br />
2079. What Do We Really Know about Arthritis Impact on<br />
Employment from Prospective Studies? A Systematic Review<br />
<strong>of</strong> the Literature. Kristina A. Theis, Ross Wilkie, Lucy Busija,<br />
Gerald Elsworth and Richard Osborne, Deakin University.<br />
2074. Fibromyalgia Patients Often Visit Many Physicians before<br />
Receiving a Diagnosis. Robert S. Katz 2 , Jessica L. Polyak 1 and<br />
Lauren Kwan, 1 <strong>Rheumatology</strong> Associates, 2 Rush University<br />
Medical Center, Chicago, IL.<br />
2075. Impact <strong>of</strong> Fibromyalgia (FMS) on Work. Robert S. Katz 3 , Sharon<br />
M. Ferbert 1 , Susan Shott 4 and Katrin F. Katz 2 , 1 Advocates for<br />
Funding Fibromyalgia Treatment, Education and Research<br />
(AFFTER), Libertyville, IL, 2 <strong>Rheumatology</strong> Associates, 3 Rush<br />
University Medical Center, Chicago, IL, 4 Rush University Medical<br />
Center.<br />
2076. Improvement <strong>of</strong> Hand Function in African <strong>American</strong>s with<br />
Scleroderma: Use <strong>of</strong> a Hand Continuous Passive Motion. Paula<br />
Fenter 2 , Samina Hayat 1 and Carla Saulsbury 1 , 1 Shreveport, LA,<br />
2<br />
Louisiana State University Health Sciences Center, Shreveport,<br />
Shreveport, LA.<br />
2077. The Mary Kirkland Center for Lupus Care (MKCLC): A Multi-<br />
Disciplinary Specialized Disease Center. Pretima Persad 2 ,<br />
Suzy Kim 2 , Monica Richey 3 , Jane E. Salmon 1 , Doruk Erkan 2 and<br />
Kyriakos A. Kirou 2 , 1 Hospital for Special Surgery, New York, NY,<br />
2<br />
Hospital for Special Surgery, New York, NY, 3 Hospital for Special<br />
Surgery.<br />
2078. TNF Blockage in Spondyloarthritis: Induction <strong>of</strong> Alveolar<br />
Bone Growth in Teeth with Periodontal Disease? Gisele<br />
Maria Campos Fabri 1 , Cynthia Savioli 2 , Carla G. S. Saad 5 ,<br />
Ana Luisa Garcia Calich 5 , Julio Cesar Bertacilli Moraes 5 , Ana<br />
Cristina Medeiros Ribeiro 5 , Jozélio Freire Carvalho 5 , Percival<br />
Sampaio-Barros 5 , Clovis Almeida Silva 4 , Rosa Maria Pereira 5 ,<br />
José Tadeu Tesseroli Siqueira 3 and Eloísa Bonfá 5 , 1 Dentistry and<br />
<strong>Rheumatology</strong> Division (CEDMAC), Faculdade de Medicina da<br />
Universidade de São Paulo, São Paulo, Brazil, 2 Dentistry and<br />
<strong>Rheumatology</strong> Division (CEDMAC), Faculdade de Medicina<br />
da Universidade de São Paulo, 3 Dentistry Division, Faculdade<br />
de Medicina da Universidade de São Paulo, 4 Paediatric<br />
<strong>Rheumatology</strong> Unit, <strong>Rheumatology</strong> Division (CEDMAC),<br />
Faculdade de Medicina da Universidade de São Paulo,<br />
5<br />
<strong>Rheumatology</strong> Division (CEDMAC), Faculdade de Medicina da<br />
Universidade de São Paulo.<br />
2010 Program Book 279
REF Industry Roundtable-supported Symposia<br />
MONDAY, NOVEMBER 8, 2010<br />
The events listed below are non-CME Programs wholly sponsored and<br />
supported by the commercial entities listed. By holding the Programs,<br />
the commercial entities have represented that the Programs have been<br />
developed and will be implemented in accordance with the requirements<br />
<strong>of</strong> the FDA and applicable standards <strong>of</strong> the PhRMA Code on Interactions<br />
with Healthcare Pr<strong>of</strong>essionals. The commercial entities are to observe all<br />
guidelines established by federal and state regulatory agencies regarding<br />
non-CME educational or promotional presentations throughout the<br />
duration <strong>of</strong> the Program. The content and views expressed during the<br />
Program are those <strong>of</strong> the commercial entities and presenters. The ACR by<br />
making this venue available does not guarantee, warrant or endorse the<br />
content <strong>of</strong> the Program nor the products discussed and reviewed during<br />
the Program.<br />
6:30 – 9:30 pm Non-CME Accredited Symposium<br />
Omni at CNN Center, International Ballroom<br />
Challenging Case Studies for Rheumatologists: An Industry-Sponsored<br />
Program<br />
Developed and <strong>of</strong>fered by Amgen, Inc. and Pfizer Inc<br />
LEARNING OBJECTIVES:<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• Assess patients for appropriate management <strong>of</strong> rheumatoid arthritis<br />
and psoriatic arthritis based on evidence from clinical studies<br />
• Individualize therapeutic strategies by developing a long-term<br />
treatment plan that takes complex issues such as disease history,<br />
longevity, and progression into account<br />
• Monitor both the potential benefits and adverse effects <strong>of</strong> treatment<br />
6:30 – 7:00 pm<br />
Welcome, Dinner and Introductions<br />
Setting Expectations for FDA-regulated Symposia<br />
Joel M. Kremer, MD; Albany Medical <strong>College</strong>, The Center for <strong>Rheumatology</strong>;<br />
Albany, NY<br />
Andrew Koenig, DO; Pfizer Medical Senior Director, Inflammation Disease<br />
Area Specialty Business Unit; <strong>College</strong>ville, PA<br />
7:00 – 7:10 pm<br />
Collective Clinical Experience <strong>of</strong> ENBREL<br />
Andrew Koenig, DO; Pfizer Medical Senior Director, Inflammation Disease<br />
Area Specialty Business Unit; <strong>College</strong>ville, PA<br />
Efficacy and safety overview<br />
ENBREL indications and ISI<br />
7:10 – 7:20 pm<br />
Case Study Overview<br />
Joel M. Kremer, MD; Albany Medical <strong>College</strong>, The Center for <strong>Rheumatology</strong>;<br />
Albany, NY<br />
7:20 – 7:45 pm<br />
Case Study #1<br />
Led by Panel Member<br />
7:45 – 8:10 pm<br />
Case Study #2<br />
Led by Panel Member<br />
8:10 – 8:35 pm<br />
Case Study #3<br />
Led by Panel Member<br />
8:35 – 8:55 pm<br />
Case Study #4 – if time allows<br />
Led by Panel Member<br />
8:55 – 9:00 pm<br />
Summary and Closing Remarks<br />
Joel M. Kremer, MD; Albany Medical <strong>College</strong>, The Center for <strong>Rheumatology</strong>;<br />
Albany, NY<br />
9:00 – 9:30 pm<br />
Dessert and Cocktail Reception<br />
Joel M. Kremer, MD; Albany Medical <strong>College</strong>, The Center for <strong>Rheumatology</strong>;<br />
Albany, NY<br />
Panel Members<br />
Joel M. Kremer, MD; Albany Medical <strong>College</strong>, The Center for <strong>Rheumatology</strong>,<br />
Albany, NY<br />
Philip Mease, MD; Seattle <strong>Rheumatology</strong> Associates; Seattle, WA<br />
Leonard Calabrese, DO; Cleveland Clinic Foundation; Cleveland, OH<br />
Roy M. Fleischmann, MD; University <strong>of</strong> Texas Southwestern Medical Center<br />
at Dallas; Dallas, TX<br />
John R. P. Tesser, MD; Arizona <strong>Rheumatology</strong> Center, Arizona Arthritis &<br />
<strong>Rheumatology</strong> Associates, P.C.; Scottsdale, AZ<br />
6:30 – 9:30 pm Non-CME Accredited Symposium<br />
Omni at CNN Center, Grand Ballroom<br />
ACTEMRA – Navigating Treatment Decisions in RA<br />
Developed and <strong>of</strong>fered by Genentech, A Member <strong>of</strong> the Roche Group<br />
Third-party organization: Health Interactions<br />
LEARNING OBJECTIVES:<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• Review the 10 treat-to-target recommendations and the evidence<br />
supporting them from the international task force<br />
• Present the benefits <strong>of</strong> applying treatment goals in clinical practice<br />
• Discuss data that demonstrates how ACTEMRA supports the concept<br />
<strong>of</strong> treating to a target in RA<br />
6:30 – 7:00 pm<br />
Registration and Dinner<br />
7:00 – 7:10 pm<br />
Introduction: Setting the Course to Better Disease Control<br />
Josef Smolen, MD; Division <strong>of</strong> <strong>Rheumatology</strong>, Department <strong>of</strong> Internal<br />
Medicine III, Medical University <strong>of</strong> Vienna; Austria<br />
7:10 – 7:30 pm<br />
International Task Force Recommendations<br />
Allan Gib<strong>of</strong>sky, MD, JD; Weill Medical <strong>College</strong>, Cornell University, Hospital<br />
for Special Surgery; New York, NY<br />
7:30 – 7:55 pm<br />
Mapping Out Treatment Goals in Clinical Practice<br />
Maxime Dougados, MD; Hôpital Cochin, Assistance Publique Hôpitaux de<br />
Paris, and René Descartes University; Paris, France<br />
7:55 – 8:35 pm<br />
Making Treatment Decisions Using ACTEMRA<br />
Jonathan Kay, MD; University <strong>of</strong> Massachusetts Medical School; Worcester,<br />
MA<br />
8:35 – 8:50 pm<br />
Panel Discussion<br />
8:50 – 9:00 pm<br />
Summary and Adjournment<br />
280<br />
2010 Program Book
REF Industry Roundtable-supported Symposia<br />
6:30 – 9:30 pm Non-CME Accredited Symposium<br />
Atlanta Marriott Marquis, Marquis Ballroom<br />
Bridging the Gap in Rheumatoid Arthritis: Challenges <strong>of</strong> RA Patient<br />
Management<br />
Developed and <strong>of</strong>fered by Centocor Ortho Biotech Inc.<br />
6:30 – 6:50 pm<br />
Registration and Seating<br />
6:50 – 7:00 pm<br />
Welcome and Introductions<br />
7:00 – 7:20 pm<br />
Current Topics in RA Patient Management<br />
Sergio Schwartzman, MD; Hospital for Special Surgery; New York, NY<br />
Anthony Turkiewicz, MD; <strong>Rheumatology</strong> Associates PC; Birmingham, AL<br />
Arthur Kavanaugh, MD; The University <strong>of</strong> California at San Diego; San Diego,<br />
CA<br />
7:20 – 7:40 pm<br />
Case 1: Considerations for a MTX-Experienced, Biologic-Naïve Patient<br />
Arthur Kavanaugh, MD; The University <strong>of</strong> California at San Diego; San Diego,<br />
CA<br />
7:40 – 7:50 pm<br />
Panel Discussion<br />
All Faculty<br />
7:50 – 8:10 pm<br />
Case 2: Considerations for a Biologic-Experienced Patient<br />
Anthony Turkiewicz, MD; <strong>Rheumatology</strong> Associates PC; Birmingham, AL<br />
8:10 – 8:20 pm<br />
Panel Discussion<br />
All Faculty<br />
8:20 – 8:50 pm<br />
Clinical Review <strong>of</strong> an Anti-TNF Therapy<br />
Sergio Schwartzman, MD; Hospital for Special Surgery; New York, NY<br />
8:50 – 9:00 pm<br />
Panel Discussion and Concluding Remarks<br />
All Faculty<br />
6:30 – 9:30 pm Non-CME Accredited Symposium<br />
Atlanta Marriott Marquis, Imperial Ballroom<br />
Applying Strategies to Predict and Measure Patient Outcomes for<br />
Rheumatoid Arthritis<br />
Developed and <strong>of</strong>fered by UCB, Inc.<br />
Third-party organization: ETHOS Health Communications<br />
LEARNING OBJECTIVES:<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• Demonstrate how early relief <strong>of</strong> signs and symptoms when treating<br />
patients with moderately to severely active rheumatoid arthritis (RA)<br />
leads to better long-term outcomes for patients<br />
• Review the utilization <strong>of</strong> tools in measuring treatment success and the<br />
applicability <strong>of</strong> these tools to clinical practice<br />
• Discuss the role <strong>of</strong> patient-reported outcomes (PROs) in measuring<br />
treatment success and applicability to daily practice<br />
6:30 – 7:00 pm<br />
Registration and Dinner<br />
7:00 – 7:05 pm<br />
Welcome and Introductions<br />
Edward Keystone, MD, FRCPC; University <strong>of</strong> Toronto; Toronto, Ontario,<br />
Canada<br />
7:05 – 7:25 pm<br />
The Importance <strong>of</strong> a Fast Response in a Chronic Disease<br />
Edward Keystone, MD, FRCPC; University <strong>of</strong> Toronto; Toronto, Ontario,<br />
Canada<br />
7:25 – 7:45 pm<br />
Measuring Success <strong>of</strong> Treatment in Daily Practice: A Clinical Point <strong>of</strong> View<br />
Alvin Wells, MD, PhD; Rosalind Franklin University <strong>of</strong> Medicine and Science;<br />
North Chicago, IL<br />
7:45 – 8:05 pm<br />
Measuring Success <strong>of</strong> Treatment Through Patient-Reported Outcomes<br />
(PROs)<br />
Vibeke Strand, MD; Stanford University; Portola Valley, CA<br />
8:05 – 8:25 pm<br />
Shaping Future Treatment Paradigms: Algorithms, Biomarkers, and<br />
Innovation in Equal Measure?<br />
Iain McInnes, FRCP, PhD, FRSE; University <strong>of</strong> Glasgow; Glasgow, Scotland<br />
8:25 – 8:55 pm<br />
Question-and-Answer Session/Panel Discussion<br />
Faculty Panel<br />
8:55 – 9:00 pm<br />
Conclusion<br />
Edward Keystone, MD, FRCPC; University <strong>of</strong> Toronto; Toronto, Ontario,<br />
Canada<br />
WEDNESDAY, NOVEMBER 10<br />
6:30 – 9:30 pm CME-Accredited Symposium<br />
For CME-accredited symposia, the sponsoring organization is responsible for<br />
panning and providing CME credit.<br />
Omni at CNN Center, International Ballroom<br />
Assessment and Treatment <strong>of</strong> Chronic Pain in the Rheumatic Diseases<br />
Jointly sponsored by the Postgraduate Institute for Medicine and ACCELMED<br />
Supported by an educational grant from Lilly USA, LLC<br />
Physician (ACCME) Accreditation Statement<br />
This activity has been planned and implemented in accordance with the<br />
Essential Areas and policies <strong>of</strong> the Accreditation Council for Continuing<br />
Medical Education (ACCME) through the joint sponsorship <strong>of</strong> Postgraduate<br />
Institute for Medicine (PIM) and ACCELMED. PIM is accredited by the<br />
ACCME to provide continuing medical education for physicians.<br />
Credit Designation Statement<br />
Postgraduate Institute for Medicine designates this educational activity for<br />
a maximum <strong>of</strong> 2.0 AMA PRA Category 1 Credit(s). Physicians should only<br />
claim credit commensurate with the extent <strong>of</strong> their participation in the<br />
activity.<br />
LEARNING OBJECTIVES:<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• Develop a plan for patient evaluation that includes assessment for<br />
chronic pain in any patient with a rheumatic disease<br />
• Identify the underlying mechanisms involved in symptom expression<br />
in chronic pain<br />
• Summarize up-to-date clinical trial data on pharmacological and<br />
nonpharmacological treatments for chronic pain associated with<br />
rheumatic diseases<br />
2010 Program Book 281
REF Industry Roundtable-supported Symposia<br />
6:30 – 7:00 pm<br />
Registration and Dinner<br />
7:00 – 7:05 pm<br />
Welcome and Overview<br />
Don L. Goldenberg, MD; Tufts University School <strong>of</strong> Medicine; Boston, MA<br />
7:05 – 7:25 pm<br />
Overview <strong>of</strong> Chronic Pain Associated with Rheumatic Diseases<br />
Don L. Goldenberg, MD; Tufts University School <strong>of</strong> Medicine; Boston, MA<br />
7:25 – 7:55 pm<br />
The Pathophysiology <strong>of</strong> Chronic Pain<br />
Daniel J. Clauw, MD; University <strong>of</strong> Michigan; Ann Arbor, MI<br />
7:55 – 8:25 pm<br />
The Pharmacological and Nonpharmacological Management <strong>of</strong> Chronic<br />
Pain in Rheumatic Diseases<br />
Mary-Ann Fitzcharles, MB, ChB, MRCP (UK) FRCP(C);The Pain Centre, McGill<br />
University Health Centre; Montreal, Quebec, Canada<br />
8:25 – 8:35 pm<br />
Applying the Evidence: A Case-based Discussion<br />
Don L. Goldenberg, MD; Tufts University School <strong>of</strong> Medicine; Boston, MA<br />
8:35 – 9:00 pm<br />
Question and Answer Session<br />
6:30 – 9:30 pm CME-Accredited Symposium<br />
For CME-accredited symposia, the sponsoring organization is responsible for<br />
panning and providing CME credit.<br />
Atlanta Marriott Marquis, Marquis Ballroom<br />
Advances in the Treatment <strong>of</strong> Systemic Lupus Erythematosus Learning<br />
Continuum<br />
Sponsored by Cleveland Clinic<br />
Supported by an educational grant from Human Genome Sciences, Inc.<br />
Physician (ACCME) Accreditation Statement<br />
This activity has been planned and implemented in accordance with the<br />
Essential Areas and policies <strong>of</strong> the Accreditation Council for Continuing<br />
Medical Education (ACCME) through the sponsorship <strong>of</strong> the Cleveland<br />
Clinic. The Cleveland Clinic Foundation Center for Continuing Education<br />
is accredited by the ACCME to provide continuing medical education for<br />
physicians.<br />
Credit Designation Statement<br />
The Cleveland Clinic Foundation Center for Continuing Education designates<br />
this educational activity for a maximum <strong>of</strong> 2.0 AMA PRA Category 1<br />
Credit(s). Physicians should only claim credit commensurate with the<br />
extent <strong>of</strong> their participation in the activity.<br />
LEARNING OBJECTIVES:<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• Review the efficacy and safety data <strong>of</strong> current treatments for systemic<br />
lupus erythematosus<br />
• List the biologic evidence base for B-cell depletion and discuss its<br />
potential application to systemic lupus erythematosus therapy<br />
• Discuss the biologic and clinical trial data for BAFF and describe their<br />
implications for clinical practice<br />
6:30 – 7:30 pm<br />
Registration and Dinner<br />
7:30 – 7:40 pm<br />
Introduction – Lupus: a Historical Perceptual<br />
Leonard Calabrese, DO; Cleveland Clinic Foundation; Cleveland, OH<br />
7:40 – 8:00 pm<br />
The Historical Problems <strong>of</strong> SLE Study Design<br />
Vibeke Strand, MD; Stanford University; Portola Valley, CA<br />
8:00 – 8:20 pm<br />
The Current Status <strong>of</strong> the Treatment <strong>of</strong> Lupus Nephritis<br />
David Jayne, MD; Addenbrooke’s Hospital; Cambridge, England<br />
8:20 – 8:40 pm<br />
B-Cell Targeting in SLE: Is B-Cell Depletion or Modulation Effective?<br />
Marc Levesque, MD, PhD; University <strong>of</strong> Pittsburgh Medical Center;<br />
Pittsburgh PA<br />
8:40 – 9:00 pm<br />
B-Cell Activating Factor (BAFF) in SLE: Biologic and Clinical Data<br />
W. Winn Chatham, MD; University <strong>of</strong> Alabama at Birmingham School <strong>of</strong><br />
Medicine; Birmingham, AL<br />
9:00 – 9:30 pm<br />
Panel Discussion and Questions<br />
wednesday, NOVEMBER 10, 2010<br />
The event listed below is a non-CME Program wholly sponsored and<br />
supported by Amgen. By holding the Program, Amgen has represented that<br />
the Program has been developed and will be implemented in accordance<br />
with the requirements <strong>of</strong> the FDA and applicable standards <strong>of</strong> the PhRMA<br />
Code on Interactions with Healthcare Pr<strong>of</strong>essionals. Amgen is to observe all<br />
guidelines established by federal and state regulatory agencies regarding<br />
non-CME educational or promotional presentations throughout the duration<br />
<strong>of</strong> the Program. The content and views expressed during the Program are<br />
those <strong>of</strong> Amgen and presenters. The ACR by making this venue available<br />
does not guarantee, warrant or endorse the content <strong>of</strong> the Program nor the<br />
products discussed and reviewed during the Program.<br />
6:30 – 9:30 pm Non-CME Accredited Symposium<br />
Omni at CNN Center, Grand Ballroom<br />
Prolia (denosumab): A New Approach in the Treatment <strong>of</strong> Postmenopausal<br />
Osteoporosis in Women at High Risk for Fracture<br />
Developed and <strong>of</strong>fered by Amgen<br />
6:30 – 7:15 pm<br />
Registration and Dinner<br />
7:15 – 7:35 pm<br />
The Prolia (denosumab) Innovation<br />
Nelson B. Watts, MD; University <strong>of</strong> Cincinnati <strong>College</strong> <strong>of</strong> Medicine;<br />
Cincinnati, OH<br />
7:35 – 8:15 pm<br />
Introducing Prolia (denosumab)<br />
Speaker to be announced<br />
8:15 – 9:00 pm<br />
Question and Answer<br />
282<br />
2010 Program Book
REF Industry Roundtable-supported Symposia<br />
thursday, NOVEMBER 11, 2010<br />
1:00 – 4:00 pm CME-Accredited Symposium<br />
For CME-accredited symposia, the sponsoring organization is responsible for<br />
panning and providing CME credit.<br />
Omni at CNN Center, International Ballroom (Sections E-F)<br />
<strong>Rheumatology</strong>—The Art <strong>of</strong> the Science: Informed Decisions, Improved<br />
Outcomes<br />
Jointly sponsored by the University <strong>of</strong> Cincinnati and NACCME<br />
Supported by an educational grant from Genentech, Inc. and Biogen Idec<br />
Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc., Abbott<br />
Laboratories, and UCB, Inc.<br />
Physician (ACCME) Accreditation Statement<br />
The University <strong>of</strong> Cincinnati is accredited by the Accreditation Council for<br />
Continuing Medical Education to provide continuing medical education for<br />
physicians.<br />
Credit Designation Statement<br />
The University <strong>of</strong> Cincinnati designates this educational activity for a<br />
maximum <strong>of</strong> 2.5 AMA PRA Category 1 Credit(s). Physicians should only<br />
claim credit commensurate with the extent <strong>of</strong> their participation in the<br />
activity.<br />
LEARNING OBJECTIVES:<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• Explain how clinical measurement tools have been used to achieve<br />
tight RA control and summarize how these tools can be used in clinical<br />
practice to optimize patient care<br />
• Describe advances in imaging techniques for the diagnosis <strong>of</strong> RA and<br />
evaluation <strong>of</strong> RA disease progression<br />
• Outline genetic associations, laboratory markers, and clinical<br />
manifestations which should be considered when initiating early,<br />
aggressive therapy<br />
• Evaluate the current ACR/EULAR diagnostic and treatment criteria and<br />
their impact on the management <strong>of</strong> RA patients<br />
• Interpret new safety and efficacy data, including those presented<br />
at ACR/ARHP, on combination therapy, triple DMARD therapy, and<br />
biologic switching<br />
• Apply clinical trial and comprehensive registry data and available<br />
guidelines regarding current and emerging pharmacologic agents into<br />
clinical practice to achieve low disease activity or remission in patients<br />
with RA<br />
• Employ best practices for treating RA in patients with comorbid<br />
conditions<br />
• Describe new treatment targets and novel approaches for RA patients<br />
who have failed on conventional therapies, including mechanisms <strong>of</strong><br />
action and safety considerations<br />
• Compare and contrast diagnostic practices and treatment approaches<br />
for patients with SpA versus RA<br />
1:00 – 1:30 pm<br />
Registration and Lunch<br />
1:30 – 1:45 pm<br />
Welcome & Introductions<br />
Sergio Schwartzman, MD; Hospital for Special Surgery; New York, NY<br />
1:45 – 2:45 pm<br />
RA Therapy in 2010: What are Today’s Best Practices?<br />
Sergio Schwartzman, MD; Hospital for Special Surgery; New York, NY<br />
2:45 – 3:45 pm<br />
Managing Inflammatory Arthritis Beyond 2010: A Look Into the Future<br />
Leonard Calabrese, DO; Cleveland Clinic Foundation; Cleveland, OH<br />
3:45 – 4:00 pm<br />
Question & Answer Session<br />
Sergio Schwartzman, MD; Hospital for Special Surgery; New York, NY<br />
Leonard Calabrese, DO; Cleveland Clinic Foundation; Cleveland, OH<br />
1:00 – 4:00 pm<br />
For CME-accredited symposia, the sponsoring organization is responsible for<br />
panning and providing CME credit.<br />
Omni at CNN Center, International Ballroom (Sections A-B-C-D)<br />
Structure Modification in Osteoarthritis<br />
Jointly sponsored by Medical Education Resources and Consensus Medical<br />
Communications<br />
Supported by an educational grant from Bioiberica<br />
Physician (ACCME) Accreditation Statement<br />
This activity has been planned and implemented in accordance with the<br />
Essential Areas and policies <strong>of</strong> the Accreditation Council for Continuing<br />
Medical Education (ACCME) through the joint sponsorship <strong>of</strong> Medical<br />
Education Resources and Consensus Medical Communications. Medical<br />
Education Resources is accredited by the ACCME to provide continuing<br />
medical education for physicians.<br />
Credit Designation Statement<br />
Medical Education Resources designates this educational activity for a<br />
maximum <strong>of</strong> 1.5 AMA PRA Category 1 Credit(s). Physicians should only<br />
claim credit commensurate with the extent <strong>of</strong> their participation in the<br />
educational activity.<br />
LEARNING OBJECTIVES:<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• Discuss the pathologic effects <strong>of</strong> OA in the synovium, cartilage and<br />
bone<br />
• Assess the structural progression in OA utilizing advanced imaging<br />
techniques<br />
• Describe the pharmacologic actions and disease modifying role <strong>of</strong><br />
chondroitin sulfate in the synovium, cartilage and bone<br />
• Describe clinical outcomes <strong>of</strong> disease modification therapy in the<br />
treatment <strong>of</strong> OA<br />
1:00 – 1:30 pm<br />
Registration and Lunch<br />
1:30 – 1:35 pm<br />
Welcome and Introduction<br />
Marc Hochberg MD, MPH; University <strong>of</strong> Maryland School <strong>of</strong> Medicine;<br />
Baltimore, MD<br />
1:35 – 1:50 pm<br />
Current Concepts: The Pathophysiology <strong>of</strong> Osteoarthritis<br />
Johanna Martel Pelletier, PhD; University <strong>of</strong> Montreal; Montreal, Quebec,<br />
Canada<br />
1:50 – 2:05 pm<br />
Assessment <strong>of</strong> Structural Progression in Osteoarthritis<br />
Philip G. Conaghan MBBS, PhD, FRACP, FRCP; Chapel Allerton Hospital;<br />
Leeds, England, UK<br />
2:05 – 2:20 pm<br />
Effects <strong>of</strong> Chondroitin Sulfate on Nuclear Factor - ĸB in OA<br />
Patrick du Souich MD, PhD; University <strong>of</strong> Montreal; Montreal, Quebec,<br />
Canada<br />
2:20 – 2:35 pm<br />
Evidence that Chondroitin Sulfate has Structure Modifying Properties in<br />
OA<br />
Jean-Pierre Pelletier MD; University <strong>of</strong> Montreal; Montreal, Quebec, Canada<br />
2:35 – 2:50 pm<br />
Current Approaches to the Management <strong>of</strong> Osteoarthritis: The Role <strong>of</strong><br />
Chondroitin Sulfate<br />
Marc Hochberg MD, MPH; University <strong>of</strong> Maryland School <strong>of</strong> Medicine;<br />
Baltimore, MD<br />
2:50 – 3:00 pm<br />
Question and Answer<br />
All Faculty<br />
2010 Program Book 283
INDUSTRY-SUPPORTED POST-CONFERENCE SYMPOSIA<br />
1:00 – 4:00 pm CME-Accredited Symposium<br />
For CME-accredited symposia, the sponsoring organization is responsible for<br />
panning and providing CME credit.<br />
Omni at CNN Center, Grand Ballroom (Section E)<br />
Pulmonary Arterial Hypertension (PAH) in Connective Tissue Diseases<br />
(CTDs): Current Concepts and Cutting-Edge Constructs in Detection,<br />
Prognosis, and Clinical Management<br />
Jointly sponsored by Medical Education Resources and Cornerstone Medical<br />
Communications<br />
Supported by an educational grant from Actelion Pharmaceuticals US, Inc.<br />
Physician (ACCME) Accreditation Statement<br />
This activity has been planned and implemented in accordance with the<br />
Essential Areas and policies <strong>of</strong> the Accreditation Council for Continuing<br />
Medical Education (ACCME) through the joint sponsorship <strong>of</strong> Medical<br />
Education Resources (MER) and Cornerstone Medical Communications.<br />
MER is accredited by the ACCME to provide continuing medical education<br />
for physicians.<br />
Credit Designation Statement<br />
Medical Education Resources designates this educational activity for a<br />
maximum <strong>of</strong> 2.0 AMA PRA Category 1 Credit(s). Physicians should only<br />
claim credit commensurate with the extent <strong>of</strong> their participation in the<br />
activity.<br />
LEARNING OBJECTIVES:<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• Describe new insights from pulmonary hypertension registries and<br />
their prognostic implications for patients with CTDs<br />
• Identify effective screening programs to detect pulmonary<br />
complications and devise specific strategies to afford earlier<br />
identification <strong>of</strong> PAH in patients with CTDs such as scleroderma<br />
• Delineate key components <strong>of</strong> the diagnostic algorithm for PAH,<br />
evaluate current treatment guidelines and new clinical trial results,<br />
and determine how these are best applied in patients with CTDs<br />
• Assess the value <strong>of</strong> measuring patient-reported outcomes as a clinical<br />
tool for optimizing care in patients with CTDs<br />
1:00 – 1:30 pm<br />
Registration and Lunch<br />
1:30 – 1:35 pm<br />
Welcome and Introduction<br />
Richard M. Silver, MD; Medical University <strong>of</strong> South Carolina; Charleston, SC<br />
1:35 – 1:55 pm<br />
Prognosis <strong>of</strong> PAH in CTD Across the Spectrum: New Insights From the<br />
REVEAL Registry<br />
Lorinda Chung, MD, MS; Stanford University School <strong>of</strong> Medicine; Stanford,<br />
CA<br />
1:55 – 2:15 pm<br />
Screening Programs and Earlier Identification <strong>of</strong> PAH in the Scleroderma<br />
Setting<br />
Eric Hachulla, MD, PhD; Université de Lille 2; Lille, France<br />
2:15 – 2:35 pm<br />
Optimal Treatment and Achieving Goals <strong>of</strong> PAH Management in Patients<br />
with CTDs<br />
Vallerie V. McLaughlin, MD, FACC, FAHA; University <strong>of</strong> Michigan Medical<br />
School; Ann Arbor, MI<br />
2:35 – 2:55 pm<br />
Patient-Reported Outcomes in Clinical Practice: Tools for Optimizing Care<br />
in the Setting <strong>of</strong> CTDs<br />
Dinesh Khanna, MD; David Geffen School <strong>of</strong> Medicine at UCLA; Los Angeles,<br />
CA<br />
2:55 – 3:25 pm<br />
Clinical Pearls from Case-based Discussion<br />
Richard M. Silver, MD; Medical University <strong>of</strong> South Carolina; Charleston, SC<br />
3:25 – 3:30 pm<br />
Concluding Remarks<br />
Vallerie V. McLaughlin, MD, FACC, FAHA; University <strong>of</strong> Michigan Medical<br />
School; Ann Arbor, MI<br />
1:00 – 4:00 pm CME-Accredited Symposium<br />
For CME-accredited symposia, the sponsoring organization is responsible for<br />
panning and providing CME credit.<br />
Embassy Suites Hotel Atlanta at Centennial Olympic Park, Legacy<br />
Ballroom<br />
Understanding Osteoarthritis Today: Risk Factors, Management, and Novel<br />
Interventions<br />
Sponsored by Cleveland Clinic<br />
Supported by an educational grant from Covidien-Mallinckrodt, Inc.<br />
Physician (ACCME) Accreditation Statement<br />
This activity has been planned and implemented in accordance with the<br />
Essential Areas and policies <strong>of</strong> the Accreditation Council for Continuing<br />
Medical Education (ACCME) through the sponsorship <strong>of</strong> the Cleveland<br />
Clinic. The Cleveland Clinic Foundation Center for Continuing Education<br />
is accredited by the ACCME to provide continuing medical education for<br />
physicians.<br />
Credit Designation Statement<br />
The Cleveland Clinic Foundation Center for Continuing Education designates<br />
this educational activity for a maximum <strong>of</strong> 2.0 AMA PRA Category 1<br />
Credit(s). Physicians should only claim credit commensurate with the<br />
extent <strong>of</strong> their participation in the activity.<br />
LEARNING OBJECTIVES:<br />
Upon completion <strong>of</strong> this session, participants should be able to:<br />
• Identify epidemiologic changes in osteoarthritis and discuss their<br />
impact on clinical practice<br />
• Assess efficacy and safety data from clinical trials <strong>of</strong> DMOADs and<br />
gauge their potential impact on clinical practice<br />
• Discuss new and emerging pain modulators as they apply to<br />
management <strong>of</strong> patients with osteoarthritis<br />
• Discuss the evidence indicating that osteoarthritis may be a<br />
potentially modifiable disease<br />
1:00 – 2:00 pm<br />
Registration and Lunch<br />
2:00 – 2:10 pm<br />
Introduction<br />
M. Elaine Husni, MD, MPH; Cleveland Clinic; Cleveland, OH<br />
2:10 – 2:30 pm<br />
Changing Epidemiology <strong>of</strong> Osteoarthritis and Identifying Risk Factors for<br />
Osteoarthritis<br />
Roland W. Moskowitz, MD; University Hospitals Case Medical Center;<br />
Cleveland, OH<br />
2:30 – 2:50 pm<br />
Therapeutic Potential <strong>of</strong> Disease-Modifying Osteoarthritis Drugs<br />
(DMOADs) Measuring Osteoarthritis Treatment Effects<br />
Clifton O. Bingham III, MD; Johns Hopkins University; Baltimore, MD<br />
2:50 – 3:05 pm<br />
Panel Discussion and Questions<br />
All Faculty<br />
284<br />
2010 Program Book
INDUSTRY-SUPPORTED POST-CONFERENCE SYMPOSIA<br />
3:05 – 3:25 pm<br />
Osteoarthritis: Unstoppable Disease vs. Potentially Modifiable<br />
Steven Abramson, MD; NYU School <strong>of</strong> Medicine; New York, NY<br />
3:25 – 3:45 pm<br />
Development <strong>of</strong> Novel Treatment Paradigm: Pain Modulators<br />
Thomas J. Schnitzer, MD, PhD;<br />
Northwestern University Feinberg School <strong>of</strong> Medicine; Chicago, IL<br />
3:45 – 4:00 pm<br />
Panel Discussion and Questions<br />
All Faculty<br />
thursday, NOVEMBER 11, 2010<br />
The event listed below is a non-CME Program wholly sponsored and<br />
supported by Pfizer Inc. By holding the Program, Pfizer Inc has represented<br />
that the Program has been developed and will be implemented in<br />
accordance with the requirements <strong>of</strong> the FDA and applicable standards <strong>of</strong><br />
the PhRMA Code on Interactions with Healthcare Pr<strong>of</strong>essionals. Pfizer Inc is<br />
to observe all guidelines established by federal and state regulatory agencies<br />
regarding non-CME educational or promotional presentations throughout<br />
the duration <strong>of</strong> the Program. The content and views expressed during the<br />
Program are those <strong>of</strong> Pfizer Inc and presenters. The ACR by making this<br />
venue available does not guarantee, warrant or endorse the content <strong>of</strong> the<br />
Program nor the products discussed and reviewed during the Program.<br />
1:00 – 4:00 pm Non-CME Accredited Symposium<br />
Omni at CNN Center, Grand Ballroom (Section A-B-C)<br />
The JAK Pathway in RA: Turning our Understanding ‘Outside In’<br />
Developed and <strong>of</strong>fered by Pfizer Inc<br />
LEARNING OBJECTIVES:<br />
To provide an overview <strong>of</strong> the mechanism <strong>of</strong> signaling by multiple cytokines<br />
through intracellular pathways, such as JAK, and the importance in the<br />
pathogenesis <strong>of</strong> RA.<br />
1:00 – 1:30 pm<br />
Registration and Lunch<br />
1:30 – 1:40 pm<br />
Welcome and Introductions<br />
1:40 – 2:00 pm<br />
How do Cytokines Talk to Cells?<br />
John J. O’Shea, MD; National Institute <strong>of</strong> Arthritis and Musculoskeletal and<br />
Skin Diseases; Bethesda, MD<br />
2:00 – 2:20 pm<br />
New Insights into the Role <strong>of</strong> the JAK Pathway in RA<br />
Peter C. Taylor MA, PhD, FRCP; Kennedy Institute <strong>of</strong> <strong>Rheumatology</strong> Division;<br />
Imperial <strong>College</strong>, London<br />
2:20 – 2:40 pm<br />
Question and Answer<br />
2:40 – 2:50 pm<br />
Concluding Remarks<br />
2:50 – 3:00 pm<br />
Adjourn<br />
2010 Program Book 285
ACR ref<br />
Industry<br />
Roundtable<br />
The Industry Roundtable brings together<br />
the ACR Research and Education Foundation<br />
and pharmaceutical industry leaders in<br />
a collaboration to provide training, research<br />
and educational opportunities in rheumatology<br />
while serving as a forum for dialogue<br />
between industry and the REF. Through<br />
Industry Roundtable support, the REF<br />
continues to increase funding for<br />
research and training.<br />
The REF would like to thank these<br />
organizations for their multi-year<br />
commitment to the REF and its programs.<br />
Together, the REF and the Industry<br />
Roundtable are investing in the<br />
future <strong>of</strong> rheumatology.
2010 ACR/ARHP Annual Meeting Leadership<br />
ACR and ARHP Officers<br />
Stanley B. Cohen, MD, ACR President<br />
David Borenstein, MD, ACR President-Elect<br />
James R. O’Dell, MD, ACR Secretary<br />
Audrey Uknis, MD, ACR Treasurer<br />
E. William St.Clair, MD, REF President<br />
David I. Daikh, MD, REF Vice President<br />
Linda S. Ehrlich-Jones, PhD, RN, ARHP President<br />
Nadine T. James, MSN, PhD, PT, ARHP<br />
President-Elect<br />
Susan E. Klepper, PhD, ARHP Secretary-Treasurer<br />
2010 ACR Annual Meeting Planning<br />
Subcommittee<br />
Joel A. Block, MD, Chair<br />
Steven R. Goldring, MD, Basic Science Sub-Chair<br />
Susan Manzi, MD, Clinical Sub-Chair<br />
Robert W. Simms, MD, Meet the Pr<strong>of</strong>essor/<br />
Workshop/Study Group Sub-Chair<br />
Carol A. Langford, MD, Clinical Chair, Abstract<br />
Selection<br />
Alisa E. Koch, MD, Basic Science Chair, Abstract<br />
Selection<br />
Abby Abelson, MD, Committee <strong>of</strong> <strong>Rheumatology</strong><br />
Training & Workforce Representative<br />
Jennifer H. Anolik, MD, PhD<br />
Joan Bathon, MD, A&R Representative<br />
Robert H. Carter, MD<br />
Mary E. Cronin, MD<br />
Barbara A. Eberhard, MBBS, MSc<br />
Keith B. Elkon, MD<br />
Polly J. Ferguson, MD, Committee on Research<br />
Representative<br />
James G. Freeman, MD<br />
Richard Furie, MD, Committee on Education,<br />
Chair<br />
Gregory Gardner, MD<br />
Alexei A. Grom, MD<br />
Bruce I. H<strong>of</strong>fman, MD<br />
Raymond S. Hong, MD<br />
Nancy Y. Liu, MD<br />
Richard F. Loeser, Jr., MD<br />
Richard J. Looney, MD<br />
Augustine M. Manadan, MD<br />
Brian F. Mandell, MD, PhD<br />
Kevin McKown, MD<br />
Zsuzsanna McMahan, MD, Fellows<br />
Representative<br />
Chester V. Oddis, MD<br />
Thomas Olenginski, MD<br />
Kathleen M. O’Neil, MD<br />
Janet L. Poole, PhD, OTR, ARHP Representative<br />
Christopher Ritchlin, MD, MPH, Pr<strong>of</strong>essional<br />
Meetings Committee, Chair<br />
Carlos D. Rose, MD<br />
Eric M. Ruderman, MD<br />
F. Jorge Sanchez-Guerrero, MD, MS<br />
Nan Shen, MD<br />
Robert Spiera, MD<br />
Paul P. Tak, MD, PhD<br />
John R.P. Tesser, MD<br />
Alexandra Villa-Forte, MD, MPH<br />
Raymond L. Yung, MD, Committee on Education,<br />
Program Sub-chair<br />
2010 Abstract Oversight Committee<br />
Robert Fuhlbrigge, MD, PhD<br />
Edward Yelin, PhD<br />
David Pisetsky, MD, PhD<br />
2010 ACR Abstract Selection Committee<br />
Alisa E. Koch, MD, Basic Science, Co-Chair<br />
Carol A. Langford, MD, MS, Clinical, Co-Chair<br />
1. Cytokines, Mediators, and Gene<br />
Regulation<br />
Alison Finnegan, PhD, Co-chair<br />
Iain B. McInnes, MD, Co-chair<br />
Michael Centola, PhD<br />
Lionel B. Ivashkiv, MD<br />
Erik Lubberts, PhD<br />
Pierre Miossec, MD, PhD<br />
2. Cell-cell Adhesion, Cell Trafficking and<br />
Angiogenesis<br />
Bruce N. Cronstein, MD, Co-chair<br />
Zoltan Szekanecz, MD, PhD, Co-chair<br />
Richard J. Bucala, MD, PhD<br />
Dorian O. Haskard, MD, PhD<br />
Katalin Mikecz, MD, PhD<br />
Douglas J. Veale, MD<br />
3. Innate Immunity and Rheumatic<br />
Disease<br />
Joseph M. Ahearn, MD, Chair<br />
John P. Atkinson, MD<br />
Susan A. Boackle, MD<br />
Robert M. Clancy, PhD<br />
Terry W. Du Clos, MD, PhD<br />
Tibor T. Glant, MD, PhD<br />
4. B-cell Biology and Targets in Autoimmune<br />
Disease<br />
Chaim Putterman, MD, Co-chair<br />
Yehuda Shoenfeld, MD, Co-chair<br />
Jennifer H. Anolik, MD, PhD<br />
Andrea Doria, MD<br />
William Stohl, MD, PhD<br />
Pierluigi Meroni, MD<br />
5. T-cell Biology and Targets in Autoimmune<br />
Disease<br />
C. Garrison Fathman, MD, Co-chair<br />
David A. Fox, MD, Co-chair<br />
Jorg J. Goronzy, MD, PhD<br />
Sujata Sarkar, MD<br />
Paul J. Utz, MD<br />
Cornelia M. Weyand, MD, PhD<br />
6. Biology and Pathology <strong>of</strong> Bone and<br />
Joint<br />
Tariq M. Haqqi, PhD, MPH, Co-chair<br />
Mary B. Goldring, PhD, Co-chair<br />
Hiroski Asahara, PhD<br />
Johanne Martel-Pelletier, PhD<br />
Georg Schett, MD<br />
Veena Taneja, PhD<br />
7. Osteoarthritis - Clinical Aspects<br />
Joanne M. Jordan, MD, MPH, Co-chair<br />
Timothy E. McAlindon MD, MPH, Co-chair<br />
Gillian A. Hawker, MD<br />
Amanda E. Nelson, MD, MSc<br />
Tuhina Neogi, MD, PhD<br />
Anita E. Wluka, PhD, MBBS<br />
8. Osteoporosis and Metabolic Bone Disease:<br />
Clinical Aspects and Pathogenesis<br />
Piet P. Geusens, MD, PhD, Co-chair<br />
Nancy E. Lane, MD, Co-chair<br />
Lenore Buckley, MD, MPH<br />
Ellen M. Gravallese, MD<br />
Mary Beth Humphrey, MD, PhD<br />
Anthony D. Woolf, MBBS<br />
9. Fibromyalgia and S<strong>of</strong>t Tissue Disorders<br />
Daniel J. Clauw, MD, Co-chair<br />
Don L. Goldenberg, MD, Co-chair<br />
Dennis C. Ang, MD<br />
Mary Ann Fitzcharles, MD<br />
Afton L. Hassett, PsyD<br />
Alan Rubinow, MD<br />
10. Orthopedics, Low Back Pain, and<br />
Rehabilitation<br />
Beth L. Jonas, MD, Co-chair<br />
Jeffery N. Katz, MD, Co-chair<br />
Aileen M. Davis, PhD<br />
Elaine Husni, MD, MPH<br />
Kenneth S. O’Rourke, MD<br />
Alfredo C. Rivadeneira, MD<br />
11. Pediatric <strong>Rheumatology</strong> - Clinical and<br />
Therapeutic Aspects<br />
Norman T. Ilowite, MD, Co-chair<br />
Daniel J. Lovell, MD, MPH, Co-chair<br />
Elga C. Rabinovich, MD, MPH, Co-chair<br />
Carol A. Wallace, MD, Co-chair<br />
Hermine Brunner, MD, MSC<br />
Edward Fels, MD<br />
Beth Gottlieb, MD, MS<br />
Thomas B. Graham, MD, MS<br />
Rayfel Schneider, MBBCH<br />
2010 Program Book 287
2010 ACR/ARHP Annual Meeting Leadership<br />
288<br />
Michael Shishov, MD, MPH<br />
Pamela O. Weiss, MD<br />
Lawrence S. Zemel, MD<br />
12. Pediatric <strong>Rheumatology</strong> - Pathogenesis and<br />
Genetics<br />
Barbara S. Adams, MD, Co-chair<br />
Nora G. Singer, MD, Co-chair<br />
Melissa E. Elder, MD, PhD<br />
Raphaela Goldbach-Mansky, MD<br />
Sampath Prahalad, MD, MSc<br />
James W. Verbsky, MD, PhD<br />
13. Infection-related Rheumatic Disease<br />
John S.H. Gaston, MD, Co-chair<br />
Dimitrios Vassilopoulos, MD, Co-chair<br />
John D. Carter, MD<br />
Cem Gabay, MD<br />
Stanley J. Naides, MD<br />
Daniel H. Solomon, MD, MPH<br />
14. Metabolic and Crystal Arthropathies<br />
Hyon K. Choi, MD, PhD, Co-chair<br />
John S. Sundy, MD, PhD, Co-chair<br />
Nicola Dalbeth, MD, MB, ChB<br />
Robert T. Keenan, MD, MPH<br />
Frederic P. Liote, MD, PhD<br />
George Nuki, MB<br />
15. Muscle Biology, Myositis and Myopathies<br />
Ingrid E. Lundberg, MD, PhD, Co-chair<br />
Frederick W. Miller, MD, PhD, Co-chair<br />
Lisa Christopher-Stine, MD<br />
Robert G. Cooper, MD<br />
Ann M. Reed, MD<br />
Lisa G. Rider, MD<br />
16. Imaging <strong>of</strong> Rheumatic Diseases<br />
Wolfgang A. Schmidt, MD, Co-chair<br />
Carl S. Winalski, MD, Co-chair<br />
John Carrino, MD<br />
Jon A. Jacobson, MD<br />
Mikkel Ostergaard, MD, PhD, DMSc<br />
Eugene Y. Kissin, MD<br />
17. RA: Clinical Aspects<br />
Jon T. Giles, MD, Co-chair<br />
Jonathan Kay, MD, Co-chair<br />
Eric L. Matteson, MD, Co-chair<br />
Deborah P. Symmons, MD, Co-chair<br />
Neal S. Birnbaum, MD<br />
Ernest Choy, MD<br />
Paul F. Dellaripa, MD<br />
Inmaculada del Rincon, MD, MS<br />
Darcy S. Majka, MD<br />
Joseph A. Markenson, MD<br />
Michael A. Stein, MD<br />
Piet L. van Riel, MD, PhD<br />
2010 Program Book<br />
18. RA Treatment - Small Molecules, Biologics<br />
and Gene Therapy<br />
Daniel E. Furst, MD, Co-chair<br />
Richard W. Martin, MD, MA, Co-chair<br />
Eric M. Ruderman, MD, Co-chair<br />
Josef S. Smolen, MD, Co-chair<br />
Marin Aringer, MD<br />
Maya H. Buch,PhD, MBChB<br />
Aaron T. Eggebeen, MD<br />
Jeffrey D. Greenberg, MD, MPH<br />
Andrew J. Head, MD<br />
Jerry A. Molitor, MD, PhD<br />
Harold E. Paulus, MD<br />
Alvin F. Wells, MD, PhD<br />
19. RA - Human Etiology and Pathogenesis<br />
Leslie J. Cr<strong>of</strong>ford, MD, Co-chair<br />
Paul-Peter Tak, MD, PhD, Co-chair<br />
Andrew P. Cope, MD<br />
Gary Firestein, MD, PhD<br />
Ulf Müller-Ladner, MD<br />
William Robinson, MD, PhD<br />
20. RA - Animal Models<br />
Linda K. Myers, MD, Co-chair<br />
Wim B. Vandenberg, PhD, Co-chair<br />
David S. Bradley, PhD<br />
Ernest Brahn, MD<br />
Kurt Redlich, MD<br />
Paul H. Wooley, PhD<br />
21. Systemic Sclerosis, Fibrosing Syndromes,<br />
and Raynaud’s - Clinical Aspects and<br />
Therapeutics<br />
Murray Baron, MD, Co-chair<br />
Maureen D. Mayes, MD, MPH, Co-chair<br />
Lorinda Chung, MD, MS<br />
Eric Hachulla, MD, PhD<br />
Laura K. Hummers, MD<br />
Sindhu Johnson, MD<br />
22. Systemic Sclerosis, Fibrosing Syndromes<br />
and Raynaud’s – Pathogenesis, Animal<br />
Models and Genetics<br />
Marco Matucci-Cerinic, MD, PhD, Co-chair<br />
Maria Trojanowska, PhD, Co-chair<br />
David S. Abraham, PhD, BSc<br />
Jorg H.W. Distler, MD<br />
Carol A. Feghali-Bostwick, PhD<br />
John Varga, MD<br />
23. Sjögren’s Syndrome<br />
Gabor G. Illei, MD, Co-chair<br />
Athanasios G. Tzioufas, MD, Co-chair<br />
Alan N. Baer, MD<br />
Stefano Bombardieri, MD<br />
Jacques-Eric Gottenberg, MD<br />
Cees G.M. Kallenberg, MD<br />
E. William St.Clair, MD<br />
24. Antiphospholipid Syndrome<br />
Doruk Erkan, MD, Co-chair<br />
Barry L. Myones, MD, Co-chair<br />
Pojen P. Chen, PhD<br />
Roger A. Levy, MD, PhD<br />
Joyce Rauch, PhD<br />
Robert A.S. Roubey, MD<br />
25. SLE - Clinical Aspects and Treatment<br />
Eliza F. Chakravarty, MD, Co-chair<br />
Elena M. Massarotti, MD, Co-chair<br />
Michelle Petri, MD, MPH, Co-chair<br />
Rosalind Ramsey-Goldman, MD, Co-chair<br />
Graciela S. Alarcon, MD, MPH<br />
Jennifer M. Grossman, MD<br />
Kenneth C. Kalunian, MD<br />
Amy H. Kao, MD, MPH<br />
S. Sam Lim, MD, MPH<br />
Kathleen Macsimowics-McKinnon, DO<br />
Peter H. Schur, MD<br />
Daniel J. Wallace, MD<br />
26. SLE - Human Etiology and Pathogenesis<br />
Mary K. Crow, MD, Co-chair<br />
George C. Tsokos, MD, Co-chair<br />
Anne Davidson, MB, BS<br />
Gary S. Gilkeson, MD<br />
Antonio La Cava, MD, PhD<br />
Andras Perl, MD, PhD<br />
27. SLE - Animal Models<br />
Philip L. Cohen, MD, Co-chair<br />
Jane E. Salmon, MD, Co-chair<br />
Marina J. Kaplan, MD<br />
Dwight H. Kono, MD<br />
Westley H. Reeves, MD<br />
Joan E. Wither, MD, PhD<br />
28. Spondylarthropathies and Psoriatic<br />
Arthritis: Clinical Aspects and<br />
Treatment<br />
Juergen Braun, MD, Co-chair<br />
Christopher T. Ritchlin, MD, Co-chair<br />
Desiree M. van der Heijde, MD, PhD,<br />
Co-chair<br />
Michael H. Weisman, MD, Co-chair<br />
Dominique Baeten, MD, PhD<br />
Daniel O. Clegg, MD<br />
Maxime Dougados, MD<br />
Luis R. Espinoza, MD<br />
Lianne S. Gensler, MD<br />
Robert D. Inman, MD<br />
Robert Landewe, MD<br />
Sergio Schwartzman, MD
2010 ACR/ARHP Annual Meeting Leadership<br />
29. Spondylarthropathies and Psoriatic<br />
Arthritis - Pathogenesis, Etiology<br />
Robert H. Sc<strong>of</strong>ield, MD, Co-chair<br />
Joel D. Taurog, MD, Co-chair<br />
Maxime A. Breban, MD, PhD<br />
Robert A. Colbert, MD, PhD<br />
Walter P. Maksymowych, MD<br />
Joachim Sieper, MD<br />
30. Vasculitis<br />
Simon Carette, MD, Co-chair<br />
Paul A. Monach, MD, PhD, Co-chair<br />
Loic P. Guillevin, MD<br />
Curry L. Koening, MD, MS<br />
Robert Spiera, MD<br />
Richard Watts, MD<br />
31. Epidemiology and Health Services<br />
Research<br />
Karen H. Costenbader, MD, MPH, Co-chair<br />
Allan C. Gelber, MD, Co-chair<br />
Liana Fraenkel, MD, MPH, Co-chair<br />
Lisa A. Mandl, MD, MPH, Co-chair<br />
Jolanda Cibere, MD, PhD<br />
Jeffery R. Curtis, MD, MPH<br />
John D. Fitzgerald, MD, PhD<br />
Elena Losina, PhD<br />
Kaleb D. Michaud, PhD<br />
Ted R. Mikuls, MD<br />
Shikha Mittoo, MD<br />
Lisa G. Suter, MD<br />
32. Quality Measures and Innovations<br />
in Practice Management and Care<br />
Delivery<br />
J. Timothy Harrington, MD, Co-chair<br />
Eric D. Newman, MD, Co-chair<br />
Gerson C. Bernhard, MD<br />
Matthew P. Bunyard, MD<br />
Theodore R. Fields, MD<br />
Steven S. Overman, MD, MPH<br />
33. Genetics, Genomics and Proteomics<br />
John B. Harley, MD, PhD, Co-chair<br />
John D. Reveille, MD, Co-chair<br />
David N. Glass, MD<br />
Robert M. Plenge, MD, PhD<br />
Betty P. Tsao, PhD<br />
34. Education<br />
Maria-Louise Barilla-LaBarca, MD, Co-chair<br />
Audrey B. Uknis, MD, Co-chair<br />
Abby G. Abelson, MD<br />
Seth Berney, MD<br />
Robert A. Kalish, MD<br />
Celso Velazquez, MD<br />
35. Miscellaneous Rheumatic and<br />
Inflammatory Diseases<br />
Kristine M. Lohr, MD, MS, Co-chair<br />
W. Winn Chatham, MD, Co-chair<br />
Keivan Dehghanpisheh, MD, PhD<br />
Richard M. Keating, MD<br />
Erika H. Noss, MD<br />
Kenneth J. Warrington, MD<br />
Basic Research Conference Abstract Reviewers<br />
Robert A. Colbert, MD, PhD<br />
Polly J. Ferguson, MD<br />
Lionel B. Ivashkiv, MD<br />
Ann Marshak-Rothstein, MD<br />
E. William St.Clair, MD<br />
Clinical Research Conference Abstract Reviewers<br />
Robert A. Colbert, MD, PhD<br />
Elizabeth W. Karlson, MD<br />
Kenneth G. Saag, MD, MSc<br />
ARHP Officers<br />
Linda S. Ehrlich-Jones, PhD, RN, ARHP President<br />
Nadine T. James, MSN, PhD, PT, ARHP President-<br />
Elect<br />
Susan E. Klepper, PhD, ARHP Secretary-Treasurer<br />
AHRP Annual Meeting Program Committee<br />
Janet L. Poole, PhD, OTR, Chair<br />
Kori A. Dewing, MSN, ARNP, Chair-elect<br />
Atul A. Deodhar, MD, MRCP<br />
Donna K. Everix, MPA, BS, PT<br />
Nadine M. Fisher, EdD<br />
Bernadette McNally, MS, PA-C<br />
Susan M. Oliver, MSc<br />
Elizabeth G. Salt, PhD, ARNP<br />
Emily C. Somers, PhD, ScM<br />
Benjamin J. Smith, PA-C, Chair, ARHP Committee<br />
on Education<br />
Sandra J. Watcher, BSN<br />
Mary Wright, BS, OT<br />
2010 ARHP ABSTRACT REVIEW PANELS<br />
Clinical Practice/Patient Care<br />
Debra Bancr<strong>of</strong>t-Rizzo, MSN, RNP-C<br />
Patricia Cornell, BSc<br />
James A. Jenkins, PhD<br />
Kim D. Jones, RNC, PhD<br />
Doreen M. Stiskal, PT, PhD<br />
Donna K. Everix, MPA, BS, PT<br />
Education/Community<br />
Gail C. Davis, RN, EdD<br />
Laura D. Bilek, PhD, PT<br />
Atul Deodhar, MD<br />
Linda S. Ehrlich-Jones, PhD, RN<br />
Geri B. Neuberger, RN, EdD<br />
Sandra J. Watcher, RN, BSN<br />
Epidemiology<br />
Alyssa B. Dufour, MA<br />
Charles G. Helmick, MD<br />
Howard J. Hillstrom, MD<br />
Helen B. Hubert, MPH, PhD<br />
Robert R. McLean, DSc, MPH<br />
Emily C. Somers, PhD, ScM<br />
Health Services Research<br />
Mary E. Christenson, PT, PhD<br />
Lisa M. Kastanek, RN, CCRC<br />
Linda C. Li, BSc (PT) MSc PhD<br />
Elizabeth A. Schlenk, PhD, RN<br />
Benjamin J. Smith, PA-C<br />
Kori A. Dewing, MN, ARNP<br />
Pediatrics<br />
Kelly K. Anthony, PhD<br />
Christine W. Kennedy, MSN, RN, CPNP<br />
Karen L. Kerr, MSN, NP, CPNP, APRN-BC<br />
Norma L. Liburd, RNC, MN<br />
Jamie E. Neal, CPNP<br />
Bernadette McNally, PA<br />
Psychology/Social Sciences<br />
Carol M. Greco, PhD<br />
Afton L. Hassett, PsyD<br />
Vanessa L. Malcarne, PhD<br />
Perry Nicassio, PhD<br />
Karen L. Smarr, PhD<br />
Janet L. Poole, PhD, OTR<br />
Rehabilitation Sciences<br />
Jill R. Blitz, PT<br />
Jane S. Brandenstein, BS, PT<br />
Talitha Cox, MA, OTR/L<br />
Lori Cyr, BSc, OT<br />
Mary Wright, BSc, OT<br />
Nadine M. Fisher, EdD<br />
Research Methodology<br />
Nancy A. Baker, ScD OTR/L<br />
Marian T. Hannan, DSc, MPH<br />
Nadine T. James, RN, MSN, PhD<br />
Norma J. Macintyre, PT, PhD<br />
Yuqing Zhang, DSc<br />
Elizabeth Salt, PhD, ARNP<br />
Special Interest<br />
Kori A. Dewing, MN, ARNP<br />
Nadine M. Fisher, EdD<br />
Bernadette McNally, PA<br />
Sandra J. Watcher, RN, BSN<br />
Mary Wright, BSc, OT<br />
Janet L .Poole, PhD, OTR<br />
2010 Program Book 289
FLOOR PLANS<br />
290<br />
2010 Program Book
FLOOR PLANS<br />
2010 Program Book 291
EXHIBIT HALL<br />
NEED A PLACE TO RELAX OR MEET WITH COLLEAGUES?<br />
YOU ASKED FOR MORE OPPORTUNITIES TO RELAX AND NETWORK<br />
AND WE’VE DELIVERED!<br />
Exhibit Hall and Replay Café Hours<br />
Monday, November 8<br />
9:00 am – 5:00 pm<br />
Tuesday, November 9<br />
9:00 am – 7:00 pm<br />
Wednesday, November 10<br />
9:00 am –2:00 pm<br />
Innovation Theater Schedule<br />
Monday, November 8<br />
10:00 - 10:45 am<br />
12:15 - 1:00 pm<br />
2:00 - 2:45 pm<br />
Tuesday, November 9<br />
10:00 - 10:45 am<br />
12:15 - 1:00 pm<br />
2:00 - 2:45 pm<br />
Refreshments<br />
Monday, November 8<br />
Complimentary C<strong>of</strong>fee and Light Refreshments<br />
9:00 - 10:00 am<br />
Afternoon Snack Break<br />
2:00 - 3:00 pm<br />
Tuesday, November 9<br />
Complimentary C<strong>of</strong>fee and Light Refreshments<br />
9:00 - 10:00 am<br />
Afternoon Snack Break<br />
2:00 - 3:00 pm<br />
Wine and Cheese Reception<br />
5:15 - 6:45 pm<br />
Wednesday, November 10<br />
Complimentary C<strong>of</strong>fee and Light Refreshments<br />
9:00 - 10:00 am<br />
Wednesday, November 10<br />
10:00 - 10:45 am<br />
12:15 - 1:00 pm<br />
Innovation Theater (booth # 555)<br />
The Innovation Theater is an intimate environment for you to relax<br />
and enjoy time with your peers while gaining insight into the latest<br />
developments in the field <strong>of</strong> rheumatology. Participating exhibitors will<br />
provide 45-minute presentations to showcase their noteworthy products<br />
and/or services. There is no need to register; however, seating is limited<br />
and available on a first-come, first-served basis.<br />
Schedule<br />
Monday, November 8<br />
10:00 – 10:45 am (light refreshments provided by the ACR)<br />
A Treatment Option for the Management <strong>of</strong> Fibromyalgia<br />
Presented by Forest Pharmaceuticals<br />
12:15 – 1:00 pm (boxed lunch provided by the ACR)<br />
Choices and Challenges in Managing Psoriatic Arthritis<br />
Presented by Centocor Ortho Biotech Inc.<br />
2:00 – 2:45 pm (light refreshments provided by the ACR)<br />
New Way RA – Empowering Your Patients to Live Well with RA<br />
Presented by Centocor Ortho Biotech Inc.<br />
Tuesday, November 9<br />
10:00 – 10:45 am (light refreshments provided by the ACR)<br />
Bridging the Gap: A Peer-led Discussion on Effective Physician/Patient<br />
Dialogue<br />
Presented by Genentech and Biogen Idec<br />
12:15 – 1:00 pm (boxed lunch provided by the ACR)<br />
Pathophysiology <strong>of</strong> Pain: Mechanisms and Manifestations<br />
Presented by Lilly USA, LLC<br />
2:00 – 2:45 pm (light refreshments provided by the ACR)<br />
Clinical Perils in <strong>Rheumatology</strong>: Uncovering Pulmonary Arterial<br />
Hypertension in Your High-Risk Patient Populations—The Importance<br />
<strong>of</strong> Aggressive Screening and Early Diagnosis<br />
Presented by Actelion Pharmaceuticals US, Inc.<br />
Wednesday, November 10<br />
10:00 – 10:45 am (light refreshments provided by the ACR)<br />
An Alternative for Patients with Signs and Symptoms <strong>of</strong> Osteoarthritis<br />
<strong>of</strong> the Knee(s)<br />
Presented by Covidien<br />
12:15 – 1:00 pm (boxed lunch provided by the ACR)<br />
New Insights into the Role <strong>of</strong> the JAK Pathways in RA<br />
Presented by Pfizer Inc<br />
CME is not <strong>of</strong>fered for sessions in the Innovation Theater.<br />
292<br />
2010 Program Book
VISIT THE EXHIBIT HALL<br />
New and innovative changes will welcome every<br />
attendee as they enter the Exhibit Hall this year.<br />
Whether you are looking to learn about the<br />
latest scientific developments, catch a replay<br />
<strong>of</strong> a session you missed, take a shot at winning<br />
the grand prize with the Exhibit Hall Passport,<br />
or find a place to relax and catch up with<br />
colleagues – visiting the Exhibit Hall is a must for<br />
your annual meeting check list.<br />
EXHIBIT HALL HOURS<br />
Monday, November 8:<br />
9:00 am – 5:00 pm<br />
Tuesday, November 9:<br />
9:00 am – 7:00 pm<br />
Wednesday, November 10:<br />
9:00 am – 2:00 pm<br />
Wine and Cheese Reception – NEW!<br />
Don’t miss your chance to network with<br />
colleagues and exhibitors during the Wine and<br />
Cheese Reception – to be held in the Exhibit<br />
Hall prior to the Study Groups on Tuesday,<br />
November 9th from 5:15 to 6:45 p.m.<br />
Exhibit Hall Passport – NEW!<br />
With your registration materials, you will find<br />
the Exhibit Hall Passport. Visit participating<br />
exhibitors to collect a stamp as you learn<br />
about new and noteworthy <strong>of</strong>ferings for<br />
rheumatologists and health pr<strong>of</strong>essionals. The<br />
first 1,000 attendees to drop <strong>of</strong>f their completed<br />
Passport at the ACR Concierge Center will<br />
receive an ACR giveaway and one lucky winner<br />
will be selected to win a Kindle DX Wireless<br />
Reading Device.<br />
EXHIBITORS<br />
Abbott<br />
Pharmaceuticals<br />
Booth # 1121<br />
www.abbott.com<br />
ACP/Annals <strong>of</strong> Internal Medicine<br />
Nonpr<strong>of</strong>it Organization; Publisher<br />
Booth # 713<br />
www.acponline.org<br />
ACR Concierge Center<br />
Drop <strong>of</strong>f your Exhibit Hall Passport here!<br />
Booth # 1311<br />
www.rheumatology.org/education<br />
ACR Replay Café<br />
Catch replays <strong>of</strong> sessions you missed!<br />
Booth # 123<br />
www.rheumatology.org/education<br />
Actelion Pharmaceuticals<br />
Pharmaceuticals<br />
Booth # 1924, 2025<br />
www.actelion.com<br />
<strong>American</strong> Podiatric Medical Association<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 601<br />
www.apma.org<br />
<strong>American</strong> Regent, Inc.<br />
Pharmaceuticals<br />
Booth # 1901<br />
www.americanregent.com<br />
Amgen, Inc.<br />
Biotech<br />
Booth # 1240<br />
www.amgen.com<br />
Amgen, Inc. and Pfizer Inc<br />
Pharmaceuticals<br />
Booth # 1429<br />
www.amgen.com<br />
www.pfizer.com<br />
Arthritis Foundation<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 700<br />
www.arthritis.org<br />
Aspirus Clinics<br />
Recruitment<br />
Booth # 823<br />
www.aspirus.org<br />
Autoimmune Diseases Association<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 623<br />
www.aarda.org<br />
Auxilium Pharmaceuticals<br />
Pharmaceuticals<br />
Booth # 2001<br />
www.auxilium.com<br />
Besse Medical<br />
Pharmaceuticals<br />
Booth # 1048<br />
www.besse.com<br />
Binding Site, The<br />
Diagnostic Equipment/Products<br />
Booth # 1334<br />
www.thebindingsite.com<br />
BioMed Central<br />
Publisher<br />
Booth # 727<br />
www.biomedcentral.com<br />
Bozeman Deaconess Hospital<br />
Recruitment<br />
Booth # 729<br />
www.bozemandeaconess.org<br />
EXHIBITORS<br />
Bristol-Myers Squibb<br />
Pharmaceuticals<br />
Booth # 1159<br />
www.bms.com<br />
British Society for <strong>Rheumatology</strong><br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 706<br />
www.rheumatology.org.uk<br />
Cellestis Inc.<br />
Diagnostic Equipment/Products<br />
Booth # 1206<br />
www.cellestis.com<br />
Centocor Ortho Biotech Inc.<br />
Pharmaceuticals<br />
Booth # 1108<br />
www.centocor.com<br />
Chugai Pharmaceutical Co., LTD.<br />
Pharmaceuticals<br />
Booth # 958<br />
www.chugai-pharm.co.jp/english<br />
Cleveland Clinic<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 714<br />
www.clevelandclinic.org<br />
Clinical and Experimental <strong>Rheumatology</strong><br />
Publisher<br />
Booth # 825<br />
www.clinexprheumatol.org<br />
Clinical Immunology Society<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 709<br />
www.clinimmsoc.org<br />
CORRONA, Inc.<br />
Data Registry<br />
Booth # 1736<br />
www.corrona.org<br />
Covidien - Mallinckrodt<br />
Pharmaceuticals<br />
Booth # 1841<br />
www.mallinckrodt.com<br />
Crescendo Bioscience, Inc.<br />
Diagnostic Equipment/Products<br />
Booth # 1951<br />
www.crescendobio.com<br />
CuraScript SD<br />
Pharmacy Services<br />
Booth # 1741<br />
www.curascriptonline.com<br />
CVS Caremark/CarePLUS<br />
Pharmacy Services<br />
Booth # 1633<br />
www.caremark.com<br />
2010 Program Book 293
EXHIBITORS<br />
294<br />
Cypress Bioscience Inc.<br />
Personalized Medicine Services<br />
Booth # 1645<br />
www.cypressbio.com<br />
Daiichi Sankyo<br />
Pharmaceuticals<br />
Booth # 928<br />
www.dsi.com<br />
DePuy Mitek<br />
Surgical Instruments/Supplies<br />
Booth # 1152<br />
www.depuymitek.com<br />
Dermpath Diagnostics<br />
Laboratory Services<br />
Booth # 938<br />
www.dermpathdiagnositics.com<br />
Diagnostic Instruments, Inc.<br />
Diagnostic Equipment/Products<br />
Booth # 920<br />
www.msultrasound.net<br />
DJO<br />
Medical Device<br />
Booth # 1046<br />
www.djoglobal.com<br />
EMD Serono<br />
Pharmaceuticals<br />
Booth # 2155<br />
www.emdserono.com<br />
Esaote Biosound<br />
Diagnostic Equipment/Products<br />
Booth # 1140<br />
www.biosound.com<br />
European League Against Rheumatism<br />
(EULAR)<br />
Booth # 818<br />
Nonpr<strong>of</strong>it Organization<br />
www.eular.org<br />
Euro-Diagnostica Inc<br />
Diagnostic and Laboratory Equipment/<br />
Products<br />
Booth # 2002<br />
www.eurodiagnostica.us.com<br />
Euroimmun US<br />
Biotech; Diagnostic Equipment/Products<br />
Booth # 737<br />
www.euroimmunus.com<br />
Exhibitchek<br />
Market Research<br />
Booth # 1044<br />
2010 Program Book<br />
Fallene LTD<br />
Sunblock/Skincare<br />
Booth # 2135<br />
www.totalblock.com<br />
Ferring Pharmaceuticals Inc.<br />
Pharmaceuticals<br />
Booth # 2000<br />
www.euflexxa.com<br />
Forest Pharmaceuticals, Inc.<br />
Pharmaceuticals<br />
Booth # 1701<br />
www.forestpharm.com<br />
Gebauer Company<br />
Pharmaceuticals/Topical Anesthetics<br />
Booth # 731<br />
www.gebauer.com<br />
GE Healthcare<br />
Diagnostic Equipment/Products<br />
Booth # 753<br />
www.geultrasound.com<br />
Genentech (includes Roche, Roche<br />
Diagnostics and Biogen Idec)<br />
Biotech<br />
Booth # 1609<br />
www.gene.com<br />
Genentech<br />
Biotech<br />
Suite D<br />
www.gene.com<br />
Genentech and Biogen Idec<br />
Biotech<br />
Booth # 2109<br />
www.gene.com<br />
Genzyme<br />
Biotech<br />
Booth # 1501<br />
www.genzyme.com<br />
Gilead Sciences, Inc.<br />
Biotech<br />
Booth # 1001<br />
www.gilead.com<br />
Gout & Uric Acid Education Society (GUAES)<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 715<br />
www.gouteducation.org<br />
Hattiesburg Clinic<br />
Recruitment<br />
Booth # 1053<br />
www.hattiesburgclinic.com<br />
Health Media Network<br />
Digital Media<br />
Booth # 839<br />
www.hmnads.com<br />
Hisamitsu Pharmaceutical<br />
Pharmaceuticals<br />
Booth # 2124<br />
www.salonpas.us<br />
Hologic<br />
Diagnostic Equipment/Products<br />
Booth # 722<br />
www.hologic.com<br />
Horizon Pharma, Inc.<br />
Pharmaceuticals<br />
Booth # 900<br />
www.horizon-pharma.com<br />
Hospital for Special Surgery<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 836<br />
www.hss.edu<br />
HRA Research<br />
Market Research<br />
Booth # 1635<br />
www.hraresearch.com<br />
Human Genome Sciences, Inc.<br />
Biotech<br />
Booth # 1749<br />
www.hgsi.com<br />
Innovation Theater<br />
Attend 45-minute exhibitor presentations<br />
Booth # 555<br />
www.rheumatology.org/education<br />
Inova Diagnostics, Inc.<br />
Biotech; Diagnostic Equipment/Products<br />
Booth # 2023<br />
www.inovadx.com<br />
International League <strong>of</strong> Associations for<br />
<strong>Rheumatology</strong> (ILAR)<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 1105<br />
www.ilar.org<br />
JAMA & Archives Journals<br />
Publisher<br />
Booth # 603<br />
pubs.ama-assn.org<br />
Johns Hopkins Arthritis Center<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 1035<br />
www.hopkins-arthritis.org<br />
Journal <strong>of</strong> Musculoskeletal Medicine, The<br />
Publisher<br />
Booth # 940<br />
www.musculoskeletalnetwork.com<br />
Journal <strong>of</strong> <strong>Rheumatology</strong>, The<br />
Publisher<br />
Booth # 808<br />
www.jrheum.org
EXHIBITORS<br />
La Lettre Du Rhumatologue - Edimark Santé<br />
Publisher<br />
Booth # 923<br />
www.edimark.fr<br />
LabCorp<br />
Laboratory Testing Services<br />
Booth # 1237<br />
www.labcorp.com<br />
Laclede Inc.<br />
Therapeutic/Patient Aid Products<br />
Booth # 2043<br />
www.laclede.com<br />
Lexicon Pharmaceuticals<br />
Pharmaceuticals<br />
www.lexpharma.com<br />
Lilly USA, LLC.<br />
Pharmaceuticals<br />
Booth # 1409, 1419<br />
www.lilly.com<br />
Lippincott, Williams and Wilkins<br />
Publisher<br />
Booth # 1637<br />
www.kluwer.com<br />
www.lww.com<br />
Lupus Clinical Trials Consortium, Inc<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 619<br />
www.dxlupus.org<br />
Lupus Initiative, The<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 1842<br />
www.thelupusinitiative.org<br />
McKesson Specialty Care Solutions<br />
Distributor<br />
Booth # 849<br />
www.mckesson.com<br />
MediUSA<br />
Therapeutic/Patient Aid Products<br />
Booth # 1840<br />
www.mediusa.com<br />
Merck<br />
Pharmaceuticals<br />
Booth # 1631, Suite E<br />
www.merck.com<br />
Merit Foundation<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 617<br />
www.meteorfoundation.com<br />
Metro Medical Supply<br />
Pharmacy Services/Supplies<br />
Booth # 2122<br />
www.metromedical.com<br />
Metroplex Clinical Research Center<br />
Phase I - IV Clinical Research Site<br />
Booth # 1235<br />
www.mcrcdallas.com<br />
Millipore<br />
Biotech, Laboratory Equipment/Products<br />
Booth # 1102<br />
www.millipore.com<br />
Myositis Association, The<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 816<br />
www.myositis.org<br />
National Data Bank for Rheumatic Diseases<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 717<br />
www.arthritis-research.org<br />
National Fibromyalgia Association<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 627<br />
www.fmaware.org<br />
National Fibromyalgia Partnership, Inc.<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 607<br />
www.nfpartnership.org<br />
National Institute <strong>of</strong> Arthritis and<br />
Musculoskeletal and Skin Diseases<br />
Government<br />
Booth # 716<br />
www.niams.nih.gov<br />
New Balance Athletic Shoe, Inc.<br />
Footwear<br />
Booth # 826<br />
www.newbalance.com<br />
NIH Patient-Reported Outcomes<br />
Measurement System (PROMIS)<br />
Non-Pr<strong>of</strong>it Organization/Governmental<br />
Agency<br />
Booth # 625<br />
www.nihpromis.org<br />
Novartis Pharmaceuticals Corporation<br />
Pharmaceuticals<br />
Booth # 1135, 1725<br />
www.novartis.com<br />
Nutramax Laboratories, Inc.<br />
Nutritional Products<br />
Booth # 1934<br />
www.nutramaxlabs.com<br />
NYU Hospital for Joint Diseases<br />
Academic Center<br />
Booth # 710<br />
www.hed.nyu.edu<br />
Oklahoma Medical Research Foundation<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 611<br />
www.lupus.omrf.org<br />
Optasia Medical, Inc.<br />
Diagnostic Equipment/Products<br />
Booth # 735<br />
www.optasiamedical.com<br />
Organization <strong>of</strong> Teratology Information<br />
Specialists<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 810<br />
www.otispregnancy.org<br />
Ossur Americas<br />
Braces/Supports<br />
Booth # 1336<br />
www.ossur.com<br />
Oxford Immunotec Inc<br />
Diagnostic Products<br />
Booth # 2041<br />
www.oxfordimmunotec.com<br />
Oxford University Press<br />
Publisher<br />
Booth # 922<br />
www.oxfordjournals.org<br />
Pacific Biomarkers, Inc.<br />
Contract Research<br />
Booth # 2148<br />
www.pacbio.com<br />
Pan <strong>American</strong> League <strong>of</strong> Associations for<br />
<strong>Rheumatology</strong> (PANLAR)<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 605<br />
www.panlar.org<br />
PAREXEL International<br />
Contract Research<br />
Booth # 802<br />
www.parexel.com<br />
PBL InterferonSource<br />
Contract Research<br />
Booth # 1903<br />
www.interferonsource.com<br />
Pediatric <strong>Rheumatology</strong> Journal<br />
Publisher<br />
Booth # 1052<br />
www.ped-rheum.com<br />
Perceptive Informatics<br />
Technology/Clinical Trials Solutions<br />
Booth # 821<br />
www.perceptive.com<br />
Pfizer Inc<br />
Pharmaceuticals<br />
Booth # 1250, 1445, 1651<br />
www.pfizer.com<br />
2010 Program Book 295
EXHIBITORS<br />
Phreesia<br />
Office S<strong>of</strong>tware/Equipment<br />
Booth # 1730<br />
www.phreesia.com<br />
Pikeville Medical Center<br />
Recruitment<br />
Booth # 955<br />
www.pikevillehospital.org<br />
Quidel Corporation<br />
Diagnostic Equipment/Products<br />
Booth # 1702<br />
www.quidel.com<br />
REF Philanthropy Showcase<br />
Attend REF Birthday Cake Celebration<br />
(Monday; 2:45 – 3:30 PM)<br />
Booth # 1331<br />
www.rheumatology.org/ref<br />
ReSearch Pharmaceutical Services<br />
Contract Research<br />
Booth # 2126<br />
www.rpsweb.com<br />
R. J. Fasenmyer Center for Clinical<br />
Immunology<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 712<br />
www.clevelandclinic.org/FasenmyerCenter<br />
RDL Reference Laboratory<br />
Diagnostic Testing<br />
Booth # 1625<br />
www.rdlinc.com<br />
Regeneron Pharmaceuticals, Inc.<br />
Pharmaceuticals<br />
Booth # 941<br />
www.regeneron.com<br />
<strong>Rheumatology</strong> News<br />
Publisher<br />
Booth # 1100<br />
www.rheumatologynews.com<br />
<strong>Rheumatology</strong> Nurses Society<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 613<br />
www.rns-network.org<br />
<strong>Rheumatology</strong> Practice News<br />
Publisher<br />
Booth # 2115<br />
www.rheumatologypracticenews.com<br />
Rheuminations, Inc.<br />
Nonopr<strong>of</strong>it Organization<br />
Booth # 832<br />
www.dxlupus.org<br />
Rottapharm Ltd<br />
Pharmaceuticals<br />
Booth # 1134<br />
www.rotta.com<br />
San<strong>of</strong>i-Aventis<br />
Pharmaceuticals<br />
Booth # 1101<br />
www.san<strong>of</strong>i-aventis.us<br />
Saunders/Mosby-Elsevier<br />
Publisher<br />
Booth # 1601<br />
www.elsevierhealth.com<br />
Savient Pharmaceuticals<br />
Biotech/Pharmaceuticals<br />
Booth # 531, Suite C<br />
www.savientpharma.com<br />
Scandinavian Journal <strong>of</strong> <strong>Rheumatology</strong><br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 711<br />
www.scandjrheumatol.dk<br />
Scleroderma Foundation<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 719<br />
www.scleroderma.org<br />
Siemens Medical Solutions USA Inc.<br />
Diagnostic Equipment/Products<br />
Booth # 924<br />
www.usa.siemens.com/healthcare<br />
Silver Ring Splint Company<br />
Ring Splints<br />
Booth # 1734<br />
www.sliverringsplint.com<br />
Sjögren’s Syndrome Foundation<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 718<br />
www.sjogrens.org<br />
Smith & Nephew<br />
Pharmaceuticals/Medical Device<br />
Booth # 1735<br />
www.smithnephew.com<br />
SonoSite<br />
Diagnostic Equipment/Products<br />
Booth # 2047<br />
www.sonosite.com<br />
Spondylitis Association <strong>of</strong> America<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 812<br />
www.spondylitis.org<br />
Springer<br />
Publisher<br />
Booth # 1055<br />
www.springer.com<br />
Surgin<br />
Surgical Instruments/Supplies<br />
Booth # 2113<br />
www.dualinjector.com<br />
Takeda Pharmaceuticals<br />
Pharmaceuticals<br />
Booth # 541<br />
www.tpna.com<br />
Terason<br />
Diagnostic Equipment/Products<br />
Booth # 1202<br />
www.terason.com<br />
TheraTest Laboratories, Inc.<br />
Diagnostic Equipment/Products<br />
Booth # 1835<br />
www.theratest.com<br />
Touch <strong>of</strong> Life Technologies<br />
Virtual Reality<br />
Booth # 1054<br />
www.toltech.net<br />
U.S. Food and Drug Administration<br />
Government Agency<br />
Booth # 615<br />
www.fda.gov<br />
UCB, Inc.<br />
Biotech<br />
Booth # 910<br />
www.ucb.com<br />
UpToDate<br />
Office S<strong>of</strong>tware/Equipment<br />
Booth # 1732<br />
www.uptodate.com<br />
URL Pharma<br />
Pharmaceuticals<br />
Booth # 1945<br />
www.urlpharma.com<br />
Vasculitis Foundation<br />
Nonpr<strong>of</strong>it Organization<br />
Booth # 814<br />
www.vasculitisfoundation.org<br />
Virtual Scopics<br />
Contract Research/Imaging Core Lab<br />
Booth # 1051<br />
www.virtualscopics.com<br />
VQ OrthoCare<br />
Therapeutic/Patient Aid Products<br />
Booth # 2123<br />
www.vqorthocare.com<br />
Wiley Blackwell<br />
Publisher<br />
Booth # 1700<br />
www.wiley.com<br />
296<br />
2010 Program Book
ACKNOWLEDGEMENTS<br />
The ACR, the ARHP and the REF wish to thank the following organizations<br />
for providing support for the 2010 ACR/ARHP Annual Scientific Meeting.<br />
Their support has been used to help <strong>of</strong>fset the cost <strong>of</strong> the meeting for<br />
attendees.<br />
Amgen, Inc. and Pfizer Inc<br />
Scientific Program Book<br />
Session Tracker<br />
Bristol-Myers Squibb Company<br />
Exhibit Hall Hanging Aisle Signs<br />
Centocor Ortho Biotech Inc.<br />
Convention Internet Center<br />
Exhibit Hall Internet Centers<br />
Genentech, A Member <strong>of</strong> the Roche Group<br />
Online Itinerary Builder with Abstracts and Scientific Syllabi<br />
Clinical Scenario Challenge<br />
Exhibit Hall Replay Café<br />
Exhibit Hall Recharge Kiosks<br />
2010 Program Book 297
ACKNOWLEDGEMENTS<br />
298<br />
In addition to the support provided for the 2010 ACR/ARHP Annual<br />
Scientific Meeting, the ACR, the ARHP and the REF wish to thank the<br />
following organizations for providing support for activities and programs<br />
held throughout the year.<br />
Abbott<br />
Industry Roundtable Member<br />
Fellows Education Fund<br />
<strong>Rheumatology</strong> Maintenance <strong>of</strong> Certification Course<br />
<strong>Rheumatology</strong> Training Directors’ Conference<br />
State-<strong>of</strong>-the-Art Clinical Symposium<br />
Musculoskeletal Ultrasound Course for Rheumatologists<br />
Advanced Practice Skills Training Course<br />
CARE 2010<br />
ACR REF/Abbott Medical and Graduate Student Achievement Award<br />
ACR REF/Abbott Medical and Pediatric Resident Research Award<br />
ACR REF/Abbott Health Pr<strong>of</strong>essional Graduate Student Research<br />
Preceptorship<br />
ACR REF/Abbott Medical Student Clinical Preceptorship<br />
ACR REF/Abbott Medical Student Research Preceptorship<br />
Annual Scientific Meeting Industry-Supported Post-Conference<br />
Symposium<br />
Actelion Pharmaceuticals US, Inc.<br />
Annual Scientific Meeting Industry-Supported Post-Conference<br />
Symposium<br />
Amgen, Inc.<br />
Industry Roundtable Member<br />
Annual Scientific Meeting Industry Roundtable Symposium<br />
ACR REF <strong>Rheumatology</strong> Scientist Development Award<br />
ACR REF/Amgen Pediatric <strong>Rheumatology</strong> Visiting Pr<strong>of</strong>essorship Program<br />
ACR REF/Amgen Pediatric <strong>Rheumatology</strong> Research Award<br />
Amgen, Inc. and Pfizer Inc<br />
Fellows Education Fund<br />
ACR REF Amgen/Pfizer <strong>Rheumatology</strong> Fellowship Training Award<br />
Annual Scientific Meeting Industry Roundtable Symposium<br />
ARHP Morning Networking Forum<br />
Bioiberica<br />
Annual Scientific Meeting Industry-Supported Post-Conference<br />
Symposium<br />
Bristol-Myers Squibb Company<br />
Fellows Education Fund<br />
Winter <strong>Rheumatology</strong> Symposium<br />
<strong>Rheumatology</strong> Maintenance <strong>of</strong> Certification Course<br />
<strong>Rheumatology</strong> Training Directors’ Conference<br />
State-<strong>of</strong>-the-Art Clinical Symposium<br />
Musculoskeletal Ultrasound Course for Rheumatologists<br />
Advanced Practice Skills Training Course<br />
CARE 2010<br />
Annual Scientific Meeting Industry-Supported Post-Conference<br />
Symposium<br />
Centocor Ortho Biotech Inc.<br />
Industry Roundtable Member<br />
Annual Scientific Meeting Industry Roundtable Symposium<br />
Annual Scientific Meeting Fellows-In-Training Travel Scholarship<br />
Annual Scientific Meeting Industry-Supported Post-Conference<br />
Symposium<br />
Covidien-Mallinckrodt, Inc.<br />
Annual Scientific Meeting Industry-Supported Post-Conference<br />
Symposium<br />
Eli Lilly and Company<br />
Industry Roundtable Member<br />
Annual Scientific Meeting Industry Roundtable Symposium<br />
Annual Scientific Meeting Fellows-In-Training Travel Scholarship<br />
State-<strong>of</strong>-the-Art Clinical Symposium<br />
2010 Program Book<br />
Genentech, A Member <strong>of</strong> the Roche Group<br />
Industry Roundtable Member<br />
Annual Scientific Meeting Industry Roundtable Symposium<br />
Fellows Education Fund<br />
2010 ACR/ARHP Membership Directory<br />
2010 Annual Scientific Meeting Registration Brochure<br />
Winter <strong>Rheumatology</strong> Symposium<br />
<strong>Rheumatology</strong> Maintenance <strong>of</strong> Certification Course<br />
<strong>Rheumatology</strong> Training Directors’ Conference<br />
State-<strong>of</strong>-the-Art Clinical Symposium<br />
Musculoskeletal Ultrasound Course for Rheumatologists<br />
Advanced Practice Skills Training Course<br />
CARE 2010<br />
ACR REF <strong>Rheumatology</strong> Scientist Development Award<br />
ARHP Networking at Noon<br />
Genentech, A Member <strong>of</strong> the Roche Group and Biogen Idec Inc.<br />
Annual Scientific Meeting Industry-Supported Post-Conference<br />
Symposium<br />
Human Genome Sciences, Inc.<br />
Industry Roundtable Member<br />
Annual Scientific Meeting Industry Roundtable Symposium<br />
Pfizer Inc<br />
Industry Roundtable Member<br />
Annual Scientific Meeting Industry-Supported Post-Conference<br />
Symposium<br />
UCB, Inc.<br />
Industry Roundtable Member<br />
Annual Scientific Meeting Industry Roundtable Symposium<br />
Annual Scientific Meeting Industry-Supported Post-Conference<br />
Symposium<br />
Annual Scientific Meeting Fellows-in-Training Travel Scholarship<br />
<strong>Rheumatology</strong> Maintenance <strong>of</strong> Certification Course<br />
<strong>Rheumatology</strong> Training Directors’ Conference<br />
State-<strong>of</strong>-the-Art Clinical Symposium<br />
Musculoskeletal Ultrasound Course for Rheumatologists<br />
Advanced Practice Skills Training Course<br />
CARE 2010<br />
It is with gratitude that the ACR Research and Education<br />
Foundation acknowledges those who have demonstrated<br />
exemplary support <strong>of</strong> the Within Our Reach: Finding a<br />
Cure for Rheumatoid Arthritis campaign.<br />
Pinnacle ($5 million +)<br />
Principal ($2.5 million +)<br />
Genentech<br />
Partner Donor ($1 million +)<br />
Arthritis Foundation<br />
Scott Schweighauser and Liz Ellrodt
ACR/ARHP/REF STAFF LISTING<br />
Administration<br />
Executive Vice President<br />
Mark Andrejeski<br />
Director, Administration & Governance<br />
Julie Anderson<br />
Executive Assistant<br />
Naama Davidai<br />
Operations & Finance<br />
Vice President, Operations & Finance<br />
Colleen Merkel<br />
Controller<br />
Susan Parrish<br />
Director, Human Resources<br />
Deborah Higginbotham<br />
Treasury Accountant<br />
Erin Conner<br />
Accounting Manager, A/R<br />
Chasity Steverson<br />
Accounting Coordinator, A/P<br />
Tawanda Hawk<br />
Accounting Assistant, A/R<br />
Donna Hunt<br />
Receptionist<br />
Tammy Davis<br />
Technology & Information Systems<br />
Vice President, Technology & Information<br />
Systems<br />
Steve Blevins<br />
Web Programmer<br />
Janet Chisholm<br />
Systems & Database Administrator<br />
Norman Kwong<br />
Network Administrator<br />
Mike Crozier<br />
Information Systems Specialist<br />
Mickey Nguyen<br />
Education<br />
Vice President, Education<br />
Donna Hoyne<br />
Senior Director, Annual Scientific Meeting<br />
Nicole Cranston<br />
Senior Director, Meetings & Conferences<br />
Ron Olejko<br />
Director, Continuing Medical Education<br />
Valerie Okrend<br />
Specialist, Educational Products &<br />
Communications<br />
Kimberly Haughton<br />
Meeting Planner<br />
Lucy Beckett<br />
Specialist, Pr<strong>of</strong>essional Meetings & Meeting<br />
Planner<br />
Susan Brewster<br />
Specialist, Annual Scientific Meeting<br />
Karol Gaddis-Flowers<br />
Specialist, Abstracts & Annual Meeting<br />
TBD<br />
Specialist, Pr<strong>of</strong>essional Development<br />
Katie Duggan<br />
Administrative Support<br />
TBD<br />
Corporate Relations<br />
Director, Corporate Relations<br />
Amy Beith Miller<br />
Director, Expositions<br />
Stacey Chandler<br />
Coordinator, Expositions & Corporate Relations<br />
TBD<br />
Socioeconomic Affairs<br />
Vice President, Socioeconomic Affairs<br />
Tiffany Schmidt, JD, MBA<br />
Director, Government Affairs<br />
Aiken Hackett<br />
Director, Practice Management<br />
Antanya Chung<br />
Senior Specialist, Government Affairs<br />
Katie Jones<br />
Reimbursement Specialist<br />
Melesia Tillman<br />
Specialist, Practice Management<br />
Laura Snapp<br />
Administrative Assistant<br />
Sarah Zirkle<br />
Communications, Marketing<br />
& Membership<br />
Senior Director, Communications Marketing<br />
& Membership<br />
Tammy Tilley<br />
Director, Membership<br />
Helen Anne Richards<br />
Director, Public Relations<br />
Erin Latimer<br />
Director, Communication & Marketing<br />
Michelle Hatch<br />
Senior Specialist, Communication & Marketing<br />
Alexa Newlin<br />
Senior Specialist, Public Relations<br />
Suzanne Forte<br />
Webmaster<br />
LaDonna Johnson-Shabazz<br />
Senior Graphic Designer<br />
Todd Machen<br />
Membership Services Coordinator<br />
Janell Martin<br />
Registry, Quality & Healthcare<br />
Informatics<br />
Vice President, Registry, Quality & Healthcare<br />
Informatics<br />
Kristen McNiff<br />
Senior Specialist, Registry, Quality & Healthcare<br />
Informatics<br />
Itara Barnes<br />
Senior Director, Quality<br />
Amy Miller<br />
Director, Guidelines<br />
TBD<br />
Specialist, Quality<br />
Regina Parker<br />
Research and Training<br />
Senior Director, Research & Training<br />
Mary Wheatley<br />
Director, Research & Training<br />
LaTanya Batts<br />
Administrative Assistant, Research and Training<br />
Devane Casteel<br />
ARHP<br />
Executive Director<br />
David Haag<br />
Managing Editor, AC&R<br />
Nancy Parker<br />
Senior Specialist, Educational Programs<br />
Joan “Happy” Tyree<br />
Program Services Specialist<br />
Ramona Hilliard<br />
Manuscript Editor, AC&R<br />
TBD<br />
Manuscript Editor, AC&R<br />
Rachel Whittaker<br />
Manuscript Editor, AC&R<br />
Maggie Perry<br />
Administrative Assistant<br />
Sharon Ross<br />
REF<br />
Executive Director<br />
Steve Echard<br />
Senior Director, Development<br />
Paula Reed<br />
Director, Development<br />
Samantha Rasnake<br />
Senior Specialist, Annual Giving<br />
Melissa Francisco<br />
Senior Specialist, Awards & Grants<br />
Damian Smalls<br />
Coordinator, Development<br />
Lauren Landreth<br />
Coordinator, Awards and Grants<br />
Amy Fore<br />
Arthritis & Rheumatism Journal<br />
Managing Editor<br />
Jane Diamond<br />
Assistant Managing Editor<br />
Patricia Reichert<br />
2010 Program Book 299
ACR/ARHP/REF STAFF LISTING<br />
Senior Manuscript Editor<br />
Lesley Allen<br />
Manuscript Editor<br />
Michael Weinberg<br />
Manuscript Editor<br />
Pat Mabley<br />
Manuscript Editor<br />
Emily Wehby<br />
Manuscript Editor<br />
Kathryn Jonell<br />
Editorial Coordinator<br />
Lee Sanford<br />
Lupus Grant<br />
Director, EDLET/HP Lupus Initiative<br />
Lisa Amaker<br />
Consortium Liaison, EDLET/HP Lupus Initiative<br />
Sheryl McCalla<br />
Administrative Assistant, EDLET/HP Lupus Initiative<br />
Cirena Rolling<br />
300<br />
2010 Program Book
A<br />
Ahmed, Rafi, PhD<br />
T cell Memory . . . . . . . . . . . . . . . . . 31<br />
Disclosure: Nothing to Disclose<br />
Allison, Jeroan, MD, MS<br />
Session I: The Essentials . . . . . . . . . . . 19<br />
Disclosure: Nothing to Disclose<br />
Ambati, Jayakrishna, MD<br />
Molecular Mechanisms <strong>of</strong> Ocular<br />
Inflammation . . . . . . . . . . . . . . . . .121<br />
Disclosure: Allergan, 5<br />
Anderson, Lee A, BSN<br />
Nursing . . . . . . . . . . . . . . . . . . . . . 64<br />
Disclosure: Nothing to Disclose<br />
Andrejeski, Mark<br />
ILAR Global Health Project . . . . . . . . . . 84<br />
Disclosure: Nothing to Disclose<br />
Andriacchi, Thomas, PhD<br />
Walk this Way: Biomechanics and<br />
Osteoarthritis . . . . . . . . . . . . . . . . . 95<br />
Disclosure: Nothing to Disclose<br />
Anolik, Jennifer H, MD, PhD<br />
Session V: Role <strong>of</strong> B cells in Autoimmunity:<br />
Lessons from Clinical Trials . . . . . . . . . . 23<br />
Disclosure: Nothing to Disclose<br />
The Revolution <strong>of</strong> Epigenetics in<br />
Autoimmunity . . . . . . . . . . . . . . . . . 47<br />
Disclosure: Nothing to Disclose<br />
Toll-like Receptors Activation <strong>of</strong> B cells in<br />
Autoimmune Disease . . . . . . . . . . . . . 28<br />
Disclosure: Nothing to Disclose<br />
Backman, Catherine L, PhD, OT(C)<br />
Evidence-based Non-pharmacological Treatment<br />
for Hip, Knee, and Hand Osteoarthritis: The New<br />
ACR Guidelines . . . . . . . . . . . . . . . . 34<br />
Disclosure: Nothing to Disclose<br />
Work Assessments: A ‘How-To’ That Could Save<br />
Your Patient’s Life/Job. . . . . . . . . . . . .131<br />
Disclosure: Nothing to Disclose<br />
Baer, Alan N, MD<br />
Year in Review . . . . . . . . . . . . . . . . . 27<br />
Disclosure: Nothing to Disclose<br />
Baker, Nancy A, ScD OTR/L<br />
Adaptations and Solutions to Help People with<br />
Scleroderma Continue to Work . . . . . . .102<br />
Disclosure: Nothing to Disclose<br />
How to Understand and Apply the Results <strong>of</strong> a<br />
Journal Article: What You Really Need to Know<br />
About Statistics . . . . . . . . . . . . . . . .134<br />
Disclosure: Nothing to Disclose<br />
Understanding Functional Activity in<br />
Rheumatoid Arthritis: What We Know and<br />
What We Don’t Know . . . . . . . . . . . . . 86<br />
Disclosure: Nothing to Disclose<br />
Work Assessments: A ‘How-To’ That Could Save<br />
Your Patient’s Life/Job. . . . . . . . . . . . .131<br />
Disclosure: Nothing to Disclose<br />
Ballestar, Esteban, PhD<br />
The Revolution <strong>of</strong> Epigenetics in<br />
Autoimmunity . . . . . . . . . . . . . . . . . 47<br />
Disclosure: Nothing to Disclose<br />
Bancr<strong>of</strong>t Rizzo, Debra, MSN, FNP-C<br />
Money Talks: How to Incentivize Staff . . . . 46<br />
Disclosure: Nothing to Disclose<br />
Bergman, Martin J, MD<br />
Rheumatoid Arthritis: Outcome Measures in<br />
Clinical Practice . . . . . . . . . . . . . . . . 52<br />
Disclosure:, 5; Abbott, 2, 5, 8; BMS, 2; Takeda,<br />
8; UCB, 8<br />
Berney, Seth M, MD<br />
Career Opportunities in <strong>Rheumatology</strong>: Making<br />
a Choice . . . . . . . . . . . . . . . . . . . .113<br />
Disclosure: Nothing to Disclose<br />
Contract Negotiations for Physicians . . . . 65<br />
Disclosure: Nothing to Disclose<br />
Beukelman, Timothy, MD, MSCE<br />
2010 ACR Recommendations for the Treatment<br />
<strong>of</strong> Juvenile Idiopathic Arthritis . . . . . . . 143<br />
Disclosure: Nothing to Disclose<br />
Bilek, Laura D, PhD, PT<br />
Evidence-based Practice: Creating and Using<br />
<strong>Rheumatology</strong> Critically Appraised Topics<br />
(RheumCATS) . . . . . . . . . . . . . . . . .102<br />
Disclosure: Nothing to Disclose<br />
Ready, Aim, Get Funded! . . . . . . . . . . 131<br />
Disclosure: Nothing to Disclose<br />
Bingham, Clifton O, MD<br />
Immunizations and Rheumatic Diseases - An<br />
Update . . . . . . . . . . . . . . . . . . . . 37<br />
Disclosure: Abbott, 9; ACR-REF, 2; BMS, 2;<br />
Genentech, 2, 5; Roche, 2, 5; UCB, 5;<br />
UpToDate, 7<br />
ACR REF Within Our Reach: Finding a Cure for<br />
Rheumatoid Arthritis . . . . . . . . . . . . . 45<br />
Disclosure: Abbott, 9; ACR-REF, 2; BMS, 2;<br />
Genentech, 2, 5; Roche, 2, 5; UCB, 5;<br />
UpToDate, 7<br />
Bisoendial, Radjesh, MD, PhD<br />
A Critical Role for Lipid Metabolism in the<br />
Interplay between Atherosclerosis and<br />
Autoimmune Disorders . . . . . . . . . . .121<br />
Disclosure: Nothing to Disclose<br />
INVITED SPEAKER /MODERATOR INDEX<br />
Arnett, Frank C, MD<br />
REF Paul Klemperer, MD, Memorial Lectureship:<br />
Systemic Sclerosis: Genetic? Autoimmune? One<br />
Disease? . . . . . . . . . . . . . . . . . . . . 98<br />
Disclosure: Nothing to Disclose<br />
Baraf, Herbert, MD<br />
The Ideal <strong>Rheumatology</strong> Practice . . . . . .104<br />
Disclosure: Nothing to Disclose<br />
Contract Negotiations for Physicians . . . . 65<br />
Disclosure: Nothing to Disclose<br />
Atkinson, John P, MD<br />
Year in Review . . . . . . . . . . . . . . . . . 27<br />
Disclosure: Compliment, INC, ; Genentech, Inc, 5;<br />
Idera Pharmaceuticals, 5; Kereos, INC, 5; Taligen<br />
Therapeutics (SAB), 1; Tanox INC, 5<br />
Atkinson, Karen, MD<br />
Clinicopathologic Conference . . . . . . . . 55<br />
Disclosure: Nothing to Disclose<br />
Austin, Janet S, PhD<br />
Living with Osteoporosis . . . . . . . . . . . 61<br />
Disclosure: Nothing to Disclose<br />
B<br />
Backhaus, Marina, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound . . . . . . . . .110<br />
Disclosure: Abbott, 2<br />
Barham, Beverly K, RN, MSN, CCRC<br />
The Multidisciplinary Approach to Hereditary<br />
Periodic Fever Syndromes . . . . . . . . . . 58<br />
Disclosure: Nothing to Disclose<br />
What’s New and Noteworthy in 2010: A<br />
Review <strong>of</strong> <strong>Rheumatology</strong> Research for Health<br />
Pr<strong>of</strong>essionals. . . . . . . . . . . . . . . . . . 76<br />
Disclosure: Nothing to Disclose<br />
Bartholomew, John R, MD<br />
Heparin and Antiphospholipid Syndromeinduced<br />
Thrombocytopenia . . . . . . . . . 31<br />
Disclosure: Nothing to Disclose<br />
Bateman, Helen E, MD<br />
Teaching and Assessing Arthrocentesis . . 112<br />
Disclosure: Nothing to Disclose<br />
Joint Simulator. . . . . . . . . . . . . . . 67, 97<br />
Disclosure: Nothing to Disclose<br />
Becker, Mara L, MD<br />
Using Pharmacogenomics to Improve Therapy<br />
for Pediatric Patients . . . . . . . . . . . . . 96<br />
Disclosure: Nothing to Disclose<br />
Belza, Basia, PhD, RN<br />
Building Effective Teams: Recommended<br />
Leadership Strategies . . . . . . . . . . . . 100<br />
Disclosure: Nothing to Disclose<br />
Blevins, Stephen, MBA<br />
Creating Presentations Using PowerPoint:<br />
Advanced . . . . . . . . . . . . . . . . . . . 61<br />
Disclosure: Nothing to Disclose<br />
Creating Presentations Using PowerPoint:<br />
Basic . . . . . . . . . . . . . . . . . . . . . . 29<br />
Disclosure: Nothing to Disclose<br />
Block, Joel A, MD<br />
Year in Review . . . . . . . . . . . . . . . . . 27<br />
Disclosure: KAI Inc./NIH, 9; Merck-Serono, 5;<br />
NiCOx, 5; OA and Cartilage, 9;Pleiad, 5<br />
ACR Plenary Session II: Discovery 2010 . . . 63<br />
Disclosure: KAI / NIH, 9; Merck-Serono, 5; NiCOx,<br />
5; OA and Cartilage, 9; Pleiad, 5<br />
Bode, Christina, PhD<br />
Successful Coping with Rheumatic Disease . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . .135<br />
Disclosure: Nothing to Disclose<br />
Boden, Scott D, MD<br />
REF Marshall J. Schiff, MD, Memorial<br />
Lectureship: Everything a Rheumatologist<br />
Should Know About Spine Surgery but Was<br />
Afraid to Ask . . . . . . . . . . . . . . . . . . 84<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book 301
INVITED SPEAKER /MODERATOR INDEX<br />
302<br />
Boehncke, Wolf-Henning, MD<br />
Psoriatic Disease: Clinical Spectrum and<br />
Comprehensive Treatment Strategies . . . . 69<br />
Disclosure: Abbott, Biogen Idec, Essex, Janssen<br />
Cilag, Wyeth, 8; Abbott, Biogen Idec, Essex,<br />
Wyeth, 2<br />
Boers, Maarten, MD, PhD, MSc<br />
Remission in Rheumatoid Arthritis. . . . . .136<br />
Disclosure: Nothing to Disclose<br />
Bong, David A, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Nothing to Disclose<br />
Bongartz, Tim, MD<br />
Perioperative Management <strong>of</strong> Selected<br />
Problems in Patients with Rheumatic<br />
Disease . . . . . . . . . . . . . . . . . . . . .122<br />
Disclosure: Nothing to Disclose<br />
Borenstein, David G, MD<br />
Pain: Evaluation and Treatment <strong>of</strong> Back<br />
Pain . . . . . . . . . . . . . . . . . . . . . . .130<br />
Disclosure: Nothing to Disclose<br />
ACR Leadership Town Hall Meeting . . . . .106<br />
Disclosure: Nothing to Disclose<br />
Boulware, Dennis W, MD<br />
ACR REF Memorial Lectureship: <strong>Rheumatology</strong><br />
Education 2010 . . . . . . . . . . . . . . . . 37<br />
Disclosure: Nothing to Disclose<br />
Boyle, Dennis J, MD<br />
Pain: Difficult Patient Interactions . . . . . . 29<br />
Disclosure: Nothing to Disclose<br />
Brady, Teresa J, PhD<br />
Physical Activity: The Arthritis Pain Reliever –<br />
The Revised Centers for Disease Control and<br />
Prevention Health Communications<br />
Campaign . . . . . . . . . . . . . . . . . . . 35<br />
Disclosure: Nothing to Disclose<br />
Top 10 in ‘10: Top 10 Public Health Advances<br />
in the First 10 Years <strong>of</strong> the Centers for Disease<br />
Control and Prevention Arthritis Program. .147<br />
Disclosure: Nothing to Disclose<br />
Branch, Jr, William T, MD<br />
ACR REF Clinician Scholar Educator Lecture. 53<br />
Disclosure: Nothing to Disclose<br />
Braun, Juergen, MD<br />
Spondyloarthropathy: An Update . . . . . . 83<br />
Disclosure: Abbott, 2, 5; Centocor, 2; MSD, 5;<br />
Pfizer, 5; San<strong>of</strong>i, 2<br />
Brescia, AnneMarie C, MD<br />
Pediatrics: Juvenile Idiopathic Arthritis for Adult<br />
Rheumatologists. . . . . . . . . . . . . . . . 36<br />
Disclosure: Nothing to Disclose<br />
Bruce, Susan P, PharmD<br />
Integrating Immunology and Biologics into<br />
Clinical Practice . . . . . . . . . . . . . . . . 25<br />
Disclosure: Nothing to Disclose<br />
Bryant, Gloryanne, BS, RHIA, RHIT, CCS<br />
ICD -10 Preparation - Developing a Blueprint for<br />
Implementation . . . . . . . . . . . . . . . 133<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book<br />
Bunyard, Matthew P, MD<br />
CORC Forum: Health Care Reform – Where Are<br />
We Heading?. . . . . . . . . . . . . . . . . .101<br />
Disclosure: Nothing to Disclose<br />
Burke, Allen, MD<br />
Histopathology <strong>of</strong> Vasculitis . . . . . . . . .113<br />
Disclosure: Nothing to Disclose<br />
Burr, David B, PhD<br />
Bisphosphonates: Mechanism <strong>of</strong> Action and<br />
Optimizing Clinical Use . . . . . . . . . . . 135<br />
Disclosure: Amgen, 5; CRC Press, 7; Eli Lilly and<br />
Co., 2; Eli Lilly and Co., 5; Eli Lilly and Col, 5;<br />
Procter and Gamble, 5; Springer, 7; The Alliance<br />
for Better Bone Health, 2<br />
Byers, Peter H, MD<br />
Hypermobility . . . . . . . . . . . . . . . . 108<br />
Disclosure: Nothing to Disclose<br />
Genetic Disorders <strong>of</strong> Connective Tissue and<br />
Joint Hypermobility . . . . . . . . . . . . . . 37<br />
Disclosure: Nothing to Disclose<br />
C<br />
Calabrese, Leonard H, DO<br />
Rheumatic Disease Update: Viral Arthritis . 61<br />
Disclosure: Nothing to Disclose<br />
Callahan, Leigh F, PhD<br />
ARHP General Session II: ARHP Distinguished<br />
Lecturer . . . . . . . . . . . . . . . . . . . . 62<br />
Disclosure: Nothing to Disclose<br />
Cancro, Michael P, PhD<br />
Session IV: Emerging Concepts in B cell Directed<br />
Therapies. . . . . . . . . . . . . . . . . . . . 23<br />
Disclosure: Human Genome Sciences, 2<br />
Caricchio, Roberto, MD<br />
Autophagy and Immune Function . . . . . . 59<br />
Disclosure: Nothing to Disclose<br />
Carkin, Julie L, MD<br />
CC - Osteoporosis Treatment Update . . . . 54<br />
Disclosure: Eli Lilly, 8; Novartis, 8; Warner-<br />
Chilcott, 8<br />
Carlone, Joyce P, MN, RN, FNP-BC<br />
When Pieces Don’t Fit . . . . . . . . . . . .120<br />
Disclosure: Nothing to Disclose<br />
ARHP Networking for Georgia Health<br />
Pr<strong>of</strong>essionals and Physicians . . . . . . . . . 64<br />
Disclosure: Nothing to Disclose<br />
Carsons, Steven E, MD<br />
Rheumatic Disease Update: Sjögren’s<br />
Syndrome . . . . . . . . . . . . . . . . . . . 58<br />
Disclosure: Nothing to Disclose<br />
Carter, Robert H, MD<br />
News from the National Institutes <strong>of</strong> Health:<br />
Updates and Opportunities. . . . . . . . . . 56<br />
Disclosure: Nothing to Disclose<br />
Caspi, Rachel, PhD<br />
Molecular Mechanisms <strong>of</strong> Ocular<br />
Inflammation . . . . . . . . . . . . . . . . .121<br />
Disclosure: Nothing to Disclose<br />
Chen, Lan X, MD, PhD<br />
Crystalline Arthropathy . . . . . . . . . . . 108<br />
Disclosure: Nothing to Disclose<br />
Synovial Fluid Analysis and Crystal<br />
Identification. . . . . . . . . . . . . . 30, 68, 76<br />
Disclosure: Nothing to Disclose<br />
Chen, Qian, PhD<br />
Molecular Mechanisms <strong>of</strong> Inflammatory<br />
Signaling in Cartilage Destruction . . . . . . 27<br />
Disclosure: Nothing to Disclose<br />
Choi, Hyon K, MD, DrPH<br />
Crystal: Management <strong>of</strong> Gout . . . . . . . . 51<br />
Disclosure: Savient, 5; Takeda, 2, 5<br />
Christenson, Mary E, PT, PhD<br />
Evidence-based Practice: Creating and Using<br />
<strong>Rheumatology</strong> Critically Appraised Topics. .102<br />
Disclosure: Nothing to Disclose<br />
Patient Participation in Research. . . . . . .119<br />
Disclosure: Nothing to Disclose<br />
Physical Activity and Osteoarthritis: Learning<br />
with the Community . . . . . . . . . . . . . 95<br />
Disclosure: Nothing to Disclose<br />
Christopher-Stine, Lisa, MD<br />
Inflammatory Myopathy Update. . . . . . . 77<br />
Disclosure: Nothing to Disclose<br />
Chrousos, George P, MD<br />
2010 Hench Lecture: Glucocorticoids-<br />
Physiologic Regulation, Mechanisms <strong>of</strong> Action<br />
and Optimizing Therapeutic Applications . . 37<br />
Disclosure: Nothing to Disclose<br />
Chung, Antanya<br />
Certified <strong>Rheumatology</strong> Coder Course . . . 20<br />
Disclosure: Nothing to Disclose<br />
Certified <strong>Rheumatology</strong> Coder Examination<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
Disclosure: Nothing to Disclose<br />
Clark, Marcus R, MD<br />
B cell Effectors and Regulators . . . . . . . 113<br />
Disclosure: Nothing to Disclose<br />
Clauw, Daniel J, MD<br />
Musculoskeletal Pain and Cognitive Issues<br />
Related to Returning Military Personnel . . 75<br />
Disclosure: Nothing to Disclose<br />
Clayburne, Gilda M, MLT<br />
Synovial Fluid Analysis and Crystal<br />
Identification. . . . . . . . . . . . . . . . . . 76<br />
Disclosure: Nothing to Disclose<br />
Clements, Philip J, MD, MPH<br />
Systemic Sclerosis: How to Perform Skin<br />
Scores . . . . . . . . . . . . . . . . . . . . . 76<br />
Disclosure: Nothing to Disclose<br />
Clowse, Megan E B, MD, MPH<br />
Pregnancy in Rheumatic Diseases . . . . . . 96<br />
Disclosure: Nothing to Disclose<br />
Colbert, Robert A, MD, PhD<br />
Pediatric Spondylarthropathies: From Genetics<br />
to the Clinic . . . . . . . . . . . . . . . . . .136<br />
Disclosure: Nothing to Disclose<br />
Epigenetics 101 . . . . . . . . . . . . . . . . 98<br />
Disclosure: Nothing to Disclose<br />
Colglazier, Christopher L, MD<br />
ICD -10 Preparation - Developing a Blueprint for<br />
Implementation . . . . . . . . . . . . . . . 133<br />
Disclosure: Forest Pharmaceuticals, 5<br />
Conaghan, Philip G, MD, PhD<br />
MRI . . . . . . . . . . . . . . . . . . . . . . . 91<br />
Disclosure: Nothing to Disclose<br />
Peripheral Magnetic Resonance Imaging in<br />
<strong>Rheumatology</strong> Practice . . . . . . . . . . . . 33<br />
Disclosure: Nothing to Disclose
Cooper, Max D, MD<br />
Introduction . . . . . . . . . . . . . . . . . . 20<br />
Disclosure: Nothing to Disclose<br />
Cope, James, MD<br />
Recovery Audit Contractor vs. Comprehensive<br />
Error Rate Testing Audits – Do You Know the<br />
Difference?. . . . . . . . . . . . . . . . . . . 66<br />
Disclosure: Nothing to Disclose<br />
Craig-Muller, Jurgen, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists -Day Two . . . . . . . . . . 22<br />
Disclosure: Nothing to Disclose<br />
Crawford, Donah Z, BS, MA<br />
Clinical Trial Essentials: Budgets, Contracts and<br />
Regulations . . . . . . . . . . . . . . . . . . 58<br />
Disclosure:, 2; Centocor, 2; Eli Lilly, Co., 2;<br />
Genentech, 2; Lexicon, 2; Regeneron, 2; Roche,<br />
2; UCB, 2<br />
ARHP Networking at Noon . . . . . . . . . . 63<br />
Disclosure: Nothing to Disclose<br />
ARHP Research Coordinators Networking. . 35<br />
Disclosure: Nothing to Disclose<br />
Cronin, Mary E, MD<br />
Review Course . . . . . . . . . . . . . . . . 23<br />
Disclosure: Nothing to Disclose<br />
Osteoarthritis - What is New in Old Joints .122<br />
Disclosure: Nothing to Disclose<br />
Adult Inflammatory Myopathy . . . . . . 35, 96<br />
Disclosure: Nothing to Disclose<br />
Crowther, Mark A, MD, MSc<br />
Perioperative Management <strong>of</strong> Selected<br />
Problems in Patients with Rheumatic<br />
Disease . . . . . . . . . . . . . . . . . . . . .122<br />
Disclosure: Artisan, 5; Leo Laboratories, 2;<br />
Pfizer, 2; Pfizer, 5<br />
Curtis, Jeffrey R, MD, MPH<br />
Session II: Applications to Musculoskeletal<br />
Medicine . . . . . . . . . . . . . . . . . . . . 19<br />
Disclosure: Amgen, 2; Centocor, 2, 5; CORRONA,<br />
2, 5; Roche, 2, 5, 8; UCB, 5<br />
Cush, John J, MD<br />
<strong>Rheumatology</strong> Roundup: Highlights from the<br />
2010 Annual Scientific Meeting . . . . . . .133<br />
Disclosure: Allos, 5; BMS, 5; Celgene, 2, 5;<br />
Centocor, 2; CORRONA, 2, 5;Genentech, 2, 5;<br />
Human Genome Sciences, 5; Nicox, 5; Pfizer, 2;<br />
Roche, 2, 5; UCB, 2, 5<br />
Rheumatoid Arthritis: Difficult Cases . . . . 83<br />
Disclosure: Allos, 5; BMS, 5; Celgene, 2, 5;<br />
Centocor, 2; CORRONA, 2, 5; Genentech, 2, 5;<br />
Human Genome Sciences, 5; Nicox, 5; Pfizer, 2;<br />
Roche, 2, 5; UCB, 2, 5<br />
D<br />
Daikh, David I, MD, PhD<br />
ACR Leadership Town Hall Meeting . . . . .106<br />
Disclosure: Nothing to Disclose<br />
ACR REF Memorial Lectureship: <strong>Rheumatology</strong><br />
Education 2010 . . . . . . . . . . . . . . . . 37<br />
Disclosure: Nothing to Disclose<br />
Davidson, Anne, MB, BS<br />
Mouse to House: Lessons Learned About Lupus<br />
Therapeutics . . . . . . . . . . . . . . . . . . 39<br />
Disclosure: Biogen IDEC, 5; EMD-Serono, 5<br />
Davis, John M, MD<br />
Rheumatoid Arthritis Treatment 2010:<br />
Traditional DMARDs, Biologic DMARDs and<br />
Newer Treatment Strategies . . . . . . . . 114<br />
Disclosure: UCB Pharma, 2<br />
De Benedetti, Fabrizio, MD, PhD<br />
New Development in Systemic Juvenile<br />
Idiopathic Arthritis - From Bench to Effective<br />
Interventions . . . . . . . . . . . . . . . . .122<br />
Disclosure: BMS, 5; F H<strong>of</strong>fman La Roche, 2, 5<br />
Deal, Chad L, MD<br />
Controversies in Osteoporosis and Low Bone<br />
Mass: Who Do We Treat, For How Long, and at<br />
What Risks? . . . . . . . . . . . . . . . . . .103<br />
Disclosure: Amgen, 5, 8; Genentech, 8; Lilly, 5, 8;<br />
Novartis, 2, 8<br />
Osteoporosis: Focus on Dual Energy X-ray<br />
Absorptiometry Interpretation. . . . . . . .120<br />
Disclosure: Amgen, 5, 8; Genentech, 8; Lilly, 5, 8;<br />
Novartis, 2, 8<br />
DeLeo, Joyce A, PhD<br />
Pain, the Brain, and the Immune System: Links<br />
to Understanding Pain Management . . . .134<br />
Disclosure: Nothing to Disclose<br />
Dellaripa, Paul F, MD<br />
Pulmonary Manifestations <strong>of</strong> Rheumatic<br />
Disease . . . . . . . . . . . . . . . . . . . 65, 96<br />
Disclosure: genentech, 2<br />
Interstitial Lung Diseases in the Rheumatic<br />
Diseases . . . . . . . . . . . . . . . . . . . .109<br />
Disclosure: genentech, 2<br />
DeMarco, Paul J, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: Sonosite, 5<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Sonosite, 5<br />
Denay, Jane M, BSN, MSN, CFNP<br />
Integrating Immunology and Biologics into<br />
Clinical Practice . . . . . . . . . . . . . . . . 75<br />
Nothing to Disclose<br />
ARHP Networking at Noon . . . . . . . . . . 63<br />
Disclosure: Nothing to Disclose<br />
Dennis, Gregory J, MD<br />
Contract Negotiations for Physicians . . . . 65<br />
Disclosure: Human Genome Sciences (HGSI), 3<br />
Denton, Christopher P, MD, PhD<br />
Scleroderma: Systemic Sclerosis . . . . . 57, 97<br />
Disclosure: Actelion Pharmaceuticals, 2;<br />
Actelion Pharmaceuticals, Pfizer, 5; Actelion<br />
Pharmaceuticals, Pfizer, GSK, 9<br />
Deodhar, Atul A, MD, MRCP<br />
CAM is a SCAM! Complementary and<br />
Alternative “Medicince” Has No Place in<br />
<strong>Rheumatology</strong> . . . . . . . . . . . . . . . . . 46<br />
Disclosure: Nothing to Disclose<br />
Iatrogenic Misadventures: Complex Cases . 85<br />
Disclosure: Nothing to Disclose<br />
Reactive Arthritis: An Update . . . . . . . . 57<br />
Disclosure: Nothing to Disclose<br />
Joint Injection Techniques . . . . . . . 29, 113<br />
Disclosure: Nothing to Disclose<br />
Deretic, Vojo, PhD<br />
Autophagy and Immune Function . . . . . . 59<br />
Disclosure: Nothing to Disclose<br />
Dewing, Kori A, MN, ARNP<br />
Osteoporosis Treatment Update . . . . . . . 54<br />
Disclosure: Nothing to Disclose<br />
Pain Management in the Age <strong>of</strong> Abuse and<br />
Litigation . . . . . . . . . . . . . . . . . . . 100<br />
Disclosure: Nothing to Disclose<br />
Diamond, Betty, MD<br />
Session V: Role <strong>of</strong> B cells in Autoimmunity:<br />
Lessons from Clinical Trials . . . . . . . . . . 23<br />
Disclosure: Nothing to Disclose<br />
Dixit, Rajiv K, MD<br />
Rheumatic Disease Update: Osteoarthritis <strong>of</strong><br />
the Spine . . . . . . . . . . . . . . . . . . . .103<br />
Disclosure: Nothing to Disclose<br />
Dodge, Carole V, OT CHT<br />
Practice Potpourri . . . . . . . . . . . . . . . 86<br />
Disclosure: Nothing to Disclose<br />
Dore, Robin K, MD<br />
The Changing Face <strong>of</strong> the <strong>Rheumatology</strong><br />
Workforce: Gender Issues in the Workplace . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 94<br />
Disclosure: Nothing to Disclose<br />
Dufour, Alyssa B, MA<br />
You’ve Got the Power: How to Use and Teach<br />
Statistical Power for Studies and Grants. . . 47<br />
Disclosure: Nothing to Disclose<br />
Dunlop, Dorothy D, PhD<br />
Basic Statistical Concepts for the Medical<br />
Researcher . . . . . . . . . . . . . . . . . . .120<br />
Disclosure: Nothing to Disclose<br />
E<br />
Edwards, Jonathan C.W, MD<br />
Session V: Role <strong>of</strong> B cells in Autoimmunity:<br />
Lessons from Clinical Trials . . . . . . . . . . 23<br />
Disclosure: Nothing to Disclose<br />
Edwards, N Lawrence, MD<br />
Crystallizing Your Assessment and Treatment <strong>of</strong><br />
Difficult to Treat Gout . . . . . . . . . . . . .114<br />
Disclosure: Savient Pharmaceuticals, 5<br />
Takeda Pharmaceuticals North America, 5<br />
Crystalline Arthropathy . . . . . . . . . . . 108<br />
Disclosure: Savient Pharmaceuticals, 5<br />
Takeda Pharmaceuticals North America, 5<br />
Ehrenstein, Michael, PhD<br />
T cell Memory . . . . . . . . . . . . . . . . . 31<br />
Disclosure: Nothing to Disclose<br />
Ehrlich-Jones, Linda S, PhD, RN<br />
An Infectious Etiology <strong>of</strong> Rheumatoid<br />
Arthritis . . . . . . . . . . . . . . . . . . . . 26<br />
Disclosure: Abbott, 1<br />
ARHP Networking at Noon . . . . . . . . . . 63<br />
Disclosure: Abbott1<br />
ARHP Networking Forum . . . . . . . . . . . 30<br />
Disclosure: Abbott, 1<br />
El Baalbaki, Ghassan, PhD<br />
Measure by Measure: Assessing Psychological<br />
Health and Well-Being in Scleroderma . . .135<br />
Disclosure: Nothing to Disclose<br />
El-Gabalawy, Hani S, MD<br />
The Preclinical Stage <strong>of</strong> Rheumatoid Arthritis:<br />
Towards Prevention <strong>of</strong> Disease? . . . . . . . 77<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book 303<br />
INVITED SPEAKER /MODERATOR INDEX
INVITED SPEAKER /MODERATOR INDEX<br />
304<br />
Elkon, Keith B, MD<br />
Cell Death: Receptors, Sensors and<br />
Inflammatory Pathways. . . . . . . . . . . .114<br />
Disclosure: Nothing to Disclose<br />
Autophagy and Immune Function . . . . . . 59<br />
Disclosure: Nothing to Disclose<br />
T cell Memory . . . . . . . . . . . . . . . . . 31<br />
Disclosure: Nothing to Disclose<br />
Embi, Peter J, MD, MS<br />
Designing a Web Site for Your Practice . . . 33<br />
Disclosure: Nothing to Disclose<br />
Emery, Helen M, MD<br />
Rheumatic Disease Update: Juvenile Idiopathic<br />
Arthritis . . . . . . . . . . . . . . . . . . . .100<br />
Disclosure: Nothing to Disclose<br />
Rehabilitative <strong>Rheumatology</strong>. . . . . . . . .111<br />
Disclosure: Nothing to Disclose<br />
Empson, Stacey, JD, MHA<br />
Transforming Rheumatologic Care with the<br />
Electronic Health Record . . . . . . . . . . . 30<br />
Disclosure: ACR, 6; IBM, 1<br />
Erickson, Mary W, OTR, MAOL<br />
Musculoskeletal Pain and Cognitive Issues<br />
Related to Returning Military Personnel . . 75<br />
Disclosure: Nothing to Disclose<br />
Erkan, Doruk, MD<br />
Antiphospholipid Syndrome . . . . . . 51, 105<br />
Disclosure: BMS, 2; Genentech, 2; Lupus Clinical<br />
Trials Consortium, 2<br />
Espinoza, Luis R, MD<br />
When Pieces Don’t Fit . . . . . . . . . . . .120<br />
Disclosure: Nothing to Disclose<br />
ILAR Global Health Project . . . . . . . . . . 84<br />
Disclosure: Nothing to Disclose<br />
Evangelisto, Amy M, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: Abbott, 5, 8<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Abbott, 5, 8<br />
F<br />
Feinstein, David E, DO<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Nothing to Disclose<br />
Felson, David T, MD, MPH<br />
Remission in Rheumatoid Arthritis. . . . . .136<br />
Disclosure: Nothing to Disclose<br />
Ferguson, Karen M, MS<br />
Integrating Immunology and Biologics into<br />
Clinical Practice . . . . . . . . . . . . . . . . 25<br />
Disclosure: Genentech, 8; McKesson, 9<br />
Ferguson, Polly J, MD<br />
Pediatrics: Periodic Fevers in Children. . . . 65<br />
Disclosure: Nothing to Disclose<br />
Kawasaki Disease in the 21st Century - Genes,<br />
Pathogenesis, and Biologics . . . . . . . . . 90<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book<br />
Fett, Nicole, MD<br />
Cutaneous Vasculitis . . . . . . . . . . . . . 36<br />
Disclosure: Nothing to Disclose<br />
Dermatological Manifestations <strong>of</strong> Rheumatic<br />
Diseases . . . . . . . . . . . . . . . . . 29, 129<br />
Disclosure: Nothing to Disclose<br />
Skin Diseases. . . . . . . . . . . . . . . . . . 93<br />
Disclosure: Nothing to Disclose<br />
Filipovich, Lisa, MD<br />
Autologous Stem Cell Transplantation in<br />
Pediatric <strong>Rheumatology</strong>: Indications and<br />
Associated Morbidity . . . . . . . . . . . . . 68<br />
Disclosure: Nothing to Disclose<br />
Filippucci, Emilio, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Nothing to Disclose<br />
Firestein, Gary S, MD<br />
Kinases as Therapeutic Targets. . . . . . . . 59<br />
Disclosure: Ambit, 5; Intellikine, 2; Merck, 5;<br />
Rigel, 5; Takeda Pharmaceuticals, 5<br />
Fisher, Nadine M, EdD<br />
Physical Activity and Osteoarthritis: Learning<br />
with the Community . . . . . . . . . . . . . 95<br />
Disclosure: Nothing to Disclose<br />
Fisseha, Senait, MD, JD<br />
Reproductive and Sexual Health Issues for<br />
Women with Rheumatic Disease. . . . . . . 54<br />
Disclosure: Nothing to Disclose<br />
Fitzgerald, G. Kelley, PhD, PT<br />
Evidence-based Non-pharmacological Treatment<br />
for Hip, Knee, and Hand Osteoarthritis: The New<br />
ACR Guidelines . . . . . . . . . . . . . . . . 34<br />
Disclosure: Nothing to Disclose<br />
Putting ACR Osteoarthritis Guidelines into<br />
Practice: Clinical Applications for the Hip and<br />
Knee . . . . . . . . . . . . . . . . . . . . . .142<br />
Disclosure: Nothing to Disclose<br />
Flood, Joseph, MD<br />
Career Opportunities in <strong>Rheumatology</strong>: Making<br />
a Choice . . . . . . . . . . . . . . . . . . . .113<br />
Disclosure: Nothing to Disclose<br />
Fox, David A, MD<br />
ILAR Global Health Project . . . . . . . . . . 84<br />
Disclosure: Nothing to Disclose<br />
Franchin, Giovanni, MD, PhD<br />
The Changing Face <strong>of</strong> the <strong>Rheumatology</strong><br />
Workforce: Gender Issues in the Workplace 94<br />
Disclosure: Nothing to Disclose<br />
Freedman, John, MD, MBA<br />
CORC Forum: Health Care Reform – Where Are<br />
We Heading?. . . . . . . . . . . . . . . . . .101<br />
Disclosure: Nothing to Disclose<br />
Furie, Richard A, MD<br />
Mouse to House: Lessons Learned About Lupus<br />
Therapeutics . . . . . . . . . . . . . . . . . . 39<br />
Disclosure: Nothing to Disclose<br />
Thieves’ Market: Show Me Your Best Cases. 69<br />
Disclosure: Nothing to Disclose<br />
ACR Plenary Session II: Discovery 2010 . . . 63<br />
Disclosure: Nothing to Disclose<br />
Excel Spreadsheets: Basic Concepts to Elevate<br />
Your Skills Beyond Those <strong>of</strong> Your Children . 57<br />
Disclosure: Nothing to Disclose<br />
Furst, Daniel E, MD<br />
The Great Debate: Is it Time to Use Biologics as<br />
First-line Therapy in Rheumatoid Arthritis?<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 39<br />
Disclosure: Abbott, Actelion, Amgen, BMS,<br />
Biogenidec, Centocor, Genentech, Gilead, GSK,<br />
Merck, Nitec, Novartis, UCB, Wyeth, Xoma,<br />
5; Abbott, Actelion, Amgen, BMS, Genentech,<br />
Gilead, GSK, Nitec, Novartis, Roche, UCB, Wyeth,<br />
Xoma, 2; Abbott, Actelion, UCB, 8; CORRONA, 3<br />
RC - Rheumatoid Arthritis: From Bench to<br />
Bedside in 40 Minutes . . . . . . . . . . . . 24<br />
Disclosure: Abbott, Actelion, Amgen, BMS,<br />
Biogenidec, Centocor, Genentech, Gilead, GSK,<br />
Merck, Nitec, Novartis, UCB, Wyeth, Xoma,<br />
5; Abbott, Actelion, Amgen, BMS, Genentech,<br />
Gilead, GSK, Nitec, Novartis, Roche, UCB, Wyeth,<br />
Xoma, 2; Abbott, Actelion, UCB, 8; CORRONA, 3<br />
Systemic Sclerosis: How to Perform Skin<br />
Scores . . . . . . . . . . . . . . . . . . . . . 76<br />
Disclosure: Abbott, Actelion, Amgen, BMS,<br />
Biogenidec, Centocor, Genentech, Gilead, GSK,<br />
Merck, Nitec, Novartis, UCB, Wyeth, Xoma,<br />
5; Abbott, Actelion, Amgen, BMS, Genentech,<br />
Gilead, GSK, Nitec, Novartis, Roche, UCB, Wyeth,<br />
Xoma, 2; Abbott, Actelion, UCB, 8; CORRONA, 3<br />
Plenary III . . . . . . . . . . . . . . . . . . .104<br />
Disclosure: Abbott, Actelion, Amgen, BMS,<br />
Biogenidec, Centocor, Genentech, Gilead, GSK,<br />
Merck, Nitec, Novartis, UCB, Wyeth, Xoma,<br />
5; Abbott, Actelion, Amgen, BMS, Genentech,<br />
Gilead, GSK, Nitec, Novartis, Roche, UCB, Wyeth,<br />
Xoma, 2; Abbott, Actelion, UCB, 8; CORRONA, 3<br />
G<br />
Gale, Judith R, MPH, DPT, PT<br />
Living with Osteoporosis . . . . . . . . . . . 61<br />
Disclosure: Nothing to Disclose<br />
Gall, Victoria, PT, MEd<br />
ARHP Networking at Noon . . . . . . . . . . 64<br />
Disclosure: Nothing to Disclose<br />
Total Shoulder Arthroplasty and Reverse Total<br />
Shoulder Arthroplasty: Surgery<br />
and Rehabilitation. . . . . . . . . . . . . . .147<br />
Disclosure: Nothing to Disclose<br />
Gardner, Gregory C, MD<br />
Review Course . . . . . . . . . . . . . . . . . 23<br />
Disclosure: Nothing to Disclose<br />
Diabetes 2010: More than Autoimmunity and<br />
Adipocytes . . . . . . . . . . . . . . . . . . . 94<br />
Disclosure: Nothing to Disclose<br />
Teaching and Assessing Arthrocentesis . . 112<br />
Disclosure: Nothing to Disclose<br />
Joint Injections (Knee and Ankle Prosthetics)<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 76<br />
Disclosure: Nothing to Disclose<br />
Joint Injections (Shoulder and Wrist<br />
Prosthetics) . . . . . . . . . . . . . . . . . . 58<br />
Disclosure: Nothing to Disclose<br />
Garnoc, Josephine C, BSN<br />
Integrating Immunology and Biologics into<br />
Clinical Practice . . . . . . . . . . . . . . . . 25<br />
Disclosure: Centocor, 8; Genentech, 8; UCB, 8<br />
Gay, Steffen, MD<br />
The Revolution <strong>of</strong> Epigenetics in<br />
Autoimmunity . . . . . . . . . . . . . . . . . 47<br />
Disclosure: Nothing to Disclose
Gerlag, Danielle Marie, MD, PhD<br />
The Preclinical Stage <strong>of</strong> Rheumatoid Arthritis:<br />
Towards Prevention <strong>of</strong> Disease? . . . . . . . 77<br />
Disclosure: Nothing to Disclose<br />
Gib<strong>of</strong>sky, Allan, MD, JD<br />
Pain Management in the Age <strong>of</strong> Abuse and<br />
Litigation . . . . . . . . . . . . . . . . . . . 100<br />
Disclosure: Abbott, 8; Amgen, 8; BMS, 8; J&J, 1;<br />
Nicox, 5; Pfizer, 1, 8; UCB, 8; United States Food<br />
and Drug Administration, 5<br />
Gibson, Kyle, MS, PhD<br />
Putting ACR Osteoarthritis Guidelines into<br />
Practice: Clinical Applications for the Hip<br />
and Knee . . . . . . . . . . . . . . . . . . . .142<br />
Disclosure: Nothing to Disclose<br />
Giles, Jon T, MD<br />
Neuro Endocrine Immunology . . . . . . . . 91<br />
Disclosure: Nothing to Disclose<br />
Ginzler, Ellen M, MD, MPH<br />
Systemic Lupus Erythematosus: Novel<br />
Treatments. . . . . . . . . . . . . . . . . . .106<br />
Disclosure: Nothing to Disclose<br />
Gitomer, Richard S, MD, MBA<br />
Session I: The Essentials . . . . . . . . . . . 19<br />
Disclosure: Nothing to Disclose<br />
Gladman, Dafna D, MD<br />
Psoriatic Disease: Clinical Spectrum and<br />
Comprehensive Treatment Strategies . . . . 69<br />
Disclosure: Abbott, Amgen, Wyeth, BMS, 5<br />
Psoriatic Arthritis . . . . . . . . . . . . . . .130<br />
Disclosure: Abbott, Amgen, Wyeth, BMS, 5;<br />
Abbott, Pfizer, Amgen, Wyeth, 2<br />
Glennie, Martin J, PhD<br />
Session IV: Emerging Concepts in B cell Directed<br />
Therapies. . . . . . . . . . . . . . . . . . . . 23<br />
Disclosure: Nothing to Disclose<br />
Goldberg, Lynne J, MD<br />
Dermatopathology <strong>of</strong> Rheumatic Diseases . 57<br />
Disclosure: Nothing to Disclose<br />
Goldring, Mary B, PhD<br />
Molecular Mechanisms <strong>of</strong> Inflammatory<br />
Signaling in Cartilage Destruction . . . . . . 27<br />
Disclosure: Nothing to Disclose<br />
Goldring, Steven R, MD<br />
Bisphosphonates: Mechanism <strong>of</strong> Action and<br />
Optimizing Clinical Use . . . . . . . . . . . 135<br />
Disclosure: Nothing to Disclose<br />
2010 Hench Lecture: Glucocorticoids-<br />
Physiologic Regulation, Mechanisms <strong>of</strong> Action<br />
and Optimizing Therapeutic Applications . . 37<br />
Disclosure: Nothing to Disclose<br />
Gottenberg, Jacques-Eric MD, PhD<br />
Sjögren’s Syndrome . . . . . . . . . . . . . . 92<br />
Gourley, Mark F, MD<br />
Myopathy: Issues in Diagnosis and<br />
Treatment . . . . . . . . . . . . . . . . . . .105<br />
Disclosure: Nothing to Disclose<br />
Goyal, Janak R, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasonography: Basic . . 29<br />
Disclosure: Nothing to Disclose<br />
Grahame, Rodney, MD<br />
Hypermobility . . . . . . . . . . . . . . . . 108<br />
Disclosure: Nothing to Disclose<br />
Joint Hypermobility Syndrome . . . . . . . . 90<br />
Disclosure: Nothing to Disclose<br />
Genetic Disorders <strong>of</strong> Connective Tissue<br />
and Joint Hypermobility . . . . . . . . . . . 37<br />
Disclosure: Nothing to Disclose<br />
Green, Carmen R, MD<br />
Disparities and Pain: Examining Research,<br />
Practice and Policy . . . . . . . . . . . . . . 95<br />
Disclosure: Nothing to Disclose<br />
Grom, Alexei A, MD<br />
Autologous Stem Cell Transplantation in<br />
Pediatric <strong>Rheumatology</strong>: Indications and<br />
Associated Morbidity . . . . . . . . . . . . . 68<br />
Disclosure: Nothing to Disclose<br />
New Development in Systemic Juvenile<br />
Idiopathic Arthritis - From Bench to Effective<br />
Interventions . . . . . . . . . . . . . . . . .121<br />
Disclosure: Nothing to Disclose<br />
Gultekin, Sakir Humayun, MD<br />
Muscle Involvement in Rheumatic Diseases . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . .101<br />
Disclosure: Nothing to Disclose<br />
Gunawardena, Harsha, MD<br />
Inflammatory Myopathy Update. . . . . . . 77<br />
Disclosure: Nothing to Disclose<br />
H<br />
Haberman, Ann M, PhD<br />
Session II: B cell Activation and Trafficking . 22<br />
Disclosure: Nothing to Disclose<br />
Hahn, Bevra H, MD<br />
Mouse to House: Lessons Learned About Lupus<br />
Therapeutics . . . . . . . . . . . . . . . . . . 39<br />
Disclosure: Alderbio Pharm, 5; Aspreva, 2;<br />
Bristol Myers Squibbs, 9<br />
Hajj-Ali, Rula, MD<br />
Central Nervous System Vasculitis . . . . . . 28<br />
Disclosure: Nothing to Disclose<br />
Hamilton, John A, PhD, DSc<br />
Macrophage Differentiation . . . . . . . . . 55<br />
Disclosure: CSL Ltd, 5; Morphosys AG, 2, 5, 7;<br />
NovoNordisk, 5<br />
Hanly, John G, MD<br />
The Brain and Systemic Lupus Erythematosus:<br />
2010 Update . . . . . . . . . . . . . . . . . . 66<br />
Disclosure: Genentech USA, 5; GSK Canada, 5;<br />
Roche Canada, 2, 5<br />
Hannan, Marian T, DSc, MPH<br />
A Foot Orthotic Is Not Just a Foot Orthotic . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . .131<br />
Disclosure: Nothing to Disclose<br />
Building Effective Teams: Recommended<br />
Leadership Strategies . . . . . . . . . . . . 100<br />
Disclosure: Nothing to Disclose<br />
You’ve Got the Power: How to Use and Teach<br />
Statistical Power for Studies and Grants. . . 47<br />
Disclosure: Nothing to Disclose<br />
Hansen, Karen E, MD<br />
Vitamin D and Bone Health. . . . . . . . . . 36<br />
Disclosure: NIH, 2<br />
Hardy, Richard R, PhD<br />
Session I: B cell Development . . . . . . . . 20<br />
Disclosure: Nothing to Disclose<br />
Harrington, J. Timothy, MD<br />
Session II: Applications to Musculoskeletal<br />
Medicine . . . . . . . . . . . . . . . . . . . . 19<br />
Disclosure: CORRONA, 5; Murray Electronics, 4;<br />
Wyeth, 8<br />
Haskard, Dorian O, DM<br />
Behçet’s Disease. . . . . . . . . . . . . . . . 88<br />
Disclosure: Nothing to Disclose<br />
Hazes, Johanna, MD, PhD<br />
Rheumatoid Arthritis: Early Rheumatoid<br />
Arthritis . . . . . . . . . . . . . . . . . . . . 36<br />
Disclosure: BMS, 8; Roche, 2; Wyeth, 2<br />
Helmick, Charles G, MD<br />
Top 10 in ‘10: Top 10 Public Health Advances<br />
in the First 10 Years <strong>of</strong> the Centers for Disease<br />
Control and Prevention Arthritis Program. .147<br />
Disclosure: Nothing to Disclose<br />
Higgs, Jay B, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Nothing to Disclose<br />
Hirsch, Irl B, MD<br />
Diabetes 2010: More than Autoimmunity and<br />
Adipocytes . . . . . . . . . . . . . . . . . . . 94<br />
Disclosure: Abbott Diabetes Care, 5; Bayer, 5;<br />
Johnson & Johnson, 5; Novo Nordisk, 2; Roche, 5<br />
Ho, Nancy A, MHA<br />
Money Talks: How to Incentivize Staff . . . . 46<br />
Disclosure: Nothing to Disclose<br />
Hochberg, Marc C, MD, MPH<br />
Evidence-based Non-pharmacological Treatment<br />
for Hip, Knee, and Hand Osteoarthritis: The New<br />
ACR Guidelines . . . . . . . . . . . . . . . . 34<br />
Disclosure:, 8; Astra-Zeneca Pharmaceutical<br />
CO, 8; Bayer HealthCare LLC, 8; Bioberica SA, 8;<br />
CombinatoRx, 8; Covidien, 8; Eli Lilly Co., 8; Endo<br />
Pharmaceuticals, 8; GlaxoSmithKline, 8; Merck<br />
& Co., Inc., 8; Merck Serono International SA, 8;<br />
NicOX SA, 8; Novartis Pharma AG, 8; Pfizer Inc.,<br />
8; Pozen, Inc., 8; San<strong>of</strong>i Aventis SA, 8; Smith &<br />
Nephew, 8; Stryker Biotech, 8<br />
Osteoarthritis - What is New in Old Joints .122<br />
Disclosure:, 8; Astra-Zeneca Pharmaceutical<br />
CO, 8; Bayer HealthCare LLC, 8; Bioberica SA, 8;<br />
CombinatoRx, 8; Covidien, 8; Eli Lilly Co., 8; Endo<br />
Pharmaceuticals, 8; GlaxoSmithKline, 8; Merck<br />
& Co., Inc., 8; Merck Serono International SA, 8;<br />
NicOX SA, 8; Novartis Pharma AG, 8; Pfizer Inc.,<br />
8; Pozen, Inc., 8; San<strong>of</strong>i Aventis SA, 8; Smith &<br />
Nephew, 8; Stryker Biotech, 8<br />
H<strong>of</strong>fman, Bruce I, MD<br />
Crystallizing Your Assessment and Treatment <strong>of</strong><br />
Difficult to Treat Gout . . . . . . . . . . . . .114<br />
Disclosure: Nothing to Disclose<br />
H<strong>of</strong>fman, Gary S, MD<br />
Giant Cell Arteritis - Diagnosis and Therapy. 69<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book 305<br />
INVITED SPEAKER /MODERATOR INDEX
INVITED SPEAKER /MODERATOR INDEX<br />
306<br />
Holers, V. Michael, MD<br />
The Biology <strong>of</strong> Citrullination . . . . . . . . . 68<br />
Disclosure: Nothing to Disclose<br />
Hong, Raymond, MD, MBA<br />
CORC Forum: Health Care Reform – Where Are<br />
We Heading?. . . . . . . . . . . . . . . . . .101<br />
Disclosure: Novartis, 8<br />
ICD -10 Preparation - Developing a Blueprint for<br />
Implementation . . . . . . . . . . . . . . . 133<br />
Disclosure: Novartis, 8<br />
Hootman, Jennifer M, PhD<br />
ARHP Networking at Noon . . . . . . . . . . 63<br />
Disclosure: Nothing to Disclose<br />
Evidence-based Practice: Creating and Using<br />
<strong>Rheumatology</strong> Critically Appraised Topics. .102<br />
Disclosure: Nothing to Disclose<br />
Ready, Aim, Get Funded! . . . . . . . . . . 131<br />
Disclosure: Nothing to Disclose<br />
Houssiau, Frederic A, MD, PhD<br />
Systemic Lupus Erythematosus: Lupus<br />
Nephritis . . . . . . . . . . . . . . . . . . . . 84<br />
Disclosure: Nothing to Disclose<br />
Huber, Adam, MD<br />
Pediatrics: Dermatomyositis . . . . . . . . . 57<br />
Disclosure: Abbott, 9<br />
Huizinga, Thomas W. J, MD<br />
The Biology <strong>of</strong> Citrullination . . . . . . . . . 68<br />
Disclosure: Nothing to Disclose<br />
Hunder, Gene G, MD<br />
Temporal Arteritis . . . . . . . . . . . . . . . 97<br />
Disclosure: Nothing to Disclose<br />
Ilowite, Norman T, MD<br />
2010 ACR Recommendations for the Treatment<br />
<strong>of</strong> Juvenile Idiopathic Arthritis . . . . . . . 143<br />
Disclosure: Regeneron, 2<br />
New Development in Systemic Juvenile<br />
Idiopathic Arthritis - From Bench to Effective<br />
Interventions . . . . . . . . . . . . . . . . .121<br />
Disclosure: Regeneron, 2<br />
Inman, Christi J, MD<br />
Transforming Rheumatologic Care with the<br />
Electronic Health Record . . . . . . . . . . . 30<br />
Disclosure: Nothing to Disclose<br />
Ishimori, Mariko L, MD<br />
Osteoarthritis - What is New in Old Joints .122<br />
Disclosure: Nothing to Disclose<br />
Ivashkiv, Lionel B, MD<br />
Stem Cell Reprogramming: Molecular<br />
Mechanisms and Clinical Applications and<br />
Implications . . . . . . . . . . . . . . . . . .102<br />
Disclosure: Nothing to Disclose<br />
Iversen, Maura D, PT, DPT, SD, MPH<br />
Building Effective Teams: Recommended<br />
Leadership Strategies . . . . . . . . . . . . 100<br />
Disclosure: Nothing to Disclose<br />
Daltroy Memorial Lecture: Adherence to<br />
Medical Regimens for Rheumatic Diseases<br />
and the Importance <strong>of</strong> Patient-Clinician<br />
Communication . . . . . . . . . . . . . . . . 61<br />
Disclosure: Nothing to Disclose<br />
Physical Activity and Osteoarthritis: Learning<br />
with the Community . . . . . . . . . . . . . 95<br />
Disclosure: Nothing to Disclose<br />
Rehabilitation in the Age <strong>of</strong> Biologics . . . . 54<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book<br />
I<br />
James, Nadine T, RN, MSN, PhD<br />
Patient Participation in Research. . . . . . .119<br />
Disclosure: Nothing to Disclose<br />
ARHP Networking at Noon . . . . . . . . . . 63<br />
Disclosure: Nothing to Disclose<br />
Janisse, Dennis J, C Ped<br />
A Foot Orthotic Is Not Just a Foot Orthotic . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . .131<br />
Disclosure: Nothing to Disclose<br />
Jarvis, James N, MD<br />
Career Opportunities in <strong>Rheumatology</strong>: Making<br />
a Choice . . . . . . . . . . . . . . . . . . . .112<br />
Disclosure: Nothing to Disclose<br />
Jayne, David, MD<br />
Treatment <strong>of</strong> Wegener’s Granulomatosis/<br />
Microscopic Polyangiitis: Understanding and<br />
Applying the Data from Recent Clinical Trials<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 48<br />
Disclosure: H<strong>of</strong>fmann La Roche, 5; Human<br />
Genome Science, 5<br />
Jennings, Michael J, RT, CBDT<br />
Building Effective Teams: Recommended<br />
Leadership Strategies . . . . . . . . . . . . 100<br />
Disclosure: Nothing to Disclose<br />
Jones, Dina L., PhD, PT<br />
ARHP Networking at Noon . . . . . . . . . . 63<br />
Disclosure: Nothing to Disclose<br />
Jones, Karla B, MS, RN, CPNP<br />
Teaching Our Pediatric Patients: Making the<br />
Complex Simple . . . . . . . . . . . . . . . 142<br />
Disclosure: Nothing to Disclose<br />
Jorgensen, Christian, MD, PhD<br />
Therapeutic Use <strong>of</strong> Mesenchymal Stem Cells in<br />
Rheumatologic Diseases . . . . . . . . . . .133<br />
Disclosure: Nothing to Disclose<br />
Joseph, Amy M, MD<br />
Hepatitis C for the Rheumatologist . . . . . 24<br />
Disclosure: Nothing to Disclose<br />
J<br />
K<br />
Kaeley, Gurjit S, MBBS<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . 17, 18<br />
Disclosure: Sonosite, Biosound Esaote, 2<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Sonosite, Biosound Esaote, 2<br />
Musculoskeletal Ultrasound . . . . . .109, 110<br />
Disclosure: Sonosite, Biosound Esaote, 2<br />
Musculoskeletal Ultrasonography: Basic . . 29<br />
Disclosure: Sonosite, Biosound Esaote, 2<br />
Kalish, Robert A, MD<br />
ACR/ABIM Maintenance <strong>of</strong> Certification<br />
Learning Session – 2010 Update . . . . . . . 21<br />
Disclosure: Nothing to Disclose<br />
<strong>Rheumatology</strong> Physical Examination <strong>of</strong> Lower<br />
Extremity and Lumbosacral Spine: Anatomical<br />
Correlates . . . . . . . . . . . . . . . . . . . 38<br />
Disclosure: Nothing to Disclose<br />
<strong>Rheumatology</strong> Physical Examination <strong>of</strong> Upper<br />
Extremity and Cervical Spine: Anatomical<br />
Correlates . . . . . . . . . . . . . . . . . . . 97<br />
Disclosure: Nothing to Disclose<br />
Kaplan, Mariana J, MD<br />
ACR/EULAR Academic Exchange Program. . 86<br />
Disclosure: Nothing to Disclose<br />
News from the National Institutes <strong>of</strong> Health:<br />
Updates and Opportunities. . . . . . . . . . 56<br />
Disclosure: Nothing to Disclose<br />
Karp, David R, MD<br />
ACR REF Within Our Reach: Finding a Cure<br />
for Rheumatoid Arthritis . . . . . . . . . . . 45<br />
Disclosure: Nothing to Disclose<br />
Kashikar-Zuck, Susmita, PhD<br />
Juvenile Fibromyalgia . . . . . . . . . . . . . 53<br />
Disclosure: National Institutes <strong>of</strong> Health, 2<br />
Kastanek, Lisa M, RN, CCRC<br />
Clinical Trial Essentials: Budgets, Contracts<br />
and Regulations . . . . . . . . . . . . . . . . 58<br />
Disclosure: BMS,UCB,Roche, 8<br />
ARHP Networking at Noon . . . . . . . . . . 63<br />
Disclosure: Disclosure: BMS,UCB,Roche, 8<br />
ARHP Research Coordinators Networking. . 35<br />
Disclosure: BMS,UCB,Roche, 8<br />
Katz, Patricia P, PhD<br />
Understanding Functional Activity in<br />
Rheumatoid Arthritis: What We Know and What<br />
We Don’t Know . . . . . . . . . . . . . . . . 86<br />
Disclosure: Nothing to Disclose<br />
Kavanaugh, Arthur, MD<br />
Immunizations and Rheumatic Diseases - An<br />
Update . . . . . . . . . . . . . . . . . . . . . 37<br />
Disclosure: Nothing to Disclose<br />
Psoriatic Disease: Clinical Spectrum and<br />
Comprehensive Treatment Strategies . . . . 69<br />
Disclosure: abbott, 2; amgen, 2; bms, 2;<br />
Centocor, 2; roche, 2; ucb, 2<br />
<strong>Rheumatology</strong> Roundup: Highlights from the<br />
2010 Annual Scientific Meeting . . . . . . .133<br />
Disclosure: Nothing to Disclose<br />
Kazi, Salahuddin, MD<br />
Integrating Immunology and Biologics into<br />
Clinical Practice . . . . . . . . . . . . . . . . 26<br />
Disclosure: Centocor, 8; Genentech, 8<br />
Session II: Applications to Musculoskeletal<br />
Medicine . . . . . . . . . . . . . . . . . . . . 19<br />
Disclosure: Centocor, 8; Genentech, 8<br />
Transforming Rheumatologic Care with the<br />
Electronic Health Record . . . . . . . . . . . 30<br />
Disclosure: Centocor, 8; Genentech, 8<br />
Electronic Health Record . . . . . . . . . . 101<br />
Disclosure: Centocor, 8; Genentech, 8<br />
Kerr, Karen L, MSN, NP, CPNP, PNP<br />
Rheumatic Disease Update: Juvenile Idiopathic<br />
Arthritis . . . . . . . . . . . . . . . . . . . .100<br />
Disclosure: Nothing to Disclose<br />
ARHP Networking at Noon . . . . . . . . . . 64<br />
Disclosure: Nothing to Disclose<br />
Keysor, Julie J, PhD, PT<br />
Work Assessments: A ‘How-To’ That Could Save<br />
Your Patient’s Life/Job. . . . . . . . . . . . .131<br />
Disclosure: Nothing to Disclose<br />
Keystone, Edward C, MD<br />
Rheumatoid Arthritis: Challenging<br />
Cases . . . . . . . . . . . . . . . . . . . 29, 106<br />
Disclosure: Abbott, 9; Abbott Laboratores, 5;<br />
Amgen, 9; Amgen Inc., 5; Astrazeneca Inc., 5;<br />
Bristol-Myers Squibb, 5, 9; Centocor Inc., 5; F.<br />
H<strong>of</strong>fman La Roche, 5, 9; Merck, 5; Pfizer, 5, 8;<br />
Schering Plough, 5, 9; UCB Pharmaceuticals, 5;<br />
Wyeth Pharmaceuticals, 5
Physical Examination Skills for Improved<br />
Detection <strong>of</strong> Synovitis and Cervical<br />
Thoracolumbar Disorders. . . . . . . . . . .120<br />
Disclosure: Nothing to Disclose<br />
Khanna, Dinesh, MD, MSc<br />
Pulmonary Hypertension in the Rheumatic<br />
Diseases . . . . . . . . . . . . . . . . . . . . 29<br />
Disclosure: Actelion, 2; Actelion, 5; Fibrogen, 5;<br />
Gilead, 2, 5; MediQuest, 5; United Therapeutics, 5<br />
Systemic Sclerosis: How to Perform Skin<br />
Scores . . . . . . . . . . . . . . . . . . . . . 76<br />
Disclosure: Actelion, 2; Actelion, 5; Fibrogen, 5;<br />
Gilead, 2, 5; MediQuest, 5; United Therapeutics, 5<br />
Kiefe, Catarina, MD, PhD<br />
Session I: The Essentials . . . . . . . . . . . 19<br />
Disclosure: Nothing to Disclose<br />
Kimpton, Kimberly F, PT<br />
Rheumatic Disease Update: Osteoarthritis <strong>of</strong> the<br />
Spine . . . . . . . . . . . . . . . . . . . . . 103<br />
Disclosure: Nothing to Disclose<br />
Kimura, Yukiko, MD<br />
ACR REF Clinician Scholar Educator Lecture. 53<br />
Disclosure: Nothing to Disclose<br />
Kincade, Paul W, PhD<br />
Session I: B cell Development . . . . . . . . 20<br />
Disclosure: Nothing to Disclose<br />
King, Charles M, MD<br />
Transforming Rheumatologic Care with the<br />
Electronic Health Record . . . . . . . . . . . 30<br />
Disclosure: Nothing to Disclose<br />
Kissin, Eugene Y, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: Amgen, 5; GE, 2; SonoSite, 9; UCB, 5<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . 22, 23<br />
Disclosure: Amgen, 5; GE, 2; SonoSite, 9; UCB, 5<br />
Musculoskeletal Ultrasound . . . . . . . . . 47<br />
Disclosure: Amgen, 5; GE, 2; SonoSite, 9; UCB, 5;<br />
Amgen, 5; GE, 2; SonoSite, 9; UCB, 5<br />
Klareskog, Lars, MD, PhD<br />
The Preclinical Stage <strong>of</strong> Rheumatoid Arthritis:<br />
Towards Prevention <strong>of</strong> Disease? . . . . . . . 77<br />
Disclosure: Nothing to Disclose<br />
Klepper, Susan E, PhD, PT<br />
What’s New and Noteworthy in 2010: A<br />
Review <strong>of</strong> <strong>Rheumatology</strong> Research for Health<br />
Pr<strong>of</strong>essionals. . . . . . . . . . . . . . . . . . 76<br />
Disclosure: Nothing to Disclose<br />
Koch, Alisa E, MD<br />
The Biology <strong>of</strong> Citrullination . . . . . . . . . 68<br />
Disclosure: Bristol-Myers Squibb, 2; CME Peer<br />
Review, LLC, 5; Cypress Bioscience, 5; Fund for<br />
Autoimmune Research, 6; Gerson Lehrman<br />
Group <strong>of</strong> Healthcare and Biomedical Advisors,<br />
5; Guidepoint Global, 5; HealthCare Venture,<br />
LLC, 5; NiCox SA, 5; Pharmacia and Upjohn<br />
Company, 2; Roche Pharmaceuticals, 2; Takeda<br />
Pharmaceuticals North America, Inc, 2; UCB<br />
Pharmaceuticals, 6<br />
ACR Plenary Session III: Discovery 2010 . . .104<br />
Disclosure: Bristol-Myers Squibb, 2; CME Peer<br />
Review, LLC, 5; Cypress Bioscience, 5; Fund for<br />
Autoimmune Research, 6; Gerson Lehrman<br />
Group <strong>of</strong> Healthcare and Biomedical Advisors, 5;<br />
Guidepoint Global, 5; HealthCare Ventures, LLC,<br />
5; NiCox SA, 5; Pharmacia and Upjohn, 2; Roche<br />
Pharmaceuticals, 2; Takeda Pharmaceuticals, 2;<br />
UCB Pharmaceuticals, 6<br />
Kolasinski, Sharon L, MD<br />
ACR REF Clinician Scholar Educator Lecture. 53<br />
Disclosure: Nothing to Disclose<br />
Kortan, Joyce M, RN<br />
Practice Potpourri . . . . . . . . . . . . . . . 86<br />
Disclosure: Amgen, 8; Bristol Meyers Squibb,<br />
8; Centocor, 8; Genetech/Roche, 8; Novartis, 9;<br />
PRIME, 9; RNS, 9; The Institute <strong>of</strong> Continuing<br />
Health Education, 9; UCB, 8; Wyeth, 8<br />
Kremer, Joel M, MD<br />
Methotrexate 2010 . . . . . . . . . . . . . . 56<br />
Disclosure: Nothing to Disclose<br />
Krohn, Kelly D, MD<br />
Knee Braces and Foot Orthosis for Knee<br />
Osteoarthritis . . . . . . . . . . . . . . . . . 76<br />
Disclosure: Nothing to Disclose<br />
Kyburz, Diego, MD<br />
Toll-like Receptors and Inflammation: Towards<br />
Innovative Treatment <strong>of</strong> Rheumatoid Arthritis<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Disclosure: Nothing to Disclose<br />
L<br />
Lafyatis, Robert A, MD<br />
Immunopathogenesis <strong>of</strong> Systemic<br />
Sclerosis . . . . . . . . . . . . . . . . . . . .136<br />
Disclosure: Actelion, 2; Celgene, 2; Medimmune,<br />
2; Novartis, 2<br />
Scleroderma-Biomarkers . . . . . . . . . . 111<br />
Disclosure: Actelion, 2; Celgene, 2; Medimmune,<br />
2; Novartis, 2<br />
Lahita, Robert G, MD, PhD<br />
Systemic Lupus Erythematosus: Novel<br />
Treatments. . . . . . . . . . . . . . . . . . . 84<br />
Disclosure: Nothing to Disclose<br />
Lakhanpal, Sharad, MB, MD<br />
Legislative Update from Capitol Hill . . . . . 52<br />
Disclosure: Nothing to Disclose<br />
Langford, Carol A, MD, MHS<br />
ACR/ABIM Maintenance <strong>of</strong> Certification<br />
Learning Session -2010 Update . . . . . . . 21<br />
Disclosure: Bristol Myers-Squibb, 9; Genentech, 9<br />
Treatment <strong>of</strong> Wegener’s Granulomatosis/<br />
Microscopic Polyangiitis: Understanding and<br />
Applying the Data from Recent Clinical Trials . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 48<br />
Disclosure: Bristol Myers-Squibb, 9; Genentech, 9<br />
ACR Plenary Session III: Discovery 2010 . . .104<br />
Disclosure: Bristol Myers-Squibb, 9; Genentech, 9<br />
Takayasu’s Arteritis . . . . . . . . . . . . . .112<br />
Disclosure: Bristol Myers-Squibb, 9; Genentech, 9<br />
Lapteva, Larissa Y, MD, MHS<br />
Update on Safety Issues in the Treatment <strong>of</strong><br />
Rheumatic Diseases – From the Food and Drug<br />
Administration and Beyond . . . . . . . . . 77<br />
Disclosure: Nothing to Disclose<br />
Law, Karen L, MD<br />
Clinicopathologic Conference . . . . . . . . 55<br />
Disclosure: Nothing to Disclose<br />
Lawry, George V, MD<br />
Evidence-based Snacks for Rheumatologists 25<br />
Disclosure: McGraw Hill, 7<br />
Musculoskeletal Exam Skills I: General<br />
Musculoskeletal Examination Skills<br />
for Educators. . . . . . . . . . . . . . . . . . 67<br />
Disclosure: McGraw Hill, 7<br />
Musculoskeletal Exam Skills II: Regional<br />
Examinations <strong>of</strong> the Shoulder and Low Back .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 97<br />
Disclosure: McGraw Hill, 7<br />
Musculoskeletal Exam Skills III: Regional<br />
Examinations <strong>of</strong> the Knee. . . . . . . . . . .102<br />
Disclosure: McGraw Hill, 7<br />
Learch, Thomas J, MD<br />
Pediatric Spondylarthropathies: From Genetics<br />
to the Clinic . . . . . . . . . . . . . . . . . .136<br />
Disclosure: Nothing to Disclose<br />
Lee, David M, MD, PhD<br />
Basic Immunology for Clinical<br />
Rheumatologists. . . . . . . . . . . . . 64, 105<br />
Disclosure: Johnson & Johnson, 5; Novartis, 1;<br />
Synovex, 1, 5, 7; UCB Pharma, 5<br />
Lemke, Greg E, PhD<br />
Cell Death: Receptors, Sensors and<br />
Inflammatory Pathways. . . . . . . . . . . .114<br />
Disclosure: Xetrios Therapeutics, 4<br />
Levine, Stuart M, MD<br />
Vasculitis: An Update . . . . . . . . . . . . 130<br />
Disclosure: Nothing to Disclose<br />
Li, Linda C, BSc (PT) MSc PhD<br />
ARHP Occupational and Physical Therapy<br />
Networking . . . . . . . . . . . . . . . . . .105<br />
Disclosure: Nothing to Disclose<br />
Liebling, Michael R, MD<br />
When Pieces Don’t Fit . . . . . . . . . . . .120<br />
Disclosure: Nothing to Disclose<br />
Liew, Foo Y, BSc, PhD, DSc<br />
Immunopathogenesis <strong>of</strong> Systemic Sclerosis. . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . .136<br />
Disclosure: Nothing to Disclose<br />
Lightfoot, Robert W, MD<br />
Labs and Treatment Options: What Do They<br />
Mean and How Do You Use? . . . . . . . . 131<br />
Disclosure: Nothing to Disclose<br />
Lim, S Sam, MD, MPH<br />
Clinicopathologic Conference . . . . . . . . 55<br />
Disclosure: Nothing to Disclose<br />
Limanni, Alex, MD<br />
Insurance Roundtable Discussion . . . . . . 94<br />
Disclosure: Nothing to Disclose<br />
Liu, Nancy Y, MD<br />
Update on Multiple Sclerosis. . . . . . . . . 59<br />
Disclosure: Nothing to Disclose<br />
Loeser, Richard F, MD<br />
Molecular Mechanisms <strong>of</strong> Inflammatory<br />
Signaling in Cartilage Destruction . . . . . . 27<br />
Disclosure: Nothing to Disclose<br />
Osteoarthritis: Update 2010 . . . . . . . . . 57<br />
Disclosure: Omeros, 2<br />
Walk this Way: Biomechanics and<br />
Osteoarthritis . . . . . . . . . . . . . . . . . 95<br />
Disclosure: Nothing to Disclose<br />
Looney, Richard J, MD<br />
Epigenetics 101 . . . . . . . . . . . . . . . . 98<br />
Disclosure: Nothing to Disclose<br />
Innate Immunity and Inflammation . . . . . 30<br />
Disclosure: Nothing to Disclose<br />
Macrophage Differentiation . . . . . . . . . 55<br />
Disclosure: Nothing to Disclose<br />
Therapeutic Use <strong>of</strong> Mesenchymal Stem Cells in<br />
Rheumatologic Diseases . . . . . . . . . . .133<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book 307<br />
INVITED SPEAKER /MODERATOR INDEX
INVITED SPEAKER /MODERATOR INDEX<br />
308<br />
Louie, Grant H, MD, MHS<br />
Finding and Using Secondary Data Resources<br />
for Research: Beyond the National Health and<br />
Nutrition Examination Survey and the Usual<br />
Suspects . . . . . . . . . . . . . . . . . . . 103<br />
Disclosure: Nothing to Disclose<br />
Lovell, Daniel J, MD, MPH<br />
2010 ACR Recommendations for the Treatment<br />
<strong>of</strong> Juvenile Idiopathic Arthritis . . . . . . . 143<br />
Disclosure: Abbott, 5; Amgen, 5; Arthritis Care<br />
& Rheumatism & Arthritis and Rheumatism, 9;<br />
Astra-Zeneca Pharmaceutical, 5; Bristol-Meyers<br />
Squibb, 9; Centocor, 9; H<strong>of</strong>fman LaRoche, 5;<br />
Novartis, 5; Pfizer, 5; Regeneron, 5; UBC, 5;<br />
Wyeth Pharm., 9; Xoma, Inc., 5<br />
Update on Safety Issues in the Treatment <strong>of</strong><br />
Rheumatic Diseases – From the Food and Drug<br />
Administration and Beyond . . . . . . . . . 77<br />
Disclosure: Abbott, 5; Amgen, 5; Arthritis Care<br />
& Rheumatism & Arthritis and Rheumatism, 9;<br />
Astra-Zeneca Pharmaceutical, 5; Bristol-Meyers<br />
Squibb, 9; Centocor, 9; H<strong>of</strong>fman LaRoche, 5;<br />
Novartis, 5; Pfizer, 5; Regeneron, 5; UBC, 5;<br />
Wyeth Pharm., 9; Xoma, Inc., 5<br />
Lundberg, Ingrid E, MD, PhD<br />
Inflammatory Myopathy Update. . . . . . . 77<br />
Disclosure: Nothing to Disclose<br />
M<br />
MacDonald, Patricia A, BSN, NP<br />
Adaptations and Solutions to Help People with<br />
Scleroderma Continue to Work . . . . . . .102<br />
Disclosure: Nothing to Disclose<br />
MacLean, Catherine H, MD, PhD<br />
Session I: The Essentials . . . . . . . . . . . 19<br />
Disclosure: WellPoint, 3<br />
Maksymowych, Walter P, MD<br />
Ankylosing Spondylitis: Disease Modification. .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 28<br />
Disclosure: Abbott, 2, 5; Merck, 2, 5; Pfizer, 2, 5<br />
Mandelin, Arthur M, MD, PhD<br />
Adult Musculoskeletal Upper/Lower<br />
Examinations . . . . . . . . . . . . . . . . . 38<br />
Disclosure: Abbott, 8; UCB, 8<br />
Mandell, Brian F, MD, PhD<br />
Curbside Consults - Ask the Pr<strong>of</strong>essors . . . 62<br />
Disclosure: merck, 9; takeda, 5; url, 5<br />
Perioperative Management <strong>of</strong> Selected<br />
Problems in Patients with Rheumatic Disease<br />
. . . . . . . . . . . . . . . . . . . . . . . . .122<br />
Disclosure: merck, 9; takeda, 5; url, 5<br />
Synovial Fluid Analysis and Crystal<br />
Identification. . . . . . . . . . . . . . 30, 68, 76<br />
Disclosure: merck, 9; takeda, 5; url, 5<br />
Mandl, Thomas, MD, PhD<br />
Sjögren’s Syndrome . . . . . . . . . . . . . . 92<br />
Marcus, Donald M, MD<br />
CAM is a SCAM! Complementary and<br />
Alternative “Medicince” Has No Place in<br />
<strong>Rheumatology</strong> . . . . . . . . . . . . . . . . . 46<br />
Disclosure: Nothing to Disclose<br />
Marder, Wendy, MD<br />
Reproductive and Sexual Health Issues for<br />
Women with Rheumatic Disease. . . . . . . 54<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book<br />
Maricic, Michael J, MD<br />
Osteoporosis: Novel Treatments . . . . . . . 36<br />
Disclosure: Lilly, Novartis, Amgen, Roche,<br />
Genetech, Proctor and Gamble, 8<br />
<strong>Rheumatology</strong> Practice 101: Starting Out in<br />
Practice for The Graduating Fellow . . . . .130<br />
Disclosure: Lilly, Novartis, Amgen, Roche,<br />
Genetech, Proctor and Gamble, 8<br />
The Ideal <strong>Rheumatology</strong> Practice . . . . . .104<br />
Disclosure: Lilly, Novartis, Amgen, Roche,<br />
Genetech, Proctor and Gamble, 8<br />
REF Oscar S. Gluck, MD, Memorial Lectureship<br />
- Osteoimmunology: Crosstalk Between the<br />
Immune and Bone Systems: Biologic and Clinical<br />
Implications . . . . . . . . . . . . . . . . . . 28<br />
Disclosure: Lilly, Novartis, Amgen, Roche,<br />
Genetech, Proctor and Gamble, 8<br />
Marshak-Rothstein, Ann, PhD<br />
The Immunology <strong>of</strong> B Cells: From Antibodies to<br />
Immunoregulation . . . . . . . . . . . . . . 20<br />
Disclosure: Idera Pharmaceuticals, 5<br />
Session III: Factors Promoting B Cell<br />
Autoreactivity and Protective Immunity. . . 23<br />
Disclosure: Idera Pharmceuticals, 5<br />
Toll-like Receptors Activation <strong>of</strong> B cells in<br />
Autoimmune Disease . . . . . . . . . . . . . 28<br />
Disclosure: Idera Pharmceuticals, 5<br />
Toll-Like Receptor Signaling in B Cells and<br />
Atoimmune Disease. . . . . . . . . . . . . . 23<br />
Disclosure: Idera Pharmceuticals, 5<br />
Martinez-Lavin, Manuel, MD<br />
Fibromyalgia . . . . . . . . . . . . . . . . . . 57<br />
Disclosure: Nothing to Disclose<br />
Massarotti, Elena M, MD<br />
Systemic Lupus Erythematosus: Difficult to Treat<br />
Systemic Lupus Erythematosus . . . . . . . 97<br />
Disclosure: Cypress Bioscience, 9; EMD Serono,<br />
9; Human Genome Sciences, 5; NIH Ace Grant--<br />
Subcontract, 9; Up to Date, 9<br />
Matteson, Eric L, MD<br />
Infections in Patients on Tumor Necrosis Factor<br />
Therapy . . . . . . . . . . . . . . . . . 56, 130<br />
Disclosure: ACR/EULAR, 2; biogen-idec, 2;<br />
centocor, 2; Centocor, 5; genentec, 2; h<strong>of</strong>fmanlarouche,<br />
2; human genome sciences, 2; mayo<br />
foundation, 2; NIH, 2; novartis, 2; pfizer, 2; UCB, 2<br />
Interstitial Lung Diseases in the Rheumatic<br />
Diseases . . . . . . . . . . . . . . . . . . . .109<br />
Disclosure: ACR/EULAR, 2; biogen-idec, 2;<br />
centocor, 2; Centocor, 5; genentec, 2; h<strong>of</strong>fmanlarouche,<br />
2; human genome sciences, 2; mayo<br />
foundation, 2; NIH, 2; novartis, 2; pfizer, 2; UCB, 2<br />
Polymyalgia Rheumatica . . . . . . . . . . . 91<br />
Disclosure: ACR/EULAR, 2; biogen-idec, 2;<br />
centocor, 2; Centocor, 5; genentec, 2; h<strong>of</strong>fmanlarouche,<br />
2; human genome sciences, 2; mayo<br />
foundation, 2; NIH, 2; novartis, 2; pfizer, 2; UCB,<br />
2; Mauri, Claudia, PhD<br />
B cell Effectors and Regulators . . . . . . . 113<br />
Disclosure: Nothing to Disclose<br />
Mayes, Maureen D, MD, MPH<br />
Systemic Sclerosis: How to Perform Skin<br />
Scores . . . . . . . . . . . . . . . . . . . . . 76<br />
Disclosure: Nothing to Disclose<br />
McCarthy, Geraldine M, MD<br />
Crystal: Pseudogout . . . . . . . . . . . . . . 64<br />
Disclosure: Nothing to Disclose<br />
McInnes, Iain B, PhD<br />
Curbside Consults - Ask the Pr<strong>of</strong>essors . . . 62<br />
Disclosure: BMS, 2, 5; Pfizer, 2; Roche, 2;<br />
Schering Plough, 2, 8<br />
McLean, Robert R, DSc, MPH<br />
Finding and Using Secondary Data Resources<br />
for Research: Beyond the National Health and<br />
Nutrition Examination Survey and the Usual<br />
Suspects . . . . . . . . . . . . . . . . . . . 103<br />
Disclosure: Nothing to Disclose<br />
How to Understand and Apply the Results <strong>of</strong> a<br />
Journal Article: What You Really Need to Know<br />
About Statistics . . . . . . . . . . . . . . . .134<br />
Disclosure: Nothing to Disclose<br />
You’ve Got the Power: How to Use and Teach<br />
Statistical Power for Studies and Grants. . . 47<br />
Disclosure: Nothing to Disclose<br />
McLellan, Alastair R, MD<br />
Session I: The Essentials . . . . . . . . . . . 19<br />
Disclosure: Nothing to Disclose<br />
McMahan, Zsuzsanna H, MD<br />
Immunizations and Rheumatic Diseases - An<br />
Update . . . . . . . . . . . . . . . . . . . . . 37<br />
Disclosure: Nothing to Disclose<br />
Thieves’ Market: Show Me Your Best<br />
Cases . . . . . . . . . . . . . . . . . . . . . . 69<br />
Disclosure: Nothing to Disclose<br />
McNally, Bernadette, MS, PAC<br />
The Multidisciplinary Approach to Hereditary<br />
Periodic Fever Syndromes . . . . . . . . . . 58<br />
Disclosure: Nothing to Disclose<br />
Using Pharmacogenomics to Improve Therapy<br />
for Pediatric Patients . . . . . . . . . . . . . 96<br />
Disclosure: Nothing to Disclose<br />
Mease, Philip J, MD<br />
Psoriatic Disease: Clinical Spectrum and<br />
Comprehensive Treatment Strategies . . . . 69<br />
Disclosure: Abbott, Amgen, BiogenIDEC, BMS,<br />
Centocor, Genentech, Roche, Wyeth and Pfizer,<br />
2; Abbott, Amgen, BiogenIDEC, BMS, Centocor,<br />
Genentech, Roche, Wyeth, Pfizer, UCB, 5<br />
Disclosure: Abbott, Amgen, BiogenIDEC, BMS,<br />
Centocor, Genentech, Roche, Wyeth, Pfizer,<br />
UCB, 8<br />
Meffre, Eric, PhD<br />
Session IV: B Cell Regulation and B Cell<br />
Regulators . . . . . . . . . . . . . . . . . . . 23<br />
Disclosure: Nothing to Disclose<br />
B cell Effectors and Regulators . . . . . . . 113<br />
Disclosure: Nothing to Disclose<br />
Melton, Alton, MD<br />
Immunodeficiency Syndromes . . . . . . . . 52<br />
Disclosure: Nothing to Disclose<br />
Merkel, Peter A, MD, MPH<br />
Vasculitis: Update . . . . . . . . . . . . . 65, 97<br />
Disclosure: Biovitrum, 5; Bristol Myers Squibb,<br />
2; Celgene, 2; EMD Serono, 5; Genentech, 2;<br />
Genzyme, 5; Nordic Group, 5; Novartis, 5; Smith<br />
Kline Beecham, 5<br />
Takayasu’s Arteritis . . . . . . . . . . . . . .112<br />
Disclosure: Biovitrum, 5; Bristol Myers Squibb,<br />
2; Celgene, 2; EMD Serono, 5; Genentech, 2;<br />
Genzyme, 5; Nordic Group, 5; Novartis, 5; Smith<br />
Kline Beecham, 5
Meroni, Pierluigi, MD<br />
Autoantibodies in Diagnosis and Follow Up <strong>of</strong><br />
Rheumatic Diseases . . . . . . . . . . . . . . 87<br />
Disclosure: Nothing to Disclose<br />
Mevorach, Dror, MD<br />
Cell Death: Receptors, Sensors and<br />
Inflammatory Pathways. . . . . . . . . . . .114<br />
Disclosure: Enlivex, 1, 3<br />
Milette, Katherine, BSc<br />
Measure by Measure: Assessing Psychological<br />
Health and Well-Being in Scleroderma . . .135<br />
Disclosure: Nothing to Disclose<br />
Miller, Donald R, PharmD<br />
Putting ACR Osteoarthritis Guidelines into<br />
Practice: Clinical Applications for the Hip and<br />
Knee . . . . . . . . . . . . . . . . . . . . . .142<br />
Disclosure: Nothing to Disclose<br />
Miller, Frederick W, MD, PhD<br />
Myositis 2010: A to Z . . . . . . . . . . . . . 98<br />
Disclosure: Nothing to Disclose<br />
Myositis . . . . . . . . . . . . . . . . . . . .110<br />
Disclosure: Nothing to Disclose<br />
Moanna, Abeer, MD<br />
Clinicopathologic Conference . . . . . . . . 55<br />
Disclosure: Nothing to Disclose<br />
Moen, Laura K, PhD<br />
News from the National Institutes <strong>of</strong> Health:<br />
Updates and Opportunities. . . . . . . . . . 56<br />
Disclosure: Nothing to Disclose<br />
Monrad, Seetha U, MD<br />
Labs and Treatment Options: What Do They<br />
Mean and How Do You Use? . . . . . . . . 131<br />
Disclosure: Nothing to Disclose<br />
Moreland, Larry W, MD<br />
Rheumatoid Arthritis: Biological Agents. . . 96<br />
Disclosure: Nothing to Disclose<br />
Morgan, Matthew W, MD<br />
Transforming Rheumatologic Care with the<br />
Electronic Health Record . . . . . . . . . . . 30<br />
Disclosure: Courtyard Group, 3, 4<br />
Morgan DeWitt, Esi M, MD, MSCE<br />
Session II: Applications to Musculoskeletal<br />
Medicine . . . . . . . . . . . . . . . . . . . . 19<br />
Disclosure: Nothing to Disclose<br />
Morrison, William, MD<br />
Musculoskeletal Imaging . . . . . . . . . . 113<br />
Disclosure: Apriomed, inc, 5; Oni, Inc(GE), 9<br />
Muller-Ladner, Ulf, MD<br />
Neuro Endocrine Immunology . . . . . . . . 91<br />
Disclosure: German Research Foundation (DFG), 2<br />
From Fat to Joints - The Vicious Side <strong>of</strong><br />
Adipokines . . . . . . . . . . . . . . . . . . . 98<br />
Disclosure: German Research Foundation (DFG), 2<br />
Murphy, Susan L, ScD, OTR<br />
Ready, Aim, Get Funded! . . . . . . . . . . 131<br />
Disclosure: Nothing to Disclose<br />
Murray, David M, PhD<br />
Session I: The Essentials . . . . . . . . . . . 19<br />
Disclosure: Nothing to Disclose<br />
Myers, Jennifer S, MD<br />
Diagnostic Errors in <strong>Rheumatology</strong>: Why They<br />
Happen and How We Can Avoid Them . . . 67<br />
Disclosure: Nothing to Disclose<br />
N<br />
Naredo, Esperanza, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 18<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Nothing to Disclose<br />
Newman, Eric D, MD<br />
Session II: Applications to Musculoskeletal<br />
Medicine . . . . . . . . . . . . . . . . . . . . 19<br />
Disclosure: Nothing to Disclose<br />
Newman, Stanton P, PhD<br />
Successful Coping with Rheumatic Disease . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . .135<br />
Disclosure: Nothing to Disclose<br />
Nigrovic, Peter A, MD<br />
Pediatric <strong>Rheumatology</strong> for Adult<br />
Rheumatologists. . . . . . . . . . . . . . . . 57<br />
Disclosure: Nothing to Disclose<br />
Nishio, Midori Jane, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: Abbott, 8<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Abbott, 8<br />
Nola, Kamala M, PharmD, MS<br />
From Managed Care to Medicare:<br />
Understanding Reimbursement . . . . . . . 75<br />
Disclosure: Nothing to Disclose<br />
Rehabilitation in the Age <strong>of</strong> Biologics . . . . 54<br />
Disclosure: Nothing to Disclose<br />
O<br />
Oatis, Carol A, PT, PhD<br />
Evidence-based Non-pharmacological Treatment<br />
for Hip, Knee, and Hand Osteoarthritis: The New<br />
ACR Guidelines . . . . . . . . . . . . . . . . 34<br />
Disclosure: Nothing to Disclose<br />
Putting ACR Osteoarthritis Guidelines into<br />
Practice: Clinical Applications for the Hip and<br />
Knee . . . . . . . . . . . . . . . . . . . . . .142<br />
Disclosure: Nothing to Disclose<br />
Oddis, Chester V, MD<br />
Inflammatory Myopathy Update. . . . . . . 77<br />
Disclosure: Nothing to Disclose<br />
Myositis 2010: A to Z . . . . . . . . . . . . . 98<br />
Disclosure: Nothing to Disclose<br />
O’Dell, James R, MD<br />
ACR Leadership Town Hall Meeting . . . . .106<br />
Disclosure: Nothing to Disclose<br />
Oeser, Annette M, BS<br />
Web-based Support <strong>of</strong> Clinical Practice and<br />
Teaching: Twittering, Blogging, and Doing the<br />
Wiki. . . . . . . . . . . . . . . . . . . . . . .120<br />
Disclosure: Nothing to Disclose<br />
You’ve Got the Power: How to Use and Teach<br />
Statistical Power for Studies and Grants. . . 47<br />
Disclosure: Nothing to Disclose<br />
Olech, Ewa, MD<br />
Peripheral Magnetic Resonance Imaging in<br />
Clinical <strong>Rheumatology</strong> . . . . . . . . . . . . 38<br />
Disclosure: Biogen Idec, 2; Bio-rad, 2<br />
Olech, Ewa, MD<br />
Peripheral Magnetic Resonance Imaging in<br />
Clinical <strong>Rheumatology</strong> . . . . . . . . . . . . 62<br />
Disclosure: Centocor, 2; Crescendo, 2;<br />
Genentech, 2, 5, 8; Pfizer, 5; Roche, 2; UCB, 2, 8;<br />
Vertex, 2<br />
Olenginski, Thomas P, MD<br />
Osteoporosis: Applying FRAX Methodology. 64<br />
Disclosure: Eli Lilly, Inc2, 5; Pfizer, Forest, Abbott,<br />
Novartis, Amgen,Sanogi-Aventis, Procter and<br />
Gamble, Genentech, 8; Roche, Genentech, 2<br />
Oliver, Susan M, RN, MSc<br />
Reproductive and Sexual Health Issues for<br />
Women with Rheumatic Disease. . . . . . . 54<br />
Disclosure: Nothing to Disclose<br />
O’Neil, Kathleen M, MD<br />
Juvenile Dermatomyositis in 2010 - From Bench<br />
to Bedside . . . . . . . . . . . . . . . . . . . 31<br />
Disclosure: Nothing to Disclose<br />
New Insights into Primary Central Nervous<br />
System Vasculitis in Children<br />
. . . . . . . . . . . . . . . . . . . . . . . . .133<br />
Disclosure: Nothing to Disclose<br />
O’Neill, Luke A, PhD<br />
Cell Death: Receptors, Sensors and<br />
Inflammatory Pathways. . . . . . . . . . . .114<br />
Disclosure: Nothing to Disclose<br />
Toll-like Receptors and Inflammation: Towards<br />
Innovative Treatment <strong>of</strong> Rheumatoid Arthritis<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Disclosure: Nothing to Disclose<br />
Opava, Christina H, PhD<br />
Patient Participation in Research. . . . . . .119<br />
Disclosure: Nothing to Disclose<br />
Patient Perspective on Outcomes: Patients as<br />
Partners in the Research Process . . . . . .111<br />
Disclosure: Nothing to Disclose<br />
What’s New and Noteworthy in 2010: A<br />
Review <strong>of</strong> <strong>Rheumatology</strong> Research for Health<br />
Pr<strong>of</strong>essionals. . . . . . . . . . . . . . . . . . 76<br />
Disclosure: Nothing to Disclose<br />
O’Rourke, Kenneth S, MD<br />
Teaching and Assessing Arthrocentesis . . 112<br />
Disclosure: Nothing to Disclose<br />
Joint Injection Techniques . . . . . . . . . .113<br />
Disclosure: Nothing to Disclose<br />
O’Shea, John J, MD<br />
Kinases as Therapeutic Targets. . . . . . . . 59<br />
Disclosure: Pfizer, 9<br />
Østergaard, Mikkel, MD, PhD, DMSc<br />
MRI . . . . . . . . . . . . . . . . . . . . . . . 91<br />
Disclosure: Nothing to Disclose<br />
Peripheral Magnetic Resonance Imaging in<br />
<strong>Rheumatology</strong> Practice . . . . . . . . . . . . 33<br />
Disclosure: Nothing to Disclose<br />
Overman, Steven S, MD, MPH<br />
CAM is a SCAM! Complementary and<br />
Alternative “Medicince” Has No Place in<br />
<strong>Rheumatology</strong> . . . . . . . . . . . . . . . . . 46<br />
Disclosure: Nothing to Disclose<br />
Oyoo, Omondi G, MD, MMed<br />
ILAR Global Health Project . . . . . . . . . . 84<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book 309<br />
INVITED SPEAKER /MODERATOR INDEX
INVITED SPEAKER /MODERATOR INDEX<br />
P<br />
Paget, Stephen A, MD<br />
Giant Cell Arteritis - Diagnosis<br />
and Therapy . . . . . . . . . . . . . . . . . . 69<br />
Disclosure: Nothing to Disclose<br />
REF Marshall J. Schiff, MD, Memorial<br />
Lectureship: Everything a Rheumatologist<br />
Should Know About Spine Surgery but Was<br />
Afraid to Ask . . . . . . . . . . . . . . . . . . 84<br />
Disclosure: Nothing to Disclose<br />
Paiva, Eduardo S, MD<br />
When Pieces Don’t Fit . . . . . . . . . . . .120<br />
Disclosure: Apsen Brazil, 5; Eli Lilly Brazil, 8;<br />
Pfizer Brazil, 8<br />
Passo, Murray H, MD<br />
Pediatrics: Difficult to Treat Juvenile Idiopathic<br />
Arthritis . . . . . . . . . . . . . . . . . . . . 29<br />
Disclosure: Pfizer, 2, 5<br />
Pennington, Scott D, MD<br />
Total Shoulder Arthroplasty and Reverse Total<br />
Shoulder Arthroplasty: Surgery<br />
and Rehabilitation. . . . . . . . . . . . . . .147<br />
Disclosure: Nothing to Disclose<br />
Perez-Masuelli, Carmen, MD<br />
The Ideal <strong>Rheumatology</strong> Practice . . . . . .104<br />
Disclosure: Nothing to Disclose<br />
Perlman, Harris R, PhD<br />
Innate Immunity and Inflammation . . . . . 30<br />
Disclosure: Nothing to Disclose<br />
Phillips, Kristine, MD, PhD<br />
Disparities and Pain: Examining Research,<br />
Practice and Policy . . . . . . . . . . . . . . 95<br />
Disclosure: Nothing to Disclose<br />
Interstitial Lung Diseases in the Rheumatic<br />
Diseases . . . . . . . . . . . . . . . . . . . .109<br />
Disclosure: Nothing to Disclose<br />
Pierangeli, Silvia S, PhD<br />
Antiphospholipid Syndrome . . . . . . . . . 87<br />
Disclosure: Nothing to Disclose<br />
Pillai, Shiv, MD, PhD<br />
Session I: B cell Development . . . . . . . . 20<br />
Disclosure: Nothing to Disclose<br />
Pincus, Theodore, MD<br />
WK - Patient Questionnaires to Monitor Status<br />
and Document Improvement in Standard Care:<br />
Practical Considerations . . . . . . . . . . .102<br />
Disclosure: Nothing to Disclose<br />
Clinical Research Methodology . . . . . . .107<br />
Disclosure: Nothing to Disclose<br />
Pisetsky, David S, MD, PhD<br />
From Fat to Joints - The Vicious Side <strong>of</strong><br />
Adipokines . . . . . . . . . . . . . . . . . . . 98<br />
Disclosure: Nothing to Disclose<br />
Plaas, Anna H, PhD<br />
Molecular Mechanisms <strong>of</strong> Inflammatory<br />
Signaling in Cartilage Destruction . . . . . . 27<br />
Disclosure: Pfizer, 2; Smith Nephew, 2<br />
Osteoarthritis . . . . . . . . . . . . . . . . .110<br />
Disclosure: Pfizer Inc, 2; Smith Nephew, 2<br />
Plass, Nicole D, BSN, MPA<br />
The Multidisciplinary Approach to Hereditary<br />
Periodic Fever Syndromes . . . . . . . . . . 58<br />
Disclosure: Nothing to Disclose<br />
Pollock, P. Scott MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: TBA<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: TBA<br />
Poole, Janet L, PhD, OTR<br />
Adaptations and Solutions to Help People with<br />
Scleroderma Continue to Work . . . . . . .102<br />
Disclosure: <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />
Research Education Foundation, 2<br />
Measure by Measure: Assessing Psychological<br />
Health and Well-Being in Scleroderma . . .135<br />
Disclosure: <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />
Research Education Foundation, 2<br />
Practice Potpourri . . . . . . . . . . . . . . . 86<br />
Disclosure: <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />
Research Education Foundation, 2<br />
ARHP General Session I - Keynote<br />
Address. . . . . . . . . . . . . . . . . . . . . 32<br />
Disclosure: <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />
Research Education Foundation, 2<br />
ARHP General Session II: ARHP Distinguished<br />
Lecturer . . . . . . . . . . . . . . . . . . . . 62<br />
Disclosure: <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />
Research Education Foundation, 2<br />
Moderators Orientation . . . . . . . . . . . 27<br />
Disclosure: <strong>American</strong> <strong>College</strong> <strong>of</strong> <strong>Rheumatology</strong><br />
Research Education Foundation, 2<br />
Pope, Janet E, MD, MPH<br />
Raynaud’s and Digital Ischemia . . . . 65, 105<br />
Disclosure: Actelion, 2, 5; Mediquest, 5; Pfizer,<br />
5; UT, 2<br />
Pope, Richard M, MD<br />
Toll-like Receptors and Inflammation: Towards<br />
Innovative Treatment <strong>of</strong> Rheumatoid Arthritis<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Disclosure: Nothing to Disclose<br />
Porter, Duncan, MD<br />
Rheumatoid Arthritis Treatment 2010:<br />
Traditional DMARDs, Biologic DMARDs and<br />
Newer Treatment Strategies . . . . . . . . 114<br />
Disclosure: Abbott, 5, 8; Pfizer, 2; Roche, 2, 5;<br />
Schering Plough, 5, 8; UCB, 5; Wyeth, 2<br />
Pruijn, Ger, PhD<br />
The Biology <strong>of</strong> Citrullination . . . . . . . . . 68<br />
Disclosure: Nothing to Disclose<br />
R<br />
Radbruch, Andreas H, PhD<br />
Session II: B cell Activation and<br />
Trafficking . . . . . . . . . . . . . . . . . . . 20<br />
Disclosure: Nothing to Disclose<br />
Radstake, Timothy RDJ, MD, PhD<br />
Toll-like Receptors and Inflammation: Towards<br />
Innovative Treatment <strong>of</strong> Rheumatoid Arthritis<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Disclosure: Nothing to Disclose<br />
Scleroderma-Biomarkers . . . . . . . . . . 111<br />
Disclosure: Nothing to Disclose<br />
Randall, Troy, PhD<br />
Session III: B cells in the Immune Response. 23<br />
Disclosure: Vaccinex, 2<br />
Rap<strong>of</strong>f, Michael A, PhD<br />
Daltroy Memorial Lecture: Adherence to<br />
Medical Regimens for Rheumatic Diseases<br />
and the Importance <strong>of</strong> Patient-Clinician<br />
Communication . . . . . . . . . . . . . . . . 61<br />
Disclosure: Nothing to Disclose<br />
ARHP Networking at Noon . . . . . . . . . . 63<br />
Disclosure: Nothing to Disclose<br />
Rawlings, David J, MD<br />
Session II: B cell Activation and Trafficking . 20<br />
Disclosure: Nothing to Disclose<br />
Ray, Laura E, MA, MLS<br />
Web-based Support <strong>of</strong> Clinical Practice and<br />
Teaching: Twittering, Blogging, and Doing the<br />
Wiki. . . . . . . . . . . . . . . . . . . . . . .120<br />
Disclosure: Nothing to Disclose<br />
ARHP Networking at Noon . . . . . . . . . . 64<br />
Disclosure: Nothing to Disclose<br />
Raza, Karim, BA, PhD<br />
The Preclinical Stage <strong>of</strong> Rheumatoid Arthritis:<br />
Towards Prevention <strong>of</strong> Disease? . . . . . . . 76<br />
Disclosure: Cellzome, 2; UCB, 2, 5; Wyeth, 2<br />
Reed, Ann M, MD<br />
Juvenile Dermatomyositis in 2010 - From Bench<br />
to Bedside . . . . . . . . . . . . . . . . . . . 31<br />
Disclosure: Nothing to Disclose<br />
Reiff, Andreas O, MD<br />
Inflammatory Eye Disease . . . . . . . . . . 35<br />
Disclosure: AMGEN, PFIZER, ABBOTT, MERCK, 8<br />
Integrating Immunology and Biologics into<br />
Clinical Practice . . . . . . . . . . . . . . . . 26<br />
Disclosure: AMGEN, PFIZER, ABBOTT, MERCK, 8<br />
Richardson, Bruce C, MD, PhD<br />
The Revolution <strong>of</strong> Epigenetics in<br />
Autoimmunity . . . . . . . . . . . . . . . . . 47<br />
Disclosure: Nothing to Disclose<br />
Rider, Lisa G, MD<br />
Practice Potpourri . . . . . . . . . . . . . . . 86<br />
Disclosure: Nothing to Disclose<br />
Myositis . . . . . . . . . . . . . . . . . . . .110<br />
Disclosure: Nothing to Disclose<br />
Ridley, David J, MD<br />
The Ideal <strong>Rheumatology</strong> Practice . . . . . .104<br />
Disclosure: BMS, 2; Celgene, 2; Centacor, 2;<br />
Genentech, 2; UCB, 2<br />
Rigby, William F. C, MD<br />
ACR REF Within Our Reach: Finding a Cure for<br />
Rheumatoid Arthritis . . . . . . . . . . . . . 45<br />
Disclosure: Nothing to Disclose<br />
Riskind, Peter, MD, PhD<br />
Update on Multiple Sclerosis. . . . . . . . . 59<br />
Disclosure: Biogen idec, 5; Teva, 5, 9<br />
Rock, Kenneth L, MD<br />
Cell Death: Receptors, Sensors and<br />
Inflammatory Pathways. . . . . . . . . . . .114<br />
Disclosure: San<strong>of</strong>i-Aventis, 2<br />
Roediger, Joan M, JD, LLM<br />
Contract Negotiations for Physicians . . . . 65<br />
Disclosure: Nothing to Disclose<br />
310<br />
2010 Program Book
Rogers, Joan C, PhD, OTR/ L<br />
Understanding Functional Activity in<br />
Rheumatoid Arthritis: What We Know and What<br />
We Don’t Know . . . . . . . . . . . . . . . . 86<br />
Disclosure: Nothing to Disclose<br />
Rose, Carlos D, MD<br />
Pediatric Spondylarthropathies: From Genetics<br />
to the Clinic . . . . . . . . . . . . . . . . . .136<br />
Disclosure: Nothing to Disclose<br />
ILAR Global Health Project . . . . . . . . . . 84<br />
Disclosure: Nothing to Disclose<br />
Rosenbaum, James T, MD<br />
Molecular Mechanisms <strong>of</strong> Ocular<br />
Inflammation . . . . . . . . . . . . . . . . .121<br />
Disclosure: Nothing to Disclose<br />
Rosenzweig, Holly L, PhD<br />
Molecular Mechanisms <strong>of</strong> Ocular<br />
Inflammation . . . . . . . . . . . . . . . . .121<br />
Disclosure: Nothing to Disclose<br />
Roth, Johannes, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 18<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . 22Disclosure:<br />
Nothing to Disclose<br />
Imaging. . . . . . . . . . . . . . . . . . . . .108<br />
Disclosure: Nothing to Disclose<br />
Roth-Wojcicki, Elizabeth L, RN MS CPNP<br />
Integrating Immunology and Biologics into<br />
Clinical Practice . . . . . . . . . . . . . . . . 25<br />
Disclosure: Nothing to Disclose<br />
Roubey, Robert A. S, MD<br />
Antiphospholipid Syndrome . . . . . . . . . 56<br />
Disclosure: Quest Diagnostics, 5<br />
Ruderman, Eric M, MD<br />
The Great Debate: Is it Time to Use Biologics as<br />
First-line Therapy in Rheumatoid Arthritis? . 39<br />
Disclosure: Nothing to Disclose<br />
Update on Safety Issues in the Treatment <strong>of</strong><br />
Rheumatic Diseases – From the Food and Drug<br />
Administration and Beyond . . . . . . . . . 77<br />
Disclosure: Nothing to Disclose<br />
Methotrexate 2010 . . . . . . . . . . . . . . 55<br />
Disclosure: Nothing to Disclose<br />
Ruffing, Victoria L, RN<br />
Patient Education on the Run . . . . . . . . 95<br />
Disclosure: Nothing to Disclose<br />
Rye, Kerry-Anne, PhD<br />
A Critical Role for Lipid Metabolism in the<br />
Interplay between Atherosclerosis and<br />
Autoimmune Disorders . . . . . . . . . . . .121<br />
Disclosure: Nothing to Disclose<br />
S<br />
Saag, Kenneth G, MD, MSc<br />
Welcome and Introductions . . . . . . . . . 19<br />
Disclosure: Amgen, 5, 8; AstraZenica, 5; Eli Lilly,<br />
5; Genentech, 5; GlaxoSmithKline, 5; Merck,<br />
5; NicOx, 5; Nitec, 5; Novartis, 5, 8; Pfizer, 5;<br />
Proctor & Gamble, 5; Takeda, 5; UCB, 5<br />
Curbside Consults - Ask the Pr<strong>of</strong>essors . . . 62<br />
Disclosure: Amgen, 5, 8; AstraZenica, 5; Eli Lilly,<br />
5; Genentech, 5; GlaxoSmithKline, 5; Merck, 5;<br />
NicOx, 5; Nitec, 5; Novartis, 5, 8; Pfizer, 5<br />
Proctor & Gamble, 5; Takeda, 5; UCB, 5<br />
Salmon, Jane E, MD<br />
Antiphospholipid Syndrome . . . . . . . . . 87<br />
Disclosure: Nothing to Disclose<br />
Salt, Elizabeth G, PhD, ARNP<br />
Juvenile Fibromyalgia . . . . . . . . . . . . . 53<br />
Disclosure: Nothing to Disclose<br />
Samuels, Jonathan, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 18<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Nothing to Disclose<br />
Sanchez-Guerrero, F. Jorge, MD<br />
The Brain and Systemic Lupus Erythematosus:<br />
2010 Update (Clinical Review) . . . . . . . . 66<br />
Disclosure: Nothing to Disclose<br />
Systemic Lupus Erythematosus: Central Nervous<br />
System . . . . . . . . . . . . . . . . . . 52, 106<br />
Disclosure: Nothing to Disclose<br />
Sandborg, Christy I, MD<br />
The Changing Face <strong>of</strong> the <strong>Rheumatology</strong><br />
Workforce: Gender Issues in the Workplace<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 94<br />
Disclosure: Nothing to Disclose<br />
Sanz, Inaki, MD<br />
Session III: B cells in the Immune<br />
Response. . . . . . . . . . . . . . . . . . . . 23<br />
Disclosure: Biogen, 2; GSK, 2, 5<br />
Scalapino, Kenneth J, MD<br />
Iatrogenic Misadventures: Complex Cases . 85<br />
Disclosure: Nothing to Disclose<br />
Scanzello, Carla R, MD, PhD<br />
Osteoarthritis . . . . . . . . . . . . . . . . .110<br />
Disclosure: Amgen, 9<br />
Schlenk, Elizabeth A, PhD, RN<br />
What’s New and Noteworthy in 2010: A Review<br />
<strong>of</strong> <strong>Rheumatology</strong> Research for Health<br />
Pr<strong>of</strong>essionals. . . . . . . . . . . . . . . . . . 76<br />
Disclosure: Nothing to Disclose<br />
ARHP Networking at Noon . . . . . . . . . . 64<br />
Disclosure: Nothing to Disclose<br />
Schlesinger, Naomi, MD<br />
Crystallizing Your Assessment and Treatment <strong>of</strong><br />
Difficult to Treat Gout . . . . . . . . . . . . .114<br />
Disclosure: Novartis, 2, 5;Takeda, 8; URL<br />
Pharma, 9<br />
Schmidt, Wolfgang A, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists-Day One . . . . . . . . . . 18<br />
Disclosure: Abbott, 2; Abbott, 8; Actelion, 2,<br />
8; Berlin Chemie, 8; BMS, 2, 8; Chugai, 2, 8;<br />
Esaote, 2, 8; Essex, 2, 8; GE, 2; Lilly, 2; Medac,<br />
2, 8; Merck, 8; MSD, 2, 8; Novartis, 2, 8; Pfizer,<br />
2, 8; Roche, 2, 8; Schering - Plough, 2, 8; UCB, 2;<br />
Wyeth, 2, 8<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Abbott, 2, 8; Actelion, 2, 8; Berlin<br />
Chemie, 8; BMS, 2, 8; Chugai, 2, 8; Esaote, 2, 8;<br />
Essex, 2, 8; GE, 2; Lilly, 2; Medac, 2, 8; Merck, 8;<br />
MSD, 2, 8; Novartis, 2, 8; Pfizer, 2, 8; Roche, 2, 8;<br />
Schering - Plough, 2, 8; UCB, 2; Wyeth, 2, 8<br />
Schneider, Rayfel, MBBCh<br />
Still’s Disease, Febrile Illnesses . . . . . . . . 83<br />
Disclosure: H<strong>of</strong>fman-La Roche, 5<br />
Schnitzer, Thomas J, MD, PhD<br />
Osteoarthritis - What is New in Old Joints .122<br />
Disclosure: AstraZeneca, 9; Eli Lilly & Co., 5;<br />
Logical Therapeutics, 5; NicOx, 1, 5; Nordic<br />
Bioscience, 2; Pfizer, 2<br />
Seo, Philip, MD<br />
Treatment <strong>of</strong> Wegener’s Granulomatosis/<br />
Microscopic Polyangiitis: Understanding and<br />
Applying the Data from Recent Clinical Trials . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 48<br />
Disclosure: Nothing to Disclose<br />
Serre, Guy B, MD, PhD<br />
The Biology <strong>of</strong> Citrullination . . . . . . . . . 68<br />
Disclosure: bioMérieux (FRANCE), 7<br />
Shadick, Nancy A, MD, MPH<br />
Rheumatoid Arthritis: Difficult Cases . . . .130<br />
Disclosure: AMGEN, 2; Biogen Idec, 2; Crescendo<br />
Biosciences, 2<br />
Rheumatoid Arthritis: Difficult Rheumatoid<br />
Arthritis . . . . . . . . . . . . . . . . . . . . 29<br />
Disclosure: AMGEN, 2; Biogen Idec, 2; Crescendo<br />
Biosciences, 2<br />
Shakoor, Najia, MD<br />
Osteoarthritis - What is New in Old Joints .122<br />
Disclosure: Nothing to Disclose<br />
Shen, Nan, MD<br />
B cell Effectors and Regulators . . . . . . . 113<br />
Disclosure: Nothing to Disclose<br />
Tolerogenic Dendritic Cells: Regulators <strong>of</strong><br />
Immune Reactivity and Therapeutic Agents in<br />
Autoimmune Disease . . . . . . . . . . . . 101<br />
Disclosure: Nothing to Disclose<br />
Sherry, David D, MD<br />
Career Opportunities in <strong>Rheumatology</strong>: Making<br />
a Choice . . . . . . . . . . . . . . . . . . . .112<br />
Disclosure: Nothing to Disclose<br />
Shulman, Neil, MD<br />
ARHP General Session I - Keynote Address . 32<br />
Disclosure: Nothing to Disclose<br />
Silver, Richard M, MD<br />
Systemic Sclerosis: New Therapeutic<br />
Approaches . . . . . . . . . . . . . . . . . .122<br />
Disclosure: Boehringer Ingelheim, 2<br />
Silverman, Gregg J, MD<br />
Session V: Emerging Concepts in B cell Directed<br />
Therapies. . . . . . . . . . . . . . . . . . . . 23<br />
Disclosure: Neostasis, 5<br />
ACR REF Within Our Reach: Finding a Cure for<br />
Rheumatoid Arthritis . . . . . . . . . . . . . 45<br />
Disclosure: Neostasis, 5<br />
Silverman, Stuart L, MD<br />
Controversies in Osteoporosis and Low Bone<br />
Mass: Who Do We Treat, For How Long, and at<br />
What Risks? . . . . . . . . . . . . . . . . . .103<br />
Disclosure: Nothing to Disclose<br />
Osteoporosis: Interpreting Dual Energy X-ray<br />
Absorptiometry and Clinical Risk Factors: The<br />
New Fracture Risk Assessment Algorithm. . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . 33, 62<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book 311<br />
INVITED SPEAKER /MODERATOR INDEX
INVITED SPEAKER /MODERATOR INDEX<br />
312<br />
Silvers, J. B, PhD<br />
CORC Forum: Health Care Reform – Where Are<br />
We Heading?. . . . . . . . . . . . . . . . . .101<br />
Disclosure: Nothing to Disclose<br />
Simkin, Peter A, MD<br />
Crystal: Management <strong>of</strong> Gout . . . . . . . . 56<br />
Disclosure: Nothing to Disclose<br />
Simms, Robert W, MD<br />
Systemic Sclerosis: New Therapeutic<br />
Approaches . . . . . . . . . . . . . . . . . .122<br />
Disclosure: Nothing to Disclose<br />
Slusher, Barbara A, PA-C, MSW<br />
Networking at Noon . . . . . . . . . . . . . 64<br />
From Managed Care to Medicare:<br />
Understanding Reimbursement . . . . . . . 75<br />
Disclosure: Nothing to Disclose<br />
Smith, Benjamin J, PA-C<br />
Rheumatic Disease Update: Sjögren’s<br />
Syndrome . . . . . . . . . . . . . . . . . . . 58<br />
Disclosure: Amgen, 5; NicOx, 5; Pfizer, 5<br />
ARHP Networking Forum . . . . . . . . . . . 30<br />
Disclosure: Amgen, 5; NicOx, 5; Pfizer, 5<br />
Smolen, Josef S, MD<br />
Remission in Rheumatoid Arthritis. . . . . .135<br />
Disclosure: Abbott, Astra-Zeneca, BMS,<br />
Centocor, Novo, Roche, San<strong>of</strong>i-Aventis, Schering-<br />
Plough, UCB, Wyeth, 5; Abbott, BMS, Centocor,<br />
Roche, Schering-Plough, UCB, Wyeth, 9; Abbott,<br />
BMS, Roche, Schering-Plough, UCB, Wyeth, 2<br />
Rheumatoid Arthritis Treatment 2010:<br />
Traditional DMARDs, Biologic DMARDs and<br />
Newer Treatment Strategies . . . . . . . . 114<br />
Disclosure: Abbott, Astra-Zeneca, BMS,<br />
Centocor, Novo, Roche, San<strong>of</strong>i-Aventis, Schering-<br />
Plough, UCB, Wyeth, 5; Abbott, BMS, Centocor,<br />
Roche, Schering-Plough, UCB, Wyeth, 9; Abbott,<br />
BMS, Roche, Schering-Plough, UCB, Wyeth, 2<br />
Solomon, Daniel H, MD, MPH<br />
Session II: Applications to Musculoskeletal<br />
Medicine . . . . . . . . . . . . . . . . . . . . 19<br />
Disclosure: abbott, amgen, 2<br />
Rheumatoid Arthritis: Safety <strong>of</strong> Novel<br />
Therapies. . . . . . . . . . . . . . . . . . . . 65<br />
Disclosure: abbott, amgen, 2<br />
Somers, Emily C, PhD, ScM<br />
Top 10 in ‘10: Top 10 Public Health Advances<br />
in the First 10 Years <strong>of</strong> the Centers for Disease<br />
Control and Prevention Arthritis Program. .147<br />
Disclosure: Nothing to Disclose<br />
Specks, Ulrich, MD<br />
Clinicopathologic Conference . . . . . . . . 55<br />
Disclosure: Nothing to Disclose<br />
Treatment <strong>of</strong> Wegener’s Granulomatosis/<br />
Microscopic Polyangiitis: Understanding and<br />
Applying the Data from Recent Clinical Trials . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 48<br />
Disclosure: Nothing to Disclose<br />
Spiera, Robert, MD<br />
Giant Cell Arteritis - Diagnosis and Therapy. 69<br />
Disclosure: Nothing to Disclose<br />
Treatment <strong>of</strong> Wegener’s Granulomatosis/<br />
Microscopic Polyangiitis: Understanding and<br />
Applying the Data from Recent Clinical Trials<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 48<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book<br />
Srivastava, Sunil Kumar, MD<br />
Inflammatory Eye Disease/Uveitis . . . . . . 83<br />
Disclosure: Bausch and Lomb, 5<br />
St.Clair, E William, MD<br />
Session VI: Role <strong>of</strong> B cells in Autoimmunity:<br />
Lessons from Clinical Trials . . . . . . . . . . 23<br />
Disclosure: Genentech, 2<br />
ACR Leadership Town Hall Meeting . . . . .106<br />
Disclosure: Genentech, 2<br />
REF Edmond L. Dubois, MD, Memorial<br />
Lectureship . . . . . . . . . . . . . . . . . . 53<br />
Disclosure: Genentech, 2<br />
REF Paul Klemperer, MD, Memorial Lectureship:<br />
Systemic Sclerosis: Genetic? Autoimmune? One<br />
Disease? . . . . . . . . . . . . . . . . . . . . 98<br />
Disclosure: Genentech, 2<br />
Starz, Terence W, MD<br />
Understanding Functional Activity in<br />
Rheumatoid Arthritis: What We Know and What<br />
We Don’t Know . . . . . . . . . . . . . . . . 86<br />
Disclosure: Pfizer, 5<br />
Steen, Virginia D, MD<br />
Mixed Connective Tissue Disease is Not Really<br />
that Mixed . . . . . . . . . . . . . . . . . . . 23<br />
Disclosure: Nothing to Disclose<br />
Sterrett, Ashley G, MD<br />
Teaching and Assessing Arthrocentesis . . 112<br />
Disclosure: Nothing to Disclose<br />
Joint Simulator. . . . . . . . . . . . . . . 67, 97<br />
Disclosure: Nothing to Disclose<br />
Stevens, Anne M, MD, PhD<br />
Integrating Immunology and Biologics into<br />
Clinical Practice . . . . . . . . . . . . . . . . 25<br />
Disclosure: Nothing to Disclose<br />
Kawasaki Disease in the 21st Century - Genes,<br />
Pathogenesis, and Biologics . . . . . . . . . 90<br />
Disclosure: Nothing to Disclose<br />
Stone, John H, MD, MPH<br />
Session VI: Role <strong>of</strong> B cells in Autoimmunity:<br />
Lessons from Clinical Trials . . . . . . . . . . 23<br />
Disclosure: Nothing to Disclose<br />
Curbside Consults - Ask the Pr<strong>of</strong>essors . . . 62<br />
Disclosure: Nothing to Disclose<br />
Treatment <strong>of</strong> Wegener’s Granulomatosis/<br />
Microscopic Polyangiitis: Understanding and<br />
Applying the Data from Recent Clinical Trials<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 48<br />
Disclosure: Nothing to Disclose<br />
Suarez-Almazor, Maria E, MD, PhD<br />
Session I: The Essentials . . . . . . . . . . . 19<br />
Disclosure: Nothing to Disclose<br />
Sukumaran, Sukesh, MBBS, MD<br />
Inflammatory Eye Disease . . . . . . . . . . 35<br />
Disclosure: Nothing to Disclose<br />
Sulich, Andrew J, MD<br />
Hand X-ray Review and Interpretation. . . . 58<br />
Disclosure: Nothing to Disclose<br />
Symmons, Deborah P, MD<br />
Economic Evaluations . . . . . . . . . . . . . 88<br />
Disclosure: Nothing to Disclose<br />
Szekanecz, Zoltan, MD, PhD, DSC<br />
A Critical Role for Lipid Metabolism in the<br />
Interplay between Atherosclerosis and<br />
Autoimmune Disorders . . . . . . . . . . . .121<br />
Disclosure: Nothing to Disclose<br />
Szer, Ilona S, MD<br />
Pediatric Systemic Lupus . . . . . . . . . . . 52<br />
Disclosure: Nothing to Disclose<br />
T<br />
Tabechian, Darren, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 18<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two . . . . . . . . . 22<br />
Disclosure: Nothing to Disclose<br />
Tak, Paul P, MD, PhD<br />
The Preclinical Stage <strong>of</strong> Rheumatoid Arthritis:<br />
Towards Prevention <strong>of</strong> Disease? . . . . . . . 76<br />
Disclosure: Roche/Genentech, 2, 5<br />
Toll-like Receptors and Inflammation: Towards<br />
Innovative Treatment <strong>of</strong> Rheumatoid Arthritis<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Disclosure: NovImmune, 5<br />
Takayanagi, Hiroshi, MD, PhD<br />
REF Oscar S. Gluck, MD, Memorial Lectureship<br />
- Osteoimmunology: Crosstalk Between the<br />
Immune and Bone Systems: Biologic and Clinical<br />
Implications . . . . . . . . . . . . . . . . . . 28<br />
Disclosure: Nothing to Disclose<br />
Tall, Alan, MD<br />
A Critical Role for Lipid Metabolism in the<br />
Interplay between Atherosclerosis and<br />
Autoimmune Disorders . . . . . . . . . . . 121<br />
Disclosure: BI, 5; Merck, 5; Novartis, 5; Pfizer, 5;<br />
Roache, 5<br />
Talley, Anne Camille, MBA<br />
The Changing Face <strong>of</strong> the <strong>Rheumatology</strong><br />
Workforce: Gender Issues in the Workplace<br />
. . . . . . . . . . . . . . . . . . . . . . . . . 94<br />
Disclosure: Merck Telerx Division, 3; Schering<br />
Plough, 5; Various Investments in Stock & bond<br />
funds, 1<br />
Talmadge, W. Tracy, PhD<br />
Reproductive and Sexual Health Issues for<br />
Women with Rheumatic Disease. . . . . . . 54<br />
Disclosure: Nothing to Disclose<br />
Tan, Filemon K, MD, PhD<br />
Immunopathogenesis <strong>of</strong> Systemic Sclerosis. . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . .136<br />
Disclosure: Nothing to Disclose<br />
Taylor, Mihaela, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 18<br />
Disclosure: Nothing to Disclose<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Nothing to Disclose<br />
Tedder, Thomas, PhD<br />
Mouse to House: Lessons Learned About Lupus<br />
Therapeutics . . . . . . . . . . . . . . . . . . 39<br />
Disclosure: Angelica Therapeutics, Inc., 1, 5<br />
MedImmune, Inc., 5<br />
Session IV: B Cell Regulation and B Cell<br />
Regulators . . . . . . . . . . . . . . . . . . . 23<br />
Disclosure: Angelica Therapeutics, Inc., 1<br />
MedImmune, Inc., 5
Terkeltaub, Robert, MD<br />
Crystallizing Your Assessment and Treatment <strong>of</strong><br />
Difficult to Treat Gout . . . . . . . . . . . . .114<br />
Disclosure: Amgen Veterinary, 5; Anadys, 5;<br />
ARDEA, 5; BioCryst, 5; Celgene, 5; Metabolex,<br />
5; NIH, 2; Novartis, 5; Nuon, 5; Pfizer, 5;<br />
Prescription Solutions, 5; Regeneron, 5; Takeda,<br />
9; UCB, 5; URL, 5; VA, 2<br />
Tesser, John RP, MD<br />
Controversies in Osteoporosis and Low Bone<br />
Mass: Who Do We Treat, For How Long, and at<br />
What Risks? . . . . . . . . . . . . . . . . . .103<br />
Disclosure: Nothing to Disclose<br />
Scleroderma: The Promise <strong>of</strong> Anti-fibrotic<br />
Therapies - A Translational Approach . . . . 67<br />
Disclosure: Nothing to Disclose<br />
Theis, Kristina A, MPH<br />
Work Assessments: A ‘How-To’ That Could Save<br />
Your Patient’s Life/Job. . . . . . . . . . . . .131<br />
Disclosure: Nothing to Disclose<br />
Thiele, Ralf G, MD<br />
Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day One. . . . . . . . . . 17<br />
Disclosure: Abbott, 8; Amgen, 5; GE Healthcare,<br />
9; Novartis, 5; Pfizer, 8; Sonosite, 9; UCB, 5<br />
MSUS - Musculoskeletal Ultrasound Course for<br />
Rheumatologists - Day Two. . . . . . . . . . 22<br />
Disclosure: Abbott, 8; Amgen, 5; GE Healthcare,<br />
9; Novartis, 5; Pfizer, 8; Sonosite, 9; UCB, 5<br />
Psoriatic Arthritis and Periarticular Imaging:<br />
Focus on Enthesitis, Dactylitis, and Nail<br />
Disease . . . . . . . . . . . . . . . . . . . . . 92<br />
Disclosure: Abbott, 8; Amgen, 5; GE Healthcare,<br />
9; Novartis, 5; Pfizer, 8; Sonosite, 9; UCB, 5<br />
Thombs, Brett D, BA, MA, PhD<br />
Measure by Measure: Assessing Psychological<br />
Health and Well-Being in Scleroderma . . .135<br />
Disclosure: Nothing to Disclose<br />
Thomson, Angus W, PhD<br />
Tolerogenic Dendritic Cells: Regulators <strong>of</strong><br />
Immune Reactivity and Therapeutic Agents in<br />
Autoimmune Disease . . . . . . . . . . . . 101<br />
Disclosure: Nothing to Disclose<br />
Tietge, Uwe J. F, MD<br />
A Critical Role for Lipid Metabolism in the<br />
Interplay between Atherosclerosis and<br />
Autoimmune Disorders . . . . . . . . . . . .121<br />
Disclosure: Nothing to Disclose<br />
Tillman, Melesia<br />
Certified <strong>Rheumatology</strong> Coder Course . . . 20<br />
Disclosure: Nothing to Disclose<br />
Ting, Tracy V, MD<br />
Juvenile Fibromyalgia . . . . . . . . . . . . . 53<br />
Disclosure: Nothing to Disclose<br />
Torgerson, Troy R, MD, PhD<br />
Integrating Immunology and Biologics into<br />
Clinical Practice . . . . . . . . . . . . . . . . 25<br />
Disclosure: Nothing to Disclose<br />
Trizuto, Jennifer L, MPT<br />
Total Shoulder Arthroplasty and Reverse<br />
Total Shoulder Arthroplasty: Surgery and<br />
Rehabilitation . . . . . . . . . . . . . . . . .147<br />
Disclosure: Nothing to Disclose<br />
Troum, Orrin M, MD<br />
Peripheral Magnetic Resonance Imaging in<br />
Clinical <strong>Rheumatology</strong> . . . . . . . . . . 38, 62<br />
Disclosure: International Society <strong>of</strong> Extremity<br />
MRI in <strong>Rheumatology</strong>, 6; Intersocietal<br />
Commission for the Accrediation <strong>of</strong> MRI<br />
Laboratories, 6<br />
Troxell, Megan, MD<br />
Renal Histopathology in Systemic Lupus<br />
Erythematosus and Vasculitis . . . . . . 33, 47<br />
Disclosure: Nothing to Disclose<br />
Tse, Shirley, MD<br />
Pediatric Spondylarthropathies: From Genetics<br />
to the Clinic . . . . . . . . . . . . . . . . . .136<br />
Disclosure: Abbott, 5; Merck/Schering Plough,<br />
5; Wyeth, 5<br />
Pediatrics: Spondyloarthritis in Children . . 96<br />
Disclosure: Abbott, 5; Merck/Schering Plough,<br />
5; Wyeth, 5<br />
Tuan, Rocky S., PhD<br />
Stem Cell Reprogramming: Molecular<br />
Mechanisms and Clinical Applications and<br />
Implications . . . . . . . . . . . . . . . . . .102<br />
Disclosure: Nothing to Disclose<br />
Tyndall, Alan G, MD<br />
Systemic Sclerosis: New Therapeutic<br />
Approaches . . . . . . . . . . . . . . . . . .122<br />
Disclosure: Nothing to Disclose<br />
Scleroderma Mimics . . . . . . . . . . . . . 65<br />
Disclosure: Nothing to Disclose<br />
U<br />
Uknis, Audrey B, MD<br />
ACR Leadership Town Hall Meeting . . . . .106<br />
Disclosure: Nothing to Disclose<br />
V<br />
Valeriano-Marcet, Joanne, MD<br />
Rheumatic Manifestations <strong>of</strong> Neoplastic<br />
Diseases . . . . . . . . . . . . . . . . . . . . 24<br />
Disclosure: Nothing to Disclose<br />
Teaching and Assessing Arthrocentesis . . 112<br />
Disclosure: Nothing to Disclose<br />
Joint Simulator. . . . . . . . . . . . . . . 67, 97<br />
Disclosure: Nothing to Disclose<br />
van de Laar, Mart A, MD<br />
Successful Coping with Rheumatic Disease 135<br />
Disclosure: Nothing to Disclose<br />
Economic Evaluations . . . . . . . . . . . . . 88<br />
Disclosure: Nothing to Disclose<br />
Van den Bosch, Filip E, MD, PhD<br />
Bowel Associated Rheumatologic Diseases . 24<br />
Disclosure: Nothing to Disclose<br />
Van Der Heijde, Desiree M, MD, PhD<br />
Ankylosing Spondylitis: 2010 Update . 36, 105<br />
Disclosure: abbott, 5; amgen, 5; bristol meyers<br />
squibb, 5; centocor, 5; chugai, 5; msd, 5;<br />
novartis, 5; pfizer, 5; roche, 5; ucb, 5<br />
Van Lent, Peter, MD<br />
Molecular Mechanisms <strong>of</strong> Inflammatory<br />
Signaling in Cartilage Destruction . . . . . . 27<br />
Disclosure: Nothing to Disclose<br />
Varga, John, MD<br />
Scleroderma: The Promise <strong>of</strong> Anti-fibrotic<br />
Therapies - A Translational Approach . . . . 67<br />
Disclosure: BMS, 2; novartis, 2<br />
Villa-Forte, Alexandra, MD, MPH<br />
Heparin and Antiphospholipid Syndromeinduced<br />
Thrombocytopenia . . . . . . . . . 31<br />
Disclosure: Nothing to Disclose<br />
Vasculitis Mimics . . . . . . . . . . . . . . . 57<br />
Disclosure: Nothing to Disclose<br />
Villasenor Ovies, Pablo, MD<br />
<strong>Rheumatology</strong> Physical Examination <strong>of</strong> Lower<br />
Extremity and Lumbosacral Spine: Anatomical<br />
Correlates . . . . . . . . . . . . . . . . . . . 38<br />
Disclosure: Nothing to Disclose<br />
<strong>Rheumatology</strong> Physical Examination <strong>of</strong> Upper<br />
Extremity and Cervical Spine: Anatomical<br />
Correlates . . . . . . . . . . . . . . . . . . . 97<br />
Disclosure: Nothing to Disclose<br />
Vivino, Frederick B, MD<br />
Controversies in Sjogren’s Syndrome . . 28, 83<br />
Disclosure: Nothing to Disclose<br />
Vogler, Larry B, MD<br />
Pediatric Spondylarthropathies: From Genetics<br />
to the Clinic . . . . . . . . . . . . . . . . . .136<br />
Disclosure: Nothing to Disclose<br />
Von Feldt, Joan Marie, MD, MS Ed<br />
Diagnostic Errors in <strong>Rheumatology</strong>: Why They<br />
Happen and How We Can Avoid Them . . . 67<br />
Disclosure: Nothing to Disclose<br />
W<br />
Wallace, Carol A, MD<br />
Remission in Rheumatoid Arthritis. . . . . .137<br />
Disclosure: Nothing to Disclose<br />
Ward, Michael M, MD<br />
Finding and Using Secondary Data Resources<br />
for Research: Beyond the National Health and<br />
Nutrition Examination Survey and the Usual<br />
Suspects . . . . . . . . . . . . . . . . . . . 103<br />
Disclosure: Nothing to Disclose<br />
Ware, John, PhD<br />
Session I: The Essentials . . . . . . . . . . . 19<br />
Disclosure: Nothing to Disclose<br />
Wasko, Mary Chester<br />
ACR/ABIM Maintenance <strong>of</strong> Certification<br />
Learning Session -2010 Update . . . . . . . 21<br />
Disclosure: Nothing to Disclose<br />
Watcher, Sandra J, BSN<br />
Inflammatory Eye Disease . . . . . . . . . . 35<br />
Disclosure: Nothing to Disclose<br />
Teaching Our Pediatric Patients: Making the<br />
Complex Simple . . . . . . . . . . . . . . . 142<br />
Disclosure: Nothing to Disclose<br />
Integrating Immunology and Biologics into<br />
Clinical Practice . . . . . . . . . . . . . . . . 25<br />
Disclosure: Nothing to Disclose<br />
INVITED SPEAKER /MODERATOR INDEX<br />
2010 Program Book 313
INVITED SPEAKER /MODERATOR INDEX<br />
Watts, Nelson B, MD<br />
Controversies in Osteoporosis and Low Bone<br />
Mass: Who Do We Treat, For How Long, and at<br />
What Risks? . . . . . . . . . . . . . . . . . .103<br />
Disclosure: Amgen, 2, 5, 9; Baxter Healthcare,<br />
5; Eli-Lilly, 2; InteKrin, 5; Johnson & Johnson, 5;<br />
MannKind, 5; MedPace, 5; Merck, 2; Novartis,<br />
9; NPS, 2, 5; Pfizer, 5; Proctor & Gamble, 5, 9;<br />
san<strong>of</strong>i-aventis, 5, 9; Takeda Pharmaceuticals, 5;<br />
Warner Chilcott, 5, 9<br />
Weaver, Cynthia A, MD<br />
Recovery Audit Contractor vs. Comprehensive<br />
Error Rate Testing Audits – Do You Know the<br />
Difference?. . . . . . . . . . . . . . . . . . . 66<br />
Disclosure: Nothing to Disclose<br />
Wedderburn, Lucy R, MD, PhD<br />
Autologous Stem Cell Transplantation in<br />
Pediatric <strong>Rheumatology</strong>: Indications and<br />
Associated Morbidity . . . . . . . . . . . . . 68<br />
Disclosure: Nothing to Disclose<br />
Weinblatt, Michael E, MD<br />
Methotrexate 2010 . . . . . . . . . . . . . . 55<br />
Disclosure: cypress, 5<br />
Weisman, Michael H, MD<br />
Year in Review . . . . . . . . . . . . . . . . . 27<br />
Disclosure: Nothing to Disclose<br />
Epidemiology <strong>of</strong> Axial Spondyloarthritis. . . 88<br />
Disclosure: Nothing to Disclose<br />
Weissmann, Gerald, MD<br />
An Infectious Etiology <strong>of</strong> Rheumatoid<br />
Arthritis . . . . . . . . . . . . . . . . . . . . 26<br />
Disclosure: Nothing to Disclose<br />
Weitz, Howard H, MD<br />
Perioperative Management <strong>of</strong> Selected<br />
Problems in Patients with Rheumatic Disease .<br />
. . . . . . . . . . . . . . . . . . . . . . . . .122<br />
Disclosure: Nothing to Disclose<br />
Wener, Mark H, MD<br />
Labs and Treatment Options: What Do They<br />
Mean and How Do You Use? . . . . . . . . 131<br />
Disclosure: BioRad Laboratories, 9<br />
RC - <strong>Rheumatology</strong> Laboratory Testing: How it is<br />
Done and Why We Need to Know . . . . . . 24<br />
Disclosure: BioRad Laboratories, 9<br />
Wiener, Aimee, ARNP C, MSN<br />
Hand X-ray Review and Interpretation. . . . 58<br />
Disclosure: Nothing to Disclose<br />
Wigley, Fredrick M, MD<br />
Systemic Sclerosis: New Therapeutic<br />
Approaches . . . . . . . . . . . . . . . . . .122<br />
Disclosure: Actelion Pharmaceutical, 9;<br />
Bristol Myers-Squibb, 5; Novartis, 5; United<br />
Therapeutics, 9<br />
Williams, David A, PhD<br />
Disparities and Pain: Examining Research,<br />
Practice and Policy . . . . . . . . . . . . . . 95<br />
Disclosure: Nothing to Disclose<br />
Williams, John, PhD<br />
News from the National Institutes <strong>of</strong> Health:<br />
Updates and Opportunities. . . . . . . . . . 56<br />
Disclosure: Nothing to Disclose<br />
Winthrop, Kevin L, MD, MPH<br />
Iatrogenic Misadventures: Complex<br />
Cases . . . . . . . . . . . . . . . . . . . . . . 85<br />
Disclosure: Genentech, 5; Oxford Immunotech,<br />
2; Wyeth, 5<br />
Practice Potpourri . . . . . . . . . . . . . . . 86<br />
Disclosure: Genentech, 5; Oxford Immunotech,<br />
2; Wyeth, 5<br />
Wolpaw, Terry M, MD, MHPE<br />
ACR REF Clinician Scholar Educator<br />
Lecture . . . . . . . . . . . . . . . . . . . . . 53<br />
Disclosure: Nothing to Disclose<br />
Clinical Teaching Strategies in the Outpatient<br />
Clinic Setting . . . . . . . . . . . . . . . . . . 66<br />
Disclosure: Nothing to Disclose<br />
Wright, Mary, BS, OT<br />
Musculoskeletal Pain and Cognitive Issues<br />
Related to Returning Military Personnel . . 75<br />
Disclosure: Nothing to Disclose<br />
Rehabilitation in the Age <strong>of</strong> Biologics . . . . 54<br />
Disclosure: Nothing to Disclose<br />
Wulffraat, Nico M, MD<br />
Autologous Stem Cell Transplantation in<br />
Pediatric <strong>Rheumatology</strong>: Indications and<br />
Associated Morbidity . . . . . . . . . . . . . 68<br />
Disclosure: Nothing to Disclose<br />
X<br />
Ximenes, Antonio C, PhD<br />
ILAR Global Health Project . . . . . . . . . . 84<br />
Disclosure: Nothing to Disclose<br />
Y<br />
Yazici, Hasan, MD<br />
Behcet’s Disease. . . . . . . . . . . . . . . . 28<br />
Disclosure: Nothing to Disclose<br />
ACR/EULAR Academic Exchange<br />
Program . . . . . . . . . . . . . . . . . . . . 86<br />
Disclosure: Nothing to Disclose<br />
Clinical Research Methodology . . . . . . .108<br />
Disclosure: Nothing to Disclose<br />
Yazici, Yusuf, MD<br />
Clinical Research Methodology . . . . . . .107<br />
Disclosure: BMS, Celgene, Centocor, Genentech,<br />
Roche, UCB, 5; BMS, Genentech, 8; Centocor, 2<br />
York, Michael R, MD<br />
Scleroderma: Systemic Sclerosis . . . . . . 106<br />
Disclosure: Nothing to Disclose<br />
Yung, Raymond L, MD<br />
Geriatric <strong>Rheumatology</strong> . . . . . . . . . . . 89<br />
Disclosure: Nothing to Disclose<br />
News from the National Institutes <strong>of</strong> Health:<br />
Updates and Opportunities . . . . . . . . . 56<br />
Disclosure: National Institute <strong>of</strong> Health, 2<br />
Z<br />
Zibit, Melanie, MEd, MBA<br />
Web-based Support <strong>of</strong> Clinical Practice and<br />
Teaching: Twittering, Blogging, and Doing the<br />
Wiki. . . . . . . . . . . . . . . . . . . . . . .120<br />
Disclosure: Nothing to Disclose<br />
314<br />
2010 Program Book
A<br />
Aarden, L 1825<br />
Aarrass, S 1519, 1534<br />
Abaci, N 2217<br />
Abad, MA 516<br />
Abbott, C 1141<br />
Abdollahi-Roodsaz, S 713, 1535,<br />
1730, 2230<br />
Abdou, NI 462<br />
Abdul Nasser, O 816<br />
Abdulahad, D 1195<br />
Abdulahad, W 1892, 2023<br />
Abe, Y 1731<br />
Abeles, AM 1845<br />
Abeles, M 1845<br />
Abellar, R 2231<br />
Abignano, G 572, 671, 673<br />
Ablin, JN 812<br />
Aboushehde, K 1939<br />
Abraham, D 674, 613, 1995, 2005<br />
Abrahamowicz, M 72, 1036, 1056,<br />
1555<br />
Abrahamyan, L 1681<br />
Abram, F 196, 938<br />
Abramson, LS 234, 1673, 1691,<br />
2017<br />
Abramson, SB 137, 707, 708,<br />
1390, 1477, 1490<br />
Abreu, J 1529<br />
Abril, A 777, 1637, 1652, 1654<br />
Abud-Mendoza, C 416, 1146,<br />
1166, 1407<br />
Abufayyah, M 2152<br />
Acar, H 1615<br />
Acasuso, M 835<br />
Accogli, A 265<br />
Achan, P 1476<br />
Achenbach, S 705, 959<br />
Ackermann, F 2239<br />
ACR/EULAR Commission To<br />
Redefine Remission in Rheumatoid<br />
Arthritis 2108<br />
ACT-SURE Study Group 1840<br />
Adachi, JD 969<br />
Adam, P 2282<br />
Adamec, J 1601<br />
Adams, J 1540, 1552<br />
Adams, MD 1673, 1691, 2017<br />
Adebajo, AO 2082<br />
Adhikari, T 1854, 1855<br />
Adkins, D 1342<br />
Adlerberth, I 1248<br />
Adoue, D 2027<br />
Adrianto, I 1579, 1585, 1586,<br />
2144, 2147<br />
Aegerter, P 1931<br />
Affandi, A 1210<br />
Afklint, E 394<br />
Afridi, KS 2112<br />
Afsarmanesh, N 998<br />
Agarwal, S 602, 603, 612, 824,<br />
1210, 1218, 1982, 2214<br />
Agarwal, V 2086<br />
Agashivala, N 2089<br />
Ager, J 468<br />
Aggarwal, R 563, 913, 925, 929,<br />
930, 1147, 1175, 1193<br />
Aghdassi, E 1156, 1165, 1178,<br />
2120<br />
Agrawal, H 853, 859<br />
Agrawal, N 2205<br />
Agrawal, S 856, 862<br />
Agudo Bilbao, M 1650<br />
Agüero-Balbin, J 1296<br />
Aguilar -Valenzuela, R 1360<br />
Aguilar-Salinas, C 459<br />
Aguilar-Valenzuela, R 12, 1361<br />
Aguilar-Valenzuela, RA 2253<br />
Aguirre, D 953<br />
Aguirre, MA 1357<br />
Ah Kioon, M-D 1707<br />
Ahearn, JM 620, 1399, 2106<br />
Ahern, MJ 177<br />
Ahl, J 105, 113<br />
Åhlin, E 695, 1015<br />
Ahluwalia, J 4<br />
Ahmad, Y 769, 795, 1177<br />
Ahmadi, N 1046, 1443, 2164,<br />
2165, 2166<br />
Ahmed, I 704, 910<br />
Ahmed, K 777, 1637, 1654<br />
Ahn, CW 1226<br />
Ahn, IE 842, 1770<br />
Ahn, JK 366, 372, 1297<br />
Aigner, S 1125<br />
Aikawa, N 224, 539, 1437<br />
Aikawa, Y 280, 1467<br />
Air, G 9, 24, 466<br />
Airo, P 824, 829, 1987, 2214, 2226<br />
Ajani, A 1052<br />
Ajeganova, S 88<br />
Ajmone Marsan, N 582<br />
Akar, S 544, 666, 1282, 1283,<br />
1921<br />
Akazawa, S 2029<br />
Akhavan, P 306, 336, 343, 1734,<br />
1769<br />
Akhlaghi, M 1289<br />
Akhmetshina, A 607, 611, 614,<br />
615, 616, 672<br />
Akhtar, N 632, 633<br />
Akhter, E 14, 487, 733, 2121<br />
Akiba, H 1731<br />
Akikusa, J 226, 248<br />
Akin, C 307<br />
Akiyama, C 434<br />
Akkineni, R 992<br />
Akkoc, N 544, 666, 1282, 1283,<br />
1921<br />
Akkoc, N 1970<br />
Akkoc, Y 544<br />
Aksentijevich, I 914, 1516, 2105<br />
Aksu, K 822<br />
Al Ghanim, N 1152<br />
Al Mayouf, S 1305<br />
Al Saleh, G 1413<br />
Al Sarraf, N 816<br />
Aláez, C 106<br />
Alaka, K 175<br />
Alarcón, G 445, 448, 476, 731,<br />
1591, 1668, 1877, 2104, 2240,<br />
2243<br />
Alarcon, RT 356<br />
Alarcón-Riquelme, ME 500, 1583,<br />
1578, 1584, 1585, 1586, 1590,<br />
1591, 1594, 1595, 2145, 2147,<br />
2148, 2274<br />
Alatorre, CI 52<br />
Alaupovic, P 1030<br />
Alavi, A 1105<br />
Alawi, F 1907<br />
Alba, MA 1314<br />
Albath-Sadiki, A 2045<br />
Albert, DA 992, 1537<br />
Alberton, V 1173<br />
Albert-Sabonnadiere, C 976<br />
Albertsson, K 1392, 1393<br />
Albesa, R 2250, 2251, 2252<br />
Albom, MS 2233<br />
Aldag, JC 49, 83<br />
Al-Dhanhani, A 2120<br />
Alegre, C 814<br />
Alele, JD 960<br />
Alessandri, E 578, 1236<br />
Alessio, M 1439, 1685, 2033<br />
Aletaha, D 73, 79, 296, 1013,<br />
1745, 1795, 2256, 2258<br />
Alevizos, I 1918, 2179<br />
Alexander, C 1606<br />
Alexander, K 464, 698<br />
Alexanderson, H 2068<br />
Alexopoulos, H 1895<br />
Alfredsson, L 64, 645, 832, 1057,<br />
1588, 2118, 2259<br />
Ali, S 807<br />
Aliabadi, P 198, 872<br />
Alias, A 44<br />
Aliprantis, AO 675, 1502<br />
Alivernini, S 1069, 1239, 1604<br />
Alizadeh, BZ 1599, 2214<br />
All CATCH Investigators 306<br />
Allaart, CF 295, 328, 334, 663,<br />
1396, 1496, 1755, 1782<br />
Allaire, SH 1349, 2143<br />
Allam, Y 976<br />
Allanore, Y 576, 580, 607, 616,<br />
728, 729, 1810, 1991, 1994, 1987,<br />
1988, 1992, 2000, 2226<br />
Allen, D 1176<br />
Allen, R 226, 248<br />
Allgood, S 1192<br />
Allievi, A 1173<br />
Allison, J 1005<br />
Allison, SJ 912<br />
Alloza, I 896<br />
Alm, GV 503<br />
Almagor, O 2100<br />
Almeida, C 1325<br />
Almeida, GJM 2059, 2061<br />
Almeida, JS 1403<br />
Almodovar, R 986<br />
Al-Mudhaffer, S 1306<br />
Alonso-Ruiz, A 873<br />
Alper, SL 1502<br />
Alsalawy, A 798<br />
Alsaleh, G 858<br />
Alten, R 392, 770, 987, 1123,<br />
1766, 1817, 1820, 2173<br />
Alth<strong>of</strong>f, C 669, 2271<br />
Altman, RD 187, 907<br />
Altpeter, M 691, 2141<br />
Alvarez, AA 1014<br />
Alvarez-Carbonell, D 2231<br />
Alvarez-Horine, S 97, 815<br />
Alvarez-Leon, E 96<br />
Alvarez-Rodriguez, L 1296<br />
Álvaro-Gracia, J 1840<br />
Alves, C 1775, 1776<br />
Alves, JF 2043<br />
Alyahya, R 1729<br />
Amalini, C 717<br />
Amano, H 1577<br />
Amano, K 1793, 1823, 1839<br />
Amarilyo, G 998<br />
Ambarus, CA 2272<br />
Ambler, N 1325<br />
Amdur, RL 970<br />
Amendola, A 176<br />
Amengual, O 5, 10, 2254<br />
Amezcua-Guerra, L 1614<br />
Amin, MA 1417, 1504, 1721<br />
Amin, S 15, 959<br />
Amir, S 697<br />
Amjadi, S 1058<br />
Amos, C 2214, 2217<br />
Amoura, Z 478, 915, 917, 1287,<br />
1651, 1658, 1660, 1908, 1911,<br />
2024, 2025, 2239<br />
Ampel, NM 415<br />
Anandarajah, A 849, 1051, 1369,<br />
1620<br />
Anania, C 1194<br />
Ananyeva, LP 580<br />
2010 Program Book 315<br />
abstract author Index
aBSTRACT author Index<br />
316<br />
Anatoly, L 598<br />
Anaya, J-M 1048, 1579, 1585,<br />
1586, 1591, 2147<br />
Ancuta, I 405<br />
Anders, H-J 441<br />
Andersen, AR 1444, 1841<br />
Andersen, LS 134, 1953<br />
Anderson, C 1201<br />
Anderson, DD 176<br />
Anderson, J 9, 331, 562, 1197<br />
Anderson, M 225<br />
Andersson, K 1248<br />
Andersson, M 1181<br />
Andersson, S 293<br />
Andrade, D 427, 1183, 1199<br />
Andrade, F 487, 2167, 1074<br />
Andrade, LEC 356, 504, 579, 498<br />
Andrade, PC 887<br />
Andrés, R 1137<br />
Andres Cerezo, L 638<br />
Ang, D 93, 797<br />
Angel, S 2035<br />
Angeles, TS 2233<br />
Angeles-Han, S 255, 256, 1405<br />
Angeletti, M 2001<br />
Angelini, F 540<br />
Angerer, H 1481<br />
Anisfeld, A 120, 125<br />
Annunziato, F 246<br />
Anolik, J 436, 733, 849, 1085,<br />
1886<br />
Anouk, M 1238<br />
Anthony, KK 1406, 2248<br />
Antivalle, M 784<br />
Antohe, J 345, 1442<br />
Antolini, CR 25<br />
Anton, A 450<br />
Anton, J 1305<br />
Antón Lopez, J 1872<br />
Antonini, G 2160<br />
Antony, J 1549<br />
Antovic, A 7<br />
Aoki, S 433<br />
Aouizerate, J 2041<br />
Aoyagi, K 1371<br />
Apaz, MT 1705<br />
Apkarian, AV 2097<br />
Appel, GB 1453, 2085<br />
Appenzeller, S 1170, 1695<br />
APPLE Investigators 1677<br />
APS Clinical Research Task Force 6<br />
Arad, U 697<br />
Arai, S 472<br />
Aranda, R 390, 416, 2168, 2173<br />
Aranow, C 445, 448, 476, 1146,<br />
1877, 2243, 2240<br />
Aranzamendi-Zaldunbide, M 1296<br />
2010 Program Book<br />
Arbillaga, H 1850<br />
Arbogast, P 54<br />
Arce, MT 1659<br />
Arce-Franco, MT 389, 1509<br />
Archambault, T 820<br />
ARChiVe Investigators <strong>of</strong> CARRA<br />
1673, 1691, 2017<br />
Ardanaz, N 1137<br />
Arden, NK 823, 841<br />
Ardoin, SP 1008, 1400, 1677,<br />
1702<br />
Arefiev, K 1213<br />
Arend, WP 2227<br />
Arendt-Nielsen, L 1385, 1557,<br />
2098<br />
Arfi, S 571<br />
Arguedas, O 210<br />
Ariani, A 1635<br />
Arias-Flores, R 1150<br />
Ariga, T 1672<br />
Arima, K 1371<br />
Aringer, M 1111<br />
Ariza Ariza, R 1944,1337<br />
Arjmand, P 267<br />
Arkachaisri, T 1683, 2006<br />
Arlet, P 917, 2027<br />
Armbrust, W 219<br />
Armstrong, C 989, 2112<br />
Armstrong, D 2019, 2107<br />
Armstrong, NE 655<br />
Armstrong, RC 269<br />
Arnaud, L 1287, 1658, 1660<br />
Arnett, F 603, 612, 725, 824, 829,<br />
1211, 1216, 1218, 1227, 2214<br />
Arnold, L 94, 105, 113, 805<br />
Arntz, OJ 713, 1501, 1532, 1535,<br />
1622, 1733<br />
Arrington, J 496, 1612<br />
Arroyo-Villa, I 1967<br />
Arthur, JM 1403<br />
Artim-Esen, B 1308<br />
ARTIS Study Group 1541, 1548<br />
Arts, E 1833<br />
Arufe, MC 1473, 1498<br />
Arufe-Gonda, MC 1483<br />
Arulmani, U 145, 1423, 2087<br />
Arundine, M 74<br />
Arveiler, B 1596<br />
Arvidson, NG 1774<br />
Asako, K 1285<br />
Asanuma, Y 1017<br />
Ascherman, D 913, 925, 929, 930,<br />
935<br />
Asensio, C 1707<br />
Asfa, S 1901<br />
Ashihara, E 1511<br />
Ashouri, J 1157<br />
Ashrafzadeh, A 2169<br />
Askanase, AD 990, 1190, 1857<br />
Askin, F 677, 681<br />
Askling, J 1015, 1054, 1057, 1541,<br />
1548, 2259<br />
Aslanidis, S 11<br />
Aslanov, R 554<br />
Asli, B 2239<br />
Asmawidjaja, P 38, 287, 715,<br />
1259, 1274, 1525<br />
Asmussen, K 134, 1953<br />
Assaad-Khalil, S 1305<br />
Assassi, S 522, 562, 612, 725, 824,<br />
1211, 1216, 1218, 1219, 1227,<br />
1982, 2185, 2214<br />
Astorri, E 1906<br />
Astudillo, L 2027<br />
Atagündüz, P 1133, 1803<br />
Atallah, M 491<br />
Atayde, SA 887<br />
Atkins, CJ 1060<br />
Atkinson, E 959<br />
Atkinson, JP 846, 1262<br />
Ator, MA 2233<br />
Atsumi, T 5, 10, 621, 1812, 1909,<br />
2254<br />
Atteno, M 532<br />
Attinger, CE 1045<br />
Attur, M 137, 707, 708, 1390,<br />
1477, 1490<br />
Atumi, T 2<br />
Atzeni, F 532, 784, 1098, 1582<br />
Au, KM 594<br />
Aubert, RE 1561<br />
Audo, R 1527<br />
Audonnet, S 1664<br />
Audrey, P 2267<br />
Augustovski, F 324<br />
Aukrust, P 479<br />
Aumaître, O 2239<br />
Austad, C 1750<br />
Austin, H 493, 1161<br />
Australo-Anglo-<strong>American</strong><br />
Spondyloarthritis Consortium<br />
1355<br />
Authier, F-J 576<br />
Autran, B 478<br />
Avalos, IB 2123<br />
Avigan, M 75<br />
Avila, M 552<br />
Avila-Armengol, HE 457<br />
Avina-Zubieta, A 1036<br />
Avitable, M 1431<br />
Avouac, J 599, 607, 614, 616, 728,<br />
1988, 1991, 2000<br />
Avshovich, N 550<br />
Avvedimento, E 2001, 2008<br />
Axelsson, T 832<br />
Axford, JS 1105<br />
Axtens, R 1560<br />
Ayanian, J 60<br />
Aydin, S 524, 553, 777, 1291,<br />
1398, 1637, 1652, 1654<br />
Ayearst, R 1966, 1975<br />
Ayers, DC 2136<br />
Ayoub, W 977<br />
Ayub, S 473<br />
Aziz, FA 58<br />
Azzari, C 261<br />
Azzini, C 1162<br />
B<br />
Baas, F 1069, 1604<br />
Baba, S 447, 746, 916, 923, 1184,<br />
1587, 1844<br />
Bacani, AK 53, 78<br />
Bachta, A 777, 1637, 1652, 1654<br />
Backhaus, M 1621, 1629, 1634<br />
Backlin, C 1015<br />
Backman, CL 1321, 1538, 2282<br />
Baddley, J 304, 404, 721, 722,<br />
1643, 2103<br />
Bade, MJ 171<br />
Bader-Meunier, B 1684, 1693<br />
Badesch, D 1223<br />
Badley, EM 1562, 2208<br />
Bae, E-K 372<br />
Bae, S 387, 445, 448, 476, 1092,<br />
1583, 1585, 1586, 1591, 1597,<br />
1605, 1714, 1877, 1941, 2028,<br />
2147, 2240, 2274<br />
Bae, Y-S 1714<br />
Baechler, EC 15, 934, 1608, 2149<br />
Baecklund, E 1015, 1899<br />
Baek, S 276, 277, 1209<br />
Baer, AN 1364, 1544, 1556, 1569,<br />
1887, 1898, 1915<br />
Baerwald, C 936, 1025<br />
Baeten, D 629, 753, 1449, 1527,<br />
1732, 1977, 2272<br />
Bagaglia, P 1109<br />
Bagavant, H 1883<br />
Bagnasco, SM 440<br />
Bagnoud, N 2151<br />
Bailey, T 1576<br />
Bain, G 606<br />
Bainbridge, L 2050<br />
Bair, MJ 175<br />
Bajocchi, G 1290, 1302, 2044<br />
Bak, L 133<br />
Baker, A 1689<br />
Baker, D 1786, 1835, 1922, 1985<br />
Baker, J 456, 1554, 1786<br />
Baker, K 951<br />
Baker, NA 2142, 2143<br />
Baker-LePain, J 624<br />
Bakewell, C 931<br />
Bakke, A 758
Bakker, AAB 1095<br />
Barendregt, B 753<br />
2167, 2260<br />
Bello, KJ 1163, 1180<br />
Bakker, MF 380, 388, 1753, 1759<br />
Barendregt, P 1775, 1776<br />
Batley, M 1830<br />
Bellomo, G 2160<br />
Bakker-Jonges, LE 1780<br />
Barham, B 1698, 2105<br />
Batstra, MR 1780<br />
Belloni-Fortina, A 1439<br />
Balandraud, N 2269<br />
Balanescu, A 848<br />
Balasubramanian, A 1540, 1552<br />
Balbir, A 1238<br />
Balbir-Gurman, A 378, 550<br />
Baldi, M 1706<br />
Baldini, C 811, 839, 1884, 1916<br />
Balfour, A 2087<br />
Baliga, R 674<br />
Baliki, MN 2097<br />
Balint, P 777, 1617, 1629, 1637,<br />
1654<br />
Balitsky, AK 13<br />
Ballal, M 989<br />
Ballantine, L 1422<br />
Balow, J 1161<br />
Balow, Jr, J 1516<br />
Balsa, A 349, 1078, 1599<br />
Balsa, D 1137<br />
Baltzis, D 1021<br />
Bambara, LM 297<br />
Band, P 947<br />
Band, PA 2225<br />
Banda, NK 2227<br />
Bandinelli, F 558, 1962<br />
Bandoli, G 2210<br />
Bandy, R 93, 797<br />
Banerjee, S 1925<br />
Bang, D 2217<br />
Bang, S-Y 1092, 1586, 1605, 1972<br />
Bangert, C 920<br />
Bankhurst, AD 947, 1055, 1567,<br />
1626, 2225<br />
Banks, SE 211<br />
Bao, G 790<br />
Baribaud, F 1968<br />
Barimani, M 1322<br />
Barker, C 967<br />
Barkham, N 1929<br />
Barkhuizen, A 1395<br />
Barnabe, CCM 119, 309, 775, 785<br />
Barnado, A 475<br />
Barnerias, C 1693<br />
Barnes, I 993<br />
Barnes, MG 653<br />
Barnetche, T 393, 408, 1596, 1816<br />
Barnhart, HX 1677<br />
Baron, G 376, 400, 1790<br />
Baron, JA 2137<br />
Baron, M 577, 1202, 1203, 1221,<br />
1225, 1346, 1347, 1348, 2196,<br />
2247<br />
Baron, R 1502<br />
Barone, F 1906<br />
Barr, SG 119, 330<br />
Barra, G 246<br />
Barra, L 1071, 1717<br />
Barrat, F 2231<br />
Barrett, A 967<br />
Barrett, J 1979<br />
Barrett, R 521, 1968<br />
Barron, KS 1698, 2105<br />
Bartel, P 493<br />
Bartelds, GM 1445<br />
Bartels, CM 1000<br />
Bartels, LW 121<br />
Bartlett, SJ 310, 1336<br />
Bartley, EJ 101<br />
Bartok, B 362<br />
Bartoli, F 593, 1962<br />
Battafarano, DF 1044, 1049, 1669,<br />
2163<br />
Battellino, M 784<br />
Batthish, M 225<br />
Batticciotto, A 784<br />
Battle, T 44<br />
Bauer, JW 2149<br />
Baum, P 1025<br />
Baumgart, T 2048<br />
Baumgartner, SW 1103<br />
Bautista, A 1811<br />
Bautista, W 517, 552<br />
Bautista-Caro, MB 1967<br />
Bax, JJ 582<br />
Bay-Jensen, AC 1466, 1500<br />
Bazin, D 875<br />
Bazzichi, L 811, 839<br />
Beard, S 1382<br />
Beasley, M 646, 649<br />
Beatriz-Christmann, R 1210<br />
Beaulieu, A 938, 1441<br />
Beauvais, C 63<br />
Bebak, M 243<br />
Becciolini, A 547<br />
Bechtel, A 594<br />
Becker, C 1125<br />
Becker, J-C 1837, 1843, 1919<br />
Becker, M 158, 165, 253, 254,<br />
2003, 2219<br />
Becvar, R 614<br />
Beebe, D 1689<br />
Beeton, C 1128<br />
Beg, SA 1856<br />
Behin, A 915<br />
Behrens, EM 233, 1354, 2219<br />
Belmatoug, N 1653<br />
Belmont, HM 996<br />
Belomestnov, P 1121<br />
Belostocki, K 1072<br />
Belouski, S 1141<br />
Belter, M 12<br />
Beltramelli, M 2033<br />
Ben Ammar, RH 1684<br />
Ben M’Barek, R 2269<br />
Bena, JF 574<br />
Benamour, S 1305<br />
Ben-Ari, R 46, 1432<br />
Benavente, Y 1280<br />
Bencardino, J 137, 707, 708<br />
Bender, S 41<br />
Benedict, A 2266<br />
Benegas, M 50<br />
Benessiano, J 1890<br />
Bengtsson, A 2022<br />
Bengtsson, C 645, 2118<br />
Benhamou, M 1762<br />
Benito-Garcia, E 89<br />
Benito-Miguel, M 349<br />
Benjamin, H 1985<br />
Bennell, K 192<br />
Bennett, A 524, 553, 1963<br />
Bennett, L 1316<br />
Bennett, M 268, 2106<br />
Bennett, RM 97, 647, 806, 814<br />
Bennin, DA 1421<br />
Bennink, MB 713, 1501, 1532,<br />
1733<br />
Bennink, R 1822<br />
Benseler, S 894, 899, 900, 1408,<br />
1673, 1691, 2017, 2019, 2107<br />
abstract author Index<br />
Bapoje, S 2013<br />
Baptista, F 626<br />
Bar, S 2055<br />
Baraf, H 157, 166, 1808<br />
Baraliakos, X 526, 668, 1958,<br />
1985, 2270<br />
Barash, J 1684<br />
Baratelli, MJ 1872<br />
Baratham, A 943<br />
Barbarroja, N 1357<br />
Barbasso Helmers, S 924<br />
Barbe, MF 2244<br />
Barber, X 1754<br />
Barberà, JA 1070<br />
Barbosa, CMP 1339<br />
Barcellos, L 502, 1602<br />
Barcelos, A 1986<br />
Barclay, M 417<br />
Bardin, T 400, 1790<br />
Barton, A 264, 266, 833, 1075,<br />
1394, 1593, 1600, 1756, 2215<br />
Barton, JL 1024<br />
Bartos, A 1185, 1196, 2275<br />
Bartrolí, J 1137<br />
Baser, O 307<br />
Bashir, MM 1198<br />
Basic, J 217<br />
Baskin, E 1705<br />
Bass, DL 757, 764<br />
Bassel, M 1346<br />
Basta, MC 1173<br />
Bastacky, S 1399<br />
Bastian, H 1780<br />
Baszis, KW 216, 1691<br />
Batal, I 1399<br />
Bateman, H 44<br />
Bathon, J 385, 386, 949, 1018,<br />
1022, 1030, 1065, 1074, 1148,<br />
1368, 1441, 1837, 2096, 2162,<br />
Behrens, F 599<br />
Behrens, T 473, 502, 1592, 1608,<br />
2149<br />
Behring, K 1059<br />
Bekker, PJ 1100, 2032<br />
Bel, M 792<br />
Belacek, J 1649<br />
Belenguer, R 1888<br />
Belilos, E 1072, 1311<br />
Belisle, P 1142, 1850<br />
Belitskaya-Lévy, I 137<br />
Bell, C 1000<br />
Bell, DA 1071, 1717<br />
Bell, K 2255<br />
Bell, MJ 778, 794<br />
Bellan, M 962, 2160<br />
Bellando-Randone, S 593<br />
Belli, B 269<br />
Bello, AE 945, 946<br />
Benson, B 814, 815<br />
Bentley, MJ 1010<br />
Benucci, M 1098, 1582<br />
Benveniste, O 915<br />
Beratarrechea, A 324<br />
Berclaz, P-Y 2172<br />
Berenbaum, F 37, 781, 1514<br />
Beresford, M 1688<br />
Beretta, L 824, 829, 1235, 2214<br />
Bérezné, A 576, 1204, 1217, 2043<br />
Berg, IJ 534<br />
Berger, FH 1069<br />
Berger, M 151<br />
Berger, T 2186<br />
Bergersen, TK 1220<br />
Berggren, O 503<br />
Berghea, F 848<br />
Berglin, E 2115<br />
Bergman, MJ 331, 644, 985, 2109<br />
2010 Program Book 317
aBSTRACT author Index<br />
318<br />
Bergman, S 2209<br />
Berman, A 50<br />
Berman, H 50<br />
Berman, J 43<br />
Bernal, A 1614<br />
Bernardi, L 290<br />
Bernasconi, C 1840<br />
Bernatsky, S 57, 214, 313, 341,<br />
342, 445, 448, 454, 476, 731, 1142,<br />
1562, 1850, 1877, 2240, 2243<br />
Bernelot Moens, HJ 314, 662,<br />
1771<br />
Bernstein, CN 1068, 1094<br />
Berry, JL 1200<br />
Berry, L 1245<br />
Berry, P 173, 1383<br />
Bershadsky, B 191<br />
Bertamino, M 207<br />
Berthelot, J-M 29, 701, 1752,<br />
1810, 2261, 2269<br />
Berthier, C 2276, 2278<br />
Bertin, P 987<br />
Bertin-Maghit, S 1116<br />
Bertoia, M 71<br />
Bertola, DR 260<br />
Bertolazzi, C 547, 1635<br />
Bertolino, AP 560, 566<br />
Bertolo, MB 356<br />
Bertrand, J 1130, 1486<br />
Bessette, L 785, 938<br />
Bessis, D 2238<br />
Bessis, N 2236<br />
Bethunaickan, R 2188, 2276<br />
Beukelman, T 213, 239, 404, 721,<br />
722, 1679, 2084, 2103<br />
Beuteux, S 1827<br />
Beutler, A 890, 908, 1943, 2264<br />
Beyer, C 607, 614, 616, 672<br />
Bhagat, L 856<br />
Bhagat, S 395, 1342<br />
Bhagwat, S 269<br />
Bhakuni, DS 2086<br />
Bhalla, V 2153<br />
Bharadwaj, R 66<br />
Bhatt, S 470<br />
Bhattacharya, I 1154<br />
Bhattacharyya, K 1925<br />
Bhavsar, R 650<br />
Bhole, V 523, 720<br />
Biagioni, B 1954<br />
Bian, A 1023, 1034, 1867<br />
Bianchi, L 261<br />
Bianconi, S 914<br />
Biasi, D 547, 671<br />
Biasi, G 1098, 1582<br />
Bichisecchi, E 1635<br />
Bieche, I 2025<br />
Biedermann, S 1121<br />
2010 Program Book<br />
Bierma-Zeinstra, SMA 124, 184<br />
Biesenbach, P 469<br />
Bigatti, S 93, 797<br />
Bijl, M 1195, 1210, 1455<br />
Bijlsma, JWJ 124, 184, 278, 333,<br />
380, 942, 952, 973, 1753, 1759,<br />
1900, 1903<br />
Bijsterbosch, J 179<br />
Bikker, A 1900, 1903<br />
Bilge, S 1970<br />
Bilgic, H 15, 934, 1608<br />
Bili, A 345, 1442<br />
Binder, W 14, 2250, 2251, 2252<br />
Bingham, C 41, 211, 391, 948,<br />
1074, 1678, 1766, 1778, 1805,<br />
2167, 2169<br />
Bingham III, CO 45<br />
Biniecka, M 360, 1510<br />
Binstadt, B 1256<br />
Binti Mohd Din, SH 2066<br />
BIOLUPUS Network 2147<br />
BIOLUPUS and GENLES Networks<br />
1584, 1585, 1586, 1591, 1595<br />
Birbara, CA 1804<br />
Bird, P 118, 141, 319, 1369<br />
Birkett, R 854<br />
Birlik, M 544, 666, 1282, 1283,<br />
1921<br />
Birmingham, DJ 1400<br />
Birmingham, JD 209<br />
Birnbaum, H 763<br />
Birnbaum, J 1887, 1915<br />
Bisch<strong>of</strong>f, S 770<br />
Bisoendial, R 629<br />
Bitman, B 398, 1117<br />
Bitner, C 1382<br />
Biton, J 2236<br />
Bittner, S 1255<br />
Bjersing, JL 103<br />
Björnådal, L 1224<br />
Bjorneboe, O 1774, 1829<br />
Blache, C 1827<br />
Blachere, N 863<br />
Blackburn, MR 602, 612<br />
Blagojevic, J 593<br />
Blake, C 2135<br />
Blanchard-Delaunay, C 1894<br />
Blanco, F 538, 541, 835, 840,<br />
1078, 1473, 1475, 1483, 1498,<br />
1920<br />
Blanco, I 939, 2095<br />
Blanco, P 1816<br />
Blanco, R 1296, 1301, 2262<br />
Blanco Alonso, R 1650<br />
Blaney-Davidson, E 1532<br />
Blaschke, S 138, 2021<br />
Blauvelt, A 758<br />
BLISS-52 and -76 Study Groups<br />
451, 452, 1146, 1456, 1848<br />
BLISS-52 and -76, and LBSL02/99<br />
Study Groups 1172<br />
BLISS-76 Study Group 457, 1454<br />
Bloch, C 915<br />
Bloch, DB 1671<br />
Block, JA 200, 765, 1147, 1175,<br />
1880, 2099<br />
Blom, A 845, 1472<br />
Bloo, H 2051<br />
Blum, S 99, 800<br />
Blumenroth, M 1615, 2081<br />
Blumenthal, DR 161, 1431<br />
Blumenthal, R 2162, 2260<br />
Blüml, S 1351<br />
Boackle, SA 730, 1591<br />
Boateng, BA 46, 1429, 1432<br />
Bobak, N 1255<br />
Bobbio Pallavicini, F 1098, 1582<br />
Bodaghi, B 1249<br />
Bodemer, C 1693<br />
Bodnár, N 519<br />
Bodukam, V 1205<br />
Boelle, P-Y 533<br />
Boers, M 392, 723, 1758, 1766,<br />
2108<br />
Bogatkevich, G 604<br />
Bohl-Bühler, M 2271<br />
Böhme, W 1444, 1841<br />
Bohnsack, JF 245, 250, 255, 256,<br />
654<br />
Boiardi, L 1290, 1302, 2044<br />
Boilard, E 363<br />
Boileau, C 1987, 1991, 1994,<br />
2000, 2226<br />
Boin, F 596, 1201, 1989, 2192<br />
Boire, G 300, 306, 343, 659, 978,<br />
1737<br />
Boissier, M-C 997, 2236<br />
Bojinca, V 848<br />
Bokarewa, M 103, 293<br />
Bokhari, A 1051<br />
Bolce, R 420, 1960, 2270<br />
Bolen, J 689, 1563, 2080<br />
Bolge, S 51, 1542, 1960<br />
Bolla, M 1477<br />
Bollag, G 273<br />
Bolosiu, H 405<br />
Bolstad, AI 1885<br />
Bolster, M 561, 591<br />
Bolton H<strong>of</strong>fman, JA 1364<br />
Bomalaski, JS 144<br />
Bombardier, C 57, 336, 341, 1734,<br />
1769, 313<br />
Bombardieri, M 1389, 1906<br />
Bombardieri, S 558, 811, 839,<br />
1011, 1884, 1896, 1916, 2036,<br />
2201<br />
Bonciani, D 1962<br />
Boncompagni, A 2033<br />
Bone, HG 2157<br />
Bonelli, M 1351<br />
Bonetti, LA 1072<br />
Bonewald, L 965<br />
Bonfa, E 284, 481, 513, 539, 626,<br />
1384, 1437, 2078, 2204<br />
Bong, DA 1617, 2223<br />
Bonilla, N 1981<br />
Bonner, A 396, 1202, 1203, 1221<br />
Bonner, M 622<br />
Bonnet, F 2010<br />
Bonnyman, A 1316<br />
Bonoldi, VLN 1644<br />
Bonome-González, V 835<br />
Boom, HD 663<br />
Boomershine, CS 115, 802, 813<br />
Boon, L 38<br />
Boonen, A 65, 557, 760, 1369<br />
Boonen, S 971<br />
Boostma, H 1910<br />
Booth, R 1484<br />
Booth, SL 872<br />
Booth-LaForce, C 1106<br />
Boots, AMH 275, 1730<br />
Bootsma, H 1889, 1892, 1896,<br />
1905<br />
Borba, EF 481, 626<br />
Borchardt, T 1479<br />
Borg, AA 172<br />
Borghi, MO 1356<br />
Borghini, S 657<br />
Bork, DJ 574<br />
Borowoy, A 1852<br />
Borriello, F 246<br />
Bortoluzzi, A 1162<br />
Borzutzky, A 229, 241<br />
Bos, NA 1889<br />
Bose, N 574<br />
Bosello, SL 355, 1239<br />
Botello-Corzo, D 1048<br />
Botsios, C 290<br />
Bottaro, A 712, 1710<br />
Botto, M 430<br />
Boucher, R 75<br />
Boudreau, R 193<br />
Bou-Gharios, G 1995<br />
Boulman, N 550, 909<br />
Bouma, S 1026<br />
Boumans, M 333, 1095, 1821,<br />
1828, 2170<br />
Boumier, P 2221<br />
Boumpas, D 496, 1829, 2265<br />
Bourdeau, T 1728<br />
Bourgeois, P 141, 787, 917, 1762,<br />
2221<br />
Bourne, T 751, 752, 1243, 1245<br />
Bourré-Tessier, J 1142, 1850
Boutin-Le Thi Huong, D 478<br />
Bout-Tabaku, SM 1907<br />
Bowes, J 833, 1600, 2215<br />
Bowes, MA 118<br />
Bowman, SJ 1896, 1910<br />
Bowness, P 1973<br />
Bowyer, SL 1677<br />
Box, JH 416, 2173<br />
Boychev, G 1419<br />
Boyd, SK 119<br />
Boyer, O 915, 1827<br />
Bøyesen, P 132, 141, 142, 1369,<br />
1444, 1841<br />
Boyle, D 34, 271, 362, 635, 639,<br />
855, 1240, 1725, 1727, 1955<br />
Boyle, JJ 2200<br />
Boynes, AM 1345<br />
Braakman-Jansen, LMA 2207,<br />
2281<br />
Bracci-Laudiero, L 18<br />
Bradley, J 1129, 2171<br />
Bradley, L 1557, 2098<br />
Bradley, N 1681<br />
Brady, A 2135<br />
Brady, TJ 689, 1465, 2062, 2080<br />
Braem, K 1980<br />
Brahn, E 285, 289<br />
Branch, VK 1188<br />
Branco, JC 1986<br />
Brand, C 1052<br />
Brand, D 1266<br />
Brandenstein, JS 1345<br />
Brandi, ML 222, 1155, 2157, 2202<br />
Brandorff, J 2119<br />
Brandt, KD 948<br />
Brasington, R 216, 1077, 1633<br />
Bratt, J 1393, 1392<br />
Brault, M 687, 2138<br />
Brault, Y 1629<br />
Braun, J 526, 665, 668, 895, 1425,<br />
1788, 1922, 1927, 1938, 1946,<br />
1948, 1958, 1961, 1985, 2270<br />
Brauner, M 997<br />
Brauner, SR 1917<br />
Breban, M 527, 533, 551, 701,<br />
1087, 1893, 1931, 1981<br />
Breda, L 261, 1685, 2033<br />
Breedveld, F 403, 1013<br />
Bremander, ABI 761, 2209<br />
Brembilla, NC 1992<br />
Bremme, K 7<br />
Brennan, M 1579, 2117<br />
Brennan, PC 1625<br />
Brennan, S 183<br />
Brenneis, C 1923<br />
Brenner, MB 602, 603, 1388<br />
Brentano, F 1389, 1528<br />
Bresci, C 1436<br />
Bresnihan, B 1032, 1105, 2065<br />
Bretz, W 1390<br />
Breuer, S 406<br />
Breuil, V 976<br />
Breunig, M 1026<br />
Briassouli, P 489<br />
Bridges, SL 299, 1077, 1368, 1386,<br />
1740<br />
Briesacher, B 322, 791<br />
Brigham, D 269<br />
Brihaye, B 2239<br />
Briley, AI 2035<br />
Brinker, A 75<br />
Brintnell, W 1717<br />
Brion, R 29<br />
Briot, K 548<br />
British Society for <strong>Rheumatology</strong><br />
Biologics Register 374, 421<br />
Britsemmer, K 85, 723, 1033<br />
Brizi, MG 837<br />
Brizzolara, R 1798<br />
Brkic, Z 1904<br />
Brock, M 35, 1518<br />
Brockbank, J 40<br />
Brocq, O 69<br />
Broder, AR 1179<br />
Broen, J 824, 829, 1210, 2004,<br />
2214<br />
Broere, F 278<br />
Broggini, V 1356<br />
Brokstad, K 1899, 1917<br />
Bromberg, MH 1406, 2248<br />
Bromberg, R 1740, 2116<br />
Brook, RD 1041<br />
Brookhart, MA 60, 2104<br />
Brooks, EB 2017<br />
Brooks, P 1766<br />
Brouard, S 753<br />
Broussard, C 575, 834<br />
Brousse, N 1651<br />
Brouwer, C 829<br />
Brouwer, E 2170<br />
Brower, KS 2061<br />
Brown, A 141<br />
Brown, D 751, 752, 2057, 2102<br />
Brown, EE 1584, 1585, 1586,<br />
1591, 1594, 1595, 2147, 2274<br />
Brown, GA 1539<br />
Brown, H 2050<br />
Brown, J 1012, 2157, 2161<br />
Brown, KK 1212<br />
Brown, M 250, 255, 256, 1355,<br />
1446, 1986, 2184<br />
Brown, R 441<br />
Brown, S 518, 559, 1949<br />
Brown, TD 176<br />
Brown, Jr, RD 2037, 2038<br />
Brox, JI 170<br />
Bruce, B 1545<br />
Bruce, H 2125<br />
Bruce, I 445, 448, 476, 766, 769,<br />
795, 833, 1067, 1177, 1200, 1323,<br />
1394, 1877, 2240, 2243<br />
Bruckdorfer, R 2005<br />
Brumwell, AN 609<br />
Brun, J 891, 1885, 1896, 1913<br />
Brunck, M 1116<br />
Bruner, G 1164, 1590<br />
Brunetta, P 1455<br />
Brunette, A 1<br />
Brunner, H 218, 268, 1012, 1434,<br />
1677, 1688, 1689, 1690, 1701,<br />
1702, 2106<br />
Brunner, J 1704<br />
Bruno, F 902<br />
Brus, HLM 662<br />
Bruyere, O 979<br />
Bryan, RL 1494<br />
Brzosko, M 1829<br />
Bshouty, Z 1176<br />
BSR Biologics Register 1323<br />
BSRBR Control Centre Consortium<br />
374, 421, 1323<br />
Bucci-Rechtweg, C 2156<br />
Buchanan, R 1942<br />
Buchbinder, R 204, 1001, 1009<br />
Buckeridge, D 1555<br />
Buckner, J 77, 658, 1094<br />
Bud<strong>of</strong>f, M 1046, 1443, 2164,<br />
2165, 2166<br />
Buehring, B 191<br />
Bueno, C 224<br />
Bugaralli, A 284<br />
Bugatti, S 623, 1397<br />
Buggy, JJ 286<br />
Buhr, K 1000<br />
Buhrmann, C 106<br />
Buischi, Y 1390<br />
Buitinga, L 2207, 2281<br />
Buján, J 1475<br />
Bukulmez, H 259<br />
Bulinckx, LM 2279<br />
Bultink, IEM 1859<br />
Bulur, A 1133, 1803<br />
Bunn, C 1207<br />
Bunn, D 766, 779, 796, 1067,<br />
1110<br />
Buoncompagni, A 265<br />
Burbine, SA 2090, 2092<br />
Burgerh<strong>of</strong>, HGM 1889<br />
Burgess, JA 1942<br />
Burghardt, AJ 136<br />
Bürgis, S 2237<br />
Burgos Vargas, R 151, 1407, 1819<br />
Burke, J 764<br />
Burke, L 403<br />
Burkhardt, H 2234<br />
Burki, V 529, 1924<br />
Burkly, L 1243, 1244, 1245<br />
Burlingame, R 735<br />
Burmester, G 630, 782, 911, 1013,<br />
1295, 1418, 1621, 1780, 1788,<br />
1817, 2003, 2271<br />
Burnham, JM 206<br />
Burns, A 1207<br />
Burns, JM 2277<br />
Burns, LC 523, 720<br />
Burns, MB 1012<br />
Burr, DB 716<br />
Burton, B 273<br />
Busch, R 331, 843<br />
Buschmann, J 668<br />
Bush, H 994<br />
Busija, L 204, 2079, 2139<br />
Buskila, D 812<br />
Buss, B 2181<br />
Busso, N 2151<br />
Bussone, G 575<br />
Butherus, K 2203<br />
Butjosa, M 1294, 1314<br />
Butter, C 1059<br />
Buttgereit, F 392, 630, 1123, 1418<br />
Butthum, B 1950<br />
Buyon, J 489, 495, 637, 656, 732,<br />
990, 1190, 1438, 1857, 2231<br />
Buyske, S 625, 1320, 1767<br />
Bykerk, V 300, 306, 308, 343, 396,<br />
659, 785, 794, 978, 1737, 1766,<br />
1778, 1840<br />
Byrjalsen, I 1466, 1474<br />
Byron, J 584<br />
Cabane, J 576<br />
Caban-Martinez, AJ 786<br />
Cabral, DA 1673, 1691, 2017<br />
Cachafeiro-Vilar, A 874<br />
Cacoub, P 400, 906, 1249, 1287,<br />
1646, 1660, 1790, 1908, 1911,<br />
2010, 2011, 2024, 2025, 2030,<br />
2036, 2039, 2042, 2046, 2131<br />
Caeiro, F 50<br />
Cagnard, N 2000<br />
Cagnoli, PC 1158<br />
Cahue, S 186, 189<br />
Cai, A 1818<br />
Cai, C 431<br />
Cai, Y 274, 1107<br />
Cairns, E 1071, 1717<br />
Cakar, E 114<br />
Cakir, V 1282, 1283<br />
Calabozo, M 873<br />
Calabrese, LH 700<br />
Calamia, K 1652, 2037, 2038<br />
C<br />
2010 Program Book 319<br />
abstract author Index
Calamia, V 840<br />
Cantó, E 1801<br />
Carter, R 1652<br />
Ceponis, A 1618<br />
Calaza, M 1076, 1078<br />
Cantor, RM 1584, 1595<br />
Carter, S 1980<br />
Ceribelli, A 501, 735, 1639<br />
aBSTRACT author Index<br />
Calcagno, G 1155, 1685, 1706,<br />
2033, 2202<br />
Calderón, J 2070<br />
Calderone, M 1682<br />
Calich, AL 481, 2078, 2204<br />
Caliz, R 1078<br />
Callahan, LF 690, 691, 1077, 1460,<br />
1461, 1462, 1463, 2071, 2140,<br />
2141<br />
Callen, J 920<br />
Callon, K 881, 1983<br />
Calmon Hamaty, F 1527<br />
Calvo, E 552<br />
Calvo, I 1434<br />
Calvo, J 1888<br />
Calvo-Alen, J 1296, 1871<br />
Camacho, EM 779<br />
Camargo, LM 628<br />
Camargo, TM 1458<br />
Cambi, A 844<br />
Cambon-Thomsen, A 2218<br />
Cambridge, G 739, 743<br />
Caminade, A-M 281<br />
Camoin, L 834<br />
Campana, C 540<br />
Campanini, M 2201<br />
Campbell, PL 1504, 1721<br />
Campbell, RT 692<br />
Campillo, S 1408, 1673, 1691,<br />
2017<br />
Campo, E 1280<br />
Campos, LM 224, 1437<br />
Camps, MT 824, 1888<br />
Camps, S 2041<br />
Can, G 544, 666, 1282, 1283<br />
Can, M 1133, 1208, 1803<br />
Canadian Scleroderma Research<br />
Group (CSRG) 1225, 1347, 1348,<br />
2247<br />
Candelieri, A 558, 1962<br />
Canestri, S 355, 744<br />
Cañete, J 20, 538, 543, 1070,<br />
1078, 1449<br />
Canhao, H 1684<br />
CANIOS 1000 Canadian Faces <strong>of</strong><br />
Lupus Investigators 1850<br />
Canizar, M 1562<br />
Cann, J 2191<br />
Canning, C 339, 1066<br />
Cannon, GW 304, 397, 970, 1099,<br />
1792<br />
Cano, C 1754<br />
Cantaert, T 753, 1449, 1977<br />
Cantagrel, A 281, 400, 1088, 1790,<br />
1893, 1894, 2218<br />
Cantarini, L 837<br />
Cantini, F 528, 1652, 1952<br />
Cantrell, RA 52<br />
Canzoni, M 547<br />
Cao, J 1513<br />
Cao, Q 438, 2191<br />
Caorsi, R 657, 1685, 1706<br />
Capacci, A 1239<br />
Capannini, S 222, 1155, 2033,<br />
2202<br />
Caparbo, VF 1546<br />
Capellino, S 1089<br />
Capelozzi, VL 605, 887<br />
Capini, C 1116<br />
Caplan, L 62, 397, 970, 1099,<br />
1395, 1792<br />
Caplice, N 22, 1726<br />
Capone, M 246<br />
Caporali, R 623, 1397<br />
Caputo, R 240, 1436<br />
Caramaschi, P 580<br />
Caramez, B 369<br />
Carassiti, D 430<br />
Carbonell, J 975<br />
Carcamo, WC 1639<br />
Carcelain, G 376<br />
Cardiel-Rios, M 1013<br />
Cardoso-Oliveira, J 356<br />
Carette, S 2198<br />
Carey, JJ 817, 818, 989, 2111,<br />
2112<br />
Carey, T 1575<br />
Caricchio, R 422, 439<br />
Carlos, F 767<br />
Carmona, L 516, 986, 1657<br />
Carneiro-Sampaio, M 260<br />
Caroli, F 657<br />
Caron, J 1497<br />
Carotti, M 1635, 1746, 1787<br />
Carpenter, DM 1326<br />
Carpenter, EL 708<br />
Carpi, F 1582<br />
Carpintero, M 852<br />
Carr, J 203, 1168<br />
CARRA Lupus Disease-Specific<br />
Group 1702<br />
Carrat, F 2131<br />
Carreira, P 824, 1171, 2214<br />
Carrera-Marin, AL 1361<br />
Carreño, L 1276<br />
Carson, CW 1606<br />
Carsons, SE 1072, 1311, 1896<br />
Carta, S 657<br />
Carter, C 51, 76, 1542<br />
Carter, E 869<br />
Carter, JD 44, 696, 1647<br />
Carter, MJ 168<br />
Cartin-Ceba, R 680<br />
Cartwright, R 895, 1425, 1435<br />
Carty, A 545, 556<br />
Carulli, J 1753, 1782<br />
Caruso, A 1302, 2044<br />
Carvalho, J 513, 539, 2078, 2204<br />
Carvalho, MS 927<br />
Carvalho-Pinto, C 1732<br />
Carvello, F 18<br />
Casali, M 1290<br />
Casalla, L 50<br />
Casanova, A 598, 1004<br />
Casas, N 1811<br />
Casciola-Rosen, L 487<br />
Casey, VA 1327, 1328, 1331<br />
Cash, TF 1880<br />
Caspi, D 697, 1159<br />
Cassarà, E 528, 1952<br />
Cassidy, C 1234<br />
Cassidy, EA 913, 925, 929, 930<br />
Castañeda, S 1229, 1301, 1505<br />
Castelar-Pinheiro, G 2262<br />
Castelino, FV 606<br />
Castell, E 210<br />
Castellvi, I 824<br />
Castillo-Gallego, C 1967<br />
Castrejón, I 990, 1857<br />
Castro, C 914<br />
Catalán Pellet, A 50<br />
Catanoso, MG 2044<br />
Catanozi, S 887<br />
Catapano, F 678<br />
CATCH Investigators 300, 343, 659<br />
CATCH Scientific Advisory<br />
Committee 396<br />
Cathebras, P 2042<br />
Catrina, AI 394<br />
Cattalini, M 1436, 1706<br />
Cattogio, L 50<br />
Cauli, A 532<br />
Cavalcanti, F 1137<br />
Cavalli, L 222<br />
Cavazza, A 2044<br />
Cavet, G 1030, 1496, 1606, 1753,<br />
1782<br />
Ceccato, F 50<br />
Ceccherini, I 657, 1706<br />
Cecilia, G 902<br />
Cefle, A 822<br />
Celik, D 2061<br />
Celis, R 20<br />
Cellucci, T 2107<br />
Cemerski, S 1350<br />
Centola, M 1030, 1496, 1606,<br />
1753, 1782<br />
Cervera, R 451, 452, 1172, 1398,<br />
1848<br />
Cha, H-S 366, 372, 1297<br />
Cha, S 2174<br />
Chabane, N 1489<br />
Chae, J 1523<br />
Chafey, P 834<br />
Chai, A 403<br />
Chaib, A 2035<br />
Chaiban, R 215<br />
Chaisson, C 1362, 1366<br />
Chaisson, RE 908<br />
Chaki, H 280, 1467<br />
Chakravarty, EF 325, 401, 991,<br />
1043, 1960<br />
Chakravarty, K 664<br />
Chalès, G 2261<br />
Chambers, C 325, 1043, 2210<br />
Chami, H 976<br />
Chams-Davatchi, C 1289<br />
Chan, E 501, 600, 735, 1639<br />
Chan, J 735, 1639<br />
Chan, PT 467, 773, 1667<br />
Chan, W 1060, 2089<br />
Chandra, P 1083, 1740, 1764,<br />
2116<br />
Chandran, V 521, 530, 536, 783,<br />
1928, 1932, 1936, 1954, 1956,<br />
1966, 1974, 1975, 1979, 1984,<br />
2273<br />
Chang, AH 189, 202, 2056<br />
Chang, BY 286<br />
Chang, D 58, 1583, 1595<br />
Chang, H 573, 1003, 2061<br />
Chang, J 692, 1571<br />
Chang, N-H 424, 425<br />
Chang, RW 1558, 2096<br />
Chang, S-K 1388<br />
Chang, X 1978<br />
Chang, Y 71<br />
Chapelle, D 260, 1698<br />
Chapman, HA 609<br />
Chapman, P 417<br />
Chapurlat, R 964, 969, 2157<br />
Charis, P 621<br />
Charles, J 1218<br />
Charles-Schoeman, C 299, 471,<br />
933, 1058<br />
Charlotte, F 1646, 1651<br />
Charlton-Menys, V 1067<br />
Charnock, B 690, 2141<br />
Charrier, C 29<br />
Charuel, J-L 915<br />
Chary-Valckenaere, I 551, 768<br />
Chary-Valkenaere, I 1931<br />
Chatelus, E 1237<br />
320<br />
2010 Program Book
Chatham, WW 457, 1146, 1454,<br />
1457, 1668<br />
Chatterjee, S 564, 574, 592<br />
Chaturvedi, S 1551<br />
Chatzidionysiou, K 55, 410, 418,<br />
1807<br />
Chatzidionysou, K 1802<br />
Chaudhari, S 1789<br />
Chaudhary, P 562<br />
Chaudhry, A 678<br />
Chauhan, A 263, 846, 1262, 1601<br />
Chaussade, S 580<br />
Chaves, I 89<br />
Chavez, M 608<br />
Chavez, R 248<br />
Chavez Chiang, N 1055<br />
Chavez-Chiang, N 947, 1567,<br />
1626, 2225<br />
Checa, AE 885<br />
CHECK Group 184<br />
Chédeville, G 236, 1674<br />
Chefo, S 165<br />
Chemel, M 29<br />
Chen, C 1362, 1366<br />
Chen, D 1080, 1127, 1804<br />
Chen, G 1270<br />
Chen, H 570<br />
Chen, J 129, 2088<br />
Chen, K 1151<br />
Chen, L 299, 304, 404, 721, 722,<br />
1077, 1117, 1639, 1643, 2084,<br />
2103<br />
Chen, M 336, 1186, 1734, 1769<br />
Chen, N 65, 557, 644, 760<br />
Chen, PP 8<br />
Chen, Q 432<br />
Chen, R 52, 1799<br />
Chen, W 286, 805, 1598, 1779,<br />
2241<br />
Chen, X 562<br />
Chen, Y 242, 243, 247, 251, 258,<br />
655, 944<br />
Chen-An, P 1500<br />
Cheng, CW 1748, 1777<br />
Cheng, Q 492, 1414<br />
Cheol-Bae, S 2243<br />
Cherascu, BN 970<br />
Chern<strong>of</strong>f, D 1753, 1782<br />
Chetcuti Zammit, S 172<br />
Cheung, AM 1156<br />
Cheung, FC 1748, 1777<br />
Cheung, Y 429, 2190<br />
Chevrant-Breton, J 2238<br />
Chevreul, K 781<br />
Chhana, A 881<br />
Chiarelli, P 888<br />
Chiari, A 2132<br />
Chiarolanza, I 1302, 2044<br />
Chiba, A 896, 2232<br />
Chibnik, LB 1082, 1588<br />
Chiesa, S 657<br />
Chifflot, H 1237<br />
Chighizola, C 590<br />
Childhood Myositis Heterogeneity<br />
Study Group 1678<br />
Chines, A 979<br />
Chiocchia, G 1087, 1413, 1981,<br />
2000<br />
Chiodo, L 468<br />
Chiorini, JA 1413, 2178<br />
Chiossone, L 1664<br />
Chiowchanwisawakit, P 667, 1959<br />
Chipping, J 796<br />
Chira, P 1008, 1409, 1673, 1691,<br />
2017<br />
Chitale, S 661, 1763<br />
Chiu, B 696<br />
Chiu, G 849, 1492<br />
Chiu, S 1233<br />
Chiu, YG 521, 1968<br />
Chizzolini, C 1987, 1992<br />
Chmiel, JS 186, 189, 2100<br />
Cho, M 163, 276, 353, 370, 1716<br />
Cho, S-H 602<br />
Cho, Y 505, 2217<br />
Chobaz, V 2151<br />
Choe, J-Y 323, 903<br />
Chohan, S 158, 165<br />
Choi, C 1597, 1714, 1941<br />
Choi, H 72, 523, 720, 879, 1036,<br />
1056, 1363, 1366, 1547, 2067,<br />
2152, 2154, 2155, 2199, 2212,<br />
2213<br />
Choi, IA 387<br />
Choi, J 1246, 2158<br />
Choi, K 1389<br />
Choi, L 75<br />
Choi, S 92, 285, 289, 359, 1209,<br />
1628, 1972<br />
Choi, T-Y 1046, 1443, 2164, 2165,<br />
2166<br />
Chong, K 1131<br />
Chopra, A 66, 1549, 1551, 1640,<br />
1642<br />
Choquette, D 74, 196<br />
Chou, RC 640, 1427<br />
Chow, YW 1278<br />
Choy, E 819, 1766, 1832<br />
Christadoss, ML 1491<br />
Christensen, R 1766<br />
Christensen, TG 1444, 1841<br />
Christiane, AE 1026<br />
Christianson, TJH 2037, 2038<br />
Christodoulou, MI 1897<br />
Christophe, R 2267<br />
Christopher-Stine, L 919<br />
Chu, AD 428<br />
Chu, B-C 338<br />
Chu, ME 58<br />
Chu, SY 1350<br />
Chu, Z 1728<br />
Chu Miow Lin, D 143, 988<br />
Chubinskaya, S 1147<br />
Chun, J 606<br />
Chun, W 885<br />
Chung, C 120, 1034, 1607, 1808,<br />
2123, 2260<br />
Chung, JB 1141<br />
Chung, L 561, 570, 573, 586,<br />
1157, 1213, 1223, 1378<br />
Chung, S 27, 500, 502, 1592,<br />
1602, 2145<br />
Chung, W 257<br />
Chung, Y-J 1589<br />
Church, L 1263<br />
Churchill, D 1645<br />
Ciapetti, A 1746, 1787<br />
Cibere, J 2055<br />
Ciciriello, S 1001, 1009<br />
Cicuttini, F 173, 183, 192, 1383<br />
Cid, M 777, 1276, 1280, 1292,<br />
1294, 1309, 1314, 1637, 1652,<br />
1654<br />
Cifaldi, M 65, 91, 307, 327, 382,<br />
535, 557, 644, 760, 763, 771, 788,<br />
2266<br />
Cifuentes, RA 1048<br />
Cigler, T 898<br />
Cimaz, R 246, 1675, 1872, 240,<br />
1305, 1436<br />
Cimbora, D 493<br />
Cimmino, MA 777, 1637, 1652,<br />
1654<br />
Cinzia, DL 240<br />
Ciregia, F 811<br />
Cistrone, C 1085<br />
Citera, G 324, 50<br />
Ciullini Mannurita, S 261<br />
Cividino, AA 57, 313, 341, 1735<br />
Clair, B 1185, 1196<br />
Clancy, MM 198<br />
Clancy, R 443, 489, 495, 637, 656,<br />
1190, 2231<br />
Clapp, L 2005<br />
Clark, E 747<br />
Clark, P 767<br />
Clark, TB 1382<br />
Clarke, A 214, 445, 448, 454, 476,<br />
731, 1142, 1146, 1170, 1848, 1850,<br />
1877, 2240, 2243<br />
Clarke, J 920<br />
Clary, G 834<br />
Clauw, DJ 100, 650<br />
Clavert, V 1237<br />
Clegg, DO 948<br />
Clemens, P 935<br />
Clements, P 598, 729, 1228, 1232,<br />
2194, 2195, 1205<br />
Clements-Baker, MI 126<br />
Clemessy, M 1991<br />
Clerico, P 1798<br />
Cleveland, C 446<br />
Clifford, B 245, 256<br />
Cliss, A 1325<br />
Close, D 1455, 2085<br />
Clower, J 152, 1713<br />
Clowse, ME 325, 461, 1043, 1154,<br />
1192, 1862<br />
Club Rhumatismes et Inflammation<br />
(CRI) 904<br />
Cluzel, P 1287<br />
Co, S 2152<br />
Coates, L 514, 1926, 1929, 2182,<br />
2183<br />
Coca, A 1886<br />
Cocuzza, M 513<br />
Codding, CE 1441<br />
Codreanu, C 405, 1013<br />
Coenen, M 824, 829, 1599, 2004,<br />
2214<br />
C<strong>of</strong>ield, S 299, 1740<br />
C<strong>of</strong>ield, SS 1368, 1779<br />
Coghlan, G 590<br />
Coghlan, JG 727<br />
Cohen, H 812<br />
Cohen, MJ 187<br />
Cohen, P 2009, 2034, 2041, 2043,<br />
2045<br />
Cohen, RB 390<br />
Cohen, SB 403, 1154<br />
Cohen Tervaert, JW 676<br />
Coker, I 1970<br />
Colaci, M 581, 1627<br />
Colato, C 671<br />
Colbert, CJ 186, 189, 202<br />
Colbert, RA 1376<br />
Colin, D 1931<br />
Colin, E 38, 1274<br />
Collaku, L 1962<br />
Collantes, E 525, 986, 2268<br />
Collantes-Estevez, E 1357<br />
Collée, G 1396<br />
Collet, C 1707<br />
Collier, DS 25<br />
Collins, C 1062, 1210<br />
Collins, ES 1105<br />
Collins, JB 1324<br />
Colmegna, I 351, 1336<br />
Colombo, PC 1183<br />
Coman, I 1185<br />
Combe, B 301, 376, 400, 1790,<br />
1946, 2042<br />
Combe, BG 303, 383, 408, 1527,<br />
1732, 1760<br />
2010 Program Book 321<br />
abstract author Index
aBSTRACT author Index<br />
322<br />
Combesure, C 792<br />
Comeau, M 1591<br />
Comeau, ME 500, 2145<br />
Compaoré, C 2269<br />
Conaghan, PG 118, 120, 140, 141,<br />
143, 181, 199, 1097, 1114, 1369,<br />
1817, 1926, 2182, 2183, 2264<br />
Condon, KW 716<br />
Conforti, ML 593<br />
Conigliaro, J 994<br />
Conn, DL 1077<br />
Conneely, K 255<br />
Connell, CA 1129, 2171<br />
Connelly, M 1406, 2248<br />
Connolly, AJ 2117<br />
Connolly, K 920<br />
Connolly, M 871, 1391, 1533<br />
Connop, B 285<br />
Connors, G 1022<br />
Conrad, K 1757<br />
Consolaro, A 208, 232<br />
Consolini, R 1685<br />
Consortium, E 2276<br />
Constantin, A 1752<br />
Constantin, AL 2218<br />
Conti, PS 1499<br />
Contin-Bordes, C 1816<br />
Contreras-Yáñez, I 337<br />
Cook, R 530, 556, 783, 1936,<br />
1954, 1956, 1964<br />
Cook, RJ 512, 545<br />
Cook, TH 430<br />
Cooke, D 2100<br />
Cooney, L 1271<br />
Cooper, C 841<br />
Cooper, S 451, 1172, 1454, 1456<br />
Cooper, T 780<br />
Cooray, D 699<br />
Cope, AP 412<br />
Cope, E 1345<br />
Corazza, L 2036<br />
Corbera-Bellalta, M 1292, 1294,<br />
1309<br />
Cordel, N 2238<br />
Cordier, J-F 2009<br />
Cordingley, L 1323<br />
Coresh, J 1364, 1544, 1556, 1569<br />
Coriat, R 580<br />
Cormier, G 2269<br />
Cornec, D 2261<br />
Cornelissen, F 287, 1259<br />
Corneth, O 287, 715, 1525<br />
Cornish, J 881, 1983<br />
Corominas, H 1801<br />
Corona, F 2033<br />
Corr, M 271, 624, 1718<br />
Corrales Martinez, AF 1650<br />
2010 Program Book<br />
Correa, MJU 579<br />
Corrigall, VM 1729<br />
Corscadden, D 1090, 1254<br />
Corsiero, E 1906<br />
Cortez, V 1060<br />
Cortis, E 209, 2033<br />
Cortot, CF 235<br />
Corvol, P 1991<br />
Cosan, F 1281, 2217<br />
Cosentino, M 1089<br />
Cosmi, L 246<br />
Cosnes, A 2238<br />
Costa, J 1986<br />
Costa Antunes, M 566<br />
Costallat, LTL 1695<br />
Costantino, F 768<br />
Coste, J 2094<br />
Coste, P 948<br />
Costedoat-Chalumeau, N 478,<br />
732, 1249, 1287, 1660, 2025, 2238,<br />
2239<br />
Costello, S 995<br />
Costenbader, K 41, 64, 325, 762,<br />
1043, 1082, 1588, 2104<br />
Cosyns, J-P 1398<br />
Cot<strong>of</strong>ana, S 182, 1380<br />
Cottrell, JED 2279<br />
Cottrell, TR 596<br />
Cotty, P 130<br />
Couchot, M 130<br />
Couderc, M 917<br />
Coughlan, RJ 989, 2111, 2112<br />
Countryman, P 125<br />
Courtney, M 1335<br />
Coury, F 1502<br />
Covarrubias, JA 2173<br />
Covini, G 1639<br />
Covucci, A 1120, 1837<br />
Cox, AJ 226<br />
Cox, E 1404<br />
Cox, SM 2282<br />
Cox, VL 87, 1047, 1428, 1856,<br />
1865<br />
Coyle, A 741<br />
Cozic, C 29<br />
Craft, JE 1246<br />
Crane, MM 58<br />
Crate, DC 1537<br />
Crema, MD 193<br />
Creswell, L 536<br />
CRI 701, 902<br />
Crighton, KA 70<br />
Criscione-Schreiber, LG 1862<br />
Crisostomo, M 2251, 2252<br />
Crispino, JD 854<br />
Criswell, LA 446, 500, 502, 789,<br />
1591, 1592, 1595, 1602, 1898,<br />
2113, 2145, 2147, 2148<br />
Crittenden, D 148, 883<br />
Croca, SC 465, 1140, 1144<br />
Cr<strong>of</strong>ford, LJ 726, 864, 994<br />
Cr<strong>of</strong>oot, M 2072<br />
Cron, RQ 208, 209, 213, 1668,<br />
1679<br />
Cronin, M 493<br />
Cronstein, BN 148, 600, 827, 956,<br />
1469, 1470, 1471, 1522<br />
Crook, K 751, 752<br />
Crooks, E 1158<br />
Crow, MK 167, 508, 1181, 1183,<br />
1199, 1612, 1990, 2193<br />
Crowe, S 9, 24, 466<br />
Crowson, CS 15, 53, 67, 78, 316,<br />
705, 777, 1304, 1379, 1550, 1570,<br />
1580, 1581, 1637, 1652, 1654,<br />
1662, 2216<br />
Croxford, R 2208<br />
Cruz-Cruz, P 1150<br />
Cruz-Martínez, J 2268<br />
Cryer, B 937, 953<br />
Csernok, E 679<br />
CSRG 1202, 1221<br />
Csuka, ME 726<br />
Cuadrado, MJ 1357<br />
Cuccioloni, M 2001<br />
Cuda, CM 853, 859, 861<br />
Cuevas-Orta, E 1166<br />
Cui, J 308, 1050, 1335, 1610, 2064<br />
Cummings, SR 982, 2157<br />
Cunningham, F 1395<br />
Cuomo, G 572<br />
Cupples, LA 1317, 1329<br />
Curran, ML 47<br />
Curtis, C 153<br />
Curtis, JR 54, 68, 86, 239, 299,<br />
304, 379, 404, 721, 722, 1005,<br />
1006, 1010, 1031, 1099, 1117,<br />
1368, 1540, 1543, 1552, 1561,<br />
1573, 1643, 1753, 1782, 1808,<br />
2084, 2103<br />
Cusack, T 2135<br />
Cush, JJ 890, 908, 1618<br />
Cusumano, P 1656<br />
Cuthbert, R 1090, 1126, 1254<br />
Cuthbertson, D 2012, 2198<br />
Cutolo, M 578, 1236, 1798<br />
Cutrone, M 1439<br />
Cuttica, R 1434, 1701, 1872<br />
Cuyun Carter, G 52<br />
Czeloth, N 1125<br />
Czerwinski, E 2157<br />
D<br />
Da Costa, D 2120<br />
Da Silva, CHM 1684<br />
Da Valle, Y 839<br />
Dabbagh, K 288<br />
Dabbous, O 878<br />
DaCosta, D 1156<br />
Dadoun, S 781, 1648<br />
Dadu, E 694<br />
Daelken, B 1125<br />
Dagfinrud, H 534<br />
Dagliyan, G 1499<br />
Dagnæs-Hansen, F 1485<br />
D’Agostino, MA 527, 533, 551,<br />
1629, 1931<br />
Daher, J 200<br />
Dahiya, N 1633<br />
Dai, H 254<br />
Dai, L 367<br />
Dai, W 965<br />
Dai, X 274, 1107<br />
Daien, CI 393<br />
Daikh, BE 1638<br />
Dairaghi, DJ 1100, 2032, 2048<br />
Daizadeh, NS 2157<br />
Dalbeth, N 146, 881, 1983, 1372<br />
Dale, N 769, 795<br />
D’Alfonso, S 1578<br />
Daliman, D 2060<br />
Dalod, M 1664<br />
D’Aloisio, AA 61<br />
Dalpoto, J 288<br />
DalPra, F 50<br />
Dalprà, S 207<br />
Daly, M 1333<br />
Dam, EB 1466<br />
Damade, R 2034<br />
D’Ambrosio, L 99<br />
Damjanov, N 217<br />
Dancea, S 345, 1442<br />
Dang, JT 2185<br />
D’Angelo, S 532<br />
Daniel, G 81<br />
Daniels, T 1898<br />
Danielson, LS 1490<br />
Danila, MI 1077<br />
Dankaerts, W 520<br />
Dankbar, B 1478<br />
Dan<strong>of</strong>f, S 919, 1022<br />
D’Antona, G 744<br />
Dao, A 269<br />
Darce Bello, M 1305<br />
Darnell, R 863<br />
Das, L 268<br />
Das, R 841<br />
Dasari, S 2110<br />
d’Ascanio, A 839<br />
Dasgupta, A 642<br />
Dasgupta, B 777, 1637, 1652,<br />
1654<br />
Dasilva, V 976<br />
Dass, S 1126
Daudon, M 875<br />
Daugas, E 2009<br />
Davatchi, F 1289<br />
Dave, M 1477<br />
Davelaar, N 1259<br />
Davey, MP 1447, 1713<br />
Davì, S 208<br />
David, JR 1721<br />
David, S 2125<br />
Davidson, A 1410, 2188, 2276<br />
Davies, R 374, 509<br />
Davies-Tuck, M 173<br />
Davignon, J-L 281<br />
Davis, AM 682<br />
Davis, C 203<br />
Davis, J 1122<br />
Davis, KW 245<br />
Davis, LA 397<br />
Davis, M 147, 350, 920<br />
Davis, WE 1007<br />
Davis III, JM 67, 1580, 1581, 2216<br />
Dawood, M 449, 1185<br />
Dawson-Hughes, B 706<br />
Dayer, J-M 1088<br />
Dayoub, E 763<br />
D’Cruz, D 444, 463, 1456, 2035<br />
De, D 1925<br />
D’Elia, G 222<br />
de Achaval, S 87, 1047, 1428,<br />
1856, 1865<br />
de Almeida, BP 513<br />
De Angelis, R 547, 1627<br />
de Baere, E 2214<br />
De Bandt, M 701, 917, 1752<br />
de Benedetti, F 18, 1434<br />
de Boer, IG 2284<br />
de Boer, KVC 1396<br />
de Boer, M 1095<br />
de Boer, TN 942<br />
de Carvalho, LM 1694<br />
De Carvalho, M 768<br />
De Cunto, C 1700<br />
De Domenico, I 1309<br />
De Gennaro, L 2008<br />
De gennes, C 1651<br />
de Glas, NA 1755<br />
de Graaf, J 1210<br />
de Greeuw, I 1613<br />
de Groot, P 1360<br />
de Hair, MJ 1069, 1604<br />
de Jager, W 719<br />
de Jong, HWAM 121<br />
de Jong, PHP 317<br />
De Keyser, F 340, 824<br />
de Keyser, F 2214<br />
de Koning, M 1091<br />
De la Fuente, A 1473, 1498<br />
de la Serna, AR 1078<br />
De la Torre, I 739, 743<br />
de Langhe, E 610<br />
de Larranaga, G 3<br />
de Launay, D 32, 1529<br />
De Libero, C 1436<br />
de Longueville, M 995<br />
de Man, YA 1073<br />
De Marchi, G 2036, 2201<br />
De Marco, G 532<br />
de Martino, M 261<br />
de Menthon, M 2041<br />
De Meulemeester, M 145, 1423,<br />
2087<br />
de Miguel, E 986, 1629<br />
de Miguel-Mendieta, E 1967<br />
De Palma, R 246<br />
De Pasquale, L 18<br />
de Rijke, YB 1073<br />
De Riva, A 843<br />
de Rooij, M 2051<br />
De Rosa, M 781<br />
De Rycke, L 753, 2272<br />
de Sa Pinto, AL 1384<br />
de Saint-Martin, L 2010, 2011<br />
de Sanjose, S 1280<br />
De Santis, M 1239<br />
de Steenwinkel, FDO 1073<br />
De Toro, FJ 1473, 1475, 1483,<br />
1498<br />
De Vera, M 72, 720, 1056<br />
de Vernejoul, M-C 964<br />
De Vita, S 2036, 2201<br />
De Vito, A 1162<br />
de Vlam, K 520<br />
De Vooght, V 610<br />
de Vos, I 2051<br />
de Vries, D 1804<br />
de Vries, N 1069, 1604<br />
de Vries, RRP 2114<br />
de Vries, TJ 1495<br />
De Waal Malefijt, M 641<br />
de Waard-van der Spek, FB 219<br />
de Wazières, B 2045<br />
de Wit, M 1013<br />
Deane, K 71, 77, 658, 1083, 1094,<br />
2116, 2119<br />
Deberg, M 835<br />
Decaluwe, H 1693<br />
Dechant, C 2130<br />
Dechartres, A 2046<br />
DeCherrie, L 2110<br />
Decktor, D 420, 1960<br />
Dedeke, AB 9, 24, 780<br />
Dedreux, I 1827<br />
Deering, DE 647<br />
Deery, MJ 843<br />
Dees, C 607, 611, 614, 616, 672<br />
Degli Esposti, M 1446<br />
Degraeve, F 2027<br />
Dehlendorf, A 263<br />
Dehlin, M 103, 293<br />
Dehlinger, V 571<br />
Dehoratius, R 420<br />
DeHoratius, RJ 1960<br />
Dejaco, C 777, 1637, 1652, 1654,<br />
2222<br />
Dejmkova, H 1649<br />
Dekker, J 184<br />
Dekker-Bakker, LMMCJ 2051<br />
del Castillo, N 1310<br />
Del Galdo, F 671, 673<br />
del Junco, DJ 725<br />
Del Medico, P 1627<br />
Del Pino, J 975<br />
Del Rincon, I 1035, 1044, 1049,<br />
2163<br />
deLaat, B 2250<br />
Delaet, I 390, 416, 1834, 2173<br />
Delano, M 742<br />
Delany, K 750<br />
Delauter, SK 1382<br />
Delavallée, L 2236<br />
DeLay, M 1728<br />
Delbrel, X 2027<br />
Delea, S 947, 1055, 1567, 1626,<br />
2225<br />
Deleon, F 978<br />
Deleuran, B 1524, 1761<br />
Delgado, A 2145<br />
Delgado, R 804<br />
Delgado-Frias, E 389<br />
Delgado-Vega, AM 1578<br />
Deligny, C 571<br />
Della Rossa, A 1884<br />
Dellacasagrande, J 16<br />
Dell’Accio, F 1476, 1503<br />
Dellaripa, PF 1212<br />
Delle Sedie, A 558<br />
Delles, C 1441<br />
Delmas, PD 964<br />
DeLongis, A 1027, 1324<br />
Del-Pino, J 1888<br />
DelVentura, JL 101<br />
Delzell, E 54, 304, 404, 721, 722,<br />
1573, 1643, 2084, 2103<br />
DeMaria, DM 1045<br />
DeMartino, JA 288, 1270<br />
Demirkaya, E 1684, 1700, 1705<br />
Demoruelle, K 1094<br />
Dempsey, A 192<br />
Dempsey-Robertson, M 223<br />
Dempster, DW 2161<br />
Den Adel, M 2170<br />
Den Broeder, A 641, 1826, 1833<br />
Den Heijer, M 1210<br />
den Uyl, D 961<br />
Denaro, V 222, 1155<br />
Dencker, D 1444, 1841<br />
Deng, W 274<br />
Deng, Y 1583, 1584<br />
Dennis, G 757, 764, 1609<br />
Denny, L 1542<br />
Dent, R 2161<br />
Denton, C 560, 566, 590, 599,<br />
613, 674, 727, 829, 1207, 1212,<br />
1995, 1996, 2005<br />
Deodhar, AA 758, 1948<br />
Depresseux, G 1398<br />
Derancourt, C 571<br />
Derber, L 77, 658, 1083, 1094,<br />
2116<br />
Derby, CA 939, 2095<br />
Derese, I 1980<br />
Derfler, K 469<br />
Derk, CT 580<br />
Derksen, R 6<br />
Dernis, E 904<br />
DeRoo, LA 61<br />
Derrett-Smith, E 674, 1207, 1995,<br />
2005<br />
Dervieux, T 827<br />
Desai, P 692<br />
Deshayes, K 2032<br />
Deshmukh, US 1883<br />
Deshpande, P 2127<br />
Deshpande, V 1671<br />
Desjarlais, JR 1350<br />
Desvignes-Engelbert, A 551<br />
Detert, J 782, 1780<br />
Detilleux, J 979<br />
Devarajan, P 268, 2106<br />
Devauchelle, V 1896, 1914<br />
Devauchelle-Pensec, V 1931, 2261<br />
Deveber, G 2019<br />
DeVellis, RF 181, 1326<br />
Develly, PC 1458<br />
Devignes, J 1<br />
Devilliers, H 478<br />
Devita, S 1896<br />
Devogelaer, J-P 2156<br />
Dhanyamraju, PK 694<br />
Dhar, JP 468<br />
Dharmage, S 1942<br />
Dhawale, R 185<br />
Dhote, R 2026, 2034<br />
Di Duca, M 657<br />
Di Iorgi, N 1684<br />
Di Padova, FE 1730<br />
Di Pietro, F 1582<br />
Diamantopoulos, A 972<br />
2010 Program Book 323<br />
abstract author Index
aBSTRACT author Index<br />
Diamond, B 426, 1191, 2083<br />
Dias, VC 398<br />
Diaz, A 1659<br />
Diaz, F 1659<br />
Diaz, MV 1863<br />
Díaz, S 1473, 1498<br />
Díaz López, C 1118<br />
Díaz Torné, C 1118, 1796, 1801<br />
Diaz-Gallo, L 824, 2214<br />
Diaz-Gonzalez, F 389, 1509<br />
Diaz-Lopez, CR 1801<br />
Diaz-Martin, A 1509<br />
Díaz-Prado, S 1475, 1483<br />
Diaz-Sanchez, B 1505<br />
Dib, H 575, 834<br />
DiBonaventura, M 51, 327, 382<br />
DiCarlo, E 167, 1080<br />
DiCarlo, J 125<br />
Dieguez-Gonzalez, R 1076<br />
Diehl, A 1154<br />
Diehl, L 1609<br />
Diekman, LA 522, 1982<br />
Diel, R 782<br />
Diemert, M-C 1911, 2025<br />
Dietz, E 1621<br />
Dieude, P 1087, 1890, 1910, 1987,<br />
1994, 2226<br />
DiFrancesco, M 1689<br />
Dijkmans, BA 90, 295, 328, 332,<br />
334, 643, 663, 1084, 1613, 1859,<br />
1933, 1091, 1445, 1496, 1825,<br />
1948<br />
Dilling, RG 2051<br />
Dillon, SP 1901<br />
Dimic, A 1096, 2168<br />
Dina, B 1689<br />
Dinarello, C 371, 1308, 1664<br />
Dincer, U 114<br />
Dinella, J 1554<br />
Dinesh, RK 1257<br />
Ding, B 832, 1588, 2161<br />
Ding, L 2012<br />
Ding, Y 1250<br />
Dinser, R 1479<br />
Dintinger, H 768<br />
Diot, E 2010, 2011, 2034, 2045<br />
DiPlacido, L 1246<br />
Direskeneli, H 777, 822, 1133,<br />
1291, 1303, 1637, 1652, 1654,<br />
1803, 2200<br />
Direz, G 130, 904<br />
DiRusso, JM 2053, 2054<br />
Dirven, L 328, 334, 1496, 1782<br />
Distler, J 560, 566, 607, 611, 614,<br />
615, 616, 672, 1991, 2000<br />
Distler, O 560, 566, 599, 607, 611,<br />
616, 1212, 614, 672, 1988<br />
Disu, T 1358<br />
Ditto, MC 784<br />
Dixon, J 173, 1383<br />
Dixon, W 342, 421<br />
Dlott, J 12<br />
Do, HT 174, 898<br />
Doan, E 12, 2253<br />
Dobrzanski, P 2233<br />
Dockhorn, R 1111<br />
Dodd, A 250<br />
Doerner, T 1910<br />
Dogan, S 1283<br />
Doherty, EH 2275<br />
Doherty, M 841<br />
Doherty, S 841<br />
Dohmen, S 1822<br />
Dolan, G 1831<br />
Dolatabadi, S 1768, 305<br />
Dolezalova, P 1705<br />
Dolhain, RJEM 1073<br />
Dolman, KM 219<br />
Dolphi, F 953<br />
Domínguez, MJ 1659<br />
Dominguez, N 2274<br />
Dominguez, PR 501<br />
Dominguez-Luis, MJ 1509<br />
Domino, SE 1504<br />
Domsic, RT 569, 586, 1231<br />
Donadio, E 839<br />
Dong, Q 1107<br />
Dong, W 698<br />
Donn, RP 445<br />
Donnell-Fink, L 2092<br />
Donnelly, S 1306<br />
Dooley, A 674, 2005<br />
Dooley, M 445, 448, 451, 476,<br />
731, 1453, 1877, 2085, 2240, 2243<br />
Doorenspleet, ME 1069, 1604<br />
Dorais, M 196, 938<br />
Doria, A 1402, 1456<br />
Döring, G 1123<br />
Dörner, T 414, 745, 1411, 1896<br />
Dorri, Y 1901<br />
Dorris, M 1448<br />
Dorsey, B 2233<br />
dos Santos, MM 1458<br />
Dotzlaw, H 886<br />
Douce, T 493<br />
Dougados, M 69, 82, 321, 400,<br />
414, 529, 542, 548, 917, 948, 1013,<br />
1104, 1629, 1648, 1760, 1790,<br />
1805, 1810, 1924, 1927, 1946<br />
Douglas, KB 730<br />
Douma, S 11<br />
Doumas, M 11<br />
Doveri, M 1884<br />
Doweyko, A 1513<br />
Doyle, A 1372<br />
Doyle, MK 326, 890, 908, 1804<br />
Drachman, JG 1273<br />
Dracou, C 1684<br />
Draeger, H 562, 725, 1211, 1218,<br />
1227<br />
Dragone, L 748, 2128<br />
Drapé, J-L 728<br />
Drappa, J 1455<br />
Dreher, D 182<br />
Drenkard, CM 790<br />
Drenth, J 1210<br />
Dressler, F 1701, 1705<br />
Drews-Botsch, C 1405<br />
Drexhage, HA 1904<br />
Dreyfus, P 1413<br />
Driban, J 122, 706, 709<br />
Driscoll, PC 1358, 1359<br />
Drosos, AA 1215<br />
Drossaert, CHC 1334<br />
Drouot, L 915<br />
Drummond, W 150<br />
D’souza, A 1901<br />
D’Souza, C 1163<br />
du Bois, RM 2119<br />
Du Clos, T 850<br />
Duan, R 2184<br />
Duarte-García, A 1853, 1881<br />
Dübel, S 2234<br />
Dubner, SE 206<br />
Dubois, A 2269<br />
Dubost, J-J 375, 701, 1890, 1910<br />
Dubourg, O 922<br />
Dubreuil, M 2199<br />
Duch, D 41<br />
Ducourau, E 988, 1945<br />
Duda, G 630, 1418<br />
Dudler, J 1819<br />
Duer-Jensen, A 133, 1370<br />
Duff, GW 831, 838<br />
Duffy, C 214, 1408<br />
Dufour, AB 1327, 1328, 1330,<br />
1331<br />
Duftner, C 777, 1637, 1654, 2222<br />
Dugan, B 2233<br />
Duhaut, P 777, 1652, 1654, 2040,<br />
2238<br />
Dulos, J 1730<br />
Dummer, W 383, 414, 2169<br />
Dumont-Fischer, D 997<br />
Duncan, B 1805, 2246<br />
Dunlop, DD 186, 189, 202, 1558,<br />
2096<br />
Dunne, A 1426<br />
Dunussi-Joannopoulos, K 1154<br />
Duny, Y 393<br />
Dupont, F 221<br />
Dupuy, A 1651<br />
Duquesne, A 905<br />
Duquesroix, B 936, 953<br />
Durand, E 533<br />
Durand-Zaleski, I 781<br />
Durez, P 123, 340, 1013, 1817,<br />
2173, 2263<br />
Durham, K 823<br />
Durmus, O 114<br />
Durnez, A 311<br />
Duryee, MJ 2235<br />
Dutmer, E 1833<br />
Dutz, JP 523, 1661<br />
Dvir-Ginzberg, M 1484<br />
Dweik, R 564<br />
Dyer, AR 1168<br />
Dzeing-Ella, A 576<br />
Ea, H-K 413, 875, 888, 2151<br />
Ea, K 1707<br />
Eastman, S 1606<br />
Eaton, C 71, 2096<br />
Eaton, J 1688, 2106<br />
Ebeling, PR 982<br />
Eberhard, A 1677<br />
Eberhard, BA 1673, 1688, 1691,<br />
1701, 1702, 2017<br />
Eberl, H 1764<br />
Eberle, E 515<br />
Eckes, B 1719<br />
Eckstein, F 182, 1380<br />
Edberg, JC 828, 868, 1584, 1591,<br />
1594, 1595, 2147<br />
Eddleman, KC 1860<br />
Ede, KC 1673, 1691, 2017<br />
Edelmann, E 138<br />
Edelstein, D 178<br />
Eder, L 455, 521, 530, 783, 1928,<br />
1936, 1954, 1956, 1974, 1979,<br />
1984<br />
Edgar, M 635, 639, 1727<br />
Edgerton, CC 346<br />
Edison, JD 1083, 2116<br />
Edlin, H 1067<br />
Edmundowicz, D 1168<br />
Edogawa, S 298<br />
Edwards, JCW 739, 743<br />
Edwards, KA 115<br />
Edwards, RR 949<br />
Eftekhari, A 2152<br />
Egbuna, OI 982<br />
Egerer, K 911<br />
Eggebeen, AT 209<br />
Eguchi, K 364, 1371, 1632<br />
Ehara, T 1709<br />
Ehman, RL 129<br />
Ehrenstein, MR 738, 740<br />
E<br />
324<br />
2010 Program Book
Ehst, B 758<br />
Eicher, JL 688<br />
Eisen, S 62, 1395<br />
Ejbjerg, B 133, 141, 1370<br />
Ekholm, L 926<br />
Eksioglu-Demiralp, E 2200<br />
Ekström Smedby, K 1015<br />
El Baalbaki, G 2247<br />
Elash<strong>of</strong>f, DA 1779, 1789<br />
Elash<strong>of</strong>f, M 326<br />
El-Gabalawy, HS 1068, 1094, 1176<br />
Elhai, M 529, 1924<br />
Elias, M 550<br />
Eliasson, H 832<br />
Eljaafari, A 1247<br />
El-Kadi, HS 420<br />
Elkayam, JG 682<br />
Elkayam, O 697, 1238<br />
Elkins, J 176<br />
Elkon, KB 494, 499<br />
Eller, M 801<br />
Ellis, J 248, 2219<br />
Ellis, L 1424<br />
Ellis, R 463<br />
El-Mansouri, FE 1489<br />
Eloranta, M-L 503<br />
Elshafie, A 695<br />
El-Shanti, H 260<br />
Elston, E 912<br />
Elsworth, G 2079, 2139<br />
Emamian, SM 1918<br />
Emerling, D 164<br />
Emerson, F 1638<br />
Emery, H 1433<br />
Emery, P 118, 141, 321, 326, 391,<br />
403, 414, 524, 553, 671, 673, 1013,<br />
1063, 1090, 1097, 1101, 1114,<br />
1126, 1127, 1136, 1254, 1791,<br />
1805, 1836, 1926, 1929, 1963,<br />
2182, 2183, 2264<br />
Emilie, D 376<br />
Emir, B 94, 813<br />
Emkey, GR 25<br />
Emu, B 1122<br />
Enama, JL 1861<br />
Endo, H 619<br />
Endreffy, E 1578<br />
Endres, J 1271, 1520, 1609<br />
Engelbrecht, M 1781<br />
Engelke, K 128<br />
Engel-Nitz, N 757, 764<br />
Englbrecht, M 128, 1027, 1634<br />
Engling, A 1125<br />
Englund, M 131, 182, 761, 963,<br />
2209<br />
Eng-Wong, J 912<br />
Enjuanes, A 1280<br />
Ennis, H 1234<br />
Ens, A 238<br />
Epifania, B 615<br />
Epstein, RS 1561<br />
Equinda, M 1390<br />
Erausquin, C 1876<br />
Ergen, A 822<br />
Ergonul, O 1133<br />
Ergun, T 1303<br />
Erik, PJ 15<br />
Eriksson, C 1847<br />
Eriksson, P 1885<br />
Erkan, D 2077, 6<br />
Erlandsson, M 103, 293<br />
Erlendsson, J 134, 1953<br />
Ernestam, S 1392, 1393<br />
Ernet, C 128<br />
Ershova, O 1125<br />
Ertl, G 1026<br />
Ertl, J 327, 382<br />
Ertl, L 2048<br />
Ervin, JE 710<br />
Esbrit, P 1475<br />
Escalante, A 1044, 1049, 2163,<br />
1035<br />
Esdaile, J 1036, 1152, 1324, 1538,<br />
2055<br />
Eshed, I 1369<br />
Espesen, J 1444, 1841<br />
Espígol-Frigolé, G 777, 1276,<br />
1292, 1314, 1637, 1654<br />
Espinosa, G 824<br />
ESPOIR Scientific Committee 1760<br />
Esposito, D 1358<br />
Essenmacher, L 468<br />
Esserman, D 19<br />
Estrach, C 661, 1763<br />
Estrada, P 1016, 1277, 1299, 1310<br />
Estrada Y Martin, R 1218, 1227<br />
Esveldt, RE 1069, 1604<br />
Etchepare, F 2221<br />
Ethirajulu, K 717<br />
Etrolpolski, M 950<br />
EULAR Sjögren’s Task Force 1896<br />
Euller Ziegler, L 917, 976, 1810,<br />
2094<br />
Evangelisto, AM 1617<br />
Evans, GW 1677<br />
Evans, HG 1263, 1838<br />
Evans, RR 152, 153<br />
Everts, V 1495<br />
Eveslage, M 1111, 1112<br />
Eweis, I 798<br />
Eyckmans, J 1468<br />
Eymard, B 915, 922<br />
Eyre, S 264, 266, 1075, 1394,<br />
1593<br />
Ezeonyeji, AN 1153<br />
F<br />
Fabian, G 1273<br />
Fabreguet, I 529, 1924<br />
Fabri, GMC 2078, 2204<br />
Fabricio-Silva, GM 356<br />
Faezi, T 1289<br />
Fahmi, H 1489<br />
Fahrleitner-Pammer, A 967<br />
Fain, O 701, 917, 1653, 1893,<br />
1894, 2239<br />
Fak, J 863<br />
Fakharzadeh, S 920<br />
Falcini, F 222, 261, 1155, 1439,<br />
1872, 2033, 2202<br />
Falgarone, G 997, 1707<br />
Falissard, B 82<br />
Falk, RJ 2048<br />
Fall, N 244, 653<br />
Falzer, P 2249<br />
Fan, H 326, 442, 1127, 1968<br />
Fang, C 1542<br />
Fang, H 474, 1163, 1180, 1858<br />
Fang, L 1107<br />
Fang, MA 169<br />
Fang, Y 1167<br />
Fantin, B 1653<br />
Faraone, S 449<br />
Fardellone, P 69, 787, 971, 2094<br />
Farewell, V 536, 1979, 2242, 2243<br />
Faria, AGA 498<br />
Farina, G 675<br />
Faris, P 775<br />
Farmer, MV 648<br />
Farmer, P 391, 401<br />
Farnarier, C 1664<br />
Farragher, TM 779<br />
Farris, AD 1267<br />
Fassold, A 361<br />
Fateh, J 2072<br />
Fathi, M 924<br />
Fauchais, A 1890, 1910<br />
Faure, G 768<br />
Faustini, F 744, 1239, 1582<br />
Fautrel, B 141, 301, 781, 787,<br />
984, 1104, 1752, 1760, 1762, 2094,<br />
2221<br />
Favarato, MHS 531<br />
Favero, L 1687<br />
Favero, V 1687<br />
Faye, A 1305, 1693<br />
Fazio, S 1034<br />
Fazzini, B 1173<br />
Fearon, U 16, 360, 871, 1391,<br />
1508, 1510, 1533, 1625<br />
Federici, C 834<br />
Federici, S 265, 1685, 1706<br />
Fedorora, T 282<br />
Feghali-Bostwick, CA 670, 2006<br />
Fehm, T 1145<br />
Fehringer, EV 168<br />
Feist, E 56, 911, 1788<br />
Feld, J 550<br />
Feldman, BM 225, 1408, 1681<br />
Feldstein, A 1543<br />
Feldtkeller, E 1923<br />
Feletar, M 1560<br />
Felli, L 1798<br />
Felsher, DW 434<br />
Felson, D 131, 197, 198, 201, 205,<br />
683, 685, 686, 723, 836, 872, 951,<br />
1373, 1385, 1464, 1557, 1564,<br />
2098, 2100, 2108, 2133<br />
Feng, J 1789<br />
Feng, R 920<br />
Feng, X 918, 1143, 1182<br />
Fenter, P 2076<br />
Ferbas, J 1141<br />
Ferbert, SM 2075<br />
Feria, M 1659<br />
Ferland, D 300, 306, 343, 659,<br />
978, 1737<br />
Fernandes, A 228, 356, 754, 2132<br />
Fernandes, BLF 1458<br />
Fernández, A 1811<br />
Fernandez, DR 437, 1185, 2275<br />
Fernández, F 1811<br />
Fernandez, I 608, 852<br />
Fernandez, L 1732<br />
Fernández, P 600<br />
Fernández LLaca, H 1650<br />
Fernández-Carballido, C 986<br />
Fernández-Gutiérrez, B 1078,<br />
1301, 1599<br />
Fernández-López, C 835<br />
Fernández-Lopez, JC 541, 1920<br />
Fernandez-Luna, JL 1296<br />
Fernández-Moreno, M 835<br />
Fernandez-Nebro, A 824<br />
Fernández-Puente, P 840, 1473<br />
Fernandez-Sueiro, JL 538, 541,<br />
1920<br />
Ferraccioli, G 297, 355, 414, 744,<br />
1098, 1239, 1582, 1627, 1787,<br />
2036<br />
Ferrant, J 1243, 1244, 1245<br />
Ferraz-Amaro, I 389<br />
Ferrazzi, V 904<br />
Ferreira, A 1423, 1425<br />
Ferreira, T 936<br />
Ferreiro, A 1078<br />
Ferri, C 297, 581, 1627, 2036,<br />
2201<br />
Ferriani, VPL 1339, 1694<br />
Ferrone, C 578<br />
Fertala, J 1999<br />
Fert-Bober, J 2167<br />
2010 Program Book 325<br />
abstract author Index
aBSTRACT author Index<br />
326<br />
Fertig, N 563, 913, 925, 929, 930<br />
Ferucci, ED 892<br />
Fervenza, FC 680, 2012<br />
Fessler, B 445, 448, 476, 1877,<br />
2012, 2240, 2243<br />
Fester, A 740<br />
Fett, N 920<br />
Feuchtenberger, M 782, 1026,<br />
1255, 1411<br />
Feudtner, C 233, 1703<br />
Fichtner, A 1806<br />
Fidelus-Gort, R 2172<br />
Field, J 783<br />
Fields, K 1405<br />
Figueiredo, CP 1546<br />
Fike, F 509<br />
Filer, A 1263<br />
Filipovich, AH 653<br />
Filippini, D 2201<br />
Filippucci, E 547, 1635<br />
Filkova, M 638<br />
Filocamo, G 207, 232<br />
Filopoulos, M 1284, 1298, 1303<br />
Finckh, A 2257, 940<br />
Fines, P 1555<br />
Finetti, M 1685, 1706<br />
Finkel, TH 233, 2219<br />
Finzel, S 128, 1634<br />
Fiocco, M 2284<br />
Fiorentino, D 573, 1213, 1378<br />
Fioretti, G 1687<br />
Fiori, G 593<br />
Fiorino, T 144<br />
Firestein, GS 271, 362, 635, 639,<br />
855, 1240, 1718, 1725, 1727<br />
Firneno, C 156<br />
Fischbach, M 1219, 1226, 1407,<br />
1705<br />
Fischer, A 591, 2119<br />
Fischer, S 1420<br />
Fisheleva, E 383, 414<br />
Fisher, M 25, 966, 1645<br />
Fisk, JD 2242<br />
Fiskesund, R 88<br />
Fitzcharles, M 100, 107<br />
Fitzgerald, GK 2059, 2052<br />
FitzGerald, J 8, 471, 933, 1058,<br />
2241<br />
FitzGerald, O 514, 555, 833, 1032,<br />
1105, 1508, 1625, 1631, 1947,<br />
2065, 2135<br />
Fitz-Gibbon, PD 316<br />
Fitzhugh, DJ 19<br />
Fitzpatrick, LR 1480<br />
Fitz-Patrick, D 150<br />
Flahault, A 533<br />
Flaherty, K 402, 1212<br />
Flahive, J 969<br />
2010 Program Book<br />
Flanagan, C 785<br />
Flanagan, WM 1555<br />
Flatø, B 2219<br />
Fleckner, J 508<br />
Fleischmann, R 321, 385, 391,<br />
420, 1114, 1127, 1136, 1154, 1753,<br />
1782, 1791, 1805, 1819, 1832,<br />
2262, 2264<br />
Fleming, R 953<br />
Fleming, S 1063<br />
Fleury, TW 1403<br />
Flick, M 1728<br />
Flipo, R-M 376, 400, 787, 904,<br />
1790<br />
Flom, PL 161<br />
Flores, P 2070<br />
Flores, R 144, 2172<br />
Florica, B 1165<br />
Flory, P 976<br />
Fluiter, K 1529<br />
Flynn, DL 289<br />
Flynn, E 264, 266<br />
Foeldvari, I 220, 227, 230, 599,<br />
1435, 1704<br />
Foged, H 1809<br />
Fogg, LF 2099<br />
Foltz, V 141, 1369, 2221<br />
Fong, AM 19<br />
Fongen, C 534<br />
Fonollosa, V 824<br />
Fonseca, C 829<br />
Fonseca, JE 1986, 1013<br />
Fontaine, K 310, 1065<br />
Fontalba, A 1296<br />
Fontes, JDT 1317<br />
Forastiero, R 3, 2251, 2252<br />
Forgues, M 2027<br />
Formisano, D 1290<br />
Førre, O 2219<br />
Forslind, K 1392, 1393<br />
Fort, JG 937<br />
Fortin, É 236<br />
Fortin, P 13, 445, 448, 476, 731,<br />
1156, 1165, 1178, 1850, 1877,<br />
2120, 2240, 2243<br />
Fortner, BV 1747<br />
Fossati, G 1517<br />
Fossati-Jimack, LM 430<br />
Fossel, A 1335, 2064<br />
Foucher, KC 2099<br />
Foulkes, R 752<br />
Fournié, J-J 281<br />
Fox, D 1271, 1520, 1609<br />
Fox, E 360, 1510<br />
Fox-Talbot, K 1074<br />
Fraenkel, L 59, 1459, 2249<br />
Fragoso, J-M 96<br />
Fragoso-Loyo, H 1853<br />
Frakes, E 175<br />
Frallonardo, P 540<br />
Frampton, C 417<br />
Francès, C 2238, 2239<br />
Franceschelli, F 1155, 2202<br />
Francesco, LT 1155<br />
Francesco, M 286<br />
Francis, B 1124<br />
Francis, HW 2031<br />
Francis, L 449, 1185, 1196<br />
Francis, S 1147<br />
Francisco, F 1876<br />
Franco Salinas, G 753<br />
Francois, A 1413, 1998<br />
Francois, F 883<br />
Franco-Maside, A 389<br />
FrancoSalinas, G 1977<br />
Franek, BS 495, 496, 1164, 1612<br />
Franek, E 982<br />
Frank, MB 243, 247, 251, 258, 655<br />
Frank, S 368, 1719<br />
Franke, L 1599<br />
Franklin, J 963<br />
Franklin, PD 2053, 2054, 2136<br />
Franks, L 1406, 2248<br />
Fransen, J 641, 1785, 1833, 2196<br />
Frantz, RP 595<br />
Fraser, AD 2224<br />
Fraser, L 463<br />
Fraser, O 1105<br />
Fraticelli, P 2036<br />
Frayssinet, H 936<br />
Frech, T 561, 1228<br />
Frederick, B 1804<br />
Frederick, M 244<br />
Frederiksen, KS 508<br />
Fredman, L 683<br />
Freebody, J 922<br />
Freedman, B 1028, 1584, 1585,<br />
1586, 1591, 2147<br />
Freeston, J 118, 141, 1369<br />
Freimuth, W 452, 457, 1146,<br />
1172, 1454, 1456, 1457, 1848<br />
French, AR 216, 1633<br />
French, MR 682<br />
Frenkel, J 905, 1706<br />
Frenkel, SR 1470<br />
Fresko, I 1279<br />
Freudenberg, J 1597<br />
Freundlich, B 1927, 1937, 669,<br />
2271<br />
Frey, B 2150<br />
Frey, JC 1328<br />
Frey, S 857<br />
Frey Law, L 205<br />
Freylaw, L 1557<br />
Frey-Law, L 1385, 2098<br />
Fridén, C 2245<br />
Friedman, A 1374<br />
Friedman, D 732<br />
Fries, J 642, 877, 1545, 2153<br />
Frits, M 308, 1050, 1778<br />
Fritz, C 526<br />
Fritzler, MJ 1216, 1227<br />
Froger, P 984<br />
Frosali, F 246<br />
Frostegård, J 88, 1194, 1578<br />
Frueh, FW 1561<br />
Fu, B 421<br />
Fuentes, I 1473, 1475, 1498<br />
Fuentes-Boquete, I 1483<br />
Fuhlbrigge, R 860<br />
Fujieda, M 652<br />
Fujieda, Y 2, 5, 10, 1909, 2254<br />
Fujii, H 1079<br />
Fujii, K 1086<br />
Fujii, T 1377<br />
Fujimoto, M 724, 1230<br />
Fujio, N 1824<br />
Fujita, T 2227<br />
Fujita, Y 1264<br />
Fujiwara, S 1708<br />
Fukazawa, C 1666<br />
Fukuda, S 2029<br />
Fukuda, T 472<br />
Fukuyo, S 1793, 1823<br />
Fuller, P 954, 955<br />
Fuller, R 1384, 2134<br />
Fulton, S 407<br />
Funahashi, K 1138, 1738, 1739<br />
Funaki, S 893<br />
Funaro, A 2001<br />
Funck-Brentano, T 2221<br />
Funovits, J 723, 2108<br />
Furet, O 1014<br />
Furie, RA 452, 1172, 1454, 1455,<br />
1456, 1457<br />
Fürnrohr, BG 607, 614<br />
Furst, D 147, 155, 347, 378, 391,<br />
561, 583, 594, 599, 726, 729, 1004,<br />
1010, 1106, 1205, 1213, 1228,<br />
1232, 1365, 1766, 1804, 1819,<br />
2194, 2195<br />
Fürst, FC 1481<br />
Fürst, M 1486<br />
Furukawa, S 10<br />
Furuya, K 921<br />
Furuya, T 968<br />
Fusetti, C 623<br />
Fusfeld, L 754<br />
FVSG 2045<br />
G<br />
Gabay, C 792, 940, 1802, 1807,<br />
2257
Gabay, OH 1484<br />
Gaber, T 630, 1418<br />
Gabriel, SE 53, 67, 78, 1550, 1570,<br />
1580, 1581, 2216<br />
Gabriele, A 125<br />
Gabrielle, M 2065<br />
Gabrielli, A 2001, 2008, 2036,<br />
2201<br />
Gaches, F 2027<br />
Gaddy, JR 780<br />
Gadina, M 260, 2217<br />
Gadler, F 832<br />
Gaedigk, R 253, 254<br />
Gaffney, PM 500, 502, 1583,<br />
1584, 1585, 1586, 1591, 1594,<br />
1595, 2144, 2145, 2146, 2147,<br />
2148, 2274<br />
Gaffo, AL 1367<br />
Gagarina, V 1484<br />
Gagnon, DR 1331<br />
Gaillez, C 1817<br />
Gal, N 1197<br />
Galanopoulou, V 1021<br />
Galant, C 2263<br />
Galasso, R 210, 1705<br />
Galdo, F 1920<br />
Galeazzi, M 615, 837<br />
Galica, AM 1327, 1328, 1331<br />
Galicier, L 2239<br />
Galindo, M 482, 1171<br />
Gall, EP 415, 1014, 1636<br />
Galla, L 259<br />
Gallacher, A 451, 452, 1172<br />
Gallagher, KT 998<br />
Gallagher, P 1947<br />
Gallagher, S 741<br />
Gallant, C 2145<br />
Gallant, MA 716<br />
Galli, M 2036, 2201<br />
Gallizzi, R 1685<br />
Gallo, A 2179<br />
Galloway, J 374, 421<br />
Gambineri, E 261<br />
Gamsa, A 107<br />
Gandjbakhch, F 141, 1369, 2221<br />
Gandon-Laloum, S 1684<br />
Ganser, G 220<br />
Gao, F 507<br />
Gao, I 138<br />
Gao, L 1119<br />
Gao, W 1510<br />
Garber, E 1244, 1245<br />
Garbutt, J 216<br />
Garchon, H-J 1981<br />
Garchow, B 422<br />
Garcia, BA 2191<br />
Garcia, L 1413<br />
Garcia, R 449, 1185, 1196<br />
Garcia de la Peña, P 824<br />
García de Vicuña, R 1276<br />
Garcia de Yebenes, MJ 975<br />
Garcia Gonzalez, A 1047, 1865<br />
Garcia Gonzalez, E 615<br />
García Llorente, JF 986<br />
García Salinas, R 50<br />
García-Arias, MJ 1229<br />
Garcia-Bello, M 1876<br />
Garcia-Carmona, Y 349<br />
García-Consuegra, J 1705<br />
García-Hernandez, FJ 824<br />
García-Honduvilla, N 1475<br />
García-Laorden, I 1876<br />
Garcia-Martinez, A 1292, 1314<br />
Garcia-Meijide, JA 1119<br />
Garcia-Vicuña, R 1229, 1505<br />
García-Yébenes, MJ 986<br />
Gardner, G 163, 1433<br />
Garen, T 1275<br />
Garg, R 339<br />
Garlantezec, R 315<br />
Garman, L 734<br />
Garneau, K 42<br />
Garnero, P 134, 1953<br />
Garrido, J 975<br />
Garris, CP 757, 764<br />
Garwick, A 1340<br />
Garza Elizondo, MA 416<br />
Garza-Garcia, A 1358, 1359<br />
Gasc, JM 1991<br />
Gascon, D 792, 940<br />
Gasparello de Almeida, R 1872<br />
Gasparini, S 1746, 1787<br />
Gaston, J.S.Hill 1424<br />
Gathany, T 1136<br />
Gatti, RA 509<br />
Gattorno, M 265, 657, 895, 905,<br />
1305, 1425, 1435, 1685, 1706<br />
Gaudin, P 63, 1752, 1829, 1931<br />
Gauditano, G 1644<br />
Gaujoux, T 413<br />
Gaujoux-Viala, C 413, 787, 984,<br />
1762<br />
Gauna, AE 2174<br />
Gautam, S 640<br />
Gauthier, C 1007<br />
Gay, RE 21, 35, 357, 679, 1093,<br />
1518, 1528, 1988<br />
Gay, S 21, 35, 357, 638, 679, 1093,<br />
1389, 1518, 1528<br />
Gaylis, NB 125, 1747<br />
Gaynor, P 105, 113<br />
Gea-Banacloche, J 1161<br />
Gebay, C 55<br />
Geborek, P 1037, 1381, 1392,<br />
1393, 1440<br />
Gebretsadik, T 1023, 1034, 1867<br />
Geenen, R 1338<br />
Geha, PY 2097<br />
Gehad, A 860<br />
Geher, P 1946<br />
Gehlbach, S 969<br />
Gelber, AC 45, 589, 919, 1364,<br />
1544, 1556, 1565, 1569, 1574,<br />
2162, 2260<br />
Gelfand, EW 2128<br />
Geli, C 1801<br />
Geller, M 1311<br />
Gellert, P 247<br />
Gelperin, K 75<br />
Genant, HK 1369<br />
Gendreau, J 805<br />
Gendreau, JF 302<br />
Gendreau, RM 98, 648, 805, 806<br />
Generini, S 558<br />
GENESYS Consortium 1987, 1994,<br />
2226<br />
Genovese, M 326, 385, 403, 411,<br />
414, 945, 946, 1097, 1103, 1114,<br />
1119, 1136, 1919, 1955, 1960,<br />
2169, 2173<br />
Gent, YYJ 1613<br />
Georg, S 1027<br />
George, E 1549<br />
George, M 919<br />
Georgescu, L 405<br />
Gerber, DA 161<br />
Gerdan, V 544, 1282, 1921<br />
Gergely, Jr, P 560, 566<br />
Geri, G 1249, 1646, 1648, 2030<br />
Gerlag, D 32, 719, 1069, 1095,<br />
1507, 1604, 1821, 1822, 2170<br />
Gerli, R 297<br />
Gerloni, V 261, 1407<br />
Gerlovin, H 2091, 2092<br />
Germanò, G 1290, 1302<br />
Gertner, E 910<br />
Gessner, A 2237<br />
Geurts, J 1535, 1733<br />
Geurts-van Bon, L 829, 2004<br />
Geusens, PP 1948<br />
Geyer, M 1479, 1722<br />
Ghali, WA 309<br />
Ghanem, A 1152<br />
Ghazan-Shahi, S 109<br />
Ghidey Alemayehu, W 2114<br />
Ghinoi, A 1302<br />
Ghiran, IC 2277<br />
Ghirmire, S 640<br />
Ghoreishi, M 1661<br />
Ghosh, A 2086<br />
Ghosh, P 163, 2086<br />
Giacomelli, C 811, 839<br />
Giacomelli, R 297<br />
Giacovelli, G 948<br />
Giampietro, C 413<br />
Giani, T 240<br />
Giannakopoulos, B 621<br />
Giannini, C 2037, 2038<br />
Giannini, EH 1407, 1688<br />
Gibney, RG 1625<br />
Gib<strong>of</strong>sky, A 1013<br />
Gibson, A 868, 1560<br />
Gibson, KA 1560<br />
Gibson, KL 252<br />
Gibson, N 198<br />
Gieger, C 711<br />
Gierut, AK 861<br />
Gigante, M 1239<br />
Gil, A 1888<br />
Gil, KM 1406, 2248<br />
Gilbert, D 915<br />
Gilbert, JL 75<br />
Gilbert, L 694<br />
Gilchrist, N 971<br />
Giles, I 1358, 1359, 2255<br />
Giles, J 1018, 1022, 1030, 1065,<br />
1074, 1441, 2162, 2167, 2260<br />
Gilkeson, GS 435, 437, 475, 510,<br />
960, 1526, 1583, 1584, 1585, 1586,<br />
1590, 1591, 1594, 2274<br />
Gilkeson, R 470, 1861<br />
Gill, M 2119<br />
Gill, N 1408<br />
Gill, RE 2063<br />
Gill, TM 1459<br />
Gilleece, Y 966, 1645<br />
Gillespie, E 473<br />
Gillespie, J 671, 673<br />
Gilliam, B 263, 1601<br />
Gilliland, WR 1083, 2116<br />
Gillis, JZ 789, 2113<br />
Gillis, R 1382<br />
Gillott, T 974<br />
Gindea, S 2186, 2187<br />
Gingrich, D 2233<br />
Ginzler, E 445, 448, 451, 476, 731,<br />
1453, 1456, 1457, 1866, 1877,<br />
2085, 2240<br />
Giorgi, M 1635<br />
Giovannini, L 1962<br />
Girerd, X 1651<br />
Giron, J 2027<br />
Girschick, H 227<br />
Gitelman, D 1689<br />
Giuggioli, D 581<br />
Giusti, L 811, 839<br />
Giustino, L 1308<br />
Gkazinou, C 646, 649<br />
Glace, B 1810<br />
Gladman, D 13, 445, 448, 450,<br />
452, 455, 476, 521, 523, 530, 536,<br />
545, 731, 772, 783, 1165, 1451,<br />
2010 Program Book 327<br />
abstract author Index
aBSTRACT author Index<br />
1456, 1850, 1868, 1869, 1874,<br />
1877, 1878, 1919, 1928, 1932,<br />
1936, 1943, 1954, 1956, 1964,<br />
1966, 1974, 1975, 1979, 1984,<br />
2240, 2243, 2273<br />
Gladstein, GS 1834, 1919<br />
Gladys Mulle, J 250<br />
Glant, T 1447, 2184<br />
Glass, DN 255, 654<br />
Glauber, H 1543<br />
Gleason, RM 807<br />
Glenmark, B 2245<br />
Glibert, H 1609<br />
Glikmann-Johnston, I 1159<br />
Glimcher, L 675<br />
Glintborg, B 1444, 1809, 1841<br />
Glocke, S 1059<br />
Glogowska, MJ 2227<br />
Gobbo, A 1831<br />
Gobbo, M 986<br />
Gobezie, R 363, 2229<br />
Godeau, B 400, 1790<br />
Godfrey, T 1560<br />
Godinho, F 1986<br />
Godmer, P 2045<br />
Goeb, V 571<br />
Goebel, K 1255<br />
Goehner, K 1011<br />
Goehring, Jr, EL 698<br />
Goekoop-Ruyterman, Y 295<br />
Goel, N 1805, 1806, 1832<br />
Goemaere, S 982<br />
Goergen, S 1917<br />
G<strong>of</strong>finet, F 2034<br />
Goh, KC 717<br />
Goktay, Y 1282, 1283<br />
Golbin, J 680<br />
Goldbach-Mansky, R 260, 905,<br />
1831<br />
Goldberg, D 850<br />
Goldberg, G 757<br />
Goldberg, J 1000<br />
Goldblum, R 160<br />
Goldenberg, D 100, 483, 1183<br />
Goldenstein-Schainberg, C 224,<br />
531, 1407<br />
Golding, A 487<br />
Goldman, CT 821<br />
Goldman, JA 420<br />
Goldmuntz, E 726<br />
Goldring, SR 167, 1080<br />
Goldsmith, DP 1341, 1698, 2105<br />
Goldstein, BL 1082<br />
Goldstein, N 1943<br />
Golightly, YM 1330<br />
Golovaty, I 2090, 2091<br />
Gómara, MJ 1070<br />
Gomberg, B 1893, 1894<br />
Gomberg-Maitland, M 569<br />
Gomez, J 87, 2241<br />
Gómez, L 1137<br />
Gómez Puerta, JA 1070<br />
Gomez Vaquero, C 1277, 1299<br />
Gómez-Gracia, I 824<br />
Gomez-Reino, J 55, 1076, 1078,<br />
1802, 1807, 1820, 2170<br />
Gómez-Reino, J-J 409<br />
Gómez-Vaquero, C 1016, 1301<br />
Gomnberg-Maitland, M 586<br />
Gonçalves, C 513, 531, 539<br />
Gono, T 447, 746, 897, 916, 923,<br />
1184, 1587, 1666, 1844<br />
Gonter, N 777, 1637, 1652, 1654<br />
González, EB 2253<br />
González-Escribano, MF 2214<br />
González-Gay, MA 824, 2214<br />
González-Vela, MDC 1650<br />
Gonzales, B 2083<br />
Gonzales-Crespo, MR 407<br />
Gonzalez, A 1076, 1078<br />
Gonzalez, E 562, 725, 1211, 1218,<br />
1219<br />
Gonzalez, JM 324<br />
Gonzalez Diaz de Rabago, E 1920<br />
Gonzalez López, M 1650<br />
Gonzalez Martin, JJ 804<br />
Gonzalez Rivera, TC 2276<br />
Gonzalez-Alvarez, I 1078<br />
Gonzalez-Alvaro, I 1505<br />
Gonzalez-Gay, M 159, 829, 882,<br />
1301, 1599, 1650<br />
Gonzalez-Rivera, T 1158<br />
Gonzalo, E 482<br />
Good, J 213<br />
Goodall, JC 1424<br />
Gooden, A 40<br />
Goodson, NJ 661, 1763<br />
Gopinath, J 1106<br />
Goran, A 382<br />
Gøransson, L 1913<br />
Gordon, C 445, 448, 453, 476,<br />
1452, 1843, 1877, 2240, 2243<br />
Gordon, JK 569, 586, 1990, 2193<br />
Gordon, TP 656<br />
Goreshi, R 920<br />
Gorla, R 297<br />
Gorlova, O 562, 2214<br />
Gorn, AH 471<br />
Gorodkin, R 1200<br />
Goronzy, JJ 351, 1079, 2127<br />
Gorski, K 1141<br />
Gorter, KJ 184<br />
Gorter, SL 219<br />
Goss, TF 754<br />
Gossec, L 63, 143, 529, 542, 1027,<br />
1104, 1648, 1924<br />
Gosset, M 37, 1514<br />
Gottenberg, JE 400, 858, 917,<br />
1088, 1237, 1413, 1693, 1790,<br />
1810, 1890, 1893, 1894, 1896,<br />
1910, 1914, 1998, 2042<br />
Gottwald, M 1059<br />
Gould, EM 944<br />
Gould, KA 423<br />
Gould, N 12<br />
Goulet, A-C 1497<br />
Goulet, M 2043<br />
Goulielmos, G 496<br />
Goupille, P 130, 376, 384, 988,<br />
1945, 2221<br />
Gourh, P 824, 829, 1982, 2214<br />
Gourley, I 1154<br />
Gourley, M 914<br />
Gove, J 892<br />
Govoni, M 1162<br />
Goyal, JR 1617<br />
Goyal, V 1549<br />
Goycochea-Robles, MV 1056<br />
Grabiec, A 1529<br />
Gracie, JA 1422<br />
Grader-Beck, T 440<br />
Grados, D 1741<br />
Graf, J 135<br />
Graf, JD 1024<br />
Graham, D 75<br />
Graham, RR 500, 1592<br />
Graham, TB 218, 1700<br />
Grahn, A 392, 945, 946, 1123<br />
Gramlich, K 894, 899, 900<br />
Gran, JT 1220, 1275<br />
Granados, J 874<br />
Grandpeix, C 2239<br />
Graninger, WB 1013, 1481, 2222<br />
Grassi, W 297, 547, 1629, 1635,<br />
1746, 1787<br />
Gratacos, J 1276<br />
Grattagliano, V 1627<br />
Gratton, SB 135<br />
Grau, A 491<br />
Grau, R 415, 1014, 1636<br />
Graudal, N 1444, 1841<br />
Grauer, A 971, 2157, 2161<br />
Gravallese, EM 716<br />
Gray, JD 1242<br />
Gray-McGuire, C 2144<br />
Grayson, P 198, 720, 2155, 2198<br />
Grecco, M 498, 504<br />
Green, C 1141, 1480<br />
Green, MJ 1926, 2182, 2183<br />
Green, N 736<br />
Green, S 193, 1164, 1875<br />
Greenberg, J 52, 148, 347, 379,<br />
515, 707, 1003, 1010, 1794, 1799<br />
Greenberg, MC 2062<br />
Greenblatt, M 675<br />
Greenlee, R 1000<br />
Greenspan, J 1898<br />
Greenwald, MW 2172<br />
Greenwell, CA 462<br />
Gregersen, P 77, 658, 825, 1094,<br />
1386, 1591, 1592, 1597, 1608,<br />
2083, 2149, 2217, 2214<br />
Gregoire, L 468<br />
Gregory, J 583<br />
Greidinger, EL 608, 852<br />
Greis, K 268<br />
Greisen, SR 1524, 1761<br />
Gremese, E 355, 744, 1098, 1582<br />
Gress, R 1161<br />
Greve, JMD 2134<br />
Grevers, LC 1495<br />
Grieco, A 2001, 2008<br />
Griffin, C 1063<br />
Griffin, K 1405<br />
Griffin, MR 54<br />
Griffin, TA 1012<br />
Griffith, SG 160<br />
Griffiths, CEM 833<br />
Griffiths, H 319<br />
Grigorian, M 614<br />
Grijalva, C 54, 404, 722, 2103<br />
Grillet, BAM 1396<br />
Grillo, I 71<br />
Grisar, J 1745<br />
Grisot, C 976<br />
Groenendael, JHLM 1396<br />
Grogan, J 1122<br />
Grogan, S 634<br />
Groh, BP 211<br />
Grom, AA 244, 653<br />
Gronwall, C 2121<br />
Groot Kormelink, T 333<br />
Gross, BH 585<br />
Gross, D 693<br />
Gross, KD 201<br />
Gross, WL 679, 2203<br />
Grossi, C 1356<br />
Grossi, S 1884, 1916<br />
Grossman, J 8, 471, 497, 1189,<br />
1583, 1584, 1595, 2241<br />
Grotle, M 170<br />
Grouard-Vogel, G 2236<br />
Grøvle, L 170<br />
Gruen, SD 2246<br />
Grundmeier, R 233<br />
Grunert, VP 381<br />
Grunke, M 1781, 2130<br />
Gu, W 274<br />
Gu, X 935, 2250<br />
Guadagnoli, M 2178<br />
Gualano, B 1384<br />
328<br />
2010 Program Book
Guan, M 965<br />
Guañabens, N 975<br />
Gudbjornsson, B 1951<br />
Gudbrandsson, B 1275<br />
Gudjonsson, JE 1951<br />
Guedj, M 1987, 2226<br />
Gueds-Pinto, H 1986<br />
Guerette, B 1101, 1102, 1113,<br />
1791<br />
Guérini, H 728<br />
Guermazi, A 131, 193, 197, 198,<br />
202, 1373, 2100<br />
Guerne, P-A 792<br />
Guerry, M-J 678<br />
Guggenbuhl, P 888<br />
Guiducci, S 593<br />
Guigonis, V 1693<br />
Guillard, G 118<br />
Guillaume, S 904<br />
Guillaume-Czitrom, S 1696<br />
Guillemin, F 781, 787, 1752, 2094<br />
Guillevin, L 400, 575, 576, 1204,<br />
1217, 1790, 2009, 2014, 20262034,<br />
2041, 2043, 2045<br />
Guillimen, F 794<br />
Guillot, X 997<br />
Guimarães, AS 228<br />
Guimarães, LS 1458<br />
Guinta, DR 97<br />
Guirado, L 1614<br />
Guis, S 1931<br />
Guissa, VR 224<br />
Gujrathi, S 390, 416<br />
Gul, A 1281, 2217, 1308<br />
Gulcu, A 1282, 1283<br />
Gülfe, A 1381<br />
Gulko, PS 1128, 1387<br />
Gullick, NJ 1263, 1838<br />
Gulseth, HC 1774<br />
Guma, M 1718<br />
Gunawardhana, L 149<br />
Gunay, N 1970<br />
Gunduz, O 544<br />
Gunnarsson, I 1846<br />
Gunraj, N 57, 313, 341<br />
Günther, J 2003<br />
Guo, J 1598<br />
Guo, S 2187<br />
Gurevitz, I 812<br />
Gurwitz, JH 322, 791<br />
Guseinova, D 208, 1700<br />
Gust, C 68, 86<br />
Gustafson, NP 2142<br />
Gustafsson, JT 1846<br />
Gustafsson, T 1194<br />
Gutala, RV 1218<br />
Guthridge, JM 24, 2274<br />
Gutierrez, M 547, 1635, 1614<br />
Gutierrez-Roelens, I 2263<br />
Gutierrez-Urena, SR 157<br />
Guttenberg, M 1907<br />
Guzman, J 1674, 2017<br />
Gúzman, R 451, 1172, 1455<br />
Gyftopoulos, S 1616<br />
Gyger, G 1225<br />
H<br />
Ha, YJ 1061, 1873<br />
Haas, CS 1417<br />
Haas, JP 654<br />
Haavardsholm, E 132, 141, 142,<br />
1369, 1779<br />
Habets, G 273<br />
Hachulla, E 580, 917, 1893, 1894,<br />
1896, 1910, 2226, 400, 576, 895,<br />
1217, 1425, 1435, 1651, 1790,<br />
1890, 1987<br />
Hack, CE 636<br />
Hackett, N 1990<br />
Hackney, BS 690<br />
Hackney, J 1609<br />
Hadd, M 269<br />
Haddix, E 1012<br />
Hadjinicolaou, A 395<br />
Hadley, S 1470<br />
Hafström, I 88<br />
Hagberg, N 503<br />
Hagen, EC 2014<br />
Haggart, E 1342<br />
Hagino, N 703<br />
Hagiwara, T 1138, 1738, 1739<br />
Haglund, E 761<br />
Hahn, BH 8, 431, 471, 497, 594,<br />
1189, 1257, 1583, 1584, 1595,<br />
2241<br />
Hahne, M 1418, 1527, 1732<br />
Haibel, H 665, 669, 1938, 1961,<br />
2271<br />
Haines, GK 853, 859<br />
Haines, K 1700<br />
Haines III, GK 1417<br />
Hajj-Ali, R 1670, 2047, 2049<br />
Hajji, O 816<br />
Hajsadeghi, F 1046, 1443, 2164,<br />
2165, 2166<br />
Hakim, F 1161<br />
Hakonarson, H 2217, 2219<br />
Halbauer, B 1621<br />
Haldorsen, K 1913<br />
Hall, DJ 1484<br />
Hall, S 1560<br />
Halladay, W 801<br />
Haller, C 2157<br />
Halliday, W 2107<br />
Hallinen, TA 759<br />
Hallmans, G 1847, 2115<br />
Halushka, MK 1074, 2167<br />
Hama, M 139, 1512, 2217<br />
Hamada, M 298<br />
Hamaguchi, M 1511<br />
Hamann, D 1091<br />
Hamburger, MI 1753, 1782<br />
Hamburger, S 146<br />
Hameed, S 1151<br />
Hamidou, M 1893<br />
Hamilton, J 1121<br />
Hammaker, D 635, 855<br />
Hammann, J 43<br />
Hammar, O 1902<br />
Hammel, L 1923<br />
Hammond, A 1325, 2063<br />
Hammond, T 1830<br />
Hammonds, CL 802<br />
Hamsten, A 832<br />
Hamuryudan, V 1013, 1288<br />
Hamza, N 1889<br />
Han, BD 1597<br />
Han, C 1136<br />
Han, H 2180<br />
Han, KH 295<br />
Han, L 1459<br />
Han, S 1488<br />
Hanami, K 1793, 1823<br />
Hanaoka, M 897, 916, 923, 1844<br />
Hanczko, R 1185, 1196<br />
Handler, C 727<br />
Haney, D 1606, 1753, 1782<br />
Hanlan, M 1335<br />
Hanly, J 445, 448, 454, 476, 731,<br />
1877, 2240, 2242, 2243<br />
Hanna, F 192<br />
Hannaford, P 646<br />
Hannan, MT 684, 1317, 1327,<br />
1328, 1329, 1330, 1331<br />
Hannon, MJ 185, 193<br />
Hannouche, D 875<br />
Hanrahan, J 1560<br />
Hans, G 163<br />
Hansen, A 134, 1444, 1809, 1841,<br />
1896, 1953<br />
Hansen, C 920<br />
Hansen, MS 133, 134, 1809, 1953<br />
Hanslik, T 533<br />
Hansmann, S 894, 899, 900<br />
Hanson, E 1698<br />
Hanumanthaiah, M 522<br />
Haqqi, TM 632, 633<br />
Haque, S 769, 795, 1177, 1200<br />
Haque, UJ 310<br />
Hara, M 746, 1184, 447, 1666<br />
Hara, R 237<br />
Hara, T 237<br />
Hara, Y 2228<br />
Harada, ND 169<br />
Haraoui, B 123, 196, 300, 306,<br />
343, 344, 659, 978, 987, 1013,<br />
1101, 1102, 1737, 1837, 2169<br />
Harari, O 1243, 1245<br />
Hardi, L 994<br />
Harding, S 1202, 1203<br />
Hardwick, D 1161<br />
Hardy, J 2251, 2252<br />
Hareendran, A 99<br />
Harel, L 1684<br />
Hargrove, JB 647<br />
Harigai, M 399, 1814, 1815<br />
Harigane, K 335<br />
Hariri, A 878<br />
Harley, JB 500, 502, 1164, 1197,<br />
1579, 1583, 1584, 1585, 1586,<br />
1590, 1591, 1594, 1595, 2144,<br />
2145, 2146, 2147, 2148, 2274<br />
Harmer, J 1560<br />
Harney, S 1333, 1726<br />
Haro, I 1070<br />
Haroche, J 478, 1287, 1651, 1658,<br />
1660, 1908, 1911<br />
Haroon, N 545, 549, 556, 1450,<br />
1964<br />
Harper, BE 1982<br />
Harper, S 1555<br />
Harrell, MI 1251<br />
Harrington, JT 1003, 1010, 1799<br />
Harrington, L 1094<br />
Harrington, TM 977<br />
Harris, HW 799, 820<br />
Harrison, AA 776, 1553<br />
Harrison, M 779<br />
Harrison, MJ 769, 795, 1405<br />
Harrold, L 156, 162, 322, 791,<br />
1003, 1010, 1794<br />
Hart, D 711, 823, 841, 1068, 1094<br />
Hart, JE 64<br />
Hart, MM 1825<br />
Hart, S 717<br />
Hartgring, SAY 278<br />
Harty, L 360<br />
Harvey, BP 1269<br />
Harvey, P 2120<br />
Harvey, WF 195, 2101<br />
Hasegawa, H 1265, 2016<br />
Hasegawa, M 724, 1230<br />
Hashimoto, T 983<br />
Hashiramoto, A 280, 348, 434,<br />
511, 893, 983, 1467<br />
Hasija, R 1700, 1705<br />
Haskard, D 430, 2200<br />
Hasni, SA 1161<br />
Hassan, A 1344<br />
Hassan, W 40<br />
Hassan El Safi, S 695<br />
2010 Program Book 329<br />
abstract author Index
aBSTRACT author Index<br />
330<br />
Hasselquist, M 134, 1953<br />
Hassett, A 110, 112, 625, 651,<br />
1320, 1767, 1872<br />
Hassett, G 1560<br />
Hassoun, PM 1223<br />
Hatemi, G 1279, 1288, 1697<br />
Hauge, E-M 1485<br />
Haugeberg, G 972<br />
Haugen, AJ 170, 1774<br />
Haugen, IK 142, 182<br />
Hauser, T 676, 2009<br />
Häuser, W 100, 110, 111, 112<br />
Haverhals, L 397, 1395<br />
Hawker, GA 682, 1562, 2208<br />
Hawkins, PN 895, 1425, 1435<br />
Hawly, M 1470, 1471<br />
Hayashi, D 131<br />
Hayat, S 2076<br />
Hayden, CL 970, 1099, 1792<br />
Hayder, M 281<br />
Hayem, G 2269<br />
Hayer, S 272, 1493<br />
Hayes, J 931<br />
Hayes, KW 186, 189, 202<br />
Hayes, OA 788<br />
Haynes, K 2084<br />
Hays, R 155, 1205, 1228, 1365<br />
Haythornthwaite, JA 1348<br />
Haythornwaite, JA 949<br />
Haywood, Jr, C 1565<br />
Hazelman, B 777, 1654<br />
Hazes, J 38, 317, 1073, 1775, 1776<br />
Hazes, M 1274, 1785, 2066<br />
Hazlett, J 33<br />
He, J 1107, 1598<br />
He, W 274, 1469<br />
Hebert, LA 1400<br />
Hebert, P 1400<br />
Heeringa, P 2015, 2023<br />
Heffernan, E 1625<br />
Heiberg, T 1750<br />
Heimbürger, M 1194<br />
Hein, MS 1376<br />
Heinberg, L 1348<br />
Heiney, C 169<br />
Heinhuis, B 371<br />
Heldmann, F 1938, 1961, 2270<br />
Helin, P 1898<br />
Hellard, SL 1885<br />
Helliwell, P 514, 1926, 2082,<br />
2182, 2183<br />
Hellmich, B 2203<br />
Helmick, CG 687, 1563, 2069,<br />
2138<br />
Hemmatazad, H 1988<br />
Hench, RP 1041<br />
Henderson, C 1831<br />
2010 Program Book<br />
Hendiani, A 725<br />
Hendler, T 1159<br />
Hendrickson, P 242, 826, 928<br />
Hendriks, R 715<br />
Henes, JC 1145<br />
Henes, M 1145<br />
Henrickson, M 1678<br />
Henríquez, C 2070<br />
Henrotin, Y 835<br />
Henry, M 183<br />
Henshaw, K 1090, 1254<br />
Hensor, E 1929<br />
Hentgen, V 905, 1696<br />
Henze, E 2021<br />
Heraoui, D 1653<br />
Herberich, E 1882<br />
Herbst, R 741<br />
Herenius, M 719, 1507, 1604,<br />
1822<br />
Herlin, T 1687<br />
Herlitz, L 2186<br />
Herlitz-Lindberg, M 1846<br />
Herman, DJ 1320<br />
Hermann, K-G 134, 669, 1369,<br />
1953, 2271<br />
Hermes, H 673<br />
Hermida-Gómez, T 1483<br />
Hermine, O 1651, 2010, 2011<br />
Hernández, MV 1070, 1118, 1796<br />
Hernández-Cruz, B 1337, 1944<br />
Hernández-Díaz, C 1614<br />
Hernandez-Diaz, S 81<br />
Hernández-Hernández, V 389<br />
Hernández-Medina, G 1881<br />
Hernandez-Molina, G 874<br />
Hernández-Núñez, E 1166<br />
Hernandez-Rodriguez, J 1280,<br />
1292, 1294, 1309, 1314<br />
Hernando, E 1490<br />
Herrera, A 1659<br />
Herrera-Garcia, AM 1509<br />
Herrero-Beaumont, G 804, 1078<br />
Herrero-Beites, AM 159, 873, 882<br />
Herrick, A 588, 824, 829, 1234,<br />
1623, 2214<br />
Herrinton, LJ 404<br />
Herrmann, AM 1255<br />
Herrmann, M 490, 2150<br />
Herrmann, S 2237<br />
Hersh, AO 484, 1673, 1691, 2017<br />
Herson, S 915, 922<br />
Hervier, B 478, 1651, 1658, 1660,<br />
1908<br />
Herzer, P 1112<br />
Heslop, PS 1568<br />
Hesselstrand, R 824, 829, 1210,<br />
1623, 2214<br />
Hessian, P 33, 1252<br />
Hesterberg, LK 1496, 1606, 1753,<br />
1782<br />
Hetherington, R 1408<br />
Hetland, ML 55, 133, 381, 1370,<br />
1444, 1524, 1761, 1802, 1807,<br />
1809, 1841<br />
Hewagama, A 1253<br />
Hewitt, S 1156<br />
Hewlett, S 1325, 1766<br />
Heymann, D 29<br />
Heymann, M-F 29<br />
Heywood, W 2255<br />
Hickey, MJ 492<br />
Hidaka, T 1812<br />
Hidalgo, C 1888<br />
Hider, S 1394<br />
Hiemann, R 911<br />
Hiepe, F 1146, 1295, 1414<br />
Hietpas, J 2100<br />
Higgins, GC 209, 1673, 1677,<br />
1691, 1701, 2017<br />
Higgs, JB 1617<br />
High, W 2013<br />
Highton, J 1252, 33<br />
Hilário, MO 1343, 1676, 1872, 228<br />
Hilberdink, WKHA 2051<br />
Hilda, D 824<br />
Hill, C 177, 584<br />
Hill, HR 245<br />
Hill, N 1004<br />
Hilliquin, P 69<br />
Hillmann, A 2237<br />
Hillstrom, HJ 1328, 1331<br />
Hilton, W 1094<br />
Hilton-Jones, D 922<br />
Himes, M 688<br />
Hinchcliff, M 591, 729, 2214<br />
Hines, AE 1395<br />
Hines, T 487<br />
Hinks, A 264, 266, 654, 1075<br />
Hinze, CH 218<br />
Hipp, BG 1764<br />
Hirai, K 921<br />
Hirakata, M 1577<br />
Hiraki, LT 762, 2104<br />
Hirata, Y 298<br />
Hirko, K 199<br />
Hirohata, S 291, 568, 1285, 1293<br />
Hiromura, K 358<br />
Hirono, S 280, 1467<br />
Hiroshima, R 1749<br />
Hirsh, JM 2013<br />
Hirth, P 273<br />
Hitchon, C 300, 306, 343, 659,<br />
978, 1176, 1737, 1850<br />
Hitzel, A 2027<br />
Hmamouchi, I 301<br />
Ho, B 1100<br />
Ho, LY 458, 467, 773, 1206, 1667,<br />
1870, 2159<br />
Ho, P 833, 1200<br />
Hoang, S 2261<br />
Hobbs, A 674<br />
Hochberg, E 1015<br />
Hochberg, F 1015<br />
Hochberg, MC 186, 390, 937, 972,<br />
2096<br />
Hochman, J 306, 343<br />
Hodge, L 1430<br />
Hodgson, L 1772<br />
Hoehle, M 127<br />
Hoekstra, M 314, 662, 1771<br />
Hoeltzel, MF 234, 253, 254<br />
Hoeper, MM 599<br />
Hoes, JN 973<br />
H<strong>of</strong>bauer, A 437, 622<br />
H<strong>of</strong>er, M 1305<br />
H<strong>of</strong>fart, CM 1703<br />
H<strong>of</strong>fman, G 1315, 2012, 2047,<br />
2049, 2198<br />
H<strong>of</strong>fman, H 905<br />
H<strong>of</strong>fman, I 340<br />
H<strong>of</strong>fman, S 622<br />
H<strong>of</strong>fman-Bolton, J 1544<br />
H<strong>of</strong>fmann-Vold, A-M 1220, 2214<br />
H<strong>of</strong>kens, W 283<br />
H<strong>of</strong>mann, F 1614<br />
H<strong>of</strong>stee, H 1623<br />
H<strong>of</strong>stra, C 1534<br />
H<strong>of</strong>tman, ADC 262<br />
Hogan, SL 1326<br />
Hoganson, DD 129, 316<br />
Hoglund, LT 2244<br />
Höglund, P 2014<br />
Hogrefe, J 50<br />
Hoi, A 492<br />
Hojjati, M 473<br />
Hokken, ACS 1073<br />
Holcomb, R 493<br />
Holers, M 71<br />
Holers, V 77, 658, 1083, 1094,<br />
2116, 2227, 2229<br />
Holgado, S 1741<br />
Holladay, MW 269<br />
Holliday, KL 836<br />
Hollister, AS 150<br />
Holl-Ulrich, K 679<br />
Holman, AJ 102, 815<br />
Holman, ER 582<br />
Holmqvist, M 64, 1057, 2259<br />
Holmström, M 7<br />
Holt, RW 203<br />
Holtkamp, G 2170<br />
Holweg, C 1609<br />
Holzenberger, M 1514
Homme, CL 730<br />
Honda, E 434<br />
Hong, JY 115, 802<br />
Hong, S 209, 803, 1038<br />
Hong, Y 369, 2158<br />
Hooker, RS 1395<br />
Hootman, JM 687, 691, 1563,<br />
2057, 2069, 2096, 2138<br />
Hoover, MJ 2053, 2054<br />
Hoover, SE 415<br />
Hopia, L 1181<br />
Hopman, W 109<br />
Hoppenreijs, EPAH 219<br />
Hori, Y 10<br />
Horita, T 2, 5, 10, 1577, 1909,<br />
2254<br />
Horiuchi, T 511<br />
Horn, A 607, 611, 614, 616, 672<br />
Horn, E 569<br />
Horne, WC 1502<br />
Horneff, G 220, 227, 230<br />
Horner, BJ 702<br />
Hornum, L 847<br />
Horowitz, ZD 146, 166<br />
Horrigan, FT 1128<br />
Hørslev-Petersen, K 133, 141,<br />
1370, 1524, 1761, 2280<br />
Horton, HM 1350<br />
Horvath, K 1340<br />
Horwitz, DA 442, 1242, 1268<br />
Hoshi, D 1793, 1823<br />
Hoshi, K 568<br />
Hoskin, TL 104, 108<br />
Hosoi, T 968<br />
Hosono, Y 1377<br />
Hossler, J 733, 1085<br />
Hot, A 354, 917, 1515, 2042<br />
Hotaling, J 931<br />
Hottiger, MO 1528<br />
Hou, A 384<br />
Hou, Y 1143<br />
Houard, X 37<br />
Houbiers, J 2170<br />
Houenou, LO 691<br />
Hough, D 451, 452, 457, 1146,<br />
1454, 1456<br />
Houssiau, F 453, 1398, 2214, 2263<br />
Houvenagel, E 2269<br />
Howard, BV 1062<br />
Howard, G 299, 1368<br />
Howard, RNG 1390, 1616<br />
Howard, T 654<br />
Howell, RD 1470<br />
Hoyer, BF 1295, 1414<br />
Hoyer, J 895, 1425, 1435<br />
Hsia, EC 326, 385, 386, 890, 908,<br />
1097, 1114, 1127, 1136, 2264<br />
Hsu, BL 890, 908, 1948<br />
Hsu, H-C 1135, 1250, 1260, 1412,<br />
2189<br />
Hsu, JJ 1702<br />
Hsu, P-Y 288<br />
Hsu, Y 1245, 1329<br />
Hu, A 1940<br />
Hu, C 1818<br />
Hu, P 2048<br />
Hu, W 1606<br />
Hu, X 1128, 1680<br />
Hua, X 1194<br />
Huang, D 1178<br />
Huang, J 1182<br />
Huang, MM 286<br />
Huang, Q 854, 1353<br />
Huang, W 1410, 2188<br />
Huang, XL 1872<br />
Huang, Y 733<br />
Huang, Z 854<br />
Hubbel, S 1901<br />
Huber, A 238, 1673, 1674, 2017,<br />
1408<br />
Huber, G 692<br />
Huber, LC 35, 1518<br />
Hubert, C 1596<br />
Hubert, H 642<br />
Huck, M 931<br />
Hudson, AP 696<br />
Hudson, M 577, 1225, 1346,<br />
1347, 1348, 1850, 2247<br />
Hueber, W 1083<br />
Huemer, C 1700<br />
Hughes, G 747<br />
Hughes, LB 1077<br />
Hughes, SL 692<br />
Hughes, T 822, 1590, 1594<br />
Hughes-Austin, J 77, 658, 1094<br />
Huijbens, R 844<br />
Huisman, AM 942<br />
Huisman, M 1775, 1776<br />
Huizing, M 914<br />
Huizinga, T 179, 334, 582, 660,<br />
1015, 1396, 1496, 1782, 1805,<br />
2114, 295, 328, 663, 1744, 1755,<br />
1780<br />
Hulejova, H 638, 926<br />
Hulot, J-S 2239<br />
Hulsmans, HMJ 328<br />
Humbert, M 599<br />
Humbría, A 1229<br />
Hummers, LK 569, 587, 589, 1201,<br />
1222, 2192<br />
Humphrey, MB 1585<br />
Hunder, GG 1304, 2037, 2038<br />
Hung, EW 726<br />
Hunt, B 154<br />
Hunt, KJ 960<br />
Hunter, CD 2235<br />
Hunter, DJ 140, 199, 203, 1362,<br />
1366, 2091, 2092<br />
Hunter, J 1422<br />
Hunzelmann, N 824, 829, 2214<br />
Hurkmans, EJ 1338, 2051, 2283<br />
Hurlburt, KJ 892<br />
Husa, M 634<br />
Husain, M 468<br />
Huscher, D 599, 770, 1212<br />
Husni, ME 191, 1937<br />
Hussain, H 885<br />
Husted, J 1928<br />
Huston III, J 2037, 2038<br />
Hutcheson, JG 1186<br />
Hutchinson, A 1405<br />
Huttenlocher, A 1421<br />
Hutto, D 1243<br />
Huynh, T 1142<br />
Hvid, M 1524, 1761<br />
Hwang, C 937<br />
Hwang, I 1386<br />
Hwang, J 366, 372, 1297<br />
Hwang, L-J 565<br />
Hyde, C 1116<br />
Hyrich, K 374, 421, 1323<br />
I<br />
Iagaru, N 1705<br />
Iagnocco, A 777, 1637, 1652, 1654<br />
Iannaccone, CK 308, 1050, 1335,<br />
1610, 1778, 2064<br />
Ibanez, D 445, 448, 450, 455, 476,<br />
772, 1868, 1869, 1874, 1877, 1878,<br />
2240<br />
Ibarra, MF 1686<br />
Ibrahim, F 664, 819<br />
Ibrahim, G 1926, 2182, 2183<br />
Ibrahim, P 273<br />
Ichida, H 897, 923<br />
Ichikawa, T 436<br />
Ideguchi, H 139, 480<br />
Ieko, M 10<br />
Iglesias-Gamarra, A 1048<br />
Iguchi, M 298<br />
Ihata, A 139<br />
Ihlebaek, C 170<br />
Iikuni, N 497<br />
Iizuka, M 2176<br />
Ikari, K 1611, 1749<br />
Ikeuchi, H 358<br />
Ikle, D 2012<br />
Ikumi, N 1708<br />
Illei, GG 1161, 1579, 1918, 2178,<br />
2179<br />
Ilowite, NT 209, 1630, 1677, 1692,<br />
1702<br />
Imadojemu, S 456<br />
Imadome, K-i 1708<br />
Imagawa, T 237<br />
Imai, M 1115<br />
Imbert-Bismut, F 1762<br />
Imboden, J 135, 136, 1024<br />
Immerman, I 1470<br />
Impens, A 402, 567, 570, 585,<br />
1205, 2072, 2073<br />
Imperio, C 784<br />
Imrey, P 2047, 2049<br />
Imundo, LF 234, 257, 1673, 1677,<br />
1678, 1691, 1701, 2017<br />
Imura, Y 1377<br />
Inamo, K 1890<br />
Inanç, N 1133, 1208, 1303, 1803<br />
Ince, A 1808<br />
Infante, O 808<br />
Ingham, M 51, 76, 1960<br />
Inman, RD 512, 545, 549, 556,<br />
696, 1450, 1451, 1948, 1964, 1969,<br />
1972<br />
Inoko, H 2217<br />
Inokuma, S 399, 703<br />
Inomata, H 1708<br />
Inoue, A 292, 352, 1824<br />
Inoue, E 968, 1053<br />
Inoue, H 433<br />
Inoue, K-i 1824<br />
Intema, F 176, 1380<br />
International League <strong>of</strong><br />
Associations for <strong>Rheumatology</strong><br />
East Africa Initiative 1336<br />
Ioan-Facsinay, A 179<br />
Ioannidis, G 969<br />
Ioannou, Y 621, 1358, 1359<br />
Ionescu, R 405, 848<br />
Ionnadis, G 126<br />
Ioseliani, M 1705<br />
Iotti, A 1173<br />
Irazola, V 324<br />
Isaacs, C 912<br />
Isaacs, J 2170<br />
Isenberg, D 445, 448, 454, 465,<br />
476, 738, 740, 1140, 1144, 1153,<br />
1187, 1358, 1359, 1453, 1877,<br />
2085, 2240, 2243, 2255<br />
Ishigaki, K 932<br />
Ishigatsubo, Y 139, 480, 1081,<br />
1293, 1300, 1512, 2217<br />
Ishiguro, N 399, 1814, 1815<br />
Ishii, K 335<br />
Ishii, T 1577<br />
Ishikura, A 2170<br />
Ishimori, ML 187, 1197<br />
Ishino, H 1511<br />
Islam, SS 2086<br />
Isola, M 2036, 2201<br />
Isozaki, T 26, 1773<br />
Israelsson, L 2118<br />
Italiaander, A 2214<br />
2010 Program Book 331<br />
abstract author Index
aBSTRACT author Index<br />
Itami, Y 1743<br />
Itano, N 1709<br />
Ito, H 365<br />
Ito, K 399<br />
Ito, M 1708<br />
Ito, S 2228<br />
Iudici, M 572<br />
Ivana, H 479<br />
Iversen, M 42, 1318<br />
Ivorra, JAR 1840<br />
Iwahashi, M 1138<br />
Iwakura, Y 1427<br />
Iwamoto, N 1371, 1632<br />
Iwamoto, T 1749<br />
Izac, B 1087<br />
Izmailova, E 1822<br />
Izmirly, PM 732, 990, 1190, 1390,<br />
1438<br />
Izumihara, T 1138, 1738, 1739<br />
Izzedine, H 906<br />
J<br />
Jackson, R 154, 165, 1062, 2096<br />
Jacob, CO 500, 1583, 1584, 1585,<br />
1586, 1591, 1595, 2145, 2147,<br />
2148, 2187<br />
Jacob, N 2187<br />
Jacobs, DR 1367<br />
Jacobs, J 380, 388, 973, 1753,<br />
1759, 1859<br />
Jacobs, P 330<br />
Jacobsen, MS 1809<br />
Jacobsen, S 454, 731<br />
Jacobson, EW 1095<br />
Jacobsson, L 774, 1020, 1054,<br />
1057, 2259<br />
Jacques, C 1514<br />
Jacques, S 1413<br />
Jacquot, S 1827<br />
Jaen, JC 1100, 2032, 2048<br />
Jain, A 1573<br />
Jain, M 637<br />
Jain, R 2110<br />
Jais, J-P 1087<br />
Jakicic, JM 193<br />
Jakob, F 967<br />
Jakobsson, K 774<br />
Jakstadt, M 630, 1418<br />
Jallal, B 741<br />
Jallouli, M 1911, 2239<br />
Jamal, SA 982<br />
James, J 9, 24, 417, 466, 734, 780,<br />
892, 1164, 1197, 1583, 1584, 1585,<br />
1586, 1591, 1594, 2147, 2274<br />
James, S 2259<br />
Jamin, C 737<br />
Jamnitski, A 1825<br />
Jan, L 1261<br />
Jan, S 42<br />
Janer, G 1137<br />
Jani, J 460<br />
Janko, C 490, 2150<br />
Jannaut-Pena, MJ 1013<br />
Janow, GL 209, 1630<br />
Jansen, G 1613<br />
Jansen, MJ 2051<br />
Jansen, TL 1833<br />
Janssen, EM 209<br />
Janwityanujit, S 1950<br />
Jaovisidha, S 1950<br />
Jara, LJ 1150<br />
Jares, P 1280<br />
Jarjour, WN 1374<br />
Järvenpää, S 80<br />
Jarvis, HG 1568<br />
Jarvis, JN 243, 247, 251, 258, 655<br />
Jaskowski, TD 245<br />
Jasson, M 1121<br />
Jatwani, S 2253<br />
Jaureguiberry, J-P 2042<br />
Javier, R-M 2269<br />
Jayakar, BA 1315<br />
Jayaraj, D 1263<br />
Jayaraman, R 717<br />
Jayne, D 676, 678, 1278, 1453,<br />
1455, 1663, 2014, 2085<br />
Jean Baptiste, G 571<br />
Jejurkar, P 286<br />
Jelinek, J 869<br />
Jenks, SA 486, 749<br />
Jennette, JC 2048<br />
Jennings, W 152<br />
Jensen, B 43<br />
Jensen, DV 1444, 1841<br />
Jensen-Urstad, K 1224<br />
Jeon, C-H 366, 1297<br />
Jeong, Y-G 370, 756<br />
Jeong, Y-J 1209<br />
Jepson, B 40<br />
Jerath, RS 1673, 1691, 2017<br />
Jesus, AA 224, 260<br />
Jewett, LR 1347, 1348<br />
Jhingran, P 757, 764<br />
Ji, J 92, 359, 1107, 1628<br />
Jia, J 965<br />
Jiang, H-R 28<br />
Jiang, K 243, 247, 251, 258, 655<br />
Jiang, L 1107<br />
Jiang, Y 255<br />
Jibatake, A 1641<br />
Jimah, J 1185, 1196<br />
Jimenez, R 1146<br />
Jimenez, SA 673, 1993, 1997,<br />
1999, 2007<br />
Jin, H 276, 277, 618<br />
Jin, S 288<br />
Jin-Chae, J 1516<br />
Jingbo, N 1557<br />
Joel, G 1197<br />
Joetham, A 2128<br />
Jog, NR 439<br />
Jogestrand, T 1194<br />
Joh, K 921<br />
Johannesen, TB 1913<br />
Johansen, JS 133, 134, 381, 1953<br />
Johansson, M 1847<br />
John, A 68, 86, 1031<br />
Johnsen, SJA 1885, 1913<br />
Johnsen, V 972<br />
Johnson, CR 1055<br />
Johnson, D 397, 970, 1031, 1040,<br />
1099, 1100, 1792, 2032, 2210<br />
Johnson, SR 2196<br />
Johnsrud, I 972<br />
Johnsrud, K 1275<br />
Johnston, KK 2053, 2054<br />
Johnston, S 338<br />
Jolly, M 496, 765, 1147, 1164,<br />
1175, 1612, 1880<br />
Jonas, A 2125<br />
Jonas, BL 1077<br />
Jonas, M 2279<br />
Jones, A 1698, 2105, 2132<br />
Jones, DL 688<br />
Jones, EA 646<br />
Jones, G 173, 649, 1383<br />
Jones, H 1995<br />
Jones, JK 698<br />
Jones, K 209, 1128<br />
Jones, P 1372, 1983<br />
Jones, RB 676, 678<br />
Jönsson, G 1037, 1440<br />
Jonsson, MV 1899<br />
Jonsson, R 1579, 1885, 1899,<br />
1917, 1913<br />
Jonuleit, H 1125<br />
Jonzon, A 832<br />
Joosten, LAB 275, 371, 1719<br />
Jordan, JM 181, 831, 838, 1326,<br />
1329, 1330, 1463, 2140<br />
Jorge, R 2055, 2132<br />
Jorgensen, P 1538<br />
Josef, S 1351<br />
Joseph, D 2049<br />
Joseph, L 1142, 1850<br />
Jouen, F 915<br />
Joung, C-I 803<br />
Jousse, S 2221<br />
Jousse-Joulin, S 1931, 2261<br />
Jovanovic, V 753<br />
Joyal, E 1831<br />
Ju, GE 1813<br />
Ju, J 353, 370, 756, 842, 1716,<br />
1770<br />
Ju, Y 1492<br />
Juanola, X 525, 2268<br />
Juarez, C 1801<br />
Juárez-Arellano, S 1853<br />
Judet, O 551<br />
Julian, A 2027<br />
Julian, L 627, 789, 1024, 2113<br />
Jun, J-B 359, 1941<br />
June, R 470<br />
Juneja, M 58<br />
Jung, J 733<br />
Jung, L 1677<br />
Jung, S 1061, 1873<br />
Jung, Y 353, 1488, 1716<br />
Jüngel, A 21, 679, 1988<br />
Junker, P 1370<br />
Juraschek, SP 1574<br />
Jurik, AG 134, 1953<br />
Jury, EC 1187<br />
Ka, K 2246<br />
Kabylafka, EI 1895<br />
Kadi, A 1087<br />
Kadis, JA 1326<br />
Kadoya, M 1511<br />
Kaeley, GS 1617<br />
Kaffenberger, B 1374<br />
Kahaleh, B 1214, 1352<br />
Kahaly, OR 1214, 1352<br />
Kahan, A 580, 728, 1820, 1991<br />
Kahn, J-E 701, 2010, 2011<br />
Kahn, V 571<br />
Kaine, JL 120, 1834<br />
Kaiser, L 792<br />
Kaiser, MJ 340<br />
Kaiser, R 1602<br />
Kaklamanis, P 2217<br />
Kalden, J 1013<br />
Kaleth, A 93, 797<br />
Källberg, H 64, 645<br />
Kallen, MA 87, 178, 1428, 1856<br />
Kallenberg, C 1195, 1210, 1889,<br />
1892, 1905, 2012, 2015, 2023<br />
Kallich, J 1540, 1552<br />
Kallinich, T 1704<br />
Kalman-Lamb, G 1936<br />
Kaloudi, O 528, 1952<br />
Kalsi, HS 738<br />
Kalstad, S 377<br />
Kalunian, K 445, 448, 453, 476,<br />
1452, 1877, 1882, 2240, 2243<br />
Kam, YNW 1389<br />
Kamatani, N 1577<br />
Kamath, T 338<br />
K<br />
332<br />
2010 Program Book
Kambayashi, T 1354<br />
Kamdar, AA 1160<br />
Kameda, H 1793, 1812, 1823<br />
Kamel, MM 798<br />
Kamen, D 448, 475, 476, 510,<br />
960, 1583, 1584, 1590, 1877, 2125,<br />
2240, 2243<br />
Kamp, S 138, 1186<br />
Kampagianni, O 2126, 2277<br />
Kanbe, K 1812<br />
Kanda, V 167<br />
Kandimalla, ER 856, 862<br />
Kane, BA 1560<br />
Kane, D 1631<br />
Kane, MA 640<br />
Kaneko, H 1042, 1619, 1844<br />
Kaneko, K 619<br />
Kang, EH 935<br />
Kang, KY 1770<br />
Kang, M-S 1714<br />
Kang, X 1464<br />
Kang, Y 1061, 1597, 1873<br />
Kantner, C 441<br />
Kanz, L 1145<br />
Kao, AH 620, 1399<br />
Kapetanovic, M 645, 1037, 1440<br />
Kaplan, MJ 1041, 1158, 2278<br />
Kaplan, S 627, 2083<br />
Kaplanski, G 1664, 2042<br />
Kapoor, A 2086<br />
Kaposi, NP 1637<br />
Kapsogeorgou, EK 1897<br />
Kara, FM 1471<br />
Karakurt, S 1803<br />
Karam, E 1526<br />
Karasawa, R 631, 652<br />
Karin, M 1718<br />
Kariuki, SN 495, 496, 1612<br />
Karjalainen, A 891<br />
Karlson, EW 64, 762, 793, 1082,<br />
1588, 1610<br />
Karol, D 1862<br />
Karouzakis, E 21, 357<br />
Karp, DR 1188<br />
Karpouzas, GA 305, 699, 1046,<br />
1443, 1768, 2164, 2165, 2166<br />
Karras, A 2011, 2034<br />
Karras, D 967<br />
Karsdal, M 1466, 1474, 1500<br />
Kasagi, S 1715<br />
Kasama, T 26, 1773, 1812<br />
Käsermann, F 494<br />
Kasinova, M 2053, 2054<br />
Kasitanon, N 1011<br />
Kaslow, RA 828<br />
Kasper, G 630, 1418<br />
Kastner, D 914, 1281, 1516, 1698,<br />
2105, 2217<br />
Kataoka, S 897, 916, 923, 1844<br />
Katayama, K 1138<br />
Kates, J 597<br />
Kato, H 1271, 1709<br />
Kato, M 2, 5, 10, 1909, 2254<br />
Katsahian, S 2014<br />
Katsicas, MM 212, 1704<br />
Katsounaros, M 1021<br />
Katsumata, Y 447, 746, 897, 916,<br />
923, 935, 1184, 1587, 1666, 1844<br />
Katsumoto, TR 609<br />
Kattah, NH 428<br />
Katz, B 1309<br />
Katz, J 31, 60, 140, 167, 1576,<br />
2090, 2091, 2092, 2137<br />
Katz, KF 2075<br />
Katz, P 625, 627, 789, 1767, 2113<br />
Katz, RS 98, 100, 110, 112, 117,<br />
2074, 2075<br />
Kaufman, I 1238<br />
Kaufman, K 500, 1579, 1583,<br />
1584, 1585, 1586, 1590, 1591,<br />
1594, 1595, 2144, 2145, 2146,<br />
2147, 2148, 2274<br />
Kaufmann, C 377<br />
Kaufmann, J 56, 1788<br />
Kaukeinen, K 52, 1799<br />
Kaul, MS 461<br />
Kaul, S 1119<br />
Kauppi, MJ 759<br />
Kausor, T 40<br />
Kautiainen, H 80, 312, 891<br />
Kavalieratos, D 1575<br />
Kavanaugh, A 1102, 1117, 1618,<br />
1781, 1791, 1806, 1808, 1930,<br />
1943, 1955<br />
Kawabata, D 1377<br />
Kawaguchi, H 1464<br />
Kawaguchi, Y 447, 746, 916, 923,<br />
1184, 1587, 1844, 897, 1666<br />
Kawahito, Y 1511<br />
Kawai, H 298<br />
Kawai, S 619<br />
Kawai, V 54, 1023, 1867, 2123<br />
Kawakami, A 364, 1371, 1632<br />
Kawakami, K 1749<br />
Kawamoto, M 746, 897, 1184,<br />
1587<br />
Kawamoto, T 1731<br />
Kawasaki, R 1772<br />
Kawasaki, Y 983<br />
Kawashiri, S-y 364, 1371, 1632<br />
Kay, J 1015, 1818<br />
Kayakabe, K 358<br />
Kaymakcalan, Z 1269<br />
Kayser, C 579<br />
Kazantseva, M 1252<br />
Kazi, S 993<br />
Keane, MB 817, 818<br />
Kearns, R 776, 1553<br />
Keating, RM 77, 658, 1094<br />
Keddache, M 654<br />
Kee, S-J 505<br />
Keeley, P 646<br />
Keen, H 1929<br />
Keenan, BT 1588<br />
Keenan, RT 148, 883<br />
Keir, G 727<br />
Keiserman, MW 2173<br />
Keitzer, R 1295<br />
Kekow, J 406<br />
Keller, A 170<br />
Keller, KK 1485<br />
Kellet, CV 523<br />
Kelley, JA 1594<br />
Kelley, L 453, 1452<br />
Kellner, HL 420, 1788<br />
Kelly, J 500, 502, 1164, 1583,<br />
1584, 1586, 1590, 1595, 2144,<br />
2145, 2146, 2147, 2148, 2274<br />
Kelly, S 390, 1843, 1919, 2170<br />
Kelman, A 401<br />
Kennedy, A 1625<br />
Kennedy, CW 255, 256<br />
Kennedy, M 268<br />
Kenny, D 1109<br />
Kenwright, A 1434, 1474<br />
Keogh, B 16<br />
Keogh, KA 680<br />
Kerekes, G 519<br />
Keren, R 233<br />
Kermani, TA 705, 1304, 1662<br />
Kern, MH 2083<br />
Kerr, AJ 1345<br />
Kerr, GS 397, 546, 970, 1099, 1792<br />
Kerr, LD 2110<br />
Kerstens, PJSM 334, 295, 328, 663<br />
Kersten-Smit, C 2051<br />
Kesel, N 679<br />
Keser, G 822<br />
Kessel, A 909<br />
Kettle, T 870<br />
Keyes, A 1887<br />
Keyes-Elstein, L 726<br />
Keysor, JJ 683, 686, 2143<br />
Keysser, G 138<br />
Keystone, EC 300, 306, 321, 343,<br />
391, 403, 416, 659, 978, 987, 995,<br />
1097, 1101, 1102, 1113, 1114,<br />
1120, 1136, 1737, 1753, 1782,<br />
1818<br />
Kezic, JM 1447<br />
Kezouh, A 342<br />
Khademi, M 1181<br />
Khalatbari, S 1041<br />
Khalid, M 1561<br />
Khalidi, N 126, 2198<br />
Khalili, AW 1901<br />
Khalili, H 825<br />
Khalilova, I 870<br />
Khamashta, M 445, 448, 476, 732,<br />
1357, 1877, 2035, 2240, 2243<br />
Khan, A 1830<br />
Khan, F 259<br />
Khan, K 1996, 2005<br />
Khan, M 780, 1670, 2224<br />
Khan, N 390<br />
Khan, U 12<br />
Khanna, D 147, 155, 347, 561,<br />
570, 583, 594, 729, 1106, 1205,<br />
1212, 1213, 1228, 1232, 1365,<br />
1572, 2194, 2195, 2196<br />
Khanna, P 155, 1365, 1572<br />
Khimdas, S 1202, 1203<br />
KHOALA Group 2094<br />
Khodair, A 816<br />
Khoja, SS 2060<br />
Khong, PL 1233<br />
Khosla, S 959<br />
Khosroshahi, A 25, 1671<br />
Khraishi, M 554, 1820, 1939<br />
Khubchandani, R 1700, 1705<br />
Kiani, A 268, 479, 485, 1148, 2122<br />
Kickingbird, LM 1690<br />
Kickler, TS 460<br />
Kiel, DP 684, 1317<br />
Kielhorn, A 56<br />
Kiener, H 829, 2214<br />
Kievit, W 59, 641, 2207<br />
Kikly, K 287<br />
Kikuchi, H 1285, 1293<br />
Kikuchi, M 237<br />
Kil, L 715<br />
Kilgallen, B 453, 1452<br />
Kilgore, ML 1005<br />
Kill, A 2003<br />
Kim, AH 1415<br />
Kim, C 387<br />
Kim, E 1092, 1488, 1605, 1941<br />
Kim, G 276, 277, 1209, 1488<br />
Kim, H 353, 370, 461, 756, 803,<br />
1464, 1523, 1716, 1751, 1770,<br />
2084<br />
Kim, I 1464<br />
Kim, J 276, 277,353, 370, 387,<br />
756, 1521, 1523, 1716, 1751<br />
Kim, KK 609<br />
Kim, L 1835<br />
Kim, M 732, 1199<br />
Kim, ND 25, 1427<br />
Kim, PW 260<br />
Kim, S 31, 276, 277, 323, 387,<br />
497, 803, 903, 1066, 1209, 1246,<br />
1523, 1673, 1691, 2017, 2077,<br />
2028, 2155<br />
Kim, T 27, 116, 359, 505, 1891,<br />
2010 Program Book 333<br />
abstract author Index
aBSTRACT author Index<br />
334<br />
1941, 1972<br />
Kim, X 1594<br />
Kim, Y 288, 876, 2028<br />
Kimberly, RP 500, 868, 1583,<br />
1584, 1585, 1586, 1591, 1594,<br />
1595, 2145, 2147, 2148<br />
Kimbler, TB 1712<br />
Kimel, M 91<br />
Kimura, Y 70, 1677, 1700<br />
Kimura-Hayama, E 459<br />
Kinaszczuk, M 1843<br />
Kinds, MB 121, 124, 952<br />
King, A 216<br />
King, C 606<br />
King, S 860<br />
King-Davis, S 152, 153<br />
Kingetsu, I 921<br />
Kingsbury, DJ 1673, 1691, 2017<br />
Kingsley, GH 664<br />
Kinjo, M 958<br />
Kinloch, AJ 1717<br />
Kiralp, MZ 114<br />
Kirbach, C 2251<br />
Kirbach, SE 788<br />
Kirchner, HL 345, 1442<br />
Kiriakidou, M 422<br />
Kirino, Y 1281, 1512, 2217<br />
Kirkham, B 385, 386, 1263, 1838,<br />
1898<br />
Kirou, KA 508, 1199, 1990, 2077,<br />
2193<br />
Kirschning, C 857<br />
Kirson, N 763<br />
Kirstin, H 61<br />
Kirwan, JR 392, 1655<br />
Kisacik, B 1921<br />
Kishimoto, M 1641, 1783<br />
Kiss, L 1399<br />
Kissima, J 1568<br />
Kissin, EY 1617, 1624<br />
Kita, J 1371, 1632<br />
Kitakawa, H 10<br />
Kitamura, N 1708<br />
Kitas, GD 664<br />
Kitazawa, M 1709<br />
Kitchen, JM 1631<br />
Kitchen, K 1325<br />
Kitchin, E 1006<br />
Kitt, MM 160<br />
Kivitz, A 944<br />
Kivitz, AJ 144, 710, 945, 946, 1919<br />
Kivovich, V 694<br />
Klaasen, R 719<br />
Klaman, LD 285<br />
Klarenbeek, NB 328, 334, 663<br />
Klarenbeek, PL 1069, 1604<br />
Klareskog, L 64, 645, 832, 1015,<br />
1097, 1588, 1817, 1917, 2118,<br />
2010 Program Book<br />
2214<br />
Klassen, LW 2235<br />
Klatt, S 361<br />
Klatzman, D 1249<br />
Klatzmann, D 2025, 2131<br />
Klause, U 381, 1764<br />
Kleber, S 1973<br />
Klein, A 220, 1696<br />
Klein, J 1457<br />
Klein, R 894<br />
Klein, W 780<br />
Kleinert, S 745, 782, 1026, 1255,<br />
1411<br />
Klein-Gitelman, M 1673, 1688,<br />
1689, 1691, 1701, 1702, 2017<br />
Klein-Gittelman, M 1677<br />
Klersy, C 2220<br />
Kleszcz, A 1756<br />
Klink, AJ 233, 1703<br />
Kloiber, S 2193<br />
Kloppenburg, M 179<br />
Klosowska, K 17, 39, 1131<br />
Klüter, A 886<br />
Knapp, L 1345<br />
Knauer, C 1123<br />
Kneitz, C 782<br />
Knevel, R 1744, 1782<br />
Knight, A 891<br />
Knight, E 515<br />
Knight, JB 1463<br />
Knops, B 1325<br />
Knowlton, N 655, 1030<br />
Knutson, KL 1580, 1581, 2216<br />
Ko, TC 1667<br />
Koarada, S 433<br />
Kobayashi, H 139, 1797<br />
Kobayashi, I 1672<br />
Kobayashi, K 139<br />
Kobayashi, S 1377<br />
Kobayashi, T 1641<br />
Kobelt, G 761<br />
Kobialko, M 406<br />
Kobie, J 849, 1085<br />
Koçak, M 1208<br />
Koch, AE 282, 1417, 1419, 1487,<br />
1504, 1721, 2007<br />
Koch, H 1125<br />
Kochi, Y 1577<br />
Kockum, I 832<br />
Kodhek, S 1336<br />
Koehoorn, M 2093<br />
Koeleman, BPC 1599, 2214<br />
Koenders, MI 275, 371, 1351,<br />
1622, 1730, 2230<br />
Koenig, AS 1103, 1927<br />
Koenig, MF 440<br />
Koening, CL 1309<br />
Koerbl, B 138<br />
Koetter, I 899, 900, 1145<br />
Koeuth, T 934, 1608, 2149<br />
Koevoets, R 295, 1755<br />
Koga, T 364, 1371, 1632<br />
Koh, E-M 366, 372, 1297<br />
Kohno, M 1511<br />
Kohsaka, H 1375<br />
Köhler, D 679<br />
Koike, T 2, 5, 10, 399, 621, 981,<br />
1814, 1815, 1909, 2254<br />
Koitschev, A 899, 900<br />
Koitschev, C 899, 900<br />
Kojima, F 864<br />
Kokkonen, H 1847, 2115<br />
Kolar, P 630, 1418<br />
Kolfenbach, JR 77, 658, 702, 1094<br />
Kollerup, G 1444, 1841<br />
Kollias, G 368, 1719, 2237<br />
Kolling, C 21, 357, 1093, 1518,<br />
1528<br />
Kollnberger, S 1973<br />
Kolta, S 548<br />
Komai, K 511, 893<br />
Komura, K 617<br />
Konatalapalli, RM 869<br />
Kondi, A 261, 1696<br />
Kondo, S 433<br />
Kondo, Y 1724<br />
Kondos, G 1168<br />
Kondragunta, V 831, 838<br />
Kone-Paut, I 895, 905, 1305,<br />
1425, 1435, 1696, 1704<br />
Kong, N 1266, 1499<br />
Kono, H 1285, 1531<br />
Koo, G 427, 866, 1199<br />
Koopman-Keemink, Y 219<br />
Kopec, J 72, 1056, 1555, 2055,<br />
2093<br />
Kopecky, EA 944<br />
Korb, A 1719, 2237<br />
Korchynskyi, O 1487<br />
Korendowych, E 833<br />
Koretzky, GA 1354<br />
Kornman, K 707, 831, 838<br />
Kornum, J 2040<br />
Korpela, M 80<br />
Korswagen, L-A 1859<br />
Kosek, E 2245<br />
Koshy, S 1128<br />
Koss, MN 2187<br />
Kostianovsky, A 2009, 2043<br />
Kosugi, Y 893<br />
Kotowicz, M 183<br />
Kotsakis, S 2175<br />
Koumakis, E 529, 1924<br />
Kovács, L 1578<br />
Koval, E 2013<br />
Koval, RJ 2013<br />
Kowal-Bielecka, O 599, 1212<br />
Kowalczyk, A 664<br />
Kowatari, K 329<br />
Koyama, Y 1086<br />
Koyano, S 1138, 1738, 1739<br />
Kozaci, D 1282, 1970<br />
Kozyrev, S 1578<br />
Kracht, M 1535<br />
Kraemer, KL 1039<br />
Kramer, HR 1018, 1065<br />
Krammer, G 1435, 2087<br />
Krasnokutsky, S 137, 707, 708<br />
Krasnow, R 877<br />
Krasowska, D 580<br />
Kraus, V 180, 181, 707<br />
Krause, A 2271<br />
Krause, ML 2216<br />
Krausz, S 1095<br />
Krege, JH 957<br />
Kreiger, PA 1354<br />
Kremer, J 1836<br />
Kremer, JM 347, 378, 379, 416,<br />
515, 1003, 1799, 1819, 1835, 2169,<br />
2262<br />
Kremser, M-L 1481<br />
Kretzler, M 2276, 2278<br />
Kreuter, A 2214<br />
Krieckaert, CL 1445<br />
Krieg, M-A 2157<br />
Krintel, SB 381<br />
Krishna Kumar, PR 1106<br />
Krishnamurthy, A 161<br />
Krishnan, E 154, 877, 878, 1378,<br />
1545, 2153<br />
Krishnan, G 574<br />
Kristjansdottir, GT 1885<br />
Krivine, A 478, 2043<br />
Kroese, F 1889, 1892<br />
Krogh, NS 1809<br />
Krohn, KD 980<br />
Krueger, GG 1943<br />
Krueger, K 782<br />
Kruize, AA 1896, 1900, 1903<br />
Krummel-Lorenz, B 1112<br />
Krusch, D 1481<br />
Krystufkova, O 926<br />
Kuan, W-P 1028<br />
Kubo, M 1577<br />
Kubota, K 1619<br />
Kubota, T 2228<br />
Kuemmerle-Deschner, J 894, 895,<br />
899, 900, 905, 1425, 1435<br />
Kuhr, K 294<br />
Kularatne, S 1613<br />
Kulkarni, OP 441
Kuller, LH 71<br />
Kumabe, M 1164<br />
Kumagai, S 1715<br />
Kumar, A 1606, 1612, 1726<br />
Kumar, D 190, 194<br />
Kumar, N 1064<br />
Kumar, S 2086, 2169<br />
Kume, K 1839<br />
Kümmerle-Deschner, J 1305<br />
Kumora, K 601<br />
Kuo, D 135<br />
Kuper, IH 314, 662, 1771<br />
Kupper, H 123, 1101, 1108, 1938<br />
Kurasawa, K 472<br />
Kurasawa, T 1793, 1823<br />
Kurhanewicz, C 136<br />
Kurien, BT 1901<br />
Kurita, T 1909<br />
Kuriya, B 81, 1737<br />
Kuroiwa, T 358<br />
Kurosaka, D 921<br />
Kurosaka, M 983<br />
Kurowska-Stolarska, M 28, 1422<br />
Kurrasch, RH 58<br />
Kurt, R 1351<br />
Kurthen, R 1788<br />
Kusunoki, N 619<br />
Kusunoki, Y 619<br />
Kuwana, M 916, 1293, 1672<br />
Kuwana, Y 1708<br />
Kuzin, I 712, 1710<br />
Kvarnstrom, M 1885, 1917<br />
Kvien, T 55, 132, 141, 142, 182,<br />
377, 534, 1013, 1027, 1603, 1750,<br />
1774, 1802, 1807, 1922, 1780<br />
Kwak, H-B 2158<br />
Kwan, L 2074<br />
Kwan Tat, S 1497<br />
Kwekkeboom, J 179<br />
Kwoh, CK 185, 193, 2096<br />
Kwok, RCL 773<br />
Kwok, S-K 353, 370, 756, 1716,<br />
1770<br />
Kwon, E 1972<br />
Kwon, H-H 323<br />
Kwon, SR 1813<br />
Kwon, Y-J 27<br />
Kwong, T 820<br />
Kyburz, D 829, 1389, 1528<br />
Kyndt, X 2045<br />
Kyogoku, M 291<br />
Kyriakidis, NC 2175<br />
Kyttaris, VC 2126, 2277<br />
La Cava, A 431, 497<br />
La Torre, F 1439, 2033, 2202<br />
L<br />
Labrecque, J 214, 731<br />
Lacaille, D 72, 523, 535, 771,<br />
1036, 1056, 1152, 1538, 1571<br />
Lachmann, H 895, 905, 1425,<br />
1663<br />
Lacraz, A 2010, 2011<br />
Lacy, E 1818<br />
Lacy, JP 2235<br />
Lafeber, FPJG 121, 124, 176, 278,<br />
333, 380, 636, 942, 952, 1380,<br />
1753, 1759, 1900, 1903<br />
Laforet, P 922<br />
Lafyatis, R 560, 566, 675, 1210,<br />
2004<br />
Lagana’, B 1098, 1582<br />
Lagoo Joshi, V 1551<br />
Lagunas, T 229<br />
Lai, C 94, 814, 819<br />
Lai, Z 1185, 1196<br />
Lainez, B 1246<br />
Laishram, GD 2086<br />
Lajeunesse, D 1497<br />
Lakos, G 2251, 2252<br />
Lales, G 221<br />
Laliberte, K 597<br />
Lalwani, N 282<br />
Lam, J 1465<br />
Lam, KSL 1233<br />
Lamana, A 1505<br />
Lambert, C 888<br />
Lambert, R 134, 551, 667, 1934,<br />
1957, 1959<br />
Lambert, S 1405<br />
Lambrianides, A 2255<br />
Lammertsma, AA 1613<br />
Lamprecht, P 2036<br />
Lan, C 1268<br />
Lan, Y 1427<br />
Lanas, A 953, 1031<br />
Lanasa, M 1192<br />
Lancaster, W 468<br />
Lancha Junior, AH 1384<br />
Lancrenon, S 888<br />
Landells, I 1939<br />
Lander, PH 1573<br />
Landewe, R 303, 1113, 1922,<br />
1949, 1985<br />
Landolt-Marticorena, C 13, 2190<br />
Landon, GC 178<br />
Lane, JA 502, 1602<br />
Lane, NE 182, 624, 957, 965, 2212<br />
Lang, BA 238<br />
Langan, MA 989, 2112<br />
Langdahl, B 967<br />
Lange, B 950<br />
Lange, R 950, 1059<br />
Langefeld, C 500, 654, 1584,<br />
1585, 1586, 1591, 1594, 1595,<br />
2145, 2148, 2274<br />
Langer, A 1004<br />
Langerak, A 2004<br />
Langford, CA 1315, 2012, 2047,<br />
2049, 2198<br />
Langleben, D 565<br />
Langman, C 1168<br />
Lanna, CCD 1169, 1842, 1849<br />
Lanni, S 2220<br />
Lanot, S 2269<br />
Lanz, S 888<br />
Lanzarotti, A 948<br />
Lapadula, G 297<br />
Lapierre, M 1931<br />
Laragione, T 1128, 1387<br />
Laria, A 744<br />
Larida, B 2252<br />
Larimi, R 1289<br />
Laroche, M 964<br />
Larroche, C 917, 1890, 1893,<br />
1894, 1910, 2042<br />
Larsson, A 103<br />
Lasigliè, D 265, 657<br />
Lasky, A 253, 254<br />
Lasky, RE 1218, 1227<br />
Lassere, M 141, 1369<br />
Laster, AJ 383<br />
Latchman, DS 1358, 1359, 2255<br />
Lateef, A 460, 1149<br />
Latek, R 1119<br />
Lateur, L 311<br />
Latinis, K 457<br />
Lattanzi, B 210, 232<br />
Lau, CS 1139, 1233, 2156<br />
Lau, H 621<br />
Laubender, R 1781<br />
Lauber, K 490<br />
Laudes, M 294<br />
Laudien, M 679<br />
Lauféron, F 1945<br />
Laughlin, S 2019, 2107<br />
Launay, D 2010, 2042<br />
Launay, J-M 1707<br />
Launay, O 533, 2043<br />
Laurendeau, I 2025<br />
Lauri, J 172<br />
Laurindo, I 356, 1013<br />
Laurino, S 678<br />
Lauwerys, B 1578<br />
Lauwerys, BR 2263<br />
LaValley, M 706, 872, 1564, 2143,<br />
2155<br />
Lavender, L 1538<br />
Laveskog, A 1181<br />
Lavie, F 518, 559, 1930, 1935,<br />
1949<br />
Law, C-L 1273<br />
Lawrence, C 1267<br />
Lawrenz, B 1145<br />
Lawson, E 1645<br />
Laxer, RM 225<br />
Lazaretti, M 1676<br />
Lazarevic, D 217<br />
Lazaro, D 161, 970, 1431<br />
Lazaro, E 2010<br />
Lazarus, MN 738, 740<br />
LBSL02/99 Study Group 1457<br />
Le, E 589, 2192<br />
Le, TT 602<br />
Le Bars, M 1817<br />
Le Blay, P 408<br />
Le Boutin, D 1249<br />
Le Gall, M 834<br />
Le G<strong>of</strong>f, B 29, 30<br />
Le Guen, J 2041<br />
Le Guenno, G 2010, 2011, 2026<br />
Le Guern, V 1398, 1890, 1910,<br />
2034, 2041, 2043, 2239<br />
Le Henaff, C 2261<br />
Le Loët, X 301, 400, 1087, 1752,<br />
1790, 1827<br />
Le Pottier, L 2177<br />
Le Thi Huong, D 2025, 2239<br />
Le Thi Huong-Boutin, D 1287<br />
Leak, A 1830<br />
Leandro, MJ 739, 743<br />
Leask, A 613<br />
Leaverton, PE 823<br />
Leberruyer, P-Y 2045<br />
Leblanc, V 1946<br />
Leblond, V 2011<br />
Lebre, C 1507, 1519<br />
Lebre, MC 1534<br />
Lechat, P 2239<br />
Lechtzin, N 1022<br />
LeClercq, S 785<br />
Lecompte, T 1<br />
Lederman, S 799, 820<br />
Lee, AT 825, 992, 1386, 1592,<br />
1597, 2214<br />
Lee, B 359, 1972<br />
Lee, C 876, 2028, 2158, 2172<br />
Lee, D 167, 363, 2229<br />
Lee, E 274, 387, 1484, 1751<br />
Lee, H-J 323, 903<br />
Lee, H-S 803, 1092, 1597, 1605,<br />
1714<br />
Lee, J 75, 276, 366, 372, 1122,<br />
1156, 1297, 1864<br />
Lee, JLF 214, 731<br />
Lee, JM 817, 818<br />
Lee, JS 1092, 1441, 1605<br />
Lee, JH 803, 1209<br />
Lee, J-W 277, 1209, 1714<br />
Lee, JY 122, 706<br />
Lee, K 148, 883, 1028, 1092,<br />
2010 Program Book 335<br />
abstract author Index
aBSTRACT author Index<br />
336<br />
1605, 1972<br />
Lee, K-H 1061, 1873<br />
Lee, L 920<br />
Lee, MB 828<br />
Lee, MS 2158<br />
Lee, S 876, 1504, 1721, 2028<br />
Lee, S-H 1038<br />
Lee, SJ 116, 505, 1891, 2056<br />
Lee, SK 27, 1061, 1873<br />
Lee, S-S 116, 505, 803, 1891<br />
Lee, SW 1061, 1873<br />
Lee, VW 1028<br />
Lee, Y 92, 95, 174, 359, 366, 372,<br />
387, 933, 949, 1050, 1058, 1297,<br />
1628, 1901<br />
Lee, Y-A 803, 1038<br />
Leeder, JS 253, 254<br />
Lefaucheur, J-P 1908, 1911<br />
Lefevre, S 1420, 1722<br />
Leffers, HC 1809<br />
Leffler, MG 206<br />
Legault, C 203<br />
Léger, J-M 2010, 2011<br />
Leggerton, CW 2173<br />
Lehane, P 391<br />
Lehman, AJ 1324, 1538<br />
Lehman, TJA 1872<br />
Lehmann, A 148, 883<br />
Lehmann, B 911<br />
Lehr, A 1420, 1722<br />
Lei, J 1265, 2016<br />
Leipe, J 2130<br />
Leirisalo-Repo, M 420<br />
Leite, I 922<br />
Leitman, S 1161<br />
Leleti, MR 2032<br />
Leman, M 376<br />
Lembo, R 1698<br />
Lemeiter, D 2236<br />
Lemoine, S 737<br />
Lems, W 967<br />
Lems, WF 332, 961, 1033, 1084,<br />
1496, 1859<br />
Len, CA 1339, 1343, 1704, 1872<br />
Lencina, V 324<br />
Lenhart, P 1405<br />
Lenh<strong>of</strong>f, MW 1328<br />
Lenief, V 354, 1515<br />
Lent, PV 2151<br />
Lenzi, M 2036, 2201<br />
Leo, J 1210<br />
Leon, G 2173<br />
Leonard, G 1170<br />
Leonard, MB 206, 1786<br />
Leoncini, G 1155, 2202<br />
Leone, J 1893<br />
Leong, A 1766<br />
2010 Program Book<br />
Lepore, L 1435, 1436<br />
Lepse, N 2015<br />
Lequen, L 701<br />
Lequerré, T 1087, 1810, 1827<br />
Lerma, C 808<br />
Leroux, G 2239<br />
Lertnawapan, R 1023<br />
Lertratanakul, A 620, 1168, 1399<br />
Leslie, K 895, 1425, 1435<br />
Lessard, CJ 1579, 1585, 2147<br />
Lessov-Schlaggar, CN 877<br />
Letierce, A 1305, 1696<br />
Leung, HW 1870<br />
Leung, L 1386<br />
Leung, YT 422<br />
Leutenegger, E 984<br />
Levartovsky, D 697<br />
Leveille, SG 684<br />
Levels, HHM 332<br />
Leveneur, Y 2027<br />
Levin, J 780<br />
Levin, R 31<br />
Levin, TL 1630<br />
Levine, AB 898<br />
Levine, BE 2186<br />
Levine, SM 677, 681<br />
Levy, AR 535, 771<br />
Levy, DM 234, 1688<br />
Levy, R 6, 451, 452, 1172, 1848,<br />
2172<br />
Levy-Neto, M 927<br />
Lew, BR 271<br />
Lewis, C 131, 201, 205, 683, 686,<br />
693, 872, 951, 1367, 1557, 2058,<br />
2100, 2133<br />
Lewis, EE 1158<br />
Lewis, JD 2084<br />
Lewis, MJ 430<br />
Ley, R 40<br />
Leyva, AL 1219<br />
Li, C 151, 747, 1598, 1607, 2205<br />
Li, EK 451, 1028<br />
Li, G 2127<br />
Li, H 1260, 2189<br />
Li, J 712, 1107, 1135, 1260, 1412,<br />
1710, 2189<br />
Li, L 1321, 1538, 2050, 2055, 2282<br />
Li, M 1028, 1954<br />
Li, Q 1188, 1942<br />
Li, R 1182, 1598<br />
Li, SC 1673, 1690, 1691, 2017<br />
Li, T 625, 1028, 1758, 1874<br />
Li, W 2136<br />
Li, X 135, 136, 336, 868, 1734,<br />
1769<br />
Li, Y 501, 735, 742, 1500, 1598<br />
Li, Z 1134, 1598, 1997<br />
Lian, JB 716<br />
Liang, J 918, 1143, 2172<br />
Liang, KP 774<br />
Liang, KV 1399<br />
Liang, MH 1538<br />
Liao, C 288<br />
Liao, KP 1588, 1610<br />
Lias, J 2071<br />
Libanati, C 2157<br />
Lidove, O 2045<br />
Lidtke, RH 2099<br />
Lie, BA 1603, 2214, 2219<br />
Lie, E 55, 377, 1802, 1807, 1922<br />
Lieberman, SM 1907<br />
Liebhaber, A 1112<br />
Liedholm, R 1899<br />
Liew, FY 28, 1422<br />
Ligeiro, D 1986<br />
Lii, H 1167<br />
Lillegraven, S 132, 142, 1369<br />
Lim, A 597<br />
Lim, B 248<br />
Lim, C 1187<br />
Lim, MJ 1813<br />
Lim, M-K 488, 830, 1589<br />
Lim, S 226, 448, 476, 790, 1431,<br />
1877, 2240, 2243<br />
Lima, FR 626, 1384<br />
Limal, N 2034, 2239<br />
Limburg, P 1195<br />
Lin, CP 2144<br />
Lin, H-Y 2087<br />
Lin, J 1464, 1647<br />
Lin, P 273<br />
Lin, WY 1609<br />
Lin, Y 564, 1167<br />
Lindegaard, H 133, 1444, 1841<br />
Lindsley, CB 1678<br />
Lindsley, HB 943<br />
Lindstrom, M 1965<br />
Lindstrom, TM 2229<br />
Linehan, T 2242<br />
Lingala, B 642, 1378, 1545, 2153<br />
Linge, CP 1387<br />
Link, R 406<br />
Link, TM 135, 136<br />
Linnik, MD 321<br />
Linn-Rasker, SP 380<br />
Lino, M 1979<br />
Linos, E 1378<br />
Linton, MF 1034<br />
Lioté, F 376, 413, 875, 888, 1707,<br />
2151, 2239<br />
Liotta, F 246<br />
Lips, P 971<br />
Lipsker, D 2238<br />
Lipsky, P 1161<br />
Lipton, RB 939, 2095<br />
Lisk, L 1453, 2085<br />
Lisse, J 415, 1014, 1636<br />
Listing, J 526, 668, 669, 1111,<br />
1112, 1923, 1938, 1958, 1985,<br />
2270, 2271<br />
Litinsky, I 1159, 1238<br />
Little, MA 1207<br />
Littlefield, M 1072<br />
Littlejohn, G 320<br />
Littman, DR 1390<br />
Liu, G 269<br />
Liu, H 385, 600, 1968<br />
Liu, J 81, 339, 1066<br />
Liu, L 404<br />
Liu, P 19<br />
Liu, X 423, 565, 1598<br />
Liu, Y 1134<br />
Liu, Z 442, 2129, 2188<br />
Liu-Bryan, R 634<br />
Livingston, S 892<br />
Li-Yu, J 151<br />
Ljung, L 891, 1054<br />
Ljunggren, O 967, 982<br />
Llahí, N 1754<br />
Llanos, C 732<br />
Llobet, JM 1801<br />
Lloyd, D 192<br />
Lloyd, R 1372<br />
Lo, C 1014<br />
Lo, E 577, 1225<br />
Lo, GH 122, 188, 195, 706, 709,<br />
2101<br />
Lo Monaco, A 1627<br />
Lo Nigro, A 540<br />
Lober, J 2247<br />
Lobo, M 1372, 1983<br />
Locher, J 1005<br />
Lockard, MA 2244<br />
Lockshin, MD 6, 1151<br />
Lococo, B 1173<br />
Lodde, BM 1095<br />
Lodewyckx, L 1468<br />
Loeser, RF 203<br />
Loeuille, D 551, 768, 1810, 1931<br />
L<strong>of</strong>t, AG 134, 1953<br />
Logeart, I 69, 1629, 1946<br />
Loh, C 424, 425<br />
Loh, YK 717<br />
Lohanatha, F 630, 1418<br />
Lok, EYC 1748, 1777<br />
Lombardi, Jr, I 2132<br />
Londoño, J 517, 552<br />
Long, SG 391<br />
Longhi, B 1695<br />
Longy-Boursier, M 701<br />
Loo, T 1936<br />
Lo<strong>of</strong>, A 2002
Looney, C 941<br />
Looney, MR 609<br />
Looney, RJ 849<br />
Lopes, JB 1546<br />
López Vives, L 1016, 1277, 1299,<br />
1310<br />
Lopez-Ben, R 1573<br />
Lopez-Benitez, JM 231, 1404<br />
López-Bote, JP 1229<br />
Lopez-Fernandez, J 389<br />
Lopez-Hoyos, M 1296, 1871<br />
Lopez-Lazaro, L 1273<br />
Lopez-Longo, FJ 1078, 1276<br />
López-Mejías, R 538<br />
Lopez-Olivo, MA 178, 407, 755,<br />
941<br />
Lopez-Pedrera, C 1357<br />
López-Reyes, AG 1614<br />
Loppin, E 315<br />
Lord, G 617<br />
Lorenz, H-M 138<br />
Lorenzen, T 1809<br />
Lorenzin, M 540<br />
Lorenzini, S 615<br />
Lories, R 610, 1468, 1980, 2263<br />
Lorrain, D 606<br />
Lorusso, M 1436<br />
Losina, E 140, 143, 199, 2090,<br />
2091, 2092, 2137<br />
Lotti, T 1962<br />
Lotufo, S 1339<br />
Lotz, M 369, 634, 1494<br />
Lough, KM 730<br />
Louie, GH 786<br />
Louie, J 347, 699<br />
Louie, M 565<br />
Lourenco, EV 431, 497<br />
Loury, DJ 286<br />
Love, TJ 793, 1951<br />
Lovell, DJ 1407, 1434, 1673, 1691,<br />
2017<br />
Lovell, K 646<br />
Low, PS 1613<br />
Lowder, C 1670<br />
Loza, E 482, 516, 975, 1657<br />
Lozano, D 1475<br />
Lozano, E 1292, 1294<br />
Lozano, F 538<br />
Lu, B 949, 1050, 2104<br />
Lu, C 1107<br />
Lu, G 621<br />
Lu, J 386<br />
Lu, LD 2233<br />
Lu, Q 507<br />
Lu, R 2274<br />
Lu, X 1598<br />
Lu, Y 1536<br />
Lubbeke-Wolff, A 2257<br />
Lubberts, E 38, 287, 715, 1259,<br />
1274, 1525<br />
Lubrano, E 532<br />
Luca, D 1122<br />
Luca, NJC 1681<br />
Lucacchini, A 811, 839<br />
Lucas, FL 1638<br />
Lucas, K 1735<br />
Lucas, M 288, 563, 929, 930<br />
Lucherini, OM 837<br />
Luchi, ME 2172<br />
Luciano, N 1884, 1916<br />
Lucier, S 781<br />
Ludivico, CL 1834<br />
Ludwicka-Bradley, A 604<br />
Luedtke, C 104, 108<br />
Luetkecosmann, S 1418<br />
Lufkin, J 1095<br />
Luggen, M 416, 1854, 1855<br />
Lui, NL 512, 545, 556<br />
Luijtens, K 1832<br />
Luime, J 317, 1775, 1776, 2066,<br />
2180<br />
Luini, A 1089<br />
Lukas, C 301, 303, 1088, 1104,<br />
2218, 2221<br />
Luker, K 624<br />
Lukert, BP 943<br />
Lukina, G 55, 1802, 1807<br />
Lumezanu, E 869<br />
Lund Hetland, M 141<br />
Lundberg, IE 924, 926, 2245<br />
Lundberg, K 1717, 2118<br />
Lundell, A-C 1248<br />
Lundsgaard, D 508<br />
Luning-Prak, E 439<br />
Lunt, M 374, 421, 445, 766, 779,<br />
796, 1067, 1110<br />
Luo, A 390, 416<br />
Luo, Y 1725<br />
Luong, F 809<br />
Luqmani, R 676, 777, 1652, 1654<br />
Luster, A 25, 606, 1427<br />
Lustig, S 1041<br />
Lüthke, K 1757<br />
Luthra, HS 705, 1662<br />
Luukkainen, R 891<br />
Luyten, FP 610, 1468, 1980<br />
Luzina, IG 432<br />
Lvovich, S 1341<br />
Lyden, AK 1319<br />
Lydon, EJ 996<br />
Lyman, S 2193<br />
Lynch, BM 1631<br />
Lynch, J 202, 624, 1555, 2100<br />
Lyons, A 817, 818<br />
M<br />
Ma, KM 1206, 2159<br />
Ma, MHY 412<br />
Ma, X 1182<br />
MacAllister, R 674<br />
Macarios, D 971<br />
Macchioni, P 777, 1302, 1637,<br />
1654, 2044<br />
MacDonald, D 554<br />
MacDonald, PA 154, 165<br />
Macdougald, O 601<br />
Macey, K 391<br />
Macfarlane, GJ 646, 649<br />
Machado, LG 1842<br />
Machado, P 1922<br />
Machicao, V 726<br />
Machida, T 435<br />
Machin, S 6<br />
Machnik, A 2234<br />
MacIntyre, NJ 1316<br />
Maciuca, R 1455<br />
Mack, C 1560<br />
Mack, M 1127<br />
Mackay, C 1562<br />
Mackey, RH 71<br />
Mackiewicz, K 999<br />
MacMullan, PA 1109, 1306<br />
Macrae, J 1431<br />
Macwana, S 2274<br />
Madaule, S 2027<br />
Madden, J 791<br />
Maddison, P 445, 448, 476, 664,<br />
1877, 2240<br />
Mader, R 550<br />
Madhok, R 2214<br />
Madigan, A 1109, 1306<br />
Madrakian, H 533<br />
Madrid, A 801<br />
Madsen, OR 134, 1444, 1841,<br />
1953<br />
Mæhlen, MT 1603<br />
Maekawa, T 1511<br />
Maese, J 1657<br />
Maeshima, A 358<br />
Maezawa, R 472<br />
Magalhães, CS 1407<br />
Magaña-Aquino, M 1166<br />
Magder, L 460, 474, 479, 485,<br />
1148, 1149, 1163, 1180, 1879,<br />
2122, 2124<br />
Maggi, D 510<br />
Maggi, E 246<br />
Maggi, L 246<br />
Maghnie, M 1684<br />
Magid, S 1576<br />
Magnani, A 210<br />
Magnani, L 1290, 1302, 2044<br />
Magni-Manzoni, S 207, 210, 2033,<br />
2220<br />
Magro, C 2193<br />
Maguire, C 1886<br />
Mahadevan, U 718<br />
Mahapatra, A 1106<br />
Mahmood, F 567, 585<br />
Mahmud, T 1830<br />
Mahr, A 533, 2014, 2026<br />
Maia Neto, FJ 2059<br />
Maier, S 1901<br />
Maillard, SM 1342, 1344<br />
Maillefert, J-F 140, 143, 1752<br />
Maines, LW 1480<br />
Maisonobe, T 1911, 2024, 2025,<br />
2046<br />
Majdan, M 1742<br />
Majgaard, O 134, 1444, 1841,<br />
1953<br />
Majhi, B 2086<br />
Majithia, V 1401, 1860<br />
Major, G 584<br />
Majoral, J-P 281<br />
Majumdar, S 136<br />
Mak, KF 1233<br />
Mak, TW 2186<br />
Makinson, G 2205<br />
MakIver, H 1926, 2182, 2183<br />
Makris, UE 1459<br />
Maksymowych, W 330, 535, 549,<br />
551, 557, 667, 760, 771, 1451,<br />
1934, 1949, 1957, 1959, 1963,<br />
1964<br />
Malamet, RL 1808<br />
Malani, S 1866<br />
Malattia, C 1434, 1700<br />
Malbos, S 548<br />
Malchau, H 2137<br />
Maldonado Cocco, J 50<br />
Malfait, A-M 823, 841<br />
Malik, R 966<br />
Malik, TH 430<br />
Malladi, AS 1898<br />
Malmstrom, V 1125, 1917, 2118<br />
Malone, DG 1617<br />
Maloney-Saxon, GL 999<br />
Malouf, J 975<br />
Malvar Perrin, A 1173<br />
Malysheva, O 1025<br />
Mammou, S 988<br />
Mamyrova, G 1678<br />
Man, Z 2157<br />
Manal, K 190<br />
Manara, M 532<br />
Manda, G 848<br />
Mandal, A 164<br />
Mandel, DR 166<br />
Mandelboim, M 697, 1238<br />
2010 Program Book 337<br />
abstract author Index
aBSTRACT author Index<br />
338<br />
Mandelin, AM 270, 714, 1506<br />
Mandl, LA 174, 898, 1080, 1576<br />
Mandl, P 777, 1629, 1637, 1654<br />
Mandl, T 1307, 1896, 1902<br />
Manfredi, A 581, 1627<br />
Manfredi, M 1098, 1582<br />
Mangge, H 1700<br />
Manheim, L 1558<br />
Mani, C 286<br />
Manjarraz-Orduno, N 825<br />
Mann, A 1395<br />
Mann, H 926<br />
Mannalithara, A 2206<br />
Mannerkorpi, K 103<br />
Manning, CA 716<br />
Manning, J 588, 1623<br />
Manning, W 1606<br />
Mannion, M 209<br />
Manno, RL 587, 589, 948<br />
Manohar, PR 1106<br />
Manson, JE 1062<br />
Manson, S 58<br />
Mansoori, L 1395<br />
Mansour, S 1221<br />
Mantilla, RD 1048, 1811<br />
Mantovani, E 1644<br />
Manuel, D 1555<br />
Manzi, S 448, 476, 620, 731, 754,<br />
1399, 1877, 2240, 445, 452, 457,<br />
1456, 2243<br />
Manzo, A 623<br />
Mao, J 216<br />
Maradit-Kremers, H 777, 1637,<br />
1652, 1654<br />
Marangoni, RG 605, 1644<br />
Maranhão, R 284<br />
Maranian, P 147, 155, 583, 729,<br />
1205, 1213, 1228, 1232, 1365,<br />
1572, 1779, 2195<br />
Maratha, A 1533<br />
Marceau, G 375<br />
Marcela, B 2070<br />
Marcelli, C 1893, 1931<br />
Marchesin, V 1100<br />
Marchesoni, A 297, 532<br />
Marchou, B 2027<br />
Marcos, J 50<br />
Marcus, R 777, 1654<br />
Marcuz, J 225<br />
Marder, W 1158, 1041<br />
Marenco, JL 1078<br />
Marengo, MF 941, 1047, 1865<br />
Margaretten, ME 1024<br />
Marguerite, G 922<br />
Marí-Alfonso, B 1301<br />
Marie, I 915, 2010, 2011<br />
Marie, SKN 927<br />
Mariette, X 548, 917, 1810, 1893,<br />
2010 Program Book<br />
1894, 1896, 1910, 376, 400, 1088,<br />
1413, 1579, 1790, 1890, 2010,<br />
2011, 2042<br />
Marijnissen, ACA 121, 124, 952,<br />
1380<br />
Marijnissen, RJ 275, 1730<br />
Marín, A 1741<br />
Marin, E 486, 733<br />
Marin, F 967<br />
Marin, MJ 1296<br />
Marín-Arriaga, N 1614<br />
Marini, R 1339, 1695<br />
Marino, F 1089<br />
Marion, J 1931<br />
Marion, M 654<br />
Marion, T 1410<br />
Mariz, HA 579<br />
Markello, T 914<br />
Märker-Hermann, E 665<br />
Markovitz, D 550<br />
Markward, NJ 1561<br />
Marotte, H 282, 1504<br />
Marques, R 89<br />
Márquez, J 1811<br />
Marrone, G 2008<br />
Marshak-Rothstein, A 736<br />
Marshall, D 1244<br />
Marshall, NJ 1064<br />
Marshall, T 796, 1067<br />
Marston, BA 1620<br />
Martel-Pelletier, J 196, 938, 1489,<br />
1497<br />
Martin, A 2261, 2269<br />
Martin, B 309, 1942<br />
Martin, C 250, 383<br />
Martin, F 1609<br />
Martin, J 824, 829, 1301, 1578,<br />
1585, 1586, 1594, 1599, 2147,<br />
2214<br />
Martin, JE 1599, 2214<br />
Martin, KR 690, 691, 1460, 1461,<br />
1462, 2140, 2141<br />
Martin, L 119, 330<br />
Martin, P 264, 266, 1394<br />
Martin, R 2119<br />
Martin, SA 94<br />
Martin, TM 1447<br />
Martin, TJ 30<br />
Martineau, G 82<br />
Martinez, A 96, 808<br />
Martínez, JB 1811<br />
Martinez, L 608, 852<br />
Martinez, M 1994<br />
Martinez, R 1256<br />
Martinez Avila, E 435<br />
Martinez Dubois, C 1650<br />
Martinez Lopez, JA 516, 1657<br />
Martínez-Caceres, E 1741<br />
Martinez-Lavin, M 96, 808, 1614<br />
Martinez-Lopez, JA 407<br />
Martínez-Martínez, MU 1166<br />
Martinez-Morillo, M 1741<br />
Martínez-Taboada, V 777, 1276,<br />
1296, 1650, 1652, 1654<br />
Martinez-Vidal, MP 482<br />
Martini, A 207, 208, 210, 232,<br />
265, 657, 905, 1407, 1434, 1684,<br />
1685, 1700, 1701, 1705, 1706<br />
Martini, G 1439, 1682, 1687, 2033<br />
Martin-Mola, E 414, 349, 1967<br />
Martino, S 1439, 1700<br />
Martins da Silva, B 1578<br />
Martinuzzo, M 3<br />
Martucci, C 1341<br />
Maruyama, J 703, 932<br />
Mary, F-TK 2167<br />
Mary, T 598<br />
Marzaioli, V 1482<br />
Marzan, K 241<br />
Marzan, KAB 2102<br />
Marzo-Ortega, H 524, 553, 1929,<br />
1963<br />
Mascaró, C 1137<br />
Mascia, MT 2036, 2201<br />
Masciocchi, M 580<br />
Mashida, A 511, 893<br />
Masi, AT 49, 83<br />
Masi, CM 1875<br />
Masi, L 222, 1155, 2202<br />
Masih, S 169<br />
Masolini, P 2201<br />
Mason, JL 2233<br />
Mason, R 1728<br />
Mason, TG 1673, 1691, 2017<br />
Massardo, L 2070<br />
Massarotti, E 1805<br />
Massarotti, EM 339<br />
Mastbergen, SC 176, 942, 1380<br />
Masteller, E 288<br />
Masuda, H 1708<br />
Masuda, I 897, 916, 923<br />
Mat, C 1288, 1312<br />
Mata, C 1296<br />
Mateo, I 1171<br />
Mateo, L 1741<br />
Mateos, J 840, 1473<br />
Mathew, AJ 1549<br />
Mathew, SD 1669<br />
Mathian, A 478, 2187<br />
Mathieu, A 728<br />
Mathieu, S 375, 542<br />
Mathsson, L 1020<br />
Matnani, RG 864<br />
Matos, M 1986<br />
Matos Costa, J 1011<br />
Matsubara, T 1138, 1738, 1739<br />
Matsui, K 1641<br />
Matsui, T 568<br />
Matsumoto, I 292, 352, 1724,<br />
2176<br />
Matsumoto, T 1265, 2016<br />
Matsuno, H 1138, 1738, 1739<br />
Matsuo, K 365<br />
Matsuo, N 2176<br />
Matteson, EL 53, 67, 78, 129, 316,<br />
326, 385, 403, 774, 777, 890, 908,<br />
1212, 1550, 1570, 1580, 1581,<br />
1637, 1652, 1654, 1818, 2216<br />
Matthys, P 1720<br />
Mattias, K 2251, 2252<br />
Mattinzoli, D 2278<br />
Mattocks, K 2249<br />
Mattson, MP 672<br />
Matucci Cerinic, M 222, 558, 560,<br />
565, 566, 580, 583, 593, 599, 1155,<br />
1987, 1962, 2033, 2196, 2202,<br />
2226<br />
Matzelle, MM 716<br />
Matzkies, F 537<br />
Matzko, CK 999<br />
Maurer, B 1988<br />
Mavers, M 861<br />
Mavragani, CP 1181<br />
Maxwell, JL 1385<br />
May, J 1766<br />
May, SL 502, 1602<br />
May Chee, M 2214<br />
Mayes, M 562, 591, 603, 612,<br />
725, 726, 824, 829, 1211, 1216,<br />
1218, 1219, 1226, 1227, 1205,<br />
2214<br />
Maynard, JW 1364, 1544, 1556,<br />
1565, 1569<br />
Mayr, G 1351<br />
Mazieres, B 917, 2094<br />
Mazlumzadeh, M 777, 1637,<br />
1652, 1654<br />
Mazodier, K 1664<br />
Mazor, KM 156<br />
Mazur-Zielinska, H 1705<br />
Mazzaro, C 2036, 2201<br />
Mazzuca, S 93, 1627<br />
Mazzuca, SA 797, 948<br />
McAdams, E 195, 2101<br />
McAdams, MA 1364, 1544, 1556,<br />
1569<br />
McAlear, C 2198<br />
McAlindon, T 95, 122, 188, 195,<br />
706, 709, 2101<br />
McBeth, J 646, 836, 1323<br />
McBurney, CA 620<br />
McCahan, J 736<br />
McCann, B 950<br />
McCarthy, C 1306, 1638<br />
McCarthy, EM 1306
McCarthy, GM 1109, 1306, 1426<br />
McCausland, J 2112<br />
McCloskey, J 912<br />
McClung, MR 982<br />
McClure, A 1593<br />
McCollum, L 84<br />
McCormack, W 16<br />
McCormick, J 871, 1391<br />
McCracken, A 1863<br />
McCraken, A 1284<br />
McCroskery, P 398<br />
McCune, J 457, 1457<br />
McCune, WJ 1158<br />
McCurdy, D 262, 509, 998, 1673,<br />
1677, 1691, 2017<br />
McDaniel, G 180<br />
McDonald, JR 62, 1395<br />
McDonald, S 843<br />
McDonnell, E 637<br />
McEarchern, JA 1273<br />
McEvoy, A 1482<br />
McGann, M 1106<br />
McGinnis, MW 19<br />
McGonagle, D 524, 553, 1929,<br />
1963<br />
McGoon, M 595, 1223<br />
McGovern, D 537<br />
McGrath, P 1408<br />
McGregor, NM 30<br />
McGuirk, P 16<br />
McHale, T 1399<br />
McHugh, K 1973<br />
McHugh, N 664, 833<br />
McInnes, IB 28, 1389, 1422, 1441,<br />
1943<br />
McKay, J 457, 1457<br />
McKee, G 1032<br />
McKeever, E 2172<br />
McKenna, MJ 1947<br />
McKenna, S 221<br />
McKeon, B 167<br />
McKeown, E 978<br />
McLaughlin, V 598, 1004<br />
McLean, RR 1317, 1327<br />
McMahon, BJ 892<br />
McMahon, M 471, 594, 1058,<br />
1189, 2241<br />
McMorrow, JP 1482, 1508, 1522<br />
McMurray, RW 1040<br />
McNallan, KT 15, 934, 1379<br />
McNally, B 245<br />
McNamara, S 989, 2111<br />
McNamee, P 646<br />
McNearney, T 562, 1211, 1218,<br />
1219, 1226, 1227, 1536<br />
McNeill, L 1424<br />
McNiff, K 993<br />
McNulty, J 1625<br />
McQueen, FM 141, 881, 1369,<br />
1372, 1779, 1983<br />
McRae, L 1562<br />
McSweeney, P 726<br />
McVie, T 299, 1740, 1779<br />
Mease, P 94, 99, 100, 113, 1096,<br />
1919, 1930, 1935, 1943, 1955,<br />
2168, 2169<br />
Medeiros, A 539<br />
Medema, JP 1732, 2178<br />
Mediero, A 1470, 1471<br />
Medina, G 1150<br />
Medina, J 1276<br />
Medinger, C 940<br />
Medsger, T 1231<br />
Medsger, TA 563, 2006<br />
Meehan, S 1190<br />
Meek, IL 1019<br />
Meesters, JJL 2284<br />
Meeuwisse, C 1829, 2265<br />
Meguro, A 2217<br />
Mehta, DP 392<br />
Mehta, M 2193<br />
Mei, Y 618<br />
Meier, S 792<br />
Meigs, JB 1317<br />
Meijer, J 1889, 1892, 1905<br />
Meiners, PM 1905<br />
Meini, A 1685, 1706<br />
Mejía, R 1811<br />
Mekinian, A 1893, 1894<br />
Mela, C 1819, 2262<br />
Melander, O 774<br />
Melchers, I 1987, 2226<br />
Melchiorre, D 532<br />
Melendez, AJ 28<br />
Melichian, DS 601<br />
Meliconi, R 1290<br />
Mellins, ED 255<br />
Mellis, SJ 710, 1121<br />
Mello, SBV 284<br />
Mello, WA 1694<br />
Mellstrom, D 2157<br />
Melo-Gomes (Andre Dos Santos),<br />
JA 1407<br />
Melson, PG 218<br />
Melton, LJ 959<br />
Menashe, L 199<br />
Menckeberg, C 1711<br />
Mendelsohn, A 1835<br />
Mendelson, CF 1349<br />
Mendelson, E 697, 1238<br />
Meng Choong, L 463<br />
Mensah, K 1492<br />
Mentre, F 1653<br />
Menz, H 173<br />
Mera, A 1076<br />
Mercer, L 421<br />
Mercieca, C 172<br />
Meriem, R 902<br />
Merikapudi, G 279<br />
Merinar, C 1540, 1552<br />
Merkel, PA 1291, 2012, 2014,<br />
2198<br />
Merle-Beral, H 1646<br />
Merli, P 2220<br />
Merlos, M 1137<br />
Meroni, P 590, 1356<br />
Merrill, J 445, 448, 452, 476,<br />
1186, 1190, 1454, 1456, 1457,<br />
1585, 1586, 1591, 1594, 1843,<br />
1877, 2147, 2240, 2241, 2243<br />
Merriman, T 33<br />
Mersten, J 1990, 2193<br />
Mertens, F 1720<br />
Meschia, JF 2037, 2038<br />
Messerschmidt, J 1634<br />
Messier, SP 203<br />
Messing, S 52, 515, 1799<br />
Messous, D 1762<br />
Mestre-Stanislas, C 1204<br />
Metcalf, B 192<br />
Meuth, SG 1255<br />
Mevorach, D 491<br />
Meyer, A 475, 510<br />
Meyer, C 2149<br />
Meyer, M 529, 1924<br />
Meyer, O 1752, 2042, 2269<br />
Miao, S 1100, 2032, 2048<br />
Miceli, C 1087<br />
Miceli-Richard, C 548, 1579<br />
Michael, JG 1403<br />
Michael, M 1333<br />
Michael, S 777<br />
Michaud, K 89, 325<br />
Michaud, KD 168, 318, 331, 346,<br />
651, 1043, 1132<br />
Michel, BA 21, 35, 357, 1518,<br />
1528, 1988<br />
Michelutti, A 355<br />
Michet, CJ 129, 777, 1652, 1654<br />
Mico, ML 1888<br />
Middleton, WD 1633<br />
Midtvet, O 1220<br />
Mielke, F 782<br />
Mielke, L 1426<br />
Miescher, S 494<br />
Mieszkalski, KL 1677<br />
Miettunen, PM 209<br />
Miggin, S 1533<br />
Migliaresi, S 2201<br />
Migone, TS 457, 1146<br />
Miguel, L 1187<br />
Mikami, M 280<br />
Mikkelsen, D 134, 1953<br />
Mikkelsen, K 377<br />
Miklossy, G 1185, 1196<br />
Mikolaitis, R 496, 765, 1147,<br />
1164, 1175, 1612, 1880, 2099<br />
Mikuls, TR 77, 168, 304, 318, 397,<br />
658, 970, 1094, 1099, 1367, 1395,<br />
1792, 2235<br />
Miles, J 1358<br />
Miller, C 1382<br />
Miller, DP 1223<br />
Miller, E 122, 188, 483, 1574<br />
Miller, FW 1678<br />
Miller, K 992<br />
Miller, LC 231<br />
Miller, ML 221<br />
Miller, P 980, 982<br />
Mills, KHG 1426<br />
Mills, P 192<br />
Milne, G 2123<br />
Milne, V 776, 1553<br />
Mimori, A 1042, 1619<br />
Mimori, T 932, 1377<br />
Mimura, T 1017<br />
Mina, R 218, 1688, 1701, 1702,<br />
2106<br />
Mina-Osario, P 1191<br />
Minden, K 227, 1704<br />
Minetti, C 1700<br />
Mínguez, S 1741<br />
Miniati, I 593<br />
Minihan, C 817, 818<br />
Minnock, P 1032, 2065<br />
Miossec, P 354, 1247, 1515<br />
Miossi, R 626<br />
Miranda-Carus, ME 349, 1967<br />
Miranda-Filloy, JA 1301<br />
Mirjafari, H 1067<br />
Misaki, K 1715<br />
Misharin, A 859, 861, 1723<br />
Mishra, N 438, 750, 2191<br />
Mishra, P 75<br />
Misra, D 720, 872<br />
Mitchel, E 54<br />
Mitchell, GH 463<br />
Mitera, T 1720<br />
Mithal, A 2206<br />
Mitomi, H 365<br />
Mitsuda, T 237<br />
Mitsugi, N 335<br />
Mitterwald-Modra, M 926<br />
Mittoo, S 1176, 1850<br />
Miura, T 1138, 1738, 1739<br />
Miwa, Y 1773<br />
Miyagi, M 363<br />
Miyake, K 1184<br />
Miyake, S 896, 2232<br />
Miyaki, S 369<br />
2010 Program Book 339<br />
abstract author Index
aBSTRACT author Index<br />
340<br />
Miyamae, T 237<br />
Miyamoto, Y 1715<br />
Miyara, M 478<br />
Miyasaka, N 1375, 1814, 1815<br />
Miyazaki, T 1512, 2016<br />
Miyazaki, Y 867, 1272, 2232<br />
Miyoshi, H 298<br />
Mizuhara, M 348<br />
Mizuki, N 2217<br />
Mizuno, M 896<br />
Mjaavatten, MD 1774, 1780<br />
Mjriafari, H 766<br />
Mo, Y-q 367<br />
Mobley, BS 2062<br />
Mochida, Y 335<br />
Modena, MG 581<br />
Modesti, M 1416<br />
Modesti, V 540<br />
Modesto, C 1872<br />
Modiano, P 2011<br />
Modica, RF 1673, 1691, 2017<br />
Mody, M 1407, 1794<br />
Mogavero, G 728<br />
Mogi, S 1115<br />
Mogil, JS 823<br />
Mohammad, A 817, 818, 1307,<br />
2018, 2022, 2112<br />
Mohan, N 185<br />
Mohand Oumoussa, B 1981<br />
Mohler III, ER 456<br />
Mohs, R 113<br />
Mohyde, M 99<br />
Moisini, I 1410<br />
Moisio, K 189, 202<br />
Moizant, F 753<br />
Mok, CC 458, 467, 477, 773, 1206,<br />
1667, 1748, 1777, 1870, 2159<br />
Mok, MY 1139, 1233<br />
Mold, C 850<br />
Moldawer, L 742<br />
Mold<strong>of</strong>sky, H 820<br />
Molfetta, L 1798<br />
Molina, J 1343<br />
Molina, MRR 1684<br />
Moll, C 538<br />
Mollahasanoglu, A 1208<br />
Moller Dohn, U 141<br />
Møller, HJ 1761<br />
Möller, I 2223<br />
Møller, J 133, 134, 1953<br />
Möller, S 1846<br />
Møller Døhn, U 1369, 1370<br />
Mollinedo, F 1509<br />
Molloy, ES 700, 1306<br />
Molloy, M 22, 1726<br />
Molta, CT 514, 1937<br />
Molth<strong>of</strong>f, CFM 1613<br />
2010 Program Book<br />
Moltó, A 1741<br />
Momohara, S 968, 1053, 1611,<br />
1749<br />
Monach, PA 2012, 2198<br />
Monclus, L 409<br />
Mong, J 1939<br />
Mongey, AB 2135<br />
Moniz Reed, D 1120, 1794<br />
Monshie-Vahabzadeh, H 546<br />
Montagna, P 1798<br />
Montagne, J 440<br />
Montanari, E 1992<br />
Montanelli, G 1235<br />
Montecucco, C 623, 766, 1013,<br />
1098, 1397, 1582, 2220<br />
Monteiro, CMC 628<br />
Montepane, M 532<br />
Montes, A 1076<br />
Montgomery, CG 1579, 1585,<br />
1586, 2147<br />
Monti, G 2036, 2201<br />
Montiel-Cervantes, LA 1150<br />
Montilla, C 538<br />
Monu, J 1051<br />
Moon, CG 1813<br />
Moon, H 876<br />
Moon, S-J 353, 756, 1716<br />
Moore, A 817, 818<br />
Moore, AB 898<br />
Moore, D 1756<br />
Moore, J 456<br />
Moore, N 286<br />
Moore, TL 263, 588, 846, 1262,<br />
1601, 1623<br />
Moorehead, S 521, 1968<br />
Moorthy, LN 1673, 1691, 1702,<br />
1872, 2017<br />
Moosavi, S 384<br />
Moosig, F 2203<br />
Moots, RJ 661, 1560, 1763<br />
Morado, IC 1301<br />
Moraes, J 224, 539, 2078, 2204<br />
Morales, A 975<br />
Moran, R 305<br />
Moran, RC 699, 1768<br />
Morand, EF 492<br />
Morassi, F 355<br />
Moreira, ES 498<br />
Moreira Navarrete, V 1944<br />
Morel, J 393, 1527, 1732, 1752,<br />
1890, 1910, 1914, 2218<br />
Morel, LM 426<br />
Morel, N 478<br />
Moreland, LW 71, 299, 390, 1062,<br />
1077, 1368, 1740, 1779<br />
Morell-Dubois, S 1204, 1217<br />
Morency, N 1451, 1934, 1957,<br />
1964<br />
Moreno-Valdés, R 1166<br />
Moret, FM 636, 1903<br />
Moreton, A 1560<br />
Morgan, AW 833<br />
Morgan, C 1323<br />
Morgan, G 242, 826, 1686<br />
Morgan, MD 676<br />
Morgan, R 1520<br />
Morgan, SL 1006<br />
Morgan DeWitt, EM 1012<br />
Mori, M 237<br />
Morimoto, S 1731<br />
Morin, F 938<br />
Morin, K 2251, 2252<br />
Morin, M-P 236<br />
Morinobu, A 1715<br />
Morishita, K 1691, 2017<br />
Morishita, T 1743<br />
Mork, C 1220<br />
Moroncini, G 2001, 2008<br />
Morris, C 850<br />
Morris, E 1251<br />
Morris, J 734<br />
Morris, MF 599<br />
Morris, MJ 1669<br />
Morris, SJ 345, 1442<br />
Morrison, S 1156, 2120<br />
Morrissey, S 2224<br />
Morva, A 737<br />
Morvan, J 2094, 2261<br />
Mosca, M 1011<br />
Moscatelli, S 1627<br />
Moseley, A 421<br />
Moser, DW 1012<br />
Moser, KL 500, 502, 1579, 1583,<br />
1584, 1585, 1586, 1591, 1594,<br />
1595, 2144, 2145, 2147, 2148,<br />
2274<br />
Mostoufi-Moab, S 206<br />
Mota, F 780<br />
Motamedi, K 1779<br />
Motojima, S 1824<br />
Möttönen, T 80<br />
Mount, DB 164<br />
Mountz, JD 1135, 1250, 1260,<br />
1412, 2189<br />
Moura, R 739, 743<br />
Mourão, AF 1986<br />
Mouterde, G 408<br />
Mouthon, L 575, 576, 580, 834,<br />
1204, 1217, 1704, 2009, 2034,<br />
2041, 2043, 2045<br />
Moutsopoulos, HM 621, 1897,<br />
1912<br />
Moyen, M 1176<br />
Moyer, AR 24<br />
Mozaffarian, N 1101, 1102<br />
Mozzicafreddo, M 2001<br />
Mrozek, N 375<br />
Mu, R 1134<br />
Mueller, DL 1256<br />
Mueller, M 2012<br />
Muhammad, K 745, 1411<br />
Muiños, E 1475<br />
Muiños-López, E 1483<br />
Mukherjee, D 2086<br />
Mukherjee, R 1096<br />
Mulero, J 525, 986, 2268<br />
Mulherin, DM 664<br />
Mullan, RM 871<br />
Mullazehi, M 2115<br />
Mulleman, D 130, 988, 1945<br />
Müller, GA 2021<br />
Muller-Esterl, W 2275<br />
Müller-Ladner, U 138, 406, 1420,<br />
1479, 1719, 1722<br />
Mumcu, G 1303<br />
Mumtaz, A 514<br />
Mumtaz, IM 1295, 1414<br />
Munekata, RV 1676<br />
Munger, K 762<br />
Muñiz, JR 389<br />
Munoz, L 490<br />
Munoz, S 1046, 1173, 1443, 2164,<br />
2165, 2166<br />
Muñoz Gomariz, E 525<br />
Muñoz-Fernández, S 986<br />
Munro, J 226, 248, 2219<br />
Munteanu, M 1762<br />
Murakami, A 1377<br />
Murali, M 1015<br />
Muranaka, K 1641<br />
Murao, H 280, 1467<br />
Muraro, P 1161<br />
Muratore, V 2220<br />
Murphey, M 869<br />
Murphy, E 989, 1482, 1508, 1522<br />
Murphy, G 22, 1333, 1726<br />
Murphy, L 689, 2062, 2080<br />
Murphy, SL 1319<br />
Murphy, V 145, 1423<br />
Murray, AK 588<br />
Murray, E 401<br />
Murthy, VL 2253<br />
Mus, A-M 38, 287, 715, 1259,<br />
1274, 1525<br />
Muscal, E 1673, 1691, 1702, 2017<br />
MUSICIAN Study Team 646<br />
Musset, L 906, 915, 1249, 1646,<br />
1911, 2024, 2025, 2030, 2046,<br />
2131, 2239<br />
Musyj, L 1674<br />
Muthuppalaniappan, M 279<br />
Mutti, A 784<br />
Myles, JD 1041<br />
Myones, BL 1160, 1690
Myouzen, K 1577<br />
Mysiw, WJ 2096<br />
Mysler, EF 1455, 2087, 2173<br />
N<br />
Na, K-S 359<br />
Nabatian, AS 1198<br />
Naccache, J-M 997<br />
Nacci, F 593<br />
Nacci, G 2001<br />
Nadig, A 822<br />
Nadji, A 1289<br />
Nadkarni, A 1767<br />
Nadler, D 1121<br />
Nagafuchi, H 1293<br />
Nagai, T 568<br />
Nagaoka, S 480, 1812<br />
Nagasawa, H 1793, 1823<br />
Nagasawa, K 433<br />
Nagpal, S 647<br />
Nah, S-S 803<br />
Nahar, E 1152<br />
Nahas, SA 509<br />
Nahass, R 1320<br />
Nahema, I 2267<br />
Naides, SJ 694<br />
Naik, H 149<br />
Naim, AB 51<br />
Nair, A 167<br />
Nair, DK 1211, 1219, 1227<br />
Nair, V 2276<br />
Naismith, D 1060<br />
Nakagawa, H 2, 1909<br />
Nakagawa, Y 2, 1511<br />
Nakajima, A 1053<br />
Nakamaru, Y 2029<br />
Nakamura, H 364, 981, 1371,<br />
1632<br />
Nakamura, T 1739<br />
Nakamura, Y 329, 1577, 2176<br />
Nakandakare, ER 887<br />
Nakase, T 298<br />
Nakashima, H 1115<br />
Nakashima, R 932, 1377<br />
Nakashita, T 1824<br />
Nalesso, G 1476, 1503<br />
Nallasivam, S 1504<br />
Nallasivan, M 974, 1665<br />
Nam, J 1090, 1254<br />
Nanda, K 1673<br />
Nandiwada, S 1256<br />
Nandula, SR 1883<br />
Nannini, C 528, 777, 1652, 1654,<br />
1952<br />
Naot, D 881<br />
Napalkov, P 698<br />
Napolioni, V 1582<br />
Narayanan, SA 1014<br />
Naredo, E 2223<br />
Nariai, A 237<br />
Narita, H 280, 1467<br />
Narongroeknawin, P 1573<br />
Narula, SK 288<br />
Narvaez, J 1016, 1078, 1118,<br />
1276, 1277, 1299, 1301, 1310,<br />
1796<br />
Naseem, S 4<br />
Nash, P 584, 599, 2173<br />
Nash, R 726<br />
Nasonov, E 55, 1802, 1807, 2087,<br />
2173<br />
Nassi, LA 1673, 1691, 2017<br />
Nataf, H 82<br />
Nath, SK 1590, 1594, 2274<br />
Natour, J 2132<br />
Natvig, B 170<br />
Naumann, L 1621<br />
Navarra, S 451, 452, 1172, 1197,<br />
1456, 1851<br />
Navarro, F 1078<br />
Navarro, TP 1169<br />
Navarro Compán, V 1944<br />
Navarro Sarabia, F 1944<br />
Navarro-Compán, V 1337<br />
Navarro-Millan, I 1117<br />
Navarro-Sarabia, F 1337<br />
Navarta, DA 324<br />
Naviglio, S 1436<br />
Navis, D 302<br />
Navratil, JS 620<br />
Nawata, M 1793, 1823<br />
Nayak, S 168<br />
Naylor, D 441<br />
Neagoe, IV 848<br />
Nearney, T 824<br />
Neeck, G 886<br />
Neel, A 1651<br />
Neff, L 1502<br />
Negrei, C 848<br />
Neidhart, M 21, 357, 679<br />
Nelissen, RLH 2265<br />
Nelson, AE 181<br />
Nelson, DR 52<br />
Nelson, JL 1060<br />
Nelson, RK 423<br />
Nelson, SL 268, 1688, 1701<br />
Nelson, V 2250, 2251, 2252<br />
Nemery, B 1720<br />
Neogi, T 205, 693, 836, 872, 951,<br />
1362, 1366, 1385, 1557, 1564,<br />
2058, 2098, 2133<br />
Neovius, M 1541, 1548<br />
Nepomuceno, R 269<br />
Neregård, P 394<br />
Nesbitt, A 1517<br />
Nespi, M 273<br />
Netea, MG 371<br />
Neumann, E 1420, 1719, 1722<br />
Neven, B 905<br />
Neves Junior, MT 1384<br />
Neville, C 1156<br />
Nevitt, M 131, 182, 201, 202, 205,<br />
624, 693, 872, 951, 971, 1464,<br />
1557, 2058, 2096, 2098, 2100,<br />
2133<br />
Newhook, T 1939<br />
Newkirk, M 1068<br />
Newman, ED 999<br />
Newton, R 2172<br />
Ng, B 87<br />
Ng, CT 360, 871, 1105, 1510, 1625<br />
Ng, F 1579<br />
Ng, WL 477<br />
Ngamjanyaporn, P 1950<br />
Ngian, G-S 584<br />
Ngo, Y 1762<br />
Nguyen, BY 725<br />
Nguyen, C 875, 1204, 1217, 2151<br />
Nguyen, D 2210<br />
Nguyen, H 2205, 2251, 2252<br />
Nguyen, JX 609<br />
Nguyen, U-SDT 684, 685<br />
Nguyen, V 432<br />
Nguyen-Khoa, B-A 698<br />
Nic An Ultaigh, S 16, 1533<br />
Nicassio, P 1211, 1768<br />
Niccoli, L 528, 1952<br />
Nicholson, G 183<br />
Nickerson-Nutter, C 275<br />
Nicklas, B 203<br />
Nicolaou, S 2152<br />
Nicolini, A 1302<br />
Nicolls, MR 1223<br />
NicUltaigh, S 1391<br />
Niederer, F 1528<br />
Niedermeier, M 2237<br />
Niederreiter, B 272, 1351<br />
Nielen, MMJ 1029, 2211<br />
Nielsen, S 1305<br />
Niemann, G 1125<br />
Nietert, PJ 604<br />
Niewerth, M 227<br />
Niewold, TB 262, 495, 496, 1147,<br />
1164, 1583, 1584, 1585, 1586,<br />
1591, 1612, 2147, 2274<br />
Nigon, D 2218<br />
Nigrovic, P 209, 363<br />
Nihei, K 10<br />
Nihtyanova, S 566, 1207<br />
Nikolov, NP 1161<br />
Nimmerjahn, F 2234<br />
Ninaber, MK 582<br />
Ninet, J 2045, 2239<br />
Nishimoto, N 1800<br />
Nishimura, K 1844<br />
Nishio, MJ 1617<br />
Nishio, S 1797<br />
Nistala, K 1344<br />
Nithiketkul, S 1950<br />
Nitichaikulvatana, P 162<br />
Nititham, J 502<br />
Nitobe, T 329<br />
Nitschke, Y 1486<br />
Niu, H 426<br />
Niu, J 131, 197, 198, 201, 205,<br />
685, 693, 1373, 1385, 1564, 1617,<br />
2058, 2098, 2133, 2143<br />
Nived, O 445, 448, 476, 731,<br />
1877, 2022, 2240, 2243<br />
Noamani, B 2190<br />
Noble, JA 502, 1602<br />
Nochlin, J 188<br />
Noda, K 921<br />
Nojima, T 1377<br />
Nojima, Y 358<br />
Nolla, JM 1016, 1118, 1277, 1299,<br />
1310<br />
Nomoto, S 365<br />
Noordenbos, T 1449<br />
Noort, A-R 1416<br />
Nordal, EB 1700<br />
Nordborg, E 777, 1637, 1654<br />
Nordenskiold, U 2063<br />
Nordin, A 1224<br />
Nordmark, B 645<br />
Nordmark, G 1579, 1885, 1899<br />
Nordström, D 55, 891, 1802, 1807<br />
Norman, G 2250, 2251, 2252<br />
Norman, J 613<br />
Norris, J 77, 658, 1083, 1094,<br />
2116<br />
North, S 1747<br />
Norton, H 947, 1055, 1626, 2225<br />
Nose, M 511, 2016<br />
Noss, EH 1388<br />
Novick, D 1664<br />
Nóvoa, FJ 1876<br />
Novotny, PJ 595<br />
Nowatzky, J 1298<br />
Nowling, TK 1251<br />
Nozaki, T 1708<br />
Nti, AA 2137<br />
Nuite, M 195, 706, 2101<br />
Nukumizu, LA 513<br />
Numéric, P 571<br />
Nunez, G 1713<br />
Nunn, PA 1270<br />
Nur, MAM 695<br />
Nurmohamed, MT 90, 332, 643,<br />
961, 1029, 1033, 1084, 1445, 1825,<br />
1840, 1933, 2211<br />
2010 Program Book 341<br />
abstract author Index
aBSTRACT author Index<br />
342<br />
Nuzzo, A 581<br />
Nyengaard, JR 1485<br />
Nygaard, H 1774<br />
Nys, M 1407<br />
Nytrova, P 1174<br />
Nzeusseu Toukap, A 2263<br />
O<br />
Oates, J 437, 622, 1403, 2123,<br />
2125<br />
Oatis, CA 684, 2053, 2054, 2136<br />
Oba, T 1814, 1815<br />
Obayashi, H 1511<br />
O’Brien, A 989, 2112<br />
O’Brien, W 148, 883<br />
O’Colmain, BJ 2062<br />
O’Connor, CR 885<br />
O’Connor, P 1929<br />
Odai, T 1773<br />
Odani, T 2, 1909<br />
Odden, AJ 402<br />
Oddis, CV 913, 925, 929, 930,<br />
1212, 1379<br />
Odeh, M 550<br />
O’Dell, JR 77, 299, 658, 1094,<br />
1368, 2235<br />
Oderkirk, J 1555<br />
Odom, J 1161<br />
O’Donnell, CI 1083<br />
O’Donnell, JL 417<br />
O’Donnell, S 1562<br />
Oelke, KR 383<br />
Oen, KG 214<br />
Oerum, H 1529<br />
Oeser, A 1023, 1034, 1607, 1867,<br />
2123<br />
Oess, S 2275<br />
Offutt, C 1122<br />
Ogale, S 68, 338, 1882<br />
Ogden, L 1311<br />
Ogdie, A 1554<br />
O’Grady, M 817, 818<br />
Oh, C 707, 708<br />
Oh, J 366, 372, 876, 1297, 2158<br />
Oh, TH 104, 108<br />
Oh, U 1161<br />
Ohinmaa, A 330<br />
Ohlsson, B 1902<br />
Ohmura, K 1377<br />
Ohno, S 139, 480, 1081, 2217<br />
Ohrndorf, S 1621, 1634<br />
Ohta, A 433<br />
Ohta, H 1839<br />
Ohta, K 652<br />
Ohta, S 1115<br />
Ohtsuka, K 26<br />
Oishi, H 351<br />
2010 Program Book<br />
Okada, A 364, 1371, 1632<br />
Okada, J 568<br />
Okada, M 1783<br />
Okada, Y 1577<br />
Okamoto, Y 447, 746, 897, 916,<br />
923, 1184, 1587, 1844<br />
Okano, T 981<br />
Okawa, J 920<br />
Okiyama, N 1375<br />
Oku, K 10, 2254<br />
Okuda, K 1138, 1738, 1739<br />
Okura, Y 1672<br />
Olds, M 1930, 1935<br />
O’Leary, D 1148, 2163<br />
Olech, E 101, 120, 125, 414<br />
Olenginski, TP 999<br />
Olferiev, M 508, 1183<br />
Olivé, A 1741<br />
Oliveira, A 1507, 1519<br />
Oliveira, SK 210<br />
Oliveira Sato, J 1872<br />
Olivier, B 922<br />
Olivieri, I 532<br />
Olsen, NJ 1188, 1491<br />
Olson, AK 828<br />
Olsson, L 825<br />
Olsson, T 832<br />
Ombrello, A 1698, 2105<br />
Ombrello, MJ 1281, 2217<br />
Omdal, R 1579, 1885, 1913<br />
O’Meara, M 1095<br />
Ometto, F 290<br />
Onat, AM 1921<br />
Onat, D 1183<br />
One Thousand Faces <strong>of</strong> Lupus<br />
1864<br />
O’Neil, KM 1673, 1690, 1691,<br />
1701, 2017<br />
O’Neill, L 16, 2111<br />
Onel, K 464, 1701<br />
Onen, F 544, 666, 1282, 1283,<br />
1921<br />
Ong, V 590, 1996<br />
Ono, Y 1285<br />
Oomae, T 298<br />
Oortwijn, A 2270<br />
Opava, CH 2245<br />
Oph<strong>of</strong>f, RA 2214<br />
Opitz, CF 599<br />
Oppermann, BP 977<br />
Optimising Patient Outcomes in<br />
Australian RheumatoLogy [OPAL]<br />
Consortium 319<br />
Orange, D 863<br />
Oranje, AP 219<br />
Orcel, P 413<br />
Oreiro, N 835<br />
Oreiro-Villar, N 541, 1920<br />
Oribe, M 1138<br />
Orie, NN 2005<br />
Origuchi, T 1371, 1632<br />
Orlov-Morozov, A 1125<br />
Ormseth, MJ 1034<br />
Ørnbjerg, LM 1444, 1841<br />
Oro, S 2238<br />
Orozco, G 1075<br />
Orozco, J 1407<br />
Ortego-Centeno, N 824, 829,<br />
1301, 2214<br />
Ortel, T 6<br />
Ortiz, AM 516, 1505<br />
Ortiz, MA 1801<br />
Ortmann, W 1608<br />
Orzechowski, NM 595<br />
Osban, J 247, 655<br />
Osborne, R 204, 1001, 1009,<br />
2079, 2139<br />
Osgood, KG 1395<br />
O’Shea, FD 512<br />
Oshikawa, H 1641<br />
Osman, M 816<br />
Ospelt, C 21, 1093, 1528<br />
Ossanna, MJ 175<br />
Östberg, T 832<br />
Østergaard, M 132, 133, 134, 141,<br />
1097, 1114, 1369, 1370, 1444,<br />
1809, 1841, 1953, 2264<br />
Ostendorf, B 138, 1615<br />
Osterroth, F 1125<br />
Osting, V 44<br />
Ostor, A 395, 1840<br />
Ostrov, BE 1002<br />
O’Sullivan, B 1116<br />
O’Sullivan, J 360, 1510<br />
Ota, T 1086<br />
Ota, Y 447, 746, 897, 916, 923,<br />
1184, 1587, 1666<br />
Otomo, K 2, 5, 10, 1909, 2254<br />
Otsuka, K 1773<br />
Otsuki, S 369<br />
Otten, MH 219, 1872<br />
Ottery, F 157, 166<br />
Ou, J-N 506<br />
Oudiz, R 598<br />
Ouellet-Hellstrom, R 54<br />
Outman, RC 1005, 1006, 1543,<br />
1561<br />
Ouyang, W 715<br />
Owada, T 472<br />
Owen, S-A 1394<br />
Owen, T 436<br />
Owens, EK 17<br />
Oyoo, OG 1336<br />
Ozaki, S 365<br />
Ozdemir, B 114<br />
Ozdemir, FT 2200<br />
Ozdogan, H 1279, 1684, 1697<br />
Ozen, S 905, 1305, 1705<br />
Ozguler, Y 1697<br />
Ozturk, MA 1921<br />
Ozyazgan, Y 1288, 1312, 1697<br />
P<br />
Pablos, JL 20, 482, 1078<br />
Paccou, J 904<br />
Pachman, LM 242, 826, 928, 1686<br />
Packham, J 264, 266, 664, 833<br />
Padovan, M 1162<br />
Padykov, L 2214<br />
Padyukov, L 832, 2118<br />
Paessler, M 1354<br />
Page, GG 949<br />
Paget, SA 43<br />
Pagnier, A 1693<br />
Pagnini, I 240, 1675<br />
Pagnoux, C 2009, 2014, 2026,<br />
2034, 2041, 2043, 2045<br />
Paikos, S 1897<br />
Paintaud, G 988, 1945<br />
Paira, S 50<br />
Pajewski, NM 1591<br />
Pajot, C 1305<br />
Pak, CH 178<br />
Pal, HK 1925<br />
Palacios, S 971<br />
Palanichamy, A 1085<br />
Palau, J 2223<br />
Palazzo, JP 1907<br />
Palframan, R 1245<br />
Pallares, L 1888<br />
Palm, O 1275<br />
Palmer, E 486, 733<br />
Palmer, G 1490<br />
Palmer, RH 98, 806<br />
Palmisani, E 207<br />
Pals, ST 1711<br />
Palter, J 1702<br />
Palumbo, K 607, 611, 614, 615,<br />
616, 672<br />
Pamer, E 1390<br />
Pan, S 1242, 1598<br />
Pan, W-H 2088<br />
Pan, Z-j 1267<br />
Panagiotakos, DB 1897<br />
Panayi, GS 1729<br />
Pandya, B 878, 879, 1363, 1547,<br />
2154<br />
Panepento, B 521, 849<br />
Pangan, A 518, 559, 1949<br />
Panghaal, V 1630<br />
Panicker, S 1270<br />
Pannier, E 2034<br />
Panopalis, P 107, 789, 2113
Pans, M 1834<br />
Parra, ER 605, 887<br />
Peda, MA 901<br />
Perry, M 562, 725<br />
Paolini, C 2001<br />
Parsa, MF 998<br />
Pedersen, R 514, 1927, 1937<br />
Pers, J-O 737, 1914, 2177<br />
Pap, T 368, 1130, 1478, 1486,<br />
1719, 2237<br />
Papadopoulos, N 1021<br />
Papageorgiou, A 1912<br />
Papagoras, C 1215<br />
Papalardo, E 1361, 2251, 2252,<br />
2253<br />
Papapoulos, S 2157<br />
Papo, T 2239<br />
Pappa, C 1395<br />
Pappas, DA 45, 1022, 1799<br />
Pappas, J 150<br />
Pappas, T 1536<br />
Pappu, R 390, 1834, 2173<br />
Paradisi, M 1439<br />
Paragh, G 519<br />
Paramarta, J 1977, 2272<br />
Parambil, J 564, 592<br />
Paran, D 697, 1159, 1238<br />
Pardeo, M 209, 2033<br />
Pardo, P 144, 1154<br />
Parimi, N 624<br />
Parish, M 1094<br />
Park, E-J 366, 372, 1297<br />
Park, GS 1103, 1117<br />
Park, HS 1716<br />
Park, JK 677, 681, 919, 2167<br />
Park, JL 255<br />
Park, JA 1751<br />
Park, JS 842<br />
Park, K 2225<br />
Park, KS 353, 370, 756, 1716,<br />
1770<br />
Park, KU 1523<br />
Park, M-C 27, 1061, 1873, 387<br />
Park, MJ 1716<br />
Park, M-K 353<br />
Park, R 1499<br />
Park, S 84, 276<br />
Park, S-H 277, 323, 353, 370, 756,<br />
903, 1209, 1716, 1770<br />
Park, S-Y 1585<br />
Park, W 1813<br />
Park, Y 276<br />
Park, Y-B 27, 387, 1061, 1873,<br />
2028<br />
Park, Y-E 277, 1209<br />
Park, Y-W 116, 505, 1891<br />
Parker, B 1177<br />
Parker, J 1207<br />
Parks, C 61, 1062<br />
Parks, EL 2097<br />
Parks, M 1576<br />
Parmar, K 42<br />
Parmar, R 1090, 1126, 1254<br />
Parolin, M 1682<br />
Parsons, L 1223<br />
Parvu, M 405, 848<br />
Paschides, CA 1215<br />
Pasco, J 183<br />
Pascoli, L 240<br />
Pascual-Ramos, V 337, 1881<br />
Pascual-Salcedo, D 1599<br />
Pasic, S 1684, 1705<br />
Pasoto, SG 481<br />
Passarelli, M 887<br />
Pasternak, R 1119<br />
Pastrak, A 285<br />
Patel, A 1740<br />
Patel, DD 19, 1487<br />
Patel, DR 1253<br />
Patel, J 1477<br />
Patel, N 895, 1425<br />
Patel, RK 1430<br />
Patel, S 126<br />
Patel, V 288, 1270<br />
Patel, Z 1531<br />
Paternotte, S 63, 529, 948, 1648,<br />
1924<br />
Paterson, JM 57, 313, 341<br />
Patil, S 456<br />
Patkar, NM 304, 404, 722, 1573,<br />
1643, 2103<br />
Patra, K 123, 1101, 1102, 1108,<br />
1113, 1791<br />
Patrizi, A 1439<br />
Patschan, D 2021<br />
Patschan, S 2021<br />
Patternotte, S 1104<br />
Patterson, N 153<br />
Pau, E 424, 425, 429<br />
Paul, B 620, 1399<br />
Pauley, KM 2174<br />
Paulo, LTP 1339<br />
Paulus, H 155, 299, 583, 1058,<br />
1365, 1368, 1779, 1789<br />
Pauly, T 368<br />
Pavelka, K 55, 638, 971, 1802,<br />
1807, 1840<br />
Pavenstädt, H 2237<br />
Pavletic, S 1161<br />
Pavy, S 548<br />
Pawar, R 2186<br />
Paxton, LA 1620<br />
Payeli, SK 1973<br />
Payet, J 529, 1924<br />
Payne, AJ 1030<br />
Payoux, P 2027<br />
Paz, E 1407<br />
Pearce, W 1168<br />
Pease, C 777, 1637, 1652, 1654<br />
Pecchi, E 37<br />
Pedersen, SJ 134, 1953<br />
Pedersen, TK 1687<br />
Pedriger, A 1910<br />
Pedro, S 89<br />
Peeters, AJ 1396<br />
Peeva, V 13, 1156, 2120<br />
Peffer, N 1968<br />
Peh, CA 676<br />
Peikert, T 680<br />
Peinado, V 1070<br />
Peiro, M 1296<br />
Peiro Callizo, ME 1650<br />
Pelajo, CF 231<br />
Pelck, R 1444, 1841<br />
Peliçari, K 1695<br />
Pelletier, J-P 196, 938, 1489, 1497<br />
Pellett, F 530, 1966, 1974, 1975,<br />
1979, 1984<br />
Peloquin, C 2067, 2212, 2213<br />
Peluso, G 355, 744, 1098, 1582<br />
Pemberton, P 1067<br />
Peña Salgredo, JL 1650<br />
Peña-Arrébola, A 2268<br />
Penadés, IC 1407<br />
Penco, F 265<br />
Pendl, J 218, 268, 2106<br />
Peng, SL 901<br />
Peng, Y 1843, 1919<br />
Penney, CJ 330<br />
Pennington, LF 748<br />
Penya, J 1137<br />
Pepe, P 811, 1916<br />
Peracchi, OAB 1676<br />
Perard, L 2239<br />
Perdriger, A 63, 701, 1890<br />
Pereira, K 356, 498, 504, 1695<br />
Pereira, RM 1384, 1437, 1546,<br />
2078, 2134<br />
Pereira Da Silva, JA 1013<br />
Perell-Gerson, KL 169<br />
Perez, E 1801<br />
Perez, MD 1678<br />
Perez-Alvarez, R 1888<br />
Perez-Pampin, E 1076, 1078<br />
Perez-Ruiz, F 159, 873, 151, 882,<br />
1572<br />
Perez-Sanchez, C 1357<br />
Pericleous, C 1358, 1359<br />
Perilongo, G 1439<br />
Perino, G 427<br />
Perl, A 437, 449, 1185, 1196, 2275<br />
Perlman, H 853, 854, 859, 861,<br />
1723<br />
Perrella, O 2201<br />
Perrot, S 97<br />
Persad, P 2077<br />
Persselin, J 155, 1365<br />
Pértega, S 835<br />
Pertega-Diaz, S 541, 1920<br />
Peschken, C 448, 476, 731, 1176,<br />
1674, 1850, 1852, 1864, 1877,<br />
2240, 2243<br />
Petchprapa, C 708<br />
Peter, WFH 2051<br />
Peterfy, C 120, 123, 125, 1369,<br />
1817<br />
Peters, C 1243, 1245<br />
Peters, MA 368, 1719<br />
Peters, MJL 90, 643, 1029, 2211<br />
Peterson, D 156, 322, 791<br />
Peterson, EJ 934<br />
Peterson, LK 748, 2128<br />
Peterson, MGE 1872<br />
Petersson, I 761, 963, 1392, 1393,<br />
2209<br />
Petri, M 14, 268, 445, 448, 452,<br />
453, 454, 460, 473, 474, 476, 479,<br />
485, 487, 731, 733, 765, 1148,<br />
1149, 1163, 1180, 1403, 1452,<br />
1454, 1456, 1457, 1591, 1592,<br />
1594, 1608, 1848, 1858, 1877,<br />
1879, 2121, 2122, 2124, 2149,<br />
2162, 2240, 2243, 2260<br />
Petrich, J 574<br />
Petronis, J 1887<br />
Petterson, S 1846<br />
Pettersson, E 1381<br />
Pettersson, T 891<br />
Pettijohn, K 509<br />
Pettinger, M 1062<br />
Pettit, A 2184<br />
Petty, RE 1674<br />
Pezic, A 248<br />
Pfaefflin, A 770<br />
Pfeffer, S 858<br />
Pham, T 260, 1752, 1810, 1831,<br />
2269<br />
PHAROS Investigators 561, 569,<br />
570, 586, 591, 729<br />
Phaujdar, S 1925<br />
Phelps, D 1395<br />
Philippe, L 858<br />
Philippet, P 1700<br />
Phillips, CR 62<br />
Phillips, K 402, 567, 585, 1212,<br />
1222, 2007, 2073<br />
Phillips, PE 1185, 1196<br />
Piatti, A 1854, 1855<br />
Pickard, L 969<br />
Pickens, SR 23, 270, 714, 1506<br />
Piera, S 2007<br />
Pierangeli, S 3, 6, 12, 1360, 1361,<br />
2250, 2251, 2252, 2253, 2255<br />
2010 Program Book 343<br />
abstract author Index
aBSTRACT author Index<br />
344<br />
Pierre, B 902<br />
Pietras, T 1799<br />
Pietrogrande, M 2036, 2201<br />
Piette, J-C 478, 1908, 1911, 2239<br />
Pike, B 1170<br />
Pike, MC 453<br />
Pikhlak, A 145, 1423<br />
Pilkington, C 1344, 1688<br />
Pillet, P 905<br />
Pillinger, MH 43, 148, 883, 1390,<br />
1616<br />
Pimentel-Santos, FM 1986<br />
Pincus, T 84, 312, 985, 990, 995,<br />
1765, 1857, 2109<br />
Pineau, C 454, 1142, 1850, 2120<br />
Pineda, C 1614, 1617, 1635<br />
Pineda, L 451, 452, 1146, 1172,<br />
1457, 1848<br />
Pinheiro, GRC 356<br />
Pinheiro, MM 628<br />
Pinkerton, M 1728<br />
Pinner, E 2246<br />
Pinney, AJ 282<br />
Pinto, ALS 626<br />
Pinto, JA 541<br />
Pinto-Tasende, J 1920<br />
Pioltelli, P 2036, 2201<br />
Pipitone, N 777, 1290, 1302,<br />
1654, 2044<br />
Piram, M 905<br />
Pirisi, M 962, 2160<br />
Pirruccio, P 1173<br />
Pisetsky, DS 1192<br />
Piskin, O 1283<br />
Pisoni, C 732<br />
Pistorio, A 208, 210, 232, 1684,<br />
1700, 1705<br />
Pitashny, M 2186<br />
Pitt, MJ 1573<br />
Pitt, S 1513<br />
Pittrow, D 599, 1212<br />
Pitzalis, C 623, 1389, 1476, 1503,<br />
1906<br />
Piva, SR 2052, 2059, 2061<br />
Pizzorni, C 578, 1236<br />
Plaisier, E 2010, 2011<br />
Planas-Rigol, E 1292, 1294<br />
Planck, SR 1447<br />
Plant, D 1600, 2215<br />
Plass, N 260<br />
Platt, A 1474<br />
Platt, PN 1064<br />
Plenge, RM 1610<br />
Plontke, S 899, 900<br />
Plotnik, J 892<br />
PLUS Study 2239<br />
Poddubnyy, D 665, 2181<br />
Pødenphant, J 1370<br />
2010 Program Book<br />
Podesta’, E 1098, 1582<br />
Pogosian, S 1035, 1049<br />
Pohjolainen, T 80<br />
Pohl, C 1766<br />
Poignant, S 2045<br />
Poiraudeau, S 1204<br />
Pokelsek, A 259<br />
Pokrzywinski, R 99<br />
Polak, AA 942<br />
Polak, J 2162<br />
Polanska, M 638<br />
Pollak-Dorocic, I 2118<br />
Pollard, R 1889, 1892<br />
Pollock, J 1325<br />
Pollock, R 1966, 1975, 1979, 1984<br />
Pollono, EN 407<br />
Polo Cueto, J 407<br />
Polyak, JL 2074<br />
Polydefkis, M 1915<br />
Polzer, K 629<br />
Pompei, O 1296<br />
Pompei Fernández, O 1650<br />
Ponchel, F 1090, 1126, 1254<br />
Ponder, L 256, 1405<br />
Pong, E 1350<br />
Pons-Estel, B 1578, 1585, 1586,<br />
1595, 2147, 2148<br />
Ponsonby, A-L 248<br />
Pool, B 881, 1983<br />
Poole, JL 1349, 1567<br />
Poór, G 777, 1013, 1637, 1654<br />
Pope, A 1972<br />
Pope, D 1325<br />
Pope, J 57, 300, 306, 306, 313,<br />
341, 343, 344, 396, 419, 659, 978,<br />
1156, 1202, 1203, 1221, 1735,<br />
1737, 1805, 1850, 1852, 1864,<br />
2120, 2196<br />
Pope, RM 23, 854, 1353, 1506<br />
Popp, CD 1345<br />
Porawska, W 2173<br />
Porras, M 517, 552, 1137<br />
Portman, M 828<br />
Porto, LCM 356<br />
Posfay-Barbe, K 792<br />
Possemato, N 558<br />
Post, W 1148, 2162, 2260<br />
Postal, M 1695<br />
Posthumus, MD 662<br />
Pott, H-G 138<br />
Pouchot, J 905, 2094<br />
Poulsen, U 1444, 1841<br />
Poupot, M 281<br />
Poupot, R 281<br />
Powchik, P 710<br />
Powell, B 273<br />
Powell, S 218<br />
Powers, JP 1100, 2032, 2048<br />
Poynard, T 1762<br />
Pozniak, K 2001<br />
Prado, DML 626<br />
Prahalad, S 245, 250, 255, 256,<br />
654, 1405<br />
Prakken, B 719<br />
Praprotnik, S 1896<br />
Pratt, DD 1324<br />
Precioso, AR 224, 481, 1437<br />
Precopio, M 862<br />
Predeteanu, D 848<br />
Preiss, R 895, 900, 1425, 1435<br />
Preissner, KT 1420<br />
Preoteasa, V 848<br />
Prescott, GJ 646<br />
Prescott, KH 880<br />
Presson, A 262<br />
Prestat-Tilly, M 1<br />
Prevosto, C 843<br />
Priam, S 37<br />
Price, DD 809, 821<br />
Price, LL 706, 709<br />
Prieto-González, S 1294, 1314<br />
Prignano, F 1962<br />
Primdahl, J 2280<br />
Prince, FHM 219, 308<br />
Princic, N 338<br />
Privitera, R 355<br />
Proctor, G 1906<br />
PROFILE 1585, 1586, 2147, 2274<br />
PROFILE Investigators 1584, 1595<br />
Proietto, J 173, 1383<br />
Pros, A 824<br />
Proudman, S 584<br />
Provan, SA 534<br />
Proven, A 891<br />
Provenzano, G 532<br />
Prozonic, J 250, 255, 256<br />
Prudhomme, L 2027<br />
Pryschep, S 351<br />
Psenak, O 1011<br />
Puchner, A 1351<br />
Puéchal, X 701, 1890, 1910, 2045<br />
Puggina, S 1687<br />
Pullman-Mooar, SW 1554<br />
Pulsatelli, L 1290<br />
Pumarejo, F 1811<br />
Punaro, L 1677<br />
Punaro, M 223, 255, 654, 1491,<br />
1688, 1690, 1702, 2219<br />
Pundt, N 1478<br />
Punzi, L 290, 297, 540, 547<br />
Puolakka, K 80, 759<br />
Purcaru, O 1832<br />
Purser, J 181<br />
Purvey, S 474<br />
Pushparaj, PN 28<br />
Put, S 1720<br />
Putova, I 1174<br />
Putterman, C 939, 1179, 2095,<br />
2186, 2187<br />
Pyrpasopoulou, A 11<br />
Q<br />
Qi, JC 621<br />
Qi, K 390<br />
Qi, M 621<br />
Qi, X 1728<br />
Qing, W 1107<br />
Qing, X 427<br />
Qiu, J 1530<br />
Qiu, Y 274<br />
Quach, C 236<br />
Quach, DL 502, 1602<br />
Quach, HL 502, 1602<br />
Quach, L 684<br />
Quaglierini, F 1011<br />
Quan, H 775<br />
Quan, J 1188<br />
Quartier, P 895, 1407, 1425, 1435,<br />
1693<br />
Quartuccio, L 2036, 2201<br />
Quataert, S 849<br />
Quattrocchi, E 58<br />
Qubti, MA 45, 919<br />
Quemeneur, T 2045<br />
Queralt, C 1280<br />
Querci, V 246<br />
Quevedo, A 1173<br />
Quevedo, JC 389, 1876<br />
Quinet, RJ 1007<br />
Quinlan, P 1576<br />
Quinzanos, I 1395<br />
Quirbach, C 2252<br />
Quismorio, FP 46, 1429, 1432<br />
Quistberg, A 1955<br />
Qureshi, AA 1937<br />
Qureshi, F 1606<br />
Qvist, P 1466, 1500<br />
R<br />
Rabe, H 1248<br />
Rabinovich, EC 209, 234, 252,<br />
1673, 1691, 1699, 2017<br />
Rabquer, BJ 282, 1419, 1721<br />
Rachabattula, S 1429<br />
Rachel, D 444<br />
Rachlis, A 225<br />
Racine, A 566<br />
Racovan, M 1062<br />
Radbruch, A 1295, 1414<br />
Raddatz, DA 515<br />
Radhakrishna, SM 1702, 2102<br />
Radin, AR 1121
Radka, S 1174<br />
Radner, H 296, 1745<br />
Radominski, S 2157<br />
Radstake, T 824, 829, 844, 1599,<br />
1210, 2002, 2004, 2214<br />
Radvanski, DC 625, 1320, 1767<br />
Raffeiner, B 290, 547<br />
Ragavan, S 1125<br />
Ragavendra, N 594<br />
Raggi, P 1023, 1034, 1867<br />
Raghu, G 931<br />
Ragi-Eis, S 971<br />
Rahimi, H 865<br />
Rahman, A 445, 448, 476, 621,<br />
1358, 1359, 1877, 2082, 2240,<br />
2243, 2255<br />
Rahman, M 326, 385, 386, 890,<br />
908, 1036, 1097, 1114, 1127, 1136,<br />
1555, 1804, 1814, 1815, 1818,<br />
1948, 2264, 2265<br />
Rahman, P 549, 1451, 1964, 1972<br />
Rai, E 2146<br />
Rainford, L 1625<br />
Rajan, E 2072<br />
Rajappa, SM 1286<br />
Rajpathak, S 1692<br />
Rajzbaum, G 967<br />
Ramirez, AA 1160<br />
Ramirez, C 1049<br />
Ramírez, J 20, 538, 543, 1070<br />
Ramming, A 1241, 1261<br />
Ramnoruth, S 1116<br />
Ramonda, R 540<br />
Ramos, E 1435<br />
Ramos, I 449, 1196, 1519<br />
Ramos, M 233, 445, 448, 476,<br />
1534, 1877, 2240<br />
Ramos, PS 500, 654, 2145, 2148<br />
Ramos-Casals, M 1888, 1896,<br />
1910, 2036, 2243<br />
Rampersad, R 19<br />
Ramsay, PP 502, 1602<br />
Ramsey, SE 238, 1674, 1691<br />
Ramsey-Goldman, R 214, 448,<br />
476, 731, 960, 1591, 1594, 1877,<br />
2240, 445, 859, 1168, 2243<br />
Rand, J 1692, 2250<br />
Ranganath, V 347, 933, 1058,<br />
1779, 1789<br />
Ranganathan, P 62, 1395<br />
Rannou, F 1204<br />
Ranque, B 576<br />
Rantalaiho, V 80, 891<br />
Rantapää-Dahlqvist, S 1054, 1847,<br />
2115<br />
Rao, JK 1575<br />
Rao, KCS 363<br />
Rao, P 1158<br />
Rao, S 535, 557, 660, 760, 763,<br />
771, 1354<br />
Raschi, E 1356<br />
Rasheed, Z 632, 633<br />
Rasmussen, A 2148<br />
Rasmussen, N 2014<br />
Rasmussen, TK 1524<br />
Rasouliyan, L 347<br />
Rastaldi, M-P 2278<br />
Rat, A-C 768, 787, 2094<br />
Raterman, HG 332, 961, 1029,<br />
1084<br />
Rath, T 294<br />
Ratziu, V 1762<br />
Ratzlaff, CR 2093<br />
Rau, L 1382<br />
Rauh, M 490<br />
Ravagnani, V 547, 1098, 1582<br />
Ravaud, P 303, 376, 400, 1790,<br />
1890, 1896, 1910, 2042<br />
Raveendran, KG 1106<br />
Ravelingien, I 1398<br />
Ravelli, A 207, 208, 210, 232, 261,<br />
1684, 1688, 1700, 1701, 1705,<br />
2220<br />
Ravenell, RL 2125<br />
Ravera, F 578, 1236<br />
Rawat, A 4<br />
Rawat, G 931<br />
Rawstron, AC 1126<br />
Raya, E 1599<br />
Raychaudhuri, SK 1971, 1976<br />
Raychaudhuri, SP 1971, 1976<br />
Raymond, R 1119<br />
Raynauld, J-P 196, 938<br />
Reaume, M 225<br />
Rebello, R 126<br />
Record, JL 1679<br />
Redden, L 1791<br />
Reddy, SM 1390<br />
Reddy, ST 933, 1058<br />
Redecha, P 427, 1199<br />
Redegeld, FA 333<br />
Redlich, K 1493, 272<br />
Redondo, N 482<br />
Reed, A 15, 255, 934, 1376, 1379,<br />
1677, 2068<br />
Reed, G 52, 379, 515, 1003, 1010,<br />
1794, 1960<br />
Reed, JH 656<br />
Reed, MR 263<br />
Reedquist, K 32, 1095, 1529<br />
Reeves, WH 501, 735, 742, 1639<br />
Reeves-Robb, R 1405<br />
Regatte, R 137<br />
Reginster, J 979, 2156, 2157<br />
Regnault, V 1<br />
Rego-Pérez, I 835<br />
Rehart, S 1722<br />
Rehman, A 44<br />
Rehrig, C 157, 166<br />
Reich, N 672<br />
Reichelt, D 138<br />
Reichmann, WM 140, 143, 199,<br />
2090, 2091, 2092<br />
Reid, A 2135<br />
Reid, DM 2156<br />
Reid, G 2152<br />
Reiff, A 241<br />
Reiff, AO 1673, 1688, 1691, 2017,<br />
2102<br />
Reilly, CM 435, 2191<br />
Reilly, M 16<br />
Reimold, A 397, 546, 880, 970,<br />
1099, 1792<br />
Reindl, C 2130<br />
Reis, RCP 1169, 1849<br />
Reis Neto, ET 628<br />
Reisman, D 194<br />
Reiss, AB 1072<br />
Reiss, W 403<br />
Rekedal, L 1318<br />
Remmers, E 914, 1281, 2217<br />
Ren, H 710<br />
Ren, J 1543<br />
Ren, P 1107<br />
Ren, Y 2056<br />
Rendal, E 1473<br />
Rendal-Vázquez, E 1483<br />
Rengel, Y 21<br />
Rennebohm, R 1678<br />
Renner, C 1973<br />
Renner, J 180, 181, 831, 838,<br />
1463, 2140<br />
Reny, J-L 2045<br />
Reppel, M 1615<br />
Resch, H 2157<br />
Resche-Rigon, M 1646, 2024,<br />
2039, 2046<br />
Respicio, G 446<br />
Restrepo, JF 1044, 1035<br />
Restuccia, G 1302, 2044<br />
Retamozo, S 50<br />
Reuschel, E 2219<br />
Reveille, J 87, 522, 725, 824,<br />
1210, 1211, 1216, 1219, 1226,<br />
1227, 1591, 1594, 1856, 1982,<br />
2185, 1972<br />
Revicki, D 91, 971<br />
Revu, S 394<br />
Reychan, I 550<br />
Reyes-Cortes, E 1526<br />
Reynard, M 321<br />
Reynolds, JA 1200<br />
Reynolds, K 1002<br />
Reynolds, MA 1074<br />
Rezaei, H 1392, 1393<br />
Rhiannon, JJ 163<br />
Rho, YH 1023, 1034, 1607, 1867<br />
Rhodus, N 1579<br />
Rhudy, JL 101<br />
Riato, L 1627<br />
Ribeiro, AL 1169, 1842, 1849<br />
Ribeiro, ACM 1437, 2078, 2204<br />
Ricciardi, D 1863<br />
Riccieri, V 580, 1627<br />
Richard, C 598<br />
Richard, D 145, 1423, 2087<br />
Richards, B 493<br />
Richards, HL 1234<br />
Richards, JS 397, 546, 970, 1099,<br />
1792<br />
Richardson, BC 1253, 1590<br />
Richardson, MN 87, 1047, 1428,<br />
1856, 1865<br />
Riche, D 1401<br />
Richey, M 2077<br />
Richez, C 1596, 1816<br />
Richman, IB 1592<br />
Richmond, JC 167<br />
Richter, J 1615<br />
Rider, LG 1678<br />
Rider, V 462<br />
Ridjab, D 1059<br />
Riedel, AA 757<br />
Rieder, SW 419<br />
Riemekasten, G 824, 829, 1987,<br />
2003, 2214, 2226<br />
Riente, L 558<br />
Riese, R 1129, 2171<br />
Riestra, R 1754<br />
Riet, A 29<br />
Rifkin, D 489<br />
Rigante, D 1872<br />
Rigby, W 378, 383, 414<br />
Righter, G 629<br />
Rigolet, A 1651<br />
Rigsby, C 1686<br />
Riley, CP 1601<br />
Rillo, O 50<br />
Rimar, D 550, 909<br />
Rincheval, N 1760<br />
Ringsdal, V 1444, 1841<br />
Rios, R 824<br />
Ripert, M 69<br />
Ripley, M 195, 2101<br />
Rischmueller, M 1579<br />
Rist, S 1890, 1893, 1910, 1914<br />
Ristori, J-M 375, 904<br />
Ritchlin, C 521, 712, 849, 1051,<br />
1492, 1710, 1835, 1919, 1935,<br />
1955, 1968<br />
Ritterhouse, LL 24<br />
Rittner, L 1170<br />
Rival, C 1448<br />
Rivas-Chacon, RF 1678<br />
2010 Program Book 345<br />
abstract author Index
aBSTRACT author Index<br />
Rizo-Rodríguez, JC 1166<br />
Rizvi, TJ 87<br />
Rizzo, W 378, 1820<br />
Roberts, C 1623<br />
Roberts, K 1538<br />
Roberts, M 1886<br />
Roberts, V 24, 780<br />
Robertson, D 1937<br />
Robinson, AB 252<br />
Robinson, B 71<br />
Robinson, DB 1068, 1094, 1176<br />
Robinson, E 1372<br />
Robinson, KC 178<br />
Robinson, M 809, 821, 1243, 1245<br />
Robinson, S 2082<br />
Robinson, W 77, 573, 1083, 1386,<br />
1740, 1764, 2116, 2117, 2229<br />
Robles, M 1834<br />
Roblin, D 1543<br />
Robustillo, M 1016, 1310<br />
Roccatello, D 2201<br />
Rocha, B 840<br />
Rocha, C 1732<br />
Roche, A 1810<br />
Rock, K 1531<br />
Roddy, J 584<br />
Rødevand, E 377<br />
Rodgers, J 2172<br />
Rodrigues, A 89<br />
Rodrigues, LA 1169, 1842, 1849<br />
Rodrigues, PT 2134<br />
Rodrigues, T 1140<br />
Rodriguez, E 44, 1171<br />
Rodriguez, M 975<br />
Rodríguez, R 543<br />
Rodríguez de Castro, F 1876<br />
Rodriguez de la Serna, A 1118<br />
Rodriguez Moreno, MR 1657<br />
Rodriguez-Ariza, A 1357<br />
Rodriguez-Gallego, C 1876<br />
Rodriguez-García, F 1881<br />
Rodríguez-Henríquez, PJ 1614<br />
Rodríguez-Lozano, C 1876, 2268<br />
Rodriguez-Moreno, J 1016<br />
Rodríguez-Reyna, T 1881<br />
Rodríguez-Rodríguez, L 1301<br />
Roehrs, T 294<br />
Roemer, F 131, 193, 197, 202,<br />
1373, 2100<br />
Roescher, N 1413, 2178<br />
Roger, VL 67<br />
Rogers, JC 2142<br />
Rogers, P 1571<br />
Roggenbuck, D 911, 1757<br />
Rohde, G 972<br />
Rojas-Villarraga, A 1048<br />
Rojkovich, B 1122, 2170<br />
Roll, P 745, 1411<br />
Rollins, K 597, 1201, 1222<br />
Rollot, F 2045<br />
Romagnani, S 246<br />
Román, J 1137<br />
Roman, M 483<br />
Roman Ivorra, JA 2157<br />
Romas, E 30, 1560<br />
Romay Penabad, Z 1360, 1361<br />
Römer, U 392<br />
Romero, A-B 409<br />
Romero-Diaz, J 445, 459, 1853<br />
Romero-Sánchez, C 552<br />
Romero-Sánchez, GT 1150<br />
Romick-Rosendale, L 268<br />
Rommel, C 362<br />
Ronacher, L 271<br />
Ronday, HK 295, 1396<br />
Rondon, F 1811<br />
Ronis, T 1008<br />
Rönnblom, L 503, 1885<br />
Ronneberger, M 1781<br />
Rönnelid, J 695, 1015, 1020, 2115<br />
Rooryck-Thambo, C 1596<br />
Roots, RK 2050<br />
Ros, S 1118, 1796<br />
Rosales, A 1543<br />
Rosario, MP 516<br />
Rosario Lozano, MP 1657<br />
Rosas, J 1754, 1888<br />
Roschel, H 1384<br />
Rose, CD 654<br />
Rose, G 752<br />
Rose, M 920<br />
Roselló, R 1276<br />
Roseman, C 1037, 1440<br />
Rosen, A 440, 487, 677, 681,<br />
1989, 2167<br />
Rosen, C 783, 1928<br />
Rosenbaum, JT 1447, 1713<br />
Rosenberg, A 214, 733, 849, 1886,<br />
1968<br />
Rosenblatt, L 1407, 1794, 1836,<br />
1837<br />
Rosenblum, GC 1072<br />
Rosengren, S 34, 1240, 1955<br />
Rosenkranz, ME 1673, 1691, 2017<br />
Rosenstein, ED 70<br />
Rosenthal, PB 1390<br />
Rosenzwajg, M 1249, 2025, 2131<br />
Rosenzweig, HL 1447, 1713<br />
Roske, A-E 56<br />
Rosner, I 550, 909<br />
Ross, JM 48<br />
Rossi, F 2044<br />
Rossi, R 581<br />
Rossi, S 2220<br />
Ross-MacDonald, P 1513<br />
Roth, J 845, 1472, 1495, 1684,<br />
2002<br />
Roth, M 1575<br />
Roth, SH 954, 955<br />
Rothfuss, M 381<br />
Rothlein, L 19<br />
Rotter, JI 187<br />
Rotunno, L 532<br />
Rouanet, S 82, 964<br />
Roubaud-Baudron, C 2041<br />
Roubey, RAS 6<br />
Roubinis, N 599<br />
Roucheux, A 1827<br />
Roure, F 529, 1924<br />
Routhu, KV 279<br />
Routsias, JG 1895, 2175<br />
Roux, C 548, 976, 2094, 2156<br />
Roux-Lombard, P 1088<br />
Rovati, LC 948<br />
Rovensky, J 2087<br />
Rovin, BH 1400<br />
Rowe, DS 396<br />
Rowles, G 1332<br />
Roy, A 1119<br />
Roy, S 65, 91, 307, 327, 382, 644,<br />
1113, 2266<br />
Rozelle, AL 2229<br />
Rozenbaum, M 550, 909<br />
Rozenberg, F 478<br />
Rua-Figueroa, I 1276, 1876<br />
Rubartelli, A 657<br />
Rubbert-Roth, A 294, 378, 384,<br />
411, 1788<br />
Rubenfire, M 567<br />
Rubin, BR 1430<br />
Rubin, L 598, 599<br />
Rubinstein, F 324<br />
Rubio-Perez, N 1407<br />
Rudd, MK 250<br />
Rudge, H 1848<br />
Rudin, A 1248<br />
Rudnev, A 1125<br />
Rudolph, KS 190, 194<br />
Rudwaleit, M 665, 669, 1923,<br />
1958, 1961, 2181, 2271<br />
Rueda, B 824, 829, 2214<br />
Ruff, V 980<br />
Ruggeri, BA 2233<br />
Ruhí, R 106<br />
Ruibal, A 1871<br />
Ruiz, B 1991, 2000<br />
Ruiz, E 1741<br />
Ruiz, JM 1118, 1796<br />
Ruiz, N 808<br />
Ruiz, O 1811<br />
Ruiz, P 435, 573<br />
Ruiz, T 1296<br />
Ruiz-Esquide, V 1070<br />
Ruiz-Irastorza, G 448, 476, 1877,<br />
2240, 2243<br />
Ruiz-Limon, P 1357<br />
Ruiz-Romero, C 840<br />
Rull-Gabayet, M 337, 874<br />
Rullé, S 1707<br />
Rullier, P 2010<br />
Rullo, OJ 262, 998<br />
Ruperto, N 207, 210, 232, 1407,<br />
1434, 1684, 1700, 1705<br />
Ruprecht, J 221<br />
Rus, H 432<br />
Rus, V 432<br />
Rushing, E 914<br />
Russell, AS 100, 330, 416, 1836<br />
Russell, IJ 97, 100, 814<br />
Russell, LP 2145<br />
Russo, RAG 212<br />
Rusu, C 1562<br />
Rüter, C 1130<br />
Ruth, JH 1417, 1419, 1504, 1721<br />
Ruth, NM 510<br />
Rüther, W 1486<br />
Rutsch, F 1486<br />
Ruutu, M 1446<br />
Ruyssen-Witrand, A 2218<br />
Ryan, J 22, 1333, 1625<br />
Ryan, M 654<br />
Ryan, P 1560<br />
Rybak, L 137, 707, 708<br />
Rybicki for ACCESS, B 1579<br />
Rygg, M 1684<br />
Ryu, HH 387<br />
Ryu, J 399<br />
Ryu, M 441<br />
S<br />
Saad, CG 481, 513, 531, 1437,<br />
2078, 2204<br />
Saad, M 1994<br />
Saad-Magalhães, C 1688, 1701,<br />
1872<br />
Saadoun, D 906, 1249, 1646,<br />
1660, 1908, 1911, 2011, 2024,<br />
2025, 2030, 2039, 2046, 2131<br />
Saag, K 152, 304, 392, 404, 721,<br />
722, 969, 1005, 1006, 1123, 1367,<br />
1543, 1561, 1573, 2084, 2103,<br />
2156<br />
Saavedra Salinas, MA 1150<br />
Saber, T 16, 1391<br />
Sabin, C 1645<br />
Saccardo, F 2036<br />
Sacchetti, SB 1339<br />
Sacco, S 2201<br />
Sack, J 1513<br />
346<br />
2010 Program Book
Sack, KE 1898<br />
Sacli, SF 1312<br />
Saddic, N 2197<br />
Sadeghi Abdollahi, B 1289<br />
Sadik, C 1427<br />
Saech, J 294<br />
Saeed, A 2224<br />
Saegusa, J 1715<br />
Safa-Leathers, S 2169<br />
SAFE-T DILI- GHPS Study Group<br />
1762<br />
Safford, M 299, 304, 1573<br />
Sagawa, A 1138, 1738, 1739<br />
Sagcal-Gironella, AC 1012, 1689<br />
Saggar, R 561, 561, 729, 729, 907,<br />
907, 1232, 1232<br />
Sague, S 326<br />
Saha, C 93, 797<br />
Sahai, M 1044, 1049, 2163<br />
Sahakian, L 471, 594, 1189, 2241<br />
Sahhar, J 584<br />
Sai, Y 1107<br />
Saidenberg-Kermanac’h, N 997<br />
Said-Nahal, R 527, 533<br />
Saiki, O 373<br />
Sailler, L 2027, 2239<br />
Sainaghi, PP 962, 2160<br />
Saito, K 1823<br />
Saito, M 1793<br />
Saito, O 513<br />
Saito, T 335<br />
Saitoh, K 1812<br />
Sakaguchi, S 1485, 2128<br />
Sakai, Y 983, 1738<br />
Sakellariou, G 1397<br />
Saketkoo, LA 1212<br />
Sakuma, Y 1749<br />
Sakurai, N 358<br />
Sakurai, T 1138, 1738, 1739<br />
Salaffi, F 547, 1635, 1746, 1787<br />
Salah, S 833<br />
Salas, J 1137<br />
Salas-Manzanedo, V 2035<br />
Salazar, JC 1811<br />
Saldaña-Barnad, M 1166<br />
Salgado, E 1171<br />
Salgado, M 1700<br />
Sallstig, P 145, 1423, 2087<br />
Sallum, AM 224, 927<br />
Salmon, D 376<br />
Salmon, JE 427, 483, 866, 1183,<br />
1199, 1441, 2077<br />
Salomonsson, S 832<br />
Salt, E 1332<br />
Saltzman, CL 176<br />
Saluja, M 1551, 1640<br />
Salvador, I 1741<br />
Salvadorini, G 558, 1962<br />
Salvarani, C 532, 777, 1290, 1302,<br />
1637, 1652, 1654, 2037, 2038,<br />
2044<br />
Salvat, C 1514<br />
Salvo, D 1290<br />
Samarawickrama, A 966<br />
Sambrook, PN 2156<br />
Sampaio-Barros, P 531, 525, 2078<br />
Sampalis, J 344<br />
Samuels, J 137, 707, 708, 1390,<br />
1616<br />
Samukawa, S 1512<br />
San Martin, J 2161<br />
Sanchez, E 444, 1590<br />
Sánchez, J 1171<br />
Sanchez, RJ 2246<br />
Sanchez-Guerrero, FJ 448, 476,<br />
1877, 2240<br />
Sanchez-Guerrero, J 445, 459,<br />
1456, 1853, 1881, 2243<br />
Sanchez-Madrid, F 1509<br />
Sanchez-Rodriguez, E 2148<br />
Sandborg, CI 1677<br />
Sander, O 1615<br />
Sanders, M 1529<br />
Sanderson, T 1766<br />
Sandler, DP 61<br />
Sanford, T 733<br />
Sangle, S 463<br />
Sangle, SR 444, 2035<br />
Sanmartí, R 20, 409, 538, 1070,<br />
1118<br />
Sansonno, D 2036<br />
Santana- de Anda, K 1881<br />
Santaniello, A 1235<br />
Santarlasci, V 246<br />
Santegoets, KCM 844<br />
Santer, DM 494, 499<br />
Santiago, B 482<br />
Santos, AM 552<br />
Santos, FH 1343<br />
Santos, H 1986<br />
Santos, P 552, 1811<br />
Santos, VC 498, 504<br />
Santos Moreno, PI 1013<br />
Santos-Ramírez, C 1754<br />
Santos-Soler, G 1754<br />
Sanz, I 486, 733, 749, 849, 712,<br />
1085, 1710, 1886<br />
Sapienza, MT 1384<br />
Sara, PR 2060<br />
Sarah, R 620<br />
Saraux, A 781, 888, 1896, 1910,<br />
1914, 1088, 1752, 1890, 1931,<br />
2094, 2221, 2261<br />
Sardy, M 441<br />
Sargent, J 675<br />
Sari, I 1970<br />
Sari, M 1675<br />
Sarin, R 1106<br />
Sarkar, RN 1925<br />
Sarmukadam, S 1551<br />
Sarnes, EF 1566<br />
Sarni, R 1676<br />
Sarsour, K 52<br />
Sartorius, J 345, 1442<br />
Saruhan-Direskeneli, G 822, 2200<br />
Sarzi Puttini, P 297, 532, 784, 815,<br />
1098, 1582<br />
Sasaki, N 2020<br />
Sato, E 628, 1793, 1812, 1823<br />
Sato, H 1797<br />
Sato, M 26, 1773<br />
Sato, S 681, 1230<br />
Satoh, M 501, 735, 1639<br />
Satoh, T 916<br />
Sattar, A 620<br />
Sattar, N 483, 1441<br />
Satumtira, N 1448<br />
Sauer, BC 1099, 1792<br />
Saulsbury, C 2076<br />
Sautet, A 1514<br />
Savage, CO 676<br />
Savioli, C 2078, 2204<br />
Savl<strong>of</strong>f, G 1747<br />
Sawada, S 1708<br />
Sawada, T 1293<br />
Sawai, T 2020<br />
Sawalha, AH 822, 1590, 1594<br />
Saxena, A 1438, 1971, 1976<br />
Saxne, T 1037, 1440<br />
Sayarlioglu, M 1921<br />
Sayles, HR 318<br />
Sayre, EC 1555, 2055<br />
Scaini, P 2201<br />
Scal, P 1340<br />
Scali, JJ 411<br />
Scalzi, L 470, 1861<br />
Scalzi, LV 1002<br />
Scanzello, CR 167<br />
Scarf, J 794<br />
Scarf, JP 778<br />
Scarpa, R 532<br />
Scarpato, S 1705, 2036, 2201<br />
Scarry, M 817, 818<br />
Schachna, L 1942<br />
Schaeverbeke, T 917, 400, 701,<br />
1596, 1790, 1816, 2042<br />
Schall, TJ 1100, 2032, 2048<br />
Schanberg, L 1406, 1677, 1688,<br />
1699, 1701, 1702, 2248<br />
Scharnert, J 1130<br />
Schechtman, J 1820<br />
Scheers-Masters, J 1431<br />
Scheinberg, M 1146, 1407<br />
Scheja, A 1623<br />
Schelbergen, R 845, 1472<br />
Schellevis, FG 1029, 2211<br />
Scher, JU 1390<br />
Scherer, A 138, 2257<br />
Scherer, HU 1780<br />
Schett, G 128, 490, 560, 566, 607,<br />
611, 614, 616, 629, 639, 672, 857,<br />
1474, 1634, 2150, 2234<br />
Schiappapietra, B 207<br />
Schieir, O 1346<br />
Schieven, G 1119, 1513<br />
Schiff, MH 945, 946<br />
Schiff, SA 625, 1767<br />
Schikler, KN 1673, 1691, 2017<br />
Schilder, AM 1859<br />
Schilders, G 1519<br />
Schilling, S 800<br />
Schillinger, D 1024<br />
Schimmel, E 1284<br />
Schiopu, E 402, 561, 567, 585,<br />
1222, 2073<br />
Schiotis, R 525, 986<br />
Schirmer, M 1637, 1652, 1654,<br />
2222<br />
Schleh, A 12<br />
Schlemmer, A 1444, 1841<br />
Schlesinger, N 145, 889, 1423,<br />
2087<br />
Schluger, N 908<br />
Schmajuk, G 484, 789, 991, 2113<br />
Schmaldienst, S 469<br />
Schmid, CH 95<br />
Schmidt, A 1130<br />
Schmidt, H 56<br />
Schmidt, J 2040<br />
Schmidt, WA 777, 1617, 1637,<br />
1652, 1654<br />
Schmidt, Z 777, 1637, 1652, 1654<br />
Schmidt-Wilcke, T 102, 650<br />
Schneck, L 148, 883<br />
Schneeweiss, S 31, 60, 339, 1066<br />
Schneider, DJ 602, 612<br />
Schneider, E 709<br />
Schneider, M 111, 138, 770, 1615,<br />
2081<br />
Schneider, R 1434<br />
Schneider, U 1295<br />
Schneiderman, J 1681<br />
Schnez, A 1781<br />
Schnitzer, T 936, 2097<br />
Schoels, M 1795<br />
Schoindre, Y 2000, 2030<br />
Scholte-Voshaar, M 1027<br />
Scholz, J 1385, 1557, 2098<br />
Schoones, JW 2051, 2283<br />
Schorn, C 490, 2150<br />
Schorscher-Petcu, A 823<br />
2010 Program Book 347<br />
abstract author Index
aBSTRACT author Index<br />
348<br />
Schoster, B 691, 1460, 1461,<br />
1462, 1463, 2140<br />
Schouffoer, AA 328, 582, 1396<br />
Schouffour, AA 1755<br />
Schousboe, JT 1539<br />
Schreiber, B 590, 727<br />
Schreiner, P 1148<br />
Schreiyaeck, C 1479<br />
Schrieber, L 584<br />
Schroeder, AE 749<br />
Schroeder, M 1615<br />
Schubert, T 1466<br />
Schuerwegh, AJ 582, 2214<br />
Schulman, KL 1031<br />
Schultz, D 468<br />
Schultz, O 294<br />
Schulz, M 886<br />
Schulze-Koops, H 1261, 1781,<br />
2130, 406, 1108, 1241<br />
Schumacher, HR 152, 153, 1554,<br />
151<br />
Schumacher, U 679<br />
Schumann, M 745<br />
Schurgers, E 1720<br />
Schwab, P 970<br />
Schwarting, A 1454<br />
Schwartz, A 468<br />
Schwartz, T 181, 691<br />
Schwarz, E 712, 1492, 1710, 1968<br />
Schwarz, H 2257<br />
Scibetta, C 1687<br />
Scindia, YM 1883<br />
Scinocca, M 1071<br />
Scirè, CA 1397, 2220, 766<br />
Sc<strong>of</strong>ield, RH 1193, 1579, 1584,<br />
1901, 2147, 1591<br />
Scolnik, M 324<br />
Scorza, R 824, 829, 1235, 2214<br />
Scott, D 412, 664, 1110<br />
Scott, J 1747<br />
Seager, N 493<br />
Seah, MY 1942<br />
Seavey, MM 2233<br />
Sebastiani, M 1627<br />
Sebba, A 411, 980<br />
Sedlis, S 148<br />
See, K 957<br />
Segal, B 569, 586, 1579, 1882<br />
Segal, N 131, 2100<br />
Segarra, M 1292, 1294<br />
Segelmark, M 676, 1307, 2018,<br />
2022<br />
Sehgal, A 2206<br />
Sehgal, R 1311<br />
Sehnert, B 2234<br />
Seiberling, M 1273<br />
Seibold, J 561, 565, 583, 585, 599,<br />
729, 1004, 1212, 1222, 2007, 2073,<br />
2010 Program Book<br />
1205<br />
Seibold, T 1411<br />
Seiders, J 606<br />
Seipelt, E 227<br />
Seitz, LC 1100, 2032, 2048<br />
Sekine, H 435<br />
Seldin, MF 502, 1592, 1602<br />
Sellam, E 1470, 1471<br />
Sellam, J 548<br />
Selvi, E 615<br />
Semanik, P 2096<br />
Semb, AG 534<br />
Semerano, L 997, 2236<br />
Semoun, O 1646, 2039<br />
Sen, R 487<br />
Senabre, JM 1754<br />
Sène, D 1646, 1890, 1908, 1910,<br />
1911, 2024, 2025, 2030, 2039,<br />
2046<br />
Senecal, J-L 731<br />
Senet, P 2010, 2011<br />
Senior, J 75<br />
Seno, T 1511<br />
Senolt, L 614, 638<br />
Sensky, T 987<br />
Seo, G-S 1051<br />
Seo, P 2012, 2031, 2198<br />
Seo, S-R 116, 505, 1891<br />
Sequeira, W 1147, 1175<br />
Serafini, T 164<br />
Serdik<strong>of</strong>f, C 2233<br />
Seres, I 519<br />
Seriolo, B 578, 1236, 1798<br />
Serné, E 1623<br />
Sernissi, F 811, 839<br />
Seror, R 1217, 1890, 1896, 1910,<br />
1914, 2010<br />
Seshan, S 1151<br />
Sesseng, S 132, 142<br />
Seto, M 1377<br />
Setoguchi, K 932<br />
Setoguchi, S 958<br />
Seton, M 25<br />
Setti, E 269<br />
Setznagl, D 1481<br />
Seung, E 1427<br />
Seyahi, E 1288, 1312, 1697<br />
Seyfert, C 368<br />
Seymour, AB 823<br />
Seymour, K 99<br />
Seymour, RB 692<br />
Sfriso, P 290<br />
Sgarlat, CM 1404<br />
Shadakshari, A 1863<br />
Shadick, N 308, 1050, 1335, 1610,<br />
1753, 1778, 1782, 2064<br />
Shafait, I 40<br />
Shah, AA 569, 1201, 1222, 2192<br />
Shaham, B 2102<br />
Shahane, A 592<br />
Shahdad, S 1455<br />
Shahouri, SH 331<br />
Shahram, F 1289, 1305<br />
Shahrara, S 23, 270, 714, 1506<br />
Shainberg, M 1405<br />
Shakib, S 1124<br />
Shakibaei, M 106<br />
Shakoor, N 205, 2099<br />
Shakoory, B 1573, 1668<br />
Shalamberidze, L 1096, 2168<br />
Shan, Y 379, 1010, 1960<br />
Shanafelt, TD 595<br />
Shanahan, EM 177<br />
Shanahan, F 22, 1333, 1726<br />
Shanahan, KR 177<br />
Shang, Q 1028<br />
Shanmugam, VK 912, 1045, 2197<br />
Shanmugarajah, S 521, 530, 545,<br />
1928, 1936, 1956, 1974, 1979,<br />
1984<br />
Shao, L 1079<br />
Shapira-Lichter, I 1159<br />
Shapiro, DJ 484<br />
Sharif, B 1555<br />
Sharif, R 522, 1211, 1216, 1218,<br />
1219, 1227<br />
Sharma, A 2086<br />
Sharma, L 131, 186, 189, 202,<br />
2096, 2100<br />
Sharma, R 1374<br />
Sharpe, A 456<br />
Sharpe, O 2117<br />
Sharpe, T 213<br />
Sharpley, DW 661, 1763<br />
Shaver, TS 331<br />
Shaw, AS 1415<br />
Shaw, J 1973<br />
Shaw, LA 748, 2128<br />
Shaw, ML 1154<br />
Shaw, S 752, 1244<br />
Shaw, T 403<br />
Shaw, TM 125<br />
Shaw, Y 755<br />
Shaykevich, T 60, 2104<br />
Shayuk, M 1858<br />
Shealy, D 1818, 1968<br />
Sheen, D-H 488, 830, 1589<br />
Sheikh, S 2107<br />
Shelef, MA 1421<br />
Shelmerdine, J 769, 795, 1177<br />
Shen, D-R 1513<br />
Shen, H 512, 530, 545, 556, 783,<br />
1954, 1964<br />
Shen, N 2274<br />
Shen, W 274<br />
Shen, Y 1496, 1753, 1782<br />
Shendre, A 828<br />
Shennan, A 2035<br />
Shepard, S 2172<br />
Sherman, JW 945, 946<br />
Sherry, DD 47, 233, 1677, 1678,<br />
1703, 1907<br />
Sherwood, JC 1476<br />
Shetty, AG 1647<br />
Shevkoplyas, SS 2277<br />
Shi, B 1353<br />
Shi, H 948<br />
Shi, J 1598<br />
Shibata, TN 365<br />
Shiboski, C 1898<br />
Shiboski, S 1898<br />
Shields, AM 1729<br />
Shiels, P 2214<br />
Shikany, J 1062<br />
Shilagard, T 1360<br />
Shim, MR 1789<br />
Shim, S 488, 830, 1589, 1597,<br />
1972<br />
Shima, Y 2228<br />
Shimada, Y 1017<br />
Shimane, K 1577<br />
Shimizu, H 1783<br />
Shimizu, N 1708<br />
Shin, H 1597, 2142<br />
Shin, K 387, 1751<br />
Shinjo, SK 927<br />
Shinozaki, N 1743<br />
Shintani, A 1023, 1034, 1867<br />
Shiow-Ling, C 1270<br />
Shiozaki, M 1708<br />
Shiozawa, K 511, 893<br />
Shiozawa, S 280, 348, 434, 511,<br />
616, 851, 867, 893, 983, 1258,<br />
1264, 1272, 1467, 1812<br />
Shipley, E 1816<br />
Shir, Y 107<br />
Shiraiwa, H 1708<br />
Shivers, D 2219<br />
Shiwen, X 613, 2005<br />
Shiyanov, P 268<br />
Shlimbaum, T 1320<br />
Shmerling, RH 684<br />
Shock, A 751, 752, 1243, 1244,<br />
1245<br />
Shoelson, AJ 2099<br />
Shoham, N 1516<br />
Shojania, K 2152<br />
Sholter, D 330<br />
Shono, E 1115, 1138, 1738, 1739<br />
Shoor, S 573<br />
Shott, S 2075<br />
Shourt, CA 1550, 1570<br />
Shreffler, JH 690, 691, 1460, 1462,
1463, 2071, 2140, 2141<br />
Singh, K 2127<br />
Snyder, RD 2012<br />
Sostek, M 937, 2206<br />
Shrestha, S 242, 826, 828, 928<br />
Singh, MK 2195<br />
So, A 145, 1423, 2087, 2151<br />
Sotnikova, T 1125<br />
Shulman, AI 209<br />
Singh, RP 497, 1257<br />
So, M 876, 2028<br />
Soto, R 1270<br />
Shults, J 206, 1786<br />
Singh, S 4<br />
So, P-W 1995<br />
Sotocinal, SG 823<br />
Shums, Z 14, 2250, 2251, 2252<br />
Singh, UN 2086<br />
Soares, MG 356<br />
Souberbielle, J-C 2030<br />
Sibbitt, WL 947, 1055, 1567, 1626,<br />
2225<br />
Sibilia, J 303, 400, 701, 858, 917,<br />
1104, 1237, 1413, 1790, 1840,<br />
1890, 1894, 1910, 1998, 2218<br />
Sibonga, J 959<br />
Siddhanta, S 1925<br />
Sidhu, P 1636<br />
Siegrist, C-A 792<br />
Sieper, J 518, 526, 559, 665, 669,<br />
1923, 1938, 1948, 1958, 1961,<br />
2181, 2270, 2271<br />
Siero, W 248<br />
Siff, SJ 178<br />
Sigal, LH 1320<br />
Sijtsma, F 1367<br />
Sikora, KA 653<br />
Silingardi, M 1302<br />
Silva, AE 628<br />
Silva, C 224, 260, 513, 539, 927,<br />
1339, 1407, 1437, 2078, 2204<br />
Silva, I 539<br />
Silva, NP 356, 498, 504, 628<br />
Silva, SGL 1343<br />
Silver, R 604, 622, 1004, 1677<br />
Silverman, E 1674, 1677<br />
Silverman, GJ 2121<br />
Silverman, SL 815, 969, 971, 980<br />
Silverstein, R 2047, 2049<br />
Silvestra-Segovia, T 1500<br />
Silvestre, RVD 1694<br />
Simard, JF 454, 1054, 1541, 1548<br />
Simecka, J 1430<br />
Simeon, C 824, 829, 2214<br />
Simil, FF 1842<br />
Siminovitch, K 2217<br />
Simkin, PA 163<br />
Simms, RW 1624<br />
Simon, A 905<br />
Simon, J 971, 2173<br />
Simonini, G 1675, 240, 246, 1436<br />
Simons, DG 647<br />
Simpfendorfer, KR 825<br />
Sims, J 260<br />
Sims, NA 30<br />
Simsek, I 1559<br />
Sinead, H 22<br />
Singer, J 1542<br />
Singer, NG 1677, 1691, 1701<br />
Singer, O 898<br />
Singh, G 2205, 2206<br />
Singh, J 304, 951, 1385, 1395,<br />
1557<br />
Singh, Y 2082<br />
Sipe, JD 49<br />
Siqueira, JTT 2078, 2204<br />
Siris, E 971<br />
Siu, G 1141<br />
Sjöwall, C 1885<br />
Skaggs, B 471, 1189, 2241<br />
Skapenko, A 1108, 1241, 1261,<br />
2130<br />
Skific, D 710, 1121<br />
Skjødt, T 134, 1953<br />
Skljarevski, V 175<br />
Skoie, IM 972<br />
Skol, AD 1612<br />
Slade, K 1354<br />
Slagboom, PE 179<br />
Slatkowsky-Christensen, B 142<br />
Slawsky, KA 754<br />
Slegen 2274<br />
SLEGEN International Consortium<br />
500, 2145, 2148<br />
Sleglova, O 1649<br />
SLICC Group 454<br />
Sloan, JA 595<br />
Sloan, VS 70, 1940<br />
Sloane, R 180<br />
Slobodin, G 550, 909<br />
Sloetjes, A 845, 1472, 1495<br />
Slot, O 884<br />
Slott Jensen, H 777, 1654<br />
Sluka, KA 1226<br />
Smail, A 2239<br />
Smeets, RL 275<br />
Smith, CD 1480, 1850<br />
Smith, CJ 318<br />
Smith, DM 1319<br />
Smith, EA 1077<br />
Smith, J 895, 1096, 1124, 1425,<br />
1607, 1965, 2168<br />
Smith, KA 734<br />
Smith, M 177, 949<br />
Smith, R 678, 1278, 1638, 1663<br />
Smith, S 647, 1119<br />
Smith, T 1983<br />
Smith, V 2214<br />
Smith, Z 1438<br />
Smolen, J 73, 79, 272, 296, 469,<br />
723, 1013, 1119, 1493, 1745, 1791,<br />
1795, 1806, 1820, 2108, 2256,<br />
2258, 2265<br />
Smolik, I 1068, 1094<br />
Snowhite, I 750<br />
Snyder, C 1831<br />
Sobel, ES 501, 735, 742<br />
Socci, N 1390<br />
Soejima, M 935<br />
Soep, JB 1677<br />
Sohn, J 359<br />
Soini, EJO 759<br />
Sokka, T 84, 312, 985, 1027<br />
Sokol, RJ 468<br />
Sokolove, J 1083, 1740, 1764,<br />
2116, 2117<br />
Solano, C 63, 1614<br />
Solans, R 1888<br />
Solari, N 207<br />
Solau-Gervais, E 315, 1752<br />
Soldano, F 2036<br />
Soldano, S 1798<br />
Soldevilla, HF 1851<br />
Solinger, AM 1308<br />
Solmaz, D 544, 666, 1283, 1921<br />
Solomon, DH 31, 42, 54, 60, 81,<br />
308, 339, 793, 958, 991, 1050,<br />
1066, 1318, 1610, 1778, 2091,<br />
2092, 2104<br />
Solomon, G 1390<br />
Solomon, JJ 2119<br />
Solomons, N 1453, 2085<br />
Soltész, P 519<br />
Solus, J 1023, 1034, 1607, 1867<br />
Somers, EC 1158, 1590<br />
Somogyi, A 2042<br />
Son, KM 1038<br />
Son, MBF 209<br />
Sondergaard, BC 1500<br />
Sonesson, S-E 832, 1322<br />
Song, GG 92, 359, 1628<br />
Song, I-H 669, 1923, 1961, 2271<br />
Song, J 186, 189, 202, 1386, 1558,<br />
2096, 2244<br />
Song, R 1038<br />
Song, YW 387, 1583, 1595, 1751<br />
Sonnaville, PBJ 1396<br />
Sonnylal, S 613<br />
Soon, GS 2019<br />
Sop, G 1970<br />
Soranzo, N 711<br />
Sordet, C 63, 1237<br />
Sorell, L 852<br />
Sørensen, IJ 134, 1953<br />
Sorge, RE 823<br />
Sorgi, ML 547<br />
Soriano, E 50, 324<br />
Soriano, T 2110<br />
Sorkin, L 1727<br />
Soubrier, M 375, 542, 917, 1104,<br />
1810<br />
Soulillou, J-P 753<br />
Soumerai, SB 791<br />
Sousa, E 1986<br />
Sousa, FL 1169, 1842, 1849<br />
Soutou, B 2238<br />
Souza, AJ 1169<br />
Souza, LO 1458<br />
Souza, M 2132<br />
Souza, S 228<br />
Sowden, E 40<br />
Soybilgic, A 464<br />
Soysal, O 666<br />
Spada, C 931<br />
Spadaro, A 532<br />
Spadoni, T 2008<br />
Spaeth, M 97<br />
Sparks, S 1192<br />
Specks, U 680, 2012<br />
Spector, TD 711, 841<br />
Speich, R 35, 1518<br />
Spencer, J 463<br />
Spera, A 805<br />
Spevak, W 273<br />
Speyer, I 1396, 1755<br />
Spiegel, L 225, 1408<br />
Spiera, R 1990, 2012, 2193<br />
Spijkervet, F 1892<br />
Spijkervet, FKL 1889, 1905<br />
Spiller, I 2181<br />
Spindler, AJ 1455<br />
Spitz, E 1752<br />
Sportes, C 1161<br />
Squier, W 922<br />
Sredni, S 242, 928<br />
Sridharan, ST 1154<br />
Srinivasan, S 1829<br />
Srivastava, S 1405<br />
St Clair, EW 461, 1368, 2265,<br />
2012, 2265<br />
Staccini, P 976<br />
Stach, C 128, 1634<br />
Stagi, S 222<br />
Stahl, GL 2227<br />
Ståhl-Hallengren, C 2022<br />
Stamm, TA 1745<br />
Stamp, LK 33, 146, 417, 870, 1252<br />
Stancati, A 1840<br />
Stanczyk, J 1093<br />
Stanek, EJ 1561<br />
Stanislawska-Biernat, E 1013<br />
2010 Program Book 349<br />
abstract author Index
aBSTRACT author Index<br />
350<br />
Stankovic-stojanovic, K 905<br />
Stankus, A 800<br />
Stapel, SO 1828<br />
Stappers, MHT 275<br />
Stark, A 468<br />
Starz, TW 2246<br />
Staud, R 809, 821<br />
Steck, R 1446<br />
Steele, R 577<br />
Steen, V 561, 569, 570, 586, 591,<br />
729, 1004, 1231, 2197<br />
Steere, AC 25<br />
Steffen, G 1988<br />
Stegeman, CA 2015, 2023<br />
Stehle, T 1419<br />
Stehman-Breen, C 982<br />
Steiman, A 1874<br />
Stein, CM 1023, 1034, 54, 1607,<br />
1867, 2123<br />
Steinberg, E 241<br />
Steinberg, G 82<br />
Steinfeld, S 2036<br />
Steinkellner, A 1561<br />
Steinmeyer, J 1420, 1722<br />
Steinsson, K 445, 448, 476, 1877,<br />
2240, 2243<br />
Stengaard-Pedersen, K 1370,<br />
1485, 1524, 1761<br />
Stephens, S 1502, 1681<br />
Sterling, KL 52<br />
Stern, S 241<br />
Sterrett, AG 44<br />
Steup, A 950<br />
Steven, KA 621<br />
Stevens, A 506, 1591, 1673, 1691,<br />
2017, 2119<br />
Stevens, S 225<br />
Stevens, W 584<br />
Stevens-Lapsley, JE 171<br />
Stewart, AK 1502<br />
Stewart, S 780<br />
Stinson, J 1408<br />
Stirnemann, J 1653, 2239<br />
Stobaugh, J 253<br />
Stockman, A 1560<br />
Stoenoiu, M 1398<br />
Stoerk, S 1026<br />
Stohl, W 2129, 2187, 457, 1146,<br />
1454, 1457<br />
Stojanov, S 905<br />
Stolarski, BE 1422<br />
Stolk, J 582<br />
Stoll, M 223, 1491<br />
Stoll, T 445, 448, 476, 1877, 2240,<br />
445<br />
Stolshek, B 1540, 1552<br />
Stoltz, RR 160<br />
Stone, D 260, 1698<br />
2010 Program Book<br />
Stone, JH 25, 1671, 2012<br />
Storan, ER 817, 818<br />
Storm, G 283<br />
Stormont, R 780<br />
Stradner, MH 1481<br />
Strand, V 65, 1063, 1096, 1125,<br />
1212, 1452, 1806, 1832, 1940,<br />
1766, 1848, 2168<br />
Strangfeld, A 1111, 1112<br />
Strassburger, K 138<br />
Stratford, PW 1316<br />
Stratton, R 613<br />
Straub, RH 361, 1089<br />
Strausbauch, MA 1580, 1581,<br />
2216<br />
Strauss, B 173, 1383<br />
Street, S 1116<br />
Stricker, K 1423<br />
Strickland, G 1772<br />
Strietholt, S 368, 1719<br />
Stringer, E 238<br />
Strippoli, R 18<br />
Strle, K 25<br />
Strömbeck, B 761<br />
Struessel, T 171<br />
Strusberg, I 1834<br />
Strutton, G 1116, 1446<br />
Stryker, S 398<br />
Studenic, P 79<br />
Stummvoll, GH 469<br />
Stump, KL 2233<br />
Sturfelt, G 445, 448, 476, 731,<br />
1020, 1307, 1877, 2022, 2240,<br />
2243<br />
Sturgess, A 584, 621<br />
Stürz, H 1420, 1722<br />
Su, G 2156<br />
Su, J 13, 1165, 1178, 1194, 2120<br />
Su, L 350, 1245, 1656, 2242, 2243<br />
Su, W 274, 1107<br />
Suarez, B 538<br />
Suarez-Almazor, ME 87, 178, 407,<br />
755, 941, 1047, 1428, 1856, 1865<br />
Subbaiah, RS 363<br />
Suda, A 480<br />
Sudman, M 654<br />
Suematsu, R 433<br />
Suffert, G 858<br />
Sufka, PH 1395<br />
Sugihara, T 1375<br />
Sugiura, T 923<br />
Suhre, K 711<br />
Suissa, S 342<br />
Sulli, A 578, 1236, 1798<br />
Sullivan, BA 1141<br />
Sullivan, C 555<br />
Sullivan, K 726, 865, 2194<br />
Sullivan, T 856<br />
Sumegi, J 653<br />
Sumida, T 292, 352, 1724, 2176<br />
Summers, K 1071<br />
Sumner, DR 200<br />
Sun, C 2274<br />
Sun, H 999, 1516, 2217<br />
Sun, L 918, 1128, 1143, 1182<br />
Sun, M 1448<br />
Sun, Y 306, 343<br />
Sun, Z 1158<br />
Sundararajan, V 1052<br />
Sundel, RP 215, 229, 235<br />
Sundy, JS 157, 160<br />
Sunesen, K 2040<br />
Sung, Y 1157, 1597, 1941<br />
Sunkureddi, PR 302<br />
Supronik, J 392<br />
Suri, D 4<br />
Susic, G 217<br />
Susini, M 528<br />
Sutcliffe, N 1896<br />
Suter, LG 2090, 2092<br />
Sutton, D 1244<br />
Sutton-Tyrrell, K 1168<br />
Suttorp-Schulten, MSA 1933<br />
Suzaki, M 1115<br />
Suzuki, A 1577<br />
Suzuki, E 435, 1526<br />
Suzuki, M 268<br />
Suzuki, T 1611<br />
Svegliati, S 2001, 2008<br />
Svenson, J 1251<br />
Svensson, KE 1829<br />
Svensson, O 937<br />
Svenungsson, E 7, 1181, 1224,<br />
1846<br />
Sverdrup, B 645<br />
Swaim, BH 167<br />
Swallow, E 763<br />
Swan, GE 877<br />
Swan, JT 1401<br />
Swaney, J 606<br />
Swanik, CB 194<br />
Swanink, R 416<br />
Swart, JF 219<br />
Swearingen, C 985, 1284, 1298,<br />
1616, 1765, 1863<br />
Swedish Congenital Heart Block<br />
Study Group 832<br />
Sweeney, SE 1712<br />
Sweetser, M 391, 403<br />
SWEFOT Study Group 1393<br />
Sweiss, N 591<br />
Swetz, KM 595<br />
Swift, L 1034<br />
Swigris, JJ 2119<br />
Swinkels, A 1325<br />
Swinnen, T 520<br />
Swistowski, DR 2197<br />
Sykoutri, D 1493<br />
Sylvestre, M-P 1036<br />
Symmons, D 374, 421, 646, 766,<br />
779, 796, 1067, 1110, 1323, 1600<br />
Syvänen, A-C 1885<br />
Szabo, SM 535, 771<br />
Szanto, S 519, 1946<br />
Szechinski, J 392, 1123<br />
Szekanecz, Z 519<br />
Szentpetery, A 1947<br />
Szklo, M 1148, 2162, 2260<br />
Szmyrka-Kaczmarek, M 1011<br />
Sznajd, J 1011<br />
Szombati, I 392<br />
Sztajnbok, F 1407, 1872<br />
Szücs, G 519<br />
Szumski, A 1927<br />
Szymanski, G 375<br />
Szymkowski, DE 1350<br />
T<br />
Taal, E 1334, 2207, 2281<br />
Taams, LS 1263, 1838<br />
Tabechian, D 849, 1620, 1968<br />
Tabrizi, EN 994<br />
Tada, M 981<br />
Tada, Y 433<br />
Taddio, A 1436<br />
Tadema, H 2015, 2023<br />
Tadey, A 1704<br />
Tadina, C 428<br />
Tadoori, R 148, 883<br />
Tager, AM 606<br />
Taglialatela, G 1536<br />
Tahara, M 1724<br />
Taillefer, SS 1346<br />
Taimeh, Z 1990<br />
Tait, T 1665<br />
Tajana Messi, E 948<br />
Tajima, R 896, 2232<br />
Tak, P 21, 32, 271, 333, 414, 629,<br />
719, 753, 1069, 1095, 1353, 1413,<br />
1416, 1449, 1487, 1507, 1519,<br />
1529, 1534, 1604, 1711, 1817,<br />
1821, 1822, 1828, 1919, 1977,<br />
2169, 2170, 2178, 2272<br />
Takagi, D 2029<br />
Takagi, K 447, 746, 916, 923,<br />
1184, 1587, 1666<br />
Takagishi, TK 704<br />
Takahashi, E 921<br />
Takahashi, K 2227<br />
Takahashi, M 36, 2227<br />
Takahashi, R 26, 1773<br />
Takahashi, S 1724<br />
Takahashi, Y 1042, 1619
Takahata, M 1492<br />
Takasaki, Y 1731<br />
Takase, K 139, 1081<br />
Takayama, L 1546<br />
Takayama, M 1285, 1531<br />
Takehara, K 724, 1230<br />
Takei, M 1708<br />
Takei, S 399<br />
Takeno, M 139, 480, 1081, 1293,<br />
1300, 1512, 2217<br />
Takeoka, M 1709<br />
Takeuchi, T 399, 1013, 1814,<br />
1815, 1793, 1812, 1823<br />
Takezaki, S 1672<br />
Taki, N 335<br />
Takimoto, M 851<br />
Takizawa, Y 932<br />
Talaei, N 2190<br />
Talarico, R 839, 1916<br />
Talia, NN 2007<br />
Taljanovic, M 1636<br />
Talpin, A 1981<br />
Talwalkar, JA 129<br />
Tam, A 613<br />
Tam, L-S 1028<br />
Tamai, M 1371, 1632<br />
Tamaki, H 1783<br />
Tamby, MC 575, 834<br />
Tamura, N 1731<br />
Tan, FK 603, 612, 824, 2214<br />
Tan, M 1004<br />
Tan, Q 1068<br />
Tan, W 1583, 1584<br />
Tan, YC 717<br />
Tanaka, C 983<br />
Tanaka, D 329<br />
Tanaka, E 1053<br />
Tanaka, J 568<br />
Tanaka, S 568<br />
Tanaka, Y 399, 292, 352, 352, 511,<br />
1793, 1812, 1814, 1815, 1823,<br />
2169<br />
Tanaka-Watanabe, Y 292<br />
Tanamas, S 173<br />
Tanangunan, R 1197<br />
Tandon, M 2179<br />
Tang, JX 856<br />
Tang, M 1122<br />
Tang, P 1107<br />
Tani, C 1011<br />
Taniguchi, A 968, 1053, 1611,<br />
1749<br />
Taniguchi, N 369<br />
Taniguchi, S 1709<br />
Tardella, M 1635<br />
Tarelli, E 1105<br />
Targan, S 537<br />
Targ<strong>of</strong>f, IN 1678<br />
Targonska-Stepniak, B 1742<br />
Taroumian, S 415<br />
Tarp, U 55, 1444, 1802, 1807,<br />
1809, 1841<br />
Tarrant, TK 19<br />
Tartelin, M-L 1247<br />
Tarumi, E 1115<br />
Tas, SW 1416<br />
Tascilar, K 1288<br />
Tashkin, DP 2194<br />
Tassi, S 657<br />
Tassinari, A 188, 709<br />
Taurog, JD 1448, 2185<br />
Tavares, R 778, 794<br />
Tavarez, ER 284<br />
Tavera, I 1292, 1314<br />
Tavoni, A 1884, 1916, 2036, 2201<br />
Tayar, JH 407<br />
Taylan, A 1970<br />
Taylor, F 1243, 1245<br />
Taylor, H 664<br />
Taylor, K 446, 502, 980, 1592,<br />
1602<br />
Taylor, M 1058, 1820<br />
Taylor, P 978, 1835<br />
Taylor, W 146, 1372, 1983<br />
Tchao, N 2012<br />
Teal, SA 565, 599<br />
Team, E 2282<br />
TEAR Trial Investigators 1368<br />
Teare, M 1756<br />
Tebo, AE 245<br />
Tegler, C 1677<br />
Tegzova, D 457, 1174, 1454<br />
Teh, L-S 40, 769, 795, 1200<br />
Tehrani, R 704<br />
Teitsma, C 1449, 1977<br />
Tejera, B 1741<br />
Tekarico, T 1185<br />
Tekin, L 114<br />
Tekstra, J 333, 1828<br />
Tektonidou, M 786, 1398, 1784<br />
Telarico, T 437, 1196, 2275<br />
Telles, RW 1169, 1842, 1849<br />
Templeton, J 2019<br />
ten Cate, R 219<br />
ten Dijke, P 1487<br />
ten Kate, R 261<br />
Tena, X 1741<br />
Teng, J 1836, 2173<br />
Teng, YKO 1828<br />
Tennant, A 2063<br />
Teodoro, WR 605, 887<br />
Terao, K 1115<br />
Terauchi, K 139<br />
Terkeltaub, R 147, 152, 153, 634,<br />
1494<br />
Ternant, D 988, 1945<br />
Terreri, M 228, 1339, 1343, 1676<br />
Terrier, B 906, 1249, 1646, 2010,<br />
2011, 2024, 2025, 2030, 2039,<br />
2042, 2046<br />
Terry, EL 101<br />
Teruel, M 2214<br />
Tesar, V 676<br />
Tesolin, P 324<br />
Tezcan, ME 1921<br />
Thacker, SG 2278<br />
Thakkar, V 1560<br />
Thamerl, SE 2015<br />
Thamsborg, G 134, 1953<br />
Thavaneswaran, A 1928, 1932,<br />
1956, 2273<br />
Theander, E 1885, 1896, 1899,<br />
1910<br />
Theate, I 2263<br />
Theis, KA 687, 689, 1563, 2069,<br />
2079, 2080, 2138, 2139<br />
Theriault, C 2243<br />
Therneau, TM 67, 1580, 1581,<br />
2216<br />
Theulin, A 858<br />
Thiel, M 1973<br />
Thiele, GM 2235<br />
Thiele, K 770<br />
Thiele, RG 849, 889, 1051, 1616,<br />
1617, 1620<br />
Thiemann, P 286<br />
Thienel, U 1119<br />
Thierry, S 2267<br />
Thierry-Palmer, M 252<br />
Thomas, B 253, 254, 2267<br />
Thomas, G 1446, 1986, 2184<br />
Thomas, J 1141<br />
Thomas, M 1146, 1172<br />
Thomas, O 74<br />
Thomas, R 1116, 1446<br />
Thomas, S 1256<br />
Thomas, T 176, 964<br />
Thombs, BD 1346, 1347, 1348,<br />
2247<br />
Thome, N 230<br />
Thompson, AE 419<br />
Thompson, C 91<br />
Thompson, JM 108<br />
Thompson, K 2243<br />
Thompson, L 9, 24, 466, 734<br />
Thompson, RN 661, 1763<br />
Thompson, S 243, 255, 654, 1729<br />
Thomsen, R 2040<br />
Thomson, W 264, 266, 654, 836,<br />
1075, 1394, 1593<br />
Thoors, U 2245<br />
Thorel, J-B 2261<br />
Thormann, A 1444, 1841<br />
Thorne, C 300<br />
Thorne, JC 57, 306, 313, 341, 343,<br />
344, 396, 659, 978, 1735, 1737<br />
Thornton, S 244, 1728<br />
Thorp, LE 200<br />
Thuemmler, K 1261<br />
Thurlings, R 333, 1821, 1822,<br />
1828<br />
Tian, W 618<br />
Tieng, AT 2186<br />
Tiersma, Y 1977<br />
Tiku, ML 1767<br />
Tily, H 1185, 1196<br />
Timenetsky, M 224, 481, 1437<br />
Tinazzi, I 671<br />
Tindall, EA 993<br />
Ting, MHX 445<br />
Tingström, J 1322<br />
Tiseo, P 710<br />
To, CH 467, 1206, 1667, 2159<br />
Tobon, GJ 1914, 2177<br />
Tochimoto, A 923, 1587, 1666<br />
Todd, A 1344<br />
Todesco, S 290<br />
Todoerti, M 1397<br />
Toedter, G 1786, 1804<br />
Toes, R 1015, 2114, 1780<br />
Toib, D 216, 1633<br />
Tokita, A 1749<br />
Tola, MR 1162<br />
Toledano, D 1287<br />
Tolstykh, I 683, 686, 872, 951,<br />
1385, 1557, 2098<br />
Tolusso, B 355, 744, 1098, 1239,<br />
1582<br />
Tom, BDM 664<br />
Tomasson, G 2198<br />
Tomcik, M 607, 611, 614, 616, 672<br />
Tomi, C 896<br />
Tomita, T 291, 298<br />
Tomlinson, B 1028<br />
Tommasini, A 1685, 1706<br />
Tomsic, M 55, 1802, 1807, 1896,<br />
2036<br />
Ton, E 380<br />
Tonev, D 286<br />
Tonks, L 1251<br />
Tonner, C 789, 2113<br />
Tonnini, C 2001<br />
Tony, H 383, 745, 782, 1026,<br />
1255, 1411<br />
Topolewski, K 635, 855<br />
Torbeyns, A 390<br />
Tornehave, D 847<br />
Torner, J 201, 693, 683, 686, 872,<br />
951, 2058, 2100, 2133<br />
Tornero, J 975<br />
Torok, KS 1683, 2006<br />
Torralba, KMD 46, 1429, 1432<br />
2010 Program Book 351<br />
abstract author Index
aBSTRACT author Index<br />
Torrenegra, A 1811<br />
Torrent, A 106<br />
Torrente, V 1118, 1796<br />
Torres, A 874<br />
Torrijos, A 975<br />
Tortorella, M 823<br />
Toska, K 1220<br />
Tosteson, A 992<br />
Toth, M 259, 1673, 1691, 2017<br />
Touboul, P-J 386<br />
Touby, E 909<br />
Touchais, S 29<br />
Touma, Z 772, 783, 1878<br />
Tourkina, E 622<br />
Tourkodimitris, S 800<br />
Tournadre, A 917, 1515<br />
Toussirot, E 701, 1810, 2269<br />
Towheed, TE 109<br />
Townsend, A 1321, 2282<br />
Townsend, M 1609<br />
Toyama, Y 1611<br />
Tracy, R 1148, 2260<br />
Traggiai, E 265<br />
Trainito, S 1687<br />
Tran, A 1446<br />
Tran, CL 1418<br />
Tran, T-A 1249, 1305<br />
Trapiella, L 824<br />
Travers, H 383, 414, 2169<br />
Treat to Target Taskforce 1013<br />
Trejo-Iriarte, CG 1475<br />
Trenkmann, M 35, 1518<br />
Trevisani, VFM 1458<br />
Triadafilopoulos, G 2205, 2206<br />
Triantafyllou, A 11<br />
Tricot, L 2042<br />
Triolo, G 297, 1627<br />
Triolo, PF 1798<br />
Trivedi, A 991<br />
Trollmo, C 1125, 1917<br />
Tron, F 915<br />
Trotta, F 297, 1162<br />
Troum, OM 120<br />
Trouw, LA 2114<br />
Truchetet, M 571, 1987, 1992<br />
Trudes, G 1437<br />
True, M 1747<br />
Truedsson, L 1037, 1440, 1578<br />
Trugman, JM 648<br />
Trunick, CM 574<br />
Trupin, L 627, 789, 991, 1024,<br />
1592, 1882, 2113<br />
Tsai, M 149<br />
Tsang, K 675<br />
Tsao, BP 262, 500, 730, 1182,<br />
1583, 1584, 1585, 1586, 1591,<br />
1595, 2145, 2147, 2148, 2274<br />
Tsao, H 42, 1335, 2064<br />
Tsatsaris, V 2034<br />
Tschopp, J 1426<br />
Tse, SM 225, 1408, 1681<br />
Tseng, C-E 990<br />
Tseng, C-h 729<br />
Tseung, L 1028<br />
Tshantshapanyan, L 1681<br />
Tsiaousis, G 1021<br />
Tsifetaki, N 1215<br />
Tso, A 1233<br />
Tsokos, GC 1583, 2126, 2277<br />
Tsoras, M 654<br />
Tsou, P 282, 1504, 2007<br />
Tsuboi, H 2176<br />
Tsuchida, T 1138<br />
Tsui, FW 549, 1450<br />
Tsuji, S 298<br />
Tsuji, WH 125<br />
Tsukano, M 1812<br />
Tsumiyama, K 851, 867, 1258,<br />
1264, 1272<br />
Tsumoto, C 298<br />
Tsuru, T 1115, 1138<br />
Tsuruno, K 1086<br />
Tsuzaka, K 1743<br />
Tu, X 52, 1799<br />
Tubach, F 376<br />
Tucker, L 1408, 1674, 1688, 1701<br />
Tugal-Tuktun, I 1305, 1308<br />
Tugwell, P 794<br />
Tumyan, A 880<br />
Tunca, M 666<br />
Tunceli, O 1542<br />
Tuncer, N 1208<br />
Tung, KSK 1448<br />
Turesson, C 774, 1020<br />
Turi, GK 1311<br />
Turk, DC 2246<br />
Turkiewicz, A 761<br />
Turkish Takayasu Study Group<br />
1291, 1313<br />
Turnbull, EM 214, 731<br />
Turner, M 1606<br />
Turner-Stokes, T 740<br />
Turrin, CO 281<br />
Twardowsky, AO 539<br />
Twilt, M 219<br />
Tymms, K 320, 584<br />
Tyndall, A 2196<br />
Tyrrell, P 2019, 2107<br />
Tyson, S 2063<br />
Tzioufas, A 1895, 1896, 1910,<br />
1912, 2036, 2175<br />
U<br />
Ubeda, C 1390<br />
Uchimura, T 237<br />
Uda, H 373<br />
Uechi, E 1783<br />
Ueda, A 139<br />
Ueda, Y 1042<br />
Ueki, Y 1812<br />
Ueland, T 479<br />
Uesato, R 329<br />
Uetani, M 1371<br />
Ugurlu, S 1288, 1697<br />
Uherek, C 1125<br />
Uhlig, T 377, 1603, 1750, 1774<br />
Uhm, W-S 1941<br />
Uhrova, J 1649<br />
Ukichi, T 921<br />
Ulgiati, D 730<br />
Ullman, S 1682<br />
Ullrich, KR 2013<br />
Ullrich, S 679<br />
Umeda, N 292, 352<br />
Umehara, H 1898<br />
Umoh, E 167<br />
Umscheid, T 1420<br />
Unitan, R 1543<br />
Upchurch, K 162<br />
Urata, Y 329<br />
Urban, A 220<br />
Urbonaviciute, V 857<br />
Uribe, A 1673, 1674, 1691, 2017<br />
Urowitz, MB 13, 445, 448, 450,<br />
455, 476, 731, 772, 1165, 1850,<br />
1868, 1869, 1874, 1877, 1878,<br />
2240, 2243<br />
Urquhart, D 1383<br />
Urstad Jensen, K 1846<br />
Ursum, J 85<br />
Urzainqui-Mayayo, A 1509<br />
Usnayo, MJG 356<br />
Ustianowski, A 421<br />
Usui, T 1377<br />
Utset, TO 457, 464, 496, 1164,<br />
1612, 1875, 1882<br />
Utsunomiya, M 1641<br />
Utz, PJ 428<br />
Uziel, Y 1704<br />
V<br />
Vacher-Lavenu, MC 1991<br />
Vaddi, K 2172<br />
Vahadat, S 546<br />
Vahldiek, J 2181<br />
Vail, A 588<br />
Vakil, E 1159<br />
Vakkalanka, S 279<br />
Valdes, A 823, 841, 1980<br />
Valdimarsson, H 1951<br />
Valduga, CJ 284<br />
Valente, RM 2173<br />
Valentini, G 572, 1627<br />
Valeriano-Marcet, J 44<br />
Valerio, CJ 727<br />
Valle, RR 517<br />
Vallejo, M 96<br />
Valle-Oñate, R 552<br />
Vallongo, C 1439<br />
Valor, L 739<br />
Valrie, CR 1406<br />
van Baarsen, LGM 271<br />
van Beuningen, HM 1501<br />
van Bon, L 844, 1210, 2002<br />
van Booma-Frankfort, C 380<br />
van de Laar, MAFJ 314, 662, 1019,<br />
1334, 1771, 1833, 2207, 2281<br />
van de Loo, FAJ 713, 1501, 1532,<br />
1535, 1622, 1733, 2230<br />
van de Sande, G 32<br />
van de Sande, M 32, 1069, 1449,<br />
1604<br />
van de Stadt, LA 1091<br />
van de Stadt, RJ 1091<br />
van den Bemt, BJF 1826<br />
van den Berg, W 275, 283, 371,<br />
713, 844, 845, 1210, 1472, 1495,<br />
1501, 1532, 1535, 1622, 1719,<br />
1730, 1733, 2002, 2230<br />
van den Brand, BT 713, 1535<br />
van den Broek, M 328, 334, 663<br />
van den Ende, CHM 2283<br />
Van den Eynde, B 2263<br />
van den Hoogen, F 1826, 2196<br />
van den Oever, IAM 643<br />
van Denderen, JC 1933<br />
van der Burg, M 753<br />
van der Giesen, FJ 2283<br />
Van der Goes, MC 973<br />
Van der Heijde, DM 142, 295, 303,<br />
518, 559, 1013, 1077, 1113, 1114,<br />
1368, 1629, 1774, 1806, 1922,<br />
1927, 1943, 1948, 1949, 1985,<br />
2270<br />
van der Helm, AHM 1782<br />
van der Helm-van Mil, AHM 660,<br />
1744, 1780<br />
van der Horst-Bruinsma, IE 1933<br />
Van der Kamp, S 1947<br />
van der Kraan, PM 1501, 1532<br />
van der Laken, CJ 1613<br />
van der Linden, MPM 1744, 1780<br />
van der Lubbe, PAHM 334<br />
van der Maas, A 1826<br />
van der Merwe, J 1904<br />
van der Neut, R 1711<br />
van der PouwKraan, TCTM 1084<br />
van der Vaart, R 1334<br />
van der Westhuizen, N 1060<br />
van der Woude, D 2114<br />
van der Wurff-Jacobs, KMG 278,<br />
352<br />
2010 Program Book
636<br />
van Dongen, CJJ 90<br />
Van Doornum, S 584, 1052, 1772<br />
van Duijnhoven, W 2265<br />
van Eck-Smit, B 1822<br />
van Eenennaam, H 1534<br />
van Eyk, J 2167<br />
van Haandel, L 253<br />
van Hamburg, JP 38, 1259, 1274<br />
van Heerde, W 1210, 2002<br />
van Helden-Meeuwsen, CG 1904<br />
van Hoeven, L 2180<br />
van Hulst, L 59<br />
van Kampen, AH 1069, 1604<br />
van Krugten, MV 334<br />
van Kuijk, AWR 1095<br />
van Laar, J 2214<br />
van Leeuwen, H 38, 1274<br />
van Lent, P 283, 845, 2002<br />
van Lent, PL 1472, 1495<br />
van Maanen, M 1529, 1711<br />
van Paassen, P 676<br />
van Riel, P 55, 59, 314, 371, 641,<br />
662, 844, 1210, 1599, 1771, 1802,<br />
1807, 1826, 1833, 2207, 2214<br />
van Roermund, PM 1380<br />
van Roon, JAG 278, 333, 636, 973,<br />
1900, 1903<br />
van Rossum, MAJ 209, 219, 1705<br />
van Ryn, J 604<br />
van Schaardenburg, D 85, 723,<br />
1033, 1091<br />
van Schaik, BD 1069, 1604<br />
van Schouwenburg, P 1445<br />
van Sijl, AM 90, 643, 2211<br />
van Suijlekom-Smit, LWA 219,<br />
1872<br />
van Tuyl, LHD 723, 961, 2108<br />
van Vollenhoven, R 55, 65, 378,<br />
391, 410, 411, 418, 445, 451, 452,<br />
454, 1172, 1392, 1393, 1454, 1802,<br />
1805, 1806, 1807, 1829, 1832,<br />
2243, 2265<br />
van Zeben, J 1775, 1776<br />
van Zoest, KPM 1416<br />
Van’t Slot, R 1599, 2214<br />
Vanags, D 441<br />
Vandam, W 2251, 2252<br />
Vandenbroeck, K 896<br />
Vander Cruyssen, B 340<br />
Vanderschueren, G 311<br />
VanMater, H 1699<br />
Vanness, DJ 2266<br />
Vanoirbeek, J 1720<br />
Vanthuyne, M 824<br />
Varache, S 2261<br />
Varanasi, KVS 279<br />
Varga, J 560, 566, 601, 617, 2214<br />
Vargas, A 96, 808<br />
Vargas, F 1811<br />
Vargas, G 1360<br />
Vargas Lebrón, C 1944<br />
Vargas-Alarcon, G 96<br />
Vargas-Guerrero, A 1614<br />
Vargas-Worackova, F 459<br />
Varisco, V 532<br />
Varley, C 758<br />
Varnier, GC 210, 232<br />
Varughese, D 1549<br />
Vasaitis, L 1885, 1899<br />
Vasconcelos, C 1398, 1578<br />
Vasconcelos, J 89<br />
Vasconcelos, MM 1458<br />
Vastesaeger, N 1829, 1948, 2265<br />
Vasudevan, A 445, 1080, 2243<br />
Vaughn, FL 823<br />
Vaz, B 415<br />
Vazquez-Mellado, J 157, 525<br />
Vazquez-Rodriguez, TR 1301<br />
Veale, D 16, 360, 871, 1032, 1105,<br />
1391, 1508, 1510, 1533, 1625,<br />
1631, 1947, 2065, 2145<br />
Veenbergen, SS 1501<br />
Veenh<strong>of</strong>, C 2051<br />
Veeraraghavan, S 279<br />
Vega, R 758<br />
Vega-Ostertag, M 3<br />
Vela-Ojeda, J 1150<br />
Velasco, F 1357<br />
Velasco, J 1446<br />
Velosa, APP 605, 887<br />
Venables, PJ 1717<br />
Vencovsky, J 926, 1174, 638, 1806<br />
Venkatraman, MM 1106<br />
Venugopalan, A 66, 1640, 1642<br />
Vera Kellet, C 1661<br />
Vera-Lastra, O 1150<br />
Verghese, J 2095<br />
Vergnaud, P 1466<br />
Verheij, RA 1029, 2211<br />
Verhoef, J 1338<br />
Vermeer, M 314, 662, 1771<br />
Vermeij, E 1622, 1733<br />
Vermeulen, EM 2051<br />
Vernon, E 378, 411, 1819, 1820,<br />
2262<br />
Verrouil, E 2094<br />
Versari, A 1290<br />
Verschueren, P 311, 2170<br />
Versnel, MA 1904<br />
Verstappen, SM 766, 779, 796,<br />
1067, 1110<br />
Vervoordeldonk, M 1353, 1529,<br />
1711<br />
Verweij, CL 1084<br />
Vessey, A 1940<br />
Vestweber, D 2234<br />
Vettori, S 572<br />
Viale, A 1390<br />
Viana, V 481, 1437<br />
Viappiani, S 1477<br />
Viatte, S 1600, 2215<br />
Vibert, J-F 533<br />
Vicente, EF 1229<br />
Victor, T 598<br />
Vidal, S 1801<br />
Vidaud, M 2025<br />
Vieira, VM 64<br />
Vielleux, M 1170<br />
Viergever, MA 121, 124, 952<br />
Vignoli, M 261<br />
Vignon, EP 952<br />
Vigus, A 245<br />
Vihervaara, V 759<br />
Vijayvergiya, R 2086<br />
Vijenthira, A 1408<br />
Vikerfors, A 7<br />
Vila, LM 1591, 1594<br />
Villa, I 1296, 1650<br />
Villa-Blanco, I 1871<br />
Villaggio, B 1798<br />
Villalba, JM 1357<br />
Villeneuve, E 1090, 1254<br />
Vina, ER 1875<br />
Vincent, A 101, 104, 108<br />
Vincent, C 1653<br />
Vincent, G 118<br />
Vincken, KL 121<br />
Vinterberg, H 133<br />
Virayavanich, W 135<br />
Virta, L 80<br />
Visconti, C 2220<br />
Visconti, RP 622<br />
Visman, I 90, 643, 1933<br />
Visser, H 1785, 2207<br />
Visser, K 1396<br />
Vissink, A 1889, 1892, 1905<br />
Vista, EG 9, 466, 1197<br />
Visvanathan, S 1127<br />
Viswanadha, S 279<br />
Viswanathan, H 971, 1540, 1552<br />
Vital, EJ 118<br />
Vital, EM 1126<br />
Vitale, A 1706<br />
Vitali, C 1896, 1910<br />
Vitalle, MS 1343<br />
Vitolo, B 623<br />
Vittadello, F 1439, 1682, 2033<br />
Vittecoq, O 1087, 1827, 1890,<br />
1910<br />
Vivier, E 1664<br />
Vivino, FB 1898, 1907<br />
Vlachoyiannopoulos, P 621<br />
Vlad, SC 2213<br />
Vlaeyen, J 520<br />
Vlahos, B 1927<br />
Vlamakis, VE 1246<br />
Vliet Vlieland, TPM 582, 1338,<br />
1755, 2051, 2283, 2284<br />
Voermans, C 1822<br />
Vogel-Claussen, J 2122<br />
Vogl, T 845, 1472, 1495<br />
Vogler, LB 255, 256, 790<br />
Voitzsch, A 1025<br />
Vojinovic, J 217<br />
Volgas, DA 1573<br />
Volin, MV 17, 23, 270, 714, 1506<br />
Voll, R 857, 2234<br />
Vollenhoven, RV 448, 476, 891,<br />
1877, 2240<br />
Vollenweider, C 1896, 1898<br />
Voloshyna, I 1072<br />
von der Recke, A 668<br />
Von Feldt, JM 456<br />
von Hinueber, U 770<br />
Von Muhlen, CA 383, 1639<br />
Von Scheven, E 1701, 1702, 1677<br />
Vonk, M 824, 829, 1210, 2002,<br />
2004, 2214<br />
Vonk Noordegraaf, A 1623<br />
Vonkeman, HE 1019, 1833<br />
Vos, K 333, 1821, 1828<br />
Voskuyl, A 332, 643, 1084, 1613,<br />
1623, 1859, 2214<br />
Vosslamber, S 1084<br />
Vosters, JL 1413, 2178<br />
Voulgarelis, M 1912, 2036<br />
Vounotrypidis, P 2035<br />
Vreijling, J 1529<br />
Vreugdenhil, SA 380<br />
Vugler, A 1244<br />
Vukatana, G 1627<br />
Vukelic, M 427, 866<br />
Vukelic, S 1990<br />
Vyse, TJ 500, 1583, 1584, 1585,<br />
1586, 1591, 1594, 1595, 2145,<br />
2147, 2148<br />
W<br />
Wachsmann, D 858, 1998<br />
Wactawski-Wende, J 1062<br />
Wada, T 568<br />
Wade, M 1201<br />
Wade, SW 1540, 1552<br />
Wadell, G 1847, 2115<br />
Wadle, A 1973<br />
Wagegg, M 630<br />
Wages, J 1030<br />
Wagman, RB 2161<br />
Wagner, B 950<br />
Wagner, C 1127<br />
Wagner, L 2280<br />
2010 Program Book 353<br />
abstract author Index
aBSTRACT author Index<br />
354<br />
Wagner, M 654<br />
Wagner-Weiner, L 464, 1673,<br />
1691, 1702, 2017, 1677<br />
Wahezi, DM 1673, 1691, 1692,<br />
2017<br />
Wahl, D 1<br />
Wahren-Herlenius, M 832, 1322,<br />
1579, 1885, 1917<br />
Waimann, C 50, 941, 1047, 1865<br />
Wainmann, C 324<br />
Waite, P 213<br />
Waiter, GD 649<br />
Wakabayashi, K 26, 1773<br />
Wakefield, I 1243, 1245<br />
Wakefield, RJ 777, 1629, 1637,<br />
1654<br />
Wakeland, EK 2146<br />
Wakhlu, A 1954<br />
Wakitani, S 981<br />
Waldman, T 763<br />
Walitt, B 71, 110, 112, 117, 651,<br />
1062<br />
Walker, D 1064, 1186, 2082<br />
Walker, R 1568<br />
Walker, S 597, 1201, 1222<br />
Walker-Bone, K 966, 1645<br />
Wallace, CA 243, 255, 1677, 1678,<br />
1702<br />
Wallace, D 234, 445, 448, 451,<br />
453, 454, 457, 471, 476, 1172,<br />
1452, 1454, 1457, 1877, 2240,<br />
2243<br />
Wallace, E 694<br />
Wallin, H 1392, 1393<br />
Wallston, KA 115, 802<br />
Wallwiener, D 1145<br />
Walsh, D 676<br />
Walsh, J 546, 967<br />
Walsh, M 676<br />
Walsh, NC 30, 716<br />
Walter, M 2066<br />
Walther, M 138<br />
Wan, X 980<br />
Wandinger, K-P 1174<br />
Wang, A 971<br />
Wang, BC 1117<br />
Wang, C 95<br />
Wang, D 423, 918, 1143, 1182,<br />
1686<br />
Wang, F 94, 105, 113<br />
Wang, H 618<br />
Wang, J 1119, 152, 153, 420, 442,<br />
509, 1107, 1266, 1268, 1499, 2129,<br />
2189<br />
Wang, J-CE 849<br />
Wang, K 836, 1464, 2217<br />
Wang, L 274, 694<br />
Wang, M 826<br />
Wang, Q 473, 2229<br />
2010 Program Book<br />
Wang, S 331, 1134<br />
Wang, T 907, 1386<br />
Wang, W 436<br />
Wang, X 1068, 1107, 1119<br />
Wang, Y 97, 98, 183, 192, 648,<br />
741, 806, 813, 814, 815, 1100,<br />
1214, 1352, 1383, 1948, 2032,<br />
2048<br />
Ward, M 522, 642, 786, 1039,<br />
1784, 1982, 2185<br />
Ward, RJ 122<br />
Ware, M 107<br />
Warfvinge, G 1899<br />
Warner, M 957<br />
Warren, RB 833<br />
Warren, ST 250<br />
Warriner, A 1006, 1543, 1561<br />
Warrington, KJ 774, 1304, 2198<br />
Wartenberg-Demand, A 1125<br />
Warzocha, U 2034<br />
Wasko, MC 385, 345, 386, 642,<br />
1039, 1442<br />
Wason, S 147<br />
Watanabe, N 1375<br />
Watanabe, R 139, 1300<br />
Watanabe, T 139<br />
Watier, H 988<br />
Watkins, M 2251, 2252<br />
Watson, K 421<br />
Watson, KD 374, 1323<br />
Watson, ME 1566<br />
Watt, S 565<br />
Wattiaux, M-J 2269<br />
Webb, C 2274<br />
Webb, R 1590<br />
Weber, DA 306, 343<br />
Weber, E 853, 859, 861, 1723<br />
Wechsler, B 478, 1249, 1658,<br />
1660<br />
Weckerle, CE 1164<br />
Weel, A 317, 1775, 1776, 2180<br />
Wegner, N 1717<br />
Wei, C 733, 1085<br />
Wei, J 601, 617<br />
Wei, N 1382<br />
Wei, X-n 367<br />
Weide, T 2237<br />
Weidensaul, DN 331<br />
Weijers, K 1613<br />
Weinberger, M 1575<br />
Weinblatt, M 41, 308, 390, 945,<br />
946, 1050, 1102, 1119, 1335, 1610,<br />
1753, 1778, 1782, 1805, 2064<br />
Weingarten, TN 108<br />
Weinstein, A 869, 1457, 2090<br />
Weinstein, J 742<br />
Weinstein, SP 152, 153<br />
Weisbarth-Riedel, E 1435<br />
Weisman, M 77, 187, 305, 471,<br />
522, 537, 658, 1094, 1197, 1768,<br />
1982, 2185<br />
Weiss, A 609, 665, 1961<br />
Weiss, H 2222<br />
Weiss, JE 234<br />
Weiss, P 233, 1703<br />
Weissmann, G 1390<br />
Weitz, M 980<br />
Welin Henriksson, EMB 1322<br />
Wellborne, F 1146<br />
Wellcome Trust Case-Control<br />
Consortium 2 1355<br />
Wells, A 727, 1120, 1212<br />
Wells, GA 723, 794, 1758, 2108<br />
Welsh, P 483<br />
Welsing, PMJ 124, 380, 388, 952,<br />
1759<br />
Wendholt, D 1478, 1719<br />
Wendling, D 2269, 904, 1752,<br />
1945<br />
Wenink, M 844, 1210<br />
Wenting, MJG 1900<br />
Wermuth, PJ 1993<br />
Wernitzsch, H 886<br />
Werth, V 920, 1198, 1213, 1521<br />
Werther, W 1031<br />
Wesseling, J 184<br />
Wessels, J 2021, 2234<br />
West, B 273<br />
West, SG 702, 2013<br />
Westedt, ML 663<br />
Westerman, M 1804<br />
Westh<strong>of</strong>f, G 1736<br />
Westhovens, R 311, 340, 390,<br />
520, 1120, 1829, 1836, 1837, 2170,<br />
2214<br />
Westlund, KN 1536<br />
Westman, K 676, 2014<br />
Westphal, L 44<br />
Westra, J 1195<br />
Wettstein, D 493<br />
Weyand, CM 351, 1079, 2127<br />
Weyer, M-G 911<br />
Whalen, E 813<br />
Whang, M-H 2158<br />
Wheeler, M 841<br />
Wheless, L 475<br />
Whipple, MO 104<br />
White, AJ 216, 1633, 1673, 2017<br />
White, D 683, 693, 2058, 2067,<br />
2133<br />
White, J 1540, 1552<br />
White, ME 1408<br />
White, P 689, 1008, 1678, 2080<br />
Whitfield, M 573, 675<br />
Whitlow, HJ 694<br />
Whitney-Mahoney, K 225<br />
Wichuk, S 1451<br />
Wicks, I 584, 1001, 1009, 1052,<br />
1772<br />
Widdifield, J 57, 313, 341<br />
Widmer, A 895, 1425, 1435<br />
Wiedeman, A 494, 506<br />
Wiegant, K 1380<br />
Wieman, M 944<br />
Wiendl, H 1255<br />
Wiener, HW 828<br />
Wierenga, W 269<br />
Wierk, A 1704<br />
Wigler, I 697<br />
Wigley, FM 560, 566, 587, 589,<br />
596, 1201, 1222, 1348, 1989, 2192<br />
Wijbrandts, C 32, 1507, 1822<br />
Wilder, T 1469, 1470<br />
Wildi, LM 938<br />
Wildman, H 1990, 2193<br />
Wildt, M 1623<br />
Wiley, G 1586, 2144, 2146<br />
Wilkie, R 2079, 2139<br />
Willemze, A 2114<br />
Williams, A 500, 827, 1591, 2145,<br />
2148<br />
Williams, DA 94, 650, 800<br />
Williams, M 1122<br />
Williams, S 321, 1526<br />
Williams, WV 2172<br />
Willis, CR 278<br />
Wilson, D 931<br />
Wilson, E 1071<br />
Wilson, G 1756<br />
Wilson, IB 1404<br />
Wilson, J 934, 1608, 2149<br />
Wilson, M 914, 1831<br />
Wilson, N 620, 1399, 2106<br />
Wilson, P 734, 1067<br />
Wimmer, M 200, 2099<br />
Windhorst, AD 1613<br />
Winfield, JB 100, 814<br />
Wing, H 627<br />
Winiarska, M 994<br />
Winkelmayer, W 2104<br />
Winthrop, K 404, 721, 722, 758,<br />
1643, 2103<br />
Wipff, J 580, 1991, 2226<br />
Wipfler-Freissmuth, E 2222<br />
Wise, B 1385, 2212<br />
Wise, C 255, 654, 2219<br />
Wise, R 596, 1201, 1989<br />
Wise, SC 289<br />
Wisniewski, SR 2052<br />
Wither, JE 424, 425, 429, 1874,<br />
2190<br />
Witko-Sarsat, V 834<br />
Witt, MN 1781<br />
Witte, S 392, 1123
Witte, T 824, 1578, 1579, 2214<br />
Wittkowski, H 2002<br />
Wluka, A 173, 183, 1383<br />
Woby, S 646<br />
W<strong>of</strong>sy, D 1453, 2085<br />
Wohlreich, M 105, 113<br />
Wolbink, G 1091, 1445, 1825,<br />
1826, 1828<br />
Wold, AE 1248<br />
Wolf, D 718<br />
Wolfe, F 89, 100, 110, 111, 112,<br />
117, 331, 346, 651, 810, 1132<br />
Wolff, C 1089<br />
Wolff, R 397, 1099<br />
Wolfson, M 1555<br />
Wollenhaupt, J 1788, 1837, 1919<br />
Wollman, J 697<br />
Wollmer, P 1902<br />
Wolvers-Tettero, I 2004<br />
Wong, A 249, 747<br />
Wong, B 225, 273, 288<br />
Wong, JB 1795<br />
Wong, LG 1870<br />
Wong, M 428, 497<br />
Wong, T 1772<br />
Wong, WS 1233<br />
Woo, J 1060<br />
Woo, JMP 262, 998<br />
Woo, J-H 359<br />
Woo, P 1434<br />
Wood, GM 1516<br />
Wood, J 717<br />
Wood, LS 823<br />
Wood, PB 102<br />
Wood, S 1129, 2171<br />
Wood, T 573<br />
Woods, JM 17, 39, 1131<br />
Woodward, AL 1673, 1691, 2017<br />
Woodward, JG 864<br />
Woodworth, T 1474, 1766<br />
Wooley, PH 1729<br />
Woolf, C 1385, 1557, 2098<br />
Wootton, J 234<br />
Worthington, J 264, 266, 824,<br />
829, 833, 1075, 1593, 1600, 1756,<br />
2214, 2215<br />
Wouters, C 1434, 1684<br />
Wouters, D 1822<br />
Wright, EA 2091, 2137<br />
Wright, J 2137<br />
Wright, N 1062<br />
Wright, S 1434<br />
Wright, T 560, 566, 1080, 1690<br />
Wright, V 1681<br />
Wrigley, T 192<br />
Wu, E 1699<br />
Wu, FQ 1680, 1872<br />
Wu, HJ 1139<br />
Wu, J 149<br />
Wu, L 1678<br />
Wu, M 8, 602, 603, 612<br />
Wu, P 1168<br />
Wu, Q 1135, 1260, 1412, 2189<br />
Wu, R 710, 1121<br />
Wu, W 1441<br />
Wu, X 507, 831, 838, 1598, 1804<br />
Wu, Z 1598<br />
Wulffraat, NM 219<br />
Wunrau, C 1478<br />
Wuttge, D 1210<br />
Wysocka, M 1198<br />
Xavier, R 1434<br />
Xian, H 1395<br />
Xiang, S 944<br />
Xiao, H 2048<br />
Xie, F 239, 404, 721, 722, 1643,<br />
2084, 2103<br />
Xie, H 826<br />
Xie, J 1772<br />
Xie, L 86, 426<br />
Xie, S 1412<br />
Xing, L 712, 1492, 1710<br />
Xu, D 28<br />
Xu, L 1464, 1564<br />
Xu, M 564, 592<br />
Xu, S 443, 1114, 1190, 1996<br />
Xu, W 386, 1097, 1114, 1943,<br />
2264<br />
Xu, Y 742<br />
Xue, W 1107<br />
X<br />
Yadav, B 1446<br />
Yadav, MK 2086<br />
Yagüe, J 1280<br />
Yajima, M 1708<br />
Yajima, N 1773<br />
Yamada, A 921<br />
Yamada, H 365<br />
Yamada, M 1672<br />
Yamada, R 1577<br />
Yamada, S 1839<br />
Yamada, T 1053<br />
Yamaguchi, K-i 1783<br />
Yamaguchi, Y 670<br />
Yamaji, K 1731<br />
Yamamoto, A 1511<br />
Yamamoto, K 1577, 1814, 292,<br />
352, 1815<br />
Yamamoto, M 280, 1641<br />
Yamamoto, N 1708<br />
Yamamoto, T 619, 1467<br />
Y<br />
Yamamura, T 896, 2232<br />
Yamanaka, H 399, 447, 746, 897,<br />
916, 923, 968, 1053, 1184, 1587,<br />
1611, 1666, 1749, 1793, 1812,<br />
1814, 1815, 1823, 1844<br />
Yamasaki, S 364, 1371, 1632<br />
Yamashita, H 1042, 1619<br />
Yamauchi, K 2020<br />
Yamazaki, H 1709<br />
Yamazaki, Y 1672<br />
Yan, C 330<br />
Yan, J 1107<br />
Yan, K 438, 2191<br />
Yan, X 1978<br />
Yanagida, T 1531<br />
Yanagimachi, M 921<br />
Yanes, J 415<br />
Yang, B 260, 634, 1494, 2217<br />
Yang, H 634, 1038<br />
Yang, L 742, 1680<br />
Yang, P 1135, 1260, 1412, 2189<br />
Yang, S 299, 304, 1117<br />
Yang, X 274, 1107<br />
Yang, Y-C 971, 982<br />
Yang, Z 1499<br />
Yano, K 1611, 1749<br />
Yao, C 1979<br />
Yao, Q 1656<br />
Yao, W 965<br />
Yao, Z 1724<br />
Yarboro, C 1161<br />
Yarlagadda, S 1253<br />
Yasuda, S 2, 5, 10, 1909, 2254<br />
Yasukawa, M 1265, 2016<br />
Yau, I 2019<br />
Yavuz, S 1133, 1208, 1803<br />
Yazbek, M 356<br />
Yazdany, J 627, 789, 991, 2113<br />
Yazdanyar, A 1039<br />
Yazici, A 822<br />
Yazici, H 84, 1288, 1312, 1697<br />
Yazici, Y 985, 990, 1298, 1857,<br />
1284, 1303, 1390, 1559, 1808,<br />
1863<br />
Ye, Z 1536<br />
Yeleswaram, S 2172<br />
Yelin, EH 60, 484, 627, 789, 991,<br />
1024, 1592, 2090, 2091, 2113<br />
Yelios<strong>of</strong>, O 1901<br />
Yentes, JM 169<br />
Yeo, E 13<br />
Yeremenko, N 629, 1449<br />
Yet Lin, L 444<br />
Yeung, RSM 249, 267<br />
Yew, M 2122<br />
Yildirim, S 1279<br />
Yildirim-Toruner, C 1191<br />
Yildiz, Y 1970<br />
Yilmaz, H 1282<br />
Yilmaz, N 1208<br />
Yilmaz, V 822, 2200<br />
Yim, CW 477<br />
Yin, F 1107<br />
Yin, H 507<br />
Yin, J 1119<br />
Yin, M 129<br />
Ying, J 1099, 1688<br />
Ying, KY 477<br />
Yip, G 1028<br />
Yip, PSF 773<br />
Yiu, KH 582<br />
Yokoe, I 1797<br />
Yokogawa, N 1907<br />
Yokota, S 237<br />
Yoo, B 387, 876, 2028<br />
Yoo, D-H 359, 1941<br />
Yoo, WH 387, 1209<br />
Yood, RA 156, 157, 166<br />
Yoon, JY 1813<br />
York, M 1210, 1624<br />
Yoshida, K 348, 511, 921, 1258,<br />
1641<br />
Yoshida, Y 1042<br />
Yoshikawa, H 291, 298<br />
Yoshimi, R 139<br />
Yoshimura, N 1464<br />
Yoshinari, NH 605, 887, 1644<br />
Yoshinari, T 1814, 1815<br />
You, X 827<br />
Youinou, P 737, 1914, 2177, 2261<br />
Young, JS 70<br />
Young, NA 1374<br />
Youssef, P 584<br />
Yow, E 1677<br />
Ytterberg, SR 15, 680, 934, 1304,<br />
2012, 2068, 2198<br />
Yu, C-M 1028<br />
Yu, C-Y 1400, 1583, 1595<br />
Yu, D 621, 862<br />
Yu, J 1107, 1540, 1552<br />
Yu, KL 467, 1667, 2159<br />
Yu, M 2127<br />
Yu, X 1266<br />
Yu, Y 1107<br />
Yuan, F 423<br />
Yücel, AE 145, 1423<br />
Yudoh, K 631, 652<br />
Yue, D 1717<br />
Yukawa, N 1377<br />
Yuksel, A 1970<br />
Yuksel, F 544, 666, 1283<br />
Yurdakul, S 1279, 1288, 1697<br />
Yusuf, E 179<br />
Yusuf, I 741<br />
2010 Program Book 355<br />
abstract author Index
aBSTRACT author Index<br />
356<br />
Zablocki, R 94, 302, 660<br />
Zacharias, LA 1606<br />
Zack, DJ 398<br />
Zaenker, M 1059<br />
Zahr, N 2238<br />
Zaiss, MM 639<br />
Zakout, S 1655<br />
Zamani, O 1172, 1454<br />
Zamanian, R 1157, 1223<br />
Zamboulis, C 11<br />
Zampogna, G 578, 1236<br />
Zanchetta, JR 2161<br />
Zanetakis, EI 420<br />
Zang, Y 608, 852<br />
Zannin, ME 1675<br />
Zanotti, B 17<br />
Zarnitsky, C 1890, 1910<br />
Zarro, VJ 885<br />
Zavada, J 1174<br />
Zavadil, J 2231<br />
Zayed, N 1489<br />
Zeboulon-Ktorza, N 527, 533<br />
Zeft, AS 209, 245, 250, 255, 256,<br />
1673, 1690, 1691, 2017<br />
Zeidel, ML 2277<br />
Zeidler, H 665<br />
Zelko, F 1689<br />
Zemel, BS 206<br />
Zemel, LS 234, 1434, 1678<br />
Zeng, L 1965<br />
Zenone, T 2042<br />
Zeringue, AL 62, 1395<br />
Zerr, P 607, 611, 614, 616, 672<br />
Zetterberg, H 103<br />
Zhai, G 711<br />
Zhang, B 367, 683, 685, 686, 723,<br />
1564, 2108<br />
Zhang, C 273<br />
Zhang, H 918, 1143, 2219<br />
Zhang, J 273, 621, 622, 1251,<br />
1526<br />
Zhang, L 456, 1536, 1554, 2047,<br />
2049, 2056<br />
Zhang, M 417, 1141<br />
Zhang, N 1256<br />
Zhang, P 1100<br />
Zhang, Q 507<br />
Zhang, R 688, 1513<br />
Zhang, S 175<br />
Zhang, W 199, 1536<br />
Zhang, X 1317, 1368<br />
Zhang, Y 197, 201, 684, 685,<br />
1362, 1366, 1564, 1680, 2067,<br />
2098, 2212, 2213, 1373, 1464,<br />
1978, 2058, 2199<br />
Zhang, Z 144, 618, 2126<br />
Zhao, H 274, 1107, 2056<br />
Z<br />
2010 Program Book<br />
Zhao, J 1583, 1584, 1595<br />
Zhao, M 507<br />
Zhao, SZ 398<br />
Zhao, Y 618, 1598, 1898, 1978<br />
Zheng, D-h 367<br />
Zheng, SG 442, 1266, 1268, 1499,<br />
2129<br />
Zhong, ZJ 451, 452, 457, 1172,<br />
1454, 1456, 1457, 1848<br />
Zhou, H 1818<br />
Zhou, L 1656<br />
Zhou, X 442, 1268, 1817, 2129<br />
Zhou, Y 274<br />
Zhou, Z 274<br />
Zhu, B 1598<br />
Zhu, F 1969<br />
Zhu, JW 609<br />
Zhu, J-F 493<br />
Zhu, L 367, 1598<br />
Zhu, X 1530<br />
Zhu, Y 720, 879, 1363, 1547,<br />
1564, 2067, 2154, 2199<br />
Zhu, Z 289<br />
Ziakas, PD 1912<br />
Zibit, M 1335<br />
Zidovetzki, R 500<br />
Ziegler, G 976<br />
Ziegler, J 1594<br />
Ziglar, L 956<br />
Zignego, AL 2036, 2201<br />
Zilberstein, M 378, 411<br />
Zimmermann, B 1420, 1722<br />
Zink, A 227,770, 1111, 1112, 1736<br />
Zinkernagel, M 1446<br />
Ziouzina, O 1932<br />
Zisman, D 550, 783, 1238<br />
Zlateva, G 813<br />
Zochling, J 584<br />
Zoma, A 445, 448, 476, 1877,<br />
2240<br />
Zou, H 442, 1266, 1499, 1530<br />
Zou, Q 1167<br />
Zou, Y-r 426<br />
Zrioual, S 354, 1515<br />
Zuily, S 1<br />
Zulian, F 1675, 1682, 1687, 1435,<br />
1439, 1685, 1706, 2033<br />
Zummer, M 1850<br />
Zuniga, R 1035<br />
Zuniga-Montes, LR 1044<br />
Zurakowski, D 229<br />
Zwerina, J 629, 672, 2234<br />
Zwerner, J 1213<br />
Zwillich, SH 1129, 2171<br />
Zwir, L 228
A<br />
α-galactosylceramide 505<br />
A2A knock out mice 1471<br />
abatacept 240, 375, 390, 400, 416, 1120, 1247,<br />
1407, 1505, 1758, 1794, 1798, 1809, 1816,<br />
1817, 1834, 1836, 1837, 1843, 1919, 1961, 2173<br />
absenteeism 1882<br />
academic detailing 984<br />
accelerometer 1319, 2096<br />
access to care 776, 789, 986, 1007, 1538, 1553,<br />
2077, 2113, 2282<br />
accuracy 947<br />
ACE-inhibitors 958<br />
acid-sensing ion channel 1523<br />
ACPA 2118<br />
acquired resistance to activated protein C 1<br />
ACR 1805, 1806, 1832, 1881<br />
ACR 1987 criteria 1770<br />
acro-osteolysis 728<br />
actin cytoskeleton 1502<br />
active diffuse cutaneous disease 2192<br />
active immunotherapy 2236<br />
active vitamin D 973<br />
activities <strong>of</strong> daily living (ADL) 172, 2063, 2068<br />
activity difficulties 2248<br />
activity monitor 93, 2061<br />
activity score 212, 225, 232, 295, 308, 317,<br />
343, 508, 524, 525, 638, 905, 1040, 1632, 1752,<br />
1758, 1792, 2017, 2124<br />
acupuncture 941<br />
acute coronary syndrome 1054<br />
acute-phase reactants 35, 1663<br />
acute-phase serum amyloid A (A-SAA) 49<br />
acylated ghrelin 1282<br />
adalimumab 123, 127, 216, 518, 559, 719,<br />
1101, 1102, 1105, 1108, 1113, 1436, 1445,<br />
1631, 1743, 1791, 1822, 1930, 1933, 1934,<br />
1935, 1938, 1949, 1960<br />
adaptive immunity 747<br />
adenosine 1522<br />
adenosine A1 receptor 1469<br />
adenosine receptors 956, 1469, 1470, 1471<br />
ADHD 449<br />
adherence 970, 1047, 1335, 1552, 1865<br />
adhesion molecules 492, 602, 860, 1261, 1391,<br />
1419, 1509<br />
adhesive capsulitis 2067<br />
adinopectin 1282<br />
adipocytes 630<br />
adipocytokines 37, 179, 471, 719, 1666<br />
adiposity 523<br />
administrative claims data 764, 1573<br />
administrative databases 1099, 1571<br />
adolescence 762<br />
adolescent patients 1008, 1340, 1409, 1437<br />
adolescents 1677<br />
adult-onset Still’s disease 26, 703, 891, 902,<br />
903<br />
adverse event reporting system 700<br />
adverse events 40, 75, 159, 161, 177, 373, 386,<br />
472, 792, 1123, 1273, 1277, 1566, 2026, 2205,<br />
2206, 2210<br />
advocacy 2110<br />
aerobic 1681<br />
African-<strong>American</strong>s 475, 510, 1077, 1216, 1875,<br />
2076, 2090, 2185<br />
Afro-Caribbean 571<br />
age 587<br />
age <strong>of</strong> onset 255<br />
aging 634, 1789<br />
AICAR TF 827<br />
AID 1389<br />
algometry 2245<br />
all-cause mortality 148<br />
allelic frequency <strong>of</strong> M694V 666<br />
allograft inflammatory factor 1511<br />
allopurinol 154, 160, 161, 992, 2088<br />
allopurinol hypersensitivity syndrome 158<br />
alpha2 1719<br />
alpha-adrenergic receptor 799<br />
alveolar hemorrhage 2009<br />
alveolitis 1212<br />
Alzheimer’s dementia 640<br />
ambrisentan 574<br />
ambulatory medical clinic 48<br />
aminopeptidase 1450<br />
aminopeptidase N 1520<br />
anakinra 163, 209, 260, 894, 900, 902, 1663<br />
analgesics 821<br />
ANAM 1855<br />
ANCA 680, 1207, 2009, 2013, 2014, 2015,<br />
2017, 2018, 2022, 2023, 2029, 2031, 2032, 2048<br />
ancestry 1164<br />
anemia 1309<br />
anergy 1256<br />
anergy mouse models 425<br />
angiogenesis 291, 358, 671, 714, 1081, 1314,<br />
1391, 1418, 1419, 1504, 1506, 1508, 1533,<br />
1991, 2278<br />
angiogenic factors 23<br />
angiopoietin 358<br />
angiopoietin-like 4 244<br />
angiotensin 1314, 2003<br />
angiotensin converting enzyme inhibitor 2125<br />
animal models 283, 285, 289, 422, 424, 425,<br />
426, 427, 431, 603, 604, 605, 607, 608, 612,<br />
614, 616, 674, 830, 866, 935, 1360, 1374, 1375,<br />
1386, 1447, 1448, 1470, 1484, 1664, 1708,<br />
1711, 1713, 1717, 1721, 1726, 1730, 1883,<br />
1901, 2005, 2048, 2151, 2184, 2189, 2190,<br />
2230, 2235, 2276<br />
ankle 180<br />
ankle support 2134<br />
ankle-brachial index 470, 1049<br />
ankylosing spondylitis (AS) 512, 513, 518, 519,<br />
522, 526, 534, 535, 537, 539, 542, 545, 546,<br />
548, 550, 551, 553, 555, 556, 558, 559, 665,<br />
667, 668, 669, 756, 761, 771, 785, 963, 1078,<br />
1279, 1337, 1355, 1450, 1451, 1921, 1922,<br />
1923, 1927, 1929, 1933, 1934, 1938, 1941,<br />
1942, 1944, 1945, 1946, 1948, 1949, 1954,<br />
1957, 1958, 1959, 1961, 1963, 1964, 1965,<br />
1970, 1972, 1973, 1978, 1980, 1982, 1986,<br />
2078, 2181, 2184, 2185, 2209, 2268, 2270, 2271<br />
annexins 1692, 2250<br />
antagonist 856<br />
anterior uveitis 528<br />
anti C1q antibodies 444<br />
anti IL 5 antibody 2203<br />
anti TNF 997<br />
anti U3-RNP 1216<br />
anti-aminoacyl-tRNA synthetase antibody 1377<br />
anti-b2glycoprotein I antibodies 2250, 2251<br />
anti-b2GP1 IgA antibodies 2165<br />
antibiotics 696, 2212<br />
antibodies 381, 543, 563, 591, 621, 658, 747,<br />
780, 864, 901, 913, 915, 988, 1174, 1191, 1194,<br />
1273, 1322, 1341, 1852, 2118, 2165<br />
antibody-secreting cell 436<br />
anticardiolipin 3, 7, 11, 12, 14, 427, 1357, 1360,<br />
1410, 2250, 2251<br />
anticardiolipin antibodies 4<br />
anti-CCP antibodies 71, 660, 735, 1015, 1021,<br />
1060, 1071, 1092, 1094, 1118, 1717, 1763,<br />
1830, 2114, 2115, 2119<br />
anti-CD20 436<br />
anti-CD20 antibody 1833<br />
anti-CD22 453, 751, 752, 1452<br />
anti-centromere antibodies (ACA) 824, 1224,<br />
1884, 2214<br />
anti-citrullinated protein/peptide antibodies<br />
(ACPA) 661, 663, 1061, 1071, 1076, 1078, 1091,<br />
1116, 1390, 1598, 1603, 1740, 1741, 1757,<br />
1764, 2116, 2117, 2215<br />
anticoagulation 1160<br />
anti-collagen antibodies 2227<br />
anti-CXCL1 270<br />
anti-CXCL5 270<br />
anti-cytokine vaccination 2236<br />
anti-cytoplasmic antibody 913<br />
anti-DNA antibody 694<br />
anti-domain I antibodies 1359<br />
anti-dsDNA 442, 462, 508, 892, 1186, 1410,<br />
1414, 1847, 1870, 2186<br />
anti-dsDNA antibody 1195<br />
anti-endothelial cell antibodies 652<br />
anti-fibrillarin antibody 1216<br />
antigen cross-presentation 851, 1272<br />
antigen induced arthritis model 1718<br />
2010 Program Book 357<br />
abstract KEYWORD INDEX
abstract KEYWORD INDEX<br />
358<br />
antigen-presenting cells 851, 867<br />
anti-HMGB1 abtibodies 1195<br />
antihypertensives 958<br />
anti-IL-1 therapy 1375<br />
anti-Jo-1 926<br />
anti-lymphocyte antibodies 749<br />
antimalarial drugs 459, 1879<br />
antimalarials 445<br />
anti-MCV 660<br />
anti-MDA5 antibody 1672<br />
anti-melanoma differentiation–associated gene<br />
5 antibody 916<br />
anti-mullerian hormone 1145<br />
anti-mutated citrullinated vimentin 1741<br />
anti-N-methyl-D-aspartate receptor antibody<br />
1844<br />
anti-NMO IgG 1174<br />
antinuclear antibodies (ANA) 210, 911, 913,<br />
1188, 1341, 1845, 1871, 2197<br />
antioxidants 1510<br />
anti-phosphatidylserine/prothrombin 14<br />
antiphospholipid antibodies 1360, 1361<br />
antiphospholipid syndrome 1, 2, 3, 4, 5, 6, 7, 8,<br />
9, 10, 11, 13, 14, 621, 1160, 1356, 1357, 1358,<br />
1359, 1360, 1692, 2251, 2253, 2254<br />
antiprothombin antibodies 12<br />
anti-prothrombin/phosphatidylserine antibodies<br />
12<br />
anti-Ro antibodies 489<br />
anti-Ro/SSA antibodies 1142<br />
anti-SRP 915<br />
antisynthetase syndrom 917<br />
antithrombin 8<br />
anti-TNF 849, 1804<br />
anti-TNF therapy 56, 76, 90, 139, 239, 290,<br />
291, 297, 305, 309, 329, 330, 338, 344, 371,<br />
374, 376, 377, 385, 386, 387, 393, 402, 405,<br />
408, 409, 415, 420, 421, 516, 538, 539, 548,<br />
640, 698, 699, 718, 753, 756, 758, 767, 768,<br />
782, 904, 908, 1032, 1054, 1059, 1097, 1099,<br />
1104, 1105, 1114, 1127, 1136, 1375, 1381,<br />
1391, 1445, 1517, 1541, 1542, 1631, 1792,<br />
1794, 1811, 1812, 1813, 1814, 1815, 1818,<br />
1825, 1827, 1835, 1838, 1929, 1941, 1943,<br />
1948, 1960, 1970, 2078, 2084, 2103, 2135,<br />
2204, 2207, 2236, 2264, 2269, 2271, 2272<br />
anti-topoisomeras I antibodies 2214<br />
anti-U1RNP autoantibodies 893<br />
anti-viral prophylaxis 387<br />
aortitis 2040<br />
AP-1 616<br />
AP-1 inhibitor 280, 1467<br />
apheresis 469<br />
apoER2 1360<br />
apoptosis 106, 249, 368, 372, 439, 486, 489,<br />
490, 491, 498, 694, 736, 853, 859, 965, 1079,<br />
1135, 1195, 1214, 1260, 1478, 1516, 2121, 2174<br />
2010 Program Book<br />
apoptotic bodies 694<br />
appointment attendance 776, 1553<br />
appointment reminders 1007<br />
APRIL 1732<br />
aquaporin 1895<br />
arbovirus 1640, 1642<br />
aromatase inhibitor 898, 912<br />
arterial stiffness 375, 1839<br />
arteriosclerosis 448, 461, 1148, 1839, 1877,<br />
2120, 2121, 2122, 2165, 2166<br />
arteriovenous anastomoses 1220<br />
arthralgia 898<br />
arthralgia syndrome 912<br />
arthritis 691, 786, 1447<br />
arthritis self management program 2062<br />
arthritis symptoms 688<br />
arthrocentesis 1431<br />
arthropathy 886<br />
arthroplasty 168, 178, 1080, 1385, 2059, 2061,<br />
2137<br />
arthroscopy 885, 1095<br />
ASAS 552<br />
ASAS criteria 544<br />
ASC 2151<br />
ASDAS 1927, 1938<br />
aspirin 2123<br />
assessment 7, 94, 402, 813, 905, 1291, 1344,<br />
1431, 1623, 1747, 1754, 1840, 1857, 2031,<br />
2063, 2109, 2110<br />
assistive devices 169<br />
association 833<br />
association studies 1578<br />
association study 824, 1974<br />
asymptomatic 1614<br />
atherosclerosis 430, 438, 448, 455, 471, 519,<br />
531, 594, 637, 719, 865, 1017, 1023, 1028,<br />
1058, 1072, 1189, 1194, 1224, 1378, 1667,<br />
1677, 1846, 1877, 2049, 2117, 2124, 2125,<br />
2162, 2241, 2259, 2260<br />
attrition 2064<br />
atypical fracture 1573<br />
audiogram 899, 900<br />
augmentation index 534, 1028<br />
autoantibodies 24, 28, 77, 428, 433, 439, 486,<br />
487, 499, 510, 575, 652, 656, 702, 715, 734,<br />
742, 743, 748, 749, 753, 857, 892, 894, 925,<br />
929, 934, 988, 1068, 1091, 1146, 1164, 1188,<br />
1226, 1231, 1250, 1258, 1264, 1272, 1448,<br />
1639, 1672, 1732, 1757, 1780, 1847, 1870,<br />
1871, 1885, 1901, 2001, 2003, 2008, 2189,<br />
2231, 2243<br />
autoantibody phenotype 1678<br />
autoantibody-inducing CD4 T cells 1258<br />
autoantibody-inducing CD4+ T cell 867<br />
autoantigens 350, 439, 487, 734, 1374, 2175,<br />
2176<br />
autoimmune arthritis 2130<br />
autoimmune diseases 264, 287, 439, 500, 700,<br />
715, 737, 758, 780, 792, 843, 895, 920, 927,<br />
962, 1002, 1048, 1107, 1161, 1188, 1225, 1229,<br />
1244, 1249, 1250, 1258, 1264, 1265, 1266,<br />
1350, 1435, 1499, 1525, 1649, 1883, 1885,<br />
1889, 1898, 1900, 1901, 2043, 2128, 2129,<br />
2160, 2176, 2177, 2217, 2234<br />
autoimmune hepatitis 892<br />
autoimmune infiltrates 1897<br />
autoimmune pancreatitis 1671<br />
autoimmune thyroid disease 1038<br />
autoinflammatory 2105<br />
autoinflammatory disease 260, 657, 1656,<br />
1706<br />
autoinflammatory syndromes 1685<br />
automated 118<br />
automatic neuropyschologic assessment metrics<br />
1854<br />
autonomic disorders 626, 809, 1025, 1902<br />
autonomic nervous system 808<br />
autophagy 965<br />
Avise PG 302<br />
axial spondyloarthritis 544, 666<br />
ayurveda 1106<br />
azathioprine 1398, 1401, 1453, 2085<br />
B<br />
B CD20 lymphocytes 1810<br />
B cell activation markers 1911<br />
B cell depleting 1802<br />
B cell depleting therapy 741<br />
B cell depletion 436<br />
B cell modulation 751<br />
B cell monoclonal proliferation markers 1911<br />
B cell tolerance 425<br />
B cells 15, 286, 333, 349, 355, 367, 424, 425,<br />
608, 623, 712, 715, 730, 733, 734, 736, 737,<br />
738, 739, 740, 741, 743, 744, 745, 746, 748,<br />
749, 750, 751, 752, 753, 825, 1085, 1088, 1126,<br />
1141, 1146, 1154, 1192, 1295, 1350, 1389,<br />
1410, 1411, 1412, 1413, 1415, 1589, 1710,<br />
1731, 1790, 1801, 1886, 1889, 1890, 1892,<br />
1906, 1917, 1977, 2178, 2187, 2189, 2274<br />
B7RP-1 1141<br />
back pain 172, 175, 869, 971, 1383, 1458,<br />
1459, 1575, 2180<br />
bacterial infections 2015<br />
BAFF 15, 24, 741, 926, 1126, 1379, 1389, 1413,<br />
1890, 1892, 1998, 2129, 2177, 2187<br />
Barrett’s esophagus 580<br />
BASDAI 212, 534<br />
BASDI 1925<br />
BAX gene expression 1214<br />
B-cell 1833, 1998<br />
Bcl-2 family 859<br />
BCX4208 150<br />
Behçet’s disease 822, 839, 1249, 1281, 1285,<br />
1289, 1293, 1297, 1305, 1308, 1307, 2200, 2217
Behcet’s syndrome 1284, 1288, 1298, 1303,<br />
1312, 1697<br />
belimumab 451, 452, 457, 1146, 1172, 1454,<br />
1456, 1457, 1848<br />
benzbromarone 2088<br />
beta2-glycoprotein I 656<br />
beta2-glycoprotein I receptors 1356<br />
bias 1132<br />
BILAG 453, 1452, 1456<br />
Bim 859<br />
bioactivity 282<br />
biologic agents 758<br />
biologic response modifiers 74, 76, 237, 300,<br />
322, 326, 385, 386, 407, 415, 419, 420, 454,<br />
514, 720, 890, 908, 1012, 1097, 1114, 1127,<br />
1136, 1542, 1648, 1714, 1795, 1799, 1804,<br />
1814, 1818, 1835, 1927, 1937, 1943, 1982,<br />
2264, 2267<br />
biologicals 891<br />
biologics 68, 88, 981, 1041, 1110, 1824, 1932<br />
biologics registries 1111, 1112<br />
bioluminescence 1622<br />
biomarkers 25, 49, 103, 134, 217, 245, 268,<br />
363, 443, 506, 541, 588, 590, 711, 724, 725,<br />
733, 808, 811, 835, 845, 861, 924, 927, 951,<br />
979, 1098, 1146, 1147, 1175, 1190, 1218, 1230,<br />
1379, 1399, 1403, 1451, 1466, 1491, 1496,<br />
1601, 1606, 1608, 1740, 1751, 1753, 1764,<br />
1782, 1784, 1804, 1886, 1890, 1899, 1904,<br />
1908, 1911, 1918, 1953, 1968, 1985, 2012,<br />
2047, 2049, 2106, 2116, 2149, 2161, 2265<br />
biomechanical testing 169, 1327, 1328, 2056,<br />
2099, 2101, 2134<br />
biomechanics 195<br />
BiP 1376, 1729<br />
Birmingham vasculitis activity score (BVAS)<br />
2035<br />
birth cohort 2067<br />
bisphosphonates 31, 970, 981, 994, 1005,<br />
1372, 1543, 1561, 1665, 2089, 2213<br />
bladder cancer 2026<br />
blastomycosis 1643<br />
Blau syndrome 1656, 1713<br />
bleomycin 622<br />
blood brain barrier 1191<br />
BLyS 451, 452, 457, 1172, 1186, 1454, 1456,<br />
1457, 1848<br />
body composition 1018, 1065<br />
body image dissatisfaction 1234<br />
body mass 95, 173, 183, 222, 231, 515, 774,<br />
1018, 1065, 1696<br />
body mass index 523<br />
bone density 121, 176, 188, 195, 206, 222, 798,<br />
958, 959, 960, 974, 979, 982, 1156, 1206, 1317,<br />
1546, 1859<br />
bone disease 241, 624, 1485, 1499, 1978, 1983<br />
bone edema 1371<br />
bone erosion 716, 881, 1499, 1610<br />
bone geometry 960<br />
bone marrow 137, 183, 630, 713, 1085, 2158<br />
bone marrow edema 135, 1963<br />
bone marrow lesion 122, 131, 709<br />
bone marrow macrophages 2158<br />
bone metabolism 548, 957, 965, 973, 981,<br />
1467, 1813, 2078, 2161<br />
bone mineral density 994, 2157<br />
bone morphogenetic proteins 610, 1468, 1487,<br />
1980<br />
bone resorption 1978<br />
bone turnover 134, 1953<br />
bone turnover markers 943, 2157<br />
bony enlargements 185<br />
botulinum toxin 114<br />
brain activity 2097<br />
brain magnetic resonance imaging 1162<br />
breast cancer 912<br />
bronchiectasis 1648<br />
Btk 286<br />
burden 204<br />
BXD2 1412<br />
C reactive protein 326, 491, 1000, 1077, 1804<br />
C1q 1184<br />
C4 498<br />
C5a receptor antagonist 2032<br />
C5aR 847<br />
C6-deficient mice 1361<br />
CACP 261<br />
cadherin 602<br />
cadherin-11 603, 1388<br />
caffeine 1362<br />
calcification 1978<br />
calcineurin 2126<br />
calcinosis 728, 1486, 1686<br />
calcitonin 1500<br />
calcium regulation 2179<br />
calibrators 2251<br />
calprotectin 537<br />
CAM provider 1575<br />
camk2 1503<br />
camptodactyly arthropathy coxa vara<br />
pericarditis 261<br />
canakinumab 894, 900<br />
cancer 468<br />
cancer treatments 977<br />
candidate gene 92, 1592<br />
cannabinoid 615, 841<br />
capillaroscopy 11, 1236, 1615<br />
capillary microscopy 1615<br />
CAPS 2228<br />
C<br />
carboxypeptidase B 1386<br />
cardiovascular disease 67, 86, 90, 148, 309,<br />
385, 389, 456, 461, 470, 479, 483, 485, 519,<br />
531, 534, 554, 581, 582, 590, 628, 643, 771,<br />
784, 793, 832, 870, 961, 1016, 1019, 1021,<br />
1026, 1029, 1030, 1034, 1039, 1041, 1049,<br />
1052, 1054, 1064, 1067, 1109, 1142, 1148,<br />
1168, 1169, 1177, 1200, 1286, 1627, 1742,<br />
1772, 1846, 1861, 1879, 2088, 2120, 2122,<br />
2163, 2167, 2209, 2211, 2259<br />
cardiovascular markers 375<br />
cardiovascular risk 871, 1016, 1026<br />
cardiovascular risk factors 542, 584<br />
carotid plaque area 455<br />
carotid ultrasound 2163<br />
carpal tunnel 1567<br />
carpal tunnel syndrome 1626<br />
CARRA 1677<br />
cartilage 122, 183, 192, 193, 215, 840, 875,<br />
885, 1369, 1380, 1466, 1468, 1475, 1476, 1480,<br />
1483, 1485, 1494, 1503, 1669, 1722, 2151<br />
cartilage damage 1373, 2256<br />
cartilage erosion 1388<br />
cartilage loss 706<br />
cartilage turnover 134, 1953<br />
cartilage volume 938<br />
case ascertainment 2093<br />
case control study 2213<br />
case-control 64<br />
catabolism 1494<br />
catenin 1503<br />
caveolin-1 622<br />
CAVI 1839<br />
CCL4 503<br />
CCP 2118<br />
CCR7 1506<br />
CD T cells 1242, 1248, 1253, 1268<br />
CD138 1186<br />
CD154 1243, 1244, 1245<br />
CD226 1987<br />
CD28 1505<br />
CD3 830<br />
CD3+ CD4- CD8- double negative T cell 434<br />
CD36 2254<br />
CD40L 267, 1243, 1244, 1245<br />
CD70 1273<br />
CD80 1505<br />
CD86 1505<br />
CDAI 73<br />
celecoxib 151, 937<br />
cell biology 634, 848, 860, 863, 1262, 1500,<br />
1971, 1976<br />
cell death 490, 1262<br />
cell fusion 842<br />
cell proliferation 505, 1262<br />
abstract KEYWORD INDEX<br />
2010 Program Book 359
abstract KEYWORD INDEX<br />
cell signaling 749, 1419<br />
cell traffiking 23, 714<br />
central nervous system involvement 103, 1162,<br />
1191, 1682, 1727, 1853, 1858, 2037, 2038, 2107<br />
central sensitization 1385, 2098<br />
cerebral angiography 2037<br />
cerebrospinal fluid 1293<br />
cerebrovascular disease 53, 78, 620, 1036,<br />
1057<br />
certolizumab pegol 718, 1517, 1805, 1806,<br />
1832<br />
cervical cancer 468<br />
cervical dysplasia 468<br />
cervical spine 102<br />
cFMS inhibitor 289<br />
c-fos 1469<br />
change over time 772<br />
channelopathy 96<br />
chaperonin 10 441<br />
CHB 489<br />
cheiroarthropathy 1624<br />
chemerin 1534<br />
chemokines 17, 19, 22, 25, 26, 39, 167, 270,<br />
501, 671, 675, 742, 1083, 1100, 1131, 1210,<br />
1230, 1240, 1403, 1417, 1427, 1476, 1507,<br />
1520, 1534, 1726, 1751, 1906, 1992, 2016, 2253<br />
chemotaxis 17, 39, 1419<br />
chest scan 997<br />
chikungunya 1640, 1642<br />
chikungunya arthritis 1549<br />
chikungunya rheumatism 1642<br />
child 245<br />
childhood 2107<br />
childhood chronic uveitis 240, 1436<br />
childhood Sjögren’s syndrome 1907<br />
children 1677, 1696, 2019<br />
Chinese 1680<br />
cholecalciferol 962<br />
cholesterol 332, 534, 594, 933, 1058, 1072<br />
cholinergic agonists 866<br />
chondrocalcinosis 872, 873, 885<br />
chondrocytes 37, 632, 633, 634, 1472, 1473,<br />
1477, 1481, 1482, 1483, 1484, 1489, 1490,<br />
1494, 1500, 1501, 1503, 1514, 1532, 2227<br />
chondroitin 940<br />
chondroitin sulfate 938<br />
chondrolysis 215<br />
chronic conditions 2208<br />
chronic fatigue syndrome 804<br />
chronic lymphocytic leukemia 2177<br />
chronic non-bacterial osteomyelitis 241<br />
chronic therapy 946<br />
chronic widespread pain 646, 649<br />
chronotherapy 392, 1123<br />
Churg-Strauss syndrome 2020, 2025, 2034,<br />
2043, 2203<br />
CIA 276, 830, 1499<br />
CIA model 286<br />
cigarette smoking 83<br />
CINOD 1477<br />
circulating endothelial cells 1283<br />
circulating endothelial progenitor cells 1283<br />
cis-associations 1608<br />
citrullination 1074, 1421<br />
citrulline 1074, 2167, 2235<br />
CLASI 1880<br />
classification criteria 85, 208, 210, 226, 552,<br />
659, 777, 838, 1151, 1225, 1637, 1652, 1654,<br />
1673, 1744, 1760, 1763, 1774, 1780, 1783,<br />
1881, 1907, 1926, 2014, 2036, 2182, 2183, 2196<br />
clinical disease activity index (CDA)I 317<br />
clinical manifestations 517<br />
clinical outcomes 1396<br />
clinical pharmacology 254<br />
clinical practice 331<br />
clinical practice guidelines 70, 211, 1011, 1560,<br />
1759<br />
clinical practice guidelines implementation 984<br />
clinical registry 993<br />
clinical remission 216, 290<br />
clinical remission criteria 308<br />
clinical research 6<br />
clinical trials 6, 94, 125, 150, 153, 154, 157,<br />
196, 220, 234, 328, 334, 414, 453, 518, 533,<br />
559, 560, 566, 663, 669, 676, 706, 710, 797,<br />
801, 814, 815, 891, 945, 946, 953, 1108, 1115,<br />
1119, 1121, 1122, 1132, 1154, 1161, 1273,<br />
1368, 1452, 1455, 1458, 1629, 1640, 1766,<br />
1781, 1805, 1806, 1811, 1832, 1875, 1930,<br />
1935, 1949, 1961, 2032, 2169<br />
clonal 1256<br />
clonal expansions 1069, 1604<br />
coagulation disorder 8, 1160<br />
cobra 311<br />
cocaine 2013<br />
coccidioidomycosis 1643<br />
coccidiomycosis 415<br />
co-expression 847<br />
cognition 98<br />
cognitive adaptibility 802<br />
cognitive behavior therapy 646, 802. 1325<br />
cognitive dysfunction 113, 1208, 1343, 1853,<br />
1854, 1855, 2070, 2242<br />
cohort 517, 527, 1853<br />
cohort study 701, 1036, 1329, 1331<br />
colchicine 147, 148, 1288, 2087<br />
collagen 106, 279, 606, 613, 1475, 1711, 1998,<br />
1999<br />
collagen antibody induced arthritis 2227<br />
collagen-induced arthritis (CIA) 277, 285, 288,<br />
289, 635, 714, 1523, 1622, 1707, 1732<br />
combination therapies 319, 937, 962, 1396<br />
communication 1332, 1575<br />
community intervention 2141<br />
community programs 689, 2062, 2110<br />
community-based cohort 1544<br />
comorbidity 58, 147, 170, 184, 879, 882, 1016,<br />
1022, 1235, 1789, 1928, 1951, 2209<br />
comparative analysis 566<br />
comparative effectiveness 1702, 1795<br />
complement 263, 430, 491, 1146, 1180, 1399,<br />
2032, 2048, 2277<br />
complement activation 1160<br />
complement C6 1361<br />
complement pathways 2227<br />
complement receptor 2 730<br />
complement split products 866<br />
complement system 498<br />
complex regional pain syndrome 1703<br />
compliance 74<br />
complications 415, 1381<br />
complimentary and alternative therapy 95,<br />
1575<br />
computed tomography (CT) 128, 136, 176, 585,<br />
869, 1046, 1443, 1486, 1810, 2027, 2164, 2166<br />
computer assisted assessment 1747<br />
computerized skin score 1439<br />
computerized tomography 1686<br />
conceptual model 204<br />
confirmatory factor analysis 2247<br />
congenital heart block 656, 732, 832, 1322,<br />
1438, 2231<br />
connective tissue diseases 618, 704, 1026,<br />
1212, 1223, 1635, 2005, 2040<br />
consensus 1701<br />
consensus formation 1702<br />
consensus methodology 1688<br />
consumer health information 2284<br />
continuum <strong>of</strong> care 2282<br />
COPCORD 66, 1551<br />
coping skills 1027, 1211<br />
copy number variant 250<br />
copy number variation 1589, 2217<br />
core competencies 1429<br />
coronary artery calcification 459<br />
coronary artery disease 456, 584, 1046, 1053,<br />
1209, 1233, 1443, 1627, 1842, 2164<br />
correlation 915<br />
cortical 647<br />
corticosteroids 54, 213, 451, 480, 678, 922,<br />
943, 1235, 1276, 1277, 1292, 1311, 1453, 1561,<br />
1566, 1567, 1626, 1649, 1859, 1879, 2037,<br />
2045, 2225<br />
cost 51, 238<br />
cost development 770<br />
cost <strong>of</strong> fracture 1540<br />
costimulation 2189<br />
360<br />
2010 Program Book
cost-utility 759, 1539<br />
couples 1324<br />
COX inhibitors 298, 942<br />
CPDAI 514<br />
CPM 2076<br />
CRAC channel 279<br />
C-reactive protein (CRP) 86, 312, 490, 850, 919,<br />
1304<br />
creatine 1384<br />
creatine kinase 915<br />
critical care 2102<br />
Crohn’s disease 1279, 1656<br />
cross cultural validation 1872<br />
CRP 148, 2258<br />
cry<strong>of</strong>ibrinogenemia 906<br />
cryoglobulinemia 1646, 2010, 2011, 2024,<br />
2030, 2036, 2039, 2042, 2046, 2201<br />
crystal-induced arthritis 144, 146, 153, 166,<br />
873, 875, 1531, 2151<br />
CSF1R Fms 273<br />
CTGF 613<br />
c-type natriuretic peptide 259<br />
curriculum 1430<br />
cutaneous lupus 2238<br />
cutaneous lupus erythematosus 1198, 1699,<br />
1880<br />
cutaneous manifestations 1213, 1521, 1850,<br />
1880<br />
cutaneous vasculitis 444<br />
cut-<strong>of</strong>f point 525<br />
CXCL12 21<br />
CXCL13 323, 1250<br />
CXCL16 1417<br />
CXCL2 1751<br />
CXCR4 354, 622<br />
CXCR5 1250<br />
CXCR6 1417<br />
cyclic citrullinated peptide 245<br />
cyclobenzaprine 820<br />
cyclooxygenase 633, 936, 1489<br />
cyclophosphamide 1401, 2026<br />
cyclosporine 874<br />
cystatin C 1023<br />
cytokine 2233<br />
cytokine receptor signaling 1525<br />
cytokines 16, 20, 25, 33, 36, 38, 77, 103, 259,<br />
272, 275, 285, 287, 292, 366, 431, 497, 505,<br />
619, 632, 635, 636, 638, 696, 715, 741, 856,<br />
862, 871, 896, 1071, 1073, 1083, 1089, 1095,<br />
1122, 1133, 1259, 1280, 1308, 1317, 1351,<br />
1354, 1403, 1424, 1515, 1525, 1526, 1533,<br />
1580, 1581, 1594, 1642, 1709, 1725, 1730,<br />
1732, 1798, 1803, 1831, 1914, 1965, 1967,<br />
1976, 1982, 1992, 1993, 2006, 2025, 2115,<br />
2176, 2216, 2253<br />
cytotoxic T lymphocyte 867, 1272<br />
D<br />
dabigatran 604<br />
dactylitis 1932<br />
daily living 1217<br />
damage 262, 2031, 2070<br />
DAM-HAQ 2256<br />
DAMPs 845<br />
DAPSA 514<br />
Darly arthritis 1067<br />
DAS 1734<br />
DAS score 1631<br />
DAS28 73, 662, 1806<br />
DAS28CRP 1782<br />
DC-STAMP 521, 1492<br />
death 72, 1166, 1378, 2157<br />
death receptor 3 348<br />
decision analysis 59, 759<br />
dectin-1 1713<br />
Delphi 2196, 2279<br />
Delphi survey 1701<br />
delta-BAFF 1413<br />
demyelinating events 57<br />
dendrimers 281<br />
dendritic cells 293, 636, 637, 847, 849, 851,<br />
852, 862, 863, 1116, 1139, 1150, 1252, 1424,<br />
1661, 1714, 1715, 1716, 1816, 1981, 2217<br />
denosumab 2157, 2161<br />
depo provera(medroxyprogesterone acetate)<br />
974<br />
depression 1024, 1862, 1882<br />
dermatomyositis 916, 920, 921, 923, 934,<br />
1198, 1376, 1378, 1521, 1686, 1693<br />
DEXA 974<br />
diabetes 339, 888, 1039, 1442, 1873<br />
diagnosis 50, 133, 532, 547, 550, 555, 558, 621,<br />
768, 880, 899, 1090, 1186, 1254, 1289, 1339,<br />
1359, 1571, 1637, 1644, 1647, 1656, 1740,<br />
1757, 1760, 1783, 1855, 1881, 1915, 1918,<br />
1926, 1931, 1950, 2180, 2181, 2183, 2246, 2261<br />
diagnostic codes 1571<br />
diagnostic criteria 100, 110, 111, 112, 572, 575,<br />
658, 780, 911, 1305, 1655, 1706, 1775, 1776,<br />
1785, 2027, 2093, 2261<br />
diagnostic delay 558, 1921<br />
diameter <strong>of</strong> pulmonary artery 585<br />
diastolic dysfunction 1059<br />
dicl<strong>of</strong>enac 954, 955<br />
diet 888<br />
differentiation 630, 1271, 1490<br />
diffuse idiopathic skeletal hyperostosis (DISH)<br />
668<br />
digital 121<br />
digital analysis 124<br />
digital ulcera 1220<br />
digital x-ray radiogrammetry (DXR) 1770<br />
dipyridamole 2126<br />
DIRA 260<br />
direct costs 754<br />
disability 173, 186, 189, 683, 686, 687, 766,<br />
922, 975, 1044, 1217, 1321, 1349, 1383, 1563,<br />
1750, 1768, 2057, 2060, 2069, 2138, 2139,<br />
2143, 2256<br />
discriminative capacity 1927<br />
discriminatory capacity 1629<br />
disease activity 372, 459, 1200, 1255, 1291,<br />
1581, 1606, 1750, 1753, 1782, 1868, 1869,<br />
1878, 1922, 2047, 2049, 2070, 2107, 2149, 2272<br />
disease activity and therapeutic response<br />
criteria 1212<br />
disease activity index 1759<br />
disease activity measure 1147<br />
disease activity score (DAS) 295, 317, 1099,<br />
1686, 1829<br />
disease burden 1928<br />
disease modification 664<br />
disease phenotype 2272<br />
disease severity 757, 1312, 1697<br />
disease worsening 1752, 1766, 1778<br />
disease-modifying antirheumatic drugs 58, 60,<br />
74, 209, 229, 412, 417, 641, 791, 1010, 1066,<br />
2282<br />
DKK-1 548, 629, 1491<br />
DMARDs 52, 54, 68, 74, 81, 82, 303, 305, 306,<br />
324, 325, 337, 338, 415, 543, 848, 991, 1047,<br />
1110, 1255, 1640, 1796, 1805, 2204<br />
DNA 509, 631, 2146<br />
DNA methylation 21, 357<br />
DNA modification 694<br />
doctors’ preferences 68<br />
dopamine 1089<br />
Doppler 1754<br />
Doppler ultrasound 567, 1004, 1162, 1322,<br />
1632<br />
dose optimization 1829, 2265<br />
dose response relation 388<br />
dose-response 1566<br />
double strand break repair 509<br />
doxycycline 318<br />
DR5 1135<br />
drug interactions 597, 801, 1575<br />
drug levels 1825<br />
drug safety 319<br />
drug survival 1942<br />
drug toxicity 2013<br />
dry eyes and dry mouth 1901<br />
dual energy CT scan 2152<br />
dual energy x-ray absorptiometry (DEXA) 206,<br />
976, 981, 1006, 1018, 1543<br />
duloxetine 105, 175<br />
durability clinical remission 308<br />
duration <strong>of</strong> RA 83<br />
dyadic coping 1324<br />
abstract KEYWORD INDEX<br />
2010 Program Book 361
abstract KEYWORD INDEX<br />
EAE 2129<br />
early arthritis 787, 1774, 2183<br />
early arthritis clinic 661<br />
early axial spondyloarthritis 669<br />
E<br />
early diagnosis 550, 585<br />
early disease 2183<br />
early inflammatory arthritis (EIA) 659, 978,<br />
1737<br />
early inflammatory polyarthritis 796, 1110<br />
early life microbial exposure 248<br />
early osteoarthritis 184<br />
early psoriatic arthritis 1962<br />
early RA 1541, 1548<br />
early response 380<br />
early rheumatoid arthritis 300, 337, 396, 1104,<br />
1837<br />
echocardiography 1004<br />
economics 51, 55, 296, 322, 754, 755, 761,<br />
764, 767, 769, 770, 781, 791, 795, 969, 1539,<br />
1548, 2091, 2139, 2246<br />
education, medical 41, 42, 43, 44, 45, 46, 47,<br />
48, 50, 162, 984, 1429, 1431, 1432, 1433, 1617,<br />
1735<br />
education, patient 40, 42, 108, 156, 211, 996,<br />
1001, 1221, 1335, 1336, 2080, 2082, 2268,<br />
2279, 2284<br />
educational advertising 2081<br />
effectiveness 1802<br />
efficacy 163, 937, 1454, 1456, 1832, 2173<br />
effusion 1754<br />
e-health 1334<br />
elderly people 1546<br />
electronic health record 1005<br />
electronic medical record 221, 998<br />
electronic monitored system 1047, 1865<br />
electronic reports 2248<br />
electrostimulation 647<br />
ELISA 1377<br />
employment 796, 2069, 2138<br />
employment impact 2079<br />
employment status 1217<br />
en bloc biopsy 921<br />
end row capillary loops 1686<br />
end stage renal disease 2018<br />
endoplasmic reticulum 1376<br />
endoscopy 298<br />
endothelial cells 834, 1183, 1190, 1214, 1352,<br />
1356, 1416, 1418, 1419, 1420, 1504, 1988,<br />
1997, 2000, 2003, 2021<br />
endothelial dysfunction 519<br />
endothelial function 628<br />
endothelial progenitor cells 456<br />
endothelial protein C receptor 1190<br />
endothelin 1294, 2003<br />
endothelin receptor A antagonist 574<br />
endothelin receptor antagonists 1214<br />
endothelin-1 2231<br />
enkephalins 1226<br />
enolase 1717<br />
entecavir 387<br />
enteric coated mycophenolic adid (EC-MPS)<br />
1402<br />
entheses 1962<br />
enthesitis 233, 512, 1619, 1633<br />
environmental factors 61, 248, 510, 533, 686,<br />
1070, 1252, 1678, 1936, 1956, 2118<br />
enzyme-linked immunoabsorbant assays (ELISA)<br />
1844<br />
eosinophilic fasciitis 1624<br />
ephrins 1991<br />
epicardial adipose tissue 2166<br />
epidemiologic studies 645<br />
epidemiology 58, 100, 248, 535, 571, 649,<br />
963, 1307, 1327, 1329, 1331, 1366, 1544, 1913,<br />
2067, 2093, 2094<br />
epigenetics 507, 750, 858, 1253, 1352, 1422,<br />
1518, 1528, 1585, 1586, 1988, 2004, 2191<br />
epistatic interactions 1596<br />
epithelial to mesenchymal transition (EMT) 602<br />
epitope mapping 2001<br />
epratuzumab 453, 751, 752, 1452<br />
Epstein Barr virus 1082, 1708<br />
EQ-5D 2207<br />
EQ-5D/SF-6D 787<br />
eQTL 1608<br />
ERAP 1969<br />
ERAP1 1972<br />
Erdheim-Chester disease 1660<br />
erectile dysfunction 1544<br />
ergocalciferol 310<br />
ERK 32<br />
ERK/MAPK expression 1523<br />
erosion 889, 1370, 1621, 2256<br />
erosive arthritis 728<br />
erosive osteoarthritis 187, 1620<br />
erythrocyte sedimentation rate (ESR) 919, 1304<br />
ESCAPE RA 1018<br />
esomeprazole 597, 937<br />
ESRD 2022<br />
estrogen 462<br />
estrogen receptor 462<br />
etanercept 69, 216, 219, 227, 229, 230, 290,<br />
398, 514, 669, 1103, 1105, 1117, 1368, 1631,<br />
1825, 1927, 1937, 1944, 1946, 1960<br />
ethnic studies 571, 1464, 1674, 1877, 2082<br />
ethnicity 446<br />
EULAR response 1829<br />
evidence based medicine 1560<br />
exercise 93, 200, 628, 646, 688, 689, 691, 692,<br />
784, 797, 1384, 1465, 1558, 1681, 2057, 2071,<br />
2135, 2268, 2283<br />
exercise program 2059<br />
exercises 1458<br />
exome 2144<br />
experimental arthritis 278, 1532<br />
expert opinion 1291<br />
expression 1593<br />
extraarticular manifestations 528, 904, 1447,<br />
1933, 1952, 2117<br />
extracellular DNA 1420<br />
extracellular matrix 1722<br />
extracellular matrix proteins 673, 887, 1294,<br />
1421, 1719<br />
extracellular RNA 1420<br />
extractable nuclear antigen 1847<br />
extra-glandular manifestations 1898<br />
eye disease 1298<br />
F<br />
facet joint injection 172<br />
factor analysis 181<br />
falls 1576<br />
familial Mediterranean fever 666, 905, 909,<br />
1516, 1696, 1706<br />
family functioning 625<br />
family physicians 1571<br />
family studies 1068, 1145, 1193, 1851, 2083,<br />
2144<br />
famotidine 945, 946<br />
Fas 853<br />
fasciitis 921<br />
fat mass 173, 1383<br />
fat mass index 1018<br />
fatigue 97, 99, 105, 113, 627, 628, 799, 800,<br />
804, 815, 817, 819, 820, 1032, 1211, 1219,<br />
1228, 1325, 1344, 1736, 1758, 1848, 1882, 2065<br />
fatigue severity scale 1219<br />
Fc gamma receptor 504<br />
Fc receptors 504, 828, 846, 868, 1350, 2230<br />
Fc-IgG receptors CD16 and CD32 538<br />
fear 520<br />
febuxostat 149, 154, 158<br />
feet involvement 1759<br />
fellowship training 45, 47<br />
ferritin 102, 916, 923<br />
fertility 1043, 1145<br />
fetal loss 1193, 1860<br />
fever 897, 2105<br />
fewer male siblings 1193<br />
FGF23 1155, 2202<br />
fibrin network 7<br />
fibrinogen 350, 1306<br />
fibroblast 1511<br />
362<br />
2010 Program Book
fibroblast like synoviocyte 27<br />
fibroblast-epithelial cell interactions 613<br />
fibroblast-like synoviocytes 366, 1388<br />
fibroblasts 17, 21, 23, 36, 39, 244, 349, 357,<br />
364, 489, 600, 606, 611, 613, 615, 616, 629,<br />
670, 679, 1089, 1131, 1210, 1274, 1389, 1420,<br />
1506, 1518, 1529, 1722, 1733, 1991, 1999,<br />
2003, 2007, 2231<br />
fibromyalgia 92, 93, 94, 95, 96, 97, 98, 99, 100,<br />
101, 102, 103, 104, 105, 107, 108, 109, 110,<br />
111, 112, 113, 115, 116, 117, 532, 646, 647,<br />
648, 650, 651, 797, 798, 799, 800, 801, 802,<br />
803, 804, 805, 806, 807, 808, 809, 810, 811,<br />
812, 813, 814, 815, 816, 817, 818, 819, 820,<br />
821, 990, 1320, 1681, 2074, 2075, 2109, 2246<br />
fibromyalgia impact questionnaire 115<br />
fibrosing 1212<br />
fibrosis 601, 609, 614, 675, 1210, 2007, 2231<br />
fine-specificity 2114<br />
first-degree relative 77<br />
flare 452, 757, 764, 1362, 1752, 1766, 1778<br />
flare criteria 1688<br />
flip 854<br />
flow cytometry 1492, 1728<br />
Flt3-ligand 293<br />
fluoroquinolone 2212<br />
fMRI 2097<br />
FMS-like tyrosine kinase3-ligand 1914<br />
foam cell 1072<br />
focus group 2281<br />
focus score 1907<br />
follicular dendritic cells 730<br />
follow-up 1963<br />
foot 173<br />
foot disorders 1327, 1328, 1329, 1330, 1331<br />
foot pain 1327<br />
formal joint count 995<br />
Fourier-transform infrared spectroscopy 875<br />
Foxp3 909, 1257<br />
Foxp3+ Treg cells 1266, 1499<br />
fracture risk 1552<br />
fractures 31, 960, 963, 966, 968, 969, 971, 976,<br />
977, 979, 980, 982, 989, 999, 1005, 1546, 2089,<br />
2112, 2157<br />
frailty 186<br />
FRAX 968, 1156<br />
free fatty acids 1034<br />
free heavy chain 1450<br />
function 806, 814<br />
functional connectivity 650<br />
functional impairment 115<br />
functional MRI 1159<br />
functional status 186, 189, 314, 555, 1749,<br />
1755, 2069, 2076, 2095, 2138, 2142<br />
fungal infection 415<br />
future expectations 2281<br />
G<br />
gadolinium contrast agents 1993<br />
gait 200, 201, 202, 2099<br />
gait parameters 2059<br />
gait velocity 2095<br />
galectin 372<br />
gallic acid 27<br />
gastric antral vascular ectasia 726<br />
gastrointestinal complications 298, 535, 726,<br />
945, 946, 953, 1902<br />
Gaucher disease 1653<br />
GAVE 726<br />
gender 440, 1188, 1257, 1557, 2096<br />
gender differences 550<br />
gene compy number 498<br />
gene expression 1188, 1251, 1257, 1578, 1990,<br />
2149<br />
gene expression pr<strong>of</strong>iles 285<br />
gene polymorphism 356, 504<br />
gene regulation 507, 1578<br />
gene therapy 1129, 1413, 1729, 1733, 2174,<br />
2178<br />
gene-environment interactions 1588<br />
generalizability theory 1316<br />
generalized osteoarthritis 182<br />
genetic ancestry 1592<br />
genetic association 831, 838, 841, 1313, 1446,<br />
1979, 2274<br />
genetic association study 1585, 1586<br />
genetic disorders 500, 837, 877, 897, 1329,<br />
1583, 1597, 1599, 1656, 1987, 2105, 2226<br />
genetic epidemiology 828, 1984<br />
genetic factors 1076<br />
genetic markers 1600, 2215<br />
genetic susceptibility 832<br />
genetic variants 1077<br />
genetics 250, 262, 822, 1078, 1355, 1593,<br />
1594, 2146, 2148<br />
GENISOS 1211<br />
genome-wide 836<br />
genome-wide association study 1600, 2219<br />
genomics 2, 242, 243, 247, 250, 251, 254, 255,<br />
258, 264, 266, 495, 496, 498, 502, 573, 653,<br />
654, 655, 823, 825, 826, 829, 830, 842, 843,<br />
928, 1075, 1084, 1099, 1280, 1301, 1386, 1577,<br />
1578, 1579, 1587, 1589, 1590, 1591, 1596,<br />
1597, 1598, 1600, 1603, 1608, 1609, 1610,<br />
1611, 1918, 1969, 1994, 2144, 2146, 2149,<br />
2214, 2215, 2219<br />
genotype-phenotype relationships 843<br />
genotyping 1885<br />
geriatrics 154, 624, 1459, 2045<br />
germinal center 432, 1412<br />
giant cell arteritis 126, 774, 1277, 1280, 1292,<br />
1294, 1296, 1299, 1301, 1304, 1309, 1310,<br />
1311, 1314, 2198, 2199<br />
gingivalis 1717<br />
global 1151<br />
global disease flare 1688<br />
global health 1336<br />
glomerulonephritis 2048<br />
glucocorticoid induced osteoporosis (GIOP)<br />
978, 2156<br />
glucocorticoids 283, 342, 392, 423, 957, 965,<br />
966, 978, 981, 983, 994, 1036, 1123, 1179,<br />
1314, 1397, 1437, 1873, 2159, 2213<br />
GLUT9 164<br />
glutathione 1185<br />
glycosylation 494<br />
golimumab 326, 386, 890, 908, 1097, 1114,<br />
1127, 1136, 1804, 1814, 1815, 1835, 1943, 2264<br />
gout 144, 145, 146, 147, 148, 150, 151, 152,<br />
154, 155, 156, 157, 158, 159, 160, 162, 163,<br />
164, 165, 166, 869, 870, 873, 876, 877, 879,<br />
880, 881, 882, 883, 884, 888, 889, 1362, 1364,<br />
1366, 1423, 1544, 1547, 1556, 1565, 1569,<br />
1572, 1574, 1616, 2087, 2150, 2152, 2153, 2154<br />
growth 1684, 1696<br />
growth factors 259, 2202<br />
GRP78 1729<br />
guideline 2051<br />
GWAS follow-up 1599<br />
gynecologic issues 104, 468<br />
H1N1 224, 450, 1437<br />
H1N1 influenza 235<br />
H1N1 influenza A/California/7/2009 481<br />
hallux valgus 1328<br />
hand 142<br />
hand disorders 187, 708, 940, 1220, 1237,<br />
1749, 2076, 2142<br />
hand dysfunction 2076<br />
hand osteoarthritis 179, 185<br />
haplotype 707, 1280<br />
HAQ 1734<br />
HBV 329<br />
HDAC 750<br />
HDAC2 2029<br />
HDL composition 332<br />
healed arteritis 1311<br />
health assessment questionnaire 166, 314,<br />
690, 779, 1204, 1423, 1425, 1460, 1549, 1755,<br />
1765<br />
health behaviors 87, 156, 776, 1318, 1332,<br />
1428, 1553, 1562, 1576, 1856, 2096<br />
health care 1337<br />
health care disparities 790<br />
health care services 2284<br />
health care utilization 790<br />
health communications 1465<br />
health disparities 1336, 1875<br />
H<br />
abstract KEYWORD INDEX<br />
2010 Program Book 363
abstract KEYWORD INDEX<br />
health education 1006, 1318, 1336, 1337,<br />
1338, 1465, 2062, 2077, 2082, 2249<br />
health information technology 998<br />
health related quality <strong>of</strong> life 1872<br />
health services research 72<br />
health services use 2055<br />
health status 184, 1462<br />
health status outcomes 1461<br />
healthcare 969<br />
health-related quality <strong>of</strong> life (HRQoL) 1407,<br />
1837<br />
healthy controls 2245<br />
healthy volunteers 1273<br />
heart disease 459, 626, 1059<br />
heart failure 1059<br />
heart rate variability 808<br />
heath utility 1558<br />
heat-shock proteins 681, 1093, 1729<br />
heavy metal 2153<br />
helplessness 2140<br />
help-seeking 2282<br />
hematopoietic stem cells 351, 426<br />
hemochromatosis 818, 886<br />
hemophagocytic lymphohistiocytosis 653<br />
hemophagocytic syndrome 26<br />
hemorrhagic cystitis 2026<br />
hepatic disorders 1178, 1762<br />
hepatic magnetic elastography 129<br />
hepatitis 387, 892, 1639, 1646, 2030, 2039,<br />
2046<br />
hepatitis C 1646, 2024, 2131<br />
hepatotoxicity 75<br />
hepcidin 1309<br />
heritability 877<br />
heterogeneity 52<br />
HFE gene 886<br />
HIDS 1698<br />
HIF 1418<br />
high density lipoprotein 1189<br />
high mobility group box 1 1195<br />
high throughput sequencing 1604<br />
highly active anti-retroviral therapies (HAART)<br />
966<br />
high-resolution computed tomography 119<br />
hip 963, 2137<br />
hip disorders 529, 972, 2094<br />
hip fracture 972<br />
hip structure analysis 960<br />
hippocampus 1159<br />
Hispanic patients 305, 1465, 1768, 2148<br />
histochemistry 927<br />
histone 507, 750<br />
histone deacethylase inhibitor (Trishostatin A)<br />
1715<br />
histone deacetylase 1484, 2191<br />
histopathology 1151<br />
histoplasmosis 1643<br />
HLA 725<br />
HLA class II associations 66<br />
HLA-B27 552, 1448, 1969, 1973<br />
HLA-DRB1 shared epitope 2118<br />
HMGB1 1297<br />
home health 1005<br />
homebound 2110<br />
hormones 747, 1040<br />
hospitalized patients 163<br />
hr-pqct 136<br />
human 1270<br />
human anti-chimeric antibodies (HACA’s) 1826<br />
human follicular helper T cell 1246<br />
human immunodeficiency virus (HIV) 966,<br />
1645<br />
human leukocyte antigens (HLA) 66, 256, 549,<br />
645, 832, 1092, 1216, 1313, 1355, 1450, 1605,<br />
1966, 1973, 1974, 1975, 1979, 2114<br />
human papillomavirus (HPV) 464, 996<br />
humanized SLE mouse 427<br />
hyaluronate 1711<br />
hydroxychloroquine 463, 484, 732, 1860, 1865,<br />
2150, 2238, 2239, 2241, 2255<br />
hygiene hypothesis 248<br />
hyper IgD 1685<br />
hyper-IgD syndrome 2105<br />
hyperimmunoglobulinemia D with periodic<br />
fever syndrome 1698<br />
hypermobility 1342<br />
hypertension 878, 888, 1367, 1565, 1569, 2155<br />
hyperuricemia 160, 161, 874, 876, 878, 879,<br />
883, 884, 992, 1363, 1367, 1547, 1614, 1861,<br />
2088, 2154, 2155<br />
hypodermis 1624<br />
hypothalamic-pituitary-adrenal axis 649<br />
hypoxia 360, 630, 1418, 1510<br />
ibandronate 964<br />
ibupr<strong>of</strong>en 945, 946<br />
ICOS 1141<br />
idiopathic pulmonary artery hypertension 598<br />
IFNa 494<br />
IFN-gamma 428<br />
IgA antiphospholipid assays 14<br />
IgG4-related systemic disease 1671<br />
IKKβ 1107<br />
IL-1 265, 897, 1622<br />
IL-1 receptor antagobist 260<br />
IL-1 suppression 891<br />
IL-1 trap 1831<br />
I<br />
IL-1ß 2150<br />
IL-10 274, 1732<br />
IL13 833<br />
IL-13 polymorphism 1984<br />
IL-15 1801<br />
IL-17 276, 323, 365, 428, 896, 1041, 1730,<br />
1838, 1970, 1992, 2130, 2232<br />
IL-17 F 1515<br />
IL-17 induced arthritis 270<br />
IL-17 receptor 1976<br />
IL-17A 1274, 1515<br />
IL-18 903, 923, 1664<br />
IL-18 binding protein 1664<br />
IL-18BP 282<br />
IL-2 therapy 2131<br />
IL-21 432, 1088, 1594<br />
IL-22 275, 715, 1992<br />
IL-23 1260, 1970<br />
IL-23R 1078<br />
IL-27 276, 714<br />
IL-32 371<br />
IL-33 28<br />
IL-5 2203<br />
IL-6 18, 1109, 1293, 1800, 1996<br />
IL-6R 1996<br />
IL-7 receptor 1900, 1903<br />
IL-9 1241<br />
ILD 402<br />
imaging 1022<br />
imaging techniques 118, 119, 120, 136, 138,<br />
540, 650, 889, 964, 1051, 1370, 1617, 1622,<br />
1624, 1625, 1628, 1634, 1728, 1822, 1887,<br />
1931, 1983, 2097<br />
imatinib 560, 566, 573, 1189, 1990, 1997,<br />
2020, 2193<br />
imiglucerase 1653<br />
immune 1313<br />
immune complexes 263, 499, 1020, 1399, 1601<br />
immune reconstitution 1161<br />
immune response 752, 1037, 1440, 1580,<br />
1581, 2216<br />
immune response to vaccination 792<br />
immune complex 504, 866<br />
immunizations 457<br />
immunogenicity 464<br />
immunoglobulin (IG) 465, 504, 828, 1085, 1604<br />
immunoglobulin free light chains 333<br />
immunohistochemistry 482, 927<br />
immunological pr<strong>of</strong>ile 1908<br />
immunology 1430<br />
immunoregulation 442<br />
immunosuppression 1157, 2043<br />
immunosuppressive drugs 1865<br />
immunotherapy 1116, 1714<br />
364<br />
2010 Program Book
impact 1063, 1325<br />
inactive disease 2220<br />
INCB028050 2172<br />
inception cohort 2273<br />
incidence 112, 568<br />
incidence rate 972<br />
inclusion body myositis 922<br />
index 1878<br />
indigenous peoples 1538<br />
indomethacin 151<br />
indoor falls 684<br />
inducible NO synthase (iNOS) 1489<br />
inefficacy 1110<br />
infection 237, 248, 313, 316, 335, 341, 342,<br />
346, 400, 403, 414, 421, 698, 758, 782, 1381,<br />
1390, 1638, 1640, 1642, 1643, 1648, 1649,<br />
1669, 1678, 1876, 1969, 2023, 2103, 2216<br />
inflammasome 265, 2228<br />
inflammation 86, 88, 106, 134, 145, 151, 260,<br />
270, 288, 360, 369, 441, 443, 499, 536, 675,<br />
679, 714, 844, 854, 855, 864, 866, 949, 1034,<br />
1041, 1081, 1109, 1130, 1239, 1270, 1296,<br />
1309, 1422, 1424, 1426, 1470, 1506, 1509,<br />
1512, 1524, 1525, 1533, 1607, 1622, 1707,<br />
1728, 1761, 1785, 1813, 1883, 1953, 2044,<br />
2078, 2109, 2150, 2162, 2200, 2204, 2229,<br />
2231, 2233, 2260<br />
inflammatory arthritis 19, 28, 300, 629, 659,<br />
712, 716, 766, 778, 794, 890, 901, 904, 978,<br />
997, 1029, 1067, 1391, 1418, 1427, 1665, 1710,<br />
1729, 1737, 2227<br />
inflammatory back pain 544<br />
inflammatory bowel disease (IBD) 223, 537,<br />
901<br />
inflammatory diseases 2217<br />
inflammatory markers 385<br />
infliximab 216, 234, 328, 352, 381, 420, 988,<br />
1276, 1300, 1436, 1542, 1680, 1743, 1826,<br />
1829, 1945, 1960, 2265<br />
influenza 224, 237, 478, 1238<br />
influenza vaccine 1694<br />
information needs 1408<br />
information technology 221, 2111, 2284<br />
infusion therapy 1002<br />
inhibitor 1358<br />
inhibitory kappaB 1487<br />
injection 947, 1567, 1626, 2225<br />
innate immune cells 866<br />
innate immunity 845, 935, 1883, 2230<br />
innate lymphocyte 2232<br />
in-patient 1576<br />
insole 2134<br />
instrument validation 1337<br />
insulin receptor 1514<br />
insulin resistance 389<br />
insulin-like growth factor 670, 1501<br />
integrins 844, 865, 1719<br />
intensive care unit 2102<br />
inter- and intra-observer agreement 1623<br />
inter- and intra-rater variability 1623<br />
inter-disciplinary consensus 1212<br />
interferon regulatory factor 433, 1712<br />
interferon signature 1904<br />
interferon-γ assay 756<br />
interferon-gamma release assay 782<br />
interferon-regulatory factor-4 435<br />
interferons 271, 428, 433, 493, 494, 496, 501,<br />
503, 850, 868, 934, 1164, 1181, 1183, 1199,<br />
1376, 1660, 1661, 1712, 1904, 2187, 2188,<br />
2189, 2278<br />
interfreon-alpha 1181<br />
interleukin (IL) -32 277<br />
interleukin 1 1831<br />
interleukin 1 receptor antagonist 271<br />
interleukin 6 1247<br />
interleukin-1 272<br />
interleukin-1 receptor associated kinase-1 1587<br />
interleukin-13 675<br />
interleukin-17 1271<br />
interleukin-18 703<br />
interleukin-1b (IL-1)- 1489<br />
interleukin-23 1271<br />
interleukin-6 30, 272, 1096, 2168<br />
interleukin-7 278<br />
interleukins (IL) 18, 19, 29, 35, 152, 153, 260,<br />
265, 271, 276, 278, 282, 353, 358, 369, 371,<br />
373, 432, 629, 637, 657, 707, 831, 895, 903,<br />
1088, 1121, 1124, 1126, 1241, 1260, 1270,<br />
1308, 1412, 1435, 1488, 1531, 1607, 1664,<br />
1831, 1903, 1970, 2158, 2203<br />
interlleukin-2 receptor alpha (sIL-2Ra) 49<br />
intermittent and constant osteoarthritis pain<br />
(ICOAP) 682<br />
international 969, 1013<br />
internet 1340, 1362<br />
internet survey 807<br />
internet use 1409<br />
interpr<strong>of</strong>essional practice 2050<br />
inter-rater discrimination 1652<br />
interstitial keratitis 1675<br />
interstitial lung disease 592, 602, 919, 932,<br />
1035, 1044, 1086, 1377, 1672, 1803, 1824<br />
interstitial pneumonia 1042<br />
intestinal Behcet’s disease 1300<br />
intestinal involvement 1297<br />
intestinal microbiota 1390<br />
intestinal parasitosis 539<br />
intima media thickness 455<br />
intimal hyperplasia 1294<br />
intima-media thickness 1028<br />
intra articular 943, 947, 2225<br />
intracellular signalling 1357<br />
intracranial hemorrhage 2037<br />
intravenous immunoglobulin (IVIG) 494, 576<br />
invasion 1387, 1421<br />
ion channels 1270<br />
iontophoresis 218<br />
IRF-1 282<br />
IRF5 1607<br />
iridocyclitis 528<br />
IR-induced DNA damage 509<br />
ITGAM 637<br />
J<br />
JAK1/JAK2 2172<br />
janus kinase (JAK) 269, 717, 1137, 1240, 2171,<br />
2172, 2233<br />
janus kinase 2 (JAK2) inhibition 2233<br />
janus-kinase-1 2200<br />
Japanese 237, 399, 1285, 1577, 1672<br />
JNK 32<br />
job 2139<br />
job loss 80, 781, 1541, 1548, 2079<br />
joint count 166, 723, 1759<br />
joint damage 2109<br />
joint destruction 32, 73, 132, 272, 367, 536,<br />
716, 887, 1470, 1479, 1482, 1495, 1600, 1610,<br />
1738, 1747, 1785, 1812, 1821, 1828, 2256,<br />
2258, 2273<br />
joint distraction 176, 1380<br />
joint examination 1781<br />
joint procedures 1539<br />
joint space distance 136<br />
joint space narrowing 132, 707, 1369<br />
joint swelling 79, 2258<br />
junctional adhesion molecule 1419<br />
juvenile arthritis 207, 220, 224, 251, 259, 1407,<br />
2219<br />
juvenile dermatomyositis 242, 252, 928, 1344,<br />
1672, 1678, 1700<br />
juvenile fibromyalgia 807<br />
juvenile idiopathic arthritis (JIA) 206, 208, 209,<br />
210, 213, 214, 216, 217, 218, 219, 222, 224,<br />
226, 227, 228, 229, 230, 231, 232, 235, 236,<br />
237, 238, 239, 243, 244, 245, 247, 248, 250,<br />
253, 254, 255, 256, 258, 263, 264, 654, 655,<br />
1012, 1339, 1404, 1405, 1406, 1408, 1434,<br />
1491, 1601, 1630, 2084, 2103, 2219, 2220, 2248<br />
juvenile idiopathic arthritis-enthesitis (ERA)<br />
219, 233, 235, 266<br />
juvenile localized scleroderma <strong>of</strong> the face 1687<br />
juvenile myositis 1379, 1678<br />
juvenile onset patients 1697<br />
juvenile polyarteritis nodosa 2033<br />
juvenile psoriatic arthritis 219<br />
juvenile scleroderma 1439, 1682, 1687, 1704<br />
juvenile sclerosis 1704<br />
juvenile spondylarthropathy 212, 225, 266,<br />
1633<br />
abstract KEYWORD INDEX<br />
2010 Program Book 365
abstract KEYWORD INDEX<br />
K/BxN 1417<br />
K2P5.1 1255<br />
kappa score 522<br />
Karn<strong>of</strong>sky performance status 1204<br />
Kawasaki disease 249, 267, 652, 828, 1680,<br />
2202<br />
kidney disease 857<br />
kinase 273, 286, 493, 635, 1119, 1493, 1513,<br />
1516, 2234<br />
kinase inhibitor 273, 288, 1107<br />
KIR (Killer Ig like receptor) 1966<br />
knee 131, 140, 180, 191, 194, 200, 201, 682,<br />
684, 693, 708, 941, 943, 947, 963, 1382, 1385,<br />
1558, 2052, 2053, 2054, 2055, 2059, 2061,<br />
2094, 2096, 2098, 2101, 2132, 2134, 2244<br />
knee loading 2099<br />
knee osteoarthritis 186, 189, 2059, 2100<br />
knee pain 685<br />
knockout line 854<br />
knowledge 1009<br />
knowledge transfer 984<br />
L 1073<br />
La/SSB 2175<br />
labial salivary gland 1900<br />
laboratory tests 312, 378, 909, 1293, 1359,<br />
1765, 1845<br />
language 1024<br />
laser Doppler imaging 579<br />
laser Doppler perfusion imaging 574<br />
late onset rheumatoid arthritis 1061<br />
latent tuberculosis infection (LTBI) 699, 782<br />
latitudes variation 783<br />
lecithin cholesterol acyl:transferas 1058<br />
leflunomide 75, 229, 319, 1796<br />
lenalidomide 1699<br />
lentivirus 1729<br />
leukocyte homing 860<br />
levamisole 2013<br />
LFA-1 503<br />
lidocaine patch 5% 944<br />
lipase 438<br />
lipids 86, 345, 385, 393, 438, 471, 1000, 1019,<br />
1030, 1033, 1064, 1187<br />
literature search 1291<br />
liver fibrosis 129<br />
liver function 319<br />
loading 190<br />
localized scleroderma 1683, 2006<br />
long term 97<br />
K<br />
L<br />
longitudinal studies 77, 110, 380, 731, 779,<br />
1219, 1400, 1406, 1459, 1541, 1548, 1685,<br />
1854, 1951, 2064, 2079<br />
long-term outcome 380, 1683<br />
low back pain 1458<br />
low disease activity 1826<br />
low dose 1944<br />
low dose aspirin 945<br />
low dose strategy 290<br />
low-field MRI 138<br />
lumbar disc herniation 1921<br />
lung 563, 596, 604, 605, 622, 704, 724, 852,<br />
907, 924, 1022, 1086, 1176, 1212, 1635, 1739,<br />
1989, 2119, 2194<br />
lupus 2189<br />
lupus anticoagulant 4, 12<br />
lupus arthritis 446<br />
lupus gradient 510<br />
lupus nephritis 268, 423, 430, 433, 434, 435,<br />
440, 467, 469, 477, 851, 867, 1140, 1144, 1151,<br />
1173, 1251, 1398, 1399, 1402, 1403, 1414,<br />
1453, 1455, 1702, 1866, 2085, 2104, 2121,<br />
2186, 2188<br />
Lyme arthritis 1638<br />
Lyme disease 1320, 1638, 1644<br />
lymph node 1069, 1710<br />
lymphadenopathy 903<br />
lymphatic draining 1710<br />
lymphocytes 422, 463, 492, 747, 846<br />
lymphocytopenia 316<br />
lymphoid neogenesis 1906<br />
lymphoma 398, 720, 1015, 1884, 1888, 1912,<br />
1914, 1916<br />
lymphotoxin 1885<br />
lymphotoxin alpha 1122<br />
M<br />
machine learning 1403<br />
macromolecular therapy 423<br />
macrophage activation syndrome 18, 208, 653,<br />
903, 1354, 1664, 1668<br />
macrophage migration 1718<br />
macrophage migration inhibitory factor (MIF)<br />
903<br />
macrophages 23, 273, 283, 359, 844, 845, 847,<br />
853, 854, 859, 861, 1100, 1135, 1353, 1506,<br />
1522, 1613, 1718, 1723, 1761, 1798, 1965,<br />
1993, 2230, 2276<br />
magnetic resonance imaging (MRI) 122, 123,<br />
125, 126, 127, 130, 132, 133, 134, 135, 137,<br />
138, 141, 142, 182, 188, 193, 197, 228, 461,<br />
524, 540, 551, 553, 650, 667, 706, 709, 921,<br />
938, 1159, 1167, 1170, 1293, 1369, 1370, 1371,<br />
1372, 1373, 1380, 1625, 1682, 1779, 1817,<br />
1929, 1934, 1957, 1958, 1959, 1963, 2100<br />
maintenance treatment 2041<br />
MAIT cell 2232<br />
major histocompatibility complex (MHC) 502,<br />
1281, 1579, 1979, 2185<br />
malalignment 131, 2100<br />
male vs female 1158<br />
malignancy 62, 214, 398, 407, 408, 468, 580,<br />
720, 731, 883, 996, 1899, 2084<br />
mammalian target <strong>of</strong> rapamycin (mTOR) 1530<br />
managed care 757, 764<br />
management 888<br />
manzamine A 1131<br />
MAP kinases 17, 39<br />
MAPK 632<br />
MAPKK 635<br />
mass communication 2081<br />
mast cells 28, 333, 896, 1449, 1732<br />
matrix metalloproteinase (MMP) 21, 267, 366,<br />
541, 1086, 1292, 1388, 1466, 1472, 1481, 1491,<br />
1497, 1530, 1628, 1797, 1800<br />
MCTD 608, 852<br />
MDRD 147<br />
measure 1927<br />
measurement scales 2065<br />
mediation analysis 1461<br />
medical resident 46, 48, 1431, 1432<br />
medication 1001<br />
medication adherence 1404<br />
medication compliance 338, 1056<br />
medication cost 1462<br />
membrane attack complex 846, 1262<br />
memory 1159<br />
men 1546<br />
meniscal tear 202, 885<br />
meniscectomy 167, 192<br />
menopause 301, 2245<br />
mental health status 2070<br />
mepolizumab 2203<br />
mesenchymal stem cells 630, 840, 918, 1134,<br />
1143, 1182, 1247, 1382, 1475, 1490, 1498<br />
messenger RNA (mRNA) 2008, 2219, 2276<br />
meta-analysis 168, 412, 419, 720, 824, 1574,<br />
1657, 1795, 2145, 2155<br />
metabolic syndrome 445, 476, 547, 871, 888,<br />
1177, 1178, 1507, 1667<br />
metabolomics 711<br />
metacarpophalangeal joints 1634<br />
metalloproteases 1484<br />
methionine sulfoxide reductase A (MsrA) 1599<br />
methodology 952<br />
methotrexate (MTX) 40, 74, 129, 220, 230,<br />
253, 254, 284, 302, 319, 335, 377, 380, 388,<br />
394, 396, 397, 417, 664, 827, 1009, 1060, 1096,<br />
1101, 1106, 1117, 1333, 1392, 1393, 1394,<br />
1395, 1439, 1596, 1670, 1796, 1806, 1812,<br />
1815, 1836, 2171, 2267<br />
methotrexate polyglutamates (MTXPG) 302<br />
methotrexate responder 1392<br />
366<br />
2010 Program Book
methylation 826, 1253, 1489<br />
methyltransferases1 1352<br />
mevalonate kinase deficiency 905<br />
MHC class I polypeptide-related sequence A<br />
511<br />
MHC-disease associations 843<br />
MICA alleles 1979<br />
microangiopathy 578, 1236<br />
microarray 1986, 1990, 2000, 2200<br />
microchimerism 1060<br />
micro-computed tomography 1634<br />
microCT 1471<br />
microCT scan 964<br />
microgravity 959<br />
microparticles 2047<br />
microRNA 35, 359, 422, 501, 842, 858, 1253,<br />
1352, 1422, 1490, 2179<br />
microscopic polyangiitis 676, 1691, 2009, 2012,<br />
2014<br />
microsporidiosis 539<br />
microvascular dysfunction 1041<br />
midtarsal arthropathy 1665<br />
migration 17, 39, 1511, 1722<br />
migration inhibitory factor (MIF) 973, 1721<br />
milnacipran 98, 648, 805, 806<br />
Milwaukee shoulder 2151<br />
mind map 2082<br />
mind-body exercise 95<br />
minocycline 318<br />
minor salivary gland 1897<br />
miR-146a 501<br />
mir-19b 858<br />
miRNA 247, 633<br />
mitochondria 360, 437, 631, 835, 1185, 1510<br />
mitochondrial dysfunction 1510<br />
mitochondrial mutagenesis 360<br />
mitochondrial mutations 1510<br />
mixed connective tissue disease (MCTD) 568,<br />
893, 1223<br />
MLR 1270<br />
MMP 368<br />
MMP-2 1387<br />
MMP-3 1491<br />
mode <strong>of</strong> action 1517<br />
modeling 190<br />
modified stoke ankylosing spondylitis spinal<br />
score (MSASSS) 549<br />
monitoring 295, 1755<br />
monoclonal antibodies 145, 710, 895, 1096,<br />
1425, 1435, 2087, 2168, 2170<br />
monocyte chemokines 23<br />
monocytes 506, 622, 657, 740, 865, 1189,<br />
1198, 1512, 1513, 1528, 1723, 1904, 1981, 2200<br />
monosodium iodoacetate 1480<br />
monotherapy 74<br />
Monte Carlo simulation 1555<br />
montelukast 1698<br />
Montreal cognitive assessment questionnaire<br />
1855<br />
mood 805<br />
morbidity and mortality 49, 53, 71, 83, 620,<br />
642, 651, 773, 930, 1044, 1052, 1057, 1140,<br />
1179, 1438, 1550, 1668, 1777, 1849, 2088,<br />
2102, 2124, 2163, 2194, 2240<br />
morphea 1661<br />
mortality 651, 1049<br />
motivational interviewing 797<br />
mouse model 823, 1446<br />
movement 2076<br />
MRI 131, 1370<br />
mRNA metabolism 364<br />
mthotrexate polyglutamates 417<br />
mTOR 1185, 1196, 1971<br />
MTX 849<br />
Muckle-Wells syndrome 265, 657, 894, 899,<br />
900, 905, 2228<br />
multicenter cohort 1852<br />
multicenter study 1691, 1864, 2172<br />
multidimensional health assessment<br />
questionnaire (MDHAQ) 990<br />
multi-disciplinary center 2077<br />
multiple medication use 2208<br />
multiple TNFi failure 1795<br />
muscle area 1065<br />
muscle density 1065<br />
muscle strength 171, 191, 203, 627, 2056,<br />
2245, 2283<br />
musculoskeletal disorders 44, 45, 242, 687,<br />
826, 907, 915, 927, 928, 1549, 2208<br />
musculoskeletal pain 2136<br />
MVK mutations 2105<br />
mycophenolate m<strong>of</strong>etil 467, 477, 1398, 1401,<br />
1402, 1453, 1670, 1866, 2085, 2192, 2241<br />
myelitis 702<br />
myeloid dendritic cells 1198<br />
myeloperoxidase (MPO) 676, 870<br />
myocardial infarction 148, 542, 1052, 2124<br />
my<strong>of</strong>ascial pain syndrome 114<br />
myoloid homeostasis 854<br />
myositis 15, 576, 914, 915, 917, 919, 921, 922,<br />
924, 925, 926, 929, 930, 932, 933, 934, 935,<br />
1374, 1376, 1379, 1679, 2068<br />
N<br />
NAD biosynthesis pathway 1595<br />
nail changes 1951<br />
nailfold capillaroscopy 1623<br />
NALP3 2151<br />
NALP3 inflammasome 2150<br />
Nam’s score 522<br />
nampt 1514<br />
naproxen 937, 2206<br />
Native <strong>American</strong>s 780, 1538<br />
natural antibodies 88, 1194<br />
natural killer (NK) cells 277, 503, 511, 860,<br />
1354, 1505<br />
natural killer T cell 505, 1264<br />
neck pain 1458, 2060<br />
necrosis 491<br />
negative binomial distribution 1564<br />
neonatal disorders 489, 495, 656, 732, 1438<br />
neonatal lupus 732<br />
neonatal outcomes 775<br />
nephritis 159, 422, 482, 906, 1400, 1401, 1526,<br />
2022<br />
nephrogenic fibrosing dermopathy 1993<br />
nerve entrapment 2223<br />
neurocognitive dysfunction 1689<br />
neuroendocrine immune (NEI) 361, 1025,<br />
1226, 1536<br />
neuroimaging 1689<br />
neurologic involvement 1165, 1208, 1293,<br />
1893, 1894, 1902, 1908, 1911, 1915<br />
neurological outcome 2019<br />
neuromuscular control 194<br />
neuromyelitis optica 702, 1174<br />
neuropathy 205<br />
neuropeptides 1536<br />
neuropsychiatric disorders 1174, 1181, 1844,<br />
1852, 1915, 2242, 2243<br />
neuropsychiatric involvement in SLE (NPSLE)<br />
1852<br />
neuropsychiatric SLE 1689<br />
neutrophils 247, 251, 492, 681, 854, 1427,<br />
1531, 2015<br />
neutrophils and tocilizumab 294<br />
new bone formation 1978<br />
NFAT 2126<br />
NFATc1 1469<br />
NF-kappaB 1412, 1487<br />
NF-kappaB P65 1532<br />
NF-kB 632, 633<br />
NGF 37<br />
NHANES 879, 1363, 1547, 2154<br />
NHI criteria 1275<br />
nine years 1963<br />
nitric oxide 437, 618, 936, 953, 1477, 2277<br />
NLRP1 2226<br />
NLRP12 657<br />
NLRP3 2228<br />
NMDA receptor 1536<br />
NMNAT2 1595<br />
nociception 841<br />
nociceptive flexion reflex (NFR) 101<br />
NOD2 1607, 1713<br />
abstract KEYWORD INDEX<br />
2010 Program Book 367
abstract KEYWORD INDEX<br />
NOD2 gene mutation 1656<br />
nod-like receptor (NLR) 1713, 2226<br />
nominal group technique (NGT) 2196<br />
nonalcoholic fatty liver disease 1666<br />
non-attendance 1007<br />
non-cardiovascular disease 49<br />
non-Hodgkin´s lymphoma 1913<br />
non-inflammatory symptoms 990<br />
non-invasive 647<br />
nonoparticles <strong>of</strong> LDE 284<br />
nonrestful sleep 820<br />
nonsteroidal antiinflammatory drugs (NSAIDs)<br />
151, 882, 942, 945, 946, 954, 955, 1477, 2205,<br />
2206<br />
north and south 783<br />
north India 4<br />
NOS3 1352<br />
novel cardiovascular risk factors 1067<br />
novel therapeutic 2032<br />
NSAIDs 298<br />
NT-proBNP 483, 1059<br />
nuclear hormone receptor 611<br />
nuclear receptor 1387, 1481<br />
nurse perspective 2279<br />
nursing consultations 2280<br />
nutrition 1366<br />
NZB/W mice 1414<br />
obesity 95, 179, 231, 297, 515, 627, 685, 939,<br />
1330, 1331, 1364, 1562, 2257<br />
observational 405, 1036<br />
observational study 1381<br />
obstetrical outcomes 775<br />
occupational therapy 1319, 2050, 2063, 2143<br />
ocrelizumab 383, 414, 1455, 2169<br />
ocular involvement 240, 256, 512, 1405, 1670<br />
odontostomatologic involvement 1687<br />
older adults 692, 2071<br />
Olf1/EBF associated zinc finger protein 1182<br />
oncostatin M 30<br />
online resources 1345<br />
onycholysis 1951<br />
open label 97<br />
open, randomized trial 891<br />
opportunistic infections 472, 700, 1310, 1643<br />
opsonisation 490<br />
optimally effective MTX dose 388<br />
optimising health care resources 776, 1553<br />
oral 1074, 1716<br />
oral microbiota 1390<br />
organ involvement 578<br />
orthopedic 1381, 1576<br />
O<br />
orthopedic surgery 1550, 1570<br />
osteoarthritis 37, 46, 121, 122, 124, 128, 131,<br />
137, 140, 142, 143, 167, 168, 169, 171, 176,<br />
178, 179, 180, 181, 184, 185, 186, 187, 188,<br />
189, 190, 191, 193, 194, 195, 196, 197, 200,<br />
201, 202, 203, 204, 205, 624, 631, 632, 633,<br />
634, 682, 683, 684, 685, 686, 692, 693, 706,<br />
707, 708, 709, 710, 711, 823, 831, 835, 838,<br />
840, 841, 845, 875, 936, 937, 938, 939, 940,<br />
941, 942, 943, 944, 948, 949, 950, 951, 952,<br />
953, 954, 955, 963, 1319, 1373, 1380, 1382,<br />
1384, 1426, 1463, 1464, 1472, 1476, 1477,<br />
1480, 1484, 1486, 1489, 1494, 1497, 1503,<br />
1532, 1555, 1557, 1558, 1620, 1628, 2051,<br />
2052, 2055, 2056, 2058, 2091, 2092, 2093,<br />
2094, 2096, 2097, 2098, 2099, 2100, 2101,<br />
2132, 2133, 2134, 2136, 2140, 2205, 2211,<br />
2229, 2244<br />
osteoblasts 630, 716, 881, 956, 1487, 1490<br />
osteoclast differentiation and bone turnover<br />
1471<br />
osteoclast inhibition 273<br />
osteoclast-mediated bone resorption 1470<br />
osteoclastogenesis 281, 353, 365, 677, 1130,<br />
1467, 1469, 1488, 1492, 1493, 1495, 2237<br />
osteoclasts 22, 521, 639, 677, 842, 1351, 1471,<br />
1485, 1492, 1493, 1502, 2158<br />
osteocytes 965<br />
osteolysis 1080<br />
osteomalacia 2082<br />
osteonecrosis 1653, 2213<br />
osteopenia 964, 1770<br />
osteophytosis 185, 1373<br />
osteopontin 262, 612, 1521, 2170<br />
osteoporosis 31, 798, 956, 957, 958, 960, 961,<br />
966, 967, 968, 969, 970, 972, 974, 976, 977,<br />
978, 980, 982, 983, 989, 994, 999, 1005, 1006,<br />
1066, 1156, 1316, 1317, 1318, 1540, 1543,<br />
1552, 1561, 1773, 2112, 2157, 2159, 2161<br />
osteoprotegerin 479, 623, 1017, 1497<br />
outcome 1315, 1626, 1736<br />
outcome measures 79, 107, 108, 117, 142, 143,<br />
181, 217, 227, 306, 337, 567, 570, 577, 586,<br />
599, 769, 772, 777, 795, 800, 920, 1014, 1112,<br />
1157, 1213, 1284, 1303, 1316, 1369, 1463,<br />
1545, 1559, 1668, 1683, 1688, 1700, 1745,<br />
1766, 1787, 1809, 1863, 1878, 1896, 1922,<br />
2091, 2095, 2137, 2222, 2225, 2280<br />
outcome studies 651<br />
outcomes 705, 1747<br />
outdoor falls 684<br />
over dispersion 1564<br />
oxidative damage 360<br />
oxidative stress 621, 631, 1357<br />
oxoguanine 631<br />
P selectin 492<br />
p21 861<br />
P<br />
P2Y12 10<br />
p38 32, 274, 1513<br />
p38 MAPK 1119<br />
paced visual serial adding test (PVSAT) 1167<br />
Paget 975, 2237<br />
PAH 402<br />
PAH-QuERI 598<br />
pain 79, 96, 97, 151, 170, 173, 174, 184, 647,<br />
682, 785, 809, 810, 814, 819, 821, 823, 836,<br />
841, 936, 939, 949, 950, 951, 1050, 1063, 1343,<br />
1385, 1464, 1551, 1557, 1567, 1568, 1645,<br />
1665, 1703, 1778, 1862, 1882, 2058, 2097,<br />
2098, 2245, 2247, 2248, 2249<br />
pain measures 2244<br />
pamidronate 1925<br />
pandemic 478<br />
pandemic H1N1 influenza 323<br />
papillary thyroid cancer 1038<br />
paradoxical effect 904<br />
parathyroid hormone 2160<br />
parenteral 396<br />
parotid gland 1887<br />
PARP-1 440<br />
Parry-Romberg syndrome 1687<br />
parvovirus B19 694, 1641<br />
PASE questionnaire 1937<br />
patell<strong>of</strong>emoral joint 2244<br />
path analysis 819<br />
pathergy phenomenon 1289<br />
pathergy test 1289<br />
pathogen-associated molecular pattern 1446<br />
pathogenesis 1374, 1971, 1993<br />
pathology 367<br />
patient care 1335<br />
patient characteristics 68<br />
patient doctor communication 1428<br />
patient global assessment 79, 166<br />
patient global impression <strong>of</strong> change 814, 950<br />
patient organizations 1923<br />
patient outcomes 1735<br />
patient perception 998<br />
patient preferences 324<br />
patient questionnaires 63, 69, 84, 115, 178,<br />
802, 985, 990, 1007, 1027, 1303, 1750, 1755,<br />
1857, 1910, 2066, 2068<br />
patient satisfaction 177, 1002<br />
patient specific functional scale 115<br />
pattern 1769<br />
pattern recognition receptors 2230<br />
pDC 494<br />
PDGF receptor 2001<br />
PDGFR inhibitor 289<br />
pediatric 1305, 2017<br />
pediatric Behçet’s disease 1305<br />
pediatric rheumatology 4, 47, 211, 214, 221,<br />
368<br />
2010 Program Book
233, 234, 240, 243, 252, 262, 268, 790, 998,<br />
1008, 1305, 1341, 1342, 1404, 1434, 1436,<br />
1673, 1674, 1675, 1676, 1679, 1684, 1685,<br />
1686, 1687, 1688, 1689, 1691, 1692, 1693,<br />
1699, 1701, 1702, 1703, 1705, 1706, 1872,<br />
2006, 2102, 2104, 2105, 2106, 2248<br />
peer support 1335<br />
pegloticase 157<br />
pegsiticase 144<br />
peptide library 2001<br />
peptidomimetics 861<br />
peptidylarginine deiminase 1074<br />
perceived helplessness 1461<br />
perfusion 1201<br />
periarticular osteopenia 1770<br />
peridontal disease 2204<br />
periodic fever 1706<br />
periodontal 1074<br />
periodontal disease 1390, 2078<br />
periodontitis 2204<br />
perioperative risk 1039<br />
peripheral neuropathy 1165<br />
peripheral vascular disease 78, 470<br />
peroxisome proliferator-activated receptor<br />
1265<br />
PET/CT 1275<br />
PGE2 365<br />
pH 1502<br />
pharmacist 1575<br />
pharmacodynamics 801<br />
pharmacoepidemiology 72, 2213<br />
pharmacogenetics 828, 1596<br />
pharmacogenomics 254<br />
pharmacokinetic-pharmacodynamics 1945<br />
pharmacokinetics 149, 150, 417, 597, 801,<br />
1222<br />
pharmacology 253, 1818, 1945<br />
phase2a 2172<br />
phenotype 1373<br />
phophatidylserine 1728<br />
phosphatase 609, 2007<br />
phosphodiesterase inhibitors 2086<br />
phospholipid-binding proteins 10<br />
phosphorylation arrays 613<br />
phosphorylcholine 88, 1194<br />
physcial function 191<br />
physical activity 93, 692, 693, 2061<br />
physical activity guidelines 1558, 2096<br />
physical examination 84, 985<br />
physical function 104, 116, 203, 520, 688, 690,<br />
1044, 1065, 1335, 1384, 2136, 2244<br />
physical performance 180<br />
physical performance measures 2244<br />
physical therapy 115, 171, 1316, 2050, 2051,<br />
2053, 2054, 2055, 2060, 2143<br />
physician education 1735<br />
physician global assessment 79, 2109<br />
PI3K 288, 362<br />
pictorial representation 2082<br />
placebo 1892<br />
plain radiographic progression 1371<br />
plasma 1072<br />
plasma cells 742, 1186, 1414<br />
plasmablasts 1295<br />
plasmacytoid dendritic cells (pDCs) 503, 1661<br />
platelet aggregation 10<br />
platelet C4d 620<br />
platelet reactivity 1109<br />
platelet-derived growth factor and receptor<br />
2007<br />
platelets 10, 267, 363, 1109, 2047<br />
pleuritis 1176<br />
pneumo renal syndrome 2009<br />
pneumococcal polysaccharide vaccine 1037<br />
pneumococcal conjugate vaccine 1037, 1440<br />
pneumococcal polysaccharide vaccine 1440<br />
pneumonia 1876<br />
podosome 1502<br />
polyamines 357<br />
polyarteritis nodosa 2016, 2024, 2033<br />
polyarthritis 796<br />
polychondritis 1669<br />
polymerase chain reaction (PCR) 1644<br />
polymorphism 33, 92, 96, 348, 397, 488, 511,<br />
538, 824, 836, 841, 1087, 1313, 1582, 1583,<br />
1591, 1595, 1602, 1885, 1909, 1972, 1994,<br />
2148, 2218<br />
polymyalgia rheumatica 777, 1276, 1296, 1304,<br />
1306, 1311, 1619, 1637, 1652, 1654, 1655<br />
polymyositis/dermatomyositis (PM/DM) 917,<br />
918, 931, 1375, 1377<br />
polyp 883<br />
polysomnography 820<br />
pooled analysis 814, 815<br />
population studies 66, 71, 571, 831, 838, 878,<br />
1299, 1327, 1328, 1331, 1336, 1363, 1538,<br />
1547, 1551, 1555, 1563, 1568, 1615, 2040,<br />
2069, 2080, 2138, 2139, 2180<br />
population-based 2137<br />
population-based study 1556<br />
positive affect 1320<br />
positron emission tomography (PET) 1613<br />
post chikungunya rheumatism 1640<br />
post marketing surveillance 399<br />
post-transcriptional regulation 364<br />
postural assessment 1316<br />
practice guidelines 396, 699, 984, 1008, 1202,<br />
1203<br />
pre-clinical 1083, 1116<br />
pre-clinical rheumatoid arthritis 1094<br />
predating disease onset 1847<br />
prediction 111, 112, 1083<br />
prediction model 311<br />
predictive validity 2108<br />
predictors 93, 300, 536, 1737, 1778<br />
predictors <strong>of</strong> treatment response 52<br />
prednisolone, prednisone 452, 1047, 1153,<br />
1396, 1439, 1773, 1865, 2038<br />
pre-eclampsia 1149<br />
pregabalin 648<br />
pregnancy 81, 325, 384, 401, 458, 475, 545,<br />
718, 775, 779, 1043, 1073, 1149, 1150, 1192,<br />
1193, 1199, 1322, 1860, 2034, 2035, 2210<br />
pre-mRNA 348<br />
prescribing trends 68, 80, 641, 1960<br />
prevalence 58, 112, 197, 975, 976, 1363, 1373,<br />
1538, 1852, 1939, 2154, 2180<br />
prevention 152, 236, 387, 478, 784, 1062,<br />
1288, 1329, 1555, 2092<br />
prilocaine 114<br />
primary care 1029, 2180<br />
primary Sjøgren’s syndrome 1900, 1903, 1904,<br />
1913, 1917<br />
primary/secondary necrosis 490<br />
pro-angiogenic cells 456<br />
procalcitonin 1649<br />
productivity 1882<br />
progesterone 747<br />
progesterone receptors 747<br />
prognosis 1312, 1912<br />
prognostic biomarker 2121<br />
prognostic factors 189, 301, 311, 388, 460, 658,<br />
796, 931, 932, 1110, 1149, 1152, 1227, 1392,<br />
1742, 1759, 1899, 1964, 2052, 2221, 2258<br />
progression 124, 707, 1769, 2273<br />
progressive multifocal leukencephalopathy 700<br />
progressive resistance exercise 2132<br />
prolifeartion 846, 1971<br />
promoters 1733<br />
prostaglandins 864, 1201, 1222, 1514<br />
prosthetic wear particles 1470<br />
protease inhibitor 1645<br />
proteinase 3 681<br />
proteinuria 252, 469, 1415<br />
proteoglycan 1447, 1480<br />
proteomics 487, 652, 834, 839, 843, 1601,<br />
2002, 2229<br />
proton pump inhibitors 2089<br />
proximal tubule 164<br />
P-selectin glycoprotein ligand-1 1246<br />
pseudogout 885<br />
psoriasis 521, 833, 1125, 1273, 1928, 1979<br />
abstract KEYWORD INDEX<br />
2010 Program Book 369
abstract KEYWORD INDEX<br />
psoriatic arthritis 20, 128, 215, 514, 515, 521,<br />
523, 528, 530, 531, 532, 536, 538, 541, 543,<br />
546, 554, 664, 758, 761, 783, 793, 833, 849,<br />
856, 1105, 1372, 1618, 1621, 1634, 1667, 1799,<br />
1919, 1920, 1926, 1928, 1930, 1932, 1935,<br />
1936, 1937, 1939, 1940, 1943, 1950, 1951,<br />
1952, 1954, 1955, 1956, 1960, 1962, 1966,<br />
1968, 1971, 1974, 1975, 1976, 1979, 1983,<br />
1984, 2130, 2182, 2183, 2273<br />
psychological status 449, 802, 1024, 1343,<br />
1862<br />
psychosocial factors 449, 683, 1320, 1321,<br />
1324, 1347, 1348, 1428, 1645, 1748, 2064<br />
PTPN2 1607<br />
PTPN22 824, 1076<br />
public health 974<br />
public relation 2081<br />
pulmonary arterial hypertension 564, 565, 568,<br />
618, 1157, 1210, 1223<br />
pulmonary complications 83, 561, 568, 569,<br />
570, 585, 586, 587, 599, 602, 618, 619, 727,<br />
829, 916, 923, 931, 1004, 1042, 1044, 1157,<br />
1166, 1218, 1227, 1231, 1395, 1669, 1720<br />
pulmonary embolism 1285<br />
pulmonary fibrosis 604<br />
pulmonary hypertension 567, 569, 570, 585,<br />
586, 592, 595, 598, 727, 1004<br />
pulmonary interstitial fibrosis 1635<br />
pulmonary rheumatoid nodules 1810<br />
purine nucleoside phosphorylase inhibition 150<br />
purpura 2013<br />
Q<br />
qualitative 1332<br />
qualitative research 1321<br />
quality appraisal 755<br />
quality improvement 221, 993<br />
quality indicators 2113<br />
quality measurement 993<br />
quality <strong>of</strong> care 59, 70, 72, 87, 162, 484, 789,<br />
985, 986, 989, 991, 993, 995, 998, 999, 1002,<br />
1007, 1010, 1011, 1056, 1332, 1334, 1338,<br />
1428, 1571, 1735, 1856, 1923, 2112, 2113, 2279<br />
quality <strong>of</strong> life 99, 116, 146, 155, 172, 207, 296,<br />
572, 595, 625, 628, 688, 759, 769, 772, 795,<br />
817, 818, 967, 975, 1063, 1096, 1165, 1204,<br />
1325, 1326, 1337, 1340, 1346, 1347, 1423,<br />
1425, 1572, 1645, 1685, 1747, 1748, 1767,<br />
1777, 1787, 1836, 1848, 1872, 1920, 1928,<br />
2070, 2072, 2073, 2090, 2195, 2207, 2281<br />
quantiferon 997<br />
quantitative imaging marker 135<br />
questionnaires 44, 207, 225, 522, 625, 813,<br />
1001, 1009, 1013, 1339, 1348, 1405, 1563,<br />
1752, 1767, 1778, 1920, 1923, 2057, 2072,<br />
2073, 2093, 2110, 2279<br />
QuickDASH 1749<br />
quinolone 2212<br />
R<br />
RA prediction model 133<br />
rabbit 1111<br />
race/ethnicity 501, 589, 1140, 1330, 1556,<br />
1557, 1565, 1592, 1875, 2095, 2145<br />
radai 1750<br />
radial tunnel syndrome 2223<br />
radiographic joint damage 1580<br />
radiographic outcomes 1496<br />
radiographic progression 669, 1120<br />
radiography 121, 124, 139, 140, 143, 181, 182,<br />
185, 187, 303, 311, 665, 668, 728, 952, 1368,<br />
1393, 1611, 1771, 1950, 1953, 1954, 1962,<br />
1985, 2257<br />
radioisotope bone scan 1665<br />
radiological progression 290<br />
Raf kinase inhibitor protein 366<br />
RAGE 632<br />
RAID 1750<br />
RAMRIS 118, 125, 1369<br />
randomized trials 574, 646, 664, 676, 690,<br />
1102, 1113, 1129, 1319, 1325, 1368, 1545,<br />
1559, 1560, 1791, 1808, 1839, 2280<br />
RANK/RANKL pathway 30, 394, 842, 1269,<br />
1482, 1488, 1492, 1497<br />
ranking 687<br />
rapamycin 1185, 1196<br />
RAPID3 1120<br />
rare variants 2144<br />
RA-related autoimmunity 77<br />
Ras GTPase 1529<br />
rats 1480<br />
raw 246.7 1492<br />
Raynaud’s phenomenon 574, 579, 593, 608,<br />
1201, 1215, 2086<br />
reactivation 329<br />
reactive arthritis 552, 696, 761, 1647<br />
reactive oxygen species 631<br />
real life 315<br />
recombinant domain I 1358<br />
recruitment 1559, 2083<br />
recurrent idiopathic pericarditis 837<br />
red blood cells 2277<br />
regeneration 1479<br />
register study 761<br />
registry 400, 454, 569, 975, 17901792, 1802,<br />
2064<br />
regulatory cells 292, 737, 1125, 1242, 1248,<br />
1256, 1257, 1261, 1265, 1267, 1268, 1374,<br />
1827, 1903, 1977, 2236<br />
regulatory natural antibodies 2121<br />
regulatory T cell 442, 738, 909, 2128, 2131<br />
rehabilitation 1321, 1342, 1458, 2050, 2060<br />
relative risk 1036<br />
reliability 140, 1316, 1616, 1623, 1629, 1749,<br />
1954<br />
remission 73, 138, 141, 232, 251, 308, 315,<br />
317, 320, 331, 337, 343, 347, 480, 655, 662,<br />
723, 766, 1050, 1051, 1103, 1278, 1396, 1631,<br />
1701, 1737, 1754, 1758, 1793, 1800, 1823,<br />
1829, 2108<br />
renal 147, 1453<br />
renal biopsy 1399<br />
renal disease 164, 441, 443, 556, 643, 725,<br />
1173, 1190, 1195, 1399, 1415, 1592<br />
renal failure 1662<br />
renal function 161, 1023<br />
replication 329<br />
reporters 1733<br />
repulsion factors 361<br />
resistance training 1384<br />
responder definition 94<br />
response 175<br />
response criteria 1809, 1922<br />
responsiveness 140, 772, 2207<br />
resveratrol 1530<br />
retinal vascular caliber 1772<br />
retreatment 1905<br />
retroperitoneal fibrosis 705, 1662<br />
revision risk 2137<br />
rheumatic diseases 962, 1026<br />
rheumatoid arthritis (RA) 16, 17, 21, 22, 27,<br />
33, 39, 41, 42, 46, 49, 50, 52, 53, 56, 57, 58, 59,<br />
60, 61, 63, 64, 66, 67, 68, 69, 70, 72, 73, 77, 78,<br />
79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 90, 101,<br />
112, 118, 119, 125, 129, 132, 133, 135, 136,<br />
138, 139, 141, 168, 274, 279, 282, 288, 290,<br />
295, 296, 297, 300, 301, 302, 303, 306, 308,<br />
309, 310, 313, 314, 315, 316, 317, 320, 321,<br />
323, 324, 326, 329, 330, 331, 332, 333, 334,<br />
335, 336, 337, 338, 339, 340, 343, 344, 345,<br />
346, 347, 348, 350, 351, 356, 357, 362, 363,<br />
365, 368, 374, 375, 378, 383, 389, 390, 391,<br />
393, 394, 397, 398, 401, 402, 403, 406, 409,<br />
413, 414, 416, 419, 421, 523, 539, 636, 638,<br />
639, 640, 643, 645, 658, 659, 660, 661, 697,<br />
698, 717, 723, 735, 739, 743, 745, 755, 756,<br />
759, 762, 770, 775, 778, 781, 785, 787, 794,<br />
827, 847, 848, 849, 853, 856, 858, 861, 871,<br />
880, 968, 970, 981, 983, 984, 987, 991, 993,<br />
995, 1009, 1013, 1014, 1015, 1016, 1017, 1018,<br />
1019, 1020, 1021, 1022, 1023, 1024, 1025,<br />
1026, 1027, 1028, 1030, 1034, 1035, 1037,<br />
1038, 1039, 1040, 1041, 1042, 1043, 1044,<br />
1045, 1047, 1048, 1049, 1050, 1052, 1053,<br />
1056, 1057, 1058, 1060, 1062, 1063, 1064,<br />
1065, 1066, 1067, 1068, 1070, 1072, 1073,<br />
1074, 1075, 1077, 1079, 1081, 1083, 1086,<br />
1087, 1089, 1091, 1094, 1096, 1101, 1102,<br />
1103, 1104, 1106, 1109, 1110, 1113, 1117,<br />
1124, 1125, 1128, 1131, 1133, 1136, 1138,<br />
1223, 1255, 1263, 1269, 1271, 1324, 1325,<br />
1332, 1333, 1369, 1370, 1386, 1392, 1395,<br />
1411, 1421, 1432, 1442, 1443, 1496, 1504,<br />
1517, 1518, 1520, 1524, 1527, 1528, 1534,<br />
1545, 1550, 1559, 1570, 1571, 1580, 1581,<br />
1582, 1588, 1589, 1593, 1596, 1597, 1598,<br />
370<br />
2010 Program Book
1599, 1600, 1603, 1605, 1606, 1609, 1610,<br />
1611, 1618, 1621, 1629, 1632, 1634, 1636,<br />
1641, 1648, 1708, 1712, 1721, 1722, 1724,<br />
1731, 1735, 1736, 1738, 1739, 1741, 1742,<br />
1743, 1744, 1745, 1747, 1748, 1749, 1750,<br />
1751, 1752, 1753, 1754, 1757, 1758, 1759,<br />
1760, 1761, 1762, 1763, 1765, 1767, 1768,<br />
1769, 1770, 1772, 1773, 1774, 1775, 1776,<br />
1777, 1778, 1779, 1780, 1781, 1782, 1783,<br />
1784, 1785, 1786, 1787, 1788, 1789, 1790,<br />
1793, 1794, 1795, 1797, 1798, 1803, 1809,<br />
1811, 1815, 1817, 1823, 1824, 1825, 1826,<br />
1834, 1835, 2063, 2064, 2065, 2066, 2081,<br />
2108, 2114, 2115, 2118, 2119, 2127, 2135,<br />
2142, 2162, 2163, 2165, 2166, 2167, 2168,<br />
2169, 2172, 2173, 2182, 2207, 2210, 2211,<br />
2215, 2216, 2217, 2218, 2221, 2222, 2245,<br />
2256, 2257, 2258, 2259, 2260, 2261, 2267,<br />
2279, 2280, 2283, 2284<br />
rheumatoid arthritis synovial tissue 371<br />
rheumatoid arthritis, animal models 269, 270,<br />
271, 272, 276, 278, 280, 281, 284, 285, 286,<br />
289, 292, 635, 713, 714, 716, 855, 896, 1130,<br />
1137, 1256, 1266, 1351, 1417, 1420, 1495,<br />
1613, 1622, 1708, 1709, 1712, 1714, 1715,<br />
1717, 1719, 1720, 1723, 1725, 1726, 1727,<br />
1728, 1731, 1733, 2128, 2227, 2232, 2234,<br />
2236, 2237<br />
rheumatoid arthritis, disease activity<br />
measurement 1003<br />
rheumatoid arthritis, pathogenesis 25, 30, 245,<br />
250, 255, 349, 352, 354, 356, 359, 361, 364,<br />
366, 370, 371, 372, 1071, 1076, 1078, 1080,<br />
1082, 1085, 1088, 1090, 1092, 1093, 1247,<br />
1252, 1254, 1353, 1390, 1391, 1417, 1505,<br />
1506, 1786, 1801, 1968, 2116, 2130<br />
rheumatoid arthritis, synovium 23, 29, 36, 291,<br />
353, 355, 360, 364, 367, 623, 1051, 1069, 1240,<br />
1387, 1416, 1508, 1515, 1527, 1529, 1535,<br />
1604, 1822<br />
rheumatoid arthritis, treatment 51, 54, 55, 62,<br />
75, 76, 120, 123, 273, 278, 280, 281, 284, 298,<br />
311, 312, 318, 319, 322, 324, 328, 330, 339,<br />
341, 342, 344, 357, 376, 377, 380, 381, 392,<br />
396, 400, 405, 407, 408, 410, 411, 412, 417,<br />
418, 420, 641, 642, 662, 663, 744, 791, 1003,<br />
1010, 1013, 1032, 1036, 1046, 1054, 1055,<br />
1084, 1095, 1097, 1098, 1099, 1100, 1105,<br />
1108, 1111, 1112, 1114, 1115, 1116, 1118,<br />
1119, 1120, 1121, 1122, 1123, 1127, 1129,<br />
1132, 1134, 1135, 1137, 1387, 1393, 1394,<br />
1396, 1397, 1440, 1444, 1445, 1467, 1507,<br />
1542, 1715, 1718, 1730, 1766, 1771, 1791,<br />
1792, 1796, 1799, 1802, 1805, 1806, 1807,<br />
1808, 1810, 1814, 1816, 1819, 1820, 1821,<br />
1827, 1828, 1829, 1830, 1832, 1833, 1838,<br />
1840, 1841, 2164, 2170, 2171, 2204, 2233,<br />
2262, 2263, 2264, 2265, 2282<br />
rheumatoid factor (RF) 660<br />
rheumatoid factor negative 1830<br />
rheumatoid factor positive 1830<br />
rheumatoid nodule 1060<br />
rheumatoid vasculitis 1020<br />
rheumatologic practice 41, 48, 310, 995, 1003,<br />
1024, 1338, 1560, 2109<br />
rheumatology fellows 1429<br />
rheumatology practice 109<br />
rheumatology practice audit 1735<br />
ribonucleoprotein (RNP) 608, 852, 1267, 2175<br />
right heart pressures 567<br />
risedronate 2156<br />
risk 1956<br />
risk assessment 5, 521, 554, 562, 589, 793,<br />
919, 972, 997, 1026, 1039, 1048, 1053, 1082,<br />
1233, 1285, 1551, 1554, 1576, 1588, 1842,<br />
1849, 1914, 2153, 2212<br />
risk factors 774, 976, 1877, 1936, 2100<br />
Ritchie articular index 295<br />
rituximab 55, 321, 332, 333, 340, 375, 391,<br />
401, 403, 405, 406, 409, 465, 678, 680, 700,<br />
738, 739, 740, 744, 767, 917, 1084, 1098, 1118,<br />
1144, 1153, 1295, 1379, 1582, 1671, 1693,<br />
1790, 1801, 1807, 1810, 1821, 1828, 1830,<br />
1833, 1889, 1892, 1893, 1894, 1905, 1955,<br />
2041, 2042, 2201, 2263<br />
RNA- and DNA-based agonists 862<br />
RNA binding protein 487<br />
RNA polymerase III antibody 1231<br />
RNA-binding protein 934<br />
RNAi therapeutics 2174<br />
Ro/SSA 2175<br />
Ro60 1901<br />
ROC curves 1775<br />
RORgamma t 1260<br />
ROS 657<br />
rural health care 2050<br />
S<br />
S100 proteins 845, 1472<br />
S100A4 614<br />
S100A8 1495, 2002<br />
sacroiliac joints 1962<br />
sacroiliitis 527, 665, 1279<br />
safety 97, 147, 163, 177, 390, 1172, 1454,<br />
1795, 2173<br />
salivary function 2179<br />
salivary gland 1413<br />
SAPHO syndrome 2269<br />
scanning electron microscopy 875<br />
scavenger receptor 1072<br />
sciatica 170<br />
SCID mice 1266<br />
scintigraphy 1887<br />
scleritis 413<br />
scleroderma 561, 562, 563, 564, 565, 567, 569,<br />
585, 587, 589, 591, 592, 594, 595, 598, 600,<br />
601, 609, 612, 617, 622, 674, 675, 726, 727,<br />
729, 1004, 1202, 1203, 1209, 1210, 1213, 1214,<br />
1228, 1232, 1238, 1349, 1352, 1661, 1683,<br />
1987, 1990, 1992, 1996, 2001, 2006, 2007,<br />
2072, 2073, 2086, 2193, 2194, 2195, 2196,<br />
2197, 2214, 2247<br />
scn9a 96<br />
score 1621<br />
scoring methods 1954<br />
SCOT trial (Scleroderma Cyclophosphamide or<br />
Transplant) 726<br />
screening 1004, 1937, 1939<br />
screening guideline adherence 1000<br />
SDAI 73<br />
seasonal variation 783<br />
secular trend 685<br />
segmental 1151<br />
SELENA-SLEDAI 1456<br />
self-directed program 691<br />
self-efficacy 2280<br />
self-management 689, 1334, 1408, 1562, 1745,<br />
2062, 2282<br />
self-reported arthritis 1460, 1462<br />
semaphorins 361<br />
semi-structured interview 1322<br />
sensitive 118<br />
sensitivity 522<br />
sensitivity and specificity 1775<br />
septic arthritis 1638<br />
sequential therapy 1792<br />
seroconversion 699<br />
serologic tests 911, 1764<br />
serotonin receptor 799<br />
serum complement 1149<br />
serum glycosylation 1105<br />
serum trough levels 1826<br />
service delivery 776, 1553<br />
severity 707, 1087, 1600, 1876, 2218<br />
sex bias 1193<br />
sex hormones 63, 361, 1257<br />
sex-differences 684<br />
sexual dysfunction 812<br />
sexual functioning 2073<br />
SF-36 1211, 1848<br />
SF-6D 2207<br />
sham acupuncture 941<br />
shared care 2280<br />
shared decision making 1024<br />
shared epitope 255, 1035, 1071, 1076, 2114,<br />
2215<br />
Sharp score 1734<br />
Sharp/van der Heijde 1368<br />
shingles 421<br />
shoewear 1331<br />
short form McGill pain questionnaire 2247<br />
shoulder disorders 177<br />
shrinking lung syndrome 1176<br />
sicca 1886<br />
side effects 31<br />
abstract KEYWORD INDEX<br />
2010 Program Book 371
abstract KEYWORD INDEX<br />
signal transduction 18, 32, 35, 289, 351, 362,<br />
370, 609, 639, 855, 868, 1196, 1412, 1416,<br />
1471, 1478, 1501, 1514, 1529, 1535, 1718,<br />
1725, 2127, 2275<br />
simplified disease activity index (SDAI) 317<br />
single item measure 2247<br />
single nucleotide polymorphism (SNP) 730,<br />
1280, 1584, 1587, 1972<br />
siRNA 1450<br />
Sirt1 knockout mice 1484<br />
sitaxentan 565<br />
Sj 1215, 1893, 1894, 1895, 1897, 1908, 1909,<br />
1911, 1914, 2174<br />
sJIA 1434<br />
Sjogren’s syndrome 103, 495, 702, 1413, 1579,<br />
1883, 1884, 1886, 1887, 1888, 1889, 1890,<br />
1891, 1896, 1898, 1899, 1901, 1902, 1904,<br />
1905, 1908, 1910, 1911, 1912, 1914, 1916,<br />
2174, 2175, 2177, 2178<br />
skeletal fluorosis 1568<br />
SKG mice 1715<br />
skin 860<br />
skin blood flow 1220<br />
skin fibrosis 596<br />
skin ulcers 932<br />
SLE indices 990<br />
SLEDAI 462, 1437, 1878<br />
SLEDAI-2K 772<br />
sleep 815<br />
sleep disorders 786, 799, 808, 820, 1228, 1406,<br />
2071<br />
SLICC 1881<br />
SLICC/ACR Damage Index (SDI) 474<br />
small fibre neuropathy 1908<br />
small interfering RNA 2174<br />
small molecule therapy 285<br />
small molecules 1119, 2233<br />
smoking 645, 661, 765, 1092, 1252, 1956,<br />
1984, 2114<br />
smooth muscle 1490<br />
SNP 1608, 1885<br />
social media 1345, 2083<br />
social support 174, 1324, 1326, 1334, 1335,<br />
1340, 1409<br />
socioeconomic factors 61, 776, 790, 1221,<br />
1460, 1463, 1553, 2140<br />
SOCS3 1501<br />
sodium channels 96<br />
soluble binding domain I apoER2 1360<br />
somatosensory 1557<br />
sonography 889, 1626, 2225<br />
SOST 548<br />
spaceflight 959<br />
spatial variation 64<br />
specialized disease center 2077<br />
speckle tracking echocardiography 582<br />
sphingosine kinase 1480<br />
spine involvement 130, 1446<br />
splicing 348, 893<br />
spondylarthropathy 130, 134, 223, 516, 517,<br />
520, 522, 524, 525, 527, 528, 529, 533, 535,<br />
540, 546, 547, 549, 550, 551, 552, 553, 558,<br />
665, 667, 697, 761, 778, 794, 986, 1037, 1279,<br />
1337, 1355, 1432, 1440, 1446, 1447, 1448,<br />
1449, 1450, 1451, 1647, 1922, 1924, 1931,<br />
1938, 1952, 1953, 1957, 1959, 1964, 1967,<br />
1969, 1973, 1977, 1981, 1985, 2078, 2180,<br />
2181, 2184, 2269, 2271, 2272<br />
spondyloarthritis 665, 904, 1938, 2181<br />
SSA/Ro 656<br />
stable isotope labelling 843<br />
standardisation 1781<br />
standardized incidence ratio 398<br />
standardized response mean 140<br />
staphylococcus aureus 758<br />
STAT3 370<br />
static alignment 195<br />
statins 72, 1028, 1056, 1677, 1833, 2255<br />
statistical methods 577, 1564, 1585, 1586,<br />
1588, 1942, 2079<br />
stem cells 1473<br />
stereology 1485<br />
steroids 335, 445<br />
Still’s disease 653, 701, 891, 902, 1831<br />
stool studies 537<br />
stress 1025<br />
stroke 2124<br />
strontium ranelate 1497<br />
structural damage 1606<br />
structural damage progression 1496<br />
subchondral bone 192, 709, 1497<br />
subcutaneous 396, 416, 1124, 1834, 2173<br />
subendocardial variability ratio 1028<br />
subset 733<br />
sulfatase 369<br />
SUMO 368<br />
superantigens 267<br />
supplementation regimens 962<br />
suprascapular nerve block 177<br />
surgery 1315<br />
surgical site infections 335<br />
surveillance 699<br />
survey 109, 1013, 1565<br />
survey criteria 100<br />
survival 2018, 2022, 2037<br />
susceptibility 255, 521, 1975, 2148, 2215<br />
sustained remission 308, 336<br />
Swefot trial 1392<br />
swine influenza 697<br />
switch 298<br />
sympathetic nerve fibers 361<br />
symptom management 1319<br />
symptom modification 664<br />
symptoms 1346<br />
synaptotagmin VII 1374<br />
synovial cells, synovial fluid 29, 30, 244, 352,<br />
354, 355, 359, 362, 369, 858, 887, 1128, 1247,<br />
1387, 1388, 1421, 1422, 1520, 1527, 1535,<br />
1536, 1604, 1971, 1978, 2219<br />
synovial tissue 847<br />
synovitis 20, 32, 118, 167, 1449, 1620, 1621,<br />
1638, 1781, 2220<br />
synthetase syndrome 913, 930, 1377<br />
syringe 1567<br />
systematic analysis 143<br />
systematic review 92, 516, 941, 952<br />
systemic inflammation 919<br />
systemic juvenile idiopathic arthritis 209<br />
systemic lupus erythematosus (SLE) 1, 4, 9, 13,<br />
24, 252, 262, 323, 422, 424, 425, 426, 427, 428,<br />
430, 431, 432, 434, 435, 436, 437, 438, 441,<br />
442, 444, 445, 446, 447, 448, 449, 450, 451,<br />
452, 453, 454, 455, 456, 457, 458, 459, 460,<br />
461, 462, 463, 464, 465, 466, 467, 468, 470,<br />
474, 475, 476, 477, 478, 479, 480, 481, 482,<br />
483, 484, 485, 486, 487, 488, 490, 491, 492,<br />
493, 494, 495, 496, 497, 498, 499, 500, 501,<br />
502, 503, 504, 505, 506, 507, 508, 509, 510,<br />
511, 620, 625, 627, 628, 637, 656, 694, 702,<br />
730, 731, 733, 735, 738, 740, 746, 748, 749,<br />
750, 751, 752, 754, 757, 762, 764, 765, 769,<br />
772, 775, 789, 790, 795, 832, 850, 857, 859,<br />
862, 865, 990, 996, 1000, 1011, 1075, 1139,<br />
1141, 1142, 1143, 1145, 1146, 1147, 1148,<br />
1149, 1150, 1151, 1152, 1153, 1154, 1155,<br />
1156, 1157, 1158, 1159, 1160, 1162, 1163,<br />
1164, 1165, 1166, 1167, 1169, 1170, 1171,<br />
1172, 1173, 1174, 1175, 1176, 1177, 1178,<br />
1179, 1180, 1181, 1182, 1183, 1184, 1185,<br />
1186, 1187, 1191, 1192, 1193, 1194, 1195,<br />
1196, 1197, 1199, 1200, 1223, 1243, 1245,<br />
1257, 1272, 1400, 1401, 1402, 1437, 1452,<br />
1454, 1456, 1457, 1577, 1578, 1583, 1584,<br />
1585, 1586, 1587, 1590, 1591, 1592, 1594,<br />
1595, 1602, 1608, 1639, 1641, 1666, 1674,<br />
1676, 1677, 1679, 1684, 1688, 1689, 1694,<br />
1695, 1701, 1702, 1784, 1842, 1843, 1844,<br />
1845, 1846, 1847, 1848, 1849, 1850, 1851,<br />
1852, 1853, 1854, 1855, 1856, 1857, 1858,<br />
1859, 1860, 1861, 1862, 1863, 1864, 1865,<br />
1866, 1868, 1869, 1870, 1871, 1872, 1873,<br />
1874, 1875, 1876, 1877, 1878, 1878, 1880,<br />
1881, 1882, 1895, 1909, 2070, 2077, 2083,<br />
2106, 2113, 2120, 2122, 2123, 2125, 2126,<br />
2144, 2145, 2146, 2148, 2149, 2175, 2190,<br />
2191, 2239, 2240, 2242, 2243, 2274, 2275,<br />
2277, 2278<br />
systemic sclerosis 560, 566, 568, 569, 570, 571,<br />
572, 573, 574, 575, 576, 577, 578, 579, 580,<br />
581, 582, 584, 586, 588, 590, 593, 596, 597,<br />
598, 599, 603, 604, 605, 606, 607, 609, 610,<br />
611, 613, 614, 615, 616, 619, 670, 671, 673,<br />
724, 725, 726, 728, 824, 829, 1201, 1204, 1206,<br />
1207, 1208, 1211, 1215, 1216, 1217, 1218,<br />
1219, 1220, 1221, 1222, 1223, 1224, 1225,<br />
372<br />
2010 Program Book
1226, 1227, 1229, 1230, 1231, 1233, 1234,<br />
1235, 1236, 1237, 1239, 1346, 1347, 1348,<br />
1587, 1623, 1624, 1627, 1704, 1987, 1988,<br />
1989, 1990, 1991, 1994, 1997, 1998, 1999,<br />
2000, 2001, 2002, 2004, 2005, 2007, 2008,<br />
2086, 2192, 2193, 2196, 2226, 2247<br />
systems biology 733<br />
T cell anergy 1264<br />
T cell help 867<br />
T cell receptor revision 1272<br />
T cells 38, 265, 275, 287, 350, 370, 372, 432,<br />
434, 435, 437, 442, 462, 488, 497, 505, 507,<br />
636, 740, 825, 830, 846, 863, 867, 909, 935,<br />
1069, 1079, 1090, 1125, 1141, 1150, 1185,<br />
1187, 1196, 1241, 1242, 1244, 1245, 1248,<br />
1249, 1250, 1251, 1254, 1255, 1256, 1258,<br />
1259, 1260, 1261, 1262, 1263, 1264, 1265,<br />
1266, 1267, 1268, 1269, 1270, 1271, 1272,<br />
1274, 1278, 1446, 1499, 1524, 1525, 1724,<br />
1801, 1838, 1843, 1900, 1903, 1919, 1967,<br />
1989, 2004, 2126, 2127, 2128, 2129, 2130,<br />
2188, 2190, 2191, 2232, 2275<br />
T follicular helper cell 432, 1141<br />
T helper cells 1992<br />
T helper subsets 635<br />
TFH 1250<br />
T-5224 280, 1467<br />
TACI 2178<br />
tadalafil 2086<br />
tai chi 690<br />
TAK1 1535<br />
Takayasu 1275, 1279, 1286, 1287, 1290, 1291,<br />
1295, 1313, 1315, 2198<br />
Takayasu’s arteritis 1282, 1283<br />
targeted resequencing 2146<br />
TASK2 1255<br />
TCZ 1434, 1840<br />
team-based learning 46, 1432<br />
technology 1334<br />
telangiectases 1234<br />
temporal arteritis 1302, 2044<br />
temporal artery biopsy 1311<br />
temporomandibular joint 213, 218, 228<br />
tender 1434<br />
tendinopathies 106<br />
tendonitis 898<br />
tendonitis/bursitis 2212<br />
tenocytes 106<br />
teratozoospermia 513<br />
teriparatide 967, 980<br />
testicular function 513<br />
testing 1543, 1561<br />
TGF-beta 244, 442, 489<br />
Th1 and Th17 1903<br />
Th1, Th2, Th17 cells 435<br />
T<br />
Th17 265, 275, 370, 715, 1241, 1249, 1274,<br />
1838, 2130<br />
Th17 cells 1970, 2129<br />
Th9 1241<br />
thalidomide 1657<br />
theophylline 149<br />
therapeutic approaches 1700<br />
therapeutic delay 558<br />
therapeutic targets 733<br />
therapy 1683, 1831, 2048<br />
therapy monitoring 138<br />
therapy response 83<br />
thermography 1439<br />
thoracic manipulation 2060<br />
thrombin 604<br />
thrombin generation 1<br />
thrombosis 1, 2, 3, 5, 6, 8, 13, 14, 374, 460,<br />
482, 906, 1243, 1357, 1602, 2255<br />
thrombospondins 1991<br />
thymic negative selection 1260<br />
thyroid 1029, 1038<br />
thyroid nodule 1038<br />
tight control 380, 1104, 1753<br />
TIM-2 1731<br />
TIM-3 372<br />
tissue factor 2254<br />
tissue inhibitor <strong>of</strong> metalloproteinase 3 (TIMP3)<br />
1478<br />
tissue regeneration 1380<br />
tissue remodelling 629<br />
tissue targeting 852<br />
tlda 1986<br />
TLR2 858<br />
TLR-2 ligand 267<br />
TLR4 1495, 1501, 1535, 1730<br />
TLR7 1410<br />
TNF 1695<br />
TNF antagonists 216<br />
TNF genes polymorphism 217<br />
TNF inhibitor 419<br />
TNF-alpha 371<br />
TNFRSF1A gene 837<br />
tobacco 1551<br />
tobacco use 470, 562, 661, 1035, 1070, 1093,<br />
1152, 1546, 1850<br />
tocilizumab 56, 120, 237, 329, 373, 378, 384,<br />
399, 411, 701, 745, 759, 1115, 1138, 1411,<br />
1434, 1788, 1793, 1797, 1800, 1808, 1809,<br />
1819, 1820, 1823, 1839, 1840, 2262<br />
tolerance 1116, 1717<br />
tolerogenic dendritic cells 1715<br />
toll-like receptor 2 16, 857<br />
toll-like receptor 4 713<br />
toll-like receptor 7 856, 862, 1584<br />
toll-like receptor 9 856, 862<br />
toll-like receptors (TLR) 424, 1296, 1391, 1501,<br />
1883, 1993, 2023<br />
tophaceous 2152<br />
tophi 157<br />
topical 944<br />
total elbow replacement 1080<br />
total joint replacement 174, 196, 1539, 1576,<br />
2053, 2054, 2090, 2136, 2137<br />
total knee arthroplasty 171<br />
trabecular morphometry 709<br />
traditional cardiovascular risk factors 1067<br />
TRAIL 1527<br />
tranilast 160<br />
transcription factor 38, 258, 507, 616, 1251,<br />
1259, 1469, 1487, 1508, 1522, 1526, 1724,<br />
2177, 2274<br />
transcriptional targeting 1733<br />
transcriptomics 1422, 1981<br />
trans-ethnic mapping 1595<br />
transforming growth factor 600, 602, 617, 673,<br />
674, 1241, 1997<br />
transition 211, 1340<br />
transition care 1008, 1409<br />
translational research 607<br />
transmigration 1420<br />
transplantation 704, 713, 874, 907, 918, 1143,<br />
1161, 2104<br />
transracial mapping 2274<br />
transverse myelitis 1174<br />
traps 905<br />
trauma 1551<br />
treatment 117, 196, 218, 676, 705, 902, 1306,<br />
1315, 1380, 1543, 1561, 1670, 1675, 2273<br />
treatment decision 82, 1899<br />
treatment preference 1875<br />
treatment protocols 1702<br />
treatment response 453, 828, 1452<br />
treatment strategies 311<br />
Treg 370, 1196<br />
Treg activator 1125<br />
Treg cells 2129<br />
treprostinil 1201, 1222<br />
treprostinil diethanolamine 597<br />
trial 1892<br />
trimethoprim-sulphamethoxazole 472<br />
triple therapy 1368<br />
tuberculosis 376, 404, 699, 768, 782, 890, 908,<br />
997, 1012, 1310, 1941<br />
tuberculosis skin test 756, 782<br />
tumor necrosis factor (TNF) 62, 88, 241, 249,<br />
345, 356, 406, 712, 897, 1020, 1133, 1198,<br />
1442, 1444, 1487, 1530, 1532, 1534, 1607,<br />
1643, 1680, 1841, 1942, 1958<br />
tumor necrosis factor receptor associated<br />
periodic syndrome 837<br />
twin study 877<br />
abstract KEYWORD INDEX<br />
2010 Program Book 373
abstract KEYWORD INDEX<br />
type I IFN signature 1084<br />
type I interferon 1188, 1379<br />
type II collagen 1709, 2235<br />
typing 2142<br />
tyrosine kinase 293, 1536<br />
tyrosine kinase inhibitor 286<br />
tyrosine phosphorylation 609<br />
UA 1371<br />
U<br />
ulcers 593, 1045, 1217, 1222, 1239, 1278, 1657<br />
ultrasonography 889<br />
ultrasound 45, 127, 455, 889, 1038, 1055,<br />
1169, 1220, 1237, 1263, 1302, 1397, 1614,<br />
1616, 1617, 1618, 1620, 1621, 1624, 1626,<br />
1629, 1630, 1631, 1633, 1634, 1635, 1636,<br />
1754, 1962, 2220, 2221, 2222, 2223, 2225<br />
undercarboxylated osteocalcin 983, 1773<br />
undifferentiated arthritis 658, 659, 1396, 1785<br />
undifferentiated spondyloarthritis 2272<br />
unexplained symptoms 170<br />
unfolded protein response 634, 1376, 1965<br />
urantide 618<br />
URAT1 164<br />
urate lowering therapy 2088<br />
uric acid 144, 150, 154, 157, 160, 161, 164,<br />
165, 877, 884, 992, 1367, 1556, 1574, 1616,<br />
2153<br />
uricase 144<br />
US adults 687<br />
USpA 1925<br />
utility 787<br />
utilization review 60, 969, 1675, 1864<br />
uveitis 230, 234, 546, 904, 1308, 1447, 1670,<br />
1933<br />
V<br />
vaccination 849<br />
vaccines 9, 224, 235, 236, 323, 450, 457, 466,<br />
478, 481, 645, 697, 792, 1037, 1238, 1437,<br />
1440, 1694, 1917, 2043<br />
validation 625, 659, 1774<br />
validity 1749, 2061, 2068<br />
value <strong>of</strong> information 759<br />
Van der Heijde modified Sharp score 1392<br />
variant 2177<br />
varicella zoster virus 421<br />
varicocele 513<br />
varus thrust 195, 202, 2101<br />
vascular involvement 1285<br />
vascular remodelling 1314<br />
vascular stiffness 519, 1200<br />
vasculitis 126, 680, 774, 822, 1045, 1207, 1249,<br />
1275, 1280, 1284, 1285, 1286, 1287, 1290,<br />
1291, 1297, 1298, 1299, 1301, 1302, 1303,<br />
1305, 1307, 1308, 1313, 1314, 1315, 1326,<br />
1512, 1646, 1663, 1669, 1673, 1675, 1691,<br />
1695, 1705, 2009, 2010, 2011, 2012, 2013,<br />
2014, 2016, 2017, 2018, 2019, 2020, 2021,<br />
2023, 2024, 2025, 2026, 2027, 2029, 2030,<br />
2032, 2035, 2036, 2037, 2038, 2039, 2040,<br />
2041, 2042, 2043, 2044, 2045, 2046, 2048,<br />
2107, 2131, 2198, 2200, 2201, 2203<br />
VCAM-1 492<br />
VEGF 1418<br />
venous thromboembolism 53, 78, 1539<br />
vertebral fracture assessment by morphometry<br />
(VFA) 976<br />
very early presentation 661<br />
vestibuloauditory symptoms 1675<br />
veterans 1099, 1792<br />
vibratory sense 205<br />
viral conversion 510<br />
virtual teaching 44<br />
viruses 804, 1197, 1478, 1642, 1694, 1891<br />
visfatin 619, 1514<br />
visit frequency 1868, 1869<br />
visual ischemic manifestations 1301<br />
vitamin D 310, 706, 1163, 1180, 2030<br />
vitamin K 1773<br />
vitamins 252, 310, 872, 1574<br />
VLA-4 865<br />
voxel based morphometry (VBM) 1167<br />
VpreB 1589<br />
vulnerable coronary plaque 1046, 1443, 2164,<br />
2165<br />
W<br />
walking 2141<br />
walking speed 2133<br />
watchful waiting 992<br />
web-based 44<br />
Wegener’s granulomatosis 676, 677, 678, 679,<br />
681, 2009, 2012, 2014, 2018, 2021, 2022, 2026,<br />
2028, 2029, 2031, 2034, 2043, 2047, 2049<br />
widespread pain 550<br />
withholding <strong>of</strong> therapy 1381<br />
Wnt 601, 629, 1468, 1503<br />
Wnt pathway 624<br />
Wnt signaling 716<br />
WOMAC 706<br />
women 1546, 2132<br />
women’s health 165, 325, 347, 447, 974, 1063,<br />
2083, 2092<br />
work activity limitation 2141<br />
work disability 1211, 1349, 2139<br />
work limitations 2069, 2138<br />
work productivity 51, 2195<br />
working age 2069, 2138<br />
worst case 2281<br />
wound fluid analysis 1239<br />
X chromosome 2004<br />
xenotropic murine leukemia virus-related virus<br />
804<br />
x-ray findings 185<br />
X<br />
Y<br />
young arthritis patients 1345<br />
Zc3h12a 364<br />
zero-inflation 1564<br />
zoledronic acid 2156<br />
zymosan-induced arthritis 1713<br />
Z<br />
374<br />
2010 Program Book
Abelson, Abby Goulder, MD<br />
Education<br />
Disclosure:Nothing to Disclose<br />
Abraham, David, MD<br />
Systemic Sclerosis, Fibrosing Syndromes, and<br />
Raynaud’s - Pathogenesis, Animal Models and<br />
Genetics<br />
Disclosure:Nothing to Disclose<br />
Adams, Barbara S, MD<br />
Pediatric <strong>Rheumatology</strong> - Pathogenesis<br />
and Genetics: Biological Basis for Pediatric<br />
Rheumatic Disease<br />
Disclosure:<br />
Aringer, Martin<br />
Rheumatoid Arthritis Treatment - Small<br />
Molecules, Biologics and Gene Therapy: Safety<br />
and Efficacy I<br />
Disclosure: Centocor, 2; Roche, 5<br />
Asahara, Hiroshi, MD, PhD<br />
Biology and Pathology <strong>of</strong> Bone and Joint:<br />
Molecular Basis <strong>of</strong> Osteoarthritis<br />
Disclosure:Nothing to Disclose<br />
Backman, Catherine L, PhD, OT(C)<br />
Keep Working with Arthritis<br />
Disclosure: Nothing to Disclose<br />
A<br />
B<br />
Baer, Alan N, MD<br />
Sjögren’s Syndrome<br />
Disclosure:Nothing to Disclose<br />
Baron, Murray<br />
Systemic Sclerosis, Fibrosing Syndromes, and<br />
Raynaud’s - Clinical Aspects and Therapeutics II<br />
Disclosure: Nothing to Disclose<br />
Birnbaum, Neal S, MD<br />
Rheumatoid Arthritis - Clinical Aspects:<br />
Preclinical RA and Early RA I<br />
Disclosure: AMgen/Pfizer, Amgen, Centocor,<br />
UCB, Genentech, 8<br />
Block, Joel A, MD<br />
Osteoarthritis - Clinical Aspects: Pain and<br />
Biomechanics<br />
Disclosure: KAI / NIH, 9; NiCOx, 5; OA and<br />
Cartilage, 9; Pleiad, 5<br />
Brandenstein, Jane S, MD<br />
Physical and Psychosocial Challenges in<br />
Scleroderma<br />
Braun, Juergen, MD<br />
Spondylarthropathies and Psoriatic Arthritis -<br />
Clinical Aspects and Treatment: Imaging I<br />
Breban, Maxime A<br />
Spondylarthritis and Psoriatic Arthritis:<br />
Pathogenesis, Etiology, and Animal Models<br />
Disclosure: Nothing to Disclose<br />
Brunner, Hermine, MD<br />
ACR/ARHP Combined Pediatric <strong>Rheumatology</strong>:<br />
Clinical and Therapeutic Aspects: Quality <strong>of</strong> Life<br />
in Children and Adolescents with Arthritis<br />
Buch, Maya H, MD, PhD<br />
Rheumatoid Arthritis Treatment - Small<br />
Molecules, Biologics and Gene Therapy: Safety<br />
and Efficacy I<br />
Disclosure: Abbott, 5; Pfizer/Wyeth, 5; Roche, 5<br />
Bunyard, Matthew P, MD<br />
Quality Measures and Innovation in Practice<br />
Management and Care Delivery<br />
Disclosure: Nothing to Disclose<br />
C<br />
Carette, Simon, MD<br />
ANCA-associated Vasculitis I<br />
Disclosure:Nothing to Disclose<br />
Carlone, Joyce P, MD<br />
Rheumatoid Arthritis: From Clinic to Home<br />
Disclosure:Nothing to Disclose<br />
Chakravarty, Eliza F, MD<br />
Systemic Lupus Erythematosus - Clinical Aspects<br />
and Treatment: Renal<br />
Disclosure:Nothing to Disclose<br />
Chatham, W. Wimm, MD<br />
Miscellaneous Rheumatic and Inflammatory<br />
Diseases<br />
Disclosure: Nothing to Disclose<br />
Chen, Pojen P, MD<br />
Antiphospholipid Syndrome I<br />
Disclosure:Nothing to Disclose<br />
Choy, Ernest, MD<br />
Rheumatoid Arthritis - Clinical Aspects:<br />
Radiographic and Other Outcomes in RA IV<br />
Disclosure: Abbott Immunology Laboratories,<br />
5; Astra Zeneca, 5; Chelsea Therapeutics, 2;<br />
Chugai Pharma, 5; Chugai Pharma, 8; Eli Lilly, 5;<br />
Eli Lilly, 8; GSK, 5; Jazz Pharmaceuticals, 2; Jazz<br />
Pharmaceuticals, 5; MSD, 2; Pfizer, 5; Roche, 2;<br />
Roche, 5; Roche, 8; Synovate, 5; UCB, 2l UCB, 5;<br />
UCB, 8; Wyeth, 5<br />
Cibere, Jolanda<br />
Epidemiology and Health Services Research:<br />
General Interest<br />
Disclosure: Amgen Inc, 2l Centocor Research and<br />
Development Inc, 2<br />
Clancy, Robert M, MD<br />
Innate Immunity and Rheumatic Disease<br />
Disclosure:Nothing to Disclose<br />
Clauw, Daniel J, MD<br />
Fibromyalgia and S<strong>of</strong>t Tissue Disorders<br />
Disclosure:Nothing to Disclose<br />
Clegg, Daniel O, MD<br />
Spondylarthropathies and Psoriatic Arthritis -<br />
Clinical Aspects and Treatment: Biomarkers II<br />
Disclosure:Nothing to Disclose<br />
Cohen, Philip L, MD<br />
Systemic Lupus Erythematosus - Animal Models<br />
Disclosure: Nothing to Disclose<br />
Cooper, Robert G, MD<br />
Muscle Biology, Myositis and Myopathies:<br />
Insights into the Pathogenesis and Outcomes <strong>of</strong><br />
Myositis<br />
Disclosure:Nothing to Disclose<br />
Cohen, Philip L, MD<br />
Systemic Lupus Erythematosus - Animal Models<br />
Disclosure: Nothing to Disclose<br />
Cope, Andrew P<br />
Rheumatoid Arthritis - Human Etiology and<br />
Pathogenesis: Anti-CCP in RA Etiology and<br />
Pathogenesis II<br />
Disclosure: Nothing to Disclose<br />
Cornell, Patricia J, BSc<br />
Issues in Lupus<br />
Disclosure:Nothing to Disclose<br />
Criswell, Lindsey A<br />
Genetics, Genomics and Proteomics: RA and<br />
Other Rheumatic Diseases<br />
Disclosure: Nothing to Disclose<br />
Cronstein, Bruce N<br />
Cell-Cell Adhesion, Cell Trafficking and<br />
Angiogenesis<br />
Disclosure: Can-Fite Biopharmaceuticals, 1;<br />
Endocyte, 5; King Pharmaceuticals, 7; NIH, 2;<br />
NYU SoM, 9; OSI Pharmaceuticals, 2; Regeneron,<br />
5 URL, 5<br />
Curtis, Jeffrey R, MD, MPH<br />
Epidemiology and Health Services Research:<br />
Gout<br />
Disclosure:Nothing to Disclose<br />
D<br />
DallEra, Maria<br />
Systemic Lupus Erythematosus - Clinical Aspects<br />
and Treatment: New Therapies<br />
Disclosure: Nothing to Disclose<br />
De Pablo, Paola, MD<br />
Systemic Lupus Erythematosus - Clinical Aspects<br />
and Treatment: SLE and Cardiovascular Disease<br />
Disclosure: Nothing to Disclose<br />
Dellaripa, Paul F, MD<br />
Rheumatoid Arthritis - Clinical Aspects: RA and<br />
Cardiovascular Disease III<br />
Disclosure:Nothing to Disclose<br />
Distler, Oliver<br />
Cytokines, Mediators, Gene Regulation I<br />
Disclosure: Actelion, Pfizer, Encysive and<br />
ERgonex, 9; Actelion, Pfizer, Encysive, FibroGen,<br />
Ergonex, NicOx, BMS, Biovitrium, 2; Biovitrium, 5<br />
Dougados, Maxime, MD<br />
Spondylarthropathies and Psoriatic Arthritis -<br />
Clinical Aspects and Treatment: Therapy III<br />
Disclosure: Abbott, 2, 5; Pfizer, 2, 5; Roche, 2, 5;<br />
San<strong>of</strong>i, 2, 5<br />
Espinoza, Luis R, MD<br />
Spondylarthropathies and Psoriatic Arthritis -<br />
Clinical Aspects and Treatment: Therapy III<br />
Disclosure:Nothing to Disclose<br />
Finnegan, Alison, PhD<br />
Cytokines, Mediators, Gene Regulation I<br />
Disclosure:Nothing to Disclose<br />
F<br />
ABSTRACT MODERATOR DISCLOSURE<br />
2010 Program Book 375
ABSTRACT MODERATOR DISCLOSURE<br />
376<br />
Firestein, Gary S, MD<br />
Rheumatoid Arthritis - Human Etiology<br />
and Pathogenesis: RA Human Etiology and<br />
Pathogenesis II<br />
Disclosure:Nothing to Disclose<br />
Fisher, Nadine M, EdD<br />
Physical Activity: Just “Move It”<br />
Disclosure:Nothing to Disclose<br />
FitzGerald, John D, MD<br />
Rheumatoid Arthritis Treatment - Small<br />
Molecules, Biologics and Gene Therapy: Existing<br />
Biologics IV<br />
Disclosure:Nothing to Disclose<br />
Furst, Daniel E, MD<br />
Infection-Related Rheumatic Disease<br />
Disclosure:Nothing to Disclose<br />
Gabay, Cem, MD<br />
Infection-Related Rheumatic Disease<br />
Disclosure:Nothing to Disclose<br />
Goker, Berna, MD<br />
Osteoporosis and Metabolic Bone Disease:<br />
Clinical Aspects and Pathogensis<br />
Disclosure:Nothing to Disclose<br />
Goldenberg, Don L, MD<br />
Fibromyalgia and S<strong>of</strong>t Tissue Disorders<br />
Disclosure:Nothing to Disclose<br />
Goronzy, Jorg J<br />
T Cell Biology and Targets in Autoimmune<br />
Disease<br />
Disclosure: Nothing to Disclose<br />
Gravallese, Ellen M<br />
Rheumatoid Arthritis - Human Etiology<br />
and Pathogenesis: RA Human Etiology and<br />
Pathogenesis II<br />
Disclosure: Nothing to Disclose<br />
Greenberg, Jeffrey, D<br />
Rheumatoid Arthritis Treatment - Small<br />
Molecules, Biologics and Gene Therapy: Novel<br />
Compounds III<br />
Disclosure:Nothing to Disclose<br />
Guillevin, Loic P<br />
ANCA-associated Vasculitis I<br />
Disclosure: ROCHE, 2, 9<br />
G<br />
H<br />
Hachulla, Eric<br />
Systemic Sclerosis, Fibrosing Syndromes, and<br />
Raynaud’s - Clinical Aspects and Therapeutics II<br />
Disclosure: ACTELION, GSK, PFIZER, LILLY, United<br />
Therapeutics, 5<br />
Haqqi, Tariq M, PhD, MPH<br />
Biology and Pathology <strong>of</strong> Bone and Joint:<br />
Molecular Basis <strong>of</strong> Osteoarthritis<br />
Disclosure:Nothing to Disclose<br />
Harley, John B, MD<br />
Genetics, Genomics and Proteomics: RA and<br />
Other Rheumatic Diseases<br />
Disclosure: Nothing to Disclose<br />
2010 Program Book<br />
Harrington, J Timothy, MD<br />
Quality Measures and Innovation in Practice<br />
Management and Care Delivery<br />
Disclosure: Murray Electronics, 1; CORRONA, 5<br />
Hawker, Gillian A, MD<br />
Osteoarthritis - Clinical Aspects: Pain and<br />
Biomechanics<br />
Disclosure:Nothing to Disclose<br />
Holoshitz, Joseph<br />
T Cell Biology and Targets in Autoimmune<br />
Disease<br />
Disclosure: Nothing to Disclose<br />
Houssiau, Frederic A, MD, PhD<br />
Systemic Lupus Erythematosus - Clinical Aspects<br />
and Treatment: Renal<br />
Disclosure: Nothing to Disclose<br />
Hummers, Laura K<br />
Systemic Sclerosis, Fibrosing Syndromes, and<br />
Raynaud’s - Clinical Aspects and Therapeutics I<br />
Disclosure: Nothing to Disclose<br />
I<br />
Iagnocco, Annamaria, MD<br />
Imaging <strong>of</strong> Rheumatic Disease: Ultrasound<br />
Disclosure: Nothing to Disclose<br />
Ilowite, Norman T, MD<br />
Pediatric <strong>Rheumatology</strong> - Clinical and<br />
Therapeutic Aspects: Therapeutics<br />
Disclosure:Nothing to Disclose<br />
Inanc, Murat, MD<br />
Systemic Lupus Erythematosus - Clinical Aspects<br />
and Treatment<br />
Disclosure: Nothing to Disclose<br />
Inman, Robert D, MD<br />
Genetics, Genomics and Proteomics: SLE<br />
Disclosure:Nothing to Disclose<br />
Jonas, Beth L<br />
Orthopedics, Low Back Pain and Rehabilitation<br />
Disclosure: Nothing to Disclose<br />
Jordan, Joanne M, MD<br />
Impact on Osteoarthritis<br />
Disclosure:Nothing to Disclose<br />
J<br />
K<br />
Kamen, Diane L<br />
Systemic Lupus Erythematosus - Clinical Aspects<br />
and Treatment<br />
Disclosure: Nothing to Disclose<br />
Kaplan, Mariana J, MD<br />
Systemic Lupus Erythematosus - Human Etiology<br />
and Pathogenesis: Etiology and Pathogenesis<br />
Disclosure:Nothing to Disclose<br />
Katz, Jeffrey N, MD<br />
Orthopedics, Low Back Pain and Rehabilitation<br />
Disclosure:Nothing to Disclose<br />
Kay, Jonathan, MD<br />
Rheumatoid Arthritis - Clinical Aspects:<br />
Preclinical RA and Early RA I<br />
Disclosure: Nothing to Disclose<br />
Kerr, Karen L, MSN, NP, CPNP, PNP<br />
ACR/ARHP Combined Pediatric <strong>Rheumatology</strong> -<br />
Clinical and Therapeutic Aspects: Quality <strong>of</strong> Life<br />
in Children and Adolescents with Arthritis<br />
Disclosure: Nothing to Disclose<br />
Kimpton, Kimberly F, PT<br />
ACR/ARHP Combined Orthopedics, Low Back<br />
Pain and Rehabilitation Abstracts: Hips and<br />
Knees: Focus on Function<br />
Disclosure: Nothing to Disclose<br />
L<br />
Lafyatis, Robert A, MD<br />
Systemic Sclerosis, Fibrosing Syndromes, and<br />
Raynaud’s - Pathogenesis, Animal Models and<br />
Genetics<br />
Disclosure: Actelion, 2; Celgene, 2;Medimmune,<br />
2; Novartis, 2<br />
Landewe, Robert<br />
Spondylarthropathies and Psoriatic Arthritis -<br />
Clinical Aspects and Treatment - Biomarkers II<br />
Disclosure: Nothing to Disclose<br />
Lane, Nancy E, MD<br />
Osteoporosis and Metabolic Bone Disease:<br />
Clinical Aspects and Pathogensis<br />
Disclosure:Nothing to Disclose<br />
Liote, Frederic P<br />
Metabolic and Crystal Arthropathies -<br />
Pathogenesis, Prevalence, Imaging, and New<br />
Therapy<br />
Disclosure: Nothing to Disclose<br />
Lohr, Kristine M, MD<br />
Miscellaneous Rheumatic and Inflammatory<br />
Diseases<br />
Disclosure: Nothing to Disclose<br />
Losina, Elena, MD<br />
Epidemiology and Health Services Research:<br />
Osteoarthritis<br />
Disclosure:Nothing to Disclose<br />
Lovell, Daniel J, MD, MPH<br />
Pediatric <strong>Rheumatology</strong> - Clinical and<br />
Therapeutic Aspects-Outcomes<br />
Disclosure: Abbott, 5; Amgen, 5; Arthritis Care<br />
& Rheumatism & Arthritis and Rheumatism, 9;<br />
Astra-Zeneca Pharmaceutical, 5; Bristol-Meyers<br />
Squibb, 9; Centocor, 9; H<strong>of</strong>fman LaRoche, 5;<br />
Novartis, 5; Pfizer, 5; Regeneron, 5; UBC, 5;<br />
Wyeth Pharm., 9; Xoma, Inc., 5<br />
Lubberts, Erik, PhD<br />
Cytokines, Mediators, Gene Regulation II<br />
Disclosure: Nothing to Disclose<br />
M<br />
Maksymowych, Walter P, MD<br />
Spondylarthritis and Psoriatic Arthritis:<br />
Pathogenesis, Etiology, and Animal Models<br />
Disclosure: Merck, 2, 5; Pfizer, 2, 5, Abbott, 2, 5<br />
Markenson, Joseph A, MD<br />
Rheumatoid Arthritis - Clinical Aspects:<br />
Outcomes Associated with Biologic Therapy for<br />
RA II<br />
Disclosure:Nothing to Disclose
Massarotti, Elena M, MD<br />
Systemic Lupus Erythematosus - Clinical Aspects<br />
and Treatment: New Therapies<br />
Disclosure:Nothing to Disclose<br />
Matteson, Eric L, MD<br />
Rheumatoid Arthritis - Clinical Aspects:<br />
Outcomes Associated with Biologic Therapy for<br />
RA II<br />
Disclosure:Nothing to Disclose<br />
Mayes, Maureen D, MD<br />
Systemic Sclerosis, Fibrosing Syndromes, and<br />
Raynaud’s - Clinical Aspects and Therapeutics I<br />
Disclosure:Nothing to Disclose<br />
McAlindon, Timothy E, MD<br />
Osteoarthritis - Clinical Aspects: Genetics, Novel<br />
Approaches, and Therapy<br />
Disclosure:Nothing to Disclose<br />
McLean, Robert R, MD<br />
Impact on Osteoarthritis<br />
Disclosure:Nothing to Disclose<br />
Michaud, Kaleb D, PhD<br />
Epidemiology and Health Services Research:<br />
Rheumatoid Arthritis<br />
Disclosure: Nothing to Disclose<br />
Mikuls, Ted R, MD<br />
Epidemiology and Health Services Research:<br />
Rheumatoid Arthritis<br />
Disclosure: Nothing to Disclose<br />
Miller, Donald R, PharmD<br />
Rheumatic Medications: More or Less?<br />
Disclosure: Nothing to Disclose<br />
Miossec, Pierre, MD<br />
Rheumatoid Arthritis - Animal Models: Insight in<br />
Pathogenesis and Novel Therapeutic Targets I<br />
Disclosure:Nothing to Disclose<br />
Mittoo, Shikha, MD<br />
Epidemiology and Health Services Research:<br />
General Interest<br />
Disclosure:Nothing to Disclose<br />
Monach, Paul A, MD<br />
Vasculitis II<br />
Disclosure:Nothing to Disclose<br />
Muller-Ladner, Ulf, MD<br />
Rheumatoid Arthritis - Human Etiology and<br />
Pathogenesis: Anti-CCP in RA Etiology and<br />
Pathogenesis II<br />
Disclosure: German Research Foundation (DFG), 2<br />
Myers, Linda K, MD<br />
Rheumatoid Arthritis - Animal Models: T cell<br />
Pathogenesis an Novel Therapeutic Targets II<br />
Disclosure:Nothing to Disclose<br />
N<br />
Neogi, Tuhina, MD, PhD<br />
Osteoarthritis - Clinical Aspects: Genetics, Novel<br />
Approaches, and Therapy<br />
Disclosure: Nothing to Disclose<br />
Nuki, George, MD<br />
Metabolic and Crystal Arthropathies:<br />
Pathogenesis, Prevalence, Imaging, and New<br />
Therapy<br />
Disclosure:Nothing to Disclose<br />
Østergaard, Mikkel, MD, PhD<br />
Imaging <strong>of</strong> Rheumatic Disease: X-ray and MRI<br />
Disclosure:Nothing to Disclose<br />
O<br />
P<br />
Perl, Andras<br />
Systemic Lupus Erythematosus - Human Etiology<br />
and Pathogenesis: Etiology and Pathogenesis<br />
Disclosure: Nothing to Disclose<br />
Peschken, Christine A<br />
Systemic Lupus Erythematosus - Clinical Aspects<br />
and Treatment: SLE and Cardiovascular Disease<br />
Disclosure: Nothing to Disclose<br />
Pierangeli, Silvia S, PhD<br />
Antiphospholipid Syndrome II<br />
Disclosure: Nothing to Disclose<br />
Putterman, Chaim<br />
B-Cell Biology and Targets in Autoimmune<br />
Disease<br />
Disclosure: biogen idec, 2<br />
R<br />
Rabinovich, Egla C<br />
Pediatric <strong>Rheumatology</strong> - Clinical and<br />
Therapeutic Aspects-Therapeutics<br />
Disclosure: Abbott, 2; CARRA, 2; Pfizer, 2<br />
Ranganath, Veena K, MD<br />
Rheumatoid Arthritis Treatment - Small<br />
Molecules, Biologics and Gene Therapy: Existing<br />
Biologics IV<br />
Disclosure: UCB, 2; H<strong>of</strong>fman and Roche; 2;<br />
Wyeth, 2<br />
Reed, Ann M, MD<br />
Muscle Biology, Myositis and Myopathies:<br />
Insights into the Pathogenesis and Outcomes <strong>of</strong><br />
Myositis<br />
Disclosure:Nothing to Disclose<br />
Roubey, Robert A S, MD<br />
Antiphospholipid Syndrome I<br />
Antiphospholipid Syndrome II<br />
Disclosure:Nothing to Disclose<br />
Ruderman, Eric M, MD<br />
Rheumatoid Arthritis Treatment - Small<br />
Molecules, Biologics and Gene Therapy: Existing<br />
Non-Biologic DMARDs II<br />
Disclosure:Nothing to Disclose<br />
S<br />
Salmon, Jane E, MD<br />
Systemic Lupus Erythematosus - Animal Models<br />
Disclosure:Nothing to Disclose<br />
Scanzello, Carla R, MD, PhD<br />
Cytokines, Mediators, Gene Regulation II<br />
Disclosure: Amgen, 9<br />
Schlenk, Elizabeth A, PhD, RN<br />
Be Creative with Rheumatic Education: Where<br />
and How to Get It<br />
Disclosure: Nothing to Disclose<br />
Schmidt, Wolfgang A, MD<br />
Imaging <strong>of</strong> Rheumatic Disease: Ultrasound<br />
Shoenfeld, Yehuda, MD<br />
B-Cell Biology and Targets in Autoimmune<br />
Disease<br />
Singer, Nora G<br />
Pediatric <strong>Rheumatology</strong> - Pathogenesis<br />
and Genetics: Biological Basis for Pediatric<br />
Rheumatic Disease<br />
Disclosure: Nothing to Disclose<br />
Solomon, Daniel H, MD<br />
Infection-Related Rheumatic Disease<br />
Disclosure:Nothing to Disclose<br />
Strand, Vibeke, MD<br />
Rheumatoid Arthritis Treatment - Small<br />
Molecules, Biologics and Gene Therapy: Novel<br />
Compounds III<br />
Disclosure:Nothing to Disclose<br />
Suter, Lisa G<br />
Epidemiology and Health Services Research:<br />
Gout<br />
Disclosure: Arthritis Foundation, 2; NIH, 2; Yale<br />
New Hospital Center for Outcomes Research, 5<br />
Symmons, Deborah P, MD<br />
Rheumatoid Arthritis - Clinical Aspects: RA and<br />
Cardiovascular Disease III<br />
Disclosure:Nothing to Disclose<br />
Szekanecz, Zoltan, MD<br />
Cell-Cell Adhesion, Cell Trafficking and<br />
Angiogenesis<br />
Disclosure:Nothing to Disclose<br />
Thombs, Brett D, BA, MA, PhD<br />
What a Pain Rheumatic Diseases Can Be!<br />
Disclosure: Nothing to Disclose<br />
Tsao, Betty P, PhD<br />
Genetics, Genomics and Proteomics: SLE<br />
Disclosure: Nothing to Disclose<br />
Tsokos, George C, MD<br />
Innate Immunity and Rheumatic Disease<br />
Disclosure: Nothing to Disclose<br />
Tzioufas, Athanasios G, MD<br />
Sjögren’s Syndrome<br />
Disclosure: Nothing to Disclose<br />
V<br />
Van Der Heijde, Desiree M, MD, PhD<br />
Spondylarthropathies and Psoriatic Arthritis -<br />
Clinical Aspects and Treatment - Imaging I<br />
Disclosure: abbott, 5; amgen, 5; bristol meyers<br />
squibb, 5; centocor, 5; chugai, 5; msd, 5;<br />
novartis, 5; pfizer, 5; roche, 5; ucb, 5<br />
T<br />
Van Den Berg, Wim, PhD<br />
Rheumatoid Arthritis - Animal Models: Insight in<br />
Pathogenesis and Novel Therapeutic Targets I<br />
Disclosure:Nothing to Disclose<br />
Van Riel, Piet L<br />
Rheumatoid Arthritis - Clinical Aspects:<br />
Radiographic and Other Outcomes in RA IV<br />
Disclosure: Abbott, 2; BMS, 2; MSD, 2; Pfizer, 2;<br />
Roche, 2; San<strong>of</strong>i Aventis, 2; Schering Plough, 2;<br />
2010 Program Book 377<br />
ABSTRACT MODERATOR DISCLOSURE
UCB, 2; Wyeth, 2<br />
Von Feldt, Joan Marie, MD, MS Ed<br />
Education<br />
Disclosure:Nothing to Disclose<br />
W<br />
Wallace, Carol A, MD<br />
Pediatric <strong>Rheumatology</strong> - Clinical and<br />
Therapeutic Aspects-Outcomes<br />
Disclosure:Nothing to Disclose<br />
Weissman, Barbara N, MD<br />
Imaging <strong>of</strong> Rheumatic Disease: X-ray and MRI<br />
Disclosure:Nothing to Disclose<br />
Wells, Alvin F, MD<br />
Rheumatoid Arthritis Treatment - Small<br />
Molecules, Biologics and Gene Therapy: Existing<br />
Non-Biologic DMARDs II<br />
Disclosure:Nothing to Disclose<br />
Weyand, Cornelia, MD, PhD<br />
Vasculitis II<br />
Disclosure:Nothing to Disclose<br />
Williams, David A, PhD<br />
Don’t Despair Over Health Disparities<br />
Disclosure: Nothing to Disclose<br />
Wooley, Paul H<br />
Rheumatoid Arthritis - Animal Models: T cell<br />
Pathogenesis an Novel Therapeutic Targets II<br />
Disclosure: Nothing to Disclose<br />
ABSTRACT MODERATOR DISCLOSURE<br />
378<br />
2010 Program Book
ACR Annual Meeting<br />
fellowS-in-training scholArship<br />
Through the ACR Fellows Education Fund,<br />
the ACR is able to present the ACR Annual<br />
Meeting Fellows-In-Training Scholarship.<br />
In addition to travel assistance, all fellow<br />
attendees at the annual meeting are<br />
invited to special educational sessions<br />
and networking events.<br />
Through programs like the ACR Annual<br />
Meeting Fellows-In-Training Scholarship,<br />
the ACR is committed to meeting the<br />
challenge <strong>of</strong> ensuring high-quality<br />
rheumatic care for years to come.<br />
The ACR wishes to thank the following<br />
organizations for their generous support<br />
<strong>of</strong> the 2010 Fellows Education Fund:<br />
Platinum<br />
GOLD<br />
SilVER<br />
Abbott<br />
SUPPORTER<br />
Bristol-Myers Squibb Company<br />
The ACR wishes to thank Centocor Ortho<br />
Biotech Inc., Lilly USA, LLC, and UCB, Inc.<br />
for their generous support <strong>of</strong> the 2010 ACR<br />
Fellows-In-Training Travel Scholarship.<br />
2010 Program Book 379
NOTES<br />
380<br />
2010 Program Book
NOTES<br />
2010 Program Book 381
NOTES<br />
382<br />
2010 Program Book
Enbrel ® (etanercept) Brief Summary<br />
SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION<br />
WARNINGS<br />
SERIOUS INFECTIONS AND MALIGNANCIES<br />
Patients treated with Enbrel are at increased risk for developing serious<br />
infections that may lead to hospitalization or death [see Warnings and<br />
Precautions and Adverse Reactions]. Most patients who developed these<br />
infections were taking concomitant immunosuppressants such as<br />
methotrexate or corticosteroids.<br />
Enbrel should be discontinued if a patient develops a serious infection<br />
or sepsis.<br />
Reported infections include:<br />
• Active tuberculosis, including reactivation <strong>of</strong> latent tuberculosis. Patients<br />
with tuberculosis have frequently presented with disseminated or<br />
extrapulmonary disease. Patients should be tested for latent tuberculosis<br />
before Enbrel use and during therapy. Treatment for latent infection<br />
should be initiated prior to Enbrel use.<br />
• Invasive fungal infections, including histoplasmosis, coccidioidomycosis,<br />
candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients<br />
with histoplasmosis or other invasive fungal infections may present with<br />
disseminated, rather than localized, disease. Antigen and antibody<br />
testing for histoplasmosis may be negative in some patients with active<br />
infection. Empiric anti-fungal therapy should be considered in patients at<br />
risk for invasive fungal infections who develop severe systemic illness.<br />
• Bacterial, viral, and other infections due to opportunistic pathogens.<br />
The risks and benefits <strong>of</strong> treatment with Enbrel should be carefully<br />
considered prior to initiating therapy in patients with chronic or recurrent<br />
infection.<br />
Patients should be closely monitored for the development <strong>of</strong> signs and<br />
symptoms <strong>of</strong> infection during and after treatment with Enbrel, including<br />
the possible development <strong>of</strong> tuberculosis in patients who tested negative<br />
for latent tuberculosis infection prior to initiating therapy.<br />
MALIGNANCIES<br />
Lymphoma and other malignancies, some fatal, have been reported<br />
in children and adolescent patients treated with TNF blockers,<br />
including Enbrel.<br />
INDICATIONS AND USAGE<br />
Rheumatoid Arthritis<br />
Enbrel is indicated for reducing signs and symptoms, inducing major clinical<br />
response, inhibiting the progression <strong>of</strong> structural damage, and improving<br />
physical function in patients with moderately to severely active rheumatoid<br />
arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX)<br />
or used alone.<br />
Polyarticular Juvenile Idiopathic Arthritis<br />
Enbrel is indicated for reducing signs and symptoms <strong>of</strong> moderately to severely<br />
active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2<br />
and older.<br />
Psoriatic Arthritis<br />
Enbrel is indicated for reducing signs and symptoms, inhibiting the<br />
progression <strong>of</strong> structural damage <strong>of</strong> active arthritis, and improving physical<br />
function in patients with psoriatic arthritis (PsA). Enbrel can be used in<br />
combination with methotrexate (MTX) in patients who do not respond<br />
adequately to MTX alone.<br />
Ankylosing Spondylitis<br />
Enbrel is indicated for reducing signs and symptoms in patients with active<br />
ankylosing spondylitis (AS).<br />
Plaque Psoriasis<br />
Enbrel is indicated for the treatment <strong>of</strong> adult patients (18 years or older) with<br />
chronic moderate to severe plaque psoriasis (PsO) who are candidates for<br />
systemic therapy or phototherapy.<br />
CONTRAINDICATIONS<br />
Enbrel should not be administered to patients with sepsis.<br />
WARNINGS AND PRECAUTIONS<br />
Infections<br />
Serious and sometimes fatal infections due to bacterial, mycobacterial,<br />
invasive fungal, viral, or other opportunistic pathogens have been reported in<br />
patients receiving TNF-blocking agents. Among opportunistic infections,<br />
tuberculosis, histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis,<br />
listeriosis, and pneumocystosis were the most commonly reported. Patients<br />
have frequently presented with disseminated rather than localized disease,<br />
and are <strong>of</strong>ten taking concomitant immunosuppressants such as methotrexate<br />
or corticosteroids with Enbrel.<br />
Treatment with Enbrel should not be initiated in patients with an active<br />
infection, including clinically important localized infections. The risks and<br />
benefits <strong>of</strong> treatment should be considered prior to initiating therapy in<br />
patients: with chronic or recurrent infection; who have been exposed to<br />
tuberculosis; who have resided or traveled in areas <strong>of</strong> endemic tuberculosis or<br />
endemic mycoses, such as histoplasmosis, coccidioidomycosis, or<br />
blastomycosis; or with underlying conditions that may predispose them to<br />
infection, such as advanced or poorly controlled diabetes [see Adverse<br />
Reactions].<br />
Patients should be closely monitored for the development <strong>of</strong> signs and<br />
symptoms <strong>of</strong> infection during and after treatment with Enbrel.<br />
Enbrel should be discontinued if a patient develops a serious infection or<br />
sepsis. A patient who develops a new infection during treatment with Enbrel<br />
should be closely monitored, undergo a prompt and complete diagnostic<br />
workup appropriate for an immunocompromised patient, and appropriate<br />
antimicrobial therapy should be initiated.<br />
Tuberculosis<br />
Cases <strong>of</strong> reactivation <strong>of</strong> tuberculosis or new tuberculosis infections have been<br />
observed in patients receiving Enbrel, including patients who have previously<br />
received treatment for latent or active tuberculosis. Data from clinical trials<br />
and preclinical studies suggest that the risk <strong>of</strong> reactivation <strong>of</strong> latent<br />
tuberculosis infection is lower with Enbrel than with TNF-blocking monoclonal<br />
antibodies. Nonetheless, postmarketing cases <strong>of</strong> tuberculosis reactivation<br />
have been reported for TNF blockers, including Enbrel. Tuberculosis has<br />
developed in patients who tested negative for latent tuberculosis prior to<br />
initiation <strong>of</strong> therapy. Patients should be evaluated for tuberculosis risk factors<br />
and tested for latent infection prior to initiating Enbrel and periodically during<br />
therapy. Tests for latent tuberculosis infection may be falsely negative while<br />
on therapy with Enbrel.<br />
Treatment <strong>of</strong> latent tuberculosis infection prior to therapy with TNF-blocking<br />
agents has been shown to reduce the risk <strong>of</strong> tuberculosis reactivation during<br />
therapy. Induration <strong>of</strong> 5 mm or greater with tuberculin skin testing should be<br />
considered a positive test result when assessing if treatment for latent<br />
tuberculosis is needed prior to initiating Enbrel, even for patients previously<br />
vaccinated with Bacille Calmette-Guerin (BCG).<br />
Anti-tuberculosis therapy should also be considered prior to initiation <strong>of</strong><br />
Enbrel in patients with a past history <strong>of</strong> latent or active tuberculosis in whom<br />
an adequate course <strong>of</strong> treatment cannot be confirmed, and for patients with a<br />
negative test for latent tuberculosis but having risk factors for tuberculosis<br />
infection. Consultation with a physician with expertise in the treatment <strong>of</strong><br />
tuberculosis is recommended to aid in the decision whether initiating antituberculosis<br />
therapy is appropriate for an individual patient.<br />
Tuberculosis should be strongly considered in patients who develop a new<br />
infection during Enbrel treatment, especially in patients who have previously<br />
or recently traveled to countries with a high prevalence <strong>of</strong> tuberculosis, or who<br />
have had close contact with a person with active tuberculosis.<br />
Invasive Fungal Infections<br />
Cases <strong>of</strong> serious and sometimes fatal fungal infections, including<br />
histoplasmosis, have been reported with TNF blockers, including Enbrel. For<br />
patients who reside or travel in regions where mycoses are endemic, invasive<br />
fungal infection should be suspected if they develop a serious systemic<br />
illness. Appropriate empiric antifungal therapy should be considered while a<br />
diagnostic workup is being performed. Antigen and antibody testing for<br />
histoplasmosis may be negative in some patients with active infection. When<br />
feasible, the decision to administer empiric antifungal therapy in these<br />
patients should be made in consultation with a physician with expertise in the<br />
diagnosis and treatment <strong>of</strong> invasive fungal infections and should take into<br />
account both the risk for severe fungal infection and the risks <strong>of</strong> antifungal<br />
therapy. In 38 Enbrel clinical trials and 4 cohort studies in all approved<br />
indications representing 27,169 patient-years <strong>of</strong> exposure (17,696 patients)<br />
from the United States and Canada, no histoplasmosis infections were<br />
reported among patients treated with Enbrel.<br />
Neurologic Events<br />
Treatment with TNF-blocking agents, including Enbrel, has been associated<br />
with rare (< 0.1%) cases <strong>of</strong> new onset or exacerbation <strong>of</strong> central nervous<br />
system demyelinating disorders, some presenting with mental status changes<br />
and some associated with permanent disability. Cases <strong>of</strong> transverse myelitis,<br />
optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral<br />
demyelinating neuropathies, and new onset or exacerbation <strong>of</strong> seizure<br />
disorders have been reported in postmarketing experience with Enbrel<br />
therapy. Prescribers should exercise caution in considering the use <strong>of</strong> Enbrel<br />
in patients with preexisting or recent-onset central or peripheral nervous<br />
system demyelinating disorders [see Adverse Reactions].<br />
Malignancies<br />
Lymphomas<br />
In the controlled portions <strong>of</strong> clinical trials <strong>of</strong> TNF-blocking agents, more cases<br />
<strong>of</strong> lymphoma have been observed among patients receiving a TNF blocker<br />
compared to control patients. During the controlled portions <strong>of</strong> Enbrel trials in<br />
adult patients with RA, AS, and PsA, 2 lymphomas were observed among<br />
3306 Enbrel-treated patients versus 0 among 1521 control patients (duration<br />
<strong>of</strong> controlled treatment ranged from 3 to 36 months).<br />
Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in<br />
controlled and uncontrolled portions <strong>of</strong> clinical trials, representing<br />
approximately 12,845 patient-years <strong>of</strong> therapy, the observed rate <strong>of</strong><br />
lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher than<br />
the rate <strong>of</strong> lymphoma expected in the general US population based on the<br />
Surveillance, Epidemiology, and End Results (SEER) Database. An increased<br />
rate <strong>of</strong> lymphoma up to several-fold has been reported in the RA patient<br />
population, and may be further increased in patients with more severe disease<br />
activity.<br />
Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36<br />
months, representing approximately 4278 patient-years <strong>of</strong> therapy, the observed<br />
rate <strong>of</strong> lymphoma was 0.05 cases per 100 patient-years, which is comparable<br />
to the rate in the general population. No cases were observed in Enbrel- or<br />
placebo-treated patients during the controlled portions <strong>of</strong> these trials.<br />
Leukemia<br />
Cases <strong>of</strong> acute and chronic leukemia have been reported in association with<br />
postmarketing TNF-blocker use in rheumatoid arthritis and other indications.<br />
Even in the absence <strong>of</strong> TNF-blocker therapy, patients with rheumatoid<br />
arthritis may be at higher risk (approximately 2-fold) than the general<br />
population for the development <strong>of</strong> leukemia.<br />
During the controlled portions <strong>of</strong> Enbrel trials, 2 cases <strong>of</strong> leukemia were<br />
observed among 5445 (0.06 cases per 100 patient-years) Enbrel-treated<br />
patients versus 0 among 2890 (0%) control patients (duration <strong>of</strong> controlled<br />
treatment ranged from 3 to 48 months).<br />
Among 15,401 patients treated with Enbrel in controlled and open portions <strong>of</strong><br />
clinical trials representing approximately 23,325 patient-years <strong>of</strong> therapy, the<br />
observed rate <strong>of</strong> leukemia was 0.03 cases per 100 patient-years.<br />
Other Malignancies<br />
Information is available from 10,953 adult patients with 17,123 patient-years<br />
and 696 pediatric patients with 1282 patient-years <strong>of</strong> experience across 45<br />
Enbrel clinical studies.<br />
For malignancies other than lymphoma and non-melanoma skin cancer, there<br />
was no difference in exposure-adjusted rates between the Enbrel and control<br />
arms in the controlled portions <strong>of</strong> clinical studies for all indications. Analysis<br />
<strong>of</strong> the malignancy rate in combined controlled and uncontrolled portions <strong>of</strong><br />
studies has demonstrated that types and rates are similar to what is expected<br />
in the general US population based on the SEER database and suggests no<br />
increase in rates over time. Whether treatment with Enbrel might influence the<br />
development and course <strong>of</strong> malignancies in adults is unknown.<br />
Non-melanoma skin cancer (NMSC)<br />
Non-melanoma skin cancer has been reported in patients treated with TNF<br />
antagonists including etanercept. Among 3306 adult rheumatology (RA, PsA,<br />
AS) patients treated with Enbrel in controlled clinical trials representing<br />
approximately 2669 patient-years <strong>of</strong> therapy, the observed rate <strong>of</strong> NMSC was<br />
0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among<br />
1521 control-treated patients representing 1077 patient-years. Among 1245<br />
adult psoriasis patients treated with Enbrel in controlled clinical trials,<br />
representing approximately 283 patient-years <strong>of</strong> therapy, the observed rate <strong>of</strong><br />
NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 100 patientyears<br />
among 720 control-treated patients representing 156 patient-years.<br />
Periodic skin examinations should be considered for all patients at increased<br />
risk for NMSC.<br />
Pediatric Patients<br />
Malignancies, some fatal, have been reported among children, adolescents,<br />
and young adults who received treatment with TNF-blocking agents (initiation<br />
<strong>of</strong> therapy at ≤ 18 years <strong>of</strong> age), including Enbrel. Approximately half the cases<br />
were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. The<br />
other cases represented a variety <strong>of</strong> different malignancies and included rare<br />
malignancies usually associated with immunosuppression and malignancies<br />
that are not usually observed in children and adolescents. The malignancies<br />
occurred after a median <strong>of</strong> 30 months <strong>of</strong> therapy (range 1 to 84 months). Most<br />
<strong>of</strong> the patients were receiving concomitant immunosuppressants. These<br />
cases were reported postmarketing and are derived from a variety <strong>of</strong> sources,<br />
including registries and spontaneous postmarketing reports.<br />
In clinical trials <strong>of</strong> 696 patients representing 1282 patient-years <strong>of</strong> therapy, no<br />
malignancies, including lymphoma or NMSC, have been reported.<br />
Postmarketing Use<br />
In global postmarketing adult and pediatric use, lymphoma and other<br />
malignancies have been reported.<br />
Patients With Heart Failure<br />
Two clinical trials evaluating the use <strong>of</strong> Enbrel in the treatment <strong>of</strong> heart failure<br />
were terminated early due to lack <strong>of</strong> efficacy. One <strong>of</strong> these studies suggested<br />
higher mortality in Enbrel-treated patients compared to placebo [see Adverse<br />
Reactions]. There have been postmarketing reports <strong>of</strong> worsening <strong>of</strong><br />
congestive heart failure (CHF), with and without identifiable precipitating<br />
factors, in patients taking Enbrel. There have also been rare (< 0.1%) reports<br />
<strong>of</strong> new onset CHF, including CHF in patients without known preexisting<br />
cardiovascular disease. Some <strong>of</strong> these patients have been under 50 years <strong>of</strong><br />
age. Physicians should exercise caution when using Enbrel in patients who<br />
also have heart failure, and monitor patients carefully.<br />
Hematologic Events<br />
Rare (< 0.1%) reports <strong>of</strong> pancytopenia, including very rare (< 0.01%) reports<br />
<strong>of</strong> aplastic anemia, some with a fatal outcome, have been reported in patients<br />
treated with Enbrel. The causal relationship to Enbrel therapy remains<br />
unclear. Although no high-risk group has been identified, caution should be<br />
exercised in patients being treated with Enbrel who have a previous history <strong>of</strong><br />
significant hematologic abnormalities. All patients should be advised to seek<br />
immediate medical attention if they develop signs and symptoms suggestive<br />
<strong>of</strong> blood dyscrasias or infection (eg, persistent fever, bruising, bleeding,<br />
pallor) while on Enbrel. Discontinuation <strong>of</strong> Enbrel therapy should be<br />
considered in patients with confirmed significant hematologic abnormalities.<br />
Two percent <strong>of</strong> patients treated concurrently with Enbrel and anakinra<br />
developed neutropenia (ANC < 1 x 10 9 /L). While neutropenic, one patient<br />
developed cellulitis that resolved with antibiotic therapy.<br />
Hepatitis B Virus Reactivation<br />
Use <strong>of</strong> TNF-blocking agents has been associated with reactivation <strong>of</strong> hepatitis<br />
B virus (HBV), including very rare cases (< 0.01%) with Enbrel, in patients who<br />
are chronic carriers <strong>of</strong> this virus. In some instances, HBV reactivation<br />
occurring in conjunction with TNF-blocker therapy has been fatal. The<br />
majority <strong>of</strong> these reports have occurred in patients concomitantly receiving<br />
other medications that suppress the immune system, which may also<br />
contribute to HBV reactivation. Patients at risk for HBV infection should be<br />
evaluated for prior evidence <strong>of</strong> HBV infection before initiating TNF-blocker<br />
therapy. Prescribers should exercise caution in prescribing TNF blockers for<br />
patients identified as carriers <strong>of</strong> HBV. Adequate data are not available on the<br />
safety or efficacy <strong>of</strong> treating patients who are carriers <strong>of</strong> HBV with anti viral<br />
therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation.<br />
Patients who are carriers <strong>of</strong> HBV and require treatment with Enbrel should be<br />
closely monitored for clinical and laboratory signs <strong>of</strong> active HBV infection<br />
throughout therapy and for several months following termination <strong>of</strong> therapy. In<br />
patients who develop HBV reactivation, consideration should be given to<br />
stopping Enbrel and initiating anti viral therapy with appropriate supportive<br />
treatment. The safety <strong>of</strong> resuming Enbrel therapy after HBV reactivation is<br />
controlled is not known. Therefore, prescribers should weigh the risks and<br />
benefits when considering resumption <strong>of</strong> therapy in this situation.<br />
Allergic Reactions<br />
Allergic reactions associated with administration <strong>of</strong> Enbrel during clinical<br />
trials have been reported in < 2% <strong>of</strong> patients. If an anaphylactic reaction or<br />
other serious allergic reaction occurs, administration <strong>of</strong> Enbrel should be<br />
discontinued immediately and appropriate therapy initiated.<br />
Caution: The needle cap on the prefilled syringe and on the SureClick<br />
autoinjector contains dry natural rubber (a derivative <strong>of</strong> latex) that may cause<br />
allergic reactions in individuals sensitive to latex.<br />
Immunizations<br />
Live vaccines should not be given concurrently with Enbrel. It is recommended<br />
that pediatric patients, if possible, be brought up-to-date with all<br />
immunizations in agreement with current immunization guidelines prior to<br />
initiating Enbrel therapy [see Drug Interactions].<br />
Autoimmunity<br />
Treatment with Enbrel may result in the formation <strong>of</strong> autoantibodies [see<br />
Adverse Reactions] and, rarely (< 0.1%), in the development <strong>of</strong> a lupus-like<br />
syndrome or autoimmune hepatitis [see Adverse Reactions], which may<br />
resolve following withdrawal <strong>of</strong> Enbrel. If a patient develops symptoms and<br />
findings suggestive <strong>of</strong> a lupus-like syndrome or autoimmune hepatitis<br />
following treatment with Enbrel, treatment should be discontinued and the<br />
patient should be carefully evaluated.<br />
Immunosuppression<br />
TNF mediates inflammation and modulates cellular immune responses. TNFblocking<br />
agents, including Enbrel, affect host defenses against infections. The<br />
effect <strong>of</strong> TNF inhibition on the development and course <strong>of</strong> malignancies is not<br />
fully understood. In a study <strong>of</strong> 49 patients with RA treated with Enbrel, there<br />
was no evidence <strong>of</strong> depression <strong>of</strong> delayed-type hypersensitivity, depression <strong>of</strong><br />
immunoglobulin levels, or change in enumeration <strong>of</strong> effector cell populations<br />
[see Adverse Reactions].<br />
Use in Wegener’s Granulomatosis Patients<br />
The use <strong>of</strong> Enbrel in patients with Wegener’s granulomatosis receiving<br />
immunosuppressive agents is not recommended. In a study <strong>of</strong> patients with<br />
Wegener’s granulomatosis, the addition <strong>of</strong> Enbrel to standard therapy (including<br />
cyclophosphamide) was associated with a higher incidence <strong>of</strong> non cutaneous
solid malignancies and was not associated with improved clinical outcomes<br />
when compared with standard therapy alone [see Drug Interactions].<br />
Use with Anakinra or Abatacept<br />
Use <strong>of</strong> Enbrel with anakinra or abatacept is not recommended [see<br />
Drug Interactions].<br />
Use in Patients with Moderate to Severe Alcoholic Hepatitis<br />
In a study <strong>of</strong> 48 hospitalized patients treated with Enbrel or placebo for<br />
moderate to severe alcoholic hepatitis, the mortality rate in patients treated<br />
with Enbrel was similar to patients treated with placebo at 1 month but<br />
significantly higher after 6 months. Physicians should use caution when using<br />
Enbrel in patients with moderate to severe alcoholic hepatitis.<br />
ADVERSE REACTIONS<br />
Across clinical studies and postmarketing experience, the most serious<br />
adverse reactions with Enbrel were infections, neurologic events, CHF, and<br />
hematologic events [see Warnings and Precautions]. The most common<br />
adverse reactions with Enbrel were infections and injection site reactions.<br />
Clinical Studies Experience<br />
Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic<br />
Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis<br />
The data described below reflect exposure to Enbrel in 2219 adult patients<br />
with RA followed for up to 80 months, in 182 patients with PsA for up to 24<br />
months, in 138 patients with AS for up to 6 months, and in 1204 adult patients<br />
with PsO for up to 18 months.<br />
In controlled trials, the proportion <strong>of</strong> Enbrel-treated patients who discontinued<br />
treatment due to adverse events was approximately 4% in the indications studied.<br />
Because clinical trials are conducted under widely varying conditions, adverse<br />
reactions rates observed in the clinical trials <strong>of</strong> a drug cannot be directly<br />
compared to rates in the clinical trials <strong>of</strong> another drug and may not predict the<br />
rates observed in clinical practice.<br />
Infections<br />
Infections, including viral, bacterial, and fungal infections, have been<br />
observed in adult and pediatric patients. Infections have been noted in all body<br />
systems and have been reported in patients receiving Enbrel alone or in<br />
combination with other immunosuppressive agents.<br />
In controlled portions <strong>of</strong> trials, the types and severity <strong>of</strong> infection were similar<br />
between Enbrel and the respective control group (placebo or MTX for RA and<br />
PsA patients) in RA, PsA, AS, and PsO patients. Rates <strong>of</strong> infections in RA<br />
and PsO patients are provided in Table 3 and Table 4, respectively.<br />
Infections consisted primarily <strong>of</strong> upper respiratory tract infection, sinusitis,<br />
and influenza.<br />
In controlled portions <strong>of</strong> trials in RA, PsA, AS, and PsO, the rates <strong>of</strong> serious<br />
infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/<br />
Enbrel + MTX-treated groups). In clinical trials in rheumatologic indications,<br />
serious infections experienced by patients have included, but are not limited<br />
to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis,<br />
pyelonephritis, sepsis, abscess, and osteomyelitis. In clinical trials in PsO,<br />
serious infections experienced by patients have included, but are not limited<br />
to, pneumonia, cellulitis, gastroenteritis, abscess, and osteomyelitis. The rate<br />
<strong>of</strong> serious infections was not increased in open-label extension trials and was<br />
similar to that observed in Enbrel- and placebo-treated patients from<br />
controlled trials.<br />
In 66 global clinical trials <strong>of</strong> 17,505 patients (21,015 patient-years <strong>of</strong> therapy),<br />
tuberculosis was observed in approximately 0.02% <strong>of</strong> patients. In 17,696<br />
patients (27,169 patient-years <strong>of</strong> therapy) from 38 clinical trials and 4 cohort<br />
studies in the US and Canada, tuberculosis was observed in approximately<br />
0.006% <strong>of</strong> patients. These studies include reports <strong>of</strong> pulmonary and<br />
extrapulmonary tuberculosis [see Warnings and Precautions].<br />
Injection Site Reactions<br />
In placebo-controlled trials in rheumatologic indications, approximately 37%<br />
<strong>of</strong> patients treated with Enbrel developed injection site reactions. In controlled<br />
trials in patients with PsO, 15% <strong>of</strong> patients treated with Enbrel developed<br />
injection site reactions during the first 3 months <strong>of</strong> treatment. All injection site<br />
reactions were described as mild to moderate (erythema, itching, pain,<br />
swelling, bleeding, bruising) and generally did not necessitate drug<br />
discontinuation. Injection site reactions generally occurred in the first month<br />
and subsequently decreased in frequency. The mean duration <strong>of</strong> injection site<br />
reactions was 3 to 5 days. Seven percent <strong>of</strong> patients experienced redness at<br />
a previous injection site when subsequent injections were given.<br />
Immunogenicity<br />
Patients with RA, PsA, AS, or PsO were tested at multiple time points for<br />
antibodies to etanercept. Antibodies to the TNF receptor portion or other<br />
protein components <strong>of</strong> the Enbrel drug product were detected at least once in<br />
sera <strong>of</strong> approximately 6% <strong>of</strong> adult patients with RA, PsA, AS, or PsO. These<br />
antibodies were all non-neutralizing. Results from JIA patients were similar to<br />
those seen in adult RA patients treated with Enbrel.<br />
In PsO studies that evaluated the exposure <strong>of</strong> etanercept for up to 120 weeks,<br />
the percentage <strong>of</strong> patients testing positive at the assessed time points <strong>of</strong> 24,<br />
48, 72, and 96 weeks ranged from 3.6%–8.7% and were all non-neutralizing.<br />
The percentage <strong>of</strong> patients testing positive increased with an increase in the<br />
duration <strong>of</strong> study; however, the clinical significance <strong>of</strong> this finding is unknown.<br />
No apparent correlation <strong>of</strong> antibody development to clinical response or<br />
adverse events was observed. The immunogenicity data <strong>of</strong> Enbrel beyond 120<br />
weeks <strong>of</strong> exposure are unknown.<br />
The data reflect the percentage <strong>of</strong> patients whose test results were considered<br />
positive for antibodies to etanercept in an ELISA assay, and are highly<br />
dependent on the sensitivity and specificity <strong>of</strong> the assay. Additionally, the<br />
observed incidence <strong>of</strong> any antibody positivity in an assay is highly dependent<br />
on several factors, including assay sensitivity and specificity, assay<br />
methodology, sample handling, timing <strong>of</strong> sample collection, concomitant<br />
medications, and underlying disease. For these reasons, comparison <strong>of</strong> the<br />
incidence <strong>of</strong> antibodies to etanercept with the incidence <strong>of</strong> antibodies to other<br />
products may be misleading.<br />
Autoantibodies<br />
Patients with RA had serum samples tested for autoantibodies at multiple<br />
time points. In RA Studies I and II, the percentage <strong>of</strong> patients evaluated for<br />
antinuclear antibodies (ANA) who developed new positive ANA (titer ≥ 1:40)<br />
was higher in patients treated with Enbrel (11%) than in placebo-treated<br />
patients (5%). The percentage <strong>of</strong> patients who developed new positive antidouble-stranded<br />
DNA antibodies was also higher by radioimmunoassay (15%<br />
<strong>of</strong> patients treated with Enbrel compared to 4% <strong>of</strong> placebo-treated patients)<br />
and by Crithidia luciliae assay (3% <strong>of</strong> patients treated with Enbrel compared to<br />
none <strong>of</strong> placebo-treated patients). The proportion <strong>of</strong> patients treated with<br />
Enbrel who developed anticardiolipin antibodies was similarly increased<br />
compared to placebo-treated patients. In RA Study III, no pattern <strong>of</strong> increased<br />
autoantibody development was seen in Enbrel patients compared to MTX<br />
patients [see Autoimmunity].<br />
Other Adverse Reactions<br />
Table 3 summarizes adverse reactions reported in adult RA patients. The<br />
types <strong>of</strong> adverse reactions seen in patients with PsA or AS were similar to the<br />
types <strong>of</strong> adverse reactions seen in patients with RA.<br />
Table 3. Percent <strong>of</strong> Adult RA Patients Experiencing Adverse<br />
Reactions in Controlled Clinical Trials<br />
Placebo Controlled a<br />
(Studies I, II, and a<br />
Phase 2 Study)<br />
Placebo<br />
(N = 152)<br />
Enbrel c<br />
(N = 349)<br />
Active Controlled b<br />
(Study III)<br />
MTX<br />
(N = 217)<br />
Enbrel c<br />
(N = 415)<br />
Reaction Percent <strong>of</strong> Patients Percent <strong>of</strong> Patients<br />
Infection d (total)<br />
Upper Respiratory<br />
Infections e<br />
Non-upper Respiratory<br />
Infections<br />
Injection Site<br />
Reactions<br />
Diarrhea<br />
Rash<br />
Pruritus<br />
Pyrexia<br />
Urticaria<br />
Hypersensitivity<br />
39<br />
30<br />
15<br />
11<br />
9<br />
2<br />
1<br />
–<br />
1<br />
–<br />
50<br />
38<br />
21<br />
37<br />
8<br />
3<br />
2<br />
3<br />
–<br />
–<br />
86<br />
70<br />
59<br />
18<br />
16<br />
19<br />
5<br />
4<br />
4<br />
1<br />
81<br />
65<br />
54<br />
43<br />
16<br />
13<br />
5<br />
2<br />
2<br />
1<br />
a<br />
Includes data from the 6-month study in which patients received<br />
concurrent MTX therapy in both arms.<br />
b<br />
Study duration <strong>of</strong> 2 years.<br />
c<br />
Any dose.<br />
d<br />
Includes bacterial, viral, and fungal infections.<br />
e<br />
Most frequent Upper Respiratory Infections were upper respiratory<br />
tract infection, sinusitis, and influenza.<br />
In placebo-controlled PsO trials, the percentages <strong>of</strong> patients reporting<br />
adverse reactions in the 50 mg twice a week dose group were similar to those<br />
observed in the 25 mg twice a week dose group or placebo group.<br />
Table 4 summarizes adverse reactions reported in adult PsO patients from<br />
Studies I and II.<br />
Table 4. Percent <strong>of</strong> Adult PsO Patients Experiencing Adverse<br />
Reactions in Placebo-Controlled Portions <strong>of</strong> Clinical Trials<br />
(Studies I & II)<br />
Reaction<br />
Infection b (total)<br />
Non-upper Respiratory<br />
Infections<br />
Upper Respiratory<br />
Infections c<br />
Injection Site<br />
Reactions<br />
Diarrhea<br />
Rash<br />
Pruritus<br />
Urticaria<br />
Hypersensitivity<br />
Pyrexia<br />
Placebo<br />
(N = 359)<br />
Enbrel a<br />
(N = 876)<br />
Percent <strong>of</strong> Patients<br />
28<br />
14<br />
17<br />
6<br />
2<br />
1<br />
2<br />
–<br />
–<br />
1<br />
27<br />
12<br />
a<br />
Includes 25 mg SC QW, 25 mg SC BIW, 50 mg SC QW, and 50 mg SC<br />
BIW doses.<br />
b<br />
Includes bacterial, viral, and fungal infections.<br />
c<br />
Most frequent Upper Respiratory Infections were upper respiratory<br />
tract infection, nasopharyngitis, and sinusitis.<br />
Adverse Reactions in Pediatric Patients<br />
In general, the adverse reactions in pediatric patients were similar in frequency<br />
and type as those seen in adult patients [see Warnings and Precautions]. The<br />
types <strong>of</strong> infections reported in pediatric patients were generally mild and<br />
consistent with those commonly seen in the general pediatric population. Two<br />
JIA patients developed varicella infection and signs and symptoms <strong>of</strong> aseptic<br />
meningitis, which resolved without sequelae.<br />
In open-label clinical studies <strong>of</strong> children with JIA, adverse reactions reported<br />
in those ages 2 to 4 years were similar to adverse reactions reported in<br />
older children.<br />
Postmarketing Experience<br />
Adverse reactions have been reported during post approval use <strong>of</strong> Enbrel in<br />
adults and pediatric patients. Because these reactions are reported voluntarily<br />
from a population <strong>of</strong> uncertain size, it is not always possible to reliably estimate<br />
their frequency or establish a causal relationship to Enbrel exposure.<br />
Adverse reactions are listed by body system below:<br />
Blood and lymphatic pancytopenia, anemia, leukopenia, neutropenia,<br />
system disorders:<br />
thrombocytopenia, lymphadenopathy, aplastic<br />
anemia [see Warnings and Precautions]<br />
Cardiac disorders:<br />
congestive heart failure [see Warnings<br />
and Precautions]<br />
General disorders:<br />
angioedema, chest pain<br />
Hepatobiliary disorders: autoimmune hepatitis, elevated transaminases<br />
Immune disorders:<br />
macrophage activation syndrome<br />
Musculoskeletal and lupus-like syndrome<br />
connective tissue disorders:<br />
Neoplasms benign, Non-melanoma skin cancers<br />
malignant, and unspecified: [see Warnings and Precautions]<br />
Nervous system disorders: convulsions, multiple sclerosis, demyelination,<br />
optic neuritis, transverse myelitis, paresthesias<br />
[see Warnings and Precautions]<br />
Ocular disorders:<br />
uveitis<br />
Respiratory, thoracic, interstitial lung disease<br />
and mediastinal disorders:<br />
17<br />
15<br />
3<br />
1<br />
1<br />
1<br />
1<br />
–<br />
Skin and subcutaneous<br />
tissue disorders:<br />
cutaneous lupus erythematous, cutaneous<br />
vasculitis (including leukocytoclastic vasculitis),<br />
erythema multiforme, Stevens-Johnson syndrome,<br />
toxic epidermal necrolysis, subcutaneous nodule,<br />
new or worsening psoriasis (all sub-types<br />
including pustular and palmoplantar)<br />
Opportunistic infections, including atypical mycobacterial infection, herpes<br />
zoster, aspergillosis, and Pneumocystis jiroveci pneumonia, and protozoal<br />
infections have also been reported in postmarketing use.<br />
DRUG INTERACTIONS<br />
Specific drug interaction studies have not been conducted with Enbrel.<br />
Vaccines<br />
Most PsA patients receiving Enbrel were able to mount effective B-cell<br />
immune responses to pneumococcal polysaccharide vaccine, but titers in<br />
aggregate were moderately lower and fewer patients had 2-fold rises in titers<br />
compared to patients not receiving Enbrel. The clinical significance <strong>of</strong> this is<br />
unknown. Patients receiving Enbrel may receive concurrent vaccinations,<br />
except for live vaccines. No data are available on the secondary transmission<br />
<strong>of</strong> infection by live vaccines in patients receiving Enbrel.<br />
Patients with a significant exposure to varicella virus should temporarily<br />
discontinue Enbrel therapy and be considered for prophylactic treatment with<br />
varicella zoster immune globulin [see Warnings and Precautions].<br />
Immune-Modulating Biologic Products<br />
In a study in which patients with active RA were treated for up to 24 weeks<br />
with concurrent Enbrel and anakinra therapy, a 7% rate <strong>of</strong> serious infections<br />
was observed, which was higher than that observed with Enbrel alone (0%)<br />
[see Warnings and Precautions] and did not result in higher ACR response<br />
rates compared to Enbrel alone. The most common infections consisted <strong>of</strong><br />
bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with<br />
pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent<br />
<strong>of</strong> patients treated concurrently with Enbrel and anakinra developed<br />
neutropenia (ANC < 1 x 10 9 /L).<br />
In clinical studies, concurrent administration <strong>of</strong> abatacept and Enbrel resulted<br />
in increased incidences <strong>of</strong> serious adverse events, including infections, and<br />
did not demonstrate increased clinical benefit [see Warnings and Precautions].<br />
Cyclophosphamide<br />
The use <strong>of</strong> Enbrel in patients receiving concurrent cyclophosphamide therapy<br />
is not recommended [see Warnings and Precautions].<br />
Sulfasalazine<br />
Patients in a clinical study who were on established therapy with sulfasalazine,<br />
to which Enbrel was added, were noted to develop a mild decrease in mean<br />
neutrophil counts in comparison to groups treated with either Enbrel or<br />
sulfasalazine alone. The clinical significance <strong>of</strong> this observation is unknown.<br />
USE IN SPECIFIC POPULATIONS<br />
Pregnancy<br />
Pregnancy Category B. Developmental toxicity studies have been performed<br />
in rats and rabbits at doses ranging from 60- to 100-fold higher than the<br />
human dose and have revealed no evidence <strong>of</strong> harm to the fetus due to Enbrel.<br />
There are, however, no studies in pregnant women. Because animal<br />
reproduction studies are not always predictive <strong>of</strong> human response, this drug<br />
should be used during pregnancy only if clearly needed.<br />
Pregnancy Registry: To monitor outcomes <strong>of</strong> pregnant women exposed to<br />
Enbrel, a pregnancy registry has been established. Physicians are encouraged<br />
to register patients by calling 1-877-311-8972.<br />
Nursing Mothers<br />
It is not known whether Enbrel is excreted in human milk or absorbed<br />
systemically after ingestion. Because many drugs and immunoglobulins are<br />
excreted in human milk, and because <strong>of</strong> the potential for serious adverse<br />
reactions in nursing infants from Enbrel, a decision should be made whether<br />
to discontinue nursing or to discontinue the drug.<br />
Pediatric Use<br />
Enbrel is indicated for treatment <strong>of</strong> polyarticular JIA in patients ages 2 years<br />
and older [see Indications and Usage, Warnings and Precautions, Adverse<br />
Reactions].<br />
Enbrel has not been studied in children < 2 years <strong>of</strong> age with JIA. The safety<br />
and efficacy <strong>of</strong> Enbrel in pediatric patients with PsO have not been studied.<br />
Geriatric Use<br />
A total <strong>of</strong> 480 RA patients ages 65 years or older have been studied in clinical<br />
trials. In PsO randomized clinical trials, a total <strong>of</strong> 138 out <strong>of</strong> 1965 subjects<br />
treated with Enbrel or placebo were age 65 or older. No overall differences in<br />
safety or effectiveness were observed between these patients and younger<br />
patients, but the number <strong>of</strong> geriatric PsO subjects is too small to determine<br />
whether they respond differently from younger subjects. Because there is a<br />
higher incidence <strong>of</strong> infections in the elderly population in general, caution<br />
should be used in treating the elderly.<br />
Use in Diabetics<br />
There have been reports <strong>of</strong> hypoglycemia following initiation <strong>of</strong> Enbrel therapy<br />
in patients receiving medication for diabetes, necessitating a reduction in<br />
anti-diabetic medication in some <strong>of</strong> these patients.<br />
Rx Only.<br />
This brief summary is based on ENBREL prescribing information<br />
v. 40: 7/2010<br />
Manufactured by:<br />
Immunex Corporation<br />
Thousand Oaks, CA 91320-1799<br />
U.S. License Number 1132<br />
Marketed by Amgen Inc. and Pfizer Inc.<br />
© 1998 – 2010 Immunex Corporation. All rights reserved.<br />
U.S. Patent Nos. 5,395,760; 5,605,690, Re. 36,755.<br />
For more information please call 1-888-436-2735 or visit www.enbrel.com<br />
© 2010 Amgen Inc., Thousand Oaks, CA 91320 and Pfizer Inc.<br />
All rights reserved.
Prescription Enbrel ® (etanercept) is administered by injection.<br />
IMPORTANT SAFETY INFORMATION<br />
SERIOUS INFECTIONS<br />
Patients treated with ENBREL are at increased risk for developing<br />
serious infections that may lead to hospitalization or death. Most<br />
patients who developed these infections were taking concomitant<br />
immunosuppressants such as methotrexate or corticosteroids or were<br />
predisposed to infection because <strong>of</strong> their underlying disease. ENBREL<br />
should not be initiated in the presence <strong>of</strong> sepsis, active infections, or<br />
allergy to ENBREL or its components. ENBREL should be discontinued<br />
if a patient develops a serious infection or sepsis. Reported infections<br />
include: 1) Active tuberculosis (TB), including reactivation <strong>of</strong> latent<br />
TB. Patients with TB have frequently presented with disseminated or<br />
extrapulmonary disease. Patients should be tested for latent TB before<br />
ENBREL use and periodically during therapy. Treatment for latent<br />
infection should be initiated prior to ENBREL use, 2) Invasive fungal<br />
infections, including histoplasmosis, coccidioidomycosis, candidiasis,<br />
aspergillosis, blastomycosis, and pneumocystosis. Patients with<br />
histoplasmosis or other invasive fungal infections may present with<br />
disseminated, rather than localized, disease. Antigen and antibody<br />
testing for histoplasmosis may be negative in some patients with active<br />
infection. Empiric antifungal therapy should be considered in patients<br />
at risk for invasive fungal infections who develop severe systemic<br />
illness, and 3) Bacterial, viral, and other infections due to opportunistic<br />
pathogens, such as listeriosis.<br />
The risks and benefits <strong>of</strong> treatment with ENBREL should be carefully<br />
considered prior to initiating therapy in patients 1) with chronic or<br />
recurrent infection, 2) who have been exposed to TB, 3) who have<br />
resided or traveled in areas <strong>of</strong> endemic TB or endemic mycoses, or<br />
4) with underlying conditions that may predispose them to infections such<br />
as advanced or poorly controlled diabetes. Patients should be closely<br />
monitored for the development <strong>of</strong> signs and symptoms <strong>of</strong> infection<br />
during and after treatment with ENBREL, including the possible<br />
development <strong>of</strong> TB in patients who tested negative for latent TB prior<br />
to initiating therapy.<br />
MALIGNANCIES<br />
Lymphoma and other malignancies, some fatal, have been reported in<br />
children and adolescent patients treated with tumor necrosis factor<br />
(TNF) blockers, including ENBREL.<br />
In clinical trials <strong>of</strong> all TNF blockers, more cases <strong>of</strong> lymphoma were seen<br />
compared to control patients. The risk <strong>of</strong> lymphoma may be up to several-fold<br />
higher in RA and psoriasis patients. The role <strong>of</strong> TNF blocker therapy in the<br />
development <strong>of</strong> malignancies is unknown.<br />
Cases <strong>of</strong> acute and chronic leukemia have been reported in association<br />
with postmarketing TNF blocker use in RA and other indications. The risk <strong>of</strong><br />
leukemia may be higher in patients with RA (approximately 2-fold) than the<br />
general population.<br />
Non-melanoma skin cancer (NMSC) has been reported in patients treated<br />
with TNF blockers, including ENBREL. Periodic skin examinations should be<br />
considered for all patients at increased risk for NMSC.<br />
Pediatric Patients<br />
In patients who initiated therapy at ≤ 18 years <strong>of</strong> age, approximately half <strong>of</strong><br />
the reported malignancies were lymphomas (Hodgkin’s and non-Hodgkin’s<br />
lymphoma). Other cases included rare malignancies usually associated<br />
with immunosuppression and malignancies that are not usually observed<br />
in children and adolescents. Most <strong>of</strong> the patients were receiving<br />
concomitant immunosuppressants.<br />
NEUROLOGIC EVENTS<br />
Treatment with TNF-blocking agents, including ENBREL, has been associated<br />
with rare (< 0.1%) cases <strong>of</strong> new onset or exacerbation <strong>of</strong> central nervous<br />
system demyelinating disorders, some presenting with mental status<br />
changes and some associated with permanent disability, and with peripheral<br />
nervous system demyelinating disorders. Cases <strong>of</strong> transverse myelitis,<br />
optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral<br />
demyelinating neuropathies, and new onset or exacerbation <strong>of</strong> seizure<br />
disorders have been reported in postmarketing experience with ENBREL<br />
therapy. Prescribers should exercise caution in considering the use <strong>of</strong><br />
ENBREL in patients with preexisting or recent-onset central or peripheral<br />
nervous system demyelinating disorders.<br />
HEMATOLOGIC EVENTS<br />
Rare cases <strong>of</strong> pancytopenia, including aplastic anemia, some fatal, have been<br />
reported. The causal relationship to ENBREL therapy remains unclear.<br />
Exercise caution when considering ENBREL in patients who have a previous<br />
history <strong>of</strong> significant hematologic abnormalities. Advise patients to seek<br />
immediate medical attention if they develop signs or symptoms <strong>of</strong> blood<br />
dyscrasias or infection. Consider discontinuing ENBREL if significant<br />
hematologic abnormalities are confirmed.<br />
WEGENER’S GRANULOMATOSIS PATIENTS<br />
The use <strong>of</strong> ENBREL in patients with Wegener’s granulomatosis receiving<br />
immunosuppressive agents (e.g., cyclophosphamide) is not recommended.<br />
HEPATITIS B VIRUS REACTIVATION<br />
Use <strong>of</strong> TNF blockers, including ENBREL, has been associated with reactivation<br />
<strong>of</strong> hepatitis B virus (HBV) in chronic carriers <strong>of</strong> this virus. The majority <strong>of</strong><br />
these reports occurred in patients on concomitant immunosuppressive<br />
agents, which may also contribute to HBV reactivation. Exercise caution when<br />
considering ENBREL in patients identified as carriers <strong>of</strong> HBV.<br />
MODERATE TO SEVERE ALCOHOLIC HEPATITIS<br />
Based on a study <strong>of</strong> patients treated for alcoholic hepatitis, exercise caution<br />
when using ENBREL in patients with moderate to severe alcoholic hepatitis.<br />
ALLERGIC REACTIONS<br />
Allergic reactions have been reported in < 2% <strong>of</strong> patients in clinical trials<br />
<strong>of</strong> ENBREL.<br />
CONGESTIVE HEART FAILURE<br />
Cases <strong>of</strong> worsening congestive heart failure (CHF) and, rarely, new onset<br />
cases have been reported in patients taking ENBREL. Caution should be used<br />
when using ENBREL in patients with CHF. These patients should be<br />
carefully monitored.<br />
IMMUNIZATIONS<br />
Live vaccines should not be administered to patients on ENBREL. JIA patients,<br />
if possible, should be brought up to date with all immunizations prior to<br />
initiating ENBREL. In patients with exposure to varicella virus, consider<br />
temporary discontinuation <strong>of</strong> ENBREL and prophylactic treatment with<br />
Varicella Zoster Immune Globulin.<br />
AUTOIMMUNITY<br />
Autoantibodies may develop with ENBREL, and rarely lupus-like syndrome or<br />
autoimmune hepatitis may occur. These may resolve upon withdrawal <strong>of</strong><br />
ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune<br />
hepatitis develops.<br />
DRUG INTERACTIONS<br />
The use <strong>of</strong> ENBREL in patients receiving concurrent cyclophosphamide<br />
therapy is not recommended. The risk <strong>of</strong> serious infection may increase with<br />
concomitant use <strong>of</strong> abatacept therapy. Concurrent therapy with ENBREL and<br />
anakinra is not recommended. Hypoglycemia has been reported following<br />
initiation <strong>of</strong> ENBREL therapy in patients receiving medication for diabetes,<br />
necessitating a reduction in anti-diabetic medication in some <strong>of</strong><br />
these patients.<br />
ADVERSE EVENTS<br />
The most commonly reported adverse events in RA clinical trials were<br />
injection site reaction, infection, and headache. In clinical trials <strong>of</strong> all other<br />
adult indications, adverse events were similar to those reported in RA<br />
clinical trials.<br />
Please see adjacent Brief Summary <strong>of</strong> Prescribing Information.<br />
© 2010 Amgen Inc., Thousand Oaks, CA 91320 and Pfizer Inc. All rights reserved.<br />
MC50381-B-1 06-10 www.enbrelhcp.com<br />
EXPERIENCE STARTS HERE
Come to booth #1429<br />
Approved in RA since 1998.<br />
ENBREL is indicated for reducing signs and symptoms, inducing major clinical<br />
response, inhibiting the progression <strong>of</strong> structural damage, and improving physical<br />
function in patients with moderately to severely active rheumatoid arthritis (RA).<br />
ENBREL can be initiated in combination with methotrexate (MTX) or used alone.<br />
See Important Safety Information on the adjacent page concerning the risks <strong>of</strong><br />
serious infections, including TB and other opportunistic infections, lymphoma<br />
and other malignancies, and other serious adverse events.<br />
You are part <strong>of</strong> Generation ENBREL, a<br />
generation <strong>of</strong> rheumatologists practicing<br />
since the approval <strong>of</strong> ENBREL. Join your<br />
peers at Booth #1429 to take a journey<br />
through our years <strong>of</strong> experience. Review<br />
data in moderate to severe rheumatoid<br />
arthritis and in psoriatic arthritis.<br />
Look for the ENBREL symposium,<br />
sponsored by Amgen and Pfizer,<br />
coming up this week.<br />
GeorGia world<br />
ConGress Center<br />
november 6–11, 2010, atlanta, Ga<br />
Please see Brief Summary <strong>of</strong> Prescribing Information on the following pages.<br />
EXPERIENCE STARTS HERE